<SEC-DOCUMENT>0001125345-19-000046.txt : 20190226
<SEC-HEADER>0001125345-19-000046.hdr.sgml : 20190226
<ACCEPTANCE-DATETIME>20190226161059
ACCESSION NUMBER:		0001125345-19-000046
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		83
CONFORMED PERIOD OF REPORT:	20181231
FILED AS OF DATE:		20190226
DATE AS OF CHANGE:		20190226

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MACROGENICS INC
		CENTRAL INDEX KEY:			0001125345
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36112
		FILM NUMBER:		19633491

	BUSINESS ADDRESS:	
		STREET 1:		9704 MEDICAL CENTER DRIVE
		CITY:			Rockville
		STATE:			MD
		ZIP:			20850
		BUSINESS PHONE:		301-251-5172

	MAIL ADDRESS:	
		STREET 1:		9704 MEDICAL CENTER DRIVE
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>mgnx-20181231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2017 Workiva--><!--r:047621fe-455e-451d-8c86-6c34d8ef3281,g:8a8d7b2b-0121-408b-a242-2fd92f2a34d5--><html xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns="http://www.w3.org/1999/xhtml" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:srt="http://fasb.org/srt/2018-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2018-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:mgnx="http://macrogenics.com/20181231" xmlns:dei="http://xbrl.sec.gov/dei/2018-01-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31"><head><meta http-equiv="Content-Type" content="text/html"></meta>


<title>Document</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" format="ixt:booleanfalse" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF8xMy9mcmFnOjcwZWQwODAzYjM4NzQxNzliMDdlNGFjZWFjYmZmNzFkL3RhYmxlOjI1YzFhODU2ZDViNDRmNmY4ZWY1ZmQxMzkxZmRjYWU0L3RhYmxlcmFuZ2U6MjVjMWE4NTZkNWI0NGY2ZjhlZjVmZDEzOTFmZGNhZTRfMi0xLTEtMS0w_4abcb9e6-3ace-4f97-a89b-8799341ccbe1">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF8xMy9mcmFnOjcwZWQwODAzYjM4NzQxNzliMDdlNGFjZWFjYmZmNzFkL3RhYmxlOjI1YzFhODU2ZDViNDRmNmY4ZWY1ZmQxMzkxZmRjYWU0L3RhYmxlcmFuZ2U6MjVjMWE4NTZkNWI0NGY2ZjhlZjVmZDEzOTFmZGNhZTRfNC0xLTEtMS0w_ae7a8af2-34e8-46f1-9bed-3f26d1a39ae9">2018</ix:nonNumeric><ix:nonNumeric contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF8xMy9mcmFnOjcwZWQwODAzYjM4NzQxNzliMDdlNGFjZWFjYmZmNzFkL3RhYmxlOjI1YzFhODU2ZDViNDRmNmY4ZWY1ZmQxMzkxZmRjYWU0L3RhYmxlcmFuZ2U6MjVjMWE4NTZkNWI0NGY2ZjhlZjVmZDEzOTFmZGNhZTRfNS0xLTEtMS0w_45b47dbe-66c8-4884-92bd-84d667714747">FY</ix:nonNumeric><ix:nonNumeric contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" name="dei:EntityWellKnownSeasonedIssuer" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF8xMy9mcmFnOjcwZWQwODAzYjM4NzQxNzliMDdlNGFjZWFjYmZmNzFkL3RhYmxlOjI1YzFhODU2ZDViNDRmNmY4ZWY1ZmQxMzkxZmRjYWU0L3RhYmxlcmFuZ2U6MjVjMWE4NTZkNWI0NGY2ZjhlZjVmZDEzOTFmZGNhZTRfOS0xLTEtMS0w_699d3b4c-3acb-4462-95f2-8f45cdd280e7">Yes</ix:nonNumeric><ix:nonNumeric contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF8xMy9mcmFnOjcwZWQwODAzYjM4NzQxNzliMDdlNGFjZWFjYmZmNzFkL3RhYmxlOjI1YzFhODU2ZDViNDRmNmY4ZWY1ZmQxMzkxZmRjYWU0L3RhYmxlcmFuZ2U6MjVjMWE4NTZkNWI0NGY2ZjhlZjVmZDEzOTFmZGNhZTRfMTAtMS0xLTEtMA_00e9af53-8b91-4066-a5c8-d0f4430c0fa4">Yes</ix:nonNumeric><ix:nonNumeric contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" name="dei:EntityVoluntaryFilers" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF8xMy9mcmFnOjcwZWQwODAzYjM4NzQxNzliMDdlNGFjZWFjYmZmNzFkL3RhYmxlOjI1YzFhODU2ZDViNDRmNmY4ZWY1ZmQxMzkxZmRjYWU0L3RhYmxlcmFuZ2U6MjVjMWE4NTZkNWI0NGY2ZjhlZjVmZDEzOTFmZGNhZTRfMTEtMS0xLTEtMA_41ef0d53-a37a-4a44-81f0-687bcdb532c9">No</ix:nonNumeric><ix:nonNumeric contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF8xMy9mcmFnOjcwZWQwODAzYjM4NzQxNzliMDdlNGFjZWFjYmZmNzFkL3RhYmxlOjI1YzFhODU2ZDViNDRmNmY4ZWY1ZmQxMzkxZmRjYWU0L3RhYmxlcmFuZ2U6MjVjMWE4NTZkNWI0NGY2ZjhlZjVmZDEzOTFmZGNhZTRfMTItMS0xLTEtMA_4b9e9760-b851-4dfa-b24e-07889a8832f2" escape="true">Large Accelerated Filer</ix:nonNumeric><ix:nonNumeric contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF8xMy9mcmFnOjcwZWQwODAzYjM4NzQxNzliMDdlNGFjZWFjYmZmNzFkL3RhYmxlOjI1YzFhODU2ZDViNDRmNmY4ZWY1ZmQxMzkxZmRjYWU0L3RhYmxlcmFuZ2U6MjVjMWE4NTZkNWI0NGY2ZjhlZjVmZDEzOTFmZGNhZTRfMTMtMS0xLTEtMA_35be98f7-cb0b-44a9-aabf-2397c1d1467c">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" format="ixt:booleanfalse" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF8xMy9mcmFnOjcwZWQwODAzYjM4NzQxNzliMDdlNGFjZWFjYmZmNzFkL3RhYmxlOjI1YzFhODU2ZDViNDRmNmY4ZWY1ZmQxMzkxZmRjYWU0L3RhYmxlcmFuZ2U6MjVjMWE4NTZkNWI0NGY2ZjhlZjVmZDEzOTFmZGNhZTRfMTQtMS0xLTEtMA_e81dce3b-5894-44ec-94f6-b07032b5b15f">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" format="ixt:booleanfalse" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF8xMy9mcmFnOjcwZWQwODAzYjM4NzQxNzliMDdlNGFjZWFjYmZmNzFkL3RhYmxlOjI1YzFhODU2ZDViNDRmNmY4ZWY1ZmQxMzkxZmRjYWU0L3RhYmxlcmFuZ2U6MjVjMWE4NTZkNWI0NGY2ZjhlZjVmZDEzOTFmZGNhZTRfMTUtMS0xLTEtNjAzMA_e7461d8c-bde9-4fc4-9eef-07fa04818393">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF8xMy9mcmFnOjcwZWQwODAzYjM4NzQxNzliMDdlNGFjZWFjYmZmNzFkL3RleHRyZWdpb246NzBlZDA4MDNiMzg3NDE3OWIwN2U0YWNlYWNiZmY3MWRfNTQ5NzU1ODE0MDI1_cae6355d-9773-4b28-bc38-c2bfc8888c28">MACROGENICS INC</ix:nonNumeric><ix:nonNumeric contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF8xMy9mcmFnOjcwZWQwODAzYjM4NzQxNzliMDdlNGFjZWFjYmZmNzFkL3RleHRyZWdpb246NzBlZDA4MDNiMzg3NDE3OWIwN2U0YWNlYWNiZmY3MWRfNTQ5NzU1ODE0MDI0_95e3faed-cce0-4ca8-9162-4c6fc7dd9c13">0001125345</ix:nonNumeric><ix:nonNumeric contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF8xMy9mcmFnOjcwZWQwODAzYjM4NzQxNzliMDdlNGFjZWFjYmZmNzFkL3RleHRyZWdpb246NzBlZDA4MDNiMzg3NDE3OWIwN2U0YWNlYWNiZmY3MWRfNTQ5NzU1ODE0MDIz_d4c94da5-681a-45b8-9961-91ea9b3ce4dd">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" format="ixt:datemonthdayyear" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF8xMy9mcmFnOjcwZWQwODAzYjM4NzQxNzliMDdlNGFjZWFjYmZmNzFkL3RleHRyZWdpb246NzBlZDA4MDNiMzg3NDE3OWIwN2U0YWNlYWNiZmY3MWRfMjE5OTAyMzI1NTg4Ng_4fe69217-b808-45d7-bcb0-db99834bffa6">12/31/2018</ix:nonNumeric><ix:nonFraction unitRef="usdPerShare" contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MjEvZnJhZzpkMjA4OGQ1M2E5NGE0ZmQwODNkMzcwODk0YjI5YzQ1Ny90YWJsZTphNmVhYjYxZWY1Mzc0M2Y4YmExNzI3ZjA3OTVlNzIxMi90YWJsZXJhbmdlOmE2ZWFiNjFlZjUzNzQzZjhiYTE3MjdmMDc5NWU3MjEyXzItMS0xLTEtMA_39473a47-9679-44c8-bd78-fa837504a40a">0.01</ix:nonFraction><ix:nonFraction unitRef="usdPerShare" contextRef="i7057397719af459ca7328a1c440a0efa_I20171231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MjEvZnJhZzpkMjA4OGQ1M2E5NGE0ZmQwODNkMzcwODk0YjI5YzQ1Ny90YWJsZTphNmVhYjYxZWY1Mzc0M2Y4YmExNzI3ZjA3OTVlNzIxMi90YWJsZXJhbmdlOmE2ZWFiNjFlZjUzNzQzZjhiYTE3MjdmMDc5NWU3MjEyXzItMy0xLTEtMA_3bb77058-35d1-47ea-9a63-3cb4e2ccea1e">0.01</ix:nonFraction><ix:nonFraction unitRef="shares" contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MjEvZnJhZzpkMjA4OGQ1M2E5NGE0ZmQwODNkMzcwODk0YjI5YzQ1Ny90YWJsZTphNmVhYjYxZWY1Mzc0M2Y4YmExNzI3ZjA3OTVlNzIxMi90YWJsZXJhbmdlOmE2ZWFiNjFlZjUzNzQzZjhiYTE3MjdmMDc5NWU3MjEyXzMtMS0xLTEtMA_8b425423-8d9c-4815-bc6c-d00550b5f16d">125,000,000</ix:nonFraction><ix:nonFraction unitRef="shares" contextRef="i7057397719af459ca7328a1c440a0efa_I20171231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MjEvZnJhZzpkMjA4OGQ1M2E5NGE0ZmQwODNkMzcwODk0YjI5YzQ1Ny90YWJsZTphNmVhYjYxZWY1Mzc0M2Y4YmExNzI3ZjA3OTVlNzIxMi90YWJsZXJhbmdlOmE2ZWFiNjFlZjUzNzQzZjhiYTE3MjdmMDc5NWU3MjEyXzMtMy0xLTEtMA_453a209d-96c9-4d67-8d21-27aa852dd8cf">125,000,000</ix:nonFraction><ix:nonFraction unitRef="shares" contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MjEvZnJhZzpkMjA4OGQ1M2E5NGE0ZmQwODNkMzcwODk0YjI5YzQ1Ny90YWJsZTphNmVhYjYxZWY1Mzc0M2Y4YmExNzI3ZjA3OTVlNzIxMi90YWJsZXJhbmdlOmE2ZWFiNjFlZjUzNzQzZjhiYTE3MjdmMDc5NWU3MjEyXzQtMS0xLTEtMA_62f70c40-b2d7-4f97-b6b2-7696ee0f4d7f">42,353,301</ix:nonFraction><ix:nonFraction unitRef="shares" contextRef="i7057397719af459ca7328a1c440a0efa_I20171231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MjEvZnJhZzpkMjA4OGQ1M2E5NGE0ZmQwODNkMzcwODk0YjI5YzQ1Ny90YWJsZTphNmVhYjYxZWY1Mzc0M2Y4YmExNzI3ZjA3OTVlNzIxMi90YWJsZXJhbmdlOmE2ZWFiNjFlZjUzNzQzZjhiYTE3MjdmMDc5NWU3MjEyXzQtMy0xLTEtMA_3c386ef8-3ad8-4495-a9a0-771331fc59e0">36,859,077</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82MTAvZnJhZzo0MDllMTRiNWFjNjI0Nzg1OTBkZTdhMzM5MWRmN2QxMi90ZXh0cmVnaW9uOjQwOWUxNGI1YWM2MjQ3ODU5MGRlN2EzMzkxZGY3ZDEyXzE1_9d65f311-1a99-4ed6-98d1-3340822cc0f5">no</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="i7057397719af459ca7328a1c440a0efa_I20171231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleCarryingValueOfAsset" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82MTAvZnJhZzo0MDllMTRiNWFjNjI0Nzg1OTBkZTdhMzM5MWRmN2QxMi90ZXh0cmVnaW9uOjQwOWUxNGI1YWM2MjQ3ODU5MGRlN2EzMzkxZGY3ZDEyXzE2MQ_ddb5a483-80f4-463f-b020-0ada6e818f95">no</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="i7057397719af459ca7328a1c440a0efa_I20171231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:AssetsHeldForSaleNotPartOfDisposalGroup" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82MTAvZnJhZzo0MDllMTRiNWFjNjI0Nzg1OTBkZTdhMzM5MWRmN2QxMi90ZXh0cmVnaW9uOjQwOWUxNGI1YWM2MjQ3ODU5MGRlN2EzMzkxZGY3ZDEyXzE4OA_02e51b89-d510-47b6-8a9f-77657717db4a">no</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="i7057397719af459ca7328a1c440a0efa_I20171231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82MTAvZnJhZzo0MDllMTRiNWFjNjI0Nzg1OTBkZTdhMzM5MWRmN2QxMi90ZXh0cmVnaW9uOjQwOWUxNGI1YWM2MjQ3ODU5MGRlN2EzMzkxZGY3ZDEyXzIxNA_93c75bda-9848-44e4-8f7a-26b406d5059d">No</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82MzUvZnJhZzo0ZGRlNWRiZTQyMzY0ODE1OGU5ZjMyYTM0NDZlMmVmMC90ZXh0cmVnaW9uOjRkZGU1ZGJlNDIzNjQ4MTU4ZTlmMzJhMzQ0NmUyZWYwXzE1_377cae13-7bbd-424b-845c-95a36b4237bc">no</ix:nonFraction><ix:nonFraction unitRef="shares" contextRef="i5511585976c54c42a03fe4ab0e7c9ec2_I20171231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82NzIvZnJhZzplODZiZjBhMTZiOGU0OGZiYTM0ZWJjMTIyODUxMWZiYy90ZXh0cmVnaW9uOmU4NmJmMGExNmI4ZTQ4ZmJhMzRlYmMxMjI4NTExZmJjXzE1_5ee6f61f-29da-4635-89d0-507d7498c978">no</ix:nonFraction><ix:nonFraction unitRef="shares" contextRef="iaaa703135e5d42e3ad357819a2febb2b_I20181231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82NzIvZnJhZzplODZiZjBhMTZiOGU0OGZiYTM0ZWJjMTIyODUxMWZiYy90ZXh0cmVnaW9uOmU4NmJmMGExNmI4ZTQ4ZmJhMzRlYmMxMjI4NTExZmJjXzEwOA_c6c1cca4-532b-4919-99b2-0cd9aa09205e">no</ix:nonFraction><ix:nonFraction unitRef="shares" contextRef="i5511585976c54c42a03fe4ab0e7c9ec2_I20171231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82NzIvZnJhZzplODZiZjBhMTZiOGU0OGZiYTM0ZWJjMTIyODUxMWZiYy90ZXh0cmVnaW9uOmU4NmJmMGExNmI4ZTQ4ZmJhMzRlYmMxMjI4NTExZmJjXzIwMQ_c26df693-86fc-43ca-a707-7a235155185c">no</ix:nonFraction><ix:nonFraction unitRef="usdPerShare" contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82NzIvZnJhZzplODZiZjBhMTZiOGU0OGZiYTM0ZWJjMTIyODUxMWZiYy90ZXh0cmVnaW9uOmU4NmJmMGExNmI4ZTQ4ZmJhMzRlYmMxMjI4NTExZmJjXzQ3NA_00dd9f6e-c22e-41ed-8293-c6a58bbf251c">.01</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i10e48d6d5c37418f95625e0a3c0c6c4a_D20180101-20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82OTcvZnJhZzplYmQ2MGE1MTA0Yjc0MDk0ODY1MDczNTY0MWU5YmRiNC90YWJsZTo5Y2ZlMzA1NTZjZmQ0NDY5OTg3YjA2NGFkMTgyZDY2Ny90YWJsZXJhbmdlOjljZmUzMDU1NmNmZDQ0Njk5ODdiMDY0YWQxODJkNjY3XzItMS0xLTEtMA_7b988feb-9c2d-4d42-b1d8-3af89502618e">68</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="iec5a69bea85a43309bedfd363a2e23bd_D20170101-20171231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82OTcvZnJhZzplYmQ2MGE1MTA0Yjc0MDk0ODY1MDczNTY0MWU5YmRiNC90YWJsZTo5Y2ZlMzA1NTZjZmQ0NDY5OTg3YjA2NGFkMTgyZDY2Ny90YWJsZXJhbmdlOjljZmUzMDU1NmNmZDQ0Njk5ODdiMDY0YWQxODJkNjY3XzItMy0xLTEtMA_35047219-7d83-4c97-b8e2-1ab61b95ee9b">67</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i460fef2e524d4f6fa38ec2499a0ea689_D20160101-20161231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82OTcvZnJhZzplYmQ2MGE1MTA0Yjc0MDk0ODY1MDczNTY0MWU5YmRiNC90YWJsZTo5Y2ZlMzA1NTZjZmQ0NDY5OTg3YjA2NGFkMTgyZDY2Ny90YWJsZXJhbmdlOjljZmUzMDU1NmNmZDQ0Njk5ODdiMDY0YWQxODJkNjY3XzItNS0xLTEtMA_de9f751a-246b-4b07-ab41-56de38b26c1c">64</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i4cee00b7a03d43ceb837d6f99f3c2a60_D20180101-20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82OTcvZnJhZzplYmQ2MGE1MTA0Yjc0MDk0ODY1MDczNTY0MWU5YmRiNC90YWJsZTo5Y2ZlMzA1NTZjZmQ0NDY5OTg3YjA2NGFkMTgyZDY2Ny90YWJsZXJhbmdlOjljZmUzMDU1NmNmZDQ0Njk5ODdiMDY0YWQxODJkNjY3XzMtMS0xLTEtMA_c717be97-afb8-4755-99b9-2a380163913b">72</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i43aa52214f03439db001c28c7a57ad3c_D20170101-20171231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82OTcvZnJhZzplYmQ2MGE1MTA0Yjc0MDk0ODY1MDczNTY0MWU5YmRiNC90YWJsZTo5Y2ZlMzA1NTZjZmQ0NDY5OTg3YjA2NGFkMTgyZDY2Ny90YWJsZXJhbmdlOjljZmUzMDU1NmNmZDQ0Njk5ODdiMDY0YWQxODJkNjY3XzMtMy0xLTEtMA_40f1a4a8-f981-412f-8700-e379b38d58fe">68</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="ibdb75168d0e0440c8357fec9636573d7_D20160101-20161231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82OTcvZnJhZzplYmQ2MGE1MTA0Yjc0MDk0ODY1MDczNTY0MWU5YmRiNC90YWJsZTo5Y2ZlMzA1NTZjZmQ0NDY5OTg3YjA2NGFkMTgyZDY2Ny90YWJsZXJhbmdlOjljZmUzMDU1NmNmZDQ0Njk5ODdiMDY0YWQxODJkNjY3XzMtNS0xLTEtMA_c936f23a-d3fd-43d3-b529-00fb6cc3a224">69</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i10e48d6d5c37418f95625e0a3c0c6c4a_D20180101-20181231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82OTcvZnJhZzplYmQ2MGE1MTA0Yjc0MDk0ODY1MDczNTY0MWU5YmRiNC90YWJsZTo5Y2ZlMzA1NTZjZmQ0NDY5OTg3YjA2NGFkMTgyZDY2Ny90YWJsZXJhbmdlOjljZmUzMDU1NmNmZDQ0Njk5ODdiMDY0YWQxODJkNjY3XzUtMS0xLTEtMA_b40d51fe-9340-40e3-9c54-b8c1019eefe6">2.4</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="iec5a69bea85a43309bedfd363a2e23bd_D20170101-20171231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82OTcvZnJhZzplYmQ2MGE1MTA0Yjc0MDk0ODY1MDczNTY0MWU5YmRiNC90YWJsZTo5Y2ZlMzA1NTZjZmQ0NDY5OTg3YjA2NGFkMTgyZDY2Ny90YWJsZXJhbmdlOjljZmUzMDU1NmNmZDQ0Njk5ODdiMDY0YWQxODJkNjY3XzUtMy0xLTEtMA_28313de3-5c2c-4b0e-bdd2-3a69e0c33f73">1.9</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i460fef2e524d4f6fa38ec2499a0ea689_D20160101-20161231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82OTcvZnJhZzplYmQ2MGE1MTA0Yjc0MDk0ODY1MDczNTY0MWU5YmRiNC90YWJsZTo5Y2ZlMzA1NTZjZmQ0NDY5OTg3YjA2NGFkMTgyZDY2Ny90YWJsZXJhbmdlOjljZmUzMDU1NmNmZDQ0Njk5ODdiMDY0YWQxODJkNjY3XzUtNS0xLTEtMA_1e4b7193-eafc-4aa9-8908-0f4ebfde848b">1.2</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i4cee00b7a03d43ceb837d6f99f3c2a60_D20180101-20181231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82OTcvZnJhZzplYmQ2MGE1MTA0Yjc0MDk0ODY1MDczNTY0MWU5YmRiNC90YWJsZTo5Y2ZlMzA1NTZjZmQ0NDY5OTg3YjA2NGFkMTgyZDY2Ny90YWJsZXJhbmdlOjljZmUzMDU1NmNmZDQ0Njk5ODdiMDY0YWQxODJkNjY3XzYtMS0xLTEtMA_b6310395-0803-4ccd-95a8-38b147084802">3.1</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i43aa52214f03439db001c28c7a57ad3c_D20170101-20171231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82OTcvZnJhZzplYmQ2MGE1MTA0Yjc0MDk0ODY1MDczNTY0MWU5YmRiNC90YWJsZTo5Y2ZlMzA1NTZjZmQ0NDY5OTg3YjA2NGFkMTgyZDY2Ny90YWJsZXJhbmdlOjljZmUzMDU1NmNmZDQ0Njk5ODdiMDY0YWQxODJkNjY3XzYtMy0xLTEtMA_5af8b728-11d4-4b6f-af41-30a2d0ca30a9">2.3</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="ibdb75168d0e0440c8357fec9636573d7_D20160101-20161231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82OTcvZnJhZzplYmQ2MGE1MTA0Yjc0MDk0ODY1MDczNTY0MWU5YmRiNC90YWJsZTo5Y2ZlMzA1NTZjZmQ0NDY5OTg3YjA2NGFkMTgyZDY2Ny90YWJsZXJhbmdlOjljZmUzMDU1NmNmZDQ0Njk5ODdiMDY0YWQxODJkNjY3XzYtNS0xLTEtMA_21fbacb4-45ed-4711-bd7e-220811df3b84">2.4</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MjIvZnJhZzpmYTcyOTAzNzI5NmM0NmRjODQ1ZmVmNDdhMGMxOWRlNi90YWJsZTo3MzUyYmUyMDQzNWM0YzNkYmE1NGQ0MjIyYWZmYzMyOS90YWJsZXJhbmdlOjczNTJiZTIwNDM1YzRjM2RiYTU0ZDQyMjJhZmZjMzI5XzEtMi0xLTEtMA_73a05b40-7ccb-4db6-ba4f-69ffb697826b">no</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="iaf5d0e8fdf374dc09283fd669e2ebf19_D20160101-20161231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MjIvZnJhZzpmYTcyOTAzNzI5NmM0NmRjODQ1ZmVmNDdhMGMxOWRlNi90YWJsZTo3MzUyYmUyMDQzNWM0YzNkYmE1NGQ0MjIyYWZmYzMyOS90YWJsZXJhbmdlOjczNTJiZTIwNDM1YzRjM2RiYTU0ZDQyMjJhZmZjMzI5XzEtMy0xLTEtMA_609b3aaa-81b1-40ea-af4b-3678a0ac5bc9">no</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MjIvZnJhZzpmYTcyOTAzNzI5NmM0NmRjODQ1ZmVmNDdhMGMxOWRlNi90YWJsZTpkNDI3NWVlNWJiYTk0NDI3ODk2N2M1NmU0NmM0OWFkZC90YWJsZXJhbmdlOmQ0Mjc1ZWU1YmJhOTQ0Mjc4OTY3YzU2ZTQ2YzQ5YWRkXzEtMi0xLTEtMA_90c60848-44b3-4965-996f-eb818f71f736">no</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="iaf5d0e8fdf374dc09283fd669e2ebf19_D20160101-20161231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MjIvZnJhZzpmYTcyOTAzNzI5NmM0NmRjODQ1ZmVmNDdhMGMxOWRlNi90YWJsZTpkNDI3NWVlNWJiYTk0NDI3ODk2N2M1NmU0NmM0OWFkZC90YWJsZXJhbmdlOmQ0Mjc1ZWU1YmJhOTQ0Mjc4OTY3YzU2ZTQ2YzQ5YWRkXzEtMy0xLTEtMA_312841f4-490e-4fa8-a64a-3f721d2e7741">no</ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="mgnx-20181231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="icb708ebbd06146938a5c8f2f100e1e48_I20180629"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-06-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i2a9c1de71523428a8c0011a2811fe66c_I20190222"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-02-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id926749df69c4fffbb4a92f70f45021f_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7057397719af459ca7328a1c440a0efa_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="ieb0bea730e3444a5b0d8559d16ad126c_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromCollaborativeAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i59ab418442044814b66164966b88c82b_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromCollaborativeAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idbcb1304940d4ff0baeab52d79003f28_D20160101-20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromCollaborativeAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-01-01</xbrli:startDate><xbrli:endDate>2016-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if637c63a87b147fa81aa860bc98e569f_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromGovernmentAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ebe96cc613b4300bdf8831b4feca588_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromGovernmentAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d5db08e41a54c13a242bb974c98539c_D20160101-20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromGovernmentAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-01-01</xbrli:startDate><xbrli:endDate>2016-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf5d0e8fdf374dc09283fd669e2ebf19_D20160101-20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2016-01-01</xbrli:startDate><xbrli:endDate>2016-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i31ded4a9b84e45a8a97b0a276a851d4a_I20151231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd7e0c72464e4f8b8d5b13e3c2810e9d_I20151231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa9ee01ece97464eaf75135e2a56dadd_I20151231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7766301ab52344be8fc41112ad51fe12_I20151231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f3f783c3c6749bfb8eab89b1ec2d1ab_I20151231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife0dac9d3bf74657b071534f4d2516f1_I20151231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2015-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie5d0cd6221f843248de666cd76601d1f_D20160101-20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-01-01</xbrli:startDate><xbrli:endDate>2016-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3fee8e2719b04b64aa1e5c31ae4f97c4_D20160101-20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-01-01</xbrli:startDate><xbrli:endDate>2016-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f0312cdde5044c9b7c7f5d13093d50d_D20160101-20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-01-01</xbrli:startDate><xbrli:endDate>2016-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb20c231125a4e898c5b8db3e1022b77_D20160101-20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-01-01</xbrli:startDate><xbrli:endDate>2016-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67cbca56d50744e8b64a458a586e3167_D20160101-20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-01-01</xbrli:startDate><xbrli:endDate>2016-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i77cf90a50960481db6ce7911359972c3_I20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8afec271b7854f828af67c5a11b81082_I20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if1ab14db8127453db201fbbcb4274eeb_I20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf25f45131ee4daea309661157e678a9_I20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i278d12a3934249bdb7dd8e95eabc5377_I20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa98382ff57d452ab6942c773d605ba7_I20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2016-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab5813033cd8418a851f487e53ebb255_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i556705a1d9294485b49514caece35ad9_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9132a8fb91054a248c772c0da0d524ec_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic816b5e523774458b622b435dcd2e03b_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i506eefa849b64cf7a445dd7f7221c8a5_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i94911b2192424281937290aad92f9145_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1cf8820c35a34978979d81f8780ea221_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i800361a265974a11ad8699946c8502e8_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie5fd1b1d68244c1fb5c42ba60484c135_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c61e1783f5a42efa8b8f1b1d3450e3f_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7250145010e441dcb223b7e59056d359_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied344051463c48e98fa4145c7382285a_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib9de5f176a0348ab931fab4225555181_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i449b3691440b4861a36b0b93e9837dbe_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2441bc1dd5c841d99c40a2087f89589a_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id2b1c6462f71494a98dce8bac5aef0c8_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5fefb74c168342b7b60f52ca08b1b7fc_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i73f75e4bcf834fc4bca320dd6083848a_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb8cb5ee17f94fffbdcab3e5ff465890_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie553de76ecaa42e2af8bd7cfe6d9d352_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>mgnx:Segment</xbrli:measure></xbrli:unit><xbrli:context id="i48784f16cceb4a92949dfc57c3d660b6_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a8fd95d96b9467b946bd865997ab910_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0e1afaa0aa004fcc98602893dc6bf0af_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c80cf2c50cc438b8e0cd14b52a82cf0_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b30daf53dd540e8972913308cc2a710_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9885584d437f4fdbb9821f6883801e5e_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id8224ea921344b21b249696a5b1fee59_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i19bf1b5616d54d289ec50510e079bd27_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e342386069b4859b038021f1292bc8e_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i836203a185014b4a9e662c9f5457029d_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i15cd0dab53764d82a187cc3da46a3761_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i69e6f22f5f224360a82e4379d7fff4b7_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i12ae7112f1294c1ba9b38f26417d21a2_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica70e0e9496b4c8ab1c2aeea43e1c55e_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id2873baa5a4b4d10bf1a5d20be263861_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3aaec4d2a9ba4186b6b54303daa9284f_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i567c39ea2c894aa18c58e1478aeb50bb_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i052ba9dcbb294d688f1b07ef8ae85f64_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i39e9aef5cb214c03982914e5c0e5ef26_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idddbaa15d66240498398d35f3a8f6a97_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id6c7535f08114b6b99ac9c52d559c896_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b9777bbf6064d76be88747d34359989_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic0acfc838ca543a182c2f9a125366f7f_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f7cc4428c0c44c98d1a04ac21c0f886_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i813c2a024ec84a0dab992916df676184_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i86696714ee304524b3bf18cd3b8cebf9_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i32a16b54a03b4f8dabcc3d55d161cd66_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c57ebf1216b40e69585d4723b4b1234_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb6cc9cda6124764a79895164b99ed24_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife3b143f5c324bffabb232b405ceac51_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i637fb60ec9d345b0aac156800fca7529_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i997657dcf4ae43db9ded89ab3af4df74_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i024ac39056e24d43aed54ab33d2c004e_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i606378e8044a40e5ad3ac2c0df524b2b_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i03cbd7f054ef4c669ff9c36ff8cd01c0_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie58f40d5d6224b7abe4022753c84d444_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i43068aee063d4a2d8d23dac8a2f9b677_D20160101-20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-01-01</xbrli:startDate><xbrli:endDate>2016-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa0ada014a394dada260f448e299bd8c_D20160101-20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:JanssenBiotechIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-01-01</xbrli:startDate><xbrli:endDate>2016-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e50d0e2361047e2a2d2ee358cd59223_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:ProventionBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7736e7c7780143f290e418da33ef66f3_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:ProventionBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i84d9b24bd0d14ea7ae88c496301087d9_D20160101-20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:ProventionBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-01-01</xbrli:startDate><xbrli:endDate>2016-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief319720f28440d5a5dd754bc9ebb8b9_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:ZaiLabLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia281f1996f934569aa16a3fd2044a2b2_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:ZaiLabLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i14ad06e9a84b4f2b9de71683c59af5f7_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie7004ecc84cf491ab540ef15e8620bb5_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i10db7e65a275498b9298e6467e2ddd37_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d107c99b86241459c22fe452644f3a9_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id8704ce91d804afb8569a95732959fd8_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:LesLaboratoiresServierAndInstitutDeRecherchesServierServierMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd9b6aa45a364d0c9cd302c42a5acd28_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8986558becfd44b1af99bbdfcf581445_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib59b65ae84da4d388e5723647e6142e6_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e5cae6e220c436aabafd5c2f3481b6c_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mgnx:LaboratoryAndOfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e13e524660f42568e18e289608955ea_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i956d155068494f53b5097a07d15631f3_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f8ff4c21a3f4b04bcd0190d63617d17_D20160101-20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-01-01</xbrli:startDate><xbrli:endDate>2016-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb5bf739a8ce42039763affce9678d7c_I20180101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InitialApplicationPeriodCumulativeEffectTransitionAxis">us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic3082c4bbda4473cb69446b2be52ec61_I20180101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i58ed5a015dbf42e19178b051b82c9683_I20180101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia6869870ff9d444da346b6b8718b80f3_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromCollaborativeAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InitialApplicationPeriodCumulativeEffectTransitionAxis">us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8195466a5e2c4a458ca23edc5bbb7661_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromCollaborativeAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InitialApplicationPeriodCumulativeEffectTransitionAxis">us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic2e9f102d8434edb8909ccdd833da1f3_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InitialApplicationPeriodCumulativeEffectTransitionAxis">us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f8c7c83e37647699033616fbb46b432_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InitialApplicationPeriodCumulativeEffectTransitionAxis">us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1158af44c1a44a528cf5faac76fc6bf6_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InitialApplicationPeriodCumulativeEffectTransitionAxis">us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i540a17d5cd3043469a51f6ba7e3d31b5_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InitialApplicationPeriodCumulativeEffectTransitionAxis">us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id7600d6be2eb4b27a2ed9c725fbeef09_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic847642706c0496581735d8af543077a_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae2c0abc66c64857918562886c9ab108_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d00247415ba468e829a69e2a8739d09_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f49a198b4bb493aad3c0563be1a1b1c_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if008fb95c70d4d6292a3deb9038402f2_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia589fee494a140259bbf8dd10ad98449_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic4ae66e3b1a040229462cc9b00c106f7_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i989637b0c825400daad1d79fd200cfc7_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mgnx:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i17b1fb07ad7e461f85ee4cfd5083f136_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mgnx:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iba7f249ad22445ea80c87ac974f09d4e_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id2ed58086aad4a0d93e3102ea5a382bc_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id0aa3dc3a1594241a90d2f208fc88fcf_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iacc09d395c06412b8bc32c6bcf83092c_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaaa703135e5d42e3ad357819a2febb2b_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mgnx:UndesignatedPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i774ad7d035574588abdffa05896955f7_D20170426-20170426"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:RegisteredDirectOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-04-26</xbrli:startDate><xbrli:endDate>2017-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i300212ce6416414283af0aa5ceb5e231_I20170426"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:RegisteredDirectOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1805f20c3a7b4d11b92ee3e187db18fe_D20170503-20170503"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-05-03</xbrli:startDate><xbrli:endDate>2017-05-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie86be88df16c4586b769baf5bf4e5efe_D20180402-20180402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:FirmCommitmentPublicUnderwrittenOfferMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-02</xbrli:startDate><xbrli:endDate>2018-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib0101bc440ae4fdeb05d3353b727f0aa_I20180402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:FirmCommitmentPublicUnderwrittenOfferMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic563779cd1db4959a683e3166bd53d26_D20180402-20180402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-02</xbrli:startDate><xbrli:endDate>2018-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e9ac3017eb644d2bd213ae5a7dabd47_I20180402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5511585976c54c42a03fe4ab0e7c9ec2_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mgnx:UndesignatedPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i37bd3dc2e0684382887e9c7141114e64_I20170518"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:TwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-05-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i225dfbff0423412ab9af487587a7a9dc_D20170501-20170531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:TwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-05-01</xbrli:startDate><xbrli:endDate>2017-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice18cbfc8512491798f071290230dc95_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:TwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a9a71bb02554506a053e4b037c5a59c_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:EquityIncentivePlan2003Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i88e7a08234064f55a3fdcac46083d417_I20131031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:StockIncentivePlan2013Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2013-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie68e03dfcb1349ea9e266215200f7c25_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:StockIncentivePlan2013Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb0c6525ae294173b7c08c959023d2af_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:StockIncentivePlan2013Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i080c9b1552014463931d10056bb7ec5b_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i69306bd3d52e4181a64ce4721f855103_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d5ecf2823e14c18aa6e251ac3292d51_D20160101-20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-01-01</xbrli:startDate><xbrli:endDate>2016-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i39e8ac06cdc74d939adfabe112ffd6a7_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c6d01ca77d7471c9706048782093e73_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f0c15f62cd64843837881b925628364_D20160101-20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-01-01</xbrli:startDate><xbrli:endDate>2016-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4cee00b7a03d43ceb837d6f99f3c2a60_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i10e48d6d5c37418f95625e0a3c0c6c4a_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec5a69bea85a43309bedfd363a2e23bd_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i460fef2e524d4f6fa38ec2499a0ea689_D20160101-20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-01-01</xbrli:startDate><xbrli:endDate>2016-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i43aa52214f03439db001c28c7a57ad3c_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibdb75168d0e0440c8357fec9636573d7_D20160101-20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-01-01</xbrli:startDate><xbrli:endDate>2016-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i109fced96e334bd2802e9cb0d4aa822f_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">mgnx:DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if3a4a990231244d6b62fcda57ef5cfdb_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">mgnx:TaxYear2025To2037Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">mgnx:DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icbf9b06e7c13465a9c3facc8db2be168_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">mgnx:IndefiniteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">mgnx:DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea603775d4f04ce4a2e3d875e241c0c8_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i62c4c7c8c31a462dab6a1676f99a1b7c_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0986b0c4e51f4d2cb580f8bcf9218691_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0229ee301314485e8d01bc8ad76d9aca_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i44dc827b9c5849c9874770cafc78df7e_D20171001-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-10-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i591dac725a2648e68258b7105447f85d_I20171031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i82b03c819e73441db6d085233d218937_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia93c5065a4f94e9f9e0c596d50d7aa2f_D20171001-20171031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-10-01</xbrli:startDate><xbrli:endDate>2017-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i91850bdafeb5443c8e0569e57b38e238_D20171001-20171031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-10-01</xbrli:startDate><xbrli:endDate>2017-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff7efae7eb26446bbaa573fe3861e53c_I20171031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if61293acd6f643bf8daf43be5cf2bd6e_D20171001-20171031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-10-01</xbrli:startDate><xbrli:endDate>2017-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8eb24f3f49444597a89f49edae260720_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a111d57d3bf49428df5748987d6471b_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd27a98828844b21ad9d5646ef79f6e2_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012ClinicalServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6011d16a582a445fa400c0dfcf98028a_D20120901-20120930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ServierDARTMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2012-09-01</xbrli:startDate><xbrli:endDate>2012-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id5778ce3b2cd44b79c13685e1d2a707d_I20120930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ServierDARTMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2012-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia01940c5140d475d823101c59b4c6ee3_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ServierAgreementMGD007OptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d3ce417f9d9482d96c963058758500b_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ServierAgreementMGD007OptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e802bb4cb124fb3a1bf94de3a31e858_D20160101-20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ServierAgreementMGD007OptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-01-01</xbrli:startDate><xbrli:endDate>2016-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida270b9128b24424808f7af121ae03e7_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ServierAgreementMGD007OptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3dae8b73ee0b42df83fe2e75389bd1b7_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ServierAgreementMGD007OptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i98b48a96e93a4ea59eb53d0d51847ea3_I20151231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ServierDARTMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b00e539a3324792b34321e6c7168fb8_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ServierDARTMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c17e3fb438e49b4bf933e03642b33d6_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ServierDARTMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i09a4e2abc6f64d09984d04c7e51e159a_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ServierDARTMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i77625ed2e7734703b52942e3929dec22_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ServierDARTMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0dd3b4b1fefc4e54956a0cd97918d963_D20160101-20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ServierDARTMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-01-01</xbrli:startDate><xbrli:endDate>2016-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c0265f36dcf411893aa87db114e0f16_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ServierDARTMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i87ceca0edd234d059fdd917ce29f5f4b_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ServierDARTMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i625f3d08dc954d518764769a7feaeefc_D20160101-20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ServierDARTMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-01-01</xbrli:startDate><xbrli:endDate>2016-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i29ff7281a75a4936a4be6c1359e216e9_D20181101-20181130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabsCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-11-01</xbrli:startDate><xbrli:endDate>2018-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e972d120beb4fdaae31b0300fbc48ee_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabsCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id73733a0f1994e42b2954427356cb7e5_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabsCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ae89b363134495b9cc3cdf7d4ce1a06_D20180101-20180131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i77f6204290544a298e027e842269f6bc_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i097ea6f211524140a29381dc3bce7129_D20171201-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a4fe51377ba48ef83d87242a98d90ec_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b14f1378bdc4abf90dd05dd5956ca30_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i47f11d0af1aa4444aae4bba0ddf73a6c_D20180501-20180531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ProventionPRV3279Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ProventionLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-01</xbrli:startDate><xbrli:endDate>2018-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id16ca02732fe4f1b8d21590f441cb5dd_I20180531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ProventionPRV3279Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ProventionLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i575e134561384052b8d5150268d0bc0c_D20180501-20180531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:AssetPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ProventionPRV031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-01</xbrli:startDate><xbrli:endDate>2018-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie95e8086ae9b4cd69fc3763d4b03138b_I20180531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:AssetPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ProventionPRV031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i918dca9fcdce44a999dec3002edfedac_I20180531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie23f02f7751b4b5d8b10bc0c6f10cf97_D20180501-20180531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-01</xbrli:startDate><xbrli:endDate>2018-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c503df7c4d74a6aa791c924760e58de_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c0bb24d85b742029840e8ff19e39e21_D20141201-20141231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:JanssenBiotechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:JanssenMGD011AgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-12-01</xbrli:startDate><xbrli:endDate>2014-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad112c3f4a95410eb177b18bf2a325e8_D20160101-20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:JanssenBiotechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:JanssenMGD011AgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-01-01</xbrli:startDate><xbrli:endDate>2016-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba7d66ba85e246e0b3b81bde3c507cd4_D20150101-20150131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:JanssenBiotechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:JanssenMGD011AgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-01-01</xbrli:startDate><xbrli:endDate>2015-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i36abedfa020b41798bb4a1de0b5826b9_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:JanssenBiotechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:JanssenMGD011AgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iafa5f3f8c3964fd3a2fb20d5a78444ae_D20160101-20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:JanssenBiotechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:JanssenMGD011AgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-01-01</xbrli:startDate><xbrli:endDate>2016-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0dbfb405829a4954939345567d9ffa41_D20160701-20160731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:JanssenMGD015AgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:JanssenBiotechIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-07-01</xbrli:startDate><xbrli:endDate>2016-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5bd2775f85934df4a35546668e5cf0a5_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:JanssenMGD015AgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:JanssenBiotechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6635b351add74cb695103957cc02cac1_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:JanssenMGD015AgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:JanssenBiotechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibdc4a8d5c6b240faac1049620a8692b6_D20160101-20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:JanssenMGD015AgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:JanssenBiotechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-01-01</xbrli:startDate><xbrli:endDate>2016-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="molecule"><xbrli:measure>mgnx:Molecule</xbrli:measure></xbrli:unit><xbrli:context id="ie5dd3f325a0e4bb2bd1f768f5d1cfb31_D20150915-20150915"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-09-15</xbrli:startDate><xbrli:endDate>2015-09-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib0d39c7c6f4e42388328978bd1a0c321_D20150915-20150915"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-09-15</xbrli:startDate><xbrli:endDate>2015-09-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icbe3942778e048a7812d0b367cba79e4_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae19a3f2560f46ea9ce3d9769293ef55_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a451cc24b4245fe93b83bc7127cf807_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i355ceffdd61e4654b0c765f0f6734378_D20160101-20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-01-01</xbrli:startDate><xbrli:endDate>2016-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="lease"><xbrli:measure>mgnx:Lease</xbrli:measure></xbrli:unit><xbrli:context id="i121ff22ae7d04521bf402d62951d21e4_D20150701-20150731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2015-07-01</xbrli:startDate><xbrli:endDate>2015-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic26431cbd9dd45ba8f73dd80dc1df8ec_D20170721-20170721"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2017-07-21</xbrli:startDate><xbrli:endDate>2017-07-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ada94a697084172b90c7bcf3c82fe1e_D20120101-20121231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2012-01-01</xbrli:startDate><xbrli:endDate>2012-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b9c8e543ab44629819b1e0b7554ce96_D20180101-20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie7fccf344bc24f03934ea77078a49726_D20180401-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98edd9ec68b24ced9b531e766587d469_D20180701-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i724f8d5b79f44384afe7b27042231bfe_D20181001-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icfb4268699e645dc87743a7e862848d6_D20170101-20170331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc68311eb541421f98636ba4e9bffdb3_D20170401-20170630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2017-04-01</xbrli:startDate><xbrli:endDate>2017-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1bf42114bac84fe587857eea6b6d8228_D20170701-20170930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2017-07-01</xbrli:startDate><xbrli:endDate>2017-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib42a39a1f0994e319ac400bbdfb12754_D20171001-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2017-10-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ed315b7b06447388b74464c7e252a0a_D20190201-20190228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:FollowUpOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-01</xbrli:startDate><xbrli:endDate>2019-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6fdc91e82d3b4cb9ab3b078b4413a743_I20190228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:FollowUpOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b259175425444a1a2fc354b79a24aa5_D20190201-20190228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-01</xbrli:startDate><xbrli:endDate>2019-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i008460346dd94dac853841c05961f142_I20190228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-02-28</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i_0_1"></div><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:14pt;font-weight:700;line-height:120%;">UNITED STATES SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">Washington, D.C.&#160;&#160;20549</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">&#160;</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:18pt;font-weight:700;line-height:120%;">FORM <ix:nonNumeric contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF8xL2ZyYWc6ZTM3ZjkzM2UxNDcxNGE3MWIzYzBlYjBlYWE0NjBhYmQvdGV4dHJlZ2lvbjplMzdmOTMzZTE0NzE0YTcxYjNjMGViMGVhYTQ2MGFiZF84Nw_ae66b717-cc63-4e89-b80f-dab3ad4cd8e9" escape="true">10-K</ix:nonNumeric>&#160;</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#160;</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">(Mark One)</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"><tr><td style="width:1.0%;"></td><td style="width:6.944282%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:89.055718%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#9746;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">For the fiscal year ended December&#160;31, 2018&#160;</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">OR</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"><tr><td style="width:1.0%;"></td><td style="width:6.944282%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:89.055718%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#9744;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#160;</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">For the transition period from&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to &#160;</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#160;</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Commission File Number 001-36112</span></div><div><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:24pt;font-weight:700;line-height:120%;">MACROGENICS, INC.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">(Exact name of registrant)</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"><tr><td style="width:1.0%;"></td><td style="width:46.093842%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.665689%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:46.240469%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Delaware&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">06-1591613</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-style:italic;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(State of organization)&#160;&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-style:italic;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(I.R.S. Employer Identification Number)</span></td></tr></table></div><div><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">9704 Medical Center Drive, Rockville, Maryland 20850</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">(Address of principal executive offices and zip code)</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#160;</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">(301)&#160;&#160;251-5172</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">(Registrant's telephone number)</span></div><div><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#160;&#160;</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"><tr><td style="width:1.0%;"></td><td style="width:46.093842%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.665689%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:46.240469%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Title of Each Class</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Name of Each Exchange on Which Registered</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Common stock, par value $0.01 per share</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">The Nasdaq Stock Market LLC</span></td></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#160;</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Securities registered pursuant to Section 12(g) of the Act: None</span></div><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Yes&#160;&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#222222;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#9745; </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> No&#160;&#160;&#160;&#9744;</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#160;</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Exchange Act.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Yes&#160;&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:9pt;line-height:120%;">&#9744;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#160;No&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#222222;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#9745;</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#160;</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Yes&#160;&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#222222;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#9745;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> No&#160;&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:9pt;line-height:120%;">&#9744;</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#160;</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Yes&#160;&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#222222;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#9745;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> No&#160;&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:9pt;line-height:120%;">&#9744;</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#160;</span></div><div style="text-align:justify;"></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div><span><br/></span></div></div></div><hr style="page-break-after:always"></hr><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein and will not be contained, to the best of the registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. </span><span style="background-color:rgb(255,255,255, 0.0);color:#222222;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#9745;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#160;</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#160;</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company.&#160;&#160;See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"><tr><td style="width:1.0%;"></td><td style="width:22.816446%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:22.963289%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:22.963289%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:23.256975%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">Large accelerated filer </span><span style="background-color:rgb(255,255,255, 0.0);color:#222222;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">&#9745;</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Accelerated filer&#160;&#160;&#9744;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">Non-accelerated filer&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:9pt;font-weight:400;line-height:100%;">&#9744;</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">Smaller reporting company&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:9pt;font-weight:400;line-height:100%;">&#9744;</span></div></td></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#160;</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Yes&#160;&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:9pt;line-height:120%;">&#9744;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> No&#160;&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#222222;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#9745;</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#160;</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The aggregate market value of the registrant's common stock, par value $0.01 per share, held by non-affiliates of the registrant on June&#160;29, 2018, the last business day of the registrant's most recently completed second fiscal quarter, was approximately$<ix:nonFraction unitRef="usd" contextRef="icb708ebbd06146938a5c8f2f100e1e48_I20180629" decimals="-5" format="ixt:numdotdecimal" name="dei:EntityPublicFloat" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF8xL2ZyYWc6ZTM3ZjkzM2UxNDcxNGE3MWIzYzBlYjBlYWE0NjBhYmQvdGV4dHJlZ2lvbjplMzdmOTMzZTE0NzE0YTcxYjNjMGViMGVhYTQ2MGFiZF8xNjQ5MjY3NDQ1MTMw_49e5a11e-f8dc-4d15-9d13-b944877083ca">842.5</ix:nonFraction> million&#160;based on the closing price of the registrant's common stock on the Nasdaq Global Select Market on that date.&#160;&#160;Exclusion of shares held by any person should not be construed to indicate that such person possesses the power, direct or indirect, to direct or cause the direction of management or policies of the registrant, or that such person is controlled by or under common control with the registrant.</span></div><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The number of shares of the registrant's common stock outstanding on February&#160;22, 2019 was <ix:nonFraction unitRef="shares" contextRef="i2a9c1de71523428a8c0011a2811fe66c_I20190222" decimals="0" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF8xL2ZyYWc6ZTM3ZjkzM2UxNDcxNGE3MWIzYzBlYjBlYWE0NjBhYmQvdGV4dHJlZ2lvbjplMzdmOTMzZTE0NzE0YTcxYjNjMGViMGVhYTQ2MGFiZF8zMTI5_a8b7086e-f654-42e0-84e0-f5afe4b500e1">48,780,321</ix:nonFraction>.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#160;</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Portions of MacroGenics, Inc.'s definitive proxy statement for the 2019 annual meeting of stockholders are incorporated by reference into Part III of this Annual Report.</span></div><div id="i_0_27"></div><div style="text-align:center;"></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div><span><br/></span></div></div></div><hr style="page-break-after:always"></hr><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">MACROGENICS, INC.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">ANNUAL REPORT ON FORM 10-K</span></div><div style="text-align:center;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">TABLE OF CONTENTS</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"><tr><td style="width:1.0%;"></td><td style="width:9.730205%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:86.269795%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;text-decoration: underline;" href="#i_0_52">PART I</a></span></div></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Item 1</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_66">Business</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Item 1A</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_78">Risk Factors</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Item 1B</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_91">Unresolved Staff Comments</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Item 2</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_103">Properties</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Item 3</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_115">Legal Proceedings</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Item 4</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_127">Mine Safety Disclosures</a></span></div></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;text-decoration: underline;" href="#i_0_139">PART II</a></span></div></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Item 5</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_152">Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Item 6</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_164">Selected Financial Data</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Item 7</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_176">Management's Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Item 7A</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_285">Quantitative and Qualitative Disclosures about Market Risk</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Item 8</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_297">Financial Statements and Supplementary Data</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Item 9</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_309">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Item 9A</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_321">Controls and Procedures</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Item 9B</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_333">Other Information</a></span></div></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;text-decoration: underline;" href="#i_0_358">PART III</a></span></div></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Item 10</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_371">Directors, Executive Officers and Corporate Governance</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Item 11</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_383">Executive Compensation</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Item 12</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_395">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Item 13</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_407">Certain Relationships and Related Transactions, and Director Independence</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Item 14</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_419">Principal Accountant Fees and Services</a></span></div></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;text-decoration: underline;" href="#i_0_431">PART IV</a></span></div></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Item 15</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_444">Exhibits and Financial Statement Schedules</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Item 16</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_456">Form 10-K Summary</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_468">Signatures</a></span></div></td></tr></table></div><div><span><br/></span></div><div id="i_0_39"></div><div style="text-align:center;margin-bottom:9pt;"></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div><span><br/></span></div></div></div><hr style="page-break-after:always"></hr><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">FORWARD-LOOKING STATEMENTS</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">This report includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements include statements that may relate to our plans, objectives, goals, strategies, future events, future revenues or performance, capital expenditures, financing needs and other information that is not historical information. Many of these statements appear, in particular, under the headings "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations". Forward-looking statements can often be identified by the use of terminology such as "subject to", "believe", "anticipate", "plan", "expect", "intend", "estimate", "project", "may", "will", "should", "would", "could", "can", the negatives thereof, variations thereon and similar expressions, or by discussions of strategy.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">All forward-looking statements, including, without limitation, our examination of historical operating trends, are based upon our current expectations and various assumptions. We believe there is a reasonable basis for our expectations and beliefs, but they are inherently uncertain. We may not realize our expectations, and our beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements. The following uncertainties and factors, among others (including those set forth under "Risk Factors"), could affect future performance and cause actual results to differ materially from those matters expressed in or implied by forward-looking statements:</span></div><div style="text-indent:-18pt;padding-left:28pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">our plans to develop and commercialize our product candidates;</span></div><div style="text-indent:-18pt;padding-left:28pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">the outcomes of our ongoing and planned clinical trials and the timing of those outcomes</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">, including when clinical trials will be initiated or completed, and when data will be reported or regulatory filings made;</span></div><div style="text-indent:-18pt;padding-left:28pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">the timing of and our ability to obtain and maintain regulatory approvals for our product candidates;</span></div><div style="text-indent:-18pt;padding-left:28pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">our estimates regarding expenses, future revenue, capital requirements and needs for additional financing;</span></div><div style="text-indent:-18pt;padding-left:28pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">our ability to enter into new collaborations or to identify additional products or product candidates with significant commercial potential that are consistent with our commercial objectives;</span></div><div style="text-indent:-18pt;padding-left:28pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">the potential benefits and </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">future operation of our existing collaborations; </span></div><div style="text-indent:-18pt;padding-left:28pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">our ability to recover the investment in our manufacturing capabilities;</span></div><div style="text-indent:-18pt;padding-left:28pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">the rate and degree of market acceptance and clinical utility of our products;</span></div><div style="text-indent:-18pt;padding-left:28pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">our commercialization, marketing and manufacturing capabilities and strategy;</span></div><div style="text-indent:-18pt;padding-left:28pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">significant competition in our industry;</span></div><div style="text-indent:-18pt;padding-left:28pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">costs of litigation and the failure to successfully defend lawsuits and other claims against us;</span></div><div style="text-indent:-18pt;padding-left:28pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">economic, political and other risks associated with our international operations;</span></div><div style="text-indent:-18pt;padding-left:28pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">our ability to receive research funding and achieve anticipated milestones under our collaborations;</span></div><div style="text-indent:-18pt;padding-left:28pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">our ability to protect and enforce patents and other intellectual property;</span></div><div style="text-indent:-18pt;padding-left:28pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">costs of compliance and our failure to comply with new and existing governmental regulations including, but not limited to, tax regulations;</span></div><div style="text-indent:-18pt;padding-left:28pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">loss or retirement of key members of management;</span></div><div style="text-indent:-18pt;padding-left:28pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">failure to successfully execute our growth strategy, including any delays in our planned future growth; and</span></div><div style="text-indent:-18pt;padding-left:28pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">our failure to maintain effective internal controls.</span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Consequently, forward-looking statements speak only as of the date that they are made and should be regarded solely as our current plans, estimates and beliefs. You should not place undue reliance on forward-looking statements. We cannot guarantee future results, events, levels of activity, performance or achievements. Except as required by law, we do not undertake and specifically decline any obligation to update, republish or revise forward-looking statements to reflect future events or circumstances or to reflect the occurrences of unanticipated events.</span></div><div id="i_0_52"></div><div style="text-indent:36pt;text-align:center;margin-bottom:9pt;"></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div><span><br/></span></div></div></div><hr style="page-break-after:always"></hr><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-indent:36pt;text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">PART I</span></div><div id="i_0_66"></div><div style="text-indent:-36pt;padding-left:36pt;margin-top:3pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">ITEM 1.&#160;BUSINESS&#160;</span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:115%;">Except as otherwise indicated herein or as the context otherwise requires, references in this annual report on Form 10-K to "MacroGenics," the "company," "we," "us" and "our" refer to MacroGenics, Inc. and its consolidated subsidiaries.</span><span style="background-color:rgb(255,255,255, 0.0);color:#1f497d;font-family:Times New Roman;font-size:10pt;line-height:115%;">&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:115%;">MacroGenics, the MacroGenics logo, DART</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:12pt;line-height:115%;">&#174;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:115%;">, TRIDENT</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:6.5pt;font-style:italic;line-height:115%;vertical-align:top;">TM</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:115%;"> and the phrase "Breakthrough Biologics, Life-Changing Medicines" are our trademarks or registered trademarks. The other trademarks, trade names and service marks appearing in this report are the property of their respective owners.</span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:115%;">Overview</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">We are a clinical-stage biopharmaceutical company focused on discovering and developing innovative antibody-based therapeutics designed to modulate the human immune response for the treatment of cancer. We currently have a pipeline of product candidates in human clinical testing, including nine immuno-oncology programs, that have been created primarily using our proprietary antibody-based technology platforms. </span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">We are developing product candidates that target various tumor-associated antigens, including HER2. We currently have a franchise of three product candidates in clinical trials that target B7-H3, a molecule in the B7 family of immune regulator proteins. B7-H3 is widely expressed by a number of different tumor types and may play a key role in regulating the immune response to various types of cancer. There are no currently approved therapeutic agents directed against B7-H3. We are also developing a franchise of three molecules that target programmed cell death protein 1 (PD-1). This protein is important in the regulation of the immune system&#8217;s response to cancer, and monoclonal antibodies that inhibit PD-1 have been approved by the U.S. Food and Drug Administration (FDA) for the treatment of numerous cancers. Within our PD-1 franchise, in addition to an anti-PD-1 monoclonal antibody that we&#8217;ve out-licensed to a partner, we are also developing two bispecific DART product candidates that engage PD-1 and LAG-3, as well as PD-1 and CTLA-4. &#160;</span></div><div><span><br/></span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">We have created our product candidates based on the following antibody-based technologies:</span></div><div style="text-indent:-18pt;padding-left:58.5pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;padding-left:14.5pt;">Fc Optimization platform, which introduces certain mutations into the Fc </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">domain of a monoclonal antibody in order to modulate antibody interaction with immune effector cells to enhance the killing of cancer cells; </span></div><div style="text-indent:-18pt;padding-left:58.5pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;padding-left:14.5pt;">Multi-specific platforms, which enable us to design antibodies that have the ability to bind to two (in the case of our bispecific DART</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;"> product candidates) or more distinct targets; and</span></div><div style="text-indent:-18pt;padding-left:58.5pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;padding-left:14.5pt;">Antibody drug conjugate</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;"> (ADC) platforms, which we have licensed from collaboration partners, and which link monoclonal antibodies that specifically target cytotoxins to cancer cells that are designed to trigger cell death in the cancer cell.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:115%;">Our Pipeline of Immuno-Oncology Product Candidates</span></div><div><span><br/></span></div><div style="text-indent:36pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">The table below depicts the current status of product candidates that are in clinical development and for which we retain all or some commercial rights:</span></div><div style="text-align:center;"><img src="mgnx-20181231_g1.jpg" alt="mgnx-20181231_g1.jpg" style="height:277;width:684;"></img></div><div style="text-indent:-18pt;padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:7pt;line-height:115%;">(a)    MGC018 is an ADC based on a duocarmycin payload with cleavable peptide linker that was licensed from Synthon Biopharmaceuticals.</span></div><div style="text-indent:-18pt;padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:7pt;line-height:115%;">(b)    MacroGenics retains rights to develop its pipeline assets in combination with MGA012 and to manufacture a portion of global clinical and commercial supply needs of MGA012. Incyte designates this molecule as &#8220;INCMGA0012&#8221;.</span></div><div><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">1</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Margetuximab</span></div><div><span><br/></span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">Margetuximab is an investigational monoclonal antibody that targets HER2-expressing tumors, including certain types of breast and gastroesophageal cancers. HER2 is critical for the growth of many types of tumors. Using our Fc Optimization platform, we have engineered the constant region&#160;(Fc region) of margetuximab to increase its ability to kill tumor cells through an Fc-dependent mechanism, including antibody dependent cell-mediated cytotoxicity&#160;(ADCC). </span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:115%;">HER2-positive Metastatic Breast Cancer. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">In</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:115%;">&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">February 2019, we announced positive results from SOPHIA, our Phase 3 clinical trial of margetuximab in HER2-positive metastatic breast cancer patients. The SOPHIA clinical trial met the trial&#8217;s first primary endpoint of prolongation of progression-free survival (PFS) in patients treated with the combination of margetuximab plus chemotherapy compared to trastuzumab plus chemotherapy. Patients in the margetuximab arm experienced a 24% risk reduction in PFS compared to patients in the trastuzumab arm (HR=0.76, p=0.033). Notably, approximately 85% of patients in the study were carriers of the CD16A (Fc&#947;RIIIa) 158F allele, which has been previously associated with diminished clinical response to trastuzumab and other antibodies. In this pre-specified subpopulation, patients in the margetuximab arm experienced a 32% risk reduction in PFS compared to patients in the trastuzumab arm (HR=0.68, p=0.005). Results of the SOPHIA study have been submitted for presentation later this year at a major scientific conference. Follow-up for determination of the impact of therapy on the sequential second primary endpoint of overall survival (OS) is ongoing, as pre-specified in the study protocol and recommended by the trial&#8217;s independent Data Safety Monitoring Committee. The FDA has granted Fast Track designation for the investigation of margetuximab for treatment of patients with metastatic or locally advanced HER2 positive breast cancer who have previously been treated with anti-HER2-targeted therapy. We anticipate submitting a Biologics License Application (BLA) to the FDA for margetuximab on the basis of the PFS results in the second half&#160;of 2019.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">The SOPHIA study enrolled 536 patients at approximately 200 trial sites across North America, Europe and Asia. The study evaluated margetuximab in a Phase 3 clinical trial in patients with advanced HER2-positive breast cancer who had received at least two prior lines of anti-HER2-directed therapy in the metastatic setting, or in the case of having received (neo)adjuvant pertuzumab, at least one prior line of anti-HER2-directed therapy in the metastatic setting, and who have received at least one and no more than three prior lines of therapy overall in the metastatic setting. Patients were treated with either margetuximab or trastuzumab in combination with one of four chemotherapy agents (capecitabine, eribulin, gemcitabine or vinorelbine). All study patients had previously received trastuzumab and pertuzumab, and approximately 90% had previously received ado-trastuzumab emtansine. The combination of margetuximab and chemotherapy demonstrated acceptable safety and tolerability, comparable overall to that of trastuzumab and chemotherapy.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:115%;">Gastric Cancer. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">We are also evaluating margetuximab in a Phase 2 clinical trial in patients with HER2-positive gastric or gastroesophageal junction cancer in combination with an anti-PD-1 monoclonal antibody. The Phase 2 clinical trial seeks to characterize the safety, tolerability, maximum tolerated dose, and antitumor activity of this combination. Enrolled patients had relapsed or refractory advanced HER2-positive gastric or gastroesophageal junction cancer with disease progression after or resistance to treatment with trastuzumab plus chemotherapy. The 25 patients in the most recently enrolled expansion cohort had HER2-positive gastric carcinoma that was 3+ by immunohistochemistry. Patients in the study were enrolled irrespective of programmed death-ligand 1 (PD-L1) expression status.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">As of a January 8, 2019 data cut-off date, objective responses were observed in 18 of 55 HER2-positive (as indicated by a 3+ score on an immunohistochemistry test) response-evaluable gastric cancer patients, including 14 confirmed and 4 unconfirmed. The objective response rate (ORR) for this population was 32.7%, with a disease control rate (DCR)&#160;(which includes partial responses and stable disease) of 69.1%. Median PFS was 4.7 months. In the subset of these patients who were also PD-L1 positive, objective responses were observed in 12 of 23 (52.2%) patients, with a DCR of 82.6% and PFS of 4.14 months. As of the data cut-off date, the study was ongoing with 13 gastric cancer patients remaining on therapy. The median OS had not been reached in either of these groups. Acceptable tolerability was observed in the safety population of 95 patients, 92 of whom were treated at the recommended Phase 2 dose of 15 mg/kg for margetuximab and 200mg for the anti-PD-1 monoclonal antibody, both on an every three week schedule of administration. Grade 3 or higher treatment-related adverse events occurred in 17.9% of patients, the most common of which was infusion-related reaction (3.2%). Following up on these results, during the first quarter of 2019, we discussed development plans with the FDA for a proposed Phase 2/3 registration-directed study of margetuximab in combination with MGA012, an anti-PD-1 monoclonal antibody. This approach is designed to coordinately engage both innate and adaptive immunity with a chemotherapy-free regimen for the treatment of patients with gastric cancer in the first line setting. We expect to initiate this study in the second half of 2019. We also plan to evaluate the merits of combining margetuximab with chemotherapy and MGA012 or MGD013, a PD-1 x LAG-3 bispecific DART molecule, in a randomized, controlled study.</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">In November 2018, we licensed the right to develop and commercialize margetuximab in mainland China, Hong Kong, Macau and Taiwan to Zai Lab Limited (Zai Lab). Zai Lab will lead clinical development in its territory by leveraging its</span></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">2</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;"> regulatory and clinical development expertise and broad regional network of investigators.  In 2010, we licensed the right to develop and commercialize margetuximab in South Korea to Green Cross Corporation (GC Pharma).</span></div><div><span><br/></span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">B7-H3 Franchise</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">We are developing multiple product candidates targeting B7-H3, a protein in the B7 family of immune regulator proteins. B7-H3 is widely expressed by a number of different tumor types and may play a key role in regulating the immune response to various types of cancer. There are no currently approved therapeutic agents directed against B7-H3. We have three clinical product candidates directed against B7-H3: enoblituzumab, MGD009 and MGC018. </span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:115%;">Enoblituzumab</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">. The most advanced product candidate in our B7-H3 franchise, enoblituzumab, is a monoclonal antibody that targets B7-H3 and has been enhanced using our Fc Optimization platform. </span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">We conducted a Phase 1 clinical study of the combination of enoblituzumab and an anti-PD-1 monoclonal antibody to evaluate the combination in patients with B7-H3-expressing melanoma, squamous cell carcinoma of the head and neck (SCCHN), non-small cell lung cancer (NSCLC) and urothelial cancer. A total of 133 patients were treated in the study and the data cut-off date was October 12, 2018.</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">In the SCCHN dose expansion cohort, of the response-evaluable patients who had not previously received anti-PD-1 or anti-PD-L1 therapy, 6 of 18 (33.3%) had confirmed partial responses (PRs). For the subset of patients with B7-H3 tumor expression &#8805;&#160;10%, 6 of 15 (40.0%) had confirmed PRs. Objective response rates ranging from 13% to 16% have previously been reported in SCCHN patients treated with anti-PD-1 alone.&#160;In the NSCLC dose expansion cohort, of the response-evaluable patients who had not previously received anti-PD-1 or anti-PD-L1 therapy and who were PD-L1 negative (i.e., PD-L1 &#8804; 1%), 5 of 14 (35.7%) had confirmed PRs. Objective response rates ranging from 8% to 17% have previously been reported in PD-L1 negative NSCLC patients treated with anti-PD-1 alone.&#160;The combination of enoblituzumab and an anti-PD-1 monoclonal antibody demonstrated acceptable tolerability in patients treated to date, with any adverse event &#8805; Grade 3 occurring in 27.1% of patients. The rate of immune-related adverse events experienced in the trial was comparable to that observed in patients who received anti-PD-1 as monotherapy. Based on these results, we intend to commence a Phase 2 study of enoblituzumab in combination with MGA012, an anti-PD-1 monoclonal antibody, in patients with SCCHN beginning in the second half of 2019.</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:115%;">MGD009.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;"> MGD009 is one of several clinical-stage molecules developed using our proprietary bispecific DART platform, which is described in greater detail below. Unlike standard monoclonal antibodies, DART molecules are bispecific, which means they can be directed against two different biological targets, and therefore lend themselves to a variety of different applications. MGD009 is a DART molecule that is designed to target both B7-H3 expressed on tumor cells as well as CD3, which is expressed on normal T cells. In preclinical models, MGD009 has re-directed T cells to reduce or eliminate B7-H3 expressing tumors. We are conducting a Phase 1 clinical trial of MGD009 in patients with B7-H3 positive tumors and in a separate study that combines MGD009 and MGA012.&#160;</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">In December 2018, the FDA imposed a partial clinical hold on these studies, which was subsequently lifted in January 2019.&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:115%;">The partial clinical hold was initiated following our reporting to the FDA of hepatic adverse events on the MGD009 monotherapy trial. Although these events had been otherwise uncomplicated and short-lived in duration, we communicated to the FDA our plans to amend the then existing MGD009 studies with additional supportive care to mitigate these events. The FDA placed the trials on partial clinical hold, pending review of additional details regarding such events and satisfactory review of the then planned amendments to the study protocols and related documents.&#160;Under the partial clinical hold, which was lifted in January 2019, no new patients were permitted to be enrolled in either study, although then-current study participants were permitted to continue to receive drug at their pre-assigned dose. </span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:115%;">MCG018</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">. Our third B7-H3-directed molecule is MGC018, an ADC that is designed to target solid tumors expressing B7-H3. We initiated a Phase 1 dose escalation study of MGC018 in the fourth quarter of 2018.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">PD-1 Franchise</span></div><div><span><br/></span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">We are pursuing multiple approaches for targeting PD-1. Marketed antibodies targeting this checkpoint molecule have shown clinical efficacy in the treatment of various tumors by releasing the "brakes" on the immune system which is often seen when tumors evade detection by the immune system.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:115%;">MGA012</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">. MGA012 is an anti-PD-1 monoclonal antibody we licensed to Incyte Corporation (Incyte) in 2017 under a global collaboration and license agreement, although we retain the right to develop the molecule in combination with product candidates from our pipeline. Incyte is pursuing development of MGA012 through registration-directed studies in MSI-high endometrial cancer, Merkel cell carcinoma and anal cancer, with initial data anticipated in 2020, in the case of MSI-high endometrial cancer and Merkel cell carcinoma, and 2021, in the case of anal cancer. Incyte is also pursuing development of MGA012 in combination with multiple product candidates from its pipeline. We are currently studying MGA012 in</span></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">3</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;"> combination with two of our DART molecules, MGD009 and MGD007, and we intend to commence additional studies of MGA012 in combination with other product candidates from our own pipeline.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:115%;">MGD013</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">. Monoclonal antibodies that target the immune checkpoints PD-1 and lymphocyte-activation gene 3 (LAG-3) have shown enhanced clinical antitumor activity when given in combination. Recognizing the therapeutic potential of dual checkpoint blockade, we have engineered MGD013, a first-in-class bispecific DART molecule, to bind PD-1 and LAG-3 concomitantly or independently and disrupt these non-redundant inhibitory pathways to further restore exhausted T-cell function. We anticipate that MGD013, if approved, could be used for the treatment of a wide range of cancers, including both solid tumors and hematological malignancies. We have established the dose and schedule for MGD013 administration and initiated dose expansion in up to nine tumor types in a Phase 1 study. We expect to present data from this ongoing study in 2019.</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:115%;">MGD019</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">. Approved monoclonal antibodies that target the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) have shown enhanced clinical antitumor activity when given in combination in various cancers, including renal cell carcinoma and NSCLC with high tumor mutational burden. MGD019, a bispecific DART molecule in our pipeline, was designed to enable co-blockade of two immune checkpoint molecules co-expressed on T cells, PD-1 and CTLA-4. We are currently evaluating MGD019 in a Phase 1 dose escalation study.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Flotetuzumab</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">Flotetuzumab is a bispecific, humanized DART molecule that recognizes both CD123 and CD3. CD123, the Interleukin-3 receptor alpha chain, has been reported to be over-expressed on cancer cells in a wide range of hematological malignancies, including acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). AML and MDS are thought to arise in and be perpetuated by a small population of leukemic stem cells (LSCs) that generally resist conventional chemotherapeutic agents. LSCs are characterized by high levels of CD123 expression that is low or absent in the corresponding hematopoietic progenitors and stem cell populations in normal human bone marrow. Flotetuzumab was designed to redirect T lymphocytes to kill CD123-expressing cells. To achieve this, the DART molecule combines an arm that recognizes CD123 on the target cancer cells, with a portion of an antibody recognizing CD3, an activating protein expressed by normal T cells, which are specialized white blood cells in the human immune system.</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">In December 2018, we presented data from our Phase 1 dose expansion study of flotetuzumab in relapsed/refractory patients with AML. In this study, we enrolled 31 patients at the recommended Phase 2 dose of 500 ng/kg/day by continuous infusion with a lead-in dosing strategy. The goal of the expansion cohort study was to evaluate the safety and preliminary anti-leukemic activity of flotetuzumab, optimize delivery and supportive care, including the management of cytokine release syndrome, and to define the pharmacokinetic and pharmacodynamic activity of flotetuzumab. In the study, flotetuzumab demonstrated anti-leukemic activity in patients with relapsed/refractory AML. In 27 response evaluable patients, the ORR was 26% (7 of 27 patients), with a composite complete response rate (combining both complete responses (CRs) and complete responses with incomplete hematological improvement (CRi)) of 19% (5 of 27 patients). Notably, in primary refractory patients, an extremely challenging population to treat, the ORR was 35% (6 of 17 patients) with a CR/CRi rate of 29% (5 out of 17 patients). The median duration of response for the patients that experienced a CR (three patients), a CRi (two patients) and a morpohologic leukemia-free state (one patient) was 3.1 months. The most common treatment-related adverse event was infusion-related reaction/cytokine release syndrome, which occurred in 93% (29 of 31) of patients. Grade 3 or greater infusion-related reaction/cytokine release syndrome was observed in 13% (4 of 31) of patients. We plan to enroll additional patients in this ongoing study and announce data in 2019. We also intend to study flotetuzumab in combination with MGA012 in a future clinical trial.&#160;&#160;</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">The FDA granted orphan drug designation to flotetuzumab for the treatment of AML. Our collaborator, Les Laboratoires Servier and Institut de Recherches Servier&#160;(collectively, Servier) has development and commercialization rights outside North America, Japan, Korea and India for flotetuzumab&#160;(S80880).</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Other DART Molecules</span></div><div><span><br/></span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:115%;">MGD007.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;"> An additional CD3-targeting DART molecule, MGD007, recognizes glycoprotein A33 (gpA33), which is expressed on gastrointestinal tumors, including more than 95% of human colon cancers, and CD3 and is being tested in patients with colorectal cancer in a Phase 1 clinical study in combination with MGA012. In </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:115%;">late</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:115%;">&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">2018, our collaborator, Servier, notified us that it declined to exercise its option to gain development and commercialization rights for MGD007 in its territories. </span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:115%;">MGD014</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">. MGD014 is a DART molecule that targets the envelope protein of human immunodeficiency virus&#160;(HIV)&#160;infected cells (Env) and T cells, via their CD3 component, to redirect the immune system's T cells to kill HIV-infected cells. DART molecules could be used independently or become a key part of a "shock-and-kill" strategy in conjunction with HIV latency-reversing agents currently under development. MGD014 is our first clinical DART molecule designed to target virus-infected cells. A Phase 1 dose escalation study of MGD014 is ongoing. We are developing MGD014 under contract number</span></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">4</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;"> HHSN272201500032C awarded to us in September 2015 by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">Our DART molecules that redirect T cells against cancer or other targets, including MGD007, MGD009, flotetuzumab and MGD014, are manufactured using a conventional antibody platform without the complexity of having to genetically modify T cells from individual patients, as would be required by approaches such as chimeric antigen receptor (CAR) T cells. </span></div><div style="text-indent:36pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Our Investment in R&amp;D</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">We continue to invest in our clinical-stage programs, advance additional preclinical product candidates, primarily using our proprietary technology platforms, and expand the potential of our platforms using our antibody and protein engineering expertise. We develop new therapeutic product candidates internally using our proprietary platforms and also in collaboration with other biopharmaceutical companies, when such relationships are advantageous for strategic or financial reasons. These arrangements have allowed us to expand and accelerate the breadth of our product candidates and also have generated a significant portion of the funding we have received to date. We also have our own manufacturing facilities intended &#160;to meet later-stage clinical and future potential commercial requirements.&#160;</span></div><div><span><br/></span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">Our Strategy</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Our goal is to be a fully integrated biotechnology company leading in the discovery, development and commercialization of breakthrough biologics for the treatment of patients with cancer.</span></div><div style="text-indent:40.5pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Key elements of our strategy are as follows:</span></div><div style="text-indent:-18pt;padding-left:58.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:115%;padding-left:14.5pt;">Oncology</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:115%;"> focus, science driven.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">  We create therapeutic biological products primarily to treat various types of cancers, including both solid tumors and hematological malignancies.  Our proprietary DART and Fc Optimization technology platforms are particularly useful for targeting and harnessing specific elements of the human immune system, allowing us to design molecules that (1) directly target cancer cells and enhance the ability of the immune system to destroy those cells, (2) re-direct effector cells to attack tumors or (3) affect mechanisms that regulate the immune response to cancer, either by stimulating pathways that enhance this response or by blocking pathways that inhibit this response, including checkpoint molecules. This field of scientific discovery, broadly known as immuno-oncology, has been developing rapidly in the last few years, and most therapeutic products to date are largely focused on affecting individual biological pathways. We believe that cancers are sufficiently complex that effective treatments must simultaneously affect more than one pathway.  We believe that we are well-positioned, particularly through the adaptability of our DART platform, to be able to create and develop therapeutic molecules designed to simultaneously target more than one pathway.</span></div><div style="padding-left:58.5pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">This same flexibility in our platforms allows us to create therapeutic molecules that may be useful for other unmet medical needs beyond cancer, such as for autoimmune disorders and infectious diseases.  Our core strategic focus is on development of cancer therapeutics, but we may also opportunistically pursue such possibilities when they arise.</span></div><div style="text-indent:-18pt;padding-left:58.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:115%;padding-left:14.5pt;">Fully integrated with a deep pipeline.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">  Our objective is to be a fully-integrated biotechnology company, and we intend to continue to grow and establish all necessary functions from early-stage research through commercialization in at least the United States.  At our current stage of development as a company, we have established early-stage discovery, process development, clinical development and clinical-stage manufacturing functions, we have completed the build-out of a facility that will support commercial manufacturing, and we intend to build a U.S.-based sales and marketing infrastructure as our development pipeline matures.</span></div><div style="padding-left:58.5pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">We have a broad portfolio of product candidates and we are not dependent upon the success of any one of them for the overall success of the company.  We continue to augment our pipeline through the discovery and development of new product candidates, primarily through utilization of our internal scientific expertise and strategically seeking external collaborations that can augment our own skills.  In 2018, we advanced three programs into clinical development.  Our goal is to continue to advance one or more programs into clinical development per year to ensure a robust pipeline and to replace product candidates that fail to progress.</span></div><div style="text-indent:-18pt;padding-left:58.5pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:115%;padding-left:14.5pt;">Leveraging collaborations.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;"> Throughout our company's history, we have entered into collaborations with other biopharmaceutical companies and intend to continue to do so. We enter into collaborations when there is a strategic advantage to us to do so and when we believe the financial terms of the collaboration are favorable for meeting our short-term and long-term strategic objectives. We are not dependent upon any one of these collaborations, but in many cases we have rights to receive sales royalties and other significant financial payments if the partnered product candidates achieve certain development and sales milestones. We endeavor to establish collaborations that preserve our right to participate in future commercialization, for example by securing co-promotion or profit-sharing rights under certain circumstances.</span></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">5</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-indent:-18pt;padding-left:58.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:115%;padding-left:14.5pt;">Investments in talent and culture. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;"> One of our most valuable assets is the quality of our employee base. We invest significant effort in selecting and retaining high caliber, talented individuals who reflect our values. As we continue to grow, we continue to seek and develop employees who are strongly committed to delivering life-changing medicines for unmet medical needs through a collaborative work environment.</span></div><div><span><br/></span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:115%;">Our Therapeutic Area Focus: Cancer</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">Cancer is a broad group of diseases in which cells divide and grow in an uncontrolled manner, forming malignancies that can invade other parts of the body. In normal tissues, the rates of new cell growth and cell death are tightly regulated and kept in balance. In cancerous tissues, this balance is disrupted as a result of mutations, causing unregulated cell growth that leads to tumor formation and growth. While tumors can grow slowly or rapidly, the dividing cells will nevertheless accumulate, and the normal organization of the tissue will become disrupted. Cancers subsequently can spread throughout the body by processes known as invasion and metastasis. Once cancer spreads to sites beyond the primary tumor, it generally becomes more difficult to treat and may be incurable. Cancer cells that arise in the lymphatic system and bone marrow are referred to as hematological malignancies. Cancer cells that arise in other tissues or organs are referred to as solid tumors. Cancer can arise in virtually any part of the body, with the most common types arising in the prostate gland, breast, lung, colon and skin.  We believe that our platforms position us very well strategically to actively develop approaches for the treatment of both solid tumors and hematologic malignancies.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">Cancer is the second leading cause of death in the United States, exceeded only by heart disease.  An increasing number of people are also living longer with cancer. The American Cancer Society has estimated that by January 2026, the population of cancer survivors in the United States will increase to almost 20.3 million people. </span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:115%;">Our Platforms and Technology Expertise</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">We apply our understanding of disease biology, immune-mediated mechanisms and next generation antibody technologies to design specifically targeted antibody-based product candidates based on our DART and Fc Optimization platforms. Through these platforms we have designed antibody-based product candidates that have the potential to improve on standard treatments by having one or more of the following attributes: (1) multiple specificities; (2) increased abilities to interact with the body's immune system to fight tumors; (3) capacity to bind more avidly to antigen targets: (4) increased potency; (5) reduced immunogenicity or (6) the ability to target cancer cells that are resistant to standard treatments. Moreover, these technology platforms are complementary and can be combined.</span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">DART and TRIDENT Platforms: Our Proprietary Approach to Engineer Multi-Specific Antibodies</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">We use our DART platform to create derivatives of antibodies with the ability to bind to two distinct targets instead of a single one found in traditional monoclonal antibodies. DART product candidates are therefore bispecific. An example of a bispecific molecule is illustrated below:</span></div><div style="text-align:center;margin-bottom:9pt;"><img src="mgnx-20181231_g2.jpg" alt="mgnx-20181231_g2.jpg" style="height:208;width:466;"></img></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">Because cancer cells have developed ways to escape the immune system, we have created DART molecules, which are alternative antibody-like structures with more potent immune properties than the parent antibody molecules from which they are derived. The two variable regions of an antibody are mono-specific and are able to target only a single type structural component of an antigen. For many years, researchers have sought to create recombinant molecules that are capable of targeting two antigens or epitopes (i.e., specific part of an antigen bound by the antibody) within the same molecule. The challenges in creating such molecules have been the instability of the resulting bispecific molecules and their inherently short half-lives, as well as the inefficiencies in manufacturing these compounds. We believe our DART platform has overcome these engineering challenges by incorporating proprietary covalent di-sulfide linkages and particular amino acid sequences that efficiently pair the chains of the DART molecule. This is designed to provide a structure with enhanced manufacturability, long-term structural</span></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">6</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;"> stability and the ability to tailor the half-lives of the DART molecules to their clinical needs. This engineered antibody-like protein has a compact and stable structure and enables the targeting of two different antigens with a single recombinant molecule.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">The DART platform has been specifically engineered to accommodate virtually any variable region sequence with predictable expression, folding and antigen recognition. We believe our multi-specific platforms may provide a significant advantage over current biological interventions in cancer, autoimmune disorders and infectious disease by enabling a range of modalities, including those described below.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">We have also advanced beyond our DART platform to establish a TRIDENT platform, which reflects the continuing evolution of our multi-specific antibody-based targeting expertise. Built on the DART module, the trivalent TRIDENT platform incorporates in an Ig-like format an additional domain capable of engaging an independent antigen. With the inclusion of a third targeting arm, TRIDENT molecules enable a broader range of mechanisms of action than bispecific targeting, allowing, for instance, the engagement of multiple antigens on a single or on different cells or enabling enhanced target selectivity by modulating the avidity of one of two antigens.</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">Our DART and TRIDENT platforms enable us to design multi-specific molecules that seek to exploit different mechanisms of action, including those set forth below.</span></div><div style="margin-bottom:9pt;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">7</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:70.514620%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:25.485380%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-13.5pt;padding-left:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">&#8226;&#160;&#160;&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;">Redirected T cell activation and killing</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">. In this version of the DART molecule, we are enabling the cancer-fighting properties of the immune effector cells, such as T lymphocytes to: (1)&#160;recognize and bind to structures expressed on a cancer cell (e.g., CD123, the first specificity in the example on the right), (2)&#160;enable the recruitment of all types of cytotoxic, or cell killing, T cells, irrespective of their ability to recognize cancer cells (e.g., CD3, a common component of the T cell antigen receptor, is the second specificity in the example on the right) and (3)&#160;trigger T cell activation, expansion, and cell killing mechanisms to destroy a cancer cell. The outcome is that any of the body's T cells, in theory, could be recruited to destroy a cancer cell and thus, are not limited to the small numbers of specific T cells that might have been generated in response to cancer to kill tumor cells. Furthermore, since any T cell could be recruited for this killing process, only small amounts of a DART molecule are required to trigger this potent immune response. Additionally, the compact structure of the DART protein makes it well suited for maintaining cell-to-cell contact, which we believe contributes to the high level of target cell killing. Similarly, DART molecules targeting CD3 and a viral antigen can be used to recruit T cells to eliminate cells infected by a virus, such as HIV-infected cells.</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><img src="mgnx-20181231_g3.jpg" alt="mgnx-20181231_g3.jpg" style="height:223;width:130;"></img></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-13.5pt;padding-left:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;">&#8226;&#160;&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:5pt;font-weight:400;line-height:100%;">&#160;&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;">Targeting of multiple co-inhibitory receptors or checkpoints, such as those involved in inhibiting T cell responses.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;"> The immune system generally prevents the development of autoimmune phenomena by regulating activated immune cells that have responded to non-self or foreign antigens. This negative feedback loop is triggered by the interactions of co-inhibitory receptors, or checkpoint molecules, expressed on the immune cells with ligands expressed by other cells, such as antigen-presenting cells. This phenomenon is exploited by cancer, whereby tumor cells express checkpoint ligands that block the development of an immune response against the tumor. Antibodies that block the interaction of checkpoint molecules with their ligands have been shown to significantly improve the clinical outcomes of patients with certain advanced cancers. Because of the diversity of immune checkpoint pathways, blockade of a single axis, while clinically significant, as shown in the case of the blockade of the PD-1/PD-L1 axis with pembrolizumab or nivolumab, will not benefit all patients. In fact, combinations of checkpoint inhibitors, such as nivolumab and ipilimumab, a CTLA-4 blocker, have resulted in significantly enhanced benefit compared to ipilimumab or nivolumab alone. We believe that DART molecules targeting two immunoregulatory pathways, such as two checkpoints in a single molecule, could afford the clinical benefit of the combination together with the potential for synergistic activity, as well as significant advantages in manufacturing, simplified clinical development, and enhanced patient convenience.</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;margin-bottom:9pt;"><img src="mgnx-20181231_g4.jpg" alt="mgnx-20181231_g4.jpg" style="height:237;width:130;"></img></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-13.5pt;padding-left:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">&#8226;&#160;&#160;&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;">Enhanced effector cell selectivity. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">T lymphocytes with lytic effector function belong preferentially to the CD8 lineage, while CD4-positive T cells preferentially provide immune regulatory function, such as the secretion of cytokines or the differentiation into regulatory T cells. Greater selectivity in the recruitment of effector T cells is an example of the range of applications of our TRIDENT technology. By encoding a CD8 recognition arm in addition to the CD3- and tumor antigen-specific arms, our TRIDENT technology allows the preferential engagement of CD8-positive T lymphocytes and redirects them against tumor cells. This strategy allows for retention of lytic effector function, while limiting the CD4 cell engagement and associated effects, such as inflammatory cytokine release.</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;margin-bottom:9pt;"><img src="mgnx-20181231_g5.jpg" alt="mgnx-20181231_g5.jpg" style="height:224;width:130;"></img></div></td></tr></table></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">In addition to the ability to tailor a DART molecule's valency, we have the capacity to modify the strength by which the binding sites attach to their targets and the molecule's half-life in the blood circulation after delivery to a patient. Furthermore, when an Fc domain is coupled with a DART molecule, additional changes can be included that can modulate the DART molecule's engagement with different immune cells.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">We are developing specific product candidates using this technology, including flotetuzumab, MGD009, MGD007, MGD013, MGD019 and MGD014, among others. </span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Fc Optimization Platform: Our Proprietary Approach to Enhance Immune-Mediated Cancer Cell Killing</span></div><div style="text-indent:36pt;margin-bottom:9pt;"></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">8</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">To enhance the body's immune ability, we developed our Fc Optimization platform which introduces certain mutations into the Fc region of an antibody and is able to modulate antibody interaction with immune effector cells. Such interaction enhances the body's immune ability to mediate the killing of cancer cells through ADCC.</span></div><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">ADCC</span></div><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#160;</span><img src="mgnx-20181231_g6.jpg" alt="mgnx-20181231_g6.jpg" style="height:185;width:216;"></img></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Fc region mediates the function of IgG antibodies by binding to different activating and inhibitory receptors, referred to as Fc&#947;Rs, on immune effector cells found within the innate immune system. By engineering Fc regions to bind with an increased affinity to the activating Fc&#947;Rs and with a reduced affinity to the inhibitory Fc&#947;Rs, we have been able to impart a more effective immune response and improve effector functions, such as ADCC. This is another example in which small changes in antibody structure can confer improvements on normal immune processes.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">We have established a proprietary platform to engineer, screen, identify and test antibodies' Fc regions with customizable activity. In particular, we have licenses to use transgenic mice that express human Fc&#947;Rs. These mice can be used for in vivo testing of antibodies that incorporate Fc domain variants, including those antibodies intended for cancer therapy.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">To date, we have successfully incorporated our Fc variants in two of our clinical-stage antibody product candidates, margetuximab and enoblituzumab. We have preclinical data demonstrating that these Fc variants have substantially improved the activity of these antibodies. In addition, clinical data&#160;from our Phase 3 SOPHIA study&#160;of margetuximab demonstrated an improvement in activity over&#160;that of trastuzumab, an analog monoclonal antibody with a wild-type, non-engineered&#160;Fc domain.</span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">Our Collaborations</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">We pursue a balanced approach between product candidates that we develop ourselves and those that we develop with our collaborators. Under our strategic collaborations to date, we have received significant non-dilutive funding and continue to have rights to additional funding upon completion of certain research, achievement of key product development milestones and royalties and other payments upon the commercial sale of products.  Each of our collaborations has a unique set of terms and conditions.</span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">Intellectual Property</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">We strive to protect the proprietary technologies that we believe are important to our business, including seeking and maintaining patents intended to protect, for example, the composition of matter of our product candidates, their methods of use, the technology platforms used to generate them, related technologies and/or other aspects of the inventions that are important to our business. We also rely on trade secrets, confidentiality and invention assignment agreements and careful monitoring of our proprietary information to protect aspects of our business that are not amenable to, or that we do not consider appropriate for, patent protection.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">Our success will depend significantly on our ability to obtain and maintain patent and other proprietary protection for commercially important technology, inventions and know-how related to our business.  In addition, there is cost and risk to our business in defending and enforcing our patents, maintaining our licenses to use intellectual property owned by third parties and preserving the confidentiality of our trade secrets and operating without infringing the valid and enforceable patents and other proprietary rights of third parties. We also rely on know-how, continuing technological innovation and in-licensing opportunities to develop, strengthen and maintain our proprietary positions. We currently use multiple industry-standard patent monitoring systems to monitor new United States Patent and Trademark Office&#160;(USPTO) filings for any applications by third parties that may infringe on our patents.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">The patent positions of biopharmaceutical companies like us are generally uncertain and involve complex legal, scientific and factual questions. In addition, the coverage claimed in a patent application can be significantly reduced before the</span></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">9</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;"> patent is issued, and its scope can be reinterpreted by the courts after issuance. Consequently, we do not know whether any of our product candidates will be protectable or remain protected by enforceable patents. We cannot predict whether the patent applications we are currently pursuing will issue as patents in any particular jurisdiction or whether the claims of any issued patents will provide sufficient proprietary protection from competitors. Any patents that we hold may be challenged, narrowed, circumvented or invalidated by third parties.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">A third party may hold patents or other intellectual property rights that are important to or necessary for the development of our product candidates or use of our technology platforms. It may be necessary for us to use the patented or proprietary technology of third parties to commercialize our product candidates, in which case we would be required to obtain a license from these third parties on commercially reasonable terms, or our business could be harmed, possibly materially. For example, certain patents held by third parties cover Fc engineering methods and mutations in Fc regions to enhance the binding of Fc regions to Fc receptors on immune cells. Although we believe that these patents are not infringed, invalid, and unenforceable, should a court find that they cover margetuximab or enoblituzumab and we are unable to invalidate them, or if licenses for them are not available on commercially reasonable terms, our business could be harmed, perhaps materially.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">Because patent applications in the United States and certain other jurisdictions can be maintained in secrecy for 18 months or potentially even longer, and because publication of discoveries in the scientific or patent literature often lags behind actual discoveries, we cannot be certain of the priority of inventions covered by pending patent applications. Moreover, we may have to participate in interference proceedings declared by the USPTO to determine priority of invention. In the ordinary course of business we participate in post-grant challenge proceedings, such as oppositions, that challenge the patentability of third party patents. Such proceedings could result in substantial cost, even if the eventual outcome is favorable to us.</span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Pipeline Patent Protection</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">As of December&#160;31, 2018, we held 79 patents in the United States with 50 patent applications pending and 428 patents in other countries of the world with 687 patent applications pending. In addition to patents and patent applications generally providing protection for various aspects of our Fc Optimization, DART, and TRIDENT platforms, we have patent and patent applications for the composition of matter of each of our clinical pipeline product candidates and, in some cases, we also have other patents and patent application related to various aspects of the technology underlying these product candidates or their methods of use.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Patent terms may be adjusted or extended, as described in greater detail below, in certain circumstances. However, assuming no adjustments or extensions, the primary composition of matter patent for each of our clinical pipeline product candidates is expected to expire in the following timeframes:</span></div><div style="margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"><tr><td style="width:1.0%;"></td><td style="width:63.689150%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:32.310850%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#d9d9d9;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Product Candidate</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#d9d9d9;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Expiration Date</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">margetuximab</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:66pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2029&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">enoblituzumab</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:66pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2031&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">flotetuzumab</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:66pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2034&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">MGD007</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:66pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2034*&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">MGD009</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:66pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2036*&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">MGA012</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:66pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2036*&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">MGD013</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:66pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2036*&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">MGD019</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:66pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2036*&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">MGC018</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:66pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2037*&#160;</span></td></tr></table></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">* pending</span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Patent Term Extension and Reference Product Exclusivity</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Hatch-Waxman Act permits a patent term extension for FDA-approved drugs, including biological products, of up to five years beyond the expiration of the patent. The length of the patent term extension is related to the length of time the drug is under regulatory review. Patent extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval and only one patent applicable to an approved drug may be extended. Similar provisions are available in Europe and other jurisdictions to extend the term of a patent that covers an approved drug. In the future, if and when our pharmaceutical product candidates receive FDA approval, we expect to apply for patent term extensions on patents covering those products. We intend to seek patent term extensions to any of our issued patents in any jurisdiction where these are available, however there is no guarantee that the applicable authorities, including the FDA in the United States, will agree with our assessment of whether such extensions should be granted, and even if granted, the length of such extensions.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">10</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Patient Protection and Affordable Care Act, as amended by the Healthcare and Education Affordability Reconciliation Act&#160;(collectively the ACA) created a regulatory scheme authorizing the FDA to approve biosimilars via an abbreviated licensure pathway. In many cases, this allows biosimilars to be brought to market without conducting the full suite of clinical trials typically required of originators. Under the ACA, a manufacturer may submit an application for licensure of a biologic product that is "biosimilar to" or "interchangeable with" a previously approved biological product or "reference product." The "biosimilar" application must include specific information demonstrating biosimilarity based on data derived from: (1) analytical studies, (2) animal studies, and&#160;(3) a clinical study or studies that are sufficient to demonstrate safety, purity, and potency in one or more appropriate conditions of use for which the reference product is licensed, except that FDA may waive some of these requirements for a given application. Under this new statutory scheme, an application for a biosimilar product may not be submitted to the FDA until four years after the date of first licensure. The FDA may not approve a biosimilar product until 12 years from the date on which the reference product was first licensed. The law does not change the duration of patents granted on biological products. Even if a product is considered to be a reference product eligible for exclusivity, another company could market a competing version of that product if the FDA approves a full BLA for such product containing the sponsor's own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of their product. There have been recent proposals to repeal or modify the ACA and it is uncertain how any of those proposals, if approved, would affect these provisions.</span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Trade Secrets</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">We also rely on trade secret protection for our confidential and proprietary information. Although we take steps to protect our proprietary information and trade secrets, including through contractual means with our employees and consultants, third parties may independently develop substantially equivalent proprietary information and techniques or otherwise gain access to our trade secrets or disclose our technology. Thus, we may not be able to meaningfully protect our trade secrets. It is our policy to require our employees, consultants, outside scientific collaborators, sponsored researchers and other advisors to execute confidentiality agreements upon the commencement of employment or consulting relationships with us. These agreements provide that all confidential information concerning our business or financial affairs developed or made known to the individual during the course of the individual's relationship with us is to be kept confidential and not disclosed to third parties except in specific circumstances. In the case of employees, the agreements provide that all inventions conceived by the individual, and which are related to our current or planned business or research and development or made during normal working hours, on our premises or using our equipment or proprietary information, are our exclusive property. In many cases our confidentiality and other agreements with consultants, outside scientific collaborators, sponsored researchers and other advisors require them to assign or grant us licenses to inventions they invent as a result the work or services they render under such agreements or grant us an option to negotiate a license to use such inventions.</span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">In-Licensed Intellectual Property</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">We have entered into patent and know-how license agreements that grant us the rights to use certain technologies related to biological manufacturing for our clinical product candidates. We anticipate using these technologies for future product candidates. These licensors have businesses dedicated to licensing this type of technology and we anticipate that licenses to use these technologies for our future products will be available. The licenses typically include yearly maintenance payments and sales royalties, and may also include upfront payments or milestone payments.</span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">Manufacturing</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">We currently manufacture our drug substance for our clinical trials at our manufacturing facilities located in Rockville, Maryland. For our antibody product candidates, we have supplemented our drug substance manufacturing capacity through an arrangement with AGC Biologics, Inc.&#160;(AGC, formerly CMC Biologics, Inc.), a contract manufacturing organization, and plan to commercially produce margetuximab at AGC assuming approval of margetuximab. We have also completed the build-out of a manufacturing suite at our headquarters building in Rockville, Maryland, which has been designed to increase our internal capacity to manufacture more drug substance lots, at larger scale and in full compliance with current Good Manufacturing Practices (cGMP) to be able to sell commercial product, when and if approved by the FDA&#160;. In addition, we currently rely on and will continue to rely on contract fill-finish service providers, primarily Ajinomoto Althea, Inc. and Baxter Healthcare Corporation, to fulfill our fill-finish needs for our current and future product candidates.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">Most of the principal materials we use in our manufacturing operations are available from more than one source. However, we obtain certain raw materials principally from only one source. In the event one of these suppliers was unable to provide the materials or product, we generally seek to maintain sufficient inventory to supply the market until an alternative source of supply can be implemented. However, in the event of an extended failure of a supplier, it is possible that we could experience an interruption in supply until we established new sources or, in some cases, implemented alternative processes.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">11</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">Production processes for biological therapeutic products are complex, highly regulated, and vary widely from product to product. Shifting or adding manufacturing capacity can be a very lengthy process requiring significant capital expenditures, process modifications, and regulatory approvals. Accordingly, if we were to experience extended plant shutdowns at one of our own facilities, extended failure of a contract supplier or contract manufacturing organization, or extraordinary unplanned increases in demand, we could experience an interruption in supply of certain products or product shortages until production could be resumed or expanded.</span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">Commercialization</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">We cannot market or promote a new product until a marketing application has been approved by the FDA. We currently have no approved products in the United States. We have not yet established a&#160;sales, marketing or product distribution infrastructure.&#160;We believe that it will be possible for us to access the United States oncology market through a specialty sales force.&#160;Subject to receiving marketing authorization in the United States, we expect to commence commercialization via&#160;our then-in-place&#160;sales and marketing organizations. We believe that these organizations will be able to serve the oncology community in treating the patient populations for which our oncology product candidates are being developed. Outside the United States, we expect to enter into arrangements with third-party commercial partners for any of our product candidates that obtain marketing approval.</span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">Competition</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:100%;">There are a large number of companies developing or marketing treatments for cancer and autoimmune disorders, including many major pharmaceutical and biotechnology companies. These treatments consist both of small molecule drug products, as well as biologic therapeutics that work by using next-generation antibody technology platforms to address specific cancer targets. In particular, margetuximab is directed against HER2 and several companies have cancer therapeutics directed against HER2 marketed or in development, such as F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (Roche), particularly through its affiliate, Genentech, Inc., as well as Puma Biotechnology, Inc., Daiichi Sankyo Company, Limited, Seattle Genetics Inc. and Synthon Biopharmaceuticals. Market competition may limit the utilization of margetuximab as a therapeutic, even if market approval and adequate reimbursement is obtained, and competition among development-stage programs for patients enrolling in clinical trials for HER2-directed therapies may delay expected timelines for our clinical trials.  </span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">In addition, the immuno-oncology field is competitive, with treatments currently approved and on the market or in development for various tumor types and patient populations from a variety of different companies such as Merck &amp; Co., Inc.&#160;(Merck), The Bristol-Myers Squibb Company (BMS), and Roche, all of which have significantly greater resources than we do. Many of our pipeline programs, if successful, will likely face significant competition both by therapeutics that are already being marketed as well as those that will be approved for marketing before our programs. In particular, we are developing a franchise of PD-1-directed product candidates, which includes a monoclonal antibody that we've outlicensed and two DART molecules. Merck, BMS,&#160;Roche,&#160;AstraZeneca plc, Pfizer Inc. and Regeneron Pharmaceuticals, Inc.&#160;all have approved products that target either the PD-1 receptor or its ligand, PD-L1, and there are several other companies that have anti-PD-1 or anti-PD-L1 antibodies in clinical development, all of which would compete with our PD-1-directed programs.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">Finally, several companies are also developing therapeutics that work by targeting multiple specificities using a single recombinant molecule. Amgen Inc. has obtained marketing approval for one product that works by targeting antigens both on immune effector cell populations and those expressed on certain cancer cells, and has other product candidates in development that use this mechanism. In addition, other companies are developing new treatments for cancer that utilize multi-specific approaches, including Abbvie Inc., Affimed Therapeutics AG Corporation, Eli Lilly and Company,&#160;Genmab A/S, Merus B.V., Regeneron,&#160;Roche,&#160;Xencor, Inc.&#160;and Zymeworks, Inc.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">Many of our competitors have significantly greater financial, manufacturing, marketing, drug development, technical and human resources than we do. Mergers and acquisitions in the pharmaceutical, biotechnology and diagnostic industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining top qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">The key competitive factors affecting the success of all of our therapeutic product candidates, if approved, are likely to be their efficacy, safety, dosing convenience, price, the effectiveness of companion diagnostics in guiding the use of related therapeutics, the level of generic or biosimilar competition and the availability of reimbursement from government and other third-party payors.  In addition, the standard of medical care provided to cancer patients continues to evolve as more scientific and medical information becomes available.  These changes in medical care relate to pharmaceutical products, but are also affected by other factors, and such changes can positively or negatively affect the prospects of our product candidates as well as those of our competitors.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">12</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are more effective, have fewer or less severe effects, are more convenient or are less expensive than any products that we may develop, or the standards of care for cancer patients change while our clinical trials are ongoing. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. In addition, our ability to compete may be affected in many cases by insurers or other third party payors seeking to encourage the use of biosimilar products. Biosimilar products are expected to become available over the coming years. For example, a trastuzumab biosimilar has been approved in the U.S. by FDA.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">The most common methods of treating patients with cancer are surgery, radiation and drug therapy. There are a variety of available drug therapies marketed for cancer. Many of these approved drugs are well established therapies and are widely accepted by physicians, patients and third party payors. In many cases, these drugs are administered in combination to enhance efficacy. While our product candidates may compete with many existing drug and other therapies, to the extent an approved drug is ultimately used in combination with or as an adjunct to these therapies, our product candidates will not be competitive with the approved drug.</span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">Government Regulation and Product Approval</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Government authorities in the United States, at the federal, state and local level, and in other countries extensively regulate, among other things, the research, development, testing, manufacture, packaging, storage, recordkeeping, labeling, advertising, promotion, distribution, marketing, import and export of pharmaceutical products such as those we are developing. The processes for obtaining regulatory approvals in the United States and in foreign countries, along with subsequent compliance with applicable statutes and regulations, require the expenditure of substantial time and financial resources.</span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">FDA Regulation</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">All of our current product candidates are subject to regulation in the United States by the FDA as biological products&#160;&#160;(biologics). The FDA subjects biologics to extensive pre- and post-market regulation. The Public Health Service Act, the Federal Food, Drug, and Cosmetic Act (FDCA)&#160;and other federal and state statutes and regulations, govern, among other things, the research, development, testing, manufacture, storage, recordkeeping, approval, labeling, promotion and marketing, distribution, post-approval monitoring and reporting, sampling, and import and export of biologics. Failure to comply with applicable U.S. requirements may subject a company to a variety of administrative or judicial sanctions, such as FDA refusal to approve pending BLAs, withdrawal of approvals, clinical holds, warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, civil penalties, or criminal penalties.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:115%;">Preclinical Studies</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">. Drug development in our industry is complex, challenging and risky; failure rates are high. Product development cycles are long - approximately 10 to 15 years from discovery to market. A potential new biological product must undergo many years of preclinical and clinical testing to establish it is pure, potent and safe.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">Preclinical studies include laboratory evaluation of product chemistry, formulation and toxicity, pharmacology, as well as animal trials to assess the characteristics and potential safety and efficacy of the product. The conduct of the preclinical tests must comply with federal regulations and requirements including FDA's good laboratory practice&#160;(GLP) regulations and the U.S. Department of Agriculture's regulations implementing the Animal Welfare Act. After laboratory analysis and preclinical testing in animals, we file an Investigational New Drug (IND) application with the FDA to begin human testing. An IND sponsor must submit the results of the preclinical tests, together with manufacturing information, analytical data, any available clinical data or literature, and a proposed clinical trial protocol, among other things, to the FDA as part of an IND application. Certain preclinical tests, such as animal tests of reproductive toxicity and carcinogenicity, may continue even after the IND application is submitted. An IND application automatically becomes effective 30 days after receipt by the FDA, unless before that time the FDA raises concerns or questions related to one or more proposed clinical trials and places the clinical trial on a clinical hold or agrees on an alternate approach with us. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. As a result, submission of an IND application may not result in the FDA allowing clinical trials to commence.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:115%;">Clinical Development</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">. Clinical trials involve the administration of the IND to human subjects (healthy volunteers or patients) under the supervision of a qualified investigator. Clinical trials must be conducted: (i) in compliance with all applicable federal regulations and guidance, including those pertaining to good clinical practice&#160;(GCP) standards that are meant to protect the rights, safety, and welfare of human subjects and to define the roles of clinical trial sponsors, investigators, and monitors; as well as (ii) under protocols detailing, among other things, the objectives of the trial, the parameters to be used in monitoring safety, and the effectiveness criteria to be evaluated. Each protocol involving testing of a new drug in the United States (whether in patients or healthy volunteers) must be included in the IND application submission, and FDA must be notified of subsequent protocol amendments. In addition, the protocol must be reviewed and approved by an institutional review board&#160;(IRB) and all study subjects must provide informed consent prior to participating in the study. Typically, each institution participating in the clinical trial will require review of the protocol before any clinical trial commences at that</span></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">13</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;"> institution. Information about certain clinical trials must be submitted within specific timeframes to the National Institutes of Health (NIH) for public dissemination on their ClinicalTrials.gov website. Progress reports detailing the results of the clinical trials must be submitted at least annually to the FDA and there are additional, more frequent reporting requirements for suspected unexpected serious adverse events.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">A study sponsor might choose to discontinue a clinical trial or a clinical development program for a variety of reasons. The FDA may impose a temporary or permanent clinical hold, or other sanctions, if it believes that the clinical trial either is not being conducted in accordance with FDA requirements or presents an unacceptable risk to the clinical trial subjects. An IRB may also require the clinical trial at the site to be halted, either temporarily or permanently, for failure to comply with the IRB's requirements, or may impose other conditions.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">Clinical trials to support BLAs for marketing approval are typically conducted in three pre-approval phases, but the phases may overlap or be combined, particularly in testing for oncology indications. In Phase 1, testing is conducted in a small group of subjects who may be patients with the target disease or condition or healthy volunteers, to evaluate its safety, determine a safe dosage range, and identify side effects. In Phase 2, the drug is given to a larger group of subjects with the target condition to further evaluate its safety and gather preliminary evidence of efficacy. Phase 3 studies typically last multiple years for oncology indications. In Phase 3, the drug is given to a large group of subjects with the target disease or condition (several hundred to several thousand), often at multiple geographical sites, to confirm its effectiveness, monitor side effects, and collect data to support drug approval. In some cases, FDA may require post-market studies, known as Phase 4 studies, to be conducted as a condition of approval in order to gather additional information on the drug's effect in various populations and any side effects associated with long-term use. Depending on the risks posed by the drugs, other post-market requirements may be imposed. Only a small percentage of investigational drugs complete all three phases and obtain marketing approval.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:115%;">Product Approval</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">. After completion of the required clinical testing, a BLA can be prepared and submitted to the FDA. FDA approval of the BLA is required before marketing of the product may begin in the United States. The BLA must include the results of preclinical, clinical and other testing and a compilation of data relating to the product's chemistry, manufacture and controls. The cost of preparing and submitting a BLA is substantial. Under federal law, the submission of most BLAs is additionally subject to a substantial application user fee, and annual product and establishment user fees also apply. These fees are typically increased annually.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">The FDA has 60 days from its receipt of a BLA to determine whether the application will be accepted for filing based on the FDA's threshold determination that it is sufficiently complete to permit substantive review. Once the submission is accepted for filing, the FDA begins a substantive review, and the review period under the Prescription Drug User Fee Act begins. The standard for reviewing a BLA is whether the product is safe, pure and potent, which has been interpreted to include that the product is safe and effective and has a favorable benefit-risk profile. FDA's current performance goals call for FDA to complete review of 90 percent of standard (non-priority) BLAs within 10 months of receipt and within six months for priority BLAs, which is 12 months and eight months, respectively, if the 60-day review of the initial application is included in the timeline.  In addition, the FDA has developed approaches intended to make certain qualifying products available to patients rapidly - Priority Review, Breakthrough Therapy, Accelerated Approval, and Fast Track.   While the timelines for approval under these pathways may be shorter, there are requirements and conditions associated with each pathway, and there can be no assurance that any of our investigational products will be able to meet the conditions or requirements necessary to receive any such designation or be able to receive the review or approval benefits associated with such designations. </span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">The FDA may refer applications for novel products or products that present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes outside clinicians and other experts, for review, evaluation and a recommendation as to whether sufficient data exist in the application to support product approval. The FDA is not bound by the recommendation of an advisory committee, but it generally follows such recommendations.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">Before approving a BLA, the FDA will typically inspect one or more clinical sites to assure compliance with GCP. Additionally, the FDA will typically inspect the facility or the facilities at which the drug is manufactured. FDA will not approve the product unless compliance with cGMPs is satisfactory.  FDA also reviews the proposed labeling submitted with the BLA and typically requires changes in the labeling text.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">After the FDA evaluates the BLA and the manufacturing and testing facilities, it issues either an approval letter or a complete response letter. Complete response letters generally outline the deficiencies in the submission and delineate the additional testing or information needed in order for the FDA to reconsider the application. If and when those deficiencies have been addressed to the FDA's satisfaction in a resubmission of the BLA, the FDA will issue an approval letter. The FDA has committed to reviewing 90 percent of resubmissions within two or six months from receipt depending on the type of information included.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">An approval letter authorizes commercial marketing of the drug for the approved indication or indications and the other conditions of use set out in the approved prescribing information.  Once granted, product approvals may be withdrawn if compliance with regulatory standards is not maintained or problems are identified following initial marketing.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">14</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">As a condition of BLA approval, the FDA may require substantial post-approval testing and surveillance to monitor the drug's safety or efficacy and may impose other conditions, including labeling restrictions that can materially affect the potential market and profitability of the product. As a condition of approval, or after approval, the FDA also may require submission of a risk evaluation and mitigation strategy&#160;(REMS) to mitigate any identified or suspected serious risks. The REMS may include medication guides, physician communication plans, assessment plans, and elements to assure safe use, such as restricted distribution methods, patient registries, or other risk minimization tools.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:115%;">Other U.S. Post-Marketing Regulatory Requirements</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">. Once a BLA is approved, a product will be subject to certain post-approval requirements, including those relating to advertising, promotion, adverse event reporting, recordkeeping, and cGMPs, as well as registration, listing, and inspection. There also are continuing, annual user fee requirements for any marketed products and the establishments at which such products are manufactured, as well as new application fees for supplemental applications with clinical data.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">FDA regulates the content and format of prescription drug labeling, advertising, and promotion, including direct-to-consumer advertising and promotional Internet communications. FDA also establishes parameters for permissible non-promotional communications between industry and the medical community, including industry-supported scientific and educational activities. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion for uses not consistent with the approved labeling, and a company that is found to have improperly promoted off-label uses or otherwise not to have met applicable promotion rules may be subject to significant liability under both the FDCA and other statutes, including the False Claims Act. See "Other Healthcare Laws and Compliance Requirements" below for more information.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">All aspects of pharmaceutical manufacture must conform to cGMPs after approval. Drug manufacturers and certain of their subcontractors are required to register their establishments with FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA during which the FDA inspects manufacturing facilities to assess compliance with cGMPs. Changes to the manufacturing process are strictly regulated and often require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMPs and impose reporting and documentation requirements upon the sponsor and any third-party manufacturers that the sponsor may decide to use. Accordingly, manufacturers must continue to expend time, money and effort in the areas of production and quality control to maintain compliance with cGMPs.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">Products may be marketed only for the approved indications and in accordance with the provisions of the approved labeling. Changes to some of the conditions established in an approved application, including changes in indications, labeling, product formulation or manufacturing processes or facilities, require submission and FDA approval of a new BLA or BLA supplement, in some cases before the change may be implemented. A BLA supplement for a new indication typically requires clinical data similar to that in the original application, and the FDA uses the same procedures and actions in reviewing BLA supplements as it does in reviewing BLAs.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">Manufacturers are subject to requirements for adverse event reporting and submission of periodic reports following FDA approval of a BLA. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, or failure of Phase 4 studies to meet their specified endpoints, may result in revisions to the approved labeling to add new safety information, the need to conduct additional post-market studies or clinical trials to assess new safety risks,  imposition of distribution or other restrictions under a REMS program, or recall of the product and withdrawal of the BLA.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">Noncompliance with postmarket requirements can result in one or more of the following consequences:</span></div><div style="text-indent:-18pt;padding-left:58.5pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;padding-left:14.5pt;">Restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls;</span></div><div style="text-indent:-18pt;padding-left:58.5pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;padding-left:14.5pt;">Warning letters;</span></div><div style="text-indent:-18pt;padding-left:58.5pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;padding-left:14.5pt;">Holds on post-approval clinical trials;</span></div><div style="text-indent:-18pt;padding-left:58.5pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;padding-left:14.5pt;">Refusal of the FDA to approve pending BLAs or supplements to approved BLAs, or suspension or revocation of product license approvals;</span></div><div style="text-indent:-18pt;padding-left:58.5pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;padding-left:14.5pt;">Product seizure or detention, or refusal to permit the import or export of products; or</span></div><div style="text-indent:-18pt;padding-left:58.5pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;padding-left:14.5pt;">Injunctions or the imposition of civil or criminal penalties.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">In addition, the distribution of prescription pharmaceutical products is subject to the Prescription Drug Marketing Act (PDMA) which regulates the distribution of drugs and drug samples at the federal level, and sets minimum standards for the registration and regulation of drug distributors by the states. Both the PDMA and state laws limit the distribution of prescription pharmaceutical product samples and impose requirements to ensure accountability in distribution.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">15</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:115%;">Approval of Biosimilars</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">. The ACA authorized the FDA to approve biosimilars via a separate, abbreviated pathway. In many cases, this allows biosimilars to be brought to market without conducting the full suite of clinical trials typically required of originators. The law establishes a period of 12 years of exclusivity for reference products in order to preserve incentives for future innovation,  and outlines statutory criteria for science-based biosimilar approval standards that take into account patient safety considerations. Under this framework, exclusivity protects innovator products by prohibiting others, for a period of 12 years, from being granted FDA approval based in part on reliance on or reference to the innovator's data in their application to the FDA. The law does not change the duration of patents granted on biological products.  There are regular legislative proposals to rescind or reduce the biologics exclusivity provisions of the ACA and it is uncertain whether or if any of those proposals may be approved, and if approved, how exclusivity for biologics would be affected. </span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Other Healthcare Laws and Compliance Requirements</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">In the United States, our activities are potentially subject to regulation by federal, state, and local authorities in addition to the FDA, including the Centers for Medicare and Medicaid Services, other divisions of the U.S. Department of Health and Human Services (e.g., the Office of Inspector General), the U.S. Department of Justice and individual U.S. Attorney offices within the Department of Justice, and state and local governments.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">For example, certain financial interactions with healthcare professionals may be subject to the anti-kickback and fraud and abuse provisions of the Social Security Act and the False Claims Act, and in addition our activities may be affected by the privacy regulations issued under the Health Insurance Portability and Accountability Act, as amended, and similar state laws.</span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">International Regulation</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">In addition to regulations in the United States, we and our collaborators, may be subject to a variety of foreign regulations governing clinical trials, drug registration, commercial sales and distribution of our product candidates outside the United States. These regulations can vary between jurisdictions and can be more onerous than regulations in the United States. Whether or not we obtain FDA approval for a product candidate, we must obtain approval from the comparable regulatory authorities of foreign countries or economic areas, such as the European Union&#160;(EU) before we may commence clinical trials or market products in those countries or areas. The approval process and requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary greatly from place to place, and the time to approval may be longer or shorter than that required for FDA approval. </span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">Certain countries outside of the United States have a process that requires the submission of a clinical trial application (CTA) much like an IND prior to the commencement of human clinical trials. In Europe, for example, a CTA must be submitted to the competent national health authority and to independent ethics committees in each country in which a company intends to conduct clinical trials. Once the CTA is approved in accordance with a country&#8217;s requirements, clinical trial development may proceed in that country. In all cases, the clinical trials must be conducted in accordance with GCP, and other applicable regulatory requirements.  A separate CTA must be submitted for each clinical trial to be conducted.</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">In the EU, for example, to obtain regulatory approval of an investigational medicinal product, we must submit a marketing authorisation application (MAA). The content of the MAA is similar to that of a New Drug Application&#160;or BLA filed in the United States, with the exception of, among other things, EU-specific document requirements. Under the EU regulatory system, a company may submit marketing authorisation applications either under a centralised or decentralised&#160;procedure. Under the centralised procedure in the EU, a MAA is submitted to the European Medicines Agency (EMA) where it will be evaluated by the Committee for Medicinal Products for Human Use (CHMP). The maximum timeframe for a CHMP evaluation of an MAA that has been validated is 210 days, excluding time taken by an applicant to respond to questions. A favorable opinion on the application by the CHMP will typically result in the granting of the marketing authorisation by the European Commission within 67 days of receipt of the opinion. Generally, the entire review process takes approximately 13-14 months. Accelerated evaluation might be granted by the CHMP in exceptional cases, when a medicinal product is expected to be of a major public health interest, particularly from the point of view of therapeutic innovation. In this circumstance, the EMA ensures that the opinion of the CHMP is given within 150 days, excluding time taken by an applicant to respond to questions.</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">As in the United States, we or our collaborators may apply for designation of a product as an orphan drug for the treatment of a specific indication in the EU before the MAA is made. Orphan drugs in Europe enjoy certain benefits, including up to 10 years of exclusivity for the approved indication unless another applicant can show that its product is safer, more effective or otherwise clinically superior to the orphan designated product. The PRIority MEdicines (PRIME) initiative was established by the EMA to help promote and foster the development of new medicines in the EU that demonstrate potential for a major therapeutic advantage in areas of unmet medical need. Benefits from the PRIME designation include early confirmation of potential for accelerated assessment, early dialogue and increased interaction with relevant regulatory committees to discuss development options, scientific advice at key development milestones, and proactive regulatory support from the EMA.</span></div><div><span><br/></span></div><div></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">16</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:115%;">&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;"> If we, or our collaborators, fail to comply with applicable foreign regulatory requirements, we may be subject to, among other things, fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution.</span></div><div><span><br/></span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Pharmaceutical Coverage, Pricing, and Reimbursement</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">In the United States and other countries, sales of any future products for which we receive regulatory approval for commercial sale will depend in part on the availability of adequate reimbursement from third-party payors, including government health administrative authorities, managed care providers, private health insurers, and other organizations. Third-party payors are increasingly examining the medical necessity and cost effectiveness of medical products and services in addition to safety and efficacy and, accordingly, significant uncertainty exists as to the reimbursement status of newly approved therapeutics. Third-party reimbursement adequate to enable us to realize an appropriate return on our investment in research and product development may not be available for our products.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">Drug prices have become a subject of increased focus in recent years. Although there are currently no direct government price controls over private sector purchases in the U.S., federal law requires pharmaceutical manufacturers to pay prescribed rebates on certain Medicaid-reimbursed drugs to enable them to be eligible for reimbursement under certain public healthcare programs such as Medicaid and Medicare Part B. Various states have adopted further mechanisms that seek to control drug prices, including by disfavoring certain higher priced drugs or by seeking supplemental rebates from manufacturers. Managed care has also become a potent force in the market place that increases downward pressure on the prices of pharmaceutical products.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">Public and private healthcare payers control costs and influence drug pricing through a variety of mechanisms, including through negotiating discounts with the manufacturers and through the use of tiered formularies and other mechanisms that provide preferential access to certain drugs over others within a therapeutic class. Payers also set other criteria to govern the uses of a drug that will be deemed medically appropriate and therefore reimbursed or otherwise covered.</span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">Facilities</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Our headquarters building, located in Rockville, Maryland, currently houses laboratory&#160;and office space and we recently completed the build-out of a suite for manufacturing at commercial quantities and scale. This space is occupied under a lease that expires in 2027 and may be extended for up to two additional seven-year terms. We also have a smaller-scale manufacturing facility in Rockville. The lease for a portion of that facility expires in March 2023 and may be extended for a five-year term, and the lease for the remainder of that facility expires in December 2019 and may be extended for up to two additional five-year terms. Finally, we have additional laboratory and office space in Rockville under two leases that each expire in 2020, and each of those leases may be extended for a five-year term. </span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">We also lease office and laboratory space in Brisbane, California under a lease that expires in November 2023.</span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">Employees</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">As of February&#160;22, 2019, we had 364 full-time employees, 307 of whom were primarily engaged in research and development activities and 61 of whom had an M.D. or Ph.D. degree.</span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">Legal Proceedings</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">From time to time we may be involved in various disputes and litigation matters that arise in the ordinary course of business. We are not currently a party to any material legal proceedings.</span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">Available Information</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Our website address is www.macrogenics.com. We post links to our website to the following filings as soon as reasonably practicable after they are electronically filed with or furnished to the Securities and Exchange Commission&#160;(SEC): annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, proxy statements, and any amendments to those reports filed or furnished pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended. All such filings are available through our website free of charge. In addition, the SEC makes available at its website (www.sec.gov), free of charge, reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC.  </span></div><div id="i_0_78"></div><div style="text-indent:-36pt;padding-left:36pt;margin-top:3pt;margin-bottom:9pt;"></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">17</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-indent:-36pt;padding-left:36pt;margin-top:3pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">ITEM 1A.&#160;RISK FACTORS&#160;&#160;</span></div><div style="margin-top:12pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Our business, uncertainties and other factors described below could have a materially adverse effect on our business, financial condition or results of operations and could cause the trading price of our common stock to decline substantially.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">Risks Related to Our Business and the Development and Commercialization of Our Product Candidates.</span></div><div style="margin-top:6pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">All of our product candidates are in preclinical or clinical development. Clinical drug development is expensive, time consuming and uncertain and we may ultimately not be able to obtain regulatory approvals for the commercialization of some or all of our product candidates.</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">The research, testing, manufacturing, labeling, approval, selling, marketing and distribution of drug products are subject to extensive regulation by the U.S. Food and Drug Administration (FDA) and non-U.S. regulatory authorities, which regulations differ from country to country. We are not permitted to market our product candidates in the United States or in other countries until we receive approval of a Biologics License Application (BLA) from the FDA or marketing approval from applicable regulatory authorities outside the United States. Our product candidates are in various stages of development and are subject to the risks of failure inherent in drug development. Based on our recently announced positive top-line results for the first primary endpoint of our SOPHIA study, we intend to submit a BLA for the approval of margetuximab in the second half of 2019. Obtaining approval of a BLA can be a lengthy, expensive and uncertain process, and as a company we have no experience with the preparation of a BLA submission or any other application for marketing approval. In addition, failure to comply with FDA and non-U.S. regulatory requirements may, either before or after product approval, if any, subject our company to administrative or judicially imposed sanctions, including:</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">restrictions on our ability to conduct clinical trials, including full or partial clinical holds on ongoing or planned trials;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">restrictions </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">on the products, manufacturers, manufacturing facilities or manufacturing process; </span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">warning letters; </span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">civil</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> and criminal penalties; </span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">injunctions; </span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">suspension</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> or withdrawal of regulatory approvals; </span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">product se</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">izures, detentions or import bans; </span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">volunt</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">ary or mandatory product recalls and publicity requirements; </span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">total or partial suspension</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> of production; </span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">imposition</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> of restrictions on operations, including costly new manufacturing requirements; and </span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">refusal to approve pending BLAs or supplements to </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">approved BLAs or analogous marketing approvals outside the United States. </span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">The FDA and foreign regulatory authorities also have substantial discretion in the drug approval process. The number of preclinical studies and clinical trials that will be required for regulatory approval varies depending on the product candidate, the disease or condition that the product candidate is designed to address, and the regulations applicable to any particular drug candidate. Regulatory agencies can delay, limit or deny approval of a product candidate for many reasons, including:</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">a product candidate may not be deemed safe or effective; </span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">the results may not c</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">onfirm the positive results from earlier preclinical studies or clinical trials; </span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">regulatory agencies may not find the </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">data from preclinical studies and clinical trials sufficient; </span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">regulatory agencies might not approve or might require changes to our manufacturing processes or facilities; or </span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">regulatory agencies may change their approval policies or adopt new re</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">gulations. </span></div><div></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">18</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">Any delay in obtaining or failure to obtain required approvals could materially adversely affect our ability to generate revenue from the particular product candidate, which likely would result in significant harm to our financial position and adversely impact our stock price. Furthermore, any regulatory approval to market a product may be subject to limitations on the indicated uses for which we may market the product. These limitations may limit the size </span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If clinical trials for our product candidates are prolonged, delayed or stopped, we may be unable to obtain regulatory approval and commercialize our product candidates on a timely basis, which would require us to incur additional costs and delay our receipt of any product revenue.</span></div><div style="margin-top:6pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">We are currently enrolling patients in clinical trials for margetuximab, enoblituzumab, flotetuzumab, MGD009, MGC018, MGA012, MGD013, MGD019, MGD007 and MGD014 and anticipate initiating or continuing clinical trials for these product candidates as monotherapies or in combination with other product candidates in 2019. In addition, our collaborators are currently enrolling patients in clinical trials for MGA012, which is being developed by Incyte Corporation. The commencement of new clinical trials could be substantially delayed or prevented by several factors, including:</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">further discussions wi</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">th the FDA or other regulatory agencies regarding the scope or design of our clinical trials; </span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">the l</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">imited number of, and competition for, suitable sites to conduct our clinical trials, many of which may already be engaged in other clinical trial programs, including some that may be for the same indication as our product candidates; </span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">any</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> delay or failure to obtain regulatory approval or agreement to commence a clinical trial in any of the countries where enrollment is planned; </span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">inability to ob</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">tain sufficient funds required for a clinical trial; </span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">clinical hold</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">s on, or other regulatory objections to, a new or ongoing clinical trial; </span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">delay or </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">failure to manufacture sufficient supplies of the product candidate for our clinical trials; </span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">delay or failure to reach agreement on acceptable clin</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">ical trial terms or clinical trial protocols with prospective sites or clinical research organizations&#160;(CROs) the terms of which can be subject to extensive negotiation and may vary significantly among different sites or CROs; and </span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">de</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">lay or failure to obtain institutional review board (IRB) approval to conduct a clinical trial at a prospective site.</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">The completion of our clinical trials could also be substantially delayed or prevented by several factors, including:</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">slower than expected rates of patient recruitment and enrollment;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">failure of patients to complete the clinical trial;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">unforeseen safety issues, including severe or unexpected drug-related adverse effects experienced by patients,</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">including possible deaths;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">lack of efficacy during clinical trials;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">termination of our clinical trials by one or more clinical trial sites;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">inability or unwillingness of patients or clinical investigators to follow our clinical trial protocols;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">inability to monitor patients adequately during or after treatment by us and/or our CROs; and</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">the need to repeat or terminate clinical trials as a result of inconclusive or negative results or unforeseen complications in testing.</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">Changes in regulatory requirements and guidance may also occur and we may need to significantly amend clinical trial protocols to reflect these changes with appropriate regulatory authorities. Amendments may require us to renegotiate terms with CROs or resubmit clinical trial protocols to IRBs for re-examination, which may impact the costs, timing or successful completion of a clinical trial. Our clinical trials may be suspended or terminated at any time by the FDA, other regulatory authorities, the IRB overseeing the clinical trial at issue, any of our clinical trial sites with respect to that site, or us, due to a number of factors, including:</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">19</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:3pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:3pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">unforeseen safety issues or any determination that a clinical trial presents unacceptable health risks;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:3pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">lack of adequate funding to continue the clinical trial due to unforeseen costs or other business decisions; and</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:3pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">upon a breach or pursuant to the terms of any agreement with, or for any other reason by, current or future collaborators that have responsibility for the clinical development of any of our product candidates.</span></div><div style="padding-left:13.5pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">For example, in December 2018, the FDA imposed a partial clinical hold on our Phase 1 monotherapy study of MGD009, as well as on a combination study of MGD009 and MGA012.  The partial clinical hold was initiated following our reporting to the FDA of hepatic adverse events on the MGD009 monotherapy trial.  Although these events had been otherwise uncomplicated and short-lived in duration, we communicated to the FDA our plans to amend the then existing  MGD009 studies with additional supportive care to mitigate these events.  The FDA placed the trials on partial clinical hold, pending review of additional details regarding such events and satisfactory review of the then planned amendments to the study protocols and related documents. &#160;Under the partial clinical hold, which was lifted in January 2019, no new patients were permitted to be enrolled in either study, although then-current study participants were permitted to continue to receive drug at their pre-assigned dose. Any failure or significant delay in completing clinical trials for our product candidates would adversely affect our ability to obtain regulatory approval and our commercial prospects and ability to generate product revenue will be diminished.</span></div><div style="margin-top:6pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">The results of previous clinical trials may not be predictive of future results, and interim or top line data may be subject to change or qualification based the complete analysis of data. In addition, the results of our current and planned clinical trials may not satisfy the requirements of the FDA or non-U.S. regulatory authorities.</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">Clinical failure can occur at any stage of clinical development. Clinical trials may produce negative or inconclusive results, and we or any of our current and future collaborators may decide, or regulators may require us, to conduct additional clinical or preclinical testing. Success in early clinical trials does not mean that future larger registration clinical trials will be successful because product candidates in later-stage clinical trials may fail to demonstrate sufficient safety and efficacy to the satisfaction of the FDA and non-U.S. regulatory authorities despite having progressed through initial clinical trials. A number of companies in the pharmaceutical industry, including those with greater resources and experience than us, have suffered significant setbacks in advanced clinical trials, even after obtaining promising results in earlier clinical trials.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">We may publicly disclose topline or interim data from time to time, which is based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study or trial. For example, we recently announced top line data for the SOPHIA trial of margetuximab for the treatment of certain metastatic breast cancer patients. We make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the topline results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Top line data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. In addition, the achievement of one primary endpoint for a trial does not guarantee that additional co-primary endpoints or secondary endpoints will be achieved. For example, the achievement by margetuximab of its first sequential endpoint for progression-free survival events in the SOPHIA trial does not indicate whether the second sequential endpoint of overall survival will be achieved.&#160;We currently expect to receive final overall survival results in 2020.  Failure to meet the second sequential endpoint of overall survival in the SOPHIA trial may have an adverse effect on our ability to obtain or retain regulatory approval of margetuximab in the U.S. or in other jurisdictions. </span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">Further, our product candidates may not be approved even if they achieve their primary endpoints in Phase 3 clinical trials or registration trials. For example, we recently announced top line data for the SOPHIA trial in which margetuximab achieved its first primary endpoint. The FDA or other non-U.S. regulatory authorities may disagree with our trial design for SOPHIA or other trials, and our interpretation of data from preclinical studies and clinical trials. In particular, the FDA may not view our data as being clinically meaningful or statistically persuasive. In addition, any of these regulatory authorities may change requirements for the approval of a product candidate even after reviewing and providing comments or advice on a protocol for a pivotal Phase 3 clinical trial. Any of these regulatory authorities may also approve a product candidate for fewer or more limited indications than we request or may grant approval contingent on the performance of costly post-marketing clinical trials. The FDA or other non-U.S. regulatory authorities may not approve the labeling claims that we believe would be necessary or desirable for the successful commercialization of our product candidates. </span></div><div style="margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We use new technologies in the development of our product candidates and the FDA and other regulatory authorities have not approved products that utilize these technologies.</span></div><div style="text-indent:36pt;"></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">20</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">Our products in development are based on new technologies, such as Fc Optimization, DART molecules and TRIDENT molecules. Given the novelty of our technologies, we intend to work closely with the FDA and other regulatory authorities to perform the requisite scientific analyses and evaluation of our methods to obtain regulatory approval for our product candidates. The validation process takes time and resources, may require independent third-party analyses, and may not be accepted by the FDA and other regulatory authorities. For some of our product candidates that are based on these technology platforms, the regulatory approval path and requirements may not be clear or evolve as more data becomes available for this product candidates, which could add significant delay and expense. Delays or failure to obtain regulatory approval of any of the product candidates that we develop would adversely affect our business.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="margin-top:6pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We may not be successful in our efforts to use and expand our technology platforms to build a pipeline of product candidates. We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">A key element of our strategy is to use and expand our technology platforms to build a pipeline of product candidates and progress these product candidates through clinical development for the treatment of a variety of different types of diseases. Although our research and development efforts to date have resulted in a pipeline of product candidates directed at various cancers, as well as autoimmune disorders and infectious diseases, we may not be able to develop product candidates that are safe and effective. Even if we are successful in continuing to build our pipeline, the potential product candidates that we identify may not be suitable for clinical development, including as a result of being shown to have harmful side effects or other characteristics that indicate that they are unlikely to be products that will receive marketing approval and achieve market acceptance. If we do not continue to successfully develop and begin to commercialize product candidates, we will face difficulty in obtaining product revenues in future periods, which could result in significant harm to our financial position and adversely affect our stock price.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">Because we have limited financial and managerial resources, we focus on research programs and product candidates that we identify for specific indications. As a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Even if we obtain FDA approval of any of our product candidates, we may never obtain approval or commercialize our products outside of the United States, which would limit our ability to realize their full market potential.</span></div><div style="margin-top:6pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">In order to market any products outside of the United States, we must establish and comply with numerous and varying regulatory requirements of other countries regarding safety and efficacy. Clinical trials conducted in one country may not be accepted by regulatory authorities in other countries, and regulatory approval in one country does not mean that regulatory approval will be obtained in any other country. Approval procedures vary among countries and may require additional preclinical studies or clinical trials or additional administrative review periods, which could result in significant delays, difficulties and costs for us. In addition, our failure to obtain regulatory approval in any country may delay or have negative effects on the process for regulatory approval in other countries. We do not have any product candidates approved for sale in any jurisdiction, including international markets, and we do not have experience in obtaining regulatory approval in international markets. If we fail to comply with regulatory requirements in international markets or to obtain and maintain required approvals, our target market will be reduced and our ability to realize the full market potential of our products will be harmed.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:1pt;line-height:120%;">&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our product candidates may have undesirable side effects which may delay or prevent further clinical development or marketing approval, or, if approval is received, require them to be taken off the market, require them to include safety warnings or otherwise limit their sales.</span></div><div style="margin-top:6pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">Although all of our product candidates have undergone or will undergo safety testing, not all adverse effects of drugs can be predicted or anticipated. Unforeseen side effects from any of our product candidates could arise either during clinical development or, if approved by regulatory authorities, after the approved product has been marketed. All of our product candidates are still in clinical or preclinical development. Ongoing or future trials of our product candidates may not support the conclusion that one or more of these product candidates have acceptable safety profiles. The results of future clinical or preclinical trials may show that our product candidates cause undesirable or unacceptable side effects, which could interrupt, delay or halt clinical trials, and result in delay of, or failure to obtain, marketing approval from the FDA and other regulatory</span></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">21</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;"> authorities, or result in marketing approval from the FDA and other regulatory authorities with restrictive label warnings or potential product liability claims.</span></div><div style="margin-top:6pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">If any of our product candidates receives marketing approval and we or others later identify undesirable or unacceptable side effects caused by such products::</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:9pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">regulatory authorities may require us to take our approved product off the market;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">regulatory authorities may require the addition of labeling statements, specific warnings, a contraindication or field alerts to physicians and pharmacies;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">we may be required to change the way the product is administered, impose other risk-management measures, conduct additional clinical trials or change the labeling of the product;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">we may be subject to limitations on how we may promote the product;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">sales of the product may decrease significantly;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">we may be subject to litigation or product liability claims; and</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">our reputation may suffer.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">Any of these events could prevent us, our collaborators or our potential future partners from achieving or maintaining market acceptance of the affected product or could substantially increase commercialization costs and expenses, which in turn could delay or prevent us from generating significant revenue from the sale of our products..</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Even if approved, if any of our product candidates do not achieve broad market acceptance among physicians, patients, the medical community, and third-party payors our revenue generated from their sales will be limited.</span></div><div style="text-indent:36pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The commercial success of our product candidates will depend upon their acceptance among physicians, patients and the medical community. The degree of market acceptance of our product candidates will depend on a number of factors, including:</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">limitations or warnings contained in the approved labeling for a product candidate;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">changes in the standard of care for the targeted indications for any of our product candidates;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">limitations in the approved clinical indications for our product candidates;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">demonstrated clinical safety and efficacy compared to other products;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">lack of significant adverse side effects;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">sales, marketing and distribution support;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">availability and extent of reimbursement from managed care plans and other third-party payors;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">timing of market introduction and perceived effectiveness of competitive products;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">the degree of cost-effectiveness of our product candidates;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">availability of alternative therapies at similar or lower cost, including generic and over-the-counter products;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">the extent to which the product candidate is approved for inclusion on formularies of hospitals and managed care organizations;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">whether the product is designated under physician treatment guidelines as a first-line therapy or as a second- or third-line therapy for particular diseases;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">adverse publicity about our product candidates or favorable publicity about competitive products;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">convenience and ease of administration of our products; and</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">potential product liability claims.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">If any of our product candidates are approved, but do not achieve an adequate level of acceptance by physicians, patients and the medical community, we may not generate sufficient revenue from these products, and we may not become or remain profitable. In addition, efforts to educate the medical community and third-party payors on the benefits of our product candidates may require significant resources and may never be successful.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">The manufacture of our product candidates is complex, and we may encounter difficulties in production.&#160; If we encounter any such difficulties, our ability to supply our product candidates for clinical trials or, if approved, for commercial sale could be delayed or halted entirely.</span></div><div style="margin-top:6pt;"><span><br/></span></div><div style="text-indent:36pt;"></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">22</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">The process of manufacturing our product candidates is extremely susceptible to product loss due to a variety of factors, including but not limited to contamination, equipment failure or improper installation or operation of equipment, vendor or operator error, contamination and inconsistency in yields, variability in product characteristics, and difficulties in scaling the production process. Even minor deviations from manufacturing processes could result in reduced production yields, product defects and other supply disruptions. If microbial, viral or other contaminations are discovered in our product candidates or in the manufacturing facilities in which our product candidates are made, such manufacturing facilities may need to be closed for an extended period of time to investigate and remedy the contamination. Any adverse developments affecting manufacturing operations for our product candidates, if any are approved, may result in shipment delays, inventory shortages, lot failures, product withdrawals or recalls, or other interruptions in the supply of our products. We may also have to take inventory write-offs and incur other charges and expenses for products that fail to meet specifications, undertake costly remediation efforts or seek more costly manufacturing alternatives.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">We have limited experience in large-scale or commercial manufacturing, and there can be no assurance that we will be able to effectively manufacture clinical or commercial quantities of our products.</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">In 2018, we completed the build-out of our commercial-scale current Good Manufacturing Practice (cGMP) manufacturing facility, which is intended to support future clinical and, if any are approved by the FDA, commercial production of our and our collaborators&#8217; product candidates. Although some of our employees have experience in the manufacturing of pharmaceutical products from prior employment at other companies, we as a company do not have experience in large-scale or commercial manufacturing. Designing and building a manufacturing facility is time-consuming, expensive, and we may not realize the benefit of this investment. As a manufacturer of pharmaceutical products, we are required to demonstrate and maintain compliance with cGMPs which include requirements related to production processes, quality control and assurance and recordkeeping. Furthermore, establishing and maintaining manufacturing operations requires a reallocation of other resources, particularly the time and attention of certain of our senior management. Any failure or delay in our manufacturing capabilities could adversely impact the clinical development or commercialization of our or our collaborators&#8217; product candidates.</span></div><div style="margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our manufacturing facilities are subject to significant government regulations and approvals, which are often costly and could result in adverse consequences to our business if we fail to comply with the regulations or maintain the approvals.</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">We must comply with the FDA&#8217;s cGMP requirements, as set out in statute, regulations and guidance. We may encounter difficulties in achieving quality control and quality assurance and may experience shortages in qualified personnel. We are subject to inspections by the FDA and comparable agencies in other jurisdictions to confirm compliance with applicable regulatory requirements. See &#8220;Other U.S. Post-Marketing Regulatory Requirements&#8221; above for additional information. Any failure to follow cGMP or other regulatory requirements or delay, interruption or other issues that arise in the manufacture, fill-finish, packaging, or storage of our product candidates as a result of a failure of our facilities or the facilities or operations of third parties to comply with regulatory requirements or pass any regulatory authority inspection could significantly impair our ability to develop and commercialize our product candidates, including leading to significant delays in the availability of drug product for our clinical trials or the termination or hold on a clinical trial, or the delay or prevention of a filing or approval of marketing applications for our product candidates. Significant noncompliance could also result in the imposition of sanctions, including fines, injunctions, civil penalties, failure of regulatory authorities to grant marketing approvals for our product candidates, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of products, operating restrictions and criminal prosecutions, any of which could damage our reputation. If we are not able to maintain regulatory compliance, we may not be permitted to market our product candidates and/or may be subject to product recalls, seizures, injunctions, or criminal prosecution.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We currently have no marketing, sales or distribution infrastructure. If we are unable to develop sales, marketing and distribution capabilities on our own or through collaborations, we will not be successful in commercializing margetuximab, if approved, or our product candidates.</span></div><div style="margin-top:6pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">We currently have no marketing, sales and distribution infrastructure and we have limited sales and marketing experience within our organization. If margetuximab or any of our other product candidates are approved, we intend to establish a sales and marketing organization with technical expertise and supporting distribution capabilities to commercialize our product candidates in the United States and, potentially, to outsource this function to a third party outside of the United States. Both of these options would be expensive and time consuming, and would require a significant allocation of resources, including the time and attention of our management. In addition, we would need to devote resources to the development and maintenance of policies to ensure compliance with various health care laws related to sales and marketing of pharmaceutical products. These costs may be incurred in advance of any approval of our product candidates. In addition, we may not be able to engage a sales force in the United States that is sufficient in size or has adequate expertise in the medical markets that we intend to target. Any failure or delay in the development of our internal sales, marketing and distribution capabilities would adversely impact the commercialization of our products.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">23</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">With respect to certain of our existing and future product candidates, we have entered into collaboration or other licensing arrangements with third party collaborators that have direct sales forces and established distribution systems. To the extent that we enter into additional collaboration agreements, our product revenue may be lower than if we directly marketed or sold any approved products. In addition, any revenue we receive will depend in whole or in part upon the efforts of these third party collaborators, which may not be successful and are generally not within our control. If we are unable to enter into additional arrangements on acceptable terms or at all, we may not be able to successfully commercialize certain approved products. If we are not successful in commercializing approved products, either on our own or through collaborations with one or more third parties, our future product revenue will suffer and we may incur significant additional losses.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We face significant competition and if our competitors develop and market products that are more effective, safer or less expensive than our product candidates, our commercial opportunities will be negatively impacted.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">The life sciences industry is highly competitive and subject to rapid and significant technological change. We are currently developing therapeutics that will compete with other drugs and therapies that currently exist or are being developed. Products we may develop in the future are also likely to face competition from other drugs and therapies, some of which we may not currently be aware. We have competitors both in the United States and internationally, including major multinational pharmaceutical companies, established biotechnology companies, specialty pharmaceutical companies, universities and other research institutions. Many of our competitors have significantly greater financial, manufacturing, marketing, drug development, technical and human resources than we do. Large pharmaceutical companies, in particular, have extensive experience in clinical testing, obtaining regulatory approvals, recruiting patients and manufacturing pharmaceutical products. These companies also have significantly greater research and marketing capabilities than we do and may also have products that have been approved or are in late stages of development, and collaborative arrangements in our target markets with leading companies and research institutions. Established pharmaceutical companies may also invest heavily to accelerate discovery and development of novel compounds or to in-license novel compounds that could make the product candidates that we develop obsolete. As a result of all of these factors, our competitors may succeed in obtaining patent protection and/or FDA approval or discovering, developing and commercializing products in our field before we do.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">Specifically, there are a large number of companies developing or marketing treatments for cancer, including many major pharmaceutical and biotechnology companies. These treatments consist both of small molecule drug products, as well as biologic therapeutics that work by using next-generation antibody technology platforms to address specific cancer targets. In addition, several companies are developing therapeutics that work by targeting multiple specificities using a single recombinant molecule. See &#8220;Competition&#8221; above for additional information.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe effects, are more convenient or are less expensive than any products that we may develop. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. In addition, our ability to compete may be affected in many cases by insurers or other third party payors seeking to encourage the use of biosimilar products. Biosimilar products are expected to become available over the coming years. For example, certain HER2 biosimilar products are approved in certain countries and others may be approved prior to margetuximab. Even if our product candidates achieve marketing approval, they may be priced at a significant premium over competitive biosimilar products if any have been approved by then.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">Smaller and other early stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These third parties compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. In addition, the biopharmaceutical industry is characterized by rapid technological change. If we fail to stay at the forefront of technological change, we may be unable to compete effectively. Technological advances or products developed by our competitors may render our technologies or product candidates obsolete, less competitive or not economical.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Reimbursement decisions by third-party payors may have an adverse effect on pricing and market acceptance. If there is not sufficient reimbursement for our products, it is less likely that our products will be widely used.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Even if our product candidates are approved for sale by the appropriate regulatory authorities, market acceptance and sales of these products will depend on reimbursement policies and may be affected by future healthcare reform measures. Government authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which drugs they will reimburse and establish payment levels and, in some cases, utilization management strategies, such as tiered formularies and prior authorization. We cannot be certain that reimbursement will be available for any products that we develop or that the reimbursement level will be adequate to allow us to operate profitably. Also, we cannot be certain that reimbursement policies will not reduce the demand for, or the price paid for, our products. Our ability to commercialize our</span></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">24</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> products may depend, in part, on the extent to which reimbursement for the products will be available from government authorities and third-party payors. If reimbursement for our products is not available or is available on a limited basis, or if the reimbursement amount for our products is inadequate, we may not be able to successfully commercialize any of our approved products.</span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Actual or anticipated changes to the laws and regulations governing the health care system may have a negative impact on cost and access to health insurance coverage and reimbursement of healthcare items and services. </span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">The United States and several foreign jurisdictions are considering, or have already enacted, a number of legislative and regulatory proposals to change the healthcare system in ways that could affect our ability to sell any of our future approved products profitably. Among policy makers and payors in the United States and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and/or expanding access to healthcare. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives, including the Patient Protection and Affordable Care Act (ACA), which became law in 2010. While it is difficult to assess the impact of the ACA in isolation, either in general or on our business specifically, it is widely thought that the ACA increases downward pressure on pharmaceutical reimbursement, which could negatively affect market acceptance of, and the price we may charge for, any products we develop that receive regulatory approval. Further, the United State and foreign governments regularly consider reform measures that affect healthcare coverage and costs. Such reforms may include changes to the coverage and reimbursement of healthcare services and products. In particular, there have been recent judicial and Congressional challenges to the ACA, which could have an impact on coverage and reimbursement for healthcare services covered by plans authorized by the ACA, and we expect there will be additional challenges and amendments to the ACA in the future.</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">In September 2017, members of the United States Congress introduced legislation with the announced intention to repeal major provisions of the ACA. Although it is unclear whether such legislation will ultimately become law, executive or legislative branch attempts to repeal, reform or to repeal and replace the ACA will likely continue. In addition, various other healthcare reform proposals have also emerged at the federal and state level. In addition, recent changes to United States tax laws could negatively impact the ACA. We cannot predict what healthcare initiatives, if any, will be implemented at the federal or state level, however, government and other regulatory oversight and future regulatory and government interference with the healthcare systems could adversely impact our business and results of operations.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">We expect to experience pricing pressures in connection with the sale of any products that we develop, due to the trend toward managed healthcare, the increasing influence of health maintenance organizations and additional legislative proposals.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Inadequate funding for the FDA, the Securities and Exchange Commission (SEC) and other government agencies could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business.</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of the SEC and other government agencies on which our operations may rely, including those that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable.</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA and the SEC, have had to furlough critical FDA, SEC and other government employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, future government shutdowns could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations.</span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If any product liability lawsuits are successfully brought against us or any of our collaborators, we may incur substantial liabilities and may be required to limit commercialization of our product candidates.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">We face an inherent risk of product liability lawsuits related to the testing of our product candidates in seriously ill patients, and will face an even greater risk if product candidates are approved by regulatory authorities and introduced commercially. Product liability claims may be brought against us or our collaborators by participants enrolled in our clinical trials, patients, health care providers or others using, administering or selling any of our future approved products. If we cannot</span></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">25</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;"> successfully defend ourselves against any such claims, we may incur substantial liabilities. Regardless of their merit or eventual outcome, liability claims may result in:</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:9pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">decreased demand for our future approved products;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:3pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">injury to our reputation;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:3pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">withdrawal of clinical trial participants;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:3pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">termination of clinical trial sites or entire trial programs;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:3pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">increased regulatory scrutiny;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:3pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">significant litigation costs;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:3pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">substantial monetary awards to or costly settlement with patients or other claimants;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:3pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">product recalls or a change in the indications for which they may be used;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:3pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">loss of revenue;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:3pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">diversion of management and scientific resources from our business operations; and</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:3pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">the inability to commercialize our product candidates.</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">If any of our product candidates are approved for commercial sale, we will be highly dependent upon consumer perceptions of us and the safety and quality of our products. We could be adversely affected if we are subject to negative publicity. We could also be adversely affected if any of our products or any similar products distributed by other companies prove to be, or are asserted to be, harmful to patients. Because of our dependence upon consumer perceptions, any adverse publicity associated with illness or other adverse effects resulting from patients&#8217; use or misuse of our products or any similar products distributed by other companies could have a material adverse impact on our financial condition or results of operations.</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">We currently hold $20 million in product liability insurance coverage in the aggregate, with a per incident limit of $20 million, which may not be adequate to cover all liabilities that we may incur. We may need to increase our insurance coverage when we begin the commercialization of our product candidates. Insurance coverage is becoming increasingly expensive. As a result, we may be unable to maintain or obtain sufficient insurance at a reasonable cost to protect us against losses that could have a material adverse effect on our business. A successful product liability claim or series of claims brought against us, particularly if judgments exceed any insurance coverage we may have, could decrease our cash resources and adversely affect our business, financial condition and results of operation.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">The contract with the National Institute of Allergy and Infectious Diseases (NIAID)&#160;makes us a government contractor. Laws and regulations affecting government contracts&#160;may&#160;make it more costly and difficult for us to successfully conduct our business.&#160;</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">We must comply with numerous laws and regulations relating to the procurement, formation, administration and performance of government contracts. Failure to comply with these laws could result in significant civil and criminal penalties. Among the most significant government contracting regulations that may affect our business are: the Federal Acquisition Regulation&#160;(FAR) and NIH-NIAID-specific regulations supplemental to the FAR, which comprehensively regulate the procurement, formation, administration and performance of government contracts; business ethics and public integrity obligations, which govern conflicts of interest and the hiring of former government employees, restrict the granting of gratuities and funding of lobbying activities and incorporate other requirements such as the Anti-Kickback Act, the Procurement Integrity Act, and the False Claims Act; export and import control laws and regulations; and laws, regulations and executive orders restricting the use and dissemination of sensitive information we may receive pursuant to our performance of the government contract. U.S. government agencies routinely audit and investigate government contractors for compliance with applicable laws and standards. If we are audited, such audit could result in disallowance of expected cost reimbursement, or if such audit were to uncover improper or illegal activities, we could be subject to civil and criminal penalties, administrative sanctions, including suspension or debarment from government contracting and significant reputational harm.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Comprehensive tax reform legislation could adversely affect our business and financial condition.</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">On December 22, 2017, Public Law no. 115-97&#160;(the Tax Act) was signed into law. The Tax Act introduced significant changes to the Internal Revenue Code of 1986, as amended.&#160;The Tax Act, among other things, contains significant changes to corporate taxation, including reduction of the corporate tax rate from a top marginal rate of 35% to a flat rate of 21%, limitation of the tax deduction for interest expense to 30% of adjusted earnings (except for certain small businesses), limitation of the deduction for net operating losses to 80% of current year taxable income in respect of losses arising in taxable years beginning</span></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">26</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;"> after 2017 and elimination of net operating loss carrybacks, one time taxation of offshore earnings at reduced rates regardless of whether they are repatriated, immediate deductions for certain new investments instead of deductions for depreciation expense over time, and modifying or repealing many business deductions and credits.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">Risks Related to Our Financial Position and Need for Additional Capital</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We have incurred significant losses since inception and anticipate that we will continue to incur losses for the foreseeable future. We have no products approved for commercial sale, and to date we have not generated any revenue or profit from product sales. We may never achieve or sustain profitability.</span></div><div style="text-indent:36pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">We are a clinical-stage biopharmaceutical company. We have incurred significant losses since our inception. As of December&#160;31, 2018, our accumulated deficit was approximately $490.3 million. We expect to continue to incur losses for the foreseeable future, and we expect these losses to increase as we continue our research and development of, and seek regulatory approvals for, our product candidates, prepare for and begin to commercialize any approved products, and add infrastructure and personnel to support our product development efforts and operations as a public company. The net losses and negative cash flows incurred to date, together with expected future losses, have had, and likely will continue to have, an adverse effect on our stockholders' deficit and working capital. The amount of future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenue.</span></div><div style="text-indent:36pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Because of the numerous risks and uncertainties associated with pharmaceutical product development and commercialization, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to achieve profitability. For example, our expenses could increase if we are required by the FDA to perform trials in addition to those that we currently expect to perform, or if there are any delays in completing our currently planned clinical trials or in the development of any of our product candidates. Our expenses would significantly increase to the extent we build out a sales&#160;force and other commercially relevant functions to support the commercialization of margetuximab, if approved, or any of our other product candidates.  </span></div><div style="text-indent:36pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">To become and remain profitable, we must succeed in developing and commercializing products with significant market potential. This will require us to be successful in a range of challenging activities for which we are only in the preliminary stages, including developing product candidates, obtaining regulatory approval for them, and manufacturing, marketing and selling those products for which we may obtain regulatory approval. We may never succeed in these activities and may never generate revenue from product sales that is significant enough to achieve profitability. Even if we achieve profitability in the future, we may not be able to sustain profitability in subsequent periods. Our failure to become or remain profitable would depress our market value and could impair our ability to raise capital, expand our business, develop other product candidates, or continue our operations. A decline in the value of our company could also cause you to lose all or part of your investment.</span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We will require substantial additional funding, which may not be available to us on acceptable terms, or at all, and, if not available, may require us to delay, scale back, or cease our product development programs or operations.</span></div><div style="text-indent:36pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">We are advancing our product candidates through clinical development. Developing and commercializing pharmaceutical products, including conducting preclinical studies and clinical trials, is expensive. In order to obtain such regulatory approval, we will be required to conduct clinical trials for each indication for each of our product candidates. We will continue to require additional funding beyond what was raised in our public offerings and through our collaborations and license agreements to complete the development and commercialization of our product candidates and to continue to advance the development of our other product candidates, and such funding may not be available on acceptable terms or at all. Although it is difficult to predict our funding requirements, based upon our current operating plan, we anticipate that our cash, cash equivalents and marketable securities as of December&#160;31, 2018, combined with the net proceeds from our February 2019 offering of common stock and proceeds from collaboration payments we anticipate receiving, will enable us to fund our operations&#160;into 2021, assuming all of our programs and collaborations advance as currently contemplated. Because successful development of our product candidates is uncertain, we are unable to estimate the actual funds we will require to complete research and development and to commercialize our product candidates.</span></div><div style="text-indent:36pt;margin-top:9pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Our future funding requirements will depend on many factors, including but not limited to:</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">the number and characteristics of other product candidates and indications that we pursue;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">the scope, progress, timing, cost and results of research, preclinical development, and clinical trials;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">the costs, timing and outcome of seeking and obtaining FDA and non-U.S. regulatory approvals;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">the costs associated with manufacturing our product candidates</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">;</span></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">27</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">the costs</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> of&#160;establishing sales, marketing, and distribution&#160;capabilities;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">our ability to maintain, expand, and defend the scope of our intellectual property portfolio, including the amount and timing of any payments we may be required to make in connection with the licensing, filing, defense and enforcement of any patents or other intellectual property rights;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">our need and ability to hire additional management, scientific, and medical personnel;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">the effect of competing products that may limit market penetration of our product candidates;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">our need to implement additional internal systems and infrastructure, including financial and reporting systems; and</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">the economic and other terms, timing of and success of our existing collaborations, and any collaboration, licensing, or other arrangements into which we may enter in the future, including the timing of receipt of any milestone or royalty payments under these agreements.</span></div><div style="text-indent:36pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Until we can generate a sufficient amount of product revenue to finance our cash requirements, which we may never do, we expect to finance future cash needs primarily through a combination of public or private equity offerings, debt financings, strategic collaborations, and grant funding. If sufficient funds on acceptable terms are not available when needed, or at all, we could be forced to significantly reduce operating expenses and delay, scale back or eliminate one or more of our development programs or our business operations.</span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish substantial rights.</span></div><div style="text-indent:36pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms of these new securities may include liquidation or other preferences that adversely affect your rights as a common stockholder. Debt financing, if available at all, may involve agreements that include covenants limiting or restricting our ability to take specific actions such as incurring additional debt, making capital expenditures, or declaring dividends. If we raise additional funds through collaborations, strategic alliances, or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, product candidates, or future revenue streams, or grant licenses on terms that are not favorable to us. We cannot assure you that we will be able to obtain additional funding if and when necessary. If we are unable to obtain adequate financing on a timely basis, we could be required to delay, scale back or eliminate one or more of our development programs or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our ability to use our net operating loss carryforwards and other tax attributes may be limited.</span></div><div style="text-indent:36pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Our ability to utilize our federal net operating losses, (NOLs) and federal tax credits is currently limited, and may be limited further, under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended. The limitations apply if an ownership change, as defined by Section&#160;382, occurs. Generally, an ownership change occurs when certain shareholders increase their aggregate ownership by more than 50 percentage points over their lowest ownership percentage in a testing period, which is typically three years or since the last ownership change. We are already subject to Section&#160;382 limitations due to acquisitions we made in 2002 and 2008.&#160; As of December&#160;31, 2018, we had federal and state NOL carryforwards of $415.6 million and research and development tax credit carryforwards of $52.3 million available. Future changes in stock ownership may also trigger an ownership change and, consequently, another Section&#160;382 limitation. Any limitation may result in expiration of a portion of the net operating loss or tax credit carryforwards before utilization which would reduce our gross deferred income tax assets and corresponding valuation allowance. As a result, if we earn net taxable income, our ability to use our pre-change NOL carryforwards and tax credit carryforwards to reduce United States federal income tax may be subject to limitations, which could potentially result in increased future cash tax liability to us. </span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">Risks Related to Our Dependence on Third Parties</span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our existing therapeutic collaborations are important to our business, and future collaborations may also be important to us. If we are unable to maintain any of these collaborations, or if these collaborations are not successful, our business could be adversely affected.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">We have limited capabilities for drug development and do not yet have any capability for sales, marketing or distribution. We have entered into collaborations with other companies that we believe can provide such capabilities, including our collaboration and license agreements with, for example, Les Laboratoires Servier and Institut de Recherches Servier (collectively, Servier), Green Cross Corporation (GC Pharma), Incyte Corporation, Zai Lab Limited and F. Hoffman La Roche</span></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">28</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;"> Ltd and Hoffman-La Roche, Inc (Roche). These collaborations also have provided us with important funding for our development programs and technology platforms and we expect to receive additional funding under these collaborations in the future. Our existing therapeutic collaborations, and any future collaborations we enter into, may pose a number of risks, including the following:</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">collaborators have significant discretion in determining the efforts and resources that they will apply to these collaborations;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">collaborators may not perform their obligations as expected;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">collaborators may not pursue development and commercialization of any product candidates that achieve regulatory approval</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> or may elect not to continue or renew development or commercialization programs based on clinical trial results, changes in the collaborators' strategic focus or available funding, or external factors, such as an acquisition, that divert resources or create competing priorities;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our products or product candidates if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">product candidates discovered in collaboration with us may be viewed by our collaborators as competitive with their own product candidates or products, which may cause collaborators to cease to devote resources to the commercialization of our product candidates;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">a collaborator with marketing and distribution rights to one or more of our product candidates that achieve regulatory approval may not commit sufficient resources to the marketing and distribution of such product or products;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">disagreements with collaborators, including disagreements over proprietary rights, contract interpretation or the preferred course of development, might cause delays or termination of the research, development or commercialization of product candidates, might lead to additional responsibilities for us with respect to product candidates, or might result in litigation or arbitration, any of which would be time-consuming and expensive;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential litigation;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability; and</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">collaborations may be terminated for the convenience of the collaborator and, if terminated, we could be required to raise additional capital to pursue further development or commercialization of the applicable product candidates. For example, each of our collaboration and license agreements may be terminated for convenience upon the completion of a specified notice period.</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">If our therapeutic collaborations do not result in the successful development and commercialization of products or if one of our collaborators terminates its agreement with us, we may not receive any future research funding or milestone or royalty payments under the collaboration. For example, Servier recently informed us that they did not intend to exercise the option to continue development of MGD007. If we do not receive the funding we expect under these agreements, our development of our technology platforms and product candidates could be delayed and we may need additional resources to develop product candidates and our technology platforms. All of the risks relating to product development, regulatory approval and commercialization described in this report also apply to the activities of our program collaborators. </span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">Additionally, subject to its contractual obligations to us, if one of our collaborators is involved in a business combination, the collaborator might deemphasize or terminate the development or commercialization of any product candidate licensed to it by us. If one of our collaborators terminates its agreement with us, we may find it more difficult to attract new collaborators.&#160;</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">29</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">For some of our product candidates, we may in the future determine to collaborate with additional pharmaceutical and biotechnology companies for development and potential commercialization of therapeutic products. We face significant competition in seeking appropriate collaborators. Our ability to reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#8217;s evaluation of a number of factors. These factors may include the design or results of clinical trials, the likelihood of approval by the FDA or similar regulatory authorities outside the United States, the potential market for the subject product candidate, the costs and complexities of manufacturing and delivering such product candidate to patients, the potential of competing products, the existence of uncertainty with respect to our ownership of technology, which can exist if there is a challenge to such ownership without regard to the merits of the challenge and industry and market conditions generally. The collaborator may also consider alternative product candidates or technologies for similar indications that may be available to collaborate on and whether such a collaboration could be more attractive than the one with us for our product candidate.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">Collaborations are complex and time-consuming to negotiate and document. In addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators. If we are unable to reach agreements with suitable collaborators on a timely basis, on acceptable terms, or at all, we may have to curtail the development of a product candidate, reduce or delay one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to fund and undertake development or commercialization activities on our own, we may need to obtain additional expertise and additional capital, which may not be available to us on acceptable terms or at all. If we fail to enter into collaborations and do not have sufficient funds or expertise to undertake the necessary development and commercialization activities, we may not be able to further develop our product candidates or bring them to market or continue to develop our technology platforms and our business may be materially and adversely affected.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">We may also be restricted under existing collaboration agreements from entering into future agreements on certain terms with potential collaborators. Aside from our agreement with GC Pharma, subject to certain specified exceptions, each of our existing therapeutic collaborations contains a restriction on our engaging in activities that are the subject of the collaboration with third parties for specified periods of time.</span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Independent clinical investigators and contract research organizations (CROs) that we engage to conduct our clinical trials may not devote sufficient time or attention to our clinical trials or be able to repeat their past success.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">We expect to continue to depend on independent clinical investigators and CROs to conduct our clinical trials. CROs may also assist us in the collection and analysis of data. There is a limited number of third-party service providers that specialize or have the expertise required to achieve our business objectives. Identifying, qualifying and managing performance of third-party service providers can be difficult, time consuming and cause delays in our development programs. These investigators and CROs will not be our employees and we will not be able to control, other than by contract, the amount of resources, including time, which they devote to our product candidates and clinical trials. If independent investigators or CROs fail to devote sufficient resources to the development of our product candidates, or if their performance is substandard, it may delay or compromise the prospects for approval and commercialization of any product candidates that we develop. In addition, the use of third-party service providers requires us to disclose our proprietary information to these parties, which could increase the risk that this information will be misappropriated. Further, the FDA requires that we comply with standards, commonly referred to as current Good Clinical Practice (GCP) for conducting, recording and reporting clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of trial subjects are protected. Failure of clinical investigators or CROs to meet their obligations to us or comply with GCP procedures could adversely affect the clinical development of our product candidates and harm our business.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Failure of third-party contractors to successfully develop and commercialize companion diagnostics for use with our product candidates could harm our ability to commercialize our product candidates.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">We plan to develop companion diagnostics for our product candidates where appropriate. At least in some cases, the FDA and similar regulatory authorities outside the United States may request or require the development and regulatory approval of a companion diagnostic as a condition to approving one or more of our product candidates, including, for example, margetuximab. We do not have experience or capabilities in developing or commercializing diagnostics and plan to rely in large part on third parties to perform these functions.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">In most cases, we will likely outsource the development, production and commercialization of companion diagnostics to third parties. By outsourcing these companion diagnostics to third parties, we become dependent on the efforts of our third party contractors to successfully develop and commercialize these companion diagnostics. Our contractors:</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">may not perform their obligations as expected;</span></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">30</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">may encounter production difficulties that could constrain the supply of the companion diagnostic;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">may have difficulties gaining acceptance of the use of the companion diagnostic in the clinical community;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">may not commit sufficient resources to the marketing and distribution of such product; and</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">may terminate their relationship with us.</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">If any companion diagnostic for use with one of our product candidates fails to gain market acceptance, our ability to derive revenues from sales of such product candidate could be harmed. If our third party contractors fail to commercialize such companion diagnostic, we may not be able to enter into arrangements with another diagnostic company to obtain supplies of an alternative diagnostic test for use in connection with such product candidate or do so on commercially reasonable terms, which could adversely affect and delay the development or commercialization of such product candidate.</span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We expect to&#160;contract with third parties for the manufacture of some of our product candidates for clinical testing in the future and expect to do so for commercialization. This reliance on third parties increases the risk that we will not have sufficient quantities of our product candidates or products or such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">We currently have two cGMP manufacturing facilities located in Rockville, Maryland, one of which was completed in 2018 and is designed to increase our internal capacity to manufacture more drug substance lots, at larger scale and in full compliance with cGMP to support future clinical and commercial production of our and our collaborators&#8217; product candidates. We manufacture drug substance at these facilities that we use for research and development purposes and for clinical trials of our and our collaborators&#8217; product candidates. Although we believe we currently have capacity to produce all of the material required for our and our collaborators&#8217; clinical trials, we may not be able to do so in the future, and may rely on arrangements with third parties.  Our current facilities may be insufficient to support our needs for our Phase 3 clinical trials for our antibody product candidates and for commercial quantities of such candidates. We do not have experience in manufacturing products at commercial scale.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">We have entered into agreements with contract manufacturing organizations to supplement our clinical supply and internal capacity as we advance our product candidate pipeline. We expect to use third parties for the manufacture of certain of our product candidates for clinical testing, as well as for commercial manufacture of some of our product candidates that receive marketing approval and that are not manufactured by one of our third party collaborators. We have entered into two long-term supply agreements with manufacturers for commercial supply, and may in the future enter into one or more additional supply agreements for our product candidates. We may be unable to reach agreement with any of these contract manufacturers, or to identify and reach arrangements on satisfactory terms with other contract manufacturers, to manufacture any of our product candidates. Additionally, the facilities used by any contract manufacturer to manufacture any of our product candidates must be the subject of a satisfactory inspection before the FDA and other regulatory authorities approve a BLA or marketing authorization for the product candidate manufactured at that facility. We will depend on these third-party manufacturing partners for compliance with the FDA&#8217;s requirements for the manufacture of our finished products. If our manufacturers cannot successfully manufacture material that conforms to our specifications and the FDA and other regulatory authorities&#8217; cGMP requirements, our product candidates will not be approved or, if already approved, may be subject to recalls.</span></div><div style="text-indent:36pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Reliance on third-party manufacturers entails risks to which we would not be subject if we manufactured the product candidates ourselves, including:</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">the possibility of a breach of the manufacturing agreements by the third parties because of factors beyond our control;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">the possibility of termination or nonrenewal of the agreements by the third parties before we are able to arrange for a qualified replacement third-party manufacturer; and</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">the possibility that we may not be able to secure a manufacturer or manufacturing capacity in a timely manner and on satisfactory terms in order to meet our manufacturing needs.</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">Any of these factors could cause the delay of approval or commercialization of our product candidates, cause us to incur higher costs or prevent us from commercializing our product candidates successfully. Furthermore, if any of our product candidates are approved and contract manufacturers fail to deliver the required commercial quantities of finished product on a timely basis and at commercially reasonable prices, and we are unable to find one or more replacement manufacturers capable of production at a substantially equivalent cost, in substantially equivalent volumes and quality and on a timely basis, we would likely be unable to meet demand for our products and could lose potential revenue. It may take several years to establish an</span></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">31</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;"> alternative source of supply for our product candidates and to have any such new source approved by the FDA or any other relevant regulatory authorities.</span></div><div style="margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">A disruption in our computer networks, including those related to cybersecurity, could adversely affect our financial performance.</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">We rely on our computer networks and systems, some of which are managed by third parties, to manage and store electronic information (including sensitive data such as confidential business information and personally identifiable data relating to employees, customers and other business partners), and to manage or support a variety of critical business processes and activities. We may face threats to our networks from unauthorized access, security breaches and other system disruptions. Despite our security measures, our infrastructure may be vulnerable to external or internal attacks. Any such security breach may compromise information stored on our networks and may result in significant data losses or theft of sensitive or proprietary information. In addition, a cybersecurity attack could result in other negative consequences, including disruption of our internal operations, increased cybersecurity protection costs, lost revenue, regulatory actions or litigation. Any disruption could also have a material adverse impact on our operations. We have not experienced any known attacks on our information technology systems that have resulted in any material system failure, accident or security breach to date.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:115%;">Risks Related to Our Intellectual Property</span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our commercial success depends significantly on our ability to operate without infringing the valid patents and other proprietary rights of third parties.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">Our success will depend in part on our ability to operate without infringing the proprietary rights of third parties. Other entities may have or obtain patents or proprietary rights that could limit our ability to make, use, sell, offer for sale or import our future approved products or impair our competitive position. For example, certain patents held by third parties cover Fc engineering methods and mutations in Fc regions to enhance the binding of Fc regions to Fc receptors on immune cells. Although we believe that these patents are not infringed, and/or are invalid and/or unenforceable, if a court should find that they cover margetuximab or enoblituzumab and we are unable to invalidate such patents, or if licenses for them are not available on commercially reasonable terms, our business could be harmed, perhaps materially.</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">Patents that we may ultimately be found to infringe could be issued to third parties. Third parties may have or obtain valid and enforceable patents or proprietary rights that could block us from developing product candidates using our technology. Our failure to obtain a license to any technology that we require may materially harm our business, financial condition and results of operations. Moreover, our failure to maintain a license to any technology that we require may also materially harm our business, financial condition, and results of operations. Furthermore, we would be exposed to a threat of litigation.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">In the pharmaceutical industry, significant litigation and other proceedings regarding patents, patent applications, trademarks and other intellectual property rights have become commonplace. The types of situations in which we may become a party to such litigation or proceedings include</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">we or our collaborators may initiate litigation or other proceedings against third parties seeking to invalidate the patents held by those third parties or to obtain a judgment that our products or processes do not infringe those third parties' patents;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">if our competitors file patent applications that claim technology also claimed by us or our licensors, we or our licensors may be required to participate in interference or opposition proceedings to determine the priority of invention, which could jeopardize our patent rights and potentially provide a third party with a dominant patent position;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">if third parties initiate litigation claiming that our processes or products infringe their patent or other intellectual property rights, we and our collaborators will need to defend against such proceedings; and</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">if a license to necessary technology is terminated, the licensor may initiate litigation claiming that our processes or products infringe or misappropriate their patent or other intellectual property rights and/or that we breached our obligations under the license agreement, and we and our collaborators would need to defend against such proceedings.</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">These lawsuits would be costly and could affect our results of operations and divert the attention of our management and scientific personnel. There is a risk that a court would decide that we or our collaborators are infringing the third party&#8217;s patents and would order us or our collaborators to stop the activities covered by the patents. In that event, we or our collaborators may not have a viable alternative to the technology protected by the patent and may need to halt work on the affected product candidate or cease commercialization of an approved product. In addition, there is a risk that a court will order</span></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">32</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;"> us or our collaborators to pay the other party damages. An adverse outcome in any litigation or other proceeding could subject us to significant liabilities to third parties and require us to cease using the technology that is at issue or to license the technology from third parties. We may not be able to obtain any required licenses on commercially acceptable terms or at all. Any of these outcomes could have a material adverse effect on our business.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">The pharmaceutical and biotechnology industries have produced a significant number of patents, and it may not always be clear to industry participants, including us, which patents cover various types of products or methods of use. The coverage of patents is subject to interpretation by the courts, and the interpretation is not always uniform or predictable. If we are sued for patent infringement, we would need to demonstrate that our products or methods either do not infringe the patent claims of the relevant patent or that the patent claims are invalid, and we may not be able to do this. Proving invalidity is difficult. For example, in the United States, proving invalidity requires a showing of clear and convincing evidence to overcome the presumption of validity enjoyed by issued patents. Even if we are successful in these proceedings, we may incur substantial costs and divert management&#8217;s time and attention in pursuing these proceedings, which could have a material adverse effect on us. If we are unable to avoid infringing the patent rights of others, we may be required to seek a license, defend an infringement action or challenge the validity of the patents in court. Patent litigation is costly and time consuming. We may not have sufficient resources to bring these actions to a successful conclusion. In addition, if we do not obtain a license, develop or obtain non-infringing technology, fail to defend an infringement action successfully or have infringed patents declared invalid, we may incur substantial monetary damages, encounter significant delays in bringing our product candidates to market and be precluded from manufacturing or selling our product candidates.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">The cost of any patent litigation or other proceeding, even if resolved in our favor, could be substantial. Some of our competitors may be able to sustain the cost of such litigation and proceedings more effectively than we can because of their substantially greater resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace. Patent litigation and other proceedings may also absorb significant management time.</span></div><div style="margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If we are unable to obtain and enforce patent protection for our product candidates and related technology, our business could be materially harmed.</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">Issued patents may be challenged, narrowed, invalidated or circumvented. In addition, court decisions may introduce uncertainty in the enforceability or scope of patents owned by biotechnology companies. The legal systems of certain countries do not favor the aggressive enforcement of patents, and the laws of foreign countries may not allow us to protect our inventions with patents to the same extent as the laws of the United States. Because patent applications in the United States and many foreign jurisdictions are typically not published until 18 months after filing, or in some cases not at all, and because publications of discoveries in scientific literature lag behind actual discoveries, we cannot be certain that we were the first to make the inventions claimed in our issued patents or pending patent applications, or that we were the first to file for protection of the inventions set forth in our patents or patent applications. As a result, we may not be able to obtain or maintain protection for certain inventions. Therefore, the enforceability and scope of our patents in the United States and in foreign countries cannot be predicted with certainty and, as a result, any patents that we own or license may not provide sufficient protection against competitors. We may not be able to obtain or maintain patent protection from our pending patent applications, from those we may file in the future, or from those we may license from third parties. Moreover, even if we are able to obtain patent protection, such patent protection may be of insufficient scope to achieve our business objectives.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">Our strategy depends on our ability to identify and seek patent protection for our discoveries. This process is expensive and time consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner or in all jurisdictions where protection may be commercially advantageous. Despite our efforts to protect our proprietary rights, unauthorized parties may be able to obtain and use information that we regard as proprietary.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">The issuance of a patent does not ensure that a court or agency finds or will find the patent valid or enforceable, so even if we obtain patents, they may not be valid or enforceable against third parties. In addition, the issuance of a patent does not give us the right to practice the patented invention. Third parties may have blocking patents that could prevent us from marketing our own patented product and practicing our own patented technology. Third parties may also seek to market biosimilar versions of any approved products. Alternatively, third parties may seek approval to market their own products similar to or otherwise competitive with our products. In these circumstances, we may need to defend and/or assert our patents, including by filing lawsuits alleging patent infringement. In any of these types of proceedings, a court or agency with jurisdiction may find our patents invalid and/or unenforceable. Even if we have valid and enforceable patents, these patents still may not provide protection against competing products or processes sufficient to achieve our business objectives.</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">The patent position of pharmaceutical or biotechnology companies, including ours, is generally uncertain and involves complex legal and factual considerations. The standards which the United States Patent and Trademark Office (USPTO) and its foreign counterparts use to grant patents are not always applied predictably or uniformly and can change. There is also no uniform, worldwide policy regarding the subject matter and scope of claims granted or allowable in pharmaceutical or</span></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">33</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;"> biotechnology patents. The laws of some foreign countries do not protect proprietary information to the same extent as the laws of the United States, and many companies have encountered significant problems and costs in protecting their proprietary information in these foreign countries. Outside the United States, patent protection must be sought in individual jurisdictions, further adding to the cost and uncertainty of obtaining adequate patent protection outside of the United States. Accordingly, we cannot predict whether additional patents protecting our technology will issue in the United States or in foreign jurisdictions, or whether any patents that do issue will have claims of adequate scope to provide competitive advantage. Moreover, we cannot predict whether third parties will be able to successfully obtain claims or the breadth of such claims. The allowance of broader claims may increase the incidence and cost of patent interference proceedings, opposition proceedings, and/or reexamination proceedings, the risk of infringement litigation, and the vulnerability of the claims to challenge. On the other hand, the allowance of narrower claims does not eliminate the potential for adversarial proceedings, and may fail to provide a competitive advantage. Our issued patents may not contain claims sufficiently broad to protect us against third parties with similar technologies or products, or provide us with any competitive advantage.</span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We may become involved in lawsuits to protect or enforce our patents, which could be expensive, time consuming and unsuccessful.</span></div><div style="text-indent:36pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Even after they have been issued, our patents and any patents which we license may be challenged, narrowed, invalidated or circumvented. If our patents are invalidated or otherwise limited or will expire prior to the commercialization of our product candidates, other companies may be better able to develop products that compete with ours, which could adversely affect our competitive business position, business prospects and financial condition.</span></div><div style="text-indent:36pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The following are examples of litigation and other adversarial proceedings or disputes that we could become a party to involving our patents or patents licensed to us:</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:9pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">we or our collaborators may initiate litigation or other proceedings against third parties to enforce our patent rights;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:3pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">third parties may initiate litigation or other proceedings seeking to invalidate patents owned by or licensed to us or to obtain a declaratory judgment that their product or technology does not infringe our patents or patents licensed to us;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:3pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">third parties may initiate opposition, reexamination or inter partes review proceedings challenging the validity or scope of our patent rights, requiring us or our collaborators and/or licensors to participate in such proceedings to defend the validity and scope of our patents;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:3pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">there may be a challenge or dispute regarding inventorship or ownership of patents currently identified as being owned by or licensed to us;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:3pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">the </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">USPTO may initiate an interference between patents or patent applications owned by or licensed to us and those of our competitors, requiring us or our collaborators and/or licensors to participate in an interference proceeding to determine the priority of invention, which could jeopardize our patent rights; or</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:3pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">third parties may seek approval to market biosimilar versions of our future approved products prior to expiration of relevant patents owned by or licensed to us, requiring us to defend our patents, including by filing lawsuits alleging patent infringement.</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">These lawsuits and proceedings would be costly and could affect our results of operations and divert the attention of our managerial and scientific personnel. There is a risk that a court or administrative body would decide that our patents are invalid or not infringed by a third party&#8217;s activities, or that the scope of certain issued claims must be further limited. An adverse outcome in a litigation or proceeding involving our own patents could limit our ability to assert our patents against these or other competitors, affect our ability to receive royalties or other licensing consideration from our licensees, and may curtail or preclude our ability to exclude third parties from making, using and selling similar or competitive products. Any of these occurrences could adversely affect our competitive business position, business prospects and financial condition.</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">The degree of future protection for our proprietary rights is uncertain because legal means afford only limited protection and may not adequately protect our rights or permit us to gain or keep our competitive advantage. For example: </span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:9pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">others may be able to develop a platform that is similar to, or better than, ours in a way that is not covered by the claims of our patents;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">others may be able to make compounds that are similar to our product candidates but that are not covered by the claims of our patents;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">we might not have been the first to make the inventions covered by patents or pending patent applications;</span></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">34</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">we might not have been the first to file patent applications for these inventions;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">any patents that we obtain may not provide us with any competitive advantages or may ultimately be found invalid or unenforceable; or</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">we may not develop additional proprietary technologies that are patentable.</span></div><div style="margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If we fail to comply with our obligations under our intellectual property licenses with third parties, we could lose license rights that are important to our business.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">We are currently party to various intellectual property license agreements. These license agreements impose, and we expect that future license agreements may impose, various diligence, milestone payment, royalty, insurance and other obligations on us. For example, we have entered into patent and know-how license agreements that grant us the right to use certain technologies related to biological manufacturing to manufacture our clinical product candidates. These licenses typically include an obligation to pay yearly maintenance payments and royalties on sales, and may also include upfront and milestone payments. If we fail to comply with our obligations under the licenses, the licensors may have the right to terminate their respective license agreements, in which event we might not be able to market any product that is covered by the agreements. Termination of the license agreements or reduction or elimination of our licensed rights may result in our having to negotiate new or reinstated licenses with less favorable terms, which could adversely affect our competitive business position and harm our business.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If we are unable to protect the confidentiality of our proprietary information, the value of our technology and products could be adversely affected.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">In addition to patent protection, we also rely on other proprietary rights, including protection of trade secrets, and other proprietary information. To maintain the confidentiality of trade secrets and proprietary information, we enter into confidentiality agreements with our employees, consultants, collaborators and others upon the commencement of their relationships with us. These agreements require that all confidential information developed by the individual or made known to the individual by us during the course of the individual&#8217;s relationship with us be kept confidential and not disclosed to third parties. Our agreements with employees and our personnel policies also provide that any inventions conceived by the individual in the course of rendering services to us shall be our exclusive property. However, we may not obtain these agreements in all circumstances, and individuals with whom we have these agreements may not comply with their terms. Thus, despite such agreement, such inventions may become assigned to third parties. In the event of unauthorized use or disclosure of our trade secrets or proprietary information, these agreements, even if obtained, may not provide meaningful protection, particularly for our trade secrets or other confidential information. To the extent that our employees, consultants or contractors use technology or know-how owned by third parties in their work for us, disputes may arise between us and those third parties as to the rights in related inventions. To the extent that an individual who is not obligated to assign rights in intellectual property to us is rightfully an inventor of intellectual property, we may need to obtain an assignment or a license to that intellectual property from that individual, or a third party or from that individual&#8217;s assignee. Such assignment or license may not be available on commercially reasonable terms or at all.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">Adequate remedies may not exist in the event of unauthorized use or disclosure of our proprietary information. The disclosure of our trade secrets would impair our competitive position and may materially harm our business, financial condition and results of operations. Costly and time consuming litigation could be necessary to enforce and determine the scope of our proprietary rights, and failure to maintain trade secret protection could adversely affect our competitive business position. In addition, others may independently discover or develop our trade secrets and proprietary information, and the existence of our own trade secrets affords no protection against such independent discovery.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">As is common in the biotechnology and pharmaceutical industries, we employ individuals who were previously or concurrently employed at research institutions and/or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. We may be subject to claims that these employees, or we, have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former employers, or that patents and applications we have filed to protect inventions of these employees, even those related to one or more of our product candidates, are rightfully owned by their former or concurrent employer. Litigation may be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to management.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Obtaining and maintaining our patent protection depends on compliance with various procedural, documentary, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span></div><div style="margin-top:6pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and/or applications will be due to the USPTO and various foreign patent offices at various points over the lifetime of our patents and</span></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">35</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">/or applications. We have systems in place to remind us to pay these fees, and we rely on our outside counsel to pay these fees when due. Additionally, the USPTO and various foreign patent offices require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. We employ reputable law firms and other professionals to help us comply, and in many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with rules applicable to the particular jurisdiction. However, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. If such an event were to occur, it could have a material adverse effect on our business. In addition, we are responsible for the payment of patent fees for patent rights that we have licensed from other parties. If any licensor of these patents does not itself elect to make these payments, and we fail to do so, we may be liable to the licensor for any costs and consequences of any resulting loss of patent rights.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">If we do not obtain protection under the Hatch-Waxman Amendments and similar foreign legislation for extending the term of patents covering each of our product candidates, our business may be materially harmed.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">Depending upon the timing, duration and conditions of FDA marketing approval of our product candidates, one or more of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent term extension of up to five years for a patent covering an approved product as compensation for effective patent term lost during product development and the FDA regulatory review process. However, we may not receive an extension if we fail to apply within applicable deadlines, fail to apply prior to expiration of relevant patents or otherwise fail to satisfy applicable requirements. Moreover, the length of the extension could be less than we request. If we are unable to obtain patent term extension or the term of any such extension is less than we request, the period during which we can enforce our patent rights for that product will be shortened and our competitors may obtain approval to market competing products sooner. As a result, our revenue from applicable products could be reduced, possibly materially, </span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">Risks Related to Legal Compliance Matters</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">If we do not comply with laws regulating the protection of the environment and health and human safety, our business could be adversely affected.</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">Our research and development involves, and may in the future involve, the use of potentially hazardous materials and chemicals. Our operations may produce hazardous waste products. Although we believe that our safety procedures for handling and disposing of these materials comply with the standards mandated by local, state and federal laws and regulations, the risk of accidental contamination or injury from these materials cannot be eliminated. If an accident occurs, we could be held liable for resulting damages, which could be substantial. We are also subject to numerous environmental, health and workplace safety laws and regulations and fire and building codes, including those governing laboratory procedures, exposure to blood-borne pathogens, use and storage of flammable agents and the handling of biohazardous materials. Although we maintain workers&#8217; compensation insurance as prescribed by the States of Maryland and California to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of these materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us. Additional federal, state and local laws and regulations affecting our operations may be adopted in the future. We may incur substantial costs to comply with, and substantial fines or penalties if we violate, any of these laws or regulations.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">If we market products in a manner that violates healthcare fraud and abuse laws, or if we violate government price reporting laws, we may be subject to civil or criminal penalties.</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">In addition to FDA restrictions on marketing of pharmaceutical products, several other types of state and federal healthcare laws commonly referred to as &#8220;fraud and abuse&#8221; laws have been applied in recent years to restrict certain marketing practices in the pharmaceutical industry. These laws include false claims and anti-kickback statutes.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">Federal false claims laws prohibit any person from knowingly presenting, or causing to be presented, a false claim for payment to the federal government or knowingly making, or causing to be made, a false statement to get a claim paid. The federal healthcare program anti-kickback statute prohibits, among other things, knowingly and willfully offering, paying, soliciting or receiving remuneration to induce, or in return for, purchasing, leasing, ordering or arranging for the purchase, lease or order of any healthcare item or service reimbursable under Medicare, Medicaid or other federally financed healthcare programs. This statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers and formulary managers on the other. Although there are several statutory exemptions and regulatory safe harbors protecting certain common activities from prosecution, the exemptions and safe harbors are drawn narrowly, and practices that involve remuneration intended to induce prescribing, purchasing or recommending may be subject to scrutiny if they do not qualify for an exemption or safe harbor. In addition, under the Sunshine Act provisions of the ACA, pharmaceutical manufacturers with one or more products for which payment is available under a federal health care program</span></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">36</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;"> are subject to federal reporting and disclosure requirements with regard to payments or other transfers of value made to physicians and teaching hospitals. Most states also have statutes or regulations similar to the federal anti-kickback law and federal false claims laws, which may apply to items such as pharmaceutical products and services reimbursed by private insurers. Some state laws also prohibit certain gifts to healthcare providers, require pharmaceutical companies to report payments to healthcare professionals, and/or require companies to adopt compliance programs or codes of conduct. Administrative, civil and criminal sanctions may be imposed under these federal and state laws.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">Over the past few years, a number of pharmaceutical and other healthcare companies have been prosecuted under these laws for a variety of promotional and marketing activities, such as: providing free trips, free goods, sham consulting fees and grants and other monetary benefits to prescribers; reporting to pricing services inflated average wholesale prices that were then used by federal programs to set reimbursement rates; engaging in off-label promotion; and submitting inflated best price information to the Medicaid Rebate Program to reduce liability for Medicaid rebates. At such time, if ever, as we market any of our future approved products and these products are paid for by governmental programs, it is possible that some of our business activities could also be subject to challenge under one or more of these &#8220;fraud and abuse&#8221; laws.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">We are subject to the U.S. Foreign Corrupt Practices Act and other anti-corruption laws. If we fail to comply with these laws, we could be subject to civil or criminal penalties, other remedial measures, and legal expenses, which could adversely affect our business, results of operations and financial condition.</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">Our operations are subject to anti-corruption laws, including the U.S. Foreign Corrupt Practices Act, (FCPA) and other anti-corruption laws that apply in countries where we do business. The FCPA and these other laws generally prohibit us and our employees and intermediaries from bribing, being bribed or making other prohibited payments to government officials or other persons to obtain or retain business or gain some other business advantage. We and our commercial partners operate in a number of jurisdictions that pose a risk of potential FCPA violations, and we participate in collaborations and relationships with third parties whose actions could potentially subject us to liability under the FCPA or other anti-corruption laws. There is no assurance that we will be completely effective in ensuring our compliance with all applicable anti-corruption laws. If we violate provisions of the FCPA or other anti-corruption laws or are subject to an investigation or audit pursuant to these laws, we may be subject to criminal and civil penalties, disgorgement and other sanctions and remedial measures and legal expenses, which could have an adverse impact on our business, financial condition and results of operations.</span></div><div style="text-align:center;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Our employees may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements and insider trading.</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">We are exposed to the risk of employee fraud or other misconduct. Misconduct by employees could include intentional failures to comply with FDA regulations, to provide accurate information to the FDA or other agencies, to comply with federal and state health care fraud and abuse laws and regulations, to report financial information or data accurately or to disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the health care industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. Employee misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. We have adopted a code of conduct, but it is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant fines or other sanctions.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:115%;">Risks Relating to Employee Matters and Managing Growth</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Our future success depends on our ability to retain key executives and to attract, retain and motivate qualified personnel.</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">We are highly dependent on the research and development, clinical and business development expertise of Scott Koenig, M.D., Ph.D., our President and Chief Executive Officer, as well as the other members of our senior management, scientific and clinical team. Although we have entered into employment agreements with certain of our executive officers, each of them may terminate their employment with us at any time. The loss of the services of our executive officers or other key employees could impede the achievement of our research, development and commercialization objectives and seriously harm our ability to successfully implement our business strategy.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">Recruiting and retaining qualified scientific, clinical, manufacturing and sales and marketing personnel will also be critical to our success. In addition, we will need to expand and effectively manage our managerial, operational, financial, development and other resources in order to successfully pursue our research, development and commercialization efforts for our existing and future product candidates. Furthermore, replacing executive officers and key employees may be difficult and</span></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">37</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;"> may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to successfully develop, gain regulatory approval of and commercialize products. Competition to hire from this limited pool is intense, and we may be unable to hire, train, retain or motivate these key personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategy. Our consultants and advisors may be employed by employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us. If we are unable to continue to attract and retain high quality personnel, our ability to pursue our growth strategy will be limited.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">We will need to grow our organization, and we may experience difficulties in managing this growth, which could disrupt our operations.</span></div><div style="text-indent:36pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">As of February&#160;22, 2019, we had&#160;364&#160;full-time employees. As our development and commercialization plans and strategies develop, we expect to expand our employee base for managerial, operational, sales, marketing, financial and other resources. Future growth would impose significant added responsibilities on members of management, including the need to identify, recruit, maintain, motivate and integrate additional employees. Also, our management may need to divert a disproportionate amount of their attention away from our day-to-day activities and devote a substantial amount of time to managing these growth activities. We may not be able to effectively manage the expansion of our operations which may result in weaknesses in our infrastructure, give rise to operational errors, loss of business opportunities, loss of employees and reduced productivity among remaining employees. Our expected growth could require significant capital expenditures and may divert financial resources from other projects, such as the development of existing and additional product candidates. If our management is unable to effectively manage our expected growth, our expenses may increase more than expected, our ability to generate and/or grow revenue could be reduced and we may not be able to implement our business strategy. Our future financial performance and our ability to commercialize our product candidates and compete effectively with others in our industry will depend, in part, on our ability to effectively manage any future growth.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:115%;">Risks Relating to Our Common Stock</span></div><div style="margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our stock price may be volatile and fluctuate substantially, which may subject us to securities class action litigation.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">Our stock price is likely to be volatile&#160;and fluctuate substantially. &#160; The stock market has recently experienced significant volatility, particularly with respect to pharmaceutical, biotechnology, and other life sciences company stocks. The volatility of pharmaceutical, biotechnology, and other life sciences company stocks often does not relate to the operating performance of the companies represented by the stock. Some of the factors that may cause the market price of our common stock to fluctuate include:</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:3pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">results and timing of our clinical trials and clinical trials of our competitors&#8217; products;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:3pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">f</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">ailure or discontinuation of any of our development programs;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:3pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">issues in manufacturing our product candidates or future approved products;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:3pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">issues in designing or constructing our commercial manufacturing facilities;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:3pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">regulatory developments or enforcement in the United States and foreign countries with respect to our product candidates or our competitors&#8217; products;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:3pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">competition from existing products or new products that may emerge;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:3pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">developments or disputes concerning patents or other proprietary rights;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:3pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">introduction of technological innovations or new commercial products by us or our competitors;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:3pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">announcements by us, our collaborators or our competitors of significant acquisitions, strategic partnerships, joint ventures, collaborations or capital commitments;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:3pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">changes in estimates or recommendations by securities analysts, if any cover our common stock;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:3pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">f</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">luctuations in the valuation of companies perceived by investors to be comparable to us;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:3pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">public concern over our product candidates or any future approved products;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:3pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">threatened or actual litigation;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:3pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">future or anticipated sales of our common stock;</span></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">38</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:3pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">share price and volume fluctuations attributable to inconsistent trading volume levels of our shares;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:3pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">additions or departures of key personnel;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:3pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">changes in the structure of health care payment systems in the United States or overseas;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:3pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">failure of any of our product candidates, if approved, to achieve commercial success;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:3pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">economic and other external factors or other disasters or crises;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:3pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">period-to-period fluctuations in our financial condition and results of operations, including the timing of receipt of any milestone or other payments under commercialization or licensing agreements;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:3pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">general market conditions and market conditions for biopharmaceutical stocks; and</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:3pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">overall fluctuations in U.S. equity markets.</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">In addition, in the past, when the market price of a stock has been volatile, holders of that stock have instituted securities class action litigation against the company that issued the stock. If any of our stockholders brought a lawsuit against us, we could incur substantial costs defending the lawsuit and divert the time and attention of our management, which could seriously harm our business.</span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Provisions of our charter, bylaws, third-party agreements and Delaware law may make an acquisition of us or a change in our management more difficult.</span></div><div style="text-indent:36pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Certain provisions of our restated certificate of incorporation and amended and restated bylaws could discourage, delay, or prevent a merger, acquisition, or other change in control that stockholders may consider favorable, including transactions in which you might otherwise receive a premium for your shares. These provisions also could limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. Stockholders who wish to participate in these transactions may not have the opportunity to do so. Furthermore, since our board of directors is responsible for appointing the members of our management team, these provisions could prevent or frustrate attempts by our stockholders to replace or remove our management by making it more difficult for stockholders to replace members of our board of directors. These provisions:</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:9pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">allow the authorized number of directors to be changed only by resolution of our board of directors;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:3pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">establish a classified board of directors, providing that not all members of the board of directors be elected at one time;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:3pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">authorize our board of directors to issue without stockholder approval blank check preferred stock that, if issued, could operate as a "poison pill" to dilute the stock ownership of a potential hostile acquirer to prevent an acquisition that is not approved by our board of directors;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:3pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">require that stockholder actions must be effected at a duly called stockholder meeting and prohibit stockholder action by written consent;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:3pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">establish advance notice requirements for stockholder nominations to our board of directors or for stockholder proposals that can be acted on at stockholder meetings;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:3pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">limit who may call stockholder meetings; and</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:3pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">require the approval of the holders of 75% of the outstanding shares of our capital stock entitled to vote in order to amend certain provisions of our restated certificate of incorporation and restated bylaws.</span></div><div style="text-indent:36pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Furthermore, in the ordinary course of our business, from time to time we discuss and enter into collaborations, licenses and other transactions with various third parties, including other pharmaceutical companies and biotechnology companies. When we deem it appropriate, our agreements with such third parties may include standstill provisions. These standstill provisions, several of which may be in force from time-to-time, typically prohibit such parties from acquiring our securities for a period of time, which may discourage such parties from acquiring MacroGenics even if doing so would be beneficial to our stockholders.</span></div><div style="text-indent:36pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">In addition, because we are incorporated in Delaware, we are governed by the provisions of Section&#160;203 of the Delaware General Corporation Law, which may, unless certain criteria are met, prohibit large stockholders, in particular those owning 15% or more of our outstanding voting stock, from merging or combining with us for a prescribed period of time. This provision could have the effect of delaying or preventing a change of control, whether or not it is desired by or beneficial to our stockholders.</span></div><div><span><br/></span></div><div id="i_0_91"></div><div style="text-indent:-36pt;padding-left:36pt;margin-top:3pt;margin-bottom:9pt;"></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">39</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-indent:-36pt;padding-left:36pt;margin-top:3pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">ITEM 1B.&#160;&#160;UNRESOLVED STAFF COMMENTS</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">None.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span><br/></span></div><div id="i_0_103"></div><div style="text-indent:-36pt;padding-left:36pt;margin-top:3pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">ITEM 2.&#160;&#160;PROPERTIES</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">We lease approximately 200,000 square feet of manufacturing, office and laboratory space in Rockville, Maryland under five leases that have terms that expire between 2019 and 2027 unless renewed.&#160; We also lease office and laboratory space in Brisbane, CA which is leased until 2023. We believe that our properties are generally in good condition, well maintained, suitable and adequate to carry on our business.&#160;&#160;We believe our capital resources are sufficient to lease any additional facilities required to meet our expected growth needs.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span><br/></span></div><div id="i_0_115"></div><div style="text-indent:-36pt;padding-left:36pt;margin-top:3pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">ITEM 3.&#160;LEGAL PROCEEDINGS</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">In the ordinary course of business, we are involved in various legal proceedings, including, among others, patent oppositions, patent revocations, patent infringement litigation and other matters incidental to our business.&#160;&#160;We are not currently a party to any material legal proceedings.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span><br/></span></div><div id="i_0_127"></div><div style="text-indent:-36pt;padding-left:36pt;margin-top:3pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">ITEM 4.&#160;&#160;MINE SAFETY DISCLOSURES</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Not applicable.</span></div><div id="i_0_139"></div><div style="text-indent:36pt;text-align:center;margin-bottom:12pt;"></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">40</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-indent:36pt;text-align:center;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">PART II</span></div><div id="i_0_152"></div><div style="text-indent:-72pt;padding-left:72pt;margin-top:3pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">ITEM 5.&#160;&#160;MARKET FOR REGISTRANT'S COMMON EQUITY,&#160;RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">Market Information</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Our common stock is listed on the Nasdaq Global Select Market under the symbol "MGNX".&#160;&#160;As of February&#160;22, 2019, we had 48,780,321 shares of common stock outstanding held by approximately 75 holders of record, which include shares held by a broker, bank or other nominee.&#160;&#160;We have never declared or paid any cash dividends.&#160;&#160;We do not anticipate declaring or paying cash dividends for the foreseeable future.&#160;&#160;Instead, we will retain our earnings, if any, for the future operation and expansion of our business.</span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">Performance Graph</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The following graph compares the five-year cumulative total return of our common stock with the  Nasdaq Composite Index (U.S.) and the Nasdaq Biotechnology Index.&#160;&#160;The comparison assumes a $100 investment on December 31, 2013 in our common stock, the stocks comprising the Nasdaq Composite Index, and the stocks comprising the Nasdaq Biotechnology Index, and assumes reinvestment of the full amount of all dividends, if any.&#160;&#160;Historical stockholder return is not necessarily indicative of the performance to be expected for any future periods.</span></div><div style="text-align:center;margin-bottom:9pt;"><img src="mgnx-20181231_g7.jpg" alt="mgnx-20181231_g7.jpg" style="height:380;width:650;"></img></div><div style="text-indent:36pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The performance graph shall not be deemed to be incorporated by reference by means of any general statement incorporating by reference this Form 10-K into any filing under the Securities Act of 1933, as amended or the Exchange Act, except to the extent that we specifically incorporate such information by reference, and shall not otherwise be deemed filed under such acts.</span></div><div style="text-indent:36pt;margin-bottom:12pt;"><span><br/></span></div><div style="text-indent:36pt;margin-bottom:12pt;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">41</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div id="i_0_164"></div><div style="text-indent:-36pt;padding-left:36pt;margin-top:3pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">ITEM 6.&#160;SELECTED FINANCIAL DATA</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The consolidated statement of operations and comprehensive loss data for the years ended&#160;December&#160;31, 2018, 2017 and 2016 and the consolidated balance sheet data as of December&#160;31, 2018 and 2017 presented below have been derived from our audited consolidated financial statements and footnotes included elsewhere in this Annual Report on Form 10-K.&#160;&#160;The consolidated statement of operations and comprehensive loss data for the years ended December&#160;31, 2015 and 2014 and the consolidated balance sheet data as of December&#160;31, 2016, 2015 and 2014 have been derived from our audited consolidated financial statements which are not included herein.&#160;&#160;Historical results are not necessarily indicative of future results.&#160;&#160;The following data should be read in conjunction with Item 7, "Management's Discussion and Analysis of Financial Condition and Results of Operations" and the consolidated financial statements and related notes included elsewhere in this Annual Report on Form 10-K.</span></div><div style="margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.122807%;"><tr><td style="width:1.0%;"></td><td style="width:40.625369%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:8.766962%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.537463%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.914454%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.537463%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.914454%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.537463%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.914454%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.537463%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.914454%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="27" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2016</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2015</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2014</span></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="27" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands, except share and per share data)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Consolidated Statement of Operations and Comprehensive Loss:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total revenues</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">60,121&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">157,742&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">91,880&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">100,854&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">47,797&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Costs and expenses:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">190,827&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">147,232&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">122,091&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">98,271&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">70,186&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">General and administrative</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">40,500&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">32,653&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">29,831&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">22,765&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">15,926&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total costs and expenses</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">231,327&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">179,885&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">151,922&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">121,036&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">86,112&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Loss from operations</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(171,206)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(22,143)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(60,042)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(20,182)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(38,315)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Other income (expense)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(247)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2,517&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1,514&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">42&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(171,453)</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(19,626)</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(58,528)</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(20,140)</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(38,313)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Other comprehensive loss:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized gain (loss) on investments</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">58&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">21&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(77)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(5)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Comprehensive loss</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(171,395)</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(19,605)</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(58,605)</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(20,145)</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(38,313)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Basic and diluted&#160;net loss per common share</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(4.19)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.54)</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.69)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.63)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.40)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Basic and diluted weighted average number of common shares</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">40,925,318&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">36,095,080&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">34,685,274&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">31,801,645&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">27,384,990&#160;</span></td></tr></table></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#160;</span></div><div style="margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.122807%;"><tr><td style="width:1.0%;"></td><td style="width:40.625369%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:8.766962%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.537463%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.914454%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.537463%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.914454%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.537463%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.914454%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.537463%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.914454%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="27" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">As of December 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2016</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2015</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2014</span></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="27" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Consolidated Balance Sheet Data:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash, cash equivalents and marketable securities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:##000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:##000000;background-color:rgb(255,255,255, 0.0);">232,863&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">305,121&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">284,982&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">339,049&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">157,591&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total assets</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">332,130&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">373,883&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">311,263&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">359,269&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">173,886&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred revenue</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:##000000;background-color:rgb(255,255,255, 0.0);">40,722&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">20,839&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">14,306&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">18,497&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">30,720&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total stockholders' equity </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">242,877&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">299,238&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">268,751&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">313,337&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">121,286&#160;</span></td></tr></table></div><div style="margin-bottom:9pt;"><span><br/></span></div><div id="i_0_176"></div><div style="text-indent:-72pt;padding-left:72pt;margin-top:3pt;margin-bottom:9pt;"><span><br/></span></div><div style="text-indent:-72pt;padding-left:72pt;margin-top:3pt;margin-bottom:9pt;"></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">42</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-indent:-72pt;padding-left:72pt;margin-top:3pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">ITEM 7.&#160;MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">&#160;</span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">The following discussion of our financial condition and results of operations should be read together with our selected consolidated financial data and the consolidated financial statements and related notes included elsewhere herein. This discussion contains forward-looking statements that involve risks and uncertainties. As a result of many factors including, but not limited to, those set forth under the sections entitled "Risk Factors" and "Forward-Looking Statements", our actual results may differ materially from those anticipated in such forward-looking statements.</span></div><div style="margin-bottom:9pt;"><span><br/></span></div><div id="i_0_189"></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">Overview</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">We are a biopharmaceutical company focused on discovering and developing innovative antibody-based therapeutics to modulate the human immune response for the treatment of cancer.  We currently have a pipeline of product candidates in human clinical testing that have been created primarily using our proprietary technology platforms.&#160;We believe our programs have the potential to have a meaningful effect on treating patients' unmet medical needs as monotherapy or, in some cases, in combination with other therapeutic agents.</span></div><div style="text-indent:36pt;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">We commenced active operations in 2000, and have since devoted substantially all of our resources to staffing our company, developing our technology platforms, identifying potential product candidates, undertaking preclinical studies, conducting clinical trials, developing collaborations, business planning and raising capital. We have not generated any revenues from the sale of any products to date. We have financed our operations primarily through the public and private offerings of our securities, collaborations with other biopharmaceutical companies, and government grants and contracts.&#160; Although it is difficult to predict our funding requirements, based upon our current operating plan, we anticipate that our cash, cash equivalents and marketable securities as of December&#160;31, 2018, combined with&#160;the net proceeds from&#160;our February 2019 offering of common stock and proceeds from collaboration payments we anticipate receiving, will enable us to fund our operations&#160;into 2021 based on our current business plan.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Through December&#160;31, 2018, we had an accumulated deficit of $490.3 million.&#160;&#160;We expect that over the next several years this deficit will increase as we increase our expenditures in research and development in connection with our ongoing activities with several clinical trials.&#160;</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span><br/></span></div><div id="i_0_201"></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">Strategic Collaborations</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">We pursue a balanced approach between product candidates that we develop ourselves and those that we develop with our collaborators. Under our strategic collaborations to date, we have received significant non-dilutive funding and continue to have rights to additional funding upon completion of certain research, achievement of key product development milestones and royalties and other payments upon the commercial sale of products. Our current strategic collaborations include the following:</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;padding-left:14.5pt;">Incyte. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">In October 2017, we entered into an exclusive global collaboration and license agreement with Incyte Corporation (Incyte) for MGA012, an investigational monoclonal antibody that inhibits programmed cell death protein 1 (PD-1). Incyte has obtained exclusive worldwide rights for the development and commercialization of MGA012 in all indications, while we retain the right to develop our pipeline assets in combination with MGA012. The transaction closed in the fourth quarter of 2017 and we received a $150.0 million upfront payment from Incyte upon the closing. </span></div><div style="padding-left:54pt;margin-top:5pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Under the terms of the collaboration, Incyte will lead global development of MGA012. Assuming successful development and commercialization by Incyte, we could receive development and regulatory milestones of up to approximately $420.0 million, of which we've already received $15.0 million, and up to $330.0 million in commercial milestones. If commercialized, we would be eligible to receive tiered royalties of 15% to 24% on any global net sales and we have the option to co-promote with Incyte.  We retain the right to develop our pipeline assets in combination with MGA012, with Incyte commercializing MGA012 and MacroGenics commercializing our asset(s), if any such potential combinations are approved. We also have an agreement with Incyte under which we are to perform&#160;development and manufacturing services for Incyte's clinical needs of MGA012.  In addition, we retain the right to manufacture a portion of both companies' global commercial supply needs of MGA012 subject to a separate commercial supply agreement. </span></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">43</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;padding-left:14.5pt;">Servier. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">In September 2012, we entered into an agreement with Les Laboratoires Servier and Institut de Recherches Servier (collectively, Servier) to develop and commercialize three DART molecules in all countries other than the United States, Canada, Mexico, Japan, South Korea and India. In February 2014, Servier exercised its option to develop and commercialize flotetuzumab, for which we received a $15.0 million license option fee. As of December 31, 2018, Servier had terminated its option to license MGD007 and the third DART molecule. We received a $20.0 million upfront option fee upon execution of the agreement.  In addition, we will be eligible to receive up to approximately $308.5 million in additional clinical, development, regulatory and sales milestone payments if Servier successfully develops, obtains regulatory approval for, and commercializes flotetuzumab.  Servier may share Phase 2 and Phase 3 development costs and would be obligated to pay us low double-digit to mid-teen royalties on product sales in its territories.</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;padding-left:14.5pt;">Zai</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;"> Lab</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">. &#160;In November 2018, we entered into a collaboration and license agreement with Zai Lab Limited (Zai Lab)&#160; under which Zai Lab obtained regional development and commercialization rights in mainland China, Hong Kong, Macau and Taiwan for (i) margetuximab, an immune-optimized anti-HER2 monoclonal antibody, (ii) MGD013, a bispecific DART molecule designed to provide coordinate blockade of PD-1 and LAG-3 for the potential treatment of a range of solid tumors and hematological malignancies, and (iii) an undisclosed multi-specific TRIDENT molecule in preclinical development. Zai Lab will lead clinical development in its territory. </span></div><div style="padding-left:54pt;margin-top:5pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Under the terms of the agreement, Zai Lab paid us an upfront payment of $25.0 million less foreign withholding tax of $2.5 million, which was received in January 2019.  Assuming successful development and commercialization of margetuximab, MGD013 and the TRIDENT molecule, we could receive up to $140.0 million in development and regulatory milestones. In addition, Zai Lab would pay us double-digit royalties on annual net sales of the assets, which may be subject to adjustment in specified circumstances.&#160;</span></div><div style="text-indent:36pt;margin-bottom:12pt;"><span><br/></span></div><div id="i_0_213"></div><div style="margin-top:3pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">Financial Operations Overview</span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Revenue</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Our revenue consists primarily of collaboration revenue, including amounts recognized relating to upfront nonrefundable payments for licenses or options to obtain future licenses, research and development funding and milestone payments earned under our collaboration and license agreements with our strategic collaborators. In addition, we have earned revenues through several grants and/or contracts with the U.S. government and other research institutions on behalf of the U.S. government, primarily with respect to research and development activities related to infectious disease product candidates.</span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Research and Development Expense</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Research and development expense consists of expenses incurred in performing research and development activities. These expenses include conducting preclinical experiments and studies, clinical trials, manufacturing efforts and regulatory filings for all product candidates, and other indirect expenses in support of our research and development activities. We capture research and development expense on a program-by-program basis for our product candidates that are in clinical development and recognize these expenses as they are incurred. The following are items we include in research and development expense:</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">Employee-related expenses, such as salaries and benefits;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">Employee-related overhead expenses, such as facilities and other allocated items;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">Stock-based compensation expense to employees engaged in research and development activities;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">Depreciation of laboratory equipment, computers and leasehold improvements;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">Fees paid to consultants, subcontractors, clinical research organizations (CROs) and other third party vendors for work performed under our preclinical and clinical trials including, but not limited to, investigator grants, laboratory work and analysis, database management, statistical analysis, and other items;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">Amounts paid to vendors and suppliers for laboratory supplies;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">Costs related to manufacturing clinical trial materials, including vialing, packaging and testing;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">License fees and other third party vendor payments related to in-licensed product candidates and technology; and</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">Costs related to compliance with regulatory requirements.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">It is difficult to determine with certainty the duration and completion costs of our current or future preclinical programs and clinical trials of our product candidates, or if, when or to what extent we will generate revenues from the commercialization and sale of any of our product candidates that obtain regulatory approval. We may never succeed in</span></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">44</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> achieving regulatory approval for any of our product candidates. The duration, costs and timing of clinical trials and development of our product candidates will depend on a variety of factors, including the uncertainties of future clinical trials and preclinical studies, uncertainties in clinical trial enrollment rates and significant and changing government regulation. In addition, the probability of success for each product candidate will depend on numerous factors, including competition, manufacturing capability and commercial viability. We will determine which programs to pursue and how much to fund each program in response to the scientific and clinical success of each product candidate, as well as an assessment of each product candidate's commercial potential.</span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">General and Administrative Expenses</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">General and administrative expenses consist of salaries and related benefit costs for employees in our executive, finance, legal and intellectual property, business development, human resources, information technology and other support functions, travel expenses and other legal and professional fees.</span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Other Income (Expense)</span></div><div style="text-indent:36pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Other income (expense) consists of interest income earned on our cash, cash equivalents and marketable securities, offset by other expenses.</span></div><div style="text-indent:36pt;margin-bottom:12pt;"><span><br/></span></div><div id="i_0_225"></div><div style="margin-top:3pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">Critical Accounting Policies and Significant Judgments and Estimates</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Our management's discussion and analysis of financial conditions and results of operations is based on our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of these consolidated financial statements requires us to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the balance sheets and the reported amount of the revenue and expenses recorded during the reporting period. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable. We review and evaluate these estimates on an on-going basis. These assumptions and estimates form the basis for making judgments about the carrying values of assets and liabilities and amounts that have been recorded as revenues and expenses. Actual results and experiences may differ from these estimates. The results of any material revisions would be reflected in the consolidated financial statements prospectively from the date of the change in estimate.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">While a summary of significant accounting policies is described fully in Note 2 in our consolidated financial statements, we believe that the following accounting policies are the most critical to assist you in fully understanding and evaluating our financial results and the effect of the estimates and judgments we used in preparing our consolidated financial statements.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Revenue Recognition</span></div><div style="text-indent:36pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Beginning January 1, 2018, we recognize revenue under Accounting Standards Update (ASU) No. 2014-09, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Revenue from Contracts with Customer</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">s and all related amendments (collectively ASC 606) when our customer obtains control of promised goods or services, in an amount that reflects the consideration which&#160;we&#160;expect to receive in exchange for those goods or services.  To determine revenue recognition for arrangements that we determine are within the scope of ASC 606, management performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) we satisfy a performance obligation.  We recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. </span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">We enter into licensing agreements that are within the scope of ASC 606, under which we may license rights to research, develop, manufacture and commercialize our product candidates to third parties. The terms of these arrangements typically include payment to us of one or more of the following: non-refundable, upfront license fees; reimbursement of certain costs; customer option exercise fees; development, regulatory and commercial milestone payments;&#160;and royalties on net sales of licensed products.&#160;We&#160;may also enter into development and manufacturing service agreements with our collaborators.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">For each arrangement that results in revenues, we identify all performance obligations, which may include a license to intellectual property and know-how, research and development activities, transition activities and/or manufacturing services. In order to determine the transaction price, in addition to any upfront payment, management estimates the amount of variable consideration at the outset of the contract either utilizing the expected value or most likely amount method, depending on the facts and circumstances relative to the contract. We constrain (reduce) the estimates of variable consideration such that it is</span></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">45</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> probable that a significant reversal of previously recognized revenue will not occur. When determining if variable consideration should be constrained, management considers whether there are factors outside our control that could result in a significant reversal of revenue. In making these assessments, management considers the likelihood and magnitude of a potential reversal of revenue. These estimates are re-assessed each reporting period as required. </span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Once the estimated transaction price is established, amounts are allocated to the performance obligations that have been identified. The transaction price is generally allocated to each separate performance obligation on a relative standalone selling price basis. We must develop assumptions that require judgment to determine the standalone selling price in order to account for these agreements. To determine the standalone selling price, management&#8217;s assumptions may include (i)  the probability of obtaining marketing approval for the product candidate, (ii) estimates regarding the timing and the expected costs to develop and commercialize the product candidate, and (iii) estimates of future cash flows from potential product sales with respect to the product candidate. Standalone selling prices used to perform the initial allocation are not updated after contract inception. We do not include a financing component to its estimated transaction price at contract inception unless we estimate that certain performance obligations will not be satisfied within one year.</span></div><div style="text-indent:36pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Amounts received prior to revenue recognition are recorded as deferred revenue. Amounts expected to be recognized as revenue within the 12&#160;months following the balance sheet date are classified as current portion of deferred revenue in the accompanying consolidated balance sheets. Amounts not expected to be recognized as revenue within the 12&#160;months following the balance sheet date are classified as deferred revenue, net of current portion. </span></div><div style="text-indent:36pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Licenses. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">If the license to our intellectual property is determined to be distinct from the other promises or performance obligations identified in the arrangement, we recognize revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and when (or as) the customer is able to use and benefit from the license. In assessing whether a promise or performance obligation is distinct from the other promises, we consider factors such as the research, development, manufacturing and commercialization capabilities of the licensee and the availability of the associated expertise in the general marketplace. In addition,&#160;we consider whether the licensee can benefit from a promise for its intended purpose without the receipt of the remaining promise, whether the value of the promise is dependent on the unsatisfied promise, whether there are other vendors that could provide the remaining promise, and whether it is separately identifiable from the remaining promise. For licenses that are combined with other promises, management utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition. The measure of progress, and thereby periods over which revenue should be recognized, are subject to estimates by management and may change over the course of the research and development and licensing agreement. Such a change could have a material impact on the amount of revenue we record in future periods. </span></div><div style="text-indent:36pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Research, Development and/or Manufacturing Services. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The promises under our agreements may include research and development or manufacturing services to be performed by&#160;us on behalf of the counterparty. If these services are determined to be distinct from the other promises or performance obligations identified in the arrangement, we recognize the transaction price allocated to these services as revenue over time based on an appropriate measure of progress when the performance by us does not create an asset with an alternative use and we have an enforceable right to payment for the performance completed to date.  If these services are determined not to be distinct from the other promises or performance obligations identified in the arrangement, we recognize the transaction price allocated to the combined performance obligation as the related performance obligations are satisfied. </span></div><div style="text-indent:36pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Customer Options. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">If an arrangement contains customer options, we evaluate whether the options are material rights because they allow the customer to acquire additional goods or services for free or at a discount. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the outset of the arrangement. We allocate the transaction price to material rights based on the relative standalone selling price, which is determined based on the identified discount and the probability that the customer will exercise the option. Amounts allocated to a material right are not recognized as revenue until, at the earliest, the option is exercised.  If the options are deemed not to be a material right, they are excluded as performance obligations at the outset of the arrangement. </span></div><div style="text-indent:36pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Milestone Payments. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">At the inception of each arrangement that includes development milestone payments, management evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within our control or the licensee's control, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. We evaluate factors such as the scientific, clinical, regulatory, commercial, and other risks that must be overcome to</span></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">46</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> achieve the particular milestone in making this assessment. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. At the end of each subsequent reporting period, management reevaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. </span></div><div style="text-indent:36pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Royalties. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">For arrangements that include sales-based royalties which are the result of a customer-vendor relationship and for which the license is deemed to be the predominant item to which the royalties relate, we recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied or partially satisfied. To date, we have not recognized any royalty revenue resulting from any of our licensing arrangements. </span></div><div style="text-indent:36pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">We analyze our collaboration arrangements to assess whether such arrangements involve joint operating activities performed by parties who are both active participants in the activities and are both exposed to significant risks and rewards dependent on the commercial success of such activities. Such arrangements generally are within the scope of ASC 808, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Collaborative Arrangements</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> (ASC 808). While ASC 808 defines collaborative arrangements and provides guidance on income statement presentation, classification, and disclosures related to such arrangements, it does not address recognition and measurement matters, such as (1)&#160;determining the appropriate unit of accounting or (2) when the recognition criteria are met. Therefore, the accounting for these arrangements is either based on an analogy to other accounting literature or an accounting policy election by management. We account for certain components of the collaboration agreement that are reflective of a vendor-customer relationship (e.g., licensing arrangement) based on an analogy to ASC 606. We account for other components based on a reasonable, rational and consistently applied accounting policy election.&#160;&#160; Reimbursements from the counter-party that are the result of a collaborative relationship with the counter-party, instead of a customer relationship, such as co-development activities, are recorded as a reduction to research and development expense as the services are performed.</span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Research and Development Expense and related Accrued Expenses</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">As part of the process of preparing our consolidated financial statements, we may be required to estimate accrued expenses. In order to obtain reasonable estimates, we review open contracts and purchase orders. In addition, we communicate with applicable personnel in order to identify services that have been performed, but for which we have not yet been invoiced. In most cases, our vendors provide us with monthly invoices in arrears for services performed. We confirm our estimates with these vendors and make adjustments as needed. The following are examples of our accrued expenses:</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">Fees paid to </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">clinical research organizations (CROs) for services performed on clinical trials;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">Fees paid to investigator sites for performance on clinical trials; </span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">Fees paid for professional services; and</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">Development expenses incurred by our collaborators that we share. &#160;</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The majority of expenses related to clinical trials performed by our CROs are dependent on the successful enrollment of patients. These expenses can vary from site to site and contract to contract. We base our estimated accruals on the time period over which the services are to be performed and the level of effort to be expended in each period based on the estimated enrollment of patients in each trial. We also receive estimates from our collaborators when we are sharing development expenses.  We use these estimates to record an increase or decrease in research and development expense, depending on how much we have each spent during the period.  We will adjust accordingly should the estimates vary from the actual expenses. However, we do not anticipate that our actual expenses will differ materially from our estimates.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">&#160; </span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Income Taxes</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Deferred tax assets and liabilities are determined based on differences between the financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. The effect on deferred tax assets and liabilities of a change in tax rates is recognized as income in the period that such tax rate changes are enacted. The measurement of a deferred tax asset is reduced, if necessary, by a valuation allowance if it is more likely than not that some portion or all of the deferred tax asset will not be realized. Financial statement recognition of a tax position taken or expected to be taken in a tax return is determined based on a more-likely-than-not threshold of that position being sustained. If the tax position meets this threshold, the benefit to be recognized is measured as the largest amount that is more than 50% likely to be realized upon ultimate settlement. Our policy is to record interest and penalties related to uncertain tax positions as a component of income tax expense.&#160;</span></div><div style="text-indent:36pt;"></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">47</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">We recorded net deferred tax assets of $172.5 million&#160; as of December&#160;31, 2018, which have been fully offset by a valuation allowance due to uncertainties surrounding our ability to realize these tax benefits. The deferred tax assets are primarily comprised of federal and state tax net operating loss (NOL) carryforwards and research and development tax credit carryforwards. As of December&#160;31, 2018, we had federal and state NOL carryforwards of $415.6 million.  Of these NOLs, $237.8 million will expire in various years beginning in 2025 through 2037.&#160;$177.8 million of NOLs were generated post December 31, 2017 and carryforward indefinitely. As of December&#160;31, 2018, we had&#160; research and development tax credit carryforwards of $52.3 million available, which will begin to expire at various dates starting in 2022. We are already subject to Section 382 limitations due to acquisitions we made in 2002 and 2008. Future changes in stock ownership may also trigger an ownership change and, consequently, another Section 382 limitation. Any limitation may result in expiration of a portion of the net operating loss or tax credit carryforwards before utilization which would reduce our gross deferred income tax assets and corresponding valuation allowance. As a result, if we earn net taxable income, our ability to use our pre-change net operating loss carryforwards and tax credit carryforwards to reduce United States federal income tax may be subject to limitations, which could potentially result in increased future cash tax liability to us.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">&#160;</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">On December 22, 2017, the Tax Cuts and Jobs Act of 2017 (the Tax Act) was signed into law making significant changes to the Internal Revenue Code, which included how the U.S. imposes income tax on multinational corporations.  Key changes in the Tax Act which are relevant to us, and generally effective January 1, 2018, include a flat corporate income tax rate of 21% to replace the marginal rates that range from 15% to 35% and the elimination of the corporate alternative minimum tax.  The Tax Act also imposes limits on executive compensations and interest expense deductions, while permitting the immediate expensing for the cost of new investments in certain property acquired after September 27, 2017.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">On December 22, 2017, the SEC issued Staff Accounting Bulletin No. 118 (SAB 118) to address the application of U.S. generally accepted accounting principles (GAAP) in situations when a registrant does not have the necessary information available, prepared, or analyzed (including computations) in reasonable detail to complete the accounting for certain income tax effects of the Tax Act.  SAB 118 allows registrants to include a provisional amount to account for the implications of the Tax Act where a reasonable estimate can be made and requires the completion of the accounting no later than one year from the date of the enactment of the Tax Act, or December 22, 2018.&#160;We recognized the provisional tax impacts related to the re-measurement of our U.S. deferred tax assets and liabilities to 21% in 2017 and included these amounts in our consolidated financial statements for the year ended December 31, 2017.  This change in value of these deferred tax assets and liabilities was offset by a corresponding change in valuation allowance, thus no tax expense or benefit was recorded. We completed our evaluation of the effects of the Tax Act during the fourth quarter of 2018, and the provisional amounts we accounted for in our December 31, 2017 provision were finalized with no adjustments.  </span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Stock-Based Compensation</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">We recognize stock-based compensation expense in accordance with the provisions of ASC Topic 718, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Compensation&#8212;Stock Compensation</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">. The fair value of stock-based payments is estimated, on the date of grant, using a Black-Scholes model. The resulting fair value is recognized on a straight-line basis over the requisite service period, which is generally the vesting period of the option. The use of a Black-Scholes model requires us to apply judgment and make assumptions and estimates that include the following:&#160;</span></div><div style="text-indent:-18pt;padding-left:46pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:6pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;padding-left:15.9pt;">Fair Value of Common Stock</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">&#8211;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> Before our entry into the public market on October 10, 2013, our Board of Directors determined the fair value of the common stock. The Board of Directors made determinations of fair value based, in part, upon contemporaneous valuations to determine fair value. The contemporaneous valuations were performed in accordance with applicable methodologies, approaches and assumptions of the technical practice-aid issued by the American Institute of Certified Public Accountants Practice Aid entitled </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Valuation of Privately-Held Company Equity Securities Issued as Compensation</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">.</span></div><div style="text-indent:-18pt;padding-left:46pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:6pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;padding-left:15.9pt;">Expected Volatility</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> &#8211; Volatility is a measure of the amount by which a financial variable such as a share price has fluctuated (historical volatility) or is expected to fluctuate (expected volatility) during a period. As we do not yet have sufficient history of our own volatility, we have identified several public entities of similar size, complexity and stage of development and estimate volatility based on the volatility of these companies.</span></div><div style="text-indent:-18pt;padding-left:46pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:6pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;padding-left:15.9pt;">Expected Dividend Yield</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> &#8211; We have never declared or paid dividends and have no plans to do so in the foreseeable future.</span></div><div style="text-indent:-18pt;padding-left:46pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:6pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;padding-left:15.9pt;">Risk-Free Interest Rate</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> &#8211; This is the U.S. Treasury rate for the week of each option grant during the year, having a term that most closely resembles the expected life of the option.</span></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">48</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-indent:-18pt;padding-left:46pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:6pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;padding-left:15.9pt;">Expected Term</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> &#8211; This is the period of time that the options granted are expected to remain unexercised. Options granted have a maximum term of ten years and we have estimated the expected life of the option term to be 6.25 years. We use a simplified method to calculate the average expected term.</span></div><div style="text-indent:-18pt;padding-left:46pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:6pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;padding-left:15.9pt;">Expected Forfeiture Rate</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> &#8211; The forfeiture rate is the estimated percentage of options granted that is expected to be forfeited or canceled on an annual basis before becoming fully vested. We estimate the forfeiture rate based on turnover data with further consideration given to the class of the employees to whom the options were granted.</span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Recent Accounting Pronouncements</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">See Note 2, Summary of Significant Accounting Policies, to the consolidated financial statements for information under the caption "Recently Issued Accounting Standards."</span></div><div id="i_0_237"></div><div style="margin-top:6pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">Results of Operations for the Years Ended December 31, 2018 and 2017</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">&#160;</span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Revenue</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The following represents a comparison of our revenue for the years ended December 31, 2018 and 2017:</span></div><div style="margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.269006%;"><tr><td style="width:1.0%;"></td><td style="width:42.771723%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.254786%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.536377%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.254786%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.536377%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.254786%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.536377%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.254786%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;height:14pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;height:14pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Increase/(Decrease)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;height:13pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(dollars in millions)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenue from collaborative agreements</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">58.6&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">155.5&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(96.9)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(62)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenue from government agreements</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1.5&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2.2&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.7)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(32)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total revenue</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">60.1&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">157.7&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(97.6)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(62)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The decrease of $96.9 million&#160;in revenue from collaborative agreements for the year ended December 31, 2018 compared to the year ended December 31, 2017 was primarily due to:</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The $150.0 million upfront payment recognized under the Incyte agreement during the year ended December 31, 2017;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">Revenue recognized under the Incyte clinical </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">supply agreement of $22.2 million&#160;and the Incyte license agreement of $18.8 million during the year ended December 31, 2018; and</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:100%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:100%;padding-left:14.5pt;">Recogn</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:100%;">ition of $4.0 million in revenue under an&#160;agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (Roche)&#160;and $6.1 million under an agreement with Provention Bio, Inc. (Provention) during the year ended December 31, 2018 (see Note 8 of the Notes to the Consolidated Financial Statements for additional information about these agreements).</span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Research and Development Expenses</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The following represents a comparison of our research and development expenses for the years ended December 31, 2018 and 2017:</span></div><div style="margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.269006%;"><tr><td style="width:1.0%;"></td><td style="width:42.771723%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.254786%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.536377%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.254786%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.536377%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.254786%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.536377%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.254786%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;height:14pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;height:14pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Increase/(Decrease)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;height:12pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(dollars in millions)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Margetuximab</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">68.4&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">48.2&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">20.2&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">42&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">MGA012</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">28.6&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">13.8&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">14.8&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">107&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Enoblituzumab</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">15.8&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">21.8&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(6.0)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(28)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Flotetuzumab (a)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">14.4&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">6.3&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">8.1&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">129&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">MGD013</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">10.3&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">5.7&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">4.6&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">81&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">MGD009</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">8.9&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">3.9&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">5.0&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">128&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">MGC018</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">7.0&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">10.1&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(3.1)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(31)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">MGD007</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">6.7&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">6.2&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">0.5&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">MGD019</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">5.5&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">6.6&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.1)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(17)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Other immune modulator programs</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">6.4&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">6.3&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">0.1&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Discovery and other pipeline programs, collectively</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">18.8&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">18.3&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">0.5&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total research and development expenses</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">190.8&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">147.2&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">43.6&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">30&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div><div style="margin-bottom:9pt;"></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">49</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">(a) Expenses are shown net of reimbursements from collaborator.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Research and development expenses&#160;were&#160;$190.8 million for the year ended December 31, 2018 compared to $147.2 million for the year ended December 31, 2017.  The increase of $43.6 million&#160;was primarily attributable to:</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:3pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">Increased clinical trial costs r</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">elated to our ongoing margetuximab Phase 3 SOPHIA study;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:3pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">Increase</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">d manufacturing costs related to the clinical supply of margetuximab;</span></div><div style="text-indent:-18pt;padding-left:54pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;padding-left:14.5pt;">Incr</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">eased clinical trial costs related to completing enrollment in a first acute myeloid leukemia (AML)&#160;dose expansion cohort of our Phase 1 flotetuzumab&#160;study in 2018 and continued enrollment in an additional cohort expansion of this study;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:3pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">Increase</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">d clinical trial costs related to the Phase 1 study of MGD009 as monotherapy and in combination with MGA012;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:3pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">I</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">ncreased development and manufacturing costs related to the clinical supply of MGA012&#160;for Incyte's clinical trials and our trials of MGA012 in combination with DART molecules;&#160;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:3pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">Clinic</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">al trial costs related to our MGD013 Phase 1 study initiated in the second half of 2017; and</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:3pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">Increased</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> headcount&#160;to support expanded manufacturing and development activities. </span></div><div style="text-indent:-27pt;padding-left:27pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">These increases were partially offset by:</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:3pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">Reduced clinical trial costs </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">related to our enoblituzumab studies;&#160;and</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:3pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">Reduced clinical trial costs for </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">MGA012, as the monotherapy trial was transferred to Incyte in 2018.</span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">General and Administrative Expenses</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The following represents a comparison of our general and administrative expenses for the years ended December 31, 2018 and 2017:</span></div><div style="margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:46.391813%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.695906%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.695906%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.384795%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.327485%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.384795%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.988304%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;height:14pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;height:14pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Increase/(Decrease)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;height:13pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(dollars in millions)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">General and administrative expenses</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">40.5&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">32.7&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">7.8&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">24&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">General and administrative expenses increased for the year ended December 31, 2018 by&#160;$7.8 million compared to 2017 primarily due to an increase in labor-related costs, including stock-based compensation expense, patent expenses and information technology-related expenses.</span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Other Income (Expense)</span></div><div style="text-indent:36pt;margin-bottom:15pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The change to other expense&#160;for the year ended December 31, 2018 from other income&#160;for the year ended December 31, 2017&#160;is primarily due the revaluation of the warrants we received as consideration under the Provention license agreement of $4.2 million.  </span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">Results of Operations for the Years Ended December 31, 2017 and 2016</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">&#160;</span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Revenue</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The following represents a comparison of our revenue for the years ended December 31, 2017 and 2016:</span></div><div style="margin-bottom:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.269006%;"><tr><td style="width:1.0%;"></td><td style="width:42.771723%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.254786%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.536377%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.254786%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.536377%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.254786%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.536377%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.254786%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;height:14pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;height:14pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Increase/(Decrease)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2016</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;height:13pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(dollars in millions)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenue from collaborative agreements</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">155.5&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">86.6&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">68.9&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">80&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenue from government agreements</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2.2&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">5.3&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(3.1)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(58)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total revenue</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">157.7&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">91.9&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">65.8&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">72&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div><div style="text-indent:40.5pt;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Revenue from collaborative agreements for the year ended December 31, 2017 includes the $150.0 million upfront payment recognized under the Incyte agreement. Revenue from collaborative agreements for the year ended December 31, 2016 includes the $75.0 million upfront payment recognized under our MGD015 agreement with Janssen Biotech, Inc. (Janssen).  The remaining change in revenue from collaborative agreements is primarily due to a $2.0 million milestone payment from</span></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">50</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> Pfizer, Inc. in 2016 and a decrease in revenue recognized under the our MGD010 agreement with Takeda Pharmaceutical Company, Limited (Takeda) of $2.1 million for the year ended December 31, 2017 compared to 2016.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Revenue from government agreements decreased for the year ended December 31, 2017 compared to 2016 primarily due to lower costs incurred under our cost plus fixed fee contract with the National Institute of Allergy and Infectious Diseases. </span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Research and Development Expenses</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The following represents a comparison of our research and development expenses for the years ended December 31, 2017 and 2016:</span></div><div style="margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.269006%;"><tr><td style="width:1.0%;"></td><td style="width:42.771723%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.254786%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.536377%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.254786%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.536377%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.254786%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.536377%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.254786%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;height:14pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;height:14pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Increase/(Decrease)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2016</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;height:13pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(dollars in millions)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Margetuximab</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">48.2&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">35.4&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">12.8&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">36&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Enoblituzumab</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">21.8&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">18.0&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">3.8&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">21&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Flotetuzumab (a)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">6.3&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">3.8&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2.5&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">66&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">MGD007</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">6.2&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">3.6&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2.6&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">72&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">MGD009</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">3.9&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">3.3&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">0.6&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">18&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">MGD010</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">3.6&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">7.8&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(4.2)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(54)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">MGA012</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">13.8&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">9.3&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">4.5&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">48&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">MGD013</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">5.7&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">8.7&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(3.0)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(34)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">MGC018</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">10.1&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">3.5&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">6.6&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">189&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">MGD019</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">6.6&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">4.8&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1.8&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">38&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Other immune modulator programs</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">6.3&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1.5&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">4.8&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">320&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Discovery and other pipeline programs, collectively</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">14.7&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">22.4&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(7.7)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(34)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total research and development expenses</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">147.2&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">122.1&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">25.1&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">21&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">(a) Expenses are shown net of reimbursements from collaborator.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">During the year ended December 31, 2017, our research and development expenses&#160;increased by $25.1 million compared to 2016. This increase was primarily due to the continued enrollment in our various clinical trials, including two margetuximab studies, multiple enoblituzumab studies, and the flotetuzumab and MGD007 Phase 1 studies.  Also contributing to the increase was the initiation of the Phase 1 clinical trial of MGA012 in late 2016, as well as Investigational New Drug (IND)-enabling activities for both MGC018 and MGD019.  These increases were partially offset by decreased spending on MGD010 due to the completion of a Phase 1 study and decreased spending on MGD013, as IND-enabling activities ended and the dose escalation study began in 2017.</span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">General and Administrative Expenses</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The following represents a comparison of our general and administrative expenses for the years ended December 31, 2017 and 2016:</span></div><div style="margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:46.391813%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.695906%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.695906%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.384795%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.327485%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.384795%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.988304%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;height:14pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;height:14pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Increase/(Decrease)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2016</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;height:13pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(dollars in millions)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">General and administrative expenses</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">32.7&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">29.8&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2.9&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">10&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">General and administrative expenses&#160;increased for the year ended December 31, 2017 by $2.9 million compared to 2016 primarily due to an increase in labor-related costs, including stock-based compensation expense, and information technology-related expenses, partially offset by lower patent expenses.</span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Other Income</span></div><div style="text-indent:36pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The increase in other income for the years ended December 31, 2017 and 2016 is primarily due to an increase in interest income earned on marketable securities.</span></div><div style="text-indent:36pt;margin-bottom:12pt;"><span><br/></span></div><div id="i_0_249"></div><div style="margin-top:3pt;margin-bottom:9pt;"></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">51</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="margin-top:3pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">Liquidity and Capital Resources</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">We have historically financed our operations primarily through public and private offerings of equity, upfront fees, milestone payments and license option fees from collaborators and reimbursement through government grants and contracts.&#160;&#160;&#160; As of December&#160;31, 2018, we had $232.9 million in cash, cash equivalents and marketable securities. In addition to our existing cash, cash equivalents and marketable securities, we are eligible to receive additional reimbursement from our collaborators, including under various government grants or contracts, for certain research and development services rendered, additional milestone and opt-in payments and grant revenue. However, our ability to receive these milestone payments is dependent upon our ability to successfully complete specified research and development activities and is therefore uncertain at this time.</span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Funding Requirements</span></div><div style="text-indent:36pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">We have not generated any revenue from product sales to date and do not expect to do so until such time as we obtain regulatory approval for and commercialize one or more of our product candidates. As we are currently in the clinical trial stage of development, it will be some time before we expect to generate revenue from product sales and it is uncertain that we ever will. We expect that we will continue to increase our operating expenses in connection with ongoing as well as additional clinical trials and preclinical development of product candidates in our pipeline. We expect to continue our collaboration arrangements and will look for additional collaboration opportunities. We also expect to continue our efforts to pursue additional grants and contracts from the U.S. government in order to further our research and development. Although it is difficult to predict our funding requirements, based upon our current operating plan, we anticipate that our existing cash, cash equivalents and marketable securities as of December&#160;31, 2018, combined with the net proceeds from our February 2019 offering of common stock and other collaboration payments we anticipate receiving, will enable us to fund our operations into 2021, assuming all of our programs and collaborations advance as currently contemplated.</span></div><div style="text-indent:36pt;margin-top:9pt;"><span><br/></span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Cash Flows</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The following table represents a summary of our cash flows for the years ended December&#160;31, 2018, 2017 and 2016:</span></div><div style="margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415205%;"><tr><td style="width:1.0%;"></td><td style="width:64.029412%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:8.882353%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.535294%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.735294%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.535294%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.882353%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;height:13pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2016</span></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;height:13pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(dollars in millions)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash provided by (used in):</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating activities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(153.2)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">14.4&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(43.7)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Investing activities</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">56.6&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">77.9&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(70.2)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Financing activities</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">105.0&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">35.3&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1.9&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Net increase (decrease) in cash and cash equivalents</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">8.4&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">127.6&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(112.0)</span></td></tr></table></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Operating Activities</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">Net cash provided by or used in operating activities reflects, among other things, the amounts used to advance our clinical trials and preclinical activities, and cash used for capital expenditures. The principal use of cash in operating activities for all periods presented was to fund our net loss, adjusted for non-cash items, with the year ended December 31, 2017 benefiting from the $150.0 million upfront payment from Incyte, resulting in cash provided by operations. Cash used for operating activities during the year ended December 31, 2016 benefited from the $75.0 million upfront payment received from Janssen.</span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Investing Activities</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Net cash provided by investing activities during the years ended December&#160;31, 2018 and December&#160;31, 2017&#160; is primarily due to maturities of marketable securities, partially offset by purchases of marketable securities and making leasehold improvements to our facilities, including the build out of a manufacturing suite at our headquarters building in Rockville, Maryland.  Net cash used in investing activities during the year&#160;ended&#160;December&#160;31, 2016 is primarily due to investing our cash in marketable securities and making leasehold improvements to our facilities.&#160; </span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Financing Activities</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Net cash provided by financing activities for the year ended December&#160;31, 2018 reflects net cash proceeds from our securities offering of approximately $103.3 million, and cash from stock option exercises and the purchase of shares under our employee stock purchase plan.  Net cash provided by financing activities for the year ended December&#160;31, 2017&#160;reflects net cash proceeds from our securities offerings of approximately&#160;$34.2 million and cash from stock option exercises and the</span></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">52</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> purchase of shares under our employee stock purchase plan.&#160;Net cash provided by financing activities for the year ended December&#160;31, 2016 includes cash from stock option exercises.&#160;</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span><br/></span></div><div id="i_0_261"></div><div style="margin-top:3pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">Contractual Obligations and Contingent Liabilities</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Our current obligations and contingent liabilities are limited to the operating leases at our facilities in Rockville, Maryland and Brisbane, California.&#160;The following table represents future minimum operating lease payments under non-cancelable operating leases as of December&#160;31, 2018:</span></div><div style="margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"><tr><td style="width:1.0%;"></td><td style="width:27.515419%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.509545%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534214%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.509545%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534214%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.509545%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534214%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.509545%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534214%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.509545%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Less than 1 year</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1 to 3 years</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">3 to 5 years</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">More than 5 years</span></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="27" style="padding-top:2px;padding-bottom:2px;height:13pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(in millions)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating Leases</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">39.1&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">6.3&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">9.5&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">9.5&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">13.8&#160;</span></td></tr></table></div><div style="text-indent:36pt;margin-bottom:9pt;"><span><br/></span></div><div id="i_0_273"></div><div style="margin-top:3pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">Off-Balance Sheet Arrangements</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">We do not have any off-balance sheet arrangements, as defined under the rules and regulations of the Securities and Exchange Commission.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span><br/></span></div><div id="i_0_285"></div><div style="text-indent:-36pt;padding-left:36pt;margin-top:3pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">ITEM 7A.                         QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Our primary objective when considering our investment activities is to preserve capital in order to fund our operations.&#160;We also seek to maximize income from our investments without assuming significant risk.&#160;&#160;Our current investment policy is to invest principally in deposits and securities issued by the U.S. government and its agencies, Government Sponsored Enterprise agency debt obligations, corporate debt obligations and money market instruments.&#160;&#160;As of December&#160;31, 2018, we had cash, cash equivalents and marketable securities of $232.9 million.&#160;Our primary exposure to market risk is related to changes in interest rates.&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;">Due to the short-term maturities of our cash equivalents and marketable securities and the low risk profile of our marketable securities, an immediate 100 basis point change in interest rates would not have a material effect on the fair market value of our cash equivalents and marketable securities. We have the ability to hold our marketable securities until maturity, and we therefore do not expect a change in market interest rates to affect our operating results or cash flows to any significant degree.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span><br/></span></div><div id="i_0_297"></div><div style="text-indent:-36pt;padding-left:36pt;margin-top:3pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">ITEM 8.&#160;FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The information required by this item is set forth on pages F-1 - F-26.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span><br/></span></div><div id="i_0_309"></div><div style="text-indent:-72pt;padding-left:72pt;margin-top:3pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">ITEM 9.&#160;CHANGES AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">FINANCIAL DISCLOSURE</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">None.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span><br/></span></div><div id="i_0_321"></div><div style="text-indent:-36pt;padding-left:36pt;margin-top:3pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">ITEM 9A.&#160;CONTROLS AND PROCEDURES</span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">Disclosure Controls and Procedures</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Our management, including our principal executive and principal financial officers, has evaluated the effectiveness of our disclosure controls and procedures as of December&#160;31, 2018. Our disclosure controls and procedures are designed to provide reasonable assurance that the information required to be disclosed in this annual report on Form 10-K has been appropriately recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission's rules and forms, and that such information is accumulated and communicated to our management, including our principal executive and principal financial officers, to allow timely decisions regarding required disclosure.&#160;&#160;Based on that evaluation, our principal executive and principal financial officers have concluded that our disclosure controls and procedures are effective at the reasonable assurance level.</span></div><div style="margin-bottom:9pt;"><span><br/></span></div><div style="margin-bottom:9pt;"></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">53</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">Changes in Internal Control</span></div><div style="text-indent:36pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;">We completed a phased implementation of a new enterprise resource planning&#160;(ERP) system during 2018, which replaced or enhanced certain internal financial, operating and other systems that are critical to our business operations. &#160;The ERP implementation affected the processes that constitute our internal control over financial reporting.  Management has taken steps to ensure that appropriate controls were designed and implemented as the new ERP system was implemented.  </span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">With the exception of the ERP implementation described above, there were no changes in the Company's internal control over financial reporting that occurred during the quarterly period ended December&#160;31, 2018 that have materially affected, or are reasonably likely to materially effect, the Company's internal control over financial reporting.</span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">Management's Report on Internal Control over Financial Reporting</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The management of the Company is responsible for establishing and maintaining adequate internal control over financial reporting.&#160;&#160;Internal control over financial reporting is defined in Rule 13a-15(f) or 15d-15(f) promulgated under the Securities Exchange Act of 1934, as amended, as a process designed by, or under the supervision of, the Company's principal executive and principal financial officers and effected by the Company's board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles and includes those policies and procedures that:</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:3pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">pertain to the management of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of the Company;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:3pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the Company are being made only in accordance with authorizations of management and directors of the Company; and</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:3pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the Company's assets that could have a material effect on the financial statements.</span></div><div style="text-indent:36pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements.&#160;&#160;Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.&#160;&#160;All internal control systems, no matter how well designed, have inherent limitations.&#160;&#160;Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Company's management assessed the effectiveness of the Company's internal control over financial reporting as of December&#160;31, 2018.&#160;&#160;In making this assessment, the Company's management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (COSO) in Internal Control-Integrated Framework.&#160; Based on our assessment, management believes that, as of December&#160;31, 2018, the Company's internal control over financial reporting is effective based on those criteria.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The effectiveness of our internal control over financial reporting as of December&#160;31, 2018 has been audited by Ernst &amp; Young, LLP, an independent registered public accounting firm, as stated in their report which is included herein on page 55.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span><br/></span></div><div id="i_0_333"></div><div style="text-indent:-36pt;padding-left:36pt;margin-top:3pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">ITEM 9B.&#160;OTHER INFORMATION</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">None.</span></div><div id="i_0_345"></div><div style="text-align:center;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">54</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:center;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:174%;">Report of Independent Registered Public Accounting Firm</span></div><div style="text-align:center;margin-top:8pt;margin-bottom:8pt;"><span><br/></span></div><div style="margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:174%;">To the Shareholders and the Board of Directors of MacroGenics, Inc. </span></div><div style="margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">Opinion on Internal Control over Financial Reporting</span></div><div style="margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">We have audited MacroGenics, Inc.&#8217;s internal control over financial reporting as of December&#160;31, 2018, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). In our opinion, MacroGenics, Inc. (the Company) maintained, in all material respects, effective internal control over financial reporting as of December&#160;31, 2018, based on the COSO criteria.</span></div><div style="margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of December&#160;31, 2018 and 2017, the related consolidated statements of operations and comprehensive loss, stockholders&#8217; equity and cash flows for each of the three years in the period ended December&#160;31, 2018, and the related notes and our report dated February&#160;26, 2019, expressed an unqualified opinion thereon. </span></div><div style="margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">Basis for Opinion</span></div><div style="margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management&#8217;s Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. </span></div><div style="margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</span></div><div style="margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">Definition and Limitations of Internal Control Over Financial Reporting</span></div><div style="margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1)&#160;pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2)&#160;provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3)&#160;provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></div><div style="margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span><br/></span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">/s/ Ernst &amp; Young LLP</span></div><div style="margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Baltimore, Maryland</span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">February&#160;26, 2019&#160;</span></div><div id="i_0_358"></div><div style="text-align:center;margin-bottom:9pt;"></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">55</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">PART III</span></div><div id="i_0_371"></div><div style="text-indent:-36pt;padding-left:36pt;margin-top:3pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">ITEM 10.&#160;DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">We incorporate herein by reference the relevant information concerning directors, executive officers and corporate governance to be included in our definitive proxy statement for the 2019 annual meeting of stockholders (the 2019 Proxy Statement).</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span><br/></span></div><div id="i_0_383"></div><div style="text-indent:-36pt;padding-left:36pt;margin-top:3pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">ITEM 11.&#160;EXECUTIVE COMPENSATION</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">We incorporate herein by reference the relevant information concerning executive compensation to be included in the 2019 Proxy Statement.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span><br/></span></div><div id="i_0_395"></div><div style="text-indent:-72pt;padding-left:72pt;margin-top:3pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">ITEM 12.&#160;SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">We incorporate herein by reference the relevant information concerning security ownership of certain beneficial owners and management to be included in the 2019 Proxy Statement.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span><br/></span></div><div id="i_0_407"></div><div style="text-indent:-72pt;padding-left:72pt;margin-top:3pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">ITEM 13. &#160;&#160;CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">We incorporate herein by reference the relevant information concerning certain other relationships and related transactions to be included in the 2019 Proxy Statement.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span><br/></span></div><div id="i_0_419"></div><div style="text-indent:-36pt;padding-left:36pt;margin-top:3pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">ITEM 14.&#160;PRINCIPAL ACCOUNTANT FEES AND SERVICES</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">We incorporate herein by reference the relevant information concerning principal accountant fees and services to be included in the 2019 Proxy Statement.</span></div><div id="i_0_431"></div><div style="text-align:center;margin-bottom:9pt;"></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">56</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">PART IV</span></div><div id="i_0_444"></div><div style="text-indent:-36pt;padding-left:36pt;margin-top:3pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">ITEM 15. &#160;EXHIBITS AND FINANCIAL STATEMENT SCHEDULES</span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">(a) The following documents are filed as part of this Annual Report on Form 10-K:</span></div><div style="text-indent:-18pt;padding-left:28pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">1.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:10.5pt;">Consolidated Financial Statements:</span></div><div style="margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415205%;"><tr><td style="width:1.0%;"></td><td style="width:71.823529%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:24.176471%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Report of Ernst &amp; Young LLP, Independent Registered Public Accounting Firm</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_495">F - </a><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_495">1</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Consolidated Balance Sheets</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_508">F - </a><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_508">2</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Consolidated Statements of Operations and Comprehensive Loss</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_535">F - </a><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_535">3</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Consolidated Statements of Stockholders' Equity</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_547">F - </a><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_547">4</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Consolidated Statements of Cash Flows</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_560">F - </a><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_560">5</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Notes to Consolidated Financial Statements</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_573">F - </a><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_573">6</a></span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td></tr></table></div><div style="text-indent:-18pt;padding-left:28pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">2.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:10.5pt;">Financial Statement Schedules:</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">All financial statement schedules have been omitted because they are not applicable, not required or the information required is shown in the financial statements or the notes thereto.&#160;</span></div><div style="text-indent:-18pt;padding-left:28pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">3.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:10.5pt;">Exhibits</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The exhibits filed as part of this Annual Report on Form 10-K are set forth on the Exhibit Index immediately following our consolidated financial statements. The Exhibit Index is incorporated herein by reference.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span><br/></span></div><div id="i_0_456"></div><div style="text-indent:-36pt;padding-left:36pt;margin-top:3pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">ITEM 16.&#160;FORM 10-K SUMMARY</span></div><div style="text-indent:36pt;margin-top:9pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Not applicable.</span></div><div><span><br/></span></div><div id="i_0_468"></div><div style="text-indent:27pt;text-align:center;margin-top:6pt;margin-bottom:9pt;"></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">57</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-indent:27pt;text-align:center;margin-top:6pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">SIGNATURES</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized:</span></div><div style="margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.538012%;"><tr><td style="width:1.0%;"></td><td style="width:46.813056%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:5.715134%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:41.471810%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">MacroGenics, Inc.</span></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">By:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">/s/ Scott Koenig</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Scott Koenig, M.D., Ph.D.</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-style:italic;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">President and CEO and Director</span></td></tr></table></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Pursuant to the requirements of the Securities Act of 1934, as amended, this Report has been signed by the following persons on behalf of the registrant and in the capacities and on the dates indicated:</span></div><div style="margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"><tr><td style="width:1.0%;"></td><td style="width:28.837004%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534214%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:34.563877%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534214%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:29.130690%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Signature</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Title</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Date</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">/s/ Scott Koenig</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">President and CEO and Director</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">February 26, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Scott Koenig, M.D., Ph.D.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(Principal Executive Officer)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">/s/ James Karrels</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Senior Vice President, Chief Financial</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">February 26, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">James Karrels</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Officer and Secretary (Principal Financial Officer)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">/s/ Lynn Cilinski</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Vice President, Controller and Treasurer</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">February 26, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Lynn Cilinski</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(Principal Accounting Officer)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">/s/ Paulo Costa</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Director</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">February 26, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Paulo Costa</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">/s/ Karen Ferrante, M.D.</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Director</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">February 26, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Karen Ferrante, M.D.</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">/s/ Matthew Fust</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Director</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">February 26, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Matthew Fust</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">/s/ Kenneth Galbraith</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Director</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">February 26, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Kenneth Galbraith</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">/s/ Edward Hurwitz</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Director</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">February 26, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Edward Hurwitz</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">/s/ Scott Jackson</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Director</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">February 26, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Scott Jackson</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">/s/ Jay Siegel, M.D.</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Director</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">February 26, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Jay Siegel, M.D.</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">/s/ David Stump, M.D.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Director</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">February 26, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">David Stump, M.D.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="margin-bottom:9pt;"><span><br/></span></div><div id="i_0_481"></div><div style="text-align:center;"></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">58</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:84.403509%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.596491%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">Page</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">Number</span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_495">Report of Ernst &amp; Young LLP, Independent Registered Public Accounting Firm</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_495">F - </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_495">1</a></span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_508">Consolidated Balance Sheets at December 31, 2018 and December 31, 2017</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_508">F - </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_508">2</a></span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_535">Consolidated Statements of Operations and Comprehensive Loss for the years ended December 31, 2018, 2017 and 2016</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_535">F - </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_535">3</a></span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_547">Consolidated Statements of Stockholders' Equity for the years ended December 31, 2018, 2017 and 2016</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_547">F - </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_547">4</a></span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_560">Consolidated Statements of Cash Flows for the years ended December 31, 2018, 2017 and 2016</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_560">F - </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_560">5</a></span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_573">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_573">F - </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_573">6</a></span></div></td></tr></table></div><div style="text-align:center;"><span><br/></span></div><div id="i_0_495"></div><div style="text-align:center;"></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div><span><br/></span></div></div></div><hr style="page-break-after:always"></hr><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">Report of Independent Registered Public Accounting Firm</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">To the Shareholders and the Board of Directors of MacroGenics, Inc. </span></div><div style="margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">Opinion on the Financial Statements</span></div><div style="margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">We have audited the accompanying consolidated balance sheets of MacroGenics, Inc. (the Company) as of December&#160;31, 2018 and 2017, the related consolidated statements of operations and comprehensive loss, stockholders&#8217; equity and cash flows for each of the three years in the period ended December&#160;31, 2018, and the related notes (collectively referred to as the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the consolidated financial position of the Company at December&#160;31, 2018 and 2017, and the consolidated results of its operations and its cash flows for each of the three years in the period ended December&#160;31, 2018, in conformity with U.S. generally accepted accounting principles.</span></div><div style="margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company&#8217;s internal control over financial reporting as of December&#160;31, 2018, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) and our report dated February&#160;26, 2019, expressed an unqualified opinion thereon. </span></div><div style="margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">Adoption of Accounting Standards Update (ASU) No. 2014-09</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">As discussed in Note 2 to the consolidated financial statements, the Company changed its method of accounting for revenue from contracts with customers in 2018 due to the adoption of ASU No. 2014-09, &#8220;Revenues from Contracts with Customers,&#8221; as amended (Topic 606).   </span></div><div style="margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">Basis for Opinion</span></div><div style="margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">These consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s consolidated financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span><br/></span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span><br/></span></div><div style="margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"><tr><td style="width:1.0%;"></td><td style="width:48.000000%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:48.000000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">/s/ Ernst &amp; Young LLP</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">We have served as the Company's auditor since 2006.</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Baltimore, Maryland</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">February 26, 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="text-indent:36pt;margin-bottom:9pt;"><span><br/></span></div><div id="i_0_508"></div><div style="text-align:center;"></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">F - 1</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">MACROGENICS, INC.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">(In thousands, except share and per share data)</span></div><div style="margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"><tr><td style="width:1.0%;"></td><td style="width:73.806452%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.730205%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533138%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.730205%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Assets</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MDgvZnJhZzo3Njg0MzE5YmEwOWQ0NmI4ODAwOTcwNWFiODM5Y2I4Ny90YWJsZTpkOThmOTg5ZjM5ZjE0MDVkODJhNThkOGIxNzhlMzFiOC90YWJsZXJhbmdlOmQ5OGY5ODlmMzlmMTQwNWQ4MmE1OGQ4YjE3OGUzMWI4XzQtMS0xLTEtMA_5b15c368-021b-4e2d-abd7-a6d015d3422c">220,128</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7057397719af459ca7328a1c440a0efa_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MDgvZnJhZzo3Njg0MzE5YmEwOWQ0NmI4ODAwOTcwNWFiODM5Y2I4Ny90YWJsZTpkOThmOTg5ZjM5ZjE0MDVkODJhNThkOGIxNzhlMzFiOC90YWJsZXJhbmdlOmQ5OGY5ODlmMzlmMTQwNWQ4MmE1OGQ4YjE3OGUzMWI4XzQtMy0xLTEtMA_93d7447d-f9dd-432f-bfe1-679c67d5c860">211,727</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Marketable securities</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MDgvZnJhZzo3Njg0MzE5YmEwOWQ0NmI4ODAwOTcwNWFiODM5Y2I4Ny90YWJsZTpkOThmOTg5ZjM5ZjE0MDVkODJhNThkOGIxNzhlMzFiOC90YWJsZXJhbmdlOmQ5OGY5ODlmMzlmMTQwNWQ4MmE1OGQ4YjE3OGUzMWI4XzUtMS0xLTEtMA_bd835bd7-33ff-4e9a-8bca-1d6425932bfa">12,735</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7057397719af459ca7328a1c440a0efa_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MDgvZnJhZzo3Njg0MzE5YmEwOWQ0NmI4ODAwOTcwNWFiODM5Y2I4Ny90YWJsZTpkOThmOTg5ZjM5ZjE0MDVkODJhNThkOGIxNzhlMzFiOC90YWJsZXJhbmdlOmQ5OGY5ODlmMzlmMTQwNWQ4MmE1OGQ4YjE3OGUzMWI4XzUtMy0xLTEtMA_a09bd003-96b0-4c3b-bdb8-397514e0e6a5">93,394</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts receivable</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MDgvZnJhZzo3Njg0MzE5YmEwOWQ0NmI4ODAwOTcwNWFiODM5Y2I4Ny90YWJsZTpkOThmOTg5ZjM5ZjE0MDVkODJhNThkOGIxNzhlMzFiOC90YWJsZXJhbmdlOmQ5OGY5ODlmMzlmMTQwNWQ4MmE1OGQ4YjE3OGUzMWI4XzYtMS0xLTEtMA_259b2c04-d37e-4e3a-b22e-d7042c6e0e4a">29,583</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7057397719af459ca7328a1c440a0efa_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MDgvZnJhZzo3Njg0MzE5YmEwOWQ0NmI4ODAwOTcwNWFiODM5Y2I4Ny90YWJsZTpkOThmOTg5ZjM5ZjE0MDVkODJhNThkOGIxNzhlMzFiOC90YWJsZXJhbmdlOmQ5OGY5ODlmMzlmMTQwNWQ4MmE1OGQ4YjE3OGUzMWI4XzYtMy0xLTEtMA_9a0f8695-9e63-4654-924e-7937ad845ffb">13,643</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid expenses</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MDgvZnJhZzo3Njg0MzE5YmEwOWQ0NmI4ODAwOTcwNWFiODM5Y2I4Ny90YWJsZTpkOThmOTg5ZjM5ZjE0MDVkODJhNThkOGIxNzhlMzFiOC90YWJsZXJhbmdlOmQ5OGY5ODlmMzlmMTQwNWQ4MmE1OGQ4YjE3OGUzMWI4XzctMS0xLTEtMA_459c1eda-dba7-4278-887c-443048608138">6,406</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7057397719af459ca7328a1c440a0efa_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MDgvZnJhZzo3Njg0MzE5YmEwOWQ0NmI4ODAwOTcwNWFiODM5Y2I4Ny90YWJsZTpkOThmOTg5ZjM5ZjE0MDVkODJhNThkOGIxNzhlMzFiOC90YWJsZXJhbmdlOmQ5OGY5ODlmMzlmMTQwNWQ4MmE1OGQ4YjE3OGUzMWI4XzctMy0xLTEtMA_32e9e6bb-8d79-4875-a4f7-e73510203733">3,151</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Other current assets</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231" decimals="-3" name="us-gaap:OtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MDgvZnJhZzo3Njg0MzE5YmEwOWQ0NmI4ODAwOTcwNWFiODM5Y2I4Ny90YWJsZTpkOThmOTg5ZjM5ZjE0MDVkODJhNThkOGIxNzhlMzFiOC90YWJsZXJhbmdlOmQ5OGY5ODlmMzlmMTQwNWQ4MmE1OGQ4YjE3OGUzMWI4XzgtMS0xLTEtMA_fb715e15-0733-4fd6-801e-19583ea7b1b0">272</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7057397719af459ca7328a1c440a0efa_I20171231" decimals="-3" name="us-gaap:OtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MDgvZnJhZzo3Njg0MzE5YmEwOWQ0NmI4ODAwOTcwNWFiODM5Y2I4Ny90YWJsZTpkOThmOTg5ZjM5ZjE0MDVkODJhNThkOGIxNzhlMzFiOC90YWJsZXJhbmdlOmQ5OGY5ODlmMzlmMTQwNWQ4MmE1OGQ4YjE3OGUzMWI4XzgtMy0xLTEtMA_a3119b7f-a2d5-4ac4-867b-5a62785dcb80">383</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total current assets</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MDgvZnJhZzo3Njg0MzE5YmEwOWQ0NmI4ODAwOTcwNWFiODM5Y2I4Ny90YWJsZTpkOThmOTg5ZjM5ZjE0MDVkODJhNThkOGIxNzhlMzFiOC90YWJsZXJhbmdlOmQ5OGY5ODlmMzlmMTQwNWQ4MmE1OGQ4YjE3OGUzMWI4XzktMS0xLTEtMA_0d6ca7e4-ec69-43e9-b716-460f1ca7608e">269,124</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7057397719af459ca7328a1c440a0efa_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MDgvZnJhZzo3Njg0MzE5YmEwOWQ0NmI4ODAwOTcwNWFiODM5Y2I4Ny90YWJsZTpkOThmOTg5ZjM5ZjE0MDVkODJhNThkOGIxNzhlMzFiOC90YWJsZXJhbmdlOmQ5OGY5ODlmMzlmMTQwNWQ4MmE1OGQ4YjE3OGUzMWI4XzktMy0xLTEtMA_b05e39b5-3976-4cd9-a8d9-da4e303ec5f2">322,298</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Property, equipment and software, net</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MDgvZnJhZzo3Njg0MzE5YmEwOWQ0NmI4ODAwOTcwNWFiODM5Y2I4Ny90YWJsZTpkOThmOTg5ZjM5ZjE0MDVkODJhNThkOGIxNzhlMzFiOC90YWJsZXJhbmdlOmQ5OGY5ODlmMzlmMTQwNWQ4MmE1OGQ4YjE3OGUzMWI4XzExLTEtMS0xLTA_adc550ba-a6ca-4425-8797-fb00b31ff703">56,712</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7057397719af459ca7328a1c440a0efa_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MDgvZnJhZzo3Njg0MzE5YmEwOWQ0NmI4ODAwOTcwNWFiODM5Y2I4Ny90YWJsZTpkOThmOTg5ZjM5ZjE0MDVkODJhNThkOGIxNzhlMzFiOC90YWJsZXJhbmdlOmQ5OGY5ODlmMzlmMTQwNWQ4MmE1OGQ4YjE3OGUzMWI4XzExLTMtMS0xLTA_0033a857-38bc-4273-b96f-218c3db281d2">49,983</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Other assets</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MDgvZnJhZzo3Njg0MzE5YmEwOWQ0NmI4ODAwOTcwNWFiODM5Y2I4Ny90YWJsZTpkOThmOTg5ZjM5ZjE0MDVkODJhNThkOGIxNzhlMzFiOC90YWJsZXJhbmdlOmQ5OGY5ODlmMzlmMTQwNWQ4MmE1OGQ4YjE3OGUzMWI4XzEzLTEtMS0xLTA_2d059c38-9685-45a7-8a81-6c40297a67d2">6,294</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7057397719af459ca7328a1c440a0efa_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MDgvZnJhZzo3Njg0MzE5YmEwOWQ0NmI4ODAwOTcwNWFiODM5Y2I4Ny90YWJsZTpkOThmOTg5ZjM5ZjE0MDVkODJhNThkOGIxNzhlMzFiOC90YWJsZXJhbmdlOmQ5OGY5ODlmMzlmMTQwNWQ4MmE1OGQ4YjE3OGUzMWI4XzEzLTMtMS0xLTA_a6e811ec-c1ab-41be-91b1-416d6ad1ec33">1,602</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total assets</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MDgvZnJhZzo3Njg0MzE5YmEwOWQ0NmI4ODAwOTcwNWFiODM5Y2I4Ny90YWJsZTpkOThmOTg5ZjM5ZjE0MDVkODJhNThkOGIxNzhlMzFiOC90YWJsZXJhbmdlOmQ5OGY5ODlmMzlmMTQwNWQ4MmE1OGQ4YjE3OGUzMWI4XzE0LTEtMS0xLTA_ee59a3c5-ee06-4014-bba2-e00f4d138fe7">332,130</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7057397719af459ca7328a1c440a0efa_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MDgvZnJhZzo3Njg0MzE5YmEwOWQ0NmI4ODAwOTcwNWFiODM5Y2I4Ny90YWJsZTpkOThmOTg5ZjM5ZjE0MDVkODJhNThkOGIxNzhlMzFiOC90YWJsZXJhbmdlOmQ5OGY5ODlmMzlmMTQwNWQ4MmE1OGQ4YjE3OGUzMWI4XzE0LTMtMS0xLTA_64fa7a4b-5392-40bc-9266-76968a2cc639">373,883</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Liabilities and stockholders' equity</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts payable</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MDgvZnJhZzo3Njg0MzE5YmEwOWQ0NmI4ODAwOTcwNWFiODM5Y2I4Ny90YWJsZTpkOThmOTg5ZjM5ZjE0MDVkODJhNThkOGIxNzhlMzFiOC90YWJsZXJhbmdlOmQ5OGY5ODlmMzlmMTQwNWQ4MmE1OGQ4YjE3OGUzMWI4XzE4LTEtMS0xLTA_645f9cd2-ce31-4bf9-bfa7-582715481341">4,005</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7057397719af459ca7328a1c440a0efa_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MDgvZnJhZzo3Njg0MzE5YmEwOWQ0NmI4ODAwOTcwNWFiODM5Y2I4Ny90YWJsZTpkOThmOTg5ZjM5ZjE0MDVkODJhNThkOGIxNzhlMzFiOC90YWJsZXJhbmdlOmQ5OGY5ODlmMzlmMTQwNWQ4MmE1OGQ4YjE3OGUzMWI4XzE4LTMtMS0xLTA_08ccc166-fd9a-4448-a212-a196c12dabda">2,451</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued expenses</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MDgvZnJhZzo3Njg0MzE5YmEwOWQ0NmI4ODAwOTcwNWFiODM5Y2I4Ny90YWJsZTpkOThmOTg5ZjM5ZjE0MDVkODJhNThkOGIxNzhlMzFiOC90YWJsZXJhbmdlOmQ5OGY5ODlmMzlmMTQwNWQ4MmE1OGQ4YjE3OGUzMWI4XzE5LTEtMS0xLTA_6b938fe4-644b-4264-97fe-6cd88fed2b53">33,021</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7057397719af459ca7328a1c440a0efa_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MDgvZnJhZzo3Njg0MzE5YmEwOWQ0NmI4ODAwOTcwNWFiODM5Y2I4Ny90YWJsZTpkOThmOTg5ZjM5ZjE0MDVkODJhNThkOGIxNzhlMzFiOC90YWJsZXJhbmdlOmQ5OGY5ODlmMzlmMTQwNWQ4MmE1OGQ4YjE3OGUzMWI4XzE5LTMtMS0xLTA_710e475c-3607-47ae-a7df-d84cad173360">38,581</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred revenue</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredRevenueCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MDgvZnJhZzo3Njg0MzE5YmEwOWQ0NmI4ODAwOTcwNWFiODM5Y2I4Ny90YWJsZTpkOThmOTg5ZjM5ZjE0MDVkODJhNThkOGIxNzhlMzFiOC90YWJsZXJhbmdlOmQ5OGY5ODlmMzlmMTQwNWQ4MmE1OGQ4YjE3OGUzMWI4XzIwLTEtMS0xLTA_3d60bc98-3548-45ae-b0aa-2b8b54e27887">21,721</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7057397719af459ca7328a1c440a0efa_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredRevenueCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MDgvZnJhZzo3Njg0MzE5YmEwOWQ0NmI4ODAwOTcwNWFiODM5Y2I4Ny90YWJsZTpkOThmOTg5ZjM5ZjE0MDVkODJhNThkOGIxNzhlMzFiOC90YWJsZXJhbmdlOmQ5OGY5ODlmMzlmMTQwNWQ4MmE1OGQ4YjE3OGUzMWI4XzIwLTMtMS0xLTA_c84f250e-14dd-4157-a1d3-95865d1db6ca">7,202</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred rent</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredRentCreditCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MDgvZnJhZzo3Njg0MzE5YmEwOWQ0NmI4ODAwOTcwNWFiODM5Y2I4Ny90YWJsZTpkOThmOTg5ZjM5ZjE0MDVkODJhNThkOGIxNzhlMzFiOC90YWJsZXJhbmdlOmQ5OGY5ODlmMzlmMTQwNWQ4MmE1OGQ4YjE3OGUzMWI4XzIxLTEtMS0xLTA_b42c9ca0-696d-4bfd-b67c-44b9ce80f332">1,018</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7057397719af459ca7328a1c440a0efa_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredRentCreditCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MDgvZnJhZzo3Njg0MzE5YmEwOWQ0NmI4ODAwOTcwNWFiODM5Y2I4Ny90YWJsZTpkOThmOTg5ZjM5ZjE0MDVkODJhNThkOGIxNzhlMzFiOC90YWJsZXJhbmdlOmQ5OGY5ODlmMzlmMTQwNWQ4MmE1OGQ4YjE3OGUzMWI4XzIxLTMtMS0xLTA_06b381fb-3588-4e0b-bbf0-53070a290b7b">1,048</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Other current liabilities</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MDgvZnJhZzo3Njg0MzE5YmEwOWQ0NmI4ODAwOTcwNWFiODM5Y2I4Ny90YWJsZTpkOThmOTg5ZjM5ZjE0MDVkODJhNThkOGIxNzhlMzFiOC90YWJsZXJhbmdlOmQ5OGY5ODlmMzlmMTQwNWQ4MmE1OGQ4YjE3OGUzMWI4XzIzLTEtMS0xLTA_394a4647-4717-4401-aaae-dc2784d0ce02">175</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7057397719af459ca7328a1c440a0efa_I20171231" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MDgvZnJhZzo3Njg0MzE5YmEwOWQ0NmI4ODAwOTcwNWFiODM5Y2I4Ny90YWJsZTpkOThmOTg5ZjM5ZjE0MDVkODJhNThkOGIxNzhlMzFiOC90YWJsZXJhbmdlOmQ5OGY5ODlmMzlmMTQwNWQ4MmE1OGQ4YjE3OGUzMWI4XzIzLTMtMS0xLTA_e96ffc35-ba76-45b1-9a4d-1478e3e60560">473</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total current liabilities</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MDgvZnJhZzo3Njg0MzE5YmEwOWQ0NmI4ODAwOTcwNWFiODM5Y2I4Ny90YWJsZTpkOThmOTg5ZjM5ZjE0MDVkODJhNThkOGIxNzhlMzFiOC90YWJsZXJhbmdlOmQ5OGY5ODlmMzlmMTQwNWQ4MmE1OGQ4YjE3OGUzMWI4XzI0LTEtMS0xLTA_793b3e36-1bde-41f2-9dd4-72fc9b466251">59,940</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7057397719af459ca7328a1c440a0efa_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MDgvZnJhZzo3Njg0MzE5YmEwOWQ0NmI4ODAwOTcwNWFiODM5Y2I4Ny90YWJsZTpkOThmOTg5ZjM5ZjE0MDVkODJhNThkOGIxNzhlMzFiOC90YWJsZXJhbmdlOmQ5OGY5ODlmMzlmMTQwNWQ4MmE1OGQ4YjE3OGUzMWI4XzI0LTMtMS0xLTA_6e9ae849-253e-458c-ab4c-eb8b33b57f76">49,755</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred revenue, net of current portion</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredRevenueNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MDgvZnJhZzo3Njg0MzE5YmEwOWQ0NmI4ODAwOTcwNWFiODM5Y2I4Ny90YWJsZTpkOThmOTg5ZjM5ZjE0MDVkODJhNThkOGIxNzhlMzFiOC90YWJsZXJhbmdlOmQ5OGY5ODlmMzlmMTQwNWQ4MmE1OGQ4YjE3OGUzMWI4XzI2LTEtMS0xLTA_5cd0e08b-0ea4-454a-bf2a-00e8b2fe562e">19,001</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7057397719af459ca7328a1c440a0efa_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredRevenueNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MDgvZnJhZzo3Njg0MzE5YmEwOWQ0NmI4ODAwOTcwNWFiODM5Y2I4Ny90YWJsZTpkOThmOTg5ZjM5ZjE0MDVkODJhNThkOGIxNzhlMzFiOC90YWJsZXJhbmdlOmQ5OGY5ODlmMzlmMTQwNWQ4MmE1OGQ4YjE3OGUzMWI4XzI2LTMtMS0xLTA_d9754e34-3270-46f3-aae4-3e8121b566a5">13,637</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred rent, net of current portion</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredRentCreditNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MDgvZnJhZzo3Njg0MzE5YmEwOWQ0NmI4ODAwOTcwNWFiODM5Y2I4Ny90YWJsZTpkOThmOTg5ZjM5ZjE0MDVkODJhNThkOGIxNzhlMzFiOC90YWJsZXJhbmdlOmQ5OGY5ODlmMzlmMTQwNWQ4MmE1OGQ4YjE3OGUzMWI4XzI3LTEtMS0xLTA_1181d43f-a1b8-40b8-b072-6230f8648a10">10,312</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7057397719af459ca7328a1c440a0efa_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredRentCreditNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MDgvZnJhZzo3Njg0MzE5YmEwOWQ0NmI4ODAwOTcwNWFiODM5Y2I4Ny90YWJsZTpkOThmOTg5ZjM5ZjE0MDVkODJhNThkOGIxNzhlMzFiOC90YWJsZXJhbmdlOmQ5OGY5ODlmMzlmMTQwNWQ4MmE1OGQ4YjE3OGUzMWI4XzI3LTMtMS0xLTA_e1140280-7538-46b9-86a9-16b88bc6d187">11,253</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total liabilities</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MDgvZnJhZzo3Njg0MzE5YmEwOWQ0NmI4ODAwOTcwNWFiODM5Y2I4Ny90YWJsZTpkOThmOTg5ZjM5ZjE0MDVkODJhNThkOGIxNzhlMzFiOC90YWJsZXJhbmdlOmQ5OGY5ODlmMzlmMTQwNWQ4MmE1OGQ4YjE3OGUzMWI4XzI5LTEtMS0xLTA_6067c7a2-8046-4e2d-b5ac-45bccaf7c92b">89,253</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7057397719af459ca7328a1c440a0efa_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MDgvZnJhZzo3Njg0MzE5YmEwOWQ0NmI4ODAwOTcwNWFiODM5Y2I4Ny90YWJsZTpkOThmOTg5ZjM5ZjE0MDVkODJhNThkOGIxNzhlMzFiOC90YWJsZXJhbmdlOmQ5OGY5ODlmMzlmMTQwNWQ4MmE1OGQ4YjE3OGUzMWI4XzI5LTMtMS0xLTA_7dd44f75-4d93-46a3-82db-01ca4b79c481">74,645</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Stockholders' equity:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Common stock, $0.01 par value -- 125,000,000 shares authorized, 42,353,301 and 36,859,077 shares outstanding at December 31, 2018 and December 31, 2017, respectively&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MDgvZnJhZzo3Njg0MzE5YmEwOWQ0NmI4ODAwOTcwNWFiODM5Y2I4Ny90YWJsZTpkOThmOTg5ZjM5ZjE0MDVkODJhNThkOGIxNzhlMzFiOC90YWJsZXJhbmdlOmQ5OGY5ODlmMzlmMTQwNWQ4MmE1OGQ4YjE3OGUzMWI4XzMyLTEtMS0xLTA_c0bd525e-d02f-4320-8a7c-c38805c8aed9">424</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7057397719af459ca7328a1c440a0efa_I20171231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MDgvZnJhZzo3Njg0MzE5YmEwOWQ0NmI4ODAwOTcwNWFiODM5Y2I4Ny90YWJsZTpkOThmOTg5ZjM5ZjE0MDVkODJhNThkOGIxNzhlMzFiOC90YWJsZXJhbmdlOmQ5OGY5ODlmMzlmMTQwNWQ4MmE1OGQ4YjE3OGUzMWI4XzMyLTMtMS0xLTA_76695ab5-3fe4-47c5-af73-63943b680fec">369</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Additional paid-in capital</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MDgvZnJhZzo3Njg0MzE5YmEwOWQ0NmI4ODAwOTcwNWFiODM5Y2I4Ny90YWJsZTpkOThmOTg5ZjM5ZjE0MDVkODJhNThkOGIxNzhlMzFiOC90YWJsZXJhbmdlOmQ5OGY5ODlmMzlmMTQwNWQ4MmE1OGQ4YjE3OGUzMWI4XzMzLTEtMS0xLTA_3fc1040c-abdd-4a2e-a5a3-c87adeec53a0">732,727</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7057397719af459ca7328a1c440a0efa_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MDgvZnJhZzo3Njg0MzE5YmEwOWQ0NmI4ODAwOTcwNWFiODM5Y2I4Ny90YWJsZTpkOThmOTg5ZjM5ZjE0MDVkODJhNThkOGIxNzhlMzFiOC90YWJsZXJhbmdlOmQ5OGY5ODlmMzlmMTQwNWQ4MmE1OGQ4YjE3OGUzMWI4XzMzLTMtMS0xLTA_7174e0f0-7721-49d4-9162-5f076b494f05">611,270</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated other comprehensive loss</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MDgvZnJhZzo3Njg0MzE5YmEwOWQ0NmI4ODAwOTcwNWFiODM5Y2I4Ny90YWJsZTpkOThmOTg5ZjM5ZjE0MDVkODJhNThkOGIxNzhlMzFiOC90YWJsZXJhbmdlOmQ5OGY5ODlmMzlmMTQwNWQ4MmE1OGQ4YjE3OGUzMWI4XzM0LTEtMS0xLTA_e542ce67-7b89-47cd-bf09-1e94c11d3210">3</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i7057397719af459ca7328a1c440a0efa_I20171231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MDgvZnJhZzo3Njg0MzE5YmEwOWQ0NmI4ODAwOTcwNWFiODM5Y2I4Ny90YWJsZTpkOThmOTg5ZjM5ZjE0MDVkODJhNThkOGIxNzhlMzFiOC90YWJsZXJhbmdlOmQ5OGY5ODlmMzlmMTQwNWQ4MmE1OGQ4YjE3OGUzMWI4XzM0LTMtMS0xLTA_ad8e12a3-2032-43b9-a96d-cc1bbf95ce41">61</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated deficit</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MDgvZnJhZzo3Njg0MzE5YmEwOWQ0NmI4ODAwOTcwNWFiODM5Y2I4Ny90YWJsZTpkOThmOTg5ZjM5ZjE0MDVkODJhNThkOGIxNzhlMzFiOC90YWJsZXJhbmdlOmQ5OGY5ODlmMzlmMTQwNWQ4MmE1OGQ4YjE3OGUzMWI4XzM1LTEtMS0xLTA_8119eeff-f193-416b-9e01-9a2dd32da6f0">490,271</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i7057397719af459ca7328a1c440a0efa_I20171231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MDgvZnJhZzo3Njg0MzE5YmEwOWQ0NmI4ODAwOTcwNWFiODM5Y2I4Ny90YWJsZTpkOThmOTg5ZjM5ZjE0MDVkODJhNThkOGIxNzhlMzFiOC90YWJsZXJhbmdlOmQ5OGY5ODlmMzlmMTQwNWQ4MmE1OGQ4YjE3OGUzMWI4XzM1LTMtMS0xLTA_2a1dc813-d1a2-4521-b345-bb3aa154a7be">312,340</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total stockholders' equity</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MDgvZnJhZzo3Njg0MzE5YmEwOWQ0NmI4ODAwOTcwNWFiODM5Y2I4Ny90YWJsZTpkOThmOTg5ZjM5ZjE0MDVkODJhNThkOGIxNzhlMzFiOC90YWJsZXJhbmdlOmQ5OGY5ODlmMzlmMTQwNWQ4MmE1OGQ4YjE3OGUzMWI4XzM2LTEtMS0xLTA_15210384-5e91-4311-b0df-652215303126">242,877</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7057397719af459ca7328a1c440a0efa_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MDgvZnJhZzo3Njg0MzE5YmEwOWQ0NmI4ODAwOTcwNWFiODM5Y2I4Ny90YWJsZTpkOThmOTg5ZjM5ZjE0MDVkODJhNThkOGIxNzhlMzFiOC90YWJsZXJhbmdlOmQ5OGY5ODlmMzlmMTQwNWQ4MmE1OGQ4YjE3OGUzMWI4XzM2LTMtMS0xLTA_fcdbe758-984d-490f-bf51-fb2691e09556">299,238</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total liabilities and stockholders' equity</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MDgvZnJhZzo3Njg0MzE5YmEwOWQ0NmI4ODAwOTcwNWFiODM5Y2I4Ny90YWJsZTpkOThmOTg5ZjM5ZjE0MDVkODJhNThkOGIxNzhlMzFiOC90YWJsZXJhbmdlOmQ5OGY5ODlmMzlmMTQwNWQ4MmE1OGQ4YjE3OGUzMWI4XzM3LTEtMS0xLTA_a3be70c6-1e98-476b-96eb-13be321f5dbb">332,130</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7057397719af459ca7328a1c440a0efa_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MDgvZnJhZzo3Njg0MzE5YmEwOWQ0NmI4ODAwOTcwNWFiODM5Y2I4Ny90YWJsZTpkOThmOTg5ZjM5ZjE0MDVkODJhNThkOGIxNzhlMzFiOC90YWJsZXJhbmdlOmQ5OGY5ODlmMzlmMTQwNWQ4MmE1OGQ4YjE3OGUzMWI4XzM3LTMtMS0xLTA_965500e8-8b98-4dca-8566-266857dfb5f2">373,883</ix:nonFraction>&#160;</span></td></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">See accompanying notes.</span></div><div id="i_0_535"></div><div style="text-align:center;"></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">F - 2</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">MACROGENICS, INC.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">(In thousands, except share and per share data)</span></div><div style="margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"><tr><td style="width:1.0%;"></td><td style="width:61.343109%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.730205%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533138%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.730205%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533138%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.730205%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2016</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenue from collaborative agreements</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ieb0bea730e3444a5b0d8559d16ad126c_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MzUvZnJhZzo4ZWUzNTdhMzJkMWI0ZGFkODM2NjUyNzM4MGIyZWFlMy90YWJsZTplOWI2MjkzZDQxYjk0Y2NjOWExMTY3YTA2YzM3YjI5NC90YWJsZXJhbmdlOmU5YjYyOTNkNDFiOTRjY2M5YTExNjdhMDZjMzdiMjk0XzMtMS0xLTEtMA_cb95960e-a027-4675-a94f-4f3a3618dc00">58,644</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i59ab418442044814b66164966b88c82b_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MzUvZnJhZzo4ZWUzNTdhMzJkMWI0ZGFkODM2NjUyNzM4MGIyZWFlMy90YWJsZTplOWI2MjkzZDQxYjk0Y2NjOWExMTY3YTA2YzM3YjI5NC90YWJsZXJhbmdlOmU5YjYyOTNkNDFiOTRjY2M5YTExNjdhMDZjMzdiMjk0XzMtMy0xLTEtMA_5e473ecd-6d5b-418e-ac88-06394c0639d3">155,516</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idbcb1304940d4ff0baeab52d79003f28_D20160101-20161231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MzUvZnJhZzo4ZWUzNTdhMzJkMWI0ZGFkODM2NjUyNzM4MGIyZWFlMy90YWJsZTplOWI2MjkzZDQxYjk0Y2NjOWExMTY3YTA2YzM3YjI5NC90YWJsZXJhbmdlOmU5YjYyOTNkNDFiOTRjY2M5YTExNjdhMDZjMzdiMjk0XzMtNS0xLTEtMA_f4a01164-493c-4863-8322-91700109fa76">86,582</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenue from government agreements</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if637c63a87b147fa81aa860bc98e569f_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MzUvZnJhZzo4ZWUzNTdhMzJkMWI0ZGFkODM2NjUyNzM4MGIyZWFlMy90YWJsZTplOWI2MjkzZDQxYjk0Y2NjOWExMTY3YTA2YzM3YjI5NC90YWJsZXJhbmdlOmU5YjYyOTNkNDFiOTRjY2M5YTExNjdhMDZjMzdiMjk0XzQtMS0xLTEtMA_f2fb272a-3cce-41e7-aeaa-1639323d722f">1,477</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7ebe96cc613b4300bdf8831b4feca588_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MzUvZnJhZzo4ZWUzNTdhMzJkMWI0ZGFkODM2NjUyNzM4MGIyZWFlMy90YWJsZTplOWI2MjkzZDQxYjk0Y2NjOWExMTY3YTA2YzM3YjI5NC90YWJsZXJhbmdlOmU5YjYyOTNkNDFiOTRjY2M5YTExNjdhMDZjMzdiMjk0XzQtMy0xLTEtMA_b356a88b-906c-4d29-8940-9f9382f3cbdf">2,226</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4d5db08e41a54c13a242bb974c98539c_D20160101-20161231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MzUvZnJhZzo4ZWUzNTdhMzJkMWI0ZGFkODM2NjUyNzM4MGIyZWFlMy90YWJsZTplOWI2MjkzZDQxYjk0Y2NjOWExMTY3YTA2YzM3YjI5NC90YWJsZXJhbmdlOmU5YjYyOTNkNDFiOTRjY2M5YTExNjdhMDZjMzdiMjk0XzQtNS0xLTEtMA_0e7b2c80-60c0-4d2f-b2ee-029419e54d25">5,298</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total revenues</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MzUvZnJhZzo4ZWUzNTdhMzJkMWI0ZGFkODM2NjUyNzM4MGIyZWFlMy90YWJsZTplOWI2MjkzZDQxYjk0Y2NjOWExMTY3YTA2YzM3YjI5NC90YWJsZXJhbmdlOmU5YjYyOTNkNDFiOTRjY2M5YTExNjdhMDZjMzdiMjk0XzUtMS0xLTEtMA_c012c026-c22b-426d-86a0-4b2705b74bc6">60,121</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MzUvZnJhZzo4ZWUzNTdhMzJkMWI0ZGFkODM2NjUyNzM4MGIyZWFlMy90YWJsZTplOWI2MjkzZDQxYjk0Y2NjOWExMTY3YTA2YzM3YjI5NC90YWJsZXJhbmdlOmU5YjYyOTNkNDFiOTRjY2M5YTExNjdhMDZjMzdiMjk0XzUtMy0xLTEtMA_1b90623e-9f41-4d72-8614-7fcaaaa2dad3">157,742</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iaf5d0e8fdf374dc09283fd669e2ebf19_D20160101-20161231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MzUvZnJhZzo4ZWUzNTdhMzJkMWI0ZGFkODM2NjUyNzM4MGIyZWFlMy90YWJsZTplOWI2MjkzZDQxYjk0Y2NjOWExMTY3YTA2YzM3YjI5NC90YWJsZXJhbmdlOmU5YjYyOTNkNDFiOTRjY2M5YTExNjdhMDZjMzdiMjk0XzUtNS0xLTEtMA_852a6458-ddfa-4a41-b350-e06f2c14b9cd">91,880</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Costs and expenses:</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MzUvZnJhZzo4ZWUzNTdhMzJkMWI0ZGFkODM2NjUyNzM4MGIyZWFlMy90YWJsZTplOWI2MjkzZDQxYjk0Y2NjOWExMTY3YTA2YzM3YjI5NC90YWJsZXJhbmdlOmU5YjYyOTNkNDFiOTRjY2M5YTExNjdhMDZjMzdiMjk0XzgtMS0xLTEtMA_ff25326c-7331-4f95-8e12-9db8b0e1dd9c">190,827</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MzUvZnJhZzo4ZWUzNTdhMzJkMWI0ZGFkODM2NjUyNzM4MGIyZWFlMy90YWJsZTplOWI2MjkzZDQxYjk0Y2NjOWExMTY3YTA2YzM3YjI5NC90YWJsZXJhbmdlOmU5YjYyOTNkNDFiOTRjY2M5YTExNjdhMDZjMzdiMjk0XzgtMy0xLTEtMA_ead3de1f-5e9a-4dd3-b47f-c391156ab603">147,232</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iaf5d0e8fdf374dc09283fd669e2ebf19_D20160101-20161231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MzUvZnJhZzo4ZWUzNTdhMzJkMWI0ZGFkODM2NjUyNzM4MGIyZWFlMy90YWJsZTplOWI2MjkzZDQxYjk0Y2NjOWExMTY3YTA2YzM3YjI5NC90YWJsZXJhbmdlOmU5YjYyOTNkNDFiOTRjY2M5YTExNjdhMDZjMzdiMjk0XzgtNS0xLTEtMA_ad0d4310-fd52-4f76-b7e5-c394467bc79d">122,091</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">General and administrative</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MzUvZnJhZzo4ZWUzNTdhMzJkMWI0ZGFkODM2NjUyNzM4MGIyZWFlMy90YWJsZTplOWI2MjkzZDQxYjk0Y2NjOWExMTY3YTA2YzM3YjI5NC90YWJsZXJhbmdlOmU5YjYyOTNkNDFiOTRjY2M5YTExNjdhMDZjMzdiMjk0XzktMS0xLTEtMA_b4f04e1f-0020-478d-a991-bb98426bda6d">40,500</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MzUvZnJhZzo4ZWUzNTdhMzJkMWI0ZGFkODM2NjUyNzM4MGIyZWFlMy90YWJsZTplOWI2MjkzZDQxYjk0Y2NjOWExMTY3YTA2YzM3YjI5NC90YWJsZXJhbmdlOmU5YjYyOTNkNDFiOTRjY2M5YTExNjdhMDZjMzdiMjk0XzktMy0xLTEtMA_4807d02d-984c-44a6-ab8d-7ec7d9479d48">32,653</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iaf5d0e8fdf374dc09283fd669e2ebf19_D20160101-20161231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MzUvZnJhZzo4ZWUzNTdhMzJkMWI0ZGFkODM2NjUyNzM4MGIyZWFlMy90YWJsZTplOWI2MjkzZDQxYjk0Y2NjOWExMTY3YTA2YzM3YjI5NC90YWJsZXJhbmdlOmU5YjYyOTNkNDFiOTRjY2M5YTExNjdhMDZjMzdiMjk0XzktNS0xLTEtMA_bd1dce49-6e37-4f4f-b9cf-a50e54c8e385">29,831</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total costs and expenses</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MzUvZnJhZzo4ZWUzNTdhMzJkMWI0ZGFkODM2NjUyNzM4MGIyZWFlMy90YWJsZTplOWI2MjkzZDQxYjk0Y2NjOWExMTY3YTA2YzM3YjI5NC90YWJsZXJhbmdlOmU5YjYyOTNkNDFiOTRjY2M5YTExNjdhMDZjMzdiMjk0XzEwLTEtMS0xLTA_c174ee33-a711-4cff-9798-bdc66e8ad429">231,327</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MzUvZnJhZzo4ZWUzNTdhMzJkMWI0ZGFkODM2NjUyNzM4MGIyZWFlMy90YWJsZTplOWI2MjkzZDQxYjk0Y2NjOWExMTY3YTA2YzM3YjI5NC90YWJsZXJhbmdlOmU5YjYyOTNkNDFiOTRjY2M5YTExNjdhMDZjMzdiMjk0XzEwLTMtMS0xLTA_571bbbbc-b7a1-4fd7-a76a-76dd55c51e8f">179,885</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iaf5d0e8fdf374dc09283fd669e2ebf19_D20160101-20161231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MzUvZnJhZzo4ZWUzNTdhMzJkMWI0ZGFkODM2NjUyNzM4MGIyZWFlMy90YWJsZTplOWI2MjkzZDQxYjk0Y2NjOWExMTY3YTA2YzM3YjI5NC90YWJsZXJhbmdlOmU5YjYyOTNkNDFiOTRjY2M5YTExNjdhMDZjMzdiMjk0XzEwLTUtMS0xLTA_2c65d75e-7b5b-4a89-b067-2f7aee323ae3">151,922</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="height:13pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="height:13pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="height:13pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="height:13pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Loss from operations</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MzUvZnJhZzo4ZWUzNTdhMzJkMWI0ZGFkODM2NjUyNzM4MGIyZWFlMy90YWJsZTplOWI2MjkzZDQxYjk0Y2NjOWExMTY3YTA2YzM3YjI5NC90YWJsZXJhbmdlOmU5YjYyOTNkNDFiOTRjY2M5YTExNjdhMDZjMzdiMjk0XzEyLTEtMS0xLTA_23bb7e38-26a5-4cdb-8992-ba4e389729a5">171,206</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MzUvZnJhZzo4ZWUzNTdhMzJkMWI0ZGFkODM2NjUyNzM4MGIyZWFlMy90YWJsZTplOWI2MjkzZDQxYjk0Y2NjOWExMTY3YTA2YzM3YjI5NC90YWJsZXJhbmdlOmU5YjYyOTNkNDFiOTRjY2M5YTExNjdhMDZjMzdiMjk0XzEyLTMtMS0xLTA_b131a3b8-8837-4a74-af5e-fe2a36092c24">22,143</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iaf5d0e8fdf374dc09283fd669e2ebf19_D20160101-20161231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MzUvZnJhZzo4ZWUzNTdhMzJkMWI0ZGFkODM2NjUyNzM4MGIyZWFlMy90YWJsZTplOWI2MjkzZDQxYjk0Y2NjOWExMTY3YTA2YzM3YjI5NC90YWJsZXJhbmdlOmU5YjYyOTNkNDFiOTRjY2M5YTExNjdhMDZjMzdiMjk0XzEyLTUtMS0xLTA_b881e8dc-0a7a-4d46-98db-57739454646d">60,042</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="height:13pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="height:13pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="height:13pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="height:13pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Other income (expense)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MzUvZnJhZzo4ZWUzNTdhMzJkMWI0ZGFkODM2NjUyNzM4MGIyZWFlMy90YWJsZTplOWI2MjkzZDQxYjk0Y2NjOWExMTY3YTA2YzM3YjI5NC90YWJsZXJhbmdlOmU5YjYyOTNkNDFiOTRjY2M5YTExNjdhMDZjMzdiMjk0XzE0LTEtMS0xLTA_9b0e79a6-b385-409e-bc66-ea97527e5803">247</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MzUvZnJhZzo4ZWUzNTdhMzJkMWI0ZGFkODM2NjUyNzM4MGIyZWFlMy90YWJsZTplOWI2MjkzZDQxYjk0Y2NjOWExMTY3YTA2YzM3YjI5NC90YWJsZXJhbmdlOmU5YjYyOTNkNDFiOTRjY2M5YTExNjdhMDZjMzdiMjk0XzE0LTMtMS0xLTA_69e78635-a9e4-4b77-a4ad-f092e6a7aeff">2,517</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iaf5d0e8fdf374dc09283fd669e2ebf19_D20160101-20161231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MzUvZnJhZzo4ZWUzNTdhMzJkMWI0ZGFkODM2NjUyNzM4MGIyZWFlMy90YWJsZTplOWI2MjkzZDQxYjk0Y2NjOWExMTY3YTA2YzM3YjI5NC90YWJsZXJhbmdlOmU5YjYyOTNkNDFiOTRjY2M5YTExNjdhMDZjMzdiMjk0XzE0LTUtMS0xLTA_d0d6abf7-1176-45ff-9efb-4cc99ec8cca7">1,514</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MzUvZnJhZzo4ZWUzNTdhMzJkMWI0ZGFkODM2NjUyNzM4MGIyZWFlMy90YWJsZTplOWI2MjkzZDQxYjk0Y2NjOWExMTY3YTA2YzM3YjI5NC90YWJsZXJhbmdlOmU5YjYyOTNkNDFiOTRjY2M5YTExNjdhMDZjMzdiMjk0XzE1LTEtMS0xLTA_5111dcb5-b11a-498e-a2cc-b099669b4f22">171,453</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MzUvZnJhZzo4ZWUzNTdhMzJkMWI0ZGFkODM2NjUyNzM4MGIyZWFlMy90YWJsZTplOWI2MjkzZDQxYjk0Y2NjOWExMTY3YTA2YzM3YjI5NC90YWJsZXJhbmdlOmU5YjYyOTNkNDFiOTRjY2M5YTExNjdhMDZjMzdiMjk0XzE1LTMtMS0xLTA_3e12925c-e0c4-463a-81f6-c5dcb5946e4d">19,626</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iaf5d0e8fdf374dc09283fd669e2ebf19_D20160101-20161231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MzUvZnJhZzo4ZWUzNTdhMzJkMWI0ZGFkODM2NjUyNzM4MGIyZWFlMy90YWJsZTplOWI2MjkzZDQxYjk0Y2NjOWExMTY3YTA2YzM3YjI5NC90YWJsZXJhbmdlOmU5YjYyOTNkNDFiOTRjY2M5YTExNjdhMDZjMzdiMjk0XzE1LTUtMS0xLTA_f825d796-ba20-4b99-8a79-a9d05a1a0b62">58,528</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Other comprehensive loss:</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized gain (loss) on investments</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MzUvZnJhZzo4ZWUzNTdhMzJkMWI0ZGFkODM2NjUyNzM4MGIyZWFlMy90YWJsZTplOWI2MjkzZDQxYjk0Y2NjOWExMTY3YTA2YzM3YjI5NC90YWJsZXJhbmdlOmU5YjYyOTNkNDFiOTRjY2M5YTExNjdhMDZjMzdiMjk0XzE4LTEtMS0xLTA_07183e70-4966-44e4-b678-0b8e1360dc3f">58</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MzUvZnJhZzo4ZWUzNTdhMzJkMWI0ZGFkODM2NjUyNzM4MGIyZWFlMy90YWJsZTplOWI2MjkzZDQxYjk0Y2NjOWExMTY3YTA2YzM3YjI5NC90YWJsZXJhbmdlOmU5YjYyOTNkNDFiOTRjY2M5YTExNjdhMDZjMzdiMjk0XzE4LTMtMS0xLTA_222e704e-546a-4972-a93d-ac70d992ed4b">21</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iaf5d0e8fdf374dc09283fd669e2ebf19_D20160101-20161231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MzUvZnJhZzo4ZWUzNTdhMzJkMWI0ZGFkODM2NjUyNzM4MGIyZWFlMy90YWJsZTplOWI2MjkzZDQxYjk0Y2NjOWExMTY3YTA2YzM3YjI5NC90YWJsZXJhbmdlOmU5YjYyOTNkNDFiOTRjY2M5YTExNjdhMDZjMzdiMjk0XzE4LTUtMS0xLTA_c87f8315-0be6-49ba-8c1a-7c03a0a36e50">77</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Comprehensive loss</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MzUvZnJhZzo4ZWUzNTdhMzJkMWI0ZGFkODM2NjUyNzM4MGIyZWFlMy90YWJsZTplOWI2MjkzZDQxYjk0Y2NjOWExMTY3YTA2YzM3YjI5NC90YWJsZXJhbmdlOmU5YjYyOTNkNDFiOTRjY2M5YTExNjdhMDZjMzdiMjk0XzE5LTEtMS0xLTA_880d921d-dfa4-4a13-b5d6-ee6433417c6a">171,395</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MzUvZnJhZzo4ZWUzNTdhMzJkMWI0ZGFkODM2NjUyNzM4MGIyZWFlMy90YWJsZTplOWI2MjkzZDQxYjk0Y2NjOWExMTY3YTA2YzM3YjI5NC90YWJsZXJhbmdlOmU5YjYyOTNkNDFiOTRjY2M5YTExNjdhMDZjMzdiMjk0XzE5LTMtMS0xLTA_8a0571eb-3c4e-401f-a4c7-0ad6f11bd24c">19,605</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iaf5d0e8fdf374dc09283fd669e2ebf19_D20160101-20161231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MzUvZnJhZzo4ZWUzNTdhMzJkMWI0ZGFkODM2NjUyNzM4MGIyZWFlMy90YWJsZTplOWI2MjkzZDQxYjk0Y2NjOWExMTY3YTA2YzM3YjI5NC90YWJsZXJhbmdlOmU5YjYyOTNkNDFiOTRjY2M5YTExNjdhMDZjMzdiMjk0XzE5LTUtMS0xLTA_52ac9a75-661e-47a9-9834-058b5c52efd7">58,605</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:13pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Basic and diluted net loss per common share</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MzUvZnJhZzo4ZWUzNTdhMzJkMWI0ZGFkODM2NjUyNzM4MGIyZWFlMy90YWJsZTplOWI2MjkzZDQxYjk0Y2NjOWExMTY3YTA2YzM3YjI5NC90YWJsZXJhbmdlOmU5YjYyOTNkNDFiOTRjY2M5YTExNjdhMDZjMzdiMjk0XzIzLTEtMS0xLTA_ec315529-8454-4c6f-b366-e0584c112881">4.19</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MzUvZnJhZzo4ZWUzNTdhMzJkMWI0ZGFkODM2NjUyNzM4MGIyZWFlMy90YWJsZTplOWI2MjkzZDQxYjk0Y2NjOWExMTY3YTA2YzM3YjI5NC90YWJsZXJhbmdlOmU5YjYyOTNkNDFiOTRjY2M5YTExNjdhMDZjMzdiMjk0XzIzLTMtMS0xLTA_edaf2459-92d6-4438-945b-17edeb70925c">0.54</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="iaf5d0e8fdf374dc09283fd669e2ebf19_D20160101-20161231" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MzUvZnJhZzo4ZWUzNTdhMzJkMWI0ZGFkODM2NjUyNzM4MGIyZWFlMy90YWJsZTplOWI2MjkzZDQxYjk0Y2NjOWExMTY3YTA2YzM3YjI5NC90YWJsZXJhbmdlOmU5YjYyOTNkNDFiOTRjY2M5YTExNjdhMDZjMzdiMjk0XzIzLTUtMS0xLTA_2be7fa2c-da7e-43c1-a5e3-83e2e5efd6f6">1.69</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Basic and diluted weighted average number of common shares</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MzUvZnJhZzo4ZWUzNTdhMzJkMWI0ZGFkODM2NjUyNzM4MGIyZWFlMy90YWJsZTplOWI2MjkzZDQxYjk0Y2NjOWExMTY3YTA2YzM3YjI5NC90YWJsZXJhbmdlOmU5YjYyOTNkNDFiOTRjY2M5YTExNjdhMDZjMzdiMjk0XzI0LTEtMS0xLTA_395015ab-245d-4611-9162-07f4cf8d403a">40,925,318</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MzUvZnJhZzo4ZWUzNTdhMzJkMWI0ZGFkODM2NjUyNzM4MGIyZWFlMy90YWJsZTplOWI2MjkzZDQxYjk0Y2NjOWExMTY3YTA2YzM3YjI5NC90YWJsZXJhbmdlOmU5YjYyOTNkNDFiOTRjY2M5YTExNjdhMDZjMzdiMjk0XzI0LTMtMS0xLTA_d811ea40-357a-460a-8374-82e80c106991">36,095,080</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="iaf5d0e8fdf374dc09283fd669e2ebf19_D20160101-20161231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MzUvZnJhZzo4ZWUzNTdhMzJkMWI0ZGFkODM2NjUyNzM4MGIyZWFlMy90YWJsZTplOWI2MjkzZDQxYjk0Y2NjOWExMTY3YTA2YzM3YjI5NC90YWJsZXJhbmdlOmU5YjYyOTNkNDFiOTRjY2M5YTExNjdhMDZjMzdiMjk0XzI0LTUtMS0xLTA_cbaa2d88-f556-4423-a7a9-b7cbd7db8983">34,685,274</ix:nonFraction>&#160;</span></td></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">See accompanying notes.</span></div><div style="text-align:center;"><span><br/></span></div><div id="i_0_547"></div><div style="text-align:center;"></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">F - 3</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">MACROGENICS, INC.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">(In thousands, except share amounts)</span></div><div style="margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.134199%;"><tr><td style="width:1.0%;"></td><td style="width:31.733624%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:6.078603%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.345852%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:3.786026%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.345852%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.078603%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.345852%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:3.786026%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.345852%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:5.532751%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.345852%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:5.969432%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.345852%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.825328%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.345852%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.388646%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:25pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;height:25pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Common Stock</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="height:25pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;height:25pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Treasury Stock</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="height:25pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;height:25pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:8pt;font-weight:700;line-height:100%;">Additional</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:8pt;font-weight:700;line-height:100%;">Paid-In</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:8pt;font-weight:700;line-height:100%;">Capital</span></div></td><td colspan="3" style="height:25pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;height:25pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:8pt;font-weight:700;line-height:100%;">Accumulated</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:8pt;font-weight:700;line-height:100%;">Deficit</span></div></td><td colspan="3" style="height:25pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;height:25pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:8pt;font-weight:700;line-height:100%;">Accumulated</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:8pt;font-weight:700;line-height:100%;">Other</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:8pt;font-weight:700;line-height:100%;">Comprehensive Loss</span></div></td><td colspan="3" style="height:25pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;height:25pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:8pt;font-weight:700;line-height:100%;">Total</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:8pt;font-weight:700;line-height:100%;">Stockholders'</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:8pt;font-weight:700;line-height:100%;">Equity</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, December 31, 2015</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i31ded4a9b84e45a8a97b0a276a851d4a_I20151231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzMtMS0xLTEtMA_bb05cc1a-c3b2-4909-834a-8436c31fa06a">34,345,754</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i31ded4a9b84e45a8a97b0a276a851d4a_I20151231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzMtMy0xLTEtMA_6cd98261-82ed-4112-bff7-e6f97ebe93b4">343</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="idd7e0c72464e4f8b8d5b13e3c2810e9d_I20151231" decimals="INF" format="ixt:zerodash" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzMtNS0xLTEtMA_147e14e5-992f-4669-a572-41400265a0f3">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idd7e0c72464e4f8b8d5b13e3c2810e9d_I20151231" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzMtNy0xLTEtMA_b9e792da-6df1-4b39-a79f-7495c2b23c99">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iaa9ee01ece97464eaf75135e2a56dadd_I20151231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzMtOS0xLTEtMA_3733d569-fd9c-4c26-a6b6-d5d96e5bb24e">547,185</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i7766301ab52344be8fc41112ad51fe12_I20151231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzMtMTEtMS0xLTA_c374c1ee-43ce-406c-a6c7-eff465991561">234,186</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i3f3f783c3c6749bfb8eab89b1ec2d1ab_I20151231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzMtMTMtMS0xLTA_772ef08b-1657-4e49-bdf5-3712a329b235">5</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ife0dac9d3bf74657b071534f4d2516f1_I20151231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzMtMTUtMS0xLTA_17ff99eb-8395-42b2-ace3-f2eb17f8f007">313,337</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Share-based compensation</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie5d0cd6221f843248de666cd76601d1f_D20160101-20161231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzQtOS0xLTEtMA_5ee49c99-e42a-4ef3-94aa-3f223a32d613">12,165</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iaf5d0e8fdf374dc09283fd669e2ebf19_D20160101-20161231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzQtMTUtMS0xLTA_114d4de6-acf2-4d2b-92c1-de08b064c3e8">12,165</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Stock plan related activity</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i3fee8e2719b04b64aa1e5c31ae4f97c4_D20160101-20161231" decimals="INF" format="ixt:numdotdecimal" name="mgnx:StockIssuedDuringPeriodSharesStockPlanActivity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzYtMS0xLTEtMA_edc04b5b-f382-44d9-aa5a-26869f87d958">524,853</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3fee8e2719b04b64aa1e5c31ae4f97c4_D20160101-20161231" decimals="-3" name="mgnx:StockIssuedDuringPeriodValueStockPlanActivity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzYtMy0xLTEtMA_5dc65ed5-462d-4060-917c-c45f70173227">6</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i6f0312cdde5044c9b7c7f5d13093d50d_D20160101-20161231" decimals="INF" format="ixt:numdotdecimal" name="mgnx:StockIssuedDuringPeriodSharesStockPlanActivity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzYtNS0xLTEtMA_8712e379-417f-466e-98c6-8ae94cb79f9c">1,862</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i6f0312cdde5044c9b7c7f5d13093d50d_D20160101-20161231" decimals="-3" sign="-" name="mgnx:StockIssuedDuringPeriodValueStockPlanActivity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzYtNy0xLTEtMA_fbbfb601-490a-4934-8cb6-3aa215190a79">39</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie5d0cd6221f843248de666cd76601d1f_D20160101-20161231" decimals="-3" format="ixt:numdotdecimal" name="mgnx:StockIssuedDuringPeriodValueStockPlanActivity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzYtOS0xLTEtMA_a0e67db9-9566-437f-b115-58a776e0b89d">1,887</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iaf5d0e8fdf374dc09283fd669e2ebf19_D20160101-20161231" decimals="-3" format="ixt:numdotdecimal" name="mgnx:StockIssuedDuringPeriodValueStockPlanActivity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzYtMTUtMS0xLTA_6640b9bf-1dcb-4db2-81c0-554268d2e540">1,854</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Retirement of treasury stock</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="i6f0312cdde5044c9b7c7f5d13093d50d_D20160101-20161231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockSharesRetired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzctNS0xLTEtMA_efe12eff-dde2-4227-82cc-a02454e46159">1,862</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6f0312cdde5044c9b7c7f5d13093d50d_D20160101-20161231" decimals="-3" sign="-" name="us-gaap:TreasuryStockRetiredParValueMethodAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzctNy0xLTEtMA_a58d5dad-f1a4-4a52-b010-48e1646732b6">39</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie5d0cd6221f843248de666cd76601d1f_D20160101-20161231" decimals="-3" name="us-gaap:TreasuryStockRetiredParValueMethodAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzctOS0xLTEtMA_8b1f3b7d-4c60-43f1-8e5a-3a796b947039">39</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iaf5d0e8fdf374dc09283fd669e2ebf19_D20160101-20161231" decimals="-3" format="ixt:zerodash" name="us-gaap:TreasuryStockRetiredParValueMethodAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzctMTUtMS0xLTA_c78df953-3d8e-4fe5-be6f-3732fb196804">&#8212;</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized loss on investments</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ifb20c231125a4e898c5b8db3e1022b77_D20160101-20161231" decimals="-3" sign="-" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzgtMTMtMS0xLTA_9fd34fc6-1b66-460c-bc48-c7c3bf59d289">77</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iaf5d0e8fdf374dc09283fd669e2ebf19_D20160101-20161231" decimals="-3" sign="-" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzgtMTUtMS0xLTA_5af1576d-5575-40ef-8b08-dcaa2aed9742">77</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i67cbca56d50744e8b64a458a586e3167_D20160101-20161231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzktMTEtMS0xLTA_0cf99b10-7b35-4708-8bee-0e2534f67a62">58,528</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iaf5d0e8fdf374dc09283fd669e2ebf19_D20160101-20161231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzktMTUtMS0xLTA_7acf5c35-1a06-4989-baf0-feab951e53b8">58,528</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, December 31, 2016</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i77cf90a50960481db6ce7911359972c3_I20161231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzEwLTEtMS0xLTA_bc91d1d2-6ae7-4f17-afdb-018507982656">34,870,607</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i77cf90a50960481db6ce7911359972c3_I20161231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzEwLTMtMS0xLTA_59388ec8-1ba3-4f2a-8ed1-3f5c6794b59b">349</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i8afec271b7854f828af67c5a11b81082_I20161231" decimals="INF" format="ixt:zerodash" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzEwLTUtMS0xLTA_5a705e13-9469-4472-a6c2-39f194d33697">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8afec271b7854f828af67c5a11b81082_I20161231" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzEwLTctMS0xLTA_56a7adf3-8cf4-4838-8a3d-5165021fccb2">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if1ab14db8127453db201fbbcb4274eeb_I20161231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzEwLTktMS0xLTA_571d229b-2a0a-4300-9f61-adb40cfb5a15">561,198</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ibf25f45131ee4daea309661157e678a9_I20161231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzEwLTExLTEtMS0w_d0e69682-c3eb-436a-840f-271fb92705a0">292,714</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i278d12a3934249bdb7dd8e95eabc5377_I20161231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzEwLTEzLTEtMS0w_fe96ebd5-6b7c-4bb9-a47d-00599a4c11f0">82</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iaa98382ff57d452ab6942c773d605ba7_I20161231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzEwLTE1LTEtMS0w_83983312-216f-44b3-8d2d-56f05c9c3815">268,751</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Share-based compensation</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iab5813033cd8418a851f487e53ebb255_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzExLTktMS0xLTA_06e513f0-1184-413a-b447-1c7c0d082910">14,744</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzExLTE1LTEtMS0w_f69ac534-ab0b-4ff0-accf-66b21f20bbaf">14,744</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Issuance of common stock, net of offering costs</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i556705a1d9294485b49514caece35ad9_D20170101-20171231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzEyLTEtMS0xLTA_41052f2e-2b96-4db3-a2a5-f073aa0b8966">1,699,284</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i556705a1d9294485b49514caece35ad9_D20170101-20171231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzEyLTMtMS0xLTA_991564a1-8162-45d0-8c6f-75c48a5b2cea">17</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iab5813033cd8418a851f487e53ebb255_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzEyLTktMS0xLTA_ba89a743-5889-4cd0-8717-989e8bf98042">34,227</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzEyLTE1LTEtMS0w_b67e833c-51a0-4b1e-bb9b-4d7d642269ed">34,244</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Stock plan related activity</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i556705a1d9294485b49514caece35ad9_D20170101-20171231" decimals="INF" format="ixt:numdotdecimal" name="mgnx:StockIssuedDuringPeriodSharesStockPlanActivity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzEzLTEtMS0xLTA_910a64ee-5f2f-4014-9d6b-9d8dca5b19b1">289,186</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i556705a1d9294485b49514caece35ad9_D20170101-20171231" decimals="-3" name="mgnx:StockIssuedDuringPeriodValueStockPlanActivity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzEzLTMtMS0xLTA_848776bc-6b89-41aa-982f-c27e5f8a2437">3</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i9132a8fb91054a248c772c0da0d524ec_D20170101-20171231" decimals="INF" format="ixt:numdotdecimal" name="mgnx:StockIssuedDuringPeriodSharesStockPlanActivity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzEzLTUtMS0xLTA_bf6127ab-09d6-4ffd-a96e-a5468c958ded">1,862</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i9132a8fb91054a248c772c0da0d524ec_D20170101-20171231" decimals="-3" sign="-" name="mgnx:StockIssuedDuringPeriodValueStockPlanActivity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzEzLTctMS0xLTA_a45ef941-ab83-4d1a-87cb-dc8ef0150cd8">40</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iab5813033cd8418a851f487e53ebb255_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="mgnx:StockIssuedDuringPeriodValueStockPlanActivity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzEzLTktMS0xLTA_03c560f6-95e9-4f0f-af93-15e80eac8cc7">1,141</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="mgnx:StockIssuedDuringPeriodValueStockPlanActivity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzEzLTE1LTEtMS0w_8041e6c6-3426-4247-8cfd-de660c4d495f">1,104</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Retirement of treasury stock</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="i9132a8fb91054a248c772c0da0d524ec_D20170101-20171231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockSharesRetired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzE0LTUtMS0xLTA_50e34cea-be8e-48bd-a8aa-7559295b1820">1,862</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9132a8fb91054a248c772c0da0d524ec_D20170101-20171231" decimals="-3" sign="-" name="us-gaap:TreasuryStockRetiredParValueMethodAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzE0LTctMS0xLTA_dc881c6f-4e4c-495f-bad3-64315953814f">40</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iab5813033cd8418a851f487e53ebb255_D20170101-20171231" decimals="-3" name="us-gaap:TreasuryStockRetiredParValueMethodAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzE0LTktMS0xLTA_99bed41d-37bb-4b0e-a216-5fc24258e485">40</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:TreasuryStockRetiredParValueMethodAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzE0LTE1LTEtMS0w_a26c1eb4-2cd6-41de-91e6-1ebed49a8b31">&#8212;</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized gain on investments</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic816b5e523774458b622b435dcd2e03b_D20170101-20171231" decimals="-3" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzE1LTEzLTEtMS0w_64250066-7fdc-47b7-9a4c-9c2da88c15da">21</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231" decimals="-3" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzE1LTE1LTEtMS0w_e927a1cd-6216-459f-82a3-1ae589ce2140">21</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i506eefa849b64cf7a445dd7f7221c8a5_D20170101-20171231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzE2LTExLTEtMS0w_7f659d48-a117-4e22-a4bb-23cd7c44f9f8">19,626</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzE2LTE1LTEtMS0w_e0e9ccce-1424-4796-8e15-6feb10761e82">19,626</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, December 31, 2017</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i94911b2192424281937290aad92f9145_I20171231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzE3LTEtMS0xLTA_ef209e03-75ee-43c1-897e-78eb44c252cf">36,859,077</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i94911b2192424281937290aad92f9145_I20171231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzE3LTMtMS0xLTA_06c42ac6-7fae-4575-a53e-639b7c0c9c7b">369</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i1cf8820c35a34978979d81f8780ea221_I20171231" decimals="INF" format="ixt:zerodash" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzE3LTUtMS0xLTA_56365589-00f1-4147-a821-08b10b4d59ec">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1cf8820c35a34978979d81f8780ea221_I20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzE3LTctMS0xLTA_e8646bad-f44a-4a7d-abe2-a74c0b595847">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i800361a265974a11ad8699946c8502e8_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzE3LTktMS0xLTA_dcca6b45-8fee-4583-9d8b-5f585f821749">611,270</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie5fd1b1d68244c1fb5c42ba60484c135_I20171231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzE3LTExLTEtMS0w_16e84727-0554-4796-a972-98c13a9a92d7">312,340</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i9c61e1783f5a42efa8b8f1b1d3450e3f_I20171231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzE3LTEzLTEtMS0w_3caf56d3-d723-452a-9e72-33fe341248b6">61</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7057397719af459ca7328a1c440a0efa_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzE3LTE1LTEtMS0w_51349617-5fe9-4afb-a64c-37b15bee7b98">299,238</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Cumulative effect of adoption of accounting standards</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie5fd1b1d68244c1fb5c42ba60484c135_I20171231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzE4LTExLTEtMS03MDM_309c2dc1-7a0c-45b8-8f22-af8703792053">6,478</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzE4LTE1LTEtMS02MDU4_05dbc602-fe67-4923-a2ba-e65f74bf5f7d">6,478</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Share-based compensation</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7250145010e441dcb223b7e59056d359_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzE4LTktMS0xLTA_75ccb138-187c-4507-b6e0-fa608328c70e">16,520</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzE4LTE1LTEtMS0w_69590b60-987e-4b36-bc33-b282d86d05a1">16,520</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Issuance of common stock, net of offering costs</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ied344051463c48e98fa4145c7382285a_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzE5LTEtMS0xLTA_f896cad3-73cc-418d-ad3e-9a3ef6b89359">5,175,000</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ied344051463c48e98fa4145c7382285a_D20180101-20181231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzE5LTMtMS0xLTA_4769669d-e15b-43bb-bce4-9957c1cde52e">52</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7250145010e441dcb223b7e59056d359_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzE5LTktMS0xLTA_41a284f1-8c0b-4ab9-a37b-62a19293c06e">103,207</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzE5LTE1LTEtMS0w_0e3cd8fc-45ae-4077-8cce-811a53b62f2f">103,259</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Stock plan related activity</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ied344051463c48e98fa4145c7382285a_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="mgnx:StockIssuedDuringPeriodSharesStockPlanActivity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzIwLTEtMS0xLTA_188990d7-5926-460a-b40c-e04f80413033">319,224</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ied344051463c48e98fa4145c7382285a_D20180101-20181231" decimals="-3" name="mgnx:StockIssuedDuringPeriodValueStockPlanActivity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzIwLTMtMS0xLTA_df58d02c-c532-49aa-98fc-407a1d572f43">3</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ib9de5f176a0348ab931fab4225555181_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="mgnx:StockIssuedDuringPeriodSharesStockPlanActivity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzIwLTUtMS0xLTA_846ac187-f956-4e2b-8e78-41841a947e91">11,070</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib9de5f176a0348ab931fab4225555181_D20180101-20181231" decimals="-3" sign="-" name="mgnx:StockIssuedDuringPeriodValueStockPlanActivity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzIwLTctMS0xLTA_8d511747-5e96-4a65-b674-e4fc57994741">260</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7250145010e441dcb223b7e59056d359_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="mgnx:StockIssuedDuringPeriodValueStockPlanActivity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzIwLTktMS0xLTA_d7c60cea-a9ec-45ee-94b0-25b6c2c4f715">1,990</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="mgnx:StockIssuedDuringPeriodValueStockPlanActivity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzIwLTE1LTEtMS0w_6e720a37-bde8-4a75-a08d-77061145d9a7">1,733</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Retirement of treasury stock</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="ib9de5f176a0348ab931fab4225555181_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockSharesRetired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzIxLTUtMS0xLTA_f0699535-07ea-45c4-b37c-ac5e7a50424f">11,070</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib9de5f176a0348ab931fab4225555181_D20180101-20181231" decimals="-3" sign="-" name="us-gaap:TreasuryStockRetiredParValueMethodAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzIxLTctMS0xLTA_a1e15238-20d8-4114-a223-47aa6f9f1e94">260</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i7250145010e441dcb223b7e59056d359_D20180101-20181231" decimals="-3" name="us-gaap:TreasuryStockRetiredParValueMethodAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzIxLTktMS0xLTA_ed2bae49-a527-4eb1-bb23-b5e5e9787663">260</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:TreasuryStockRetiredParValueMethodAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzIxLTE1LTEtMS0w_cb1381b6-ca38-4206-a0a6-5bd2cce5fdee">&#8212;</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized gain on investments</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i449b3691440b4861a36b0b93e9837dbe_D20180101-20181231" decimals="-3" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzIyLTEzLTEtMS0w_54f32fab-5450-4fe0-95f1-0e210a0224cf">58</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" decimals="-3" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzIyLTE1LTEtMS0w_6b87d47c-9ce7-426e-bce3-7825f29642af">58</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i2441bc1dd5c841d99c40a2087f89589a_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzIzLTExLTEtMS0w_137d95df-0ebf-4e83-9926-27074b999049">171,453</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzIzLTE1LTEtMS0w_03124a6f-d581-4bff-8023-8ffb27792ab5">171,453</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, December 31, 2018</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="id2b1c6462f71494a98dce8bac5aef0c8_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzI0LTEtMS0xLTA_461cb633-225f-480f-969a-b53f62804bc3">42,353,301</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id2b1c6462f71494a98dce8bac5aef0c8_I20181231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzI0LTMtMS0xLTA_5a014938-b170-4800-ae7a-4d9e9fe37bdd">424</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i5fefb74c168342b7b60f52ca08b1b7fc_I20181231" decimals="INF" format="ixt:zerodash" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzI0LTUtMS0xLTA_05e1ad41-e73b-491e-af88-97dc5c957eac">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5fefb74c168342b7b60f52ca08b1b7fc_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzI0LTctMS0xLTA_e9b8b014-373d-478d-95d4-691b79edea80">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i73f75e4bcf834fc4bca320dd6083848a_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzI0LTktMS0xLTA_05260c46-6cf0-4095-815b-748d03423146">732,727</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="icb8cb5ee17f94fffbdcab3e5ff465890_I20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzI0LTExLTEtMS0w_57f8d85b-c384-4fdd-92d5-07a9e5dd9624">490,271</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie553de76ecaa42e2af8bd7cfe6d9d352_I20181231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzI0LTEzLTEtMS0w_bc2d2dab-4ccc-4185-8fdc-d3a80bfb9d3a">3</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzI0LTE1LTEtMS0w_63debbe1-99e5-48fc-9bd7-6d367b1a96b4">242,877</ix:nonFraction>&#160;</span></td></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">See accompanying notes.</span></div><div id="i_0_560"></div><div style="text-align:center;"></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">F - 4</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">MACROGENICS, INC.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">(In thousands)</span></div><div style="margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"><tr><td style="width:1.0%;"></td><td style="width:61.343109%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.730205%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533138%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.730205%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533138%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.730205%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2016</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating activities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzMtMS0xLTEtMA_3839f3a4-578b-46b5-a6ce-295e25f67921">171,453</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzMtMy0xLTEtMA_3a34732b-ed9a-4a05-b46d-659dab4295e6">19,626</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iaf5d0e8fdf374dc09283fd669e2ebf19_D20160101-20161231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzMtNS0xLTEtMA_ea69a792-d0f6-4c31-9fbd-bd43047305a6">58,528</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Adjustments to reconcile net loss to net cash provided by (used in) operating activities:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Depreciation and amortization</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzUtMS0xLTEtMA_7acb6d66-d319-4fb6-9ec8-add6b18f8c5e">8,279</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzUtMy0xLTEtMA_077b4bfb-004c-4fad-86f5-498dc2f327a8">7,228</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iaf5d0e8fdf374dc09283fd669e2ebf19_D20160101-20161231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzUtNS0xLTEtMA_c978a03b-6ac0-4f83-9518-658ce261d5de">7,608</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Share-based compensation</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzYtMS0xLTEtMA_50cf2a3c-891e-4c8f-b791-5c6634fc3264">16,520</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzYtMy0xLTEtMA_a5d5971f-b253-4f53-ae7a-04b73810d75a">14,744</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iaf5d0e8fdf374dc09283fd669e2ebf19_D20160101-20161231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzYtNS0xLTEtMA_368e49c9-2cad-4861-8062-438e2625c8f8">12,165</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Changes in operating assets and liabilities:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts receivable</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzgtMS0xLTEtMA_28b26d83-de4d-4d1e-97bc-d9e65617f864">15,941</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzgtMy0xLTEtMA_a19a451b-2bb9-436b-8920-bdd6695681ef">10,878</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iaf5d0e8fdf374dc09283fd669e2ebf19_D20160101-20161231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzgtNS0xLTEtMA_8862c67a-ab67-43f3-95b8-33642c565edf">1,540</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid expenses</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzktMS0xLTEtMA_666b0b36-5737-4f68-bad0-817fd13bed78">3,255</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzktMy0xLTEtMA_d15f4ca8-b72f-4791-b51a-4d8df3c703d6">332</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iaf5d0e8fdf374dc09283fd669e2ebf19_D20160101-20161231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzktNS0xLTEtMA_f4dda0e3-0b15-4d5e-a198-ecf4321d04c5">1,677</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Other assets</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzExLTEtMS0xLTA_898307e8-3fcf-423b-9107-3b433a79a4cf">4,580</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzExLTMtMS0xLTA_7761b464-c1c0-40dc-8bfc-81a3cb429b15">262</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iaf5d0e8fdf374dc09283fd669e2ebf19_D20160101-20161231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzExLTUtMS0xLTA_44d62d18-9950-4d07-9138-a64c230ca7cd">276</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts payable</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzEyLTEtMS0xLTA_ce6e96fc-56ce-4ef7-a4e8-c0ae65ba2328">1,554</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzEyLTMtMS0xLTA_c31b7ae9-395d-4189-8dab-c8b35c5146f0">1,544</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iaf5d0e8fdf374dc09283fd669e2ebf19_D20160101-20161231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzEyLTUtMS0xLTA_7db0a7c0-87a1-40a0-a66c-82d11febac31">2,232</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued expenses</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzEzLTEtMS0xLTA_95f6f971-1e56-4603-ba1e-79b08ea914da">3,506</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzEzLTMtMS0xLTA_89b8977f-31a3-4c15-8bf4-de0dfdff8213">12,832</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iaf5d0e8fdf374dc09283fd669e2ebf19_D20160101-20161231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzEzLTUtMS0xLTA_2c57e4a3-bd66-4a6e-9c46-464cda80233a">4,659</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred revenue</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInDeferredRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzE1LTEtMS0xLTA_0a4535d3-6165-4e87-aa3c-a4a82a0c6b9c">13,405</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInDeferredRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzE1LTMtMS0xLTA_3dd67c97-96fc-47b7-9a11-c523ce698a23">6,533</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iaf5d0e8fdf374dc09283fd669e2ebf19_D20160101-20161231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInDeferredRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzE1LTUtMS0xLTA_9e5b2ae7-bbda-4725-98df-90f441e809d6">4,191</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred rent</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" decimals="-3" sign="-" name="mgnx:IncreaseDecreaseInDeferredRent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzE2LTEtMS0xLTA_04bf8056-6d1e-4d9a-8250-5f276d3c3cf0">971</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="mgnx:IncreaseDecreaseInDeferredRent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzE2LTMtMS0xLTA_41537f2a-ab8a-4d18-8e10-21e5f5825933">6,115</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iaf5d0e8fdf374dc09283fd669e2ebf19_D20160101-20161231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="mgnx:IncreaseDecreaseInDeferredRent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzE2LTUtMS0xLTA_ede4d34b-c125-4cac-ae07-2c2dd0015c13">1,134</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Other liabilities</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzE3LTEtMS0xLTA_c71cecba-56aa-4e37-a4bd-769a6de28821">298</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzE3LTMtMS0xLTA_11195fb8-3c1a-4c52-87db-68b8810320f7">1,593</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iaf5d0e8fdf374dc09283fd669e2ebf19_D20160101-20161231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzE3LTUtMS0xLTA_3a6580c2-d061-488c-be8a-0296d8fbf0a7">3,549</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash provided by (used in) operating activities</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzE4LTEtMS0xLTA_727423a8-9bdd-4818-8133-a9fc93aa2c93">153,234</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzE4LTMtMS0xLTA_d53d630a-c927-49cd-8801-c8d7689d36b7">14,405</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iaf5d0e8fdf374dc09283fd669e2ebf19_D20160101-20161231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzE4LTUtMS0xLTA_f805f2ac-8eb1-46f3-9af2-317f02cdd9d8">43,679</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="height:13pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash flows from investing activities</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Purchases of marketable securities</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzIxLTEtMS0xLTA_2fe21985-20fc-4a6d-a2be-7a7f822a04d3">132,750</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzIxLTMtMS0xLTA_4c873aa6-7448-4e8f-8efa-3ceb28939ec8">135,122</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iaf5d0e8fdf374dc09283fd669e2ebf19_D20160101-20161231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzIxLTUtMS0xLTA_32778d63-b286-4771-b558-3612c566410b">347,762</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Proceeds from sales and maturities of marketable securities</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzIyLTEtMS0xLTA_54697c0a-c5b3-428c-a4cb-e89c6c909459">214,348</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzIyLTMtMS0xLTA_3766e288-28ea-457a-b5c4-e0b21f5e7531">242,401</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iaf5d0e8fdf374dc09283fd669e2ebf19_D20160101-20161231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzIyLTUtMS0xLTA_3a14a9b0-5c5b-40dc-a7c3-ff2d6526ae39">288,894</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Purchases of property, equipment and software</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzIzLTEtMS0xLTA_400c7167-aae4-4b53-88f6-417d45b95e71">24,954</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzIzLTMtMS0xLTA_cd7fee8d-be75-42b2-9c3b-a42f277395ae">29,403</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iaf5d0e8fdf374dc09283fd669e2ebf19_D20160101-20161231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzIzLTUtMS0xLTA_d54429e0-66c1-47cb-a6e3-7221c1eb629f">11,381</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash provided by (used in) investing activities</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzI0LTEtMS0xLTA_94c15471-00c9-488d-8ebc-d2e6b0d69219">56,644</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzI0LTMtMS0xLTA_f4fa9b26-a4bb-4bbe-8149-9d4626a48069">77,876</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iaf5d0e8fdf374dc09283fd669e2ebf19_D20160101-20161231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzI0LTUtMS0xLTA_a644ff01-c5ba-43e8-aecd-e607cf9d26a2">70,249</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="height:13pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash flows from financing activities</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Proceeds from issuance of common stock, net of offering costs</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzI3LTEtMS0xLTA_c1f92f9c-67bf-4ac1-8b12-d4c28d0d95f5">103,259</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzI3LTMtMS0xLTA_5c1e207e-7be6-4b23-8c08-ba74b1eff7fd">34244</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iaf5d0e8fdf374dc09283fd669e2ebf19_D20160101-20161231" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzI3LTUtMS0xLTA_728c747a-a0e0-42f3-8b70-1eb61f5df12f">&#8212;</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Proceeds from stock option exercises and ESPP purchases</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="mgnx:ProceedsfromStockOptionsExercisedAndESPPPurchases" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzI4LTEtMS0xLTA_82084f22-8a89-4382-9c07-ded204d90b67">1,992</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="mgnx:ProceedsfromStockOptionsExercisedAndESPPPurchases" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzI4LTMtMS0xLTA_046e427d-78a2-4326-b44e-0b98147f796f">1,144</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iaf5d0e8fdf374dc09283fd669e2ebf19_D20160101-20161231" decimals="-3" format="ixt:numdotdecimal" name="mgnx:ProceedsfromStockOptionsExercisedAndESPPPurchases" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzI4LTUtMS0xLTA_a8cbb39b-2542-417c-8c08-bedf0e797b37">1,893</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Purchase of treasury stock</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzI5LTEtMS0xLTA_7cbe0bd4-93e5-4d30-b29b-c57e6a04ef69">260</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzI5LTMtMS0xLTA_0d23290f-1d40-45bf-8118-3dcd8711b983">40</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iaf5d0e8fdf374dc09283fd669e2ebf19_D20160101-20161231" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzI5LTUtMS0xLTA_25f7836a-8d28-4964-8a27-1e31918262d1">39</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash provided by financing activities</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzMwLTEtMS0xLTA_b36f5210-aafc-4866-9a86-6071773161be">104,991</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzMwLTMtMS0xLTA_074a9455-5f08-49ba-842e-5bb77f433bee">35,348</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iaf5d0e8fdf374dc09283fd669e2ebf19_D20160101-20161231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzMwLTUtMS0xLTA_fd7e00c4-cc82-48c1-a9d2-7b645f35c050">1,854</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Net change in cash and cash equivalents</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzMxLTEtMS0xLTA_a9ea94e7-6b26-42af-8a6d-d9fdd4377ff1">8,401</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzMxLTMtMS0xLTA_d9a42052-c84e-4e30-9239-78095b14c479">127,629</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iaf5d0e8fdf374dc09283fd669e2ebf19_D20160101-20161231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzMxLTUtMS0xLTA_4b0a36cd-7f63-4893-a544-13dedb29e5d0">112,074</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents at beginning of period</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7057397719af459ca7328a1c440a0efa_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzMyLTEtMS0xLTA_825cfa0f-6d0d-4025-8e9b-f960a56d43e9">211,727</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iaa98382ff57d452ab6942c773d605ba7_I20161231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzMyLTMtMS0xLTA_0f9a6fed-2944-41ca-99da-5b2dcb3e59af">84,098</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ife0dac9d3bf74657b071534f4d2516f1_I20151231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzMyLTUtMS0xLTA_787aa5a6-9738-4e45-b5be-19626fd9a9b2">196,172</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents at end of period</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzMzLTEtMS0xLTA_90b11745-5d23-4ac6-9335-2df4c4b5e16c">220,128</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7057397719af459ca7328a1c440a0efa_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzMzLTMtMS0xLTA_dd77be48-316a-4eef-bc93-4c960ed2604a">211,727</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iaa98382ff57d452ab6942c773d605ba7_I20161231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzMzLTUtMS0xLTA_e2a2182b-2e17-4b3a-a758-9a28bb8c331d">84,098</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-cash operating and investing activities:&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair value of warrants received&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="mgnx:FairValueOfWarrantsReceived" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzM1LTEtMS0xLTYwNjA_93ac4ea9-4123-4e25-9325-81c8aaabee22">6,130</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231" decimals="-3" format="ixt:zerodash" name="mgnx:FairValueOfWarrantsReceived" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzM1LTMtMS0xLTYwNjc_bcf86bbc-e241-4980-921e-c39f634500ae">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iaf5d0e8fdf374dc09283fd669e2ebf19_D20160101-20161231" decimals="-3" format="ixt:zerodash" name="mgnx:FairValueOfWarrantsReceived" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzM1LTUtMS0xLTYwNjk_985a3088-2fb2-4378-8ef2-3aa86e553f73">&#8212;</ix:nonFraction>&#160;</span></td></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">See accompanying notes.</span></div><div id="i_0_573"></div><div style="text-align:center;"></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">F - 5</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">MACROGENICS, INC.</span></div><div style="text-align:center;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div id="i_0_586"></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">1. <ix:nonNumeric contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81ODYvZnJhZzo4YWNhYmQxMjk3MWY0MTU2YTQ0NzczODViY2IxMmQ3NC90ZXh0cmVnaW9uOjhhY2FiZDEyOTcxZjQxNTZhNDQ3NzM4NWJjYjEyZDc0XzgwOQ_4cf802f4-2ec3-41e5-964e-2ce17bbcef6a" continuedAt="ia36b8c7cb6d14bbb86d249bbc00d272e" escape="true">Organization and Nature of Operations</ix:nonNumeric></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"><ix:continuation id="ia36b8c7cb6d14bbb86d249bbc00d272e">MacroGenics, Inc. (the Company) is incorporated in the state of Delaware. The Company is a biopharmaceutical company focused on discovering and developing innovative antibody-based therapeutics designed to modulate the human immune response for the treatment of cancer. The Company currently has a pipeline of product candidates in human clinical testing that have been created primarily using its proprietary technology platforms. The Company believes its programs have the potential to have a meaningful effect on treating patients' unmet medical needs as monotherapy or, in some cases, in combination with other therapeutic agents.</ix:continuation></span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span><br/></span></div><div id="i_0_598"></div><div style="margin-top:3pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">2. <ix:nonNumeric contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90ZXh0cmVnaW9uOjIxM2RlYmY3Njg3MzQ3NmE5YTk0YzgyMTZiN2I4YTlmXzQxNDQx_fc98c50d-19a8-49d1-8c61-aeb9dd1d8db4" continuedAt="i2f1bc8d7f7464839ac7a072f775e1916" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="i2f1bc8d7f7464839ac7a072f775e1916" continuedAt="i0fdc5cfc51f84e478131bcf8455537e1"><ix:nonNumeric contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90ZXh0cmVnaW9uOjIxM2RlYmY3Njg3MzQ3NmE5YTk0YzgyMTZiN2I4YTlmXzQxNDQy_85324903-a6c2-4a88-9ce1-77b4d2bb8b29" escape="true"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Basis of Presentation and Principles of Consolidation</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The consolidated financial statements include the accounts of MacroGenics, Inc. and its wholly owned subsidiary, MacroGenics UK Limited.&#160; All intercompany accounts and transactions have been eliminated in consolidation. The Company currently operates in <ix:nonFraction unitRef="segment" contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90ZXh0cmVnaW9uOjIxM2RlYmY3Njg3MzQ3NmE5YTk0YzgyMTZiN2I4YTlmXzM2MA_d84fe185-6040-466c-8995-d54e7d4110ba">one</ix:nonFraction> operating segment. Operating segments are defined as components of an enterprise about which separate discrete information is available for the chief operating decision maker, or decision making group, in deciding how to allocate resources and assessing performance. The Company views its operations and manages its business in <ix:nonFraction unitRef="segment" contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90ZXh0cmVnaW9uOjIxM2RlYmY3Njg3MzQ3NmE5YTk0YzgyMTZiN2I4YTlmXzY5MQ_d84fe185-6040-466c-8995-d54e7d4110ba">one</ix:nonFraction> segment, which is developing monoclonal antibody-based therapeutics for cancer, autoimmune and infectious diseases.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90ZXh0cmVnaW9uOjIxM2RlYmY3Njg3MzQ3NmE5YTk0YzgyMTZiN2I4YTlmXzQxNDQz_be9910b9-ffc0-4d2a-b305-5a38ca6692af" escape="true"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Use of Estimates</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The preparation of the financial statements in accordance with generally accepted accounting principles (GAAP) requires the Company to make estimates and judgments in certain circumstances that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. In preparing these consolidated financial statements, management has made its best estimates and judgments of certain amounts included in the financial statements, giving due consideration to materiality. On an ongoing basis, the Company evaluates its estimates, including those related to revenue recognition, fair values of assets, stock-based compensation, income taxes, preclinical study and clinical trial accruals and other contingencies. Management bases its estimates on historical experience or on various other assumptions that it believes to be reasonable under the circumstances. Actual results could differ from these estimates.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90ZXh0cmVnaW9uOjIxM2RlYmY3Njg3MzQ3NmE5YTk0YzgyMTZiN2I4YTlmXzQxNDQ0_65d15092-5b21-4fbe-a7d6-cece6e460207" escape="true"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Cash, Cash Equivalents and Marketable Securities</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Company considers all investments in highly liquid financial instruments with a maturity of 90 days or less at the date of purchase to be cash equivalents. Cash and cash equivalents includes investments in money market funds with commercial banks and financial institutions, securities issued by the U.S. government and its agencies, Government Sponsored Enterprise agency debt obligations and corporate debt obligations. Cash equivalents are stated at amortized cost, plus accrued interest, which approximates fair value.</span></div><div style="text-indent:25pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Company carries marketable securities classified as available-for-sale at fair value as determined by prices for identical or similar securities at the balance sheet date. Marketable securities consist of Level 2 financial instruments in the fair-value hierarchy. The Company records unrealized gains and losses as a component of other comprehensive loss within the statements of operations and comprehensive loss and as a separate component of stockholders' equity. Realized gains or losses on available-for-sale securities are determined using the specific identification method and the Company includes net realized gains and losses in other income (expense).</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;">At each balance sheet date, the Company assesses available-for-sale securities in an unrealized loss position to determine whether the unrealized loss is other-than-temporary. The Company considers factors including: the significance of the decline in value compared to the cost basis, underlying factors contributing to a decline in the prices of securities in a single asset class, the length of time the market value of the security has been less than its cost basis, the security's relative performance versus its peers, sector or asset class, expected market volatility and the market and economy in general. The Company also evaluates whether it is more likely than not that it will be required to sell a security prior to recovery of its fair value.&#160; An impairment loss is recognized at the time the Company determines that a decline in the fair value below its cost basis is other-than-temporary. There were <ix:nonFraction unitRef="usd" contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90ZXh0cmVnaW9uOjIxM2RlYmY3Njg3MzQ3NmE5YTk0YzgyMTZiN2I4YTlmXzM5NjQ_d100fc20-02d7-4c70-b97c-c180f4c03a73">no</ix:nonFraction> unrealized losses at December&#160;31, 2018 or </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">2017</span><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;"> that the Company determined to be other-than-temporary.</span></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:9pt;"><span><br/></span></div><div style="margin-bottom:9pt;"></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">F - 6</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="i0fdc5cfc51f84e478131bcf8455537e1" continuedAt="i1b2adc63a6cb4ea1ba966f05f240724a"><ix:nonNumeric contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" name="us-gaap:TradeAndOtherAccountsReceivablePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90ZXh0cmVnaW9uOjIxM2RlYmY3Njg3MzQ3NmE5YTk0YzgyMTZiN2I4YTlmXzQxNDQ1_0922a557-2555-453b-ab33-ac160d2f0aea" escape="true"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Accounts Receivable</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Accounts receivable that management has the intent and ability to collect are reported in the consolidated balance sheets at outstanding amounts, less an allowance for doubtful accounts. The Company writes off uncollectible receivables when the likelihood of collection is remote.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Company evaluates the collectability of accounts receivable on a regular basis. The allowance, if any, is based upon various factors including the financial condition and payment history of customers, an overall review of collections experience on other accounts and economic factors or events expected to affect future collections experience. <ix:nonFraction unitRef="usd" contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90ZXh0cmVnaW9uOjIxM2RlYmY3Njg3MzQ3NmE5YTk0YzgyMTZiN2I4YTlmXzQ3MDU_b6e7930b-6468-4289-807b-cc0151b08d59">No</ix:nonFraction> allowance was recorded as of December&#160;31, 2018 or 2017, as the Company has a history of collecting on all outstanding accounts.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90ZXh0cmVnaW9uOjIxM2RlYmY3Njg3MzQ3NmE5YTk0YzgyMTZiN2I4YTlmXzQxNDQ2_7a3125d0-f0fb-4ece-a137-24991a170345" escape="true"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Fair Value of Financial Instruments</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Company's financial instruments consist of cash and cash equivalents, marketable securities, accounts receivable, accounts payable and accrued expenses.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;">The carrying amount of accounts receivable, accounts payable and accrued expenses are generally considered to be representative of their respective fair values because of their short-term nature.&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> The Company accounts for recurring and non-recurring fair value measurements in accordance with the Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 820, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Fair Value Measurements and Disclosures</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> (ASC 820). ASC 820 defines fair value, establishes a fair value hierarchy for assets and liabilities measured at fair value, and requires expanded disclosures about fair value measurements. The ASC 820 hierarchy ranks the quality of reliability of inputs, or assumptions, used in the determination of fair value and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following three categories:</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">Level 1 &#8211; Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities.</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">Level 2 &#8211; Fair value is determined by using inputs other than Level 1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models, such as interest rates and yield curves that can be corroborated by observable market data.</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">Level 3 &#8211; Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgments to be made by a reporting entity &#8211; e.g., determining an appropriate adjustment to a discount factor for illiquidity associated with a given security.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Company evaluates financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them each reporting period. This determination requires the Company to make subjective judgments as to the significance of inputs used in determining fair value and where such inputs lie within the ASC 820 hierarchy.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90ZXh0cmVnaW9uOjIxM2RlYmY3Njg3MzQ3NmE5YTk0YzgyMTZiN2I4YTlmXzE1MzkzMTYyOTQxNzMy_6858f260-287b-41bf-9461-2c0b58755337" continuedAt="ie7cc17dba53041a893de04c6275159ca" escape="true"><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Financial assets measured at fair value on a recurring basis were as follows (in thousands):</span></div><div style="margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"><tr><td style="width:1.0%;"></td><td style="width:36.325991%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.747430%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.121586%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:13.565345%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.268429%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:13.271659%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.121586%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.977974%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value Measurement at December 31, 2018</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Quoted Prices in</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Active Markets for</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Identical Assets</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Significant Other</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Observable Inputs</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Significant</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Unobservable</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Inputs</span></div></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 3</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Assets:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i48784f16cceb4a92949dfc57c3d660b6_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTo1YTIyZWFmOWY2Mzg0YjQxOTc2ODIyYzcxOTMxNzk3My90YWJsZXJhbmdlOjVhMjJlYWY5ZjYzODRiNDE5NzY4MjJjNzE5MzE3OTczXzQtMS0xLTEtMA_3d3ee037-b05a-470c-b222-cdeb66738e02">46,257</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4a8fd95d96b9467b946bd865997ab910_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTo1YTIyZWFmOWY2Mzg0YjQxOTc2ODIyYzcxOTMxNzk3My90YWJsZXJhbmdlOjVhMjJlYWY5ZjYzODRiNDE5NzY4MjJjNzE5MzE3OTczXzQtMy0xLTEtMA_143cda57-b2cb-405d-80af-b689e6a2cc54">46,257</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0e1afaa0aa004fcc98602893dc6bf0af_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTo1YTIyZWFmOWY2Mzg0YjQxOTc2ODIyYzcxOTMxNzk3My90YWJsZXJhbmdlOjVhMjJlYWY5ZjYzODRiNDE5NzY4MjJjNzE5MzE3OTczXzQtNS0xLTEtMA_3ab66356-d9fb-47cc-b7bf-069a3bead6af">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5c80cf2c50cc438b8e0cd14b52a82cf0_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTo1YTIyZWFmOWY2Mzg0YjQxOTc2ODIyYzcxOTMxNzk3My90YWJsZXJhbmdlOjVhMjJlYWY5ZjYzODRiNDE5NzY4MjJjNzE5MzE3OTczXzQtNy0xLTEtMA_328b9426-0a4e-4497-b471-bdc0eacb7353">&#8212;</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S Treasury securities</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8b30daf53dd540e8972913308cc2a710_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTo1YTIyZWFmOWY2Mzg0YjQxOTc2ODIyYzcxOTMxNzk3My90YWJsZXJhbmdlOjVhMjJlYWY5ZjYzODRiNDE5NzY4MjJjNzE5MzE3OTczXzUtMS0xLTEtMA_2f72228c-8762-43d1-9616-d794cb4841ef">12,488</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9885584d437f4fdbb9821f6883801e5e_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTo1YTIyZWFmOWY2Mzg0YjQxOTc2ODIyYzcxOTMxNzk3My90YWJsZXJhbmdlOjVhMjJlYWY5ZjYzODRiNDE5NzY4MjJjNzE5MzE3OTczXzUtMy0xLTEtMA_7e0da6d5-62ba-47a4-8107-00aa381af620">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id8224ea921344b21b249696a5b1fee59_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTo1YTIyZWFmOWY2Mzg0YjQxOTc2ODIyYzcxOTMxNzk3My90YWJsZXJhbmdlOjVhMjJlYWY5ZjYzODRiNDE5NzY4MjJjNzE5MzE3OTczXzUtNS0xLTEtMA_d7c798eb-c1f9-413d-812c-1e38732a3718">12,488</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i19bf1b5616d54d289ec50510e079bd27_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTo1YTIyZWFmOWY2Mzg0YjQxOTc2ODIyYzcxOTMxNzk3My90YWJsZXJhbmdlOjVhMjJlYWY5ZjYzODRiNDE5NzY4MjJjNzE5MzE3OTczXzUtNy0xLTEtMA_f1813106-4952-41eb-96b1-daf0065f76b2">&#8212;</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6e342386069b4859b038021f1292bc8e_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTo1YTIyZWFmOWY2Mzg0YjQxOTc2ODIyYzcxOTMxNzk3My90YWJsZXJhbmdlOjVhMjJlYWY5ZjYzODRiNDE5NzY4MjJjNzE5MzE3OTczXzctMS0xLTEtMA_7496d69f-0761-413d-82b8-636507fe87e3">100,214</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i836203a185014b4a9e662c9f5457029d_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTo1YTIyZWFmOWY2Mzg0YjQxOTc2ODIyYzcxOTMxNzk3My90YWJsZXJhbmdlOjVhMjJlYWY5ZjYzODRiNDE5NzY4MjJjNzE5MzE3OTczXzctMy0xLTEtMA_cbdacaa1-807d-4fb8-97c2-b18bb8c58043">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i15cd0dab53764d82a187cc3da46a3761_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTo1YTIyZWFmOWY2Mzg0YjQxOTc2ODIyYzcxOTMxNzk3My90YWJsZXJhbmdlOjVhMjJlYWY5ZjYzODRiNDE5NzY4MjJjNzE5MzE3OTczXzctNS0xLTEtMA_0756aca8-7106-42f4-83a7-f00d0ad161f3">100,214</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i69e6f22f5f224360a82e4379d7fff4b7_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTo1YTIyZWFmOWY2Mzg0YjQxOTc2ODIyYzcxOTMxNzk3My90YWJsZXJhbmdlOjVhMjJlYWY5ZjYzODRiNDE5NzY4MjJjNzE5MzE3OTczXzctNy0xLTEtMA_41525fc4-fa99-40d4-b002-b57de7df16c1">&#8212;</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Common stock warrants</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231" decimals="-3" format="ixt:numdotdecimal" name="mgnx:WarrantsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTo1YTIyZWFmOWY2Mzg0YjQxOTc2ODIyYzcxOTMxNzk3My90YWJsZXJhbmdlOjVhMjJlYWY5ZjYzODRiNDE5NzY4MjJjNzE5MzE3OTczXzgtMS0xLTEtMjI1NA_358c341d-faf0-4e41-b44f-c339c7fe1484">1,890</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i12ae7112f1294c1ba9b38f26417d21a2_I20181231" decimals="-3" format="ixt:zerodash" name="mgnx:WarrantsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTo1YTIyZWFmOWY2Mzg0YjQxOTc2ODIyYzcxOTMxNzk3My90YWJsZXJhbmdlOjVhMjJlYWY5ZjYzODRiNDE5NzY4MjJjNzE5MzE3OTczXzgtMy0xLTEtNjA3Ng_03f60169-c831-4631-b076-96fefe5b8a18">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ica70e0e9496b4c8ab1c2aeea43e1c55e_I20181231" decimals="-3" format="ixt:zerodash" name="mgnx:WarrantsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTo1YTIyZWFmOWY2Mzg0YjQxOTc2ODIyYzcxOTMxNzk3My90YWJsZXJhbmdlOjVhMjJlYWY5ZjYzODRiNDE5NzY4MjJjNzE5MzE3OTczXzgtNS0xLTEtNjExMw_69f748c1-8f5f-425b-b9c6-6a511f7d3ee4">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id2873baa5a4b4d10bf1a5d20be263861_I20181231" decimals="-3" format="ixt:numdotdecimal" name="mgnx:WarrantsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTo1YTIyZWFmOWY2Mzg0YjQxOTc2ODIyYzcxOTMxNzk3My90YWJsZXJhbmdlOjVhMjJlYWY5ZjYzODRiNDE5NzY4MjJjNzE5MzE3OTczXzgtNy0xLTEtMjI1NA_b2e95cd4-0070-4e70-8639-27c5e066a6f9">1,890</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">Total assets measured at fair value </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(a)</sup></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTo1YTIyZWFmOWY2Mzg0YjQxOTc2ODIyYzcxOTMxNzk3My90YWJsZXJhbmdlOjVhMjJlYWY5ZjYzODRiNDE5NzY4MjJjNzE5MzE3OTczXzgtMS0xLTEtMA_e7d186f8-c3bc-4adf-b127-76fe288e363d">160,849</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i12ae7112f1294c1ba9b38f26417d21a2_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTo1YTIyZWFmOWY2Mzg0YjQxOTc2ODIyYzcxOTMxNzk3My90YWJsZXJhbmdlOjVhMjJlYWY5ZjYzODRiNDE5NzY4MjJjNzE5MzE3OTczXzgtMy0xLTEtMA_aa0feb97-e988-49d5-a263-4b11b8a260e3">46,257</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ica70e0e9496b4c8ab1c2aeea43e1c55e_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTo1YTIyZWFmOWY2Mzg0YjQxOTc2ODIyYzcxOTMxNzk3My90YWJsZXJhbmdlOjVhMjJlYWY5ZjYzODRiNDE5NzY4MjJjNzE5MzE3OTczXzgtNS0xLTEtMA_3924f900-4dac-42a2-9f46-b318541b52e7">112,702</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id2873baa5a4b4d10bf1a5d20be263861_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTo1YTIyZWFmOWY2Mzg0YjQxOTc2ODIyYzcxOTMxNzk3My90YWJsZXJhbmdlOjVhMjJlYWY5ZjYzODRiNDE5NzY4MjJjNzE5MzE3OTczXzgtNy0xLTEtMA_04bef749-4a11-461d-8822-10c0b3610a81">1,890</ix:nonFraction>&#160;</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:9pt;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">F - 7</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="i1b2adc63a6cb4ea1ba966f05f240724a" continuedAt="i83c8a899e0874d78a446fda990814b0a"><ix:continuation id="ie7cc17dba53041a893de04c6275159ca"><div style="margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"><tr><td style="width:1.0%;"></td><td style="width:36.325991%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.747430%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.121586%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:13.565345%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.268429%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:13.271659%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.121586%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.977974%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value Measurement at December 31, 2017</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Quoted Prices in</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Active Markets for</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Identical Assets</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Significant Other</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Observable Inputs</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Significant</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Unobservable</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Inputs</span></div></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 3</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Assets:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3aaec4d2a9ba4186b6b54303daa9284f_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTo2MTNkYjQ4N2U5MjY0YjFlOTQ5MjQ4MWU3NGY0MTQxOS90YWJsZXJhbmdlOjYxM2RiNDg3ZTkyNjRiMWU5NDkyNDgxZTc0ZjQxNDE5XzQtMS0xLTEtMA_bd36cbc1-061f-4cba-85f3-c571623fbe4b">61,512</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i567c39ea2c894aa18c58e1478aeb50bb_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTo2MTNkYjQ4N2U5MjY0YjFlOTQ5MjQ4MWU3NGY0MTQxOS90YWJsZXJhbmdlOjYxM2RiNDg3ZTkyNjRiMWU5NDkyNDgxZTc0ZjQxNDE5XzQtMy0xLTEtMA_a85eabd3-3833-455e-a3dd-236336d08013">61,512</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i052ba9dcbb294d688f1b07ef8ae85f64_I20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTo2MTNkYjQ4N2U5MjY0YjFlOTQ5MjQ4MWU3NGY0MTQxOS90YWJsZXJhbmdlOjYxM2RiNDg3ZTkyNjRiMWU5NDkyNDgxZTc0ZjQxNDE5XzQtNS0xLTEtMA_c17521fa-e4f6-48d9-b245-b11d965286b7">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i39e9aef5cb214c03982914e5c0e5ef26_I20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTo2MTNkYjQ4N2U5MjY0YjFlOTQ5MjQ4MWU3NGY0MTQxOS90YWJsZXJhbmdlOjYxM2RiNDg3ZTkyNjRiMWU5NDkyNDgxZTc0ZjQxNDE5XzQtNy0xLTEtMA_35921836-abf1-47e5-8b9a-4f8b4ec335c1">&#8212;</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S Treasury securities</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idddbaa15d66240498398d35f3a8f6a97_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTo2MTNkYjQ4N2U5MjY0YjFlOTQ5MjQ4MWU3NGY0MTQxOS90YWJsZXJhbmdlOjYxM2RiNDg3ZTkyNjRiMWU5NDkyNDgxZTc0ZjQxNDE5XzUtMS0xLTEtMA_a210a379-cc1b-40d9-9e7f-f7a6533ef0ca">3,989</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id6c7535f08114b6b99ac9c52d559c896_I20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTo2MTNkYjQ4N2U5MjY0YjFlOTQ5MjQ4MWU3NGY0MTQxOS90YWJsZXJhbmdlOjYxM2RiNDg3ZTkyNjRiMWU5NDkyNDgxZTc0ZjQxNDE5XzUtMy0xLTEtMA_8799a290-2c2d-4b80-9589-33ddb6e6c5b0">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4b9777bbf6064d76be88747d34359989_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTo2MTNkYjQ4N2U5MjY0YjFlOTQ5MjQ4MWU3NGY0MTQxOS90YWJsZXJhbmdlOjYxM2RiNDg3ZTkyNjRiMWU5NDkyNDgxZTc0ZjQxNDE5XzUtNS0xLTEtMA_4fe24f7b-fc80-4034-8793-8f84a1aeee7f">3,989</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic0acfc838ca543a182c2f9a125366f7f_I20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTo2MTNkYjQ4N2U5MjY0YjFlOTQ5MjQ4MWU3NGY0MTQxOS90YWJsZXJhbmdlOjYxM2RiNDg3ZTkyNjRiMWU5NDkyNDgxZTc0ZjQxNDE5XzUtNy0xLTEtMA_8c6ecb92-fba6-41f4-b7ef-854afb1002fa">&#8212;</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Government-sponsored enterprises</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2f7cc4428c0c44c98d1a04ac21c0f886_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTo2MTNkYjQ4N2U5MjY0YjFlOTQ5MjQ4MWU3NGY0MTQxOS90YWJsZXJhbmdlOjYxM2RiNDg3ZTkyNjRiMWU5NDkyNDgxZTc0ZjQxNDE5XzYtMS0xLTEtMA_c5bcf043-9114-43ad-9b1a-ef0220ed1a25">11,991</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i813c2a024ec84a0dab992916df676184_I20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTo2MTNkYjQ4N2U5MjY0YjFlOTQ5MjQ4MWU3NGY0MTQxOS90YWJsZXJhbmdlOjYxM2RiNDg3ZTkyNjRiMWU5NDkyNDgxZTc0ZjQxNDE5XzYtMy0xLTEtMA_f98f9853-275b-4c14-9f9e-dc8d34135672">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i86696714ee304524b3bf18cd3b8cebf9_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTo2MTNkYjQ4N2U5MjY0YjFlOTQ5MjQ4MWU3NGY0MTQxOS90YWJsZXJhbmdlOjYxM2RiNDg3ZTkyNjRiMWU5NDkyNDgxZTc0ZjQxNDE5XzYtNS0xLTEtMA_47e15791-454c-4ef3-8a07-0ae95a84deb0">11,991</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i32a16b54a03b4f8dabcc3d55d161cd66_I20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTo2MTNkYjQ4N2U5MjY0YjFlOTQ5MjQ4MWU3NGY0MTQxOS90YWJsZXJhbmdlOjYxM2RiNDg3ZTkyNjRiMWU5NDkyNDgxZTc0ZjQxNDE5XzYtNy0xLTEtMA_7be78a52-5613-4598-95cb-79f431564129">&#8212;</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4c57ebf1216b40e69585d4723b4b1234_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTo2MTNkYjQ4N2U5MjY0YjFlOTQ5MjQ4MWU3NGY0MTQxOS90YWJsZXJhbmdlOjYxM2RiNDg3ZTkyNjRiMWU5NDkyNDgxZTc0ZjQxNDE5XzctMS0xLTEtMA_799c6cfd-38a6-46e1-913a-73cd11e5ecf7">78,418</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifb6cc9cda6124764a79895164b99ed24_I20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTo2MTNkYjQ4N2U5MjY0YjFlOTQ5MjQ4MWU3NGY0MTQxOS90YWJsZXJhbmdlOjYxM2RiNDg3ZTkyNjRiMWU5NDkyNDgxZTc0ZjQxNDE5XzctMy0xLTEtMA_bfa11ac1-f639-48f2-a74c-9449a047fc0e">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ife3b143f5c324bffabb232b405ceac51_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTo2MTNkYjQ4N2U5MjY0YjFlOTQ5MjQ4MWU3NGY0MTQxOS90YWJsZXJhbmdlOjYxM2RiNDg3ZTkyNjRiMWU5NDkyNDgxZTc0ZjQxNDE5XzctNS0xLTEtMA_dcfed84c-e29e-471f-bffa-2476f5413c7e">78,418</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i637fb60ec9d345b0aac156800fca7529_I20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTo2MTNkYjQ4N2U5MjY0YjFlOTQ5MjQ4MWU3NGY0MTQxOS90YWJsZXJhbmdlOjYxM2RiNDg3ZTkyNjRiMWU5NDkyNDgxZTc0ZjQxNDE5XzctNy0xLTEtMA_94ee0858-6471-4e1d-b51f-96e803c7222e">&#8212;</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">Total assets measured at fair value </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(</sup><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">b)</sup></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7057397719af459ca7328a1c440a0efa_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTo2MTNkYjQ4N2U5MjY0YjFlOTQ5MjQ4MWU3NGY0MTQxOS90YWJsZXJhbmdlOjYxM2RiNDg3ZTkyNjRiMWU5NDkyNDgxZTc0ZjQxNDE5XzgtMS0xLTEtMA_1205d312-dd98-469c-b1ff-0109375dfcdd">155,910</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i997657dcf4ae43db9ded89ab3af4df74_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTo2MTNkYjQ4N2U5MjY0YjFlOTQ5MjQ4MWU3NGY0MTQxOS90YWJsZXJhbmdlOjYxM2RiNDg3ZTkyNjRiMWU5NDkyNDgxZTc0ZjQxNDE5XzgtMy0xLTEtMA_994df209-05a7-4827-a858-155879f4ca79">61,512</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i024ac39056e24d43aed54ab33d2c004e_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTo2MTNkYjQ4N2U5MjY0YjFlOTQ5MjQ4MWU3NGY0MTQxOS90YWJsZXJhbmdlOjYxM2RiNDg3ZTkyNjRiMWU5NDkyNDgxZTc0ZjQxNDE5XzgtNS0xLTEtMA_fb66856a-a61c-48a2-b61b-ab5e97b2a131">94,398</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i606378e8044a40e5ad3ac2c0df524b2b_I20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTo2MTNkYjQ4N2U5MjY0YjFlOTQ5MjQ4MWU3NGY0MTQxOS90YWJsZXJhbmdlOjYxM2RiNDg3ZTkyNjRiMWU5NDkyNDgxZTc0ZjQxNDE5XzgtNy0xLTEtMA_96da9e00-0555-4e96-8f86-83c8b869b44d">&#8212;</ix:nonFraction>&#160;</span></td></tr></table></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">(a) Total assets measured at fair value at December&#160;31, 2018 includes approximately $<ix:nonFraction unitRef="usd" contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90ZXh0cmVnaW9uOjIxM2RlYmY3Njg3MzQ3NmE5YTk0YzgyMTZiN2I4YTlmXzI3NDg3NzkxMTEyOTY_b8de7f41-766d-445d-904f-47c457f3caaa">146.2</ix:nonFraction> million reported in cash and cash equivalents on the balance sheet.</span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">(b) Total assets measured at fair value at December&#160;31, 2017 includes approximately $<ix:nonFraction unitRef="usd" contextRef="i7057397719af459ca7328a1c440a0efa_I20171231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90ZXh0cmVnaW9uOjIxM2RlYmY3Njg3MzQ3NmE5YTk0YzgyMTZiN2I4YTlmXzc1MDM_d2671c73-e4fe-40b9-adda-8a86dc69c620">62.5</ix:nonFraction> million reported in cash and cash equivalents on the balance sheet.</span></div></ix:continuation><div style="text-indent:36pt;margin-top:15pt;margin-bottom:15pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The fair value of Level 2 securities is determined from market pricing and other observable market inputs for similar securities obtained from various third-party data providers. These inputs either represent quoted prices for similar assets in active markets or have been derived from observable market data.  </span><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;">The fair value of Level 3 securities is determined using the Black-Scholes option-pricing model.  There were no transfers between levels during the periods presented.&#160;</span></div><ix:nonNumeric contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90ZXh0cmVnaW9uOjIxM2RlYmY3Njg3MzQ3NmE5YTk0YzgyMTZiN2I4YTlmXzQxNDQ5_4c6ebf2a-14e7-4cf7-97a7-add8539b3d4a" escape="true"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Concentration of Credit Risk</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents, marketable securities and accounts receivable. </span><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Company maintains&#160;its cash and money market funds with financial institutions that are federally insured. While balances deposited in these institutions often exceed Federal Deposit Insurance Corporation limits, the Company has not experienced any losses on related accounts to date.&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Company's investment policy limits investments to certain types of debt securities issued by the U.S. government, its agencies and institutions with investment-grade credit ratings and places restrictions on maturities and concentration by type and issuer.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> The counterparties are various corporations, financial institutions and government agencies of high credit standing.</span></div></ix:nonNumeric><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Company's revenue relates to agreements with various collaborators and&#160;contracts and research grants received from U.S. government agencies.&#160;<ix:nonNumeric contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90ZXh0cmVnaW9uOjIxM2RlYmY3Njg3MzQ3NmE5YTk0YzgyMTZiN2I4YTlmXzQxNDUw_6e075025-90d9-4d56-8ac3-c66a2894e548" continuedAt="i016c388bd5ae484094d0d4ea9e384f1f" escape="true">The following table includes those collaborators that represent more than 10% of total revenue earned in the periods indicated:</ix:nonNumeric></span></div><ix:continuation id="i016c388bd5ae484094d0d4ea9e384f1f" continuedAt="i8db8759fbb304e528c0be36cf0841b1b"><div style="margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.269006%;"><tr><td style="width:1.0%;"></td><td style="width:67.219440%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:7.720177%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.536377%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.720177%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.683652%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.720177%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;height:13pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2016</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Incyte Corporation (Incyte)</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i03cbd7f054ef4c669ff9c36ff8cd01c0_D20180101-20181231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTo4NzcwMmFhNTI5ZDQ0Njg1ODc1MDBkMjRiNWE3Mjc2Yy90YWJsZXJhbmdlOjg3NzAyYWE1MjlkNDQ2ODU4NzUwMGQyNGI1YTcyNzZjXzItMS0xLTEtMA_64dbce1f-5f1b-4565-b885-bf4c1bc01d72">68</ix:nonFraction>%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="ie58f40d5d6224b7abe4022753c84d444_D20170101-20171231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTo4NzcwMmFhNTI5ZDQ0Njg1ODc1MDBkMjRiNWE3Mjc2Yy90YWJsZXJhbmdlOjg3NzAyYWE1MjlkNDQ2ODU4NzUwMGQyNGI1YTcyNzZjXzItMy0xLTEtNTYz_a7796733-4b2b-4b32-bffa-092c358a086b">96</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i43068aee063d4a2d8d23dac8a2f9b677_D20160101-20161231" decimals="2" format="ixt:zerodash" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTo4NzcwMmFhNTI5ZDQ0Njg1ODc1MDBkMjRiNWE3Mjc2Yy90YWJsZXJhbmdlOjg3NzAyYWE1MjlkNDQ2ODU4NzUwMGQyNGI1YTcyNzZjXzItNS0xLTEtNjExNg_4b84994b-b118-49e3-a973-3309908201da">&#8212;</ix:nonFraction>%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Janssen Biotech, Inc. (Janssen)</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">*&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">*&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="iaa0ada014a394dada260f448e299bd8c_D20160101-20161231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTo4NzcwMmFhNTI5ZDQ0Njg1ODc1MDBkMjRiNWE3Mjc2Yy90YWJsZXJhbmdlOjg3NzAyYWE1MjlkNDQ2ODU4NzUwMGQyNGI1YTcyNzZjXzMtNS0xLTEtMA_65f88054-5af1-4c7c-88d6-1690831e4452">85</ix:nonFraction>%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Provention Bio, Inc. (Provention)</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i2e50d0e2361047e2a2d2ee358cd59223_D20180101-20181231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTo4NzcwMmFhNTI5ZDQ0Njg1ODc1MDBkMjRiNWE3Mjc2Yy90YWJsZXJhbmdlOjg3NzAyYWE1MjlkNDQ2ODU4NzUwMGQyNGI1YTcyNzZjXzUtMS0xLTEtMA_8d3cc3db-f9e0-4a65-8707-98b1179f4305">10</ix:nonFraction>%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i7736e7c7780143f290e418da33ef66f3_D20170101-20171231" decimals="2" format="ixt:zerodash" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTo4NzcwMmFhNTI5ZDQ0Njg1ODc1MDBkMjRiNWE3Mjc2Yy90YWJsZXJhbmdlOjg3NzAyYWE1MjlkNDQ2ODU4NzUwMGQyNGI1YTcyNzZjXzUtMy0xLTEtMA_5fd81e92-6361-4d56-a760-9df766562255">&#8212;</ix:nonFraction>%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i84d9b24bd0d14ea7ae88c496301087d9_D20160101-20161231" decimals="2" format="ixt:zerodash" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTo4NzcwMmFhNTI5ZDQ0Njg1ODc1MDBkMjRiNWE3Mjc2Yy90YWJsZXJhbmdlOjg3NzAyYWE1MjlkNDQ2ODU4NzUwMGQyNGI1YTcyNzZjXzUtNS0xLTEtMA_5b4b6b87-6521-4f0d-ad2a-72394c1d32fc">&#8212;</ix:nonFraction>%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr></table></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The following table includes those counterparties that represent more than 10% of accounts receivable at the date indicated:</span></div><div style="margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"><tr><td style="width:1.0%;"></td><td style="width:73.806452%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.730205%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533138%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.730205%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Zai Lab Limited (Zai Lab)</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="ief319720f28440d5a5dd754bc9ebb8b9_D20180101-20181231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTo1NTdhMzAyNDJlNWE0MjQ4ODc0OTc2NmNkYWM3NzY5YS90YWJsZXJhbmdlOjU1N2EzMDI0MmU1YTQyNDg4NzQ5NzY2Y2RhYzc3NjlhXzItMS0xLTEtMA_b38cb87d-ca75-4580-81aa-a5c08723a99f">76</ix:nonFraction>%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="ia281f1996f934569aa16a3fd2044a2b2_D20170101-20171231" decimals="2" format="ixt:zerodash" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTo1NTdhMzAyNDJlNWE0MjQ4ODc0OTc2NmNkYWM3NzY5YS90YWJsZXJhbmdlOjU1N2EzMDI0MmU1YTQyNDg4NzQ5NzY2Y2RhYzc3NjlhXzItMy0xLTEtMA_cef80289-1516-4a86-bfbe-9cb49ede7b6d">&#8212;</ix:nonFraction>%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Incyte</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i14ad06e9a84b4f2b9de71683c59af5f7_D20180101-20181231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTo1NTdhMzAyNDJlNWE0MjQ4ODc0OTc2NmNkYWM3NzY5YS90YWJsZXJhbmdlOjU1N2EzMDI0MmU1YTQyNDg4NzQ5NzY2Y2RhYzc3NjlhXzMtMS0xLTEtMA_1bc6400a-7558-4bde-979b-6c7b9206f3f9">16</ix:nonFraction>%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="ie7004ecc84cf491ab540ef15e8620bb5_D20170101-20171231" decimals="2" format="ixt:zerodash" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTo1NTdhMzAyNDJlNWE0MjQ4ODc0OTc2NmNkYWM3NzY5YS90YWJsZXJhbmdlOjU1N2EzMDI0MmU1YTQyNDg4NzQ5NzY2Y2RhYzc3NjlhXzMtMy0xLTEtMA_967cfdb1-b8a5-4b8a-aee6-42cda2ca122a">&#8212;</ix:nonFraction>%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (Roche)</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i10db7e65a275498b9298e6467e2ddd37_D20180101-20181231" decimals="2" format="ixt:zerodash" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTo1NTdhMzAyNDJlNWE0MjQ4ODc0OTc2NmNkYWM3NzY5YS90YWJsZXJhbmdlOjU1N2EzMDI0MmU1YTQyNDg4NzQ5NzY2Y2RhYzc3NjlhXzQtMS0xLTEtMTYxNA_d8d7217a-a8c7-45a9-ab9f-40e09f9c29cc">&#8212;</ix:nonFraction>%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i7d107c99b86241459c22fe452644f3a9_D20170101-20171231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTo1NTdhMzAyNDJlNWE0MjQ4ODc0OTc2NmNkYWM3NzY5YS90YWJsZXJhbmdlOjU1N2EzMDI0MmU1YTQyNDg4NzQ5NzY2Y2RhYzc3NjlhXzQtMy0xLTEtMA_6f1ab327-c349-4a19-8688-32bcaa12685e">73</ix:nonFraction>%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Les Laboratoires Servier and Institut de Recherches Servier (Servier)</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">*&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="id8704ce91d804afb8569a95732959fd8_D20170101-20171231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTo1NTdhMzAyNDJlNWE0MjQ4ODc0OTc2NmNkYWM3NzY5YS90YWJsZXJhbmdlOjU1N2EzMDI0MmU1YTQyNDg4NzQ5NzY2Y2RhYzc3NjlhXzUtMy0xLTEtMTYxNA_8476199f-3fcc-4c44-bc8c-14c85baafcd5">12</ix:nonFraction>%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:continuation><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"><ix:continuation id="i8db8759fbb304e528c0be36cf0841b1b">* Balance is less than 10%</ix:continuation>&#160;</span></div></ix:continuation><div style="margin-bottom:9pt;"></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">F - 8</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="i83c8a899e0874d78a446fda990814b0a" continuedAt="if8194055135d4086a7fd2322e2f0095f"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90ZXh0cmVnaW9uOjIxM2RlYmY3Njg3MzQ3NmE5YTk0YzgyMTZiN2I4YTlmXzQxNDUx_f9b91b1a-ed63-4a04-b446-030892e80eb4" continuedAt="ifac0880fe0d94d528f13e8db3cff43e5" escape="true">Property, Equipment and Software</ix:nonNumeric></span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"><ix:continuation id="ifac0880fe0d94d528f13e8db3cff43e5">Property, equipment and software are stated at cost. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation or amortization are removed from the accounts and any resulting gain or loss is credited or charged to operations. Repairs and maintenance costs are expensed as incurred.</ix:continuation>&#160;<ix:nonNumeric contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" name="mgnx:PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90ZXh0cmVnaW9uOjIxM2RlYmY3Njg3MzQ3NmE5YTk0YzgyMTZiN2I4YTlmXzIxOTkwMjM0MTQ2OTA_82bdd9ee-80df-4794-ac00-fae5029018cc" continuedAt="i1a5d975630654d23bfe906b16563cd87" escape="true">Depreciation and amortization are computed using the straight-line method over the following estimated useful lives:</ix:nonNumeric></span></div><div style="margin-bottom:9pt;"><ix:continuation id="i1a5d975630654d23bfe906b16563cd87"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"><tr><td style="width:1.0%;"></td><td style="width:48.000000%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:48.000000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Computer equipment</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="icd9b6aa45a364d0c9cd302c42a5acd28_D20180101-20181231" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTo2NjkwZWQxNTRhOGQ0ZDEzYmY2ODM0ODc2NjkxOTFmZS90YWJsZXJhbmdlOjY2OTBlZDE1NGE4ZDRkMTNiZjY4MzQ4NzY2OTE5MWZlXzAtMS0xLTEtMA_6be17bdd-73eb-4746-8210-d02852e5d4c7">3</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Software</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i8986558becfd44b1af99bbdfcf581445_D20180101-20181231" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTo2NjkwZWQxNTRhOGQ0ZDEzYmY2ODM0ODc2NjkxOTFmZS90YWJsZXJhbmdlOjY2OTBlZDE1NGE4ZDRkMTNiZjY4MzQ4NzY2OTE5MWZlXzEtMS0xLTEtMA_e93930fe-2dc2-42bf-99ad-5f4d81a2f80c">3</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Furniture</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ib59b65ae84da4d388e5723647e6142e6_D20180101-20181231" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTo2NjkwZWQxNTRhOGQ0ZDEzYmY2ODM0ODc2NjkxOTFmZS90YWJsZXJhbmdlOjY2OTBlZDE1NGE4ZDRkMTNiZjY4MzQ4NzY2OTE5MWZlXzItMS0xLTEtMA_1d67763a-cd19-4a43-97c7-6b494aa139ba">10</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Laboratory and office equipment</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i4e5cae6e220c436aabafd5c2f3481b6c_D20180101-20181231" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTo2NjkwZWQxNTRhOGQ0ZDEzYmY2ODM0ODc2NjkxOTFmZS90YWJsZXJhbmdlOjY2OTBlZDE1NGE4ZDRkMTNiZjY4MzQ4NzY2OTE5MWZlXzMtMS0xLTEtMA_29348f16-efe1-4099-9ac5-2d7458318da0">5</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Leasehold improvements</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Shorter of lease term or useful life</span></td></tr></table></ix:continuation></div><ix:nonNumeric contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90ZXh0cmVnaW9uOjIxM2RlYmY3Njg3MzQ3NmE5YTk0YzgyMTZiN2I4YTlmXzQxNDUz_118e6759-af92-466e-bcd3-2677c0b69cac" escape="true"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Impairment of Long-Lived Assets</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Company assesses the recoverability of its long-lived assets in accordance with the provisions of ASC 360, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Property, Plant and Equipment</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">. ASC 360 requires that long-lived assets be reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of the long-lived asset is measured by a comparison of the carrying amount of the asset to future undiscounted net cash flows expected to be generated by the asset or asset group. If carrying value exceeds the sum of undiscounted cash flows, the Company then determines the fair value of the underlying asset group. Any impairment to be recognized is measured by the amount by which the carrying amount of the asset group exceeds the estimated fair value of the asset group. Assets to be disposed of are reported at the lower of the carrying amount or fair value, less costs to sell. For the years ended&#160;December&#160;31, 2018,&#160;2017 and 2016, the Company determined that there were <ix:nonFraction unitRef="usd" contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleCarryingValueOfAsset" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90ZXh0cmVnaW9uOjIxM2RlYmY3Njg3MzQ3NmE5YTk0YzgyMTZiN2I4YTlmXzEwNzUx_e5791973-520a-4ea9-940a-0ae367633c69">no</ix:nonFraction> impaired assets.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90ZXh0cmVnaW9uOjIxM2RlYmY3Njg3MzQ3NmE5YTk0YzgyMTZiN2I4YTlmXzQxNDU0_4b76ed62-9309-4e89-ba2b-eb693e95c81d" escape="true"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Income Taxes</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Deferred tax assets and liabilities are determined based on differences between the financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. The effect on deferred tax assets and liabilities of a change in tax rates is recognized as income in the period that such tax rate changes are enacted. The measurement of a deferred tax asset is reduced, if necessary, by a valuation allowance if it is more likely than not that some portion or all of the deferred tax asset will not be realized. Financial statement recognition of a tax position taken or expected to be taken in a tax return is determined based on a more-likely-than-not threshold of that position being sustained. If the tax position meets this threshold, the benefit to be recognized is measured as the largest amount that is more likely than not to be realized upon ultimate settlement. The Company's policy is to record interest and penalties related to uncertain tax positions as a component of income tax expense.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90ZXh0cmVnaW9uOjIxM2RlYmY3Njg3MzQ3NmE5YTk0YzgyMTZiN2I4YTlmXzQxNDU1_239547e5-3b50-476d-99f7-58e533b75507" continuedAt="i1fa93eb9e3b04f96a67027af5d10de86" escape="true"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Revenues</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#160;</span></div><div style="text-indent:40.5pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Beginning on January 1, 2018, the Company&#160;recognizes revenue under Accounting Standards Update (ASU) No. 2014-09, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Revenue from Contracts with Customer</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">s and all related amendments (collectively ASC 606) when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services.&#160;&#160;To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation.  The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. </span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Company enters into licensing agreements that are within the scope of ASC 606, under which it may license rights to research, develop, manufacture and commercialize its product candidates to third parties. The terms of these arrangements typically include payment to the Company of one or more of the following: non-refundable, upfront license fees; reimbursement of certain costs; customer option exercise fees; development, regulatory and commercial milestone payments;&#160;and royalties on net sales of licensed products.   The Company may also enter into development and manufacturing service agreements&#160;with its collaborators.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">For each arrangement that results in revenues, the Company identifies all performance obligations, which may include a license to intellectual property and know-how, research and development activities, transition activities and/or manufacturing services. In order to determine the transaction price, in addition to any upfront payment, the Company estimates the amount of variable consideration at the outset of the contract either utilizing the expected value or most likely amount method, depending</span></div></ix:nonNumeric></ix:continuation><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">F - 9</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="if8194055135d4086a7fd2322e2f0095f" continuedAt="i58cfcfd501044e28b4bce4893b9e0092"><ix:continuation id="i1fa93eb9e3b04f96a67027af5d10de86" continuedAt="i1281ff5e380b4512aebee8e3911739b7"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> on the facts and circumstances relative to the contract. The Company constrains (reduces) the estimates of variable consideration such that it is probable that a significant reversal of previously recognized revenue will not occur. When determining if variable consideration should be constrained, management considers whether there are factors outside the Company&#8217;s control that could result in a significant reversal of revenue. In making these assessments, the Company considers the likelihood and magnitude of a potential reversal of revenue. These estimates are re-assessed each reporting period as required. </span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Once the estimated transaction price is established, amounts are allocated to the performance obligations that have been identified. The transaction price is generally allocated to each separate performance obligation on a relative standalone selling price basis. The Company must develop assumptions that require judgment to determine the standalone selling price in order to account for these agreements. To determine the standalone selling price, the Company&#8217;s assumptions may include (i)  the probability of obtaining marketing approval for the product candidate, (ii) estimates regarding the timing and the expected costs to develop and commercialize the product candidate, and (iii) estimates of future cash flows from potential product sales with respect to the product candidate. Standalone selling prices used to perform the initial allocation are not updated after contract inception. The Company does not include a financing component to its estimated transaction price at contract inception unless it estimates that certain performance obligations will not be satisfied within one year.</span></div><div style="text-indent:36pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Amounts received prior to revenue recognition are recorded as deferred revenue. Amounts expected to be recognized as revenue within the 12&#160;months following the balance sheet date are classified as current portion of deferred revenue in the accompanying consolidated balance sheets. Amounts not expected to be recognized as revenue within the 12&#160;months following the balance sheet date are classified as deferred revenue, net of current portion. </span></div><div style="text-indent:36pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Licenses. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">If the license to the Company&#8217;s intellectual property is determined to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and when (or as) the customer is able to use and benefit from the license. In assessing whether a promise or performance obligation is distinct from the other promises, the Company considers factors such as the research, development, manufacturing and commercialization capabilities of the licensee and the availability of the associated expertise in the general marketplace. In addition, the Company considers whether the licensee can benefit from a promise for its intended purpose without the receipt of the remaining promise, whether the value of the promise is dependent on the unsatisfied promise, whether there are other vendors that could provide the remaining promise, and whether it is separately identifiable from the remaining promise. For licenses that are combined with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. The measure of progress, and thereby periods over which revenue should be recognized, are subject to estimates by management and may change over the course of the research and development and licensing agreement. Such a change could have a material impact on the amount of revenue the Company records in future periods. </span></div><div style="text-indent:36pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Research, Development and/or Manufacturing Services. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The promises under the Company&#8217;s agreements may include research and development or manufacturing services to be performed by the Company on behalf of the counterparty. If these services are determined to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes the transaction price allocated to these services as revenue over time based on an appropriate measure of progress when the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date.  If these services are determined not to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes the transaction price allocated to the combined performance obligation as the related performance obligations are satisfied. </span></div><div style="text-indent:36pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Customer Options. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">If an arrangement contains customer options, the Company evaluates whether the options are material rights because they allow the customer to acquire additional goods or services for free or at a discount. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the outset of the arrangement. The Company allocates the transaction price to material rights based on the relative standalone selling price, which is determined based on the identified discount and the probability that the customer will exercise the option. Amounts allocated to a material right are not recognized as revenue until, at the earliest, the option is exercised.  If the options are deemed not to be a material right, they are excluded as performance obligations at the outset of the arrangement. </span></div><div style="text-indent:36pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Milestone Payments. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">At the inception of each arrangement that includes development milestone payments, the Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not</span></div></ix:continuation></ix:continuation><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">F - 10</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="i58cfcfd501044e28b4bce4893b9e0092" continuedAt="iaceada50662e470cb64119596ebe6ff9"><ix:continuation id="i1281ff5e380b4512aebee8e3911739b7"><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. At the end of each subsequent reporting period, the Company reevaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. </span></div><div style="text-indent:36pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Royalties. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">For arrangements that include sales-based royalties which are the result of a customer-vendor relationship and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied or partially satisfied. To date, the Company has not recognized any royalty revenue resulting from any of its licensing arrangements. </span></div><div style="text-indent:36pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Company analyzes its collaboration arrangements to assess whether such arrangements involve joint operating activities performed by parties who are both active participants in the activities and are both exposed to significant risks and rewards dependent on the commercial success of such activities. Such arrangements generally are within the scope of ASC 808, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Collaborative Arrangements</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> (ASC 808). While ASC 808 defines collaborative arrangements and provides guidance on income statement presentation, classification, and disclosures related to such arrangements, it does not address recognition and measurement matters, such as (1)&#160;determining the appropriate unit of accounting or (2) when the recognition criteria are met. Therefore, the accounting for these arrangements is either based on an analogy to other accounting literature or an accounting policy election by the Company. The Company accounts for certain components of the collaboration agreement that are reflective of a vendor-customer relationship (e.g., licensing arrangement) based on an analogy to ASC 606. The Company accounts for other components based on a reasonable, rational and consistently applied accounting policy election.&#160;&#160; Reimbursements from the counter-party that are the result of a collaborative relationship with the counter-party, instead of a customer relationship, such as co-development activities, are recorded as a reduction to research and development expense as the services are performed.</span></div><div style="text-indent:36pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">For a complete discussion of accounting for revenue from collaborative and other agreements, see Note 8, Collaboration and Other Agreements.</span></div></ix:continuation><ix:nonNumeric contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90ZXh0cmVnaW9uOjIxM2RlYmY3Njg3MzQ3NmE5YTk0YzgyMTZiN2I4YTlmXzQxNDU2_939e04cf-d45f-4e1d-b5c0-7389745fb06a" escape="true"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Research and Development Costs</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Research and development expenditures are expensed as incurred. Research and development costs primarily consist of employee related expenses, including salaries and benefits, expenses incurred under agreements with contract research organizations, investigative sites and consultants that conduct the Company's clinical trials, the cost of acquiring and manufacturing clinical trial materials and other allocated expenses, license fees for and milestone payments related to in-licensed products and technologies, stock-based compensation expense, and costs associated with non-clinical activities and regulatory approvals.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Right-to-develop agreements may contain cost-sharing provisions whereby the Company and the collaborator share the cost of research and development activities.&#160; Reimbursement of research and development expenses received in connection with these agreements is recorded as a reduction of such expenses.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90ZXh0cmVnaW9uOjIxM2RlYmY3Njg3MzQ3NmE5YTk0YzgyMTZiN2I4YTlmXzQxNDU3_0389f585-1933-4797-b7fa-c941fb582192" escape="true"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Comprehensive Loss</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;">Comprehensive loss represents net loss adjusted for the change during the periods attributed to unrealized gains and losses on available-for-sale securities.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" name="us-gaap:CompensationRelatedCostsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90ZXh0cmVnaW9uOjIxM2RlYmY3Njg3MzQ3NmE5YTk0YzgyMTZiN2I4YTlmXzQxNDU4_09a1bcaa-8609-4eb2-861d-ceaca534457d" continuedAt="i9aa4510cd1164bcc8878f864c5d67995" escape="true"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Stock-based Compensation</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Stock-based payments are accounted for in accordance with the provisions of ASC 718, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Compensation &#8211; Stock Compensation</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">. The fair value of stock-based payments is estimated, on the date of grant, using the Black-Scholes model. The resulting fair value is recognized ratably over the requisite service period, which is generally the vesting period of the option.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">For all time-vesting awards granted, expense is amortized using the straight-line attribution method. For awards that contain a performance condition, expense is amortized using the accelerated attribution method. Recognition of stock-based compensation expense is based on the value of the portion of stock-based awards that is ultimately expected to vest during the period.</span></div></ix:nonNumeric></ix:continuation><div style="text-indent:36pt;margin-bottom:9pt;"></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">F - 11</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="iaceada50662e470cb64119596ebe6ff9" continuedAt="i00e3e009f5cf4692afb97b8687297611"><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"><ix:continuation id="i9aa4510cd1164bcc8878f864c5d67995">The Company utilizes the Black-Scholes model for estimating fair value of its stock options granted. Option valuation models, including the Black-Scholes model, require the input of highly subjective assumptions, and changes in the assumptions used can materially affect the grant-date fair value of an award. These assumptions include the risk-free rate of interest, expected dividend yield, expected volatility and the expected life of the award.</ix:continuation></span></div><ix:nonNumeric contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90ZXh0cmVnaW9uOjIxM2RlYmY3Njg3MzQ3NmE5YTk0YzgyMTZiN2I4YTlmXzQxNDU5_13d90d7e-f3ab-4452-9cf1-e775b35eaaee" escape="true"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Net Loss Per Share</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Basic loss per common share is determined by dividing loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted loss per share is computed by dividing the loss attributable to common stockholders by the weighted-average number of common share equivalents outstanding for the period. The treasury stock method is used to determine the dilutive effect of the Company's stock option grants.  <ix:nonFraction unitRef="shares" contextRef="i3e13e524660f42568e18e289608955ea_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90ZXh0cmVnaW9uOjIxM2RlYmY3Njg3MzQ3NmE5YTk0YzgyMTZiN2I4YTlmXzI3NDg3NzkyMjA3MDc_3c3ba971-2c9b-44c7-abd2-44641654b9de">5,273,964</ix:nonFraction> stock options (common stock equivalents) were excluded from the calculation of diluted net loss per share for the year ended </span><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;">December&#160;31, 2018&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">because their inclusion would have been anti-dilutive.  <ix:nonFraction unitRef="shares" contextRef="i956d155068494f53b5097a07d15631f3_D20170101-20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90ZXh0cmVnaW9uOjIxM2RlYmY3Njg3MzQ3NmE5YTk0YzgyMTZiN2I4YTlmXzI3NDg3NzkyMjA5MjA_98955524-9a1f-4cab-b02d-e14e0284eae3">4,504,642</ix:nonFraction> stock options and <ix:nonFraction unitRef="shares" contextRef="i4f8ff4c21a3f4b04bcd0190d63617d17_D20160101-20161231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90ZXh0cmVnaW9uOjIxM2RlYmY3Njg3MzQ3NmE5YTk0YzgyMTZiN2I4YTlmXzI3NDg3NzkyMjA5NDE_10233662-2ae5-4bb6-b4cc-ee44c1c3f12d">3,838,060</ix:nonFraction> stock options were excluded from the calculation of diluted net loss per share for the years ended December&#160;31, 2017 and 2016, respectively,</span><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">because their inclusion would have been anti-dilutive.</span></div></ix:nonNumeric><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Recently Adopted Accounting Standards</span></div><div style="text-indent:36pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">In May 2014, the FASB issued ASC 606. The Company adopted ASC 606 on January 1, 2018 using the modified retrospective method for all contracts that were not completed as of January 1, 2018. For contracts that were modified before the effective date, the Company reflected the aggregate effect of all modifications when identifying performance obligations and allocating transaction price in accordance with available practical expedients.  </span><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;">Comparative prior period information continues to be reported under the accounting standards in effect for the period presented. </span></div><ix:nonNumeric contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" name="us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90ZXh0cmVnaW9uOjIxM2RlYmY3Njg3MzQ3NmE5YTk0YzgyMTZiN2I4YTlmXzE1MzkzMTYyOTQxNzI4_b60199d8-0392-4e44-b92b-c29202ef18a4" escape="true"><div style="text-indent:36pt;text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;">As a result of applying the modified retrospective method to adopt the new guidance, the following adjustments were made to accounts on the consolidated balance sheet as of January 1, 2018 (in thousands):</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Arial;font-size:10pt;line-height:232%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853801%;"><tr><td style="width:1.0%;"></td><td style="width:52.465593%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:12.641288%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532064%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.641288%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.678477%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.641288%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Pre-Adoption</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">ASC 606 Adjustment</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Post-Adoption</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">Deferred revenue, current</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ieb5bf739a8ce42039763affce9678d7c_I20180101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredRevenueCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZToyZDYyODg1MGI2OGQ0NDUxYjQ5MmMwMmYxMjk4NGM0Yi90YWJsZXJhbmdlOjJkNjI4ODUwYjY4ZDQ0NTFiNDkyYzAyZjEyOTg0YzRiXzEtMS0xLTEtNjA4MQ_290cab2c-a500-4e97-8044-19430e5287a4">7,202</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic3082c4bbda4473cb69446b2be52ec61_I20180101" decimals="-3" name="us-gaap:DeferredRevenueCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZToyZDYyODg1MGI2OGQ0NDUxYjQ5MmMwMmYxMjk4NGM0Yi90YWJsZXJhbmdlOjJkNjI4ODUwYjY4ZDQ0NTFiNDkyYzAyZjEyOTg0YzRiXzEtMy0xLTEtNjEyNw_e6938d60-5790-4573-832f-c9866de82405">540</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i58ed5a015dbf42e19178b051b82c9683_I20180101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredRevenueCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZToyZDYyODg1MGI2OGQ0NDUxYjQ5MmMwMmYxMjk4NGM0Yi90YWJsZXJhbmdlOjJkNjI4ODUwYjY4ZDQ0NTFiNDkyYzAyZjEyOTg0YzRiXzEtNS0xLTEtNjEyOQ_c26fbd18-d192-4aa9-a770-9cc0751e5259">7,742</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">Deferred revenue, net of current portion</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ieb5bf739a8ce42039763affce9678d7c_I20180101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredRevenueNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZToyZDYyODg1MGI2OGQ0NDUxYjQ5MmMwMmYxMjk4NGM0Yi90YWJsZXJhbmdlOjJkNjI4ODUwYjY4ZDQ0NTFiNDkyYzAyZjEyOTg0YzRiXzItMS0xLTEtNjEyMw_a65b8652-4373-4eb4-b887-91a5a09d44c7">13,637</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic3082c4bbda4473cb69446b2be52ec61_I20180101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredRevenueNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZToyZDYyODg1MGI2OGQ0NDUxYjQ5MmMwMmYxMjk4NGM0Yi90YWJsZXJhbmdlOjJkNjI4ODUwYjY4ZDQ0NTFiNDkyYzAyZjEyOTg0YzRiXzItMy0xLTEtNjEzMQ_e9310710-a380-4329-9934-e8b830426dea">5,939</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i58ed5a015dbf42e19178b051b82c9683_I20180101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredRevenueNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZToyZDYyODg1MGI2OGQ0NDUxYjQ5MmMwMmYxMjk4NGM0Yi90YWJsZXJhbmdlOjJkNjI4ODUwYjY4ZDQ0NTFiNDkyYzAyZjEyOTg0YzRiXzItNS0xLTEtNjEzMw_3f312f78-c1cc-4be7-a2a1-3d8752a84202">19,576</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">Accumulated deficit</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ieb5bf739a8ce42039763affce9678d7c_I20180101" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZToyZDYyODg1MGI2OGQ0NDUxYjQ5MmMwMmYxMjk4NGM0Yi90YWJsZXJhbmdlOjJkNjI4ODUwYjY4ZDQ0NTFiNDkyYzAyZjEyOTg0YzRiXzMtMS0xLTEtNjEyNQ_44898e75-5744-4b7f-b88e-f98a91b9181b">312,340</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ic3082c4bbda4473cb69446b2be52ec61_I20180101" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZToyZDYyODg1MGI2OGQ0NDUxYjQ5MmMwMmYxMjk4NGM0Yi90YWJsZXJhbmdlOjJkNjI4ODUwYjY4ZDQ0NTFiNDkyYzAyZjEyOTg0YzRiXzMtMy0xLTEtNjEzNQ_ba3961fa-a5c1-426e-8a60-9efbd03ba210">6,478</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i58ed5a015dbf42e19178b051b82c9683_I20180101" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZToyZDYyODg1MGI2OGQ0NDUxYjQ5MmMwMmYxMjk4NGM0Yi90YWJsZXJhbmdlOjJkNjI4ODUwYjY4ZDQ0NTFiNDkyYzAyZjEyOTg0YzRiXzMtNS0xLTEtNjEzNw_275804a4-ea16-4858-b7e5-d65eb665e73a">318,818</ix:nonFraction>)</span></td></tr></table></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;">The transition adjustment resulted primarily from changes in </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">the pattern of revenue recognition for upfront fees and license grant fees.  </span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;">The following table shows the impact of adoption to the consolidated statement of income and balance sheet (in thousands):</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Arial;font-size:10pt;line-height:120%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"><tr><td style="width:1.0%;"></td><td style="width:42.199706%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:12.096916%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534214%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:16.942731%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534214%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:19.292217%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;height:13pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December 31, 2018&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">As Reported&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Balances Without Adoption of ASC 606&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Effect of Change Higher/(Lower)&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenue from collaborative agreements&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ieb0bea730e3444a5b0d8559d16ad126c_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTozODNmZGYwNDBkMjM0ZDg5OTBmNjk3NmU5OWYxOGZjYy90YWJsZXJhbmdlOjM4M2ZkZjA0MGQyMzRkODk5MGY2OTc2ZTk5ZjE4ZmNjXzgtMS0xLTEtMTUxMQ_0af2975e-1a6b-4496-ac62-8a455ac528cd">58,644</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia6869870ff9d444da346b6b8718b80f3_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTozODNmZGYwNDBkMjM0ZDg5OTBmNjk3NmU5OWYxOGZjYy90YWJsZXJhbmdlOjM4M2ZkZjA0MGQyMzRkODk5MGY2OTc2ZTk5ZjE4ZmNjXzItMy0xLTEtNjE2Mw_9d5395bd-7355-4727-9ac2-777633b81b33">58,104</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8195466a5e2c4a458ca23edc5bbb7661_D20180101-20181231" decimals="-3" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTozODNmZGYwNDBkMjM0ZDg5OTBmNjk3NmU5OWYxOGZjYy90YWJsZXJhbmdlOjM4M2ZkZjA0MGQyMzRkODk5MGY2OTc2ZTk5ZjE4ZmNjXzItNS0xLTEtNjE3MA_ac712970-5b86-45f1-b1b7-6c2664b1d784">540</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTozODNmZGYwNDBkMjM0ZDg5OTBmNjk3NmU5OWYxOGZjYy90YWJsZXJhbmdlOjM4M2ZkZjA0MGQyMzRkODk5MGY2OTc2ZTk5ZjE4ZmNjXzktMS0xLTEtMTUxMQ_efc3fc49-78d2-46c3-bce7-723092ceaf1d">171,453</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ic2e9f102d8434edb8909ccdd833da1f3_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTozODNmZGYwNDBkMjM0ZDg5OTBmNjk3NmU5OWYxOGZjYy90YWJsZXJhbmdlOjM4M2ZkZjA0MGQyMzRkODk5MGY2OTc2ZTk5ZjE4ZmNjXzMtMy0xLTEtNjE4OA_cbd32179-b5d5-438e-bc04-235a81e6dd71">171,993</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i5f8c7c83e37647699033616fbb46b432_D20180101-20181231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTozODNmZGYwNDBkMjM0ZDg5OTBmNjk3NmU5OWYxOGZjYy90YWJsZXJhbmdlOjM4M2ZkZjA0MGQyMzRkODk5MGY2OTc2ZTk5ZjE4ZmNjXzMtNS0xLTEtNjE5MA_dcd13121-b545-4c56-a568-b8b30a265373">540</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Basic and diluted net loss per common share&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTozODNmZGYwNDBkMjM0ZDg5OTBmNjk3NmU5OWYxOGZjYy90YWJsZXJhbmdlOjM4M2ZkZjA0MGQyMzRkODk5MGY2OTc2ZTk5ZjE4ZmNjXzEwLTEtMS0xLTE1MTE_6d4a8c3d-477d-4b15-a8ca-028e026adbca">4.19</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="ic2e9f102d8434edb8909ccdd833da1f3_D20180101-20181231" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTozODNmZGYwNDBkMjM0ZDg5OTBmNjk3NmU5OWYxOGZjYy90YWJsZXJhbmdlOjM4M2ZkZjA0MGQyMzRkODk5MGY2OTc2ZTk5ZjE4ZmNjXzQtMy0xLTEtNjE5Mg_ddf5630f-f904-4404-8ecc-07e19e0fae6f">4.20</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i5f8c7c83e37647699033616fbb46b432_D20180101-20181231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTozODNmZGYwNDBkMjM0ZDg5OTBmNjk3NmU5OWYxOGZjYy90YWJsZXJhbmdlOjM4M2ZkZjA0MGQyMzRkODk5MGY2OTc2ZTk5ZjE4ZmNjXzQtNS0xLTEtNjE5NA_7efa876d-f76e-470b-a4ba-d8ea7470bc83">0.01</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="height:21pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="15" style="height:21pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;height:13pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">As of December 31, 2018</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">As Reported&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Balances Without Adoption of ASC 606&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Effect of Change Higher/(Lower)&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred revenue, current&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredRevenueCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTozODNmZGYwNDBkMjM0ZDg5OTBmNjk3NmU5OWYxOGZjYy90YWJsZXJhbmdlOjM4M2ZkZjA0MGQyMzRkODk5MGY2OTc2ZTk5ZjE4ZmNjXzgtMS0xLTEtNjE5Ng_6b2c59cf-c321-4308-9d84-f8620ab62702">21,721</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1158af44c1a44a528cf5faac76fc6bf6_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredRevenueCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTozODNmZGYwNDBkMjM0ZDg5OTBmNjk3NmU5OWYxOGZjYy90YWJsZXJhbmdlOjM4M2ZkZjA0MGQyMzRkODk5MGY2OTc2ZTk5ZjE4ZmNjXzgtMy0xLTEtNjIwMg_a46f2201-3425-4cb3-ab78-6cb5b9f13fd9">22,210</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i540a17d5cd3043469a51f6ba7e3d31b5_I20181231" decimals="-3" sign="-" name="us-gaap:DeferredRevenueCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTozODNmZGYwNDBkMjM0ZDg5OTBmNjk3NmU5OWYxOGZjYy90YWJsZXJhbmdlOjM4M2ZkZjA0MGQyMzRkODk5MGY2OTc2ZTk5ZjE4ZmNjXzgtNS0xLTEtNjIwNA_5f8cc177-1ff2-4ae8-ad6b-a53cec11c30b">489</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred revenue, net of current portion&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredRevenueNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTozODNmZGYwNDBkMjM0ZDg5OTBmNjk3NmU5OWYxOGZjYy90YWJsZXJhbmdlOjM4M2ZkZjA0MGQyMzRkODk5MGY2OTc2ZTk5ZjE4ZmNjXzktMS0xLTEtNjE5OA_4f49d574-3a64-4614-b54a-422c5d118956">19,001</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1158af44c1a44a528cf5faac76fc6bf6_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredRevenueNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTozODNmZGYwNDBkMjM0ZDg5OTBmNjk3NmU5OWYxOGZjYy90YWJsZXJhbmdlOjM4M2ZkZjA0MGQyMzRkODk5MGY2OTc2ZTk5ZjE4ZmNjXzktMy0xLTEtNjIwNg_c9f464c1-1c7a-43fd-9267-a5221ce79c07">12,573</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i540a17d5cd3043469a51f6ba7e3d31b5_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredRevenueNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTozODNmZGYwNDBkMjM0ZDg5OTBmNjk3NmU5OWYxOGZjYy90YWJsZXJhbmdlOjM4M2ZkZjA0MGQyMzRkODk5MGY2OTc2ZTk5ZjE4ZmNjXzktNS0xLTEtNjIwOA_38075b96-4a8f-41d5-b033-a14e5f0e17fd">6,428</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated deficit&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTozODNmZGYwNDBkMjM0ZDg5OTBmNjk3NmU5OWYxOGZjYy90YWJsZXJhbmdlOjM4M2ZkZjA0MGQyMzRkODk5MGY2OTc2ZTk5ZjE4ZmNjXzE2LTEtMS0xLTE1MTE_be5eb039-9ac0-4c8b-bf4c-7c836eaff4e0">490,271</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1158af44c1a44a528cf5faac76fc6bf6_I20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTozODNmZGYwNDBkMjM0ZDg5OTBmNjk3NmU5OWYxOGZjYy90YWJsZXJhbmdlOjM4M2ZkZjA0MGQyMzRkODk5MGY2OTc2ZTk5ZjE4ZmNjXzEwLTMtMS0xLTYyMTA_ef2b58c8-9aba-4205-af62-c7b9fb7c4aec">484,332</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i540a17d5cd3043469a51f6ba7e3d31b5_I20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTozODNmZGYwNDBkMjM0ZDg5OTBmNjk3NmU5OWYxOGZjYy90YWJsZXJhbmdlOjM4M2ZkZjA0MGQyMzRkODk5MGY2OTc2ZTk5ZjE4ZmNjXzEwLTUtMS0xLTYyMTI_de474ea5-358b-4a4b-9ef7-bdf71570586e">5,939</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Arial;font-size:10pt;line-height:232%;">&#160;</span></div></ix:continuation><div style="text-indent:36pt;text-align:justify;"></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">F - 12</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="i00e3e009f5cf4692afb97b8687297611" continuedAt="ie1cb338617c849f29ed9b4d63e52b1a3"><ix:nonNumeric contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90ZXh0cmVnaW9uOjIxM2RlYmY3Njg3MzQ3NmE5YTk0YzgyMTZiN2I4YTlmXzE1MzkzMTYyOTM5NjA2_6b2faee2-914b-4b30-ab29-98ca2a35d324" escape="true"><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;">The following table presents changes in the Company&#8217;s contract liabilities during the year ended December 31, 2018 (in thousands):</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Arial;font-size:10pt;line-height:120%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"><tr><td style="width:1.0%;"></td><td style="width:41.024963%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:17.530103%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534214%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.397944%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534214%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.572687%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534214%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:13.271659%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at Beginning of Period&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Additions&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Deductions&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at End of Period&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160; Deferred revenue (current and non-current)&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7057397719af459ca7328a1c440a0efa_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTozMTkwNDU0NjBiMzI0ZGFjOWY5NmFiZDU5ODE3YTdlOS90YWJsZXJhbmdlOjMxOTA0NTQ2MGIzMjRkYWM5Zjk2YWJkNTk4MTdhN2U5XzEtMS0xLTEtMTUxMQ_dc41c4c6-5528-455d-8b71-2ac97215b2ef">27,318</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTozMTkwNDU0NjBiMzI0ZGFjOWY5NmFiZDU5ODE3YTdlOS90YWJsZXJhbmdlOjMxOTA0NTQ2MGIzMjRkYWM5Zjk2YWJkNTk4MTdhN2U5XzEtMy0xLTEtMTUxMQ_05de90d0-5589-4096-a2f5-2c709391a1d3">22,992</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTozMTkwNDU0NjBiMzI0ZGFjOWY5NmFiZDU5ODE3YTdlOS90YWJsZXJhbmdlOjMxOTA0NTQ2MGIzMjRkYWM5Zjk2YWJkNTk4MTdhN2U5XzEtNS0xLTEtMTUxMQ_5e871f3c-3102-460e-bcd8-67477d0aea9d">9,588</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTozMTkwNDU0NjBiMzI0ZGFjOWY5NmFiZDU5ODE3YTdlOS90YWJsZXJhbmdlOjMxOTA0NTQ2MGIzMjRkYWM5Zjk2YWJkNTk4MTdhN2U5XzEtNy0xLTEtMTUxMQ_30b3dce4-831f-455b-a884-1e35c5913143">40,722</ix:nonFraction>&#160;</span></td></tr></table></div></ix:nonNumeric><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Arial;font-size:10pt;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;">During the year ended December 31, 2018, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90ZXh0cmVnaW9uOjIxM2RlYmY3Njg3MzQ3NmE5YTk0YzgyMTZiN2I4YTlmXzI3NDg3NzkyMjIzMjI_0680de15-e441-4ec4-a013-c57becbb69b2">9.6</ix:nonFraction> million in revenue as a result of changes in the contract liability balance.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">In May 2017, the FASB issued ASU 2017-09, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Compensation &#8211; Stock Compensation (Topic 718): Scope Modification Accounting</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">. The new standard is intended to reduce the diversity in practice and cost and complexity when applying the guidance in Topic 718 to a change to the terms or conditions of a share-based payment award. The new standard was effective beginning January 1, 2018. The adoption of this standard did not have a material impact on the Company&#8217;s financial position or results of operations upon adoption. </span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">On December 22, 2017, the Tax Cuts and Jobs Act of 2017 (the Tax Act) was signed into law making significant changes to the Internal Revenue Code, which included how the U.S. imposes income tax on multinational corporations.  Key changes in the Tax Act which are relevant to the Company, and generally effective January 1, 2018, include a flat corporate income tax rate of 21% to replace the marginal rates that range from 15% to 35% and the elimination of the corporate alternative minimum tax.  The Tax Act also imposes limits on executive compensations and interest expense deductions, while permitting the immediate expensing for the cost of new investments in certain property acquired after September 27, 2017.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">On December 22, 2017, the SEC issued Staff Accounting Bulletin No. 118 (SAB 118) to address the application of U.S. GAAP in situations when a registrant does not have the necessary information available, prepared, or analyzed (including computations) in reasonable detail to complete the accounting for certain income tax effects of the Tax Act.  SAB 118 allowed registrants to include a provisional amount to account for the implications of the Tax Act where a reasonable estimate can be made and required the completion of the accounting no later than one year from the date of the enactment of the Tax Act, or December 22, 2018. The Company has recognized the provisional tax impacts related to the re-measurement of its U.S. deferred tax assets and liabilities to 21% in 2017 and included these amounts in its consolidated financial statements for the year ended December 31, 2017.  This change in value of these deferred tax assets and liabilities was offset by a corresponding change in valuation allowance, thus no tax expense or benefit was recorded. The Company completed its evaluation of the effects of the Tax Act during the fourth quarter of 2018, and the provisional amounts the Company accounted for in its December 31, 2017 provision were finalized with no adjustments.  &#160;</span></div><ix:nonNumeric contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90ZXh0cmVnaW9uOjIxM2RlYmY3Njg3MzQ3NmE5YTk0YzgyMTZiN2I4YTlmXzQxNDYy_4fc67a3c-b393-4061-9ee0-4c80e303b7c5" continuedAt="i17a35106b40f4d6482e216172bae5353" escape="true"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Recently Issued Accounting Standards </span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">In February 2016, the FASB issued ASU No. 2016-02, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:115%;">Leases</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;"> (ASU 2016-02) that provides principles for the recognition, measurement, presentation and disclosure of leases for both lessees and lessors.  ASU 2016-02 requires a lessee to recognize assets and liabilities on the balance sheet for operating leases and changes many key definitions, including the definition of a lease. ASU 2016-02 includes a short-term lease exception for leases with an original term of 12 months or less, in which a lessee can make an accounting policy election not to recognize lease assets and lease liabilities. Lessees will continue to differentiate between finance leases (previously referred to as capital leases) and operating leases, using classification criteria that are substantially similar to the previous guidance. Originally, entities were required to adopt ASU 2016-02 using a modified retrospective transition approach for all leases existing at, or entered into after, the date of initial application. However, in July 2018, the FASB issued ASU 2018-11, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:115%;">Leases (Topic 842): Targeted Improvements,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;"> which now allows entities the option of recognizing the cumulative effect of applying the new standard as an adjustment to the opening balance of retained earnings in the year of adoption while continuing to present all prior periods under previous lease accounting guidance. In July 2018, the FASB also issued ASU 2018-10, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:115%;">Codification Improvements to Topic 842, Leases, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">which clarifies how to apply certain aspects of ASU 2016-02. ASU 2016-02, ASU 2018-10 and ASU 2018-11 (now commonly referred to as ASC Topic 842 (ASC 842)) is effective for the Company&#8217;s fiscal year beginning January 1, 2019. Although early adoption is permitted, the Company has not elected to do so. The Company plans to elect the transition option provided under ASU 2018-11, which will not require adjustments to comparative periods nor require modified disclosures in those comparative periods. Upon adoption, the Company expects to elect the transition package of practical expedients permitted within the new standard, which among other things, allows the carryforward of the historical lease classification.  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:115%;">Based on its current lease portfolio, the Company estimates that the adoption ASC 842 will result in approximately $16.0 million of right of use assets and $28.0 million of lease liabilities being reflected on its consolidated balance sheet at the date of adoption. </span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">In November 2018, the FASB issued ASU 2018-18, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:115%;">Collaborative Arrangements (Topic 808)&#8212;Clarifying the interaction between Topic 808 and Topic 606</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;"> (ASU 2018-18). The amendments provide guidance on whether certain</span></div></ix:nonNumeric></ix:continuation><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">F - 13</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="ie1cb338617c849f29ed9b4d63e52b1a3"><ix:continuation id="i17a35106b40f4d6482e216172bae5353"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;"> transactions between collaborative arrangement participants should be accounted for as revenue under ASC 606. It also specifically (i) addresses when the participant should be considered a customer in the context of a unit of account, (ii) adds unit-of-account guidance in ASC 808 to align with guidance in ASC 606, and (iii) precludes presenting revenue from a collaborative arrangement together with revenue recognized under ASC 606 if the collaborative arrangement participant is not a customer. The guidance will be effective for fiscal years beginning after December 15, 2019. Early adoption is permitted and should be applied retrospectively. The Company does not anticipate the adoption of this standard will have a material impact on its consolidated financial statements.</span></div><div style="text-indent:36pt;margin-top:5pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Company has evaluated all other ASUs issued through the date the consolidated financials were issued and believes that the adoption of these will not have a material impact on the Company's consolidated financial statements.</span></div></ix:continuation></ix:continuation><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#ee2724;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#160;&#160;</span></div><div id="i_0_623"></div><div style="margin-top:3pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">3. <ix:nonNumeric contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82MjMvZnJhZzo1YTgzOGJhYzMwZmY0YzQ5YjJmMmU4MTZkM2UwMGQxNy90ZXh0cmVnaW9uOjVhODM4YmFjMzBmZjRjNDliMmYyZTgxNmQzZTAwZDE3XzczNA_75e5bf17-c3f7-4940-8e17-d61c46f711ad" continuedAt="i86e74dcae6a64302b97d998ab511d227" escape="true">Marketable Securities</ix:nonNumeric></span></div><ix:continuation id="i86e74dcae6a64302b97d998ab511d227" continuedAt="ia3a25e047dee4999a3f8a6dd914c80a6"><ix:nonNumeric contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" name="us-gaap:AvailableForSaleSecuritiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82MjMvZnJhZzo1YTgzOGJhYzMwZmY0YzQ5YjJmMmU4MTZkM2UwMGQxNy90ZXh0cmVnaW9uOjVhODM4YmFjMzBmZjRjNDliMmYyZTgxNmQzZTAwZDE3XzczNQ_8c85e699-310d-481a-aa54-37c915cef514" continuedAt="i4f9b7001f529411e98873b2fb7ed8a1e" escape="true"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;">Available-for-sale marketable securities as of December&#160;31, 2018 and 2017 were as follows (in thousands):</span></div><div style="margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"><tr><td style="width:1.0%;"></td><td style="width:48.807636%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.747430%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534214%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.747430%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534214%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.747430%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534214%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.747430%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:16pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;height:16pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2018</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Amortized</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Cost</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Gross</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Unrealized</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Gains</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Gross</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Unrealized</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Losses</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Fair</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Value</span></div></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id7600d6be2eb4b27a2ed9c725fbeef09_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82MjMvZnJhZzo1YTgzOGJhYzMwZmY0YzQ5YjJmMmU4MTZkM2UwMGQxNy90YWJsZTo2NDEwZmUyMzk5NzQ0NWY4YjQzYjJkYjlmODI4YzEzMy90YWJsZXJhbmdlOjY0MTBmZTIzOTk3NDQ1ZjhiNDNiMmRiOWY4MjhjMTMzXzQtMS0xLTEtMA_957b0ec9-2b23-4291-a844-3ed0faa900ef">12,738</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id7600d6be2eb4b27a2ed9c725fbeef09_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82MjMvZnJhZzo1YTgzOGJhYzMwZmY0YzQ5YjJmMmU4MTZkM2UwMGQxNy90YWJsZTo2NDEwZmUyMzk5NzQ0NWY4YjQzYjJkYjlmODI4YzEzMy90YWJsZXJhbmdlOjY0MTBmZTIzOTk3NDQ1ZjhiNDNiMmRiOWY4MjhjMTMzXzQtMy0xLTEtMA_3a6652c5-1da7-4a25-9033-c66e6a9767e6">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id7600d6be2eb4b27a2ed9c725fbeef09_I20181231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82MjMvZnJhZzo1YTgzOGJhYzMwZmY0YzQ5YjJmMmU4MTZkM2UwMGQxNy90YWJsZTo2NDEwZmUyMzk5NzQ0NWY4YjQzYjJkYjlmODI4YzEzMy90YWJsZXJhbmdlOjY0MTBmZTIzOTk3NDQ1ZjhiNDNiMmRiOWY4MjhjMTMzXzQtNS0xLTEtMA_3b8f6639-12df-4d83-b698-3f005aa09f8a">3</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id7600d6be2eb4b27a2ed9c725fbeef09_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82MjMvZnJhZzo1YTgzOGJhYzMwZmY0YzQ5YjJmMmU4MTZkM2UwMGQxNy90YWJsZTo2NDEwZmUyMzk5NzQ0NWY4YjQzYjJkYjlmODI4YzEzMy90YWJsZXJhbmdlOjY0MTBmZTIzOTk3NDQ1ZjhiNDNiMmRiOWY4MjhjMTMzXzQtNy0xLTEtMA_9434529b-b267-43e2-bc48-8572471c375d">12,735</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr></table></div><div style="text-align:center;margin-bottom:9pt;"><span><br/></span></div><div style="text-align:center;margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"><tr><td style="width:1.0%;"></td><td style="width:48.807636%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.747430%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534214%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.747430%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534214%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.747430%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534214%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.747430%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;height:13pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2017</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Amortized</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Cost</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Gross</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Unrealized</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Gains</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Gross</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Unrealized</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Losses</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Fair</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Value</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. Treasury securities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic847642706c0496581735d8af543077a_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82MjMvZnJhZzo1YTgzOGJhYzMwZmY0YzQ5YjJmMmU4MTZkM2UwMGQxNy90YWJsZTpiZWJlOGE0MWIyMGM0YzY1ODJkYTk5NTg0Yzc1M2Q2Yi90YWJsZXJhbmdlOmJlYmU4YTQxYjIwYzRjNjU4MmRhOTk1ODRjNzUzZDZiXzItMS0xLTEtMA_5701e208-85b1-4d8c-9bdc-88dd07ca32aa">3,995</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic847642706c0496581735d8af543077a_I20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82MjMvZnJhZzo1YTgzOGJhYzMwZmY0YzQ5YjJmMmU4MTZkM2UwMGQxNy90YWJsZTpiZWJlOGE0MWIyMGM0YzY1ODJkYTk5NTg0Yzc1M2Q2Yi90YWJsZXJhbmdlOmJlYmU4YTQxYjIwYzRjNjU4MmRhOTk1ODRjNzUzZDZiXzItMy0xLTEtMA_05dcb930-b003-43b0-be0a-975ccfc5944e">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ic847642706c0496581735d8af543077a_I20171231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82MjMvZnJhZzo1YTgzOGJhYzMwZmY0YzQ5YjJmMmU4MTZkM2UwMGQxNy90YWJsZTpiZWJlOGE0MWIyMGM0YzY1ODJkYTk5NTg0Yzc1M2Q2Yi90YWJsZXJhbmdlOmJlYmU4YTQxYjIwYzRjNjU4MmRhOTk1ODRjNzUzZDZiXzItNS0xLTEtMA_c0dda6da-64a4-4b73-ac0b-ecea2a6a56e1">6</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic847642706c0496581735d8af543077a_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82MjMvZnJhZzo1YTgzOGJhYzMwZmY0YzQ5YjJmMmU4MTZkM2UwMGQxNy90YWJsZTpiZWJlOGE0MWIyMGM0YzY1ODJkYTk5NTg0Yzc1M2Q2Yi90YWJsZXJhbmdlOmJlYmU4YTQxYjIwYzRjNjU4MmRhOTk1ODRjNzUzZDZiXzItNy0xLTEtMA_81decdd1-c526-4961-949b-0b4d5cf9ba23">3,989</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Government-sponsored enterprises</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iae2c0abc66c64857918562886c9ab108_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82MjMvZnJhZzo1YTgzOGJhYzMwZmY0YzQ5YjJmMmU4MTZkM2UwMGQxNy90YWJsZTpiZWJlOGE0MWIyMGM0YzY1ODJkYTk5NTg0Yzc1M2Q2Yi90YWJsZXJhbmdlOmJlYmU4YTQxYjIwYzRjNjU4MmRhOTk1ODRjNzUzZDZiXzMtMS0xLTEtMA_6370ee77-7ce1-4c89-95d0-b00b28f87f18">11,998</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iae2c0abc66c64857918562886c9ab108_I20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82MjMvZnJhZzo1YTgzOGJhYzMwZmY0YzQ5YjJmMmU4MTZkM2UwMGQxNy90YWJsZTpiZWJlOGE0MWIyMGM0YzY1ODJkYTk5NTg0Yzc1M2Q2Yi90YWJsZXJhbmdlOmJlYmU4YTQxYjIwYzRjNjU4MmRhOTk1ODRjNzUzZDZiXzMtMy0xLTEtMA_f0b9289a-85ac-4f16-bc37-aa3173d5caa5">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iae2c0abc66c64857918562886c9ab108_I20171231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82MjMvZnJhZzo1YTgzOGJhYzMwZmY0YzQ5YjJmMmU4MTZkM2UwMGQxNy90YWJsZTpiZWJlOGE0MWIyMGM0YzY1ODJkYTk5NTg0Yzc1M2Q2Yi90YWJsZXJhbmdlOmJlYmU4YTQxYjIwYzRjNjU4MmRhOTk1ODRjNzUzZDZiXzMtNS0xLTEtMA_fbf85b73-6369-4e80-b59b-843619b14458">7</ix:nonFraction>)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iae2c0abc66c64857918562886c9ab108_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82MjMvZnJhZzo1YTgzOGJhYzMwZmY0YzQ5YjJmMmU4MTZkM2UwMGQxNy90YWJsZTpiZWJlOGE0MWIyMGM0YzY1ODJkYTk5NTg0Yzc1M2Q2Yi90YWJsZXJhbmdlOmJlYmU4YTQxYjIwYzRjNjU4MmRhOTk1ODRjNzUzZDZiXzMtNy0xLTEtMA_e4ba5493-b3ba-499d-84ae-acbadd65c0bc">11,991</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4d00247415ba468e829a69e2a8739d09_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82MjMvZnJhZzo1YTgzOGJhYzMwZmY0YzQ5YjJmMmU4MTZkM2UwMGQxNy90YWJsZTpiZWJlOGE0MWIyMGM0YzY1ODJkYTk5NTg0Yzc1M2Q2Yi90YWJsZXJhbmdlOmJlYmU4YTQxYjIwYzRjNjU4MmRhOTk1ODRjNzUzZDZiXzQtMS0xLTEtMA_07975abe-e403-471e-9113-4f2fbefe2c38">77,462</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4d00247415ba468e829a69e2a8739d09_I20171231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82MjMvZnJhZzo1YTgzOGJhYzMwZmY0YzQ5YjJmMmU4MTZkM2UwMGQxNy90YWJsZTpiZWJlOGE0MWIyMGM0YzY1ODJkYTk5NTg0Yzc1M2Q2Yi90YWJsZXJhbmdlOmJlYmU4YTQxYjIwYzRjNjU4MmRhOTk1ODRjNzUzZDZiXzQtMy0xLTEtMA_4be97cf7-6012-4db3-a07f-38a49b82dff0">2</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i4d00247415ba468e829a69e2a8739d09_I20171231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82MjMvZnJhZzo1YTgzOGJhYzMwZmY0YzQ5YjJmMmU4MTZkM2UwMGQxNy90YWJsZTpiZWJlOGE0MWIyMGM0YzY1ODJkYTk5NTg0Yzc1M2Q2Yi90YWJsZXJhbmdlOmJlYmU4YTQxYjIwYzRjNjU4MmRhOTk1ODRjNzUzZDZiXzQtNS0xLTEtMA_b858af6c-cf04-4ce1-9ca6-77e463ad30bc">50</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4d00247415ba468e829a69e2a8739d09_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82MjMvZnJhZzo1YTgzOGJhYzMwZmY0YzQ5YjJmMmU4MTZkM2UwMGQxNy90YWJsZTpiZWJlOGE0MWIyMGM0YzY1ODJkYTk5NTg0Yzc1M2Q2Yi90YWJsZXJhbmdlOmJlYmU4YTQxYjIwYzRjNjU4MmRhOTk1ODRjNzUzZDZiXzQtNy0xLTEtMA_269726d2-7341-4bd6-9ac2-dbea957daaa7">77,414</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7057397719af459ca7328a1c440a0efa_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82MjMvZnJhZzo1YTgzOGJhYzMwZmY0YzQ5YjJmMmU4MTZkM2UwMGQxNy90YWJsZTpiZWJlOGE0MWIyMGM0YzY1ODJkYTk5NTg0Yzc1M2Q2Yi90YWJsZXJhbmdlOmJlYmU4YTQxYjIwYzRjNjU4MmRhOTk1ODRjNzUzZDZiXzUtMS0xLTEtMA_5f00053b-b48e-423f-b55f-d6b48e17ac86">93,455</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7057397719af459ca7328a1c440a0efa_I20171231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82MjMvZnJhZzo1YTgzOGJhYzMwZmY0YzQ5YjJmMmU4MTZkM2UwMGQxNy90YWJsZTpiZWJlOGE0MWIyMGM0YzY1ODJkYTk5NTg0Yzc1M2Q2Yi90YWJsZXJhbmdlOmJlYmU4YTQxYjIwYzRjNjU4MmRhOTk1ODRjNzUzZDZiXzUtMy0xLTEtMA_53e83e5b-51c4-40ae-9580-7b9bdf5f3099">2</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i7057397719af459ca7328a1c440a0efa_I20171231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82MjMvZnJhZzo1YTgzOGJhYzMwZmY0YzQ5YjJmMmU4MTZkM2UwMGQxNy90YWJsZTpiZWJlOGE0MWIyMGM0YzY1ODJkYTk5NTg0Yzc1M2Q2Yi90YWJsZXJhbmdlOmJlYmU4YTQxYjIwYzRjNjU4MmRhOTk1ODRjNzUzZDZiXzUtNS0xLTEtMA_05c8320a-e922-4a7a-9ae2-e6b91ffffb02">63</ix:nonFraction>)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7057397719af459ca7328a1c440a0efa_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82MjMvZnJhZzo1YTgzOGJhYzMwZmY0YzQ5YjJmMmU4MTZkM2UwMGQxNy90YWJsZTpiZWJlOGE0MWIyMGM0YzY1ODJkYTk5NTg0Yzc1M2Q2Yi90YWJsZXJhbmdlOmJlYmU4YTQxYjIwYzRjNjU4MmRhOTk1ODRjNzUzZDZiXzUtNy0xLTEtMA_84806449-cd56-4fd2-90d0-41ad8925f40d">93,394</ix:nonFraction>&#160;</span></td></tr></table></div></ix:nonNumeric><div style="margin-top:15pt;margin-bottom:9pt;"><ix:continuation id="i4f9b7001f529411e98873b2fb7ed8a1e" continuedAt="i4ca53e498b3948cb8f57d2e91c89b4d7"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">All of the Company's available-for-sale securities held at </span><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;">December&#160;31, 2018</span></ix:continuation><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"><ix:continuation id="i4ca53e498b3948cb8f57d2e91c89b4d7">&#160;and 2017&#160;had maturity dates of less than one year.</ix:continuation>  </span></div></ix:continuation><div style="text-align:center;margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"><tr><td style="width:1.0%;"></td><td style="width:67.354839%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:12.076246%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.665689%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.903226%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr></table></div><div style="text-indent:36pt;"><ix:continuation id="ia3a25e047dee4999a3f8a6dd914c80a6" continuedAt="i9a953fa538b24af5819fe14c10bb1173"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">All available-for-sale securities in an unrealized loss position as of </span><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;">December&#160;31, 2018</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> and 2017 were in a loss position for less than twelve months.&#160; There were <ix:nonFraction unitRef="usd" contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82MjMvZnJhZzo1YTgzOGJhYzMwZmY0YzQ5YjJmMmU4MTZkM2UwMGQxNy90ZXh0cmVnaW9uOjVhODM4YmFjMzBmZjRjNDliMmYyZTgxNmQzZTAwZDE3XzUwMA_17c9e8bd-3a53-4891-a668-5e19c8c177f4">no</ix:nonFraction> unrealized losses at </span><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;">December&#160;31, 2018</span></ix:continuation><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"><ix:continuation id="i9a953fa538b24af5819fe14c10bb1173"> or 2017 that the Company determined to be other-than-temporary.  The Company recorded interest income of $<ix:nonFraction unitRef="usd" contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82MjMvZnJhZzo1YTgzOGJhYzMwZmY0YzQ5YjJmMmU4MTZkM2UwMGQxNy90ZXh0cmVnaW9uOjVhODM4YmFjMzBmZjRjNDliMmYyZTgxNmQzZTAwZDE3XzYzMA_8d72a13e-4c84-47a1-aa18-015a9bd0f8ce">2.3</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82MjMvZnJhZzo1YTgzOGJhYzMwZmY0YzQ5YjJmMmU4MTZkM2UwMGQxNy90ZXh0cmVnaW9uOjVhODM4YmFjMzBmZjRjNDliMmYyZTgxNmQzZTAwZDE3XzYzNA_b93528d7-d3db-42d6-b547-291392253666">2.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iaf5d0e8fdf374dc09283fd669e2ebf19_D20160101-20161231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82MjMvZnJhZzo1YTgzOGJhYzMwZmY0YzQ5YjJmMmU4MTZkM2UwMGQxNy90ZXh0cmVnaW9uOjVhODM4YmFjMzBmZjRjNDliMmYyZTgxNmQzZTAwZDE3XzY0MQ_cb643ae4-7736-41d0-86f1-6c3df23e12b8">2.3</ix:nonFraction> million during the years ended December&#160;31, 2018, 2017 and 2016, respectively, which is included in other income (expense) on the consolidated statements of operations and comprehensive loss.</ix:continuation>&#160;</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span><br/></span></div><div id="i_0_648"></div><div style="margin-top:3pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">4. <ix:nonNumeric contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82NDgvZnJhZzo1NjdmZTIxZGIwYTU0ZGNlYjZlMmZkOWI1MmMwYmJhYy90ZXh0cmVnaW9uOjU2N2ZlMjFkYjBhNTRkY2ViNmUyZmQ5YjUyYzBiYmFjXzc0Nw_4f9ae054-1d1e-44f4-bca8-91922347847c" continuedAt="i5a4ec3d94ce347bc8fa0fa27b948d12b" escape="true">Property, Equipment and Software</ix:nonNumeric></span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"><ix:continuation id="i5a4ec3d94ce347bc8fa0fa27b948d12b" continuedAt="id779dbba222549bfb6be2fad2822f187"><ix:nonNumeric contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82NDgvZnJhZzo1NjdmZTIxZGIwYTU0ZGNlYjZlMmZkOWI1MmMwYmJhYy90ZXh0cmVnaW9uOjU2N2ZlMjFkYjBhNTRkY2ViNmUyZmQ5YjUyYzBiYmFjXzE1OTQyOTE4NjAzNTg4_b4417821-d53c-4403-bbde-bf466aa99414" continuedAt="i53f5aa2604e943568cb292a0293b35d0" escape="true">Property, equipment and software consists of the following (in thousands):</ix:nonNumeric></ix:continuation></span></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">F - 14</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="id779dbba222549bfb6be2fad2822f187"><div style="margin-bottom:9pt;"><ix:continuation id="i53f5aa2604e943568cb292a0293b35d0"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"><tr><td style="width:1.0%;"></td><td style="width:73.806452%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.730205%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533138%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.730205%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Computer equipment</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4f49a198b4bb493aad3c0563be1a1b1c_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82NDgvZnJhZzo1NjdmZTIxZGIwYTU0ZGNlYjZlMmZkOWI1MmMwYmJhYy90YWJsZTo0NTNjNzRkMjk5OGQ0ZDJlOGVhNTM1M2JiYzc5ZmM4Ni90YWJsZXJhbmdlOjQ1M2M3NGQyOTk4ZDRkMmU4ZWE1MzUzYmJjNzlmYzg2XzItMS0xLTEtMA_af3a0846-8e25-4e03-92ae-17fe5017dec3">2,360</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if008fb95c70d4d6292a3deb9038402f2_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82NDgvZnJhZzo1NjdmZTIxZGIwYTU0ZGNlYjZlMmZkOWI1MmMwYmJhYy90YWJsZTo0NTNjNzRkMjk5OGQ0ZDJlOGVhNTM1M2JiYzc5ZmM4Ni90YWJsZXJhbmdlOjQ1M2M3NGQyOTk4ZDRkMmU4ZWE1MzUzYmJjNzlmYzg2XzItMy0xLTEtMA_29d24c49-9979-4234-ac29-0511e58bda41">2,261</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Software</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia589fee494a140259bbf8dd10ad98449_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82NDgvZnJhZzo1NjdmZTIxZGIwYTU0ZGNlYjZlMmZkOWI1MmMwYmJhYy90YWJsZTo0NTNjNzRkMjk5OGQ0ZDJlOGVhNTM1M2JiYzc5ZmM4Ni90YWJsZXJhbmdlOjQ1M2M3NGQyOTk4ZDRkMmU4ZWE1MzUzYmJjNzlmYzg2XzMtMS0xLTEtMA_96d211f5-94cb-4fa2-a914-567558f4debb">7,011</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic4ae66e3b1a040229462cc9b00c106f7_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82NDgvZnJhZzo1NjdmZTIxZGIwYTU0ZGNlYjZlMmZkOWI1MmMwYmJhYy90YWJsZTo0NTNjNzRkMjk5OGQ0ZDJlOGVhNTM1M2JiYzc5ZmM4Ni90YWJsZXJhbmdlOjQ1M2M3NGQyOTk4ZDRkMmU4ZWE1MzUzYmJjNzlmYzg2XzMtMy0xLTEtMA_4253a701-561a-4c00-b3e5-ca0b37b45952">5,111</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Furniture and office equipment</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i989637b0c825400daad1d79fd200cfc7_I20181231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82NDgvZnJhZzo1NjdmZTIxZGIwYTU0ZGNlYjZlMmZkOWI1MmMwYmJhYy90YWJsZTo0NTNjNzRkMjk5OGQ0ZDJlOGVhNTM1M2JiYzc5ZmM4Ni90YWJsZXJhbmdlOjQ1M2M3NGQyOTk4ZDRkMmU4ZWE1MzUzYmJjNzlmYzg2XzQtMS0xLTEtMA_8f7faa3d-59dd-411a-9c0e-5646640d02c1">668</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i17b1fb07ad7e461f85ee4cfd5083f136_I20171231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82NDgvZnJhZzo1NjdmZTIxZGIwYTU0ZGNlYjZlMmZkOWI1MmMwYmJhYy90YWJsZTo0NTNjNzRkMjk5OGQ0ZDJlOGVhNTM1M2JiYzc5ZmM4Ni90YWJsZXJhbmdlOjQ1M2M3NGQyOTk4ZDRkMmU4ZWE1MzUzYmJjNzlmYzg2XzQtMy0xLTEtMA_3bf171d5-d1de-47fd-be3e-a316fd9f3ff4">656</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Lab equipment</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iba7f249ad22445ea80c87ac974f09d4e_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82NDgvZnJhZzo1NjdmZTIxZGIwYTU0ZGNlYjZlMmZkOWI1MmMwYmJhYy90YWJsZTo0NTNjNzRkMjk5OGQ0ZDJlOGVhNTM1M2JiYzc5ZmM4Ni90YWJsZXJhbmdlOjQ1M2M3NGQyOTk4ZDRkMmU4ZWE1MzUzYmJjNzlmYzg2XzUtMS0xLTEtMA_e265dad4-c584-4926-a35e-cd1d4244afba">36,062</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id2ed58086aad4a0d93e3102ea5a382bc_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82NDgvZnJhZzo1NjdmZTIxZGIwYTU0ZGNlYjZlMmZkOWI1MmMwYmJhYy90YWJsZTo0NTNjNzRkMjk5OGQ0ZDJlOGVhNTM1M2JiYzc5ZmM4Ni90YWJsZXJhbmdlOjQ1M2M3NGQyOTk4ZDRkMmU4ZWE1MzUzYmJjNzlmYzg2XzUtMy0xLTEtMA_f49fe8d3-0d5a-4612-acd5-da4e883605c0">20,549</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Leasehold improvements</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id0aa3dc3a1594241a90d2f208fc88fcf_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82NDgvZnJhZzo1NjdmZTIxZGIwYTU0ZGNlYjZlMmZkOWI1MmMwYmJhYy90YWJsZTo0NTNjNzRkMjk5OGQ0ZDJlOGVhNTM1M2JiYzc5ZmM4Ni90YWJsZXJhbmdlOjQ1M2M3NGQyOTk4ZDRkMmU4ZWE1MzUzYmJjNzlmYzg2XzYtMS0xLTEtMA_751db86b-8ae1-4855-8de7-a80d405c3356">48,328</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iacc09d395c06412b8bc32c6bcf83092c_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82NDgvZnJhZzo1NjdmZTIxZGIwYTU0ZGNlYjZlMmZkOWI1MmMwYmJhYy90YWJsZTo0NTNjNzRkMjk5OGQ0ZDJlOGVhNTM1M2JiYzc5ZmM4Ni90YWJsZXJhbmdlOjQ1M2M3NGQyOTk4ZDRkMmU4ZWE1MzUzYmJjNzlmYzg2XzYtMy0xLTEtMA_a2553e87-61d3-47f0-b803-ca95ab7e683e">17,525</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Construction in progress</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231" decimals="-3" name="us-gaap:ConstructionInProgressGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82NDgvZnJhZzo1NjdmZTIxZGIwYTU0ZGNlYjZlMmZkOWI1MmMwYmJhYy90YWJsZTo0NTNjNzRkMjk5OGQ0ZDJlOGVhNTM1M2JiYzc5ZmM4Ni90YWJsZXJhbmdlOjQ1M2M3NGQyOTk4ZDRkMmU4ZWE1MzUzYmJjNzlmYzg2XzctMS0xLTEtMA_d817ed3a-c36a-45c2-ba8c-c7f5d9f04854">218</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7057397719af459ca7328a1c440a0efa_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ConstructionInProgressGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82NDgvZnJhZzo1NjdmZTIxZGIwYTU0ZGNlYjZlMmZkOWI1MmMwYmJhYy90YWJsZTo0NTNjNzRkMjk5OGQ0ZDJlOGVhNTM1M2JiYzc5ZmM4Ni90YWJsZXJhbmdlOjQ1M2M3NGQyOTk4ZDRkMmU4ZWE1MzUzYmJjNzlmYzg2XzctMy0xLTEtMA_05e911c0-4d3b-4b07-b56b-1a268764f832">32,800</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Property, equipment and software</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82NDgvZnJhZzo1NjdmZTIxZGIwYTU0ZGNlYjZlMmZkOWI1MmMwYmJhYy90YWJsZTo0NTNjNzRkMjk5OGQ0ZDJlOGVhNTM1M2JiYzc5ZmM4Ni90YWJsZXJhbmdlOjQ1M2M3NGQyOTk4ZDRkMmU4ZWE1MzUzYmJjNzlmYzg2XzgtMS0xLTEtMA_598db1ae-526e-436d-959a-e219bab86e96">94,647</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7057397719af459ca7328a1c440a0efa_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82NDgvZnJhZzo1NjdmZTIxZGIwYTU0ZGNlYjZlMmZkOWI1MmMwYmJhYy90YWJsZTo0NTNjNzRkMjk5OGQ0ZDJlOGVhNTM1M2JiYzc5ZmM4Ni90YWJsZXJhbmdlOjQ1M2M3NGQyOTk4ZDRkMmU4ZWE1MzUzYmJjNzlmYzg2XzgtMy0xLTEtMA_56b85f7f-9ebf-470e-b4c7-4563c33c2c91">78,902</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Less accumulated depreciation and amortization</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82NDgvZnJhZzo1NjdmZTIxZGIwYTU0ZGNlYjZlMmZkOWI1MmMwYmJhYy90YWJsZTo0NTNjNzRkMjk5OGQ0ZDJlOGVhNTM1M2JiYzc5ZmM4Ni90YWJsZXJhbmdlOjQ1M2M3NGQyOTk4ZDRkMmU4ZWE1MzUzYmJjNzlmYzg2XzktMS0xLTEtMA_df80fcfe-3177-4d2b-862d-a6d67a961998">37,935</ix:nonFraction>)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i7057397719af459ca7328a1c440a0efa_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82NDgvZnJhZzo1NjdmZTIxZGIwYTU0ZGNlYjZlMmZkOWI1MmMwYmJhYy90YWJsZTo0NTNjNzRkMjk5OGQ0ZDJlOGVhNTM1M2JiYzc5ZmM4Ni90YWJsZXJhbmdlOjQ1M2M3NGQyOTk4ZDRkMmU4ZWE1MzUzYmJjNzlmYzg2XzktMy0xLTEtMA_29fd7901-22a7-4770-9527-481a055253ab">28,919</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Property, equipment and software, net</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82NDgvZnJhZzo1NjdmZTIxZGIwYTU0ZGNlYjZlMmZkOWI1MmMwYmJhYy90YWJsZTo0NTNjNzRkMjk5OGQ0ZDJlOGVhNTM1M2JiYzc5ZmM4Ni90YWJsZXJhbmdlOjQ1M2M3NGQyOTk4ZDRkMmU4ZWE1MzUzYmJjNzlmYzg2XzEwLTEtMS0xLTA_0933cd4b-b53e-4840-ba74-088150a88f74">56,712</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7057397719af459ca7328a1c440a0efa_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82NDgvZnJhZzo1NjdmZTIxZGIwYTU0ZGNlYjZlMmZkOWI1MmMwYmJhYy90YWJsZTo0NTNjNzRkMjk5OGQ0ZDJlOGVhNTM1M2JiYzc5ZmM4Ni90YWJsZXJhbmdlOjQ1M2M3NGQyOTk4ZDRkMmU4ZWE1MzUzYmJjNzlmYzg2XzEwLTMtMS0xLTA_821fcd96-164c-49a0-9e82-9dc774455349">49,983</ix:nonFraction>&#160;</span></td></tr></table></ix:continuation></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Construction in progress at December 31, 2017 consisted of the costs incurred for the build-out of a manufacturing suite at the Company's headquarters building in Rockville, Maryland, which was completed in mid-2018.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">We had $<ix:nonFraction unitRef="usd" contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231" decimals="INF" format="ixt:numdotdecimal" name="mgnx:PropertyPlantAndEquipmentNonCashAdditions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82NDgvZnJhZzo1NjdmZTIxZGIwYTU0ZGNlYjZlMmZkOWI1MmMwYmJhYy90ZXh0cmVnaW9uOjU2N2ZlMjFkYjBhNTRkY2ViNmUyZmQ5YjUyYzBiYmFjXzMzMg_8a2afb91-f6ba-40e0-9212-cfcda9fde4f5">0.6</ix:nonFraction> million in property, equipment and software at December&#160;31, 2018 that was purchased in 2018 but was not paid for by year end.&#160; Property, equipment and software balance at December&#160;31, 2017 includes approximately $<ix:nonFraction unitRef="usd" contextRef="i7057397719af459ca7328a1c440a0efa_I20171231" decimals="-5" format="ixt:numdotdecimal" name="mgnx:PropertyPlantAndEquipmentNonCashAdditions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82NDgvZnJhZzo1NjdmZTIxZGIwYTU0ZGNlYjZlMmZkOWI1MmMwYmJhYy90ZXh0cmVnaW9uOjU2N2ZlMjFkYjBhNTRkY2ViNmUyZmQ5YjUyYzBiYmFjXzUyMg_805bd26e-abe0-43d0-96c5-188c8fddb43a">9.6</ix:nonFraction> million in assets that were purchased in 2017 but were not paid for by year end.  Depreciation and amortization expense related to property, equipment and software for the years ended December&#160;31, 2018, 2017 and 2016 was $<ix:nonFraction unitRef="usd" contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82NDgvZnJhZzo1NjdmZTIxZGIwYTU0ZGNlYjZlMmZkOWI1MmMwYmJhYy90ZXh0cmVnaW9uOjU2N2ZlMjFkYjBhNTRkY2ViNmUyZmQ5YjUyYzBiYmFjXzcxOQ_c71c791c-b771-45ea-9ee2-faef9811741f">9.2</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82NDgvZnJhZzo1NjdmZTIxZGIwYTU0ZGNlYjZlMmZkOWI1MmMwYmJhYy90ZXh0cmVnaW9uOjU2N2ZlMjFkYjBhNTRkY2ViNmUyZmQ5YjUyYzBiYmFjXzcyMw_bbade065-0d06-4738-b072-7964907ec712">7.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iaf5d0e8fdf374dc09283fd669e2ebf19_D20160101-20161231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82NDgvZnJhZzo1NjdmZTIxZGIwYTU0ZGNlYjZlMmZkOWI1MmMwYmJhYy90ZXh0cmVnaW9uOjU2N2ZlMjFkYjBhNTRkY2ViNmUyZmQ5YjUyYzBiYmFjXzczMA_994d06ea-854d-4b6b-ad70-050ae71ab48c">6.8</ix:nonFraction> million, respectively.</span></div></ix:continuation><div style="text-indent:36pt;margin-bottom:9pt;"><span><br/></span></div><div id="i_0_660"></div><div style="margin-top:3pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">5. <ix:nonNumeric contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82NjAvZnJhZzpiMTI4ZDRiZDkxZWQ0OTQ3OTk2OWMwMTRkYzJkMWViZC90ZXh0cmVnaW9uOmIxMjhkNGJkOTFlZDQ5NDc5OTY5YzAxNGRjMmQxZWJkXzE1OTQyOTE4NjEwMjc2_bdf75b16-2525-4bf0-8e13-0118e4cf59e3" continuedAt="ia4fec549f99f442a915aaa2a19491e66" escape="true">Stockholders' Equity</ix:nonNumeric></span></div><ix:continuation id="ia4fec549f99f442a915aaa2a19491e66" continuedAt="i0a91fe6677624c0cb7b4466601287de6"><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#160;The Company's amended and restated certificate of incorporation authorizes <ix:nonFraction unitRef="shares" contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82NjAvZnJhZzpiMTI4ZDRiZDkxZWQ0OTQ3OTk2OWMwMTRkYzJkMWViZC90ZXh0cmVnaW9uOmIxMjhkNGJkOTFlZDQ5NDc5OTY5YzAxNGRjMmQxZWJkXzEwNQ_11bfcd29-dafa-4adf-8da4-4fed5321e518">125,000,000</ix:nonFraction> shares of common stock, and <ix:nonFraction unitRef="shares" contextRef="iaaa703135e5d42e3ad357819a2febb2b_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82NjAvZnJhZzpiMTI4ZDRiZDkxZWQ0OTQ3OTk2OWMwMTRkYzJkMWViZC90ZXh0cmVnaW9uOmIxMjhkNGJkOTFlZDQ5NDc5OTY5YzAxNGRjMmQxZWJkXzEzNg_856c1a61-b365-48d6-b542-e60866daf6c1">5,000,000</ix:nonFraction> shares of undesignated preferred stock, both with a par value of $<ix:nonFraction unitRef="usdPerShare" contextRef="iaaa703135e5d42e3ad357819a2febb2b_I20181231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82NjAvZnJhZzpiMTI4ZDRiZDkxZWQ0OTQ3OTk2OWMwMTRkYzJkMWViZC90ZXh0cmVnaW9uOmIxMjhkNGJkOTFlZDQ5NDc5OTY5YzAxNGRjMmQxZWJkXzIwNA_872a11c1-7245-4e8b-b5c8-000f711013d7">.01</ix:nonFraction> per share.&#160;&#160;There were <ix:nonFraction unitRef="shares" contextRef="iaaa703135e5d42e3ad357819a2febb2b_I20181231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82NjAvZnJhZzpiMTI4ZDRiZDkxZWQ0OTQ3OTk2OWMwMTRkYzJkMWViZC90ZXh0cmVnaW9uOmIxMjhkNGJkOTFlZDQ5NDc5OTY5YzAxNGRjMmQxZWJkXzIzMA_2c79fea5-c16b-4826-bcbb-55c2d9417c2d">no</ix:nonFraction> shares of undesignated preferred stock issued or outstanding as of December&#160;31, 2018 or 2017.</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">On April 26, 2017, the Company entered into a definitive agreement with an institutional healthcare investor to purchase <ix:nonFraction unitRef="shares" contextRef="i774ad7d035574588abdffa05896955f7_D20170426-20170426" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82NjAvZnJhZzpiMTI4ZDRiZDkxZWQ0OTQ3OTk2OWMwMTRkYzJkMWViZC90ZXh0cmVnaW9uOmIxMjhkNGJkOTFlZDQ5NDc5OTY5YzAxNGRjMmQxZWJkXzE3NTk_e0fa09fa-0178-4763-bb09-fab137e4dde8">1,100,000</ix:nonFraction> shares of its common stock at a purchase price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i300212ce6416414283af0aa5ceb5e231_I20170426" decimals="2" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82NjAvZnJhZzpiMTI4ZDRiZDkxZWQ0OTQ3OTk2OWMwMTRkYzJkMWViZC90ZXh0cmVnaW9uOmIxMjhkNGJkOTFlZDQ5NDc5OTY5YzAxNGRjMmQxZWJkXzE4MTI_d644d05a-1223-4933-b83d-0d64ed00ccb3">21.50</ix:nonFraction> per share in a registered direct offering. Proceeds to the Company, before deducting estimated offering expenses, were $<ix:nonFraction unitRef="usd" contextRef="i774ad7d035574588abdffa05896955f7_D20170426-20170426" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82NjAvZnJhZzpiMTI4ZDRiZDkxZWQ0OTQ3OTk2OWMwMTRkYzJkMWViZC90ZXh0cmVnaW9uOmIxMjhkNGJkOTFlZDQ5NDc5OTY5YzAxNGRjMmQxZWJkXzE5MzQ_b3e98758-046f-4e53-8ccf-a535b1a042b8">23.7</ix:nonFraction> million. The shares were offered pursuant to the Company&#8217;s effective shelf registration on Form S-3 that was filed with the SEC on November 2, 2016.</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">On May 3, 2017, the Company entered into a sales agreement with an agent to sell, from time to time, shares of its common stock having an aggregate sales price of up to $<ix:nonFraction unitRef="usd" contextRef="i1805f20c3a7b4d11b92ee3e187db18fe_D20170503-20170503" decimals="-5" format="ixt:numdotdecimal" name="mgnx:CommonStockMaximumAmountAvailableForIssuance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82NjAvZnJhZzpiMTI4ZDRiZDkxZWQ0OTQ3OTk2OWMwMTRkYzJkMWViZC90ZXh0cmVnaW9uOmIxMjhkNGJkOTFlZDQ5NDc5OTY5YzAxNGRjMmQxZWJkXzIyNTA_8c01ebd9-72da-4dfb-95f8-cabeea8e2087">75.0</ix:nonFraction> million through an &#8220;at the market offering&#8221; (ATM Offering) as defined in Rule 415 under the Securities Act of 1933, as amended.  The shares that may be sold under the sales agreement would be issued and sold pursuant to the Company's shelf registration statement on Form S-3 that was filed with the SEC on November 2, 2016. During the year ended December 31, 2017, the Company sold <ix:nonFraction unitRef="shares" contextRef="i1805f20c3a7b4d11b92ee3e187db18fe_D20170503-20170503" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82NjAvZnJhZzpiMTI4ZDRiZDkxZWQ0OTQ3OTk2OWMwMTRkYzJkMWViZC90ZXh0cmVnaW9uOmIxMjhkNGJkOTFlZDQ5NDc5OTY5YzAxNGRjMmQxZWJkXzI2MTI_d09428fe-2658-4349-8e06-0f97546a23a7">599,284</ix:nonFraction> shares of common stock resulting in net proceeds of $<ix:nonFraction unitRef="usd" contextRef="i1805f20c3a7b4d11b92ee3e187db18fe_D20170503-20170503" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82NjAvZnJhZzpiMTI4ZDRiZDkxZWQ0OTQ3OTk2OWMwMTRkYzJkMWViZC90ZXh0cmVnaW9uOmIxMjhkNGJkOTFlZDQ5NDc5OTY5YzAxNGRjMmQxZWJkXzI2Njc_497f4742-8d2b-4762-88ca-3eded4d8bdbd">10.8</ix:nonFraction> million related to the ATM Offering.&#160;</span></div></ix:continuation><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;"><ix:continuation id="i0a91fe6677624c0cb7b4466601287de6">On April 2, 2018, the Company completed a firm-commitment underwritten public offering, in which the Company sold <ix:nonFraction unitRef="shares" contextRef="ie86be88df16c4586b769baf5bf4e5efe_D20180402-20180402" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82NjAvZnJhZzpiMTI4ZDRiZDkxZWQ0OTQ3OTk2OWMwMTRkYzJkMWViZC90ZXh0cmVnaW9uOmIxMjhkNGJkOTFlZDQ5NDc5OTY5YzAxNGRjMmQxZWJkXzI3NDg3NzkwNzU1NDM_383716c4-cf38-4b9f-8949-31e2ea5ff7a6">4,500,000</ix:nonFraction> shares of its common stock at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ib0101bc440ae4fdeb05d3353b727f0aa_I20180402" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82NjAvZnJhZzpiMTI4ZDRiZDkxZWQ0OTQ3OTk2OWMwMTRkYzJkMWViZC90ZXh0cmVnaW9uOmIxMjhkNGJkOTFlZDQ5NDc5OTY5YzAxNGRjMmQxZWJkXzI3NDg3NzkwNzU1NjA_633b36ad-9b8f-4feb-9a41-e272103348cc">21.25</ix:nonFraction> per share.  Additionally, the underwriters of the offering exercised the full amount of their over-allotment option resulting in the sale of an additional <ix:nonFraction unitRef="shares" contextRef="ic563779cd1db4959a683e3166bd53d26_D20180402-20180402" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82NjAvZnJhZzpiMTI4ZDRiZDkxZWQ0OTQ3OTk2OWMwMTRkYzJkMWViZC90ZXh0cmVnaW9uOmIxMjhkNGJkOTFlZDQ5NDc5OTY5YzAxNGRjMmQxZWJkXzI3NDg3NzkwNzU1Njk_0bbec367-3f8e-4fdd-818e-43dd5b2f3daa">675,000</ix:nonFraction> shares of the Company's common stock at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i0e9ac3017eb644d2bd213ae5a7dabd47_I20180402" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82NjAvZnJhZzpiMTI4ZDRiZDkxZWQ0OTQ3OTk2OWMwMTRkYzJkMWViZC90ZXh0cmVnaW9uOmIxMjhkNGJkOTFlZDQ5NDc5OTY5YzAxNGRjMmQxZWJkXzI3NDg3NzkwNzU1Nzc_18e80e15-2f46-44d7-a8f4-27ba5b8ba66e">21.25</ix:nonFraction> per share.  Upon closing, the Company received net proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="ie86be88df16c4586b769baf5bf4e5efe_D20180402-20180402" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82NjAvZnJhZzpiMTI4ZDRiZDkxZWQ0OTQ3OTk2OWMwMTRkYzJkMWViZC90ZXh0cmVnaW9uOmIxMjhkNGJkOTFlZDQ5NDc5OTY5YzAxNGRjMmQxZWJkXzI3NDg3NzkwNzU1OTM_e46906ab-2b65-4844-bc42-bd5f30fd31bf">103.0</ix:nonFraction>&#160;million from this offering, net of underwriting discounts and commissions and other offering expenses.</ix:continuation> </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:9pt;"><span><br/></span></div><div id="i_0_685"></div><div style="margin-top:3pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">6. <ix:nonNumeric contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90ZXh0cmVnaW9uOmI5MjNjYzI4YTQ4OTQ0ODg5ZWJhNTRkYjU5NTFkNjRhXzY1NTc_3ce78871-54a9-420c-a564-29dfb5040540" continuedAt="i797614507be64396bc0ce424d77fb2f8" escape="true">Stock-based Compensation</ix:nonNumeric></span></div><ix:continuation id="i797614507be64396bc0ce424d77fb2f8" continuedAt="if0b173528d604eb2b94beb4616f52780"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Employee Stock Purchase Plan</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">In May 2017, the Company&#8217;s stockholders approved the 2016 Employee Stock Purchase Plan (the 2016 ESPP). The 2016 ESPP is structured as a qualified employee stock purchase plan under Section 423 of the Internal Revenue Code of 1986, as amended, and is not subject to the provisions of the Employee Retirement Income Security Act of 1974.  The Company reserved <ix:nonFraction unitRef="shares" contextRef="i37bd3dc2e0684382887e9c7141114e64_I20170518" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90ZXh0cmVnaW9uOmI5MjNjYzI4YTQ4OTQ0ODg5ZWJhNTRkYjU5NTFkNjRhXzQyMg_54c4f2c6-f662-4d0d-bf0b-f413a8acc638">800,000</ix:nonFraction> shares of common stock for issuance under the 2016 ESPP. The 2016 ESPP allows eligible employees to purchase shares of the Company&#8217;s common stock at a discount through payroll deductions of up to <ix:nonFraction unitRef="number" contextRef="i225dfbff0423412ab9af487587a7a9dc_D20170501-20170531" decimals="INF" name="mgnx:EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90ZXh0cmVnaW9uOmI5MjNjYzI4YTQ4OTQ0ODg5ZWJhNTRkYjU5NTFkNjRhXzYyMQ_b7c36614-3835-4687-bda3-0e90711360ba">10</ix:nonFraction>% of their eligible compensation, subject to any plan limitations. The 2016 ESPP provides for six-month offering periods ending on May 31 and November 30 of each year.  At the end of each offering period, employees are able to purchase shares at <ix:nonFraction unitRef="number" contextRef="i225dfbff0423412ab9af487587a7a9dc_D20170501-20170531" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90ZXh0cmVnaW9uOmI5MjNjYzI4YTQ4OTQ0ODg5ZWJhNTRkYjU5NTFkNjRhXzg2OA_a3ff23a3-5cc9-44b2-937c-ad33052d8c80">85</ix:nonFraction>% of the fair market</span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">F - 15</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="if0b173528d604eb2b94beb4616f52780" continuedAt="iee5b82ed60274881977f2fc6a4526f56"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> value of the Company&#8217;s common stock on the last day of the offering period.  During the year ended December&#160;31, 2018, employees purchased <ix:nonFraction unitRef="shares" contextRef="ice18cbfc8512491798f071290230dc95_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90ZXh0cmVnaW9uOmI5MjNjYzI4YTQ4OTQ0ODg5ZWJhNTRkYjU5NTFkNjRhXzEwMTM_9c4d3ae9-90ce-4e14-bba9-b51dd594694b">44,862</ix:nonFraction> shares of common stock under the 2016 ESPP for net proceeds to the Company of approximately $<ix:nonFraction unitRef="usd" contextRef="ice18cbfc8512491798f071290230dc95_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90ZXh0cmVnaW9uOmI5MjNjYzI4YTQ4OTQ0ODg5ZWJhNTRkYjU5NTFkNjRhXzExMDg_230f65e6-d670-4bcc-b9f1-d76b966d11f5">0.8</ix:nonFraction> million.  </span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Employee Stock Option Plans</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Effective February 2003, the Company implemented the 2003 Equity Incentive Plan (2003 Plan), and it was amended and approved by the Company's stockholders in 2005. Stock options granted under the 2003 Plan may be either incentive stock options as defined by the Internal Revenue Code (IRC), or non-qualified stock options.  In 2013, the 2003 Plan was terminated, and no further awards may be issued under the plan.  Any shares of common stock subject to awards under the 2003 Plan that expire, terminate, or are otherwise surrendered, canceled, forfeited or repurchased without having been fully exercised, or resulting in any common stock being issued, will become available for issuance under the 2013 Stock Incentive Plan (2013 Plan), up to a specified number of shares.&#160; As of December&#160;31, 2018, under the 2003 Plan, there were options to purchase an aggregate of <ix:nonFraction unitRef="shares" contextRef="i0a9a71bb02554506a053e4b037c5a59c_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90ZXh0cmVnaW9uOmI5MjNjYzI4YTQ4OTQ0ODg5ZWJhNTRkYjU5NTFkNjRhXzIyNzM_5f711b81-4bbf-4d49-96e2-f6a6f5bd6c12">746,803</ix:nonFraction> shares of common stock outstanding at a weighted average exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i0a9a71bb02554506a053e4b037c5a59c_I20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90ZXh0cmVnaW9uOmI5MjNjYzI4YTQ4OTQ0ODg5ZWJhNTRkYjU5NTFkNjRhXzIzNTE_1afbf72e-e976-44af-a8f0-1a15f86a5868">2.03</ix:nonFraction> per share.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">In October 2013, the Company implemented the 2013  Plan.&#160;&#160;The 2013 Plan provides for the grant of stock options and other stock-based awards, as well as cash-based performance awards. The aggregate number of shares of common stock initially available for issuance pursuant to awards under the 2013 Plan was <ix:nonFraction unitRef="shares" contextRef="i88e7a08234064f55a3fdcac46083d417_I20131031" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90ZXh0cmVnaW9uOmI5MjNjYzI4YTQ4OTQ0ODg5ZWJhNTRkYjU5NTFkNjRhXzI2NzM_3ff16964-e807-440d-b486-1dd09a75d225">1,960,168</ix:nonFraction> shares.&#160;&#160;The number of shares of common stock reserved for issuance will automatically increase on January 1 of each year from January 1, 2014 through and including January 1, 2023, by the lesser of (a) <ix:nonFraction unitRef="shares" contextRef="ie68e03dfcb1349ea9e266215200f7c25_I20181231" decimals="INF" format="ixt:numdotdecimal" name="mgnx:CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90ZXh0cmVnaW9uOmI5MjNjYzI4YTQ4OTQ0ODg5ZWJhNTRkYjU5NTFkNjRhXzI4Nzk_405bdded-333b-4f9f-a232-86d0ad64b287">1,960,168</ix:nonFraction> shares, (b) <ix:nonFraction unitRef="number" contextRef="ibb0c6525ae294173b7c08c959023d2af_D20180101-20181231" decimals="3" name="mgnx:PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90ZXh0cmVnaW9uOmI5MjNjYzI4YTQ4OTQ0ODg5ZWJhNTRkYjU5NTFkNjRhXzI4OTQ_cc61b7ea-f6ef-4862-9b45-7aefd9ebb6f4">4.0</ix:nonFraction>% of the total number of shares of common stock outstanding on December 31 of the preceding calendar year, or (c) the number of shares of common stock determined by the Board of Directors. During the year ended December&#160;31, 2018, the maximum number of shares of common stock authorized to be issued by the Company under the 2013 Plan was increased to <ix:nonFraction unitRef="shares" contextRef="ibb0c6525ae294173b7c08c959023d2af_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="mgnx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90ZXh0cmVnaW9uOmI5MjNjYzI4YTQ4OTQ0ODg5ZWJhNTRkYjU5NTFkNjRhXzMyMzE_792241e7-848e-4fae-a17a-b0535b6c0fd1">8,244,131</ix:nonFraction>.&#160;&#160;If an option expires or terminates for any reason without having been fully exercised, if any shares of restricted stock are forfeited, or if any award terminates, expires or is settled without all or a portion of the shares of common stock covered by the award being issued, such shares are available for the grant of additional awards. However, any shares that are withheld (or delivered) to pay withholding taxes or to pay the exercise price of an option are not available for the grant of additional awards. As of December&#160;31, 2018, under the 2013 Plan, there were options to purchase an aggregate of <ix:nonFraction unitRef="shares" contextRef="ie68e03dfcb1349ea9e266215200f7c25_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90ZXh0cmVnaW9uOmI5MjNjYzI4YTQ4OTQ0ODg5ZWJhNTRkYjU5NTFkNjRhXzM4MjY_fa3dcbc5-4c03-4624-87ab-5398bf52c274">4,527,161</ix:nonFraction> shares of common stock outstanding at a weighted average exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ie68e03dfcb1349ea9e266215200f7c25_I20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90ZXh0cmVnaW9uOmI5MjNjYzI4YTQ4OTQ0ODg5ZWJhNTRkYjU5NTFkNjRhXzM5MDQ_09d2fec4-fae7-4bd2-8af1-532be5fa5483">25.56</ix:nonFraction> per share.</span></div><ix:nonNumeric contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90ZXh0cmVnaW9uOmI5MjNjYzI4YTQ4OTQ0ODg5ZWJhNTRkYjU5NTFkNjRhXzE1OTQyOTE4NjEwNTc2_52d94200-b75a-4552-9b7f-67045a21f3a8" escape="true"><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The following stock-based compensation amounts were recognized for the periods indicated (in thousands):</span></div><div style="margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"><tr><td style="width:1.0%;"></td><td style="width:61.343109%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.730205%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533138%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.730205%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533138%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.730205%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2016</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i080c9b1552014463931d10056bb7ec5b_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90YWJsZTplNGJlNDg5YmU5Yzk0YjUzOWI1NWY5M2RjNWQ0ZDFmNS90YWJsZXJhbmdlOmU0YmU0ODliZTljOTRiNTM5YjU1ZjkzZGM1ZDRkMWY1XzMtMS0xLTEtMA_5daadb42-ecb0-423f-8904-44100e0c1830">7,919</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i69306bd3d52e4181a64ce4721f855103_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90YWJsZTplNGJlNDg5YmU5Yzk0YjUzOWI1NWY5M2RjNWQ0ZDFmNS90YWJsZXJhbmdlOmU0YmU0ODliZTljOTRiNTM5YjU1ZjkzZGM1ZDRkMWY1XzMtMy0xLTEtMA_7412e917-1466-4c3e-9d01-13bfc2e43d5c">7,388</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0d5ecf2823e14c18aa6e251ac3292d51_D20160101-20161231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90YWJsZTplNGJlNDg5YmU5Yzk0YjUzOWI1NWY5M2RjNWQ0ZDFmNS90YWJsZXJhbmdlOmU0YmU0ODliZTljOTRiNTM5YjU1ZjkzZGM1ZDRkMWY1XzMtNS0xLTEtMA_167f1052-42eb-4f99-8c3c-d77d3919c77d">5,778</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">General and administrative&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i39e8ac06cdc74d939adfabe112ffd6a7_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90YWJsZTplNGJlNDg5YmU5Yzk0YjUzOWI1NWY5M2RjNWQ0ZDFmNS90YWJsZXJhbmdlOmU0YmU0ODliZTljOTRiNTM5YjU1ZjkzZGM1ZDRkMWY1XzQtMS0xLTEtMA_5176725b-0065-45a5-a02b-498f13108755">8,601</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0c6d01ca77d7471c9706048782093e73_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90YWJsZTplNGJlNDg5YmU5Yzk0YjUzOWI1NWY5M2RjNWQ0ZDFmNS90YWJsZXJhbmdlOmU0YmU0ODliZTljOTRiNTM5YjU1ZjkzZGM1ZDRkMWY1XzQtMy0xLTEtMA_5470205d-6301-4323-ae2d-981f65b74da3">7,356</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4f0c15f62cd64843837881b925628364_D20160101-20161231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90YWJsZTplNGJlNDg5YmU5Yzk0YjUzOWI1NWY5M2RjNWQ0ZDFmNS90YWJsZXJhbmdlOmU0YmU0ODliZTljOTRiNTM5YjU1ZjkzZGM1ZDRkMWY1XzQtNS0xLTEtMA_a610e328-a651-4a61-852b-9a910de2493c">6,387</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total stock-based compensation expense</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90YWJsZTplNGJlNDg5YmU5Yzk0YjUzOWI1NWY5M2RjNWQ0ZDFmNS90YWJsZXJhbmdlOmU0YmU0ODliZTljOTRiNTM5YjU1ZjkzZGM1ZDRkMWY1XzUtMS0xLTEtMA_efc6d388-aa94-4fc8-b24a-325a9dfdba20">16,520</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90YWJsZTplNGJlNDg5YmU5Yzk0YjUzOWI1NWY5M2RjNWQ0ZDFmNS90YWJsZXJhbmdlOmU0YmU0ODliZTljOTRiNTM5YjU1ZjkzZGM1ZDRkMWY1XzUtMy0xLTEtMA_b83d376b-98fb-44de-b1ba-2aa1f4e4b916">14,744</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iaf5d0e8fdf374dc09283fd669e2ebf19_D20160101-20161231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90YWJsZTplNGJlNDg5YmU5Yzk0YjUzOWI1NWY5M2RjNWQ0ZDFmNS90YWJsZXJhbmdlOmU0YmU0ODliZTljOTRiNTM5YjU1ZjkzZGM1ZDRkMWY1XzUtNS0xLTEtMA_44d88ff9-c8e6-4945-bb6d-bdfd38f61e03">12,165</ix:nonFraction>&#160;</span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Employee Stock Options</span></div><ix:nonNumeric contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90ZXh0cmVnaW9uOmI5MjNjYzI4YTQ4OTQ0ODg5ZWJhNTRkYjU5NTFkNjRhXzE1OTQyOTE4NjEwNTc3_1b4e803f-411a-4b3e-8186-16b4f89b0ec1" escape="true"><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model using the assumptions in the following table:</span></div><div style="margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"><tr><td style="width:1.0%;"></td><td style="width:61.343109%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.730205%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533138%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.730205%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533138%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.730205%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2016</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected dividend yield</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90YWJsZTplNGJmMTc5OWVmYWM0NjVkOTRiYWI5ZWE1ZDRkMWVlNS90YWJsZXJhbmdlOmU0YmYxNzk5ZWZhYzQ2NWQ5NGJhYjllYTVkNGQxZWU1XzItMS0xLTEtMA_eee94b73-b3bb-4ef3-bc75-70005328f53c">0</ix:nonFraction>%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90YWJsZTplNGJmMTc5OWVmYWM0NjVkOTRiYWI5ZWE1ZDRkMWVlNS90YWJsZXJhbmdlOmU0YmYxNzk5ZWZhYzQ2NWQ5NGJhYjllYTVkNGQxZWU1XzItMy0xLTEtMA_e8e2beea-ed20-4843-8b86-113c0a904d30">0</ix:nonFraction>%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="iaf5d0e8fdf374dc09283fd669e2ebf19_D20160101-20161231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90YWJsZTplNGJmMTc5OWVmYWM0NjVkOTRiYWI5ZWE1ZDRkMWVlNS90YWJsZXJhbmdlOmU0YmYxNzk5ZWZhYzQ2NWQ5NGJhYjllYTVkNGQxZWU1XzItNS0xLTEtMA_ae47d61a-c93a-45fe-8e1a-8c72e509ced2">0</ix:nonFraction>%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected volatility</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">68% - 72%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">67% - 68%</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">64% - 69%</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Risk-free interest rate</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2.4% - 3.1%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1.9% - 2.3%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1.2% - 2.4%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected term</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90YWJsZTplNGJmMTc5OWVmYWM0NjVkOTRiYWI5ZWE1ZDRkMWVlNS90YWJsZXJhbmdlOmU0YmYxNzk5ZWZhYzQ2NWQ5NGJhYjllYTVkNGQxZWU1XzUtMS0xLTEtMA_326baf22-02dc-4142-90bf-9d66779903f4">6.25</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90YWJsZTplNGJmMTc5OWVmYWM0NjVkOTRiYWI5ZWE1ZDRkMWVlNS90YWJsZXJhbmdlOmU0YmYxNzk5ZWZhYzQ2NWQ5NGJhYjllYTVkNGQxZWU1XzUtMy0xLTEtMA_ac99f4c0-e593-4f7b-b7bc-8910b19606c4">6.25</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="iaf5d0e8fdf374dc09283fd669e2ebf19_D20160101-20161231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90YWJsZTplNGJmMTc5OWVmYWM0NjVkOTRiYWI5ZWE1ZDRkMWVlNS90YWJsZXJhbmdlOmU0YmYxNzk5ZWZhYzQ2NWQ5NGJhYjllYTVkNGQxZWU1XzUtNS0xLTEtMA_e86b0c4d-7758-4300-a010-be62409d3ddb">6.25</ix:nonNumeric> years</span></td></tr></table></div></ix:nonNumeric><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">Expected Dividend Yield</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> &#8211; The Company has never declared or paid dividends and has no plans to do so in the foreseeable future.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">Expected Volatility</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> &#8211; Volatility is a measure of the amount by which a financial variable such as a share price has fluctuated (historical volatility) or is expected to fluctuate (expected volatility) during a period.&#160;&#160;As the Company does not yet have sufficient history of its own volatility, the Company has identified several public entities of similar size, complexity and stage of development and estimates volatility based on the volatility of these companies.</span></div></ix:continuation><div style="text-indent:36pt;margin-bottom:9pt;"></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">F - 16</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="iee5b82ed60274881977f2fc6a4526f56"><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">Risk-Free Interest Rate</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> &#8211; This is the U.S. Treasury rate for the week of each option grant during the year, having a term that most closely resembles the expected life of the option.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">Expected Term</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> &#8211; This is the period of time that the options granted are expected to remain unexercised. Options granted have a maximum term of <ix:nonNumeric contextRef="i4cee00b7a03d43ceb837d6f99f3c2a60_D20180101-20181231" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90ZXh0cmVnaW9uOmI5MjNjYzI4YTQ4OTQ0ODg5ZWJhNTRkYjU5NTFkNjRhXzUxMzk_076fbb78-8d1e-410a-a55b-719803b79a4b">ten years</ix:nonNumeric>. The Company uses a simplified method to calculate the average expected term.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">In addition to the assumptions above, the Company estimates the forfeiture rate based on turnover data with further consideration given to the class of the employees to whom the options were granted.&#160;&#160;The forfeiture rate is the estimated percentage of options granted that is expected to be forfeited or canceled on an annual basis before becoming fully vested.</span></div><ix:nonNumeric contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" name="mgnx:ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90ZXh0cmVnaW9uOmI5MjNjYzI4YTQ4OTQ0ODg5ZWJhNTRkYjU5NTFkNjRhXzE1OTQyOTE4NjEwNTc4_0f4c68ba-e487-4c98-b96b-ded6ff2512e4" escape="true"><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The following table summarizes stock option activity for 2018:</span></div><div style="margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"><tr><td style="width:1.0%;"></td><td style="width:48.807636%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.747430%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534214%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.747430%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534214%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.747430%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534214%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.747430%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Weighted-Average</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Exercise Price</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Weighted-Average</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Remaining</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Contractual Term</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">(Years)</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Aggregate Intrinsic Value</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">(in thousands)</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding, December 31, 2017</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i7057397719af459ca7328a1c440a0efa_I20171231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90YWJsZTo5ZWE1OTM0ZjYzOWI0ZGNmOTJlMTE5NWQxMzZhYzY1Ny90YWJsZXJhbmdlOjllYTU5MzRmNjM5YjRkY2Y5MmUxMTk1ZDEzNmFjNjU3XzEtMS0xLTEtMA_65bec360-499c-4acb-8485-29ead08b12ae">4,504,642</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i7057397719af459ca7328a1c440a0efa_I20171231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90YWJsZTo5ZWE1OTM0ZjYzOWI0ZGNmOTJlMTE5NWQxMzZhYzY1Ny90YWJsZXJhbmdlOjllYTU5MzRmNjM5YjRkY2Y5MmUxMTk1ZDEzNmFjNjU3XzEtMy0xLTEtMA_3383bfd8-28ce-4793-a4cb-52fef72db918">19.79</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90YWJsZTo5ZWE1OTM0ZjYzOWI0ZGNmOTJlMTE5NWQxMzZhYzY1Ny90YWJsZXJhbmdlOjllYTU5MzRmNjM5YjRkY2Y5MmUxMTk1ZDEzNmFjNjU3XzEtNS0xLTEtMA_1cc2aed6-7348-4fe3-aeff-f458ef9a1aa8">7.0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Granted</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90YWJsZTo5ZWE1OTM0ZjYzOWI0ZGNmOTJlMTE5NWQxMzZhYzY1Ny90YWJsZXJhbmdlOjllYTU5MzRmNjM5YjRkY2Y5MmUxMTk1ZDEzNmFjNjU3XzItMS0xLTEtMA_ae74c6a7-19a7-4094-aee2-5649b9a14bd1">1,269,844</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90YWJsZTo5ZWE1OTM0ZjYzOWI0ZGNmOTJlMTE5NWQxMzZhYzY1Ny90YWJsZXJhbmdlOjllYTU5MzRmNjM5YjRkY2Y5MmUxMTk1ZDEzNmFjNjU3XzItMy0xLTEtMA_8cf0393b-fd61-48b0-a3cf-e39845fa6cda">27.18</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Options exercised</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90YWJsZTo5ZWE1OTM0ZjYzOWI0ZGNmOTJlMTE5NWQxMzZhYzY1Ny90YWJsZXJhbmdlOjllYTU5MzRmNjM5YjRkY2Y5MmUxMTk1ZDEzNmFjNjU3XzMtMS0xLTEtMA_607aab0e-4778-4fbe-9021-e7777cb79db8">285,432</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90YWJsZTo5ZWE1OTM0ZjYzOWI0ZGNmOTJlMTE5NWQxMzZhYzY1Ny90YWJsZXJhbmdlOjllYTU5MzRmNjM5YjRkY2Y5MmUxMTk1ZDEzNmFjNjU3XzMtMy0xLTEtMA_32b72eb0-9356-46fb-a13f-b9055a004d4b">4.22</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Forfeited or expired</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90YWJsZTo5ZWE1OTM0ZjYzOWI0ZGNmOTJlMTE5NWQxMzZhYzY1Ny90YWJsZXJhbmdlOjllYTU5MzRmNjM5YjRkY2Y5MmUxMTk1ZDEzNmFjNjU3XzQtMS0xLTEtMA_f0c11b58-2a51-43c5-b9d0-b77d3485f314">215,090</ix:nonFraction>)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90YWJsZTo5ZWE1OTM0ZjYzOWI0ZGNmOTJlMTE5NWQxMzZhYzY1Ny90YWJsZXJhbmdlOjllYTU5MzRmNjM5YjRkY2Y5MmUxMTk1ZDEzNmFjNjU3XzQtMy0xLTEtMA_81d62785-576e-4dcd-928f-6e76ad444c4a">24.43</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding, December 31, 2018</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90YWJsZTo5ZWE1OTM0ZjYzOWI0ZGNmOTJlMTE5NWQxMzZhYzY1Ny90YWJsZXJhbmdlOjllYTU5MzRmNjM5YjRkY2Y5MmUxMTk1ZDEzNmFjNjU3XzUtMS0xLTEtMA_a02696da-dd19-4ca6-ba17-812c878babba">5,273,964</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90YWJsZTo5ZWE1OTM0ZjYzOWI0ZGNmOTJlMTE5NWQxMzZhYzY1Ny90YWJsZXJhbmdlOjllYTU5MzRmNjM5YjRkY2Y5MmUxMTk1ZDEzNmFjNjU3XzUtMy0xLTEtMA_c842b2a2-77cb-4efd-96db-fff9b85a520a">22.23</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90YWJsZTo5ZWE1OTM0ZjYzOWI0ZGNmOTJlMTE5NWQxMzZhYzY1Ny90YWJsZXJhbmdlOjllYTU5MzRmNjM5YjRkY2Y5MmUxMTk1ZDEzNmFjNjU3XzUtNS0xLTEtMA_04901d3f-9017-4f95-b162-615e3ce53491">6.8</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90YWJsZTo5ZWE1OTM0ZjYzOWI0ZGNmOTJlMTE5NWQxMzZhYzY1Ny90YWJsZXJhbmdlOjllYTU5MzRmNjM5YjRkY2Y5MmUxMTk1ZDEzNmFjNjU3XzUtNy0xLTEtMA_d9aa3357-043a-4b52-bb07-24d7ba23f729">7,969</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2018:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Exercisable</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90YWJsZTo5ZWE1OTM0ZjYzOWI0ZGNmOTJlMTE5NWQxMzZhYzY1Ny90YWJsZXJhbmdlOjllYTU5MzRmNjM5YjRkY2Y5MmUxMTk1ZDEzNmFjNjU3XzgtMS0xLTEtMA_cd46334b-efe6-4761-b1c6-44a6b70a46dc">3,544,139</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90YWJsZTo5ZWE1OTM0ZjYzOWI0ZGNmOTJlMTE5NWQxMzZhYzY1Ny90YWJsZXJhbmdlOjllYTU5MzRmNjM5YjRkY2Y5MmUxMTk1ZDEzNmFjNjU3XzgtMy0xLTEtMA_dd159f59-3cd0-4d65-8fa8-bb519f28cf8d">20.60</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90YWJsZTo5ZWE1OTM0ZjYzOWI0ZGNmOTJlMTE5NWQxMzZhYzY1Ny90YWJsZXJhbmdlOjllYTU5MzRmNjM5YjRkY2Y5MmUxMTk1ZDEzNmFjNjU3XzgtNS0xLTEtMA_6a1fa66f-7dc6-4cb7-b6ab-2431a39dae26">5.9</ix:nonNumeric></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90YWJsZTo5ZWE1OTM0ZjYzOWI0ZGNmOTJlMTE5NWQxMzZhYzY1Ny90YWJsZXJhbmdlOjllYTU5MzRmNjM5YjRkY2Y5MmUxMTk1ZDEzNmFjNjU3XzgtNy0xLTEtMA_955049f2-260d-4477-abfc-5675114fcce0">7,969</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Vested and expected to vest</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90YWJsZTo5ZWE1OTM0ZjYzOWI0ZGNmOTJlMTE5NWQxMzZhYzY1Ny90YWJsZXJhbmdlOjllYTU5MzRmNjM5YjRkY2Y5MmUxMTk1ZDEzNmFjNjU3XzktMS0xLTEtMA_a121c927-ff7d-4828-ad4f-9d6f779c3f87">5,086,009</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90YWJsZTo5ZWE1OTM0ZjYzOWI0ZGNmOTJlMTE5NWQxMzZhYzY1Ny90YWJsZXJhbmdlOjllYTU5MzRmNjM5YjRkY2Y5MmUxMTk1ZDEzNmFjNjU3XzktMy0xLTEtMA_99227824-6ebd-4a3d-a1fd-c4dde6f10dbd">22.10</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90YWJsZTo5ZWE1OTM0ZjYzOWI0ZGNmOTJlMTE5NWQxMzZhYzY1Ny90YWJsZXJhbmdlOjllYTU5MzRmNjM5YjRkY2Y5MmUxMTk1ZDEzNmFjNjU3XzktNS0xLTEtMA_d03462e9-564b-42ec-ac2a-f746fefe356a">6.7</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90YWJsZTo5ZWE1OTM0ZjYzOWI0ZGNmOTJlMTE5NWQxMzZhYzY1Ny90YWJsZXJhbmdlOjllYTU5MzRmNjM5YjRkY2Y5MmUxMTk1ZDEzNmFjNjU3XzktNy0xLTEtMA_431f338a-a247-466b-ae2b-7ae33b44bd3f">7,969</ix:nonFraction>&#160;</span></td></tr></table></div></ix:nonNumeric><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">During 2018, 2017 and 2016 the Company issued <ix:nonFraction unitRef="shares" contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90ZXh0cmVnaW9uOmI5MjNjYzI4YTQ4OTQ0ODg5ZWJhNTRkYjU5NTFkNjRhXzU3MjA_d363e164-e7e1-4d33-97f2-394e508f3e4c">274,362</ix:nonFraction>, <ix:nonFraction unitRef="shares" contextRef="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90ZXh0cmVnaW9uOmI5MjNjYzI4YTQ4OTQ0ODg5ZWJhNTRkYjU5NTFkNjRhXzU3MjQ_ce0d48cf-53c3-4383-8ec6-d93c8b2b4dd7">253,036</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="iaf5d0e8fdf374dc09283fd669e2ebf19_D20160101-20161231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90ZXh0cmVnaW9uOmI5MjNjYzI4YTQ4OTQ0ODg5ZWJhNTRkYjU5NTFkNjRhXzU3MzE_040c7c50-8f3e-4819-b2fd-5ed2056a2c68">526,715</ix:nonFraction> net shares of common stock, respectively, in conjunction with stock option exercises.&#160;&#160;The Company received cash proceeds from the exercise of stock options of approximately $<ix:nonFraction unitRef="usd" contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90ZXh0cmVnaW9uOmI5MjNjYzI4YTQ4OTQ0ODg5ZWJhNTRkYjU5NTFkNjRhXzU5MjM_5c37b79b-f01a-405f-9a6b-d484efb2a9ee">0.9</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90ZXh0cmVnaW9uOmI5MjNjYzI4YTQ4OTQ0ODg5ZWJhNTRkYjU5NTFkNjRhXzU5Mjc_9f117940-a6cd-4530-904e-1b161f1beaf6">0.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iaf5d0e8fdf374dc09283fd669e2ebf19_D20160101-20161231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90ZXh0cmVnaW9uOmI5MjNjYzI4YTQ4OTQ0ODg5ZWJhNTRkYjU5NTFkNjRhXzU5MzQ_5ded3c2b-f057-4216-9f18-6bb4e5ac588c">1.9</ix:nonFraction> million during 2018, 2017 and 2016, respectively.</span></div><div style="text-indent:36pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The weighted-average grant-date fair value of options granted during 2018, 2017 and 2016 was $<ix:nonFraction unitRef="usdPerShare" contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90ZXh0cmVnaW9uOmI5MjNjYzI4YTQ4OTQ0ODg5ZWJhNTRkYjU5NTFkNjRhXzYwNjE_83259ea1-15c7-4165-8a36-c1f72578bf56">17.90</ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90ZXh0cmVnaW9uOmI5MjNjYzI4YTQ4OTQ0ODg5ZWJhNTRkYjU5NTFkNjRhXzYwNjU_00f7462f-98e4-499f-9607-fe72d3a1c4f6">12.53</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="iaf5d0e8fdf374dc09283fd669e2ebf19_D20160101-20161231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90ZXh0cmVnaW9uOmI5MjNjYzI4YTQ4OTQ0ODg5ZWJhNTRkYjU5NTFkNjRhXzYwNzI_459212ec-6523-4b40-ba3a-4c1d9495569e">15.17</ix:nonFraction> per share, respectively. The total intrinsic value of options exercised during 2018, 2017 and 2016 was approximately $<ix:nonFraction unitRef="usd" contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90ZXh0cmVnaW9uOmI5MjNjYzI4YTQ4OTQ0ODg5ZWJhNTRkYjU5NTFkNjRhXzYxODY_7f9f3c29-6eb4-438d-bacd-4c5f208521cb">5.2</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90ZXh0cmVnaW9uOmI5MjNjYzI4YTQ4OTQ0ODg5ZWJhNTRkYjU5NTFkNjRhXzYxOTA_a8fed63a-5178-4d22-bf91-9af5ea89be71">4.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iaf5d0e8fdf374dc09283fd669e2ebf19_D20160101-20161231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90ZXh0cmVnaW9uOmI5MjNjYzI4YTQ4OTQ0ODg5ZWJhNTRkYjU5NTFkNjRhXzYxOTc_910a6138-e4a8-40fc-8315-3d236b207e38">10.8</ix:nonFraction> million, respectively.&#160;&#160;The total fair value of stock options which vested during 2018, 2017 and 2016 was $<ix:nonFraction unitRef="usd" contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90ZXh0cmVnaW9uOmI5MjNjYzI4YTQ4OTQ0ODg5ZWJhNTRkYjU5NTFkNjRhXzYyOTI_dbbb5697-1c4b-4a4d-a324-34e771ab6fb4">16.4</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90ZXh0cmVnaW9uOmI5MjNjYzI4YTQ4OTQ0ODg5ZWJhNTRkYjU5NTFkNjRhXzYyOTY_1380bdde-b51f-43c2-8020-17f3dc854106">14.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iaf5d0e8fdf374dc09283fd669e2ebf19_D20160101-20161231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90ZXh0cmVnaW9uOmI5MjNjYzI4YTQ4OTQ0ODg5ZWJhNTRkYjU5NTFkNjRhXzYzMDM_938eb0d9-ff75-49c1-9d8b-5e8da8ffaa03">11.6</ix:nonFraction> million, respectively.&#160;&#160;As of December&#160;31, 2018, the total unrecognized compensation expense related to non-vested stock options, net of related forfeiture estimates, was $<ix:nonFraction unitRef="usd" contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90ZXh0cmVnaW9uOmI5MjNjYzI4YTQ4OTQ0ODg5ZWJhNTRkYjU5NTFkNjRhXzY0NjM_19ab1f51-089b-4235-a2be-b4274d3ee210">24.2</ix:nonFraction> million, which the Company expects to recognize over a weighted-average period of approximately <ix:nonNumeric contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90ZXh0cmVnaW9uOmI5MjNjYzI4YTQ4OTQ0ODg5ZWJhNTRkYjU5NTFkNjRhXzY1NTQ_ef378ce7-db3a-4c15-ad95-b157e0df3029">2.6</ix:nonNumeric> years.</span></div></ix:continuation><div style="text-indent:36pt;"><span><br/></span></div><div id="i_0_710"></div><div style="margin-top:3pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">7.&#160;&#160;<ix:nonNumeric contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90ZXh0cmVnaW9uOmI0ZjY4YmIzMzBkMzRkMWZiM2QyZDdiYjQ5YmI3ZWM5XzQ3MzI_7e443723-df68-4078-abfb-132378f36db8" continuedAt="i367986f0166e41039b18568b1dfae561" escape="true">Income Taxes&#160;</ix:nonNumeric></span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"><ix:continuation id="i367986f0166e41039b18568b1dfae561" continuedAt="i627e94cad2cb48bbaffbc74107e67c54">For the years ended December&#160;31, 2018, 2017 and 2016 there was <ix:nonFraction unitRef="usd" contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90ZXh0cmVnaW9uOmI0ZjY4YmIzMzBkMzRkMWZiM2QyZDdiYjQ5YmI3ZWM5XzY2_678d1df5-8681-4ec1-b140-bb5327712ae3">no</ix:nonFraction> provision for income taxes due to taxable losses generated, fully offset by a valuation allowance.</ix:continuation></span></div><div style="text-indent:36pt;margin-bottom:9pt;"></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">F - 17</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="i627e94cad2cb48bbaffbc74107e67c54" continuedAt="i823a032d172843d087616214fb210d8a"><ix:nonNumeric contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90ZXh0cmVnaW9uOmI0ZjY4YmIzMzBkMzRkMWZiM2QyZDdiYjQ5YmI3ZWM5XzE1MzkzMTYyODA2MzMy_6fe35d26-7f37-40c6-931d-3b08eb99e7d3" escape="true"><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The significant components of the Company's deferred income tax assets (liabilities) were as follows (in thousands):</span></div><div style="margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"><tr><td style="width:1.0%;"></td><td style="width:73.806452%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.730205%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533138%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.730205%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred income tax assets:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Federal U.S. net operating loss carryforward</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZTpmMThmN2Q2NTczNGY0NDM3YmY2ZTIzYjg3MzQ3OTVkMi90YWJsZXJhbmdlOmYxOGY3ZDY1NzM0ZjQ0MzdiZjZlMjNiODczNDc5NWQyXzMtMS0xLTEtMA_a8be6003-2dff-4ea7-967a-42c37a62c829">87,284</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7057397719af459ca7328a1c440a0efa_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZTpmMThmN2Q2NTczNGY0NDM3YmY2ZTIzYjg3MzQ3OTVkMi90YWJsZXJhbmdlOmYxOGY3ZDY1NzM0ZjQ0MzdiZjZlMjNiODczNDc5NWQyXzMtMy0xLTEtMA_d95d6bac-f5f4-4d03-a271-5692f3321ca8">50,346</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">State net operating loss carryforward</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZTpmMThmN2Q2NTczNGY0NDM3YmY2ZTIzYjg3MzQ3OTVkMi90YWJsZXJhbmdlOmYxOGY3ZDY1NzM0ZjQ0MzdiZjZlMjNiODczNDc5NWQyXzQtMS0xLTEtMA_92d41715-99dc-46c6-8b7b-523685597171">22,809</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7057397719af459ca7328a1c440a0efa_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZTpmMThmN2Q2NTczNGY0NDM3YmY2ZTIzYjg3MzQ3OTVkMi90YWJsZXJhbmdlOmYxOGY3ZDY1NzM0ZjQ0MzdiZjZlMjNiODczNDc5NWQyXzQtMy0xLTEtMA_070ddf5b-0978-4362-ac5b-1f183e9a437e">7,551</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development credit, net</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZTpmMThmN2Q2NTczNGY0NDM3YmY2ZTIzYjg3MzQ3OTVkMi90YWJsZXJhbmdlOmYxOGY3ZDY1NzM0ZjQ0MzdiZjZlMjNiODczNDc5NWQyXzUtMS0xLTEtMA_18946647-3383-47ab-8d89-35a17572332c">29,750</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7057397719af459ca7328a1c440a0efa_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZTpmMThmN2Q2NTczNGY0NDM3YmY2ZTIzYjg3MzQ3OTVkMi90YWJsZXJhbmdlOmYxOGY3ZDY1NzM0ZjQ0MzdiZjZlMjNiODczNDc5NWQyXzUtMy0xLTEtMA_515e01df-67d9-410d-88d0-e09cc314f681">21,284</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Orphan drug credit, net</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZTpmMThmN2Q2NTczNGY0NDM3YmY2ZTIzYjg3MzQ3OTVkMi90YWJsZXJhbmdlOmYxOGY3ZDY1NzM0ZjQ0MzdiZjZlMjNiODczNDc5NWQyXzYtMS0xLTEtMA_c4c53c69-cd7d-4bc3-bde8-60489a74ef33">22,580</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7057397719af459ca7328a1c440a0efa_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZTpmMThmN2Q2NTczNGY0NDM3YmY2ZTIzYjg3MzQ3OTVkMi90YWJsZXJhbmdlOmYxOGY3ZDY1NzM0ZjQ0MzdiZjZlMjNiODczNDc5NWQyXzYtMy0xLTEtMA_ce719036-9feb-4612-a5a9-07f4bc913281">21,708</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred rent</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZTpmMThmN2Q2NTczNGY0NDM3YmY2ZTIzYjg3MzQ3OTVkMi90YWJsZXJhbmdlOmYxOGY3ZDY1NzM0ZjQ0MzdiZjZlMjNiODczNDc5NWQyXzctMS0xLTEtMA_2f652e7a-8e71-4bf3-a987-22840f8d13c1">3,118</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7057397719af459ca7328a1c440a0efa_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZTpmMThmN2Q2NTczNGY0NDM3YmY2ZTIzYjg3MzQ3OTVkMi90YWJsZXJhbmdlOmYxOGY3ZDY1NzM0ZjQ0MzdiZjZlMjNiODczNDc5NWQyXzctMy0xLTEtMA_65856730-84e5-43be-b4f4-1a0b98e57acd">3,385</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred revenue</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsDeferredIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZTpmMThmN2Q2NTczNGY0NDM3YmY2ZTIzYjg3MzQ3OTVkMi90YWJsZXJhbmdlOmYxOGY3ZDY1NzM0ZjQ0MzdiZjZlMjNiODczNDc5NWQyXzgtMS0xLTEtMA_67f673c9-bd5f-4f37-9a44-f8df008feb12">3,736</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7057397719af459ca7328a1c440a0efa_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsDeferredIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZTpmMThmN2Q2NTczNGY0NDM3YmY2ZTIzYjg3MzQ3OTVkMi90YWJsZXJhbmdlOmYxOGY3ZDY1NzM0ZjQ0MzdiZjZlMjNiODczNDc5NWQyXzgtMy0xLTEtMA_d1ecd77f-28d6-4260-8b44-dca4437384ec">2,982</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Depreciation</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZTpmMThmN2Q2NTczNGY0NDM3YmY2ZTIzYjg3MzQ3OTVkMi90YWJsZXJhbmdlOmYxOGY3ZDY1NzM0ZjQ0MzdiZjZlMjNiODczNDc5NWQyXzktMS0xLTEtMA_feb33eab-95e4-4f6d-8145-2ce7b0068f9a">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7057397719af459ca7328a1c440a0efa_I20171231" decimals="-3" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZTpmMThmN2Q2NTczNGY0NDM3YmY2ZTIzYjg3MzQ3OTVkMi90YWJsZXJhbmdlOmYxOGY3ZDY1NzM0ZjQ0MzdiZjZlMjNiODczNDc5NWQyXzktMy0xLTEtMA_1575f622-94ad-49dc-afb9-3214a0593f6c">155</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZTpmMThmN2Q2NTczNGY0NDM3YmY2ZTIzYjg3MzQ3OTVkMi90YWJsZXJhbmdlOmYxOGY3ZDY1NzM0ZjQ0MzdiZjZlMjNiODczNDc5NWQyXzEwLTEtMS0xLTA_2c69d4c6-8729-4359-8f19-ddc06d3f9af5">6,854</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7057397719af459ca7328a1c440a0efa_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZTpmMThmN2Q2NTczNGY0NDM3YmY2ZTIzYjg3MzQ3OTVkMi90YWJsZXJhbmdlOmYxOGY3ZDY1NzM0ZjQ0MzdiZjZlMjNiODczNDc5NWQyXzEwLTMtMS0xLTA_860b4f5c-4243-498c-b8de-bcef6e3a9d0c">5,847</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross deferred income tax assets</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZTpmMThmN2Q2NTczNGY0NDM3YmY2ZTIzYjg3MzQ3OTVkMi90YWJsZXJhbmdlOmYxOGY3ZDY1NzM0ZjQ0MzdiZjZlMjNiODczNDc5NWQyXzExLTEtMS0xLTA_e8809f42-69a8-4919-a052-524ce807d64e">176,131</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7057397719af459ca7328a1c440a0efa_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZTpmMThmN2Q2NTczNGY0NDM3YmY2ZTIzYjg3MzQ3OTVkMi90YWJsZXJhbmdlOmYxOGY3ZDY1NzM0ZjQ0MzdiZjZlMjNiODczNDc5NWQyXzExLTMtMS0xLTA_1400bcc9-1f86-4da9-872d-12e4cc3034f8">113,258</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Valuation allowance</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZTpmMThmN2Q2NTczNGY0NDM3YmY2ZTIzYjg3MzQ3OTVkMi90YWJsZXJhbmdlOmYxOGY3ZDY1NzM0ZjQ0MzdiZjZlMjNiODczNDc5NWQyXzEyLTEtMS0xLTA_34ee440b-615e-43f7-8bd6-80d569a55159">172,457</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i7057397719af459ca7328a1c440a0efa_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZTpmMThmN2Q2NTczNGY0NDM3YmY2ZTIzYjg3MzQ3OTVkMi90YWJsZXJhbmdlOmYxOGY3ZDY1NzM0ZjQ0MzdiZjZlMjNiODczNDc5NWQyXzEyLTMtMS0xLTA_07ccff5a-1b96-4f28-8943-bd3c95a375ff">112,453</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Net deferred income tax assets</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZTpmMThmN2Q2NTczNGY0NDM3YmY2ZTIzYjg3MzQ3OTVkMi90YWJsZXJhbmdlOmYxOGY3ZDY1NzM0ZjQ0MzdiZjZlMjNiODczNDc5NWQyXzEzLTEtMS0xLTA_69fdb66a-4754-42a2-9efc-b3afda12050f">3,674</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7057397719af459ca7328a1c440a0efa_I20171231" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZTpmMThmN2Q2NTczNGY0NDM3YmY2ZTIzYjg3MzQ3OTVkMi90YWJsZXJhbmdlOmYxOGY3ZDY1NzM0ZjQ0MzdiZjZlMjNiODczNDc5NWQyXzEzLTMtMS0xLTA_ce5c49bb-6a07-4721-b7b3-8ec1f6d41b5b">805</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred income tax liabilities:</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Depreciation</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZTpmMThmN2Q2NTczNGY0NDM3YmY2ZTIzYjg3MzQ3OTVkMi90YWJsZXJhbmdlOmYxOGY3ZDY1NzM0ZjQ0MzdiZjZlMjNiODczNDc5NWQyXzE2LTEtMS0xLTM5NzE_fde696d3-c6bf-4a97-9f86-dd65e0d6fdd9">1,911</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7057397719af459ca7328a1c440a0efa_I20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZTpmMThmN2Q2NTczNGY0NDM3YmY2ZTIzYjg3MzQ3OTVkMi90YWJsZXJhbmdlOmYxOGY3ZDY1NzM0ZjQ0MzdiZjZlMjNiODczNDc5NWQyXzE2LTMtMS0xLTM5NzE_9c88bb2c-c437-426a-9e80-05dc5c7fe622">&#8212;</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid expenditures</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesPrepaidExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZTpmMThmN2Q2NTczNGY0NDM3YmY2ZTIzYjg3MzQ3OTVkMi90YWJsZXJhbmdlOmYxOGY3ZDY1NzM0ZjQ0MzdiZjZlMjNiODczNDc5NWQyXzE2LTEtMS0xLTA_ae0d8604-d46f-4134-901f-f8e4572768b3">1,763</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i7057397719af459ca7328a1c440a0efa_I20171231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPrepaidExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZTpmMThmN2Q2NTczNGY0NDM3YmY2ZTIzYjg3MzQ3OTVkMi90YWJsZXJhbmdlOmYxOGY3ZDY1NzM0ZjQ0MzdiZjZlMjNiODczNDc5NWQyXzE2LTMtMS0xLTA_437f7314-1e03-4bc0-9e4b-5a0db74cc2da">805</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross deferred income tax liabilities</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZTpmMThmN2Q2NTczNGY0NDM3YmY2ZTIzYjg3MzQ3OTVkMi90YWJsZXJhbmdlOmYxOGY3ZDY1NzM0ZjQ0MzdiZjZlMjNiODczNDc5NWQyXzE3LTEtMS0xLTA_0ff69b22-9e97-474e-8d09-ee7ba9c6fa74">3,674</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i7057397719af459ca7328a1c440a0efa_I20171231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZTpmMThmN2Q2NTczNGY0NDM3YmY2ZTIzYjg3MzQ3OTVkMi90YWJsZXJhbmdlOmYxOGY3ZDY1NzM0ZjQ0MzdiZjZlMjNiODczNDc5NWQyXzE3LTMtMS0xLTA_ed5a9632-8448-43fe-a640-cb62444dd7f4">805</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Net deferred income tax asset/(liability)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZTpmMThmN2Q2NTczNGY0NDM3YmY2ZTIzYjg3MzQ3OTVkMi90YWJsZXJhbmdlOmYxOGY3ZDY1NzM0ZjQ0MzdiZjZlMjNiODczNDc5NWQyXzE4LTEtMS0xLTA_07fdba8e-3da2-4201-bbbd-e7ccecbad5e1">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7057397719af459ca7328a1c440a0efa_I20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZTpmMThmN2Q2NTczNGY0NDM3YmY2ZTIzYjg3MzQ3OTVkMi90YWJsZXJhbmdlOmYxOGY3ZDY1NzM0ZjQ0MzdiZjZlMjNiODczNDc5NWQyXzE4LTMtMS0xLTA_82cd9ed8-f75c-4175-94e5-b6963b1497dd">&#8212;</ix:nonFraction>&#160;</span></td></tr></table></div></ix:nonNumeric><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">The Company recognizes valuation allowances to reduce deferred tax assets to the amount that is more likely than not to be realized. In assessing the likelihood of realization, management considers (i) future reversals of existing taxable temporary differences; (ii) future taxable income exclusive of reversing temporary difference and carryforwards; (iii) taxable income in prior carryback years if carryback is permitted under applicable tax law; and (iv) tax planning strategies. The Company's net deferred income tax asset is not more likely than not to be utilized due to the lack of sufficient sources of future taxable income and cumulative book losses which have resulted over the years. </span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">As of December&#160;31, 2018, the Company has U.S. federal and state net operating loss (NOL) carryforwards of approximately $<ix:nonFraction unitRef="usd" contextRef="i109fced96e334bd2802e9cb0d4aa822f_I20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90ZXh0cmVnaW9uOmI0ZjY4YmIzMzBkMzRkMWZiM2QyZDdiYjQ5YmI3ZWM5XzEyOTA_1689e4ab-08e2-44f1-967f-95445a4c6aaa">415.6</ix:nonFraction> million.  Of these NOLs, $<ix:nonFraction unitRef="usd" contextRef="if3a4a990231244d6b62fcda57ef5cfdb_I20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90ZXh0cmVnaW9uOmI0ZjY4YmIzMzBkMzRkMWZiM2QyZDdiYjQ5YmI3ZWM5XzI3NDg3NzkwODMzNTY_1fbfbcde-0240-467c-81b9-6d1f50e44b78">237.8</ix:nonFraction> million&#160;will expire in various years beginning in 2025 through 2037. $<ix:nonFraction unitRef="usd" contextRef="icbf9b06e7c13465a9c3facc8db2be168_I20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90ZXh0cmVnaW9uOmI0ZjY4YmIzMzBkMzRkMWZiM2QyZDdiYjQ5YmI3ZWM5XzI3NDg3NzkwODMzNzI_75776794-bb02-40eb-b0ec-7659aea3a3ff">177.8</ix:nonFraction> million of NOLs were generated post&#160;December 31, 2017 and carryforward indefinitely.  In addition, the Company has U.S. federal tax credits of $<ix:nonFraction unitRef="usd" contextRef="iea603775d4f04ce4a2e3d875e241c0c8_I20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90ZXh0cmVnaW9uOmI0ZjY4YmIzMzBkMzRkMWZiM2QyZDdiYjQ5YmI3ZWM5XzE0MTI_19219829-c2a9-434e-a6b1-2373352aa4c7">52.3</ix:nonFraction> million which will expire in various years beginning in 2022 through 2038.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The use of the Company's U.S. federal NOL and tax credit carryforwards in future years are restricted due to changes in the Company's ownership and tax attributes acquired through the Company's acquisitions. As of December&#160;31, 2018, $<ix:nonFraction unitRef="usd" contextRef="i62c4c7c8c31a462dab6a1676f99a1b7c_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="mgnx:OperatingLossCarryforwardsLimitationsOnUseAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90ZXh0cmVnaW9uOmI0ZjY4YmIzMzBkMzRkMWZiM2QyZDdiYjQ5YmI3ZWM5XzE2OTc_cefeb950-b77d-4801-b62f-509ecd6d6274">13.5</ix:nonFraction> million of the Company's U.S. Federal NOLs are limited for use over the years 2019 &#8211; 2028 in which a range of such amounts could be utilized on an annual basis of $<ix:nonFraction unitRef="usd" contextRef="i0986b0c4e51f4d2cb580f8bcf9218691_I20181231" decimals="-5" format="ixt:numdotdecimal" name="mgnx:OperatingLossCarryforwardsAnnualLimitationAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90ZXh0cmVnaW9uOmI0ZjY4YmIzMzBkMzRkMWZiM2QyZDdiYjQ5YmI3ZWM5XzE4NTE_273b54fa-12a1-4ddf-aa9c-702276583d2f">0.2</ix:nonFraction> million to $<ix:nonFraction unitRef="usd" contextRef="i0229ee301314485e8d01bc8ad76d9aca_I20181231" decimals="-5" format="ixt:numdotdecimal" name="mgnx:OperatingLossCarryforwardsAnnualLimitationAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90ZXh0cmVnaW9uOmI0ZjY4YmIzMzBkMzRkMWZiM2QyZDdiYjQ5YmI3ZWM5XzE4NTc_e99d8dfe-16b5-4c1b-a1ac-4d06627ce4dc">1.4</ix:nonFraction> million. The remaining $<ix:nonFraction unitRef="usd" contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231" decimals="-5" format="ixt:numdotdecimal" name="mgnx:OperatingLossCarryforwardsNotSubjectToLimitation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90ZXh0cmVnaW9uOmI0ZjY4YmIzMzBkMzRkMWZiM2QyZDdiYjQ5YmI3ZWM5XzE4NzU_ddab8cb1-4ec5-4712-ad48-44b93852b555">402.1</ix:nonFraction> million of NOLs is not limited and can be offset against future taxable income, subject to certain limitations for newly enacted tax legislation.  The Company adopted ASU 2016-09 as of January 1, 2017.  Accordingly, the Company recognized the previously unrecognized excess tax benefits of approximately $<ix:nonFraction unitRef="usd" contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90ZXh0cmVnaW9uOmI0ZjY4YmIzMzBkMzRkMWZiM2QyZDdiYjQ5YmI3ZWM5XzIxNzQ_b4295b09-c5d1-4a94-afae-8da18d384a32">18.6</ix:nonFraction> million ($<ix:nonFraction unitRef="usd" contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="mgnx:EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTaxBenefitTaxEffectedAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90ZXh0cmVnaW9uOmI0ZjY4YmIzMzBkMzRkMWZiM2QyZDdiYjQ5YmI3ZWM5XzIxNzg_86732701-175b-4d1e-870d-a090b4c0764f">6.5</ix:nonFraction> million tax effected) recorded as deferred tax assets with a corresponding offsetting full valuation allowance at the beginning of 2017 without any tax impact.&#160;&#160;</span></div></ix:continuation><div style="text-indent:36pt;margin-bottom:9pt;"></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">F - 18</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="i823a032d172843d087616214fb210d8a" continuedAt="i753315afa3a54f6e85b77226f98b5ffd"><ix:nonNumeric contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90ZXh0cmVnaW9uOmI0ZjY4YmIzMzBkMzRkMWZiM2QyZDdiYjQ5YmI3ZWM5XzE1MzkzMTYyODA2MzMz_2806e6a0-707b-4e8a-a8a2-e1f117fabdf2" escape="true"><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The reconciliation of the reported estimated income tax benefit to the amount that would result by applying the U.S. federal statutory tax rate to the net income is as follows (in thousands):</span></div><div style="margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"><tr><td style="width:1.0%;"></td><td style="width:61.343109%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.730205%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533138%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.730205%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533138%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.730205%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2016</span></td></tr><tr><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">United States federal tax at statutory rate</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZToxMDU3OWFjNGM4OGM0YzkwOWYxMDY1YjY4ODRhNTVlMS90YWJsZXJhbmdlOjEwNTc5YWM0Yzg4YzRjOTA5ZjEwNjViNjg4NGE1NWUxXzMtMS0xLTEtMA_4e4bcc17-4f00-4a0b-90dc-e60e5e9111d7">36,005</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZToxMDU3OWFjNGM4OGM0YzkwOWYxMDY1YjY4ODRhNTVlMS90YWJsZXJhbmdlOjEwNTc5YWM0Yzg4YzRjOTA5ZjEwNjViNjg4NGE1NWUxXzMtMy0xLTEtMA_6612c2c3-e399-411a-bafa-c344d70ad76f">6,869</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iaf5d0e8fdf374dc09283fd669e2ebf19_D20160101-20161231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZToxMDU3OWFjNGM4OGM0YzkwOWYxMDY1YjY4ODRhNTVlMS90YWJsZXJhbmdlOjEwNTc5YWM0Yzg4YzRjOTA5ZjEwNjViNjg4NGE1NWUxXzMtNS0xLTEtMA_7bb06b38-19b8-4ebe-b8a1-b3e817b3659f">20,489</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">State taxes (net of federal benefit)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZToxMDU3OWFjNGM4OGM0YzkwOWYxMDY1YjY4ODRhNTVlMS90YWJsZXJhbmdlOjEwNTc5YWM0Yzg4YzRjOTA5ZjEwNjViNjg4NGE1NWUxXzQtMS0xLTEtMA_f3050192-c29d-4eab-b57c-cd2ea294d323">11,133</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZToxMDU3OWFjNGM4OGM0YzkwOWYxMDY1YjY4ODRhNTVlMS90YWJsZXJhbmdlOjEwNTc5YWM0Yzg4YzRjOTA5ZjEwNjViNjg4NGE1NWUxXzQtMy0xLTEtMA_e3b6aa8f-1929-4a40-8eec-4b9a407c2c45">735</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iaf5d0e8fdf374dc09283fd669e2ebf19_D20160101-20161231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZToxMDU3OWFjNGM4OGM0YzkwOWYxMDY1YjY4ODRhNTVlMS90YWJsZXJhbmdlOjEwNTc5YWM0Yzg4YzRjOTA5ZjEwNjViNjg4NGE1NWUxXzQtNS0xLTEtMA_1a41c4ce-7d3e-4684-8cfb-6a5a22e6b0ba">3,116</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred income tax adjustments</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="mgnx:EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZToxMDU3OWFjNGM4OGM0YzkwOWYxMDY1YjY4ODRhNTVlMS90YWJsZXJhbmdlOjEwNTc5YWM0Yzg4YzRjOTA5ZjEwNjViNjg4NGE1NWUxXzUtMS0xLTEtMA_699999ae-850f-479f-bc45-a0d5cc0d488d">4,435</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231" decimals="-3" name="mgnx:EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZToxMDU3OWFjNGM4OGM0YzkwOWYxMDY1YjY4ODRhNTVlMS90YWJsZXJhbmdlOjEwNTc5YWM0Yzg4YzRjOTA5ZjEwNjViNjg4NGE1NWUxXzUtMy0xLTEtMA_3be9d29c-f54e-47f6-af24-2a23904a3091">607</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iaf5d0e8fdf374dc09283fd669e2ebf19_D20160101-20161231" decimals="-3" name="mgnx:EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZToxMDU3OWFjNGM4OGM0YzkwOWYxMDY1YjY4ODRhNTVlMS90YWJsZXJhbmdlOjEwNTc5YWM0Yzg4YzRjOTA5ZjEwNjViNjg4NGE1NWUxXzUtNS0xLTEtMA_54a3fdb2-635d-4b03-b029-3b6e11f99d0f">173</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred state blended rate adjustments</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="mgnx:EffectiveIncomeTaxReconciliationStateDeferredTaxesAdjustmentsAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZToxMDU3OWFjNGM4OGM0YzkwOWYxMDY1YjY4ODRhNTVlMS90YWJsZXJhbmdlOjEwNTc5YWM0Yzg4YzRjOTA5ZjEwNjViNjg4NGE1NWUxXzYtMS0xLTEtMA_26a94562-a0fd-4c09-8a40-0e8575c7c38e">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231" decimals="-3" name="mgnx:EffectiveIncomeTaxReconciliationStateDeferredTaxesAdjustmentsAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZToxMDU3OWFjNGM4OGM0YzkwOWYxMDY1YjY4ODRhNTVlMS90YWJsZXJhbmdlOjEwNTc5YWM0Yzg4YzRjOTA5ZjEwNjViNjg4NGE1NWUxXzYtMy0xLTEtMA_30c1b089-4f95-40d9-b57d-c2c001db3210">485</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iaf5d0e8fdf374dc09283fd669e2ebf19_D20160101-20161231" decimals="-3" name="mgnx:EffectiveIncomeTaxReconciliationStateDeferredTaxesAdjustmentsAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZToxMDU3OWFjNGM4OGM0YzkwOWYxMDY1YjY4ODRhNTVlMS90YWJsZXJhbmdlOjEwNTc5YWM0Yzg4YzRjOTA5ZjEwNjViNjg4NGE1NWUxXzYtNS0xLTEtMA_eb42a570-c309-47ef-b9dd-a9d780275ad4">32</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred federal rate change reduction in corporate rate</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZToxMDU3OWFjNGM4OGM0YzkwOWYxMDY1YjY4ODRhNTVlMS90YWJsZXJhbmdlOjEwNTc5YWM0Yzg4YzRjOTA5ZjEwNjViNjg4NGE1NWUxXzctMS0xLTEtMA_24fd43ae-dcae-43ea-9492-9e7cd7041941">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZToxMDU3OWFjNGM4OGM0YzkwOWYxMDY1YjY4ODRhNTVlMS90YWJsZXJhbmdlOjEwNTc5YWM0Yzg4YzRjOTA5ZjEwNjViNjg4NGE1NWUxXzctMy0xLTEtMA_c9976cb3-878f-47a1-81af-586c728bc772">39,447</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iaf5d0e8fdf374dc09283fd669e2ebf19_D20160101-20161231" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZToxMDU3OWFjNGM4OGM0YzkwOWYxMDY1YjY4ODRhNTVlMS90YWJsZXJhbmdlOjEwNTc5YWM0Yzg4YzRjOTA5ZjEwNjViNjg4NGE1NWUxXzctNS0xLTEtMA_67708562-0ec6-42dc-be97-c2ed8b38afa2">&#8212;</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Research credit, net</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZToxMDU3OWFjNGM4OGM0YzkwOWYxMDY1YjY4ODRhNTVlMS90YWJsZXJhbmdlOjEwNTc5YWM0Yzg4YzRjOTA5ZjEwNjViNjg4NGE1NWUxXzgtMS0xLTEtMA_f8e2352b-0812-40aa-94bc-3a4934f88522">8,466</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZToxMDU3OWFjNGM4OGM0YzkwOWYxMDY1YjY4ODRhNTVlMS90YWJsZXJhbmdlOjEwNTc5YWM0Yzg4YzRjOTA5ZjEwNjViNjg4NGE1NWUxXzgtMy0xLTEtMA_50284858-4918-47f9-b50e-f6e580eee2ae">8,455</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iaf5d0e8fdf374dc09283fd669e2ebf19_D20160101-20161231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZToxMDU3OWFjNGM4OGM0YzkwOWYxMDY1YjY4ODRhNTVlMS90YWJsZXJhbmdlOjEwNTc5YWM0Yzg4YzRjOTA5ZjEwNjViNjg4NGE1NWUxXzgtNS0xLTEtMA_cba78d12-e1f8-45e6-ad37-59bd4d80d61b">2,551</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Orphan drug credit, net</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" decimals="-3" name="us-gaap:IncomeTaxReconciliationTaxCreditsOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZToxMDU3OWFjNGM4OGM0YzkwOWYxMDY1YjY4ODRhNTVlMS90YWJsZXJhbmdlOjEwNTc5YWM0Yzg4YzRjOTA5ZjEwNjViNjg4NGE1NWUxXzExLTEtMS0xLTA_73eaccb3-c883-4302-b672-45fbce633873">872</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationTaxCreditsOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZToxMDU3OWFjNGM4OGM0YzkwOWYxMDY1YjY4ODRhNTVlMS90YWJsZXJhbmdlOjEwNTc5YWM0Yzg4YzRjOTA5ZjEwNjViNjg4NGE1NWUxXzExLTMtMS0xLTA_dc1c6a22-305b-4508-b5d5-3470a0b0b3e7">1,853</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iaf5d0e8fdf374dc09283fd669e2ebf19_D20160101-20161231" decimals="-3" name="us-gaap:IncomeTaxReconciliationTaxCreditsOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZToxMDU3OWFjNGM4OGM0YzkwOWYxMDY1YjY4ODRhNTVlMS90YWJsZXJhbmdlOjEwNTc5YWM0Yzg4YzRjOTA5ZjEwNjViNjg4NGE1NWUxXzExLTUtMS0xLTA_fcabfceb-55d3-4e83-b181-726380d491f0">571</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Other permanent items</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" decimals="-3" name="us-gaap:IncomeTaxReconciliationOtherReconcilingItems" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZToxMDU3OWFjNGM4OGM0YzkwOWYxMDY1YjY4ODRhNTVlMS90YWJsZXJhbmdlOjEwNTc5YWM0Yzg4YzRjOTA5ZjEwNjViNjg4NGE1NWUxXzEyLTEtMS0xLTA_7e1e2b3d-e696-4395-be6c-e35cd32e7102">148</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231" decimals="-3" name="us-gaap:IncomeTaxReconciliationOtherReconcilingItems" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZToxMDU3OWFjNGM4OGM0YzkwOWYxMDY1YjY4ODRhNTVlMS90YWJsZXJhbmdlOjEwNTc5YWM0Yzg4YzRjOTA5ZjEwNjViNjg4NGE1NWUxXzEyLTMtMS0xLTA_d6a09879-ad97-496b-a252-10f920ca4df9">276</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iaf5d0e8fdf374dc09283fd669e2ebf19_D20160101-20161231" decimals="-3" name="us-gaap:IncomeTaxReconciliationOtherReconcilingItems" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZToxMDU3OWFjNGM4OGM0YzkwOWYxMDY1YjY4ODRhNTVlMS90YWJsZXJhbmdlOjEwNTc5YWM0Yzg4YzRjOTA5ZjEwNjViNjg4NGE1NWUxXzEyLTUtMS0xLTA_d7b19a34-58f9-4466-88ac-e13956992c07">145</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Equity-based compensation</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" decimals="-3" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZToxMDU3OWFjNGM4OGM0YzkwOWYxMDY1YjY4ODRhNTVlMS90YWJsZXJhbmdlOjEwNTc5YWM0Yzg4YzRjOTA5ZjEwNjViNjg4NGE1NWUxXzEzLTEtMS0xLTA_548a6593-d49f-4ef9-a8fa-9247a018980d">758</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZToxMDU3OWFjNGM4OGM0YzkwOWYxMDY1YjY4ODRhNTVlMS90YWJsZXJhbmdlOjEwNTc5YWM0Yzg4YzRjOTA5ZjEwNjViNjg4NGE1NWUxXzEzLTMtMS0xLTA_446cdf27-4c3b-4564-af85-c95d5dec2c78">2,067</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iaf5d0e8fdf374dc09283fd669e2ebf19_D20160101-20161231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZToxMDU3OWFjNGM4OGM0YzkwOWYxMDY1YjY4ODRhNTVlMS90YWJsZXJhbmdlOjEwNTc5YWM0Yzg4YzRjOTA5ZjEwNjViNjg4NGE1NWUxXzEzLTUtMS0xLTA_cf7d028d-7973-4fb2-85f4-382b19481203">1,997</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Change in valuation allowance</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZToxMDU3OWFjNGM4OGM0YzkwOWYxMDY1YjY4ODRhNTVlMS90YWJsZXJhbmdlOjEwNTc5YWM0Yzg4YzRjOTA5ZjEwNjViNjg4NGE1NWUxXzE0LTEtMS0xLTA_fc72b5fb-2d05-4a5d-b926-e6b024f5ef7d">60,005</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZToxMDU3OWFjNGM4OGM0YzkwOWYxMDY1YjY4ODRhNTVlMS90YWJsZXJhbmdlOjEwNTc5YWM0Yzg4YzRjOTA5ZjEwNjViNjg4NGE1NWUxXzE0LTMtMS0xLTA_1e2728fc-f9a4-4171-9825-f732520453f2">24,000</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iaf5d0e8fdf374dc09283fd669e2ebf19_D20160101-20161231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZToxMDU3OWFjNGM4OGM0YzkwOWYxMDY1YjY4ODRhNTVlMS90YWJsZXJhbmdlOjEwNTc5YWM0Yzg4YzRjOTA5ZjEwNjViNjg4NGE1NWUxXzE0LTUtMS0xLTA_bb4255d5-fbb2-4761-9b32-f2d74b5309cc">24,444</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Income tax expense/(benefit)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZToxMDU3OWFjNGM4OGM0YzkwOWYxMDY1YjY4ODRhNTVlMS90YWJsZXJhbmdlOjEwNTc5YWM0Yzg4YzRjOTA5ZjEwNjViNjg4NGE1NWUxXzE1LTEtMS0xLTA_e564d7c9-8ec8-442d-b851-86c9140a9218">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZToxMDU3OWFjNGM4OGM0YzkwOWYxMDY1YjY4ODRhNTVlMS90YWJsZXJhbmdlOjEwNTc5YWM0Yzg4YzRjOTA5ZjEwNjViNjg4NGE1NWUxXzE1LTMtMS0xLTA_14aa8b38-ceca-4778-ae3f-0f26dcd334ec">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iaf5d0e8fdf374dc09283fd669e2ebf19_D20160101-20161231" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZToxMDU3OWFjNGM4OGM0YzkwOWYxMDY1YjY4ODRhNTVlMS90YWJsZXJhbmdlOjEwNTc5YWM0Yzg4YzRjOTA5ZjEwNjViNjg4NGE1NWUxXzE1LTUtMS0xLTA_7599707f-7e2f-49cc-a771-7f863ef0de67">&#8212;</ix:nonFraction>&#160;</span></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90ZXh0cmVnaW9uOmI0ZjY4YmIzMzBkMzRkMWZiM2QyZDdiYjQ5YmI3ZWM5XzE1MzkzMTYyODA2MzM0_7a3aafb9-def3-4db5-a89c-f82c76b336fd" escape="true"><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">A reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows (in thousands):</span></div><div style="margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"><tr><td style="width:1.0%;"></td><td style="width:61.343109%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.730205%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533138%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.730205%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533138%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.730205%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2016</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Beginning balance</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7057397719af459ca7328a1c440a0efa_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZTpjN2M1OGZmZWZhODE0M2E0OTRiZWY2NmU1ZThjODEwZi90YWJsZXJhbmdlOmM3YzU4ZmZlZmE4MTQzYTQ5NGJlZjY2ZTVlOGM4MTBmXzItMS0xLTEtMA_290f7685-87ea-447f-ba5b-816f7d8db870">3,395</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iaa98382ff57d452ab6942c773d605ba7_I20161231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZTpjN2M1OGZmZWZhODE0M2E0OTRiZWY2NmU1ZThjODEwZi90YWJsZXJhbmdlOmM3YzU4ZmZlZmE4MTQzYTQ5NGJlZjY2ZTVlOGM4MTBmXzItMy0xLTEtMA_754ab482-c232-4d3d-b85a-be4cb9ea1277">2,465</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ife0dac9d3bf74657b071534f4d2516f1_I20151231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZTpjN2M1OGZmZWZhODE0M2E0OTRiZWY2NmU1ZThjODEwZi90YWJsZXJhbmdlOmM3YzU4ZmZlZmE4MTQzYTQ5NGJlZjY2ZTVlOGM4MTBmXzItNS0xLTEtMA_22dff0f8-07a3-400b-bea6-984b91e2f50c">2,425</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Increases for current year tax positions</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZTpjN2M1OGZmZWZhODE0M2E0OTRiZWY2NmU1ZThjODEwZi90YWJsZXJhbmdlOmM3YzU4ZmZlZmE4MTQzYTQ5NGJlZjY2ZTVlOGM4MTBmXzMtMS0xLTEtMA_0cb3f648-37c7-459a-bf15-6a0411159be2">642</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZTpjN2M1OGZmZWZhODE0M2E0OTRiZWY2NmU1ZThjODEwZi90YWJsZXJhbmdlOmM3YzU4ZmZlZmE4MTQzYTQ5NGJlZjY2ZTVlOGM4MTBmXzMtMy0xLTEtMA_38b35e71-d2b8-4107-8f63-41c2ca2cf126">569</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iaf5d0e8fdf374dc09283fd669e2ebf19_D20160101-20161231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZTpjN2M1OGZmZWZhODE0M2E0OTRiZWY2NmU1ZThjODEwZi90YWJsZXJhbmdlOmM3YzU4ZmZlZmE4MTQzYTQ5NGJlZjY2ZTVlOGM4MTBmXzMtNS0xLTEtMA_969e2ef4-a93f-416b-8d54-462171637093">308</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Increases/(decreases) for prior year tax positions</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZTpjN2M1OGZmZWZhODE0M2E0OTRiZWY2NmU1ZThjODEwZi90YWJsZXJhbmdlOmM3YzU4ZmZlZmE4MTQzYTQ5NGJlZjY2ZTVlOGM4MTBmXzQtMS0xLTEtMA_ab56c58f-4b1f-484b-be2f-8831b67bfc17">281</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZTpjN2M1OGZmZWZhODE0M2E0OTRiZWY2NmU1ZThjODEwZi90YWJsZXJhbmdlOmM3YzU4ZmZlZmE4MTQzYTQ5NGJlZjY2ZTVlOGM4MTBmXzQtMy0xLTEtMA_ab3f20c0-66cc-473b-a1d4-e353691b83b3">361</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iaf5d0e8fdf374dc09283fd669e2ebf19_D20160101-20161231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZTpjN2M1OGZmZWZhODE0M2E0OTRiZWY2NmU1ZThjODEwZi90YWJsZXJhbmdlOmM3YzU4ZmZlZmE4MTQzYTQ5NGJlZjY2ZTVlOGM4MTBmXzQtNS0xLTEtMA_1edfaff9-c337-417f-b062-61c16622243c">268</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Ending balance</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZTpjN2M1OGZmZWZhODE0M2E0OTRiZWY2NmU1ZThjODEwZi90YWJsZXJhbmdlOmM3YzU4ZmZlZmE4MTQzYTQ5NGJlZjY2ZTVlOGM4MTBmXzYtMS0xLTEtMA_e326fb22-2abc-4029-94dc-67d1892b8892">4,318</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7057397719af459ca7328a1c440a0efa_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZTpjN2M1OGZmZWZhODE0M2E0OTRiZWY2NmU1ZThjODEwZi90YWJsZXJhbmdlOmM3YzU4ZmZlZmE4MTQzYTQ5NGJlZjY2ZTVlOGM4MTBmXzYtMy0xLTEtMA_18d84c92-bec3-4ff7-aea0-6d53b22966da">3,395</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iaa98382ff57d452ab6942c773d605ba7_I20161231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZTpjN2M1OGZmZWZhODE0M2E0OTRiZWY2NmU1ZThjODEwZi90YWJsZXJhbmdlOmM3YzU4ZmZlZmE4MTQzYTQ5NGJlZjY2ZTVlOGM4MTBmXzYtNS0xLTEtMA_bbb12525-ccbc-43e9-86c5-9f01a3b2cbbb">2,465</ix:nonFraction>&#160;</span></td></tr></table></div></ix:nonNumeric><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">As of December&#160;31, 2018 and 2017, of the total gross unrecognized tax benefits, approximately $<ix:nonFraction unitRef="usd" contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90ZXh0cmVnaW9uOmI0ZjY4YmIzMzBkMzRkMWZiM2QyZDdiYjQ5YmI3ZWM5XzMwMDA_210a1bf0-2086-4977-b22b-097d1f96a833">4.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i7057397719af459ca7328a1c440a0efa_I20171231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90ZXh0cmVnaW9uOmI0ZjY4YmIzMzBkMzRkMWZiM2QyZDdiYjQ5YmI3ZWM5XzMwMDc_cdb4e5fd-242e-4b5b-8aa0-adefa3adc88b">3.4</ix:nonFraction> million would favorably impact the Company's effective income tax rate, respectively. Although, due to the Company's determination that the deferred income tax asset would not more likely than not be realized, a valuation allowance would be recorded, therefore, zero net impact would result within the Company's effective income tax rate. The Company's uncertain income tax position liability has been recorded to deferred income taxes to offset the tax attribute carryforward amounts.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">For the years ended December&#160;31, 2018, 2017 and 2016, the Company has not recognized any interest or penalties related to the uncertain income tax positions due to the fact such position is related to tax attribute carryforwards which have not yet been utilized. The Company does not expect its unrecognized income tax position to significantly decrease within the next twelve months.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Company's U.S. Federal and state income tax returns from 2001&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;">forward remain open to examination due to the carryover of unused net operating losses and tax credits.</span></div></ix:continuation><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"><ix:continuation id="i753315afa3a54f6e85b77226f98b5ffd">As more fully described in Note 2 to the consolidated financial statements, the Tax Act was signed into law making significant changes to the Internal Revenue Code on December 22, 2017.  Under ASC 740, the effects of the new legislation are to be recognized in the period of enactment.  As such, recognition of the tax impact of the Tax Act was required in the interim and annual periods that include December 22, 2017.  As a result, the Company revalued the deferred tax asset as of December 31, 2017, fully offset by a valuation allowance without impact to the financial statements.</ix:continuation> </span></div><div style="text-indent:36pt;"><span><br/></span></div><div id="i_0_747"></div><div style="margin-top:3pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">8. <ix:nonNumeric contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" name="mgnx:CollaborationAndLicenseAgreementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzMwMzA1_04debd13-3bd8-4c8a-b899-97a08a1b0406" continuedAt="i3dcc561ec6a74934a473f6679f5d1f80" escape="true">Collaboration and Other Agreements</ix:nonNumeric></span></div><ix:continuation id="i3dcc561ec6a74934a473f6679f5d1f80" continuedAt="i010941ffd2bb4074a0dc33a8ef8d7f21"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Incyte</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">In October 2017, the Company entered into an exclusive global collaboration and license agreement with Incyte for MGA012&#160;(also known as INCMGA0012), an investigational monoclonal antibody that inhibits programmed cell death protein 1 (PD-1) (Incyte Agreement). Incyte has obtained exclusive worldwide rights for the development and commercialization of MGA012 in all indications, while the Company retains the right to develop its pipeline assets in combination with MGA012.  The Company received a $<ix:nonFraction unitRef="usd" contextRef="i44dc827b9c5849c9874770cafc78df7e_D20171001-20171231" decimals="-5" format="ixt:numdotdecimal" name="mgnx:NonRefundableUpfrontFees" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzUyNQ_d27b3381-eb6e-4ce0-9bac-4e8781ecf5b1">150.0</ix:nonFraction> million upfront payment from Incyte when the transaction closed in the fourth quarter of 2017.</span></div></ix:continuation><div style="text-indent:36pt;margin-bottom:9pt;"></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">F - 19</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="i010941ffd2bb4074a0dc33a8ef8d7f21" continuedAt="i43247e2f675f4ae3974e731fabf0c05d"><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Under the terms of the Incyte Agreement, Incyte will lead global development of MGA012.  Assuming successful development and commercialization by Incyte, the Company could receive up to approximately $<ix:nonFraction unitRef="usd" contextRef="i591dac725a2648e68258b7105447f85d_I20171031" decimals="-5" format="ixt:numdotdecimal" name="mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzgzNQ_bca0ccf7-a68d-41c9-9a4b-98422ca81e64">420.0</ix:nonFraction> million in development and regulatory milestones, and up to $<ix:nonFraction unitRef="usd" contextRef="i591dac725a2648e68258b7105447f85d_I20171031" decimals="-5" format="ixt:numdotdecimal" name="mgnx:PotentialCommercialMilestonePaymentsUnderAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3Xzg5MA_e5e92156-8366-437f-992c-828f537284c6">330.0</ix:nonFraction> million in commercial milestones. As of December&#160;31, 2018, the Company has recognized $<ix:nonFraction unitRef="usd" contextRef="i82b03c819e73441db6d085233d218937_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzMyOTg1MzQ5NzIyMzQ_8cb8bd2b-484f-446a-9a32-dc768d3280ed">15.0</ix:nonFraction> million in development milestones under this agreement.  If commercialized, the Company would be eligible to receive tiered royalties of <ix:nonFraction unitRef="number" contextRef="ia93c5065a4f94e9f9e0c596d50d7aa2f_D20171001-20171031" decimals="2" name="mgnx:ProceedsfromRoyaltiesPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzEzODE_586daebe-816b-48a2-bf41-8ca4f1f81b55">15</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i91850bdafeb5443c8e0569e57b38e238_D20171001-20171031" decimals="2" name="mgnx:ProceedsfromRoyaltiesPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzEzODc_f117cddc-d82a-41ec-b201-393321972d40">24</ix:nonFraction>% on any global net sales. The Company retains the right to develop its pipeline assets in combination with MGA012, with Incyte commercializing MGA012 and the Company commercializing its asset(s), if any such potential combinations are approved. In addition, the Company retains the right to manufacture a portion of both companies' global commercial supply needs of MGA012, subject to a separate commercial supply agreement. Finally, Incyte funded the Company's activities related to the ongoing monotherapy clinical study and will continue to fund certain related clinical activities. &#160;</span></div><div style="text-indent:42pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Upon the adoption of ASC 606, the Company evaluated the Incyte Agreement under the provisions of ASC 606 and identified the following two performance obligations under the agreement: (i) the license of MGA012 and (ii) the performance of certain clinical activities through a brief technology transfer period.  The Company determined that the license and clinical activities are separate performance obligations because they are capable of being distinct, and are distinct in the context of the contract. The license has standalone functionality as it is sublicensable, Incyte has significant capabilities in performing clinical trials, and Incyte is capable of performing these activities without the Company's involvement; the Company performed the activities during the transfer period as a matter of convenience.  The Company determined that the transaction price of the Incyte Agreement at inception was $<ix:nonFraction unitRef="usd" contextRef="iff7efae7eb26446bbaa573fe3861e53c_I20171031" decimals="-5" format="ixt:numdotdecimal" name="mgnx:CollaborativeAgreementTransactionPrice" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzMyOTg1MzQ5NzIyNTE_48d05c3c-46d7-44da-a8db-8716eed7876d">154.0</ix:nonFraction> million, consisting of the consideration to which the Company was entitled in exchange for the license and an estimate of the consideration for clinical activities to be performed.  The transaction price was allocated to each performance obligation based on their relative standalone selling price.  The standalone selling price of the license was determined using the adjusted market assessment approach considering similar collaboration and license agreements.  The standalone selling price for agreed-upon clinical activities to be performed was determined using the expected cost approach based on similar arrangements the Company has with other parties.  The potential development and regulatory milestone payments are </span><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;">fully constrained until the Company concludes that achievement of the milestone is probable and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">and as such have been excluded from the transaction price.  Any consideration related to sales-based milestones and royalties will be recognized when the related sales occur, as they were determined to relate predominantly to the license granted to Incyte and, therefore, have also been excluded from the transaction price.  The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur. </span><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;">During the&#160;year ended December&#160;31, 2018, it became probable that a significant reversal of cumulative revenue would not occur for three development milestones totaling </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">$<ix:nonFraction unitRef="usd" contextRef="i82b03c819e73441db6d085233d218937_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzMyOTg1MzQ5NzIyNTQ_8cb8bd2b-484f-446a-9a32-dc768d3280ed">15.0</ix:nonFraction> million</span><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;"> related to MGA012 meeting certain clinical proof-of-concept criteria. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#160;Therefore</span><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;"> the associated consideration was added to the estimated transaction price and was recognized as revenue.  </span></div><div style="text-indent:42pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Company recognized the </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">$<ix:nonFraction unitRef="usd" contextRef="i44dc827b9c5849c9874770cafc78df7e_D20171001-20171231" decimals="-5" format="ixt:numdotdecimal" name="mgnx:NonRefundableUpfrontFees" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzMyOTg1MzQ5NzIyNzA_d27b3381-eb6e-4ce0-9bac-4e8781ecf5b1">150.0</ix:nonFraction> million</span><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;"> allocated to the </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">license when it satisfied its performance obligation and transferred the license to Incyte in December 2017.  The $<ix:nonFraction unitRef="usd" contextRef="if61293acd6f643bf8daf43be5cf2bd6e_D20171001-20171031" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueRecognitionMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzMyOTg1MzQ5NzIyODc_b8238625-c9d7-4098-bb76-442e8fd9ee37">4.0</ix:nonFraction> million allocated to the clinical activities&#160;was recognized over the period from the effective date of the agreement until such time as the clinical activities were transferred to Incyte using an input method according to research and development costs incurred to date compared to estimated total research and development costs.  These clinical activities were substantially completed as of June 30, 2018.  Prior to the adoption of ASC 606 on January 1, 2018, the accounting for this agreement did not materially differ from the accounting under ASC 606.  The Company recognized revenue of&#160;$<ix:nonFraction unitRef="usd" contextRef="i8eb24f3f49444597a89f49edae260720_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzMyOTg1MzQ5NzIzNzc_851e0ddb-34a2-4fc2-a60a-dc98997d8a22">18.8</ix:nonFraction> million&#160;and $<ix:nonFraction unitRef="usd" contextRef="i6a111d57d3bf49428df5748987d6471b_D20170101-20171231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzMyOTg1MzQ5NzIzMTY_a8c6ef15-f6a0-4822-a823-92464af4b8a4">151.1</ix:nonFraction> million&#160;under the Incyte Agreement during the years ended December&#160;31, 2018 and&#160;2017, respectively.   The revenue recognized during the year ended December&#160;31, 2018 included milestone revenue of $<ix:nonFraction unitRef="usd" contextRef="i82b03c819e73441db6d085233d218937_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzM4NDgyOTA4NDE5NzA_8cb8bd2b-484f-446a-9a32-dc768d3280ed">15.0</ix:nonFraction> million.</span></div><div style="text-indent:42pt;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Company also has an agreement with Incyte, which was signed in 2018, under which the Company is to perform development and&#160;manufacturing services for Incyte&#8217;s clinical needs of MGA012.  The Company evaluated this agreement under ASC 606 and identified one performance obligation under the agreement - to perform services related to manufacturing the clinical supply of MGA012.  The transaction price is based on the costs incurred to develop and manufacture drug product and drug substance, and is recognized over time as the services are provided, as the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date.   During the year ended December&#160;31, 2018, the Company recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="idd27a98828844b21ad9d5646ef79f6e2_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzMyOTg1MzQ5NzIzODE_813c68f6-03d8-4194-9d5a-96221a7833f9">22.2</ix:nonFraction> million for services performed under this agreement. </span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Servier </span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">In September 2012, the Company entered into a collaboration agreement with Servier and granted it exclusive options to obtain three separate exclusive licenses to develop and commercialize DART molecules, consisting of those designated by the Company as flotetuzumab (also known as MGD006 or S80880) and MGD007, as well as a third DART molecule, in all countries other than the United States, Canada, Mexico, Japan, South Korea and India (Servier Agreement). During 2014, Servier exercised its exclusive option to develop and commercialize flotetuzumab.  During 2016 Servier notified the Company</span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">F - 20</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="i43247e2f675f4ae3974e731fabf0c05d" continuedAt="i9d3f60df538b490a8274beeb9626a92b"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> that it did not intend to exercise the option for the third DART molecule, and in November 2018, Servier notified the Company that it did not intend to exercise the option for MGD007.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Upon execution of the agreement, Servier made a nonrefundable payment of $<ix:nonFraction unitRef="usd" contextRef="i6011d16a582a445fa400c0dfcf98028a_D20120901-20120930" decimals="-5" format="ixt:numdotdecimal" name="mgnx:NonRefundableUpfrontFees" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzE3MTQ0_e20a75af-8bff-4c10-83b2-bdf8391ba08a">20.0</ix:nonFraction> million to the Company. In addition, if Servier successfully develops, obtains regulatory approval for, and commercializes flotetuzumab, the Company will be eligible to receive up to&#160;$<ix:nonFraction unitRef="usd" contextRef="id5778ce3b2cd44b79c13685e1d2a707d_I20120930" decimals="INF" format="ixt:numdotdecimal" name="mgnx:PotentialClinicalMilestonePaymentsUnderAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzE3MjQy_08ad33e1-90d8-4e4c-bce3-d445a98441cc">22.5</ix:nonFraction> million in clinical milestone payments, $<ix:nonFraction unitRef="usd" contextRef="id5778ce3b2cd44b79c13685e1d2a707d_I20120930" decimals="INF" format="ixt:numdotdecimal" name="mgnx:PotentialRegulatoryMilestonePaymentsUnderAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzE3Mjc3_c512d925-586b-4271-b6ce-431270e862b6">76.0</ix:nonFraction> million in regulatory milestone payments&#160;and $<ix:nonFraction unitRef="usd" contextRef="id5778ce3b2cd44b79c13685e1d2a707d_I20120930" decimals="INF" format="ixt:numdotdecimal" name="mgnx:PotentialSalesMilestonePaymentsUnderAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzE3MzE3_cf0411cb-a2c4-438b-bf2e-79174c2377bf">210.0</ix:nonFraction> million in sales milestone payments. In addition to these milestones, the Company and Servier will share Phase 2 and Phase 3 development costs.&#160; Under this agreement, Servier would be obligated to pay the Company from low double-digit to mid-teen royalties on net product sales in its territories.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Upon the adoption of ASC&#160;606, the Company evaluated the Servier Agreement under the provisions of ASC 606 and concluded that Servier is a customer prior to the exercise of any of the three options.  The Company identified the following material promises under the arrangement for each of the three molecules:  (i) a limited evaluation license to conduct activities under the research plan and  (ii)  research and development services concluding with an option trigger data package.  The Servier Agreement also provided exclusive options for an exclusive license to research, develop, manufacture and commercialize each subject molecule. The Company evaluated these options and concluded that the options were not issued at a significant and incremental discount, and therefore do not provide material rights.  As such, they are excluded as performance obligations at the outset of the arrangement. The Company determined that each license and the related research and development services were not distinct from one another, as the license has limited value without the performance of the research and development activities.  As such, the Company determined that these promises should be combined into a single performance obligation for each molecule, resulting in a total of three performance obligations; one for flotetuzumab, one for MGD007, and one for the third DART molecule. </span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Company determined that the $<ix:nonFraction unitRef="usd" contextRef="i6011d16a582a445fa400c0dfcf98028a_D20120901-20120930" decimals="-5" format="ixt:numdotdecimal" name="mgnx:NonRefundableUpfrontFees" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzU0OTc1NTk3MTc4Ng_1579b4ac-e547-4e9e-8cf1-2bec386c39b8">20.0</ix:nonFraction> million</span><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">upfront payment from Servier constituted the entirety of the consideration to be included in the transaction price as of the outset of the arrangement, and the transaction price was allocated to the three performance obligations based on their relative standalone selling price. </span><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;">The milestone payments that the Company was eligible to receive prior to the exercise of the options were excluded from the transaction price, as all milestone amounts were fully constrained based on the probability of achievement. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> Two milestones were achieved in 2014 when the INDs for flotetuzumab and MGD007 were cleared by the Food and Drug Administration (FDA).  Upon achievement of each milestone, the constraint related to the $<ix:nonFraction unitRef="usd" contextRef="i6011d16a582a445fa400c0dfcf98028a_D20120901-20120930" decimals="-5" format="ixt:numdotdecimal" name="mgnx:MilestonePayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzU0OTc1NTk3MTgwMQ_a64c0cab-9e38-4c24-9b6c-b5132e373473">5.0</ix:nonFraction> million milestone payment was removed and the transaction price was re-assessed. This variable consideration was allocated to each specific performance obligation in accordance with ASC 606.</span></div><div style="text-indent:36pt;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Revenue associated with each performance obligation is being recognized as the research and development services are provided using an input method according to research and development costs incurred to date compared to estimated total research and development costs. The transfer of control occurs over this time period and, in management&#8217;s judgment, is the best measure of progress towards satisfying the performance obligation.  The full transaction price allocated to flotetuzumab and the third DART molecule was recognized as revenue prior to the adoption of ASC 606 on January 1, 2018 as the option periods had ended. The development period for MGD007 was estimated to be 75 months, ending in December 2018, therefore the transaction price allocated to MGD007 was&#160;being recognized through that date.  When Servier notified the Company that it was not exercising the option for MGD007 in November 2018, the Company recognized the remaining deferred revenue related to MGD007.  Upon the adoption of ASC 606 on January 1, 2018, the pattern of revenue recognition for the upfront fee and the accounting for the milestones received in 2014 changed, but there was no material impact to revenue recognized during the year ended December 31, 2018.  During the years ended December 31, 2018, 2017 and 2016 the Company recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="ia01940c5140d475d823101c59b4c6ee3_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzU0OTc1NTk3MTg4MA_f83274a3-c45b-445b-858f-315ef5a153c0">1.9</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i9d3ce417f9d9482d96c963058758500b_D20170101-20171231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzU0OTc1NTk3MTg2Ng_cb645608-3a61-4bd2-8e4d-4579e587e4df">1.1</ix:nonFraction> million&#160;and $<ix:nonFraction unitRef="usd" contextRef="i5e802bb4cb124fb3a1bf94de3a31e858_D20160101-20161231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzU0OTc1NTk3MTg1Mg_035942d3-6a28-4361-b342-284214d0ec8a">1.1</ix:nonFraction> million, respectively, related to the MGD007 option.  At December 31, 2018, <ix:nonFraction unitRef="usd" contextRef="ida270b9128b24424808f7af121ae03e7_I20181231" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzU0OTc1NTk3MTgyMg_a8d20ce1-e0bf-4071-a835-e2f380be7b10">no</ix:nonFraction> revenue related to the MGD007 option was deferred.  The deferred revenue balance related to the MGD007 option as of December 31, 2017, prior to the adoption of ASC 606, was $<ix:nonFraction unitRef="usd" contextRef="i3dae8b73ee0b42df83fe2e75389bd1b7_I20171231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredRevenueCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzU0OTc1NTk3MTgzOA_02e4c669-c804-4586-8299-72186d9ff2a6">1.1</ix:nonFraction> million, all of which was current.</span></div><div style="text-indent:36pt;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">As discussed above, in 2014, Servier exercised its option to obtain a license to develop and commercialize flotetuzumab in its territories and paid the Company a $<ix:nonFraction unitRef="usd" contextRef="i98b48a96e93a4ea59eb53d0d51847ea3_I20151231" decimals="-5" format="ixt:numdotdecimal" name="mgnx:OptionExerciseFee" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzU0OTc1NTk3MTgxNw_952b7f51-0a2d-4eb9-9e64-0c23c9f416fe">15.0</ix:nonFraction> million license grant fee.  Upon exercise, the Company's contractual obligations include (i) granting Servier an exclusive license to its intellectual property, (ii) technical, scientific and intellectual property support to the research plan and (iii)  participation on an executive committee and a research and development committee. Under the terms of the Servier Agreement, the Company and Servier will share costs incurred to develop flotetuzumab during the license term. Due to the fact that both parties share costs and are exposed to significant risks and rewards dependent on the commercial success of the product, the Company determined that the arrangement is a collaborative arrangement within the scope of ASC 808.  The arrangement consists of two components; the license of flotetuzumab and the research and development activities, including committee participation, to support the research plan.  </span><span style="background-color:#ffffff;color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Under the provisions of ASC 808, the Company has determined that it will use ASC 606 by analogy to recognize the revenue related to the license.  The Company evaluated its performance obligation to provide Servier with an exclusive license to </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">develop and commercialize flotetuzumab and determined that its transaction price is equal to the license grant fee payment of $15.0 million and Servier consumes the benefits of the license over time as the research and development activities are</span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">F - 21</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="i9d3f60df538b490a8274beeb9626a92b" continuedAt="iadb0274610cc414695fe0c9cd9129191"><div style="margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> performed. Therefore, the Company will recognize the transaction price over the development period, using an input method according to research and development costs incurred to date compared to estimated total research and development costs. The additional potential clinical, regulatory and sales milestones are </span><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;">fully constrained </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">and have been excluded from the transaction price.&#160;</span></div><div style="text-indent:36pt;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Prior to the adoption of ASC 606 on January 1, 2018, the Company recognized the license grant fee over the expected period of development on a straight-line basis. The deferred revenue balance related to the flotetuzumab license grant fee as of December 31, 2017, prior to the adoption of ASC 606, was $<ix:nonFraction unitRef="usd" contextRef="i3b00e539a3324792b34321e6c7168fb8_I20171231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzI3NDg3NzkyMjkwOTc_3151f796-ca37-4351-8733-2c6c5b3d0c86">7.4</ix:nonFraction> million. The adoption of ASC 606 increased that balance by approximately $<ix:nonFraction unitRef="usd" contextRef="i6c17e3fb438e49b4bf933e03642b33d6_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzI3NDg3NzkyMjkxNjU_62b22102-b63e-4bbb-8ee2-489582989292">6.4</ix:nonFraction>&#160;million. The adoption of ASC 606 increased revenue recognized during the year ended December 31, 2018 by $<ix:nonFraction unitRef="usd" contextRef="i6c17e3fb438e49b4bf933e03642b33d6_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzI3NDg3NzkyMjkyNjU_a8203951-ef59-4bef-b9d6-be7c8652899f">0.1</ix:nonFraction>&#160;million, and it will increase the revenue to be recognized in the future as the pattern of revenue recognition has changed. During the years ended December 31, 2018, 2017 and 2016 the Company recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="i09a4e2abc6f64d09984d04c7e51e159a_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzI3NDg3NzkyMjk4OTU_5e1f0919-0a4a-4ee1-b888-e21ec5761ec4">1.2</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i77625ed2e7734703b52942e3929dec22_D20170101-20171231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzI3NDg3NzkyMjk4OTk_176b64d1-3db0-416d-8a55-442f41483404">1.4</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="i0dd3b4b1fefc4e54956a0cd97918d963_D20160101-20161231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzI3NDg3NzkyMjk5MDc_52cddb32-880d-427e-9053-f6b62373b840">2.2</ix:nonFraction> million, respectively, related to the flotetuzumab license grant fee.  At December 31, 2018, $<ix:nonFraction unitRef="usd" contextRef="i7c0265f36dcf411893aa87db114e0f16_I20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzI3NDg3NzkyMjk5OTM_7bede7d1-913e-4494-9843-18a2a2dcf4f7">12.6</ix:nonFraction> million of revenue related to the flotetuzumab license grant fee was deferred, $<ix:nonFraction unitRef="usd" contextRef="i7c0265f36dcf411893aa87db114e0f16_I20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzI3NDg3NzkyMzAwNjU_1787b9f6-7640-4ee5-b093-0badc503ac24">0.9</ix:nonFraction> million of which was current and $<ix:nonFraction unitRef="usd" contextRef="i7c0265f36dcf411893aa87db114e0f16_I20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzI3NDg3NzkyMzAwOTM_2945e6d3-28b1-432d-8fb4-6acff37d5da4">11.7</ix:nonFraction> million of which was non-current.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The research and development activities component of the arrangement is not analogous to ASC 606, therefore the Company will follow its policy to record expense incurred as research and development expense and reimbursements received from Servier will be recognized as an offset to research and development expense on the consolidated statement of operations and comprehensive loss during the development period.  During the three years ended December 31, 2018, 2017&#160;and 2016&#160;the Company recorded approximately $<ix:nonFraction unitRef="usd" contextRef="i6c17e3fb438e49b4bf933e03642b33d6_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="mgnx:CollaborationArrangementOffsetToResearchAndDevelopmentCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzQzOTgwNDY2MDA0ODE_bc9beb8d-95cd-404c-9ba0-bc48693454b0">6.0</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i87ceca0edd234d059fdd917ce29f5f4b_D20170101-20171231" decimals="-5" format="ixt:numdotdecimal" name="mgnx:CollaborationArrangementOffsetToResearchAndDevelopmentCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzQzOTgwNDY2MDA1MTk_9acd8b41-16d8-48d0-a266-0050f10911fe">3.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i625f3d08dc954d518764769a7feaeefc_D20160101-20161231" decimals="-5" format="ixt:numdotdecimal" name="mgnx:CollaborationArrangementOffsetToResearchAndDevelopmentCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzQzOTgwNDY2MDA1MzQ_4dcb6784-f90b-4b83-8126-5caee174c0fd">2.6</ix:nonFraction> million, respectively, as an offset to research and development expense under this collaborative arrangement.</span><span style="background-color:#ffffff;color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#160;</span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Zai Lab  </span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">In November 2018, the Company entered into a collaboration and license agreement with Zai Lab (Zai Lab Agreement) under which Zai Lab obtained regional development and commercialization rights in mainland China, Hong Kong, Macau and Taiwan for (i) margetuximab, an immune-optimized anti-HER2 monoclonal antibody, (ii) MGD013, a bispecific DART molecule designed to provide coordinate blockade of PD-1 and LAG-3 for the potential treatment of a range of solid tumors and hematological malignancies, and (iii) an undisclosed multi-specific TRIDENT molecule in preclinical development. Zai Lab will lead clinical development of these molecules in its territory. </span></div><div style="text-indent:36pt;margin-top:5pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Under the terms of the Zai Lab Agreement, Zai Lab paid the Company an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i29ff7281a75a4936a4be6c1359e216e9_D20181101-20181130" decimals="-5" format="ixt:numdotdecimal" name="mgnx:NonRefundableUpfrontFees" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzY1OTcwNjk5MzA4NjI_7b000da2-87e5-4943-950d-8b216ea6d09a">25.0</ix:nonFraction>&#160;million, less foreign withholding tax of $<ix:nonFraction unitRef="usd" contextRef="i29ff7281a75a4936a4be6c1359e216e9_D20181101-20181130" decimals="-5" format="ixt:numdotdecimal" name="mgnx:NonrefundablePaymentTaxWithholding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzY1OTcwNjk5MzA4OTg_17087981-fe18-4a02-a0c4-948445331445">2.50</ix:nonFraction>&#160;million, which was received in January 2019.  Assuming successful development and commercialization of margetuximab, MGD013 and the TRIDENT molecule, the Company could receive up to $<ix:nonFraction unitRef="usd" contextRef="i7e972d120beb4fdaae31b0300fbc48ee_I20181231" decimals="-5" format="ixt:numdotdecimal" name="mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzY1OTcwNjk5MzEwNzU_86f37c5a-3a14-4c5a-9fba-103f0c9d995d">140.0</ix:nonFraction> million in development and regulatory milestones. In addition, Zai Lab would pay the Company double-digit royalties on annual net sales of the assets, which may be subject to adjustment in specified circumstances.</span></div><div style="text-indent:36pt;margin-top:5pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Company evaluated the Zai Lab Agreement under the provisions of ASC 606 and identified the following material promises under the arrangement for each of the two product candidates, margetuximab and MGD013:  (i)  an exclusive license to develop and commercialize the product candidate in Zai Lab&#8217;s territory and (ii) certain research and development activities.  The Company determined that each license and the related research and development activities were not distinct from one another, as the license has limited value without the performance of the research and development activities.  As such, the Company determined that these promises should be combined into a single performance obligation for each product candidate.  Activities related to margetuximab and MGD013 are separate performance obligations from each other because they are capable of being distinct, and are distinct in the context of the contract.  The Company evaluated the promises related to the TRIDENT molecule and determined they were immaterial in context of the contract, therefore there is no performance obligation related to that molecule.  The Company determined that the $<ix:nonFraction unitRef="usd" contextRef="i29ff7281a75a4936a4be6c1359e216e9_D20181101-20181130" decimals="-5" format="ixt:numdotdecimal" name="mgnx:NonRefundableUpfrontFees" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzY1OTcwNjk5MzI0NDc_7b000da2-87e5-4943-950d-8b216ea6d09a">25.0</ix:nonFraction> million (less foreign withholding tax of $<ix:nonFraction unitRef="usd" contextRef="i29ff7281a75a4936a4be6c1359e216e9_D20181101-20181130" decimals="-5" format="ixt:numdotdecimal" name="mgnx:NonrefundablePaymentTaxWithholding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzY1OTcwNjk5MzI0ODM_17087981-fe18-4a02-a0c4-948445331445">2.5</ix:nonFraction> million) upfront payment from Zai Lab constituted the entirety of the consideration to be included in the transaction price as of the outset of the arrangement, and the transaction price was allocated to the two performance obligations based on their relative standalone selling price.  The standalone selling price of the performance obligations was determined using the adjusted market assessment approach considering similar collaboration and license agreements.  The potential development and regulatory milestone payments are fully constrained until the Company concludes that achievement of the milestone is probable, and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such have been excluded from the transaction price.  Any consideration related to royalties will be recognized when the related sales occur, as they were determined to relate predominantly to the license granted to Zai Lab and, therefore, have also been excluded from the transaction price.  The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur.</span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#160;&#160;Due to the relatively short-term nature of the recognition period, the revenue associated with the MGD013 performance obligation is being recognized on a straight-line basis as the Company performs research and development</span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">F - 22</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="iadb0274610cc414695fe0c9cd9129191" continuedAt="i245d103c7226471d9cc8299309ca79c1"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> activities under the agreement.  The fixed consideration related to the margetuximab performance obligation is also being recognized on a straight-line basis as the Company performs research and development activities under the agreement.  Straight-line recognition is materially consistent with the pattern of performance of the research and development activities of each product candidate.  The variable consideration related to the margetuximab performance obligation will be recognized upon certain regulatory achievements.  During the year ended December 31, 2018, the Company recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="id73733a0f1994e42b2954427356cb7e5_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzY1OTcwNjk5MzQ1Mjg_e8c46488-e65d-4ce0-9040-68cab7d8dc42">1.3</ix:nonFraction> million related to the Zai Lab Agreement.  At December 31, 2018, $<ix:nonFraction unitRef="usd" contextRef="i7e972d120beb4fdaae31b0300fbc48ee_I20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzY1OTcwNjk5MzQ1ODg_1a04f8f6-2cde-43d9-bea7-e578db445b02">21.1</ix:nonFraction> million of revenue was deferred under this agreement, $<ix:nonFraction unitRef="usd" contextRef="i7e972d120beb4fdaae31b0300fbc48ee_I20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzY1OTcwNjk5MzQ2Mzc_37ab8596-cf42-4089-95e4-06ef43133581">16.1</ix:nonFraction> million of which was current.</span></div><div style="margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Roche</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">In December 2017, the Company entered into a research collaboration and license agreement with Roche to jointly discover and develop novel bispecific molecules to undisclosed targets (Roche Agreement).  During the research term, both companies will leverage their respective platforms, including the Company's DART platform and Roche's CrossMAb and DutaFab technologies to select a bispecific format and lead product candidate.  Roche would then further develop and commercialize any such product candidate.  Each company will be responsible for their own expenses during the research period. </span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Under the terms of the Roche Agreement, Roche received rights to use certain of the Company&#8217;s intellectual property rights to exploit collaboration compounds and products, and paid the Company an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i8ae89b363134495b9cc3cdf7d4ce1a06_D20180101-20180131" decimals="-5" format="ixt:numdotdecimal" name="mgnx:NonRefundableUpfrontFees" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzI3NDg3NzkyMTUwMzM_36679533-589e-48c1-b819-f457e47795e5">10.0</ix:nonFraction> million which was received in January 2018. The Company will also be eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="i77f6204290544a298e027e842269f6bc_I20181231" decimals="-5" format="ixt:numdotdecimal" name="mgnx:PotentialMilestonePaymentsandRoyaltiesonFutureSalesunderAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzI3NDg3NzkyMTUxMjM_45972fd9-950f-4089-a3be-da2ee1f649a1">370.0</ix:nonFraction> million in potential milestone payments and royalties on future sales.  As of December&#160;31, 2018, the Company has not recognized any milestone revenue under this agreement.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Upon the adoption of ASC 606, the Company evaluated the Roche Agreement under the provisions of ASC 606 and identified the following promises under the agreement: (i) the non-exclusive, non-transferable, non-sublicensable license to the Company's intellectual property and (ii) the performance of certain activities during the research period.  The Company determined that the license is capable of being distinct, but is not distinct in the context of the contract because it has limited value to Roche without the research activities required to be performed by the Company.  Therefore, the Company concluded that there is one performance obligation under the agreement.  The Company determined that the transaction price of the Roche Agreement was $<ix:nonFraction unitRef="usd" contextRef="i8ae89b363134495b9cc3cdf7d4ce1a06_D20180101-20180131" decimals="-5" format="ixt:numdotdecimal" name="mgnx:NonRefundableUpfrontFees" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzI3NDg3NzkyMTU5OTc_b49fc543-9fad-4237-b35c-3998479bf445">10.0</ix:nonFraction> million.  The potential milestone payments are </span><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;">fully constrained </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">and have been excluded from the transaction price.  Any consideration related to sales-based royalties will be recognized when the related sales occur as they were determined to relate predominantly to the license granted to Roche and therefore have also been excluded from the transaction price.    </span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The $<ix:nonFraction unitRef="usd" contextRef="i8ae89b363134495b9cc3cdf7d4ce1a06_D20180101-20180131" decimals="-5" format="ixt:numdotdecimal" name="mgnx:NonRefundableUpfrontFees" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzI3NDg3NzkyMTYzNjM_b49fc543-9fad-4237-b35c-3998479bf445">10.0</ix:nonFraction> million transaction price is being recognized over the expected research period, which is <ix:nonNumeric contextRef="i097ea6f211524140a29381dc3bce7129_D20171201-20171231" format="ixt-sec:durmonth" name="mgnx:UpfrontPaymentRecognitionPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzI3NDg3NzkyMTY0NDg_56f1aec2-4f41-4523-9e1d-8421e089e5ec">30</ix:nonNumeric> months, using a cost-based input method to measure performance.   Prior to the adoption of ASC 606 on January 1, 2018, the accounting for this agreement did not materially differ from the accounting under ASC 606. The Company recognized revenue under this agreement of  $<ix:nonFraction unitRef="usd" contextRef="i5a4fe51377ba48ef83d87242a98d90ec_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzI3NDg3NzkyMTY3MTQ_80b16e99-8b30-4720-9e5e-eeade368aa3f">4.0</ix:nonFraction> million during the year ended December&#160;31, 2018.  At December&#160;31, 2018, $<ix:nonFraction unitRef="usd" contextRef="i77f6204290544a298e027e842269f6bc_I20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzI3NDg3NzkyMTY3NTE_7ac127c3-33d0-4aeb-9770-1de0c4bf9916">6.0</ix:nonFraction> million of revenue was deferred under this agreement, $<ix:nonFraction unitRef="usd" contextRef="i77f6204290544a298e027e842269f6bc_I20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzI3NDg3NzkyMTY4MDA_600cbe92-b637-4244-87f9-a3a74e13219b">4.0</ix:nonFraction> million of which was current and $<ix:nonFraction unitRef="usd" contextRef="i77f6204290544a298e027e842269f6bc_I20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzI3NDg3NzkyMTY4Mjg_3ea32612-a8c1-4bf7-86fe-f2a7230ffad9">2.0</ix:nonFraction> million of which was non-current.&#160;At December&#160;31, 2017, $<ix:nonFraction unitRef="usd" contextRef="i9b14f1378bdc4abf90dd05dd5956ca30_I20171231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzI3NDg3NzkyMTY4NjQ_7e5c5d4c-4d0a-4089-b196-9f2a06d3b583">10.0</ix:nonFraction> million of revenue was deferred under this agreement,  $<ix:nonFraction unitRef="usd" contextRef="i9b14f1378bdc4abf90dd05dd5956ca30_I20171231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredRevenueCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzI3NDg3NzkyMTY5MTQ_f7dc4473-5f89-4c6a-bff7-b21f66fa887e">4.0</ix:nonFraction> million of which was current and $<ix:nonFraction unitRef="usd" contextRef="i9b14f1378bdc4abf90dd05dd5956ca30_I20171231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredRevenueNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzI3NDg3NzkyMTY5NDI_27f806cb-7020-479b-b729-65e20d2bea90">6.0</ix:nonFraction> million of which was non-current.&#160;</span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Provention</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">In May 2018, the Company entered into a license agreement with Provention pursuant to which the Company granted Provention exclusive global rights for the purpose of developing and commercializing MGD010 (renamed PRV-3279), a CD32B x CD79B DART molecule being developed for the treatment of autoimmune indications (Provention License Agreement).  As partial consideration for the Provention License Agreement, Provention granted the Company a warrant to purchase shares of Provention&#8217;s common stock at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i47f11d0af1aa4444aae4bba0ddf73a6c_D20180501-20180531" decimals="INF" name="mgnx:CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzQzOTgwNDY2Njk5MTc_69f83b4c-1da1-4126-83da-6fdf1720bbd5">2.50</ix:nonFraction> per share. The warrant expires on May 7, 2025.  If Provention successfully develops, obtains regulatory approval for, and commercializes PRV-3279, the Company will be eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="id16ca02732fe4f1b8d21590f441cb5dd_I20180531" decimals="-5" format="ixt:numdotdecimal" name="mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzQzOTgwNDY2Njk5MzU_c9195d13-7575-4e62-adb7-af5e3935dd13">65.0</ix:nonFraction> million in development and regulatory milestones and up to $<ix:nonFraction unitRef="usd" contextRef="id16ca02732fe4f1b8d21590f441cb5dd_I20180531" decimals="-5" format="ixt:numdotdecimal" name="mgnx:PotentialCommercialMilestonePaymentsUnderAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzQzOTgwNDY2Njk5NTI_89d8368e-6237-450e-b1ff-72884b82faa0">225.0</ix:nonFraction> million in commercial milestones.  As of December 31, 2018, the Company has not recognized any milestone revenue under this agreement.  If commercialized, the Company would be eligible to receive single-digit royalties on net sales of the product.  The license agreement may be terminated by either party upon a material breach or bankruptcy of the other party, by Provention without cause upon prior notice to the Company, and by the Company in the event that Provention challenges the validity of any licensed patent under the agreement, but only with respect to the challenged patent.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#160;Also in May 2018, the Company entered into an asset purchase agreement with Provention pursuant to which Provention acquired the Company&#8217;s interest in teplizumab (renamed PRV-031), a monoclonal antibody being developed for the treatment of type 1 diabetes (Asset Purchase Agreement).  As partial consideration for the Asset Purchase Agreement, Provention granted the Company a warrant to purchase shares of Provention&#8217;s common stock at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i575e134561384052b8d5150268d0bc0c_D20180501-20180531" decimals="INF" name="mgnx:CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzQzOTgwNDY2Njk5NjA_29f01b72-d889-40f6-8780-61bedb0851f2">2.50</ix:nonFraction> per</span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">F - 23</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="i245d103c7226471d9cc8299309ca79c1" continuedAt="if363e813fbef4f989892e5a5111e3eef"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> share.  The warrant expires on May 7, 2025.  If Provention successfully develops, obtains regulatory approval for, and commercializes PRV-031, the Company will be eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="ie95e8086ae9b4cd69fc3763d4b03138b_I20180531" decimals="-5" format="ixt:numdotdecimal" name="mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzQzOTgwNDY2Njk5NzY_fbcb10b6-6eed-4783-bda8-b44b9f144dbc">170.0</ix:nonFraction> million in regulatory milestones and up to $<ix:nonFraction unitRef="usd" contextRef="ie95e8086ae9b4cd69fc3763d4b03138b_I20180531" decimals="-5" format="ixt:numdotdecimal" name="mgnx:PotentialCommercialMilestonePaymentsUnderAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzQzOTgwNDY2Njk5OTM_ffec0cc1-0462-4f71-b662-8219ef42401a">225.0</ix:nonFraction> million in commercial milestones.  If commercialized, the Company would be eligible to receive single-digit royalties on net sales of the product.  Provention has also agreed to pay third-party obligations, including low single-digit royalties, a portion of which is creditable against royalties payable to the Company, aggregate milestone payments of up to approximately $<ix:nonFraction unitRef="usd" contextRef="ie95e8086ae9b4cd69fc3763d4b03138b_I20180531" decimals="-5" format="ixt:numdotdecimal" name="mgnx:PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzQzOTgwNDY2NzAwMDg_b2dbf843-428e-4572-907b-f16c47e89eea">1.3</ix:nonFraction> million and other consideration, for certain third-party intellectual property under agreements Provention is assuming pursuant to the Asset Purchase Agreement. Further, Provention is required to pay the Company a low double-digit percentage of certain consideration to the extent it is received in connection with a future grant of rights to PRV-031 by Provention to a third party. </span></div><div style="text-indent:36pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Company evaluated the Provention License Agreement and Asset Purchase Agreement under the provisions of ASC 606 and determined that they should be accounted for as a single contract and identified two performance obligations within that contract: (i) the license of MGD010 and (ii) the title to teplizumab.  The Company determined that the transaction price of the Provention agreements was $<ix:nonFraction unitRef="usd" contextRef="i918dca9fcdce44a999dec3002edfedac_I20180531" decimals="-5" format="ixt:numdotdecimal" name="mgnx:CollaborativeAgreementTransactionPrice" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzQzOTgwNDY2NzAwMjM_57a85b0f-34e4-47d5-bf5b-7d3c36f6cbbd">6.1</ix:nonFraction> million, based on the Black-Scholes valuation of the warrants to purchase a total of <ix:nonFraction unitRef="shares" contextRef="i918dca9fcdce44a999dec3002edfedac_I20180531" decimals="INF" format="ixt:numdotdecimal" name="mgnx:CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzQzOTgwNDY2NzAwMzU_15da8e2b-4db0-4413-a071-dc1c04b6fb83">2,432,688</ix:nonFraction> shares of Provention's common stock.  The transaction price was allocated to each performance obligation based on the number of shares of common stock the Company is entitled to purchase under each warrant.  The potential development and regulatory milestone payments are fully constrained until the Company concludes that achievement of the milestone is probable and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such have been excluded from the transaction price.  Any consideration related to sales-based milestones and royalties will be recognized when the related sales occur, therefore they have also been excluded from the transaction price.  The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur. </span></div><div style="text-indent:36pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Company recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="ie23f02f7751b4b5d8b10bc0c6f10cf97_D20180501-20180531" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzQzOTgwNDY2NzAwNTE_3335534b-5a21-4f43-aabf-8a6f158ab6ec">6.1</ix:nonFraction> million when it satisfied its performance obligations and transferred the MGD010 license and teplizumab assets to Provention in May 2018.  The warrants are reported in other assets on the balance sheet at December&#160;31, 2018 and will be revalued at each reporting period until exercised or the warrants lapse.  &#160;The Company revalued the warrants based on current Black-Scholes parameters&#160;as of December&#160;31, 2018,&#160;and recorded a decrease of $<ix:nonFraction unitRef="usd" contextRef="i5c503df7c4d74a6aa791c924760e58de_D20180101-20181231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:FairValueAdjustmentOfWarrants" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzQzOTgwNDY2NzAwNjY_2bbffab8-0d58-4dc8-8ab8-67fe7c0b5f7e">4.2</ix:nonFraction> million in other assets.  This revaluation is reflected in other income (expense) on the consolidated statements of operations and comprehensive loss for the year ended December&#160;31, 2018.</span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Janssen</span><span style="background-color:rgb(255,255,255, 0.0);color:#ee2724;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">In December 2014, the Company entered into a collaboration and license agreement with Janssen for the development and commercialization of MGD011 (also known as JNJ-64052781 or duvortuxizumab), a product candidate that incorporates the Company's proprietary DART technology to simultaneously target CD19 and CD3 for the potential treatment of B-cell hematological malignancies (MGD011 Agreement). The Company contemporaneously entered into an agreement with JJDC under which JJDC agreed to purchase <ix:nonFraction unitRef="shares" contextRef="i9c0bb24d85b742029840e8ff19e39e21_D20141201-20141231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzMyOTg1MzQ5NjkyNzY_388caaa8-3271-44d3-b95a-3a7818b0c149">1,923,077</ix:nonFraction> new shares of the Company's common stock for proceeds of $<ix:nonFraction unitRef="usd" contextRef="i9c0bb24d85b742029840e8ff19e39e21_D20141201-20141231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzMyOTg1MzQ5NjkzMzY_5fce28a3-2119-411a-8d1e-c24f699cc331">75.0</ix:nonFraction> million.&#160;&#160;Upon closing the transaction in January 2015, the Company received a $<ix:nonFraction unitRef="usd" contextRef="iad112c3f4a95410eb177b18bf2a325e8_D20160101-20161231" decimals="-5" format="ixt:numdotdecimal" name="mgnx:NonRefundableUpfrontFees" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzMyOTg1MzQ5Njk0MTA_f05f82a7-7ff0-4e50-8011-15795ef4b883">50.0</ix:nonFraction> million upfront payment from Janssen as well as the $<ix:nonFraction unitRef="usd" contextRef="iba7d66ba85e246e0b3b81bde3c507cd4_D20150101-20150131" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzMyOTg1MzQ5Njk0NTc_c13555f0-b76d-43af-99db-5bb19ecc31cc">75.0</ix:nonFraction> million investment in the Company's common stock.&#160;&#160; In August 2017, Janssen notified the Company that they were terminating the MGD011 Agreement.&#160;<ix:nonFraction unitRef="usd" contextRef="i36abedfa020b41798bb4a1de0b5826b9_D20180101-20181231" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzU0OTc1NTk3MTcyNw_5bba558c-5461-49fe-aeaa-2802b2c8895c">No</ix:nonFraction> revenue was recognized under the MGD011 Agreement during the years ended December 31, 2017 and 2018.  The Company recognized revenue of &#160;$<ix:nonFraction unitRef="usd" contextRef="iafa5f3f8c3964fd3a2fb20d5a78444ae_D20160101-20161231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzU0OTc1NTk3MTcyMg_f07604a6-b522-4b29-a6ae-877b30d15a74">2.0</ix:nonFraction> million&#160;during the year ended December 31, 2016.  </span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">In May 2016, the Company entered into a collaboration and license agreement with Janssen, a related party through ownership of the Company's common stock, for the development and commercialization of MGD015, a product candidate that incorporates the Company's proprietary DART technology to simultaneously target CD3 and an undisclosed tumor target for the potential treatment of various hematological malignancies and solid tumors (MGD015 Agreement). Under the MGD015 Agreement, the Company granted an exclusive license to Janssen to develop and commercialize MGD015.  The Company received a $<ix:nonFraction unitRef="usd" contextRef="i0dbfb405829a4954939345567d9ffa41_D20160701-20160731" decimals="-5" format="ixt:numdotdecimal" name="mgnx:NonRefundableUpfrontFees" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzMyOTg1MzQ5NzAxOTQ_4c48f1e8-e7dc-4bf5-a328-37caa29d4b74">75.0</ix:nonFraction> million upfront payment from Janssen upon closing the transaction, which was recognized as revenue in 2016.  In January 2018, Janssen notified the Company that they were terminating the MGD015 Agreement. <ix:nonFraction unitRef="usd" contextRef="i5bd2775f85934df4a35546668e5cf0a5_D20180101-20181231" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzU0OTc1NTk3MTc2Nw_c77edbb9-e21b-4f52-a822-14379849743f">No</ix:nonFraction>&#160;revenue was recognized under the MGD015 Agreement during the year ended December 31, 2018. The Company recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="i6635b351add74cb695103957cc02cac1_D20170101-20171231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzU0OTc1NTk3MTc0NA_29ca3929-feec-4d0a-99ca-df238ddaf4f1">0.6</ix:nonFraction> million and&#160;$<ix:nonFraction unitRef="usd" contextRef="ibdc4a8d5c6b240faac1049620a8692b6_D20160101-20161231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzU0OTc1NTk3MTc2MA_03bdd0d7-5a0b-4340-8090-94a05c4ebb2d">75.8</ix:nonFraction> million&#160;during the years ended December 31, 2017 and 2016, respectively. </span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The revenue under both the MGD011 and MGD015 Agreements was fully recognized prior to the adoption of ASC&#160;606.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">NIAID Contract</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Company entered into a contract with the National Institute of Allergy and Infectious Diseases (NIAID), effective as of September&#160;15, 2015,&#160;to perform product development and to advance up to <ix:nonFraction unitRef="molecule" contextRef="ie5dd3f325a0e4bb2bd1f768f5d1cfb31_D20150915-20150915" decimals="INF" format="ixt-sec:numwordsen" name="mgnx:NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzI5NDE1_097642b1-4dbf-49d9-9221-1434af522076">two</ix:nonFraction> DART molecules, including MGD014. Under this contract, the Company will develop these product candidates for Phase 1/2 clinical trials as therapeutic agents, in combination with latency reversing treatments, to deplete cells infected with human immunodeficiency virus (HIV) infection. </span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">F - 24</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="if363e813fbef4f989892e5a5111e3eef"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> NIAID does not receive goods or services from the Company under this contract, therefore the Company does not consider NIAID to be a customer and concluded this contract is outside the scope of ASC 606.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">This contract includes a base period of $<ix:nonFraction unitRef="usd" contextRef="ie5dd3f325a0e4bb2bd1f768f5d1cfb31_D20150915-20150915" decimals="-5" format="ixt:numdotdecimal" name="mgnx:FundedValueOfBasePeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzI5NzQz_402cd8bc-630d-4f9d-94de-6f6d438192f2">7.5</ix:nonFraction> million to support development of MGD014 through IND application submission with the FDA, as well as up to $<ix:nonFraction unitRef="usd" contextRef="ib0d39c7c6f4e42388328978bd1a0c321_D20150915-20150915" decimals="INF" format="ixt:numdotdecimal" name="mgnx:AdditionalDevelopmentFundingOptionsUnderAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzI5ODQ1_55b5b29b-623d-4a88-94b6-2ad55f34ec0a">17.0</ix:nonFraction> million in additional development funding via NIAID options. Should NIAID fully exercise such options, the Company could receive total payments of up to $<ix:nonFraction unitRef="usd" contextRef="ib0d39c7c6f4e42388328978bd1a0c321_D20150915-20150915" decimals="INF" format="ixt:numdotdecimal" name="mgnx:TotalPotentialValueUnderAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzI5OTkz_df7bd22c-a40c-494c-a87d-339bed92d484">24.5</ix:nonFraction> million. The total potential period of performance under the award is from September 15, 2015 through September&#160;14, 2022.  During the year ended December 31, 2017, NIAID exercised the first option in the amount of $<ix:nonFraction unitRef="usd" contextRef="icbe3942778e048a7812d0b367cba79e4_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="mgnx:ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzMwMTcx_218c2ca3-c961-43dc-bb6e-64e33bf6d36a">10.8</ix:nonFraction> million. The Company recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="iae19a3f2560f46ea9ce3d9769293ef55_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzMwMjA5_f868acec-4ef7-43db-97f1-2c0bdbf1a472">1.3</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i8a451cc24b4245fe93b83bc7127cf807_D20170101-20171231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzMwMjEz_d0701468-310d-487f-a83b-95e40be5016e">1.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i355ceffdd61e4654b0c765f0f6734378_D20160101-20161231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzMwMjIw_2cd2e840-bc14-4a2a-bdb3-50234874f7f7">5.1</ix:nonFraction> million under this contract during the years ended December&#160;31, 2018, 2017 and 2016, respectively.</span></div></ix:continuation><div style="text-indent:36pt;margin-bottom:9pt;"><span><br/></span></div><div id="i_0_772"></div><div style="text-align:justify;margin-top:3pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">9. <ix:nonNumeric contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NzIvZnJhZzo1ZGU1YzhjMGI3YzQ0YTMyODg2OTM5Nzc0M2Q5MmJiMy90ZXh0cmVnaW9uOjVkZTVjOGMwYjdjNDRhMzI4ODY5Mzk3NzQzZDkyYmIzXzI2MTQ_d6eeff55-3547-4b99-90fd-6adc8729bdea" continuedAt="ia53a1fc60a5f41b7a39c9422ddc24b68" escape="true">Commitments and Contingencies</ix:nonNumeric></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"><ix:continuation id="ia53a1fc60a5f41b7a39c9422ddc24b68" continuedAt="i5ed97c7dc0c04f508f3cbe49b7701d24">&#160;</ix:continuation></span></div><ix:continuation id="i5ed97c7dc0c04f508f3cbe49b7701d24"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Operating Leases</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Company leases manufacturing, office and laboratory space in Rockville, Maryland under <ix:nonFraction unitRef="lease" contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" decimals="INF" format="ixt-sec:numwordsen" name="mgnx:NumberOfLease" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NzIvZnJhZzo1ZGU1YzhjMGI3YzQ0YTMyODg2OTM5Nzc0M2Q5MmJiMy90ZXh0cmVnaW9uOjVkZTVjOGMwYjdjNDRhMzI4ODY5Mzk3NzQzZDkyYmIzXzE1MA_0cab8532-9d36-42c9-b569-2ca6e552132d">five</ix:nonFraction> leases that have terms that expire between 2019 and 2027 unless renewed.&#160;&#160;During the year ended December&#160;31, 2017, the&#160;Company entered into an agreement to sublease a portion of the space&#160;it leases.  As of December 31, 2018,&#160;the Company will receive $<ix:nonFraction unitRef="usd" contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NzIvZnJhZzo1ZGU1YzhjMGI3YzQ0YTMyODg2OTM5Nzc0M2Q5MmJiMy90ZXh0cmVnaW9uOjVkZTVjOGMwYjdjNDRhMzI4ODY5Mzk3NzQzZDkyYmIzXzI3NDg3NzkwNzMxMDc_8f38218b-bee2-4280-9356-92e21b99a339">1.1</ix:nonFraction> million in future payments under this sublease.  The Company also leases office and laboratory space in Brisbane, California under a lease that expires in November 2023.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> The Rockville leases include a lease executed in July 2015 for space that the Company uses as its headquarters with office, laboratory, and manufacturing space.&#160;&#160; Under the terms of the lease, which commenced on January&#160;1, 2016, the Company received an assignment fee from the former tenant and a tenant improvement allowance from the landlord totaling $<ix:nonFraction unitRef="usd" contextRef="i121ff22ae7d04521bf402d62951d21e4_D20150701-20150731" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsForProceedsFromTenantAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NzIvZnJhZzo1ZGU1YzhjMGI3YzQ0YTMyODg2OTM5Nzc0M2Q5MmJiMy90ZXh0cmVnaW9uOjVkZTVjOGMwYjdjNDRhMzI4ODY5Mzk3NzQzZDkyYmIzXzgxOQ_a4f33697-acc8-41d7-a875-205728b3fa20">5.1</ix:nonFraction> million.&#160;&#160;During 2017, the Company executed a lease amendment for its headquarters building which extends the term of the lease to August 2027, restructures the rent due under the lease, and provides for an additional tenant improvement allowance from the landlord of $<ix:nonFraction unitRef="usd" contextRef="ic26431cbd9dd45ba8f73dd80dc1df8ec_D20170721-20170721" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsForProceedsFromTenantAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NzIvZnJhZzo1ZGU1YzhjMGI3YzQ0YTMyODg2OTM5Nzc0M2Q5MmJiMy90ZXh0cmVnaW9uOjVkZTVjOGMwYjdjNDRhMzI4ODY5Mzk3NzQzZDkyYmIzXzEwODQ_39079c59-58ed-4d89-88f9-a627bbbae2de">7.5</ix:nonFraction> million.  The assignment fee and tenant improvement allowances have been recorded as deferred rent and are being recognized over the new lease term.</span></div><div style="text-indent:36pt;margin-top:3pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">All of the leases contain rent escalation clauses and certain leases contain rent abatements.&#160;&#160;For financial reporting purposes, rent expense is charged to operations on a straight-line basis over the term of the lease.&#160;&#160;As of December&#160;31, 2018 and 2017, the Company had recorded a deferred rent liability of $<ix:nonFraction unitRef="usd" contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredRentCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NzIvZnJhZzo1ZGU1YzhjMGI3YzQ0YTMyODg2OTM5Nzc0M2Q5MmJiMy90ZXh0cmVnaW9uOjVkZTVjOGMwYjdjNDRhMzI4ODY5Mzk3NzQzZDkyYmIzXzIwODg_20050fc8-47e8-47ff-ab56-e115f6757c0a">11.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i7057397719af459ca7328a1c440a0efa_I20171231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredRentCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NzIvZnJhZzo1ZGU1YzhjMGI3YzQ0YTMyODg2OTM5Nzc0M2Q5MmJiMy90ZXh0cmVnaW9uOjVkZTVjOGMwYjdjNDRhMzI4ODY5Mzk3NzQzZDkyYmIzXzIwOTU_1f5e14a9-c626-4f01-99f7-b1fbed9fe958">12.3</ix:nonFraction> million, respectively. Rent expense for the years ended December&#160;31, 2018, 2017 and 2016 was $<ix:nonFraction unitRef="usd" contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasesRentExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NzIvZnJhZzo1ZGU1YzhjMGI3YzQ0YTMyODg2OTM5Nzc0M2Q5MmJiMy90ZXh0cmVnaW9uOjVkZTVjOGMwYjdjNDRhMzI4ODY5Mzk3NzQzZDkyYmIzXzIxNjQ_330efefb-7ad0-4ac5-88dc-c1a433e8fc46">4.4</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasesRentExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NzIvZnJhZzo1ZGU1YzhjMGI3YzQ0YTMyODg2OTM5Nzc0M2Q5MmJiMy90ZXh0cmVnaW9uOjVkZTVjOGMwYjdjNDRhMzI4ODY5Mzk3NzQzZDkyYmIzXzIxNjg_25aad2dc-eea8-4abb-9fb1-74a5c62320df">3.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iaf5d0e8fdf374dc09283fd669e2ebf19_D20160101-20161231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasesRentExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NzIvZnJhZzo1ZGU1YzhjMGI3YzQ0YTMyODg2OTM5Nzc0M2Q5MmJiMy90ZXh0cmVnaW9uOjVkZTVjOGMwYjdjNDRhMzI4ODY5Mzk3NzQzZDkyYmIzXzIxNzU_c0cd305a-2315-440c-9dc2-4b13d1fa361a">3.0</ix:nonFraction> million, respectively.</span></div><ix:nonNumeric contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" name="us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NzIvZnJhZzo1ZGU1YzhjMGI3YzQ0YTMyODg2OTM5Nzc0M2Q5MmJiMy90ZXh0cmVnaW9uOjVkZTVjOGMwYjdjNDRhMzI4ODY5Mzk3NzQzZDkyYmIzXzE1OTQyOTE4NjA2NzQ3_638b7aae-019b-42b5-993b-5717aef7c2a4" escape="true"><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Future minimum lease payments under noncancelable operating leases as of December&#160;31, 2018 are as follows (in thousands):</span></div><div style="margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"><tr><td style="width:1.0%;"></td><td style="width:86.269795%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.730205%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NzIvZnJhZzo1ZGU1YzhjMGI3YzQ0YTMyODg2OTM5Nzc0M2Q5MmJiMy90YWJsZTphZTMyZWViMWUwMjQ0ZmQwOTFiMmQyZTZkMDcxNGVkYS90YWJsZXJhbmdlOmFlMzJlZWIxZTAyNDRmZDA5MWIyZDJlNmQwNzE0ZWRhXzAtMS0xLTEtMA_2c3a1a7a-e160-4e27-8b47-02a6298cde55">6,323</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NzIvZnJhZzo1ZGU1YzhjMGI3YzQ0YTMyODg2OTM5Nzc0M2Q5MmJiMy90YWJsZTphZTMyZWViMWUwMjQ0ZmQwOTFiMmQyZTZkMDcxNGVkYS90YWJsZXJhbmdlOmFlMzJlZWIxZTAyNDRmZDA5MWIyZDJlNmQwNzE0ZWRhXzEtMS0xLTEtMA_4119c33a-7011-4aad-b7da-73ea3effbe9e">4,757</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NzIvZnJhZzo1ZGU1YzhjMGI3YzQ0YTMyODg2OTM5Nzc0M2Q5MmJiMy90YWJsZTphZTMyZWViMWUwMjQ0ZmQwOTFiMmQyZTZkMDcxNGVkYS90YWJsZXJhbmdlOmFlMzJlZWIxZTAyNDRmZDA5MWIyZDJlNmQwNzE0ZWRhXzItMS0xLTEtMA_98ab460c-a1dc-4757-abcb-42fbfcc013d2">4,724</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NzIvZnJhZzo1ZGU1YzhjMGI3YzQ0YTMyODg2OTM5Nzc0M2Q5MmJiMy90YWJsZTphZTMyZWViMWUwMjQ0ZmQwOTFiMmQyZTZkMDcxNGVkYS90YWJsZXJhbmdlOmFlMzJlZWIxZTAyNDRmZDA5MWIyZDJlNmQwNzE0ZWRhXzMtMS0xLTEtMA_0960fcba-6c35-4a49-8360-c3d395ec2294">4,865</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2023</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NzIvZnJhZzo1ZGU1YzhjMGI3YzQ0YTMyODg2OTM5Nzc0M2Q5MmJiMy90YWJsZTphZTMyZWViMWUwMjQ0ZmQwOTFiMmQyZTZkMDcxNGVkYS90YWJsZXJhbmdlOmFlMzJlZWIxZTAyNDRmZDA5MWIyZDJlNmQwNzE0ZWRhXzQtMS0xLTEtMA_fffaaac2-387e-41de-9e7a-630c7494a5d2">4,680</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Thereafter</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NzIvZnJhZzo1ZGU1YzhjMGI3YzQ0YTMyODg2OTM5Nzc0M2Q5MmJiMy90YWJsZTphZTMyZWViMWUwMjQ0ZmQwOTFiMmQyZTZkMDcxNGVkYS90YWJsZXJhbmdlOmFlMzJlZWIxZTAyNDRmZDA5MWIyZDJlNmQwNzE0ZWRhXzUtMS0xLTEtMA_5cd83f7f-f638-44ff-ba22-2bfac0a08025">13,786</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NzIvZnJhZzo1ZGU1YzhjMGI3YzQ0YTMyODg2OTM5Nzc0M2Q5MmJiMy90YWJsZTphZTMyZWViMWUwMjQ0ZmQwOTFiMmQyZTZkMDcxNGVkYS90YWJsZXJhbmdlOmFlMzJlZWIxZTAyNDRmZDA5MWIyZDJlNmQwNzE0ZWRhXzYtMS0xLTEtMA_792646f4-528c-423c-9b86-c6ddfc7a25ee">39,135</ix:nonFraction>&#160;</span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Contingencies</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">From time to time, the Company may be subject to various litigation and related matters arising in the ordinary course of business. The Company does not believe it is currently subject to any material matters where there is at least a reasonable possibility that a material loss may be incurred.</span></div></ix:continuation><div style="text-indent:36pt;margin-bottom:9pt;"><span><br/></span></div><div id="i_0_784"></div><div style="margin-top:3pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">10. <ix:nonNumeric contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83ODQvZnJhZzpmNTg2NmU3ZGFkMzI0YzRlODBjNzdhMDhiMjkyZWMwOC90ZXh0cmVnaW9uOmY1ODY2ZTdkYWQzMjRjNGU4MGM3N2EwOGIyOTJlYzA4XzY0NQ_8c470d44-4d99-4c6e-b1a1-708ced6ead83" continuedAt="i1242e5e96e5149f08c96e66e61548c20" escape="true">Employee Benefit Plan</ix:nonNumeric></span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"><ix:continuation id="i1242e5e96e5149f08c96e66e61548c20" continuedAt="ie9037387430243448cffe07e8906817f">In 2002, the Company established the MacroGenics 401(k) Plan (the Plan) for its employees under Section 401(k) of the IRC. Under this Plan, all employees at least <ix:nonNumeric contextRef="i6ada94a697084172b90c7bcf3c82fe1e_D20120101-20121231" format="ixt-sec:duryear" name="mgnx:EmployeesEligibleAgeToParticipateInBenefitPlan" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83ODQvZnJhZzpmNTg2NmU3ZGFkMzI0YzRlODBjNzdhMDhiMjkyZWMwOC90ZXh0cmVnaW9uOmY1ODY2ZTdkYWQzMjRjNGU4MGM3N2EwOGIyOTJlYzA4XzE5NA_2b10b975-4c0d-47bd-b1ba-831a88c1d2ff">21</ix:nonNumeric> years of age are eligible to participate in the Plan, starting on the first day of each month. Employees may contribute up to <ix:nonFraction unitRef="number" contextRef="i6ada94a697084172b90c7bcf3c82fe1e_D20120101-20121231" decimals="INF" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83ODQvZnJhZzpmNTg2NmU3ZGFkMzI0YzRlODBjNzdhMDhiMjkyZWMwOC90ZXh0cmVnaW9uOmY1ODY2ZTdkYWQzMjRjNGU4MGM3N2EwOGIyOTJlYzA4XzMyMw_d11544c1-17b0-4e82-b44e-87b4286a8de4">100</ix:nonFraction>% of their salary, subject to government maximums.</ix:continuation></span></div><div style="text-indent:36pt;margin-bottom:9pt;"></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">F - 25</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"><ix:continuation id="ie9037387430243448cffe07e8906817f">Employees are <ix:nonFraction unitRef="number" contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" decimals="INF" name="mgnx:DefinedContributionPlanEmployeesContributionVestedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83ODQvZnJhZzpmNTg2NmU3ZGFkMzI0YzRlODBjNzdhMDhiMjkyZWMwOC90ZXh0cmVnaW9uOmY1ODY2ZTdkYWQzMjRjNGU4MGM3N2EwOGIyOTJlYzA4XzM5MA_dc7ab68c-7e3a-4394-8bfd-18d53229de03">100</ix:nonFraction>% vested in their contributions to the Plan. The Company's contribution to the Plan, as determined by the Board of Directors, is discretionary. The Company's contributions to the Plan totaled $<ix:nonFraction unitRef="usd" contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83ODQvZnJhZzpmNTg2NmU3ZGFkMzI0YzRlODBjNzdhMDhiMjkyZWMwOC90ZXh0cmVnaW9uOmY1ODY2ZTdkYWQzMjRjNGU4MGM3N2EwOGIyOTJlYzA4XzU4Mw_18a07b19-2880-4aa7-9366-371e0d47aaa4">1.3</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83ODQvZnJhZzpmNTg2NmU3ZGFkMzI0YzRlODBjNzdhMDhiMjkyZWMwOC90ZXh0cmVnaW9uOmY1ODY2ZTdkYWQzMjRjNGU4MGM3N2EwOGIyOTJlYzA4XzU4Nw_8a781501-9443-4d31-a1de-a12386b2afa3">1.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iaf5d0e8fdf374dc09283fd669e2ebf19_D20160101-20161231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83ODQvZnJhZzpmNTg2NmU3ZGFkMzI0YzRlODBjNzdhMDhiMjkyZWMwOC90ZXh0cmVnaW9uOmY1ODY2ZTdkYWQzMjRjNGU4MGM3N2EwOGIyOTJlYzA4XzU5NA_4b60c745-282a-40ab-a0bc-5d2b592e0fb3">1.0</ix:nonFraction> million for the years ended December&#160;31, 2018, 2017 and 2016, respectively.</ix:continuation></span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span><br/></span></div><div id="i_0_796"></div><div style="margin-top:3pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">11.&#160;&#160;<ix:nonNumeric contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" name="us-gaap:QuarterlyFinancialInformationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83OTYvZnJhZzo1OTVjZDUzNjhiMGY0OWE0YTAwMWNhZmQzY2I5YTQ1ZS90ZXh0cmVnaW9uOjU5NWNkNTM2OGIwZjQ5YTRhMDAxY2FmZDNjYjlhNDVlXzIxOTkwMjMyNTU2MTY_2625cb88-c813-49f4-9b45-ceff197602c4" continuedAt="i77b2484024ac40cb925c8462b616c051" escape="true">Quarterly Financial Information (unaudited)</ix:nonNumeric></span></div><div style="margin-top:3pt;margin-bottom:9pt;"><ix:continuation id="i77b2484024ac40cb925c8462b616c051"><ix:nonNumeric contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" name="us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83OTYvZnJhZzo1OTVjZDUzNjhiMGY0OWE0YTAwMWNhZmQzY2I5YTQ1ZS90ZXh0cmVnaW9uOjU5NWNkNTM2OGIwZjQ5YTRhMDAxY2FmZDNjYjlhNDVlXzIxOTkwMjMyNTU2MTc_4a8531d1-ebae-4e88-8fbf-d30b6c983303" escape="true"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"><tr><td style="width:1.0%;"></td><td style="width:48.807636%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.747430%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534214%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.747430%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534214%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.747430%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534214%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.747430%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">1st Quarter</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">2nd Quarter</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">3rd Quarter</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">4th Quarter</span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands, except per share data)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenue</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8b9c8e543ab44629819b1e0b7554ce96_D20180101-20180331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83OTYvZnJhZzo1OTVjZDUzNjhiMGY0OWE0YTAwMWNhZmQzY2I5YTQ1ZS90YWJsZTo2ZDAyNmFiMDJjZWE0MjUyOGU3NTU3ODk4YjYzMzQyNi90YWJsZXJhbmdlOjZkMDI2YWIwMmNlYTQyNTI4ZTc1NTc4OThiNjMzNDI2XzMtMS0xLTEtMA_582d6f82-cd86-44e6-aa38-e6a0e0f206f5">4,695</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie7fccf344bc24f03934ea77078a49726_D20180401-20180630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83OTYvZnJhZzo1OTVjZDUzNjhiMGY0OWE0YTAwMWNhZmQzY2I5YTQ1ZS90YWJsZTo2ZDAyNmFiMDJjZWE0MjUyOGU3NTU3ODk4YjYzMzQyNi90YWJsZXJhbmdlOjZkMDI2YWIwMmNlYTQyNTI4ZTc1NTc4OThiNjMzNDI2XzMtMy0xLTEtMA_f415da6d-fcfd-4548-a7ad-a2c33dca9494">18,834</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i98edd9ec68b24ced9b531e766587d469_D20180701-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83OTYvZnJhZzo1OTVjZDUzNjhiMGY0OWE0YTAwMWNhZmQzY2I5YTQ1ZS90YWJsZTo2ZDAyNmFiMDJjZWE0MjUyOGU3NTU3ODk4YjYzMzQyNi90YWJsZXJhbmdlOjZkMDI2YWIwMmNlYTQyNTI4ZTc1NTc4OThiNjMzNDI2XzMtNS0xLTEtMA_73b3a659-415b-446e-b4f2-14e5d66f0fa0">20,798</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i724f8d5b79f44384afe7b27042231bfe_D20181001-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83OTYvZnJhZzo1OTVjZDUzNjhiMGY0OWE0YTAwMWNhZmQzY2I5YTQ1ZS90YWJsZTo2ZDAyNmFiMDJjZWE0MjUyOGU3NTU3ODk4YjYzMzQyNi90YWJsZXJhbmdlOjZkMDI2YWIwMmNlYTQyNTI4ZTc1NTc4OThiNjMzNDI2XzMtNy0xLTEtMA_415d9b62-43df-4b01-b5c4-25e324d44d21">15,794</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8b9c8e543ab44629819b1e0b7554ce96_D20180101-20180331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83OTYvZnJhZzo1OTVjZDUzNjhiMGY0OWE0YTAwMWNhZmQzY2I5YTQ1ZS90YWJsZTo2ZDAyNmFiMDJjZWE0MjUyOGU3NTU3ODk4YjYzMzQyNi90YWJsZXJhbmdlOjZkMDI2YWIwMmNlYTQyNTI4ZTc1NTc4OThiNjMzNDI2XzQtMS0xLTEtMA_8c667151-487e-4f50-ad00-f765a5a3ebab">49,536</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie7fccf344bc24f03934ea77078a49726_D20180401-20180630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83OTYvZnJhZzo1OTVjZDUzNjhiMGY0OWE0YTAwMWNhZmQzY2I5YTQ1ZS90YWJsZTo2ZDAyNmFiMDJjZWE0MjUyOGU3NTU3ODk4YjYzMzQyNi90YWJsZXJhbmdlOjZkMDI2YWIwMmNlYTQyNTI4ZTc1NTc4OThiNjMzNDI2XzQtMy0xLTEtMA_4821a726-625c-4b21-b2ed-7a739f396aad">43,244</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i98edd9ec68b24ced9b531e766587d469_D20180701-20180930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83OTYvZnJhZzo1OTVjZDUzNjhiMGY0OWE0YTAwMWNhZmQzY2I5YTQ1ZS90YWJsZTo2ZDAyNmFiMDJjZWE0MjUyOGU3NTU3ODk4YjYzMzQyNi90YWJsZXJhbmdlOjZkMDI2YWIwMmNlYTQyNTI4ZTc1NTc4OThiNjMzNDI2XzQtNS0xLTEtMA_27ce1a0a-820b-4d80-89d9-275770c55be3">34,029</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i724f8d5b79f44384afe7b27042231bfe_D20181001-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83OTYvZnJhZzo1OTVjZDUzNjhiMGY0OWE0YTAwMWNhZmQzY2I5YTQ1ZS90YWJsZTo2ZDAyNmFiMDJjZWE0MjUyOGU3NTU3ODk4YjYzMzQyNi90YWJsZXJhbmdlOjZkMDI2YWIwMmNlYTQyNTI4ZTc1NTc4OThiNjMzNDI2XzQtNy0xLTEtMA_c0d71e36-bd2c-4d63-bae9-f9e2b41a2004">44,644</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss per share, basic and diluted </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="i8b9c8e543ab44629819b1e0b7554ce96_D20180101-20180331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83OTYvZnJhZzo1OTVjZDUzNjhiMGY0OWE0YTAwMWNhZmQzY2I5YTQ1ZS90YWJsZTo2ZDAyNmFiMDJjZWE0MjUyOGU3NTU3ODk4YjYzMzQyNi90YWJsZXJhbmdlOjZkMDI2YWIwMmNlYTQyNTI4ZTc1NTc4OThiNjMzNDI2XzUtMS0xLTEtMA_2db347b5-a75d-4027-9f4f-86f3cad87b0c">1.34</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="ie7fccf344bc24f03934ea77078a49726_D20180401-20180630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83OTYvZnJhZzo1OTVjZDUzNjhiMGY0OWE0YTAwMWNhZmQzY2I5YTQ1ZS90YWJsZTo2ZDAyNmFiMDJjZWE0MjUyOGU3NTU3ODk4YjYzMzQyNi90YWJsZXJhbmdlOjZkMDI2YWIwMmNlYTQyNTI4ZTc1NTc4OThiNjMzNDI2XzUtMy0xLTEtMA_8c987898-415d-4d3c-9450-21b2e1729702">1.03</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="i98edd9ec68b24ced9b531e766587d469_D20180701-20180930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83OTYvZnJhZzo1OTVjZDUzNjhiMGY0OWE0YTAwMWNhZmQzY2I5YTQ1ZS90YWJsZTo2ZDAyNmFiMDJjZWE0MjUyOGU3NTU3ODk4YjYzMzQyNi90YWJsZXJhbmdlOjZkMDI2YWIwMmNlYTQyNTI4ZTc1NTc4OThiNjMzNDI2XzUtNS0xLTEtMA_5dd41eea-36aa-482b-ae61-936c41f0d18e">0.81</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="i724f8d5b79f44384afe7b27042231bfe_D20181001-20181231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83OTYvZnJhZzo1OTVjZDUzNjhiMGY0OWE0YTAwMWNhZmQzY2I5YTQ1ZS90YWJsZTo2ZDAyNmFiMDJjZWE0MjUyOGU3NTU3ODk4YjYzMzQyNi90YWJsZXJhbmdlOjZkMDI2YWIwMmNlYTQyNTI4ZTc1NTc4OThiNjMzNDI2XzUtNy0xLTEtMA_6df40bc8-f66d-48ca-837f-924537d554b6">1.06</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenue</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icfb4268699e645dc87743a7e862848d6_D20170101-20170331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83OTYvZnJhZzo1OTVjZDUzNjhiMGY0OWE0YTAwMWNhZmQzY2I5YTQ1ZS90YWJsZTo2ZDAyNmFiMDJjZWE0MjUyOGU3NTU3ODk4YjYzMzQyNi90YWJsZXJhbmdlOjZkMDI2YWIwMmNlYTQyNTI4ZTc1NTc4OThiNjMzNDI2XzktMS0xLTEtMA_04c542a1-d117-49af-9a7a-6a607bca9e4d">2,055</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icc68311eb541421f98636ba4e9bffdb3_D20170401-20170630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83OTYvZnJhZzo1OTVjZDUzNjhiMGY0OWE0YTAwMWNhZmQzY2I5YTQ1ZS90YWJsZTo2ZDAyNmFiMDJjZWE0MjUyOGU3NTU3ODk4YjYzMzQyNi90YWJsZXJhbmdlOjZkMDI2YWIwMmNlYTQyNTI4ZTc1NTc4OThiNjMzNDI2XzktMy0xLTEtMA_da8e9264-1c3a-4b3d-a210-5dc8f1a46afa">1,666</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1bf42114bac84fe587857eea6b6d8228_D20170701-20170930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83OTYvZnJhZzo1OTVjZDUzNjhiMGY0OWE0YTAwMWNhZmQzY2I5YTQ1ZS90YWJsZTo2ZDAyNmFiMDJjZWE0MjUyOGU3NTU3ODk4YjYzMzQyNi90YWJsZXJhbmdlOjZkMDI2YWIwMmNlYTQyNTI4ZTc1NTc4OThiNjMzNDI2XzktNS0xLTEtMA_4d5724de-8dbe-4b5f-b9c8-76c28d46fe7c">1,663</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib42a39a1f0994e319ac400bbdfb12754_D20171001-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83OTYvZnJhZzo1OTVjZDUzNjhiMGY0OWE0YTAwMWNhZmQzY2I5YTQ1ZS90YWJsZTo2ZDAyNmFiMDJjZWE0MjUyOGU3NTU3ODk4YjYzMzQyNi90YWJsZXJhbmdlOjZkMDI2YWIwMmNlYTQyNTI4ZTc1NTc4OThiNjMzNDI2XzktNy0xLTEtMA_30d42ed0-ca29-4905-908f-5dcb7a7bcacd">152,359</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income (loss)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="icfb4268699e645dc87743a7e862848d6_D20170101-20170331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83OTYvZnJhZzo1OTVjZDUzNjhiMGY0OWE0YTAwMWNhZmQzY2I5YTQ1ZS90YWJsZTo2ZDAyNmFiMDJjZWE0MjUyOGU3NTU3ODk4YjYzMzQyNi90YWJsZXJhbmdlOjZkMDI2YWIwMmNlYTQyNTI4ZTc1NTc4OThiNjMzNDI2XzEwLTEtMS0xLTA_9258e77a-be41-4971-b2d7-a41deec636e2">37,655</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="icc68311eb541421f98636ba4e9bffdb3_D20170401-20170630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83OTYvZnJhZzo1OTVjZDUzNjhiMGY0OWE0YTAwMWNhZmQzY2I5YTQ1ZS90YWJsZTo2ZDAyNmFiMDJjZWE0MjUyOGU3NTU3ODk4YjYzMzQyNi90YWJsZXJhbmdlOjZkMDI2YWIwMmNlYTQyNTI4ZTc1NTc4OThiNjMzNDI2XzEwLTMtMS0xLTA_54dff957-fc53-4da6-b49a-2e4b7c4e249b">40,654</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1bf42114bac84fe587857eea6b6d8228_D20170701-20170930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83OTYvZnJhZzo1OTVjZDUzNjhiMGY0OWE0YTAwMWNhZmQzY2I5YTQ1ZS90YWJsZTo2ZDAyNmFiMDJjZWE0MjUyOGU3NTU3ODk4YjYzMzQyNi90YWJsZXJhbmdlOjZkMDI2YWIwMmNlYTQyNTI4ZTc1NTc4OThiNjMzNDI2XzEwLTUtMS0xLTA_73753da6-cdc4-412b-95dc-dc7465b1ed5c">47,043</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib42a39a1f0994e319ac400bbdfb12754_D20171001-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83OTYvZnJhZzo1OTVjZDUzNjhiMGY0OWE0YTAwMWNhZmQzY2I5YTQ1ZS90YWJsZTo2ZDAyNmFiMDJjZWE0MjUyOGU3NTU3ODk4YjYzMzQyNi90YWJsZXJhbmdlOjZkMDI2YWIwMmNlYTQyNTI4ZTc1NTc4OThiNjMzNDI2XzEwLTctMS0xLTA_0fbaa809-a214-4131-a568-ceb36db27794">105,727</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income (loss) per share, basic</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="icfb4268699e645dc87743a7e862848d6_D20170101-20170331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83OTYvZnJhZzo1OTVjZDUzNjhiMGY0OWE0YTAwMWNhZmQzY2I5YTQ1ZS90YWJsZTo2ZDAyNmFiMDJjZWE0MjUyOGU3NTU3ODk4YjYzMzQyNi90YWJsZXJhbmdlOjZkMDI2YWIwMmNlYTQyNTI4ZTc1NTc4OThiNjMzNDI2XzExLTEtMS0xLTA_30071b9c-5ac5-479d-815d-21172014d5e8">1.08</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="icc68311eb541421f98636ba4e9bffdb3_D20170401-20170630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83OTYvZnJhZzo1OTVjZDUzNjhiMGY0OWE0YTAwMWNhZmQzY2I5YTQ1ZS90YWJsZTo2ZDAyNmFiMDJjZWE0MjUyOGU3NTU3ODk4YjYzMzQyNi90YWJsZXJhbmdlOjZkMDI2YWIwMmNlYTQyNTI4ZTc1NTc4OThiNjMzNDI2XzExLTMtMS0xLTA_d82d6b01-3296-4835-b539-a9f7fd746d2d">1.14</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="i1bf42114bac84fe587857eea6b6d8228_D20170701-20170930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83OTYvZnJhZzo1OTVjZDUzNjhiMGY0OWE0YTAwMWNhZmQzY2I5YTQ1ZS90YWJsZTo2ZDAyNmFiMDJjZWE0MjUyOGU3NTU3ODk4YjYzMzQyNi90YWJsZXJhbmdlOjZkMDI2YWIwMmNlYTQyNTI4ZTc1NTc4OThiNjMzNDI2XzExLTUtMS0xLTA_dd534bef-cb28-438f-863f-9ea03e250da0">1.28</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="ib42a39a1f0994e319ac400bbdfb12754_D20171001-20171231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83OTYvZnJhZzo1OTVjZDUzNjhiMGY0OWE0YTAwMWNhZmQzY2I5YTQ1ZS90YWJsZTo2ZDAyNmFiMDJjZWE0MjUyOGU3NTU3ODk4YjYzMzQyNi90YWJsZXJhbmdlOjZkMDI2YWIwMmNlYTQyNTI4ZTc1NTc4OThiNjMzNDI2XzExLTctMS0xLTA_867b73f2-3426-417c-a511-a8e440f7cce4">2.87</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income (loss) per share, diluted</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="icfb4268699e645dc87743a7e862848d6_D20170101-20170331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83OTYvZnJhZzo1OTVjZDUzNjhiMGY0OWE0YTAwMWNhZmQzY2I5YTQ1ZS90YWJsZTo2ZDAyNmFiMDJjZWE0MjUyOGU3NTU3ODk4YjYzMzQyNi90YWJsZXJhbmdlOjZkMDI2YWIwMmNlYTQyNTI4ZTc1NTc4OThiNjMzNDI2XzEyLTEtMS0xLTA_5644e30d-6205-41bd-aa2a-38a0e4cdcb1a">1.08</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="icc68311eb541421f98636ba4e9bffdb3_D20170401-20170630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83OTYvZnJhZzo1OTVjZDUzNjhiMGY0OWE0YTAwMWNhZmQzY2I5YTQ1ZS90YWJsZTo2ZDAyNmFiMDJjZWE0MjUyOGU3NTU3ODk4YjYzMzQyNi90YWJsZXJhbmdlOjZkMDI2YWIwMmNlYTQyNTI4ZTc1NTc4OThiNjMzNDI2XzEyLTMtMS0xLTA_456e59a3-aeda-4f35-aa9a-7070de53defb">1.14</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="i1bf42114bac84fe587857eea6b6d8228_D20170701-20170930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83OTYvZnJhZzo1OTVjZDUzNjhiMGY0OWE0YTAwMWNhZmQzY2I5YTQ1ZS90YWJsZTo2ZDAyNmFiMDJjZWE0MjUyOGU3NTU3ODk4YjYzMzQyNi90YWJsZXJhbmdlOjZkMDI2YWIwMmNlYTQyNTI4ZTc1NTc4OThiNjMzNDI2XzEyLTUtMS0xLTA_ed861afd-f094-4837-a0f6-7f9690da7edc">1.28</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="ib42a39a1f0994e319ac400bbdfb12754_D20171001-20171231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83OTYvZnJhZzo1OTVjZDUzNjhiMGY0OWE0YTAwMWNhZmQzY2I5YTQ1ZS90YWJsZTo2ZDAyNmFiMDJjZWE0MjUyOGU3NTU3ODk4YjYzMzQyNi90YWJsZXJhbmdlOjZkMDI2YWIwMmNlYTQyNTI4ZTc1NTc4OThiNjMzNDI2XzEyLTctMS0xLTA_0d3505d8-18d9-4a0b-b6ef-b4b64bbc2436">2.80</ix:nonFraction>&#160;</span></td></tr></table></ix:nonNumeric></ix:continuation></div><div style="margin-top:3pt;margin-bottom:9pt;"><span><br/></span></div><div id="i_0_870"></div><div style="margin-top:3pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">12.&#160;&#160;<ix:nonNumeric contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF84NzAvZnJhZzozMDMwOTJjNzA1M2I0Zjg2YjJlOWNmZTU5YWY2NjNiNy90ZXh0cmVnaW9uOjMwMzA5MmM3MDUzYjRmODZiMmU5Y2ZlNTlhZjY2M2I3XzIxOTkwMjMyNTk1NDg_213f32d7-cab3-4240-82c7-4ae867f416df" continuedAt="i077874eae39040eaba6a5aa40cb9aa40" escape="true">Subsequent Event</ix:nonNumeric></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"><ix:continuation id="i077874eae39040eaba6a5aa40cb9aa40">In February 2019, the Company completed a follow-on equity offering, in which the Company sold <ix:nonFraction unitRef="shares" contextRef="i7ed315b7b06447388b74464c7e252a0a_D20190201-20190228" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF84NzAvZnJhZzozMDMwOTJjNzA1M2I0Zjg2YjJlOWNmZTU5YWY2NjNiNy90ZXh0cmVnaW9uOjMwMzA5MmM3MDUzYjRmODZiMmU5Y2ZlNTlhZjY2M2I3XzU0OTc1NTgxNzg3NQ_69ed7190-b896-4858-bab1-3bd226bd70f0">5,500,000</ix:nonFraction> shares of its common stock at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i6fdc91e82d3b4cb9ab3b078b4413a743_I20190228" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF84NzAvZnJhZzozMDMwOTJjNzA1M2I0Zjg2YjJlOWNmZTU5YWY2NjNiNy90ZXh0cmVnaW9uOjMwMzA5MmM3MDUzYjRmODZiMmU5Y2ZlNTlhZjY2M2I3XzU0OTc1NTgxNzg4Mw_bcca5c7f-917f-4ea7-bd82-9b0abc440bfd">20.00</ix:nonFraction> per share.  Additionally, the underwriters of the offering exercised the full amount of their over-allotment option resulting in the sale of an additional <ix:nonFraction unitRef="shares" contextRef="i1b259175425444a1a2fc354b79a24aa5_D20190201-20190228" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF84NzAvZnJhZzozMDMwOTJjNzA1M2I0Zjg2YjJlOWNmZTU5YWY2NjNiNy90ZXh0cmVnaW9uOjMwMzA5MmM3MDUzYjRmODZiMmU5Y2ZlNTlhZjY2M2I3XzU0OTc1NTgxNzg2NA_e06559fb-02a6-49cd-a7a8-964303ee8669">825,000</ix:nonFraction> shares of the Company&#8217;s common stock at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i008460346dd94dac853841c05961f142_I20190228" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF84NzAvZnJhZzozMDMwOTJjNzA1M2I0Zjg2YjJlOWNmZTU5YWY2NjNiNy90ZXh0cmVnaW9uOjMwMzA5MmM3MDUzYjRmODZiMmU5Y2ZlNTlhZjY2M2I3XzU0OTc1NTgxNzg1NQ_ba2e6b10-ff79-4ed0-b554-d138fedd30c8">20.00</ix:nonFraction> per share.  The Company received net proceeds of $<ix:nonFraction unitRef="usd" contextRef="i7ed315b7b06447388b74464c7e252a0a_D20190201-20190228" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF84NzAvZnJhZzozMDMwOTJjNzA1M2I0Zjg2YjJlOWNmZTU5YWY2NjNiNy90ZXh0cmVnaW9uOjMwMzA5MmM3MDUzYjRmODZiMmU5Y2ZlNTlhZjY2M2I3XzU0OTc1NTgxNzg0Ng_802e3805-74d0-4e21-a847-5bd43f1b117f">118.5</ix:nonFraction> million from this offering, net of underwriting discounts and commissions and other estimated offering expenses.</ix:continuation></span></div><div id="i_0_808"></div><div style="text-align:center;-sec-extract:summary;"></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">F - 26</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">EXHIBIT INDEX</span></div><div style="margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"><tr><td style="width:1.0%;"></td><td style="width:7.677419%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.519062%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:84.803519%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Exhibit</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">No.</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Description</span></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">3.1&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">Restated Certificate of Incorporation of the Company and Certificate of Correction to the Restated Certificate of Incorporation of the Company (incorporated by reference to Exhibits </span><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1125345/000119312513402831/d613759dex31.htm">3.1</a></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;"> and </span><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1125345/000119312513402831/d613759dex33.htm">3.3</a></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">, respectively, to the Company's Current Report on Form 8-K filed on October 18, 2013)</span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">3.2&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1125345/000119312513386872/d575431dex34.htm">Amended and Restated By-Laws of the Company (incorporated by reference to Exhibit 3.4 to the Registration Statement on Form S-1 (File No. 333-190994) filed by the Company on October 1, 2013)</a></span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">4.1&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1125345/000119312513394786/d575431dex42.htm">Specimen Stock Certificate (incorporated by reference to Exhibit 4.2 to the Registration Statement on Form S-1 (File No. 333-190994) filed by the Company on October 9, 2013)</a></span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">4.2&#8224;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1125345/000119312515075224/d838054dex43.htm">Investor Agreement by and between Johnson and Johnson Innovation-JJDC, Inc. and the Company, dated December 19, 2014 (incorporated by reference to Exhibit 4.3 to the Company's Annual Report on Form 10-K filed on March 3, 2015)</a></span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">10.1&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1125345/000119312513386872/d575431dex1014.htm">Form of Indemnification Agreement (incorporated by reference to Exhibit 10.14 to the Registration Statement on Form S-1 (File No. 333-190994) filed by the Company on October 1, 2013)</a></span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">10.2&#8224;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1125345/000119312513391750/d575431dex1020.htm">Option for a License Agreement by and between the Company and Les Laboratoires Servier and Institut de Recherches Servier, dated September 19, 2012 (incorporated by reference to Exhibit 10.20 to the Registration Statement on Form S-1 (File No. 333-190994) filed by the Company on October 4, 2013)</a></span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">10.3&#8224;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1125345/000112534518000022/exhibit10-3201710xkfinal.htm">Global Collaboration and License Agreement by and between the Company and Incyte Corporation, dated October 24, 2017</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1125345/000112534518000022/exhibit10-3201710xkfinal.htm">&#160;</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1125345/000112534518000022/exhibit10-3201710xkfinal.htm">(incorporated by reference to Exhibit </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1125345/000112534518000022/exhibit10-3201710xkfinal.htm">10</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1125345/000112534518000022/exhibit10-3201710xkfinal.htm">.3 to the Company's Annual Report on Form 10-K filed on </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1125345/000112534518000022/exhibit10-3201710xkfinal.htm">February 27, 2018</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1125345/000112534518000022/exhibit10-3201710xkfinal.htm">)</a></span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">10.4+</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1125345/000119312513357191/d575431dex103.htm">Company 2003 Equity Incentive Plan (incorporated by reference to Exhibit 10.3 to the Registration Statement on Form S-1 (File No. 333-190994) filed by the Company on September 4, 2013)</a></span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">10.5+</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1125345/000119312513357191/d575431dex104.htm">Form of Incentive Stock Option Agreement under 2003 Equity Incentive Plan (incorporated by reference to Exhibit 10.4 to the Registration Statement on Form S-1 (File No. 333-190994) filed by the Company on September 4, 2013)</a></span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">10.6+</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1125345/000119312513386872/d575431dex105.htm">Company 2013 Equity Incentive Plan (incorporated by reference to Exhibit 10.5 to the Registration Statement on Form S-1 (File No. 333-190994) filed by the Company on October 1, 2013)</a></span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">10.7+</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1125345/000119312513386872/d575431dex106.htm">Form of Incentive Stock Option Agreement under 2013 Equity Incentive Plan (incorporated by reference to Exhibit 10.6 to the Registration Statement on Form S-1 (File No. 333-190994) filed by the Company on October 1, 2013)</a></span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">10.8+</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1125345/000119312513386872/d575431dex107.htm">Form of Nonstatutory Stock Option Agreement under 2013 Equity Incentive Plan (incorporated by reference to Exhibit 10.7 to the Registration Statement on Form S-1 (File No. 333-190994) filed by the Company on October 1, 2013)</a></span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">10.9+</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1125345/000112534515000013/exhibit10-2.htm">Form of Restricted Stock Units Grant Notice under 2013 Equity Incentive Plan (incorporated by reference to Exhibit 10.2 to the Company's Quarterly Report on Form 10-Q filed on May 6, 2015)</a></span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">10.10+</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1125345/000155278116002035/e00576_ex4-1.htm">2016 Employee Stock Purchase Plan (incorporated by reference to Exhibit 4.1 to the Registration Statement on Form S-8 (File No. 333-214386) filed by the Company on November 2, 2016)</a></span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">10.11+</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1125345/000112534516000046/exhibit1014.htm">Employment Agreement between the Company and Scott Koenig, M.D., Ph.D. (incorporated by reference to Exhibit 10.14 to the Company's Annual Report on Form 10-K filed by the Company on February 29, 2016)</a></span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">10.12+</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1125345/000112534516000046/exhibit1015.htm">Employment Agreement between the Company and James Karrels (incorporated by reference to Exhibit 10.15 to the Company's Annual Report on Form 10-K filed by the Company on February 29, 2016)</a></span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">10.13+</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1125345/000112534516000056/exhibit10-1.htm">Employment Agreement between the Company and Jon Wigginton, M.D. (incorporated by reference to Exhibit 10.1 to the Company's Quarterly Report on Form 10-Q filed on May 4, 2016)</a></span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">10.14+</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1125345/000112534516000056/exhibit10-2.htm">Restricted Stock Units Grant Notice and Agreement between the Company and Jon Wigginton, M.D. (incorporated by reference to Exhibit 10.2 to the Company's Quarterly Report on Form 10-Q filed on May 4, 2016)</a></span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">10.15+</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1125345/000112534516000056/exhibit10-3.htm">Employment Agreement between the Company and Ezio Bonvini, M.D. (incorporated by reference to Exhibit 10.3 to the Company's Quarterly Report on Form 10-Q filed on May 4, 2016)</a></span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">10.16+</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1125345/000112534517000041/exhibit1016.htm">Employment Agreement between the Company and Eric Risser (incorporated by reference to Exhibit 10.16 to the Company's Annual Report on Form 10-K filed on February 28, 2017)</a></span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div><span><br/></span></div></div></div><hr style="page-break-after:always"></hr><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"><tr><td style="width:1.0%;"></td><td style="width:7.677419%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.519062%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:84.803519%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:120%;">10.17&#8224;</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1125345/000112534518000058/exhibit101incyteamendment.htm">Amendment No, 1 to the Global Collaboration and License Agreement by and between the Company and Incyte Corporation, dated March 15, 2018</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1125345/000112534518000058/exhibit101incyteamendment.htm">&#160;</a></span><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1125345/000112534518000058/exhibit101incyteamendment.htm">(incorporated by reference to Exhibit 10.</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1125345/000112534518000058/exhibit101incyteamendment.htm">1</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1125345/000112534518000058/exhibit101incyteamendment.htm"> to the Company's Quarterly Report on Form 10-Q filed on May </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1125345/000112534518000058/exhibit101incyteamendment.htm">7</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1125345/000112534518000058/exhibit101incyteamendment.htm">, 201</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1125345/000112534518000058/exhibit101incyteamendment.htm">7</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1125345/000112534518000058/exhibit101incyteamendment.htm">)</a></span></div></td></tr><tr><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:120%;">10.18&#8224;</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="exhibit1018to2018form1.htm">First Amendment to Option for a License Agreement by and between the Company and Les Laboratoires Servier and Institut de Recherches Servier, dated June 14, 2017</a></span></div></td></tr><tr><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:120%;">10.19&#8224;</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="exhibit1019to2018form1.htm">Second Amendment to Option for a License Agreement by and between the Company and Les Laboratoires Servier and Institut de Recherches Servier, dated March 1, 2018</a></span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">23.1&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="mgnxexhibit23-1201810xk.htm">Consent of Ernst &amp; Young, LLP, Independent Registered Public Accounting Firm</a></span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">31.1&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="mgnxexhibit31-1201810xk.htm">Rule 13a-14(a) Certification of Principal Executive Officer</a></span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">31.2&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="mgnxexhibit31-2201810xk.htm">Rule 13a-14(a) Certification of Principal Financial Officer</a></span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">32.1&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="mgnxexhibit32-1201810xk.htm">Section 1350 Certification of Principal Executive Officer</a></span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">32.2&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="mgnxexhibit32-2201810xk.htm">Section 1350 Certification of Principal Financial Officer</a></span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">101.INS</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">XBRL Instance Document</span></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">101.SCH</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">XBRL Schema Document</span></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">101.CAL</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">XBRL Calculation Linkbase Document</span></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">101.DEF</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">XBRL Definition Linkbase Document</span></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">101.LAB</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">XBRL Labels Linkbase Document</span></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">101.PRE</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">XBRL Presentation Linkbase Document</span></td></tr></table></div><div style="text-indent:-36pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8224;&#160;Portions of this exhibit (indicated by asterisks) have been omitted pursuant to a request for confidential treatment granted by the SEC.</span></div><div style="text-indent:-36pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">+&#160;Indicates management contract or compensatory plan.</span></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.18
<SEQUENCE>2
<FILENAME>exhibit1018to2018form1.htm
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2019 Workiva -->
<title>Document</title></head><body><div id="i_0_1"></div><div style="height:72pt;width:100%;"><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:115%;">THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH &#91;***&#93; AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</font></div></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:400;line-height:120%;">AMENDMENT N&#176;1 TO </font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:400;line-height:120%;">OPTION FOR A LICENSE AGREEMENT</font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:400;line-height:120%;">THIS AMENDMENT N&#176;1 (hereinafter referred to as the &#8220;Amendment N&#176;1&#8221;) entered into as of the 14</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:7.8pt;font-weight:400;line-height:120%;vertical-align:top;">th</sup><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:400;line-height:120%;"> day of June, 2017 (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Amendment N&#176;1 Effective Date</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) by and between MacroGenics, Inc. a Delaware corporation having a place of business at 9704 Medical Center Drive, Rockville, MD, USA 20850 (&#8220;MacroGenics&#8221;), and Les Laboratoires Servier, a company organized and existing under the laws of France, having a principal office located at 50 rue Carnot 92284 Suresnes (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">LLS</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) and Institut de Recherches Servier, a company organized and existing under the laws of France, having a principal office located at 3 rue de la Republique - 92150 Suresnes - France (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">IdRS</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) and LLS and IdRS hereinafter collectively referred to as &#8220;Servier&#8221;).</font></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:400;line-height:120%;">MacroGenics and Servier are each referred to herein by name or as a &#8220;Party&#8221; or, collectively, as &#8220;Parties.&#8221;</font></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:400;line-height:120%;">WHEREAS, Servier and MacroGenics are parties to the Option for a License Agreement, dated September 19, 2012 (hereinafter referred to as the &#8220;Agreement&#8221;), which set forth notably the terms and conditions of an option grant and an exclusive license to enable Servier to research, develop and commercialize DARTS mentioned in the Agreement, upon exercise of the exclusive option by Servier with respect to such DARTS&#59;</font></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:400;line-height:120%;">WHEREAS, Servier and MacroGenics wish to execute an Amendment N&#176;1 to the Agreement, in accordance with Section 16.10 of the Agreement, in order to provide for alternate terms with respect to certain of the Parties&#8217; rights and obligations under Section 7.1.1 of the Agreement</font></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:400;line-height:120%;">NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties agree to the following terms and conditions&#58;</font></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:400;line-height:120%;">All capitalized terms used in this Amendment N&#176;1 but not otherwise defined herein, shall have the meanings ascribed to such terms in the Agreement.</font></div><div><font><br></font></div><div style="position:relative;width:100%;height:72pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:115%;">THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH &#91;***&#93; AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</font></div></div><div style="text-indent:-36pt;padding-left:36pt;text-align:justify;"><font><br></font></div><div style="text-indent:-36pt;padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:700;line-height:120%;">1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:700;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:700;line-height:120%;">TRANSFER OF MACROGENICS MANUFACTURING KNOW-HOW FOR &#91;***&#93; </font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:400;line-height:120%;">Section 7.1.1 of the Agreement is hereby amended to add the following as the second sentence of such Section&#58;</font></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">&#8220;Notwithstanding the foregoing, for the &#91;***&#93; designated as &#91;***&#93; which is included in the &#91;***&#93;, upon a decision of the Joint Manufacturing Committee (&#8220;JMC&#8221;) (a subcommittee of the JSC established in accordance with Section 2.5.3) and on a schedule and a product comparability plan agreed upon by the JMC, MacroGenics shall disclose (and provide copies, as applicable) to either Servier or a Third Party manufacturer that is mutually acceptable to both Parties, all MacroGenics Know-How necessary or useful to enable Servier or such Third Party manufacturer (as appropriate) to Manufacture applicable Licensed Product included in the &#91;***&#93; based on a manufacturing process determined by MacroGenics.&#8221;</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:700;line-height:120%;">2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:700;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:700;line-height:120%;">TERM</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:400;line-height:120%;">This Amendment N&#176;1 shall be effective on the Amendment N&#176;1 Effective Date and ends at the expiration of the Agreement.</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:700;line-height:120%;">3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:700;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:700;line-height:120%;">OTHER TERMS AND CONDITIONS OF THE AGREEMENT</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:400;line-height:120%;">All other terms and conditions of the Agreement not modified by the Amendment N&#176;1 shall remain unaltered and given full force and effect.</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:400;line-height:120%;">&#91;Remainder of page intentionally blank&#93;</font></div><div id="i_0_36"></div><div style="text-align:justify;"><font><br></font></div><div style="position:relative;width:100%;height:72pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:115%;">THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH &#91;***&#93; AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</font></div></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:12pt;line-height:120%;">IN WITNESS WHEREOF, the Parties, intending to be legally bound, have caused this Amendment to be executed by their respective duly authorized representatives as of the Amendment Effective Date.</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:4.891026%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:69.955128%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:19.153846%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">MACROGENICS, INC.&#160;</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></font></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></font></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">By&#58;&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;&#160;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Name&#58;&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;&#160;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Title&#58;&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;&#160;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></font></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">LES LABORATOIRES SERVIER&#160;</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></font></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></font></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></font></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">By&#58;&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;&#160;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Name&#58;&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;&#160;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Title&#58;&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;&#160;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></font></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></font></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></font></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">By&#58;&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;&#160;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Name&#58;&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;&#160;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Title&#58;&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;&#160;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></font></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></font></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></font></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></font></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">INSTITUT DE RECHERCHES SERVIER&#160;</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></font></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></font></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></font></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">By&#58;&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;&#160;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Name&#58;&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;&#160;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Title&#58;&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;&#160;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="text-align:justify;"><font><br></font></div><div style="position:relative;width:100%;height:72pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.19
<SEQUENCE>3
<FILENAME>exhibit1019to2018form1.htm
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2019 Workiva -->
<title>Document</title></head><body><div id="i_0_21"></div><div style="height:72pt;width:100%;"><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:115%;">THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH &#91;***&#93; AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</font></div><div><font><br></font></div></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:12pt;line-height:115%;">SECOND AMENDMENT to OPTION FOR A LICENSE AGREEMENT</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:12pt;line-height:115%;">This Second Amendment entered into on the date of last signature to this First Amendment by and between MacroGenics, Inc. a Delaware corporation having a principal office located at 9704 Medical Center Drive, Rockville, MD  20850 (&#8220;MacroGenics&#8221;) &#8243;), and Les Laboratoires Servier, a company organized and existing under the laws of France, having a principal office located at 50 rue Carnot 92284 Suresnes (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:12pt;line-height:115%;text-decoration: underline;">LLS</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:12pt;line-height:115%;">&#8221;) and Institut de Recherches Servier, a company organized and existing under the laws of France, having a principal office located at 3 rue de la R&#233;publique - 92150 Suresnes - France (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:12pt;line-height:115%;text-decoration: underline;">IdRS</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:12pt;line-height:115%;">&#8221;) and LLS and IdRS hereinafter collectively referred to as &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:12pt;line-height:115%;text-decoration: underline;">Servier</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:12pt;line-height:115%;">&#8221;).  MacroGenics and Servier are each referred to herein by name or as a &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:12pt;line-height:115%;text-decoration: underline;">Party</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:12pt;line-height:115%;">&#8221; or, collectively, as &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:12pt;line-height:115%;text-decoration: underline;">Parties</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:12pt;line-height:115%;">.&#8221;</font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:12pt;line-height:115%;">WHEREAS, Servier and MacroGenics executed an Option for a License Agreement on September 19, 2012, as amended on 14 June 2017 (the &#8220;Agreement&#8221;)&#59;</font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:12pt;line-height:115%;">WHEREAS, the Parties wish to further amend the Agreement as set forth below&#59;</font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:12pt;line-height:115%;">NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties agree to the following terms and conditions&#58;</font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:12pt;line-height:115%;">1.   All capitalized terms used in this Second Amendment, but not otherwise defined herein, shall have the meanings ascribed to such terms in the Agreement.</font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:12pt;line-height:115%;">2.   Article 1.64(b) shall be deleted in its entirety and replaced with the following&#58;</font></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:12pt;line-height:115%;">&#8220;with respect to each of the A33 Program &#91;***&#93;.&#8221;</font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:12pt;line-height:115%;">3.   This Second Amendment and the Agreement constitute the entire agreement of the parties and supersedes any and all prior agreements, written or oral, between Servier and MacroGenics relating to the subject matter of this First Amendment and the Agreement and neither may be amended unless agreed to in writing by both parties.</font></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:12pt;font-style:italic;line-height:115%;">&#91;Signature page follows&#93;</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div id="i_0_26"></div><div></div><div style="position:relative;width:100%;height:72pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:115%;">THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH &#91;***&#93; AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</font></div><div><font><br></font></div></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:12pt;line-height:115%;">IN WITNESS WHEREOF, the parties, intending to be legally bound, have caused this First Amendment to be executed by their respective duly authorized representative.</font></div><div><font><br></font></div><div><font><br></font></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:4.891026%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:30.692308%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:8.416667%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:4.891026%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:41.108974%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;height:17pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:700;line-height:115%;">MacroGenics, Inc.</font></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="height:17pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;height:17pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:700;line-height:115%;">Les Laboratoires</font></div></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Name&#58;&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;&#160;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Name&#58;&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;&#160;</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;&#160;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></font></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></font></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Title&#58;&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;&#160;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Title&#58;&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;&#160;</font></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></font></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Date&#58;&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;&#160;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Date&#58;&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;&#160;</font></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Institut de Recherches Servier &#160;</font></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></font></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Name&#58;&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;&#160;</font></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></font></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></font></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></font></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Title&#58;&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;&#160;</font></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></font></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Date&#58;&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;&#160;</font></td></tr></table></div><div><font><br></font></div><div style="position:relative;width:100%;height:72pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>mgnxexhibit23-1201810xk.htm
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2019 Workiva -->
<title>Document</title></head><body><div id="i_0_1"></div><div style="height:42.75pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">EXHIBIT 23.1</font></div><div style="text-align:center;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">We consent to the incorporation by reference in the following Registration Statements&#58;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:12pt;line-height:120%;">&#160;</font></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:10.5pt;">Registration Statement (Form S-8 No. 333-192277) pertaining to the 2000 Stock Option Incentive Plan, the 2003 Equity Incentive Plan, and 2013 Equity Incentive Plan of MacroGenics, Inc.&#59; </font></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:12pt;line-height:115%;">2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;padding-left:8pt;">Registration Statements (Form S-8 No. 333-202470</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">,</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;"> Form S-8 No. 333-209812</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;"> and </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">Form S-8 No. 333-217620</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">) pertaining to the 2013 Equity Incentive Plan of MacroGenics, Inc.&#59;</font></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:10.5pt;">Registration Statement (Form S-8 No. 333-214386) pertaining to the 2016 Employee Stock Purchase Plan of MacroGenics, Inc.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#59;</font></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">4.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:10.5pt;">Registration Statement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> (Form</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> S-3 ASR No. 333-214385) of MacroGenics, Inc.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#59;</font></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">5.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:10.5pt;">Registration Statement (Form S-</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">8</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> No. 333-2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">23682</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">) </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">pertaining to the 2013 Equity Incentive Plan </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">of MacroGenics, Inc.</font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">of our reports dated </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">February&#160;26, 2019</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">, with respect to the consolidated financial statements of MacroGenics, Inc. and the effectiveness of internal control over financial reporting of MacroGenics, Inc.&#160;included in this Annual Report (Form 10-K) of MacroGenics, Inc. for the year ended </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">December&#160;31, 2018</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">.</font></div><div style="margin-top:18pt;"><font><br></font></div><div style="margin-top:18pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#47;s&#47; Ernst&#160;&#38; Young LLP</font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Baltimore, Maryland</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">February&#160;26, 2019</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#160;</font></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>mgnxexhibit31-1201810xk.htm
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2019 Workiva -->
<title>Document</title></head><body><div id="i_0_1"></div><div style="height:42.75pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">EXHIBIT 31.1</font></div><div style="margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">I, Scott Koenig, certify that&#58;</font></div><div style="text-indent:-36pt;padding-left:72pt;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:28.5pt;">I have reviewed this Annual Report on Form 10-K for the period ended </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">December&#160;31, 2018</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> of MacroGenics, Inc.&#59;</font></div><div style="text-indent:-36pt;padding-left:72pt;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:28.5pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="text-indent:-36pt;padding-left:72pt;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:28.5pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="text-indent:-36pt;padding-left:72pt;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">4.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:28.5pt;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="text-indent:-36pt;padding-left:126pt;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">a.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:29.07pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="text-indent:-36pt;padding-left:126pt;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">b.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:28.5pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="text-indent:-36pt;padding-left:126pt;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">c.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:29.07pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="text-indent:-36pt;padding-left:126pt;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">d.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:28.5pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="text-indent:-36pt;padding-left:72pt;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">5.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:28.5pt;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="text-indent:-36pt;padding-left:126pt;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">a.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:29.07pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="text-indent:-36pt;padding-left:126pt;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">b.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:28.5pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="padding-left:126pt;"><font><br></font></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"><tr><td style="width:1.0%;"></td><td style="width:46.680352%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:2.439296%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:46.680352%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; Scott&#160;Koenig</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Scott Koenig, M.D., Ph.D.</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">President and Chief Executive Officer</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">(Principal Executive Officer)</font></div></td></tr></table></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Dated&#58;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">February&#160;26, 2019</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#160;</font></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>mgnxexhibit31-2201810xk.htm
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2019 Workiva -->
<title>Document</title></head><body><div id="i_0_1"></div><div style="height:42.75pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">EXHIBIT 31.2</font></div><div style="margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">I, James Karrels, certify that&#58;</font></div><div style="text-indent:-36pt;padding-left:72pt;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:28.5pt;">I have reviewed this Annual Report on Form 10-K for the period ended </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">December&#160;31, 2018</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> of MacroGenics, Inc.&#59;</font></div><div style="text-indent:-36pt;padding-left:72pt;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:28.5pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="text-indent:-36pt;padding-left:72pt;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:28.5pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="text-indent:-36pt;padding-left:72pt;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">4.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:28.5pt;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#58;</font></div><div style="text-indent:-36pt;padding-left:144pt;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">a.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:29.07pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="text-indent:-36pt;padding-left:144pt;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">b.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:28.5pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="text-indent:-36pt;padding-left:144pt;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">c.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:29.07pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="text-indent:-36pt;padding-left:144pt;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">d.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:28.5pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="text-indent:-36pt;padding-left:72pt;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">5.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:28.5pt;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)</font></div><div style="text-indent:-36pt;padding-left:144pt;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">a.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:29.07pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="text-indent:-36pt;padding-left:144pt;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">b.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:28.5pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"><tr><td style="width:1.0%;"></td><td style="width:46.680352%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:2.439296%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:46.680352%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; James Karrels</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">James Karrels</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">Senior Vice President and Chief Financial Officer</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">(Principal Financial Officer)</font></div></td></tr></table></div><div style="margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Dated&#58;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">February&#160;26, 2019</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#160;</font></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>mgnxexhibit32-1201810xk.htm
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2019 Workiva -->
<title>Document</title></head><body><div id="i_0_1"></div><div style="height:42.75pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">EXHIBIT 32.1</font></div><div style="text-align:center;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">Certification of Principal Executive Officer Pursuant to 18 U.S.C. 1350 (Section 906 of the Sarbanes-Oxley Act of 2002)</font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">I, Scott Koenig, President and Chief Executive Officer (principal executive officer) of MacroGenics, Inc. (the &#8220;Registrant&#8221;), certify, to the best of my knowledge, based upon a review of the Annual Report on Form 10-K for the period ended </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">December&#160;31, 2018</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> of the Registrant (the &#8220;Report&#8221;), that&#58;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:12pt;line-height:120%;">&#160;</font></div><div style="text-indent:-18pt;padding-left:20.23pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:10.5pt;">The Report fully complies with the requirements of Section&#160;13(a) or 15(d)&#160;of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="text-indent:-18pt;padding-left:20.23pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:10.5pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-indent:288pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;text-decoration: underline;">&#47;s&#47; Scott Koeni</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;text-decoration: underline;">g</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;text-decoration: underline;">&#160;</font></div><div style="text-indent:288pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Name&#58; Scott Koenig, M.D., Ph.D.</font></div><div style="text-indent:288pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Date&#58;  </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">February&#160;26, 2019</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#160;</font></div><div><font><br></font></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>8
<FILENAME>mgnxexhibit32-2201810xk.htm
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2019 Workiva -->
<title>Document</title></head><body><div id="i_0_1"></div><div style="height:42.75pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">EXHIBIT 32.2</font></div><div style="text-align:center;margin-top:6pt;"><font><br></font></div><div style="text-align:center;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">Certification of Principal Financial Officer Pursuant to 18 U.S.C. 1350 (Section 906 of the Sarbanes-Oxley Act of 2002)</font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">I, James Karrels, Senior Vice President and Chief Financial Officer (principal financial officer) of MacroGenics, Inc. (the &#8220;Registrant&#8221;), certify, to the best of my knowledge, based upon a review of the Annual Report on Form 10-K for the period ended </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">December&#160;31, 2018</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> of the Registrant (the &#8220;Report&#8221;), that&#58;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:12pt;line-height:120%;">&#160;</font></div><div style="text-indent:-18pt;padding-left:20.23pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:10.5pt;">The Report fully complies with the requirements of Section&#160;13(a) or 15(d)&#160;of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="text-indent:-18pt;padding-left:20.23pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:10.5pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.</font></div><div><font><br></font></div><div style="text-indent:288pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;text-decoration: underline;">&#47;s&#47; James Karrels</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;text-decoration: underline;">&#160;</font></div><div style="text-indent:288pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Name&#58; James Karrels</font></div><div style="text-indent:288pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Date&#58; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">February&#160;26, 2019</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#160;</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>mgnx-20181231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2017 Workiva-->
<!--r:047621fe-455e-451d-8c86-6c34d8ef3281,g:8a8d7b2b-0121-408b-a242-2fd92f2a34d5-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:mgnx="http://macrogenics.com/20181231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:link="http://www.xbrl.org/2003/linkbase" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://macrogenics.com/20181231">
  <xs:import namespace="http://fasb.org/srt/2018-01-31" schemaLocation="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2018-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2018-01-31" schemaLocation="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd"/>
  <xs:element id="mgnx_CommonStockMaximumAmountAvailableForIssuance" abstract="false" name="CommonStockMaximumAmountAvailableForIssuance" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_NonRefundableUpfrontFees" abstract="false" name="NonRefundableUpfrontFees" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_PotentialSalesMilestonePaymentsUnderAgreement" abstract="false" name="PotentialSalesMilestonePaymentsUnderAgreement" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_LesLaboratoiresServierAndInstitutDeRecherchesServierServierMember" abstract="true" name="LesLaboratoiresServierAndInstitutDeRecherchesServierServierMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_DocumentAndEntityInformationAbstract" abstract="true" name="DocumentAndEntityInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mgnx_NumberOfLease" abstract="false" name="NumberOfLease" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mgnx_ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement" abstract="false" name="ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_ServierAgreementMGD007OptionMember" abstract="true" name="ServierAgreementMGD007OptionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_EquityIncentivePlan2003Member" abstract="true" name="EquityIncentivePlan2003Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_FollowUpOfferingMember" abstract="true" name="FollowUpOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts" abstract="false" name="CollaborationArrangementOffsetToResearchAndDevelopmentCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_ZaiLabsCollaborationAndLicenseAgreementMember" abstract="true" name="ZaiLabsCollaborationAndLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_ZaiLabsMember" abstract="true" name="ZaiLabsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_FundedValueOfBasePeriod" abstract="false" name="FundedValueOfBasePeriod" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock" abstract="false" name="CollaborationAndLicenseAgreementsDisclosureTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="mgnx_OptionExerciseFee" abstract="false" name="OptionExerciseFee" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_TotalPotentialValueUnderAgreement" abstract="false" name="TotalPotentialValueUnderAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_OperatingLossCarryforwardsAnnualLimitationAmount" abstract="false" name="OperatingLossCarryforwardsAnnualLimitationAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement" abstract="false" name="NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases" abstract="false" name="ProceedsfromStockOptionsExercisedAndESPPPurchases" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" abstract="false" name="PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember" abstract="true" name="TwoThousandSixteenEmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare" abstract="false" name="CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="mgnx_TaxYear2025To2037Member" abstract="true" name="TaxYear2025To2037Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_AtTheMarketOfferingMember" abstract="true" name="AtTheMarketOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_ProventionPRV031Member" abstract="true" name="ProventionPRV031Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_UndesignatedPreferredStockMember" abstract="true" name="UndesignatedPreferredStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_OperatingLossCarryforwardsNotSubjectToLimitation" abstract="false" name="OperatingLossCarryforwardsNotSubjectToLimitation" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_JanssenBiotechIncMember" abstract="true" name="JanssenBiotechIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTaxBenefitTaxEffectedAmount" abstract="false" name="EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTaxBenefitTaxEffectedAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement" abstract="false" name="AdditionalDevelopmentFundingOptionsUnderAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" abstract="true" name="NationalInstituteOfAllergyAndInfectiousDiseasesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_RegisteredDirectOfferingMember" abstract="true" name="RegisteredDirectOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_UpfrontPaymentRecognitionPeriod" abstract="false" name="UpfrontPaymentRecognitionPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="mgnx_StockIssuedDuringPeriodValueStockPlanActivity" abstract="false" name="StockIssuedDuringPeriodValueStockPlanActivity" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares" abstract="false" name="CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="mgnx_ProventionBioMember" abstract="true" name="ProventionBioMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan" abstract="false" name="PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember" abstract="true" name="DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_FairValueOfWarrantsReceived" abstract="false" name="FairValueOfWarrantsReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_AssetPurchaseAgreementMember" abstract="true" name="AssetPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_EffectiveIncomeTaxReconciliationStateDeferredTaxesAdjustmentsAmount" abstract="false" name="EffectiveIncomeTaxReconciliationStateDeferredTaxesAdjustmentsAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_NonrefundablePaymentTaxWithholding" abstract="false" name="NonrefundablePaymentTaxWithholding" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_StockIncentivePlan2013Member" abstract="true" name="StockIncentivePlan2013Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_StockIssuedDuringPeriodSharesStockPlanActivity" abstract="false" name="StockIssuedDuringPeriodSharesStockPlanActivity" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="mgnx_RevenuesFromLicenseAgreementsMember" abstract="true" name="RevenuesFromLicenseAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_LaboratoryAndOfficeEquipmentMember" abstract="true" name="LaboratoryAndOfficeEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount" abstract="false" name="EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" abstract="false" name="DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock" abstract="false" name="ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="mgnx_JanssenMGD011AgreementMember" abstract="true" name="JanssenMGD011AgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_ProventionPRV3279Member" abstract="true" name="ProventionPRV3279Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_PropertyPlantAndEquipmentNonCashAdditions" abstract="false" name="PropertyPlantAndEquipmentNonCashAdditions" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_CollaborationAndLicenseAgreementsAbstract" abstract="true" name="CollaborationAndLicenseAgreementsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement" abstract="false" name="PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_PotentialMilestonePaymentsandRoyaltiesonFutureSalesunderAgreement" abstract="false" name="PotentialMilestonePaymentsandRoyaltiesonFutureSalesunderAgreement" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_ServierDARTMember" abstract="true" name="ServierDARTMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_CollaborativeAgreementTransactionPrice" abstract="false" name="CollaborativeAgreementTransactionPrice" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_ProventionLicenseAgreementMember" abstract="true" name="ProventionLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_MilestonePayment" abstract="false" name="MilestonePayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock" abstract="false" name="PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance" abstract="false" name="CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="mgnx_RevenueFromGovernmentAgreementsMember" abstract="true" name="RevenueFromGovernmentAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_IncyteMGA012ClinicalServicesMember" abstract="true" name="IncyteMGA012ClinicalServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_IndefiniteMember" abstract="true" name="IndefiniteMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_WarrantsFairValueDisclosure" abstract="false" name="WarrantsFairValueDisclosure" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_PotentialClinicalMilestonePaymentsUnderAgreement" abstract="false" name="PotentialClinicalMilestonePaymentsUnderAgreement" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_IncreaseDecreaseInDeferredRent" abstract="false" name="IncreaseDecreaseInDeferredRent" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_IncyteMGA012AgreementMember" abstract="true" name="IncyteMGA012AgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_ZaiLabLimitedMember" abstract="true" name="ZaiLabLimitedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_FirmCommitmentPublicUnderwrittenOfferMember" abstract="true" name="FirmCommitmentPublicUnderwrittenOfferMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_PotentialCommercialMilestonePaymentsUnderAgreement" abstract="false" name="PotentialCommercialMilestonePaymentsUnderAgreement" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member" abstract="true" name="F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_ProceedsfromRoyaltiesPercent" abstract="false" name="ProceedsfromRoyaltiesPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" abstract="false" name="EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="mgnx_FurnitureAndOfficeEquipmentMember" abstract="true" name="FurnitureAndOfficeEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_JanssenMGD015AgreementMember" abstract="true" name="JanssenMGD015AgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_RevenueFromCollaborativeAgreementsMember" abstract="true" name="RevenueFromCollaborativeAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan" abstract="false" name="EmployeesEligibleAgeToParticipateInBenefitPlan" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="mgnx_ServierMember" abstract="true" name="ServierMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_PotentialRegulatoryMilestonePaymentsUnderAgreement" abstract="false" name="PotentialRegulatoryMilestonePaymentsUnderAgreement" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage" abstract="false" name="DefinedContributionPlanEmployeesContributionVestedPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount" abstract="false" name="OperatingLossCarryforwardsLimitationsOnUseAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_IncyteCorporationMember" abstract="true" name="IncyteCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mgnx-20181231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mgnx-20181231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mgnx-20181231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mgnx-20181231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="DocumentandEntityInformation" roleURI="http://macrogenics.com/role/DocumentandEntityInformation">
        <link:definition>0001001 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETS" roleURI="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS">
        <link:definition>1001002 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>1002003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS">
        <link:definition>1003004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
        <link:definition>1004005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>1005006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandNatureofOperations" roleURI="http://macrogenics.com/role/OrganizationandNatureofOperations">
        <link:definition>2101101 - Disclosure - Organization and Nature of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>2102102 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2203201 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesTables" roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesTables">
        <link:definition>2304301 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesDetails" roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesDetails">
        <link:definition>2405401 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails" roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails">
        <link:definition>2406402 - Disclosure - Summary of Significant Accounting Policies - Summary of Fair Value Measurement Financial Asset and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedDetails" roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedDetails">
        <link:definition>2407403 - Disclosure - Summary of Significant Accounting Policies - Summary of Collaborators that Represent More Than 10% of Total Revenue Earned (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofAccountsReceivableDetails" roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofAccountsReceivableDetails">
        <link:definition>2408404 - Disclosure - Summary of Significant Accounting Policies - Summary of Collaborators that Represent More Than 10% of Accounts Receivable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails" roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails">
        <link:definition>2409405 - Disclosure - Summary of Significant Accounting Policies - Estimated Useful Lives (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromtheCalculationofDilutedLossPerShareDetails" roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromtheCalculationofDilutedLossPerShareDetails">
        <link:definition>2410406 - Disclosure - Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from the Calculation of Diluted Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesAdoptionof606Details" roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesAdoptionof606Details">
        <link:definition>2411407 - Disclosure - Summary of Significant Accounting Policies - Adoption of 606 (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignficantAccountingPoliciesContractWithCustomerLiabilityDetails" roleURI="http://macrogenics.com/role/SummaryofSignficantAccountingPoliciesContractWithCustomerLiabilityDetails">
        <link:definition>2412408 - Disclosure - Summary of Signficant Accounting Policies - Contract With Customer Liability (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecurities" roleURI="http://macrogenics.com/role/MarketableSecurities">
        <link:definition>2113103 - Disclosure - Marketable Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesTables" roleURI="http://macrogenics.com/role/MarketableSecuritiesTables">
        <link:definition>2314302 - Disclosure - Marketable Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesDetails" roleURI="http://macrogenics.com/role/MarketableSecuritiesDetails">
        <link:definition>2415409 - Disclosure - Marketable Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesDetails_1" roleURI="http://macrogenics.com/role/MarketableSecuritiesDetails_1">
        <link:definition>2415409 - Disclosure - Marketable Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesAvailableForSaleSecuritiesDetails" roleURI="http://macrogenics.com/role/MarketableSecuritiesAvailableForSaleSecuritiesDetails">
        <link:definition>2416410 - Disclosure - Marketable Securities - Available-For-Sale Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyEquipmentandSoftware" roleURI="http://macrogenics.com/role/PropertyEquipmentandSoftware">
        <link:definition>2117104 - Disclosure - Property, Equipment and Software</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyEquipmentandSoftwareTables" roleURI="http://macrogenics.com/role/PropertyEquipmentandSoftwareTables">
        <link:definition>2318303 - Disclosure - Property, Equipment and Software (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyEquipmentandSoftwareDetails" roleURI="http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails">
        <link:definition>2419411 - Disclosure - Property, Equipment and Software (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://macrogenics.com/role/StockholdersEquity">
        <link:definition>2120105 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityDetails" roleURI="http://macrogenics.com/role/StockholdersEquityDetails">
        <link:definition>2421412 - Disclosure - Stockholders' Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensation" roleURI="http://macrogenics.com/role/StockbasedCompensation">
        <link:definition>2122106 - Disclosure - Stock-based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationTables" roleURI="http://macrogenics.com/role/StockbasedCompensationTables">
        <link:definition>2323304 - Disclosure - Stock-based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationEmployeeStockPurchasePlanDetails" roleURI="http://macrogenics.com/role/StockbasedCompensationEmployeeStockPurchasePlanDetails">
        <link:definition>2424413 - Disclosure - Stock-based Compensation - Employee Stock Purchase Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationStockBasedCompensationExpenseDetails" roleURI="http://macrogenics.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails">
        <link:definition>2425414 - Disclosure - Stock-based Compensation - Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationOptionPricingAssumptionsDetails" roleURI="http://macrogenics.com/role/StockbasedCompensationOptionPricingAssumptionsDetails">
        <link:definition>2426415 - Disclosure - Stock-based Compensation - Option Pricing Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails" roleURI="http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails">
        <link:definition>2427416 - Disclosure - Stock-based Compensation - Stock Option and Restricted Stock Unit Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://macrogenics.com/role/IncomeTaxes">
        <link:definition>2128107 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://macrogenics.com/role/IncomeTaxesTables">
        <link:definition>2329305 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails" roleURI="http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails">
        <link:definition>2430417 - Disclosure - Income Taxes - Components of the Company's Deferred Tax Assets (Liabilities) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails" roleURI="http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails">
        <link:definition>2431418 - Disclosure - Income Taxes - Reconciliation of Reported Estimated Income Tax Benefit (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesReconciliationoftheBeginningandEndingAmountofGrossUnrecognizedTaxBenefitsDetails" roleURI="http://macrogenics.com/role/IncomeTaxesReconciliationoftheBeginningandEndingAmountofGrossUnrecognizedTaxBenefitsDetails">
        <link:definition>2432419 - Disclosure - Income Taxes - Reconciliation of the Beginning and Ending Amount of Gross Unrecognized Tax Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandOtherAgreements" roleURI="http://macrogenics.com/role/CollaborationandOtherAgreements">
        <link:definition>2133108 - Disclosure - Collaboration and Other Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandOtherAgreementsIncyteCorporationDetails" roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails">
        <link:definition>2434420 - Disclosure - Collaboration and Other Agreements, Incyte Corporation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandOtherAgreementsZaiLabDetails" roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails">
        <link:definition>2435421 - Disclosure - Collaboration and Other Agreements, Zai Lab (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandOtherAgreementsServierDetails" roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsServierDetails">
        <link:definition>2436422 - Disclosure - Collaboration and Other Agreements, Servier (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandOtherAgreementsRocheDetails" roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsRocheDetails">
        <link:definition>2437423 - Disclosure - Collaboration and Other Agreements, Roche (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandOtherAgreementsProventionDetails" roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsProventionDetails">
        <link:definition>2438424 - Disclosure - Collaboration and Other Agreements, Provention (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandOtherAgreementsJanssenBiotechIncDetails" roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenBiotechIncDetails">
        <link:definition>2439425 - Disclosure - Collaboration and Other Agreements, Janssen Biotech, Inc. (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandOtherAgreementsNIAIDContractDetails" roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails">
        <link:definition>2440426 - Disclosure - Collaboration and Other Agreements, NIAID Contract (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://macrogenics.com/role/CommitmentsandContingencies">
        <link:definition>2141109 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesTables" roleURI="http://macrogenics.com/role/CommitmentsandContingenciesTables">
        <link:definition>2342306 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesDetails" roleURI="http://macrogenics.com/role/CommitmentsandContingenciesDetails">
        <link:definition>2443427 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlan" roleURI="http://macrogenics.com/role/EmployeeBenefitPlan">
        <link:definition>2144110 - Disclosure - Employee Benefit Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlanDetails" roleURI="http://macrogenics.com/role/EmployeeBenefitPlanDetails">
        <link:definition>2445428 - Disclosure - Employee Benefit Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="QuarterlyFinancialInformationUnaudited" roleURI="http://macrogenics.com/role/QuarterlyFinancialInformationUnaudited">
        <link:definition>2146111 - Disclosure - Quarterly Financial Information (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="QuarterlyFinancialInformationUnauditedTables" roleURI="http://macrogenics.com/role/QuarterlyFinancialInformationUnauditedTables">
        <link:definition>2347307 - Disclosure - Quarterly Financial Information (Unaudited) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="QuarterlyFinancialInformationUnauditedDetails" roleURI="http://macrogenics.com/role/QuarterlyFinancialInformationUnauditedDetails">
        <link:definition>2448429 - Disclosure - Quarterly Financial Information (Unaudited) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://macrogenics.com/role/SubsequentEvents">
        <link:definition>2149112 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsDetails" roleURI="http://macrogenics.com/role/SubsequentEventsDetails">
        <link:definition>2450430 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>10
<FILENAME>mgnx-20181231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2017 Workiva-->
<!--r:047621fe-455e-451d-8c86-6c34d8ef3281,g:8a8d7b2b-0121-408b-a242-2fd92f2a34d5-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://macrogenics.com/role/DocumentandEntityInformation" xlink:type="simple" xlink:href="mgnx-20181231.xsd#DocumentandEntityInformation"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/DocumentandEntityInformation" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="mgnx-20181231.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_53c6127c-2389-449e-92ee-28839a2bc7ff" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_b11badfe-455e-47cf-9494-7ae04ea9399a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_53c6127c-2389-449e-92ee-28839a2bc7ff" xlink:to="loc_us-gaap_AssetsCurrent_b11badfe-455e-47cf-9494-7ae04ea9399a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_7efd6a97-1034-41aa-acbd-84d984cece28" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_53c6127c-2389-449e-92ee-28839a2bc7ff" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_7efd6a97-1034-41aa-acbd-84d984cece28" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_001a9435-addf-47b9-95db-d5b65740c0f9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_53c6127c-2389-449e-92ee-28839a2bc7ff" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_001a9435-addf-47b9-95db-d5b65740c0f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_93120310-6c9f-4316-8fc4-1256fb4ea250" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_2aa2f33f-f9d5-45fb-ba24-5c335694b373" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_93120310-6c9f-4316-8fc4-1256fb4ea250" xlink:to="loc_us-gaap_Liabilities_2aa2f33f-f9d5-45fb-ba24-5c335694b373" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_44b83c11-7182-4498-a8ff-4c0c2db74b4b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_93120310-6c9f-4316-8fc4-1256fb4ea250" xlink:to="loc_us-gaap_StockholdersEquity_44b83c11-7182-4498-a8ff-4c0c2db74b4b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_f68096ff-97c1-40ba-b959-c3f4303166a2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_fefe7818-3adc-4871-8c27-07117ae74983" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f68096ff-97c1-40ba-b959-c3f4303166a2" xlink:to="loc_us-gaap_AccountsPayableCurrent_fefe7818-3adc-4871-8c27-07117ae74983" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_921c52b1-ad36-4187-a8d3-2e9d9ee1b2d5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f68096ff-97c1-40ba-b959-c3f4303166a2" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_921c52b1-ad36-4187-a8d3-2e9d9ee1b2d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueCurrent_f4a5084c-3538-4f85-9c76-2c8d4af877f2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredRevenueCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f68096ff-97c1-40ba-b959-c3f4303166a2" xlink:to="loc_us-gaap_DeferredRevenueCurrent_f4a5084c-3538-4f85-9c76-2c8d4af877f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRentCreditCurrent_166a1078-915b-4fe0-9821-704ef690d14d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredRentCreditCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f68096ff-97c1-40ba-b959-c3f4303166a2" xlink:to="loc_us-gaap_DeferredRentCreditCurrent_166a1078-915b-4fe0-9821-704ef690d14d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_5bdf599e-64c5-4fa9-9bef-d1fb2b609f36" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f68096ff-97c1-40ba-b959-c3f4303166a2" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_5bdf599e-64c5-4fa9-9bef-d1fb2b609f36" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_89dab631-ebbb-4fbf-a124-90399d081144" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_2e86274f-44c8-42ee-abd9-d13d2fb2ac93" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_89dab631-ebbb-4fbf-a124-90399d081144" xlink:to="loc_us-gaap_LiabilitiesCurrent_2e86274f-44c8-42ee-abd9-d13d2fb2ac93" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent_58b9e76f-404b-4e60-bbd0-daa885c1d2ff" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredRevenueNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_89dab631-ebbb-4fbf-a124-90399d081144" xlink:to="loc_us-gaap_DeferredRevenueNoncurrent_58b9e76f-404b-4e60-bbd0-daa885c1d2ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRentCreditNoncurrent_282b2320-ba1b-4a1d-94bb-7eb6280aafb5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_89dab631-ebbb-4fbf-a124-90399d081144" xlink:to="loc_us-gaap_DeferredRentCreditNoncurrent_282b2320-ba1b-4a1d-94bb-7eb6280aafb5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_35c2157d-b154-4144-88a2-b8c24fd7f563" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d5e8a89d-bc4d-4499-85d7-44ddd2b1526b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_35c2157d-b154-4144-88a2-b8c24fd7f563" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d5e8a89d-bc4d-4499-85d7-44ddd2b1526b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesCurrent_d83f41e9-5d47-4bbe-8361-0c1b340872d4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_35c2157d-b154-4144-88a2-b8c24fd7f563" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesCurrent_d83f41e9-5d47-4bbe-8361-0c1b340872d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_99b7c23f-9138-4f1f-9159-e32a0b05214b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_35c2157d-b154-4144-88a2-b8c24fd7f563" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_99b7c23f-9138-4f1f-9159-e32a0b05214b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssets_7aeaee09-21a7-457a-9b87-037497988180" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssets"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_35c2157d-b154-4144-88a2-b8c24fd7f563" xlink:to="loc_us-gaap_OtherAssets_7aeaee09-21a7-457a-9b87-037497988180" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_e4739cca-bc6b-4f61-aeab-3ca2f2e4d359" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_35c2157d-b154-4144-88a2-b8c24fd7f563" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_e4739cca-bc6b-4f61-aeab-3ca2f2e4d359" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_84a7f77c-ed6b-41a0-b743-3d6a6d0df5ff" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_bb9c7027-c336-444c-bdbc-e2444d2a857f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_84a7f77c-ed6b-41a0-b743-3d6a6d0df5ff" xlink:to="loc_us-gaap_CommonStockValue_bb9c7027-c336-444c-bdbc-e2444d2a857f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_815944fd-7433-4dd5-83c0-c9826c0540ca" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_84a7f77c-ed6b-41a0-b743-3d6a6d0df5ff" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_815944fd-7433-4dd5-83c0-c9826c0540ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_5f514ee1-acbb-4984-84fc-18c9b3303ef2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_84a7f77c-ed6b-41a0-b743-3d6a6d0df5ff" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_5f514ee1-acbb-4984-84fc-18c9b3303ef2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_70a05b33-f870-4f29-991b-2057c2caee45" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_84a7f77c-ed6b-41a0-b743-3d6a6d0df5ff" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_70a05b33-f870-4f29-991b-2057c2caee45" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="mgnx-20181231.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="mgnx-20181231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_0b0e79ce-7472-4912-86aa-124c29f91e42" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_66018ca4-9500-4e78-a4c7-99d408156090" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_0b0e79ce-7472-4912-86aa-124c29f91e42" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_66018ca4-9500-4e78-a4c7-99d408156090" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_4d1c2ea0-ebf1-48c3-970d-2922c1f6f344" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_0b0e79ce-7472-4912-86aa-124c29f91e42" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_4d1c2ea0-ebf1-48c3-970d-2922c1f6f344" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_fdeccdb7-fb9f-411e-a86a-e2ae2400071a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a78e63c3-5731-41f0-9573-6e08993dc413" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_fdeccdb7-fb9f-411e-a86a-e2ae2400071a" xlink:to="loc_us-gaap_NetIncomeLoss_a78e63c3-5731-41f0-9573-6e08993dc413" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_59324915-f169-417b-9e4f-ecf35ee36564" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_fdeccdb7-fb9f-411e-a86a-e2ae2400071a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_59324915-f169-417b-9e4f-ecf35ee36564" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_bb2b8adb-207d-4310-b47d-e260ad515dbb" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_3eea8452-4b16-499a-9ccb-d041e7447ff7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_bb2b8adb-207d-4310-b47d-e260ad515dbb" xlink:to="loc_us-gaap_Revenues_3eea8452-4b16-499a-9ccb-d041e7447ff7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_539f5529-4635-486f-9547-76495a82e1c1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_bb2b8adb-207d-4310-b47d-e260ad515dbb" xlink:to="loc_us-gaap_CostsAndExpenses_539f5529-4635-486f-9547-76495a82e1c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_0f43c81f-c630-4f2a-98c0-69dbcff7209f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_700947b4-c5f3-4c61-b73e-72dff685c9b5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_0f43c81f-c630-4f2a-98c0-69dbcff7209f" xlink:to="loc_us-gaap_OperatingIncomeLoss_700947b4-c5f3-4c61-b73e-72dff685c9b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_7203761c-777c-47f4-a3d5-c8ef043c5340" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_0f43c81f-c630-4f2a-98c0-69dbcff7209f" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_7203761c-777c-47f4-a3d5-c8ef043c5340" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="mgnx-20181231.xsd#CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="mgnx-20181231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_925c62c7-f002-4b3d-9c43-4f75e0f87346" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_b4b5c28f-1a50-470d-a5b7-36d1b47d3fe7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_925c62c7-f002-4b3d-9c43-4f75e0f87346" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_b4b5c28f-1a50-470d-a5b7-36d1b47d3fe7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_65e14c98-c8fc-486b-b58e-b4513867aa25" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_925c62c7-f002-4b3d-9c43-4f75e0f87346" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_65e14c98-c8fc-486b-b58e-b4513867aa25" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_a8fe5231-77dd-484a-bf6b-8bd889c20e98" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_925c62c7-f002-4b3d-9c43-4f75e0f87346" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_a8fe5231-77dd-484a-bf6b-8bd889c20e98" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_cd4625b3-e097-486a-bf5e-c601d39f771c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_dbc2462d-88cc-4cc2-b860-49e33b269e85" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_cd4625b3-e097-486a-bf5e-c601d39f771c" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_dbc2462d-88cc-4cc2-b860-49e33b269e85" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases_f309cdf2-7de0-4140-a182-835eea61f36b" xlink:href="mgnx-20181231.xsd#mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_cd4625b3-e097-486a-bf5e-c601d39f771c" xlink:to="loc_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases_f309cdf2-7de0-4140-a182-835eea61f36b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_4013f026-f7c0-4c8d-973b-2fde7d678a7e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_cd4625b3-e097-486a-bf5e-c601d39f771c" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_4013f026-f7c0-4c8d-973b-2fde7d678a7e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_58cfda94-79b5-4b39-ae4c-900aaa7ceb51" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_36d6513b-2842-4cf7-b161-e8da1c0d1965" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_58cfda94-79b5-4b39-ae4c-900aaa7ceb51" xlink:to="loc_us-gaap_NetIncomeLoss_36d6513b-2842-4cf7-b161-e8da1c0d1965" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_67d29de5-2a5f-4e1b-85d0-134645554610" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_58cfda94-79b5-4b39-ae4c-900aaa7ceb51" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_67d29de5-2a5f-4e1b-85d0-134645554610" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_11f46e46-e65e-427e-8c16-2a8aae6355f3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_58cfda94-79b5-4b39-ae4c-900aaa7ceb51" xlink:to="loc_us-gaap_ShareBasedCompensation_11f46e46-e65e-427e-8c16-2a8aae6355f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_a895d5b1-8221-4ddc-8997-52e0a255e0f2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_58cfda94-79b5-4b39-ae4c-900aaa7ceb51" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_a895d5b1-8221-4ddc-8997-52e0a255e0f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_be04a578-9a39-4d90-b320-d4271247905b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_58cfda94-79b5-4b39-ae4c-900aaa7ceb51" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_be04a578-9a39-4d90-b320-d4271247905b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_8c7c8fac-a0e6-4293-8343-21e4946c667c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_58cfda94-79b5-4b39-ae4c-900aaa7ceb51" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_8c7c8fac-a0e6-4293-8343-21e4946c667c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_0a5047df-b186-4de6-9908-0b18d3294b08" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_58cfda94-79b5-4b39-ae4c-900aaa7ceb51" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_0a5047df-b186-4de6-9908-0b18d3294b08" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_de3a0b24-6eba-4191-b3b4-c08fc3bfef0c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_58cfda94-79b5-4b39-ae4c-900aaa7ceb51" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_de3a0b24-6eba-4191-b3b4-c08fc3bfef0c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncreaseDecreaseInDeferredRent_6efaab1a-a32b-4910-9505-62423fe322ec" xlink:href="mgnx-20181231.xsd#mgnx_IncreaseDecreaseInDeferredRent"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_58cfda94-79b5-4b39-ae4c-900aaa7ceb51" xlink:to="loc_mgnx_IncreaseDecreaseInDeferredRent_6efaab1a-a32b-4910-9505-62423fe322ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_20f57f82-8928-46c6-9f2c-6de40d842a11" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_58cfda94-79b5-4b39-ae4c-900aaa7ceb51" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_20f57f82-8928-46c6-9f2c-6de40d842a11" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_18fe2b2d-a475-418d-a03b-f76867635ac3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_c5f3688d-0ed7-4c94-b772-e921d07b313b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_18fe2b2d-a475-418d-a03b-f76867635ac3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_c5f3688d-0ed7-4c94-b772-e921d07b313b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_ddac12d3-0d7f-486c-bc60-60a3c3c243a4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_18fe2b2d-a475-418d-a03b-f76867635ac3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_ddac12d3-0d7f-486c-bc60-60a3c3c243a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_7402dee6-f8ee-4817-86d0-5869eaf519ef" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_18fe2b2d-a475-418d-a03b-f76867635ac3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_7402dee6-f8ee-4817-86d0-5869eaf519ef" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/OrganizationandNatureofOperations" xlink:type="simple" xlink:href="mgnx-20181231.xsd#OrganizationandNatureofOperations"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/OrganizationandNatureofOperations" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="mgnx-20181231.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="mgnx-20181231.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="mgnx-20181231.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="mgnx-20181231.xsd#SummaryofSignificantAccountingPoliciesDetails"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails" xlink:type="simple" xlink:href="mgnx-20181231.xsd#SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_c6155c97-23d4-4b02-9def-ef3820aa3be1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_a85f35b5-d366-4df8-a665-f3df148dd99a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_c6155c97-23d4-4b02-9def-ef3820aa3be1" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_a85f35b5-d366-4df8-a665-f3df148dd99a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecurities_7f5e8e45-2877-4174-94cd-4b4e239d5f6b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_c6155c97-23d4-4b02-9def-ef3820aa3be1" xlink:to="loc_us-gaap_AvailableForSaleSecurities_7f5e8e45-2877-4174-94cd-4b4e239d5f6b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_WarrantsFairValueDisclosure_9783818f-9387-4ee7-a22a-99cd3da74442" xlink:href="mgnx-20181231.xsd#mgnx_WarrantsFairValueDisclosure"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_c6155c97-23d4-4b02-9def-ef3820aa3be1" xlink:to="loc_mgnx_WarrantsFairValueDisclosure_9783818f-9387-4ee7-a22a-99cd3da74442" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedDetails" xlink:type="simple" xlink:href="mgnx-20181231.xsd#SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedDetails"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofAccountsReceivableDetails" xlink:type="simple" xlink:href="mgnx-20181231.xsd#SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofAccountsReceivableDetails"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofAccountsReceivableDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails" xlink:type="simple" xlink:href="mgnx-20181231.xsd#SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromtheCalculationofDilutedLossPerShareDetails" xlink:type="simple" xlink:href="mgnx-20181231.xsd#SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromtheCalculationofDilutedLossPerShareDetails"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromtheCalculationofDilutedLossPerShareDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesAdoptionof606Details" xlink:type="simple" xlink:href="mgnx-20181231.xsd#SummaryofSignificantAccountingPoliciesAdoptionof606Details"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesAdoptionof606Details" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryofSignficantAccountingPoliciesContractWithCustomerLiabilityDetails" xlink:type="simple" xlink:href="mgnx-20181231.xsd#SummaryofSignficantAccountingPoliciesContractWithCustomerLiabilityDetails"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/SummaryofSignficantAccountingPoliciesContractWithCustomerLiabilityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/MarketableSecurities" xlink:type="simple" xlink:href="mgnx-20181231.xsd#MarketableSecurities"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/MarketableSecurities" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/MarketableSecuritiesTables" xlink:type="simple" xlink:href="mgnx-20181231.xsd#MarketableSecuritiesTables"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/MarketableSecuritiesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/MarketableSecuritiesDetails" xlink:type="simple" xlink:href="mgnx-20181231.xsd#MarketableSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/MarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_652af150-c434-48ea-8ae1-0a8b8df91ffa" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/MarketableSecuritiesDetails_1" xlink:type="simple" xlink:href="mgnx-20181231.xsd#MarketableSecuritiesDetails_1"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/MarketableSecuritiesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_64437d04-bfcb-4229-b5ce-35ace298520c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_71fe082a-8ad1-457a-85da-d102d5823088" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_64437d04-bfcb-4229-b5ce-35ace298520c" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_71fe082a-8ad1-457a-85da-d102d5823088" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_fa9bde03-cc9d-44d4-ba79-03e2e73dca18" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_64437d04-bfcb-4229-b5ce-35ace298520c" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_fa9bde03-cc9d-44d4-ba79-03e2e73dca18" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_4c44077a-3a53-43ed-b284-372cb07b5136" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_64437d04-bfcb-4229-b5ce-35ace298520c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_4c44077a-3a53-43ed-b284-372cb07b5136" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/MarketableSecuritiesAvailableForSaleSecuritiesDetails" xlink:type="simple" xlink:href="mgnx-20181231.xsd#MarketableSecuritiesAvailableForSaleSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/MarketableSecuritiesAvailableForSaleSecuritiesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/PropertyEquipmentandSoftware" xlink:type="simple" xlink:href="mgnx-20181231.xsd#PropertyEquipmentandSoftware"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/PropertyEquipmentandSoftware" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/PropertyEquipmentandSoftwareTables" xlink:type="simple" xlink:href="mgnx-20181231.xsd#PropertyEquipmentandSoftwareTables"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/PropertyEquipmentandSoftwareTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails" xlink:type="simple" xlink:href="mgnx-20181231.xsd#PropertyEquipmentandSoftwareDetails"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_ffc836eb-e44b-4e15-9a12-e7db7596b064" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_6374150d-47a2-4944-869e-39b6699212a6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_ffc836eb-e44b-4e15-9a12-e7db7596b064" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_6374150d-47a2-4944-869e-39b6699212a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_e7027fd9-75bf-44fd-a458-7860730e15f2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_ffc836eb-e44b-4e15-9a12-e7db7596b064" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_e7027fd9-75bf-44fd-a458-7860730e15f2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockholdersEquity" xlink:type="simple" xlink:href="mgnx-20181231.xsd#StockholdersEquity"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/StockholdersEquity" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/StockholdersEquityDetails" xlink:type="simple" xlink:href="mgnx-20181231.xsd#StockholdersEquityDetails"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/StockholdersEquityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/StockbasedCompensation" xlink:type="simple" xlink:href="mgnx-20181231.xsd#StockbasedCompensation"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/StockbasedCompensation" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/StockbasedCompensationTables" xlink:type="simple" xlink:href="mgnx-20181231.xsd#StockbasedCompensationTables"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/StockbasedCompensationTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/StockbasedCompensationEmployeeStockPurchasePlanDetails" xlink:type="simple" xlink:href="mgnx-20181231.xsd#StockbasedCompensationEmployeeStockPurchasePlanDetails"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/StockbasedCompensationEmployeeStockPurchasePlanDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="mgnx-20181231.xsd#StockbasedCompensationStockBasedCompensationExpenseDetails"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/StockbasedCompensationOptionPricingAssumptionsDetails" xlink:type="simple" xlink:href="mgnx-20181231.xsd#StockbasedCompensationOptionPricingAssumptionsDetails"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/StockbasedCompensationOptionPricingAssumptionsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails" xlink:type="simple" xlink:href="mgnx-20181231.xsd#StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/IncomeTaxes" xlink:type="simple" xlink:href="mgnx-20181231.xsd#IncomeTaxes"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/IncomeTaxes" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="mgnx-20181231.xsd#IncomeTaxesTables"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/IncomeTaxesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails" xlink:type="simple" xlink:href="mgnx-20181231.xsd#IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_775fe29d-80a0-47cc-8bc1-802d08d3611f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_013af614-57e7-4248-8985-c1e50a37927f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_775fe29d-80a0-47cc-8bc1-802d08d3611f" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_013af614-57e7-4248-8985-c1e50a37927f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_b3db02dc-4021-42c6-9f34-0899934cac6a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_775fe29d-80a0-47cc-8bc1-802d08d3611f" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_b3db02dc-4021-42c6-9f34-0899934cac6a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_e0ae1d75-62f8-4861-8ef0-5977b67c486d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_331544d8-5b06-426d-9054-b05573da219f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_e0ae1d75-62f8-4861-8ef0-5977b67c486d" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_331544d8-5b06-426d-9054-b05573da219f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_d361af63-5b53-4a24-bd23-123aa00c4354" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_e0ae1d75-62f8-4861-8ef0-5977b67c486d" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_d361af63-5b53-4a24-bd23-123aa00c4354" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_09f8bc01-46f8-450e-87cc-d2945c5b3fd6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_d0639a90-8f81-4c72-8914-d90b52b3acb7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_09f8bc01-46f8-450e-87cc-d2945c5b3fd6" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_d0639a90-8f81-4c72-8914-d90b52b3acb7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_e57e4fb4-4674-4bb3-883c-b6d567abd6d1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_09f8bc01-46f8-450e-87cc-d2945c5b3fd6" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_e57e4fb4-4674-4bb3-883c-b6d567abd6d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_3b47b882-7256-47fe-850c-0716cf3ea1ae" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_09f8bc01-46f8-450e-87cc-d2945c5b3fd6" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_3b47b882-7256-47fe-850c-0716cf3ea1ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther_174b8b01-8956-4935-bd44-5a6abad6b218" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_09f8bc01-46f8-450e-87cc-d2945c5b3fd6" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther_174b8b01-8956-4935-bd44-5a6abad6b218" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_caaa5667-8050-419f-8da0-7caa2f738323" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_09f8bc01-46f8-450e-87cc-d2945c5b3fd6" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_caaa5667-8050-419f-8da0-7caa2f738323" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_74317c35-d937-4f83-ba9d-20d1dc081cb1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_09f8bc01-46f8-450e-87cc-d2945c5b3fd6" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_74317c35-d937-4f83-ba9d-20d1dc081cb1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_d9adc523-8170-4cc8-b171-b3b8a63b7ea6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_09f8bc01-46f8-450e-87cc-d2945c5b3fd6" xlink:to="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_d9adc523-8170-4cc8-b171-b3b8a63b7ea6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_12e1dc32-7ffa-4c37-978f-808139bfc84d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_09f8bc01-46f8-450e-87cc-d2945c5b3fd6" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_12e1dc32-7ffa-4c37-978f-808139bfc84d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_4f2103fe-3d07-408b-ba43-527bac48ae54" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_fb804e04-66b3-4d6c-9177-c62330217c76" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_4f2103fe-3d07-408b-ba43-527bac48ae54" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_fb804e04-66b3-4d6c-9177-c62330217c76" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_2a7de81f-1049-417b-9a7f-aaaf8f43746d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_4f2103fe-3d07-408b-ba43-527bac48ae54" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_2a7de81f-1049-417b-9a7f-aaaf8f43746d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails" xlink:type="simple" xlink:href="mgnx-20181231.xsd#IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_7be04863-b3db-4565-9d55-d9464a8007e3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_c330c43a-5ab1-4510-a7b5-5f6990157c80" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_7be04863-b3db-4565-9d55-d9464a8007e3" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_c330c43a-5ab1-4510-a7b5-5f6990157c80" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_c1fc27e7-266c-49db-9f02-c15c85e2db04" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_7be04863-b3db-4565-9d55-d9464a8007e3" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_c1fc27e7-266c-49db-9f02-c15c85e2db04" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount_03a2a76f-cb0b-4395-8720-e6cf32b6ee25" xlink:href="mgnx-20181231.xsd#mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_7be04863-b3db-4565-9d55-d9464a8007e3" xlink:to="loc_mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount_03a2a76f-cb0b-4395-8720-e6cf32b6ee25" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_EffectiveIncomeTaxReconciliationStateDeferredTaxesAdjustmentsAmount_95592fdd-7f7b-4041-87f4-870e2c028ef0" xlink:href="mgnx-20181231.xsd#mgnx_EffectiveIncomeTaxReconciliationStateDeferredTaxesAdjustmentsAmount"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_7be04863-b3db-4565-9d55-d9464a8007e3" xlink:to="loc_mgnx_EffectiveIncomeTaxReconciliationStateDeferredTaxesAdjustmentsAmount_95592fdd-7f7b-4041-87f4-870e2c028ef0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_569ec521-3852-4d29-b122-709c017a8153" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_7be04863-b3db-4565-9d55-d9464a8007e3" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_569ec521-3852-4d29-b122-709c017a8153" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_d18c330b-3beb-45d7-9524-d8890acf422a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_7be04863-b3db-4565-9d55-d9464a8007e3" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_d18c330b-3beb-45d7-9524-d8890acf422a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsOther_15e1ae81-1197-456e-8c76-9842e1ddc9f8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsOther"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_7be04863-b3db-4565-9d55-d9464a8007e3" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsOther_15e1ae81-1197-456e-8c76-9842e1ddc9f8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherReconcilingItems_2e8a9602-9056-474a-ac94-9d914d6cab27" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_7be04863-b3db-4565-9d55-d9464a8007e3" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherReconcilingItems_2e8a9602-9056-474a-ac94-9d914d6cab27" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_9c5614b0-04ef-4351-bf87-351f89f97a9b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_7be04863-b3db-4565-9d55-d9464a8007e3" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_9c5614b0-04ef-4351-bf87-351f89f97a9b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_4e1f6bd1-9974-46c9-884a-14e19b44784a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_7be04863-b3db-4565-9d55-d9464a8007e3" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_4e1f6bd1-9974-46c9-884a-14e19b44784a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/IncomeTaxesReconciliationoftheBeginningandEndingAmountofGrossUnrecognizedTaxBenefitsDetails" xlink:type="simple" xlink:href="mgnx-20181231.xsd#IncomeTaxesReconciliationoftheBeginningandEndingAmountofGrossUnrecognizedTaxBenefitsDetails"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/IncomeTaxesReconciliationoftheBeginningandEndingAmountofGrossUnrecognizedTaxBenefitsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreements" xlink:type="simple" xlink:href="mgnx-20181231.xsd#CollaborationandOtherAgreements"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreements" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails" xlink:type="simple" xlink:href="mgnx-20181231.xsd#CollaborationandOtherAgreementsIncyteCorporationDetails"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails" xlink:type="simple" xlink:href="mgnx-20181231.xsd#CollaborationandOtherAgreementsZaiLabDetails"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsServierDetails" xlink:type="simple" xlink:href="mgnx-20181231.xsd#CollaborationandOtherAgreementsServierDetails"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsServierDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsRocheDetails" xlink:type="simple" xlink:href="mgnx-20181231.xsd#CollaborationandOtherAgreementsRocheDetails"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsRocheDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsProventionDetails" xlink:type="simple" xlink:href="mgnx-20181231.xsd#CollaborationandOtherAgreementsProventionDetails"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsProventionDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenBiotechIncDetails" xlink:type="simple" xlink:href="mgnx-20181231.xsd#CollaborationandOtherAgreementsJanssenBiotechIncDetails"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenBiotechIncDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails" xlink:type="simple" xlink:href="mgnx-20181231.xsd#CollaborationandOtherAgreementsNIAIDContractDetails"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="mgnx-20181231.xsd#CommitmentsandContingencies"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/CommitmentsandContingencies" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/CommitmentsandContingenciesTables" xlink:type="simple" xlink:href="mgnx-20181231.xsd#CommitmentsandContingenciesTables"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/CommitmentsandContingenciesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="mgnx-20181231.xsd#CommitmentsandContingenciesDetails"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/CommitmentsandContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_a9a37e39-6db5-4307-af76-06f0ced86d57" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_aa668ffb-2b77-4d67-ae7f-2dae3a2f1073" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_a9a37e39-6db5-4307-af76-06f0ced86d57" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_aa668ffb-2b77-4d67-ae7f-2dae3a2f1073" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_ca2ea6d8-ea4f-4561-8a41-02489ec6924f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_a9a37e39-6db5-4307-af76-06f0ced86d57" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_ca2ea6d8-ea4f-4561-8a41-02489ec6924f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_d69ad691-cba9-4939-a11a-21d32930e022" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_a9a37e39-6db5-4307-af76-06f0ced86d57" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_d69ad691-cba9-4939-a11a-21d32930e022" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_35dd09b1-f8e2-467d-918e-9f61322e6f2c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_a9a37e39-6db5-4307-af76-06f0ced86d57" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_35dd09b1-f8e2-467d-918e-9f61322e6f2c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_c746cbca-963e-43cc-a696-9ccf197f6ab0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_a9a37e39-6db5-4307-af76-06f0ced86d57" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_c746cbca-963e-43cc-a696-9ccf197f6ab0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_b301cd08-2624-4451-bfd6-a2c257cb4d5b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_a9a37e39-6db5-4307-af76-06f0ced86d57" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_b301cd08-2624-4451-bfd6-a2c257cb4d5b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/EmployeeBenefitPlan" xlink:type="simple" xlink:href="mgnx-20181231.xsd#EmployeeBenefitPlan"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/EmployeeBenefitPlan" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/EmployeeBenefitPlanDetails" xlink:type="simple" xlink:href="mgnx-20181231.xsd#EmployeeBenefitPlanDetails"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/EmployeeBenefitPlanDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/QuarterlyFinancialInformationUnaudited" xlink:type="simple" xlink:href="mgnx-20181231.xsd#QuarterlyFinancialInformationUnaudited"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/QuarterlyFinancialInformationUnaudited" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/QuarterlyFinancialInformationUnauditedTables" xlink:type="simple" xlink:href="mgnx-20181231.xsd#QuarterlyFinancialInformationUnauditedTables"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/QuarterlyFinancialInformationUnauditedTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/QuarterlyFinancialInformationUnauditedDetails" xlink:type="simple" xlink:href="mgnx-20181231.xsd#QuarterlyFinancialInformationUnauditedDetails"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/QuarterlyFinancialInformationUnauditedDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/SubsequentEvents" xlink:type="simple" xlink:href="mgnx-20181231.xsd#SubsequentEvents"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/SubsequentEvents" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="mgnx-20181231.xsd#SubsequentEventsDetails"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/SubsequentEventsDetails" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>11
<FILENAME>mgnx-20181231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2017 Workiva-->
<!--r:047621fe-455e-451d-8c86-6c34d8ef3281,g:8a8d7b2b-0121-408b-a242-2fd92f2a34d5-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://macrogenics.com/role/DocumentandEntityInformation" xlink:type="simple" xlink:href="mgnx-20181231.xsd#DocumentandEntityInformation"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/DocumentandEntityInformation" xlink:type="extended" id="i904181b7a681473cb908fb865ed0ae20_c5f3366a-8f13-48d2-9dd7-34878226e03e"/>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="mgnx-20181231.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended" id="i47491c4d8907445195f1102ddae1f129_e8f975b2-804f-4784-aeb0-72fd292bf782"/>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="mgnx-20181231.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended" id="i685d9e9093034af2a6dd08dd2731cbc8_452347eb-f3ae-4230-b01b-08b4e11df75f"/>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="mgnx-20181231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="extended" id="i36f76602d9474b249f957c24ad839b7e_8804eed8-6be6-4430-9bd6-74d6ddca0c4f">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_8fd20123-de08-42e9-8a7e-b3ae537710cc" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_266d0964-2896-4d29-bf7c-e073788852c6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_8fd20123-de08-42e9-8a7e-b3ae537710cc" xlink:to="loc_us-gaap_StatementTable_266d0964-2896-4d29-bf7c-e073788852c6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis_f505f3c4-621d-4e50-8f8f-b045643fd40f" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_266d0964-2896-4d29-bf7c-e073788852c6" xlink:to="loc_srt_RestatementAxis_f505f3c4-621d-4e50-8f8f-b045643fd40f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_f505f3c4-621d-4e50-8f8f-b045643fd40f_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RestatementAxis_f505f3c4-621d-4e50-8f8f-b045643fd40f" xlink:to="loc_srt_RestatementDomain_f505f3c4-621d-4e50-8f8f-b045643fd40f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_984d443f-e6a8-46f0-bb49-962a35d14051" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RestatementAxis_f505f3c4-621d-4e50-8f8f-b045643fd40f" xlink:to="loc_srt_RestatementDomain_984d443f-e6a8-46f0-bb49-962a35d14051" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_e310fd35-3f7c-4e3e-ac56-a1e010abd5fd" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_266d0964-2896-4d29-bf7c-e073788852c6" xlink:to="loc_srt_ProductOrServiceAxis_e310fd35-3f7c-4e3e-ac56-a1e010abd5fd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e310fd35-3f7c-4e3e-ac56-a1e010abd5fd_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_e310fd35-3f7c-4e3e-ac56-a1e010abd5fd" xlink:to="loc_srt_ProductsAndServicesDomain_e310fd35-3f7c-4e3e-ac56-a1e010abd5fd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_18b8cd4f-0d4b-4c2f-a5cc-364d5cbc4ba6" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_e310fd35-3f7c-4e3e-ac56-a1e010abd5fd" xlink:to="loc_srt_ProductsAndServicesDomain_18b8cd4f-0d4b-4c2f-a5cc-364d5cbc4ba6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueFromCollaborativeAgreementsMember_1b1cfdcc-81c0-4c64-965c-ca28fea69443" xlink:href="mgnx-20181231.xsd#mgnx_RevenueFromCollaborativeAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_18b8cd4f-0d4b-4c2f-a5cc-364d5cbc4ba6" xlink:to="loc_mgnx_RevenueFromCollaborativeAgreementsMember_1b1cfdcc-81c0-4c64-965c-ca28fea69443" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueFromGovernmentAgreementsMember_f68d5c4a-6dad-4c0c-b71c-7d4200e209b5" xlink:href="mgnx-20181231.xsd#mgnx_RevenueFromGovernmentAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_18b8cd4f-0d4b-4c2f-a5cc-364d5cbc4ba6" xlink:to="loc_mgnx_RevenueFromGovernmentAgreementsMember_f68d5c4a-6dad-4c0c-b71c-7d4200e209b5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_d7bad097-7dbf-44b7-a3a7-e219051a51c6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8fd20123-de08-42e9-8a7e-b3ae537710cc" xlink:to="loc_us-gaap_RevenuesAbstract_d7bad097-7dbf-44b7-a3a7-e219051a51c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_d17d4da3-d7e2-40e0-8cf4-e4740d38faab" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_d7bad097-7dbf-44b7-a3a7-e219051a51c6" xlink:to="loc_us-gaap_Revenues_d17d4da3-d7e2-40e0-8cf4-e4740d38faab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_bb5586c9-5a56-4ee2-b83a-32e820c77c81" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8fd20123-de08-42e9-8a7e-b3ae537710cc" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_bb5586c9-5a56-4ee2-b83a-32e820c77c81" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_f1315db3-7a5d-4135-851d-4df5610af2ee" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_bb5586c9-5a56-4ee2-b83a-32e820c77c81" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_f1315db3-7a5d-4135-851d-4df5610af2ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_e55ee927-d51b-42a1-a6f8-a67ae39f695b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_bb5586c9-5a56-4ee2-b83a-32e820c77c81" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_e55ee927-d51b-42a1-a6f8-a67ae39f695b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_f498beaa-8524-49f2-84b8-1007e2f41729" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_bb5586c9-5a56-4ee2-b83a-32e820c77c81" xlink:to="loc_us-gaap_CostsAndExpenses_f498beaa-8524-49f2-84b8-1007e2f41729" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_3b3be713-657b-4b5b-8297-d0ae1ead6d1a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8fd20123-de08-42e9-8a7e-b3ae537710cc" xlink:to="loc_us-gaap_OperatingIncomeLoss_3b3be713-657b-4b5b-8297-d0ae1ead6d1a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_bb4584f3-dd35-4f08-b6de-833846a6875e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8fd20123-de08-42e9-8a7e-b3ae537710cc" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_bb4584f3-dd35-4f08-b6de-833846a6875e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d660e7e7-d9b7-4749-b495-546fafd98229" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8fd20123-de08-42e9-8a7e-b3ae537710cc" xlink:to="loc_us-gaap_NetIncomeLoss_d660e7e7-d9b7-4749-b495-546fafd98229" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_b720082d-39c4-47c6-9bb2-2b6b2d825a64" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8fd20123-de08-42e9-8a7e-b3ae537710cc" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_b720082d-39c4-47c6-9bb2-2b6b2d825a64" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_b691ffc8-b4de-4b50-a971-c8dc2189d535" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_b720082d-39c4-47c6-9bb2-2b6b2d825a64" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_b691ffc8-b4de-4b50-a971-c8dc2189d535" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_df9ddce7-60ea-46ab-8524-ea8fa0b58839" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8fd20123-de08-42e9-8a7e-b3ae537710cc" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_df9ddce7-60ea-46ab-8524-ea8fa0b58839" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_2c2afe41-d5cc-4119-9b14-c3281088c14c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8fd20123-de08-42e9-8a7e-b3ae537710cc" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_2c2afe41-d5cc-4119-9b14-c3281088c14c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_26180cad-c95a-41d2-b02c-569ed38b2bad" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8fd20123-de08-42e9-8a7e-b3ae537710cc" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_26180cad-c95a-41d2-b02c-569ed38b2bad" xlink:type="arc" order="9"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="mgnx-20181231.xsd#CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended" id="ic3ae27545b8241899920172e712cbd22_986c077d-ce8a-4a7b-8698-470430e555a3">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_aeaa09ec-2ab3-411e-b07e-19b59343e626" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_79fb755a-f835-49ef-a83d-28eed7dc8c20" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_aeaa09ec-2ab3-411e-b07e-19b59343e626" xlink:to="loc_us-gaap_StatementTable_79fb755a-f835-49ef-a83d-28eed7dc8c20" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_eb416f4f-c9ee-4363-81e0-c0416ab789f8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_79fb755a-f835-49ef-a83d-28eed7dc8c20" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_eb416f4f-c9ee-4363-81e0-c0416ab789f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_eb416f4f-c9ee-4363-81e0-c0416ab789f8_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_eb416f4f-c9ee-4363-81e0-c0416ab789f8" xlink:to="loc_us-gaap_EquityComponentDomain_eb416f4f-c9ee-4363-81e0-c0416ab789f8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_c767fc3a-d04d-4366-a338-06bce7933903" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_eb416f4f-c9ee-4363-81e0-c0416ab789f8" xlink:to="loc_us-gaap_EquityComponentDomain_c767fc3a-d04d-4366-a338-06bce7933903" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_47668085-fb91-4dec-8441-84d9375a52a9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_c767fc3a-d04d-4366-a338-06bce7933903" xlink:to="loc_us-gaap_CommonStockMember_47668085-fb91-4dec-8441-84d9375a52a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_8ef2fddc-c807-4b03-a17a-51050dc691b2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_c767fc3a-d04d-4366-a338-06bce7933903" xlink:to="loc_us-gaap_TreasuryStockMember_8ef2fddc-c807-4b03-a17a-51050dc691b2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_134e5409-d245-425d-8921-56987ac4c4f0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_c767fc3a-d04d-4366-a338-06bce7933903" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_134e5409-d245-425d-8921-56987ac4c4f0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_4f90cceb-de41-4ed4-ab0c-11052dbe3b37" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_c767fc3a-d04d-4366-a338-06bce7933903" xlink:to="loc_us-gaap_RetainedEarningsMember_4f90cceb-de41-4ed4-ab0c-11052dbe3b37" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e956f466-67de-420b-9470-d8dc5ec584fc" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_c767fc3a-d04d-4366-a338-06bce7933903" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e956f466-67de-420b-9470-d8dc5ec584fc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_880c7639-cb8e-484e-bba8-e22ff71c6a0e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_aeaa09ec-2ab3-411e-b07e-19b59343e626" xlink:to="loc_us-gaap_StockholdersEquity_880c7639-cb8e-484e-bba8-e22ff71c6a0e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_0cc17649-19c7-4d85-885a-43b33aaa08e0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_aeaa09ec-2ab3-411e-b07e-19b59343e626" xlink:to="loc_us-gaap_SharesIssued_0cc17649-19c7-4d85-885a-43b33aaa08e0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_bb1f4b86-c6a8-478a-be6b-fb620d5e952d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_aeaa09ec-2ab3-411e-b07e-19b59343e626" xlink:to="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_bb1f4b86-c6a8-478a-be6b-fb620d5e952d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_71e8a441-9fe3-4760-b1c4-d1ac0295ea05" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_aeaa09ec-2ab3-411e-b07e-19b59343e626" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_71e8a441-9fe3-4760-b1c4-d1ac0295ea05" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_2a69edf0-9609-4aaa-ae37-b9d4e356170f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_aeaa09ec-2ab3-411e-b07e-19b59343e626" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_2a69edf0-9609-4aaa-ae37-b9d4e356170f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_9eb647ea-00a1-4add-8bb7-0983e824713f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_aeaa09ec-2ab3-411e-b07e-19b59343e626" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_9eb647ea-00a1-4add-8bb7-0983e824713f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_StockIssuedDuringPeriodValueStockPlanActivity_51304edc-8b39-4b14-93a1-fbc1e74b3fbf" xlink:href="mgnx-20181231.xsd#mgnx_StockIssuedDuringPeriodValueStockPlanActivity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_aeaa09ec-2ab3-411e-b07e-19b59343e626" xlink:to="loc_mgnx_StockIssuedDuringPeriodValueStockPlanActivity_51304edc-8b39-4b14-93a1-fbc1e74b3fbf" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity_dddba1ca-be37-488e-ac8b-1bd3f80307a4" xlink:href="mgnx-20181231.xsd#mgnx_StockIssuedDuringPeriodSharesStockPlanActivity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_aeaa09ec-2ab3-411e-b07e-19b59343e626" xlink:to="loc_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity_dddba1ca-be37-488e-ac8b-1bd3f80307a4" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockRetiredParValueMethodAmount_81cfd536-7e08-4b0e-b3ac-223f40d0cce7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TreasuryStockRetiredParValueMethodAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_aeaa09ec-2ab3-411e-b07e-19b59343e626" xlink:to="loc_us-gaap_TreasuryStockRetiredParValueMethodAmount_81cfd536-7e08-4b0e-b3ac-223f40d0cce7" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesRetired_99f558a0-18b0-44f1-b7d9-f4d6e2c9a9de" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TreasuryStockSharesRetired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_aeaa09ec-2ab3-411e-b07e-19b59343e626" xlink:to="loc_us-gaap_TreasuryStockSharesRetired_99f558a0-18b0-44f1-b7d9-f4d6e2c9a9de" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_698e9ac9-cb8f-4cae-ab48-cba781eb8716" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_aeaa09ec-2ab3-411e-b07e-19b59343e626" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_698e9ac9-cb8f-4cae-ab48-cba781eb8716" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_7267e94e-7b95-4f1e-b05f-97501360297e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_aeaa09ec-2ab3-411e-b07e-19b59343e626" xlink:to="loc_us-gaap_NetIncomeLoss_7267e94e-7b95-4f1e-b05f-97501360297e" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_cc789b0c-8c6a-4b5c-ae52-1e6dcb502ced" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_b909fdf7-757c-4771-b9e5-9f075483959d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesIssued"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="mgnx-20181231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended" id="i3623870f58ec44e793774288753b64cc_f9f726e3-783f-451c-8c5b-52ab7603f38d"/>
  <link:roleRef roleURI="http://macrogenics.com/role/OrganizationandNatureofOperations" xlink:type="simple" xlink:href="mgnx-20181231.xsd#OrganizationandNatureofOperations"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/OrganizationandNatureofOperations" xlink:type="extended" id="iaf204bfb942b4c0ca837a8cba501d372_95d392a1-a422-4cf9-b8d3-a1c015a1e9bd"/>
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="mgnx-20181231.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended" id="ie66cda55b3f741aab1ef28939fee0e6c_d40fef78-d258-48d5-9055-21452b5af681"/>
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="mgnx-20181231.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended" id="idc0d53de327244249e6ffd173fc1e97f_9f637cf7-559f-45f2-a601-5d8f314a78ce"/>
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="mgnx-20181231.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended" id="ie4d88f2dde9f44aeb82c27302588f117_284ba0a9-4dc6-42d9-9cfd-3b45864c63ab"/>
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="mgnx-20181231.xsd#SummaryofSignificantAccountingPoliciesDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="extended" id="ib1eb40d29681487e945e9ffae623ec78_2a59a534-03f5-4946-907b-3c87bbfa10a1"/>
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails" xlink:type="simple" xlink:href="mgnx-20181231.xsd#SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails" xlink:type="extended" id="i85a55164e38f47308c63a050ecc8b193_a513edf6-2992-4a2a-bab2-203eed826aeb">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5d33ea3d-4caa-4f4e-9a24-754d18e569d1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5ebb27db-19e6-444b-aff6-71ff008f9d6e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5d33ea3d-4caa-4f4e-9a24-754d18e569d1" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5ebb27db-19e6-444b-aff6-71ff008f9d6e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9ec6f98c-4886-4905-84d2-dff7c11b7c18" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5ebb27db-19e6-444b-aff6-71ff008f9d6e" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9ec6f98c-4886-4905-84d2-dff7c11b7c18" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9ec6f98c-4886-4905-84d2-dff7c11b7c18_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9ec6f98c-4886-4905-84d2-dff7c11b7c18" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9ec6f98c-4886-4905-84d2-dff7c11b7c18_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_01e1b2dd-1628-4b82-9d4c-a86683ab61fa" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9ec6f98c-4886-4905-84d2-dff7c11b7c18" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_01e1b2dd-1628-4b82-9d4c-a86683ab61fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_cba3be27-c62e-4c10-aa1a-246375bf97d1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_01e1b2dd-1628-4b82-9d4c-a86683ab61fa" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_cba3be27-c62e-4c10-aa1a-246375bf97d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_4027f0c4-851e-41a1-b37d-e45c664d2c2f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_01e1b2dd-1628-4b82-9d4c-a86683ab61fa" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_4027f0c4-851e-41a1-b37d-e45c664d2c2f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_82d33a74-55ae-48a5-9b14-c76b0b98df14" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_01e1b2dd-1628-4b82-9d4c-a86683ab61fa" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_82d33a74-55ae-48a5-9b14-c76b0b98df14" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_7a8a2e1e-6919-4517-aac4-b992e33dc751" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5ebb27db-19e6-444b-aff6-71ff008f9d6e" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_7a8a2e1e-6919-4517-aac4-b992e33dc751" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_7a8a2e1e-6919-4517-aac4-b992e33dc751_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_7a8a2e1e-6919-4517-aac4-b992e33dc751" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_7a8a2e1e-6919-4517-aac4-b992e33dc751_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_2f880cdd-4f29-4579-9bb4-16cb865b5ed2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_7a8a2e1e-6919-4517-aac4-b992e33dc751" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_2f880cdd-4f29-4579-9bb4-16cb865b5ed2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_3902032e-8c78-44c3-bfaf-da1a286fbc45" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_2f880cdd-4f29-4579-9bb4-16cb865b5ed2" xlink:to="loc_us-gaap_MoneyMarketFundsMember_3902032e-8c78-44c3-bfaf-da1a286fbc45" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_eaf1201f-b529-4aed-b71c-246b7d520891" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_2f880cdd-4f29-4579-9bb4-16cb865b5ed2" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_eaf1201f-b529-4aed-b71c-246b7d520891" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_0c2fa6d0-23e7-4bd9-9522-8733afcad44c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_2f880cdd-4f29-4579-9bb4-16cb865b5ed2" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_0c2fa6d0-23e7-4bd9-9522-8733afcad44c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_9caec703-f167-4858-871b-ec154fb65b8e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_2f880cdd-4f29-4579-9bb4-16cb865b5ed2" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_9caec703-f167-4858-871b-ec154fb65b8e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_0e86a8d6-f1a9-489e-8996-682adfcbb3bc" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5d33ea3d-4caa-4f4e-9a24-754d18e569d1" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_0e86a8d6-f1a9-489e-8996-682adfcbb3bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_d6cc54c8-5bec-4d5c-9287-1c28eb9c9c5d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_0e86a8d6-f1a9-489e-8996-682adfcbb3bc" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_d6cc54c8-5bec-4d5c-9287-1c28eb9c9c5d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecurities_f7afc0c1-b010-444b-8617-54c202e2b1da" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_0e86a8d6-f1a9-489e-8996-682adfcbb3bc" xlink:to="loc_us-gaap_AvailableForSaleSecurities_f7afc0c1-b010-444b-8617-54c202e2b1da" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_dec64ce9-fa02-436c-ac64-6907f4232070" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_0e86a8d6-f1a9-489e-8996-682adfcbb3bc" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_dec64ce9-fa02-436c-ac64-6907f4232070" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_WarrantsFairValueDisclosure_3b7e9132-3d8e-4ae9-a454-35b8808e6b76" xlink:href="mgnx-20181231.xsd#mgnx_WarrantsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_0e86a8d6-f1a9-489e-8996-682adfcbb3bc" xlink:to="loc_mgnx_WarrantsFairValueDisclosure_3b7e9132-3d8e-4ae9-a454-35b8808e6b76" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_af5377fb-e75d-4ebb-a3df-84c5895218e1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_0e86a8d6-f1a9-489e-8996-682adfcbb3bc" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_af5377fb-e75d-4ebb-a3df-84c5895218e1" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedDetails" xlink:type="simple" xlink:href="mgnx-20181231.xsd#SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedDetails" xlink:type="extended" id="i75b3847ba09644d9b248a8ed15070358_8a175ab1-f7c4-411d-abec-cdd22cdb626e">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_08230e48-e9a2-4074-8f4b-756ce82ae1b5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_59b0d61a-5f83-453b-9b3a-71e30645081f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_08230e48-e9a2-4074-8f4b-756ce82ae1b5" xlink:to="loc_us-gaap_ConcentrationRiskTable_59b0d61a-5f83-453b-9b3a-71e30645081f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_75c071bb-a303-431a-bbd8-659187c3f2b5" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_59b0d61a-5f83-453b-9b3a-71e30645081f" xlink:to="loc_srt_MajorCustomersAxis_75c071bb-a303-431a-bbd8-659187c3f2b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_75c071bb-a303-431a-bbd8-659187c3f2b5_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_75c071bb-a303-431a-bbd8-659187c3f2b5" xlink:to="loc_srt_NameOfMajorCustomerDomain_75c071bb-a303-431a-bbd8-659187c3f2b5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_b5a87fc7-eeda-468d-9a21-1d342182221e" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_75c071bb-a303-431a-bbd8-659187c3f2b5" xlink:to="loc_srt_NameOfMajorCustomerDomain_b5a87fc7-eeda-468d-9a21-1d342182221e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteCorporationMember_da3e55e8-b527-48ee-a56e-4696041b9c70" xlink:href="mgnx-20181231.xsd#mgnx_IncyteCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_b5a87fc7-eeda-468d-9a21-1d342182221e" xlink:to="loc_mgnx_IncyteCorporationMember_da3e55e8-b527-48ee-a56e-4696041b9c70" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_JanssenBiotechIncMember_66299644-7059-4fde-8f25-0867d20b7e74" xlink:href="mgnx-20181231.xsd#mgnx_JanssenBiotechIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_b5a87fc7-eeda-468d-9a21-1d342182221e" xlink:to="loc_mgnx_JanssenBiotechIncMember_66299644-7059-4fde-8f25-0867d20b7e74" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionBioMember_25242f4d-2729-452b-b647-5fcacfd95d80" xlink:href="mgnx-20181231.xsd#mgnx_ProventionBioMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_b5a87fc7-eeda-468d-9a21-1d342182221e" xlink:to="loc_mgnx_ProventionBioMember_25242f4d-2729-452b-b647-5fcacfd95d80" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a06714fe-fbfb-4ccb-8415-34e30f8d1d82" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_59b0d61a-5f83-453b-9b3a-71e30645081f" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a06714fe-fbfb-4ccb-8415-34e30f8d1d82" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_a06714fe-fbfb-4ccb-8415-34e30f8d1d82_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a06714fe-fbfb-4ccb-8415-34e30f8d1d82" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_a06714fe-fbfb-4ccb-8415-34e30f8d1d82_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_c69439f9-c8d8-475b-92de-6b40d517e7c9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a06714fe-fbfb-4ccb-8415-34e30f8d1d82" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_c69439f9-c8d8-475b-92de-6b40d517e7c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_024ec909-dcb1-49c0-ba9c-92efca5e1c40" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_c69439f9-c8d8-475b-92de-6b40d517e7c9" xlink:to="loc_us-gaap_SalesRevenueNetMember_024ec909-dcb1-49c0-ba9c-92efca5e1c40" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_12c93043-e9a7-43b7-bd80-04b2bc074a6f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_59b0d61a-5f83-453b-9b3a-71e30645081f" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_12c93043-e9a7-43b7-bd80-04b2bc074a6f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_12c93043-e9a7-43b7-bd80-04b2bc074a6f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_12c93043-e9a7-43b7-bd80-04b2bc074a6f" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_12c93043-e9a7-43b7-bd80-04b2bc074a6f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_e29a1a48-82fe-4655-86a3-1e666e5c2947" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_12c93043-e9a7-43b7-bd80-04b2bc074a6f" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_e29a1a48-82fe-4655-86a3-1e666e5c2947" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_45af469b-4f4e-472a-9006-c6171d38c31d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_e29a1a48-82fe-4655-86a3-1e666e5c2947" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_45af469b-4f4e-472a-9006-c6171d38c31d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_244ded6b-87f8-493d-af3e-42f3cd9e9e88" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_08230e48-e9a2-4074-8f4b-756ce82ae1b5" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_244ded6b-87f8-493d-af3e-42f3cd9e9e88" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofAccountsReceivableDetails" xlink:type="simple" xlink:href="mgnx-20181231.xsd#SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofAccountsReceivableDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofAccountsReceivableDetails" xlink:type="extended" id="ie8d357b03dfc4b7e94df469c48758aed_970d8c8b-e14d-4c94-b2d5-ef41430f6cec">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_bd9e9217-d050-434f-ad70-aacd54b3ef28" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_9bcde865-7f1e-4c2c-a728-06c799af8f3b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_bd9e9217-d050-434f-ad70-aacd54b3ef28" xlink:to="loc_us-gaap_ConcentrationRiskTable_9bcde865-7f1e-4c2c-a728-06c799af8f3b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_cac5cdcd-3511-45bc-ba01-00faf18ff72d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_9bcde865-7f1e-4c2c-a728-06c799af8f3b" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_cac5cdcd-3511-45bc-ba01-00faf18ff72d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_cac5cdcd-3511-45bc-ba01-00faf18ff72d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_cac5cdcd-3511-45bc-ba01-00faf18ff72d" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_cac5cdcd-3511-45bc-ba01-00faf18ff72d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_ab6a2dbe-ed73-498e-bdb5-6116b7a25ceb" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_cac5cdcd-3511-45bc-ba01-00faf18ff72d" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_ab6a2dbe-ed73-498e-bdb5-6116b7a25ceb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_6f3e30ad-fab3-4894-90d1-0eed56811fb5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_ab6a2dbe-ed73-498e-bdb5-6116b7a25ceb" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_6f3e30ad-fab3-4894-90d1-0eed56811fb5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_b86cf8b2-b8c8-4370-b595-8346b99cb613" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_9bcde865-7f1e-4c2c-a728-06c799af8f3b" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_b86cf8b2-b8c8-4370-b595-8346b99cb613" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_b86cf8b2-b8c8-4370-b595-8346b99cb613_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_b86cf8b2-b8c8-4370-b595-8346b99cb613" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_b86cf8b2-b8c8-4370-b595-8346b99cb613_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_e57235e5-355e-493c-acee-b006a9011d2a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_b86cf8b2-b8c8-4370-b595-8346b99cb613" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_e57235e5-355e-493c-acee-b006a9011d2a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_0a1f4dcd-1887-4142-858b-c10bc4b252e8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_e57235e5-355e-493c-acee-b006a9011d2a" xlink:to="loc_us-gaap_AccountsReceivableMember_0a1f4dcd-1887-4142-858b-c10bc4b252e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_c8881d93-8bfd-488e-96af-c975f9d33a83" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_9bcde865-7f1e-4c2c-a728-06c799af8f3b" xlink:to="loc_srt_MajorCustomersAxis_c8881d93-8bfd-488e-96af-c975f9d33a83" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_c8881d93-8bfd-488e-96af-c975f9d33a83_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_c8881d93-8bfd-488e-96af-c975f9d33a83" xlink:to="loc_srt_NameOfMajorCustomerDomain_c8881d93-8bfd-488e-96af-c975f9d33a83_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_984b0f57-a059-4ac7-8535-24dd6f56fc7a" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_c8881d93-8bfd-488e-96af-c975f9d33a83" xlink:to="loc_srt_NameOfMajorCustomerDomain_984b0f57-a059-4ac7-8535-24dd6f56fc7a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabLimitedMember_ec231203-ded6-4d70-afab-a2b39af1f145" xlink:href="mgnx-20181231.xsd#mgnx_ZaiLabLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_984b0f57-a059-4ac7-8535-24dd6f56fc7a" xlink:to="loc_mgnx_ZaiLabLimitedMember_ec231203-ded6-4d70-afab-a2b39af1f145" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteCorporationMember_ce2a5571-c856-4365-ac99-06568611e03e" xlink:href="mgnx-20181231.xsd#mgnx_IncyteCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_984b0f57-a059-4ac7-8535-24dd6f56fc7a" xlink:to="loc_mgnx_IncyteCorporationMember_ce2a5571-c856-4365-ac99-06568611e03e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member_ce687695-20de-4053-804e-28758243df7b" xlink:href="mgnx-20181231.xsd#mgnx_F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_984b0f57-a059-4ac7-8535-24dd6f56fc7a" xlink:to="loc_mgnx_F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member_ce687695-20de-4053-804e-28758243df7b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_LesLaboratoiresServierAndInstitutDeRecherchesServierServierMember_109b8d1f-c133-42c3-b811-2c30211e7e78" xlink:href="mgnx-20181231.xsd#mgnx_LesLaboratoiresServierAndInstitutDeRecherchesServierServierMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_984b0f57-a059-4ac7-8535-24dd6f56fc7a" xlink:to="loc_mgnx_LesLaboratoiresServierAndInstitutDeRecherchesServierServierMember_109b8d1f-c133-42c3-b811-2c30211e7e78" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_d3ebe46d-aaab-4f4a-81e7-bf5a32b151b1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_bd9e9217-d050-434f-ad70-aacd54b3ef28" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_d3ebe46d-aaab-4f4a-81e7-bf5a32b151b1" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails" xlink:type="simple" xlink:href="mgnx-20181231.xsd#SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails" xlink:type="extended" id="i66806276f0324d618d2bb7c4f8da14cb_fb5fc086-e353-4511-ac5f-e2c54a1c2f80">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e49e1ac7-e333-49f0-9f8e-92d7130997af" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_55ebeb83-7324-447d-bdc5-e0556bc659d4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e49e1ac7-e333-49f0-9f8e-92d7130997af" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_55ebeb83-7324-447d-bdc5-e0556bc659d4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d1f52d1c-1d52-4705-8a52-70f55b801189" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_55ebeb83-7324-447d-bdc5-e0556bc659d4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d1f52d1c-1d52-4705-8a52-70f55b801189" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d1f52d1c-1d52-4705-8a52-70f55b801189_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d1f52d1c-1d52-4705-8a52-70f55b801189" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d1f52d1c-1d52-4705-8a52-70f55b801189_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_574c7332-2f43-4210-8c5d-d82a1ab19939" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d1f52d1c-1d52-4705-8a52-70f55b801189" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_574c7332-2f43-4210-8c5d-d82a1ab19939" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_0e3dde8a-1f5a-45c9-9b3b-e17dc0f9685d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_574c7332-2f43-4210-8c5d-d82a1ab19939" xlink:to="loc_us-gaap_ComputerEquipmentMember_0e3dde8a-1f5a-45c9-9b3b-e17dc0f9685d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_e703914e-12d9-4cc8-a233-3a5806b359c7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_574c7332-2f43-4210-8c5d-d82a1ab19939" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_e703914e-12d9-4cc8-a233-3a5806b359c7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_b6922d74-7f00-4c13-8db4-4d6d3a9a25af" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_574c7332-2f43-4210-8c5d-d82a1ab19939" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_b6922d74-7f00-4c13-8db4-4d6d3a9a25af" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_LaboratoryAndOfficeEquipmentMember_dfa3fa2f-2d49-4175-9c7c-5a5eabc8a497" xlink:href="mgnx-20181231.xsd#mgnx_LaboratoryAndOfficeEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_574c7332-2f43-4210-8c5d-d82a1ab19939" xlink:to="loc_mgnx_LaboratoryAndOfficeEquipmentMember_dfa3fa2f-2d49-4175-9c7c-5a5eabc8a497" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_46b3e029-c25c-44b8-9ea1-03904cbdd83d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_574c7332-2f43-4210-8c5d-d82a1ab19939" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_46b3e029-c25c-44b8-9ea1-03904cbdd83d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_7b0233f6-3dfa-4ca7-aca9-5cea08c028ae" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e49e1ac7-e333-49f0-9f8e-92d7130997af" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_7b0233f6-3dfa-4ca7-aca9-5cea08c028ae" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromtheCalculationofDilutedLossPerShareDetails" xlink:type="simple" xlink:href="mgnx-20181231.xsd#SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromtheCalculationofDilutedLossPerShareDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromtheCalculationofDilutedLossPerShareDetails" xlink:type="extended" id="i0aed4662ed8b4aa099d83c32b7ce5f45_565e4b92-cbab-42de-97e6-4682c860ccb7">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d63b7dc6-27d1-4f57-a59a-3fb118fc669b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_45e5dc06-a28f-4bb1-9b65-bbb7751a3d71" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d63b7dc6-27d1-4f57-a59a-3fb118fc669b" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_45e5dc06-a28f-4bb1-9b65-bbb7751a3d71" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_f05e02fb-0e0b-4db1-89d1-6e93f2900292" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_45e5dc06-a28f-4bb1-9b65-bbb7751a3d71" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_f05e02fb-0e0b-4db1-89d1-6e93f2900292" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f05e02fb-0e0b-4db1-89d1-6e93f2900292_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_f05e02fb-0e0b-4db1-89d1-6e93f2900292" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f05e02fb-0e0b-4db1-89d1-6e93f2900292_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2cd12a0d-8e52-4ac6-9099-3b3f2e449990" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_f05e02fb-0e0b-4db1-89d1-6e93f2900292" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2cd12a0d-8e52-4ac6-9099-3b3f2e449990" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember_a0efc592-8c74-4940-9500-a2604661c452" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2cd12a0d-8e52-4ac6-9099-3b3f2e449990" xlink:to="loc_us-gaap_StockOptionMember_a0efc592-8c74-4940-9500-a2604661c452" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1c0a3862-2dad-4743-ade3-9306ba16c829" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d63b7dc6-27d1-4f57-a59a-3fb118fc669b" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1c0a3862-2dad-4743-ade3-9306ba16c829" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesAdoptionof606Details" xlink:type="simple" xlink:href="mgnx-20181231.xsd#SummaryofSignificantAccountingPoliciesAdoptionof606Details"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesAdoptionof606Details" xlink:type="extended" id="if9d803aa9f584c51a66cc5ab27bbfd37_f574b238-7810-436b-ba2c-34eb88506dff">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_81652820-242c-4325-8c73-e2e225a6bd67" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_efbeb687-4868-4b82-8f77-af467e11c075" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_81652820-242c-4325-8c73-e2e225a6bd67" xlink:to="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_efbeb687-4868-4b82-8f77-af467e11c075" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_366dc0a3-6d68-4539-8edf-310d41773ba4" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_efbeb687-4868-4b82-8f77-af467e11c075" xlink:to="loc_srt_ProductOrServiceAxis_366dc0a3-6d68-4539-8edf-310d41773ba4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_366dc0a3-6d68-4539-8edf-310d41773ba4_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_366dc0a3-6d68-4539-8edf-310d41773ba4" xlink:to="loc_srt_ProductsAndServicesDomain_366dc0a3-6d68-4539-8edf-310d41773ba4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a566d283-a7f4-4a4b-bc29-fc5805cb3732" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_366dc0a3-6d68-4539-8edf-310d41773ba4" xlink:to="loc_srt_ProductsAndServicesDomain_a566d283-a7f4-4a4b-bc29-fc5805cb3732" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueFromCollaborativeAgreementsMember_45c19156-1809-467f-84d8-3dcefd1334f1" xlink:href="mgnx-20181231.xsd#mgnx_RevenueFromCollaborativeAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_a566d283-a7f4-4a4b-bc29-fc5805cb3732" xlink:to="loc_mgnx_RevenueFromCollaborativeAgreementsMember_45c19156-1809-467f-84d8-3dcefd1334f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_b1a129b2-b1f6-4ccc-94d1-b111a0b55bfa" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_efbeb687-4868-4b82-8f77-af467e11c075" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_b1a129b2-b1f6-4ccc-94d1-b111a0b55bfa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_b1a129b2-b1f6-4ccc-94d1-b111a0b55bfa_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_b1a129b2-b1f6-4ccc-94d1-b111a0b55bfa" xlink:to="loc_us-gaap_TypeOfAdoptionMember_b1a129b2-b1f6-4ccc-94d1-b111a0b55bfa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_370838ce-de9f-456e-9f24-494524a0fbfc" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_b1a129b2-b1f6-4ccc-94d1-b111a0b55bfa" xlink:to="loc_us-gaap_TypeOfAdoptionMember_370838ce-de9f-456e-9f24-494524a0fbfc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201409Member_644d36b3-9426-43a1-8654-4f28da4b4918" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_370838ce-de9f-456e-9f24-494524a0fbfc" xlink:to="loc_us-gaap_AccountingStandardsUpdate201409Member_644d36b3-9426-43a1-8654-4f28da4b4918" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_c1c7aacd-c756-406d-a651-046595a23b7d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_efbeb687-4868-4b82-8f77-af467e11c075" xlink:to="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_c1c7aacd-c756-406d-a651-046595a23b7d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_c1c7aacd-c756-406d-a651-046595a23b7d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_c1c7aacd-c756-406d-a651-046595a23b7d" xlink:to="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_c1c7aacd-c756-406d-a651-046595a23b7d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_5f460a0e-451d-43c7-9521-1991f94f47d5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_c1c7aacd-c756-406d-a651-046595a23b7d" xlink:to="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_5f460a0e-451d-43c7-9521-1991f94f47d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member_a0dfed20-4d1f-422b-80c2-0263ae73b6ca" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_5f460a0e-451d-43c7-9521-1991f94f47d5" xlink:to="loc_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member_a0dfed20-4d1f-422b-80c2-0263ae73b6ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_aa6d0a11-c293-43c5-a1f5-4d2f79bc0494" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_5f460a0e-451d-43c7-9521-1991f94f47d5" xlink:to="loc_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_aa6d0a11-c293-43c5-a1f5-4d2f79bc0494" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueCurrent_303c0c9a-12bb-4f5a-a7c6-1e015ea77d12" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredRevenueCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_81652820-242c-4325-8c73-e2e225a6bd67" xlink:to="loc_us-gaap_DeferredRevenueCurrent_303c0c9a-12bb-4f5a-a7c6-1e015ea77d12" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent_2704a7cc-6a4e-41a5-9a51-cea8f930ba08" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredRevenueNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_81652820-242c-4325-8c73-e2e225a6bd67" xlink:to="loc_us-gaap_DeferredRevenueNoncurrent_2704a7cc-6a4e-41a5-9a51-cea8f930ba08" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ff671913-68d6-4be6-b0a6-72e622d67833" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_81652820-242c-4325-8c73-e2e225a6bd67" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ff671913-68d6-4be6-b0a6-72e622d67833" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_b704700c-a125-49ac-8828-ccb855b9df0d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_81652820-242c-4325-8c73-e2e225a6bd67" xlink:to="loc_us-gaap_Revenues_b704700c-a125-49ac-8828-ccb855b9df0d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_02c16341-97aa-48b9-80bc-5c5e624b7484" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_81652820-242c-4325-8c73-e2e225a6bd67" xlink:to="loc_us-gaap_NetIncomeLoss_02c16341-97aa-48b9-80bc-5c5e624b7484" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_6d3c32e1-166b-4d16-b97d-71b1c4016792" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_81652820-242c-4325-8c73-e2e225a6bd67" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_6d3c32e1-166b-4d16-b97d-71b1c4016792" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryofSignficantAccountingPoliciesContractWithCustomerLiabilityDetails" xlink:type="simple" xlink:href="mgnx-20181231.xsd#SummaryofSignficantAccountingPoliciesContractWithCustomerLiabilityDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/SummaryofSignficantAccountingPoliciesContractWithCustomerLiabilityDetails" xlink:type="extended" id="iee76b2ba140343bcac9fc0f8b83171cc_12e8a409-77c6-42d8-af90-d0b32fe21187"/>
  <link:roleRef roleURI="http://macrogenics.com/role/MarketableSecurities" xlink:type="simple" xlink:href="mgnx-20181231.xsd#MarketableSecurities"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/MarketableSecurities" xlink:type="extended" id="i6e808f80b4644cbba38990fa836ec4a3_8cd1cb32-a6b4-4761-8598-37c7c1c11fc9"/>
  <link:roleRef roleURI="http://macrogenics.com/role/MarketableSecuritiesTables" xlink:type="simple" xlink:href="mgnx-20181231.xsd#MarketableSecuritiesTables"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/MarketableSecuritiesTables" xlink:type="extended" id="iffa1f7341ae848398ce46bf0fffea0d1_3468bb24-87b4-4c75-b1c5-45adda52662e"/>
  <link:roleRef roleURI="http://macrogenics.com/role/MarketableSecuritiesDetails" xlink:type="simple" xlink:href="mgnx-20181231.xsd#MarketableSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/MarketableSecuritiesDetails" xlink:type="extended" id="ic8c40f28eeff4584979d6b12e4481976_bcd76f93-f80e-40c1-b61c-c6209c15b8fd">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_aa1f39aa-81ee-4f46-a92b-07d5f1ba10fc" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_c942e003-e09f-430c-86b0-d98bd6bfeba8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_aa1f39aa-81ee-4f46-a92b-07d5f1ba10fc" xlink:to="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_c942e003-e09f-430c-86b0-d98bd6bfeba8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_5424fb1f-1688-4a55-ae2c-ed72240e8593" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_c942e003-e09f-430c-86b0-d98bd6bfeba8" xlink:to="loc_us-gaap_FinancialInstrumentAxis_5424fb1f-1688-4a55-ae2c-ed72240e8593" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5424fb1f-1688-4a55-ae2c-ed72240e8593_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_5424fb1f-1688-4a55-ae2c-ed72240e8593" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5424fb1f-1688-4a55-ae2c-ed72240e8593_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f1159ef8-522c-4ca3-9be7-2d5d58e27a35" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_5424fb1f-1688-4a55-ae2c-ed72240e8593" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f1159ef8-522c-4ca3-9be7-2d5d58e27a35" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_b6c177ac-7719-4ac2-ab7b-15f8827ab152" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f1159ef8-522c-4ca3-9be7-2d5d58e27a35" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_b6c177ac-7719-4ac2-ab7b-15f8827ab152" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_8fc4599c-499c-4e02-bbe4-269db6048136" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f1159ef8-522c-4ca3-9be7-2d5d58e27a35" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_8fc4599c-499c-4e02-bbe4-269db6048136" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_65e5a589-feea-4182-8ad9-387f2d447a68" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f1159ef8-522c-4ca3-9be7-2d5d58e27a35" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_65e5a589-feea-4182-8ad9-387f2d447a68" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_d5bc4210-b4da-493f-bd4e-cbc6aa61afb3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_aa1f39aa-81ee-4f46-a92b-07d5f1ba10fc" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_d5bc4210-b4da-493f-bd4e-cbc6aa61afb3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_c8bacbed-fb24-46a7-9a9b-93137ca9897d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_aa1f39aa-81ee-4f46-a92b-07d5f1ba10fc" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_c8bacbed-fb24-46a7-9a9b-93137ca9897d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_addbde1c-28c6-4804-9eaf-e222f32b6f78" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_aa1f39aa-81ee-4f46-a92b-07d5f1ba10fc" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_addbde1c-28c6-4804-9eaf-e222f32b6f78" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3407f6d0-d26b-483f-9819-b82ad28ad301" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_aa1f39aa-81ee-4f46-a92b-07d5f1ba10fc" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3407f6d0-d26b-483f-9819-b82ad28ad301" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/MarketableSecuritiesAvailableForSaleSecuritiesDetails" xlink:type="simple" xlink:href="mgnx-20181231.xsd#MarketableSecuritiesAvailableForSaleSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/MarketableSecuritiesAvailableForSaleSecuritiesDetails" xlink:type="extended" id="i434667b7741d48508fc9309cafe2ee63_4d9aa575-5cf6-4225-ad15-88781658b086"/>
  <link:roleRef roleURI="http://macrogenics.com/role/PropertyEquipmentandSoftware" xlink:type="simple" xlink:href="mgnx-20181231.xsd#PropertyEquipmentandSoftware"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/PropertyEquipmentandSoftware" xlink:type="extended" id="i717c62bb44074dd7b495bf0bf0ad88b4_17a83a06-90c0-49fe-9c02-a57f32c98454"/>
  <link:roleRef roleURI="http://macrogenics.com/role/PropertyEquipmentandSoftwareTables" xlink:type="simple" xlink:href="mgnx-20181231.xsd#PropertyEquipmentandSoftwareTables"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/PropertyEquipmentandSoftwareTables" xlink:type="extended" id="ic4d4e11c20134fd8b670091cc81450dd_81e20f0f-d0a9-40f5-9dcb-ef4cd8916e4c"/>
  <link:roleRef roleURI="http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails" xlink:type="simple" xlink:href="mgnx-20181231.xsd#PropertyEquipmentandSoftwareDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails" xlink:type="extended" id="i83a6c99a6d9f435fb12e21a30af8728c_ca458806-c1c6-418e-88a6-93221ae92ae5">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ce0493b5-8db3-416d-b290-9cc5c28c6a2a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_ab7d6a94-a566-4672-8d3c-d5aa4f46ca0d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ce0493b5-8db3-416d-b290-9cc5c28c6a2a" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_ab7d6a94-a566-4672-8d3c-d5aa4f46ca0d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0d90ca06-7233-462c-bd3d-286b58600eed" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_ab7d6a94-a566-4672-8d3c-d5aa4f46ca0d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0d90ca06-7233-462c-bd3d-286b58600eed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0d90ca06-7233-462c-bd3d-286b58600eed_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0d90ca06-7233-462c-bd3d-286b58600eed" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0d90ca06-7233-462c-bd3d-286b58600eed_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_208ab8b8-a56b-481f-b871-f53565f15c28" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0d90ca06-7233-462c-bd3d-286b58600eed" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_208ab8b8-a56b-481f-b871-f53565f15c28" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_757a0d81-3469-40f0-8156-788133f880cf" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_208ab8b8-a56b-481f-b871-f53565f15c28" xlink:to="loc_us-gaap_ComputerEquipmentMember_757a0d81-3469-40f0-8156-788133f880cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_3f35161e-73b2-4369-acdd-40478e2c96b2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_208ab8b8-a56b-481f-b871-f53565f15c28" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_3f35161e-73b2-4369-acdd-40478e2c96b2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_FurnitureAndOfficeEquipmentMember_ec03183a-1d3a-4d90-893b-e86089aadfaa" xlink:href="mgnx-20181231.xsd#mgnx_FurnitureAndOfficeEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_208ab8b8-a56b-481f-b871-f53565f15c28" xlink:to="loc_mgnx_FurnitureAndOfficeEquipmentMember_ec03183a-1d3a-4d90-893b-e86089aadfaa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_1efe83cb-7540-4cd3-b0ed-62687fecdbcc" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_208ab8b8-a56b-481f-b871-f53565f15c28" xlink:to="loc_us-gaap_EquipmentMember_1efe83cb-7540-4cd3-b0ed-62687fecdbcc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_7fe83822-1642-48b9-952d-69474c94ef36" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_208ab8b8-a56b-481f-b871-f53565f15c28" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_7fe83822-1642-48b9-952d-69474c94ef36" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_65667ec0-db6a-4213-984b-7564dc0671d9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ce0493b5-8db3-416d-b290-9cc5c28c6a2a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_65667ec0-db6a-4213-984b-7564dc0671d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross_a723a29e-b74c-4302-bd2c-b3d3a6ed51bf" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ce0493b5-8db3-416d-b290-9cc5c28c6a2a" xlink:to="loc_us-gaap_ConstructionInProgressGross_a723a29e-b74c-4302-bd2c-b3d3a6ed51bf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_ee6eebd1-81e7-4c14-9951-37fef26ce04b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ce0493b5-8db3-416d-b290-9cc5c28c6a2a" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_ee6eebd1-81e7-4c14-9951-37fef26ce04b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_5029f1e0-9218-4329-86f2-94c19744689c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ce0493b5-8db3-416d-b290-9cc5c28c6a2a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_5029f1e0-9218-4329-86f2-94c19744689c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PropertyPlantAndEquipmentNonCashAdditions_e0bbe639-8a2b-4374-9584-caef519f6fc4" xlink:href="mgnx-20181231.xsd#mgnx_PropertyPlantAndEquipmentNonCashAdditions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ce0493b5-8db3-416d-b290-9cc5c28c6a2a" xlink:to="loc_mgnx_PropertyPlantAndEquipmentNonCashAdditions_e0bbe639-8a2b-4374-9584-caef519f6fc4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_bb1abe87-ecaa-4baa-8c6e-a341f7902673" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ce0493b5-8db3-416d-b290-9cc5c28c6a2a" xlink:to="loc_us-gaap_Depreciation_bb1abe87-ecaa-4baa-8c6e-a341f7902673" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockholdersEquity" xlink:type="simple" xlink:href="mgnx-20181231.xsd#StockholdersEquity"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/StockholdersEquity" xlink:type="extended" id="i6347f9494a1a45deb6f2ff17fe70f067_4f055885-db8c-4fdf-b9be-b2ad93112cb0"/>
  <link:roleRef roleURI="http://macrogenics.com/role/StockholdersEquityDetails" xlink:type="simple" xlink:href="mgnx-20181231.xsd#StockholdersEquityDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/StockholdersEquityDetails" xlink:type="extended" id="ic3878c67a44949c4ae9791597380c24b_9fa174c1-d966-47e9-874a-e54f25a957ab">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_40f3086a-a886-46e0-b529-47b608e8f998" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_d0d1edca-ecfd-4d29-a838-6f6d8731be1f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_40f3086a-a886-46e0-b529-47b608e8f998" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_d0d1edca-ecfd-4d29-a838-6f6d8731be1f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_e37f7981-976a-49a7-adef-b617f1ea2e2b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d0d1edca-ecfd-4d29-a838-6f6d8731be1f" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_e37f7981-976a-49a7-adef-b617f1ea2e2b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e37f7981-976a-49a7-adef-b617f1ea2e2b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_e37f7981-976a-49a7-adef-b617f1ea2e2b" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e37f7981-976a-49a7-adef-b617f1ea2e2b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f44a2347-c5ec-46b7-93d2-a2e91a268adc" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_e37f7981-976a-49a7-adef-b617f1ea2e2b" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f44a2347-c5ec-46b7-93d2-a2e91a268adc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RegisteredDirectOfferingMember_0b53bb37-1c80-41f1-9b66-3db009df13bb" xlink:href="mgnx-20181231.xsd#mgnx_RegisteredDirectOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f44a2347-c5ec-46b7-93d2-a2e91a268adc" xlink:to="loc_mgnx_RegisteredDirectOfferingMember_0b53bb37-1c80-41f1-9b66-3db009df13bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_AtTheMarketOfferingMember_67e2e490-de1d-4191-b503-437fb07c8275" xlink:href="mgnx-20181231.xsd#mgnx_AtTheMarketOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f44a2347-c5ec-46b7-93d2-a2e91a268adc" xlink:to="loc_mgnx_AtTheMarketOfferingMember_67e2e490-de1d-4191-b503-437fb07c8275" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_FirmCommitmentPublicUnderwrittenOfferMember_a7ab4d07-b3de-4465-a3ea-142f80d164d7" xlink:href="mgnx-20181231.xsd#mgnx_FirmCommitmentPublicUnderwrittenOfferMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f44a2347-c5ec-46b7-93d2-a2e91a268adc" xlink:to="loc_mgnx_FirmCommitmentPublicUnderwrittenOfferMember_a7ab4d07-b3de-4465-a3ea-142f80d164d7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_04aadb46-ef26-4432-9f99-3e59e17bfa9e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f44a2347-c5ec-46b7-93d2-a2e91a268adc" xlink:to="loc_us-gaap_OverAllotmentOptionMember_04aadb46-ef26-4432-9f99-3e59e17bfa9e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_feefa782-ddca-49ce-9eaa-cfc65f878adb" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d0d1edca-ecfd-4d29-a838-6f6d8731be1f" xlink:to="loc_us-gaap_StatementClassOfStockAxis_feefa782-ddca-49ce-9eaa-cfc65f878adb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_feefa782-ddca-49ce-9eaa-cfc65f878adb_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_feefa782-ddca-49ce-9eaa-cfc65f878adb" xlink:to="loc_us-gaap_ClassOfStockDomain_feefa782-ddca-49ce-9eaa-cfc65f878adb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_808ab1c4-8faa-4653-9e53-d9b388b693aa" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_feefa782-ddca-49ce-9eaa-cfc65f878adb" xlink:to="loc_us-gaap_ClassOfStockDomain_808ab1c4-8faa-4653-9e53-d9b388b693aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_UndesignatedPreferredStockMember_9370487f-1757-4ce0-93d7-042bcd622c46" xlink:href="mgnx-20181231.xsd#mgnx_UndesignatedPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_808ab1c4-8faa-4653-9e53-d9b388b693aa" xlink:to="loc_mgnx_UndesignatedPreferredStockMember_9370487f-1757-4ce0-93d7-042bcd622c46" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_413b7a63-b4a0-4882-af36-bd9532890e82" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_40f3086a-a886-46e0-b529-47b608e8f998" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_413b7a63-b4a0-4882-af36-bd9532890e82" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_279ef8d1-1c75-4267-ba1b-ee67d73ffcda" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_40f3086a-a886-46e0-b529-47b608e8f998" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_279ef8d1-1c75-4267-ba1b-ee67d73ffcda" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_bee4d2ac-043d-4982-89b9-18f53b473259" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_40f3086a-a886-46e0-b529-47b608e8f998" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_bee4d2ac-043d-4982-89b9-18f53b473259" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_6a8484c3-d934-422a-a9df-78a3abb96df4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_40f3086a-a886-46e0-b529-47b608e8f998" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_6a8484c3-d934-422a-a9df-78a3abb96df4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_5a2c7c95-b08b-411b-a0eb-fbf3421f36f8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_40f3086a-a886-46e0-b529-47b608e8f998" xlink:to="loc_us-gaap_PreferredStockSharesIssued_5a2c7c95-b08b-411b-a0eb-fbf3421f36f8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_b9ed801c-97b7-4314-a9aa-89be3d2cfe59" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_40f3086a-a886-46e0-b529-47b608e8f998" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_b9ed801c-97b7-4314-a9aa-89be3d2cfe59" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_4194b988-5c24-4e11-beaf-528aaae938bb" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_40f3086a-a886-46e0-b529-47b608e8f998" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_4194b988-5c24-4e11-beaf-528aaae938bb" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_af146fa3-46f4-4496-a9df-babb1ece9d2a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_8ec70843-33dc-4b64-945f-b12a0f64a159" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_40f3086a-a886-46e0-b529-47b608e8f998" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_8ec70843-33dc-4b64-945f-b12a0f64a159" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_edf1ec3c-81fc-4be8-823e-491fab4379ed" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_40f3086a-a886-46e0-b529-47b608e8f998" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_edf1ec3c-81fc-4be8-823e-491fab4379ed" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CommonStockMaximumAmountAvailableForIssuance_f967e6a7-c71c-41e7-b836-734aead24c6a" xlink:href="mgnx-20181231.xsd#mgnx_CommonStockMaximumAmountAvailableForIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_40f3086a-a886-46e0-b529-47b608e8f998" xlink:to="loc_mgnx_CommonStockMaximumAmountAvailableForIssuance_f967e6a7-c71c-41e7-b836-734aead24c6a" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_b85de70e-7ae9-4e50-a1e2-9d0dcdd14682" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_40f3086a-a886-46e0-b529-47b608e8f998" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_b85de70e-7ae9-4e50-a1e2-9d0dcdd14682" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_049bb5ce-03c5-4221-884d-88a467c9b8bd" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_40f3086a-a886-46e0-b529-47b608e8f998" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_049bb5ce-03c5-4221-884d-88a467c9b8bd" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_1ca0984e-754b-4e90-9823-d76e3332ae0e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_40f3086a-a886-46e0-b529-47b608e8f998" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_1ca0984e-754b-4e90-9823-d76e3332ae0e" xlink:type="arc" order="14"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockbasedCompensation" xlink:type="simple" xlink:href="mgnx-20181231.xsd#StockbasedCompensation"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/StockbasedCompensation" xlink:type="extended" id="i4eb7554c0e3a4664a94f10620f1b3a15_14b41b5f-de99-4524-a19f-0c51129befa7"/>
  <link:roleRef roleURI="http://macrogenics.com/role/StockbasedCompensationTables" xlink:type="simple" xlink:href="mgnx-20181231.xsd#StockbasedCompensationTables"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/StockbasedCompensationTables" xlink:type="extended" id="i7519952f04704e2c92f0d3a4cf369404_14f01ba0-dc78-495f-9e3d-f194f0e2fbe8"/>
  <link:roleRef roleURI="http://macrogenics.com/role/StockbasedCompensationEmployeeStockPurchasePlanDetails" xlink:type="simple" xlink:href="mgnx-20181231.xsd#StockbasedCompensationEmployeeStockPurchasePlanDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/StockbasedCompensationEmployeeStockPurchasePlanDetails" xlink:type="extended" id="ie970b89a685949359a002ee017af4004_c905925a-b05f-442f-a00a-b58618c160ec">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_16009664-8633-4d29-afaf-bf74d8a68add" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7bf5773e-2127-400d-a98c-92db67c532e4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_16009664-8633-4d29-afaf-bf74d8a68add" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7bf5773e-2127-400d-a98c-92db67c532e4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_ec0f6a21-dd6b-451e-88e2-f8d447b1d89d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7bf5773e-2127-400d-a98c-92db67c532e4" xlink:to="loc_us-gaap_PlanNameAxis_ec0f6a21-dd6b-451e-88e2-f8d447b1d89d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_ec0f6a21-dd6b-451e-88e2-f8d447b1d89d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_ec0f6a21-dd6b-451e-88e2-f8d447b1d89d" xlink:to="loc_us-gaap_PlanNameDomain_ec0f6a21-dd6b-451e-88e2-f8d447b1d89d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_7c17e904-b82c-4dce-8ede-0afd0f50647c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_ec0f6a21-dd6b-451e-88e2-f8d447b1d89d" xlink:to="loc_us-gaap_PlanNameDomain_7c17e904-b82c-4dce-8ede-0afd0f50647c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember_a1c826f6-0407-4bb3-b5ea-cd31711831e5" xlink:href="mgnx-20181231.xsd#mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_7c17e904-b82c-4dce-8ede-0afd0f50647c" xlink:to="loc_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember_a1c826f6-0407-4bb3-b5ea-cd31711831e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_c32c02ab-09b9-49a6-a84c-d438e3204a46" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_16009664-8633-4d29-afaf-bf74d8a68add" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_c32c02ab-09b9-49a6-a84c-d438e3204a46" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent_88b8e379-9e16-45a9-bc30-f93c545a4696" xlink:href="mgnx-20181231.xsd#mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_16009664-8633-4d29-afaf-bf74d8a68add" xlink:to="loc_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent_88b8e379-9e16-45a9-bc30-f93c545a4696" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_0aa27e73-fe39-4058-85f4-fedeb9b0e396" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_16009664-8633-4d29-afaf-bf74d8a68add" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_0aa27e73-fe39-4058-85f4-fedeb9b0e396" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_5bb4748b-38ee-4013-a50f-9745600fb756" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_16009664-8633-4d29-afaf-bf74d8a68add" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_5bb4748b-38ee-4013-a50f-9745600fb756" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_812b9d4b-5fdf-4e06-b1d1-2badace981aa" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_16009664-8633-4d29-afaf-bf74d8a68add" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_812b9d4b-5fdf-4e06-b1d1-2badace981aa" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="mgnx-20181231.xsd#StockbasedCompensationStockBasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails" xlink:type="extended" id="ieb4b08ea42064dc696bf344ebfaecc18_c6f5bdd3-0dd0-4c31-92b6-fa9b86210f3c">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d630a3d6-7624-4e12-961a-1a7bc4dc1d2b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_957ba553-a5da-449e-895f-ca881dbe44e7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d630a3d6-7624-4e12-961a-1a7bc4dc1d2b" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_957ba553-a5da-449e-895f-ca881dbe44e7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_7db8b23c-ba2c-4ef8-bd98-e9ad4069dcd0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_957ba553-a5da-449e-895f-ca881dbe44e7" xlink:to="loc_us-gaap_PlanNameAxis_7db8b23c-ba2c-4ef8-bd98-e9ad4069dcd0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_7db8b23c-ba2c-4ef8-bd98-e9ad4069dcd0_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_7db8b23c-ba2c-4ef8-bd98-e9ad4069dcd0" xlink:to="loc_us-gaap_PlanNameDomain_7db8b23c-ba2c-4ef8-bd98-e9ad4069dcd0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_12018fb3-4326-4253-af37-276dcf3ccfd9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_7db8b23c-ba2c-4ef8-bd98-e9ad4069dcd0" xlink:to="loc_us-gaap_PlanNameDomain_12018fb3-4326-4253-af37-276dcf3ccfd9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_EquityIncentivePlan2003Member_cef385cd-3eac-43b3-81d2-8caf7751ba92" xlink:href="mgnx-20181231.xsd#mgnx_EquityIncentivePlan2003Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_12018fb3-4326-4253-af37-276dcf3ccfd9" xlink:to="loc_mgnx_EquityIncentivePlan2003Member_cef385cd-3eac-43b3-81d2-8caf7751ba92" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_StockIncentivePlan2013Member_8d0de137-568a-4e4b-9527-b9fc193630a3" xlink:href="mgnx-20181231.xsd#mgnx_StockIncentivePlan2013Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_12018fb3-4326-4253-af37-276dcf3ccfd9" xlink:to="loc_mgnx_StockIncentivePlan2013Member_8d0de137-568a-4e4b-9527-b9fc193630a3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_851049c4-2024-4efe-8f09-7dead32ef9ad" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d630a3d6-7624-4e12-961a-1a7bc4dc1d2b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_851049c4-2024-4efe-8f09-7dead32ef9ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease_6a6b8ac9-b778-43b6-b7a5-0a2bd3563cab" xlink:href="mgnx-20181231.xsd#mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d630a3d6-7624-4e12-961a-1a7bc4dc1d2b" xlink:to="loc_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease_6a6b8ac9-b778-43b6-b7a5-0a2bd3563cab" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f7f5a103-0214-49d9-9b03-32d324e0e990" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d630a3d6-7624-4e12-961a-1a7bc4dc1d2b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f7f5a103-0214-49d9-9b03-32d324e0e990" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6e2330e9-c223-41fa-9adf-eea09453df64" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d630a3d6-7624-4e12-961a-1a7bc4dc1d2b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6e2330e9-c223-41fa-9adf-eea09453df64" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance_dd9c948d-b3ee-4af7-a854-94000000767a" xlink:href="mgnx-20181231.xsd#mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d630a3d6-7624-4e12-961a-1a7bc4dc1d2b" xlink:to="loc_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance_dd9c948d-b3ee-4af7-a854-94000000767a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan_793dfd35-1e4f-4f04-8676-fb05b1e9e440" xlink:href="mgnx-20181231.xsd#mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d630a3d6-7624-4e12-961a-1a7bc4dc1d2b" xlink:to="loc_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan_793dfd35-1e4f-4f04-8676-fb05b1e9e440" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1f931af8-60e2-4ab3-b79b-1e7b19a93a4c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_5b70d301-fdc9-41fd-9a17-89eb35149a99" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1f931af8-60e2-4ab3-b79b-1e7b19a93a4c" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_5b70d301-fdc9-41fd-9a17-89eb35149a99" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_4d74b4a6-7cac-402d-a5b1-586913a65458" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_5b70d301-fdc9-41fd-9a17-89eb35149a99" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_4d74b4a6-7cac-402d-a5b1-586913a65458" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_4d74b4a6-7cac-402d-a5b1-586913a65458_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_4d74b4a6-7cac-402d-a5b1-586913a65458" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_4d74b4a6-7cac-402d-a5b1-586913a65458_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_eb94ab17-1a04-413a-9ff6-2e932d40d024" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_4d74b4a6-7cac-402d-a5b1-586913a65458" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_eb94ab17-1a04-413a-9ff6-2e932d40d024" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_c768bce8-c138-401e-8a8a-ae3c74944f5d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_eb94ab17-1a04-413a-9ff6-2e932d40d024" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_c768bce8-c138-401e-8a8a-ae3c74944f5d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_f8786fd6-637e-40ca-8167-b8f354699485" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_eb94ab17-1a04-413a-9ff6-2e932d40d024" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_f8786fd6-637e-40ca-8167-b8f354699485" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_2dcdfd90-c2a7-4c2b-ae2a-3d831d34cb73" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1f931af8-60e2-4ab3-b79b-1e7b19a93a4c" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_2dcdfd90-c2a7-4c2b-ae2a-3d831d34cb73" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockbasedCompensationOptionPricingAssumptionsDetails" xlink:type="simple" xlink:href="mgnx-20181231.xsd#StockbasedCompensationOptionPricingAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/StockbasedCompensationOptionPricingAssumptionsDetails" xlink:type="extended" id="i63bd4946cb5e4029a647b8530f21896b_6cd073e6-173c-42bb-9d37-32eb5e61e6c7">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0285489a-b399-4c43-8c22-959dca139667" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7476a420-e009-4109-bd9e-e7a5593e507b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0285489a-b399-4c43-8c22-959dca139667" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7476a420-e009-4109-bd9e-e7a5593e507b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b76f3584-6126-480f-8bb5-58a975a189de" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7476a420-e009-4109-bd9e-e7a5593e507b" xlink:to="loc_srt_RangeAxis_b76f3584-6126-480f-8bb5-58a975a189de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b76f3584-6126-480f-8bb5-58a975a189de_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_b76f3584-6126-480f-8bb5-58a975a189de" xlink:to="loc_srt_RangeMember_b76f3584-6126-480f-8bb5-58a975a189de_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_61c21bfc-e31c-4df3-84a1-631483b91f23" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_b76f3584-6126-480f-8bb5-58a975a189de" xlink:to="loc_srt_RangeMember_61c21bfc-e31c-4df3-84a1-631483b91f23" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_d59b81e6-c56a-47ff-85fb-05a33288fd82" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_61c21bfc-e31c-4df3-84a1-631483b91f23" xlink:to="loc_srt_MinimumMember_d59b81e6-c56a-47ff-85fb-05a33288fd82" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a29d596b-9e91-4b7e-92bc-8cb3121aabc5" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_61c21bfc-e31c-4df3-84a1-631483b91f23" xlink:to="loc_srt_MaximumMember_a29d596b-9e91-4b7e-92bc-8cb3121aabc5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_e25488df-e53b-43d0-a7b5-790d5ea1a303" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0285489a-b399-4c43-8c22-959dca139667" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_e25488df-e53b-43d0-a7b5-790d5ea1a303" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_3cf19135-2bdd-42f5-b35b-44b32947b352" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0285489a-b399-4c43-8c22-959dca139667" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_3cf19135-2bdd-42f5-b35b-44b32947b352" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_8ebfc1f3-dca6-4238-b0c4-4904c69e0186" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0285489a-b399-4c43-8c22-959dca139667" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_8ebfc1f3-dca6-4238-b0c4-4904c69e0186" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_9db80b2d-1750-4c69-b23c-16066f617937" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0285489a-b399-4c43-8c22-959dca139667" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_9db80b2d-1750-4c69-b23c-16066f617937" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_6b80ade1-7e15-4627-ba6f-15e638c880fe" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0285489a-b399-4c43-8c22-959dca139667" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_6b80ade1-7e15-4627-ba6f-15e638c880fe" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails" xlink:type="simple" xlink:href="mgnx-20181231.xsd#StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails" xlink:type="extended" id="i18aa4494e53d4fd7b43ba013fdbc0fe2_dfd5e506-4eec-46d6-a250-f4ea445838d3"/>
  <link:roleRef roleURI="http://macrogenics.com/role/IncomeTaxes" xlink:type="simple" xlink:href="mgnx-20181231.xsd#IncomeTaxes"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/IncomeTaxes" xlink:type="extended" id="i7c819011f44048b1adddd750cc49f3a7_5d96da9a-aeb3-4507-ad68-fc25cea53664"/>
  <link:roleRef roleURI="http://macrogenics.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="mgnx-20181231.xsd#IncomeTaxesTables"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/IncomeTaxesTables" xlink:type="extended" id="i4edcc0fbd703486cabfc4c021eb6284b_c0c3a14a-6e0c-4a0e-9f43-4cafff4662c4"/>
  <link:roleRef roleURI="http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails" xlink:type="simple" xlink:href="mgnx-20181231.xsd#IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails" xlink:type="extended" id="ia6f3955dec7540f4ae5451f40f9378cc_7f248438-e43f-4930-a719-65969f53c330">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_c86d8758-7ffc-46fb-8beb-5095b8f04af6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_bd540ada-85bb-4ffc-9791-d52629a13d31" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_c86d8758-7ffc-46fb-8beb-5095b8f04af6" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_bd540ada-85bb-4ffc-9791-d52629a13d31" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodAxis_00f94235-c250-42d9-808a-f04255b31abd" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_bd540ada-85bb-4ffc-9791-d52629a13d31" xlink:to="loc_us-gaap_TaxPeriodAxis_00f94235-c250-42d9-808a-f04255b31abd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain_00f94235-c250-42d9-808a-f04255b31abd_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxPeriodAxis_00f94235-c250-42d9-808a-f04255b31abd" xlink:to="loc_us-gaap_TaxPeriodDomain_00f94235-c250-42d9-808a-f04255b31abd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain_6cd1f1ec-541d-44d7-9506-2ff3f51af607" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxPeriodAxis_00f94235-c250-42d9-808a-f04255b31abd" xlink:to="loc_us-gaap_TaxPeriodDomain_6cd1f1ec-541d-44d7-9506-2ff3f51af607" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_TaxYear2025To2037Member_1a1883c2-e18e-4622-b17f-3418b9e67543" xlink:href="mgnx-20181231.xsd#mgnx_TaxYear2025To2037Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_6cd1f1ec-541d-44d7-9506-2ff3f51af607" xlink:to="loc_mgnx_TaxYear2025To2037Member_1a1883c2-e18e-4622-b17f-3418b9e67543" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IndefiniteMember_a0928d42-21f0-4477-a5ca-839252a0b4b0" xlink:href="mgnx-20181231.xsd#mgnx_IndefiniteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_6cd1f1ec-541d-44d7-9506-2ff3f51af607" xlink:to="loc_mgnx_IndefiniteMember_a0928d42-21f0-4477-a5ca-839252a0b4b0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_e3dea45a-8655-4066-94a5-fbce784be3b3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_bd540ada-85bb-4ffc-9791-d52629a13d31" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_e3dea45a-8655-4066-94a5-fbce784be3b3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_e3dea45a-8655-4066-94a5-fbce784be3b3_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_e3dea45a-8655-4066-94a5-fbce784be3b3" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_e3dea45a-8655-4066-94a5-fbce784be3b3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_d1bf9670-616b-4206-93b9-15db0d126a2a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_e3dea45a-8655-4066-94a5-fbce784be3b3" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_d1bf9670-616b-4206-93b9-15db0d126a2a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember_0e4b2881-0f87-4378-bf57-db09ef3aa935" xlink:href="mgnx-20181231.xsd#mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_d1bf9670-616b-4206-93b9-15db0d126a2a" xlink:to="loc_mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember_0e4b2881-0f87-4378-bf57-db09ef3aa935" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_5f34b5f1-5fed-4352-9828-2dbcf06ad828" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember_0e4b2881-0f87-4378-bf57-db09ef3aa935" xlink:to="loc_us-gaap_DomesticCountryMember_5f34b5f1-5fed-4352-9828-2dbcf06ad828" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b51e1868-3ce9-480f-b6fb-eb950be11985" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_bd540ada-85bb-4ffc-9791-d52629a13d31" xlink:to="loc_srt_RangeAxis_b51e1868-3ce9-480f-b6fb-eb950be11985" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b51e1868-3ce9-480f-b6fb-eb950be11985_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_b51e1868-3ce9-480f-b6fb-eb950be11985" xlink:to="loc_srt_RangeMember_b51e1868-3ce9-480f-b6fb-eb950be11985_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_122e76f5-66bc-43d9-a455-d5f98cb25d30" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_b51e1868-3ce9-480f-b6fb-eb950be11985" xlink:to="loc_srt_RangeMember_122e76f5-66bc-43d9-a455-d5f98cb25d30" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_cd6ab1ac-2042-4fc7-89a5-5f4aaef09561" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_122e76f5-66bc-43d9-a455-d5f98cb25d30" xlink:to="loc_srt_MinimumMember_cd6ab1ac-2042-4fc7-89a5-5f4aaef09561" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_3cc2683f-d623-4464-9cd4-0afbda8dafe0" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_122e76f5-66bc-43d9-a455-d5f98cb25d30" xlink:to="loc_srt_MaximumMember_3cc2683f-d623-4464-9cd4-0afbda8dafe0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_9dd31963-7917-43ca-a5df-44dd935d9a4c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_c86d8758-7ffc-46fb-8beb-5095b8f04af6" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_9dd31963-7917-43ca-a5df-44dd935d9a4c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_f13cced8-a4d2-4406-92fb-0d1c5d4b6b69" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_c86d8758-7ffc-46fb-8beb-5095b8f04af6" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_f13cced8-a4d2-4406-92fb-0d1c5d4b6b69" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount_3ce81bb0-90d3-4736-89f8-dfa002c7d009" xlink:href="mgnx-20181231.xsd#mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_c86d8758-7ffc-46fb-8beb-5095b8f04af6" xlink:to="loc_mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount_3ce81bb0-90d3-4736-89f8-dfa002c7d009" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_OperatingLossCarryforwardsAnnualLimitationAmount_1ea2ec91-b5bd-463c-999b-fa6db9821090" xlink:href="mgnx-20181231.xsd#mgnx_OperatingLossCarryforwardsAnnualLimitationAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_c86d8758-7ffc-46fb-8beb-5095b8f04af6" xlink:to="loc_mgnx_OperatingLossCarryforwardsAnnualLimitationAmount_1ea2ec91-b5bd-463c-999b-fa6db9821090" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_OperatingLossCarryforwardsNotSubjectToLimitation_9c07a02f-49c4-4afe-838a-c4c6c04e6b06" xlink:href="mgnx-20181231.xsd#mgnx_OperatingLossCarryforwardsNotSubjectToLimitation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_c86d8758-7ffc-46fb-8beb-5095b8f04af6" xlink:to="loc_mgnx_OperatingLossCarryforwardsNotSubjectToLimitation_9c07a02f-49c4-4afe-838a-c4c6c04e6b06" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_e5fc864d-6eb7-4ce4-a1a4-d8462311b10b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_c86d8758-7ffc-46fb-8beb-5095b8f04af6" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_e5fc864d-6eb7-4ce4-a1a4-d8462311b10b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTaxBenefitTaxEffectedAmount_626d5eee-acf5-4efc-a20c-571f1f88e9ce" xlink:href="mgnx-20181231.xsd#mgnx_EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTaxBenefitTaxEffectedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_c86d8758-7ffc-46fb-8beb-5095b8f04af6" xlink:to="loc_mgnx_EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTaxBenefitTaxEffectedAmount_626d5eee-acf5-4efc-a20c-571f1f88e9ce" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails" xlink:type="simple" xlink:href="mgnx-20181231.xsd#IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails" xlink:type="extended" id="icdc6329ab1264ddb8634aef5f7c4f8f8_65d72881-22f6-45df-82ac-c5281c5e5fbd"/>
  <link:roleRef roleURI="http://macrogenics.com/role/IncomeTaxesReconciliationoftheBeginningandEndingAmountofGrossUnrecognizedTaxBenefitsDetails" xlink:type="simple" xlink:href="mgnx-20181231.xsd#IncomeTaxesReconciliationoftheBeginningandEndingAmountofGrossUnrecognizedTaxBenefitsDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/IncomeTaxesReconciliationoftheBeginningandEndingAmountofGrossUnrecognizedTaxBenefitsDetails" xlink:type="extended" id="ie348e6ad31644719937152817f80525a_bfdd1dce-ba11-438d-95b1-520becd19272">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationLineItems_8dc2ff63-61ca-4ce3-ae63-7b05c013e2bc" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExaminationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationTable_b3fcb091-88b2-46a6-a8b7-6fedcb630803" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExaminationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_8dc2ff63-61ca-4ce3-ae63-7b05c013e2bc" xlink:to="loc_us-gaap_IncomeTaxExaminationTable_b3fcb091-88b2-46a6-a8b7-6fedcb630803" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_690e0010-84a9-41ab-942c-574f32be0826" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_b3fcb091-88b2-46a6-a8b7-6fedcb630803" xlink:to="loc_srt_RangeAxis_690e0010-84a9-41ab-942c-574f32be0826" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_690e0010-84a9-41ab-942c-574f32be0826_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_690e0010-84a9-41ab-942c-574f32be0826" xlink:to="loc_srt_RangeMember_690e0010-84a9-41ab-942c-574f32be0826_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_adfd41bb-3bf5-4e90-9149-6d4758aa72a9" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_690e0010-84a9-41ab-942c-574f32be0826" xlink:to="loc_srt_RangeMember_adfd41bb-3bf5-4e90-9149-6d4758aa72a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_77fee547-b0ac-4d2b-a2a0-79e589911c71" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_adfd41bb-3bf5-4e90-9149-6d4758aa72a9" xlink:to="loc_srt_MinimumMember_77fee547-b0ac-4d2b-a2a0-79e589911c71" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_f1a6353d-5b65-4dca-9cb5-d623e083ddc7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_8dc2ff63-61ca-4ce3-ae63-7b05c013e2bc" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_f1a6353d-5b65-4dca-9cb5-d623e083ddc7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_8e84790f-9914-40e6-a741-75b5f952d5c4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_f1a6353d-5b65-4dca-9cb5-d623e083ddc7" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_8e84790f-9914-40e6-a741-75b5f952d5c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_b31d2aa4-8b4a-420a-a178-fc1b52291b4d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_f1a6353d-5b65-4dca-9cb5-d623e083ddc7" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_b31d2aa4-8b4a-420a-a178-fc1b52291b4d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_e76743eb-ab0c-4d77-8564-e294f6aa84c6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_f1a6353d-5b65-4dca-9cb5-d623e083ddc7" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_e76743eb-ab0c-4d77-8564-e294f6aa84c6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_e98b773b-4bbc-4bb2-802f-fe86d4b5ed37" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_f1a6353d-5b65-4dca-9cb5-d623e083ddc7" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_e98b773b-4bbc-4bb2-802f-fe86d4b5ed37" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_61ea50aa-9b61-47b7-b968-9310ca9d0256" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_83081ce3-9371-41fc-b8b7-65e3cc6e5153" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_8dc2ff63-61ca-4ce3-ae63-7b05c013e2bc" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_83081ce3-9371-41fc-b8b7-65e3cc6e5153" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_3f7fcefb-3da8-43db-89aa-a0c6e6cdb0c8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_8dc2ff63-61ca-4ce3-ae63-7b05c013e2bc" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_3f7fcefb-3da8-43db-89aa-a0c6e6cdb0c8" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreements" xlink:type="simple" xlink:href="mgnx-20181231.xsd#CollaborationandOtherAgreements"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreements" xlink:type="extended" id="ia0740d8b83ce4191b29f526862dc5fc6_27594388-13fb-471e-996d-1bf5e2f0ad90"/>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails" xlink:type="simple" xlink:href="mgnx-20181231.xsd#CollaborationandOtherAgreementsIncyteCorporationDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails" xlink:type="extended" id="i208f6750c2fe4f7fbe5977db5c25ecf3_89009f33-4eb6-4618-b68d-1e1c56db4599">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_43e7dce1-cb85-4618-ad01-89ec9e29d8c0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_fdce6867-8367-4d43-84c3-a45d0a9e8624" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_43e7dce1-cb85-4618-ad01-89ec9e29d8c0" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_fdce6867-8367-4d43-84c3-a45d0a9e8624" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_a3481602-1cc5-4987-b87d-a4227534c8f2" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_fdce6867-8367-4d43-84c3-a45d0a9e8624" xlink:to="loc_srt_ProductOrServiceAxis_a3481602-1cc5-4987-b87d-a4227534c8f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a3481602-1cc5-4987-b87d-a4227534c8f2_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_a3481602-1cc5-4987-b87d-a4227534c8f2" xlink:to="loc_srt_ProductsAndServicesDomain_a3481602-1cc5-4987-b87d-a4227534c8f2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d2aac256-81b2-46fb-ad43-c8a41aaeb66f" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_a3481602-1cc5-4987-b87d-a4227534c8f2" xlink:to="loc_srt_ProductsAndServicesDomain_d2aac256-81b2-46fb-ad43-c8a41aaeb66f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromLicenseAgreementsMember_140d863b-16c6-45d0-af7a-af45e8b40b93" xlink:href="mgnx-20181231.xsd#mgnx_RevenuesFromLicenseAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d2aac256-81b2-46fb-ad43-c8a41aaeb66f" xlink:to="loc_mgnx_RevenuesFromLicenseAgreementsMember_140d863b-16c6-45d0-af7a-af45e8b40b93" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_1f8f39a9-8270-433d-adc6-526ee2c9a6fb" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_fdce6867-8367-4d43-84c3-a45d0a9e8624" xlink:to="loc_srt_RangeAxis_1f8f39a9-8270-433d-adc6-526ee2c9a6fb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1f8f39a9-8270-433d-adc6-526ee2c9a6fb_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_1f8f39a9-8270-433d-adc6-526ee2c9a6fb" xlink:to="loc_srt_RangeMember_1f8f39a9-8270-433d-adc6-526ee2c9a6fb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5a9581c9-bf62-483a-a060-4a25e96715a6" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_1f8f39a9-8270-433d-adc6-526ee2c9a6fb" xlink:to="loc_srt_RangeMember_5a9581c9-bf62-483a-a060-4a25e96715a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_853be223-4ff7-465d-bdc2-322407615a12" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_5a9581c9-bf62-483a-a060-4a25e96715a6" xlink:to="loc_srt_MaximumMember_853be223-4ff7-465d-bdc2-322407615a12" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_632027d7-98e8-4fd1-a17e-221107f4d593" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_5a9581c9-bf62-483a-a060-4a25e96715a6" xlink:to="loc_srt_MinimumMember_632027d7-98e8-4fd1-a17e-221107f4d593" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_2028b21d-9911-47d4-b4f0-7ffdd941baa4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_fdce6867-8367-4d43-84c3-a45d0a9e8624" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_2028b21d-9911-47d4-b4f0-7ffdd941baa4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2028b21d-9911-47d4-b4f0-7ffdd941baa4_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_2028b21d-9911-47d4-b4f0-7ffdd941baa4" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2028b21d-9911-47d4-b4f0-7ffdd941baa4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_971b4a14-d8c8-4349-80c2-89a504b1fe85" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_2028b21d-9911-47d4-b4f0-7ffdd941baa4" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_971b4a14-d8c8-4349-80c2-89a504b1fe85" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteMGA012AgreementMember_fb8aa65d-ec24-47fe-a576-183e3fa7fc10" xlink:href="mgnx-20181231.xsd#mgnx_IncyteMGA012AgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_971b4a14-d8c8-4349-80c2-89a504b1fe85" xlink:to="loc_mgnx_IncyteMGA012AgreementMember_fb8aa65d-ec24-47fe-a576-183e3fa7fc10" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteMGA012ClinicalServicesMember_e494c568-0930-40e0-9707-7a60250486dd" xlink:href="mgnx-20181231.xsd#mgnx_IncyteMGA012ClinicalServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_971b4a14-d8c8-4349-80c2-89a504b1fe85" xlink:to="loc_mgnx_IncyteMGA012ClinicalServicesMember_e494c568-0930-40e0-9707-7a60250486dd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_8b2c64b2-e033-46d1-98ca-4bf07adb43c9" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_fdce6867-8367-4d43-84c3-a45d0a9e8624" xlink:to="loc_srt_CounterpartyNameAxis_8b2c64b2-e033-46d1-98ca-4bf07adb43c9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8b2c64b2-e033-46d1-98ca-4bf07adb43c9_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_8b2c64b2-e033-46d1-98ca-4bf07adb43c9" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8b2c64b2-e033-46d1-98ca-4bf07adb43c9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8912928a-c51f-4a9d-bbeb-e4784164732f" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_8b2c64b2-e033-46d1-98ca-4bf07adb43c9" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8912928a-c51f-4a9d-bbeb-e4784164732f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteCorporationMember_8c84a89a-9081-440d-985f-59468b5d33b8" xlink:href="mgnx-20181231.xsd#mgnx_IncyteCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8912928a-c51f-4a9d-bbeb-e4784164732f" xlink:to="loc_mgnx_IncyteCorporationMember_8c84a89a-9081-440d-985f-59468b5d33b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees_f8a45fe6-9388-4cd7-9c69-c5738aa30202" xlink:href="mgnx-20181231.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_43e7dce1-cb85-4618-ad01-89ec9e29d8c0" xlink:to="loc_mgnx_NonRefundableUpfrontFees_f8a45fe6-9388-4cd7-9c69-c5738aa30202" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_acaf6c9a-c7f8-43ef-8ffa-2b2e0e3d6762" xlink:href="mgnx-20181231.xsd#mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_43e7dce1-cb85-4618-ad01-89ec9e29d8c0" xlink:to="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_acaf6c9a-c7f8-43ef-8ffa-2b2e0e3d6762" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_722da759-7429-427b-b70c-29e90c855f3f" xlink:href="mgnx-20181231.xsd#mgnx_PotentialCommercialMilestonePaymentsUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_43e7dce1-cb85-4618-ad01-89ec9e29d8c0" xlink:to="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_722da759-7429-427b-b70c-29e90c855f3f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_4067be7b-ed42-4480-8897-036acc4afa86" xlink:href="mgnx-20181231.xsd#mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_43e7dce1-cb85-4618-ad01-89ec9e29d8c0" xlink:to="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_4067be7b-ed42-4480-8897-036acc4afa86" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsfromRoyaltiesPercent_72ad17f1-d8a3-458d-89f3-5c30cb3525f6" xlink:href="mgnx-20181231.xsd#mgnx_ProceedsfromRoyaltiesPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_43e7dce1-cb85-4618-ad01-89ec9e29d8c0" xlink:to="loc_mgnx_ProceedsfromRoyaltiesPercent_72ad17f1-d8a3-458d-89f3-5c30cb3525f6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementTransactionPrice_32d95bc6-69ac-4f8c-b2c5-caede00e154c" xlink:href="mgnx-20181231.xsd#mgnx_CollaborativeAgreementTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_43e7dce1-cb85-4618-ad01-89ec9e29d8c0" xlink:to="loc_mgnx_CollaborativeAgreementTransactionPrice_32d95bc6-69ac-4f8c-b2c5-caede00e154c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_8ce7b99e-3e4b-42f2-932d-ac50474071a5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_43e7dce1-cb85-4618-ad01-89ec9e29d8c0" xlink:to="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_8ce7b99e-3e4b-42f2-932d-ac50474071a5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_196f008c-07c2-452f-ad9f-605ce888d62b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_43e7dce1-cb85-4618-ad01-89ec9e29d8c0" xlink:to="loc_us-gaap_Revenues_196f008c-07c2-452f-ad9f-605ce888d62b" xlink:type="arc" order="8"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails" xlink:type="simple" xlink:href="mgnx-20181231.xsd#CollaborationandOtherAgreementsZaiLabDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails" xlink:type="extended" id="i21a54cd4db874e16ab1aa7984ce189ae_faf4c9a4-8c6f-4e56-8cb3-34470c54e02d">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_43567f36-e313-4196-8c09-ac3f957a4745" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_cbb30734-d3cf-4f21-b5bc-a01eec25c912" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_43567f36-e313-4196-8c09-ac3f957a4745" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_cbb30734-d3cf-4f21-b5bc-a01eec25c912" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_4da5506e-a14e-4172-8c4a-71038e4618a1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_cbb30734-d3cf-4f21-b5bc-a01eec25c912" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_4da5506e-a14e-4172-8c4a-71038e4618a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_4da5506e-a14e-4172-8c4a-71038e4618a1_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_4da5506e-a14e-4172-8c4a-71038e4618a1" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_4da5506e-a14e-4172-8c4a-71038e4618a1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_f4871f5e-5132-40a9-993f-768b8e6158a2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_4da5506e-a14e-4172-8c4a-71038e4618a1" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_f4871f5e-5132-40a9-993f-768b8e6158a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabsCollaborationAndLicenseAgreementMember_a7e6fd24-676a-42ca-973d-a196d2ed5bb3" xlink:href="mgnx-20181231.xsd#mgnx_ZaiLabsCollaborationAndLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_f4871f5e-5132-40a9-993f-768b8e6158a2" xlink:to="loc_mgnx_ZaiLabsCollaborationAndLicenseAgreementMember_a7e6fd24-676a-42ca-973d-a196d2ed5bb3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_41088f3e-9f89-4383-b2e4-8b50d58d8057" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_cbb30734-d3cf-4f21-b5bc-a01eec25c912" xlink:to="loc_srt_CounterpartyNameAxis_41088f3e-9f89-4383-b2e4-8b50d58d8057" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_41088f3e-9f89-4383-b2e4-8b50d58d8057_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_41088f3e-9f89-4383-b2e4-8b50d58d8057" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_41088f3e-9f89-4383-b2e4-8b50d58d8057_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_37699405-cec6-4679-af37-083446c8b95f" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_41088f3e-9f89-4383-b2e4-8b50d58d8057" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_37699405-cec6-4679-af37-083446c8b95f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabsMember_52c3739f-f197-4eec-85cf-28dbdb58c045" xlink:href="mgnx-20181231.xsd#mgnx_ZaiLabsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_37699405-cec6-4679-af37-083446c8b95f" xlink:to="loc_mgnx_ZaiLabsMember_52c3739f-f197-4eec-85cf-28dbdb58c045" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees_f576e658-a9b7-410b-9595-a30d634f3e6c" xlink:href="mgnx-20181231.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_43567f36-e313-4196-8c09-ac3f957a4745" xlink:to="loc_mgnx_NonRefundableUpfrontFees_f576e658-a9b7-410b-9595-a30d634f3e6c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonrefundablePaymentTaxWithholding_53416c6d-3eee-4b91-951f-f56939de089d" xlink:href="mgnx-20181231.xsd#mgnx_NonrefundablePaymentTaxWithholding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_43567f36-e313-4196-8c09-ac3f957a4745" xlink:to="loc_mgnx_NonrefundablePaymentTaxWithholding_53416c6d-3eee-4b91-951f-f56939de089d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_461e2b98-86d7-4ecb-8a7b-880c3198ee1f" xlink:href="mgnx-20181231.xsd#mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_43567f36-e313-4196-8c09-ac3f957a4745" xlink:to="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_461e2b98-86d7-4ecb-8a7b-880c3198ee1f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_2a93227a-6c0c-46dd-95f7-4b989b5d5aa0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_43567f36-e313-4196-8c09-ac3f957a4745" xlink:to="loc_us-gaap_Revenues_2a93227a-6c0c-46dd-95f7-4b989b5d5aa0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_1e1679ca-095a-4d1b-a930-fc10a471a20e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_43567f36-e313-4196-8c09-ac3f957a4745" xlink:to="loc_us-gaap_ContractWithCustomerLiability_1e1679ca-095a-4d1b-a930-fc10a471a20e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_07d16243-4255-41aa-81f2-d438605057d4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_43567f36-e313-4196-8c09-ac3f957a4745" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_07d16243-4255-41aa-81f2-d438605057d4" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsServierDetails" xlink:type="simple" xlink:href="mgnx-20181231.xsd#CollaborationandOtherAgreementsServierDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsServierDetails" xlink:type="extended" id="i070d02611bea4c24a8e3d1bddd1978f8_729d93fc-f862-4dab-a5ca-fb259c99b969">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_da4ecdf3-c90a-4924-81aa-7ea9ee88f48e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b249c0b1-ea70-4db9-bd9b-bdcff15e12b0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_da4ecdf3-c90a-4924-81aa-7ea9ee88f48e" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b249c0b1-ea70-4db9-bd9b-bdcff15e12b0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_92f13ccb-e8db-40a1-a901-e8faad4dc755" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b249c0b1-ea70-4db9-bd9b-bdcff15e12b0" xlink:to="loc_srt_ProductOrServiceAxis_92f13ccb-e8db-40a1-a901-e8faad4dc755" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_92f13ccb-e8db-40a1-a901-e8faad4dc755_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_92f13ccb-e8db-40a1-a901-e8faad4dc755" xlink:to="loc_srt_ProductsAndServicesDomain_92f13ccb-e8db-40a1-a901-e8faad4dc755_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_39f05338-7b5e-4a69-9430-187e9037cd3f" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_92f13ccb-e8db-40a1-a901-e8faad4dc755" xlink:to="loc_srt_ProductsAndServicesDomain_39f05338-7b5e-4a69-9430-187e9037cd3f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromLicenseAgreementsMember_0da19ee3-8ae5-46e5-95d5-a6656ca3d76a" xlink:href="mgnx-20181231.xsd#mgnx_RevenuesFromLicenseAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_39f05338-7b5e-4a69-9430-187e9037cd3f" xlink:to="loc_mgnx_RevenuesFromLicenseAgreementsMember_0da19ee3-8ae5-46e5-95d5-a6656ca3d76a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_b2906b68-aca0-48a9-ac9e-99ef3225d511" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b249c0b1-ea70-4db9-bd9b-bdcff15e12b0" xlink:to="loc_srt_CounterpartyNameAxis_b2906b68-aca0-48a9-ac9e-99ef3225d511" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b2906b68-aca0-48a9-ac9e-99ef3225d511_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_b2906b68-aca0-48a9-ac9e-99ef3225d511" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b2906b68-aca0-48a9-ac9e-99ef3225d511_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_58ca8a54-bd11-440a-9faf-5e7ad3a3cb3a" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_b2906b68-aca0-48a9-ac9e-99ef3225d511" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_58ca8a54-bd11-440a-9faf-5e7ad3a3cb3a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ServierMember_5d1fd906-dfd0-49e6-957f-0cf74c335f21" xlink:href="mgnx-20181231.xsd#mgnx_ServierMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_58ca8a54-bd11-440a-9faf-5e7ad3a3cb3a" xlink:to="loc_mgnx_ServierMember_5d1fd906-dfd0-49e6-957f-0cf74c335f21" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_bae35e1b-ac81-4e2d-9fa8-05a70affc584" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b249c0b1-ea70-4db9-bd9b-bdcff15e12b0" xlink:to="loc_srt_RangeAxis_bae35e1b-ac81-4e2d-9fa8-05a70affc584" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_bae35e1b-ac81-4e2d-9fa8-05a70affc584_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_bae35e1b-ac81-4e2d-9fa8-05a70affc584" xlink:to="loc_srt_RangeMember_bae35e1b-ac81-4e2d-9fa8-05a70affc584_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7054d686-9b34-43d5-8c58-04c27b8c09f2" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_bae35e1b-ac81-4e2d-9fa8-05a70affc584" xlink:to="loc_srt_RangeMember_7054d686-9b34-43d5-8c58-04c27b8c09f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_2a040df0-22e0-43fd-bab6-608b53c051fd" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_7054d686-9b34-43d5-8c58-04c27b8c09f2" xlink:to="loc_srt_MaximumMember_2a040df0-22e0-43fd-bab6-608b53c051fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_c0951e4d-f03e-489f-8dc6-0f0c581f176e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b249c0b1-ea70-4db9-bd9b-bdcff15e12b0" xlink:to="loc_us-gaap_TypeOfArrangementAxis_c0951e4d-f03e-489f-8dc6-0f0c581f176e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c0951e4d-f03e-489f-8dc6-0f0c581f176e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_c0951e4d-f03e-489f-8dc6-0f0c581f176e" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c0951e4d-f03e-489f-8dc6-0f0c581f176e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_eb789d5c-ed9f-40c4-95f9-2dc2ad20a450" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_c0951e4d-f03e-489f-8dc6-0f0c581f176e" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_eb789d5c-ed9f-40c4-95f9-2dc2ad20a450" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ServierDARTMember_504f15e9-15af-4ec1-8852-72f82b136afb" xlink:href="mgnx-20181231.xsd#mgnx_ServierDARTMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_eb789d5c-ed9f-40c4-95f9-2dc2ad20a450" xlink:to="loc_mgnx_ServierDARTMember_504f15e9-15af-4ec1-8852-72f82b136afb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ServierAgreementMGD007OptionMember_3afb7817-02e2-4961-99cf-cf758af8444b" xlink:href="mgnx-20181231.xsd#mgnx_ServierAgreementMGD007OptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_eb789d5c-ed9f-40c4-95f9-2dc2ad20a450" xlink:to="loc_mgnx_ServierAgreementMGD007OptionMember_3afb7817-02e2-4961-99cf-cf758af8444b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees_c766b833-0187-47c1-a57c-2916792919bd" xlink:href="mgnx-20181231.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_da4ecdf3-c90a-4924-81aa-7ea9ee88f48e" xlink:to="loc_mgnx_NonRefundableUpfrontFees_c766b833-0187-47c1-a57c-2916792919bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialClinicalMilestonePaymentsUnderAgreement_3f0b7468-dfaf-4b96-81c1-2927b7931cf0" xlink:href="mgnx-20181231.xsd#mgnx_PotentialClinicalMilestonePaymentsUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_da4ecdf3-c90a-4924-81aa-7ea9ee88f48e" xlink:to="loc_mgnx_PotentialClinicalMilestonePaymentsUnderAgreement_3f0b7468-dfaf-4b96-81c1-2927b7931cf0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialRegulatoryMilestonePaymentsUnderAgreement_9830ee6d-396b-4294-a73c-d576e8f58d11" xlink:href="mgnx-20181231.xsd#mgnx_PotentialRegulatoryMilestonePaymentsUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_da4ecdf3-c90a-4924-81aa-7ea9ee88f48e" xlink:to="loc_mgnx_PotentialRegulatoryMilestonePaymentsUnderAgreement_9830ee6d-396b-4294-a73c-d576e8f58d11" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialSalesMilestonePaymentsUnderAgreement_881dd25f-a3ae-4fd3-9ef3-6dbdb934b72d" xlink:href="mgnx-20181231.xsd#mgnx_PotentialSalesMilestonePaymentsUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_da4ecdf3-c90a-4924-81aa-7ea9ee88f48e" xlink:to="loc_mgnx_PotentialSalesMilestonePaymentsUnderAgreement_881dd25f-a3ae-4fd3-9ef3-6dbdb934b72d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_MilestonePayment_9c6d5052-7aee-4f56-8d2e-b1d80e8e2222" xlink:href="mgnx-20181231.xsd#mgnx_MilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_da4ecdf3-c90a-4924-81aa-7ea9ee88f48e" xlink:to="loc_mgnx_MilestonePayment_9c6d5052-7aee-4f56-8d2e-b1d80e8e2222" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_a8ee78df-ff6b-4db2-b850-490759c595aa" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_da4ecdf3-c90a-4924-81aa-7ea9ee88f48e" xlink:to="loc_us-gaap_Revenues_a8ee78df-ff6b-4db2-b850-490759c595aa" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueCurrent_f1cab902-e082-4d68-9bf1-f2d067157072" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredRevenueCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_da4ecdf3-c90a-4924-81aa-7ea9ee88f48e" xlink:to="loc_us-gaap_DeferredRevenueCurrent_f1cab902-e082-4d68-9bf1-f2d067157072" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_OptionExerciseFee_ddd8adfc-5479-4a20-9937-f50366439128" xlink:href="mgnx-20181231.xsd#mgnx_OptionExerciseFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_da4ecdf3-c90a-4924-81aa-7ea9ee88f48e" xlink:to="loc_mgnx_OptionExerciseFee_ddd8adfc-5479-4a20-9937-f50366439128" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts_d82978c1-a2d5-42c4-ba88-1473e204595e" xlink:href="mgnx-20181231.xsd#mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_da4ecdf3-c90a-4924-81aa-7ea9ee88f48e" xlink:to="loc_mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts_d82978c1-a2d5-42c4-ba88-1473e204595e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_1ec6f494-a141-48e4-87c3-654f8392ccb2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_da4ecdf3-c90a-4924-81aa-7ea9ee88f48e" xlink:to="loc_us-gaap_ContractWithCustomerLiability_1ec6f494-a141-48e4-87c3-654f8392ccb2" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_1fdbf558-f186-4673-9c12-ad200f4a102a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_da4ecdf3-c90a-4924-81aa-7ea9ee88f48e" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_1fdbf558-f186-4673-9c12-ad200f4a102a" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_f4295603-446d-4035-9ced-5d4c03eeef94" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_da4ecdf3-c90a-4924-81aa-7ea9ee88f48e" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_f4295603-446d-4035-9ced-5d4c03eeef94" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenue_99bddc5e-b871-4308-a7bb-22ba2895c855" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_da4ecdf3-c90a-4924-81aa-7ea9ee88f48e" xlink:to="loc_us-gaap_DeferredRevenue_99bddc5e-b871-4308-a7bb-22ba2895c855" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_b792c69c-90de-44d2-b11e-9c5384c59635" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_da4ecdf3-c90a-4924-81aa-7ea9ee88f48e" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_b792c69c-90de-44d2-b11e-9c5384c59635" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_376e0c61-ebaf-4852-b2d3-b669524a5466" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_da4ecdf3-c90a-4924-81aa-7ea9ee88f48e" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_376e0c61-ebaf-4852-b2d3-b669524a5466" xlink:type="arc" order="15"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsRocheDetails" xlink:type="simple" xlink:href="mgnx-20181231.xsd#CollaborationandOtherAgreementsRocheDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsRocheDetails" xlink:type="extended" id="i20a01103585a469faf57d07a8b3953df_f5b9e1d1-263c-41eb-b6e3-f1dcda837db7">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_be607a02-ba39-4264-9a1b-da232b2a9ba0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_441fbabd-372a-4fce-8424-4af400adb3ac" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_be607a02-ba39-4264-9a1b-da232b2a9ba0" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_441fbabd-372a-4fce-8424-4af400adb3ac" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_05d1fd9f-9670-4304-8640-0472c8be99c6" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_441fbabd-372a-4fce-8424-4af400adb3ac" xlink:to="loc_srt_CounterpartyNameAxis_05d1fd9f-9670-4304-8640-0472c8be99c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_05d1fd9f-9670-4304-8640-0472c8be99c6_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_05d1fd9f-9670-4304-8640-0472c8be99c6" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_05d1fd9f-9670-4304-8640-0472c8be99c6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6265ff68-acc1-4331-ab4d-cfb564d4ab05" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_05d1fd9f-9670-4304-8640-0472c8be99c6" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6265ff68-acc1-4331-ab4d-cfb564d4ab05" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member_2a1e8a90-7352-42ae-bb6d-ae58990572a6" xlink:href="mgnx-20181231.xsd#mgnx_F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6265ff68-acc1-4331-ab4d-cfb564d4ab05" xlink:to="loc_mgnx_F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member_2a1e8a90-7352-42ae-bb6d-ae58990572a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees_7eecda31-245d-433c-8fba-3e14fe0ce493" xlink:href="mgnx-20181231.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_be607a02-ba39-4264-9a1b-da232b2a9ba0" xlink:to="loc_mgnx_NonRefundableUpfrontFees_7eecda31-245d-433c-8fba-3e14fe0ce493" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialMilestonePaymentsandRoyaltiesonFutureSalesunderAgreement_32060e69-06a6-4b72-bc5b-749183fc7f45" xlink:href="mgnx-20181231.xsd#mgnx_PotentialMilestonePaymentsandRoyaltiesonFutureSalesunderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_be607a02-ba39-4264-9a1b-da232b2a9ba0" xlink:to="loc_mgnx_PotentialMilestonePaymentsandRoyaltiesonFutureSalesunderAgreement_32060e69-06a6-4b72-bc5b-749183fc7f45" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_UpfrontPaymentRecognitionPeriod_5cfcae4a-1a4b-4a68-80ab-c50b2d32b6af" xlink:href="mgnx-20181231.xsd#mgnx_UpfrontPaymentRecognitionPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_be607a02-ba39-4264-9a1b-da232b2a9ba0" xlink:to="loc_mgnx_UpfrontPaymentRecognitionPeriod_5cfcae4a-1a4b-4a68-80ab-c50b2d32b6af" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_4a580c45-96fb-4d3c-9099-6ce8ad1d69ba" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_be607a02-ba39-4264-9a1b-da232b2a9ba0" xlink:to="loc_us-gaap_Revenues_4a580c45-96fb-4d3c-9099-6ce8ad1d69ba" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_2526aac2-b474-477e-8993-679d5db25f29" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_be607a02-ba39-4264-9a1b-da232b2a9ba0" xlink:to="loc_us-gaap_ContractWithCustomerLiability_2526aac2-b474-477e-8993-679d5db25f29" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_6fe9175f-65c6-4828-bbc4-33fd18f3fd26" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_be607a02-ba39-4264-9a1b-da232b2a9ba0" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_6fe9175f-65c6-4828-bbc4-33fd18f3fd26" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_3291b37a-90f2-4926-8cf2-85a397b1f7eb" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_be607a02-ba39-4264-9a1b-da232b2a9ba0" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_3291b37a-90f2-4926-8cf2-85a397b1f7eb" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenue_f8d4bb4e-1c54-49e6-a4b3-3d591bef1320" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_be607a02-ba39-4264-9a1b-da232b2a9ba0" xlink:to="loc_us-gaap_DeferredRevenue_f8d4bb4e-1c54-49e6-a4b3-3d591bef1320" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueCurrent_bf6a8ef6-2d52-4bc0-93fe-40d2dd02c602" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredRevenueCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_be607a02-ba39-4264-9a1b-da232b2a9ba0" xlink:to="loc_us-gaap_DeferredRevenueCurrent_bf6a8ef6-2d52-4bc0-93fe-40d2dd02c602" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent_a44616ef-3f4e-40fd-ae04-740f11ca45c7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredRevenueNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_be607a02-ba39-4264-9a1b-da232b2a9ba0" xlink:to="loc_us-gaap_DeferredRevenueNoncurrent_a44616ef-3f4e-40fd-ae04-740f11ca45c7" xlink:type="arc" order="10"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsProventionDetails" xlink:type="simple" xlink:href="mgnx-20181231.xsd#CollaborationandOtherAgreementsProventionDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsProventionDetails" xlink:type="extended" id="i07a620145d5c42be937c54fc8170516c_651d949b-3145-49aa-892c-842011f3d12d">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b1099a72-88b9-4960-9d3b-8ac6a5de6a3b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b13011c4-cc80-4b10-8929-9ec70b8ee768" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b1099a72-88b9-4960-9d3b-8ac6a5de6a3b" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b13011c4-cc80-4b10-8929-9ec70b8ee768" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_e4e787d1-1896-4cd6-94b6-b53cefcccb39" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b13011c4-cc80-4b10-8929-9ec70b8ee768" xlink:to="loc_srt_ProductOrServiceAxis_e4e787d1-1896-4cd6-94b6-b53cefcccb39" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e4e787d1-1896-4cd6-94b6-b53cefcccb39_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_e4e787d1-1896-4cd6-94b6-b53cefcccb39" xlink:to="loc_srt_ProductsAndServicesDomain_e4e787d1-1896-4cd6-94b6-b53cefcccb39_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c9f6ac7d-7062-4274-ad88-dfb83cde40c9" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_e4e787d1-1896-4cd6-94b6-b53cefcccb39" xlink:to="loc_srt_ProductsAndServicesDomain_c9f6ac7d-7062-4274-ad88-dfb83cde40c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromLicenseAgreementsMember_43d5265e-431f-4310-9c5c-15bbd04b642a" xlink:href="mgnx-20181231.xsd#mgnx_RevenuesFromLicenseAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c9f6ac7d-7062-4274-ad88-dfb83cde40c9" xlink:to="loc_mgnx_RevenuesFromLicenseAgreementsMember_43d5265e-431f-4310-9c5c-15bbd04b642a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_ad242bd3-abff-42c9-8ed9-33c14ca54760" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b13011c4-cc80-4b10-8929-9ec70b8ee768" xlink:to="loc_us-gaap_TypeOfArrangementAxis_ad242bd3-abff-42c9-8ed9-33c14ca54760" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ad242bd3-abff-42c9-8ed9-33c14ca54760_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_ad242bd3-abff-42c9-8ed9-33c14ca54760" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ad242bd3-abff-42c9-8ed9-33c14ca54760_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_75655ff2-6886-420d-837b-a9ff86fc8dba" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_ad242bd3-abff-42c9-8ed9-33c14ca54760" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_75655ff2-6886-420d-837b-a9ff86fc8dba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionLicenseAgreementMember_62a2c2e3-aa30-4933-87bb-4e06be52ff0a" xlink:href="mgnx-20181231.xsd#mgnx_ProventionLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_75655ff2-6886-420d-837b-a9ff86fc8dba" xlink:to="loc_mgnx_ProventionLicenseAgreementMember_62a2c2e3-aa30-4933-87bb-4e06be52ff0a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_AssetPurchaseAgreementMember_04afd116-98b1-4232-879b-a57a609b096b" xlink:href="mgnx-20181231.xsd#mgnx_AssetPurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_75655ff2-6886-420d-837b-a9ff86fc8dba" xlink:to="loc_mgnx_AssetPurchaseAgreementMember_04afd116-98b1-4232-879b-a57a609b096b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_0c60b5a9-1bef-40b3-8b9e-d93994aae145" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b13011c4-cc80-4b10-8929-9ec70b8ee768" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_0c60b5a9-1bef-40b3-8b9e-d93994aae145" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_0c60b5a9-1bef-40b3-8b9e-d93994aae145_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_0c60b5a9-1bef-40b3-8b9e-d93994aae145" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_0c60b5a9-1bef-40b3-8b9e-d93994aae145_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_afda66b2-f103-413b-ab34-70c417938dff" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_0c60b5a9-1bef-40b3-8b9e-d93994aae145" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_afda66b2-f103-413b-ab34-70c417938dff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionPRV3279Member_794c5cef-c18d-405a-871b-4be124a2c013" xlink:href="mgnx-20181231.xsd#mgnx_ProventionPRV3279Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_afda66b2-f103-413b-ab34-70c417938dff" xlink:to="loc_mgnx_ProventionPRV3279Member_794c5cef-c18d-405a-871b-4be124a2c013" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionPRV031Member_ef5c431c-1cf1-4f26-9908-b3cd0346b2d0" xlink:href="mgnx-20181231.xsd#mgnx_ProventionPRV031Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_afda66b2-f103-413b-ab34-70c417938dff" xlink:to="loc_mgnx_ProventionPRV031Member_ef5c431c-1cf1-4f26-9908-b3cd0346b2d0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_5c469cbe-bfd5-4c13-9c14-3b5f1ac50c69" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_5c469cbe-bfd5-4c13-9c14-3b5f1ac50c69_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_482108f7-2b63-4dba-9b55-5db389aa326f" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromLicenseAgreementsMember_ae6c8854-56f3-49f1-bcf7-3152103429e8" xlink:href="mgnx-20181231.xsd#mgnx_RevenuesFromLicenseAgreementsMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_68d569bb-b6c0-42f2-bd71-50abd387ded2" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b13011c4-cc80-4b10-8929-9ec70b8ee768" xlink:to="loc_srt_CounterpartyNameAxis_68d569bb-b6c0-42f2-bd71-50abd387ded2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_68d569bb-b6c0-42f2-bd71-50abd387ded2_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_68d569bb-b6c0-42f2-bd71-50abd387ded2" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_68d569bb-b6c0-42f2-bd71-50abd387ded2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bc308b98-5430-4063-8613-3ca98b4b64d7" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_68d569bb-b6c0-42f2-bd71-50abd387ded2" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bc308b98-5430-4063-8613-3ca98b4b64d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionBioMember_db801c41-8e2c-4e0e-b59f-fb8d028c2b07" xlink:href="mgnx-20181231.xsd#mgnx_ProventionBioMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bc308b98-5430-4063-8613-3ca98b4b64d7" xlink:to="loc_mgnx_ProventionBioMember_db801c41-8e2c-4e0e-b59f-fb8d028c2b07" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare_abd897e1-e541-494c-868f-e51287c386ce" xlink:href="mgnx-20181231.xsd#mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b1099a72-88b9-4960-9d3b-8ac6a5de6a3b" xlink:to="loc_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare_abd897e1-e541-494c-868f-e51287c386ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_ab65c94d-2602-4cea-8788-629185053e14" xlink:href="mgnx-20181231.xsd#mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b1099a72-88b9-4960-9d3b-8ac6a5de6a3b" xlink:to="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_ab65c94d-2602-4cea-8788-629185053e14" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_5acc290d-8d45-41ab-ae37-479512fb0fea" xlink:href="mgnx-20181231.xsd#mgnx_PotentialCommercialMilestonePaymentsUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b1099a72-88b9-4960-9d3b-8ac6a5de6a3b" xlink:to="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_5acc290d-8d45-41ab-ae37-479512fb0fea" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement_6c1142db-ccf6-4b72-89d7-08274ab2cc1e" xlink:href="mgnx-20181231.xsd#mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b1099a72-88b9-4960-9d3b-8ac6a5de6a3b" xlink:to="loc_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement_6c1142db-ccf6-4b72-89d7-08274ab2cc1e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementTransactionPrice_d201420a-aaa2-46e4-9d69-70936adc93b0" xlink:href="mgnx-20181231.xsd#mgnx_CollaborativeAgreementTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b1099a72-88b9-4960-9d3b-8ac6a5de6a3b" xlink:to="loc_mgnx_CollaborativeAgreementTransactionPrice_d201420a-aaa2-46e4-9d69-70936adc93b0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares_a0f63072-2ad7-41bc-af30-034fed54437f" xlink:href="mgnx-20181231.xsd#mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b1099a72-88b9-4960-9d3b-8ac6a5de6a3b" xlink:to="loc_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares_a0f63072-2ad7-41bc-af30-034fed54437f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_f8716412-1fc0-48c9-b5dd-1a6ccc848b58" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b1099a72-88b9-4960-9d3b-8ac6a5de6a3b" xlink:to="loc_us-gaap_Revenues_f8716412-1fc0-48c9-b5dd-1a6ccc848b58" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_4db825d2-eaa2-4c80-b44e-633c0437bb3f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b1099a72-88b9-4960-9d3b-8ac6a5de6a3b" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_4db825d2-eaa2-4c80-b44e-633c0437bb3f" xlink:type="arc" order="8"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenBiotechIncDetails" xlink:type="simple" xlink:href="mgnx-20181231.xsd#CollaborationandOtherAgreementsJanssenBiotechIncDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenBiotechIncDetails" xlink:type="extended" id="iac73eba975a44504815feba2e3e0368c_494b8594-389d-4c56-acb8-54c281dfd9fc">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1557c743-ff7a-4500-9ebd-320c61e36ede" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2f20e879-3bd1-488e-913d-49e25249fab9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1557c743-ff7a-4500-9ebd-320c61e36ede" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2f20e879-3bd1-488e-913d-49e25249fab9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_15bd07b6-1ea2-40ce-b70c-5d0c8ec2e62f" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2f20e879-3bd1-488e-913d-49e25249fab9" xlink:to="loc_srt_ProductOrServiceAxis_15bd07b6-1ea2-40ce-b70c-5d0c8ec2e62f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_15bd07b6-1ea2-40ce-b70c-5d0c8ec2e62f_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_15bd07b6-1ea2-40ce-b70c-5d0c8ec2e62f" xlink:to="loc_srt_ProductsAndServicesDomain_15bd07b6-1ea2-40ce-b70c-5d0c8ec2e62f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d6150b16-1d11-48a0-8b1d-39a0bd2c51ae" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_15bd07b6-1ea2-40ce-b70c-5d0c8ec2e62f" xlink:to="loc_srt_ProductsAndServicesDomain_d6150b16-1d11-48a0-8b1d-39a0bd2c51ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromLicenseAgreementsMember_80fb15ed-3f1b-4171-b303-72c6c2f72614" xlink:href="mgnx-20181231.xsd#mgnx_RevenuesFromLicenseAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d6150b16-1d11-48a0-8b1d-39a0bd2c51ae" xlink:to="loc_mgnx_RevenuesFromLicenseAgreementsMember_80fb15ed-3f1b-4171-b303-72c6c2f72614" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_0e67ba68-858c-4ae1-8525-a8230fa403ee" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2f20e879-3bd1-488e-913d-49e25249fab9" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_0e67ba68-858c-4ae1-8525-a8230fa403ee" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_0e67ba68-858c-4ae1-8525-a8230fa403ee_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_0e67ba68-858c-4ae1-8525-a8230fa403ee" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_0e67ba68-858c-4ae1-8525-a8230fa403ee_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_ffa05ee3-577d-4dfc-86ac-5ce6dcb39866" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_0e67ba68-858c-4ae1-8525-a8230fa403ee" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_ffa05ee3-577d-4dfc-86ac-5ce6dcb39866" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_JanssenMGD011AgreementMember_810a6546-0c7e-4b53-b9f6-9c3ef14abe5e" xlink:href="mgnx-20181231.xsd#mgnx_JanssenMGD011AgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_ffa05ee3-577d-4dfc-86ac-5ce6dcb39866" xlink:to="loc_mgnx_JanssenMGD011AgreementMember_810a6546-0c7e-4b53-b9f6-9c3ef14abe5e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_JanssenMGD015AgreementMember_0ec05020-31a7-43d8-8643-192cea421e93" xlink:href="mgnx-20181231.xsd#mgnx_JanssenMGD015AgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_ffa05ee3-577d-4dfc-86ac-5ce6dcb39866" xlink:to="loc_mgnx_JanssenMGD015AgreementMember_0ec05020-31a7-43d8-8643-192cea421e93" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_5d2a025f-0494-46b4-be72-1a4a1c41567a" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2f20e879-3bd1-488e-913d-49e25249fab9" xlink:to="loc_srt_CounterpartyNameAxis_5d2a025f-0494-46b4-be72-1a4a1c41567a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5d2a025f-0494-46b4-be72-1a4a1c41567a_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_5d2a025f-0494-46b4-be72-1a4a1c41567a" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5d2a025f-0494-46b4-be72-1a4a1c41567a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_80cb688b-9132-4f6c-a5c0-7b1b04824f39" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_5d2a025f-0494-46b4-be72-1a4a1c41567a" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_80cb688b-9132-4f6c-a5c0-7b1b04824f39" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_JanssenBiotechIncMember_aaf252eb-aa13-4133-ad31-549ec71109c6" xlink:href="mgnx-20181231.xsd#mgnx_JanssenBiotechIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_80cb688b-9132-4f6c-a5c0-7b1b04824f39" xlink:to="loc_mgnx_JanssenBiotechIncMember_aaf252eb-aa13-4133-ad31-549ec71109c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_887e33f1-3ba5-4cce-9cee-2c329fc1dc40" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1557c743-ff7a-4500-9ebd-320c61e36ede" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_887e33f1-3ba5-4cce-9cee-2c329fc1dc40" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_6d53b83d-8a9b-4139-88cf-824d66abe61d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1557c743-ff7a-4500-9ebd-320c61e36ede" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_6d53b83d-8a9b-4139-88cf-824d66abe61d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees_f3462c4c-f4c7-41fd-9253-d7b3d19c162e" xlink:href="mgnx-20181231.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1557c743-ff7a-4500-9ebd-320c61e36ede" xlink:to="loc_mgnx_NonRefundableUpfrontFees_f3462c4c-f4c7-41fd-9253-d7b3d19c162e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_138aee7d-0123-4aaf-b1c3-34dc2af651c3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1557c743-ff7a-4500-9ebd-320c61e36ede" xlink:to="loc_us-gaap_Revenues_138aee7d-0123-4aaf-b1c3-34dc2af651c3" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails" xlink:type="simple" xlink:href="mgnx-20181231.xsd#CollaborationandOtherAgreementsNIAIDContractDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails" xlink:type="extended" id="i735de12f3b264d6083c6a8578483c482_ffb4f9c6-818a-4991-8040-6db3d8b449dd">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b176e728-fd44-48d2-b6e3-f565648e7b48" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b6a98327-8524-402c-bfd1-977f8c226797" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b176e728-fd44-48d2-b6e3-f565648e7b48" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b6a98327-8524-402c-bfd1-977f8c226797" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_36b0ad24-70f7-466b-ba8b-3823e962c6e5" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b6a98327-8524-402c-bfd1-977f8c226797" xlink:to="loc_srt_ProductOrServiceAxis_36b0ad24-70f7-466b-ba8b-3823e962c6e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_36b0ad24-70f7-466b-ba8b-3823e962c6e5_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_36b0ad24-70f7-466b-ba8b-3823e962c6e5" xlink:to="loc_srt_ProductsAndServicesDomain_36b0ad24-70f7-466b-ba8b-3823e962c6e5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_1ce90057-1dc6-4c65-883c-5a7395964cc2" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_36b0ad24-70f7-466b-ba8b-3823e962c6e5" xlink:to="loc_srt_ProductsAndServicesDomain_1ce90057-1dc6-4c65-883c-5a7395964cc2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromLicenseAgreementsMember_7553dfcf-cc4b-4da1-a529-ebea77ea2710" xlink:href="mgnx-20181231.xsd#mgnx_RevenuesFromLicenseAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1ce90057-1dc6-4c65-883c-5a7395964cc2" xlink:to="loc_mgnx_RevenuesFromLicenseAgreementsMember_7553dfcf-cc4b-4da1-a529-ebea77ea2710" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_c08d3ffb-02ce-4f2e-8543-8718e00de041" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b6a98327-8524-402c-bfd1-977f8c226797" xlink:to="loc_srt_CounterpartyNameAxis_c08d3ffb-02ce-4f2e-8543-8718e00de041" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c08d3ffb-02ce-4f2e-8543-8718e00de041_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_c08d3ffb-02ce-4f2e-8543-8718e00de041" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c08d3ffb-02ce-4f2e-8543-8718e00de041_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c0baa5b7-1b53-4df9-b015-13fe27ecf40d" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_c08d3ffb-02ce-4f2e-8543-8718e00de041" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c0baa5b7-1b53-4df9-b015-13fe27ecf40d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember_49f83ed3-fc5d-457d-b271-d31a0c525751" xlink:href="mgnx-20181231.xsd#mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c0baa5b7-1b53-4df9-b015-13fe27ecf40d" xlink:to="loc_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember_49f83ed3-fc5d-457d-b271-d31a0c525751" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_7625ddbb-d879-4250-ab6b-940aa756ce46" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b6a98327-8524-402c-bfd1-977f8c226797" xlink:to="loc_srt_RangeAxis_7625ddbb-d879-4250-ab6b-940aa756ce46" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7625ddbb-d879-4250-ab6b-940aa756ce46_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_7625ddbb-d879-4250-ab6b-940aa756ce46" xlink:to="loc_srt_RangeMember_7625ddbb-d879-4250-ab6b-940aa756ce46_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_74bb8511-b500-4a09-a82f-fa8042a31461" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_7625ddbb-d879-4250-ab6b-940aa756ce46" xlink:to="loc_srt_RangeMember_74bb8511-b500-4a09-a82f-fa8042a31461" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_9dd3c340-6012-4adc-b410-5aa60c9e824b" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_74bb8511-b500-4a09-a82f-fa8042a31461" xlink:to="loc_srt_MaximumMember_9dd3c340-6012-4adc-b410-5aa60c9e824b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement_6d7dcd3f-eb33-4269-b8eb-2f34e03e53e1" xlink:href="mgnx-20181231.xsd#mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b176e728-fd44-48d2-b6e3-f565648e7b48" xlink:to="loc_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement_6d7dcd3f-eb33-4269-b8eb-2f34e03e53e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_FundedValueOfBasePeriod_f906d7f7-2f14-4932-80ae-b09f395fd197" xlink:href="mgnx-20181231.xsd#mgnx_FundedValueOfBasePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b176e728-fd44-48d2-b6e3-f565648e7b48" xlink:to="loc_mgnx_FundedValueOfBasePeriod_f906d7f7-2f14-4932-80ae-b09f395fd197" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement_88eabff3-8780-4967-949a-31e6558b2149" xlink:href="mgnx-20181231.xsd#mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b176e728-fd44-48d2-b6e3-f565648e7b48" xlink:to="loc_mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement_88eabff3-8780-4967-949a-31e6558b2149" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_TotalPotentialValueUnderAgreement_a81de2d0-3d8d-4d43-9a09-56dcfc3c3ad5" xlink:href="mgnx-20181231.xsd#mgnx_TotalPotentialValueUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b176e728-fd44-48d2-b6e3-f565648e7b48" xlink:to="loc_mgnx_TotalPotentialValueUnderAgreement_a81de2d0-3d8d-4d43-9a09-56dcfc3c3ad5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement_990d65eb-9b40-4371-a93f-b236983c0631" xlink:href="mgnx-20181231.xsd#mgnx_ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b176e728-fd44-48d2-b6e3-f565648e7b48" xlink:to="loc_mgnx_ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement_990d65eb-9b40-4371-a93f-b236983c0631" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_542c8ccc-6ed1-4e13-bf0b-51aaf63120d8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b176e728-fd44-48d2-b6e3-f565648e7b48" xlink:to="loc_us-gaap_Revenues_542c8ccc-6ed1-4e13-bf0b-51aaf63120d8" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="mgnx-20181231.xsd#CommitmentsandContingencies"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/CommitmentsandContingencies" xlink:type="extended" id="ie3d2081076164531bd089e0665b23765_f4061c56-081e-48b5-81b7-8b56e55b2288"/>
  <link:roleRef roleURI="http://macrogenics.com/role/CommitmentsandContingenciesTables" xlink:type="simple" xlink:href="mgnx-20181231.xsd#CommitmentsandContingenciesTables"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/CommitmentsandContingenciesTables" xlink:type="extended" id="i4852f675560749eba8369f3fea599a9f_eede4b1c-46c6-4940-9b0e-7ea0faee527d"/>
  <link:roleRef roleURI="http://macrogenics.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="mgnx-20181231.xsd#CommitmentsandContingenciesDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/CommitmentsandContingenciesDetails" xlink:type="extended" id="ib53de5f97ca94d3ab85afae3fcfe6c67_88d6d61a-bc65-493c-8322-5b93f9a1bdf6"/>
  <link:roleRef roleURI="http://macrogenics.com/role/EmployeeBenefitPlan" xlink:type="simple" xlink:href="mgnx-20181231.xsd#EmployeeBenefitPlan"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/EmployeeBenefitPlan" xlink:type="extended" id="i750960b5907b404b933ac3aefa2f8066_8e4ef061-e677-48b4-92a3-bee5bf5936f8"/>
  <link:roleRef roleURI="http://macrogenics.com/role/EmployeeBenefitPlanDetails" xlink:type="simple" xlink:href="mgnx-20181231.xsd#EmployeeBenefitPlanDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/EmployeeBenefitPlanDetails" xlink:type="extended" id="ic632052177d047979011c33b2e125b3d_a54c42b4-36ad-422f-997c-f78e182ca9fe"/>
  <link:roleRef roleURI="http://macrogenics.com/role/QuarterlyFinancialInformationUnaudited" xlink:type="simple" xlink:href="mgnx-20181231.xsd#QuarterlyFinancialInformationUnaudited"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/QuarterlyFinancialInformationUnaudited" xlink:type="extended" id="ia22d480308ef420391db49f81db4d4e9_03af4b7d-766d-40e2-b49d-21a3d59537a7"/>
  <link:roleRef roleURI="http://macrogenics.com/role/QuarterlyFinancialInformationUnauditedTables" xlink:type="simple" xlink:href="mgnx-20181231.xsd#QuarterlyFinancialInformationUnauditedTables"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/QuarterlyFinancialInformationUnauditedTables" xlink:type="extended" id="icc8150bfdadd4bc99d6257b25a4799f8_0e66a8ae-c1a2-4abd-bd77-141934342bd4"/>
  <link:roleRef roleURI="http://macrogenics.com/role/QuarterlyFinancialInformationUnauditedDetails" xlink:type="simple" xlink:href="mgnx-20181231.xsd#QuarterlyFinancialInformationUnauditedDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/QuarterlyFinancialInformationUnauditedDetails" xlink:type="extended" id="i59c8f33c572e459d93c263349f5adb42_651bf586-a231-4000-8c28-01dcbec358ac"/>
  <link:roleRef roleURI="http://macrogenics.com/role/SubsequentEvents" xlink:type="simple" xlink:href="mgnx-20181231.xsd#SubsequentEvents"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/SubsequentEvents" xlink:type="extended" id="i6aa0d33d940846c0853ccefde7eba2fb_2b0690a4-32d7-4332-af1a-670b48d252bd"/>
  <link:roleRef roleURI="http://macrogenics.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="mgnx-20181231.xsd#SubsequentEventsDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/SubsequentEventsDetails" xlink:type="extended" id="i166aa2b351244b9b8164d60a6a4b9e8c_8171b498-13c3-4ff6-b83a-fa2850d60ef6">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_3ead1dad-408a-4092-9ff2-6cda3eeb5d16" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_07e8d511-9561-42ea-a5b3-6c92ca570dbf" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_3ead1dad-408a-4092-9ff2-6cda3eeb5d16" xlink:to="loc_us-gaap_SubsequentEventTable_07e8d511-9561-42ea-a5b3-6c92ca570dbf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_4df031c7-6d66-4c31-8b73-700d00e3fd69" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_07e8d511-9561-42ea-a5b3-6c92ca570dbf" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_4df031c7-6d66-4c31-8b73-700d00e3fd69" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4df031c7-6d66-4c31-8b73-700d00e3fd69_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_4df031c7-6d66-4c31-8b73-700d00e3fd69" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4df031c7-6d66-4c31-8b73-700d00e3fd69_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1c20f150-c586-4a09-8e7f-335725614d96" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_4df031c7-6d66-4c31-8b73-700d00e3fd69" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1c20f150-c586-4a09-8e7f-335725614d96" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_FollowUpOfferingMember_6e70cd77-49ec-4f02-b107-315d9a5ceff0" xlink:href="mgnx-20181231.xsd#mgnx_FollowUpOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1c20f150-c586-4a09-8e7f-335725614d96" xlink:to="loc_mgnx_FollowUpOfferingMember_6e70cd77-49ec-4f02-b107-315d9a5ceff0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_c1887d3b-b09b-4d3c-99e0-68a45e5d7cae" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1c20f150-c586-4a09-8e7f-335725614d96" xlink:to="loc_us-gaap_OverAllotmentOptionMember_c1887d3b-b09b-4d3c-99e0-68a45e5d7cae" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_3f3e8831-1e02-440c-9ee9-c79fe57eb0d7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_07e8d511-9561-42ea-a5b3-6c92ca570dbf" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_3f3e8831-1e02-440c-9ee9-c79fe57eb0d7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_3f3e8831-1e02-440c-9ee9-c79fe57eb0d7_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_3f3e8831-1e02-440c-9ee9-c79fe57eb0d7" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_3f3e8831-1e02-440c-9ee9-c79fe57eb0d7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_2528bbdc-dbcd-4636-a323-d5f7e948a2a0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_3f3e8831-1e02-440c-9ee9-c79fe57eb0d7" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_2528bbdc-dbcd-4636-a323-d5f7e948a2a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_615f52f5-5622-46ab-b879-659159310c36" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_2528bbdc-dbcd-4636-a323-d5f7e948a2a0" xlink:to="loc_us-gaap_SubsequentEventMember_615f52f5-5622-46ab-b879-659159310c36" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_aed07de6-ff81-4056-914e-d3ad20018d85" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_3ead1dad-408a-4092-9ff2-6cda3eeb5d16" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_aed07de6-ff81-4056-914e-d3ad20018d85" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_5c57f936-8816-45a2-8805-8dd1eaacdac5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_3ead1dad-408a-4092-9ff2-6cda3eeb5d16" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_5c57f936-8816-45a2-8805-8dd1eaacdac5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_5aff002b-b5ed-497a-87f3-7fdc7022bc61" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_3ead1dad-408a-4092-9ff2-6cda3eeb5d16" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_5aff002b-b5ed-497a-87f3-7fdc7022bc61" xlink:type="arc" order="3"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>12
<FILENAME>mgnx-20181231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2017 Workiva-->
<!--r:047621fe-455e-451d-8c86-6c34d8ef3281,g:8a8d7b2b-0121-408b-a242-2fd92f2a34d5-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_025fd8b4-0b71-4949-a247-98d1e3046543_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of the Beginning and Ending Amount of Gross Unrecognized Tax Benefits</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_IncyteMGA012ClinicalServicesMember_ce59727a-3520-477c-a23e-8c5b7d907f41_terseLabel_en-US" xlink:label="lab_mgnx_IncyteMGA012ClinicalServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incyte MGA012 Clinical Services</link:label>
    <link:label id="lab_mgnx_IncyteMGA012ClinicalServicesMember_label_en-US" xlink:label="lab_mgnx_IncyteMGA012ClinicalServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incyte MGA012 Clinical Services [Member]</link:label>
    <link:label id="lab_mgnx_IncyteMGA012ClinicalServicesMember_documentation_en-US" xlink:label="lab_mgnx_IncyteMGA012ClinicalServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incyte MGA012 Clinical Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteMGA012ClinicalServicesMember" xlink:href="mgnx-20181231.xsd#mgnx_IncyteMGA012ClinicalServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_IncyteMGA012ClinicalServicesMember" xlink:to="lab_mgnx_IncyteMGA012ClinicalServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_51d45de1-a575-4d36-9a68-8564cf57b569_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount_b7539d6b-0690-45be-a86d-a313201bce35_terseLabel_en-US" xlink:label="lab_mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss for limited use</link:label>
    <link:label id="lab_mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount_label_en-US" xlink:label="lab_mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards Limitations On Use Amount</link:label>
    <link:label id="lab_mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount_documentation_en-US" xlink:label="lab_mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of net operating loss carryforward, which are limited for use over the range of years.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount" xlink:href="mgnx-20181231.xsd#mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount" xlink:to="lab_mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_8ad8f3f2-054c-478b-8b43-e2a83a5d1719_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent of fair market value to purchase shares</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_03c63c05-2d23-4491-a340-ca61546752f5_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_1f0a02e4-de8a-4d6b-b07b-8704d00a3774_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_ae340476-233f-4d31-a226-9373b6324ab8_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_StockIncentivePlan2013Member_9a18f4c2-08fe-4baf-87d7-cd2703b27168_terseLabel_en-US" xlink:label="lab_mgnx_StockIncentivePlan2013Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Incentive Plan 2013</link:label>
    <link:label id="lab_mgnx_StockIncentivePlan2013Member_label_en-US" xlink:label="lab_mgnx_StockIncentivePlan2013Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Incentive Plan 2013 [Member]</link:label>
    <link:label id="lab_mgnx_StockIncentivePlan2013Member_documentation_en-US" xlink:label="lab_mgnx_StockIncentivePlan2013Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Incentive Plan 2013 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_StockIncentivePlan2013Member" xlink:href="mgnx-20181231.xsd#mgnx_StockIncentivePlan2013Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_StockIncentivePlan2013Member" xlink:to="lab_mgnx_StockIncentivePlan2013Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_b4c3d980-9514-45d9-9587-754a3ba6f136_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8130df04-e2a2-4b7a-8e7f-abd454e4ca2b_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_977acb4c-3dae-424f-94a7-a15dd1362cc5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_10ef2066-3c24-43b2-9fe9-b329b7f843e4_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare_26a9127a-72d7-4e64-bf63-ea00963ab27f_terseLabel_en-US" xlink:label="lab_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration received common stock warrant exercise price (in usd per share)</link:label>
    <link:label id="lab_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare_label_en-US" xlink:label="lab_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement Consideration Received Common Stock Warrant Exercise Price Per Share</link:label>
    <link:label id="lab_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare_documentation_en-US" xlink:label="lab_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement Consideration Received Common Stock Warrant Exercise Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare" xlink:href="mgnx-20181231.xsd#mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare" xlink:to="lab_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_76907f44-77fd-4953-b4d5-c1de83e08c3d_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_988a8918-ae83-4480-b83b-99bdcebe4290_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation cost related to non-vested stock-based compensation arrangements</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_FirmCommitmentPublicUnderwrittenOfferMember_ef7eb487-08b8-43bb-abfc-b992cf89788c_terseLabel_en-US" xlink:label="lab_mgnx_FirmCommitmentPublicUnderwrittenOfferMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Firm Commitment Public Underwritten Offer</link:label>
    <link:label id="lab_mgnx_FirmCommitmentPublicUnderwrittenOfferMember_label_en-US" xlink:label="lab_mgnx_FirmCommitmentPublicUnderwrittenOfferMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Firm Commitment Public Underwritten Offer [Member]</link:label>
    <link:label id="lab_mgnx_FirmCommitmentPublicUnderwrittenOfferMember_documentation_en-US" xlink:label="lab_mgnx_FirmCommitmentPublicUnderwrittenOfferMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Firm Commitment Public Underwritten Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_FirmCommitmentPublicUnderwrittenOfferMember" xlink:href="mgnx-20181231.xsd#mgnx_FirmCommitmentPublicUnderwrittenOfferMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_FirmCommitmentPublicUnderwrittenOfferMember" xlink:to="lab_mgnx_FirmCommitmentPublicUnderwrittenOfferMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_7289911e-ac47-4d02-bbaf-e29a2663a091_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical trial activities selling price amount</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Multiple-deliverable Arrangements, Determination of Selling Price, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount" xlink:to="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTaxBenefitTaxEffectedAmount_514f63f5-67cc-453a-83c3-20248d7c2f86_terseLabel_en-US" xlink:label="lab_mgnx_EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTaxBenefitTaxEffectedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Previously unrecognized excess tax benefits, tax effected portion</link:label>
    <link:label id="lab_mgnx_EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTaxBenefitTaxEffectedAmount_label_en-US" xlink:label="lab_mgnx_EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTaxBenefitTaxEffectedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Share-based Compensation, Excess Tax Benefit, Tax Effected Amount</link:label>
    <link:label id="lab_mgnx_EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTaxBenefitTaxEffectedAmount_documentation_en-US" xlink:label="lab_mgnx_EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTaxBenefitTaxEffectedAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Share-based Compensation, Excess Tax Benefit, Tax Effected Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTaxBenefitTaxEffectedAmount" xlink:href="mgnx-20181231.xsd#mgnx_EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTaxBenefitTaxEffectedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTaxBenefitTaxEffectedAmount" xlink:to="lab_mgnx_EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTaxBenefitTaxEffectedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_e11d9da1-b26f-42d2-b45b-c584020ebc5a_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer equipment</link:label>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_label_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember" xlink:to="lab_us-gaap_ComputerEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_e79df9ad-a154-43e6-8485-4938b38e9447_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property, equipment and software</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cfb1c864-40de-43cc-b1f1-1c523904e9ee_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock_7be71804-d413-4fda-a6d2-d40d7be9bfc8_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based Compensation</link:label>
    <link:label id="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Related Costs, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_WarrantsFairValueDisclosure_f550718a-f204-453c-b7f1-7d2bcd0d1f83_terseLabel_en-US" xlink:label="lab_mgnx_WarrantsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock warrants</link:label>
    <link:label id="lab_mgnx_WarrantsFairValueDisclosure_label_en-US" xlink:label="lab_mgnx_WarrantsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Fair Value Disclosure</link:label>
    <link:label id="lab_mgnx_WarrantsFairValueDisclosure_documentation_en-US" xlink:label="lab_mgnx_WarrantsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_WarrantsFairValueDisclosure" xlink:href="mgnx-20181231.xsd#mgnx_WarrantsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_WarrantsFairValueDisclosure" xlink:to="lab_mgnx_WarrantsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_8097c3e6-d1cd-42ce-9394-8850798174cb_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration of Credit Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_aff4c553-577e-4524-bdb2-647ad2551c8e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value, Vested and expected to vest</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_49489bb9-d4f3-45eb-b2c5-ddbeb69043ee_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_5005d028-e181-416f-8a32-61475072efe5_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_0246f3c5-3847-4a00-9076-3cd43552c1e2_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research credit, net</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_3d241b30-1fae-4c0c-a9e8-65a96b63f677_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_65a2a4e1-1f97-4a98-b1ce-0e6106cf1ef1_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_cb402a42-3802-4478-ac13-af624b0a0420_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_edb9aef2-4f78-4a6c-92f8-a7c2734b80c6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_8538128e-e363-494c-a14f-bccf398ac32a_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_b5c891d4-f1e5-4320-b3b5-0e19e9eebbdb_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_1fe9b771-99af-4009-92e6-69a133ca5222_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of employee contribution to salary</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:to="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_423a26d1-d327-48cc-9d3a-d2873f81e538_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_21b940a3-cf97-40a6-a7f8-94398b261dd1_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value, Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_7ecfe1c4-ea35-4336-8d54-72e408b2e244_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue recognized</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_5f476809-0692-490a-abb4-9b7ca8e1f65a_negatedLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deductions</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_e07991e2-9e31-4ea8-9ab0-58558a9966c8_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in revenue recognized from ASC 606 adoption</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_f5213e61-8ed7-47e1-bbdd-784ce00b2358_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, equipment and software, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_6fe4aab3-e800-426c-b090-0b4145aa2448_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, equipment and software, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_51353bd7-74b6-493b-a24f-9b0838af0c1c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value, Outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_6fc9cbed-5014-4e34-a096-1202e1fe3bb6_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_f6254052-3060-4f9a-9d79-090128b80bf6_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Undesignated preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_da12e7fb-4664-41c0-a0d0-7384b3402cf2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Other Observable Inputs, Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_3158d7ee-91df-42c3-b944-15dd3bb26256_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance_db576f2b-c099-4137-862f-27737671ee88_terseLabel_en-US" xlink:label="lab_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock reserved for future issuance (in shares)</link:label>
    <link:label id="lab_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Capital Shares Minimum Increase In Shares Reserved For Future Issuance</link:label>
    <link:label id="lab_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance_documentation_en-US" xlink:label="lab_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Capital Shares Minimum Increase In Shares Reserved For Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance" xlink:href="mgnx-20181231.xsd#mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance" xlink:to="lab_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_3a990412-da14-4f4b-bb85-609df252a34b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_NonrefundablePaymentTaxWithholding_e682bc38-278e-4265-a098-dfb254e41e46_terseLabel_en-US" xlink:label="lab_mgnx_NonrefundablePaymentTaxWithholding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax withholding</link:label>
    <link:label id="lab_mgnx_NonrefundablePaymentTaxWithholding_label_en-US" xlink:label="lab_mgnx_NonrefundablePaymentTaxWithholding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-refundable Payment, Tax Withholding</link:label>
    <link:label id="lab_mgnx_NonrefundablePaymentTaxWithholding_documentation_en-US" xlink:label="lab_mgnx_NonrefundablePaymentTaxWithholding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-refundable Payment, Tax Withholding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonrefundablePaymentTaxWithholding" xlink:href="mgnx-20181231.xsd#mgnx_NonrefundablePaymentTaxWithholding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_NonrefundablePaymentTaxWithholding" xlink:to="lab_mgnx_NonrefundablePaymentTaxWithholding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_b0bb97eb-0c30-4e2b-8c37-b78a0cf03e56_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_92544e7a-65b1-43a0-946e-84d6f73e4bdc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of New Accounting Pronouncements and Changes in Accounting Principles</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of New Accounting Pronouncements and Changes in Accounting Principles [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:to="lab_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_ee8974bd-9e59-413c-8133-796dec762829_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_ffcc8c61-3acd-45f2-939e-db82aef5d0d9_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited or expired</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_55388fb0-97bd-48c0-8dcb-f4cd969d6b09_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_f9645aa3-9fdc-4dfd-88bf-9e707ebfb7a3_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash operating and investing activities:</link:label>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_label_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroup_08912ef5-acf1-4282-b013-559593a5c536_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroup" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets held-for-sale</link:label>
    <link:label id="lab_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroup_label_en-US" xlink:label="lab_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroup" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets Held-for-sale, Not Part of Disposal Group</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroup" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsHeldForSaleNotPartOfDisposalGroup"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroup" xlink:to="lab_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroup" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_a52f53c9-b63a-4e72-abfc-269132ba714e_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2b71e349-e84a-452a-969d-3f214536927c_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssued_06c19566-c403-408d-83ae-51b6a30d8299_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_3860de77-05e7-4e3a-8978-e38a0ffc920c_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_label_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued" xlink:to="lab_us-gaap_SharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_ca87e79c-5747-43f8-8ac2-98e0ca00fce2_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_630ed602-60bc-4bf3-8765-5daceaeb4fc7_terseLabel_en-US" xlink:label="lab_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts recognized</link:label>
    <link:label id="lab_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_label_en-US" xlink:label="lab_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development And Regulatory Milestone Payments Under Agreement, Recognized</link:label>
    <link:label id="lab_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_documentation_en-US" xlink:label="lab_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development And Regulatory Milestone Payments Under Agreement, Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" xlink:href="mgnx-20181231.xsd#mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" xlink:to="lab_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_JanssenMGD015AgreementMember_09f0598a-0945-4bb5-ad38-0705ca5f052b_terseLabel_en-US" xlink:label="lab_mgnx_JanssenMGD015AgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen MGD015 Agreement</link:label>
    <link:label id="lab_mgnx_JanssenMGD015AgreementMember_label_en-US" xlink:label="lab_mgnx_JanssenMGD015AgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen MGD015 Agreement [Member]</link:label>
    <link:label id="lab_mgnx_JanssenMGD015AgreementMember_documentation_en-US" xlink:label="lab_mgnx_JanssenMGD015AgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen MGD015 Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_JanssenMGD015AgreementMember" xlink:href="mgnx-20181231.xsd#mgnx_JanssenMGD015AgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_JanssenMGD015AgreementMember" xlink:to="lab_mgnx_JanssenMGD015AgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_473dd4dc-d08c-49d9-ae38-0b2392ee4902_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_7a79800f-f124-417b-b683-ae4b67c612c9_terseLabel_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_label_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade and Other Accounts Receivable, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_NonRefundableUpfrontFees_f6149952-4805-4375-9d31-258b9e11bc63_terseLabel_en-US" xlink:label="lab_mgnx_NonRefundableUpfrontFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-refundable upfront payment</link:label>
    <link:label id="lab_mgnx_NonRefundableUpfrontFees_label_en-US" xlink:label="lab_mgnx_NonRefundableUpfrontFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-refundable upfront payment</link:label>
    <link:label id="lab_mgnx_NonRefundableUpfrontFees_documentation_en-US" xlink:label="lab_mgnx_NonRefundableUpfrontFees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial fee received from collaboration or license agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees" xlink:href="mgnx-20181231.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_NonRefundableUpfrontFees" xlink:to="lab_mgnx_NonRefundableUpfrontFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_502b4678-888e-472c-afba-faf2bb490c90_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_FundedValueOfBasePeriod_81f4e31a-1eb5-4d6c-a873-e1e2d586916a_verboseLabel_en-US" xlink:label="lab_mgnx_FundedValueOfBasePeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base period value</link:label>
    <link:label id="lab_mgnx_FundedValueOfBasePeriod_label_en-US" xlink:label="lab_mgnx_FundedValueOfBasePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funded Value of Base Period</link:label>
    <link:label id="lab_mgnx_FundedValueOfBasePeriod_documentation_en-US" xlink:label="lab_mgnx_FundedValueOfBasePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funded value of base period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_FundedValueOfBasePeriod" xlink:href="mgnx-20181231.xsd#mgnx_FundedValueOfBasePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_FundedValueOfBasePeriod" xlink:to="lab_mgnx_FundedValueOfBasePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan_9f20592f-d870-4e83-a507-766b896d40f7_terseLabel_en-US" xlink:label="lab_mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eligible age to participate in plan</link:label>
    <link:label id="lab_mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan_label_en-US" xlink:label="lab_mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employees Eligible Age To Participate In Benefit Plan</link:label>
    <link:label id="lab_mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan_documentation_en-US" xlink:label="lab_mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Refers to minimum eligible age of employee to participate in benefit plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan" xlink:href="mgnx-20181231.xsd#mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan" xlink:to="lab_mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_CollaborativeAgreementTransactionPrice_f1b554f8-e8e4-4220-a4c9-5417e326c55d_terseLabel_en-US" xlink:label="lab_mgnx_CollaborativeAgreementTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction price</link:label>
    <link:label id="lab_mgnx_CollaborativeAgreementTransactionPrice_label_en-US" xlink:label="lab_mgnx_CollaborativeAgreementTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement Transaction Price</link:label>
    <link:label id="lab_mgnx_CollaborativeAgreementTransactionPrice_documentation_en-US" xlink:label="lab_mgnx_CollaborativeAgreementTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement Transaction Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementTransactionPrice" xlink:href="mgnx-20181231.xsd#mgnx_CollaborativeAgreementTransactionPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_CollaborativeAgreementTransactionPrice" xlink:to="lab_mgnx_CollaborativeAgreementTransactionPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_61595bf6-9919-478c-914e-91c8bae27366_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5d39b6c4-5743-4b40-a2d0-a852a9a89433_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_e92d909a-06b5-48e4-bc4c-796e4055723e_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_c5be93ef-cef2-4fe3-9edd-53fb1213c169_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_3a6586e3-0202-40d8-a99d-bebd0b676645_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_5459a7de-4355-42db-b274-9747fa279646_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_d0c0f0f6-f5ee-4dea-8270-3635e18a9b96_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allocated Share-based Compensation Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0d670801-3de0-460c-be39-ab954c0b605c_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity_1bc09625-477a-45df-a22d-2ba113af7de5_terseLabel_en-US" xlink:label="lab_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock plan related activity (in shares)</link:label>
    <link:label id="lab_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity_label_en-US" xlink:label="lab_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period Shares Stock Plan Activity</link:label>
    <link:label id="lab_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity_documentation_en-US" xlink:label="lab_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares issued due to stock plan related activity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity" xlink:href="mgnx-20181231.xsd#mgnx_StockIssuedDuringPeriodSharesStockPlanActivity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity" xlink:to="lab_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssuedPricePerShare_5d61180d-9d69-42fc-8ce6-0b6162788e2a_terseLabel_en-US" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock purchase price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharesIssuedPricePerShare_label_en-US" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssuedPricePerShare" xlink:to="lab_us-gaap_SharesIssuedPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_0ec7e363-df2e-4607-a198-68383984d53d_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred income tax asset/(liability)</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_58d102dc-1b65-440a-ac57-bcff24327c7c_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_cf80a453-4e9a-4323-823e-80c90318559a_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Deferred Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_IndefiniteMember_111bf12a-ce94-49ff-896c-6ae025c4a538_terseLabel_en-US" xlink:label="lab_mgnx_IndefiniteMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite</link:label>
    <link:label id="lab_mgnx_IndefiniteMember_label_en-US" xlink:label="lab_mgnx_IndefiniteMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite [Member]</link:label>
    <link:label id="lab_mgnx_IndefiniteMember_documentation_en-US" xlink:label="lab_mgnx_IndefiniteMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IndefiniteMember" xlink:href="mgnx-20181231.xsd#mgnx_IndefiniteMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_IndefiniteMember" xlink:to="lab_mgnx_IndefiniteMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_e820c50d-72c7-4680-828f-bec9dd162a88_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_CommonStockMaximumAmountAvailableForIssuance_c83b2b84-7170-45f6-8e83-649da06af252_terseLabel_en-US" xlink:label="lab_mgnx_CommonStockMaximumAmountAvailableForIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock maximum amount available for issuance</link:label>
    <link:label id="lab_mgnx_CommonStockMaximumAmountAvailableForIssuance_label_en-US" xlink:label="lab_mgnx_CommonStockMaximumAmountAvailableForIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Maximum Amount Available For Issuance</link:label>
    <link:label id="lab_mgnx_CommonStockMaximumAmountAvailableForIssuance_documentation_en-US" xlink:label="lab_mgnx_CommonStockMaximumAmountAvailableForIssuance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Maximum Amount Available For Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CommonStockMaximumAmountAvailableForIssuance" xlink:href="mgnx-20181231.xsd#mgnx_CommonStockMaximumAmountAvailableForIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_CommonStockMaximumAmountAvailableForIssuance" xlink:to="lab_mgnx_CommonStockMaximumAmountAvailableForIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_b71b3aa8-7ce2-4e69-a249-fcc9c01381bc_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Undesignated preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_8dd6b9cd-8053-4928-a523-84c9cbb9b46b_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_554eea91-1f4e-4d1f-92d1-de908dbef95f_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_9cef1b99-a12c-4a19-83a3-5ec5068a8946_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_90f2670b-6be0-461c-bcbd-3b76ec00195a_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_507eac25-f255-4a02-88f1-a67f39323b05_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross deferred income tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_CollaborationAndLicenseAgreementsAbstract_50f0389d-c3b6-4f79-8857-5ade353e06c4_terseLabel_en-US" xlink:label="lab_mgnx_CollaborationAndLicenseAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and License Agreements [Abstract]</link:label>
    <link:label id="lab_mgnx_CollaborationAndLicenseAgreementsAbstract_label_en-US" xlink:label="lab_mgnx_CollaborationAndLicenseAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and License Agreements [Abstract]</link:label>
    <link:label id="lab_mgnx_CollaborationAndLicenseAgreementsAbstract_documentation_en-US" xlink:label="lab_mgnx_CollaborationAndLicenseAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsAbstract" xlink:href="mgnx-20181231.xsd#mgnx_CollaborationAndLicenseAgreementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_CollaborationAndLicenseAgreementsAbstract" xlink:to="lab_mgnx_CollaborationAndLicenseAgreementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_0a0c1ad6-94d2-413d-adc9-86ec96a7c34d_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_ca4cfd6b-de06-457f-a6ab-e448c483c924_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent" xlink:to="lab_us-gaap_PrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock_270d1efe-80e5-478f-8c04-4e9e7f9d6e8f_terseLabel_en-US" xlink:label="lab_mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Useful Lives</link:label>
    <link:label id="lab_mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock_label_en-US" xlink:label="lab_mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property Plant And Equipment Estimated Useful Life Table [Text Block]</link:label>
    <link:label id="lab_mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock_documentation_en-US" xlink:label="lab_mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property plant and equipment estimated useful life.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock" xlink:href="mgnx-20181231.xsd#mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock" xlink:to="lab_mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_44eca696-fd1e-454e-801d-9f76c0c3b01c_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ZaiLabsMember_b1ee5290-61d7-4330-8c4e-cc669df88354_terseLabel_en-US" xlink:label="lab_mgnx_ZaiLabsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Lab</link:label>
    <link:label id="lab_mgnx_ZaiLabsMember_label_en-US" xlink:label="lab_mgnx_ZaiLabsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Labs [Member]</link:label>
    <link:label id="lab_mgnx_ZaiLabsMember_documentation_en-US" xlink:label="lab_mgnx_ZaiLabsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Labs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabsMember" xlink:href="mgnx-20181231.xsd#mgnx_ZaiLabsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ZaiLabsMember" xlink:to="lab_mgnx_ZaiLabsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_PropertyPlantAndEquipmentNonCashAdditions_891dbb99-f717-43a1-9b68-bbb187702170_terseLabel_en-US" xlink:label="lab_mgnx_PropertyPlantAndEquipmentNonCashAdditions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment purchased but not yet paid</link:label>
    <link:label id="lab_mgnx_PropertyPlantAndEquipmentNonCashAdditions_label_en-US" xlink:label="lab_mgnx_PropertyPlantAndEquipmentNonCashAdditions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Non-cash Additions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PropertyPlantAndEquipmentNonCashAdditions" xlink:href="mgnx-20181231.xsd#mgnx_PropertyPlantAndEquipmentNonCashAdditions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_PropertyPlantAndEquipmentNonCashAdditions" xlink:to="lab_mgnx_PropertyPlantAndEquipmentNonCashAdditions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_e34ae318-e11f-47ec-85b3-c0817dec6bdf_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockSharesRetired_73e5e9c1-206b-4f26-88ad-80f5a0488de4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesRetired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement of treasury stock (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesRetired_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesRetired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares, Retired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesRetired" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TreasuryStockSharesRetired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesRetired" xlink:to="lab_us-gaap_TreasuryStockSharesRetired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_07601908-f28b-4d7e-a7bd-27d5e1d9bbca_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromTenantAllowance_27dde7e8-c9e9-4858-808f-1b14e8fef883_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromTenantAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease incentives</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromTenantAllowance_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromTenantAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for (Proceeds from) Tenant Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromTenantAllowance" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForProceedsFromTenantAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromTenantAllowance" xlink:to="lab_us-gaap_PaymentsForProceedsFromTenantAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxPeriodAxis_523f29b1-70db-4a35-84c8-5e018578e77c_terseLabel_en-US" xlink:label="lab_us-gaap_TaxPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxPeriodAxis_label_en-US" xlink:label="lab_us-gaap_TaxPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxPeriodAxis" xlink:to="lab_us-gaap_TaxPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_418ea1a7-d464-45fc-ab54-4c4fb5be9a6b_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of shares vested</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember_fb97867e-a2c0-4553-a50d-a5156a58cec4_terseLabel_en-US" xlink:label="lab_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 Employee Stock Purchase Plan</link:label>
    <link:label id="lab_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Sixteen Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember_documentation_en-US" xlink:label="lab_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Sixteen Employee Stock Purchase Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember" xlink:href="mgnx-20181231.xsd#mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember" xlink:to="lab_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_2336cb3c-3250-4251-a26e-a034867e5378_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_IncyteCorporationMember_82cf9f45-e9d3-43e3-85e1-5503fd513a72_terseLabel_en-US" xlink:label="lab_mgnx_IncyteCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incyte Corporation (Incyte)</link:label>
    <link:label id="lab_mgnx_IncyteCorporationMember_label_en-US" xlink:label="lab_mgnx_IncyteCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incyte Corporation [Member]</link:label>
    <link:label id="lab_mgnx_IncyteCorporationMember_documentation_en-US" xlink:label="lab_mgnx_IncyteCorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incyte Corporation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteCorporationMember" xlink:href="mgnx-20181231.xsd#mgnx_IncyteCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_IncyteCorporationMember" xlink:to="lab_mgnx_IncyteCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_3912e136-af58-400b-9216-6a1730245118_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_1edb2660-30bb-4f79-ad5d-7891e2eceeb6_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_8c96e5ed-bbe6-4c03-93dd-9002b0d22d5f_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Undesignated preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredRentCreditNoncurrent_984d1663-fac1-4be8-a1f8-e18d85b682c8_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRentCreditNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred rent, net of current portion</link:label>
    <link:label id="lab_us-gaap_DeferredRentCreditNoncurrent_label_en-US" xlink:label="lab_us-gaap_DeferredRentCreditNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Rent Credit, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRentCreditNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRentCreditNoncurrent" xlink:to="lab_us-gaap_DeferredRentCreditNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecurities_8156aae6-9978-4489-98a7-0bf0f3a02c0e_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_6efd22cf-1b99-445b-b20e-58162449f6c6_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_2a2b6194-e4cf-4222-8325-9d1aa1813346_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_c8f14f59-4e99-4cda-8584-1783ca6155e6_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination_8bf72acc-bf45-4921-9472-018b2e149bdf_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Increase (Decrease) for Contract Acquired in Business Combination</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_794822a2-ba15-4b21-b631-f0855a914220_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) per share, diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_3ecc222e-187f-4540-adf5-dc948d8dc455_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock, net of offering costs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_43c4252e-37f4-41fd-a8f6-87944c890e05_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares issued or sold (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_PotentialClinicalMilestonePaymentsUnderAgreement_f6cc29a3-5c44-4a8d-a9ac-0a4e3bca3704_terseLabel_en-US" xlink:label="lab_mgnx_PotentialClinicalMilestonePaymentsUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential clinical milestone payments under agreement</link:label>
    <link:label id="lab_mgnx_PotentialClinicalMilestonePaymentsUnderAgreement_label_en-US" xlink:label="lab_mgnx_PotentialClinicalMilestonePaymentsUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Clinical Milestone Payments Under Agreement</link:label>
    <link:label id="lab_mgnx_PotentialClinicalMilestonePaymentsUnderAgreement_documentation_en-US" xlink:label="lab_mgnx_PotentialClinicalMilestonePaymentsUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total potential clinical milestone payments company could earn under agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialClinicalMilestonePaymentsUnderAgreement" xlink:href="mgnx-20181231.xsd#mgnx_PotentialClinicalMilestonePaymentsUnderAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_PotentialClinicalMilestonePaymentsUnderAgreement" xlink:to="lab_mgnx_PotentialClinicalMilestonePaymentsUnderAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_213ff545-735f-4a24-90f7-ceeddf8856b3_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_FollowUpOfferingMember_81feac3e-27e4-4919-9fde-4602ad1ed7f3_terseLabel_en-US" xlink:label="lab_mgnx_FollowUpOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Follow Up Offering</link:label>
    <link:label id="lab_mgnx_FollowUpOfferingMember_label_en-US" xlink:label="lab_mgnx_FollowUpOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Follow Up Offering [Member]</link:label>
    <link:label id="lab_mgnx_FollowUpOfferingMember_documentation_en-US" xlink:label="lab_mgnx_FollowUpOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Follow Up Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_FollowUpOfferingMember" xlink:href="mgnx-20181231.xsd#mgnx_FollowUpOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_FollowUpOfferingMember" xlink:to="lab_mgnx_FollowUpOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_ecfb84a6-d3dc-4901-ad1a-bb21d0170a73_totalLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_4135c184-1d53-43f9-8fe9-44b7fcea4efb_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anti-dilutive stock options</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_b6083d6a-c386-4a2b-9741-ce9a506b9103_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments Due, Next Twelve Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_9d97836d-4e21-4392-a262-b50187c9b8f4_terseLabel_en-US" xlink:label="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial Application Period Cumulative Effect Transition [Axis]</link:label>
    <link:label id="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_label_en-US" xlink:label="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial Application Period Cumulative Effect Transition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" xlink:to="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_290216bf-5d2e-4b65-9468-b06808e8db8a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_43d72702-11cb-4ced-9247-8f071a8b73ea_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_752db482-d932-4d4e-835c-30f1eb69ece0_verboseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherReconcilingItems_0b9fe49c-b493-457e-8d24-9c25d673fa6e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other permanent items</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherReconcilingItems_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:to="lab_us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_680dac33-61b6-4ddc-9b7e-d0bdc88bcc4f_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Five Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_c6b3b00c-7309-4f61-98d7-7f836814c998_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income tax assets:</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Deferred Tax Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0cbd5cb6-1f7a-4b3f-8315-22ddb56340d3_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts_bcea0b48-f5ba-4252-aaec-d0d027d18c85_terseLabel_en-US" xlink:label="lab_mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offset to research and development costs under collaboration arrangement</link:label>
    <link:label id="lab_mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts_label_en-US" xlink:label="lab_mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangement Offset to Research and Development Costs</link:label>
    <link:label id="lab_mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts_documentation_en-US" xlink:label="lab_mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Refers to collaboration arrangement offset to research and development costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts" xlink:href="mgnx-20181231.xsd#mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts" xlink:to="lab_mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_0babc3b8-bb3e-49a3-bc4e-e99b3bd4ce72_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Equipment and Software</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember_ea9b747d-a617-45ec-af04-15907b9eafdd_terseLabel_en-US" xlink:label="lab_mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Federal and State</link:label>
    <link:label id="lab_mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember_label_en-US" xlink:label="lab_mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority and State and Local Jurisdiction [Member] [Member]</link:label>
    <link:label id="lab_mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember_documentation_en-US" xlink:label="lab_mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority and State and Local Jurisdiction [Member] [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember" xlink:href="mgnx-20181231.xsd#mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember" xlink:to="lab_mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_bd775f05-3cb8-4e71-b6e6-64ac2cae14a0_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenditures</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Prepaid Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_c2ada5d2-aa87-4c6f-bb9d-bda326b8c7c1_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement_ccceda2d-84d4-4ac7-9d8f-b6eb141970fe_terseLabel_en-US" xlink:label="lab_mgnx_ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from additional development funding options under agreement</link:label>
    <link:label id="lab_mgnx_ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement_label_en-US" xlink:label="lab_mgnx_ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised Additional Development Funding Options Under Agreement</link:label>
    <link:label id="lab_mgnx_ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement_documentation_en-US" xlink:label="lab_mgnx_ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised Additional Development Funding Options Under Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement" xlink:href="mgnx-20181231.xsd#mgnx_ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement" xlink:to="lab_mgnx_ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_PotentialRegulatoryMilestonePaymentsUnderAgreement_367c4d4a-f50c-4172-a608-fedbe377f262_terseLabel_en-US" xlink:label="lab_mgnx_PotentialRegulatoryMilestonePaymentsUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential regulatory milestone payments under agreement</link:label>
    <link:label id="lab_mgnx_PotentialRegulatoryMilestonePaymentsUnderAgreement_label_en-US" xlink:label="lab_mgnx_PotentialRegulatoryMilestonePaymentsUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Regulatory Milestone Payments Under Agreement</link:label>
    <link:label id="lab_mgnx_PotentialRegulatoryMilestonePaymentsUnderAgreement_documentation_en-US" xlink:label="lab_mgnx_PotentialRegulatoryMilestonePaymentsUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total potential regulatory milestones company could earn under agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialRegulatoryMilestonePaymentsUnderAgreement" xlink:href="mgnx-20181231.xsd#mgnx_PotentialRegulatoryMilestonePaymentsUnderAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_PotentialRegulatoryMilestonePaymentsUnderAgreement" xlink:to="lab_mgnx_PotentialRegulatoryMilestonePaymentsUnderAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_fb2dcb96-49b2-4c17-8afd-ea16da2b9b3a_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Equipment and Software</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_9df5cc41-f3c4-4f3b-8fd9-83c8f09727e1_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock, net of offering costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_7e8884dc-c45a-43af-b8e3-e905df6da180_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently Issued Accounting Standards</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_f582b3e7-0457-4478-b928-df4cbbc789bc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_7eef5837-6c47-4815-a9cc-01310060308d_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_5568d5a5-705e-43d5-b97d-84cb037313ad_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales revenue, net</link:label>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_label_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Revenue, Net [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetMember" xlink:to="lab_us-gaap_SalesRevenueNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_1a1793e9-2eff-4b44-b29f-66a7c91298dd_terseLabel_en-US" xlink:label="lab_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential commercial milestone payments</link:label>
    <link:label id="lab_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_label_en-US" xlink:label="lab_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Commercial Milestone Payments Under Agreement</link:label>
    <link:label id="lab_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_documentation_en-US" xlink:label="lab_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Commercial Milestone Payments Under Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement" xlink:href="mgnx-20181231.xsd#mgnx_PotentialCommercialMilestonePaymentsUnderAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement" xlink:to="lab_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d635063c-e0f5-47a3-8457-5924619c9fc5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_aa430935-e0d8-4de5-9c30-6318116cfce8_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_JanssenMGD011AgreementMember_db3c7bd1-5648-463f-9d95-f63900263b9c_terseLabel_en-US" xlink:label="lab_mgnx_JanssenMGD011AgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen MGD011 Agreement</link:label>
    <link:label id="lab_mgnx_JanssenMGD011AgreementMember_label_en-US" xlink:label="lab_mgnx_JanssenMGD011AgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen MGD011 Agreement [Member]</link:label>
    <link:label id="lab_mgnx_JanssenMGD011AgreementMember_documentation_en-US" xlink:label="lab_mgnx_JanssenMGD011AgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen MGD011 Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_JanssenMGD011AgreementMember" xlink:href="mgnx-20181231.xsd#mgnx_JanssenMGD011AgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_JanssenMGD011AgreementMember" xlink:to="lab_mgnx_JanssenMGD011AgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_5b048890-1e01-4cc6-b1e2-60ccc576fc00_terseLabel_en-US" xlink:label="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial Application Period Cumulative Effect Transition [Domain]</link:label>
    <link:label id="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_label_en-US" xlink:label="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial Application Period Cumulative Effect Transition [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" xlink:to="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_8e94b710-e677-4eb6-91a2-d54731fd03bd_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of treasury stock</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments Related to Tax Withholding for Share-based Compensation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_7c0e1a90-8295-4e65-a2d3-ef6c8b4c7b57_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockOptionMember_e91d4ff4-0d11-42d1-be06-e4c2418430c7_terseLabel_en-US" xlink:label="lab_us-gaap_StockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_StockOptionMember_label_en-US" xlink:label="lab_us-gaap_StockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockOptionMember" xlink:to="lab_us-gaap_StockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ServierMember_628f3f93-e9db-43e6-8fc3-e07bc92c57bc_terseLabel_en-US" xlink:label="lab_mgnx_ServierMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Servier</link:label>
    <link:label id="lab_mgnx_ServierMember_label_en-US" xlink:label="lab_mgnx_ServierMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Servier [Member]</link:label>
    <link:label id="lab_mgnx_ServierMember_documentation_en-US" xlink:label="lab_mgnx_ServierMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty in collaboration agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ServierMember" xlink:href="mgnx-20181231.xsd#mgnx_ServierMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ServierMember" xlink:to="lab_mgnx_ServierMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_261791d5-a57a-4752-b185-5d68cb66d077_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State taxes (net of federal benefit)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredRevenue_4ce6597a-2743-4ef7-83e5-bf666c9ba4bf_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_DeferredRevenue_label_en-US" xlink:label="lab_us-gaap_DeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenue" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenue" xlink:to="lab_us-gaap_DeferredRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_4a049015-d847-4caa-878e-33c8f7463ad5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_86087d7d-d69c-4594-83c0-84a0bfc3a20a_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increases for prior year tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_eff5f38e-0746-4f84-9527-f5ea9027b6e3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average grant-date fair value of options granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_a02dcba7-7c0c-4c4d-bcdb-6566f03f19f9_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_d71ee017-296f-4bf9-b68c-f667576761cc_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_e6118eb8-d5f9-4704-b848-194633e44a9e_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining contractual term, Outstanding</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_8dd1cf39-52e5-4c86-bca4-7472849196b4_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_108e2262-3e83-4bda-b49e-9ca37433348a_verboseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government-sponsored enterprises</link:label>
    <link:label id="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_b9f0849f-5e9e-4e7a-948e-50446d6047cf_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government-sponsored enterprises</link:label>
    <link:label id="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government-sponsored Enterprises Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_bb7b3ddd-9c84-4b91-8131-8772c57f5e20_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_c07162b2-797e-47e4-b089-eee5ace47b34_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</link:label>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_label_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_c4e9f127-1839-4734-9162-b3ef86a94c08_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options granted, maximum term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3d33c9e1-801d-43b3-b617-79bc7e372faa_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_a46fe373-d51d-45cd-9f58-84448c6faff2_terseLabel_en-US" xlink:label="lab_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Change Higher/(Lower)</link:label>
    <link:label id="lab_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_label_en-US" xlink:label="lab_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Difference between Revenue Guidance in Effect before and after Topic 606 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" xlink:to="lab_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_b4192715-4d5c-42a7-955a-be45756f203a_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares_5d0478af-fb6e-4d7b-86d1-8a38901eb0c2_terseLabel_en-US" xlink:label="lab_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock warrants (in shares)</link:label>
    <link:label id="lab_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares_label_en-US" xlink:label="lab_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement Consideration Received Common Stock Warrants Number Of Shares</link:label>
    <link:label id="lab_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares_documentation_en-US" xlink:label="lab_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement Consideration Received Common Stock Warrants Number Of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares" xlink:href="mgnx-20181231.xsd#mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares" xlink:to="lab_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_859206b7-c4bb-4c50-9a76-25b28cafea0f_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_5a174b39-0d5a-4663-9b44-6fa1ba6c00c6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock purchased by employees (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_1ff92494-5a60-45b4-b039-26ea2c976dbd_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive loss:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_RevenuesFromLicenseAgreementsMember_8d2e279c-69fe-47dc-96c8-6088e37ca54f_terseLabel_en-US" xlink:label="lab_mgnx_RevenuesFromLicenseAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues From License Agreements</link:label>
    <link:label id="lab_mgnx_RevenuesFromLicenseAgreementsMember_label_en-US" xlink:label="lab_mgnx_RevenuesFromLicenseAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues From License Agreements [Member]</link:label>
    <link:label id="lab_mgnx_RevenuesFromLicenseAgreementsMember_documentation_en-US" xlink:label="lab_mgnx_RevenuesFromLicenseAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues From License Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromLicenseAgreementsMember" xlink:href="mgnx-20181231.xsd#mgnx_RevenuesFromLicenseAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_RevenuesFromLicenseAgreementsMember" xlink:to="lab_mgnx_RevenuesFromLicenseAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_afec15aa-1eec-4243-bc4f-21d816dfea8c_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Deferred Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_7a30d487-abd7-4cfb-a6b9-cead9a2f6866_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_0d47b657-e0d4-492d-aeb9-22ac8c58de1d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Unobservable Inputs, Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock_388380bc-1fd6-4690-89c6-387ab956adcb_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Minimum Future Lease Payments</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Disclosure [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" xlink:to="lab_us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_b2c47470-e4fe-4645-846d-6320e025c9fe_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross deferred income tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_e4cf3825-2f2d-40bb-bb1e-dba960e61c33_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized loss on investments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_75503da4-6739-449c-b841-70b70dfa9122_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated useful lives</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_27dd7e82-d948-4708-8bf4-c9d22e0c8bf3_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_10649670-35ca-405f-b711-379a6f5dd01f_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_350e6880-cb06-42bd-a044-cc827a13c4e2_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RestatementDomain_33798676-d5d3-4b98-9ee3-4d8025fd8fa3_terseLabel_en-US" xlink:label="lab_srt_RestatementDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement [Domain]</link:label>
    <link:label id="lab_srt_RestatementDomain_label_en-US" xlink:label="lab_srt_RestatementDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RestatementDomain" xlink:to="lab_srt_RestatementDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_45cd26d2-da20-4526-8e21-d3dbe00e3ed2_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments Due</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_a4493357-7d51-4abb-99c1-388a47a877cf_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future minimum rental payments required under all non-cancelable operating leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_7af7ec02-ce3b-48b7-8b05-98c2ac21692d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company's Consolidated Quarterly Results of Operations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly Financial Information [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_e2887bf3-e89a-472c-8ac9-f45a7ee98b82_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Costs</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_3fa61b68-d26a-4653-ac41-2703d62fa894_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_dc44a5cd-9717-4183-b477-59ff52580226_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_a0cae8d1-5625-4a8d-b0c4-70d33faaf0bc_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_185069f4-606a-4273-bde2-d30da106aa25_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member_0c767ffa-33b0-40c5-befa-d3794110fb63_terseLabel_en-US" xlink:label="lab_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-Adoption</link:label>
    <link:label id="lab_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member_label_en-US" xlink:label="lab_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Calculated under Revenue Guidance in Effect before Topic 606 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member" xlink:to="lab_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredRentCredit_0e638128-1ff2-4dd0-895d-2a201ee38101_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRentCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred rent liability</link:label>
    <link:label id="lab_us-gaap_DeferredRentCredit_label_en-US" xlink:label="lab_us-gaap_DeferredRentCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Rent Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRentCredit" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredRentCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRentCredit" xlink:to="lab_us-gaap_DeferredRentCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleCarryingValueOfAsset_374d5a6a-d42a-42bf-b172-354bebdd5986_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleCarryingValueOfAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impaired assets</link:label>
    <link:label id="lab_us-gaap_ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleCarryingValueOfAsset_label_en-US" xlink:label="lab_us-gaap_ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleCarryingValueOfAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impaired Assets to be Disposed of by Method Other than Sale, Carrying Value of Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleCarryingValueOfAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleCarryingValueOfAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleCarryingValueOfAsset" xlink:to="lab_us-gaap_ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleCarryingValueOfAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_47e38576-7717-4fcd-9b87-96fe5035e489_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_5cccf78f-5238-4693-b7b0-f04822d92bfc_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis" xlink:to="lab_us-gaap_FairValueByAssetClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_0493259a-fb22-4c85-b170-10b7a87a99de_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_f7a7c794-fc86-4ca3-a3c9-9afc8b331f71_terseLabel_en-US" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Software</link:label>
    <link:label id="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_label_en-US" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Software and Software Development Costs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:to="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockMember_2adf66cb-7026-4e92-99e8-45683845c1ee_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockMember" xlink:to="lab_us-gaap_TreasuryStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan_a3d8cda5-6f3a-449e-b3e7-954119967d07_terseLabel_en-US" xlink:label="lab_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of common stock share outstanding</link:label>
    <link:label id="lab_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan_label_en-US" xlink:label="lab_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Shares Of Companys Common Stock Outstanding For Increase In Shares Reserved For Issuance Under Stock Plan</link:label>
    <link:label id="lab_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan_documentation_en-US" xlink:label="lab_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of shares of company's common stock outstanding for increase in shares reserved for issuance under stock plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan" xlink:href="mgnx-20181231.xsd#mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan" xlink:to="lab_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_80468397-5aea-44cb-8a39-53da9e6bd9b7_terseLabel_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Over-Allotment Option</link:label>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_label_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Over-Allotment Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OverAllotmentOptionMember" xlink:to="lab_us-gaap_OverAllotmentOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_9c192c02-e757-4214-a1e5-1c1ab2ee5561_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_8c572a97-de27-491b-8326-b8b02c666031_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increases for current year tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_OperatingLossCarryforwardsNotSubjectToLimitation_b1b725dd-c8b4-48e8-accb-bc7c7ad8ec4f_terseLabel_en-US" xlink:label="lab_mgnx_OperatingLossCarryforwardsNotSubjectToLimitation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining portion of net operating losses</link:label>
    <link:label id="lab_mgnx_OperatingLossCarryforwardsNotSubjectToLimitation_label_en-US" xlink:label="lab_mgnx_OperatingLossCarryforwardsNotSubjectToLimitation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards Not Subject To Limitation</link:label>
    <link:label id="lab_mgnx_OperatingLossCarryforwardsNotSubjectToLimitation_documentation_en-US" xlink:label="lab_mgnx_OperatingLossCarryforwardsNotSubjectToLimitation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss carryforwards not subject to limitation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_OperatingLossCarryforwardsNotSubjectToLimitation" xlink:href="mgnx-20181231.xsd#mgnx_OperatingLossCarryforwardsNotSubjectToLimitation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_OperatingLossCarryforwardsNotSubjectToLimitation" xlink:to="lab_mgnx_OperatingLossCarryforwardsNotSubjectToLimitation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredRevenueNoncurrent_f0255a30-0ec9-49dc-8902-fe61563ac1dc_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, net of current portion</link:label>
    <link:label id="lab_us-gaap_DeferredRevenueNoncurrent_1fef0398-3483-4dc1-84b6-4ab55aa4d804_netLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueNoncurrent" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, net of current portion</link:label>
    <link:label id="lab_us-gaap_DeferredRevenueNoncurrent_5a88cc23-c161-4d79-923f-a67c54d4c07c_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue included in long-term liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredRevenueNoncurrent_label_en-US" xlink:label="lab_us-gaap_DeferredRevenueNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredRevenueNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueNoncurrent" xlink:to="lab_us-gaap_DeferredRevenueNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_a45f95d4-c540-417a-899d-98cd7cb3f2ca_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_8f8f6086-9e24-4f3d-bc22-d3135fd49844_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_265d4c7b-df75-40f8-9279-e2c5df4cae8d_terseLabel_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Percentage of Customer Concentration</link:label>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_label_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedules of Concentration of Risk, by Risk Factor [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:to="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ProventionBioMember_cf8b5e18-4b96-4562-a8a9-ff94e7630d36_terseLabel_en-US" xlink:label="lab_mgnx_ProventionBioMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provention Bio, Inc. (Provention)</link:label>
    <link:label id="lab_mgnx_ProventionBioMember_label_en-US" xlink:label="lab_mgnx_ProventionBioMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provention Bio [Member]</link:label>
    <link:label id="lab_mgnx_ProventionBioMember_documentation_en-US" xlink:label="lab_mgnx_ProventionBioMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provention Bio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionBioMember" xlink:href="mgnx-20181231.xsd#mgnx_ProventionBioMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ProventionBioMember" xlink:to="lab_mgnx_ProventionBioMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_0112fc06-cdab-4ff5-b9d6-5c95f55058cd_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_b612c20e-780a-4d6e-931c-1707ea368026_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic and diluted weighted average number of common shares</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_fac04a15-2920-4aa9-be8e-a27576254b76_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_8bd6ec29-2f77-47c1-a911-5822675013d7_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_3ec40617-d404-4cdd-89d8-cc8cbbc4751d_negatedLabel_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Adjustment of Warrants</link:label>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_label_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Adjustment of Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAdjustmentOfWarrants" xlink:to="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_54b4bcbe-0ece-4122-8a1c-d4c3dd465c00_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of the Company's Deferred Income Tax Assets (Liabilities)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockRetiredParValueMethodAmount_c184b460-54f9-4e53-8004-554cedc84ee2_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockRetiredParValueMethodAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement of treasury stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockRetiredParValueMethodAmount_label_en-US" xlink:label="lab_us-gaap_TreasuryStockRetiredParValueMethodAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Retired, Par Value Method, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockRetiredParValueMethodAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TreasuryStockRetiredParValueMethodAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockRetiredParValueMethodAmount" xlink:to="lab_us-gaap_TreasuryStockRetiredParValueMethodAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_d143e4a4-70e7-4e8e-9cdf-3dcb78669599_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_9ddd2e74-6198-460b-9644-e9edd1582dd5_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_12039dad-0c5a-470e-b76a-99b5b29ded87_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Adoption [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_label_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Adoption [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfAdoptionMember" xlink:to="lab_us-gaap_TypeOfAdoptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock_135e869a-8517-4480-8b4c-6987e40a9718_terseLabel_en-US" xlink:label="lab_mgnx_ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock Option and Restricted Stock Unit Activity</link:label>
    <link:label id="lab_mgnx_ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_mgnx_ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Share Based Compensation Stock Options And Restricted Stock Units Activity Table [Text Block]</link:label>
    <link:label id="lab_mgnx_ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock_documentation_en-US" xlink:label="lab_mgnx_ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Share Based Compensation Stock Options And Restricted Stock Units Activity Table [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock" xlink:href="mgnx-20181231.xsd#mgnx_ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_mgnx_ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_10ccc476-5544-420e-b664-a9fe9c50c34f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decreases for prior year tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_190460ac-9762-4199-ac69-8f3ef0080220_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Debt Securities, Available-for-sale, Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesTextBlock_ea8899c5-b451-4ce2-ae63-9dede02a88b3_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-For-Sale Securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesTextBlock_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_13b528d9-4648-488c-ae66-febc0cd52abc_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_c7fd76cc-1986-467f-9c0e-b47deccfe4dc_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State net operating loss carryforward</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, State and Local</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_da459a0f-304b-4652-81c9-1939283d8cc1_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Marketable Securities</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_bc8b3bb5-09a0-4c82-9384-330790f714d6_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred rent</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Deferred Rent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases_e1f3b65a-649b-4080-8112-4535690c3c49_terseLabel_en-US" xlink:label="lab_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from stock option exercises and ESPP purchases</link:label>
    <link:label id="lab_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases_label_en-US" xlink:label="lab_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised And ESPP Purchases</link:label>
    <link:label id="lab_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases_documentation_en-US" xlink:label="lab_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised And ESPP Purchases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases" xlink:href="mgnx-20181231.xsd#mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases" xlink:to="lab_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_2cc86686-5093-4ffa-b905-3fe6545c3ca2_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_866d7228-6c1a-43ce-8478-afce6af62457_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_d6e4fc47-8574-4386-b1ff-f0f024db8acf_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesRentExpenseNet_c0d58748-8bbe-4506-92db-d2e2cbc273f2_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesRentExpenseNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rent expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesRentExpenseNet_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesRentExpenseNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Rent Expense, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseNet" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesRentExpenseNet" xlink:to="lab_us-gaap_OperatingLeasesRentExpenseNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssets_5fbf6991-73c1-493d-bab5-288d4169d591_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssets_label_en-US" xlink:label="lab_us-gaap_OtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssets" xlink:to="lab_us-gaap_OtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_7e943d76-6558-4ae2-b3d1-3c1babb2d580_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_FurnitureAndOfficeEquipmentMember_31a09ced-11ee-4e76-ba7d-58af0298cf04_terseLabel_en-US" xlink:label="lab_mgnx_FurnitureAndOfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and office equipment</link:label>
    <link:label id="lab_mgnx_FurnitureAndOfficeEquipmentMember_label_en-US" xlink:label="lab_mgnx_FurnitureAndOfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture And Office Equipment [Member]</link:label>
    <link:label id="lab_mgnx_FurnitureAndOfficeEquipmentMember_documentation_en-US" xlink:label="lab_mgnx_FurnitureAndOfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and office equipment are movable furniture, fixtures, or other equipment that have no permanent connection to the structure of a building or utilities. These items depreciate substantially but definitely are important costs to consider when valuing a company, especially in liquidation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_FurnitureAndOfficeEquipmentMember" xlink:href="mgnx-20181231.xsd#mgnx_FurnitureAndOfficeEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_FurnitureAndOfficeEquipmentMember" xlink:to="lab_mgnx_FurnitureAndOfficeEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_b1a96f6d-11bb-408e-ac88-e5dd05db809b_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_84a04cbe-5ac8-4de3-a4f0-1ce680f1021d_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_f504799e-22c5-4d3c-b1b9-ec032c7bac1f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3646c103-77be-4b41-a0df-89cddf8d350c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_eb27d313-6343-4ec0-8d3d-57c855560f2e_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, equipment and software</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_2e23f7ee-987e-479d-815f-e9e9abd3a508_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_e01df26a-1226-4080-805f-74ffa352aff5_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity-based compensation</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Compensation Cost, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1732186a-4cda-4223-8dad-a043a45bde8d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_ffd48b76-6553-4d5d-884f-c4a1fdf49e9d_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</link:label>
    <link:label id="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_label_en-US" xlink:label="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:to="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities_9545dbaf-99be-4e89-896e-1043e68080be_terseLabel_en-US" xlink:label="lab_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale securities, other than temporary impairment losses</link:label>
    <link:label id="lab_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities_label_en-US" xlink:label="lab_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other than Temporary Impairment Losses, Investments, Available-for-sale Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities" xlink:to="lab_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_23773a96-5968-4323-a26a-0205bec73f79_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_LesLaboratoiresServierAndInstitutDeRecherchesServierServierMember_0ad4f411-5181-41f5-b32e-755cf5661631_terseLabel_en-US" xlink:label="lab_mgnx_LesLaboratoiresServierAndInstitutDeRecherchesServierServierMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Les Laboratoires Servier and Institut de Recherches Servier (Servier)</link:label>
    <link:label id="lab_mgnx_LesLaboratoiresServierAndInstitutDeRecherchesServierServierMember_label_en-US" xlink:label="lab_mgnx_LesLaboratoiresServierAndInstitutDeRecherchesServierServierMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Les Laboratoires Servier And Institut De Recherches Servier (Servier) [Member]</link:label>
    <link:label id="lab_mgnx_LesLaboratoiresServierAndInstitutDeRecherchesServierServierMember_documentation_en-US" xlink:label="lab_mgnx_LesLaboratoiresServierAndInstitutDeRecherchesServierServierMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Les Laboratoires Servier And Institut De Recherches Servier (Servier)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_LesLaboratoiresServierAndInstitutDeRecherchesServierServierMember" xlink:href="mgnx-20181231.xsd#mgnx_LesLaboratoiresServierAndInstitutDeRecherchesServierServierMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_LesLaboratoiresServierAndInstitutDeRecherchesServierServierMember" xlink:to="lab_mgnx_LesLaboratoiresServierAndInstitutDeRecherchesServierServierMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther_f89bac75-5bc7-4562-94fc-7976f6dfb3d0_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Orphan drug credit, net</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount_84ea321e-ecf0-4146-8b32-0e9d0ecf20ca_terseLabel_en-US" xlink:label="lab_mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income tax adjustments</link:label>
    <link:label id="lab_mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount_label_en-US" xlink:label="lab_mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Deferred Tax Adjustments, Amount</link:label>
    <link:label id="lab_mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount_documentation_en-US" xlink:label="lab_mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to deferred tax adjustments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount" xlink:href="mgnx-20181231.xsd#mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount" xlink:to="lab_mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_d32536e7-409e-4ae1-933f-fc35ab1481f1_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_2b44d7de-47c2-4b9a-83ba-575666bba2cc_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_249e8f24-1e78-446f-b8a9-c764d4413f07_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementMember_56c19514-1bb3-4e5c-b9a1-040ffc4859e3_terseLabel_en-US" xlink:label="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Lab Agreement</link:label>
    <link:label id="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementMember_label_en-US" xlink:label="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Labs Collaboration And License Agreement [Member]</link:label>
    <link:label id="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementMember_documentation_en-US" xlink:label="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Labs Collaboration And License Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabsCollaborationAndLicenseAgreementMember" xlink:href="mgnx-20181231.xsd#mgnx_ZaiLabsCollaborationAndLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ZaiLabsCollaborationAndLicenseAgreementMember" xlink:to="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_ac0d8091-b3c2-40ba-b4d6-30f926f70271_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_7057d9e7-5292-4459-bc53-ab457c98f126_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_37ed97c7-749e-4e00-b465-97740fd06ec0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_573afaef-4516-4f1a-8492-136b99c2ea75_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds of stock sale</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_4e85d0f0-bf69-4ae0-ac1a-42e2e207ff02_verboseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds of stock sale</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ServierDARTMember_aafdb818-2c14-4eb8-898b-c6c0f65a79b9_terseLabel_en-US" xlink:label="lab_mgnx_ServierDARTMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Servier DART</link:label>
    <link:label id="lab_mgnx_ServierDARTMember_label_en-US" xlink:label="lab_mgnx_ServierDARTMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Servier DART [Member]</link:label>
    <link:label id="lab_mgnx_ServierDARTMember_documentation_en-US" xlink:label="lab_mgnx_ServierDARTMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents agreement with Servier for DARTs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ServierDARTMember" xlink:href="mgnx-20181231.xsd#mgnx_ServierDARTMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ServierDARTMember" xlink:to="lab_mgnx_ServierDARTMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_d9ae3c73-dad8-4ea3-a4ab-b2527ddf2ced_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_7c8f26f7-efc6-4d53-97bd-345005265676_terseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain on investments</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Loss) on Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:to="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_551302fa-338f-466d-907b-e15107f90eb3_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement_fe6eb4ba-6003-432e-bb83-552423e07879_terseLabel_en-US" xlink:label="lab_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential milestone payment to third parties for intellectual property under agreement</link:label>
    <link:label id="lab_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement_label_en-US" xlink:label="lab_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Milestone Payment To Third Parties For Intellectual Property Under Agreement</link:label>
    <link:label id="lab_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement_documentation_en-US" xlink:label="lab_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Milestone Payment To Third Parties For Intellectual Property Under Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement" xlink:href="mgnx-20181231.xsd#mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement" xlink:to="lab_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_8d12e960-9c1f-485c-b94a-c9923fc70f2f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quoted Prices in Active Markets for Identical Assets, Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b01d89f3-2cfa-4ac6-a9ee-a14041318dd5_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_30bb3241-1259-4388-b2ef-fa0c5651990e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Reported Estimated Income Tax Benefit</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_ba5bbaa9-52db-43bc-bebf-e2d97628c13d_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_81f7516e-c861-4858-adb8-3f67516e1fa5_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressGross_a6252b78-218e-45d6-82f6-9b9134e5a16e_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressGross_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressGross" xlink:to="lab_us-gaap_ConstructionInProgressGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_58e6327a-abb3-4d25-91d6-328ea7e21e46_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized interest or penalties</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_fba42250-6314-4d24-8913-9527126d5c39_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of common stock (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease_b3f633a7-c471-4b9e-a2ff-389c2626a143_terseLabel_en-US" xlink:label="lab_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increased number of shares authorized (in shares)</link:label>
    <link:label id="lab_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease_label_en-US" xlink:label="lab_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized After Increase</link:label>
    <link:label id="lab_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease_documentation_en-US" xlink:label="lab_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation arrangement by share based payment award number of shares authorized after increase.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease" xlink:href="mgnx-20181231.xsd#mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease" xlink:to="lab_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_6642e5fd-28e0-4cc3-bea8-655ecbbd52a7_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ServierAgreementMGD007OptionMember_faf8d06a-3746-49f0-9876-e58095386bf1_terseLabel_en-US" xlink:label="lab_mgnx_ServierAgreementMGD007OptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Servier Agreement - MGD007 Option</link:label>
    <link:label id="lab_mgnx_ServierAgreementMGD007OptionMember_label_en-US" xlink:label="lab_mgnx_ServierAgreementMGD007OptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Servier Agreement - MGD007 Option [Member]</link:label>
    <link:label id="lab_mgnx_ServierAgreementMGD007OptionMember_documentation_en-US" xlink:label="lab_mgnx_ServierAgreementMGD007OptionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Servier Agreement - MGD007 Option</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ServierAgreementMGD007OptionMember" xlink:href="mgnx-20181231.xsd#mgnx_ServierAgreementMGD007OptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ServierAgreementMGD007OptionMember" xlink:to="lab_mgnx_ServierAgreementMGD007OptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_RevenueFromCollaborativeAgreementsMember_4d49b63f-bf93-4592-96dc-28863ff1e9c1_terseLabel_en-US" xlink:label="lab_mgnx_RevenueFromCollaborativeAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from collaborative agreements</link:label>
    <link:label id="lab_mgnx_RevenueFromCollaborativeAgreementsMember_label_en-US" xlink:label="lab_mgnx_RevenueFromCollaborativeAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Collaborative Agreements [Member]</link:label>
    <link:label id="lab_mgnx_RevenueFromCollaborativeAgreementsMember_documentation_en-US" xlink:label="lab_mgnx_RevenueFromCollaborativeAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Collaborative Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueFromCollaborativeAgreementsMember" xlink:href="mgnx-20181231.xsd#mgnx_RevenueFromCollaborativeAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_RevenueFromCollaborativeAgreementsMember" xlink:to="lab_mgnx_RevenueFromCollaborativeAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_b08e92ff-ddcc-4757-889b-f5ca8cf762a3_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development credit, net</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ec571faf-f8eb-47b3-9381-d6c9030d682e_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and Other Agreements [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_e3a9772f-b843-4841-93f6-a37dd5e47b23_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_42f23d62-0f9f-4919-8248-130be8642eaa_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation arrangement by share-based payment award, options, outstanding, number (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8b52ff6c-179b-4648-9da3-0bc401ae908b_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 31, 2016</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_be991925-b3ca-4488-ab5e-363ddc528c52_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 31, 2017</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ProventionPRV3279Member_9476c5f7-348d-4d1f-8ac2-8958acedb421_terseLabel_en-US" xlink:label="lab_mgnx_ProventionPRV3279Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provention PRV3279</link:label>
    <link:label id="lab_mgnx_ProventionPRV3279Member_label_en-US" xlink:label="lab_mgnx_ProventionPRV3279Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provention PRV3279 [Member]</link:label>
    <link:label id="lab_mgnx_ProventionPRV3279Member_documentation_en-US" xlink:label="lab_mgnx_ProventionPRV3279Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provention PRV3279</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionPRV3279Member" xlink:href="mgnx-20181231.xsd#mgnx_ProventionPRV3279Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ProventionPRV3279Member" xlink:to="lab_mgnx_ProventionPRV3279Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_16310881-848e-4b0c-b9ed-4c9720dd105d_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_0e0054c0-3e94-45e2-a1c9-eb2857a224aa_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_OptionExerciseFee_6349bb3b-f7a3-405e-af61-27c35cd24b68_terseLabel_en-US" xlink:label="lab_mgnx_OptionExerciseFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option exercise fee</link:label>
    <link:label id="lab_mgnx_OptionExerciseFee_label_en-US" xlink:label="lab_mgnx_OptionExerciseFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option Exercise Fee</link:label>
    <link:label id="lab_mgnx_OptionExerciseFee_documentation_en-US" xlink:label="lab_mgnx_OptionExerciseFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment from collaborator upon exercise of option to develop and commercialize product.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_OptionExerciseFee" xlink:href="mgnx-20181231.xsd#mgnx_OptionExerciseFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_OptionExerciseFee" xlink:to="lab_mgnx_OptionExerciseFee" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_MilestonePayment_11339f3f-5806-4e55-885e-9cf40d7f1362_terseLabel_en-US" xlink:label="lab_mgnx_MilestonePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payment removed</link:label>
    <link:label id="lab_mgnx_MilestonePayment_label_en-US" xlink:label="lab_mgnx_MilestonePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment</link:label>
    <link:label id="lab_mgnx_MilestonePayment_documentation_en-US" xlink:label="lab_mgnx_MilestonePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_MilestonePayment" xlink:href="mgnx-20181231.xsd#mgnx_MilestonePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_MilestonePayment" xlink:to="lab_mgnx_MilestonePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_RevenueFromGovernmentAgreementsMember_0987312f-0938-4bf5-bec5-e9cedec39de9_terseLabel_en-US" xlink:label="lab_mgnx_RevenueFromGovernmentAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from government agreements</link:label>
    <link:label id="lab_mgnx_RevenueFromGovernmentAgreementsMember_label_en-US" xlink:label="lab_mgnx_RevenueFromGovernmentAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Government Agreements [Member]</link:label>
    <link:label id="lab_mgnx_RevenueFromGovernmentAgreementsMember_documentation_en-US" xlink:label="lab_mgnx_RevenueFromGovernmentAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Government Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueFromGovernmentAgreementsMember" xlink:href="mgnx-20181231.xsd#mgnx_RevenueFromGovernmentAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_RevenueFromGovernmentAgreementsMember" xlink:to="lab_mgnx_RevenueFromGovernmentAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_9c0f631e-083a-4d4b-b0e4-9f72ced5958d_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation expense recognition period</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_3fa214ab-d0a7-4a91-a332-21bc7dff0e4e_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance recorded</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for Doubtful Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_b8a6796d-5743-4438-95f4-4d49267a376c_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share, basic and diluted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member_5c2993e5-27da-4c18-a4a7-cca37ff9c927_terseLabel_en-US" xlink:label="lab_mgnx_F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (Roche)</link:label>
    <link:label id="lab_mgnx_F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member_48ca595e-b9d4-4883-acde-5e13a5c7b6eb_verboseLabel_en-US" xlink:label="lab_mgnx_F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Roche</link:label>
    <link:label id="lab_mgnx_F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member_label_en-US" xlink:label="lab_mgnx_F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. [Member]</link:label>
    <link:label id="lab_mgnx_F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member_documentation_en-US" xlink:label="lab_mgnx_F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member" xlink:href="mgnx-20181231.xsd#mgnx_F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member" xlink:to="lab_mgnx_F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_0bd0886a-bb49-43bd-8c52-1895882aad71_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined contribution plan, employer discretionary contribution amount</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Employer Discretionary Contribution Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_7da29ab1-517c-45fd-8bcc-210d9349f73c_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sales and maturities of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_d8a6e3a3-b397-4990-94ea-7c292ed68079_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_8505fc95-d2d2-485b-8d71-fe4b3b70c495_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining contractual term, Vested and expected to vest</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c1f9ec04-7e07-44ce-b0ab-a8a792e034da_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_16293f69-a425-423e-9500-a10c622c26f7_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets measured at fair value</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_10b06fc8-5b1c-4fce-b8bf-e99ce068c09b_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock, net of offering costs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement_76a7cf7e-ac34-412f-8e97-25a6fe4aa72e_terseLabel_en-US" xlink:label="lab_mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional development funding options</link:label>
    <link:label id="lab_mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement_label_en-US" xlink:label="lab_mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional development funding options under agreement</link:label>
    <link:label id="lab_mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement_documentation_en-US" xlink:label="lab_mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional funding available under agreement at counterparty's option</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement" xlink:href="mgnx-20181231.xsd#mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement" xlink:to="lab_mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ProventionLicenseAgreementMember_5eeeb490-23e5-4240-a34d-d83e19824f21_terseLabel_en-US" xlink:label="lab_mgnx_ProventionLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provention License Agreement</link:label>
    <link:label id="lab_mgnx_ProventionLicenseAgreementMember_label_en-US" xlink:label="lab_mgnx_ProventionLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provention License Agreement [Member]</link:label>
    <link:label id="lab_mgnx_ProventionLicenseAgreementMember_documentation_en-US" xlink:label="lab_mgnx_ProventionLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provention License Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionLicenseAgreementMember" xlink:href="mgnx-20181231.xsd#mgnx_ProventionLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ProventionLicenseAgreementMember" xlink:to="lab_mgnx_ProventionLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_IncreaseDecreaseInDeferredRent_2376574f-5757-4da4-b075-3b8b3d118b7e_terseLabel_en-US" xlink:label="lab_mgnx_IncreaseDecreaseInDeferredRent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred rent</link:label>
    <link:label id="lab_mgnx_IncreaseDecreaseInDeferredRent_label_en-US" xlink:label="lab_mgnx_IncreaseDecreaseInDeferredRent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Deferred Rent</link:label>
    <link:label id="lab_mgnx_IncreaseDecreaseInDeferredRent_documentation_en-US" xlink:label="lab_mgnx_IncreaseDecreaseInDeferredRent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The increase (decrease) during the reporting period in deferred rent.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncreaseDecreaseInDeferredRent" xlink:href="mgnx-20181231.xsd#mgnx_IncreaseDecreaseInDeferredRent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_IncreaseDecreaseInDeferredRent" xlink:to="lab_mgnx_IncreaseDecreaseInDeferredRent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_76e8fc9c-177e-4e11-ac99-4aa4f6c36ba2_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_720fa70e-66a2-4c95-b906-9a23490b79da_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Previously unrecognized excess tax benefits</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Share-based Compensation, Excess Tax Benefit, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_a5c360af-c7dc-41ab-a1ff-b95613bb6276_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Initial Application Period Cumulative Effect Transition [Table]</link:label>
    <link:label id="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_label_en-US" xlink:label="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Initial Application Period Cumulative Effect Transition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:to="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExaminationTable_199d5413-a3f9-4eed-a7db-c21dd8a1bf61_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Examination [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExaminationTable_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Examination [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationTable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExaminationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExaminationTable" xlink:to="lab_us-gaap_IncomeTaxExaminationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_0cfccea9-60da-4a2a-ac33-27ffd1495e44_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_e5e42ee7-75d6-4212-a6a2-a83f33efe34d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_884e67bb-5966-458f-850d-b61469bb2bb7_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_600d7de0-b5aa-4a61-9a26-44c86265de46_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_c788d204-590b-4435-a3b4-6a21ec201818_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Three Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_37981cd5-309f-43cd-9e9e-e7c1baa8ba6f_verboseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S Treasury securities</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_971938bd-a6ab-4ad2-a8dc-27475ac9debd_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Treasury securities</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember" xlink:to="lab_us-gaap_USTreasurySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_5a59f439-b13b-47e1-b74c-494044afc281_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) per share, basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCreditsOther_afd70084-cb72-4781-a553-0bbcf65e8ff8_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsOther" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Orphan drug credit, net</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCreditsOther_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Other, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsOther" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxCreditsOther" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxCreditsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_8b5a8ec6-6616-411a-947a-276dde7469b3_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:to="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_8fdee18c-a46a-498b-a67d-900bf64a1da9_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly Financial Information Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_c6a59d7b-413d-4b4f-bad2-99be727ceea5_periodStartLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_17c2dd51-b90f-41b2-9093-9d988236c7e1_periodEndLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_e5eb6edc-574c-4a1f-9e13-6e096fd47941_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement_b4aa6d8c-18ee-4129-a6ca-4ee881860d79_terseLabel_en-US" xlink:label="lab_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercialization of molecules</link:label>
    <link:label id="lab_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement_label_en-US" xlink:label="lab_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Molecules To Be Developed And Commercialized Under Agreement</link:label>
    <link:label id="lab_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement_documentation_en-US" xlink:label="lab_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of molecules to be developed and commercialized as per collaboration.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement" xlink:href="mgnx-20181231.xsd#mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement" xlink:to="lab_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_906c31c1-3a88-4382-b1eb-2ef95dd98b89_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal U.S. net operating loss carryforward</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Domestic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_edc676ad-3c77-422c-9195-f38215c5cdb4_terseLabel_en-US" xlink:label="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative effect of adoption of accounting standards</link:label>
    <link:label id="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_label_en-US" xlink:label="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect of New Accounting Principle in Period of Adoption</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:to="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredRentCreditCurrent_63088b06-87bb-4391-b942-309f7a3e90bb_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRentCreditCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred rent</link:label>
    <link:label id="lab_us-gaap_DeferredRentCreditCurrent_label_en-US" xlink:label="lab_us-gaap_DeferredRentCreditCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Rent Credit, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRentCreditCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredRentCreditCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRentCreditCurrent" xlink:to="lab_us-gaap_DeferredRentCreditCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_UndesignatedPreferredStockMember_7a977e77-8c80-441d-bc7c-dbc42b9974ec_terseLabel_en-US" xlink:label="lab_mgnx_UndesignatedPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Undesignated Preferred Stock</link:label>
    <link:label id="lab_mgnx_UndesignatedPreferredStockMember_label_en-US" xlink:label="lab_mgnx_UndesignatedPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Undesignated Preferred Stock [Member]</link:label>
    <link:label id="lab_mgnx_UndesignatedPreferredStockMember_documentation_en-US" xlink:label="lab_mgnx_UndesignatedPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Undesignated Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_UndesignatedPreferredStockMember" xlink:href="mgnx-20181231.xsd#mgnx_UndesignatedPreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_UndesignatedPreferredStockMember" xlink:to="lab_mgnx_UndesignatedPreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals_3ad6b081-e67e-4d31-b510-e15d27d15bb1_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future sublease payments to be received</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments Due, Future Minimum Sublease Rentals</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201409Member_71558ab3-293c-4995-8269-dadd18f3667c_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201409Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2014-09</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201409Member_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201409Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2014-09 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201409Member" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201409Member" xlink:to="lab_us-gaap_AccountingStandardsUpdate201409Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_e6368f8d-f365-44d5-b3da-40ebbce916be_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.01 par value -- 125,000,000 shares authorized, 42,353,301 and 36,859,077 shares outstanding at December 31, 2018 and December 31, 2017, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_01459a1d-c5a4-4388-afde-aa7c45a329ba_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_377031f7-3510-4e1f-9743-7198f1e1edd9_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred income tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_7c80efbc-c16d-4809-8898-b7d2edce67d1_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_AssetPurchaseAgreementMember_61759a3b-ea7e-4df2-8297-a0aa34eda333_terseLabel_en-US" xlink:label="lab_mgnx_AssetPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Purchase Agreement</link:label>
    <link:label id="lab_mgnx_AssetPurchaseAgreementMember_label_en-US" xlink:label="lab_mgnx_AssetPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Purchase Agreement [Member]</link:label>
    <link:label id="lab_mgnx_AssetPurchaseAgreementMember_documentation_en-US" xlink:label="lab_mgnx_AssetPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_AssetPurchaseAgreementMember" xlink:href="mgnx-20181231.xsd#mgnx_AssetPurchaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_AssetPurchaseAgreementMember" xlink:to="lab_mgnx_AssetPurchaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_28a07ab8-eb24-4d7a-9ec2-21d5b8600f89_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_JanssenBiotechIncMember_ce3349f5-9a42-4fad-ab2c-11d1e02d0e07_verboseLabel_en-US" xlink:label="lab_mgnx_JanssenBiotechIncMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen Biotech, Inc. (Janssen)</link:label>
    <link:label id="lab_mgnx_JanssenBiotechIncMember_f23346aa-8dd7-41cc-9609-464a3463f805_terseLabel_en-US" xlink:label="lab_mgnx_JanssenBiotechIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen Biotech Inc.</link:label>
    <link:label id="lab_mgnx_JanssenBiotechIncMember_label_en-US" xlink:label="lab_mgnx_JanssenBiotechIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen Biotech Inc [Member]</link:label>
    <link:label id="lab_mgnx_JanssenBiotechIncMember_documentation_en-US" xlink:label="lab_mgnx_JanssenBiotechIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty in collaboration agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_JanssenBiotechIncMember" xlink:href="mgnx-20181231.xsd#mgnx_JanssenBiotechIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_JanssenBiotechIncMember" xlink:to="lab_mgnx_JanssenBiotechIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_f4160549-7219-4965-8af9-b1cba8ae99bc_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RestatementAxis_a788c47a-8384-4600-848b-298b6bf0fc4e_terseLabel_en-US" xlink:label="lab_srt_RestatementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement [Axis]</link:label>
    <link:label id="lab_srt_RestatementAxis_label_en-US" xlink:label="lab_srt_RestatementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RestatementAxis" xlink:to="lab_srt_RestatementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_RegisteredDirectOfferingMember_216a2487-097e-4e7a-9837-6a57173ca1cf_terseLabel_en-US" xlink:label="lab_mgnx_RegisteredDirectOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Registered Direct Offering</link:label>
    <link:label id="lab_mgnx_RegisteredDirectOfferingMember_label_en-US" xlink:label="lab_mgnx_RegisteredDirectOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Registered Direct Offering [Member]</link:label>
    <link:label id="lab_mgnx_RegisteredDirectOfferingMember_documentation_en-US" xlink:label="lab_mgnx_RegisteredDirectOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Registered Direct Offering [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RegisteredDirectOfferingMember" xlink:href="mgnx-20181231.xsd#mgnx_RegisteredDirectOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_RegisteredDirectOfferingMember" xlink:to="lab_mgnx_RegisteredDirectOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredRevenueCurrent_e26875d5-a9c8-427d-865a-35b209492e52_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_DeferredRevenueCurrent_0cd9d021-18ef-4f96-976f-fc4c51ec05b0_netLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueCurrent" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, current</link:label>
    <link:label id="lab_us-gaap_DeferredRevenueCurrent_20dbb4ca-e5ba-490b-8464-4f20413ac887_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue included in current liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredRevenueCurrent_label_en-US" xlink:label="lab_us-gaap_DeferredRevenueCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredRevenueCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueCurrent" xlink:to="lab_us-gaap_DeferredRevenueCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_5d24c473-9b98-4016-92e9-2fdee38c2f5c_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_02919a72-feb1-43e4-a18e-c87f3e29be91_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_cf05fd48-c117-4128-a1dd-7f3df8de5892_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_f7b87f73-fc52-49b0-89b8-a023d3385163_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_AtTheMarketOfferingMember_f56f4acd-23f7-49f1-a511-7a34c4060299_terseLabel_en-US" xlink:label="lab_mgnx_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At The Market Offering</link:label>
    <link:label id="lab_mgnx_AtTheMarketOfferingMember_label_en-US" xlink:label="lab_mgnx_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At The Market Offering [Member]</link:label>
    <link:label id="lab_mgnx_AtTheMarketOfferingMember_documentation_en-US" xlink:label="lab_mgnx_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At The Market Offering [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_AtTheMarketOfferingMember" xlink:href="mgnx-20181231.xsd#mgnx_AtTheMarketOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_AtTheMarketOfferingMember" xlink:to="lab_mgnx_AtTheMarketOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_2867c0ea-f3bf-431b-a61a-4563622b4853_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_46865bb8-e6b7-4804-99ed-106de576cf15_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_a416c8ca-2a52-4504-9e55-2c8b56052ede_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_b142cc14-f878-431e-967f-94705f92705d_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining contractual term, Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_7696f6af-85fe-4537-a83a-31e706113753_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_EquityIncentivePlan2003Member_0485f705-1e70-48c9-956f-26b493c992b8_terseLabel_en-US" xlink:label="lab_mgnx_EquityIncentivePlan2003Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Incentive Plan 2003</link:label>
    <link:label id="lab_mgnx_EquityIncentivePlan2003Member_label_en-US" xlink:label="lab_mgnx_EquityIncentivePlan2003Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Incentive Plan 2003 [Member]</link:label>
    <link:label id="lab_mgnx_EquityIncentivePlan2003Member_documentation_en-US" xlink:label="lab_mgnx_EquityIncentivePlan2003Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Incentive Plan 2003</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_EquityIncentivePlan2003Member" xlink:href="mgnx-20181231.xsd#mgnx_EquityIncentivePlan2003Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_EquityIncentivePlan2003Member" xlink:to="lab_mgnx_EquityIncentivePlan2003Member" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent_6b4fb179-b479-4829-b50f-8559ea61a691_terseLabel_en-US" xlink:label="lab_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock discount percent</link:label>
    <link:label id="lab_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent_label_en-US" xlink:label="lab_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan, Maximum Annual Contributions Per Employee, Percent</link:label>
    <link:label id="lab_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent_documentation_en-US" xlink:label="lab_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan, Maximum Annual Contributions Per Employee, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" xlink:href="mgnx-20181231.xsd#mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" xlink:to="lab_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_e40df529-e84e-4bb5-87ae-ac044d2b7f0e_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_4802dff7-64dd-47bb-9040-65719019b4e6_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_936082bd-7c50-4795-b525-7a6b49ae6fe5_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxPeriodDomain_952467fc-aa9c-4f2d-8f7e-791710bf0987_terseLabel_en-US" xlink:label="lab_us-gaap_TaxPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxPeriodDomain_label_en-US" xlink:label="lab_us-gaap_TaxPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxPeriodDomain" xlink:to="lab_us-gaap_TaxPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_018b72da-4094-4223-908f-7dd056c5fcbc_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total costs and expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_b404fc68-2386-4467-beb7-38b33a4c15e0_verboseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_258efd9a-e919-4d56-bf91-59ae68469bca_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_7ab3b817-fe66-4a8e-9577-83ee186655ca_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_7f2e6041-020c-45c2-8d47-c752b59f6904_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense/(benefit)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquipmentMember_15d1a52a-ef4f-45e4-83b8-285eed6b8ccc_terseLabel_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lab equipment</link:label>
    <link:label id="lab_us-gaap_EquipmentMember_label_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquipmentMember" xlink:to="lab_us-gaap_EquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_6340b994-f594-4f46-9b1c-3b71402f39cb_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_78b862b8-931f-4891-952b-ffc98a33c89b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_7bee3f45-14ea-44f1-b164-89c83324414b_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_f82fe4a8-cacb-4042-aa83-1bdcec53ecf9_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, noncurrent</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_607082e1-dd29-4cc8-8e09-c029b098e5bd_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_bdc79cb3-ce87-4308-a13f-3ac5b0ac9739_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income tax liabilities:</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Deferred Tax Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ZaiLabLimitedMember_98d98fc3-dad3-4b53-aa61-0c582395341c_terseLabel_en-US" xlink:label="lab_mgnx_ZaiLabLimitedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Lab Limited (Zai Lab)</link:label>
    <link:label id="lab_mgnx_ZaiLabLimitedMember_label_en-US" xlink:label="lab_mgnx_ZaiLabLimitedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Lab Limited [Member]</link:label>
    <link:label id="lab_mgnx_ZaiLabLimitedMember_documentation_en-US" xlink:label="lab_mgnx_ZaiLabLimitedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Lab Limited</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabLimitedMember" xlink:href="mgnx-20181231.xsd#mgnx_ZaiLabLimitedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ZaiLabLimitedMember" xlink:to="lab_mgnx_ZaiLabLimitedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_a386a90c-3db6-4eaf-9570-248a9d5544e1_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_b0f7ae18-a1e5-4637-8def-29bba2e41344_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_52e80e92-65d1-42e0-9068-82afef2eda85_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeOther_91a2d3a3-d0dd-41e7-8b7a-60bfe8556f64_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income, Other</link:label>
    <link:label id="lab_us-gaap_InterestIncomeOther_label_en-US" xlink:label="lab_us-gaap_InterestIncomeOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOther" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestIncomeOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeOther" xlink:to="lab_us-gaap_InterestIncomeOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_9c63e9d0-fce8-4c73-822c-d97a65e69dcf_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits that Would Impact Effective Tax Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_4a97fa9d-f464-4aa9-9a3e-b1b02ad02f4e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred federal rate change reduction in corporate rate</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_TaxYear2025To2037Member_8b64e958-0c1c-4544-8e97-524fd5aea2a5_terseLabel_en-US" xlink:label="lab_mgnx_TaxYear2025To2037Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Year 2025 To 2037</link:label>
    <link:label id="lab_mgnx_TaxYear2025To2037Member_label_en-US" xlink:label="lab_mgnx_TaxYear2025To2037Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Year 2025 To 2037 [Member]</link:label>
    <link:label id="lab_mgnx_TaxYear2025To2037Member_documentation_en-US" xlink:label="lab_mgnx_TaxYear2025To2037Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Year 2025 To 2037</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_TaxYear2025To2037Member" xlink:href="mgnx-20181231.xsd#mgnx_TaxYear2025To2037Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_TaxYear2025To2037Member" xlink:to="lab_mgnx_TaxYear2025To2037Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_5e61905a-3e56-40c8-96d5-a245cfe1b05e_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_c83e90e0-121b-40f4-b967-21962bdbccae_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic and diluted net loss per common share (in usd per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Basic and Diluted Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_a9893910-7e11-49f1-8228-7076fda4094c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Two Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_7c635695-8f5d-413e-a520-4a079c3c4cbd_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_f5f04176-abee-4ea6-ac4a-5f50616310d7_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_a569a7d9-d894-4a44-92b2-e24286716652_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExaminationLineItems_39200f3c-9ebb-4bab-9658-3dc18793e2ae_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Examination [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExaminationLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Examination [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExaminationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems" xlink:to="lab_us-gaap_IncomeTaxExaminationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_71c42304-a5ed-4e0f-9024-4f7c60b3be3b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_6c267475-b21c-43cb-86db-4b18a95be9cc_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_b80c0dd3-9465-47a6-bf1c-74057a0d9811_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Employee Stock Options Award Valuation Assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_1dcd293e-e1cc-4898-8cd1-224bf1fc4855_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Benefit Plan</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension and Other Postretirement Benefits Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_6026c38b-4253-4694-81a9-b6ee0f4218c3_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_9a5eb614-47f4-4b0e-80b9-86bd42ef6224_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_8bf6c205-f578-4b8c-b9f1-899aaf7de06b_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and Nature of Operations</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_da6a2694-db13-492e-be8b-00ccfb6addc7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ProceedsfromRoyaltiesPercent_bfffc31d-5a15-4044-bb37-f956cec9b95c_terseLabel_en-US" xlink:label="lab_mgnx_ProceedsfromRoyaltiesPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential proceeds from royalties percent</link:label>
    <link:label id="lab_mgnx_ProceedsfromRoyaltiesPercent_label_en-US" xlink:label="lab_mgnx_ProceedsfromRoyaltiesPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Royalties, Percent</link:label>
    <link:label id="lab_mgnx_ProceedsfromRoyaltiesPercent_documentation_en-US" xlink:label="lab_mgnx_ProceedsfromRoyaltiesPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Royalties, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsfromRoyaltiesPercent" xlink:href="mgnx-20181231.xsd#mgnx_ProceedsfromRoyaltiesPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ProceedsfromRoyaltiesPercent" xlink:to="lab_mgnx_ProceedsfromRoyaltiesPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_8ca9afe8-a681-437b-a177-5226e35261f7_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_NumberOfLease_7faeacce-db84-447a-8ca3-1e7194d49bbd_terseLabel_en-US" xlink:label="lab_mgnx_NumberOfLease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of leases</link:label>
    <link:label id="lab_mgnx_NumberOfLease_label_en-US" xlink:label="lab_mgnx_NumberOfLease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Lease</link:label>
    <link:label id="lab_mgnx_NumberOfLease_documentation_en-US" xlink:label="lab_mgnx_NumberOfLease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the number of lease during the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NumberOfLease" xlink:href="mgnx-20181231.xsd#mgnx_NumberOfLease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_NumberOfLease" xlink:to="lab_mgnx_NumberOfLease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_3059e622-fe1d-466b-b139-07ed93ec4bf0_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Undesignated preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_2f308f91-203e-4a61-80c4-f63b661492ac_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due Thereafter</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_93313849-b520-4852-8c75-b08d71c017ab_terseLabel_en-US" xlink:label="lab_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential development and regulatory milestone payments</link:label>
    <link:label id="lab_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_label_en-US" xlink:label="lab_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Development and Regulatory Milestone Payments Under Agreement</link:label>
    <link:label id="lab_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_documentation_en-US" xlink:label="lab_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Development and Regulatory Milestone Payments Under Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" xlink:href="mgnx-20181231.xsd#mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" xlink:to="lab_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_89ce63f2-57d4-4cdf-ba0f-fc60fb3e20c4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Trading, and Equity Securities, FV-NI [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Trading, and Equity Securities, FV-NI [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:to="lab_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_58101184-0156-464b-ba8d-775545791069_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_90fcf332-1330-4935-b143-69ccec41f77c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5a2528d4-100c-4c12-83f1-db721e00d59a_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 31, 2016</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_ac075690-2a6e-4500-b9dd-d77b4317875a_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 31, 2017</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesCurrent_adc4181e-cf63-4951-ab3f-81babc377fdf_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_PotentialSalesMilestonePaymentsUnderAgreement_c2323e66-038b-4108-adf7-29ffa3f3847f_verboseLabel_en-US" xlink:label="lab_mgnx_PotentialSalesMilestonePaymentsUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential sales milestone payments under agreement</link:label>
    <link:label id="lab_mgnx_PotentialSalesMilestonePaymentsUnderAgreement_label_en-US" xlink:label="lab_mgnx_PotentialSalesMilestonePaymentsUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Sales Milestone Payments Under Agreement</link:label>
    <link:label id="lab_mgnx_PotentialSalesMilestonePaymentsUnderAgreement_documentation_en-US" xlink:label="lab_mgnx_PotentialSalesMilestonePaymentsUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total potential sales milestones company could earn under agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialSalesMilestonePaymentsUnderAgreement" xlink:href="mgnx-20181231.xsd#mgnx_PotentialSalesMilestonePaymentsUnderAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_PotentialSalesMilestonePaymentsUnderAgreement" xlink:to="lab_mgnx_PotentialSalesMilestonePaymentsUnderAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_8270926c-9b77-4449-9f37-1f3911d1baf0_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for federal or state income taxes</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_9420fbf3-9b1c-4401-8653-9c5c70d7b9ec_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTable" xlink:to="lab_us-gaap_ConcentrationRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_c7bbd73d-953c-4436-9bc4-3dab34cdd11d_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_62624f6c-4737-4409-83c8-282b9605a5fa_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_OperatingLossCarryforwardsAnnualLimitationAmount_c1779eeb-3c04-4268-83c1-678be0c9ed29_terseLabel_en-US" xlink:label="lab_mgnx_OperatingLossCarryforwardsAnnualLimitationAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating losses limited for use utilized on an annual basis</link:label>
    <link:label id="lab_mgnx_OperatingLossCarryforwardsAnnualLimitationAmount_label_en-US" xlink:label="lab_mgnx_OperatingLossCarryforwardsAnnualLimitationAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards Annual Limitation Amount</link:label>
    <link:label id="lab_mgnx_OperatingLossCarryforwardsAnnualLimitationAmount_documentation_en-US" xlink:label="lab_mgnx_OperatingLossCarryforwardsAnnualLimitationAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of net operating loss which are limited for use, utilized on a annual basis.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_OperatingLossCarryforwardsAnnualLimitationAmount" xlink:href="mgnx-20181231.xsd#mgnx_OperatingLossCarryforwardsAnnualLimitationAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_OperatingLossCarryforwardsAnnualLimitationAmount" xlink:to="lab_mgnx_OperatingLossCarryforwardsAnnualLimitationAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_66fc7221-8e4e-4a9c-be9c-eed21c70b947_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_cf0596cd-961d-40db-8fd9-6e4d633b78e3_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Federal tax credits carry forward</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_923d4a3b-fef6-45e3-b727-cbc1dcebb535_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in balance related to adoption of ASC 606</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Measure of Progress</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1ecba6c6-2e95-4ebb-a039-8104cc7e0747_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash provided by (used in) operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_999b310e-df2f-4cbd-a99b-38596c8c7db9_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationTextBlock_5841ff11-200c-4352-adaf-45f67761e43a_terseLabel_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly Financial Information (Unaudited)</link:label>
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationTextBlock_label_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly Financial Information [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:to="lab_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_StockIssuedDuringPeriodValueStockPlanActivity_33246ae7-4ea6-4e30-8a2b-23534f5c9ea7_terseLabel_en-US" xlink:label="lab_mgnx_StockIssuedDuringPeriodValueStockPlanActivity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock plan related activity</link:label>
    <link:label id="lab_mgnx_StockIssuedDuringPeriodValueStockPlanActivity_label_en-US" xlink:label="lab_mgnx_StockIssuedDuringPeriodValueStockPlanActivity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period Value Stock Plan Activity</link:label>
    <link:label id="lab_mgnx_StockIssuedDuringPeriodValueStockPlanActivity_documentation_en-US" xlink:label="lab_mgnx_StockIssuedDuringPeriodValueStockPlanActivity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value of shares issued due to stock plan related activity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_StockIssuedDuringPeriodValueStockPlanActivity" xlink:href="mgnx-20181231.xsd#mgnx_StockIssuedDuringPeriodValueStockPlanActivity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_StockIssuedDuringPeriodValueStockPlanActivity" xlink:to="lab_mgnx_StockIssuedDuringPeriodValueStockPlanActivity" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_f40fe58d-9591-4a52-b39b-ecd2ea08a8b0_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_f8467289-1ef4-44c2-8036-6275efebaeef_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0c76180b-967d-4483-bfa5-e7d9b43f10d0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1a314a57-334a-4d25-8fd5-1f351baac4da_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_b01ac02f-ce66-476c-8ceb-8664209e9a7c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited or expired</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_a00b3d7a-f373-47bb-a3d6-f00b8b4ba456_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_24c0c3ee-6efb-4053-9410-5b33059095a2_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskLineItems" xlink:to="lab_us-gaap_ConcentrationRiskLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_f8edd84b-18cd-4e67-8d86-4b4fd7f50a35_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_b52a6fcb-1c4f-4ce7-8bac-25c5a95f7873_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock_540b440c-45ab-4edd-8b80-b71dc75e5e58_terseLabel_en-US" xlink:label="lab_mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and Other Agreements</link:label>
    <link:label id="lab_mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock_label_en-US" xlink:label="lab_mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration And License Agreements Disclosure [Text Block]</link:label>
    <link:label id="lab_mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock_documentation_en-US" xlink:label="lab_mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The entire disclosure for collaboration and license agreements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock" xlink:href="mgnx-20181231.xsd#mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock" xlink:to="lab_mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_a3e7bf99-1208-4c5b-ac6e-c7da0755fa82_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_0908ca68-4c62-4475-9b57-745241df7a7e_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_39dd4049-e831-4684-9091-a54b2ab6091d_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization expense</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_ef8630ab-501c-4d68-a7af-91a882960e75_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Federal Government</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_FairValueOfWarrantsReceived_115f4b3e-515f-49c9-9c29-56c909f5bcd7_verboseLabel_en-US" xlink:label="lab_mgnx_FairValueOfWarrantsReceived" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of warrants received</link:label>
    <link:label id="lab_mgnx_FairValueOfWarrantsReceived_label_en-US" xlink:label="lab_mgnx_FairValueOfWarrantsReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Of Warrants Received</link:label>
    <link:label id="lab_mgnx_FairValueOfWarrantsReceived_documentation_en-US" xlink:label="lab_mgnx_FairValueOfWarrantsReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Of Warrants Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_FairValueOfWarrantsReceived" xlink:href="mgnx-20181231.xsd#mgnx_FairValueOfWarrantsReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_FairValueOfWarrantsReceived" xlink:to="lab_mgnx_FairValueOfWarrantsReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7220cf9c-4bdf-486b-80bc-42bf0d2f94e6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_UpfrontPaymentRecognitionPeriod_7ed342fe-1a73-4c02-8d69-023f1afc5bd7_terseLabel_en-US" xlink:label="lab_mgnx_UpfrontPaymentRecognitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected period of development</link:label>
    <link:label id="lab_mgnx_UpfrontPaymentRecognitionPeriod_label_en-US" xlink:label="lab_mgnx_UpfrontPaymentRecognitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront Payment Recognition Period</link:label>
    <link:label id="lab_mgnx_UpfrontPaymentRecognitionPeriod_documentation_en-US" xlink:label="lab_mgnx_UpfrontPaymentRecognitionPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Refers to upfront payment recognition period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_UpfrontPaymentRecognitionPeriod" xlink:href="mgnx-20181231.xsd#mgnx_UpfrontPaymentRecognitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_UpfrontPaymentRecognitionPeriod" xlink:to="lab_mgnx_UpfrontPaymentRecognitionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_EffectiveIncomeTaxReconciliationStateDeferredTaxesAdjustmentsAmount_40a42ce5-fda3-4b80-a248-4fd7a65a3fbb_negatedLabel_en-US" xlink:label="lab_mgnx_EffectiveIncomeTaxReconciliationStateDeferredTaxesAdjustmentsAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred state blended rate adjustments</link:label>
    <link:label id="lab_mgnx_EffectiveIncomeTaxReconciliationStateDeferredTaxesAdjustmentsAmount_label_en-US" xlink:label="lab_mgnx_EffectiveIncomeTaxReconciliationStateDeferredTaxesAdjustmentsAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Reconciliation State Deferred Taxes Adjustments, Amount</link:label>
    <link:label id="lab_mgnx_EffectiveIncomeTaxReconciliationStateDeferredTaxesAdjustmentsAmount_documentation_en-US" xlink:label="lab_mgnx_EffectiveIncomeTaxReconciliationStateDeferredTaxesAdjustmentsAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to deferred state blended rate adjustments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_EffectiveIncomeTaxReconciliationStateDeferredTaxesAdjustmentsAmount" xlink:href="mgnx-20181231.xsd#mgnx_EffectiveIncomeTaxReconciliationStateDeferredTaxesAdjustmentsAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_EffectiveIncomeTaxReconciliationStateDeferredTaxesAdjustmentsAmount" xlink:to="lab_mgnx_EffectiveIncomeTaxReconciliationStateDeferredTaxesAdjustmentsAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_ed7ec281-5fde-4068-8afc-bbced46f4651_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Fair Value Measurement Financial Assets</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_b8b5e134-cfbd-4767-b2d1-ac0909a050b9_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_e7202320-b127-4b2d-b8a5-3655a8b23d81_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage_d0ac98e3-fa41-40cb-919b-c12f846e888a_terseLabel_en-US" xlink:label="lab_mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of employee vested contribution</link:label>
    <link:label id="lab_mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage_label_en-US" xlink:label="lab_mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Employees Contribution, Vested Percentage</link:label>
    <link:label id="lab_mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage_documentation_en-US" xlink:label="lab_mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage vested of employee's contributions to defined contribution plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage" xlink:href="mgnx-20181231.xsd#mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage" xlink:to="lab_mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_ee97e3a9-7e29-4022-b783-646a95012c8c_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_6cff8588-ddf4-442d-bdfb-d86ec82341ef_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercised or RSUs vested</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8e4ab3a5-fde5-4298-9a9f-246c6b089f01_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ProventionPRV031Member_61622338-48dc-46a9-9efe-b00c2a331328_terseLabel_en-US" xlink:label="lab_mgnx_ProventionPRV031Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provention PRV031</link:label>
    <link:label id="lab_mgnx_ProventionPRV031Member_label_en-US" xlink:label="lab_mgnx_ProventionPRV031Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provention PRV031 [Member]</link:label>
    <link:label id="lab_mgnx_ProventionPRV031Member_documentation_en-US" xlink:label="lab_mgnx_ProventionPRV031Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provention PRV031</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionPRV031Member" xlink:href="mgnx-20181231.xsd#mgnx_ProventionPRV031Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ProventionPRV031Member" xlink:to="lab_mgnx_ProventionPRV031Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_04f32663-e12c-4500-99ad-6dcb49692106_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_d83d6542-55ac-48f1-a6ff-71c23ba33f6a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_e5000a88-4460-456a-90cc-a945b44f6ccb_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_7c285794-6b13-411a-a217-c5f1a5d306cc_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Four Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_9b825f06-cc8f-4b94-a2af-0039f2e73f50_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States federal tax at statutory rate</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_366c25a4-26ad-42be-9d2f-d7036145d3fe_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_dbb8e888-1c59-4a83-8f19-b8c1daa622db_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_e629f285-1be3-40e5-9ec5-f6cfe0cf728f_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_2f45bec5-75e1-43dc-b766-5c13cb0cd02d_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, current</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_8b75af9e-2d0e-4e8c-8047-73d211299a52_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation, number of shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_33762668-981d-448a-9916-4391f28389c2_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_3443778d-073f-4c4b-b502-38b3222cdb9d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercised or RSUs vested</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_9dcfbf02-0c6e-4cfc-82fd-70e72cbd2053_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_85c4fdbc-68fc-4bdc-8518-34206c3e302e_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_c1f22eec-288d-4ea7-8295-1a8c589fa5d2_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of all significant revenue earned</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_3b144e4f-53af-47dd-b67a-cbbf52ccce4b_verboseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of significant accounts receivable</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember_d28d063e-4fd5-4dda-8ce4-2c9c5ac9b0bd_terseLabel_en-US" xlink:label="lab_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NIAID</link:label>
    <link:label id="lab_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember_label_en-US" xlink:label="lab_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">National Institute of Allergy and Infectious Diseases [Member]</link:label>
    <link:label id="lab_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember_documentation_en-US" xlink:label="lab_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents a collaborators with which entity has an agreement related to contracts and research grants received from U.S. government agencies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:href="mgnx-20181231.xsd#mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:to="lab_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_eb60b2c6-5a1d-419c-9e96-c713b3234b15_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_344dd06c-6c11-49d0-a903-7586e99c1429_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_b59acfbc-8afb-472a-b277-6c9fdc1d0d28_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_6127e584-8605-491f-8376-3806878c5267_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_f0247076-20b8-4bcc-a416-b91502b982e4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_PotentialMilestonePaymentsandRoyaltiesonFutureSalesunderAgreement_61214924-2cf0-401f-b426-fcdcdd947a3b_terseLabel_en-US" xlink:label="lab_mgnx_PotentialMilestonePaymentsandRoyaltiesonFutureSalesunderAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential milestone payments and royalties on future sales</link:label>
    <link:label id="lab_mgnx_PotentialMilestonePaymentsandRoyaltiesonFutureSalesunderAgreement_label_en-US" xlink:label="lab_mgnx_PotentialMilestonePaymentsandRoyaltiesonFutureSalesunderAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Milestone Payments and Royalties on Future Sales under Agreement</link:label>
    <link:label id="lab_mgnx_PotentialMilestonePaymentsandRoyaltiesonFutureSalesunderAgreement_documentation_en-US" xlink:label="lab_mgnx_PotentialMilestonePaymentsandRoyaltiesonFutureSalesunderAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Milestone Payments and Royalties on Future Sales under Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialMilestonePaymentsandRoyaltiesonFutureSalesunderAgreement" xlink:href="mgnx-20181231.xsd#mgnx_PotentialMilestonePaymentsandRoyaltiesonFutureSalesunderAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_PotentialMilestonePaymentsandRoyaltiesonFutureSalesunderAgreement" xlink:to="lab_mgnx_PotentialMilestonePaymentsandRoyaltiesonFutureSalesunderAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_9935fe0f-3108-4374-b3ef-f5cbf6a393cc_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_99e9b669-df8a-462d-b887-3d46667e5502_verboseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_7e397a19-9d40-4026-ba3a-22109104d8f2_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash proceeds from exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_IncyteMGA012AgreementMember_ede783bb-cb10-41af-b67e-96103066a714_terseLabel_en-US" xlink:label="lab_mgnx_IncyteMGA012AgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incyte MGA012 Agreement</link:label>
    <link:label id="lab_mgnx_IncyteMGA012AgreementMember_label_en-US" xlink:label="lab_mgnx_IncyteMGA012AgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incyte MGA012 Agreement [Member]</link:label>
    <link:label id="lab_mgnx_IncyteMGA012AgreementMember_documentation_en-US" xlink:label="lab_mgnx_IncyteMGA012AgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incyte MGA012 Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteMGA012AgreementMember" xlink:href="mgnx-20181231.xsd#mgnx_IncyteMGA012AgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_IncyteMGA012AgreementMember" xlink:to="lab_mgnx_IncyteMGA012AgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_e601d3fe-ad5d-44cf-bc69-0b9bc504759f_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_LaboratoryAndOfficeEquipmentMember_653096b5-8677-45d1-8d05-a2d38bf5bce8_terseLabel_en-US" xlink:label="lab_mgnx_LaboratoryAndOfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory and office equipment</link:label>
    <link:label id="lab_mgnx_LaboratoryAndOfficeEquipmentMember_label_en-US" xlink:label="lab_mgnx_LaboratoryAndOfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory and Office Equipment [Member]</link:label>
    <link:label id="lab_mgnx_LaboratoryAndOfficeEquipmentMember_documentation_en-US" xlink:label="lab_mgnx_LaboratoryAndOfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">A facility that provides controlled conditions in which scientific or technological research, experiments, and measurement may be performed. and tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_LaboratoryAndOfficeEquipmentMember" xlink:href="mgnx-20181231.xsd#mgnx_LaboratoryAndOfficeEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_LaboratoryAndOfficeEquipmentMember" xlink:to="lab_mgnx_LaboratoryAndOfficeEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_DocumentAndEntityInformationAbstract_label_en-US" xlink:label="lab_mgnx_DocumentAndEntityInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document And Entity Information [Abstract]</link:label>
    <link:label id="lab_mgnx_DocumentAndEntityInformationAbstract_documentation_en-US" xlink:label="lab_mgnx_DocumentAndEntityInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document and entity information.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DocumentAndEntityInformationAbstract" xlink:href="mgnx-20181231.xsd#mgnx_DocumentAndEntityInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_DocumentAndEntityInformationAbstract" xlink:to="lab_mgnx_DocumentAndEntityInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_388ddf3a-1857-41c0-ab64-b4def6daced4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_fac028f5-ed3f-4673-b772-c0943ddca676_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_ac5bb751-6c42-4834-b0c5-f30cf80c3a8e_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rollforward of Contract Liabilities</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset and Liability [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_a8c2c9a8-cca5-4e62-ba1d-418849dbb801_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_TotalPotentialValueUnderAgreement_d1181fe7-ad77-4a46-8939-222ce4305855_terseLabel_en-US" xlink:label="lab_mgnx_TotalPotentialValueUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total potential value</link:label>
    <link:label id="lab_mgnx_TotalPotentialValueUnderAgreement_label_en-US" xlink:label="lab_mgnx_TotalPotentialValueUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total potential value of agreement</link:label>
    <link:label id="lab_mgnx_TotalPotentialValueUnderAgreement_documentation_en-US" xlink:label="lab_mgnx_TotalPotentialValueUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Refers to total potential value under agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_TotalPotentialValueUnderAgreement" xlink:href="mgnx-20181231.xsd#mgnx_TotalPotentialValueUnderAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_TotalPotentialValueUnderAgreement" xlink:to="lab_mgnx_TotalPotentialValueUnderAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_4b101714-9848-48fd-994c-a675ce5a4e9d_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_b25d3772-4e46-4e86-8ffa-d20b52cc480e_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Current Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>13
<FILENAME>mgnx-20181231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2017 Workiva-->
<!--r:047621fe-455e-451d-8c86-6c34d8ef3281,g:8a8d7b2b-0121-408b-a242-2fd92f2a34d5-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://macrogenics.com/role/DocumentandEntityInformation" xlink:type="simple" xlink:href="mgnx-20181231.xsd#DocumentandEntityInformation"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/DocumentandEntityInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DocumentAndEntityInformationAbstract_76fb1363-c61e-4570-916c-b4c97d62b062" xlink:href="mgnx-20181231.xsd#mgnx_DocumentAndEntityInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_b66022bb-5211-4316-93de-a31a357da30f" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_DocumentAndEntityInformationAbstract_76fb1363-c61e-4570-916c-b4c97d62b062" xlink:to="loc_dei_DocumentType_b66022bb-5211-4316-93de-a31a357da30f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_416ce29e-c87d-4acb-8bfe-656bfb71b5db" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_DocumentAndEntityInformationAbstract_76fb1363-c61e-4570-916c-b4c97d62b062" xlink:to="loc_dei_AmendmentFlag_416ce29e-c87d-4acb-8bfe-656bfb71b5db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_6aad4c7f-a383-4e74-87ea-bb7c577ad035" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_DocumentAndEntityInformationAbstract_76fb1363-c61e-4570-916c-b4c97d62b062" xlink:to="loc_dei_DocumentPeriodEndDate_6aad4c7f-a383-4e74-87ea-bb7c577ad035" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_06024233-a5cb-4c10-8aff-8798510abdca" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_DocumentAndEntityInformationAbstract_76fb1363-c61e-4570-916c-b4c97d62b062" xlink:to="loc_dei_DocumentFiscalYearFocus_06024233-a5cb-4c10-8aff-8798510abdca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_27a4a6a0-101e-45b4-a49a-ef438233cbad" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_DocumentAndEntityInformationAbstract_76fb1363-c61e-4570-916c-b4c97d62b062" xlink:to="loc_dei_DocumentFiscalPeriodFocus_27a4a6a0-101e-45b4-a49a-ef438233cbad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_8dbebb74-10e3-4d5b-a50a-de704d133f6a" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_DocumentAndEntityInformationAbstract_76fb1363-c61e-4570-916c-b4c97d62b062" xlink:to="loc_dei_EntityRegistrantName_8dbebb74-10e3-4d5b-a50a-de704d133f6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_8d6fcfff-2986-45b1-9a27-69f7575b2b45" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_DocumentAndEntityInformationAbstract_76fb1363-c61e-4570-916c-b4c97d62b062" xlink:to="loc_dei_EntityCentralIndexKey_8d6fcfff-2986-45b1-9a27-69f7575b2b45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_8d91d4a1-bfec-459c-8533-5c0ec9a9e83c" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_DocumentAndEntityInformationAbstract_76fb1363-c61e-4570-916c-b4c97d62b062" xlink:to="loc_dei_CurrentFiscalYearEndDate_8d91d4a1-bfec-459c-8533-5c0ec9a9e83c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_f4a8d903-d7f6-43be-992c-58b20d30fd23" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_DocumentAndEntityInformationAbstract_76fb1363-c61e-4570-916c-b4c97d62b062" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_f4a8d903-d7f6-43be-992c-58b20d30fd23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_19d264a8-88d9-4fb9-9154-9fff1ef035ba" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_DocumentAndEntityInformationAbstract_76fb1363-c61e-4570-916c-b4c97d62b062" xlink:to="loc_dei_EntityCurrentReportingStatus_19d264a8-88d9-4fb9-9154-9fff1ef035ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_4e91601d-2d7c-4c96-8f57-bbaeae04f2c1" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_DocumentAndEntityInformationAbstract_76fb1363-c61e-4570-916c-b4c97d62b062" xlink:to="loc_dei_EntityVoluntaryFilers_4e91601d-2d7c-4c96-8f57-bbaeae04f2c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_4b052dfa-99d7-4113-a551-0db1199227b2" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_DocumentAndEntityInformationAbstract_76fb1363-c61e-4570-916c-b4c97d62b062" xlink:to="loc_dei_EntityFilerCategory_4b052dfa-99d7-4113-a551-0db1199227b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_df94e6ad-62d3-4a34-8c3e-358a36560245" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_DocumentAndEntityInformationAbstract_76fb1363-c61e-4570-916c-b4c97d62b062" xlink:to="loc_dei_EntityEmergingGrowthCompany_df94e6ad-62d3-4a34-8c3e-358a36560245" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_c08597f3-742e-4e40-9bca-19fd284e77d7" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_DocumentAndEntityInformationAbstract_76fb1363-c61e-4570-916c-b4c97d62b062" xlink:to="loc_dei_EntitySmallBusiness_c08597f3-742e-4e40-9bca-19fd284e77d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_d42289c0-9bc5-49bc-b01e-319f48381940" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_DocumentAndEntityInformationAbstract_76fb1363-c61e-4570-916c-b4c97d62b062" xlink:to="loc_dei_EntityShellCompany_d42289c0-9bc5-49bc-b01e-319f48381940" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_5a097e2f-83cb-4f78-9d8d-77c3b3dbf408" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_DocumentAndEntityInformationAbstract_76fb1363-c61e-4570-916c-b4c97d62b062" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_5a097e2f-83cb-4f78-9d8d-77c3b3dbf408" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_27f13c12-b304-4db6-b8bd-72d7b02b1f37" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_DocumentAndEntityInformationAbstract_76fb1363-c61e-4570-916c-b4c97d62b062" xlink:to="loc_dei_EntityPublicFloat_27f13c12-b304-4db6-b8bd-72d7b02b1f37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="mgnx-20181231.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_45f0dee8-fd34-4c2d-9c61-e9aa481e7af3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_eff3ef07-59c7-4dd4-aa1a-e60c31b4156d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_45f0dee8-fd34-4c2d-9c61-e9aa481e7af3" xlink:to="loc_us-gaap_AssetsAbstract_eff3ef07-59c7-4dd4-aa1a-e60c31b4156d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_39dd940c-6196-4fe0-8681-f753cac1d1d5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_eff3ef07-59c7-4dd4-aa1a-e60c31b4156d" xlink:to="loc_us-gaap_AssetsCurrentAbstract_39dd940c-6196-4fe0-8681-f753cac1d1d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ee018cbf-a4a3-4a42-af60-eca43fb0fda3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_39dd940c-6196-4fe0-8681-f753cac1d1d5" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ee018cbf-a4a3-4a42-af60-eca43fb0fda3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesCurrent_63268e6d-5b63-4e07-a6fa-6691e051e84a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_39dd940c-6196-4fe0-8681-f753cac1d1d5" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesCurrent_63268e6d-5b63-4e07-a6fa-6691e051e84a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_6834a0ae-f1d1-4cdf-8b34-00ac66872c14" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_39dd940c-6196-4fe0-8681-f753cac1d1d5" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_6834a0ae-f1d1-4cdf-8b34-00ac66872c14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_02f1ba7c-36b9-48cb-b0b8-9655689c1bca" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_39dd940c-6196-4fe0-8681-f753cac1d1d5" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_02f1ba7c-36b9-48cb-b0b8-9655689c1bca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssets_2dc0c174-c13a-4d9b-8b07-fca267498c71" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_39dd940c-6196-4fe0-8681-f753cac1d1d5" xlink:to="loc_us-gaap_OtherAssets_2dc0c174-c13a-4d9b-8b07-fca267498c71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_6176318d-b61b-4b41-a07d-3b9bb325022a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_39dd940c-6196-4fe0-8681-f753cac1d1d5" xlink:to="loc_us-gaap_AssetsCurrent_6176318d-b61b-4b41-a07d-3b9bb325022a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_e6dda50c-5409-4ce7-b4c8-356afb09262c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_eff3ef07-59c7-4dd4-aa1a-e60c31b4156d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_e6dda50c-5409-4ce7-b4c8-356afb09262c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_acf626f9-af0d-44bc-9d93-f65f56474758" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_eff3ef07-59c7-4dd4-aa1a-e60c31b4156d" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_acf626f9-af0d-44bc-9d93-f65f56474758" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_74b34455-fbeb-4680-a253-fcbfa3799126" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_eff3ef07-59c7-4dd4-aa1a-e60c31b4156d" xlink:to="loc_us-gaap_Assets_74b34455-fbeb-4680-a253-fcbfa3799126" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b1740a08-ece3-45c7-8e6b-6eab7c988313" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_45f0dee8-fd34-4c2d-9c61-e9aa481e7af3" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b1740a08-ece3-45c7-8e6b-6eab7c988313" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_366c443e-3da5-4050-be84-6ec7c81e3907" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b1740a08-ece3-45c7-8e6b-6eab7c988313" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_366c443e-3da5-4050-be84-6ec7c81e3907" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_52064b40-ab6e-4a4d-9735-ed4e42818755" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_366c443e-3da5-4050-be84-6ec7c81e3907" xlink:to="loc_us-gaap_AccountsPayableCurrent_52064b40-ab6e-4a4d-9735-ed4e42818755" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_8570e508-c99b-48b3-9c47-ab0406c9ff77" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_366c443e-3da5-4050-be84-6ec7c81e3907" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_8570e508-c99b-48b3-9c47-ab0406c9ff77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueCurrent_b44eb16d-ed60-4068-a129-484c998f911d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredRevenueCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_366c443e-3da5-4050-be84-6ec7c81e3907" xlink:to="loc_us-gaap_DeferredRevenueCurrent_b44eb16d-ed60-4068-a129-484c998f911d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRentCreditCurrent_adda9d7d-a259-4391-8d77-9425ab4e6f38" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredRentCreditCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_366c443e-3da5-4050-be84-6ec7c81e3907" xlink:to="loc_us-gaap_DeferredRentCreditCurrent_adda9d7d-a259-4391-8d77-9425ab4e6f38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_c8cdff61-5f44-4de6-8c3b-8a486e40fd3f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_366c443e-3da5-4050-be84-6ec7c81e3907" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_c8cdff61-5f44-4de6-8c3b-8a486e40fd3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_de5367b4-2894-4a55-a0bc-c11421ef6485" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_366c443e-3da5-4050-be84-6ec7c81e3907" xlink:to="loc_us-gaap_LiabilitiesCurrent_de5367b4-2894-4a55-a0bc-c11421ef6485" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent_e5e747a8-8c30-4a63-9d68-be1df1604bb4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredRevenueNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b1740a08-ece3-45c7-8e6b-6eab7c988313" xlink:to="loc_us-gaap_DeferredRevenueNoncurrent_e5e747a8-8c30-4a63-9d68-be1df1604bb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRentCreditNoncurrent_b7a0029a-ac63-4f3d-ba46-8f77f9e31ebe" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b1740a08-ece3-45c7-8e6b-6eab7c988313" xlink:to="loc_us-gaap_DeferredRentCreditNoncurrent_b7a0029a-ac63-4f3d-ba46-8f77f9e31ebe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_0a3a81f4-baa6-4521-9c49-17221ac86ab8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b1740a08-ece3-45c7-8e6b-6eab7c988313" xlink:to="loc_us-gaap_Liabilities_0a3a81f4-baa6-4521-9c49-17221ac86ab8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_f73bc5d7-8a29-442f-abca-8b0124d960b2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b1740a08-ece3-45c7-8e6b-6eab7c988313" xlink:to="loc_us-gaap_StockholdersEquityAbstract_f73bc5d7-8a29-442f-abca-8b0124d960b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_7fe21995-b4d5-4a42-85b2-18dda44ff0bf" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_f73bc5d7-8a29-442f-abca-8b0124d960b2" xlink:to="loc_us-gaap_CommonStockValue_7fe21995-b4d5-4a42-85b2-18dda44ff0bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_d272480d-e6f4-4d62-9708-6ff9bfaef24c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_f73bc5d7-8a29-442f-abca-8b0124d960b2" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_d272480d-e6f4-4d62-9708-6ff9bfaef24c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_e2529a16-23c9-4956-b6f3-6eaed93afb58" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_f73bc5d7-8a29-442f-abca-8b0124d960b2" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_e2529a16-23c9-4956-b6f3-6eaed93afb58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_760f2697-e90d-4694-8435-0601ad947c35" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_f73bc5d7-8a29-442f-abca-8b0124d960b2" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_760f2697-e90d-4694-8435-0601ad947c35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_851ff948-7bbd-4817-9004-84abd918bfaf" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_f73bc5d7-8a29-442f-abca-8b0124d960b2" xlink:to="loc_us-gaap_StockholdersEquity_851ff948-7bbd-4817-9004-84abd918bfaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_82684762-844b-44d8-913c-e2187f5216da" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b1740a08-ece3-45c7-8e6b-6eab7c988313" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_82684762-844b-44d8-913c-e2187f5216da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="mgnx-20181231.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_dba293de-8259-4619-8fad-384d6c24cff2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_aa512937-78ab-4521-8b58-c253c26d26c5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_dba293de-8259-4619-8fad-384d6c24cff2" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_aa512937-78ab-4521-8b58-c253c26d26c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_2e125156-8bd7-435c-94a5-45b896c1659f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_dba293de-8259-4619-8fad-384d6c24cff2" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_2e125156-8bd7-435c-94a5-45b896c1659f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_fbb5b15b-c82b-4147-8454-8fab0a4d2710" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_dba293de-8259-4619-8fad-384d6c24cff2" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_fbb5b15b-c82b-4147-8454-8fab0a4d2710" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="mgnx-20181231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_c432bdec-86f3-46f7-8867-c0f04a6b7777" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_266d0964-2896-4d29-bf7c-e073788852c6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_c432bdec-86f3-46f7-8867-c0f04a6b7777" xlink:to="loc_us-gaap_StatementTable_266d0964-2896-4d29-bf7c-e073788852c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis_f505f3c4-621d-4e50-8f8f-b045643fd40f" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_266d0964-2896-4d29-bf7c-e073788852c6" xlink:to="loc_srt_RestatementAxis_f505f3c4-621d-4e50-8f8f-b045643fd40f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_984d443f-e6a8-46f0-bb49-962a35d14051" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementAxis_f505f3c4-621d-4e50-8f8f-b045643fd40f" xlink:to="loc_srt_RestatementDomain_984d443f-e6a8-46f0-bb49-962a35d14051" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_e310fd35-3f7c-4e3e-ac56-a1e010abd5fd" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_266d0964-2896-4d29-bf7c-e073788852c6" xlink:to="loc_srt_ProductOrServiceAxis_e310fd35-3f7c-4e3e-ac56-a1e010abd5fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_18b8cd4f-0d4b-4c2f-a5cc-364d5cbc4ba6" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_e310fd35-3f7c-4e3e-ac56-a1e010abd5fd" xlink:to="loc_srt_ProductsAndServicesDomain_18b8cd4f-0d4b-4c2f-a5cc-364d5cbc4ba6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueFromCollaborativeAgreementsMember_1b1cfdcc-81c0-4c64-965c-ca28fea69443" xlink:href="mgnx-20181231.xsd#mgnx_RevenueFromCollaborativeAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_18b8cd4f-0d4b-4c2f-a5cc-364d5cbc4ba6" xlink:to="loc_mgnx_RevenueFromCollaborativeAgreementsMember_1b1cfdcc-81c0-4c64-965c-ca28fea69443" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueFromGovernmentAgreementsMember_f68d5c4a-6dad-4c0c-b71c-7d4200e209b5" xlink:href="mgnx-20181231.xsd#mgnx_RevenueFromGovernmentAgreementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_18b8cd4f-0d4b-4c2f-a5cc-364d5cbc4ba6" xlink:to="loc_mgnx_RevenueFromGovernmentAgreementsMember_f68d5c4a-6dad-4c0c-b71c-7d4200e209b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_8fd20123-de08-42e9-8a7e-b3ae537710cc" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_266d0964-2896-4d29-bf7c-e073788852c6" xlink:to="loc_us-gaap_StatementLineItems_8fd20123-de08-42e9-8a7e-b3ae537710cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_d7bad097-7dbf-44b7-a3a7-e219051a51c6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8fd20123-de08-42e9-8a7e-b3ae537710cc" xlink:to="loc_us-gaap_RevenuesAbstract_d7bad097-7dbf-44b7-a3a7-e219051a51c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_d17d4da3-d7e2-40e0-8cf4-e4740d38faab" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_d7bad097-7dbf-44b7-a3a7-e219051a51c6" xlink:to="loc_us-gaap_Revenues_d17d4da3-d7e2-40e0-8cf4-e4740d38faab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_bb5586c9-5a56-4ee2-b83a-32e820c77c81" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8fd20123-de08-42e9-8a7e-b3ae537710cc" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_bb5586c9-5a56-4ee2-b83a-32e820c77c81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_f1315db3-7a5d-4135-851d-4df5610af2ee" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_bb5586c9-5a56-4ee2-b83a-32e820c77c81" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_f1315db3-7a5d-4135-851d-4df5610af2ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_e55ee927-d51b-42a1-a6f8-a67ae39f695b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_bb5586c9-5a56-4ee2-b83a-32e820c77c81" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_e55ee927-d51b-42a1-a6f8-a67ae39f695b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_f498beaa-8524-49f2-84b8-1007e2f41729" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_bb5586c9-5a56-4ee2-b83a-32e820c77c81" xlink:to="loc_us-gaap_CostsAndExpenses_f498beaa-8524-49f2-84b8-1007e2f41729" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_3b3be713-657b-4b5b-8297-d0ae1ead6d1a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8fd20123-de08-42e9-8a7e-b3ae537710cc" xlink:to="loc_us-gaap_OperatingIncomeLoss_3b3be713-657b-4b5b-8297-d0ae1ead6d1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_bb4584f3-dd35-4f08-b6de-833846a6875e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8fd20123-de08-42e9-8a7e-b3ae537710cc" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_bb4584f3-dd35-4f08-b6de-833846a6875e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d660e7e7-d9b7-4749-b495-546fafd98229" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8fd20123-de08-42e9-8a7e-b3ae537710cc" xlink:to="loc_us-gaap_NetIncomeLoss_d660e7e7-d9b7-4749-b495-546fafd98229" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_b720082d-39c4-47c6-9bb2-2b6b2d825a64" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8fd20123-de08-42e9-8a7e-b3ae537710cc" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_b720082d-39c4-47c6-9bb2-2b6b2d825a64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_b691ffc8-b4de-4b50-a971-c8dc2189d535" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_b720082d-39c4-47c6-9bb2-2b6b2d825a64" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_b691ffc8-b4de-4b50-a971-c8dc2189d535" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_df9ddce7-60ea-46ab-8524-ea8fa0b58839" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8fd20123-de08-42e9-8a7e-b3ae537710cc" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_df9ddce7-60ea-46ab-8524-ea8fa0b58839" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_2c2afe41-d5cc-4119-9b14-c3281088c14c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8fd20123-de08-42e9-8a7e-b3ae537710cc" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_2c2afe41-d5cc-4119-9b14-c3281088c14c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_26180cad-c95a-41d2-b02c-569ed38b2bad" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8fd20123-de08-42e9-8a7e-b3ae537710cc" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_26180cad-c95a-41d2-b02c-569ed38b2bad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="mgnx-20181231.xsd#CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_62c7a51b-1ffa-4641-a2f2-4656c46b2a84" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_79fb755a-f835-49ef-a83d-28eed7dc8c20" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_62c7a51b-1ffa-4641-a2f2-4656c46b2a84" xlink:to="loc_us-gaap_StatementTable_79fb755a-f835-49ef-a83d-28eed7dc8c20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_eb416f4f-c9ee-4363-81e0-c0416ab789f8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_79fb755a-f835-49ef-a83d-28eed7dc8c20" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_eb416f4f-c9ee-4363-81e0-c0416ab789f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_c767fc3a-d04d-4366-a338-06bce7933903" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_eb416f4f-c9ee-4363-81e0-c0416ab789f8" xlink:to="loc_us-gaap_EquityComponentDomain_c767fc3a-d04d-4366-a338-06bce7933903" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_47668085-fb91-4dec-8441-84d9375a52a9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_c767fc3a-d04d-4366-a338-06bce7933903" xlink:to="loc_us-gaap_CommonStockMember_47668085-fb91-4dec-8441-84d9375a52a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_8ef2fddc-c807-4b03-a17a-51050dc691b2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_c767fc3a-d04d-4366-a338-06bce7933903" xlink:to="loc_us-gaap_TreasuryStockMember_8ef2fddc-c807-4b03-a17a-51050dc691b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_134e5409-d245-425d-8921-56987ac4c4f0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_c767fc3a-d04d-4366-a338-06bce7933903" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_134e5409-d245-425d-8921-56987ac4c4f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_4f90cceb-de41-4ed4-ab0c-11052dbe3b37" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_c767fc3a-d04d-4366-a338-06bce7933903" xlink:to="loc_us-gaap_RetainedEarningsMember_4f90cceb-de41-4ed4-ab0c-11052dbe3b37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e956f466-67de-420b-9470-d8dc5ec584fc" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_c767fc3a-d04d-4366-a338-06bce7933903" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e956f466-67de-420b-9470-d8dc5ec584fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_aeaa09ec-2ab3-411e-b07e-19b59343e626" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_79fb755a-f835-49ef-a83d-28eed7dc8c20" xlink:to="loc_us-gaap_StatementLineItems_aeaa09ec-2ab3-411e-b07e-19b59343e626" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_880c7639-cb8e-484e-bba8-e22ff71c6a0e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_aeaa09ec-2ab3-411e-b07e-19b59343e626" xlink:to="loc_us-gaap_StockholdersEquity_880c7639-cb8e-484e-bba8-e22ff71c6a0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_0cc17649-19c7-4d85-885a-43b33aaa08e0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_aeaa09ec-2ab3-411e-b07e-19b59343e626" xlink:to="loc_us-gaap_SharesIssued_0cc17649-19c7-4d85-885a-43b33aaa08e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_bb1f4b86-c6a8-478a-be6b-fb620d5e952d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_aeaa09ec-2ab3-411e-b07e-19b59343e626" xlink:to="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_bb1f4b86-c6a8-478a-be6b-fb620d5e952d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_71e8a441-9fe3-4760-b1c4-d1ac0295ea05" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_aeaa09ec-2ab3-411e-b07e-19b59343e626" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_71e8a441-9fe3-4760-b1c4-d1ac0295ea05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_2a69edf0-9609-4aaa-ae37-b9d4e356170f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_aeaa09ec-2ab3-411e-b07e-19b59343e626" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_2a69edf0-9609-4aaa-ae37-b9d4e356170f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_9eb647ea-00a1-4add-8bb7-0983e824713f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_aeaa09ec-2ab3-411e-b07e-19b59343e626" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_9eb647ea-00a1-4add-8bb7-0983e824713f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_StockIssuedDuringPeriodValueStockPlanActivity_51304edc-8b39-4b14-93a1-fbc1e74b3fbf" xlink:href="mgnx-20181231.xsd#mgnx_StockIssuedDuringPeriodValueStockPlanActivity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_aeaa09ec-2ab3-411e-b07e-19b59343e626" xlink:to="loc_mgnx_StockIssuedDuringPeriodValueStockPlanActivity_51304edc-8b39-4b14-93a1-fbc1e74b3fbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity_dddba1ca-be37-488e-ac8b-1bd3f80307a4" xlink:href="mgnx-20181231.xsd#mgnx_StockIssuedDuringPeriodSharesStockPlanActivity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_aeaa09ec-2ab3-411e-b07e-19b59343e626" xlink:to="loc_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity_dddba1ca-be37-488e-ac8b-1bd3f80307a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockRetiredParValueMethodAmount_81cfd536-7e08-4b0e-b3ac-223f40d0cce7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TreasuryStockRetiredParValueMethodAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_aeaa09ec-2ab3-411e-b07e-19b59343e626" xlink:to="loc_us-gaap_TreasuryStockRetiredParValueMethodAmount_81cfd536-7e08-4b0e-b3ac-223f40d0cce7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesRetired_99f558a0-18b0-44f1-b7d9-f4d6e2c9a9de" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TreasuryStockSharesRetired"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_aeaa09ec-2ab3-411e-b07e-19b59343e626" xlink:to="loc_us-gaap_TreasuryStockSharesRetired_99f558a0-18b0-44f1-b7d9-f4d6e2c9a9de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_698e9ac9-cb8f-4cae-ab48-cba781eb8716" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_aeaa09ec-2ab3-411e-b07e-19b59343e626" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_698e9ac9-cb8f-4cae-ab48-cba781eb8716" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_7267e94e-7b95-4f1e-b05f-97501360297e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_aeaa09ec-2ab3-411e-b07e-19b59343e626" xlink:to="loc_us-gaap_NetIncomeLoss_7267e94e-7b95-4f1e-b05f-97501360297e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_cc789b0c-8c6a-4b5c-ae52-1e6dcb502ced" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_aeaa09ec-2ab3-411e-b07e-19b59343e626" xlink:to="loc_us-gaap_StockholdersEquity_cc789b0c-8c6a-4b5c-ae52-1e6dcb502ced" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_b909fdf7-757c-4771-b9e5-9f075483959d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_aeaa09ec-2ab3-411e-b07e-19b59343e626" xlink:to="loc_us-gaap_SharesIssued_b909fdf7-757c-4771-b9e5-9f075483959d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="mgnx-20181231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_7f063ed6-da3a-4fea-bebe-00d450ebf568" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_5a9d78d8-2d47-4d5d-b955-629bced7dc91" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_7f063ed6-da3a-4fea-bebe-00d450ebf568" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_5a9d78d8-2d47-4d5d-b955-629bced7dc91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f2337392-f6d7-4baa-8de9-a745a0122b10" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_5a9d78d8-2d47-4d5d-b955-629bced7dc91" xlink:to="loc_us-gaap_NetIncomeLoss_f2337392-f6d7-4baa-8de9-a745a0122b10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_14fdbc9c-f0ea-4bdc-88c8-20144115af85" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_5a9d78d8-2d47-4d5d-b955-629bced7dc91" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_14fdbc9c-f0ea-4bdc-88c8-20144115af85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_6165c466-beea-4c97-9612-b8d29d8308a7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_14fdbc9c-f0ea-4bdc-88c8-20144115af85" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_6165c466-beea-4c97-9612-b8d29d8308a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_71fcbe70-e1ed-4316-a300-1c6ee4eb3983" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_14fdbc9c-f0ea-4bdc-88c8-20144115af85" xlink:to="loc_us-gaap_ShareBasedCompensation_71fcbe70-e1ed-4316-a300-1c6ee4eb3983" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_dd03c4fc-9c92-4694-b7bf-c1c96ad2549e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_14fdbc9c-f0ea-4bdc-88c8-20144115af85" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_dd03c4fc-9c92-4694-b7bf-c1c96ad2549e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_b72db0a4-e4ca-4357-a0a7-5d2bdd67dd03" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_dd03c4fc-9c92-4694-b7bf-c1c96ad2549e" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_b72db0a4-e4ca-4357-a0a7-5d2bdd67dd03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_41336107-4d34-4705-92c0-5e208951cb9e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_dd03c4fc-9c92-4694-b7bf-c1c96ad2549e" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_41336107-4d34-4705-92c0-5e208951cb9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_74546587-ee15-47e7-9651-cecd6d927f3f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_dd03c4fc-9c92-4694-b7bf-c1c96ad2549e" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_74546587-ee15-47e7-9651-cecd6d927f3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_e3ff449a-6dd6-4047-ab63-0b27f2072038" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_dd03c4fc-9c92-4694-b7bf-c1c96ad2549e" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_e3ff449a-6dd6-4047-ab63-0b27f2072038" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_b1caa9ce-7988-406d-a789-297a3df96ce4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_dd03c4fc-9c92-4694-b7bf-c1c96ad2549e" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_b1caa9ce-7988-406d-a789-297a3df96ce4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_e2c93471-f0e9-49a9-876b-ba7e9ab0db5c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_dd03c4fc-9c92-4694-b7bf-c1c96ad2549e" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_e2c93471-f0e9-49a9-876b-ba7e9ab0db5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncreaseDecreaseInDeferredRent_2b746498-96f4-4578-bef9-26dd8af38406" xlink:href="mgnx-20181231.xsd#mgnx_IncreaseDecreaseInDeferredRent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_dd03c4fc-9c92-4694-b7bf-c1c96ad2549e" xlink:to="loc_mgnx_IncreaseDecreaseInDeferredRent_2b746498-96f4-4578-bef9-26dd8af38406" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_e7bb388c-7537-419a-8769-fc38037dc145" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_dd03c4fc-9c92-4694-b7bf-c1c96ad2549e" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_e7bb388c-7537-419a-8769-fc38037dc145" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_6bdf395d-44fb-4590-9978-5a38cfc231f6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_5a9d78d8-2d47-4d5d-b955-629bced7dc91" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_6bdf395d-44fb-4590-9978-5a38cfc231f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_f54bbd86-37ce-4a2e-ae7f-7d7181851c4d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_7f063ed6-da3a-4fea-bebe-00d450ebf568" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_f54bbd86-37ce-4a2e-ae7f-7d7181851c4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_1370083e-e8f9-474c-baf7-61eefd3d6570" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_f54bbd86-37ce-4a2e-ae7f-7d7181851c4d" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_1370083e-e8f9-474c-baf7-61eefd3d6570" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_5dd6623c-e3b4-4af6-bdfa-bd9a2e9198b6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_f54bbd86-37ce-4a2e-ae7f-7d7181851c4d" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_5dd6623c-e3b4-4af6-bdfa-bd9a2e9198b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_26beba77-8fed-44b7-9db1-e8ea21a3fb04" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_f54bbd86-37ce-4a2e-ae7f-7d7181851c4d" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_26beba77-8fed-44b7-9db1-e8ea21a3fb04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_3a8d4502-1256-4cf6-aa72-95e0a8f9c1c8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_f54bbd86-37ce-4a2e-ae7f-7d7181851c4d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_3a8d4502-1256-4cf6-aa72-95e0a8f9c1c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_004247d6-4f61-4b3b-9f7f-896b73b53319" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_7f063ed6-da3a-4fea-bebe-00d450ebf568" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_004247d6-4f61-4b3b-9f7f-896b73b53319" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_892f207a-20a0-4520-9f49-0ee539e59f23" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_004247d6-4f61-4b3b-9f7f-896b73b53319" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_892f207a-20a0-4520-9f49-0ee539e59f23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases_59797de7-7dcd-4c70-a033-acea033827f3" xlink:href="mgnx-20181231.xsd#mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_004247d6-4f61-4b3b-9f7f-896b73b53319" xlink:to="loc_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases_59797de7-7dcd-4c70-a033-acea033827f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_09d8c3db-9358-4281-bdbf-3ef1ffe9cafc" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_004247d6-4f61-4b3b-9f7f-896b73b53319" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_09d8c3db-9358-4281-bdbf-3ef1ffe9cafc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_093d6912-0f28-4d67-90b4-57c0ca697d4d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_004247d6-4f61-4b3b-9f7f-896b73b53319" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_093d6912-0f28-4d67-90b4-57c0ca697d4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_a08c4257-1494-4ac7-8bdf-be7d7456c88a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_7f063ed6-da3a-4fea-bebe-00d450ebf568" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_a08c4257-1494-4ac7-8bdf-be7d7456c88a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0ffc70aa-3596-418d-bc2a-1d8065f13381" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_7f063ed6-da3a-4fea-bebe-00d450ebf568" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0ffc70aa-3596-418d-bc2a-1d8065f13381" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e9a4acce-7f87-4cef-91c9-2c849d2fdd96" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_7f063ed6-da3a-4fea-bebe-00d450ebf568" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e9a4acce-7f87-4cef-91c9-2c849d2fdd96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_b65dcb87-05ca-4d9f-b36c-3f8b010f66e1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_7f063ed6-da3a-4fea-bebe-00d450ebf568" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_b65dcb87-05ca-4d9f-b36c-3f8b010f66e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_FairValueOfWarrantsReceived_5a3741cd-213b-468c-8969-d0cd109f9d5a" xlink:href="mgnx-20181231.xsd#mgnx_FairValueOfWarrantsReceived"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_b65dcb87-05ca-4d9f-b36c-3f8b010f66e1" xlink:to="loc_mgnx_FairValueOfWarrantsReceived_5a3741cd-213b-468c-8969-d0cd109f9d5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/OrganizationandNatureofOperations" xlink:type="simple" xlink:href="mgnx-20181231.xsd#OrganizationandNatureofOperations"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/OrganizationandNatureofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e7bc4a2d-f657-48c5-9921-60c5094c92f3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_87488a2c-c192-485c-b8f9-ee36c1f56f6f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e7bc4a2d-f657-48c5-9921-60c5094c92f3" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_87488a2c-c192-485c-b8f9-ee36c1f56f6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="mgnx-20181231.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_e166cde2-4696-4814-a80c-3bb234fa1b85" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_57fe3fb2-5e49-45f7-9078-0a132d818659" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e166cde2-4696-4814-a80c-3bb234fa1b85" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_57fe3fb2-5e49-45f7-9078-0a132d818659" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="mgnx-20181231.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_c40c57f1-80a5-4d36-a7be-58d6ceeb7af6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_a4ecc327-c41a-4c0e-bbc1-ee66fcd168f6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c40c57f1-80a5-4d36-a7be-58d6ceeb7af6" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_a4ecc327-c41a-4c0e-bbc1-ee66fcd168f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_fd010569-2000-4ccb-a1e4-13ebf22df058" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c40c57f1-80a5-4d36-a7be-58d6ceeb7af6" xlink:to="loc_us-gaap_UseOfEstimates_fd010569-2000-4ccb-a1e4-13ebf22df058" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_b0925a1f-ac3e-4701-8c2f-910c945beed0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c40c57f1-80a5-4d36-a7be-58d6ceeb7af6" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_b0925a1f-ac3e-4701-8c2f-910c945beed0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_a3b074af-c6b6-4ab6-9816-2ffa68687c80" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c40c57f1-80a5-4d36-a7be-58d6ceeb7af6" xlink:to="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_a3b074af-c6b6-4ab6-9816-2ffa68687c80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_101ec86f-3388-428f-8474-f09c9568d0e2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c40c57f1-80a5-4d36-a7be-58d6ceeb7af6" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_101ec86f-3388-428f-8474-f09c9568d0e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_f64575b7-0a2a-49de-bf29-2badfd148e50" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c40c57f1-80a5-4d36-a7be-58d6ceeb7af6" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_f64575b7-0a2a-49de-bf29-2badfd148e50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_b202588e-1172-47ca-9194-865762652c25" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c40c57f1-80a5-4d36-a7be-58d6ceeb7af6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_b202588e-1172-47ca-9194-865762652c25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_28a2aaf5-56b5-41e7-a123-f73ac01a26cd" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c40c57f1-80a5-4d36-a7be-58d6ceeb7af6" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_28a2aaf5-56b5-41e7-a123-f73ac01a26cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_f9c1acd5-cca0-4577-9c5d-765a0f4ca3a0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c40c57f1-80a5-4d36-a7be-58d6ceeb7af6" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_f9c1acd5-cca0-4577-9c5d-765a0f4ca3a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_de046535-1572-470f-a339-35509cafbc96" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c40c57f1-80a5-4d36-a7be-58d6ceeb7af6" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_de046535-1572-470f-a339-35509cafbc96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_5422146a-1759-4a9b-9134-cf6a69f77a1f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c40c57f1-80a5-4d36-a7be-58d6ceeb7af6" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_5422146a-1759-4a9b-9134-cf6a69f77a1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_88b06faf-5a26-4aa3-884e-eac49fb1a427" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c40c57f1-80a5-4d36-a7be-58d6ceeb7af6" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_88b06faf-5a26-4aa3-884e-eac49fb1a427" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_83a371e7-aeb8-4b68-8542-289b91674917" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c40c57f1-80a5-4d36-a7be-58d6ceeb7af6" xlink:to="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_83a371e7-aeb8-4b68-8542-289b91674917" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_8754d7f7-8dd8-4ac0-9cc2-a5edaacd4ddb" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c40c57f1-80a5-4d36-a7be-58d6ceeb7af6" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_8754d7f7-8dd8-4ac0-9cc2-a5edaacd4ddb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_490155e1-316f-449c-86eb-b42360bf9432" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c40c57f1-80a5-4d36-a7be-58d6ceeb7af6" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_490155e1-316f-449c-86eb-b42360bf9432" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="mgnx-20181231.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_d3251b9d-d4d8-49f4-8834-a780b83d0024" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_0952977d-f6f3-4370-bbcc-40247f06f838" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d3251b9d-d4d8-49f4-8834-a780b83d0024" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_0952977d-f6f3-4370-bbcc-40247f06f838" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_f43ec3dc-3d3e-4cf4-a32d-9c18c81c019a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d3251b9d-d4d8-49f4-8834-a780b83d0024" xlink:to="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_f43ec3dc-3d3e-4cf4-a32d-9c18c81c019a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock_08d36716-5182-44ed-92b8-087584c04421" xlink:href="mgnx-20181231.xsd#mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d3251b9d-d4d8-49f4-8834-a780b83d0024" xlink:to="loc_mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock_08d36716-5182-44ed-92b8-087584c04421" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_53495024-2d5c-419c-bf49-8fd18d880fab" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d3251b9d-d4d8-49f4-8834-a780b83d0024" xlink:to="loc_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_53495024-2d5c-419c-bf49-8fd18d880fab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_c3a43681-ad88-426a-a553-5d29252f85a4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d3251b9d-d4d8-49f4-8834-a780b83d0024" xlink:to="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_c3a43681-ad88-426a-a553-5d29252f85a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="mgnx-20181231.xsd#SummaryofSignificantAccountingPoliciesDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_a5466b94-dfaa-4210-99d3-5d35b6c773db" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_ece444da-0591-4032-ab1d-3041616bbf18" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a5466b94-dfaa-4210-99d3-5d35b6c773db" xlink:to="loc_us-gaap_NumberOfOperatingSegments_ece444da-0591-4032-ab1d-3041616bbf18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities_308c32d2-1701-4169-94d1-ec5a16cf868b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a5466b94-dfaa-4210-99d3-5d35b6c773db" xlink:to="loc_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities_308c32d2-1701-4169-94d1-ec5a16cf868b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_a5eef97b-4a08-4c54-bab1-0e188599ce70" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a5466b94-dfaa-4210-99d3-5d35b6c773db" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_a5eef97b-4a08-4c54-bab1-0e188599ce70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleCarryingValueOfAsset_9ae5deac-b83d-4a5f-ace8-03910d986e3f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleCarryingValueOfAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a5466b94-dfaa-4210-99d3-5d35b6c773db" xlink:to="loc_us-gaap_ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleCarryingValueOfAsset_9ae5deac-b83d-4a5f-ace8-03910d986e3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroup_b15222d9-24cf-49f1-831f-a1a602b741cb" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsHeldForSaleNotPartOfDisposalGroup"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a5466b94-dfaa-4210-99d3-5d35b6c773db" xlink:to="loc_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroup_b15222d9-24cf-49f1-831f-a1a602b741cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_660549fb-fa3d-441a-b4b8-1717e0b78640" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a5466b94-dfaa-4210-99d3-5d35b6c773db" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_660549fb-fa3d-441a-b4b8-1717e0b78640" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails" xlink:type="simple" xlink:href="mgnx-20181231.xsd#SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_d7622711-56ad-400c-973c-89a62f6ce897" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5ebb27db-19e6-444b-aff6-71ff008f9d6e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d7622711-56ad-400c-973c-89a62f6ce897" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5ebb27db-19e6-444b-aff6-71ff008f9d6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9ec6f98c-4886-4905-84d2-dff7c11b7c18" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5ebb27db-19e6-444b-aff6-71ff008f9d6e" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9ec6f98c-4886-4905-84d2-dff7c11b7c18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_01e1b2dd-1628-4b82-9d4c-a86683ab61fa" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9ec6f98c-4886-4905-84d2-dff7c11b7c18" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_01e1b2dd-1628-4b82-9d4c-a86683ab61fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_cba3be27-c62e-4c10-aa1a-246375bf97d1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_01e1b2dd-1628-4b82-9d4c-a86683ab61fa" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_cba3be27-c62e-4c10-aa1a-246375bf97d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_4027f0c4-851e-41a1-b37d-e45c664d2c2f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_01e1b2dd-1628-4b82-9d4c-a86683ab61fa" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_4027f0c4-851e-41a1-b37d-e45c664d2c2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_82d33a74-55ae-48a5-9b14-c76b0b98df14" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_01e1b2dd-1628-4b82-9d4c-a86683ab61fa" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_82d33a74-55ae-48a5-9b14-c76b0b98df14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_7a8a2e1e-6919-4517-aac4-b992e33dc751" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5ebb27db-19e6-444b-aff6-71ff008f9d6e" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_7a8a2e1e-6919-4517-aac4-b992e33dc751" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_2f880cdd-4f29-4579-9bb4-16cb865b5ed2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_7a8a2e1e-6919-4517-aac4-b992e33dc751" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_2f880cdd-4f29-4579-9bb4-16cb865b5ed2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_3902032e-8c78-44c3-bfaf-da1a286fbc45" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_2f880cdd-4f29-4579-9bb4-16cb865b5ed2" xlink:to="loc_us-gaap_MoneyMarketFundsMember_3902032e-8c78-44c3-bfaf-da1a286fbc45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_eaf1201f-b529-4aed-b71c-246b7d520891" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_2f880cdd-4f29-4579-9bb4-16cb865b5ed2" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_eaf1201f-b529-4aed-b71c-246b7d520891" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_0c2fa6d0-23e7-4bd9-9522-8733afcad44c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_2f880cdd-4f29-4579-9bb4-16cb865b5ed2" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_0c2fa6d0-23e7-4bd9-9522-8733afcad44c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_9caec703-f167-4858-871b-ec154fb65b8e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_2f880cdd-4f29-4579-9bb4-16cb865b5ed2" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_9caec703-f167-4858-871b-ec154fb65b8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5d33ea3d-4caa-4f4e-9a24-754d18e569d1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5ebb27db-19e6-444b-aff6-71ff008f9d6e" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5d33ea3d-4caa-4f4e-9a24-754d18e569d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_0e86a8d6-f1a9-489e-8996-682adfcbb3bc" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5d33ea3d-4caa-4f4e-9a24-754d18e569d1" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_0e86a8d6-f1a9-489e-8996-682adfcbb3bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_d6cc54c8-5bec-4d5c-9287-1c28eb9c9c5d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_0e86a8d6-f1a9-489e-8996-682adfcbb3bc" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_d6cc54c8-5bec-4d5c-9287-1c28eb9c9c5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecurities_f7afc0c1-b010-444b-8617-54c202e2b1da" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_0e86a8d6-f1a9-489e-8996-682adfcbb3bc" xlink:to="loc_us-gaap_AvailableForSaleSecurities_f7afc0c1-b010-444b-8617-54c202e2b1da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_dec64ce9-fa02-436c-ac64-6907f4232070" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_0e86a8d6-f1a9-489e-8996-682adfcbb3bc" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_dec64ce9-fa02-436c-ac64-6907f4232070" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_WarrantsFairValueDisclosure_3b7e9132-3d8e-4ae9-a454-35b8808e6b76" xlink:href="mgnx-20181231.xsd#mgnx_WarrantsFairValueDisclosure"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_0e86a8d6-f1a9-489e-8996-682adfcbb3bc" xlink:to="loc_mgnx_WarrantsFairValueDisclosure_3b7e9132-3d8e-4ae9-a454-35b8808e6b76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_af5377fb-e75d-4ebb-a3df-84c5895218e1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_0e86a8d6-f1a9-489e-8996-682adfcbb3bc" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_af5377fb-e75d-4ebb-a3df-84c5895218e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedDetails" xlink:type="simple" xlink:href="mgnx-20181231.xsd#SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_5ff6a0ea-03f1-4189-be85-90dbfb0079a5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_59b0d61a-5f83-453b-9b3a-71e30645081f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5ff6a0ea-03f1-4189-be85-90dbfb0079a5" xlink:to="loc_us-gaap_ConcentrationRiskTable_59b0d61a-5f83-453b-9b3a-71e30645081f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_75c071bb-a303-431a-bbd8-659187c3f2b5" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_59b0d61a-5f83-453b-9b3a-71e30645081f" xlink:to="loc_srt_MajorCustomersAxis_75c071bb-a303-431a-bbd8-659187c3f2b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_b5a87fc7-eeda-468d-9a21-1d342182221e" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_75c071bb-a303-431a-bbd8-659187c3f2b5" xlink:to="loc_srt_NameOfMajorCustomerDomain_b5a87fc7-eeda-468d-9a21-1d342182221e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteCorporationMember_da3e55e8-b527-48ee-a56e-4696041b9c70" xlink:href="mgnx-20181231.xsd#mgnx_IncyteCorporationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_b5a87fc7-eeda-468d-9a21-1d342182221e" xlink:to="loc_mgnx_IncyteCorporationMember_da3e55e8-b527-48ee-a56e-4696041b9c70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_JanssenBiotechIncMember_66299644-7059-4fde-8f25-0867d20b7e74" xlink:href="mgnx-20181231.xsd#mgnx_JanssenBiotechIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_b5a87fc7-eeda-468d-9a21-1d342182221e" xlink:to="loc_mgnx_JanssenBiotechIncMember_66299644-7059-4fde-8f25-0867d20b7e74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionBioMember_25242f4d-2729-452b-b647-5fcacfd95d80" xlink:href="mgnx-20181231.xsd#mgnx_ProventionBioMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_b5a87fc7-eeda-468d-9a21-1d342182221e" xlink:to="loc_mgnx_ProventionBioMember_25242f4d-2729-452b-b647-5fcacfd95d80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a06714fe-fbfb-4ccb-8415-34e30f8d1d82" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_59b0d61a-5f83-453b-9b3a-71e30645081f" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a06714fe-fbfb-4ccb-8415-34e30f8d1d82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_c69439f9-c8d8-475b-92de-6b40d517e7c9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a06714fe-fbfb-4ccb-8415-34e30f8d1d82" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_c69439f9-c8d8-475b-92de-6b40d517e7c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_024ec909-dcb1-49c0-ba9c-92efca5e1c40" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_c69439f9-c8d8-475b-92de-6b40d517e7c9" xlink:to="loc_us-gaap_SalesRevenueNetMember_024ec909-dcb1-49c0-ba9c-92efca5e1c40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_12c93043-e9a7-43b7-bd80-04b2bc074a6f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_59b0d61a-5f83-453b-9b3a-71e30645081f" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_12c93043-e9a7-43b7-bd80-04b2bc074a6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_e29a1a48-82fe-4655-86a3-1e666e5c2947" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_12c93043-e9a7-43b7-bd80-04b2bc074a6f" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_e29a1a48-82fe-4655-86a3-1e666e5c2947" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_45af469b-4f4e-472a-9006-c6171d38c31d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_e29a1a48-82fe-4655-86a3-1e666e5c2947" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_45af469b-4f4e-472a-9006-c6171d38c31d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_08230e48-e9a2-4074-8f4b-756ce82ae1b5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_59b0d61a-5f83-453b-9b3a-71e30645081f" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_08230e48-e9a2-4074-8f4b-756ce82ae1b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_244ded6b-87f8-493d-af3e-42f3cd9e9e88" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_08230e48-e9a2-4074-8f4b-756ce82ae1b5" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_244ded6b-87f8-493d-af3e-42f3cd9e9e88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofAccountsReceivableDetails" xlink:type="simple" xlink:href="mgnx-20181231.xsd#SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofAccountsReceivableDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofAccountsReceivableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_61e177db-8f5f-4669-930d-2c76da0369b1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_9bcde865-7f1e-4c2c-a728-06c799af8f3b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_61e177db-8f5f-4669-930d-2c76da0369b1" xlink:to="loc_us-gaap_ConcentrationRiskTable_9bcde865-7f1e-4c2c-a728-06c799af8f3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_cac5cdcd-3511-45bc-ba01-00faf18ff72d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_9bcde865-7f1e-4c2c-a728-06c799af8f3b" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_cac5cdcd-3511-45bc-ba01-00faf18ff72d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_ab6a2dbe-ed73-498e-bdb5-6116b7a25ceb" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_cac5cdcd-3511-45bc-ba01-00faf18ff72d" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_ab6a2dbe-ed73-498e-bdb5-6116b7a25ceb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_6f3e30ad-fab3-4894-90d1-0eed56811fb5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_ab6a2dbe-ed73-498e-bdb5-6116b7a25ceb" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_6f3e30ad-fab3-4894-90d1-0eed56811fb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_b86cf8b2-b8c8-4370-b595-8346b99cb613" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_9bcde865-7f1e-4c2c-a728-06c799af8f3b" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_b86cf8b2-b8c8-4370-b595-8346b99cb613" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_e57235e5-355e-493c-acee-b006a9011d2a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_b86cf8b2-b8c8-4370-b595-8346b99cb613" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_e57235e5-355e-493c-acee-b006a9011d2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_0a1f4dcd-1887-4142-858b-c10bc4b252e8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_e57235e5-355e-493c-acee-b006a9011d2a" xlink:to="loc_us-gaap_AccountsReceivableMember_0a1f4dcd-1887-4142-858b-c10bc4b252e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_c8881d93-8bfd-488e-96af-c975f9d33a83" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_9bcde865-7f1e-4c2c-a728-06c799af8f3b" xlink:to="loc_srt_MajorCustomersAxis_c8881d93-8bfd-488e-96af-c975f9d33a83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_984b0f57-a059-4ac7-8535-24dd6f56fc7a" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_c8881d93-8bfd-488e-96af-c975f9d33a83" xlink:to="loc_srt_NameOfMajorCustomerDomain_984b0f57-a059-4ac7-8535-24dd6f56fc7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabLimitedMember_ec231203-ded6-4d70-afab-a2b39af1f145" xlink:href="mgnx-20181231.xsd#mgnx_ZaiLabLimitedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_984b0f57-a059-4ac7-8535-24dd6f56fc7a" xlink:to="loc_mgnx_ZaiLabLimitedMember_ec231203-ded6-4d70-afab-a2b39af1f145" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteCorporationMember_ce2a5571-c856-4365-ac99-06568611e03e" xlink:href="mgnx-20181231.xsd#mgnx_IncyteCorporationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_984b0f57-a059-4ac7-8535-24dd6f56fc7a" xlink:to="loc_mgnx_IncyteCorporationMember_ce2a5571-c856-4365-ac99-06568611e03e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member_ce687695-20de-4053-804e-28758243df7b" xlink:href="mgnx-20181231.xsd#mgnx_F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_984b0f57-a059-4ac7-8535-24dd6f56fc7a" xlink:to="loc_mgnx_F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member_ce687695-20de-4053-804e-28758243df7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_LesLaboratoiresServierAndInstitutDeRecherchesServierServierMember_109b8d1f-c133-42c3-b811-2c30211e7e78" xlink:href="mgnx-20181231.xsd#mgnx_LesLaboratoiresServierAndInstitutDeRecherchesServierServierMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_984b0f57-a059-4ac7-8535-24dd6f56fc7a" xlink:to="loc_mgnx_LesLaboratoiresServierAndInstitutDeRecherchesServierServierMember_109b8d1f-c133-42c3-b811-2c30211e7e78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_bd9e9217-d050-434f-ad70-aacd54b3ef28" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_9bcde865-7f1e-4c2c-a728-06c799af8f3b" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_bd9e9217-d050-434f-ad70-aacd54b3ef28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_d3ebe46d-aaab-4f4a-81e7-bf5a32b151b1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_bd9e9217-d050-434f-ad70-aacd54b3ef28" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_d3ebe46d-aaab-4f4a-81e7-bf5a32b151b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails" xlink:type="simple" xlink:href="mgnx-20181231.xsd#SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_4951776e-7a85-4708-9df5-2ad117be3508" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_55ebeb83-7324-447d-bdc5-e0556bc659d4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4951776e-7a85-4708-9df5-2ad117be3508" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_55ebeb83-7324-447d-bdc5-e0556bc659d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d1f52d1c-1d52-4705-8a52-70f55b801189" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_55ebeb83-7324-447d-bdc5-e0556bc659d4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d1f52d1c-1d52-4705-8a52-70f55b801189" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_574c7332-2f43-4210-8c5d-d82a1ab19939" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d1f52d1c-1d52-4705-8a52-70f55b801189" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_574c7332-2f43-4210-8c5d-d82a1ab19939" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_0e3dde8a-1f5a-45c9-9b3b-e17dc0f9685d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_574c7332-2f43-4210-8c5d-d82a1ab19939" xlink:to="loc_us-gaap_ComputerEquipmentMember_0e3dde8a-1f5a-45c9-9b3b-e17dc0f9685d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_e703914e-12d9-4cc8-a233-3a5806b359c7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_574c7332-2f43-4210-8c5d-d82a1ab19939" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_e703914e-12d9-4cc8-a233-3a5806b359c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_b6922d74-7f00-4c13-8db4-4d6d3a9a25af" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_574c7332-2f43-4210-8c5d-d82a1ab19939" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_b6922d74-7f00-4c13-8db4-4d6d3a9a25af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_LaboratoryAndOfficeEquipmentMember_dfa3fa2f-2d49-4175-9c7c-5a5eabc8a497" xlink:href="mgnx-20181231.xsd#mgnx_LaboratoryAndOfficeEquipmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_574c7332-2f43-4210-8c5d-d82a1ab19939" xlink:to="loc_mgnx_LaboratoryAndOfficeEquipmentMember_dfa3fa2f-2d49-4175-9c7c-5a5eabc8a497" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_46b3e029-c25c-44b8-9ea1-03904cbdd83d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_574c7332-2f43-4210-8c5d-d82a1ab19939" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_46b3e029-c25c-44b8-9ea1-03904cbdd83d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e49e1ac7-e333-49f0-9f8e-92d7130997af" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_55ebeb83-7324-447d-bdc5-e0556bc659d4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e49e1ac7-e333-49f0-9f8e-92d7130997af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_7b0233f6-3dfa-4ca7-aca9-5cea08c028ae" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e49e1ac7-e333-49f0-9f8e-92d7130997af" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_7b0233f6-3dfa-4ca7-aca9-5cea08c028ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromtheCalculationofDilutedLossPerShareDetails" xlink:type="simple" xlink:href="mgnx-20181231.xsd#SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromtheCalculationofDilutedLossPerShareDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromtheCalculationofDilutedLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_63a5867e-635f-47ec-b693-c3db7fb73667" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_45e5dc06-a28f-4bb1-9b65-bbb7751a3d71" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_63a5867e-635f-47ec-b693-c3db7fb73667" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_45e5dc06-a28f-4bb1-9b65-bbb7751a3d71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_f05e02fb-0e0b-4db1-89d1-6e93f2900292" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_45e5dc06-a28f-4bb1-9b65-bbb7751a3d71" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_f05e02fb-0e0b-4db1-89d1-6e93f2900292" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2cd12a0d-8e52-4ac6-9099-3b3f2e449990" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_f05e02fb-0e0b-4db1-89d1-6e93f2900292" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2cd12a0d-8e52-4ac6-9099-3b3f2e449990" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember_a0efc592-8c74-4940-9500-a2604661c452" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2cd12a0d-8e52-4ac6-9099-3b3f2e449990" xlink:to="loc_us-gaap_StockOptionMember_a0efc592-8c74-4940-9500-a2604661c452" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d63b7dc6-27d1-4f57-a59a-3fb118fc669b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_45e5dc06-a28f-4bb1-9b65-bbb7751a3d71" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d63b7dc6-27d1-4f57-a59a-3fb118fc669b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1c0a3862-2dad-4743-ade3-9306ba16c829" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d63b7dc6-27d1-4f57-a59a-3fb118fc669b" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1c0a3862-2dad-4743-ade3-9306ba16c829" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesAdoptionof606Details" xlink:type="simple" xlink:href="mgnx-20181231.xsd#SummaryofSignificantAccountingPoliciesAdoptionof606Details"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesAdoptionof606Details" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_c5f5ab37-b4ab-418f-90e1-2c8b57688f6a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_efbeb687-4868-4b82-8f77-af467e11c075" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c5f5ab37-b4ab-418f-90e1-2c8b57688f6a" xlink:to="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_efbeb687-4868-4b82-8f77-af467e11c075" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_366dc0a3-6d68-4539-8edf-310d41773ba4" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_efbeb687-4868-4b82-8f77-af467e11c075" xlink:to="loc_srt_ProductOrServiceAxis_366dc0a3-6d68-4539-8edf-310d41773ba4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a566d283-a7f4-4a4b-bc29-fc5805cb3732" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_366dc0a3-6d68-4539-8edf-310d41773ba4" xlink:to="loc_srt_ProductsAndServicesDomain_a566d283-a7f4-4a4b-bc29-fc5805cb3732" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueFromCollaborativeAgreementsMember_45c19156-1809-467f-84d8-3dcefd1334f1" xlink:href="mgnx-20181231.xsd#mgnx_RevenueFromCollaborativeAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_a566d283-a7f4-4a4b-bc29-fc5805cb3732" xlink:to="loc_mgnx_RevenueFromCollaborativeAgreementsMember_45c19156-1809-467f-84d8-3dcefd1334f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_b1a129b2-b1f6-4ccc-94d1-b111a0b55bfa" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_efbeb687-4868-4b82-8f77-af467e11c075" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_b1a129b2-b1f6-4ccc-94d1-b111a0b55bfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_370838ce-de9f-456e-9f24-494524a0fbfc" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_b1a129b2-b1f6-4ccc-94d1-b111a0b55bfa" xlink:to="loc_us-gaap_TypeOfAdoptionMember_370838ce-de9f-456e-9f24-494524a0fbfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201409Member_644d36b3-9426-43a1-8654-4f28da4b4918" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_370838ce-de9f-456e-9f24-494524a0fbfc" xlink:to="loc_us-gaap_AccountingStandardsUpdate201409Member_644d36b3-9426-43a1-8654-4f28da4b4918" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_c1c7aacd-c756-406d-a651-046595a23b7d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_efbeb687-4868-4b82-8f77-af467e11c075" xlink:to="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_c1c7aacd-c756-406d-a651-046595a23b7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_5f460a0e-451d-43c7-9521-1991f94f47d5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_c1c7aacd-c756-406d-a651-046595a23b7d" xlink:to="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_5f460a0e-451d-43c7-9521-1991f94f47d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member_a0dfed20-4d1f-422b-80c2-0263ae73b6ca" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_5f460a0e-451d-43c7-9521-1991f94f47d5" xlink:to="loc_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member_a0dfed20-4d1f-422b-80c2-0263ae73b6ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_aa6d0a11-c293-43c5-a1f5-4d2f79bc0494" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_5f460a0e-451d-43c7-9521-1991f94f47d5" xlink:to="loc_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_aa6d0a11-c293-43c5-a1f5-4d2f79bc0494" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_81652820-242c-4325-8c73-e2e225a6bd67" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_efbeb687-4868-4b82-8f77-af467e11c075" xlink:to="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_81652820-242c-4325-8c73-e2e225a6bd67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueCurrent_303c0c9a-12bb-4f5a-a7c6-1e015ea77d12" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredRevenueCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_81652820-242c-4325-8c73-e2e225a6bd67" xlink:to="loc_us-gaap_DeferredRevenueCurrent_303c0c9a-12bb-4f5a-a7c6-1e015ea77d12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent_2704a7cc-6a4e-41a5-9a51-cea8f930ba08" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredRevenueNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_81652820-242c-4325-8c73-e2e225a6bd67" xlink:to="loc_us-gaap_DeferredRevenueNoncurrent_2704a7cc-6a4e-41a5-9a51-cea8f930ba08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ff671913-68d6-4be6-b0a6-72e622d67833" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_81652820-242c-4325-8c73-e2e225a6bd67" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ff671913-68d6-4be6-b0a6-72e622d67833" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_b704700c-a125-49ac-8828-ccb855b9df0d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_81652820-242c-4325-8c73-e2e225a6bd67" xlink:to="loc_us-gaap_Revenues_b704700c-a125-49ac-8828-ccb855b9df0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_02c16341-97aa-48b9-80bc-5c5e624b7484" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_81652820-242c-4325-8c73-e2e225a6bd67" xlink:to="loc_us-gaap_NetIncomeLoss_02c16341-97aa-48b9-80bc-5c5e624b7484" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_6d3c32e1-166b-4d16-b97d-71b1c4016792" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_81652820-242c-4325-8c73-e2e225a6bd67" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_6d3c32e1-166b-4d16-b97d-71b1c4016792" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryofSignficantAccountingPoliciesContractWithCustomerLiabilityDetails" xlink:type="simple" xlink:href="mgnx-20181231.xsd#SummaryofSignficantAccountingPoliciesContractWithCustomerLiabilityDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/SummaryofSignficantAccountingPoliciesContractWithCustomerLiabilityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_d44eacad-0f5d-4fab-bdd9-5aedd603874c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_2c9b74ee-03f1-4005-a30e-cba31a33d748" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d44eacad-0f5d-4fab-bdd9-5aedd603874c" xlink:to="loc_us-gaap_ContractWithCustomerLiability_2c9b74ee-03f1-4005-a30e-cba31a33d748" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination_5a5efd6d-f628-4b04-adff-428db8f469cf" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d44eacad-0f5d-4fab-bdd9-5aedd603874c" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination_5a5efd6d-f628-4b04-adff-428db8f469cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_b5f5afa4-aa03-407f-bd77-966b2bdce54a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d44eacad-0f5d-4fab-bdd9-5aedd603874c" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_b5f5afa4-aa03-407f-bd77-966b2bdce54a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_015e8f1b-e579-4faf-8bb2-5284e916a77c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d44eacad-0f5d-4fab-bdd9-5aedd603874c" xlink:to="loc_us-gaap_ContractWithCustomerLiability_015e8f1b-e579-4faf-8bb2-5284e916a77c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/MarketableSecurities" xlink:type="simple" xlink:href="mgnx-20181231.xsd#MarketableSecurities"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/MarketableSecurities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_e69a3610-001f-4b73-9507-01fb0c3f651a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_f326e54b-3cab-4787-97e0-2e09e4f2201d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_e69a3610-001f-4b73-9507-01fb0c3f651a" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_f326e54b-3cab-4787-97e0-2e09e4f2201d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/MarketableSecuritiesTables" xlink:type="simple" xlink:href="mgnx-20181231.xsd#MarketableSecuritiesTables"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/MarketableSecuritiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_fb432e1b-f768-48c5-83e3-201dee9ad307" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesTextBlock_af92a44d-b14d-46f0-9b75-0c7aaf4034ef" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_fb432e1b-f768-48c5-83e3-201dee9ad307" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesTextBlock_af92a44d-b14d-46f0-9b75-0c7aaf4034ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/MarketableSecuritiesDetails" xlink:type="simple" xlink:href="mgnx-20181231.xsd#MarketableSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/MarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_b378a953-9224-490b-9211-f1ceeb1cb3dd" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_c942e003-e09f-430c-86b0-d98bd6bfeba8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_b378a953-9224-490b-9211-f1ceeb1cb3dd" xlink:to="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_c942e003-e09f-430c-86b0-d98bd6bfeba8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_5424fb1f-1688-4a55-ae2c-ed72240e8593" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_c942e003-e09f-430c-86b0-d98bd6bfeba8" xlink:to="loc_us-gaap_FinancialInstrumentAxis_5424fb1f-1688-4a55-ae2c-ed72240e8593" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f1159ef8-522c-4ca3-9be7-2d5d58e27a35" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_5424fb1f-1688-4a55-ae2c-ed72240e8593" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f1159ef8-522c-4ca3-9be7-2d5d58e27a35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_b6c177ac-7719-4ac2-ab7b-15f8827ab152" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f1159ef8-522c-4ca3-9be7-2d5d58e27a35" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_b6c177ac-7719-4ac2-ab7b-15f8827ab152" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_8fc4599c-499c-4e02-bbe4-269db6048136" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f1159ef8-522c-4ca3-9be7-2d5d58e27a35" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_8fc4599c-499c-4e02-bbe4-269db6048136" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_65e5a589-feea-4182-8ad9-387f2d447a68" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f1159ef8-522c-4ca3-9be7-2d5d58e27a35" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_65e5a589-feea-4182-8ad9-387f2d447a68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_aa1f39aa-81ee-4f46-a92b-07d5f1ba10fc" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_c942e003-e09f-430c-86b0-d98bd6bfeba8" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_aa1f39aa-81ee-4f46-a92b-07d5f1ba10fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_d5bc4210-b4da-493f-bd4e-cbc6aa61afb3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_aa1f39aa-81ee-4f46-a92b-07d5f1ba10fc" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_d5bc4210-b4da-493f-bd4e-cbc6aa61afb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_c8bacbed-fb24-46a7-9a9b-93137ca9897d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_aa1f39aa-81ee-4f46-a92b-07d5f1ba10fc" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_c8bacbed-fb24-46a7-9a9b-93137ca9897d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_addbde1c-28c6-4804-9eaf-e222f32b6f78" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_aa1f39aa-81ee-4f46-a92b-07d5f1ba10fc" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_addbde1c-28c6-4804-9eaf-e222f32b6f78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3407f6d0-d26b-483f-9819-b82ad28ad301" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_aa1f39aa-81ee-4f46-a92b-07d5f1ba10fc" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3407f6d0-d26b-483f-9819-b82ad28ad301" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/MarketableSecuritiesAvailableForSaleSecuritiesDetails" xlink:type="simple" xlink:href="mgnx-20181231.xsd#MarketableSecuritiesAvailableForSaleSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/MarketableSecuritiesAvailableForSaleSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_af226f3e-ba46-4821-aca8-543170fd45c4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities_ac8e4743-08e2-412d-bfca-68b46b071d2d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_af226f3e-ba46-4821-aca8-543170fd45c4" xlink:to="loc_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities_ac8e4743-08e2-412d-bfca-68b46b071d2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOther_aeb48d1f-e446-4cbf-a903-9d510ca5f409" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestIncomeOther"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_af226f3e-ba46-4821-aca8-543170fd45c4" xlink:to="loc_us-gaap_InterestIncomeOther_aeb48d1f-e446-4cbf-a903-9d510ca5f409" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/PropertyEquipmentandSoftware" xlink:type="simple" xlink:href="mgnx-20181231.xsd#PropertyEquipmentandSoftware"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/PropertyEquipmentandSoftware" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_42ca65ef-3914-4981-88b8-cd2104b1ecb6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_0c271d6c-9032-4858-87d8-fa44e2ab30be" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_42ca65ef-3914-4981-88b8-cd2104b1ecb6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_0c271d6c-9032-4858-87d8-fa44e2ab30be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/PropertyEquipmentandSoftwareTables" xlink:type="simple" xlink:href="mgnx-20181231.xsd#PropertyEquipmentandSoftwareTables"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/PropertyEquipmentandSoftwareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_83623da1-c1a0-4364-8ce6-d0ef8f1c5bca" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_39ab49bb-43e5-4ed5-a2e8-c88f790405d0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_83623da1-c1a0-4364-8ce6-d0ef8f1c5bca" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_39ab49bb-43e5-4ed5-a2e8-c88f790405d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails" xlink:type="simple" xlink:href="mgnx-20181231.xsd#PropertyEquipmentandSoftwareDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_c6ed2029-8a21-4e70-9d57-40477d1a93f9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_ab7d6a94-a566-4672-8d3c-d5aa4f46ca0d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_c6ed2029-8a21-4e70-9d57-40477d1a93f9" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_ab7d6a94-a566-4672-8d3c-d5aa4f46ca0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0d90ca06-7233-462c-bd3d-286b58600eed" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_ab7d6a94-a566-4672-8d3c-d5aa4f46ca0d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0d90ca06-7233-462c-bd3d-286b58600eed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_208ab8b8-a56b-481f-b871-f53565f15c28" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0d90ca06-7233-462c-bd3d-286b58600eed" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_208ab8b8-a56b-481f-b871-f53565f15c28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_757a0d81-3469-40f0-8156-788133f880cf" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_208ab8b8-a56b-481f-b871-f53565f15c28" xlink:to="loc_us-gaap_ComputerEquipmentMember_757a0d81-3469-40f0-8156-788133f880cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_3f35161e-73b2-4369-acdd-40478e2c96b2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_208ab8b8-a56b-481f-b871-f53565f15c28" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_3f35161e-73b2-4369-acdd-40478e2c96b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_FurnitureAndOfficeEquipmentMember_ec03183a-1d3a-4d90-893b-e86089aadfaa" xlink:href="mgnx-20181231.xsd#mgnx_FurnitureAndOfficeEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_208ab8b8-a56b-481f-b871-f53565f15c28" xlink:to="loc_mgnx_FurnitureAndOfficeEquipmentMember_ec03183a-1d3a-4d90-893b-e86089aadfaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_1efe83cb-7540-4cd3-b0ed-62687fecdbcc" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_208ab8b8-a56b-481f-b871-f53565f15c28" xlink:to="loc_us-gaap_EquipmentMember_1efe83cb-7540-4cd3-b0ed-62687fecdbcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_7fe83822-1642-48b9-952d-69474c94ef36" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_208ab8b8-a56b-481f-b871-f53565f15c28" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_7fe83822-1642-48b9-952d-69474c94ef36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ce0493b5-8db3-416d-b290-9cc5c28c6a2a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_ab7d6a94-a566-4672-8d3c-d5aa4f46ca0d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ce0493b5-8db3-416d-b290-9cc5c28c6a2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_65667ec0-db6a-4213-984b-7564dc0671d9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ce0493b5-8db3-416d-b290-9cc5c28c6a2a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_65667ec0-db6a-4213-984b-7564dc0671d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross_a723a29e-b74c-4302-bd2c-b3d3a6ed51bf" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ce0493b5-8db3-416d-b290-9cc5c28c6a2a" xlink:to="loc_us-gaap_ConstructionInProgressGross_a723a29e-b74c-4302-bd2c-b3d3a6ed51bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_ee6eebd1-81e7-4c14-9951-37fef26ce04b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ce0493b5-8db3-416d-b290-9cc5c28c6a2a" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_ee6eebd1-81e7-4c14-9951-37fef26ce04b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_5029f1e0-9218-4329-86f2-94c19744689c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ce0493b5-8db3-416d-b290-9cc5c28c6a2a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_5029f1e0-9218-4329-86f2-94c19744689c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PropertyPlantAndEquipmentNonCashAdditions_e0bbe639-8a2b-4374-9584-caef519f6fc4" xlink:href="mgnx-20181231.xsd#mgnx_PropertyPlantAndEquipmentNonCashAdditions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ce0493b5-8db3-416d-b290-9cc5c28c6a2a" xlink:to="loc_mgnx_PropertyPlantAndEquipmentNonCashAdditions_e0bbe639-8a2b-4374-9584-caef519f6fc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_bb1abe87-ecaa-4baa-8c6e-a341f7902673" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ce0493b5-8db3-416d-b290-9cc5c28c6a2a" xlink:to="loc_us-gaap_Depreciation_bb1abe87-ecaa-4baa-8c6e-a341f7902673" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockholdersEquity" xlink:type="simple" xlink:href="mgnx-20181231.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_632eabc3-29bd-4e6a-8a4c-a4f6b2112cd5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_ef963595-47c5-4afa-a71f-0184c5b2f265" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_632eabc3-29bd-4e6a-8a4c-a4f6b2112cd5" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_ef963595-47c5-4afa-a71f-0184c5b2f265" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockholdersEquityDetails" xlink:type="simple" xlink:href="mgnx-20181231.xsd#StockholdersEquityDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/StockholdersEquityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_2d3a5fe8-fce3-4958-a2ad-cefd21d71a0e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_d0d1edca-ecfd-4d29-a838-6f6d8731be1f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_2d3a5fe8-fce3-4958-a2ad-cefd21d71a0e" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_d0d1edca-ecfd-4d29-a838-6f6d8731be1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_e37f7981-976a-49a7-adef-b617f1ea2e2b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d0d1edca-ecfd-4d29-a838-6f6d8731be1f" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_e37f7981-976a-49a7-adef-b617f1ea2e2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f44a2347-c5ec-46b7-93d2-a2e91a268adc" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_e37f7981-976a-49a7-adef-b617f1ea2e2b" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f44a2347-c5ec-46b7-93d2-a2e91a268adc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RegisteredDirectOfferingMember_0b53bb37-1c80-41f1-9b66-3db009df13bb" xlink:href="mgnx-20181231.xsd#mgnx_RegisteredDirectOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f44a2347-c5ec-46b7-93d2-a2e91a268adc" xlink:to="loc_mgnx_RegisteredDirectOfferingMember_0b53bb37-1c80-41f1-9b66-3db009df13bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_AtTheMarketOfferingMember_67e2e490-de1d-4191-b503-437fb07c8275" xlink:href="mgnx-20181231.xsd#mgnx_AtTheMarketOfferingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f44a2347-c5ec-46b7-93d2-a2e91a268adc" xlink:to="loc_mgnx_AtTheMarketOfferingMember_67e2e490-de1d-4191-b503-437fb07c8275" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_FirmCommitmentPublicUnderwrittenOfferMember_a7ab4d07-b3de-4465-a3ea-142f80d164d7" xlink:href="mgnx-20181231.xsd#mgnx_FirmCommitmentPublicUnderwrittenOfferMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f44a2347-c5ec-46b7-93d2-a2e91a268adc" xlink:to="loc_mgnx_FirmCommitmentPublicUnderwrittenOfferMember_a7ab4d07-b3de-4465-a3ea-142f80d164d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_04aadb46-ef26-4432-9f99-3e59e17bfa9e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f44a2347-c5ec-46b7-93d2-a2e91a268adc" xlink:to="loc_us-gaap_OverAllotmentOptionMember_04aadb46-ef26-4432-9f99-3e59e17bfa9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_feefa782-ddca-49ce-9eaa-cfc65f878adb" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d0d1edca-ecfd-4d29-a838-6f6d8731be1f" xlink:to="loc_us-gaap_StatementClassOfStockAxis_feefa782-ddca-49ce-9eaa-cfc65f878adb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_808ab1c4-8faa-4653-9e53-d9b388b693aa" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_feefa782-ddca-49ce-9eaa-cfc65f878adb" xlink:to="loc_us-gaap_ClassOfStockDomain_808ab1c4-8faa-4653-9e53-d9b388b693aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_UndesignatedPreferredStockMember_9370487f-1757-4ce0-93d7-042bcd622c46" xlink:href="mgnx-20181231.xsd#mgnx_UndesignatedPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_808ab1c4-8faa-4653-9e53-d9b388b693aa" xlink:to="loc_mgnx_UndesignatedPreferredStockMember_9370487f-1757-4ce0-93d7-042bcd622c46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_40f3086a-a886-46e0-b529-47b608e8f998" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d0d1edca-ecfd-4d29-a838-6f6d8731be1f" xlink:to="loc_us-gaap_ClassOfStockLineItems_40f3086a-a886-46e0-b529-47b608e8f998" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_413b7a63-b4a0-4882-af36-bd9532890e82" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_40f3086a-a886-46e0-b529-47b608e8f998" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_413b7a63-b4a0-4882-af36-bd9532890e82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_279ef8d1-1c75-4267-ba1b-ee67d73ffcda" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_40f3086a-a886-46e0-b529-47b608e8f998" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_279ef8d1-1c75-4267-ba1b-ee67d73ffcda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_bee4d2ac-043d-4982-89b9-18f53b473259" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_40f3086a-a886-46e0-b529-47b608e8f998" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_bee4d2ac-043d-4982-89b9-18f53b473259" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_6a8484c3-d934-422a-a9df-78a3abb96df4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_40f3086a-a886-46e0-b529-47b608e8f998" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_6a8484c3-d934-422a-a9df-78a3abb96df4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_5a2c7c95-b08b-411b-a0eb-fbf3421f36f8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_40f3086a-a886-46e0-b529-47b608e8f998" xlink:to="loc_us-gaap_PreferredStockSharesIssued_5a2c7c95-b08b-411b-a0eb-fbf3421f36f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_b9ed801c-97b7-4314-a9aa-89be3d2cfe59" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_40f3086a-a886-46e0-b529-47b608e8f998" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_b9ed801c-97b7-4314-a9aa-89be3d2cfe59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_4194b988-5c24-4e11-beaf-528aaae938bb" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_40f3086a-a886-46e0-b529-47b608e8f998" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_4194b988-5c24-4e11-beaf-528aaae938bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_af146fa3-46f4-4496-a9df-babb1ece9d2a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_40f3086a-a886-46e0-b529-47b608e8f998" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_af146fa3-46f4-4496-a9df-babb1ece9d2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_8ec70843-33dc-4b64-945f-b12a0f64a159" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_40f3086a-a886-46e0-b529-47b608e8f998" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_8ec70843-33dc-4b64-945f-b12a0f64a159" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_edf1ec3c-81fc-4be8-823e-491fab4379ed" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_40f3086a-a886-46e0-b529-47b608e8f998" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_edf1ec3c-81fc-4be8-823e-491fab4379ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CommonStockMaximumAmountAvailableForIssuance_f967e6a7-c71c-41e7-b836-734aead24c6a" xlink:href="mgnx-20181231.xsd#mgnx_CommonStockMaximumAmountAvailableForIssuance"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_40f3086a-a886-46e0-b529-47b608e8f998" xlink:to="loc_mgnx_CommonStockMaximumAmountAvailableForIssuance_f967e6a7-c71c-41e7-b836-734aead24c6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_b85de70e-7ae9-4e50-a1e2-9d0dcdd14682" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_40f3086a-a886-46e0-b529-47b608e8f998" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_b85de70e-7ae9-4e50-a1e2-9d0dcdd14682" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_049bb5ce-03c5-4221-884d-88a467c9b8bd" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_40f3086a-a886-46e0-b529-47b608e8f998" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_049bb5ce-03c5-4221-884d-88a467c9b8bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_1ca0984e-754b-4e90-9823-d76e3332ae0e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_40f3086a-a886-46e0-b529-47b608e8f998" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_1ca0984e-754b-4e90-9823-d76e3332ae0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockbasedCompensation" xlink:type="simple" xlink:href="mgnx-20181231.xsd#StockbasedCompensation"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/StockbasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a76727f0-9655-4614-8fc2-f123c7752533" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_d1ff8c97-4e01-43c1-93a2-6c89779d957a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a76727f0-9655-4614-8fc2-f123c7752533" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_d1ff8c97-4e01-43c1-93a2-6c89779d957a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockbasedCompensationTables" xlink:type="simple" xlink:href="mgnx-20181231.xsd#StockbasedCompensationTables"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/StockbasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_583306e1-3d34-452d-a478-4a2180506e39" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_5a1fb403-60e1-4545-a6e5-3d37de9bbeb3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_583306e1-3d34-452d-a478-4a2180506e39" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_5a1fb403-60e1-4545-a6e5-3d37de9bbeb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_3f0860d3-928b-44e3-862c-6e78d4059f5c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_583306e1-3d34-452d-a478-4a2180506e39" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_3f0860d3-928b-44e3-862c-6e78d4059f5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock_3152240f-50a7-4ffd-a96e-09c78c6d1ac8" xlink:href="mgnx-20181231.xsd#mgnx_ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_583306e1-3d34-452d-a478-4a2180506e39" xlink:to="loc_mgnx_ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock_3152240f-50a7-4ffd-a96e-09c78c6d1ac8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockbasedCompensationEmployeeStockPurchasePlanDetails" xlink:type="simple" xlink:href="mgnx-20181231.xsd#StockbasedCompensationEmployeeStockPurchasePlanDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/StockbasedCompensationEmployeeStockPurchasePlanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d595c29c-01ed-4000-8be8-7db21e025bbc" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7bf5773e-2127-400d-a98c-92db67c532e4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d595c29c-01ed-4000-8be8-7db21e025bbc" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7bf5773e-2127-400d-a98c-92db67c532e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_ec0f6a21-dd6b-451e-88e2-f8d447b1d89d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7bf5773e-2127-400d-a98c-92db67c532e4" xlink:to="loc_us-gaap_PlanNameAxis_ec0f6a21-dd6b-451e-88e2-f8d447b1d89d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_7c17e904-b82c-4dce-8ede-0afd0f50647c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_ec0f6a21-dd6b-451e-88e2-f8d447b1d89d" xlink:to="loc_us-gaap_PlanNameDomain_7c17e904-b82c-4dce-8ede-0afd0f50647c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember_a1c826f6-0407-4bb3-b5ea-cd31711831e5" xlink:href="mgnx-20181231.xsd#mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_7c17e904-b82c-4dce-8ede-0afd0f50647c" xlink:to="loc_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember_a1c826f6-0407-4bb3-b5ea-cd31711831e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_16009664-8633-4d29-afaf-bf74d8a68add" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7bf5773e-2127-400d-a98c-92db67c532e4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_16009664-8633-4d29-afaf-bf74d8a68add" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_c32c02ab-09b9-49a6-a84c-d438e3204a46" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_16009664-8633-4d29-afaf-bf74d8a68add" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_c32c02ab-09b9-49a6-a84c-d438e3204a46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent_88b8e379-9e16-45a9-bc30-f93c545a4696" xlink:href="mgnx-20181231.xsd#mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_16009664-8633-4d29-afaf-bf74d8a68add" xlink:to="loc_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent_88b8e379-9e16-45a9-bc30-f93c545a4696" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_0aa27e73-fe39-4058-85f4-fedeb9b0e396" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_16009664-8633-4d29-afaf-bf74d8a68add" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_0aa27e73-fe39-4058-85f4-fedeb9b0e396" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_5bb4748b-38ee-4013-a50f-9745600fb756" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_16009664-8633-4d29-afaf-bf74d8a68add" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_5bb4748b-38ee-4013-a50f-9745600fb756" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_812b9d4b-5fdf-4e06-b1d1-2badace981aa" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_16009664-8633-4d29-afaf-bf74d8a68add" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_812b9d4b-5fdf-4e06-b1d1-2badace981aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="mgnx-20181231.xsd#StockbasedCompensationStockBasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_71e62dd9-577e-4bff-b0e1-baf3491d663f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_957ba553-a5da-449e-895f-ca881dbe44e7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_71e62dd9-577e-4bff-b0e1-baf3491d663f" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_957ba553-a5da-449e-895f-ca881dbe44e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_7db8b23c-ba2c-4ef8-bd98-e9ad4069dcd0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_957ba553-a5da-449e-895f-ca881dbe44e7" xlink:to="loc_us-gaap_PlanNameAxis_7db8b23c-ba2c-4ef8-bd98-e9ad4069dcd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_12018fb3-4326-4253-af37-276dcf3ccfd9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_7db8b23c-ba2c-4ef8-bd98-e9ad4069dcd0" xlink:to="loc_us-gaap_PlanNameDomain_12018fb3-4326-4253-af37-276dcf3ccfd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_EquityIncentivePlan2003Member_cef385cd-3eac-43b3-81d2-8caf7751ba92" xlink:href="mgnx-20181231.xsd#mgnx_EquityIncentivePlan2003Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_12018fb3-4326-4253-af37-276dcf3ccfd9" xlink:to="loc_mgnx_EquityIncentivePlan2003Member_cef385cd-3eac-43b3-81d2-8caf7751ba92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_StockIncentivePlan2013Member_8d0de137-568a-4e4b-9527-b9fc193630a3" xlink:href="mgnx-20181231.xsd#mgnx_StockIncentivePlan2013Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_12018fb3-4326-4253-af37-276dcf3ccfd9" xlink:to="loc_mgnx_StockIncentivePlan2013Member_8d0de137-568a-4e4b-9527-b9fc193630a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d630a3d6-7624-4e12-961a-1a7bc4dc1d2b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_957ba553-a5da-449e-895f-ca881dbe44e7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d630a3d6-7624-4e12-961a-1a7bc4dc1d2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_851049c4-2024-4efe-8f09-7dead32ef9ad" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d630a3d6-7624-4e12-961a-1a7bc4dc1d2b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_851049c4-2024-4efe-8f09-7dead32ef9ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease_6a6b8ac9-b778-43b6-b7a5-0a2bd3563cab" xlink:href="mgnx-20181231.xsd#mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d630a3d6-7624-4e12-961a-1a7bc4dc1d2b" xlink:to="loc_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease_6a6b8ac9-b778-43b6-b7a5-0a2bd3563cab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f7f5a103-0214-49d9-9b03-32d324e0e990" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d630a3d6-7624-4e12-961a-1a7bc4dc1d2b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f7f5a103-0214-49d9-9b03-32d324e0e990" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6e2330e9-c223-41fa-9adf-eea09453df64" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d630a3d6-7624-4e12-961a-1a7bc4dc1d2b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6e2330e9-c223-41fa-9adf-eea09453df64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance_dd9c948d-b3ee-4af7-a854-94000000767a" xlink:href="mgnx-20181231.xsd#mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d630a3d6-7624-4e12-961a-1a7bc4dc1d2b" xlink:to="loc_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance_dd9c948d-b3ee-4af7-a854-94000000767a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan_793dfd35-1e4f-4f04-8676-fb05b1e9e440" xlink:href="mgnx-20181231.xsd#mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d630a3d6-7624-4e12-961a-1a7bc4dc1d2b" xlink:to="loc_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan_793dfd35-1e4f-4f04-8676-fb05b1e9e440" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_5b70d301-fdc9-41fd-9a17-89eb35149a99" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_71e62dd9-577e-4bff-b0e1-baf3491d663f" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_5b70d301-fdc9-41fd-9a17-89eb35149a99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_4d74b4a6-7cac-402d-a5b1-586913a65458" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_5b70d301-fdc9-41fd-9a17-89eb35149a99" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_4d74b4a6-7cac-402d-a5b1-586913a65458" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_eb94ab17-1a04-413a-9ff6-2e932d40d024" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_4d74b4a6-7cac-402d-a5b1-586913a65458" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_eb94ab17-1a04-413a-9ff6-2e932d40d024" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_c768bce8-c138-401e-8a8a-ae3c74944f5d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_eb94ab17-1a04-413a-9ff6-2e932d40d024" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_c768bce8-c138-401e-8a8a-ae3c74944f5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_f8786fd6-637e-40ca-8167-b8f354699485" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_eb94ab17-1a04-413a-9ff6-2e932d40d024" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_f8786fd6-637e-40ca-8167-b8f354699485" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1f931af8-60e2-4ab3-b79b-1e7b19a93a4c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_5b70d301-fdc9-41fd-9a17-89eb35149a99" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1f931af8-60e2-4ab3-b79b-1e7b19a93a4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_2dcdfd90-c2a7-4c2b-ae2a-3d831d34cb73" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1f931af8-60e2-4ab3-b79b-1e7b19a93a4c" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_2dcdfd90-c2a7-4c2b-ae2a-3d831d34cb73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockbasedCompensationOptionPricingAssumptionsDetails" xlink:type="simple" xlink:href="mgnx-20181231.xsd#StockbasedCompensationOptionPricingAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/StockbasedCompensationOptionPricingAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1cec8eea-22ed-4848-b85a-e737a5c11092" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7476a420-e009-4109-bd9e-e7a5593e507b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1cec8eea-22ed-4848-b85a-e737a5c11092" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7476a420-e009-4109-bd9e-e7a5593e507b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b76f3584-6126-480f-8bb5-58a975a189de" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7476a420-e009-4109-bd9e-e7a5593e507b" xlink:to="loc_srt_RangeAxis_b76f3584-6126-480f-8bb5-58a975a189de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_61c21bfc-e31c-4df3-84a1-631483b91f23" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_b76f3584-6126-480f-8bb5-58a975a189de" xlink:to="loc_srt_RangeMember_61c21bfc-e31c-4df3-84a1-631483b91f23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_d59b81e6-c56a-47ff-85fb-05a33288fd82" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_61c21bfc-e31c-4df3-84a1-631483b91f23" xlink:to="loc_srt_MinimumMember_d59b81e6-c56a-47ff-85fb-05a33288fd82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a29d596b-9e91-4b7e-92bc-8cb3121aabc5" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_61c21bfc-e31c-4df3-84a1-631483b91f23" xlink:to="loc_srt_MaximumMember_a29d596b-9e91-4b7e-92bc-8cb3121aabc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0285489a-b399-4c43-8c22-959dca139667" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7476a420-e009-4109-bd9e-e7a5593e507b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0285489a-b399-4c43-8c22-959dca139667" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_e25488df-e53b-43d0-a7b5-790d5ea1a303" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0285489a-b399-4c43-8c22-959dca139667" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_e25488df-e53b-43d0-a7b5-790d5ea1a303" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_3cf19135-2bdd-42f5-b35b-44b32947b352" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0285489a-b399-4c43-8c22-959dca139667" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_3cf19135-2bdd-42f5-b35b-44b32947b352" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_8ebfc1f3-dca6-4238-b0c4-4904c69e0186" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0285489a-b399-4c43-8c22-959dca139667" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_8ebfc1f3-dca6-4238-b0c4-4904c69e0186" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_9db80b2d-1750-4c69-b23c-16066f617937" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0285489a-b399-4c43-8c22-959dca139667" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_9db80b2d-1750-4c69-b23c-16066f617937" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_6b80ade1-7e15-4627-ba6f-15e638c880fe" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0285489a-b399-4c43-8c22-959dca139667" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_6b80ade1-7e15-4627-ba6f-15e638c880fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails" xlink:type="simple" xlink:href="mgnx-20181231.xsd#StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0462ce78-d8a0-4313-9fbb-a2af700e7a3f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_3d52d050-f72e-4d35-9699-e8477833a6d2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0462ce78-d8a0-4313-9fbb-a2af700e7a3f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_3d52d050-f72e-4d35-9699-e8477833a6d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3fbe63c6-f559-4aaf-b08d-531307c6c548" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_3d52d050-f72e-4d35-9699-e8477833a6d2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3fbe63c6-f559-4aaf-b08d-531307c6c548" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_71fb5ae0-acec-44f4-b3d1-9fb635718b2f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_3d52d050-f72e-4d35-9699-e8477833a6d2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_71fb5ae0-acec-44f4-b3d1-9fb635718b2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_e634d8fb-4a9c-40c4-9c7d-50be2ad4e7fa" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_3d52d050-f72e-4d35-9699-e8477833a6d2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_e634d8fb-4a9c-40c4-9c7d-50be2ad4e7fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_9044a1ce-7884-4b75-b322-9ca6e73a91e8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_3d52d050-f72e-4d35-9699-e8477833a6d2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_9044a1ce-7884-4b75-b322-9ca6e73a91e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7b886bf2-c389-4ab4-8cc9-2ca2c399d68f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_3d52d050-f72e-4d35-9699-e8477833a6d2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7b886bf2-c389-4ab4-8cc9-2ca2c399d68f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_4132539e-d2c3-4780-98d1-865afb0eed05" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_3d52d050-f72e-4d35-9699-e8477833a6d2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_4132539e-d2c3-4780-98d1-865afb0eed05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_221ac48d-ddd4-4b6e-a1db-bf88ab7627a8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_3d52d050-f72e-4d35-9699-e8477833a6d2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_221ac48d-ddd4-4b6e-a1db-bf88ab7627a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_914c8155-bae1-4fd1-bce3-b349f0ccde9d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0462ce78-d8a0-4313-9fbb-a2af700e7a3f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_914c8155-bae1-4fd1-bce3-b349f0ccde9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_e72a29d9-30cb-4d93-9af7-21f93fe94dbc" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_914c8155-bae1-4fd1-bce3-b349f0ccde9d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_e72a29d9-30cb-4d93-9af7-21f93fe94dbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_6f97df85-1765-4a6e-ae12-64423b4c05cb" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_914c8155-bae1-4fd1-bce3-b349f0ccde9d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_6f97df85-1765-4a6e-ae12-64423b4c05cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_f68c788f-82fc-4b14-a997-a67fb62391b1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_914c8155-bae1-4fd1-bce3-b349f0ccde9d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_f68c788f-82fc-4b14-a997-a67fb62391b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_17d5cfc9-517d-4f75-9c59-ec1206586f45" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_914c8155-bae1-4fd1-bce3-b349f0ccde9d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_17d5cfc9-517d-4f75-9c59-ec1206586f45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1cb380e3-7e7e-4083-8c65-cf9aa56ce000" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_914c8155-bae1-4fd1-bce3-b349f0ccde9d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1cb380e3-7e7e-4083-8c65-cf9aa56ce000" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_02c50699-6075-45c4-9d6e-e4772d9c0bcd" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_914c8155-bae1-4fd1-bce3-b349f0ccde9d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_02c50699-6075-45c4-9d6e-e4772d9c0bcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_6dcbb21d-fb7e-453f-9024-d6d5c83f3557" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_914c8155-bae1-4fd1-bce3-b349f0ccde9d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_6dcbb21d-fb7e-453f-9024-d6d5c83f3557" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_867fecd6-8335-4511-96f7-3f0bd6699b0e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0462ce78-d8a0-4313-9fbb-a2af700e7a3f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_867fecd6-8335-4511-96f7-3f0bd6699b0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_0366a655-90c9-489a-8a8e-272e9b2174bd" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_867fecd6-8335-4511-96f7-3f0bd6699b0e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_0366a655-90c9-489a-8a8e-272e9b2174bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_8dadfbdb-77bd-47e1-bfc3-6727670eacef" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_867fecd6-8335-4511-96f7-3f0bd6699b0e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_8dadfbdb-77bd-47e1-bfc3-6727670eacef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_b42c71ee-9505-4d14-9c11-434ae5fdeeb4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_867fecd6-8335-4511-96f7-3f0bd6699b0e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_b42c71ee-9505-4d14-9c11-434ae5fdeeb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_fbab122b-b365-4fe3-aa16-786d6eca161f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_867fecd6-8335-4511-96f7-3f0bd6699b0e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_fbab122b-b365-4fe3-aa16-786d6eca161f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_4ec1976c-01ca-439b-aaa4-0352013ac3d0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_867fecd6-8335-4511-96f7-3f0bd6699b0e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_4ec1976c-01ca-439b-aaa4-0352013ac3d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_b714b632-eff9-4b51-b8e3-c44cbf088e9c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_867fecd6-8335-4511-96f7-3f0bd6699b0e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_b714b632-eff9-4b51-b8e3-c44cbf088e9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_cedd8155-bc2b-4ade-9416-d77691c027ce" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0462ce78-d8a0-4313-9fbb-a2af700e7a3f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_cedd8155-bc2b-4ade-9416-d77691c027ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_2d6c26f1-8b5b-4c3e-b730-2f950f04f364" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0462ce78-d8a0-4313-9fbb-a2af700e7a3f" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_2d6c26f1-8b5b-4c3e-b730-2f950f04f364" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_fe192d11-4cce-4440-8c2e-3e7fd6cf3d08" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0462ce78-d8a0-4313-9fbb-a2af700e7a3f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_fe192d11-4cce-4440-8c2e-3e7fd6cf3d08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_882376bb-4abe-4579-930e-43a7274c26ce" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0462ce78-d8a0-4313-9fbb-a2af700e7a3f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_882376bb-4abe-4579-930e-43a7274c26ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_b134cb09-2aa4-4308-96a9-1eca0ff85015" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0462ce78-d8a0-4313-9fbb-a2af700e7a3f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_b134cb09-2aa4-4308-96a9-1eca0ff85015" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_42e9f0c8-ce2a-4654-8378-d92d7d1b733b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0462ce78-d8a0-4313-9fbb-a2af700e7a3f" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_42e9f0c8-ce2a-4654-8378-d92d7d1b733b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_5a5dd316-f5f2-4c13-ae3d-03e8969fdf81" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0462ce78-d8a0-4313-9fbb-a2af700e7a3f" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_5a5dd316-f5f2-4c13-ae3d-03e8969fdf81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/IncomeTaxes" xlink:type="simple" xlink:href="mgnx-20181231.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_d5baf602-140c-4ef4-b23b-0398d818200f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_1ca25aec-d878-49ab-ab13-f61db08e37c3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d5baf602-140c-4ef4-b23b-0398d818200f" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_1ca25aec-d878-49ab-ab13-f61db08e37c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="mgnx-20181231.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_3798e1a2-bcac-45bf-a0df-f576974d2182" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_f3f76cff-2642-4659-b6fc-444030124bb4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3798e1a2-bcac-45bf-a0df-f576974d2182" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_f3f76cff-2642-4659-b6fc-444030124bb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_b37f2906-c827-45a5-9842-fe3e83b2ff14" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3798e1a2-bcac-45bf-a0df-f576974d2182" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_b37f2906-c827-45a5-9842-fe3e83b2ff14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_5b53fe6d-3b43-44d3-8154-8bae93d113c9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3798e1a2-bcac-45bf-a0df-f576974d2182" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_5b53fe6d-3b43-44d3-8154-8bae93d113c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails" xlink:type="simple" xlink:href="mgnx-20181231.xsd#IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_dcf1b6b9-d1fd-4f1f-9bba-c39e304b66e1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_e6fcdce4-1a66-4ccd-97fb-33d09a05fde9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_dcf1b6b9-d1fd-4f1f-9bba-c39e304b66e1" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_e6fcdce4-1a66-4ccd-97fb-33d09a05fde9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_eb27f415-b043-4304-b7a1-881527a72c21" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_dcf1b6b9-d1fd-4f1f-9bba-c39e304b66e1" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_eb27f415-b043-4304-b7a1-881527a72c21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_5df42e64-e8ef-4bd7-9a8a-bc28c6797e49" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_eb27f415-b043-4304-b7a1-881527a72c21" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_5df42e64-e8ef-4bd7-9a8a-bc28c6797e49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_fd7c0ea4-3545-4d07-819c-1a280637284a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_eb27f415-b043-4304-b7a1-881527a72c21" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_fd7c0ea4-3545-4d07-819c-1a280637284a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_72d5d679-25e1-4c45-9269-1aad9dd7a962" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_eb27f415-b043-4304-b7a1-881527a72c21" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_72d5d679-25e1-4c45-9269-1aad9dd7a962" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther_42a3426b-b628-4273-a962-c3f964a18cd6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_eb27f415-b043-4304-b7a1-881527a72c21" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther_42a3426b-b628-4273-a962-c3f964a18cd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_185b9c95-d9c1-4929-b8e3-caf764102ea9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_eb27f415-b043-4304-b7a1-881527a72c21" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_185b9c95-d9c1-4929-b8e3-caf764102ea9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_39ac2d2f-f6a8-4dc2-8969-c0598e64ad70" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_eb27f415-b043-4304-b7a1-881527a72c21" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_39ac2d2f-f6a8-4dc2-8969-c0598e64ad70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_1f9c2fc0-6434-4b09-a391-058a8d295c7e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_eb27f415-b043-4304-b7a1-881527a72c21" xlink:to="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_1f9c2fc0-6434-4b09-a391-058a8d295c7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_7c50e5ef-8986-4a52-ac3e-ff89e17ab09f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_eb27f415-b043-4304-b7a1-881527a72c21" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_7c50e5ef-8986-4a52-ac3e-ff89e17ab09f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_614f55c2-28a5-40fb-9118-b44853e10d8c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_eb27f415-b043-4304-b7a1-881527a72c21" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_614f55c2-28a5-40fb-9118-b44853e10d8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_a28714d7-7e78-4a46-a01d-e0875618b296" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_eb27f415-b043-4304-b7a1-881527a72c21" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_a28714d7-7e78-4a46-a01d-e0875618b296" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_97561349-2c45-486d-9233-eb25f5699a2d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_eb27f415-b043-4304-b7a1-881527a72c21" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_97561349-2c45-486d-9233-eb25f5699a2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_a4a6821c-41c2-45b0-9fbf-10a8b8b371ec" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_dcf1b6b9-d1fd-4f1f-9bba-c39e304b66e1" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_a4a6821c-41c2-45b0-9fbf-10a8b8b371ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_99e2bc7c-72b4-461d-af42-2eeb4f127df1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_a4a6821c-41c2-45b0-9fbf-10a8b8b371ec" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_99e2bc7c-72b4-461d-af42-2eeb4f127df1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_57712624-73e1-4b56-9323-2a344da41bd0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_a4a6821c-41c2-45b0-9fbf-10a8b8b371ec" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_57712624-73e1-4b56-9323-2a344da41bd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_c8d12eff-b8f2-4627-a84e-bbda0d1b766a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_a4a6821c-41c2-45b0-9fbf-10a8b8b371ec" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_c8d12eff-b8f2-4627-a84e-bbda0d1b766a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_40acfbf0-e4b1-4fd2-ab1f-d687c1887858" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_a4a6821c-41c2-45b0-9fbf-10a8b8b371ec" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_40acfbf0-e4b1-4fd2-ab1f-d687c1887858" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_bd540ada-85bb-4ffc-9791-d52629a13d31" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_dcf1b6b9-d1fd-4f1f-9bba-c39e304b66e1" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_bd540ada-85bb-4ffc-9791-d52629a13d31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodAxis_00f94235-c250-42d9-808a-f04255b31abd" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxPeriodAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_bd540ada-85bb-4ffc-9791-d52629a13d31" xlink:to="loc_us-gaap_TaxPeriodAxis_00f94235-c250-42d9-808a-f04255b31abd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain_6cd1f1ec-541d-44d7-9506-2ff3f51af607" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodAxis_00f94235-c250-42d9-808a-f04255b31abd" xlink:to="loc_us-gaap_TaxPeriodDomain_6cd1f1ec-541d-44d7-9506-2ff3f51af607" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_TaxYear2025To2037Member_1a1883c2-e18e-4622-b17f-3418b9e67543" xlink:href="mgnx-20181231.xsd#mgnx_TaxYear2025To2037Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_6cd1f1ec-541d-44d7-9506-2ff3f51af607" xlink:to="loc_mgnx_TaxYear2025To2037Member_1a1883c2-e18e-4622-b17f-3418b9e67543" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IndefiniteMember_a0928d42-21f0-4477-a5ca-839252a0b4b0" xlink:href="mgnx-20181231.xsd#mgnx_IndefiniteMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_6cd1f1ec-541d-44d7-9506-2ff3f51af607" xlink:to="loc_mgnx_IndefiniteMember_a0928d42-21f0-4477-a5ca-839252a0b4b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_e3dea45a-8655-4066-94a5-fbce784be3b3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_bd540ada-85bb-4ffc-9791-d52629a13d31" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_e3dea45a-8655-4066-94a5-fbce784be3b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_d1bf9670-616b-4206-93b9-15db0d126a2a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_e3dea45a-8655-4066-94a5-fbce784be3b3" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_d1bf9670-616b-4206-93b9-15db0d126a2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember_0e4b2881-0f87-4378-bf57-db09ef3aa935" xlink:href="mgnx-20181231.xsd#mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_d1bf9670-616b-4206-93b9-15db0d126a2a" xlink:to="loc_mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember_0e4b2881-0f87-4378-bf57-db09ef3aa935" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_5f34b5f1-5fed-4352-9828-2dbcf06ad828" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember_0e4b2881-0f87-4378-bf57-db09ef3aa935" xlink:to="loc_us-gaap_DomesticCountryMember_5f34b5f1-5fed-4352-9828-2dbcf06ad828" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b51e1868-3ce9-480f-b6fb-eb950be11985" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_bd540ada-85bb-4ffc-9791-d52629a13d31" xlink:to="loc_srt_RangeAxis_b51e1868-3ce9-480f-b6fb-eb950be11985" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_122e76f5-66bc-43d9-a455-d5f98cb25d30" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_b51e1868-3ce9-480f-b6fb-eb950be11985" xlink:to="loc_srt_RangeMember_122e76f5-66bc-43d9-a455-d5f98cb25d30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_cd6ab1ac-2042-4fc7-89a5-5f4aaef09561" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_122e76f5-66bc-43d9-a455-d5f98cb25d30" xlink:to="loc_srt_MinimumMember_cd6ab1ac-2042-4fc7-89a5-5f4aaef09561" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_3cc2683f-d623-4464-9cd4-0afbda8dafe0" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_122e76f5-66bc-43d9-a455-d5f98cb25d30" xlink:to="loc_srt_MaximumMember_3cc2683f-d623-4464-9cd4-0afbda8dafe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_c86d8758-7ffc-46fb-8beb-5095b8f04af6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_bd540ada-85bb-4ffc-9791-d52629a13d31" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLineItems_c86d8758-7ffc-46fb-8beb-5095b8f04af6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_9dd31963-7917-43ca-a5df-44dd935d9a4c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_c86d8758-7ffc-46fb-8beb-5095b8f04af6" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_9dd31963-7917-43ca-a5df-44dd935d9a4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_f13cced8-a4d2-4406-92fb-0d1c5d4b6b69" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_c86d8758-7ffc-46fb-8beb-5095b8f04af6" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_f13cced8-a4d2-4406-92fb-0d1c5d4b6b69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount_3ce81bb0-90d3-4736-89f8-dfa002c7d009" xlink:href="mgnx-20181231.xsd#mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_c86d8758-7ffc-46fb-8beb-5095b8f04af6" xlink:to="loc_mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount_3ce81bb0-90d3-4736-89f8-dfa002c7d009" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_OperatingLossCarryforwardsAnnualLimitationAmount_1ea2ec91-b5bd-463c-999b-fa6db9821090" xlink:href="mgnx-20181231.xsd#mgnx_OperatingLossCarryforwardsAnnualLimitationAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_c86d8758-7ffc-46fb-8beb-5095b8f04af6" xlink:to="loc_mgnx_OperatingLossCarryforwardsAnnualLimitationAmount_1ea2ec91-b5bd-463c-999b-fa6db9821090" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_OperatingLossCarryforwardsNotSubjectToLimitation_9c07a02f-49c4-4afe-838a-c4c6c04e6b06" xlink:href="mgnx-20181231.xsd#mgnx_OperatingLossCarryforwardsNotSubjectToLimitation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_c86d8758-7ffc-46fb-8beb-5095b8f04af6" xlink:to="loc_mgnx_OperatingLossCarryforwardsNotSubjectToLimitation_9c07a02f-49c4-4afe-838a-c4c6c04e6b06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_e5fc864d-6eb7-4ce4-a1a4-d8462311b10b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_c86d8758-7ffc-46fb-8beb-5095b8f04af6" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_e5fc864d-6eb7-4ce4-a1a4-d8462311b10b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTaxBenefitTaxEffectedAmount_626d5eee-acf5-4efc-a20c-571f1f88e9ce" xlink:href="mgnx-20181231.xsd#mgnx_EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTaxBenefitTaxEffectedAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_c86d8758-7ffc-46fb-8beb-5095b8f04af6" xlink:to="loc_mgnx_EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTaxBenefitTaxEffectedAmount_626d5eee-acf5-4efc-a20c-571f1f88e9ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails" xlink:type="simple" xlink:href="mgnx-20181231.xsd#IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_882c6c9b-9b32-4d4d-8f6d-3cb6eb7a4049" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_62db9d50-dba7-496e-a156-f12177d96249" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_882c6c9b-9b32-4d4d-8f6d-3cb6eb7a4049" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_62db9d50-dba7-496e-a156-f12177d96249" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_17f603d7-e0ec-4466-b402-a26ffc049d9f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_882c6c9b-9b32-4d4d-8f6d-3cb6eb7a4049" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_17f603d7-e0ec-4466-b402-a26ffc049d9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount_ca2f2d32-a893-48fe-8c1f-f39142dcc194" xlink:href="mgnx-20181231.xsd#mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_882c6c9b-9b32-4d4d-8f6d-3cb6eb7a4049" xlink:to="loc_mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount_ca2f2d32-a893-48fe-8c1f-f39142dcc194" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_EffectiveIncomeTaxReconciliationStateDeferredTaxesAdjustmentsAmount_fb4f86da-b154-4a2b-8cec-2a8616c1dd30" xlink:href="mgnx-20181231.xsd#mgnx_EffectiveIncomeTaxReconciliationStateDeferredTaxesAdjustmentsAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_882c6c9b-9b32-4d4d-8f6d-3cb6eb7a4049" xlink:to="loc_mgnx_EffectiveIncomeTaxReconciliationStateDeferredTaxesAdjustmentsAmount_fb4f86da-b154-4a2b-8cec-2a8616c1dd30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_e5878df5-8a6a-489b-8dc9-ad8dd03a4d8c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_882c6c9b-9b32-4d4d-8f6d-3cb6eb7a4049" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_e5878df5-8a6a-489b-8dc9-ad8dd03a4d8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_f13af372-b197-4917-bde8-b79785bfc605" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_882c6c9b-9b32-4d4d-8f6d-3cb6eb7a4049" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_f13af372-b197-4917-bde8-b79785bfc605" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsOther_45d1518a-f5c6-498e-9ae5-164d2a978c74" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsOther"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_882c6c9b-9b32-4d4d-8f6d-3cb6eb7a4049" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsOther_45d1518a-f5c6-498e-9ae5-164d2a978c74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherReconcilingItems_fdb4ab53-60a9-4297-88ec-7fb9f1b53bc1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_882c6c9b-9b32-4d4d-8f6d-3cb6eb7a4049" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherReconcilingItems_fdb4ab53-60a9-4297-88ec-7fb9f1b53bc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_dfe236a0-3c28-442e-97ee-14941ccd36b8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_882c6c9b-9b32-4d4d-8f6d-3cb6eb7a4049" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_dfe236a0-3c28-442e-97ee-14941ccd36b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_393da852-2cbd-4d4a-8df1-fc9a3c16fc93" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_882c6c9b-9b32-4d4d-8f6d-3cb6eb7a4049" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_393da852-2cbd-4d4a-8df1-fc9a3c16fc93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_8decc97f-3be2-4518-8983-9cdbf116882f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_882c6c9b-9b32-4d4d-8f6d-3cb6eb7a4049" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_8decc97f-3be2-4518-8983-9cdbf116882f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/IncomeTaxesReconciliationoftheBeginningandEndingAmountofGrossUnrecognizedTaxBenefitsDetails" xlink:type="simple" xlink:href="mgnx-20181231.xsd#IncomeTaxesReconciliationoftheBeginningandEndingAmountofGrossUnrecognizedTaxBenefitsDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/IncomeTaxesReconciliationoftheBeginningandEndingAmountofGrossUnrecognizedTaxBenefitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_a527996d-6ac9-4944-a940-f87ffeb77d4f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationTable_b3fcb091-88b2-46a6-a8b7-6fedcb630803" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExaminationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_a527996d-6ac9-4944-a940-f87ffeb77d4f" xlink:to="loc_us-gaap_IncomeTaxExaminationTable_b3fcb091-88b2-46a6-a8b7-6fedcb630803" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_690e0010-84a9-41ab-942c-574f32be0826" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_b3fcb091-88b2-46a6-a8b7-6fedcb630803" xlink:to="loc_srt_RangeAxis_690e0010-84a9-41ab-942c-574f32be0826" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_adfd41bb-3bf5-4e90-9149-6d4758aa72a9" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_690e0010-84a9-41ab-942c-574f32be0826" xlink:to="loc_srt_RangeMember_adfd41bb-3bf5-4e90-9149-6d4758aa72a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_77fee547-b0ac-4d2b-a2a0-79e589911c71" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_adfd41bb-3bf5-4e90-9149-6d4758aa72a9" xlink:to="loc_srt_MinimumMember_77fee547-b0ac-4d2b-a2a0-79e589911c71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationLineItems_8dc2ff63-61ca-4ce3-ae63-7b05c013e2bc" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExaminationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_b3fcb091-88b2-46a6-a8b7-6fedcb630803" xlink:to="loc_us-gaap_IncomeTaxExaminationLineItems_8dc2ff63-61ca-4ce3-ae63-7b05c013e2bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_f1a6353d-5b65-4dca-9cb5-d623e083ddc7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_8dc2ff63-61ca-4ce3-ae63-7b05c013e2bc" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_f1a6353d-5b65-4dca-9cb5-d623e083ddc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_8e84790f-9914-40e6-a741-75b5f952d5c4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_f1a6353d-5b65-4dca-9cb5-d623e083ddc7" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_8e84790f-9914-40e6-a741-75b5f952d5c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_b31d2aa4-8b4a-420a-a178-fc1b52291b4d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_f1a6353d-5b65-4dca-9cb5-d623e083ddc7" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_b31d2aa4-8b4a-420a-a178-fc1b52291b4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_e76743eb-ab0c-4d77-8564-e294f6aa84c6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_f1a6353d-5b65-4dca-9cb5-d623e083ddc7" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_e76743eb-ab0c-4d77-8564-e294f6aa84c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_e98b773b-4bbc-4bb2-802f-fe86d4b5ed37" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_f1a6353d-5b65-4dca-9cb5-d623e083ddc7" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_e98b773b-4bbc-4bb2-802f-fe86d4b5ed37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_61ea50aa-9b61-47b7-b968-9310ca9d0256" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_f1a6353d-5b65-4dca-9cb5-d623e083ddc7" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_61ea50aa-9b61-47b7-b968-9310ca9d0256" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_83081ce3-9371-41fc-b8b7-65e3cc6e5153" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_8dc2ff63-61ca-4ce3-ae63-7b05c013e2bc" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_83081ce3-9371-41fc-b8b7-65e3cc6e5153" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_3f7fcefb-3da8-43db-89aa-a0c6e6cdb0c8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_8dc2ff63-61ca-4ce3-ae63-7b05c013e2bc" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_3f7fcefb-3da8-43db-89aa-a0c6e6cdb0c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreements" xlink:type="simple" xlink:href="mgnx-20181231.xsd#CollaborationandOtherAgreements"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_9cd649cc-97e6-4096-af40-0392763d694d" xlink:href="mgnx-20181231.xsd#mgnx_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock_fd2fc462-e277-4bef-a4f1-2dba4dfb9c89" xlink:href="mgnx-20181231.xsd#mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_9cd649cc-97e6-4096-af40-0392763d694d" xlink:to="loc_mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock_fd2fc462-e277-4bef-a4f1-2dba4dfb9c89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails" xlink:type="simple" xlink:href="mgnx-20181231.xsd#CollaborationandOtherAgreementsIncyteCorporationDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_d6134ea0-5005-4e68-93d6-fa0e49cb89cf" xlink:href="mgnx-20181231.xsd#mgnx_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_fdce6867-8367-4d43-84c3-a45d0a9e8624" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_d6134ea0-5005-4e68-93d6-fa0e49cb89cf" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_fdce6867-8367-4d43-84c3-a45d0a9e8624" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_a3481602-1cc5-4987-b87d-a4227534c8f2" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_fdce6867-8367-4d43-84c3-a45d0a9e8624" xlink:to="loc_srt_ProductOrServiceAxis_a3481602-1cc5-4987-b87d-a4227534c8f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d2aac256-81b2-46fb-ad43-c8a41aaeb66f" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_a3481602-1cc5-4987-b87d-a4227534c8f2" xlink:to="loc_srt_ProductsAndServicesDomain_d2aac256-81b2-46fb-ad43-c8a41aaeb66f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromLicenseAgreementsMember_140d863b-16c6-45d0-af7a-af45e8b40b93" xlink:href="mgnx-20181231.xsd#mgnx_RevenuesFromLicenseAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d2aac256-81b2-46fb-ad43-c8a41aaeb66f" xlink:to="loc_mgnx_RevenuesFromLicenseAgreementsMember_140d863b-16c6-45d0-af7a-af45e8b40b93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_1f8f39a9-8270-433d-adc6-526ee2c9a6fb" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_fdce6867-8367-4d43-84c3-a45d0a9e8624" xlink:to="loc_srt_RangeAxis_1f8f39a9-8270-433d-adc6-526ee2c9a6fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5a9581c9-bf62-483a-a060-4a25e96715a6" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_1f8f39a9-8270-433d-adc6-526ee2c9a6fb" xlink:to="loc_srt_RangeMember_5a9581c9-bf62-483a-a060-4a25e96715a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_853be223-4ff7-465d-bdc2-322407615a12" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_5a9581c9-bf62-483a-a060-4a25e96715a6" xlink:to="loc_srt_MaximumMember_853be223-4ff7-465d-bdc2-322407615a12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_632027d7-98e8-4fd1-a17e-221107f4d593" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_5a9581c9-bf62-483a-a060-4a25e96715a6" xlink:to="loc_srt_MinimumMember_632027d7-98e8-4fd1-a17e-221107f4d593" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_2028b21d-9911-47d4-b4f0-7ffdd941baa4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_fdce6867-8367-4d43-84c3-a45d0a9e8624" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_2028b21d-9911-47d4-b4f0-7ffdd941baa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_971b4a14-d8c8-4349-80c2-89a504b1fe85" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_2028b21d-9911-47d4-b4f0-7ffdd941baa4" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_971b4a14-d8c8-4349-80c2-89a504b1fe85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteMGA012AgreementMember_fb8aa65d-ec24-47fe-a576-183e3fa7fc10" xlink:href="mgnx-20181231.xsd#mgnx_IncyteMGA012AgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_971b4a14-d8c8-4349-80c2-89a504b1fe85" xlink:to="loc_mgnx_IncyteMGA012AgreementMember_fb8aa65d-ec24-47fe-a576-183e3fa7fc10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteMGA012ClinicalServicesMember_e494c568-0930-40e0-9707-7a60250486dd" xlink:href="mgnx-20181231.xsd#mgnx_IncyteMGA012ClinicalServicesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_971b4a14-d8c8-4349-80c2-89a504b1fe85" xlink:to="loc_mgnx_IncyteMGA012ClinicalServicesMember_e494c568-0930-40e0-9707-7a60250486dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_8b2c64b2-e033-46d1-98ca-4bf07adb43c9" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_fdce6867-8367-4d43-84c3-a45d0a9e8624" xlink:to="loc_srt_CounterpartyNameAxis_8b2c64b2-e033-46d1-98ca-4bf07adb43c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8912928a-c51f-4a9d-bbeb-e4784164732f" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_8b2c64b2-e033-46d1-98ca-4bf07adb43c9" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8912928a-c51f-4a9d-bbeb-e4784164732f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteCorporationMember_8c84a89a-9081-440d-985f-59468b5d33b8" xlink:href="mgnx-20181231.xsd#mgnx_IncyteCorporationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8912928a-c51f-4a9d-bbeb-e4784164732f" xlink:to="loc_mgnx_IncyteCorporationMember_8c84a89a-9081-440d-985f-59468b5d33b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_43e7dce1-cb85-4618-ad01-89ec9e29d8c0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_fdce6867-8367-4d43-84c3-a45d0a9e8624" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_43e7dce1-cb85-4618-ad01-89ec9e29d8c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees_f8a45fe6-9388-4cd7-9c69-c5738aa30202" xlink:href="mgnx-20181231.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_43e7dce1-cb85-4618-ad01-89ec9e29d8c0" xlink:to="loc_mgnx_NonRefundableUpfrontFees_f8a45fe6-9388-4cd7-9c69-c5738aa30202" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_acaf6c9a-c7f8-43ef-8ffa-2b2e0e3d6762" xlink:href="mgnx-20181231.xsd#mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_43e7dce1-cb85-4618-ad01-89ec9e29d8c0" xlink:to="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_acaf6c9a-c7f8-43ef-8ffa-2b2e0e3d6762" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_722da759-7429-427b-b70c-29e90c855f3f" xlink:href="mgnx-20181231.xsd#mgnx_PotentialCommercialMilestonePaymentsUnderAgreement"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_43e7dce1-cb85-4618-ad01-89ec9e29d8c0" xlink:to="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_722da759-7429-427b-b70c-29e90c855f3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_4067be7b-ed42-4480-8897-036acc4afa86" xlink:href="mgnx-20181231.xsd#mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_43e7dce1-cb85-4618-ad01-89ec9e29d8c0" xlink:to="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_4067be7b-ed42-4480-8897-036acc4afa86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsfromRoyaltiesPercent_72ad17f1-d8a3-458d-89f3-5c30cb3525f6" xlink:href="mgnx-20181231.xsd#mgnx_ProceedsfromRoyaltiesPercent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_43e7dce1-cb85-4618-ad01-89ec9e29d8c0" xlink:to="loc_mgnx_ProceedsfromRoyaltiesPercent_72ad17f1-d8a3-458d-89f3-5c30cb3525f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementTransactionPrice_32d95bc6-69ac-4f8c-b2c5-caede00e154c" xlink:href="mgnx-20181231.xsd#mgnx_CollaborativeAgreementTransactionPrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_43e7dce1-cb85-4618-ad01-89ec9e29d8c0" xlink:to="loc_mgnx_CollaborativeAgreementTransactionPrice_32d95bc6-69ac-4f8c-b2c5-caede00e154c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_8ce7b99e-3e4b-42f2-932d-ac50474071a5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_43e7dce1-cb85-4618-ad01-89ec9e29d8c0" xlink:to="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_8ce7b99e-3e4b-42f2-932d-ac50474071a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_196f008c-07c2-452f-ad9f-605ce888d62b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_43e7dce1-cb85-4618-ad01-89ec9e29d8c0" xlink:to="loc_us-gaap_Revenues_196f008c-07c2-452f-ad9f-605ce888d62b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails" xlink:type="simple" xlink:href="mgnx-20181231.xsd#CollaborationandOtherAgreementsZaiLabDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_f31a11c8-eeb0-4296-95cc-859ad392c883" xlink:href="mgnx-20181231.xsd#mgnx_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_cbb30734-d3cf-4f21-b5bc-a01eec25c912" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_f31a11c8-eeb0-4296-95cc-859ad392c883" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_cbb30734-d3cf-4f21-b5bc-a01eec25c912" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_4da5506e-a14e-4172-8c4a-71038e4618a1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_cbb30734-d3cf-4f21-b5bc-a01eec25c912" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_4da5506e-a14e-4172-8c4a-71038e4618a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_f4871f5e-5132-40a9-993f-768b8e6158a2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_4da5506e-a14e-4172-8c4a-71038e4618a1" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_f4871f5e-5132-40a9-993f-768b8e6158a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabsCollaborationAndLicenseAgreementMember_a7e6fd24-676a-42ca-973d-a196d2ed5bb3" xlink:href="mgnx-20181231.xsd#mgnx_ZaiLabsCollaborationAndLicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_f4871f5e-5132-40a9-993f-768b8e6158a2" xlink:to="loc_mgnx_ZaiLabsCollaborationAndLicenseAgreementMember_a7e6fd24-676a-42ca-973d-a196d2ed5bb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_41088f3e-9f89-4383-b2e4-8b50d58d8057" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_cbb30734-d3cf-4f21-b5bc-a01eec25c912" xlink:to="loc_srt_CounterpartyNameAxis_41088f3e-9f89-4383-b2e4-8b50d58d8057" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_37699405-cec6-4679-af37-083446c8b95f" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_41088f3e-9f89-4383-b2e4-8b50d58d8057" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_37699405-cec6-4679-af37-083446c8b95f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabsMember_52c3739f-f197-4eec-85cf-28dbdb58c045" xlink:href="mgnx-20181231.xsd#mgnx_ZaiLabsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_37699405-cec6-4679-af37-083446c8b95f" xlink:to="loc_mgnx_ZaiLabsMember_52c3739f-f197-4eec-85cf-28dbdb58c045" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_43567f36-e313-4196-8c09-ac3f957a4745" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_cbb30734-d3cf-4f21-b5bc-a01eec25c912" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_43567f36-e313-4196-8c09-ac3f957a4745" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees_f576e658-a9b7-410b-9595-a30d634f3e6c" xlink:href="mgnx-20181231.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_43567f36-e313-4196-8c09-ac3f957a4745" xlink:to="loc_mgnx_NonRefundableUpfrontFees_f576e658-a9b7-410b-9595-a30d634f3e6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonrefundablePaymentTaxWithholding_53416c6d-3eee-4b91-951f-f56939de089d" xlink:href="mgnx-20181231.xsd#mgnx_NonrefundablePaymentTaxWithholding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_43567f36-e313-4196-8c09-ac3f957a4745" xlink:to="loc_mgnx_NonrefundablePaymentTaxWithholding_53416c6d-3eee-4b91-951f-f56939de089d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_461e2b98-86d7-4ecb-8a7b-880c3198ee1f" xlink:href="mgnx-20181231.xsd#mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_43567f36-e313-4196-8c09-ac3f957a4745" xlink:to="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_461e2b98-86d7-4ecb-8a7b-880c3198ee1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_2a93227a-6c0c-46dd-95f7-4b989b5d5aa0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_43567f36-e313-4196-8c09-ac3f957a4745" xlink:to="loc_us-gaap_Revenues_2a93227a-6c0c-46dd-95f7-4b989b5d5aa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_1e1679ca-095a-4d1b-a930-fc10a471a20e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_43567f36-e313-4196-8c09-ac3f957a4745" xlink:to="loc_us-gaap_ContractWithCustomerLiability_1e1679ca-095a-4d1b-a930-fc10a471a20e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_07d16243-4255-41aa-81f2-d438605057d4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_43567f36-e313-4196-8c09-ac3f957a4745" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_07d16243-4255-41aa-81f2-d438605057d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsServierDetails" xlink:type="simple" xlink:href="mgnx-20181231.xsd#CollaborationandOtherAgreementsServierDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsServierDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_6e919162-69d5-4104-9f9d-56c6fa9bf467" xlink:href="mgnx-20181231.xsd#mgnx_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b249c0b1-ea70-4db9-bd9b-bdcff15e12b0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_6e919162-69d5-4104-9f9d-56c6fa9bf467" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b249c0b1-ea70-4db9-bd9b-bdcff15e12b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_92f13ccb-e8db-40a1-a901-e8faad4dc755" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b249c0b1-ea70-4db9-bd9b-bdcff15e12b0" xlink:to="loc_srt_ProductOrServiceAxis_92f13ccb-e8db-40a1-a901-e8faad4dc755" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_39f05338-7b5e-4a69-9430-187e9037cd3f" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_92f13ccb-e8db-40a1-a901-e8faad4dc755" xlink:to="loc_srt_ProductsAndServicesDomain_39f05338-7b5e-4a69-9430-187e9037cd3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromLicenseAgreementsMember_0da19ee3-8ae5-46e5-95d5-a6656ca3d76a" xlink:href="mgnx-20181231.xsd#mgnx_RevenuesFromLicenseAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_39f05338-7b5e-4a69-9430-187e9037cd3f" xlink:to="loc_mgnx_RevenuesFromLicenseAgreementsMember_0da19ee3-8ae5-46e5-95d5-a6656ca3d76a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_b2906b68-aca0-48a9-ac9e-99ef3225d511" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b249c0b1-ea70-4db9-bd9b-bdcff15e12b0" xlink:to="loc_srt_CounterpartyNameAxis_b2906b68-aca0-48a9-ac9e-99ef3225d511" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_58ca8a54-bd11-440a-9faf-5e7ad3a3cb3a" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_b2906b68-aca0-48a9-ac9e-99ef3225d511" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_58ca8a54-bd11-440a-9faf-5e7ad3a3cb3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ServierMember_5d1fd906-dfd0-49e6-957f-0cf74c335f21" xlink:href="mgnx-20181231.xsd#mgnx_ServierMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_58ca8a54-bd11-440a-9faf-5e7ad3a3cb3a" xlink:to="loc_mgnx_ServierMember_5d1fd906-dfd0-49e6-957f-0cf74c335f21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_bae35e1b-ac81-4e2d-9fa8-05a70affc584" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b249c0b1-ea70-4db9-bd9b-bdcff15e12b0" xlink:to="loc_srt_RangeAxis_bae35e1b-ac81-4e2d-9fa8-05a70affc584" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7054d686-9b34-43d5-8c58-04c27b8c09f2" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_bae35e1b-ac81-4e2d-9fa8-05a70affc584" xlink:to="loc_srt_RangeMember_7054d686-9b34-43d5-8c58-04c27b8c09f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_2a040df0-22e0-43fd-bab6-608b53c051fd" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_7054d686-9b34-43d5-8c58-04c27b8c09f2" xlink:to="loc_srt_MaximumMember_2a040df0-22e0-43fd-bab6-608b53c051fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_c0951e4d-f03e-489f-8dc6-0f0c581f176e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b249c0b1-ea70-4db9-bd9b-bdcff15e12b0" xlink:to="loc_us-gaap_TypeOfArrangementAxis_c0951e4d-f03e-489f-8dc6-0f0c581f176e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_eb789d5c-ed9f-40c4-95f9-2dc2ad20a450" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_c0951e4d-f03e-489f-8dc6-0f0c581f176e" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_eb789d5c-ed9f-40c4-95f9-2dc2ad20a450" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ServierDARTMember_504f15e9-15af-4ec1-8852-72f82b136afb" xlink:href="mgnx-20181231.xsd#mgnx_ServierDARTMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_eb789d5c-ed9f-40c4-95f9-2dc2ad20a450" xlink:to="loc_mgnx_ServierDARTMember_504f15e9-15af-4ec1-8852-72f82b136afb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ServierAgreementMGD007OptionMember_3afb7817-02e2-4961-99cf-cf758af8444b" xlink:href="mgnx-20181231.xsd#mgnx_ServierAgreementMGD007OptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_eb789d5c-ed9f-40c4-95f9-2dc2ad20a450" xlink:to="loc_mgnx_ServierAgreementMGD007OptionMember_3afb7817-02e2-4961-99cf-cf758af8444b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_da4ecdf3-c90a-4924-81aa-7ea9ee88f48e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b249c0b1-ea70-4db9-bd9b-bdcff15e12b0" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_da4ecdf3-c90a-4924-81aa-7ea9ee88f48e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees_c766b833-0187-47c1-a57c-2916792919bd" xlink:href="mgnx-20181231.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_da4ecdf3-c90a-4924-81aa-7ea9ee88f48e" xlink:to="loc_mgnx_NonRefundableUpfrontFees_c766b833-0187-47c1-a57c-2916792919bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialClinicalMilestonePaymentsUnderAgreement_3f0b7468-dfaf-4b96-81c1-2927b7931cf0" xlink:href="mgnx-20181231.xsd#mgnx_PotentialClinicalMilestonePaymentsUnderAgreement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_da4ecdf3-c90a-4924-81aa-7ea9ee88f48e" xlink:to="loc_mgnx_PotentialClinicalMilestonePaymentsUnderAgreement_3f0b7468-dfaf-4b96-81c1-2927b7931cf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialRegulatoryMilestonePaymentsUnderAgreement_9830ee6d-396b-4294-a73c-d576e8f58d11" xlink:href="mgnx-20181231.xsd#mgnx_PotentialRegulatoryMilestonePaymentsUnderAgreement"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_da4ecdf3-c90a-4924-81aa-7ea9ee88f48e" xlink:to="loc_mgnx_PotentialRegulatoryMilestonePaymentsUnderAgreement_9830ee6d-396b-4294-a73c-d576e8f58d11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialSalesMilestonePaymentsUnderAgreement_881dd25f-a3ae-4fd3-9ef3-6dbdb934b72d" xlink:href="mgnx-20181231.xsd#mgnx_PotentialSalesMilestonePaymentsUnderAgreement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_da4ecdf3-c90a-4924-81aa-7ea9ee88f48e" xlink:to="loc_mgnx_PotentialSalesMilestonePaymentsUnderAgreement_881dd25f-a3ae-4fd3-9ef3-6dbdb934b72d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_MilestonePayment_9c6d5052-7aee-4f56-8d2e-b1d80e8e2222" xlink:href="mgnx-20181231.xsd#mgnx_MilestonePayment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_da4ecdf3-c90a-4924-81aa-7ea9ee88f48e" xlink:to="loc_mgnx_MilestonePayment_9c6d5052-7aee-4f56-8d2e-b1d80e8e2222" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_a8ee78df-ff6b-4db2-b850-490759c595aa" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_da4ecdf3-c90a-4924-81aa-7ea9ee88f48e" xlink:to="loc_us-gaap_Revenues_a8ee78df-ff6b-4db2-b850-490759c595aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueCurrent_f1cab902-e082-4d68-9bf1-f2d067157072" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredRevenueCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_da4ecdf3-c90a-4924-81aa-7ea9ee88f48e" xlink:to="loc_us-gaap_DeferredRevenueCurrent_f1cab902-e082-4d68-9bf1-f2d067157072" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_OptionExerciseFee_ddd8adfc-5479-4a20-9937-f50366439128" xlink:href="mgnx-20181231.xsd#mgnx_OptionExerciseFee"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_da4ecdf3-c90a-4924-81aa-7ea9ee88f48e" xlink:to="loc_mgnx_OptionExerciseFee_ddd8adfc-5479-4a20-9937-f50366439128" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts_d82978c1-a2d5-42c4-ba88-1473e204595e" xlink:href="mgnx-20181231.xsd#mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_da4ecdf3-c90a-4924-81aa-7ea9ee88f48e" xlink:to="loc_mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts_d82978c1-a2d5-42c4-ba88-1473e204595e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_1ec6f494-a141-48e4-87c3-654f8392ccb2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_da4ecdf3-c90a-4924-81aa-7ea9ee88f48e" xlink:to="loc_us-gaap_ContractWithCustomerLiability_1ec6f494-a141-48e4-87c3-654f8392ccb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_1fdbf558-f186-4673-9c12-ad200f4a102a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_da4ecdf3-c90a-4924-81aa-7ea9ee88f48e" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_1fdbf558-f186-4673-9c12-ad200f4a102a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_f4295603-446d-4035-9ced-5d4c03eeef94" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_da4ecdf3-c90a-4924-81aa-7ea9ee88f48e" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_f4295603-446d-4035-9ced-5d4c03eeef94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenue_99bddc5e-b871-4308-a7bb-22ba2895c855" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredRevenue"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_da4ecdf3-c90a-4924-81aa-7ea9ee88f48e" xlink:to="loc_us-gaap_DeferredRevenue_99bddc5e-b871-4308-a7bb-22ba2895c855" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_b792c69c-90de-44d2-b11e-9c5384c59635" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_da4ecdf3-c90a-4924-81aa-7ea9ee88f48e" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_b792c69c-90de-44d2-b11e-9c5384c59635" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_376e0c61-ebaf-4852-b2d3-b669524a5466" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_da4ecdf3-c90a-4924-81aa-7ea9ee88f48e" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_376e0c61-ebaf-4852-b2d3-b669524a5466" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsRocheDetails" xlink:type="simple" xlink:href="mgnx-20181231.xsd#CollaborationandOtherAgreementsRocheDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsRocheDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_01c1d9c1-5517-42bb-be55-b7713126d507" xlink:href="mgnx-20181231.xsd#mgnx_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_441fbabd-372a-4fce-8424-4af400adb3ac" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_01c1d9c1-5517-42bb-be55-b7713126d507" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_441fbabd-372a-4fce-8424-4af400adb3ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_05d1fd9f-9670-4304-8640-0472c8be99c6" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_441fbabd-372a-4fce-8424-4af400adb3ac" xlink:to="loc_srt_CounterpartyNameAxis_05d1fd9f-9670-4304-8640-0472c8be99c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6265ff68-acc1-4331-ab4d-cfb564d4ab05" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_05d1fd9f-9670-4304-8640-0472c8be99c6" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6265ff68-acc1-4331-ab4d-cfb564d4ab05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member_2a1e8a90-7352-42ae-bb6d-ae58990572a6" xlink:href="mgnx-20181231.xsd#mgnx_F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6265ff68-acc1-4331-ab4d-cfb564d4ab05" xlink:to="loc_mgnx_F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member_2a1e8a90-7352-42ae-bb6d-ae58990572a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_be607a02-ba39-4264-9a1b-da232b2a9ba0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_441fbabd-372a-4fce-8424-4af400adb3ac" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_be607a02-ba39-4264-9a1b-da232b2a9ba0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees_7eecda31-245d-433c-8fba-3e14fe0ce493" xlink:href="mgnx-20181231.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_be607a02-ba39-4264-9a1b-da232b2a9ba0" xlink:to="loc_mgnx_NonRefundableUpfrontFees_7eecda31-245d-433c-8fba-3e14fe0ce493" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialMilestonePaymentsandRoyaltiesonFutureSalesunderAgreement_32060e69-06a6-4b72-bc5b-749183fc7f45" xlink:href="mgnx-20181231.xsd#mgnx_PotentialMilestonePaymentsandRoyaltiesonFutureSalesunderAgreement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_be607a02-ba39-4264-9a1b-da232b2a9ba0" xlink:to="loc_mgnx_PotentialMilestonePaymentsandRoyaltiesonFutureSalesunderAgreement_32060e69-06a6-4b72-bc5b-749183fc7f45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_UpfrontPaymentRecognitionPeriod_5cfcae4a-1a4b-4a68-80ab-c50b2d32b6af" xlink:href="mgnx-20181231.xsd#mgnx_UpfrontPaymentRecognitionPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_be607a02-ba39-4264-9a1b-da232b2a9ba0" xlink:to="loc_mgnx_UpfrontPaymentRecognitionPeriod_5cfcae4a-1a4b-4a68-80ab-c50b2d32b6af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_4a580c45-96fb-4d3c-9099-6ce8ad1d69ba" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_be607a02-ba39-4264-9a1b-da232b2a9ba0" xlink:to="loc_us-gaap_Revenues_4a580c45-96fb-4d3c-9099-6ce8ad1d69ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_2526aac2-b474-477e-8993-679d5db25f29" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_be607a02-ba39-4264-9a1b-da232b2a9ba0" xlink:to="loc_us-gaap_ContractWithCustomerLiability_2526aac2-b474-477e-8993-679d5db25f29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_6fe9175f-65c6-4828-bbc4-33fd18f3fd26" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_be607a02-ba39-4264-9a1b-da232b2a9ba0" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_6fe9175f-65c6-4828-bbc4-33fd18f3fd26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_3291b37a-90f2-4926-8cf2-85a397b1f7eb" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_be607a02-ba39-4264-9a1b-da232b2a9ba0" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_3291b37a-90f2-4926-8cf2-85a397b1f7eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenue_f8d4bb4e-1c54-49e6-a4b3-3d591bef1320" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredRevenue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_be607a02-ba39-4264-9a1b-da232b2a9ba0" xlink:to="loc_us-gaap_DeferredRevenue_f8d4bb4e-1c54-49e6-a4b3-3d591bef1320" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueCurrent_bf6a8ef6-2d52-4bc0-93fe-40d2dd02c602" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredRevenueCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_be607a02-ba39-4264-9a1b-da232b2a9ba0" xlink:to="loc_us-gaap_DeferredRevenueCurrent_bf6a8ef6-2d52-4bc0-93fe-40d2dd02c602" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent_a44616ef-3f4e-40fd-ae04-740f11ca45c7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredRevenueNoncurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_be607a02-ba39-4264-9a1b-da232b2a9ba0" xlink:to="loc_us-gaap_DeferredRevenueNoncurrent_a44616ef-3f4e-40fd-ae04-740f11ca45c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsProventionDetails" xlink:type="simple" xlink:href="mgnx-20181231.xsd#CollaborationandOtherAgreementsProventionDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsProventionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_0ee758bf-9ecc-4b36-8b61-7b8a27007266" xlink:href="mgnx-20181231.xsd#mgnx_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b13011c4-cc80-4b10-8929-9ec70b8ee768" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_0ee758bf-9ecc-4b36-8b61-7b8a27007266" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b13011c4-cc80-4b10-8929-9ec70b8ee768" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_e4e787d1-1896-4cd6-94b6-b53cefcccb39" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b13011c4-cc80-4b10-8929-9ec70b8ee768" xlink:to="loc_srt_ProductOrServiceAxis_e4e787d1-1896-4cd6-94b6-b53cefcccb39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c9f6ac7d-7062-4274-ad88-dfb83cde40c9" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_e4e787d1-1896-4cd6-94b6-b53cefcccb39" xlink:to="loc_srt_ProductsAndServicesDomain_c9f6ac7d-7062-4274-ad88-dfb83cde40c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromLicenseAgreementsMember_43d5265e-431f-4310-9c5c-15bbd04b642a" xlink:href="mgnx-20181231.xsd#mgnx_RevenuesFromLicenseAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c9f6ac7d-7062-4274-ad88-dfb83cde40c9" xlink:to="loc_mgnx_RevenuesFromLicenseAgreementsMember_43d5265e-431f-4310-9c5c-15bbd04b642a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_ad242bd3-abff-42c9-8ed9-33c14ca54760" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b13011c4-cc80-4b10-8929-9ec70b8ee768" xlink:to="loc_us-gaap_TypeOfArrangementAxis_ad242bd3-abff-42c9-8ed9-33c14ca54760" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_75655ff2-6886-420d-837b-a9ff86fc8dba" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_ad242bd3-abff-42c9-8ed9-33c14ca54760" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_75655ff2-6886-420d-837b-a9ff86fc8dba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionLicenseAgreementMember_62a2c2e3-aa30-4933-87bb-4e06be52ff0a" xlink:href="mgnx-20181231.xsd#mgnx_ProventionLicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_75655ff2-6886-420d-837b-a9ff86fc8dba" xlink:to="loc_mgnx_ProventionLicenseAgreementMember_62a2c2e3-aa30-4933-87bb-4e06be52ff0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_AssetPurchaseAgreementMember_04afd116-98b1-4232-879b-a57a609b096b" xlink:href="mgnx-20181231.xsd#mgnx_AssetPurchaseAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_75655ff2-6886-420d-837b-a9ff86fc8dba" xlink:to="loc_mgnx_AssetPurchaseAgreementMember_04afd116-98b1-4232-879b-a57a609b096b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_0c60b5a9-1bef-40b3-8b9e-d93994aae145" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b13011c4-cc80-4b10-8929-9ec70b8ee768" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_0c60b5a9-1bef-40b3-8b9e-d93994aae145" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_afda66b2-f103-413b-ab34-70c417938dff" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_0c60b5a9-1bef-40b3-8b9e-d93994aae145" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_afda66b2-f103-413b-ab34-70c417938dff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionPRV3279Member_794c5cef-c18d-405a-871b-4be124a2c013" xlink:href="mgnx-20181231.xsd#mgnx_ProventionPRV3279Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_afda66b2-f103-413b-ab34-70c417938dff" xlink:to="loc_mgnx_ProventionPRV3279Member_794c5cef-c18d-405a-871b-4be124a2c013" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionPRV031Member_ef5c431c-1cf1-4f26-9908-b3cd0346b2d0" xlink:href="mgnx-20181231.xsd#mgnx_ProventionPRV031Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_afda66b2-f103-413b-ab34-70c417938dff" xlink:to="loc_mgnx_ProventionPRV031Member_ef5c431c-1cf1-4f26-9908-b3cd0346b2d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_5c469cbe-bfd5-4c13-9c14-3b5f1ac50c69" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_482108f7-2b63-4dba-9b55-5db389aa326f" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromLicenseAgreementsMember_ae6c8854-56f3-49f1-bcf7-3152103429e8" xlink:href="mgnx-20181231.xsd#mgnx_RevenuesFromLicenseAgreementsMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_68d569bb-b6c0-42f2-bd71-50abd387ded2" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b13011c4-cc80-4b10-8929-9ec70b8ee768" xlink:to="loc_srt_CounterpartyNameAxis_68d569bb-b6c0-42f2-bd71-50abd387ded2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bc308b98-5430-4063-8613-3ca98b4b64d7" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_68d569bb-b6c0-42f2-bd71-50abd387ded2" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bc308b98-5430-4063-8613-3ca98b4b64d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionBioMember_db801c41-8e2c-4e0e-b59f-fb8d028c2b07" xlink:href="mgnx-20181231.xsd#mgnx_ProventionBioMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bc308b98-5430-4063-8613-3ca98b4b64d7" xlink:to="loc_mgnx_ProventionBioMember_db801c41-8e2c-4e0e-b59f-fb8d028c2b07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b1099a72-88b9-4960-9d3b-8ac6a5de6a3b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b13011c4-cc80-4b10-8929-9ec70b8ee768" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b1099a72-88b9-4960-9d3b-8ac6a5de6a3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare_abd897e1-e541-494c-868f-e51287c386ce" xlink:href="mgnx-20181231.xsd#mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b1099a72-88b9-4960-9d3b-8ac6a5de6a3b" xlink:to="loc_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare_abd897e1-e541-494c-868f-e51287c386ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_ab65c94d-2602-4cea-8788-629185053e14" xlink:href="mgnx-20181231.xsd#mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b1099a72-88b9-4960-9d3b-8ac6a5de6a3b" xlink:to="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_ab65c94d-2602-4cea-8788-629185053e14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_5acc290d-8d45-41ab-ae37-479512fb0fea" xlink:href="mgnx-20181231.xsd#mgnx_PotentialCommercialMilestonePaymentsUnderAgreement"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b1099a72-88b9-4960-9d3b-8ac6a5de6a3b" xlink:to="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_5acc290d-8d45-41ab-ae37-479512fb0fea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement_6c1142db-ccf6-4b72-89d7-08274ab2cc1e" xlink:href="mgnx-20181231.xsd#mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b1099a72-88b9-4960-9d3b-8ac6a5de6a3b" xlink:to="loc_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement_6c1142db-ccf6-4b72-89d7-08274ab2cc1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementTransactionPrice_d201420a-aaa2-46e4-9d69-70936adc93b0" xlink:href="mgnx-20181231.xsd#mgnx_CollaborativeAgreementTransactionPrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b1099a72-88b9-4960-9d3b-8ac6a5de6a3b" xlink:to="loc_mgnx_CollaborativeAgreementTransactionPrice_d201420a-aaa2-46e4-9d69-70936adc93b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares_a0f63072-2ad7-41bc-af30-034fed54437f" xlink:href="mgnx-20181231.xsd#mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b1099a72-88b9-4960-9d3b-8ac6a5de6a3b" xlink:to="loc_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares_a0f63072-2ad7-41bc-af30-034fed54437f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_f8716412-1fc0-48c9-b5dd-1a6ccc848b58" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b1099a72-88b9-4960-9d3b-8ac6a5de6a3b" xlink:to="loc_us-gaap_Revenues_f8716412-1fc0-48c9-b5dd-1a6ccc848b58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_4db825d2-eaa2-4c80-b44e-633c0437bb3f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b1099a72-88b9-4960-9d3b-8ac6a5de6a3b" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_4db825d2-eaa2-4c80-b44e-633c0437bb3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenBiotechIncDetails" xlink:type="simple" xlink:href="mgnx-20181231.xsd#CollaborationandOtherAgreementsJanssenBiotechIncDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenBiotechIncDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_b293191c-b118-46cc-99c7-8bb5db39a5d2" xlink:href="mgnx-20181231.xsd#mgnx_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2f20e879-3bd1-488e-913d-49e25249fab9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_b293191c-b118-46cc-99c7-8bb5db39a5d2" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2f20e879-3bd1-488e-913d-49e25249fab9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_15bd07b6-1ea2-40ce-b70c-5d0c8ec2e62f" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2f20e879-3bd1-488e-913d-49e25249fab9" xlink:to="loc_srt_ProductOrServiceAxis_15bd07b6-1ea2-40ce-b70c-5d0c8ec2e62f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d6150b16-1d11-48a0-8b1d-39a0bd2c51ae" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_15bd07b6-1ea2-40ce-b70c-5d0c8ec2e62f" xlink:to="loc_srt_ProductsAndServicesDomain_d6150b16-1d11-48a0-8b1d-39a0bd2c51ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromLicenseAgreementsMember_80fb15ed-3f1b-4171-b303-72c6c2f72614" xlink:href="mgnx-20181231.xsd#mgnx_RevenuesFromLicenseAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d6150b16-1d11-48a0-8b1d-39a0bd2c51ae" xlink:to="loc_mgnx_RevenuesFromLicenseAgreementsMember_80fb15ed-3f1b-4171-b303-72c6c2f72614" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_0e67ba68-858c-4ae1-8525-a8230fa403ee" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2f20e879-3bd1-488e-913d-49e25249fab9" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_0e67ba68-858c-4ae1-8525-a8230fa403ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_ffa05ee3-577d-4dfc-86ac-5ce6dcb39866" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_0e67ba68-858c-4ae1-8525-a8230fa403ee" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_ffa05ee3-577d-4dfc-86ac-5ce6dcb39866" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_JanssenMGD011AgreementMember_810a6546-0c7e-4b53-b9f6-9c3ef14abe5e" xlink:href="mgnx-20181231.xsd#mgnx_JanssenMGD011AgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_ffa05ee3-577d-4dfc-86ac-5ce6dcb39866" xlink:to="loc_mgnx_JanssenMGD011AgreementMember_810a6546-0c7e-4b53-b9f6-9c3ef14abe5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_JanssenMGD015AgreementMember_0ec05020-31a7-43d8-8643-192cea421e93" xlink:href="mgnx-20181231.xsd#mgnx_JanssenMGD015AgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_ffa05ee3-577d-4dfc-86ac-5ce6dcb39866" xlink:to="loc_mgnx_JanssenMGD015AgreementMember_0ec05020-31a7-43d8-8643-192cea421e93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_5d2a025f-0494-46b4-be72-1a4a1c41567a" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2f20e879-3bd1-488e-913d-49e25249fab9" xlink:to="loc_srt_CounterpartyNameAxis_5d2a025f-0494-46b4-be72-1a4a1c41567a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_80cb688b-9132-4f6c-a5c0-7b1b04824f39" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_5d2a025f-0494-46b4-be72-1a4a1c41567a" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_80cb688b-9132-4f6c-a5c0-7b1b04824f39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_JanssenBiotechIncMember_aaf252eb-aa13-4133-ad31-549ec71109c6" xlink:href="mgnx-20181231.xsd#mgnx_JanssenBiotechIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_80cb688b-9132-4f6c-a5c0-7b1b04824f39" xlink:to="loc_mgnx_JanssenBiotechIncMember_aaf252eb-aa13-4133-ad31-549ec71109c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1557c743-ff7a-4500-9ebd-320c61e36ede" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2f20e879-3bd1-488e-913d-49e25249fab9" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1557c743-ff7a-4500-9ebd-320c61e36ede" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_887e33f1-3ba5-4cce-9cee-2c329fc1dc40" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1557c743-ff7a-4500-9ebd-320c61e36ede" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_887e33f1-3ba5-4cce-9cee-2c329fc1dc40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_6d53b83d-8a9b-4139-88cf-824d66abe61d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1557c743-ff7a-4500-9ebd-320c61e36ede" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_6d53b83d-8a9b-4139-88cf-824d66abe61d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees_f3462c4c-f4c7-41fd-9253-d7b3d19c162e" xlink:href="mgnx-20181231.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1557c743-ff7a-4500-9ebd-320c61e36ede" xlink:to="loc_mgnx_NonRefundableUpfrontFees_f3462c4c-f4c7-41fd-9253-d7b3d19c162e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_138aee7d-0123-4aaf-b1c3-34dc2af651c3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1557c743-ff7a-4500-9ebd-320c61e36ede" xlink:to="loc_us-gaap_Revenues_138aee7d-0123-4aaf-b1c3-34dc2af651c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails" xlink:type="simple" xlink:href="mgnx-20181231.xsd#CollaborationandOtherAgreementsNIAIDContractDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_93da69eb-9500-4816-9d3b-6c5e56bf85d0" xlink:href="mgnx-20181231.xsd#mgnx_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b6a98327-8524-402c-bfd1-977f8c226797" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_93da69eb-9500-4816-9d3b-6c5e56bf85d0" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b6a98327-8524-402c-bfd1-977f8c226797" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_36b0ad24-70f7-466b-ba8b-3823e962c6e5" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b6a98327-8524-402c-bfd1-977f8c226797" xlink:to="loc_srt_ProductOrServiceAxis_36b0ad24-70f7-466b-ba8b-3823e962c6e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_1ce90057-1dc6-4c65-883c-5a7395964cc2" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_36b0ad24-70f7-466b-ba8b-3823e962c6e5" xlink:to="loc_srt_ProductsAndServicesDomain_1ce90057-1dc6-4c65-883c-5a7395964cc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromLicenseAgreementsMember_7553dfcf-cc4b-4da1-a529-ebea77ea2710" xlink:href="mgnx-20181231.xsd#mgnx_RevenuesFromLicenseAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1ce90057-1dc6-4c65-883c-5a7395964cc2" xlink:to="loc_mgnx_RevenuesFromLicenseAgreementsMember_7553dfcf-cc4b-4da1-a529-ebea77ea2710" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_c08d3ffb-02ce-4f2e-8543-8718e00de041" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b6a98327-8524-402c-bfd1-977f8c226797" xlink:to="loc_srt_CounterpartyNameAxis_c08d3ffb-02ce-4f2e-8543-8718e00de041" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c0baa5b7-1b53-4df9-b015-13fe27ecf40d" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_c08d3ffb-02ce-4f2e-8543-8718e00de041" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c0baa5b7-1b53-4df9-b015-13fe27ecf40d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember_49f83ed3-fc5d-457d-b271-d31a0c525751" xlink:href="mgnx-20181231.xsd#mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c0baa5b7-1b53-4df9-b015-13fe27ecf40d" xlink:to="loc_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember_49f83ed3-fc5d-457d-b271-d31a0c525751" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_7625ddbb-d879-4250-ab6b-940aa756ce46" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b6a98327-8524-402c-bfd1-977f8c226797" xlink:to="loc_srt_RangeAxis_7625ddbb-d879-4250-ab6b-940aa756ce46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_74bb8511-b500-4a09-a82f-fa8042a31461" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_7625ddbb-d879-4250-ab6b-940aa756ce46" xlink:to="loc_srt_RangeMember_74bb8511-b500-4a09-a82f-fa8042a31461" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_9dd3c340-6012-4adc-b410-5aa60c9e824b" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_74bb8511-b500-4a09-a82f-fa8042a31461" xlink:to="loc_srt_MaximumMember_9dd3c340-6012-4adc-b410-5aa60c9e824b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b176e728-fd44-48d2-b6e3-f565648e7b48" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b6a98327-8524-402c-bfd1-977f8c226797" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b176e728-fd44-48d2-b6e3-f565648e7b48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement_6d7dcd3f-eb33-4269-b8eb-2f34e03e53e1" xlink:href="mgnx-20181231.xsd#mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b176e728-fd44-48d2-b6e3-f565648e7b48" xlink:to="loc_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement_6d7dcd3f-eb33-4269-b8eb-2f34e03e53e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_FundedValueOfBasePeriod_f906d7f7-2f14-4932-80ae-b09f395fd197" xlink:href="mgnx-20181231.xsd#mgnx_FundedValueOfBasePeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b176e728-fd44-48d2-b6e3-f565648e7b48" xlink:to="loc_mgnx_FundedValueOfBasePeriod_f906d7f7-2f14-4932-80ae-b09f395fd197" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement_88eabff3-8780-4967-949a-31e6558b2149" xlink:href="mgnx-20181231.xsd#mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b176e728-fd44-48d2-b6e3-f565648e7b48" xlink:to="loc_mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement_88eabff3-8780-4967-949a-31e6558b2149" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_TotalPotentialValueUnderAgreement_a81de2d0-3d8d-4d43-9a09-56dcfc3c3ad5" xlink:href="mgnx-20181231.xsd#mgnx_TotalPotentialValueUnderAgreement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b176e728-fd44-48d2-b6e3-f565648e7b48" xlink:to="loc_mgnx_TotalPotentialValueUnderAgreement_a81de2d0-3d8d-4d43-9a09-56dcfc3c3ad5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement_990d65eb-9b40-4371-a93f-b236983c0631" xlink:href="mgnx-20181231.xsd#mgnx_ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b176e728-fd44-48d2-b6e3-f565648e7b48" xlink:to="loc_mgnx_ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement_990d65eb-9b40-4371-a93f-b236983c0631" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_542c8ccc-6ed1-4e13-bf0b-51aaf63120d8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b176e728-fd44-48d2-b6e3-f565648e7b48" xlink:to="loc_us-gaap_Revenues_542c8ccc-6ed1-4e13-bf0b-51aaf63120d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="mgnx-20181231.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1dcf5f23-7c4b-4789-ad89-a73bded11ee9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_0895b616-5871-4ede-a64a-c371ba4fbce8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1dcf5f23-7c4b-4789-ad89-a73bded11ee9" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_0895b616-5871-4ede-a64a-c371ba4fbce8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CommitmentsandContingenciesTables" xlink:type="simple" xlink:href="mgnx-20181231.xsd#CommitmentsandContingenciesTables"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CommitmentsandContingenciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5ae08144-630f-4e4c-a813-56c782e77536" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock_e4a69ed7-2df6-459e-aeba-759bcf72abcf" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5ae08144-630f-4e4c-a813-56c782e77536" xlink:to="loc_us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock_e4a69ed7-2df6-459e-aeba-759bcf72abcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="mgnx-20181231.xsd#CommitmentsandContingenciesDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CommitmentsandContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b890edca-c668-4086-8ed9-a0cb36394ef2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NumberOfLease_e1b37a0d-cbcc-4d7d-9672-a80deb70dd51" xlink:href="mgnx-20181231.xsd#mgnx_NumberOfLease"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b890edca-c668-4086-8ed9-a0cb36394ef2" xlink:to="loc_mgnx_NumberOfLease_e1b37a0d-cbcc-4d7d-9672-a80deb70dd51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals_2fb3ecdd-60d9-4cfb-a303-93c0fd254d17" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b890edca-c668-4086-8ed9-a0cb36394ef2" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals_2fb3ecdd-60d9-4cfb-a303-93c0fd254d17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromTenantAllowance_431d16bf-d93a-4a96-ae48-a4f68ed18391" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForProceedsFromTenantAllowance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b890edca-c668-4086-8ed9-a0cb36394ef2" xlink:to="loc_us-gaap_PaymentsForProceedsFromTenantAllowance_431d16bf-d93a-4a96-ae48-a4f68ed18391" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRentCredit_b1632deb-472a-4156-aa96-8c060eaad452" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredRentCredit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b890edca-c668-4086-8ed9-a0cb36394ef2" xlink:to="loc_us-gaap_DeferredRentCredit_b1632deb-472a-4156-aa96-8c060eaad452" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseNet_c733327c-1871-43f2-a6fb-c2d0712e90be" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b890edca-c668-4086-8ed9-a0cb36394ef2" xlink:to="loc_us-gaap_OperatingLeasesRentExpenseNet_c733327c-1871-43f2-a6fb-c2d0712e90be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_6470cd67-cf13-474e-a80c-9e94d6f72091" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b890edca-c668-4086-8ed9-a0cb36394ef2" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_6470cd67-cf13-474e-a80c-9e94d6f72091" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_6fd5a749-eb1b-4eac-9e9f-0afc18bae079" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_6470cd67-cf13-474e-a80c-9e94d6f72091" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_6fd5a749-eb1b-4eac-9e9f-0afc18bae079" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_5e097bd8-feb0-410b-a75f-2087b0c91e53" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_6470cd67-cf13-474e-a80c-9e94d6f72091" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_5e097bd8-feb0-410b-a75f-2087b0c91e53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_4143c7f7-75e2-4e70-93a0-3e5969a666d5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_6470cd67-cf13-474e-a80c-9e94d6f72091" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_4143c7f7-75e2-4e70-93a0-3e5969a666d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_33a72750-ce91-4da4-b9fc-580b371bd201" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_6470cd67-cf13-474e-a80c-9e94d6f72091" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_33a72750-ce91-4da4-b9fc-580b371bd201" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_fd9fe2ab-070d-4a45-90da-0463a3596b22" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_6470cd67-cf13-474e-a80c-9e94d6f72091" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_fd9fe2ab-070d-4a45-90da-0463a3596b22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_a28cb2ec-571a-442a-b76b-8da687195fed" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_6470cd67-cf13-474e-a80c-9e94d6f72091" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_a28cb2ec-571a-442a-b76b-8da687195fed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_a41b1c80-8ca7-4691-8a5a-f5d11e470100" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_6470cd67-cf13-474e-a80c-9e94d6f72091" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_a41b1c80-8ca7-4691-8a5a-f5d11e470100" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/EmployeeBenefitPlan" xlink:type="simple" xlink:href="mgnx-20181231.xsd#EmployeeBenefitPlan"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/EmployeeBenefitPlan" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_5701c75c-e269-4a24-bed6-0692955e6c06" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_fcdb2d3a-6af6-4aa5-8608-f3b63b1c6223" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_5701c75c-e269-4a24-bed6-0692955e6c06" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_fcdb2d3a-6af6-4aa5-8608-f3b63b1c6223" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/EmployeeBenefitPlanDetails" xlink:type="simple" xlink:href="mgnx-20181231.xsd#EmployeeBenefitPlanDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/EmployeeBenefitPlanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_badffcac-60c8-43e0-bc8a-4f4dd7e71177" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan_cc07ab5f-5566-4abc-84fb-9ebeb2089bbc" xlink:href="mgnx-20181231.xsd#mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_badffcac-60c8-43e0-bc8a-4f4dd7e71177" xlink:to="loc_mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan_cc07ab5f-5566-4abc-84fb-9ebeb2089bbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_ac0d5ef1-025c-4a86-ad7d-6d295846ff47" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_badffcac-60c8-43e0-bc8a-4f4dd7e71177" xlink:to="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_ac0d5ef1-025c-4a86-ad7d-6d295846ff47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage_34ae84d4-a9d2-4b24-86b4-8447121352d5" xlink:href="mgnx-20181231.xsd#mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_badffcac-60c8-43e0-bc8a-4f4dd7e71177" xlink:to="loc_mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage_34ae84d4-a9d2-4b24-86b4-8447121352d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_8e7c1704-3e77-4830-b746-c62ba982b1ed" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_badffcac-60c8-43e0-bc8a-4f4dd7e71177" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_8e7c1704-3e77-4830-b746-c62ba982b1ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/QuarterlyFinancialInformationUnaudited" xlink:type="simple" xlink:href="mgnx-20181231.xsd#QuarterlyFinancialInformationUnaudited"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/QuarterlyFinancialInformationUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_308d3df0-0db2-43d0-adc1-cf4c548c6eb1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationTextBlock_7fb06414-dc55-47e8-9568-c586e7badff9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_308d3df0-0db2-43d0-adc1-cf4c548c6eb1" xlink:to="loc_us-gaap_QuarterlyFinancialInformationTextBlock_7fb06414-dc55-47e8-9568-c586e7badff9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/QuarterlyFinancialInformationUnauditedTables" xlink:type="simple" xlink:href="mgnx-20181231.xsd#QuarterlyFinancialInformationUnauditedTables"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/QuarterlyFinancialInformationUnauditedTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_a27c240f-f0aa-435c-a999-161881c16968" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_925adfe7-28e8-47e1-8c7b-89f069d97c4b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_a27c240f-f0aa-435c-a999-161881c16968" xlink:to="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_925adfe7-28e8-47e1-8c7b-89f069d97c4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/QuarterlyFinancialInformationUnauditedDetails" xlink:type="simple" xlink:href="mgnx-20181231.xsd#QuarterlyFinancialInformationUnauditedDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/QuarterlyFinancialInformationUnauditedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_044b1dd0-dfbf-4056-a0e7-714919d60403" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_6a80444d-81bc-41d6-817a-0df6cb4884a5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_044b1dd0-dfbf-4056-a0e7-714919d60403" xlink:to="loc_us-gaap_Revenues_6a80444d-81bc-41d6-817a-0df6cb4884a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d3873aa5-cb28-4f93-a480-043874a437a4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_044b1dd0-dfbf-4056-a0e7-714919d60403" xlink:to="loc_us-gaap_NetIncomeLoss_d3873aa5-cb28-4f93-a480-043874a437a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_2d09443d-e54f-4169-a413-42bb25e2f11b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_044b1dd0-dfbf-4056-a0e7-714919d60403" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_2d09443d-e54f-4169-a413-42bb25e2f11b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_05814fe9-b095-4e8a-895b-6c4bdd5a91aa" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_044b1dd0-dfbf-4056-a0e7-714919d60403" xlink:to="loc_us-gaap_EarningsPerShareBasic_05814fe9-b095-4e8a-895b-6c4bdd5a91aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_7fe6bdea-9177-4b12-99b4-e1f19cae6bfc" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_044b1dd0-dfbf-4056-a0e7-714919d60403" xlink:to="loc_us-gaap_EarningsPerShareDiluted_7fe6bdea-9177-4b12-99b4-e1f19cae6bfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/SubsequentEvents" xlink:type="simple" xlink:href="mgnx-20181231.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_433b3065-7b5e-487a-8bd9-85bbcf142399" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_ce30f9bf-69c6-458d-8c0b-38e30789f781" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_433b3065-7b5e-487a-8bd9-85bbcf142399" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_ce30f9bf-69c6-458d-8c0b-38e30789f781" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="mgnx-20181231.xsd#SubsequentEventsDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_e129314d-b2bd-4eaa-83b5-efebbf633983" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_07e8d511-9561-42ea-a5b3-6c92ca570dbf" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_e129314d-b2bd-4eaa-83b5-efebbf633983" xlink:to="loc_us-gaap_SubsequentEventTable_07e8d511-9561-42ea-a5b3-6c92ca570dbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_4df031c7-6d66-4c31-8b73-700d00e3fd69" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_07e8d511-9561-42ea-a5b3-6c92ca570dbf" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_4df031c7-6d66-4c31-8b73-700d00e3fd69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1c20f150-c586-4a09-8e7f-335725614d96" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_4df031c7-6d66-4c31-8b73-700d00e3fd69" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1c20f150-c586-4a09-8e7f-335725614d96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_FollowUpOfferingMember_6e70cd77-49ec-4f02-b107-315d9a5ceff0" xlink:href="mgnx-20181231.xsd#mgnx_FollowUpOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1c20f150-c586-4a09-8e7f-335725614d96" xlink:to="loc_mgnx_FollowUpOfferingMember_6e70cd77-49ec-4f02-b107-315d9a5ceff0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_c1887d3b-b09b-4d3c-99e0-68a45e5d7cae" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1c20f150-c586-4a09-8e7f-335725614d96" xlink:to="loc_us-gaap_OverAllotmentOptionMember_c1887d3b-b09b-4d3c-99e0-68a45e5d7cae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_3f3e8831-1e02-440c-9ee9-c79fe57eb0d7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_07e8d511-9561-42ea-a5b3-6c92ca570dbf" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_3f3e8831-1e02-440c-9ee9-c79fe57eb0d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_2528bbdc-dbcd-4636-a323-d5f7e948a2a0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_3f3e8831-1e02-440c-9ee9-c79fe57eb0d7" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_2528bbdc-dbcd-4636-a323-d5f7e948a2a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_615f52f5-5622-46ab-b879-659159310c36" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_2528bbdc-dbcd-4636-a323-d5f7e948a2a0" xlink:to="loc_us-gaap_SubsequentEventMember_615f52f5-5622-46ab-b879-659159310c36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_3ead1dad-408a-4092-9ff2-6cda3eeb5d16" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_07e8d511-9561-42ea-a5b3-6c92ca570dbf" xlink:to="loc_us-gaap_SubsequentEventLineItems_3ead1dad-408a-4092-9ff2-6cda3eeb5d16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_aed07de6-ff81-4056-914e-d3ad20018d85" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_3ead1dad-408a-4092-9ff2-6cda3eeb5d16" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_aed07de6-ff81-4056-914e-d3ad20018d85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_5c57f936-8816-45a2-8805-8dd1eaacdac5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_3ead1dad-408a-4092-9ff2-6cda3eeb5d16" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_5c57f936-8816-45a2-8805-8dd1eaacdac5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_5aff002b-b5ed-497a-87f3-7fdc7022bc61" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_3ead1dad-408a-4092-9ff2-6cda3eeb5d16" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_5aff002b-b5ed-497a-87f3-7fdc7022bc61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>mgnx-20181231_g1.jpg
<TEXT>
begin 644 mgnx-20181231_g1.jpg
M_]C_X  02D9)1@ ! 0$!+0$L  #_X0!F17AI9@  34T *@    @ !0,!  4
M   !    2@,"  (    ,    4E$0  $    ! 0   %$1  0    !   N2U$2
M  0    !   N)        8:@  "QCTE#0R!0<F]F:6QE /_B#%A)0T-?4%)/
M1DE,10 ! 0  #$A,:6YO A   &UN=')21T(@6%E:( ?.  ( "0 & #$  &%C
M<W!-4T94     $E%0R!S4D="                  #VU@ !     -,M2% @
M(
M    $6-P<G0   %0    ,V1E<V,   &$    ;'=T<'0   'P    %&)K<'0
M  ($    %')865H   (8    %&=865H   (L    %&)865H   )     %&1M
M;F0   )4    <&1M9&0   +$    B'9U960   -,    AG9I97<   /4
M)&QU;6D   /X    %&UE87,   0,    )'1E8V@   0P    #')44D,   0\
M   (#&=44D,   0\   (#&)44D,   0\   (#'1E>'0     0V]P>7)I9VAT
M("AC*2 Q.3DX($AE=VQE='0M4&%C:V%R9"!#;VUP86YY  !D97-C
M !)S4D="($E%0S8Q.38V+3(N,0              $G-21T(@245#-C$Y-C8M
M,BXQ
M          !865H@        \U$  0    $6S%A96B
M    6%E:(        &^B   X]0   Y!865H@        8ID  +>%   8VEA9
M6B         DH   #X0  +;/9&5S8P         6245#(&AT=' Z+R]W=W<N
M:65C+F-H               6245#(&AT=' Z+R]W=W<N:65C+F-H
M                                                     &1E<V,
M        +DE%0R V,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E
M("T@<U)'0@              +DE%0R V,3DV-BTR+C$@1&5F875L="!21T(@
M8V]L;W5R('-P86-E("T@<U)'0@                            !D97-C
M         "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y
M-C8M,BXQ               L4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N
M(&EN($E%0S8Q.38V+3(N,0                                  =FEE
M=P      $Z3^ !1?+@ 0SQ0  ^W,  03"P #7)X    !6%E:(       3 E6
M %    !7'^=M96%S          $                        "CP    )S
M:6<@     $-25"!C=7)V        !      %  H #P 4 !D '@ C "@ +0 R
M #< .P!  $4 2@!/ %0 60!> &, : !M '( =P!\ ($ A@"+ )  E0": )\
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M>!%X;GC,>2IYB7GG>D9ZI7L$>V-[PGPA?(%\X7U!?:%^ 7YB?L)_(W^$?^6
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M# P,#/_  !$(!>H.EP,!(@ "$0$#$0'_Q  ?   !!0$! 0$! 0
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M]O?X^?K_V@ , P$  A$#$0 _ /W\HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^&?^(D
MW]BO_HM'_EHZ[_\ (5?<U?PSU[.4Y?3Q7/[1M6MMYW\GV,ZDFMC^K+_B)-_8
MK_Z+1_Y:.N__ "%1_P 1)O[%?_1:/_+1UW_Y"K^4VBO9_P!7<-_-+[U_D9^U
M9_5E_P 1)O[%?_1:/_+1UW_Y"H_XB3?V*_\ HM'_ ):.N_\ R%7\IM%'^KN&
M_FE]Z_R#VK/ZLO\ B)-_8K_Z+1_Y:.N__(5'_$2;^Q7_ -%H_P#+1UW_ .0J
M_E-HH_U=PW\TOO7^0>U9_5E_Q$F_L5_]%H_\M'7?_D*C_B)-_8K_ .BT?^6C
MKO\ \A5_*;11_J[AOYI?>O\ (/:L_JR_XB3?V*_^BT?^6CKO_P A4?\ $2;^
MQ7_T6C_RT==_^0J_E-HH_P!7<-_-+[U_D'M6?U9?\1)O[%?_ $6C_P M'7?_
M )"H_P"(DW]BO_HM'_EHZ[_\A5_*;11_J[AOYI?>O\@]JS^K+_B)-_8K_P"B
MT?\ EHZ[_P#(5'_$2;^Q7_T6C_RT==_^0J_E-HH_U=PW\TOO7^0>U9_5E_Q$
MF_L5_P#1:/\ RT==_P#D*C_B)-_8K_Z+1_Y:.N__ "%7\IM%'^KN&_FE]Z_R
M#VK/ZLO^(DW]BO\ Z+1_Y:.N_P#R%1_Q$F_L5_\ 1:/_ "T==_\ D*OY3:*/
M]7<-_-+[U_D'M6?U9?\ $2;^Q7_T6C_RT==_^0J/^(DW]BO_ *+1_P"6CKO_
M ,A5_*;11_J[AOYI?>O\@]JS^K+_ (B3?V*_^BT?^6CKO_R%1_Q$F_L5_P#1
M:/\ RT==_P#D*OY3:*/]7<-_-+[U_D'M6?U9?\1)O[%?_1:/_+1UW_Y"H_XB
M3?V*_P#HM'_EHZ[_ /(5?RFT4?ZNX;^:7WK_ "#VK/ZLO^(DW]BO_HM'_EHZ
M[_\ (5'_ !$F_L5_]%H_\M'7?_D*OY3:*/\ 5W#?S2^]?Y![5G]67_$2;^Q7
M_P!%H_\ +1UW_P"0J/\ B)-_8K_Z+1_Y:.N__(5?RFT4?ZNX;^:7WK_(/:L_
MJR_XB3?V*_\ HM'_ ):.N_\ R%1_Q$F_L5_]%H_\M'7?_D*OY3:*/]7<-_-+
M[U_D'M6?U9?\1)O[%?\ T6C_ ,M'7?\ Y"H_XB3?V*_^BT?^6CKO_P A5_*;
M11_J[AOYI?>O\@]JS^K+_B)-_8K_ .BT?^6CKO\ \A4?\1)O[%?_ $6C_P M
M'7?_ )"K^4VBC_5W#?S2^]?Y![5G]67_ !$F_L5_]%H_\M'7?_D*C_B)-_8K
M_P"BT?\ EHZ[_P#(5?RFT4?ZNX;^:7WK_(/:L_JR_P"(DW]BO_HM'_EHZ[_\
MA4?\1)O[%?\ T6C_ ,M'7?\ Y"K^4VBC_5W#?S2^]?Y![5G]67_$2;^Q7_T6
MC_RT==_^0J/^(DW]BO\ Z+1_Y:.N_P#R%7\IM%'^KN&_FE]Z_P @]JS^K+_B
M)-_8K_Z+1_Y:.N__ "%1_P 1)O[%?_1:/_+1UW_Y"K^4VBC_ %=PW\TOO7^0
M>U9_5E_Q$F_L5_\ 1:/_ "T==_\ D*C_ (B3?V*_^BT?^6CKO_R%7\IM%'^K
MN&_FE]Z_R#VK/ZLO^(DW]BO_ *+1_P"6CKO_ ,A4?\1)O[%?_1:/_+1UW_Y"
MK^4VBC_5W#?S2^]?Y![5G]67_$2;^Q7_ -%H_P#+1UW_ .0J/^(DW]BO_HM'
M_EHZ[_\ (5?RFT4?ZNX;^:7WK_(/:L_JR_XB3?V*_P#HM'_EHZ[_ /(5'_$2
M;^Q7_P!%H_\ +1UW_P"0J_E-HH_U=PW\TOO7^0>U9_5E_P 1)O[%?_1:/_+1
MUW_Y"H_XB3?V*_\ HM'_ ):.N_\ R%7\IM%'^KN&_FE]Z_R#VK/ZLO\ B)-_
M8K_Z+1_Y:.N__(5'_$2;^Q7_ -%H_P#+1UW_ .0J_E-HH_U=PW\TOO7^0>U9
M_5E_Q$F_L5_]%H_\M'7?_D*C_B)-_8K_ .BT?^6CKO\ \A5_*;11_J[AOYI?
M>O\ (/:L_JR_XB3?V*_^BT?^6CKO_P A4?\ $2;^Q7_T6C_RT==_^0J_E-HH
M_P!7<-_-+[U_D'M6?U9?\1)O[%?_ $6C_P M'7?_ )"H_P"(DW]BO_HM'_EH
MZ[_\A5_*;11_J[AOYI?>O\@]JS^K+_B)-_8K_P"BT?\ EHZ[_P#(5'_$2;^Q
M7_T6C_RT==_^0J_E-HH_U=PW\TOO7^0>U9_5E_Q$F_L5_P#1:/\ RT==_P#D
M*C_B)-_8K_Z+1_Y:.N__ "%7\IM%'^KN&_FE]Z_R#VK/ZLO^(DW]BO\ Z+1_
MY:.N_P#R%1_Q$F_L5_\ 1:/_ "T==_\ D*OY3:*/]7<-_-+[U_D'M6?U9?\
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M?^6CKO\ \A5_*;11_J[AOYI?>O\ (/:L_JR_XB3?V*_^BT?^6CKO_P A4?\
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MQ$F_L5_]%H_\M'7?_D*C_B)-_8K_ .BT?^6CKO\ \A5_*;11_J[AOYI?>O\
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M_A+_ +5_9'_$HO\ 4/M?V;R?._X]8)=FW[1%]_;G?QG!QX9_P;9?\H5O@O\
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M5'_$2;^Q7_T6C_RT==_^0J_E-HH_U=PW\TOO7^0>U9_5E_Q$F_L5_P#1:/\
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M_P"0J/\ B)-_8K_Z+1_Y:.N__(5?RFT4?ZNX;^:7WK_(/:L_JR_XB3?V*_\
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M "%7\IM%'^KN&_FE]Z_R#VK/ZLO^(DW]BO\ Z+1_Y:.N_P#R%1_Q$F_L5_\
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MV*_^BT?^6CKO_P A5_*;11_J[AOYI?>O\@]JS^K+_B)-_8K_ .BT?^6CKO\
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M !$F_L5_]%H_\M'7?_D*OY3:*/\ 5W#?S2^]?Y![5G]67_$2;^Q7_P!%H_\
M+1UW_P"0J/\ B)-_8K_Z+1_Y:.N__(5?RFT4?ZNX;^:7WK_(/:L_JR_XB3?V
M*_\ HM'_ ):.N_\ R%1_Q$F_L5_]%H_\M'7?_D*OY3:*/]7<-_-+[U_D'M6?
MU9?\1)O[%?\ T6C_ ,M'7?\ Y"H_XB3?V*_^BT?^6CKO_P A5_*;11_J[AOY
MI?>O\@]JS^K+_B)-_8K_ .BT?^6CKO\ \A4?\1)O[%?_ $6C_P M'7?_ )"K
M^4VBC_5W#?S2^]?Y![5G]67_ !$F_L5_]%H_\M'7?_D*C_B)-_8K_P"BT?\
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M5'_$2;^Q7_T6C_RT==_^0J_E-HH_U=PW\TOO7^0>U9_5E_Q$F_L5_P#1:/\
MRT==_P#D*C_B)-_8K_Z+1_Y:.N__ "%7\IM%'^KN&_FE]Z_R#VK/ZLO^(DW]
MBO\ Z+1_Y:.N_P#R%1_Q$F_L5_\ 1:/_ "T==_\ D*OY3:*/]7<-_-+[U_D'
MM6?U9?\ $2;^Q7_T6C_RT==_^0J/^(DW]BO_ *+1_P"6CKO_ ,A5_*;11_J[
MAOYI?>O\@]JS^K+_ (B3?V*_^BT?^6CKO_R%1_Q$F_L5_P#1:/\ RT==_P#D
M*OY3:*/]7<-_-+[U_D'M6?U9?\1)O[%?_1:/_+1UW_Y"H_XB3?V*_P#HM'_E
MHZ[_ /(5?RFT4?ZNX;^:7WK_ "#VK/ZLO^(DW]BO_HM'_EHZ[_\ (5'_ !$F
M_L5_]%H_\M'7?_D*OY3:*/\ 5W#?S2^]?Y![5G]67_$2;^Q7_P!%H_\ +1UW
M_P"0J/\ B)-_8K_Z+1_Y:.N__(5?RFT4?ZNX;^:7WK_(/:L_JR_XB3?V*_\
MHM'_ ):.N_\ R%1_Q$F_L5_]%H_\M'7?_D*OY3:*/]7<-_-+[U_D'M6?U9?\
M1)O[%?\ T6C_ ,M'7?\ Y"H_XB3?V*_^BT?^6CKO_P A5_*;11_J[AOYI?>O
M\@]JS^K+_B)-_8K_ .BT?^6CKO\ \A4?\1)O[%?_ $6C_P M'7?_ )"K^4VB
MC_5W#?S2^]?Y![5G]67_ !$F_L5_]%H_\M'7?_D*C_B)-_8K_P"BT?\ EHZ[
M_P#(5?RFT4?ZNX;^:7WK_(/:L_JR_P"(DW]BO_HM'_EHZ[_\A4?\1)O[%?\
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MFT4?ZNX;^:7WK_(/:L_JR_XB3?V*_P#HM'_EHZ[_ /(5'_$2;^Q7_P!%H_\
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M%>__ *NX;^:7WK_(R]JS^K+_ (B3?V*_^BT?^6CKO_R%1_Q$F_L5_P#1:/\
MRT==_P#D*OY3:*/]7<-_-+[U_D'M6?U9?\1)O[%?_1:/_+1UW_Y"H_XB3?V*
M_P#HM'_EHZ[_ /(5?RFT4?ZNX;^:7WK_ "#VK/ZLO^(DW]BO_HM'_EHZ[_\
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MQ$F_L5_]%H_\M'7?_D*C_B)-_8K_ .BT?^6CKO\ \A5_*;11_J[AOYI?>O\
M(/:L_JR_XB3?V*_^BT?^6CKO_P A4?\ $2;^Q7_T6C_RT==_^0J_E-HH_P!7
M<-_-+[U_D'M6?U9?\1)O[%?_ $6C_P M'7?_ )"H_P"(DW]BO_HM'_EHZ[_\
MA5_*;11_J[AOYI?>O\@]JS^K+_B)-_8K_P"BT?\ EHZ[_P#(5'_$2;^Q7_T6
MC_RT==_^0J_E-HH_U=PW\TOO7^0>U9_5E_Q$F_L5_P#1:/\ RT==_P#D*C_B
M)-_8K_Z+1_Y:.N__ "%7\IM%'^KN&_FE]Z_R#VK/ZLO^(DW]BO\ Z+1_Y:.N
M_P#R%1_Q$F_L5_\ 1:/_ "T==_\ D*OY3:*/]7<-_-+[U_D'M6?U9?\ $2;^
MQ7_T6C_RT==_^0J/^(DW]BO_ *+1_P"6CKO_ ,A5_*;11_J[AOYI?>O\@]JS
M^K+_ (B3?V*_^BT?^6CKO_R%1_Q$F_L5_P#1:/\ RT==_P#D*OY3:*/]7<-_
M-+[U_D'M6?U9?\1)O[%?_1:/_+1UW_Y"H_XB3?V*_P#HM'_EHZ[_ /(5?RFT
M4?ZNX;^:7WK_ "#VK/ZLO^(DW]BO_HM'_EHZ[_\ (5'_ !$F_L5_]%H_\M'7
M?_D*OY3:*/\ 5W#?S2^]?Y![5G]67_$2;^Q7_P!%H_\ +1UW_P"0J/\ B)-_
M8K_Z+1_Y:.N__(5?RFT4?ZNX;^:7WK_(/:L_JR_XB3?V*_\ HM'_ ):.N_\
MR%1_Q$F_L5_]%H_\M'7?_D*OY3:*/]7<-_-+[U_D'M6?U9?\1)O[%?\ T6C_
M ,M'7?\ Y"H_XB3?V*_^BT?^6CKO_P A5_*;11_J[AOYI?>O\@]JS^K+_B)-
M_8K_ .BT?^6CKO\ \A4?\1)O[%?_ $6C_P M'7?_ )"K^4VBC_5W#?S2^]?Y
M![5G]67_ !$F_L5_]%H_\M'7?_D*C_B)-_8K_P"BT?\ EHZ[_P#(5?RFT4?Z
MNX;^:7WK_(/:L_JR_P"(DW]BO_HM'_EHZ[_\A4?\1)O[%?\ T6C_ ,M'7?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@#W/\ X)@?\I+?V>/^RF^&_P#TZVU?
MV2U_&U_P3 _Y26_L\?\ 93?#?_IUMJ_LEKY+B/\ B0]#>EL?QM?\%/\ _E);
M^T/_ -E-\2?^G6YKPRO<_P#@I_\ \I+?VA_^RF^)/_3K<UX97U%#^''T1@%%
M%%:@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M *?=.KXBM_R,_P#M]?FCH^P?RFT445]N<X4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% ']67_!ME_P H5O@O_P!QS_T^ZC7PS_P>A?\ -MO_
M ',__N'K[F_X-LO^4*WP7_[CG_I]U&OAG_@]"_YMM_[F?_W#U\;@_P#D:O\
MQ2_4Z)? ?AG1117V1SA1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M44 %%%% !1110 4444 %%%% ']67_!ME_P H5O@O_P!QS_T^ZC7PS_P>A?\
M-MO_ ',__N'K[F_X-LO^4*WP7_[CG_I]U&OAG_@]"_YMM_[F?_W#U\;@_P#D
M:O\ Q2_4Z)? ?AG1117V1SA1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7
MZL_\&?O_ "DM\<?]DRO_ /TZZ37Y35^K/_!G[_RDM\<?]DRO_P#TZZ37!FG^
MZ3]"H[G[F?\ !3__ )1I?M#_ /9,O$G_ *:KFOXVJ_LE_P""G_\ RC2_:'_[
M)EXD_P#35<U_&U7E\.?PY^II6"BBBOHS$**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH *_N8K^&>O[F*^7XD_Y=_/\ 0VH]3^4W_@Y-_P"4U/QH_P"X'_Z8
MM.KX9K[F_P"#DW_E-3\:/^X'_P"F+3J^&:][ _[M3_PK\D9RW84445U$A111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% ']'_ /P9^_\ *-+QQ_V4V_\ _35I
M->Y_\')O_*%;XT?]P/\ ]/NG5X9_P9^_\HTO''_93;__ --6DU[G_P ')O\
MRA6^-'_<#_\ 3[IU?$5O^1G_ -OK\T='V#^4VBBBOMSG"BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** /W,_X,O?\ FY+_ +EC_P!S%?N97X9_\&7O_-R7_<L?^YBO
MW,KX/.O]\G\OR1TT_A"BBBO++"BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH *_AGK^YBOX9Z^HX;_P"7GR_4QK= HHHKZ@Q"BBB@ HHHH **** "
MBBB@ HHHH **** /U9_X)L?\&QW_  \+_8K\%_&#_A=W_"(?\)?]N_XE'_"'
M?VA]D^S7]Q:?Z[[=%OW?9]_W%QOQSC)]S_X@O?\ JY+_ ,Q]_P#?*O<_^">/
M_*I3X@_[)E\0/_2G6J_G=^&OQ0\3?!GQK9>)?!_B+7?"?B+3=_V35=&OY;&]
MM=\;1OY<T3*Z[HW=#@C*LP/!(KP:,L77J55"KRJ,FDN5,U?*DM#ZM_X*D_\
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M\./HC ****U **** "BBB@ HHHH *_2#_@C]_P &^W_#UW]FG7/B)_PMS_A
M?[%\33^'/[/_ .$6_M3SO*M;2X\[S?MD.W/VK;MVG&S.XYP/S?K^C_\ X,_?
M^4:7CC_LIM__ .FK2:\W-L14HX?GI.SNOZU+II-ZGAG_ !!>_P#5R7_F/O\
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M-/\ M<]I]H\G2;VXB_>P.DJ[98HV^5AG;@Y!(/[)_P#!JI_P4"^('[7O[/\
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M,?G74=PUU'N*B-_*MSA"63+A4X;_ (* ?\&GO@?X$_ [QY\2O 'Q>\5V>C^
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MH_[@?_I]TZOAG_@R]_YN2_[EC_W,5\S0Q-5Y;4J.3NI;W=_L]35I<Z1^;_\
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M*O&'Q9^'_P#PEGB+3?'5WHUM=_V[J5CY=HEAI\RQ[+:XC0XDGE.XJ6.[&<
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MDW4BKIR6-LR2R3I+(81YPDN6VHCNY48_:[_@M=X'\3?#'_@W \2>&O&FL?\
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MY_B/HRQ^-D$DC3Q7QDO)%EDD6>Y FECD>)YVE3$@#5^L_P#P4$^,GQJ^-_\
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M_P &V7_*%;X+_P#<<_\ 3[J->=B/^152_P 7_P D7'XV?RFT445]D<Y_1_\
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M^7Y-[<;HXED;[5Y95_+0D_X/ O\ E&EX'_[*;8?^FK5JZO\ X-_-)\(_M?\
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M,KZBA_#CZ(P"BBBM0"BBB@ HHHH **** /ZLM'_8O_X>%_\ !O\ ?"OX/_\
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M*"%4;=N,BMIDY<%0 'CP6)8+684U2R_]TK:*]NS_ ,R8N\M3Y]_X*=?L&?\
M!13_ (*"?MER?$6/X<Z[HNA^$-3D;X>65MXQT/3YO#-HDX>"=1%J+^7?/Y<,
MDTRR,QD10K".*%$_2#]D7]FSXU?M4_\ !'[Q'\$OVJ-%_L?X@7VF:AX476=9
MN[#Q+-?PF,-I^KR+;N4,]M(\8&^4S/)8+.T@>3</R7_;Z_X*Z?\ !0+_ ()\
M_M3>*/AEXN^+E\DFCW4CZ3J-QX'T&WC\0::9'6VU"$+:R+Y<RIDJLCF-Q)$Q
M$D;J/.- _P""_P!^WUXJ\%:_XETOXC:[J7AWPG]G_MO5;7P%H\UEH_VB0QV_
MVF9; I#YL@*)O(WL"%R>*SJ8/%5:,%'D25FFK_UK^97,D^I\W_L7_P#!-CXU
M?\%"_P#A)/\ A3_@O_A+_P#A$/LO]K_\3>PT_P"R?:?.\G_CZGBW[OL\OW-V
M-G.,C/N?_$-E^VI_T1?_ ,N[0O\ Y-KY3^"_[4'Q+_9N_M+_ (5W\1/'7@'^
MVO*_M#_A'->NM+^W>5O\KS?(D3S-GF2;=V=N]L8R<]S_ ,//_P!I;_HX?XY_
M^%YJO_Q^O9JK%<W[MQMYIW_,S5NIY3\4/AKK7P9^)?B+P?XELO[-\1>$]3N=
M&U6T\Z.;[+=V\K0S1[XV9&VR(PW(Q4XR"1@U_1%_P>!?\HTO _\ V4VP_P#3
M5JU?SG>*/%&I^-_$VHZUK6HWVL:QK%U+>W]_>SO<75[<2.7DFED<EGD=F+,S
M$EB22237]&/_  >!?\HTO __ &4VP_\ 35JU<&/O]:P]^[_0J/PL^&?^#/W_
M )26^./^R97_ /Z==)KE/^"R7[57B[]B/_@XY\>?%/P+-8P^)_"-UHUQ:B]M
MA<6MPDGAVQAF@E3@F.6&22-BK*X#DHZ.%<=7_P &?O\ RDM\<?\ 9,K_ /\
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MOAE^V!X7OM9CCNF32M1\3>(=/\22>(--O8Y%NM/N1&\S21Q,K'=<R.9$O1$
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M_P KLJUI6.3_ .#NSPOIN@?\%//#=W8:=8V-UKGP\TZ]U&:WMUCDU"X6^U&
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M'9&>X44458!1110 4444 %%%% !7]S%?PSU_<Q7R_$G_ "[^?Z&U'J?RF_\
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MDC7X+HKLP^7N%;V]:?/+9:6M\B7+2R/Z[/V7_C1_PS=_P0\^'?Q$_LW^VO\
MA ?@9IOB/^S_ +1]G^W?8] BN/)\W:_E[_+V[MK;<YVG&#_-'_P^#_:F_P"%
ME_\ "6?\- ?%;^U/[3_M?R/^$BN/[,\[S?-V?8-WV3R-W'V?RO)V?)LV?+7]
M$7_.M-_W;-_[JU?RFUY^2T82=5R2>O4JHW9']-7_  <!ZOX1_:__ ." E[\4
MXM+OOLLUKX9\<^&!>N8+K3GOKFUA5I4BD,;2?9-0GC9"TB R$C)5''X$?L#?
MM!?&;X&?$OQ-IWP'M-=NOB!\2/#-UX4C.@Z?/?:U!:/+!>7$EBL.72<1V9'F
MJK-'&9738ZI*G[F?\%#O^52GP_\ ]DR^'_\ Z4Z+7*?\&>OP.\(VW[(?Q$^)
M2Z#8GQY?>,+CPS)K3J7NETV&RT^Y2U0DD1QF:=W<(%,A6/>6\J/9CA,1'#X*
MHVN9*327W#DKR1\%_"__ ((N?\%$/B=\:O#OQ1_LOQUX>\8^(?LTG_"<:WX\
MAM-:TR&:!;?S;I_M1U&+R[9MCQ>69EC5H_+)'EU^L_\ P<*>%]3U_P#X(->,
MKOXAZ=X4OO'>AVOAR]O)M,MWDL-/U=M2L8+J:P:<&6.,B>YC1FQ(89F5C\S
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MBBBOI3$**** "BBB@ HHHH **** /Z/_ /@S]_Y1I>./^RFW_P#Z:M)KW/\
MX.3?^4*WQH_[@?\ Z?=.KPS_ (,_?^4:7CC_ +*;?_\ IJTFO<_^#DW_ )0K
M?&C_ +@?_I]TZOB*W_(S_P"WU^:.C[!_*;1117VYSA1110![G_P3 _Y26_L\
M?]E-\-_^G6VK]S/^#P+_ )1I>!_^RFV'_IJU:OYSO"_BC4_!'B;3M:T74;[1
M]8T>ZBO;"_LIWM[JRN(W#QS12(0R2(RAE92"I (((K^I;XP>#_AO_P '&_\
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M#]FGXG?";[5Y/C'2?$Q\6_9I9(E^VV%S:VMIOA7?YK^3+:8E.P(GVFV&XF3
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M?\VV_P#<S_\ N'K[F_X-LO\ E"M\%_\ N.?^GW4:^&?^#T+_ )MM_P"YG_\
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M8\(:[H_Q .^'3+W0?'FD:;_PCMH5D1;.Q,>H;X(%CEE7:&+/YLK2-(\DCO\
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MFHO;7+037MW-"T;322M#N5&^2%,(H+&667Z[_P"#4O\ 9W_X7_XU^-'[57Q
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M^TV%Q:?Z[RI=FW[1O^XV=F.,Y'AE%7#!T81E",;*6^_7\OD',S[F_P""T/\
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MMU#;:K>WEJ\5Q<N5C>ZGDCLKX(XB$<$:% %>5WG_ "F_X.3?^4U/QH_[@?\
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M5ZD8J,5&.R,PHHHJ@"BBB@ HHHH **** "BBB@ HHHH ]S_X)@?\I+?V>/\
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M,Z*SQ.!HXBWM8WM_70<9-;'W-_P^A_XW4_\ #8'_  K;_N4O^$A_Z@7]D?\
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M** "BBB@ HHHH **** /ZLO^#;+_ )0K?!?_ +CG_I]U&OAG_@]"_P";;?\
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M3_7>5+LV_:-_W&SLQQG(\,HK&&%I0I>PBO=U5M>N_F/F=[GU9_P6!_X*<_\
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M -.NDU^4U?JS_P &?O\ RDM\<?\ 9,K_ /\ 3KI-<&:?[I/T*CN?N9_P4_\
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M /A$/MW_ !*/[0_L_P"U_:;"XM/]=Y4NS;]HW_<;.S'&<CW/_@M#_P %H?\
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M7$UR35M7B1S'@V,JPVZVLFT3(9"DK@2JT;0R1J]?F%\#?CEXN_9J^+>@^._
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M44 %%%% !1110 5_<Q7\,]?W,5\OQ)_R[^?Z&U'J?RF_\')O_*:GXT?]P/\
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MM/*\W_9W_P 5?E-117/0PM*C?V:M?5[C<F]S](/VA_\ @X)_X7W_ ,$E-/\
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MEY+ ]H&:2X:U);=.2#*26<CYOS1HK*GE>&A9J.SNM7NOG^&P<[/T1_X)3?\
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MDD;>9"SEXY$='4EUW&.25'^?:*BI3C.+A-73 _??X/\ _!Y5X'UOQ-/%X_\
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MMJ\2.8\&QE6&W6UDVB9#(4E<"56C:&2-7K\EZ**TP^%I4(\M)6$Y-[GZL_\
M!2?_ (.<?^'A?[%?C3X/_P#"D?\ A$/^$O\ L/\ Q-_^$Q_M#[)]FO[>[_U/
MV&+?N^S[/OKC?GG&#X9_P1>_X+0_\.A?^%D_\6V_X6%_PL+^R_\ F8?[)_L_
M[%]L_P"G:?S-_P!K_P!G;Y?\6[CX9HK..7X>-)T%'W7JU=^7G?H/F=[GT%^W
M_P#M\:G^VI^WUXC^/6BZ7??#G6-8NM-O;"WLM8>XNM'N+*SM;>.:*[2.%A(&
MMA*K*BE"1@DKN/Z>?"7_ (.^M-\9_"37/#OQO^!-CKUU?:%?6\HT&]1](\0W
M$A98K*XLKQ7-O:20N8YI3-<G*DB!@^Q/Q!HHK9?0JPC"<=([;Z I-'ZT>"/^
M#K/Q=X+_ &IK?Q-;?"FQT_X0Z!X//A7PW\,M(\0#3K#27,EF_P!MDG6T*S2(
MMJT,2""-(89-J!29FF^"O^"D_P"VC_P\+_;4\:?&#_A&_P#A$/\ A+_L/_$H
M_M#^T/LGV:PM[3_7>5%OW?9]_P!Q<;\<XR?#**JC@:%*7/3C9VMUV_KKN#DW
MN?M#\:_^#QOQ=XO^'5S8^!?@O8^"_$_VJTN+75;WQ0-8M42*ZBEF@EM?L4)D
MCGA22!BLL;H)BZ.KJI'<V_\ P>=::WAF\EE_9XODUA+J!+6U3QLK6LUN4F,T
MCS?80R2(RP!$$3AQ)(2\9C59?PEHKE_L?!VMR?B_\Q^TD?5G_!5G_@KG\0/^
M"L7Q+T75/%FEZ'X;\.^#_MD7AS1-,C+_ &*.YE5G>>X?YYYVCBMT9P(XSY 9
M(8BS[O*?V+?VTOB!^P)^T!I'Q(^&^K_V9KFF9AN+>8&2RUBT8J9;.[B!'FP2
M;5RN0RLJ.C)(B.OE-%=T</3C3]DE[O8F[O<_=KX&_P#!Y5IMSJ&@V?Q*^!]]
M8VHM0FM:QX9U];J1KA83F2VL+B*,"-Y@!L>[)C1R=\I7#^&_MM?\':?Q3_:&
M^$EYX4^&7@6Q^#LFLVLUIJ.N)KDFK:O$CF/!L95AMUM9-HF0R%)7 E5HVADC
M5Z_)>BN..482,N=0_%V^X?M)'=?LO_&C_AF[]I;X=_$3^S?[:_X0'Q-IOB/^
MS_M'V?[=]CNHKCR?-VOY>_R]N[:VW.=IQ@_<W_!8'_@X)_X>N_LTZ'\._P#A
M4?\ P@7]B^)H/$?]H?\ "4_VIYWE6MW;^3Y7V.';G[5NW;CC9C:<Y'YOT5U5
M,+2G4C5DM8[;BYG:Q>\+^*-3\$>)M.UK1=1OM'UC1[J*]L+^RG>WNK*XC</'
M-%(A#)(C*&5E(*D @@BOVP^$O_!WUIOC/X2:YX=^-_P)L=>NK[0KZWE&@WJ/
MI'B&XD++%97%E>*YM[22%S'-*9KDY4D0,'V)^(-%3B<'1Q%O:J]MAQDUL?K1
MX(_X.L_%W@O]J:W\36WPIL=/^$.@>#SX5\-_#+2/$ TZPTES)9O]MDG6T*S2
M(MJT,2""-(89-J!29FF^"O\ @I/^VC_P\+_;4\:?&#_A&_\ A$/^$O\ L/\
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MM6W;M.-F=QS@?*=%%:4J<:<%"&R$W?4****T **** /ZLO\ @VR_Y0K?!?\
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MM3SO*M;NW\GROL<.W/VK=NW'&S&TYR.%_P""+W_!:'_AT+_PLG_BVW_"PO\
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MYO\ S*<VU8_5G_@FQ_P<X_\ #O3]BOP7\'_^%(_\)?\ \(A]N_XF_P#PF/\
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MD\>-:WUI:>*DU>?QEJ*([J92\>FI+:V<GERB%)%@A=XA(H9\SEOR9_X+1?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 >Y_\$P/^4EO[/'_93?#?_IUM
MJ_LEK^-K_@F!_P I+?V>/^RF^&__ $ZVU?V2U\EQ'_$AZ&]+8_C:_P""G_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% ']'_\ P9^_\HTO''_93;__ --6DU[G_P '
M)O\ RA6^-'_<#_\ 3[IU>&?\&?O_ "C2\<?]E-O_ /TU:37N?_!R;_RA6^-'
M_<#_ /3[IU?$5O\ D9_]OK\T='V#^4VBBBOMSG"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH _JR_P"#;+_E"M\%_P#N.?\ I]U&OAG_ (/0
MO^;;?^YG_P#</7W-_P &V7_*%;X+_P#<<_\ 3[J-?#/_  >A?\VV_P#<S_\
MN'KXW!_\C5_XI?J=$O@/PSHHHK[(YPHHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !!^_LT_]#Q\<_\ P<Z5_P#*ZOU9HH_M3%_SL.2)^4W_ !!^_LT_]#Q\<_\
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MX^.?_@YTK_Y74?\ $'[^S3_T/'QS_P#!SI7_ ,KJ_5FBC^U,7_.PY(GY3?\
M$'[^S3_T/'QS_P#!SI7_ ,KJ/^(/W]FG_H>/CG_X.=*_^5U?JS11_:F+_G8<
MD3\IO^(/W]FG_H>/CG_X.=*_^5U'_$'[^S3_ -#Q\<__  <Z5_\ *ZOU9HH_
MM3%_SL.2)^4W_$'[^S3_ -#Q\<__  <Z5_\ *ZC_ (@_?V:?^AX^.?\ X.=*
M_P#E=7ZLT4?VIB_YV')$_*;_ (@_?V:?^AX^.?\ X.=*_P#E=1_Q!^_LT_\
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M9HH_M3%_SL.2)^4W_$'[^S3_ -#Q\<__  <Z5_\ *ZC_ (@_?V:?^AX^.?\
MX.=*_P#E=7ZLT4?VIB_YV')$_*;_ (@_?V:?^AX^.?\ X.=*_P#E=1_Q!^_L
MT_\ 0\?'/_P<Z5_\KJ_5FBC^U,7_ #L.2)^4W_$'[^S3_P!#Q\<__!SI7_RN
MH_X@_?V:?^AX^.?_ (.=*_\ E=7ZLT4?VIB_YV')$_*;_B#]_9I_Z'CXY_\
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M75^K-%']J8O^=AR1/RF_X@_?V:?^AX^.?_@YTK_Y74?\0?O[-/\ T/'QS_\
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M (@_?V:?^AX^.?\ X.=*_P#E=7ZLT4?VIB_YV')$_*;_ (@_?V:?^AX^.?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M3--U>31I8M9@AAG::.&&8LHBEE79MG0 E@<AN,8)]EK\\?\ @VD_Y,4\6?\
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M%_M\Z%XXO/ /AGQPUQX%@MYKBQU&WLK:?46G6X,45N?M31[V-NZYE>-067+
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M[TJPUM$UM9;6_P#L<MCILLTLDTNJ6L#;;C4$0*BAMK+PVUFKG_BE_P %2/\
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M;RN/^"<?_!-'XD_$C1[S3[3QDMI'HOA5;B[@AD;5+QQ!%+"DR2)<26R-+>&
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M519V-O:_VA?6D5] ;:"WE4:O/&S68:1[!4B4;9(' /T^HHHH **** "BBB@
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MG_@<O\P_U;RC_H%I_P#@N/\ D>]?\/.?CC_T._\ Y1[#_P",4?\ #SGXX_\
M0[_^4>P_^,5X+11_K)F__054_P# Y?YA_JWE'_0+3_\ !<?\CWK_ (><_''_
M *'?_P H]A_\8H_X><_''_H=_P#RCV'_ ,8KP6BC_63-_P#H*J?^!R_S#_5O
M*/\ H%I_^"X_Y'O7_#SGXX_]#O\ ^4>P_P#C%'_#SGXX_P#0[_\ E'L/_C%>
M"T4?ZR9O_P!!53_P.7^8?ZMY1_T"T_\ P7'_ "/>O^'G/QQ_Z'?_ ,H]A_\
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MWK_AYS\<?^AW_P#*/8?_ !BC_AYS\<?^AW_\H]A_\8KP6BC_ %DS?_H*J?\
M@<O\P_U;RC_H%I_^"X_Y'O7_  \Y^./_ $.__E'L/_C%'_#SGXX_]#O_ .4>
MP_\ C%>"T4?ZR9O_ -!53_P.7^8?ZMY1_P! M/\ \%Q_R/>O^'G/QQ_Z'?\
M\H]A_P#&*/\ AYS\<?\ H=__ "CV'_QBO!:*/]9,W_Z"JG_@<O\ ,/\ 5O*/
M^@6G_P""X_Y'O7_#SGXX_P#0[_\ E'L/_C%'_#SGXX_]#O\ ^4>P_P#C%>"T
M4?ZR9O\ ]!53_P #E_F'^K>4?] M/_P7'_(]Z_X><_''_H=__*/8?_&*/^'G
M/QQ_Z'?_ ,H]A_\ &*\%HH_UDS?_ *"JG_@<O\P_U;RC_H%I_P#@N/\ D>]?
M\/.?CC_T._\ Y1[#_P",4?\ #SGXX_\ 0[_^4>P_^,5X+11_K)F__054_P#
MY?YA_JWE'_0+3_\ !<?\CWK_ (><_''_ *'?_P H]A_\8H_X><_''_H=_P#R
MCV'_ ,8KP6BC_63-_P#H*J?^!R_S#_5O*/\ H%I_^"X_Y'O7_#SGXX_]#O\
M^4>P_P#C%'_#SGXX_P#0[_\ E'L/_C%>"T4?ZR9O_P!!53_P.7^8?ZMY1_T"
MT_\ P7'_ "/>O^'G/QQ_Z'?_ ,H]A_\ &*/^'G/QQ_Z'?_RCV'_QBO!:*/\
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M/_C%>"T4?ZR9O_T%5/\ P.7^8?ZMY1_T"T__  7'_(]Z_P"'G/QQ_P"AW_\
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M'_QBO!:*/]9,W_Z"JG_@<O\ ,/\ 5O*/^@6G_P""X_Y'O7_#SGXX_P#0[_\
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MC_D>]?\ #SGXX_\ 0[_^4>P_^,4?\/.?CC_T._\ Y1[#_P",5X+11_K)F_\
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M@M%'^LF;_P#054_\#E_F'^K>4?\ 0+3_ /!<?\CWK_AYS\<?^AW_ /*/8?\
MQBC_ (><_''_ *'?_P H]A_\8KP6BC_63-_^@JI_X'+_ ##_ %;RC_H%I_\
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M>#?3)--#'%;F1#&K,X:1]XC5Q%,8_'],_P"#GKX'^'_VCO"WPS^*'PY_: ^
M.K>+-C6]_P#$[PG!H%A:12-)'%<3DW3RQV[S1-%Y_EF)&#%W1$D= #]'Z***
M "BBO'_VZ?VZ?AQ_P3H_9QUKXH?%#6O[*\/Z5B&WMX562_UJ\96,5C9Q%E\V
MXDVMA<A557D=HXHY)% /8**_+'6?^#M'X+^'/@UI/Q&U#X$_M86/P]UZ[:PT
MSQ/<>"K&+1M1N%,H:&&[;4!#)(#!."BN2##)Q\C8_0[X6_M+^%?V@_V<;'XI
M?#&[_P"%D>&=;TJ35=%_L26%9M9VJW^C1_:7ACBN#(C0F.X>'RI0R2F(J^T
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M\K=OV?-C'- 'ZO45\@?L;?\ !;[X'_M\_MD^(?@Q\+;KQ!XDU#P_X5A\8?\
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M]C=W7D?8O[/\KR?L]S!MS]KDW;MV=J8VX.?S/_X-Z?\ @X6^"_\ P2:_8O\
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M1/$WA?$UWX;\3V\%GJLMF=@%]"D,TT<MN)'$;,KEHWV"14$L)D /K^BO#_\
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M._L$?\)5_P 0_'[1/_"'?\A;^WK_ .T?ZG_D'?8M+_M#_6_+_P >/VGI\_\
M<^?;7AW_  1T^,/[./PB\=^-IOV@-&TF^^W6%LF@W>KZ$^M6%MMD<W,9@5)<
M329@*2&(X6&4;TW[9.1X/FJXFNW)I22Y8.S>VK[[Z>C-O;6C3AHM-WT/)?\
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M (+,?\%3M+_;N\"6/A/X>^'=6D^'OA/7H[N_\37]H\7VR_,=Y%:QQ $B*&2
M7$JB;;-)M/[N+R7W^A6IX_\ M93C?V6G72UM;KO?Y['/&5#ZJT_B_'^K'U3_
M ,&X>OV/A3_@GMXYU35+VTTW3--\:W]U>7EU,L,%K#'INGL\DCL0J(J@DL2
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MP;\0[]O[562^\V2TUR4S3R[48!Q#.B-*N&<+(LP_=H84/K7_  :Y_P#-<O\
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ME:MI]C\0OB_\8-.M_#\-^DZVI1;:XL)9Y9HXW"1Q3ZI9!A@R$2DHC[&Q^MU
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M5>*/_31=5\ _\&XG_*4W_@IQ_P!E53_T[^)*^_O^"L7_ "BR_:6_[)5XH_\
M31=4 ?$/_!N'_P %"?@%\#O^",?P;\+>-OCA\'_!_B;2_P"V_MFD:WXRT[3[
M^T\S7-0EC\R":99$W1NCC<!E74C@@U]O?\/8OV6?^CEOV?\ _P .'I'_ ,D5
M^,/_  1G_P"#7_X!?\%$O^";/PW^,7C;Q=\8-+\3>,/[3^V6NB:KIT%A%]FU
M2\LX_+2:QED&8[="=TC98L1@8 ^H/^(*G]EG_H?OV@/_  >:1_\ *R@#G_\
M@G+\6?"OQQ_X.Z?VHO%/@GQ-X?\ &'AG5/A5:_8]7T348=0L+ORXO"T4GESP
MLT;[9$=#M)PR,#R"*T/^#F?Q9I?@+_@I)_P39UW7=2T_1=$T7XE7%_J&H7]P
MEM:V%O%JGAQY9I97(2.-$5F9V("@$D@"O+_^"(7[%7A7_@G;_P '.G[0WP=\
M$ZAX@U3PSX/^%2?8[K6YX9[^7[2_AN\D\QX8HHSB2X<#;&N%"@Y.2>P_X.O_
M (*:7^TI^VA_P3_^'.NW&H6FB>/_ !KJ7AO4)[!TCNH;>\OO#UO*\3.KHL@2
M1BI9& (&5(X(!^EW_#V+]EG_ *.6_9__ /#AZ1_\D5[!\+?BSX5^./@2Q\4^
M"?$WA_QAX9U3S/L>KZ)J,.H6%WY<C12>7/"S1OMD1T.TG#(P/((K\H?^(*G]
MEG_H?OV@/_!YI'_RLK]'OV"OV*O"O_!.W]D[PI\'?!.H>(-4\,^#_MGV.ZUN
M>&>_E^TWD]Y)YCPQ11G$EPX&V-<*%!R<D@'YP_L;_P#*Y)^UC_V2JQ_])O"E
M?I=^V'^V'X!_84^ 6O?$;XC:]I^BZ)HMI<30037MM;76MW$5M-<+862SR1I/
M>2I!((H0X+D=@"1^(/QX_P""7_@'_@K+_P '4_[37PY^(VK^,-%T31?!6E^)
M()_#=U;6UT]Q%IOAVW5&:>"9#&4NI"0$!R%^8 $'P_\ X*"?\$/KS_@@A\;/
M#_QP7P'X?_:I_9[M]5B^W6'B>"ZM9O##?;XY((KT6LRQ2^9"J6ZW4T4MG)+-
M(DUD"]NDH!]P?\&5'P,\5>"?V'OB=XZU;5/$$?AGQUXKCMM!T2[MIHK!/L,&
MRYU.U9G\N3[1).+:1HT&&TD*SN5VQ?L]7G_[*OQ2^''QH_9Q\%^)/A#?>']0
M^&6H:5"OAM]$A6WL(+.)?*2WCA"KY'D[#$8"B-"T31LB,A4>/_\ !5S_ (*N
M?#C_ ()*_LXR^-O&TO\ :OB#5?-M?"OA6UG6._\ $UXJ@E%)#>5;Q[D::X92
ML2LH DEDAAE ,#_@O7^TOX5_9?\ ^"1_QRU'Q3=^3_PEWA6_\&Z1:QRPK<ZA
MJ.IVTMG!'$DCIYFSS6GD5"SK!;SN%;80>?\ ^#;SX6Z]\'_^")7P#TGQ%8_V
M=J%YI5[K<47G1S;[/4-3N[^SES&S >9:W,$FTG<N_:P5@RCYP^ /_!*SXN?\
M%;?VN/#W[37[;>FZ?H_@31[07OPY^!GFR3QZ DDA9!K,<D:(TA2."::,@R7,
MCQQW"V\5M]@/ZW4 %?G!^S3^WK\6/B!_P<M_M"?L_:OXK^V?"+P/\/[36]$T
M'^S+./[%>/!X?=I?M*Q"Y?+7UT=KRLO[WI\J[3]O7]FG_@I=\0/VL?%>K_L_
M?M"?!_P/\(KS['_8.B:WIL$U_9;;.!+GS&;1KDG?=+.XS,_RNH^7[J_EA\ O
M@%^WYJG_  7W^-WA?PO\;OA?IO[3VF^"K:X\7>+[BPA;1M4TLPZ(8X(8SI3H
ML@233@2+2,Y@D^<Y)D /Z;J\O_;6_9?TO]M3]D?XC?"?6&T^&S\?>'[O1X[N
M\TY-1CTRXDC(M[T0,RAY+>?RITPRD20H59& 8?,'_!+_ . 7[?GPK^/NL:A^
MU1\;OA?\2OA[-X?FM]/TSPW80P74&J&YMFBG9DTJT/EB!;I2/,89D7Y#C<OW
M?0!^:'_!IG^U!JO[1_\ P1^T'2]874)KSX4^(+_P5'?7FHO>R7]O&L-[;XW*
M##'#!?16J1!F"QVB;2JD1I^E]?D#_P &XG_*4W_@IQ_V55/_ $[^)*_7Z@#Y
MO_X*._\ !+_P#_P5*\*^"?#7Q0UCQ@O@WP;X@C\22^']'NK:TM=?N(T:-$NY
M6@>Z6,127$>+:: D7,A+%UB:,^)?_!+_ , _%3_@I=\/?VJ-0U?QA#\0OAKX
M?E\-Z9I]O=6RZ-/;R)J",\T30-,TF-2GP5F492/Y3AMWTA10!^,/_!W;IGQ'
M^$FL?LI_M#^"?"W]O:3\ ?%=YJ^I7DT33V&F7CW6D3:>+R.-UE%O--9/&74J
MH8I&9$>6(-^AW_!/W_@K/\!?^"FGA5+SX4^.M/U+6XK07>H>&+__ $+7]) 2
M R^;:.=[1QO<Q1-<0^9;F0E4E<BOI"OR1_X*!?\ !II\+_BYXJ?XC?LW^(]0
M_9]^*6FW9UG3X+"65M >_1Y[B*2)487&FR&X>W"RVKF&WC@'E6A;F@#];J_!
M'_@K[;:5_P %9/\ @YM^!?[+'B"\U"'X>_#6T5];L+BR18[^XDL6UV_CAF@E
M2X\N[L+?3[4R&13!(DCQH<$R_2'_  ;P_P#!4GXR?$[XI^-/V0_VE_#?B"W^
M-OP7TI[[^W=097N=2TZ&:V@\N^?<?.N%^U6SQ7D9D2[@D$C,77SKGYO^+'AJ
MX^!?_![WX/\ $7C"33_#NB>/[2*]T"\O+^"./44F\)SZ/"!\_P LDFH6TMLD
M;[9'D"!5(DC+ '[W4444 ?A#_P $:?#N@_\ !*__ (.6_P!HK]E_1?$7V3P%
MXXTK[7X<TC[!))YUXD%OK%C:>>YFF7['IMYJ<7FR3*L_E;G'F-$@]@_;(_Y7
M)/V3O^R57W_I-XKKQ_\ 90\.Z#^UW_P>C_&'QMX=\19T_P"$>E7=W*OV"3_B
M87EGI%CX:O+3,A0Q^5=74[>:%=7^RX4%9%D!_P %O?!OQD^('_!SI^SSI'[/
MWBSP_P"!_B[>?"I_[!UO6X5FL++:_B1[GS%:WN0=]JLZ#,+_ #.I^7[R@'[O
M5^$/_!N)/KWQ(_X+Z?MS^-O"NK_VS\(KO5==:ZO--U>.;2M1O+OQ$\VDW"QI
M)BXW6L.I-%.BNJ(\@WKYP#^@?$7_ ()$?\%.OVT='C\ _&_]L3X?Z5\,M5\]
M=:?P?9/'?W,36L\7V=X;;3].^UV\OF^7)!-<B(JV\I(T:*?T>_X)L?\ !-CX
M<?\ !*W]G$_#/X9GQ!<:3<:K<:W?W^MWJW5_J5Y,L<9ED*)'$NV&&"(+%'&N
MV%2079W< _-'X0_M"^ ?V:_^#OO]JG7?B-XX\'^ -$N_AKI]A!J'B36;;2K6
M:X:S\+NL*RSNB-(4CD8(#DB-CC"G'Z7?\/8OV6?^CEOV?_\ PX>D?_)%?CC\
M>/\ @E_X!_X*R_\ !U/^TU\.?B-J_C#1=$T7P5I?B2"?PW=6UM=/<1:;X=MU
M1FG@F0QE+J0D! <A?F !!^D/^(*G]EG_ *'[]H#_ ,'FD?\ RLH \O\ ^#NO
M]MWX+_M*?\$V_!.A?#GXO?"_Q_K=I\2K"_GT_P -^*K'5;J&W72]51IFB@E=
MUC#R1J7(P#(HSEAG]SJ_F1_X.%O^#>GX+_\ !)K]B_PQ\1OASXG^*&M:WK7C
M6U\-SP>)-1L;FU2WEL;^X9U6"SA<2![6, ER,%OE)((_INH _('_ (,J?^46
M7C[_ +*KJ/\ Z:-'K]#O^"E'[7MO^P7^P9\5?BY--I\-YX+\/SW&DK?VL]S:
MW.J28@T^"5(")#'+>2V\3$,H42$ET4%U_/'_ (,J?^467C[_ +*KJ/\ Z:-'
MKP__ (/._P!LW2[SQ5\%?V;M234--T26[@^(GB;6+;3$O;JUMR]UIUL+)&NH
M4FD5/[2>2&7RPQ%H%G0&3 !S_P"Q/_P1"M_C5_P:Q>,[J]T'4&^*7CF[N_BU
MX;6+PU.NL[]-BE@TVP1(Y%EOH[NT2\-N6!C4:Z9(XI&"O)^C_P#P;8?M>V_[
M7W_!'[X5SM-I[:W\-[0^ -7M[.UG@CLWTU4BM%)E)\R1]/:PF=XV,9DG<#80
M8T^4/A/_ ,'@G['?P.^%GAGP3X6^&?[0&E^&?!^E6NB:19_V5ID_V2SMH4A@
MB\R356D?;&BKN=F8XR23DU\O_P#!L)^W-\./A-_P62^*OPK^%>C>(+?X1?M"
M>==^$XM6TY8M5T"738KN_M[2<_;IQ]GBM9=0@,N^>69XK1R(M\JJ ?M]^WC_
M ,$Y/!/_  46_P"%:V?Q$U/Q!)X9^&_BNV\8+X;MH["32O$=Y;\11ZBES:S2
M2VXC>>-H8WB61+F4/N(C*:&L_P#!/WP#XC_X*%Z3^TQJ$>H7WQ"T'P4W@?3(
M+@6TNGZ=;M=2W#7<*M"9H[PB>> RK* 89I$V?.Q/N%% !1110 4444 %%%%
M!1110 4444 %%%% !1110!^2/_!3G_D^'QO_ -N'_I!;5X+7O7_!3G_D^'QO
M_P!N'_I!;5X+7\D\2?\ (WQ7_7R?_I3/ZZX:_P"11A?^O=/_ -)04445XI[0
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_;"_:*^+'PO^'WA3X1W:Z'\(O"/BK5=#TBXNK=&NI+:>Y@N+EYO,M!<+<^:
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M  D&G^&]5GTI/#'PQ\)BWL+#,D\DUS \HM=/DMVF#'S+:9_,:=74.K,XZ_\
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M*2?9+4[08\GT#_@]6_Y19> ?^RJZ=_Z:-8H_X,J?^467C[_LJNH_^FC1Z/\
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M7ZI?ZO9^==W5H=.\QRUU;V]BHA*1_-;K:$-&D7DO( =!_P '</[-'A7XP?\
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MYUF(:Y22XU+[8+@2R9F-C;/L^59']0_X(1? S_AJ#_@V!\+_  S_ +4_L/\
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MXGMM*F:P_L^*WU&6X2*XND9Y$M]2CO[FR=C 8DVA'+FZ2(_J]\"_^"@?P/\
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MO[K5+C3](.GWUE$T<NQI(TN9YE\DS&8VHBC5VE0@ ^SO^"-G["UG_P $[?\
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M(M.TW1;>U25YHY7N+*)6MH9(XHYXW($8S0!\(_\ !E3_ ,HLO'W_ &574?\
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MMM8O(DBS#'@[3+YDIW'=(W&/JCX3?";PW\"OAQH_A'PCH]IH/AS08!;6-C;
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MJL$\R&,I=1@$N#D-\H !/TA10!^0/[&__*Y)^UC_ -DJL?\ TF\*5^IWQ^^
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M_$;0K?4+31/'WA^P\2:?!?QI'=0V]Y;1W$22JC.BR!)%#!78 @X8CD]A110
M4444 %%%% !1110 4444 %%%% !1110 4444 ?DC_P %.?\ D^'QO_VX?^D%
MM7@M>]?\%.?^3X?&_P#VX?\ I!;5X+7\D\2?\C?%?]?)_P#I3/ZZX:_Y%&%_
MZ]T__24%%%%>*>T%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 ?6_\ P1F_Y.?U[_L5KC_TKLZ_3&OS._X(S?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M]FZ;]MN+S[-Y]Q+<R_O;B225MTTTC?,YQNP,  #T"B@#Y_\ VU?^"67[/O\
MP42_L^3XQ?"_P_XPU#2_+6UU3=-I^JQ11^<4M_MMJ\5R;<-<3/Y!D,1=]Y3<
M P\0\)_\&R_[#G@OQ5INL6?P(T^:\TF[BO8([_Q)K5_:N\;AU$MO/>/#-&2
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M*WPO_P"B;^ O_"?M/_C='_#*WPO_ .B;^ O_  G[3_XW1_Q"3%_]!$?N8?\
M$7,)_P! \OO1^*E%?M7_ ,,K?"__ *)OX"_\)^T_^-T?\,K?"_\ Z)OX"_\
M"?M/_C='_$),7_T$1^YA_P 1<PG_ $#R^]'XJ45^U?\ PRM\+_\ HF_@+_PG
M[3_XW1_PRM\+_P#HF_@+_P )^T_^-T?\0DQ?_01'[F'_ !%S"?\ 0/+[T?BI
M17[5_P##*WPO_P"B;^ O_"?M/_C='_#*WPO_ .B;^ O_  G[3_XW1_Q"3%_]
M!$?N8?\ $7,)_P! \OO1^*E%?M7_ ,,K?"__ *)OX"_\)^T_^-T?\,K?"_\
MZ)OX"_\ "?M/_C='_$),7_T$1^YA_P 1<PG_ $#R^]'XJ45^U?\ PRM\+_\
MHF_@+_PG[3_XW1_PRM\+_P#HF_@+_P )^T_^-T?\0DQ?_01'[F'_ !%S"?\
M0/+[T?BI17[5_P##*WPO_P"B;^ O_"?M/_C='_#*WPO_ .B;^ O_  G[3_XW
M1_Q"3%_]!$?N8?\ $7,)_P! \OO1^*E%?M7_ ,,K?"__ *)OX"_\)^T_^-T?
M\,K?"_\ Z)OX"_\ "?M/_C='_$),7_T$1^YA_P 1<PG_ $#R^]'XJ45^U?\
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M;^ O_"?M/_C='_#*WPO_ .B;^ O_  G[3_XW1_Q"3%_]!$?N8?\ $7,)_P!
M\OO1^*E%?M7_ ,,K?"__ *)OX"_\)^T_^-T?\,K?"_\ Z)OX"_\ "?M/_C='
M_$),7_T$1^YA_P 1<PG_ $#R^]'XJ45^U?\ PRM\+_\ HF_@+_PG[3_XW1_P
MRM\+_P#HF_@+_P )^T_^-T?\0DQ?_01'[F'_ !%S"?\ 0/+[T?BI17[5_P##
M*WPO_P"B;^ O_"?M/_C='_#*WPO_ .B;^ O_  G[3_XW1_Q"3%_]!$?N8?\
M$7,)_P! \OO1^*E%?M7_ ,,K?"__ *)OX"_\)^T_^-T?\,K?"_\ Z)OX"_\
M"?M/_C='_$),7_T$1^YA_P 1<PG_ $#R^]'XJ45^U?\ PRM\+_\ HF_@+_PG
M[3_XW1_PRM\+_P#HF_@+_P )^T_^-T?\0DQ?_01'[F'_ !%S"?\ 0/+[T?BI
M17[5_P##*WPO_P"B;^ O_"?M/_C='_#*WPO_ .B;^ O_  G[3_XW1_Q"3%_]
M!$?N8?\ $7,)_P! \OO1^*E%?M7_ ,,K?"__ *)OX"_\)^T_^-T?\,K?"_\
MZ)OX"_\ "?M/_C='_$),7_T$1^YA_P 1<PG_ $#R^]'XJ45^U?\ PRM\+_\
MHF_@+_PG[3_XW1_PRM\+_P#HF_@+_P )^T_^-T?\0DQ?_01'[F'_ !%S"?\
M0/+[T?BI17[5_P##*WPO_P"B;^ O_"?M/_C='_#*WPO_ .B;^ O_  G[3_XW
M1_Q"3%_]!$?N8?\ $7,)_P! \OO1^*E%?M7_ ,,K?"__ *)OX"_\)^T_^-T?
M\,K?"_\ Z)OX"_\ "?M/_C='_$),7_T$1^YA_P 1<PG_ $#R^]'XJ45^U?\
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M'/V/?#.G_M%ZMI^O?&*PN]4M]=U.P2V2UU%$U.[6SGB6WCBC$<EF+9E!CCD
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M^)M$U67PQXDM(6W6$NHP06\[SV9+-(+>2.YB8))\\;%XRTH032>7_MD^!/\
M@HS^T%^VUK&A?!OQQ\+_ (#? ?PS=Z<ECXFO--M=7UGQ3;W-M;M>R"VE2Z#2
M6<Z7*I&XL!()4!>0?O(P#]#Z*_%']MC]LK]N_P#X(4?&7P9X^^,GQ:\'_M%?
MLX^)O$%IX;O[F+PAI^D:S8AQ%<SNEG;_ &8QWC007Z6Y^U7%N1$6F6-GB4?M
M=0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 45^6/P4^
M'_!53]I[Q5<>*/B-\?OA?^S'HFJ6C/!X3\-^#M-\5W6DW$3I"L;+.LB>7,B2
M7!D&I3E3(J[$!*0\_P#\$\?^"AW[6G[-?_!6G2OV/_VP-5\'^/\ 4O'WA^Z\
M2>$_%GAO3[>-IBMNTRHS1"U1+-4T_4XR)+/[0;@+\Q@9' !^MU%?D#_P=:_\
M%1_CM_P37_X4+_PI7QU_PA?_  FG_"0_VS_Q)=/U'[9]E_LOR/\ C[@EV;?M
M$WW-N=_.<+CT#PCI?_!03_@HSX$U'XQ>!/CM\/\ ]G3P%XJTHZM\+?"2>"K+
M6[_6M.FDNIM/N-<GG^TBQN)K5[$N;22Y15D)^SQR1LD@!^GU%?DC_P $7O\
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M=MTLA):^'+*1YHO[2D,H$,D@,%P45SY,(MY9[DK%&(YP#]#Z*_*'XB_L:_\
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MV<\2V\<48CDLQ;,H,<<@##S$63>H^[Z^?_\ @K%_RBR_:6_[)5XH_P#31=4
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M /H:BL_PCXE@\:>$]+UBU2:.UU:TBO(5E $BI(@=0P!(S@C."1GN:\:\7?\
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M-$D+JB.2 K,,8D'?.0>*YWXX?M=>&_@%XLM]'UBQURYNKFT6\5K.&)XPC.Z
M$M(ISF,]L8(YH ]4HKYY_P"'E7@7_H$^+/\ P%M__C]>[>$?$L'C3PGI>L6J
M31VNK6D5Y"LH D5)$#J& )&<$9P2,]S0!H45X5XN_P""@O@SP7XLU31[K3/$
M\EUI-W+9S-%;P&-GC<HQ4F8'&0<9 ..PK1^%/[<'A/XO^/K#P[ING^(H+[4?
M,\M[J"%8EV1M(<E96/1#C /./K0![)16?XN\2P>"_">J:Q=)-):Z3:2WDRQ
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MU+3_ !%/?:=Y?F/:P0M$V^-9!@M*IZ.,Y YS]:YW_AY5X%_Z!/BS_P !;?\
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M_P ?KHOA3^W!X3^+_CZP\.Z;I_B*"^U'S/+>Z@A6)=D;2')65CT0XP#SCZT
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MP>$_A!X^O_#NI:?XBGOM.\OS'M8(6B;?&L@P6E4]'&<@<Y^M 'LE%>%>$?\
M@H+X,\:>+-+T>UTSQ/'=:M=Q6<+2V\ C5Y'"*6(F)QDC. 3CL:]UH **^>?^
M'E7@7_H$^+/_  %M_P#X_79? _\ :Z\-_'WQ9<:/H]CKEM=6UHUXS7D,21E%
M=$(!61CG,@[8P#S0!ZI17._%;XEV/P@\ W_B+4H;N>QT[R_,2U56E;?(L8P&
M91U<9R1QGZ5XW_P\J\"_] GQ9_X"V_\ \?H ^AJ*XWX'_'#2?C[X3N-8T>WU
M"VM;:[:S9;R-$D+JB.2 K,,8D'?.0>*S_CS^TKH7[/']E?VU::M=?VQYWD_8
MHHWV^5LW;M[KC/F#&,]#TH ]"HKYY_X>5>!?^@3XL_\  6W_ /C]>[>$?$L'
MC3PGI>L6J31VNK6D5Y"LH D5)$#J& )&<$9P2,]S0!H45XW\5OVX/"?P@\?7
M_AW4M/\ $4]]IWE^8]K!"T3;XUD&"TJGHXSD#G/UK.\(_P#!07P9XT\6:7H]
MKIGB>.ZU:[BLX6EMX!&KR.$4L1,3C)&< G'8T >ZT45\\_\ #RKP+_T"?%G_
M ("V_P#\?H ^AJ*\K^!_[77AOX^^++C1]'L=<MKJVM&O&:\AB2,HKHA *R,<
MYD';& >:[+XK?$NQ^$'@&_\ $6I0W<]CIWE^8EJJM*V^18Q@,RCJXSDCC/TH
M Z*BOGG_ (>5>!?^@3XL_P# 6W_^/UZI\#_CAI/Q]\)W&L:/;ZA;6MM=M9LM
MY&B2%U1') 5F&,2#OG(/% '945Y7\</VNO#?P"\66^CZQ8ZY<W5S:+>*UG#$
M\81G= "6D4YS&>V,$<UQO_#RKP+_ - GQ9_X"V__ ,?H ^AJ*S_"/B6#QIX3
MTO6+5)H[75K2*\A64 2*DB!U# $C.",X)&>YKQKQ=_P4%\&>"_%FJ:/=:9XG
MDNM)NY;.9HK> QL\;E&*DS XR#C(!QV% 'NM%>%>$?\ @H+X,\:>+-+T>UTS
MQ/'=:M=Q6<+2V\ C5Y'"*6(F)QDC. 3CL:]E\7>)8/!?A/5-8NDFDM=)M);R
M98@#(R1H78*"0,X!QD@9[B@#0HKYY_X>5>!?^@3XL_\  6W_ /C]=E\#_P!K
MKPW\??%EQH^CV.N6UU;6C7C->0Q)&45T0@%9&.<R#MC /- 'JE%<;\</CAI/
MP"\)V^L:Q;ZA<VMS=K9JMG&CR!V1W!(9E&,1GOG)'%>5_P##RKP+_P! GQ9_
MX"V__P ?H ^AJ*XWX'_'#2?C[X3N-8T>WU"VM;:[:S9;R-$D+JB.2 K,,8D'
M?.0>*YWXX?M=>&_@%XLM]'UBQURYNKFT6\5K.&)XPC.Z $M(ISF,]L8(YH ]
M4HKYY_X>5>!?^@3XL_\  6W_ /C]>[>$?$L'C3PGI>L6J31VNK6D5Y"LH D5
M)$#J& )&<$9P2,]S0!H45X5XN_X*"^#/!?BS5-'NM,\3R76DW<MG,T5O 8V>
M-RC%29@<9!QD X["CPC_ ,%!?!GC3Q9I>CVNF>)X[K5KN*SA:6W@$:O(X12Q
M$Q.,D9P"<=C0![K16?XN\2P>"_">J:Q=)-):Z3:2WDRQ &1DC0NP4$@9P#C)
M SW%>$_\/*O O_0)\6?^ MO_ /'Z /H:BO*_@?\ M=>&_C[XLN-'T>QURVNK
M:T:\9KR&)(RBNB$ K(QSF0=L8!YKHOCA\<-)^ 7A.WUC6+?4+FUN;M;-5LXT
M>0.R.X)#,HQB,]\Y(XH [*BOGG_AY5X%_P"@3XL_\!;?_P"/UZI\#_CAI/Q]
M\)W&L:/;ZA;6MM=M9LMY&B2%U1') 5F&,2#OG(/% '945Y7\</VNO#?P"\66
M^CZQ8ZY<W5S:+>*UG#$\81G= "6D4YS&>V,$<UQO_#RKP+_T"?%G_@+;_P#Q
M^@#Z&HK/\(^)8/&GA/2]8M4FCM=6M(KR%90!(J2('4, 2,X(S@D9[FO&O%W_
M  4%\&>"_%FJ:/=:9XGDNM)NY;.9HK> QL\;E&*DS XR#C(!QV% 'NM%>%>$
M?^"@O@SQIXLTO1[73/$\=UJUW%9PM+;P"-7D<(I8B8G&2,X!..QKV7Q=XE@\
M%^$]4UBZ2:2UTFTEO)EB ,C)&A=@H) S@'&2!GN* -"BOGG_ (>5>!?^@3XL
M_P# 6W_^/UV7P/\ VNO#?Q]\67&CZ/8ZY;75M:->,UY#$D9171" 5D8YS(.V
M, \T >J45QOQP^.&D_ +PG;ZQK%OJ%S:W-VMFJV<:/('9'<$AF48Q&>^<D<5
MY7_P\J\"_P#0)\6?^ MO_P#'Z /H:BN=^%/Q+L?B_P" ;#Q%IL-W!8ZCYGEI
M=*JRKLD:,Y"LPZH<8)XQ]*XWXX?M=>&_@%XLM]'UBQURYNKFT6\5K.&)XPC.
MZ $M(ISF,]L8(YH ]4HKYY_X>5>!?^@3XL_\!;?_ ./U]#4 %%>%>+O^"@O@
MSP7XLU31[K3/$\EUI-W+9S-%;P&-GC<HQ4F8'&0<9 ..PK1^%/[<'A/XO^/K
M#P[ING^(H+[4?,\M[J"%8EV1M(<E96/1#C /./K0![)16?XN\2P>"_">J:Q=
M)-):Z3:2WDRQ &1DC0NP4$@9P#C) SW%>$_\/*O O_0)\6?^ MO_ /'Z /H:
MBO/?@-^TKH7[0_\ :O\ 8MIJUK_8_D^=]MBC3=YN_;MV.V<>6<YQU'6M#XX?
M'#2?@%X3M]8UBWU"YM;F[6S5;.-'D#LCN"0S*,8C/?.2.* .RHKYY_X>5>!?
M^@3XL_\  6W_ /C]>R?"GXEV/Q?\ V'B+38;N"QU'S/+2Z55E79(T9R%9AU0
MXP3QCZ4 =%17E?QP_:Z\-_ +Q9;Z/K%CKES=7-HMXK6<,3QA&=T ):13G,9[
M8P1S7&_\/*O O_0)\6?^ MO_ /'Z /H:BBO"O%W_  4%\&>"_%FJ:/=:9XGD
MNM)NY;.9HK> QL\;E&*DS XR#C(!QV% 'NM%>-_"G]N#PG\7_'UAX=TW3_$4
M%]J/F>6]U!"L2[(VD.2LK'HAQ@'G'UKU3Q=XE@\%^$]4UBZ2:2UTFTEO)EB
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M W_B+4H;N>QT[R_,2U56E;?(L8P&91U<9R1QGZ5XW_P\J\"_] GQ9_X"V_\
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M^TI^Q?\ %[X<Z%<:?::WX_\ !6L^&]/GOW>.UAN+RQFMXGE9%=UC#R*6*HQ
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M*K[_ -)O%==!\.O^#A?X^Q?LXR7'BW_@GS^U!<?%VS\B%+#2/">HP^&]5PL
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MI_B+XI> +2XM_%VC+!;22:S:PVTJQSBU*)+>R26DEU92B.9KHQFQ2V0-&70
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M\&]/U632=$\;>,F-QKUO/;?8Y6MWB5KJ+[1/#.)"#8/!%'*\:W#RQK*_O_\
MP1T_8S\5>+_^#;S1?@7XVTWQ!\,_$WC#PKXO\,7D6MZ+-!?Z)_:.HZK''/)9
MS&*0XCN$E",4WJ5PP#!J^4/^"-O[9G[2_P#P1Z^#5S^SK\<_V0?VD/&&B>#[
MNZOM"UWP!X;3Q#'9)=F"Z&GJ;=5M;B/S9KV=K@7LLB23" Q@)^[ /'_VZ?@E
M^UI\(O\ @I)_P3WF_:P^,O@_XJ:WJGQ@B3P_:>&]'M[6UT:WBU3P\99&GCL[
M1Y9)WD4&-HB(Q:J5=C*RI_1=7X _M??#7]KC]N[_ (*:_L3_ !\\?? [X@>
M_#,/Q TF*S\#V,%SKT/@C1[:]T6]DUG4[B',=K<7DEW=)(D]M:211:/$LBN8
MRP_?Z@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M#MA_9]C/.;IX_/DFW2%54MF1F/1%&,XX^M=%10!R?Q1^!OA;XS_8?^$FTO\
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M&NPZEXBT;^T+Z" 6J2?:YX=L89F"XC=1U=CG&>?I7<44 >3?\,-_"W_H5_\
MRI7?_P =KUFBB@#S'7_V./AOXHUV]U*^\.>??:C.]U<2?VA=+YDCL69L+( ,
MDDX  JYX&_94\ _#;Q3:ZUHN@_8M3LM_DS?;;B39N1D;Y7D*G*L1R._K7H5%
M %37]#M?%&A7NFWT7GV.HP/:W$>XKYD;J59<J01D$C((->8_\,-_"W_H5_\
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M5EIMC%Y%CIT"6MO'N+>7&BA57+$DX  R235NB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M)E^'^1ZO^I>1_P#0-'\?\SZW_P"'S/Q0_P"@#X"_\ KO_P"2:/\ A\S\4/\
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M0?ZEY'_T#1_'_,^M_P#A\S\4/^@#X"_\ KO_ .2:/^'S/Q0_Z /@+_P"N_\
MY)KY(HH_UTSO_H)E^'^0?ZEY'_T#1_'_ #/K?_A\S\4/^@#X"_\  *[_ /DF
MC_A\S\4/^@#X"_\  *[_ /DFODBBC_73._\ H)E^'^0?ZEY'_P! T?Q_S/K?
M_A\S\4/^@#X"_P# *[_^2:/^'S/Q0_Z /@+_ , KO_Y)KY(HH_UTSO\ Z"9?
MA_D'^I>1_P#0-'\?\SZW_P"'S/Q0_P"@#X"_\ KO_P"2:/\ A\S\4/\ H ^
MO_ *[_\ DFODBBC_ %TSO_H)E^'^0?ZEY'_T#1_'_,^M_P#A\S\4/^@#X"_\
M KO_ .2:/^'S/Q0_Z /@+_P"N_\ Y)KY(HH_UTSO_H)E^'^0?ZEY'_T#1_'_
M #/K?_A\S\4/^@#X"_\  *[_ /DFC_A\S\4/^@#X"_\  *[_ /DFODBBC_73
M._\ H)E^'^0?ZEY'_P! T?Q_S/K?_A\S\4/^@#X"_P# *[_^2:/^'S/Q0_Z
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M?_A\S\4/^@#X"_\  *[_ /DFC_A\S\4/^@#X"_\  *[_ /DFODBBC_73._\
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M_P#0-'\?\SZW_P"'S/Q0_P"@#X"_\ KO_P"2:/\ A\S\4/\ H ^ O_ *[_\
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M^'^0?ZEY'_T#1_'_ #/K?_A\S\4/^@#X"_\  *[_ /DFC_A\S\4/^@#X"_\
M *[_ /DFODBBC_73._\ H)E^'^0?ZEY'_P! T?Q_S/K?_A\S\4/^@#X"_P#
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MH_UTSO\ Z"9?A_D'^I>1_P#0-'\?\SZW_P"'S/Q0_P"@#X"_\ KO_P"2:/\
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M8.BH2=1*Z[<LG;[TCWJBBBOVH_$PHHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M (2[^VO%;6_BO9H\6I9QY/V.SN=[C[+I]QNNOM%V/*\GR(O]*M]W[S[_ *^
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MC^#]2T3]H+QJWAOQ%/K%K<S75E;B^TBWWVC13QHDFR_F.9$D&5C^7 (;[OH
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MO^D8_P"T!_W]U?\ ^4='_!QW_P I3?\ @F/_ -E5?_T[^&Z_7Z@#\H?V*O\
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M='U5?B/X*L+#_2;#1].N!;!HI;J;%V]P;.^T2,J_FH&L[@A\G?, ?K]1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110!^2/_  4Y_P"3X?&__;A_Z06U>"U[U_P4Y_Y/A\;_ /;A_P"D%M7@M?R3
MQ)_R-\5_U\G_ .E,_KKAK_D487_KW3_])04445XI[04444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M:86&H?V='>12Z?). =/M?L<T=RPG:=?M+:@J*7\J,'/_ .#JW_@JGX-_;T^
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M6K302^7(JR)NC=6VNJL,X(!R*_1[_@D[_P HLOV:?^R5>%__ $T6M 'Y _\
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M9Z?J=I?WDN9&4'R[6VGDV@[FV;5#,54_.'_!!C_@LY^R7\*?^"2W@?PKJWQ
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MZZX:_P"11A?^O=/_ -)04445XI[04444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?K=_P3&_Y,
M>\$?]O\ _P"E]S7Y(U^MW_!,;_DQ[P1_V_\ _I?<U^G>%'_(WJ?]>W_Z5 _+
M_%C_ )%%/_KXO_29GO5%%%?T$?SV%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MQ+Y_]K^(=*\/6EGJNJ^?,L\_VBYCC667S)E61]['<ZACD@&O0** /E__ (+
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M/_TIG]=<-?\ (HPO_7NG_P"DH****\4]H**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OUN_X
M)C?\F/>"/^W_ /\ 2^YK\D:_6[_@F-_R8]X(_P"W_P#]+[FOT[PH_P"1O4_Z
M]O\ ]*@?E_BQ_P BBG_U\7_I,SWJBBBOZ"/Y["BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#R/XG?L*?"OXR>.+[Q
M)XD\+?VEK6I>7]HN/[2O(?,V1K&ORQRJHPB*. ,XSUR:P?\ AV-\#O\ H2/_
M "L7_P#\?KWJBO)J</Y74FZE3#4W)N[;A%MM[MNVK9Z]/B#-*<%3IXFHHI62
M4Y))+9)7T2/!?^'8WP._Z$C_ ,K%_P#_ !^C_AV-\#O^A(_\K%__ /'Z]ZHK
M/_5O*/\ H%I_^ 1_R+_UES?_ *"JG_@<O\SP7_AV-\#O^A(_\K%__P#'Z/\
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M]9<W_P"@JI_X'+_,\%_X=C? [_H2/_*Q?_\ Q^C_ (=C? [_ *$C_P K%_\
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M^'8WP._Z$C_RL7__ ,?H_P"'8WP._P"A(_\ *Q?_ /Q^O>J*/]6\H_Z!:?\
MX!'_ "#_ %ES?_H*J?\ @<O\SP7_ (=C? [_ *$C_P K%_\ _'Z/^'8WP._Z
M$C_RL7__ ,?KWJBC_5O*/^@6G_X!'_(/]9<W_P"@JI_X'+_,\%_X=C? [_H2
M/_*Q?_\ Q^C_ (=C? [_ *$C_P K%_\ _'Z]ZHH_U;RC_H%I_P#@$?\ (/\
M67-_^@JI_P"!R_S/!?\ AV-\#O\ H2/_ "L7_P#\?H_X=C? [_H2/_*Q?_\
MQ^O>J*/]6\H_Z!:?_@$?\@_UES?_ *"JG_@<O\SP7_AV-\#O^A(_\K%__P#'
MZ/\ AV-\#O\ H2/_ "L7_P#\?KWJBC_5O*/^@6G_ . 1_P @_P!9<W_Z"JG_
M ('+_,\%_P"'8WP._P"A(_\ *Q?_ /Q^C_AV-\#O^A(_\K%__P#'Z]ZHH_U;
MRC_H%I_^ 1_R#_67-_\ H*J?^!R_S/!?^'8WP._Z$C_RL7__ ,?H_P"'8WP.
M_P"A(_\ *Q?_ /Q^O>J*/]6\H_Z!:?\ X!'_ "#_ %ES?_H*J?\ @<O\SP7_
M (=C? [_ *$C_P K%_\ _'Z/^'8WP._Z$C_RL7__ ,?KWJBC_5O*/^@6G_X!
M'_(/]9<W_P"@JI_X'+_,\%_X=C? [_H2/_*Q?_\ Q^C_ (=C? [_ *$C_P K
M%_\ _'Z]ZHH_U;RC_H%I_P#@$?\ (/\ 67-_^@JI_P"!R_S/!?\ AV-\#O\
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MP._Z$C_RL7__ ,?KWJBC_5O*/^@6G_X!'_(/]9<W_P"@JI_X'+_,\%_X=C?
M[_H2/_*Q?_\ Q^C_ (=C? [_ *$C_P K%_\ _'Z]ZHH_U;RC_H%I_P#@$?\
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M?KWJBC_5O*/^@6G_ . 1_P @_P!9<W_Z"JG_ ('+_,\%_P"'8WP._P"A(_\
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M_P"'8WP._P"A(_\ *Q?_ /Q^O>J*/]6\H_Z!:?\ X!'_ "#_ %ES?_H*J?\
M@<O\SP7_ (=C? [_ *$C_P K%_\ _'Z/^'8WP._Z$C_RL7__ ,?KWJBC_5O*
M/^@6G_X!'_(/]9<W_P"@JI_X'+_,\%_X=C? [_H2/_*Q?_\ Q^C_ (=C? [_
M *$C_P K%_\ _'Z]ZHH_U;RC_H%I_P#@$?\ (/\ 67-_^@JI_P"!R_S/!?\
MAV-\#O\ H2/_ "L7_P#\?H_X=C? [_H2/_*Q?_\ Q^O>J*/]6\H_Z!:?_@$?
M\@_UES?_ *"JG_@<O\SP7_AV-\#O^A(_\K%__P#'Z/\ AV-\#O\ H2/_ "L7
M_P#\?KWJBC_5O*/^@6G_ . 1_P @_P!9<W_Z"JG_ ('+_,\%_P"'8WP._P"A
M(_\ *Q?_ /Q^C_AV-\#O^A(_\K%__P#'Z]ZHH_U;RC_H%I_^ 1_R#_67-_\
MH*J?^!R_S/!?^'8WP._Z$C_RL7__ ,?H_P"'8WP._P"A(_\ *Q?_ /Q^O>J*
M/]6\H_Z!:?\ X!'_ "#_ %ES?_H*J?\ @<O\SP7_ (=C? [_ *$C_P K%_\
M_'Z/^'8WP._Z$C_RL7__ ,?KWJBC_5O*/^@6G_X!'_(/]9<W_P"@JI_X'+_,
M\%_X=C? [_H2/_*Q?_\ Q^C_ (=C? [_ *$C_P K%_\ _'Z]ZHH_U;RC_H%I
M_P#@$?\ (/\ 67-_^@JI_P"!R_S/!?\ AV-\#O\ H2/_ "L7_P#\?H_X=C?
M[_H2/_*Q?_\ Q^O>J*/]6\H_Z!:?_@$?\@_UES?_ *"JG_@<O\SP7_AV-\#O
M^A(_\K%__P#'Z/\ AV-\#O\ H2/_ "L7_P#\?KWJBC_5O*/^@6G_ . 1_P @
M_P!9<W_Z"JG_ ('+_,\%_P"'8WP._P"A(_\ *Q?_ /Q^O7/AC\,=#^#?@>Q\
M-^&['^S=%TWS/L]OYTDWE[Y&D;YI&9CEW8\DXSCI@5O45U83*<#A9^TPU&$)
M6M>,8IV[726FB.7%YOCL5#V>*K3G&][2E)J_>S;UU84445Z!YX4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MVJ7?;)=V\,"[8U=SOE7(0@98A3TW_#\?X3?]"]\1/_ "S_\ DJOSI_X* ?\
M!O5\ O\ @C'^R-XM_:4\$ZY\8/%GB;X;_8_L>E:WKNG+877VZ]@TV3S##IRR
M?+'>.XVL/F1<Y&16G_P14_9M_P"'P?[+&O\ Q,_MK_A7?]A^*[CPQ_9OV3^U
M_/\ *M+.Y\_S=\&W/VO;LV''EYW'=@5&W4#] _\ A^/\)O\ H7OB)_X 6?\
M\E4?\/Q_A-_T+WQ$_P# "S_^2J\[_P"'"7_55O\ RV/_ +KH_P"'"7_55O\
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M5;_RV/\ [KH]T#T3_A^/\)O^A>^(G_@!9_\ R51_P_'^$W_0O?$3_P  +/\
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MPE_U5;_RV/\ [KH]T#T3_A^/\)O^A>^(G_@!9_\ R51_P_'^$W_0O?$3_P
M+/\ ^2J\[_X<)?\ 55O_ "V/_NNC_APE_P!56_\ +8_^ZZ/= ]$_X?C_  F_
MZ%[XB?\ @!9__)5'_#\?X3?]"]\1/_ "S_\ DJO._P#APE_U5;_RV/\ [KH_
MX<)?]56_\MC_ .ZZ/= ]$_X?C_";_H7OB)_X 6?_ ,E4?\/Q_A-_T+WQ$_\
M "S_ /DJO._^'"7_ %5;_P MC_[KH_X<)?\ 55O_ "V/_NNCW0/1/^'X_P )
MO^A>^(G_ ( 6?_R51_P_'^$W_0O?$3_P L__ )*KSO\ X<)?]56_\MC_ .ZZ
M/^'"7_55O_+8_P#NNCW0/1/^'X_PF_Z%[XB?^ %G_P#)5'_#\?X3?]"]\1/_
M   L_P#Y*KSO_APE_P!56_\ +8_^ZZ/^'"7_ %5;_P MC_[KH]T#T3_A^/\
M";_H7OB)_P" %G_\E4?\/Q_A-_T+WQ$_\ +/_P"2J\[_ .'"7_55O_+8_P#N
MNC_APE_U5;_RV/\ [KH]T#T3_A^/\)O^A>^(G_@!9_\ R51_P_'^$W_0O?$3
M_P  +/\ ^2J\[_X<)?\ 55O_ "V/_NNC_APE_P!56_\ +8_^ZZ/= ]$_X?C_
M  F_Z%[XB?\ @!9__)5'_#\?X3?]"]\1/_ "S_\ DJO._P#APE_U5;_RV/\
M[KH_X<)?]56_\MC_ .ZZ/= ]$_X?C_";_H7OB)_X 6?_ ,E4?\/Q_A-_T+WQ
M$_\  "S_ /DJO._^'"7_ %5;_P MC_[KH_X<)?\ 55O_ "V/_NNCW0/1/^'X
M_P )O^A>^(G_ ( 6?_R51_P_'^$W_0O?$3_P L__ )*KSO\ X<)?]56_\MC_
M .ZZ/^'"7_55O_+8_P#NNCW0/1/^'X_PF_Z%[XB?^ %G_P#)5'_#\?X3?]"]
M\1/_   L_P#Y*KSO_APE_P!56_\ +8_^ZZ/^'"7_ %5;_P MC_[KH]T#T3_A
M^/\ ";_H7OB)_P" %G_\E4?\/Q_A-_T+WQ$_\ +/_P"2J\[_ .'"7_55O_+8
M_P#NNC_APE_U5;_RV/\ [KH]T#T3_A^/\)O^A>^(G_@!9_\ R51_P_'^$W_0
MO?$3_P  +/\ ^2J\[_X<)?\ 55O_ "V/_NNC_APE_P!56_\ +8_^ZZ/= ]$_
MX?C_  F_Z%[XB?\ @!9__)5'_#\?X3?]"]\1/_ "S_\ DJO._P#APE_U5;_R
MV/\ [KH_X<)?]56_\MC_ .ZZ/= ]$_X?C_";_H7OB)_X 6?_ ,E4?\/Q_A-_
MT+WQ$_\  "S_ /DJO._^'"7_ %5;_P MC_[KH_X<)?\ 55O_ "V/_NNCW0/1
M/^'X_P )O^A>^(G_ ( 6?_R51_P_'^$W_0O?$3_P L__ )*KSO\ X<)?]56_
M\MC_ .ZZ/^'"7_55O_+8_P#NNCW0/1/^'X_PF_Z%[XB?^ %G_P#)5'_#\?X3
M?]"]\1/_   L_P#Y*KSO_APE_P!56_\ +8_^ZZ/^'"7_ %5;_P MC_[KH]T#
MT3_A^/\ ";_H7OB)_P" %G_\E4?\/Q_A-_T+WQ$_\ +/_P"2J\[_ .'"7_55
MO_+8_P#NNC_APE_U5;_RV/\ [KH]T#T3_A^/\)O^A>^(G_@!9_\ R51_P_'^
M$W_0O?$3_P  +/\ ^2J\[_X<)?\ 55O_ "V/_NNC_APE_P!56_\ +8_^ZZ/=
M ]$_X?C_  F_Z%[XB?\ @!9__)5'_#\?X3?]"]\1/_ "S_\ DJO._P#APE_U
M5;_RV/\ [KH_X<)?]56_\MC_ .ZZ/= ]$_X?C_";_H7OB)_X 6?_ ,E4?\/Q
M_A-_T+WQ$_\  "S_ /DJO._^'"7_ %5;_P MC_[KH_X<)?\ 55O_ "V/_NNC
MW0/1/^'X_P )O^A>^(G_ ( 6?_R51_P_'^$W_0O?$3_P L__ )*KSO\ X<)?
M]56_\MC_ .ZZ/^'"7_55O_+8_P#NNCW0/1/^'X_PF_Z%[XB?^ %G_P#)5'_#
M\?X3?]"]\1/_   L_P#Y*KSO_APE_P!56_\ +8_^ZZ/^'"7_ %5;_P MC_[K
MH]T#T3_A^/\ ";_H7OB)_P" %G_\E4?\/Q_A-_T+WQ$_\ +/_P"2J\[_ .'"
M7_55O_+8_P#NNC_APE_U5;_RV/\ [KH]T#T3_A^/\)O^A>^(G_@!9_\ R51_
MP_'^$W_0O?$3_P  +/\ ^2J\[_X<)?\ 55O_ "V/_NNC_APE_P!56_\ +8_^
MZZ/= ]$_X?C_  F_Z%[XB?\ @!9__)5'_#\?X3?]"]\1/_ "S_\ DJO._P#A
MPE_U5;_RV/\ [KH_X<)?]56_\MC_ .ZZ/= ]$_X?C_";_H7OB)_X 6?_ ,E4
M?\/Q_A-_T+WQ$_\  "S_ /DJO._^'"7_ %5;_P MC_[KH_X<)?\ 55O_ "V/
M_NNCW0/1/^'X_P )O^A>^(G_ ( 6?_R51_P_'^$W_0O?$3_P L__ )*KSO\
MX<)?]56_\MC_ .ZZ/^'"7_55O_+8_P#NNCW0/1/^'X_PF_Z%[XB?^ %G_P#)
M5'_#\?X3?]"]\1/_   L_P#Y*KSO_APE_P!56_\ +8_^ZZ/^'"7_ %5;_P M
MC_[KH]T#T3_A^/\ ";_H7OB)_P" %G_\E4?\/Q_A-_T+WQ$_\ +/_P"2J\[_
M .'"7_55O_+8_P#NNC_APE_U5;_RV/\ [KH]T#T3_A^/\)O^A>^(G_@!9_\
MR51_P_'^$W_0O?$3_P  +/\ ^2J\[_X<)?\ 55O_ "V/_NNC_APE_P!56_\
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M6_\ +8_^ZZ/= ]$_X?C_  F_Z%[XB?\ @!9__)5'_#\?X3?]"]\1/_ "S_\
MDJO._P#APE_U5;_RV/\ [KH_X<)?]56_\MC_ .ZZ/= ]$_X?C_";_H7OB)_X
M 6?_ ,E4?\/Q_A-_T+WQ$_\  "S_ /DJO._^'"7_ %5;_P MC_[KH_X<)?\
M55O_ "V/_NNCW0/1/^'X_P )O^A>^(G_ ( 6?_R51_P_'^$W_0O?$3_P L__
M )*KSO\ X<)?]56_\MC_ .ZZ/^'"7_55O_+8_P#NNCW0/1/^'X_PF_Z%[XB?
M^ %G_P#)5'_#\?X3?]"]\1/_   L_P#Y*KSO_APE_P!56_\ +8_^ZZ/^'"7_
M %5;_P MC_[KH]T#T3_A^/\ ";_H7OB)_P" %G_\E4?\/Q_A-_T+WQ$_\ +/
M_P"2J\[_ .'"7_55O_+8_P#NNC_APE_U5;_RV/\ [KH]T#T3_A^/\)O^A>^(
MG_@!9_\ R51_P_'^$W_0O?$3_P  +/\ ^2J\[_X<)?\ 55O_ "V/_NNC_APE
M_P!56_\ +8_^ZZ/= ]$_X?C_  F_Z%[XB?\ @!9__)5'_#\?X3?]"]\1/_ "
MS_\ DJO._P#APE_U5;_RV/\ [KH_X<)?]56_\MC_ .ZZ/= ]$_X?C_";_H7O
MB)_X 6?_ ,E4?\/Q_A-_T+WQ$_\  "S_ /DJO._^'"7_ %5;_P MC_[KH_X<
M)?\ 55O_ "V/_NNCW0/1/^'X_P )O^A>^(G_ ( 6?_R51_P_'^$W_0O?$3_P
M L__ )*KSO\ X<)?]56_\MC_ .ZZ/^'"7_55O_+8_P#NNCW0/1/^'X_PF_Z%
M[XB?^ %G_P#)5'_#\?X3?]"]\1/_   L_P#Y*KSO_APE_P!56_\ +8_^ZZ/^
M'"7_ %5;_P MC_[KH]T#T3_A^/\ ";_H7OB)_P" %G_\E4?\/Q_A-_T+WQ$_
M\ +/_P"2J\[_ .'"7_55O_+8_P#NNC_APE_U5;_RV/\ [KH]T#T3_A^/\)O^
MA>^(G_@!9_\ R51_P_'^$W_0O?$3_P  +/\ ^2J\[_X<)?\ 55O_ "V/_NNC
M_APE_P!56_\ +8_^ZZ/= ]$_X?C_  F_Z%[XB?\ @!9__)5'_#\?X3?]"]\1
M/_ "S_\ DJO._P#APE_U5;_RV/\ [KH_X<)?]56_\MC_ .ZZ/= ]$_X?C_";
M_H7OB)_X 6?_ ,E4?\/Q_A-_T+WQ$_\  "S_ /DJO._^'"7_ %5;_P MC_[K
MH_X<)?\ 55O_ "V/_NNCW0/1/^'X_P )O^A>^(G_ ( 6?_R51_P_'^$W_0O?
M$3_P L__ )*KSO\ X<)?]56_\MC_ .ZZ/^'"7_55O_+8_P#NNCW0/1/^'X_P
MF_Z%[XB?^ %G_P#)5'_#\?X3?]"]\1/_   L_P#Y*KSO_APE_P!56_\ +8_^
MZZ/^'"7_ %5;_P MC_[KH]T#T3_A^/\ ";_H7OB)_P" %G_\E4?\/Q_A-_T+
MWQ$_\ +/_P"2J\[_ .'"7_55O_+8_P#NNC_APE_U5;_RV/\ [KH]T#T3_A^/
M\)O^A>^(G_@!9_\ R51_P_'^$W_0O?$3_P  +/\ ^2J\[_X<)?\ 55O_ "V/
M_NNC_APE_P!56_\ +8_^ZZ/= ]$_X?C_  F_Z%[XB?\ @!9__)5'_#\?X3?]
M"]\1/_ "S_\ DJO._P#APE_U5;_RV/\ [KH_X<)?]56_\MC_ .ZZ/= ]$_X?
MC_";_H7OB)_X 6?_ ,E4?\/Q_A-_T+WQ$_\  "S_ /DJO._^'"7_ %5;_P M
MC_[KH_X<)?\ 55O_ "V/_NNCW0/1/^'X_P )O^A>^(G_ ( 6?_R51_P_'^$W
M_0O?$3_P L__ )*KSO\ X<)?]56_\MC_ .ZZ/^'"7_55O_+8_P#NNCW0/1/^
M'X_PF_Z%[XB?^ %G_P#)5'_#\?X3?]"]\1/_   L_P#Y*KSO_APE_P!56_\
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MT#T3_A^/\)O^A>^(G_@!9_\ R51_P_'^$W_0O?$3_P  +/\ ^2J\[_X<)?\
M55O_ "V/_NNC_APE_P!56_\ +8_^ZZ/= ]$_X?C_  F_Z%[XB?\ @!9__)5'
M_#\?X3?]"]\1/_ "S_\ DJO._P#APE_U5;_RV/\ [KH_X<)?]56_\MC_ .ZZ
M/= ]$_X?C_";_H7OB)_X 6?_ ,E4?\/Q_A-_T+WQ$_\  "S_ /DJO._^'"7_
M %5;_P MC_[KH_X<)?\ 55O_ "V/_NNCW0/1/^'X_P )O^A>^(G_ ( 6?_R5
M1_P_'^$W_0O?$3_P L__ )*KSO\ X<)?]56_\MC_ .ZZ/^'"7_55O_+8_P#N
MNCW0/1/^'X_PF_Z%[XB?^ %G_P#)5'_#\?X3?]"]\1/_   L_P#Y*KSO_APE
M_P!56_\ +8_^ZZ/^'"7_ %5;_P MC_[KH]T#T3_A^/\ ";_H7OB)_P" %G_\
ME4?\/Q_A-_T+WQ$_\ +/_P"2J\[_ .'"7_55O_+8_P#NNC_APE_U5;_RV/\
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M_APE_P!56_\ +8_^ZZ/^'"7_ %5;_P MC_[KH]T#T3_A^/\ ";_H7OB)_P"
M%G_\E4?\/Q_A-_T+WQ$_\ +/_P"2J\[_ .'"7_55O_+8_P#NNC_APE_U5;_R
MV/\ [KH]T#T3_A^/\)O^A>^(G_@!9_\ R51_P_'^$W_0O?$3_P  +/\ ^2J\
M[_X<)?\ 55O_ "V/_NNC_APE_P!56_\ +8_^ZZ/= ]$_X?C_  F_Z%[XB?\
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M5;_RV/\ [KH]T#T3_A^/\)O^A>^(G_@!9_\ R51_P_'^$W_0O?$3_P  +/\
M^2J\[_X<)?\ 55O_ "V/_NNC_APE_P!56_\ +8_^ZZ/= ]$_X?C_  F_Z%[X
MB?\ @!9__)5'_#\?X3?]"]\1/_ "S_\ DJO._P#APE_U5;_RV/\ [KH_X<)?
M]56_\MC_ .ZZ/= ]$_X?C_";_H7OB)_X 6?_ ,E4?\/Q_A-_T+WQ$_\  "S_
M /DJO._^'"7_ %5;_P MC_[KH_X<)?\ 55O_ "V/_NNCW0/1/^'X_P )O^A>
M^(G_ ( 6?_R51_P_'^$W_0O?$3_P L__ )*KSO\ X<)?]56_\MC_ .ZZ/^'"
M7_55O_+8_P#NNCW0/1/^'X_PF_Z%[XB?^ %G_P#)5'_#\?X3?]"]\1/_   L
M_P#Y*KSO_APE_P!56_\ +8_^ZZ/^'"7_ %5;_P MC_[KH]T#T3_A^/\ ";_H
M7OB)_P" %G_\E4?\/Q_A-_T+WQ$_\ +/_P"2J\[_ .'"7_55O_+8_P#NNC_A
MPE_U5;_RV/\ [KH]T#T3_A^/\)O^A>^(G_@!9_\ R51_P_'^$W_0O?$3_P
M+/\ ^2J\[_X<)?\ 55O_ "V/_NNC_APE_P!56_\ +8_^ZZ/= ]$_X?C_  F_
MZ%[XB?\ @!9__)5'_#\?X3?]"]\1/_ "S_\ DJO._P#APE_U5;_RV/\ [KH_
MX<)?]56_\MC_ .ZZ/= ]$_X?C_";_H7OB)_X 6?_ ,E4?\/Q_A-_T+WQ$_\
M "S_ /DJO._^'"7_ %5;_P MC_[KH_X<)?\ 55O_ "V/_NNCW0/1/^'X_P )
MO^A>^(G_ ( 6?_R51_P_'^$W_0O?$3_P L__ )*KSO\ X<)?]56_\MC_ .ZZ
M/^'"7_55O_+8_P#NNCW0/1/^'X_PF_Z%[XB?^ %G_P#)5'_#\?X3?]"]\1/_
M   L_P#Y*KSO_APE_P!56_\ +8_^ZZ/^'"7_ %5;_P MC_[KH]T#T3_A^/\
M";_H7OB)_P" %G_\E4?\/Q_A-_T+WQ$_\ +/_P"2J\[_ .'"7_55O_+8_P#N
MNC_APE_U5;_RV/\ [KH]T#T3_A^/\)O^A>^(G_@!9_\ R51_P_'^$W_0O?$3
M_P  +/\ ^2J\[_X<)?\ 55O_ "V/_NNC_APE_P!56_\ +8_^ZZ/= ]$_X?C_
M  F_Z%[XB?\ @!9__)5'_#\?X3?]"]\1/_ "S_\ DJO._P#APE_U5;_RV/\
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M_NNCW0/1/^'X_P )O^A>^(G_ ( 6?_R51_P_'^$W_0O?$3_P L__ )*KSO\
MX<)?]56_\MC_ .ZZ/^'"7_55O_+8_P#NNCW0/1/^'X_PF_Z%[XB?^ %G_P#)
M5'_#\?X3?]"]\1/_   L_P#Y*KSO_APE_P!56_\ +8_^ZZ/^'"7_ %5;_P M
MC_[KH]T#T3_A^/\ ";_H7OB)_P" %G_\E4?\/Q_A-_T+WQ$_\ +/_P"2J\[_
M .'"7_55O_+8_P#NNC_APE_U5;_RV/\ [KH]T#T3_A^/\)O^A>^(G_@!9_\
MR51_P_'^$W_0O?$3_P  +/\ ^2J\[_X<)?\ 55O_ "V/_NNC_APE_P!56_\
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M6_\ +8_^ZZ/= ]$_X?C_  F_Z%[XB?\ @!9__)5'_#\?X3?]"]\1/_ "S_\
MDJO._P#APE_U5;_RV/\ [KH_X<)?]56_\MC_ .ZZ/= ]$_X?C_";_H7OB)_X
M 6?_ ,E4?\/Q_A-_T+WQ$_\  "S_ /DJO._^'"7_ %5;_P MC_[KH_X<)?\
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M'X_PF_Z%[XB?^ %G_P#)5'_#\?X3?]"]\1/_   L_P#Y*KSO_APE_P!56_\
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MT#T3_A^/\)O^A>^(G_@!9_\ R51_P_'^$W_0O?$3_P  +/\ ^2J\[_X<)?\
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ME4?\/Q_A-_T+WQ$_\ +/_P"2J\[_ .'"7_55O_+8_P#NNC_APE_U5;_RV/\
M[KH]T#T3_A^/\)O^A>^(G_@!9_\ R51_P_'^$W_0O?$3_P  +/\ ^2J\[_X<
M)?\ 55O_ "V/_NNC_APE_P!56_\ +8_^ZZ/= ]$_X?C_  F_Z%[XB?\ @!9_
M_)5'_#\?X3?]"]\1/_ "S_\ DJO._P#APE_U5;_RV/\ [KH_X<)?]56_\MC_
M .ZZ/= ]$_X?C_";_H7OB)_X 6?_ ,E4?\/Q_A-_T+WQ$_\  "S_ /DJO._^
M'"7_ %5;_P MC_[KH_X<)?\ 55O_ "V/_NNCW0/1/^'X_P )O^A>^(G_ ( 6
M?_R51_P_'^$W_0O?$3_P L__ )*KSO\ X<)?]56_\MC_ .ZZ/^'"7_55O_+8
M_P#NNCW0/1/^'X_PF_Z%[XB?^ %G_P#)5'_#\?X3?]"]\1/_   L_P#Y*KSO
M_APE_P!56_\ +8_^ZZ/^'"7_ %5;_P MC_[KH]T#T3_A^/\ ";_H7OB)_P"
M%G_\E4?\/Q_A-_T+WQ$_\ +/_P"2J\[_ .'"7_55O_+8_P#NNC_APE_U5;_R
MV/\ [KH]T#T3_A^/\)O^A>^(G_@!9_\ R51_P_'^$W_0O?$3_P  +/\ ^2J\
M[_X<)?\ 55O_ "V/_NNC_APE_P!56_\ +8_^ZZ/= ]$_X?C_  F_Z%[XB?\
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M5;_RV/\ [KH]T#T3_A^/\)O^A>^(G_@!9_\ R51_P_'^$W_0O?$3_P  +/\
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MPE_U5;_RV/\ [KH]T#T3_A^/\)O^A>^(G_@!9_\ R51_P_'^$W_0O?$3_P
M+/\ ^2J\[_X<)?\ 55O_ "V/_NNC_APE_P!56_\ +8_^ZZ/= ]$_X?C_  F_
MZ%[XB?\ @!9__)5'_#\?X3?]"]\1/_ "S_\ DJO._P#APE_U5;_RV/\ [KH_
MX<)?]56_\MC_ .ZZ/= ]$_X?C_";_H7OB)_X 6?_ ,E4?\/Q_A-_T+WQ$_\
M "S_ /DJO._^'"7_ %5;_P MC_[KH_X<)?\ 55O_ "V/_NNCW0/1/^'X_P )
MO^A>^(G_ ( 6?_R51_P_'^$W_0O?$3_P L__ )*KSO\ X<)?]56_\MC_ .ZZ
M/^'"7_55O_+8_P#NNCW0/1/^'X_PF_Z%[XB?^ %G_P#)5'_#\?X3?]"]\1/_
M   L_P#Y*KSO_APE_P!56_\ +8_^ZZ/^'"7_ %5;_P MC_[KH]T#T3_A^/\
M";_H7OB)_P" %G_\E4?\/Q_A-_T+WQ$_\ +/_P"2J\[_ .'"7_55O_+8_P#N
MNC_APE_U5;_RV/\ [KH]T#T3_A^/\)O^A>^(G_@!9_\ R51_P_'^$W_0O?$3
M_P  +/\ ^2J\[_X<)?\ 55O_ "V/_NNC_APE_P!56_\ +8_^ZZ/= ]$_X?C_
M  F_Z%[XB?\ @!9__)5'_#\?X3?]"]\1/_ "S_\ DJO._P#APE_U5;_RV/\
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M_NNCW0/1/^'X_P )O^A>^(G_ ( 6?_R51_P_'^$W_0O?$3_P L__ )*KSO\
MX<)?]56_\MC_ .ZZ/^'"7_55O_+8_P#NNCW0/1/^'X_PF_Z%[XB?^ %G_P#)
M5'_#\?X3?]"]\1/_   L_P#Y*KSO_APE_P!56_\ +8_^ZZ/^'"7_ %5;_P M
MC_[KH]T#T3_A^/\ ";_H7OB)_P" %G_\E4?\/Q_A-_T+WQ$_\ +/_P"2J\[_
M .'"7_55O_+8_P#NNC_APE_U5;_RV/\ [KH]T#T3_A^/\)O^A>^(G_@!9_\
MR51_P_'^$W_0O?$3_P  +/\ ^2J\[_X<)?\ 55O_ "V/_NNC_APE_P!56_\
M+8_^ZZ/= ]$_X?C_  F_Z%[XB?\ @!9__)5'_#\?X3?]"]\1/_ "S_\ DJO.
M_P#APE_U5;_RV/\ [KH_X<)?]56_\MC_ .ZZ/= ^JOV1OVY/"?[9W_"0?\(O
MI_B*P_X1O[-]I_M6"&+S//\ -V;/+EDSCR6SG'48SSCV:OG?]@G]@G_AB#_A
M+/\ BK/^$H_X2?['_P PS[%]F\CS_P#IK)NW>=[8V]\\?1%0[7T ****0!11
M10 4444 ?('_  6K_9$^ 7[:/[+&@>%OVC/BA_PJ;P38>*[?5;'5_P#A(].T
M'[3J*6EY%';>??1R1-NAFN'\M0'/E9!PK ]__P $N/@%\+/V7_V$_ O@7X*^
M-?\ A8GPRT/[?_8WB'^V+35_[0\W4+F>?_2;1$@DV7$LT?R*-OE[3EE8GX!_
MX/5O^467@'_LJNG?^FC6*]__ .#7'_E!1\#/^X__ .I!J= 'W_1110 4444
M%%%% !1110 4444 ?/\ _P %1_\ A1/_  PGXZ_X:7_Y(E_H'_"1_P#(0_Z"
M%M]E_P"0?_I7_'W]F_U?_ ODW5P'_!%3_AD__AEC7_\ ACK_ ))E_P )7<?V
MG_R&/^0Q]DL_-_Y"G[__ (]_LGW?W?I\V^O/_P#@Z._Y04?'/_N ?^I!IE>
M?\&5/_*++Q]_V574?_31H] 'Z_4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M+1_Q$+A__H(_\DG_ /(A_P 0[XA_Z!__ ">'_P D?>E%?!?_  ^Z_P"J8_\
MEQ__ '+1_P /NO\ JF/_ )<?_P!RT?\ $0N'_P#H(_\ ))__ "(?\0[XA_Z!
M_P#R>'_R1]Z45\%_\/NO^J8_^7'_ /<M'_#[K_JF/_EQ_P#W+1_Q$+A__H(_
M\DG_ /(A_P 0[XA_Z!__ ">'_P D?>E%?!?_  ^Z_P"J8_\ EQ__ '+1_P /
MNO\ JF/_ )<?_P!RT?\ $0N'_P#H(_\ ))__ "(?\0[XA_Z!_P#R>'_R1]Z4
M5\%_\/NO^J8_^7'_ /<M'_#[K_JF/_EQ_P#W+1_Q$+A__H(_\DG_ /(A_P 0
M[XA_Z!__ ">'_P D?>E%?!?_  ^Z_P"J8_\ EQ__ '+1_P /NO\ JF/_ )<?
M_P!RT?\ $0N'_P#H(_\ ))__ "(?\0[XA_Z!_P#R>'_R1]Z45\%_\/NO^J8_
M^7'_ /<M'_#[K_JF/_EQ_P#W+1_Q$+A__H(_\DG_ /(A_P 0[XA_Z!__ ">'
M_P D?>E%?!?_  ^Z_P"J8_\ EQ__ '+1_P /NO\ JF/_ )<?_P!RT?\ $0N'
M_P#H(_\ ))__ "(?\0[XA_Z!_P#R>'_R1]Z45\%_\/NO^J8_^7'_ /<M'_#[
MK_JF/_EQ_P#W+1_Q$+A__H(_\DG_ /(A_P 0[XA_Z!__ ">'_P D?>E%?!?_
M  ^Z_P"J8_\ EQ__ '+1_P /NO\ JF/_ )<?_P!RT?\ $0N'_P#H(_\ ))__
M "(?\0[XA_Z!_P#R>'_R1]Z45\%_\/NO^J8_^7'_ /<M'_#[K_JF/_EQ_P#W
M+1_Q$+A__H(_\DG_ /(A_P 0[XA_Z!__ ">'_P D?>E%?!?_  ^Z_P"J8_\
MEQ__ '+1_P /NO\ JF/_ )<?_P!RT?\ $0N'_P#H(_\ ))__ "(?\0[XA_Z!
M_P#R>'_R1]Z45\%_\/NO^J8_^7'_ /<M'_#[K_JF/_EQ_P#W+1_Q$+A__H(_
M\DG_ /(A_P 0[XA_Z!__ ">'_P D?>E%?!?_  ^Z_P"J8_\ EQ__ '+1_P /
MNO\ JF/_ )<?_P!RT?\ $0N'_P#H(_\ ))__ "(?\0[XA_Z!_P#R>'_R1]Z4
M5\%_\/NO^J8_^7'_ /<M'_#[K_JF/_EQ_P#W+1_Q$+A__H(_\DG_ /(A_P 0
M[XA_Z!__ ">'_P D?>E%?!?_  ^Z_P"J8_\ EQ__ '+1_P /NO\ JF/_ )<?
M_P!RT?\ $0N'_P#H(_\ ))__ "(?\0[XA_Z!_P#R>'_R1]Z45\%_\/NO^J8_
M^7'_ /<M'_#[K_JF/_EQ_P#W+1_Q$+A__H(_\DG_ /(A_P 0[XA_Z!__ ">'
M_P D?>E%?!?_  ^Z_P"J8_\ EQ__ '+1_P /NO\ JF/_ )<?_P!RT?\ $0N'
M_P#H(_\ ))__ "(?\0[XA_Z!_P#R>'_R1]Z45\%_\/NO^J8_^7'_ /<M'_#[
MK_JF/_EQ_P#W+1_Q$+A__H(_\DG_ /(A_P 0[XA_Z!__ ">'_P D?>E%?!?_
M  ^Z_P"J8_\ EQ__ '+1_P /NO\ JF/_ )<?_P!RT?\ $0N'_P#H(_\ ))__
M "(?\0[XA_Z!_P#R>'_R1]Z45\%_\/NO^J8_^7'_ /<M'_#[K_JF/_EQ_P#W
M+1_Q$+A__H(_\DG_ /(A_P 0[XA_Z!__ ">'_P D?>E%?!?_  ^Z_P"J8_\
MEQ__ '+1_P /NO\ JF/_ )<?_P!RT?\ $0N'_P#H(_\ ))__ "(?\0[XA_Z!
M_P#R>'_R1]Z45\%_\/NO^J8_^7'_ /<M'_#[K_JF/_EQ_P#W+1_Q$+A__H(_
M\DG_ /(A_P 0[XA_Z!__ ">'_P D?>E%?!?_  ^Z_P"J8_\ EQ__ '+1_P /
MNO\ JF/_ )<?_P!RT?\ $0N'_P#H(_\ ))__ "(?\0[XA_Z!_P#R>'_R1]Z4
M5\%_\/NO^J8_^7'_ /<M'_#[K_JF/_EQ_P#W+1_Q$+A__H(_\DG_ /(A_P 0
M[XA_Z!__ ">'_P D?>E%?!?_  ^Z_P"J8_\ EQ__ '+1_P /NO\ JF/_ )<?
M_P!RT?\ $0N'_P#H(_\ ))__ "(?\0[XA_Z!_P#R>'_R1]Z45\%_\/NO^J8_
M^7'_ /<M'_#[K_JF/_EQ_P#W+1_Q$+A__H(_\DG_ /(A_P 0[XA_Z!__ ">'
M_P D?>E%?!?_  ^Z_P"J8_\ EQ__ '+1_P /NO\ JF/_ )<?_P!RT?\ $0N'
M_P#H(_\ ))__ "(?\0[XA_Z!_P#R>'_R1]Z45\%_\/NO^J8_^7'_ /<M'_#[
MK_JF/_EQ_P#W+1_Q$+A__H(_\DG_ /(A_P 0[XA_Z!__ ">'_P D?>E%?!?_
M  ^Z_P"J8_\ EQ__ '+1_P /NO\ JF/_ )<?_P!RT?\ $0N'_P#H(_\ ))__
M "(?\0[XA_Z!_P#R>'_R1]Z45\%_\/NO^J8_^7'_ /<M'_#[K_JF/_EQ_P#W
M+1_Q$+A__H(_\DG_ /(A_P 0[XA_Z!__ ">'_P D?>E%?!?_  ^Z_P"J8_\
MEQ__ '+1_P /NO\ JF/_ )<?_P!RT?\ $0N'_P#H(_\ ))__ "(?\0[XA_Z!
M_P#R>'_R1]Z45\%_\/NO^J8_^7'_ /<M'_#[K_JF/_EQ_P#W+1_Q$+A__H(_
M\DG_ /(A_P 0[XA_Z!__ ">'_P D?>E%?!?_  ^Z_P"J8_\ EQ__ '+1_P /
MNO\ JF/_ )<?_P!RT?\ $0N'_P#H(_\ ))__ "(?\0[XA_Z!_P#R>'_R1]Z4
M5\%_\/NO^J8_^7'_ /<M'_#[K_JF/_EQ_P#W+1_Q$+A__H(_\DG_ /(A_P 0
M[XA_Z!__ ">'_P D?>E%?!?_  ^Z_P"J8_\ EQ__ '+1_P /NO\ JF/_ )<?
M_P!RT?\ $0N'_P#H(_\ ))__ "(?\0[XA_Z!_P#R>'_R1]Z45\%_\/NO^J8_
M^7'_ /<M'_#[K_JF/_EQ_P#W+1_Q$+A__H(_\DG_ /(A_P 0[XA_Z!__ ">'
M_P D?>E%?!?_  ^Z_P"J8_\ EQ__ '+1_P /NO\ JF/_ )<?_P!RT?\ $0N'
M_P#H(_\ ))__ "(?\0[XA_Z!_P#R>'_R1]Z45\%_\/NO^J8_^7'_ /<M'_#[
MK_JF/_EQ_P#W+1_Q$+A__H(_\DG_ /(A_P 0[XA_Z!__ ">'_P D?>E%?!?_
M  ^Z_P"J8_\ EQ__ '+1_P /NO\ JF/_ )<?_P!RT?\ $0N'_P#H(_\ ))__
M "(?\0[XA_Z!_P#R>'_R1]Z45\%_\/NO^J8_^7'_ /<M'_#[K_JF/_EQ_P#W
M+1_Q$+A__H(_\DG_ /(A_P 0[XA_Z!__ ">'_P D?>E%?!?_  ^Z_P"J8_\
MEQ__ '+1_P /NO\ JF/_ )<?_P!RT?\ $0N'_P#H(_\ ))__ "(?\0[XA_Z!
M_P#R>'_R1]Z45\%_\/NO^J8_^7'_ /<M'_#[K_JF/_EQ_P#W+1_Q$+A__H(_
M\DG_ /(A_P 0[XA_Z!__ ">'_P D?>E%?!?_  ^Z_P"J8_\ EQ__ '+1_P /
MNO\ JF/_ )<?_P!RT?\ $0N'_P#H(_\ ))__ "(?\0[XA_Z!_P#R>'_R1]Z4
M5\%_\/NO^J8_^7'_ /<M'_#[K_JF/_EQ_P#W+1_Q$+A__H(_\DG_ /(A_P 0
M[XA_Z!__ ">'_P D?>E%?!?_  ^Z_P"J8_\ EQ__ '+1_P /NO\ JF/_ )<?
M_P!RT?\ $0N'_P#H(_\ ))__ "(?\0[XA_Z!_P#R>'_R1]Z45\%_\/NO^J8_
M^7'_ /<M'_#[K_JF/_EQ_P#W+1_Q$+A__H(_\DG_ /(A_P 0[XA_Z!__ ">'
M_P D?>E%?!?_  ^Z_P"J8_\ EQ__ '+1_P /NO\ JF/_ )<?_P!RT?\ $0N'
M_P#H(_\ ))__ "(?\0[XA_Z!_P#R>'_R1]Z45\%_\/NO^J8_^7'_ /<M?6_[
M,?QO_P"&CO@=H?C/^R_[&_MGS_\ 0_M/VCR?*N)(?O[4W9\O=]T8SCG&3ZF4
M\597F=9T,%5YI)7:Y9+2Z5]4ENT>7FW"N:9915?'4N6+=D^:+U:;MHV]DSO:
M***^@/G@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M%'QS_P"X!_ZD&F5X!_P94_\ *++Q]_V574?_ $T:/0!^OU%%% !17PG\7O\
M@X0^#'P7^+'BCP=JGAGXGW&I^$]7N]&O);73K%H))K>9X7:,M>*Q0LA()521
MC(!XKG?^(EOX$_\ 0I_%K_P5Z?\ _)M>I')<=)<RINQS/&44[.2/T.HKSO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBOF__@J!_P %0/ /
M_!)KX!:/\1OB-H_C#6M$UKQ!#X;@@\-VMM<W27$MM<W"NRSSPH(PEK("0Y.2
MORD$D 'TA17'_L]?&O2_VE/@%X'^(VA6^H6FB>/O#]AXDT^"_C2.ZAM[RVCN
M(DE5&=%D"2*&"NP!!PQ')\__ ."AW_!0+P#_ ,$R_P!F#5?BM\1GU"71--N[
M6P@T_3#;-J>K7$\JHL-K%/-"DTBIYDS('!$,$SX(0T >X45X_P#L%?MK>%?^
M"B7[)WA3XQ>"=/\ $&E^&?&'VS[':ZW!#!?Q?9KR>SD\Q(998QF2W<C;(V5*
MDX.0-#]M#]KWP;^P7^S!XP^+GQ FU"'PIX+M$N+M;"U-S=7+R2I!!!$@(!DE
MGEBB4NRQJ9 7=$#.H!ZA17C_ .P5^VMX5_X*)?LG>%/C%X)T_P 0:7X9\8?;
M/L=KK<$,%_%]FO)[.3S$AEEC&9+=R-LC94J3@Y ]@H **** "BBOA#_@X6_X
M*@>/O^"37[%_ACXC?#G1_!^M:WK7C6U\-SP>)+6YN;5+>6QO[AG58)X7$@>U
MC )<C!;Y22" #[OHKR_]B+XUZK^TI^Q?\(?B-KMOI]IK?C[P5HWB34(+"-X[
M6&XO+&&XE2)79W6,/(P4,[$ #+$\GU"@ HKY?_X+,?MK>*O^"=O_  39^)'Q
MB\$Z?X?U3Q-X/_LS[':ZW!-/82_:=4L[.3S$AEBD.([AR-LBX8*3D9!]0_8B
M^->J_M*?L7_"'XC:[;Z?::WX^\%:-XDU""PC>.UAN+RQAN)4B5V=UC#R,%#.
MQ  RQ/) /4**** "BBOG_P#X*G?M9>*OV%_^"??Q0^+/@GPA_P )QXF\%:4+
MRSTIDF>$;IHXI+J=809&M[6.1[F4*4S%;R R1#,B 'T!17S_ /\ !+']K+Q5
M^W1_P3[^%_Q9\;>$/^$'\3>-=*-Y>:4J3)"=LTD4=U LP$BV]U'&ES$&+XBN
M(P))1B1_H"@ HKR_]MWXUZK^S7^Q?\7OB-H5OI]WK?@'P5K/B33X+^-Y+6:X
ML[&:XB2549':,O&H8*ZD@G# \CR__@C/^VMXJ_X*)?\ !-GX;_&+QMI_A_2_
M$WC#^T_MEKHD$T%A%]FU2\LX_+2:6609CMT)W2-EBQ&!@  ^H**** "BBB@
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M$B?.X++<-5I5ZV)DWR-^\G>_GYWZ/S/0K8BI&4(4U:ZV?]=#] _^(F?X3_\
M"=_9_P#A ?B)_P (S]@\S[?ML_M_VSS,>3]E\[R_)\OYO-\_=N^7RL?/7Z!?
M";XL^&_CK\.-'\7>$=8M->\.:] +FQOK8G9,N2""" R.K!E9& 9&5E8*RD#\
ME_\ @X0_8"\#_ ?PAX-^)7P_\+>'?"-OJ>KR:-KMMIWF6Z74SVRO:-%:J/L\
M2(EI<[S&(RS2J2')9E[C_@D9\>-5^$?_  1+^-'B;_A)/[,N_!E_KB^'KF_G
M1X=-N#IEI);11)-F/Y[R;*Q8(>6<C:S.07B\LPM7!PQ6#33;2LW?=V\^OX=!
M4<15C6=*MK97/K3]M#_@KK\&_P!AOQ4/#OB;4=6USQ7'Y+W.B:!:K=75C%*C
MNDDS2/'#'PJGRS)YN)8FV%&#5X)\-/\ @Y6^$/B779K/Q-X1\<>&+>75S:V=
M]''!?P+8EE"7=R%=9(G +,\,*3[0ORO*3BOSQ_X)5?LG0_\ !0_]N:/3?&]]
M>:MH]K!=>*?$[SW\JWVL*LB*4\[#.SRW-Q%YC%D8QF8K(K[37Z'?\%8_^"1_
MPIL?V*O$'BKX<^ ;3P_XN^'>DV\]J^E7/V5+K3[5LW/VI9&V3NMLTTIF;-S(
MT,8\Q_N-TU,MRS#588.OS2G*UVG9*_\ 7GH9QQ&)J1=6%DET/O?X3?%GPW\=
M?AQH_B[PCK%IKWAS7H!<V-];$[)ER0000&1U8,K(P#(RLK!64@?@+_SG6_[K
MQ_[L%?0__!LQ\:]>L_CMX^^'/VCS?#.I:"?$GD2/(WV6\@N+>WWQ+N\M?,CN
M<2'86;R(/F 3!^2_C[\+O^%X_P#!6'QKX)^W?V7_ ,)A\6K[1/MGD^?]D^TZ
MQ)#YOE[EW[=^[;N7.,9'6NO*\O6$Q6(H.6G+OY/_ ",L5B/:TZ<TM;GZH_'/
M_@XC^"7PF\=ZIX?T?3?%OC:32;^*TDU/2H[8:5=)YB"XDMYFF#R^6AEV$1B.
M5XP%D$;B8>^?L4?\%*?A3^WM9W4?@?5KR#7M/@^U7V@:K;_9=2M(?-:,2;06
MCE0D*2T,D@3S8@^QG"UY+\0/^""/P \2_L^MX.T70[SP_KUM YL?%?VN6YU)
M;MDA4SSJ76.=&,"EH=J1KYDWDB!I"]?E'_P1O^-?_"CO^"CGPUO)KC5H]/\
M$%^WAN[@L'Q]K^W(UO DJEE#PK=/;RL#G'DA@K,JBO.I9;E^+PM2>$YE."OK
MUT^[6S[-/R.B6(KTJL55M:78]P_X.6_^3Z_"?_8AV?\ Z<-1K]._@%XLT'P%
M_P $GO!6N^*=,_MKPSHOPEL;_5]/^SQW/V^SBT>-YX?*D(CDWQJR['(5LX)
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MJJ,J%T;TJF5Y=1JT:=12;J):)Z7=M6_72R\WV.>.*Q$X3E&WNGT1X-_X+*?
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M /@H5_P4Z^#?_!+_ .%EKXI^+GBC^R?[6^T1Z)I%G;M=ZKX@GAA,K0VT"_\
M $,LIC@C>:$22Q^8I/B'_!#C_@N/X-_X*]?!IK6Z33_"OQH\*VBOXH\+I(1'
M.F53^TK#>2\EF[LH926DMY'6.0L&AFG^(/V&?AM<?\%2?^#IWX_?%KQCHFH7
M?@W]F"[DT'1+2\U.#4;+3M4LY6TRP AG3>L<CVVJZFBP(HM[I48RE\&8 ^@-
M9_X.T?@OX<^#6D_$;4/@3^UA8_#W7KMK#3/$]QX*L8M&U&X4RAH8;MM0$,D@
M,$X**Y(,,G'R-C[^_9#_ &T/A?\ MZ?!J'X@?"/QAI_C3PI-=S6#7=O'+!);
M7$1 >&:"9$FAD *.$E12T<D;@%)$9O0/%GA/2_'OA74M"UW3-/UK1-:M);#4
M-/O[=+FUO[>5"DL,L3@I)&Z,RLC A@2""#7X8_\ !*?_ (17_@E-_P '/WQP
M_9;\#?\ "06_PR^).E0?V1IDGDWOV/48=*AUN#S;F3$XMX+>?58(\-([>;!Y
MOFLIF4 Y_P#X+Z?\K37[%?\ W(W_ *EU]7ZW?\%0/^"H'@'_ ()-? +1_B-\
M1M'\8:UHFM>((?#<$'ANUMKFZ2XEMKFX5V6>>%!&$M9 2')R5^4@DC\D?^"^
MG_*TU^Q7_P!R-_ZEU]7T!_P>K?\ *++P#_V573O_ $T:Q0!^IW[/7QKTO]I3
MX!>!_B-H5OJ%IHGC[P_8>)-/@OXTCNH;>\MH[B))51G19 DBA@KL 0<,1R?C
M#]I?_@X[^!_[/_[9-W\!_#_A3XP?&SXC:=OAO+#X:>'X-<^SWD:R27%B US%
M)+<01Q,\RQ(ZQ896821RI'Q_QJ_:@U7]CK_@U)\-^/-"74%UNU^!7A?1]/N;
M#47TZZTVXU*PT_38KV*=%+I);/=K.NW!8PA0R$[UT/\ @UH_86L_V/\ _@E1
MX3\27FB_V?XV^,W_ !6&LW$IM9II;.4L-+C26%=WV?[#Y5PL,CNT<M[<YV%V
MC4 ^0/\ @L5_P7]^!_\ P4,_X);?M)_"'2=/^('PV^)N@?V,H\-^/M+@TF_U
M&6#Q%8"[MX$CN)O](MO+)E@DV2A=[*C+%,8_U>_X)._\HLOV:?\ LE7A?_TT
M6M?(/_!W#^S1X5^,'_!(7Q)XZU:TQXF^$>JZ;JN@WT44/G)]LOK;3KFV>1D:
M06\D=R)&CC9-TMK;,Q(CVGZ^_P""3O\ RBR_9I_[)5X7_P#31:T ?0%%%% '
MX _\$"_^5IK]M3_N>?\ U+K&OW^K\ ?^"!?_ "M-?MJ?]SS_ .I=8U^_U 'S
M?_P2_P#^"H'@'_@K+\ M8^(WPYT?QAHNB:+X@F\-SP>)+6VMKI[B*VMKAG58
M)YD,92ZC )<'(;Y0 ">P_;U_;6\*_P#!.W]D[Q7\8O&VG^(-4\,^#_L?VRUT
M2"&>_E^TWD%G'Y:32Q1G$EPA.Z1<*&(R< _G#_P94_\ *++Q]_V574?_ $T:
M/7O_ /P='?\ *"CXY_\ < _]2#3* /L_]GKXUZ7^TI\ O _Q&T*WU"TT3Q]X
M?L/$FGP7\:1W4-O>6T=Q$DJHSHL@210P5V (.&(Y/YX_"_\ X.Y?V1_B%\+/
M&GBG4;CX@>#?^$1^SQVND:WI-LVJ^)IYX;N5(;""UN9]V/LA1Y9S#!&]Q;AY
M5\T&OK[_ ()._P#*++]FG_LE7A?_ --%K7XH_P#!D;\ ?!OCGXR_'/XA:QX>
MT_4O&7@"TT2R\.:G<*9)-&2_&IK>&%2=BR2);1(9 /,$9D16"2RJX!]_^$_^
M#J;]GE_VG]-^$_Q \&?'#X(>(KZ[BL[NX^(OANUT6UT-YHA+ ;X"[DFMXY \
M6)'B\M1,DCLD6Z1?0/C]_P '!_PC^$7[7'B'X)^#_ /QP^/7COP?:&XU^W^%
M?A>/Q#'HSI((IH)C]HC?S(7>)92BM''),L3.)5DC3R#_ (.^_P!E_2_C/_P2
M6OO'DS:?::W\'?$&GZQ:7+Z<D]U<V]Y<)IL]E'.6#P1N]W;SOC<'-C$I7.UT
M^GO^"('P4TOX.?\ !+GX/WEG<:AJFM_$CP_:_$'Q/K6IND^IZ_K.L0I?W=U=
M3A5>XDWS")9)=TGDP0JSN4W$ H?\$MO^"WWP/_X*X?\ "26?PWNO$&B>)O"^
M)KOPWXGMX+/59;,[ +Z%(9IHY;<2.(V97+1OL$BH)83)]'_'[X_>#?V6O@UX
MA^(7Q"\0Z?X5\&^%;0WFIZG>,1';ID*H"J"\DCNRHD:!I))'1$5G95/XX_%C
M]FCPK^SO_P 'H_P5U'PM:?V?_P +0\*ZEXRU>UCBABMH]1ETC7K.>2)(T7'G
M?8EGD9R[O//.Y8[P%/\ @Y(T+7O^"A'_  5P_9'_ &.[.W\01^&=8QXM\0OI
MNMQVWVRSN+F:*YG6&9?)%Q8V&F:C+%(_FLWVR1$CR2LH!] :)_P=<? _X@?\
M)U>>!?@_^U!\2/#/PZ\V;6_$GACP/!=Z596:^<5OIG:\22VMY(X)9%:Y2%MD
M;EE4JP7Z._X)G_\ !:7X"_\ !5S3KZ'X8>(-0M?%>CVGV_4_">O6GV'6=/M_
M/>%9BJL\,T9(0E[>641BX@$AC>14KZ@\)^$]+\!>%=-T+0M,T_1=$T6TBL-/
MT^PMTMK6PMXD"10Q1( D<:(JJJ* %    %?A#_P<!>$_ /\ P1Y_X+ _LO?M
M6>!-,U#PSJGC;Q!J=_\ $"UT>WMIH]5M[=K&&_FM[:8"-+R[L]1NXY'WH'DV
M2@QS&29P#]+_ /@JW_P6K^%G_!'S_A O^%F:!\0-<_X6)_:']F_\(Q8VEUY'
MV+[+YOG?:+F#;G[7'MV[L[7SMP,^?^/_ /@Y._9Q\'?M]:+^SGIR_$#Q9XVU
M7Q7!X)NK[2M$2/2M&UB346TY[:XDNIH)6\J8!GD@BEC*,"CR'*CX _X/G/\
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MT3Q]X?L/$FGP7\:1W4-O>6T=Q$DJHSHL@210P5V (.&(Y/Y8_P#!ZM_RBR\
M_P#95=._]-&L5]G?L1?&O2_V:_\ @AK\(?B-KMOJ%WHG@'X%:-XDU""PC22Z
MFM[/P_#<2I$KLB-(4C8*&=021E@.0 ?6%%?D#_Q&K?LL_P#0@_M ?^"/2/\
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MT%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !7ZW?\$QO^3'O!'_;_ /\ I?<U^2-?K=_P3&_Y
M,>\$?]O_ /Z7W-?IWA1_R-ZG_7M_^E0/R_Q8_P"113_Z^+_TF9[U1117]!'\
M]A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M&XO+F.WB>5DU%W6,/(I8JC$ '"D\']3J "BBB@ HHHH **** "BBB@ HHHH
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M[:?-9^ ?#]IH\EW9Z<FG1ZG<1Q@7%Z8%9@DEQ/YL[Y9B9)G+,[$L?C#XB_\
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MM3M!CR?0/^#U;_E%EX!_[*KIW_IHUB@#[^_X)._\HLOV:?\ LE7A?_TT6M>
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0+J+Z<%;4K*:V$Q@>)9'2-T)GD5T9E/S*X;Y"DG<?\%I/^"KF@_MU?\ "/\
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M\M;75-TVGZK%%'YQ2W^VVKQ7)MPUQ,_D&0Q%WWE-P##P#_B%Q_83_P"B&_\
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M^%U^!?\ A-/^$+^U_P!C?\3K4--^Q_:O(\__ (])XM^[[/#]_=C9QC+9^@*
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M)9VT*0P1>9(S2/MC15W.S,<9))R: .@HHHH _('_ (,J?^467C[_ +*KJ/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K];O^"8W_)CW
M@C_M_P#_ $ON:_)&OUN_X)C?\F/>"/\ M_\ _2^YK].\*/\ D;U/^O;_ /2H
M'Y?XL?\ (HI_]?%_Z3,]ZHHHK^@C^>PHHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MH?\ !SW^P=XR_;X_X)<ZAI?P_LM0UOQ7\/?$%IXSM-"L+07%UKZ00W-K/;Q
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M+P#_ -E5T[_TT:Q7Z/?L5?L%?"?_ ()V_"S4/!/P=\*?\(?X9U359-;NK/\
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M_P#:G\:_&OP+X%_L/XF_$3[=_P )#K/]M:A=?VA]MNX[VY_<33O!'ON(D?\
M=QKMV[5VJ2I] _:C_9<\"?MI? G7/AG\3-#_ .$D\$^)?L_]I:;]MN+/[3Y%
MQ%<Q?O;>2.5=LT,;?*XSMP<@D$ ^ ?\ @A%\#/\ AJ#_ (-@?"_PS_M3^P_^
M%B>%?&?AC^TOLWVK^S_MNJZQ;>?Y6]/,V>;NV;UW;<;ESD?/_P#P:H?MW^%?
MV8? GQ _9#^,GC#_ (0_XN^"_B!?6VCZ-X@U:'[!)YDEO92Z5IT_FM"]PNI)
M<.;:(CS6O#)#YV9V3]?OV7/V7/ G[%OP)T/X9_#/0_\ A&_!/AK[1_9NF_;;
MB\^S>?<2W,O[VXDDE;=--(WS.<;L#   \?\ VQ?^",'[+_[?/CN'Q3\5/A!X
M?\0>)H]WFZO:7-UH]_?YCAB'VJ>READNMD<$21^>7\M5(3:&8$ ^</\ @XS_
M ."J?@W]GK]B_P")GP5\(ZEI_C7XW_$+P_J&A/X5TN(ZI=>']+DL?/U/4-0B
MAD5[..+2Y)IHWDY)*2>7)!'.R=A_P:X_\H*/@9_W'_\ U(-3KT_]GG_@AU^R
MO^RIX5^(6C^ _A+I^B6?Q2\/S^%?$LCZQJ-Y=7VESHZ36D=Q/<236\<@?+B!
MXRY2)B2T497W#]ES]ESP)^Q;\"=#^&?PST/_ (1OP3X:^T?V;IOVVXO/LWGW
M$MS+^]N)))6W332-\SG&[ P   #\0?\ @@-\?/"O_!#S_@H)^TI^R;\>OB)_
MPB\,FJVEYX5U76[V&Q\-S^1#/*;J1C</#8W%_83Z?, [<BW6"203)#&_[/?'
M3_@H'\#_ -FCX6:7XV\=?%GX?^&_#/B#2I=;T2\N=;@/_"16<4*3-+IT:L9+
M[]W+$RK;+(S^=$%#%U!Y_P#;5_X)9?L^_P#!1+^SY/C%\+_#_C#4-+\M;75-
MTVGZK%%'YQ2W^VVKQ7)MPUQ,_D&0Q%WWE-P##Q#PG_P;+_L.>"_%6FZQ9_ C
M3YKS2;N*]@CO_$FM7]J[QN'42V\]X\,T9( :.5&C<95E9200#[/^$_Q2T'XX
M_"SPSXV\+7W]J>&?&&E6NMZ1>>3)!]KL[F%)H)?+D59$W1NK;756&<$ Y%=!
M6?X3\)Z7X"\*Z;H6A:9I^BZ)HMI%8:?I]A;I;6MA;Q($BABB0!(XT15544 *
M    *T* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M'8WP._Z$C_RL7_\ \?H_X=C? [_H2/\ RL7_ /\ 'Z\__B%&;_\ /RG]\O\
MY ]#_B+&4?\ /NI]T?\ Y,_)&BOUN_X=C? [_H2/_*Q?_P#Q^C_AV-\#O^A(
M_P#*Q?\ _P ?H_XA1F__ #\I_?+_ .0#_B+&4?\ /NI]T?\ Y,_)&BOUN_X=
MC? [_H2/_*Q?_P#Q^C_AV-\#O^A(_P#*Q?\ _P ?H_XA1F__ #\I_?+_ .0#
M_B+&4?\ /NI]T?\ Y,_)&BOUN_X=C? [_H2/_*Q?_P#Q^C_AV-\#O^A(_P#*
MQ?\ _P ?H_XA1F__ #\I_?+_ .0#_B+&4?\ /NI]T?\ Y,_)&BOUN_X=C? [
M_H2/_*Q?_P#Q^C_AV-\#O^A(_P#*Q?\ _P ?H_XA1F__ #\I_?+_ .0#_B+&
M4?\ /NI]T?\ Y,_)&BOUN_X=C? [_H2/_*Q?_P#Q^C_AV-\#O^A(_P#*Q?\
M_P ?H_XA1F__ #\I_?+_ .0#_B+&4?\ /NI]T?\ Y,_)&BOUN_X=C? [_H2/
M_*Q?_P#Q^C_AV-\#O^A(_P#*Q?\ _P ?H_XA1F__ #\I_?+_ .0#_B+&4?\
M/NI]T?\ Y,_)&BOUN_X=C? [_H2/_*Q?_P#Q^C_AV-\#O^A(_P#*Q?\ _P ?
MH_XA1F__ #\I_?+_ .0#_B+&4?\ /NI]T?\ Y,_)&BOUN_X=C? [_H2/_*Q?
M_P#Q^C_AV-\#O^A(_P#*Q?\ _P ?H_XA1F__ #\I_?+_ .0#_B+&4?\ /NI]
MT?\ Y,_)&BOUN_X=C? [_H2/_*Q?_P#Q^C_AV-\#O^A(_P#*Q?\ _P ?H_XA
M1F__ #\I_?+_ .0#_B+&4?\ /NI]T?\ Y,_)&BOUN_X=C? [_H2/_*Q?_P#Q
M^C_AV-\#O^A(_P#*Q?\ _P ?H_XA1F__ #\I_?+_ .0#_B+&4?\ /NI]T?\
MY,_)&BOUN_X=C? [_H2/_*Q?_P#Q^C_AV-\#O^A(_P#*Q?\ _P ?H_XA1F__
M #\I_?+_ .0#_B+&4?\ /NI]T?\ Y,_)&BOUN_X=C? [_H2/_*Q?_P#Q^C_A
MV-\#O^A(_P#*Q?\ _P ?H_XA1F__ #\I_?+_ .0#_B+&4?\ /NI]T?\ Y,_)
M&BOUN_X=C? [_H2/_*Q?_P#Q^C_AV-\#O^A(_P#*Q?\ _P ?H_XA1F__ #\I
M_?+_ .0#_B+&4?\ /NI]T?\ Y,_)&BOUN_X=C? [_H2/_*Q?_P#Q^C_AV-\#
MO^A(_P#*Q?\ _P ?H_XA1F__ #\I_?+_ .0#_B+&4?\ /NI]T?\ Y,_)&BOU
MN_X=C? [_H2/_*Q?_P#Q^C_AV-\#O^A(_P#*Q?\ _P ?H_XA1F__ #\I_?+_
M .0#_B+&4?\ /NI]T?\ Y,_)&BOUN_X=C? [_H2/_*Q?_P#Q^C_AV-\#O^A(
M_P#*Q?\ _P ?H_XA1F__ #\I_?+_ .0#_B+&4?\ /NI]T?\ Y,_)&BOUN_X=
MC? [_H2/_*Q?_P#Q^C_AV-\#O^A(_P#*Q?\ _P ?H_XA1F__ #\I_?+_ .0#
M_B+&4?\ /NI]T?\ Y,_)&BOUN_X=C? [_H2/_*Q?_P#Q^C_AV-\#O^A(_P#*
MQ?\ _P ?H_XA1F__ #\I_?+_ .0#_B+&4?\ /NI]T?\ Y,_)&BOUN_X=C? [
M_H2/_*Q?_P#Q^C_AV-\#O^A(_P#*Q?\ _P ?H_XA1F__ #\I_?+_ .0#_B+&
M4?\ /NI]T?\ Y,_)&BOUN_X=C? [_H2/_*Q?_P#Q^C_AV-\#O^A(_P#*Q?\
M_P ?H_XA1F__ #\I_?+_ .0#_B+&4?\ /NI]T?\ Y,_)&BOUN_X=C? [_H2/
M_*Q?_P#Q^C_AV-\#O^A(_P#*Q?\ _P ?H_XA1F__ #\I_?+_ .0#_B+&4?\
M/NI]T?\ Y,_)&BOUN_X=C? [_H2/_*Q?_P#Q^C_AV-\#O^A(_P#*Q?\ _P ?
MH_XA1F__ #\I_?+_ .0#_B+&4?\ /NI]T?\ Y,_)&BOUN_X=C? [_H2/_*Q?
M_P#Q^C_AV-\#O^A(_P#*Q?\ _P ?H_XA1F__ #\I_?+_ .0#_B+&4?\ /NI]
MT?\ Y,_)&BOUN_X=C? [_H2/_*Q?_P#Q^C_AV-\#O^A(_P#*Q?\ _P ?H_XA
M1F__ #\I_?+_ .0#_B+&4?\ /NI]T?\ Y,_)&BOUN_X=C? [_H2/_*Q?_P#Q
M^C_AV-\#O^A(_P#*Q?\ _P ?H_XA1F__ #\I_?+_ .0#_B+&4?\ /NI]T?\
MY,_)&BOUN_X=C? [_H2/_*Q?_P#Q^C_AV-\#O^A(_P#*Q?\ _P ?H_XA1F__
M #\I_?+_ .0#_B+&4?\ /NI]T?\ Y,_)&BOUN_X=C? [_H2/_*Q?_P#Q^C_A
MV-\#O^A(_P#*Q?\ _P ?H_XA1F__ #\I_?+_ .0#_B+&4?\ /NI]T?\ Y,_)
M&BOUN_X=C? [_H2/_*Q?_P#Q^C_AV-\#O^A(_P#*Q?\ _P ?H_XA1F__ #\I
M_?+_ .0#_B+&4?\ /NI]T?\ Y,_)&BOUN_X=C? [_H2/_*Q?_P#Q^C_AV-\#
MO^A(_P#*Q?\ _P ?H_XA1F__ #\I_?+_ .0#_B+&4?\ /NI]T?\ Y,_)&BOU
MN_X=C? [_H2/_*Q?_P#Q^C_AV-\#O^A(_P#*Q?\ _P ?H_XA1F__ #\I_?+_
M .0#_B+&4?\ /NI]T?\ Y,_)&BOUN_X=C? [_H2/_*Q?_P#Q^C_AV-\#O^A(
M_P#*Q?\ _P ?H_XA1F__ #\I_?+_ .0#_B+&4?\ /NI]T?\ Y,_)&BOUN_X=
MC? [_H2/_*Q?_P#Q^C_AV-\#O^A(_P#*Q?\ _P ?H_XA1F__ #\I_?+_ .0#
M_B+&4?\ /NI]T?\ Y,_)&BOUN_X=C? [_H2/_*Q?_P#Q^C_AV-\#O^A(_P#*
MQ?\ _P ?H_XA1F__ #\I_?+_ .0#_B+&4?\ /NI]T?\ Y,_)&BOUN_X=C? [
M_H2/_*Q?_P#Q^C_AV-\#O^A(_P#*Q?\ _P ?H_XA1F__ #\I_?+_ .0#_B+&
M4?\ /NI]T?\ Y,_)&BOUN_X=C? [_H2/_*Q?_P#Q^C_AV-\#O^A(_P#*Q?\
M_P ?H_XA1F__ #\I_?+_ .0#_B+&4?\ /NI]T?\ Y,_)&BOUN_X=C? [_H2/
M_*Q?_P#Q^C_AV-\#O^A(_P#*Q?\ _P ?H_XA1F__ #\I_?+_ .0#_B+&4?\
M/NI]T?\ Y,_)&BOUN_X=C? [_H2/_*Q?_P#Q^C_AV-\#O^A(_P#*Q?\ _P ?
MH_XA1F__ #\I_?+_ .0#_B+&4?\ /NI]T?\ Y,_)&BOUN_X=C? [_H2/_*Q?
M_P#Q^C_AV-\#O^A(_P#*Q?\ _P ?H_XA1F__ #\I_?+_ .0#_B+&4?\ /NI]
MT?\ Y,_)&BOUN_X=C? [_H2/_*Q?_P#Q^C_AV-\#O^A(_P#*Q?\ _P ?H_XA
M1F__ #\I_?+_ .0#_B+&4?\ /NI]T?\ Y,_)&BOUN_X=C? [_H2/_*Q?_P#Q
M^C_AV-\#O^A(_P#*Q?\ _P ?H_XA1F__ #\I_?+_ .0#_B+&4?\ /NI]T?\
MY,_)&BOUN_X=C? [_H2/_*Q?_P#Q^C_AV-\#O^A(_P#*Q?\ _P ?H_XA1F__
M #\I_?+_ .0#_B+&4?\ /NI]T?\ Y,_)&BOUN_X=C? [_H2/_*Q?_P#Q^C_A
MV-\#O^A(_P#*Q?\ _P ?H_XA1F__ #\I_?+_ .0#_B+&4?\ /NI]T?\ Y,_)
M&BOUN_X=C? [_H2/_*Q?_P#Q^C_AV-\#O^A(_P#*Q?\ _P ?H_XA1F__ #\I
M_?+_ .0#_B+&4?\ /NI]T?\ Y,_)&BOUN_X=C? [_H2/_*Q?_P#Q^C_AV-\#
MO^A(_P#*Q?\ _P ?H_XA1F__ #\I_?+_ .0#_B+&4?\ /NI]T?\ Y,_)&BOU
MN_X=C? [_H2/_*Q?_P#Q^C_AV-\#O^A(_P#*Q?\ _P ?H_XA1F__ #\I_?+_
M .0#_B+&4?\ /NI]T?\ Y,_)&BOUN_X=C? [_H2/_*Q?_P#Q^C_AV-\#O^A(
M_P#*Q?\ _P ?H_XA1F__ #\I_?+_ .0#_B+&4?\ /NI]T?\ Y,_)&BOUN_X=
MC? [_H2/_*Q?_P#Q^C_AV-\#O^A(_P#*Q?\ _P ?H_XA1F__ #\I_?+_ .0#
M_B+&4?\ /NI]T?\ Y,_)&BOUN_X=C? [_H2/_*Q?_P#Q^C_AV-\#O^A(_P#*
MQ?\ _P ?H_XA1F__ #\I_?+_ .0#_B+&4?\ /NI]T?\ Y,_)&BOUN_X=C? [
M_H2/_*Q?_P#Q^C_AV-\#O^A(_P#*Q?\ _P ?H_XA1F__ #\I_?+_ .0#_B+&
M4?\ /NI]T?\ Y,_)&OUN_P""8W_)CW@C_M__ /2^YH_X=C? [_H2/_*Q?_\
MQ^O7/AC\,=#^#?@>Q\-^&['^S=%TWS/L]OYTDWE[Y&D;YI&9CEW8\DXSCI@5
M]CP3P3CLGQT\3B9P<7!Q]UR;NY1?6*TT?4^.XXXXP.<X&&%PL)J2FI>\HI64
M9+I)ZZKH;U%%%?J)^6!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M;Y?E_;G\W[/YWVC;M^3?YN.=U 'ZF45R?_"_/ O_ $.GA/\ \&]O_P#%T?\
M"_/ O_0Z>$__  ;V_P#\70!UE%<G_P +\\"_]#IX3_\ !O;_ /Q='_"_/ O_
M $.GA/\ \&]O_P#%T =917)_\+\\"_\ 0Z>$_P#P;V__ ,71_P +\\"_]#IX
M3_\ !O;_ /Q= '645R?_  OSP+_T.GA/_P &]O\ _%T?\+\\"_\ 0Z>$_P#P
M;V__ ,70!UE%<G_POSP+_P!#IX3_ /!O;_\ Q='_  OSP+_T.GA/_P &]O\
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M]O\ _%T =917)_\ "_/ O_0Z>$__  ;V_P#\71_POSP+_P!#IX3_ /!O;_\
MQ= '645R?_"_/ O_ $.GA/\ \&]O_P#%T?\ "_/ O_0Z>$__  ;V_P#\70!U
ME%<G_P +\\"_]#IX3_\ !O;_ /Q='_"_/ O_ $.GA/\ \&]O_P#%T =917)_
M\+\\"_\ 0Z>$_P#P;V__ ,71_P +\\"_]#IX3_\ !O;_ /Q= '645R?_  OS
MP+_T.GA/_P &]O\ _%T?\+\\"_\ 0Z>$_P#P;V__ ,70!UE%<G_POSP+_P!#
MIX3_ /!O;_\ Q='_  OSP+_T.GA/_P &]O\ _%T =917)_\ "_/ O_0Z>$__
M  ;V_P#\71_POSP+_P!#IX3_ /!O;_\ Q= '645R?_"_/ O_ $.GA/\ \&]O
M_P#%T?\ "_/ O_0Z>$__  ;V_P#\70!UE%<G_P +\\"_]#IX3_\ !O;_ /Q=
M'_"_/ O_ $.GA/\ \&]O_P#%T =917)_\+\\"_\ 0Z>$_P#P;V__ ,71_P +
M\\"_]#IX3_\ !O;_ /Q= '645R?_  OSP+_T.GA/_P &]O\ _%T?\+\\"_\
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M>$__  ;V_P#\71_POSP+_P!#IX3_ /!O;_\ Q= '645R?_"_/ O_ $.GA/\
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MOSP+_P!#IX3_ /!O;_\ Q='_  OSP+_T.GA/_P &]O\ _%T =917)_\ "_/
MO_0Z>$__  ;V_P#\71_POSP+_P!#IX3_ /!O;_\ Q= '645R?_"_/ O_ $.G
MA/\ \&]O_P#%T?\ "_/ O_0Z>$__  ;V_P#\70!UE%<G_P +\\"_]#IX3_\
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M<G_POSP+_P!#IX3_ /!O;_\ Q='_  OSP+_T.GA/_P &]O\ _%T =917)_\
M"_/ O_0Z>$__  ;V_P#\71_POSP+_P!#IX3_ /!O;_\ Q= '645R?_"_/ O_
M $.GA/\ \&]O_P#%T?\ "_/ O_0Z>$__  ;V_P#\70!UE%<G_P +\\"_]#IX
M3_\ !O;_ /Q='_"_/ O_ $.GA/\ \&]O_P#%T =917)_\+\\"_\ 0Z>$_P#P
M;V__ ,71_P +\\"_]#IX3_\ !O;_ /Q= '645R?_  OSP+_T.GA/_P &]O\
M_%T?\+\\"_\ 0Z>$_P#P;V__ ,70!UE%<G_POSP+_P!#IX3_ /!O;_\ Q='_
M  OSP+_T.GA/_P &]O\ _%T =917)_\ "_/ O_0Z>$__  ;V_P#\71_POSP+
M_P!#IX3_ /!O;_\ Q= '645R?_"_/ O_ $.GA/\ \&]O_P#%T?\ "_/ O_0Z
M>$__  ;V_P#\70!UE%<G_P +\\"_]#IX3_\ !O;_ /Q='_"_/ O_ $.GA/\
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M]O\ _%T?\+\\"_\ 0Z>$_P#P;V__ ,70!UE%<G_POSP+_P!#IX3_ /!O;_\
MQ='_  OSP+_T.GA/_P &]O\ _%T =917)_\ "_/ O_0Z>$__  ;V_P#\71_P
MOSP+_P!#IX3_ /!O;_\ Q= '645R?_"_/ O_ $.GA/\ \&]O_P#%T?\ "_/
MO_0Z>$__  ;V_P#\70!UE%<G_P +\\"_]#IX3_\ !O;_ /Q='_"_/ O_ $.G
MA/\ \&]O_P#%T =917)_\+\\"_\ 0Z>$_P#P;V__ ,71_P +\\"_]#IX3_\
M!O;_ /Q= '645R?_  OSP+_T.GA/_P &]O\ _%T?\+\\"_\ 0Z>$_P#P;V__
M ,70!UE%<G_POSP+_P!#IX3_ /!O;_\ Q='_  OSP+_T.GA/_P &]O\ _%T
M=917)_\ "_/ O_0Z>$__  ;V_P#\71_POSP+_P!#IX3_ /!O;_\ Q= '645R
M?_"_/ O_ $.GA/\ \&]O_P#%T?\ "_/ O_0Z>$__  ;V_P#\70!UE%<G_P +
M\\"_]#IX3_\ !O;_ /Q='_"_/ O_ $.GA/\ \&]O_P#%T =917)_\+\\"_\
M0Z>$_P#P;V__ ,71_P +\\"_]#IX3_\ !O;_ /Q= '645R?_  OSP+_T.GA/
M_P &]O\ _%T?\+\\"_\ 0Z>$_P#P;V__ ,70!UE%<G_POSP+_P!#IX3_ /!O
M;_\ Q='_  OSP+_T.GA/_P &]O\ _%T =917)_\ "_/ O_0Z>$__  ;V_P#\
M71_POSP+_P!#IX3_ /!O;_\ Q= '645R?_"_/ O_ $.GA/\ \&]O_P#%T?\
M"_/ O_0Z>$__  ;V_P#\70!UE%<G_P +\\"_]#IX3_\ !O;_ /Q='_"_/ O_
M $.GA/\ \&]O_P#%T =917)_\+\\"_\ 0Z>$_P#P;V__ ,71_P +\\"_]#IX
M3_\ !O;_ /Q= '645R?_  OSP+_T.GA/_P &]O\ _%T?\+\\"_\ 0Z>$_P#P
M;V__ ,70!UE%<G_POSP+_P!#IX3_ /!O;_\ Q='_  OSP+_T.GA/_P &]O\
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M]O\ _%T =917)_\ "_/ O_0Z>$__  ;V_P#\71_POSP+_P!#IX3_ /!O;_\
MQ= '645R?_"_/ O_ $.GA/\ \&]O_P#%T?\ "_/ O_0Z>$__  ;V_P#\70!U
ME%<G_P +\\"_]#IX3_\ !O;_ /Q='_"_/ O_ $.GA/\ \&]O_P#%T =917)_
M\+\\"_\ 0Z>$_P#P;V__ ,71_P +\\"_]#IX3_\ !O;_ /Q= '645R?_  OS
MP+_T.GA/_P &]O\ _%T?\+\\"_\ 0Z>$_P#P;V__ ,70!UE%<G_POSP+_P!#
MIX3_ /!O;_\ Q='_  OSP+_T.GA/_P &]O\ _%T =917)_\ "_/ O_0Z>$__
M  ;V_P#\71_POSP+_P!#IX3_ /!O;_\ Q= '645R?_"_/ O_ $.GA/\ \&]O
M_P#%T?\ "_/ O_0Z>$__  ;V_P#\70!UE%<G_P +\\"_]#IX3_\ !O;_ /Q=
M'_"_/ O_ $.GA/\ \&]O_P#%T =917)_\+\\"_\ 0Z>$_P#P;V__ ,71_P +
M\\"_]#IX3_\ !O;_ /Q= '645R?_  OSP+_T.GA/_P &]O\ _%T?\+\\"_\
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M>$__  ;V_P#\71_POSP+_P!#IX3_ /!O;_\ Q= '645R?_"_/ O_ $.GA/\
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MOSP+_P!#IX3_ /!O;_\ Q='_  OSP+_T.GA/_P &]O\ _%T =917)_\ "_/
MO_0Z>$__  ;V_P#\71_POSP+_P!#IX3_ /!O;_\ Q= '645R?_"_/ O_ $.G
MA/\ \&]O_P#%T?\ "_/ O_0Z>$__  ;V_P#\70!UE%<G_P +\\"_]#IX3_\
M!O;_ /Q='_"_/ O_ $.GA/\ \&]O_P#%T =917)_\+\\"_\ 0Z>$_P#P;V__
M ,71_P +\\"_]#IX3_\ !O;_ /Q= '645R?_  OSP+_T.GA/_P &]O\ _%T?
M\+\\"_\ 0Z>$_P#P;V__ ,70!UE%<G_POSP+_P!#IX3_ /!O;_\ Q='_  OS
MP+_T.GA/_P &]O\ _%T =917)_\ "_/ O_0Z>$__  ;V_P#\71_POSP+_P!#
MIX3_ /!O;_\ Q= '645R?_"_/ O_ $.GA/\ \&]O_P#%T?\ "_/ O_0Z>$__
M  ;V_P#\70!UE%<G_P +\\"_]#IX3_\ !O;_ /Q='_"_/ O_ $.GA/\ \&]O
M_P#%T =917)_\+\\"_\ 0Z>$_P#P;V__ ,71_P +\\"_]#IX3_\ !O;_ /Q=
M '645R?_  OSP+_T.GA/_P &]O\ _%T?\+\\"_\ 0Z>$_P#P;V__ ,70!UE%
M<G_POSP+_P!#IX3_ /!O;_\ Q='_  OSP+_T.GA/_P &]O\ _%T =917)_\
M"_/ O_0Z>$__  ;V_P#\71_POSP+_P!#IX3_ /!O;_\ Q= '645R?_"_/ O_
M $.GA/\ \&]O_P#%T?\ "_/ O_0Z>$__  ;V_P#\70!UE%<G_P +\\"_]#IX
M3_\ !O;_ /Q='_"_/ O_ $.GA/\ \&]O_P#%T =917)_\+\\"_\ 0Z>$_P#P
M;V__ ,71_P +\\"_]#IX3_\ !O;_ /Q= '645R?_  OSP+_T.GA/_P &]O\
M_%T?\+\\"_\ 0Z>$_P#P;V__ ,70!UE%<G_POSP+_P!#IX3_ /!O;_\ Q='_
M  OSP+_T.GA/_P &]O\ _%T =917)_\ "_/ O_0Z>$__  ;V_P#\71_POSP+
M_P!#IX3_ /!O;_\ Q= '645R?_"_/ O_ $.GA/\ \&]O_P#%T?\ "_/ O_0Z
M>$__  ;V_P#\70!UE%<G_P +\\"_]#IX3_\ !O;_ /Q='_"_/ O_ $.GA/\
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M]O\ _%T?\+\\"_\ 0Z>$_P#P;V__ ,70!UE%<G_POSP+_P!#IX3_ /!O;_\
MQ='_  OSP+_T.GA/_P &]O\ _%T =917)_\ "_/ O_0Z>$__  ;V_P#\71_P
MOSP+_P!#IX3_ /!O;_\ Q= '645R?_"_/ O_ $.GA/\ \&]O_P#%T?\ "_/
MO_0Z>$__  ;V_P#\70!UE%<G_P +\\"_]#IX3_\ !O;_ /Q='_"_/ O_ $.G
MA/\ \&]O_P#%T =917)_\+\\"_\ 0Z>$_P#P;V__ ,71_P +\\"_]#IX3_\
M!O;_ /Q= '645R?_  OSP+_T.GA/_P &]O\ _%T?\+\\"_\ 0Z>$_P#P;V__
M ,70!UE%<G_POSP+_P!#IX3_ /!O;_\ Q='_  OSP+_T.GA/_P &]O\ _%T
M=917)_\ "_/ O_0Z>$__  ;V_P#\71_POSP+_P!#IX3_ /!O;_\ Q= '645R
M?_"_/ O_ $.GA/\ \&]O_P#%T?\ "_/ O_0Z>$__  ;V_P#\70!UE%<G_P +
M\\"_]#IX3_\ !O;_ /Q='_"_/ O_ $.GA/\ \&]O_P#%T =917)_\+\\"_\
M0Z>$_P#P;V__ ,71_P +\\"_]#IX3_\ !O;_ /Q= '645R?_  OSP+_T.GA/
M_P &]O\ _%T?\+\\"_\ 0Z>$_P#P;V__ ,70!UE%<G_POSP+_P!#IX3_ /!O
M;_\ Q='_  OSP+_T.GA/_P &]O\ _%T =917)_\ "_/ O_0Z>$__  ;V_P#\
M71_POSP+_P!#IX3_ /!O;_\ Q= '645R?_"_/ O_ $.GA/\ \&]O_P#%T?\
M"_/ O_0Z>$__  ;V_P#\70!UE%<G_P +\\"_]#IX3_\ !O;_ /Q='_"_/ O_
M $.GA/\ \&]O_P#%T =917)_\+\\"_\ 0Z>$_P#P;V__ ,71_P +\\"_]#IX
M3_\ !O;_ /Q= '645R?_  OSP+_T.GA/_P &]O\ _%T?\+\\"_\ 0Z>$_P#P
M;V__ ,70!UE%<G_POSP+_P!#IX3_ /!O;_\ Q='_  OSP+_T.GA/_P &]O\
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M]O\ _%T =917)_\ "_/ O_0Z>$__  ;V_P#\71_POSP+_P!#IX3_ /!O;_\
MQ= '645R?_"_/ O_ $.GA/\ \&]O_P#%T?\ "_/ O_0Z>$__  ;V_P#\70!U
ME%<G_P +\\"_]#IX3_\ !O;_ /Q='_"_/ O_ $.GA/\ \&]O_P#%T =917)_
M\+\\"_\ 0Z>$_P#P;V__ ,71_P +\\"_]#IX3_\ !O;_ /Q= '645R?_  OS
MP+_T.GA/_P &]O\ _%T?\+\\"_\ 0Z>$_P#P;V__ ,70!UE%<G_POSP+_P!#
MIX3_ /!O;_\ Q='_  OSP+_T.GA/_P &]O\ _%T =917)_\ "_/ O_0Z>$__
M  ;V_P#\71_POSP+_P!#IX3_ /!O;_\ Q= '645R?_"_/ O_ $.GA/\ \&]O
M_P#%T?\ "_/ O_0Z>$__  ;V_P#\70!UE%<G_P +\\"_]#IX3_\ !O;_ /Q=
M'_"_/ O_ $.GA/\ \&]O_P#%T =917)_\+\\"_\ 0Z>$_P#P;V__ ,71_P +
M\\"_]#IX3_\ !O;_ /Q= '645R?_  OSP+_T.GA/_P &]O\ _%T?\+\\"_\
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M>$__  ;V_P#\71_POSP+_P!#IX3_ /!O;_\ Q= '645R?_"_/ O_ $.GA/\
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M\HW_ -OH_P"'7G_4\?\ E&_^WU]944 ?)O\ PZ\_ZGC_ ,HW_P!OH_X=>?\
M4\?^4;_[?7UE10!\F_\ #KS_ *GC_P HW_V^C_AUY_U/'_E&_P#M]?65% 'R
M;_PZ\_ZGC_RC?_;Z/^'7G_4\?^4;_P"WU]944 ?)O_#KS_J>/_*-_P#;Z/\
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MU/'_ )1O_M]?65% 'R;_ ,.O/^IX_P#*-_\ ;Z/^'7G_ %/'_E&_^WU]944
M?)O_  Z\_P"IX_\ *-_]OH_X=>?]3Q_Y1O\ [?7UE10!\F_\.O/^IX_\HW_V
M^C_AUY_U/'_E&_\ M]?65% 'R;_PZ\_ZGC_RC?\ V^C_ (=>?]3Q_P"4;_[?
M7UE10!\F_P##KS_J>/\ RC?_ &^C_AUY_P!3Q_Y1O_M]?65% 'R;_P .O/\
MJ>/_ "C?_;Z/^'7G_4\?^4;_ .WU]944 ?)O_#KS_J>/_*-_]OH_X=>?]3Q_
MY1O_ +?7UE10!\F_\.O/^IX_\HW_ -OH_P"'7G_4\?\ E&_^WU]944 ?)O\
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MO_#KS_J>/_*-_P#;Z/\ AUY_U/'_ )1O_M]?65% 'R;_ ,.O/^IX_P#*-_\
M;Z/^'7G_ %/'_E&_^WU]944 ?)O_  Z\_P"IX_\ *-_]OH_X=>?]3Q_Y1O\
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ME10!\F_\.O/^IX_\HW_V^C_AUY_U/'_E&_\ M]?65% 'R;_PZ\_ZGC_RC?\
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M_*-_]OH_X=>?]3Q_Y1O_ +?7UE10!\F_\.O/^IX_\HW_ -OH_P"'7G_4\?\
ME&_^WU]944 ?)O\ PZ\_ZGC_ ,HW_P!OH_X=>?\ 4\?^4;_[?7UE10!\F_\
M#KS_ *GC_P HW_V^C_AUY_U/'_E&_P#M]?65% 'R;_PZ\_ZGC_RC?_;Z/^'7
MG_4\?^4;_P"WU]944 ?)O_#KS_J>/_*-_P#;Z/\ AUY_U/'_ )1O_M]?65%
M'R;_ ,.O/^IX_P#*-_\ ;Z/^'7G_ %/'_E&_^WU]944 ?)O_  Z\_P"IX_\
M*-_]OH_X=>?]3Q_Y1O\ [?7UE10!\F_\.O/^IX_\HW_V^C_AUY_U/'_E&_\
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M5% 'R;_PZ\_ZGC_RC?\ V^C_ (=>?]3Q_P"4;_[?7UE10!\F_P##KS_J>/\
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M\HW_ -OH_P"'7G_4\?\ E&_^WU]944 ?)O\ PZ\_ZGC_ ,HW_P!OH_X=>?\
M4\?^4;_[?7UE10!\F_\ #KS_ *GC_P HW_V^C_AUY_U/'_E&_P#M]?65% 'R
M;_PZ\_ZGC_RC?_;Z/^'7G_4\?^4;_P"WU]944 ?)O_#KS_J>/_*-_P#;Z/\
MAUY_U/'_ )1O_M]?65% 'R;_ ,.O/^IX_P#*-_\ ;Z/^'7G_ %/'_E&_^WU]
M944 ?)O_  Z\_P"IX_\ *-_]OH_X=>?]3Q_Y1O\ [?7UE10!\F_\.O/^IX_\
MHW_V^C_AUY_U/'_E&_\ M]?65% 'R;_PZ\_ZGC_RC?\ V^C_ (=>?]3Q_P"4
M;_[?7UE10!\F_P##KS_J>/\ RC?_ &^C_AUY_P!3Q_Y1O_M]?65% 'R;_P .
MO/\ J>/_ "C?_;Z/^'7G_4\?^4;_ .WU]944 ?)O_#KS_J>/_*-_]OH_X=>?
M]3Q_Y1O_ +?7UE10!\F_\.O/^IX_\HW_ -OH_P"'7G_4\?\ E&_^WU]944 ?
M)O\ PZ\_ZGC_ ,HW_P!OH_X=>?\ 4\?^4;_[?7UE10!\F_\ #KS_ *GC_P H
MW_V^C_AUY_U/'_E&_P#M]?65% 'R;_PZ\_ZGC_RC?_;Z/^'7G_4\?^4;_P"W
MU]944 ?)O_#KS_J>/_*-_P#;Z/\ AUY_U/'_ )1O_M]?65% 'R;_ ,.O/^IX
M_P#*-_\ ;Z/^'7G_ %/'_E&_^WU]944 ?)O_  Z\_P"IX_\ *-_]OH_X=>?]
M3Q_Y1O\ [?7UE10!\F_\.O/^IX_\HW_V^C_AUY_U/'_E&_\ M]?65% 'DW[+
MW[+W_#-O]N?\3S^VO[:^S_\ +E]G\GRO-_Z:/NSYGMC'?/'K-%% !1110 44
M44 %%%% 'Y _\'JW_*++P#_V573O_31K%>__ /!KC_R@H^!G_<?_ /4@U.M#
M_@X6_P""H'C[_@DU^Q?X8^(WPYT?P?K6MZUXUM?#<\'B2UN;FU2WEL;^X9U6
M">%Q('M8P"7(P6^4D@CT_P#X(S_MK>*O^"B7_!-GX;_&+QMI_A_2_$WC#^T_
MMEKHD$T%A%]FU2\LX_+2:6609CMT)W2-EBQ&!@  ^H**** "BBB@ HHHH **
M** "BBB@#X@_X.//A/XJ^./_  1C^,GA;P3X9\0>,/$VJ?V)]CTC1-.FU"_N
M_+US3Y9/+@A5I'VQH[G:#A48G@$UXA_P:*?L]^/OV:_^";?C;0OB-X'\8> -
M;N_B5?W\&G^)-&N=*NIK=M+TI%F6*=$=HR\<BAP,$QL,Y4X^C_\ @O5^U'X[
M_8N_X)/?%;XF?#/7/^$:\;>&_P"R/[-U+[%;WGV;S]8L;:7]U<1R1-NAFD7Y
MD.-V1@@$>/\ _!K_ /MZ_%C_ (*(_L"^+O&WQB\5_P#"8>)M+^(%YHEK>?V9
M9Z?Y5G'IVFS)%Y=K%%&<27$S;BI8[\$X   /T?HHHH **** "BBB@ HHHH *
M*X?XE_M.?#7X+:[#I?C'XA>!_">IW$ NHK/6==M;">2$LRB14E=6*%D<!@,$
MHPZ@U;^%OQ]\"_''[=_PA/C7PEXP_LOR_MG]B:Q;ZA]D\S=Y?F>2[;-VQ\;L
M9V-CH:T]C/EY[.W>VA/-&]KZG6T445F4%%%% !117G?CK]KOX3_"_P 576A>
M)OBA\._#NMV.S[3I^I^([.TNK?>BNF^*20.NY&5AD#(8'H150IRF[05_04I)
M;GHE%5- U^Q\5Z%9:II=[::EIFI01W5G>6LRS074,BADDC=25=&4@A@2""".
M*MU.VC&%%>=^.OVN_A/\+_%5UH7B;XH?#OP[K=CL^TZ?J?B.SM+JWWHKIOBD
MD#KN1E89 R&!Z$5W.@:_8^*]"LM4TN]M-2TS4H([JSO+699H+J&10R21NI*N
MC*00P)!!!'%7*G.*4I)V9*DF[(MT45P_Q+_:<^&OP6UV'2_&/Q"\#^$]3N(!
M=16>LZ[:V$\D)9E$BI*ZL4+(X# 8)1AU!I1A*3M%78W)+5G<454T#7['Q7H5
MEJFEWMIJ6F:E!'=6=Y:S+-!=0R*&22-U)5T92"&!((((XJW4[:,84444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M?]43_P#+P_\ N&ORKHH_U5RO_GU_Y-+_ ##^T,1_-^"_R/U4_P"(FC_JB?\
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MZ*/]5<K_ .?7_DTO\P_M#$?S?@O\C]5/^(FC_JB?_EX?_<-'_$31_P!43_\
M+P_^X:_*NBC_ %5RO_GU_P"32_S#^T,1_-^"_P C]5/^(FC_ *HG_P"7A_\
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MO\P_M#$?S?@O\C]5/^(FC_JB?_EX?_<-'_$31_U1/_R\/_N&ORKHH_U5RO\
MY]?^32_S#^T,1_-^"_R/U^^!/_!PW_PNOXW^#?!O_"H?[-_X2[7++1?MG_"5
M>=]D^TW"0^9L^QKOV[]VW<N<8R.M?I57\UG["?\ R>]\&_\ L>=$_P#2^"OZ
M4Z^(XKRW#8.K3CAH\J:=]6^OFV>MEU>=6+<W<****^3/1"BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M"E6 ^*M?_P"#DGX!Z-KM[9V^A_$_5K>UN)(8KZUTFT6"\56($L8ENDD".!N
MD1&P1N53D#;#Y?B:S<:4&VM_(BIB*<$G)[GZ!45YW^RW^U)X-_;%^#>F^./
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M"^W"X _IVKDXHP_+[&O)6G)>]ZJW^9MEM2_/!/1/3\0K\\/V^?VT/C#\8_\
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M\'SG_-KO_<U_^X6@#]_J_.#_ (.@/V]?BQ_P3N_8%\(^-O@[XK_X0_Q-JGQ
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M_9_^!O\ :W_,D_8[:[_L3R_W7^M_L[4=WF^7Y_\ Q^S8\['[O'E)]'_\$O\
M1OV_/A7\?=8\'?M4:M\+_B5\/9O#\VLZ?XZ\-I#!=0:H;FVABTEHDCM#Y8@6
MZG+_ &)AF11]I./*7[OHH _GQ\$?M^?\%#/V]/\ @KO^T1\!/@C\?/!_A&S^
M&OB#Q)<:?#XD\.Z6MK;:78ZTMA% LR:7<S22*)X0#("6",6<M][Z0\:^/O\
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M%K.05BD+2>6NU59I$_+'_@OI_P K37[%?_<C?^I=?5^OW_!2?]IW]GW]E_\
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M)62)VC<89692"?H_]CK]OSX-_P#!0#P)-XB^#OQ"\/\ CC3[/;]LBM)&AO\
M3-TDT<?VJSF5+FV\QH)C'YT:>8J%DW+AB >P45\__MS_ /!4?X$_\$U_^$7_
M .%U^.O^$+_X33[7_8W_ !)=0U'[9]E\CS_^/2"79M^T0_?VYW\9PV.?\?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\?_ &U?V]?A/_P3
MN^%FG^-OC%XK_P"$/\,ZIJL>B6MY_9EYJ'FWDD,TR1>7:Q2R#,=O,VXJ%&S!
M.2 ?8*^,/^#A']E_2_VJ_P#@C]\;M+U!M/MKSPCX?F\:Z9?7&G)>R6-QI2F]
M;R=S*8I)X(9[4RJP*1W<G#J6C8 ^K_A/\4M!^./PL\,^-O"U]_:GAGQAI5KK
M>D7GDR0?:[.YA2:"7RY%61-T;JVUU5AG! .17/\ [4?[4?@3]B[X$ZY\3/B9
MKG_"->"?#?V?^TM2^Q7%Y]F\^XBMHOW5O')*VZ::-?E0XW9. "1\8?\ !KC^
MU[<?M:?\$?O T&I3:A=ZW\*;NX\ 7UQ<6L%O'*EFL4MDL(B/S1QZ?<V,)=U6
M1I(9"VX_O'\ _P"#K_Q9I?[1OBK]E']DN'4M/TW6_C!\2K&_N]32X2YNO#=N
M7_LJ":2P!5Y(YGU.X9',D88Z=*@+$LT8!^IW[+G[4?@3]M'X$Z'\3/AGKG_"
M2^"?$GVC^S=2^Q7%G]I\BXEMI?W5Q''*NV:&1?F09VY&003H?'[X_>#?V6O@
MUXA^(7Q"\0Z?X5\&^%;0WFIZG>,1';ID*H"J"\DCNRHD:!I))'1$5G95/Y0_
M\&>_Q.\9>$/@U^T!^SEXYT_4+76_@'XU5)%N-8%]'IKWAN8+C3847=%''#=Z
M9<S%HI&CEDO9& !R\G8?\'BG[2__  I__@E1;^!;6[\/G4/BYXKL=*N+&[E_
MT]].LRVHRW-K&'4GR[JVL(Y)"KHJW04@-)&P /T>_9<_:C\"?MH_ G0_B9\,
M]<_X27P3XD^T?V;J7V*XL_M/D7$MM+^ZN(XY5VS0R+\R#.W(R""?0*\/_P""
M:_[(=O\ L%_L&?"KX1PPZ?#>>"_#\%OJS6%U/<VMSJDF9]0GB><"0QRWDMQ*
MH*J%$@ 1% 1?,/VE_P#@OC^R%^R)\4[OP3XZ^-OA^S\3:=O6^L]*L+_7/[/E
M2:2&2WN)+&">.&X22)U>"1EE3 +( RD@'U_17R_^QU_P6?\ V7_V^?'<WA;X
M5_%_P_X@\31[?*TB[MKK1[^_S'-*?LL%[%#)=;(X)7D\@/Y:J"^T,I/T!\6/
MBEH/P.^%GB;QMXIOO[+\,^#]*NM;U>\\F2?[)9VT+S3R^7&K2/MC1FVHK,<8
M )P* .@KY _X+5_\%6_^'/G[+&@?$S_A O\ A8G]N>*[?PQ_9O\ ;?\ 9'D>
M;:7ESY_F_9Y]V/LFW9L&?,SN&W!-/_X+X_LA:C^SC=?%@?&WP_;^";?59M$2
M>[L+^UO[Z\A6S::*UL)8%O+KREO[1I&@AD6-9@S$!6(^ /\ @ZS_ &H_ G[:
M/_!#SX2?$SX9ZY_PDO@GQ)\5;;^S=2^Q7%G]I\BPUVVE_=7$<<J[9H9%^9!G
M;D9!!(!^OW[)WQT_X:@_98^&GQ,_LO\ L/\ X6)X5TOQ/_9OVG[5_9_VVTBN
M?(\W8GF;/-V[]B[MN=JYP/0*^?\ _@D[_P HLOV:?^R5>%__ $T6M<?^UY_P
M7%_97_80^,LWP]^*7Q:T_P .^,K2TAO+K3+?1]1U62R28%HQ,UG;S)#(R8<1
MR%9/+DC?;LD1F .P_P""H_[<_P#P[7_83\=?&K_A%_\ A-/^$+^P?\2;^TO[
M-^V?:M0MK+_7^5+LV_:-_P#JVSLV\9W#T#]D[XZ?\-0?LL?#3XF?V7_8?_"Q
M/"NE^)_[-^T_:O[/^VVD5SY'F[$\S9YNW?L7=MSM7.!^6/\ P6O_ ."N?[.O
M_!1S_@BC^T?H7P:^)FG^+];\.VGAV_OM/?3KW3+I;=O$>FIYT<5Y#"\T:OM5
MWB#",R1!RIDCW?9_[(/[4?@3]B[_ ((>? ;XF?$S7/\ A&O!/AOX5>#_ .TM
M2^Q7%Y]F\^PL+:+]U;QR2MNFFC7Y4.-V3@ D 'U_17/_  G^*6@_''X6>&?&
MWA:^_M3PSXPTJUUO2+SR9(/M=G<PI-!+Y<BK(FZ-U;:ZJPS@@'(KR_XL?\%(
M?@E\"_VN/!_P*\8>/M/\._%+Q]:17F@:1>6ES''J*323PP@7?E_95DDEMI8T
MC>59'D"(JEI(PP![A7A__!2']M[2_P#@G#^Q+X^^-&L:'J'B6S\%6D+QZ79S
M)#)?7%Q<PVEO&9&R(XS//%OD"N4CWLJ2, C>H?%CXI:#\#OA9XF\;>*;[^R_
M#/@_2KK6]7O/)DG^R6=M"\T\OEQJTC[8T9MJ*S'& "<"OG_4_P#@J!^S9\6_
M^"??BGXX:MXB_M;]GOY]$UC5=7\':I]@U.*::.QDB%I/:"6[MWFN!;NT<4D1
M;S48YCE"@'8?\$WOVWM+_P""CW[$O@'XT:/H>H>&K/QK:3/)I=Y,DTEC<6]S
M-:7$8D7 DC$\$NR0JA>/8S)&Q*+[A7E_[%_QW^%_[2G[,'@_Q=\%[K3[OX6W
M=H]AX=-AI4NE6L-O9RO9^3%:RQ1/#'$]N\:IY:@",;1MP3Y_^V]_P5S_ &=?
M^"<?BK0]"^,OQ,T_PAK?B*T>_L=/33KW4[IK=7V>=)%9PS/#&S[E1Y0HD,<H
M0L8Y-H!ZA^UC\=/^&7_V6/B7\3/[+_MS_A7?A75/$_\ 9OVG[+_:'V*TEN?(
M\W8_E[_*V[]C;=V=K8P?/_\ @EQ^W/\ \/*/V$_ OQJ_X1?_ (0O_A-/M_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?&MUH\_AWPVULUK>W"6-A,UZWD6EJGF.D\<9S&3B!?F(P% /N^BBB@#^>/\
MYSK?]UX_]V"OK3_@YG_9H_Y$'XQ6]WZ>#;^UDE_Z^+RUDB0)_P!?@D9I/^>
M5?OFM;_AQW\6/^'DW_"XO^$A^'?_  C/_"R_^$R^R_;[S[?]C_M3[9Y>S[+Y
M?G>7QM\S;NXW8YK[X_;K_9H_X;!_9'\<_#E+O[#>>(K ?89VE\J-+R&1+BV\
MUMCD0F>*,2;4+>67VX;!'VF*S:C#%X>K3E=15I>5]'_F>/3PLW2J0DM6[H_
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M=F6(C6KJWLK/O_7^9])?MJ?\JX^C?]B'X-_]'Z77R7_P;2?\GU^+/^Q#O/\
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M\OAVUUA]37X9W'V59DN+[,+/;R;X1:HKR*9;?4=+>:::18@?VNKX0_X)._\
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M4R_#'3]7O-3U>WD166%TOE1VC+QB)TAN[</#<3B03KB(_?W[%_[(?@W]@O\
M9@\'_"/X?PZA#X4\%VCV]HU_=&YNKEY)7GGGE<@ R2SRRRL$58U,A"(B!44
M_-']LC_E<D_9._[)5??^DWBNOU^K\D?^"*'BS5?^"DO_  6!_:@_;*T_4M0/
MPGL[1?A'X%@N+A[J/4+>%K*XEGA64QS649%M!=FW:W4&36I!O,D,I?\ 6Z@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^;_ /@I
MA_P2L^$?_!5[X-6/@_XI:;J$<FBW?VW1=?T>6.VUG0W)3SA;S21R)Y<R($DC
MD1XW 1MHDBBDC_)'_C8Y_P &Y/\ U=!^S+X?_P"N^H?V)I</YWVD>5I^G_\
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M>W=HHK60?:;C3V:&0W;37+M%/=6+0F%O+:, _H>HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ KQ_]M7]O7X3_ /!.[X6:?XV^,7BO
M_A#_  SJFJQZ):WG]F7FH>;>20S3)%Y=K%+(,QV\S;BH4;,$Y(!]@KC_ (U_
ML]^ ?VE/"MOH7Q&\#^#_ !_HEI=K?P:?XDT:VU6UAN%1T698IT=%D"22*' R
M!(PSACD ^,/^(HW]A/\ Z+E_Y9GB#_Y!H_XBC?V$_P#HN7_EF>(/_D&O?_\
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MB.JLKJ05(!!!%>X4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MQ?\ "JOB[\,-5L=4N[_PQ;K8?\))+=ZM!&+J8PE#'J$5U="X6]4F5MKI)O\
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MO1/ /A_Q=XDU""PC22ZFM[/6-6N)4B5V1&D*1L%#.H)(RP'(^</^#6W]C/\
MX;0_X61^V=^T%IW_  LKXF^,?%:6WAC5?%6B^;]A^P^3*^IV#.?(_P"/CRK:
M)H(5^Q_V4\4+JK/&ON'_  1/^"FJ_M*?\&K&E?#G0KC3[36_'_@KQQX;T^>_
M=X[6&XO-2UFWB>5D5W6,/(I8JC$ '"D\'C_^#/\ _:C^V_L;>,?V>O&6N?V?
M\3?@[XKU+R?!NI67]GZKHNCRM"TFZ-HT>39J<M^LNXO)"\L:2;%>!2 >W_\
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MZBB9AN@9[B*(*;AZ_8[Q9_P3*_9#\!>%=2UW7?V>_P!F_1=$T6TEO]0U"_\
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M']4J^?S+#X>C54<-/G5M_.[T.[#U*DXWJ*S"BBBO/.@^ /\ @Z._Y04?'/\
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M%Q")LA1Y@0%3\H?\05/[+/\ T/W[0'_@\TC_ .5E?K]10!X?^P=_P3J^$?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M )"K[_HH_P!8,Q_Y_,/J=#^5'P!_Q#C?!#_H:OBK_P"#*P_^0J/^(<;X(?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M6A)KT9,HQ>Z/)?\ A@;X$_\ 1%?A+_X2&G__ !FC_A@;X$_]$5^$O_A(:?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M%'P-_9\^+'@?XI:7JGB;QQ_;&B6OF_:;3^V;RX\[="ZK\DB!3AV4\GC&>H%
M'T-17S'X^_9F^,VO>.M:OM+^('V+3+V_GGM+?^W;Z/R(6D9D3:J%5VJ0, X&
M,"M;_AGSXL?\*+_L/_A./^*F_M[[?_:']LWG_'G]GV>3YNS?_K/FV8V]\YH
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M_P ,H?'3_HI7_EPZA_\ &ZZSQ?\ L^?%C5_A;X/TO3_''V76]'^V_P!JW?\
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MQ_9O]FZ#:V&H?\3F\A^U7B;O-F^1#OW97YVPQQR* /H:BOGGX&_L^?%CP/\
M%+2]4\3>./[8T2U\W[3:?VS>7'G;H75?DD0*<.RGD\8SU KD_P#AE#XZ?]%*
M_P#+AU#_ .-T ?65%?//B_\ 9\^+&K_"WP?I>G^./LNMZ/\ ;?[5N_[9O$^V
M^;,&A^=4W/L0$?.!MS@9%9/@']F;XS:#XZT6^U3X@?;=,LK^">[M_P"W;Z3S
MX5D5G3:R!6W*",$X.<&@#Z<HKYC\??LS?&;7O'6M7VE_$#[%IE[?SSVEO_;M
M]'Y$+2,R)M5"J[5(& <#&!6M_P ,^?%C_A1?]A_\)Q_Q4W]O?;_[0_MF\_X\
M_L^SR?-V;_\ 6?-LQM[YS0!]#45\F_\ #*'QT_Z*5_Y<.H?_ !NNL^.7[/GQ
M8\<?%+5-4\,^./['T2Z\K[-:?VS>6_D[845ODC0J,NK'@\YSU)H ^AJ*^>?"
M'[/GQ8TCX6^,-+U#QQ]JUO6/L7]E7?\ ;-X_V+RIBTWSLFY-Z$#Y =V,' KD
M_P#AE#XZ?]%*_P#+AU#_ .-T ?65%?//Q7_9\^+'BO\ X1K^P_'']F_V;H-K
M8:A_Q.;R'[5>)N\V;Y$._=E?G;#''(K7_9J^"7Q)^&WCJ[OO&'B[^W],FL'@
MBM_[5NKK9,9(V#[95"C"JXR#GYL=S0![?17R;_PRA\=/^BE?^7#J'_QNNL\7
M_L^?%C5_A;X/TO3_ !Q]EUO1_MO]JW?]LWB?;?-F#0_.J;GV("/G VYP,B@#
MZ&HKYC\ _LS?&;0?'6BWVJ?$#[;IEE?P3W=O_;M])Y\*R*SIM9 K;E!&"<'.
M#1X^_9F^,VO>.M:OM+^('V+3+V_GGM+?^W;Z/R(6D9D3:J%5VJ0, X&,"@#Z
M<HKYY_X9\^+'_"B_[#_X3C_BIO[>^W_VA_;-Y_QY_9]GD^;LW_ZSYMF-O?.:
MY/\ X90^.G_12O\ RX=0_P#C= 'UE17SS\<OV?/BQXX^*6J:IX9\<?V/HEUY
M7V:T_MF\M_)VPHK?)&A49=6/!YSGJ31X0_9\^+&D?"WQAI>H>./M6MZQ]B_L
MJ[_MF\?[%Y4Q:;YV3<F]"!\@.[&#@4 ?0U%?)O\ PRA\=/\ HI7_ )<.H?\
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MD0[]V5^=L,<<BCX&_L^?%CP/\4M+U3Q-XX_MC1+7S?M-I_;-Y<>=NA=5^21
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ML^.7[/GQ8\<?%+5-4\,^./['T2Z\K[-:?VS>6_D[845ODC0J,NK'@\YSU)H
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M#;G R* /H:BOGGX&_L^?%CP/\4M+U3Q-XX_MC1+7S?M-I_;-Y<>=NA=5^21
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MJ_\ @ML/_DVC_B(Y^"'_ $*OQ5_\%MA_\FU?^K^8_P#/ED_7*'\R/O\ HKX
M_P"(CGX(?]"K\5?_  6V'_R;1_Q$<_!#_H5?BK_X+;#_ .3:/]7\Q_Y\L/KE
M#^9'W_17P!_Q$<_!#_H5?BK_ ."VP_\ DVC_ (B.?@A_T*OQ5_\ !;8?_)M'
M^K^8_P#/EA]<H?S(^_Z*^ /^(CGX(?\ 0J_%7_P6V'_R;1_Q$<_!#_H5?BK_
M ."VP_\ DVC_ %?S'_GRP^N4/YD??]%? '_$1S\$/^A5^*O_ (+;#_Y-H_XB
M.?@A_P!"K\5?_!;8?_)M'^K^8_\ /EA]<H?S(^_Z*^ /^(CGX(?]"K\5?_!;
M8?\ R;1_Q$<_!#_H5?BK_P""VP_^3:/]7\Q_Y\L/KE#^9'W_ $5\ ?\ $1S\
M$/\ H5?BK_X+;#_Y-H_XB.?@A_T*OQ5_\%MA_P#)M'^K^8_\^6'URA_,C[_H
MKX _XB.?@A_T*OQ5_P#!;8?_ ";1_P 1'/P0_P"A5^*O_@ML/_DVC_5_,?\
MGRP^N4/YD??]%? '_$1S\$/^A5^*O_@ML/\ Y-H_XB.?@A_T*OQ5_P#!;8?_
M ";1_J_F/_/EA]<H?S(^_P"BO@#_ (B.?@A_T*OQ5_\ !;8?_)M'_$1S\$/^
MA5^*O_@ML/\ Y-H_U?S'_GRP^N4/YD??]%? '_$1S\$/^A5^*O\ X+;#_P"3
M:/\ B(Y^"'_0J_%7_P %MA_\FT?ZOYC_ ,^6'URA_,C[_HKX _XB.?@A_P!"
MK\5?_!;8?_)M'_$1S\$/^A5^*O\ X+;#_P"3:/\ 5_,?^?+#ZY0_F1]_T5\
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M5\ ?\1'/P0_Z%7XJ_P#@ML/_ )-H_P"(CGX(?]"K\5?_  6V'_R;1_J_F/\
MSY8?7*'\R/O^BO@#_B(Y^"'_ $*OQ5_\%MA_\FT?\1'/P0_Z%7XJ_P#@ML/_
M )-H_P!7\Q_Y\L/KE#^9'W_17P!_Q$<_!#_H5?BK_P""VP_^3:/^(CGX(?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M+7W]J>&?&&E6NMZ1>>3)!]KL[F%)H)?+D59$W1NK;756&<$ Y%=!0 45X_\
MMZ_MK>%?^"=O[)WBOXQ>-M/\0:IX9\'_ &/[9:Z)!#/?R_:;R"SC\M)I8HSB
M2X0G=(N%#$9. >P_9Z^->E_M*? +P/\ $;0K?4+31/'WA^P\2:?!?QI'=0V]
MY;1W$22JC.BR!)%#!78 @X8CD@'8445X?XL_X*;?LV^ O%6I:%KO[0?P/T76
M]%NY;#4-/O\ QUI=M=6%Q$Y26&6)YP\<B.K*R, 5(((!% 'N%%?/_P#P]B_9
M9_Z.6_9__P##AZ1_\D5V'P4_;=^"_P"TIXJN-"^'/Q>^%_C_ %NTM&OY]/\
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M%X1\<>#_ !5K?@F[^P>(M/T?6;:^NM N-\J>3=Q1.SV\F^&9=D@4YBD&,J<
M'84444 %%%% !1110 4444 %%%% !1110 4444 ?@#_P6T_Y2=?$S_N%_P#I
MILZ^5:^JO^"VG_*3KXF?]PO_ ---G7RK7[IE'^XT?\$?_24?(XG^-+U?YA11
M17H&(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 >J_L)_\GO?!O\ ['G1/_2^"OZ4
MZ_FL_83_ .3WO@W_ -CSHG_I?!7]*=?FO'7\>EZ/\SWLI^"7J%%%%?"GK!11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!^0/\ P>K?\HLO /\
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M)_AS\1M7\'ZUK>M>-;KQ)!/X;NKFYM4MY;&PMU1FG@A<2![60D!",%?F))
M/N^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^#3_ !)XJL=*NIK=G=%F6*>5':,O'(H<#!,;#.5./F#P+^U[;_L%_P#!M_\
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MQ%:65M^_AG2>39;RNG[R1MV[<VY@&'[O?L5?\$9OV;/^"=OQ3U#QM\'?AO\
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MI#G"G''_ /!)W_E%E^S3_P!DJ\+_ /IHM:_GA_X-;/\ @E5X$_X*<^._BO\
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MX?\ P46^)GBK_B:^-O"?BN'P3I6I?ZC[+HZW^HVRVWE1[8FQ#HVFKYCH9/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MXBU#X4_&CP!=V]QX7^(>BVYDU#3DCG$WD2JDL+S1J^Z6(B5)+>8^9&X#S1S
M'V?7X0_L-^'=!_X*"?\ !WI\6_C?\.?$7_"0?#GX6:4MW_;^FV$EUI6JWAT*
MVT'[(MUE8TW2/>S12C>LZ:?(8@\;>:OT!\1?^"!/[5GQ;_9QC^$_B3_@HQ\0
M-6\$_OUN()O H^WZG%,LZRV]Y?C4Q>7=NZW$JF"XFDB*[%V8CC"_9W_!,_\
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M^Q_[.^P_;?\ IZN/,\S[9_L[?+_BW< !_P '1W_*"CXY_P#< _\ 4@TRO?\
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MF4?\&N/_ "@H^!G_ ''_ /U(-3KW_P#X*C_L,?\ #RC]A/QU\%/^$H_X0O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MT;HXW 95U(X(- 'V_1110 4444 %%%% !1110 4444 ? '_!T=_R@H^.?_<
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MNH_XAE_^JV?^6?\ _=U'^M65_P#/W_R67^0?V?B/Y?Q7^9^5=%?JI_Q#+_\
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M?V?B/Y?Q7^9^5=%?JI_Q#+_]5L_\L_\ ^[J/^(9?_JMG_EG_ /W=1_K5E?\
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M'I7Z55\1Q7F6&QE6G+#2YDD[Z-=?-(];+J$Z46IJP4445\F>B%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MG_A4I_\ )%?;U% 'Q#_PI;]HS_G\\6?^%2G_ ,D4?\*6_:,_Y_/%G_A4I_\
M)%?;U% 'Q#_PI;]HS_G\\6?^%2G_ ,D4?\*6_:,_Y_/%G_A4I_\ )%?;U% '
MQ#_PI;]HS_G\\6?^%2G_ ,D4?\*6_:,_Y_/%G_A4I_\ )%?;U% 'Q#_PI;]H
MS_G\\6?^%2G_ ,D4?\*6_:,_Y_/%G_A4I_\ )%?;U% 'Q#_PI;]HS_G\\6?^
M%2G_ ,D4?\*6_:,_Y_/%G_A4I_\ )%?;U% 'Q#_PI;]HS_G\\6?^%2G_ ,D4
M?\*6_:,_Y_/%G_A4I_\ )%?;U% 'Q#_PI;]HS_G\\6?^%2G_ ,D4?\*6_:,_
MY_/%G_A4I_\ )%?;U% 'Q#_PI;]HS_G\\6?^%2G_ ,D4?\*6_:,_Y_/%G_A4
MI_\ )%?;U% 'Q#_PI;]HS_G\\6?^%2G_ ,D4?\*6_:,_Y_/%G_A4I_\ )%?;
MU% 'Q#_PI;]HS_G\\6?^%2G_ ,D4?\*6_:,_Y_/%G_A4I_\ )%?;U% 'Q#_P
MI;]HS_G\\6?^%2G_ ,D4?\*6_:,_Y_/%G_A4I_\ )%?;U% 'Q#_PI;]HS_G\
M\6?^%2G_ ,D4?\*6_:,_Y_/%G_A4I_\ )%?;U% 'Q#_PI;]HS_G\\6?^%2G_
M ,D4?\*6_:,_Y_/%G_A4I_\ )%?;U% 'Q#_PI;]HS_G\\6?^%2G_ ,D4?\*6
M_:,_Y_/%G_A4I_\ )%?;U% 'Q#_PI;]HS_G\\6?^%2G_ ,D4?\*6_:,_Y_/%
MG_A4I_\ )%?;U% 'Q#_PI;]HS_G\\6?^%2G_ ,D4?\*6_:,_Y_/%G_A4I_\
M)%?;U% 'Q#_PI;]HS_G\\6?^%2G_ ,D4?\*6_:,_Y_/%G_A4I_\ )%?;U% '
MQ#_PI;]HS_G\\6?^%2G_ ,D4?\*6_:,_Y_/%G_A4I_\ )%?;U% 'Q#_PI;]H
MS_G\\6?^%2G_ ,D4?\*6_:,_Y_/%G_A4I_\ )%?;U% 'Q#_PI;]HS_G\\6?^
M%2G_ ,D4?\*6_:,_Y_/%G_A4I_\ )%?;U% 'Q#_PI;]HS_G\\6?^%2G_ ,D4
M?\*6_:,_Y_/%G_A4I_\ )%?;U% 'Q#_PI;]HS_G\\6?^%2G_ ,D4?\*6_:,_
MY_/%G_A4I_\ )%?;U% 'Q#_PI;]HS_G\\6?^%2G_ ,D4?\*6_:,_Y_/%G_A4
MI_\ )%?;U% 'Q#_PI;]HS_G\\6?^%2G_ ,D4?\*6_:,_Y_/%G_A4I_\ )%?;
MU% 'Q#_PI;]HS_G\\6?^%2G_ ,D4?\*6_:,_Y_/%G_A4I_\ )%?;U% 'Q#_P
MI;]HS_G\\6?^%2G_ ,D4?\*6_:,_Y_/%G_A4I_\ )%?;U% 'Q#_PI;]HS_G\
M\6?^%2G_ ,D4?\*6_:,_Y_/%G_A4I_\ )%?;U% 'Q#_PI;]HS_G\\6?^%2G_
M ,D4?\*6_:,_Y_/%G_A4I_\ )%?;U% 'Q#_PI;]HS_G\\6?^%2G_ ,D4?\*6
M_:,_Y_/%G_A4I_\ )%?;U% 'Q#_PI;]HS_G\\6?^%2G_ ,D4?\*6_:,_Y_/%
MG_A4I_\ )%?;U% 'Q#_PI;]HS_G\\6?^%2G_ ,D4?\*6_:,_Y_/%G_A4I_\
M)%?;U% 'Q#_PI;]HS_G\\6?^%2G_ ,D4?\*6_:,_Y_/%G_A4I_\ )%?;U% '
MQ#_PI;]HS_G\\6?^%2G_ ,D4?\*6_:,_Y_/%G_A4I_\ )%?;U% 'Q#_PI;]H
MS_G\\6?^%2G_ ,D4?\*6_:,_Y_/%G_A4I_\ )%?;U% 'Q#_PI;]HS_G\\6?^
M%2G_ ,D4?\*6_:,_Y_/%G_A4I_\ )%?;U% 'Q#_PI;]HS_G\\6?^%2G_ ,D4
M?\*6_:,_Y_/%G_A4I_\ )%?;U% 'Q#_PI;]HS_G\\6?^%2G_ ,D4?\*6_:,_
MY_/%G_A4I_\ )%?;U% 'Q#_PI;]HS_G\\6?^%2G_ ,D4?\*6_:,_Y_/%G_A4
MI_\ )%?;U% 'Q#_PI;]HS_G\\6?^%2G_ ,D4?\*6_:,_Y_/%G_A4I_\ )%?;
MU% 'Q#_PI;]HS_G\\6?^%2G_ ,D4?\*6_:,_Y_/%G_A4I_\ )%?;U% 'Q#_P
MI;]HS_G\\6?^%2G_ ,D4?\*6_:,_Y_/%G_A4I_\ )%?;U% 'Q#_PI;]HS_G\
M\6?^%2G_ ,D4?\*6_:,_Y_/%G_A4I_\ )%?;U% 'Q#_PI;]HS_G\\6?^%2G_
M ,D4?\*6_:,_Y_/%G_A4I_\ )%?;U% 'Q#_PI;]HS_G\\6?^%2G_ ,D4?\*6
M_:,_Y_/%G_A4I_\ )%?;U% 'Q#_PI;]HS_G\\6?^%2G_ ,D4?\*6_:,_Y_/%
MG_A4I_\ )%?;U% 'Q#_PI;]HS_G\\6?^%2G_ ,D4?\*6_:,_Y_/%G_A4I_\
M)%?;U% 'Q#_PI;]HS_G\\6?^%2G_ ,D4?\*6_:,_Y_/%G_A4I_\ )%?;U% '
MQ#_PI;]HS_G\\6?^%2G_ ,D4?\*6_:,_Y_/%G_A4I_\ )%?;U% 'Q#_PI;]H
MS_G\\6?^%2G_ ,D4?\*6_:,_Y_/%G_A4I_\ )%?;U% 'Q#_PI;]HS_G\\6?^
M%2G_ ,D4?\*6_:,_Y_/%G_A4I_\ )%?;U% 'Q#_PI;]HS_G\\6?^%2G_ ,D4
M?\*6_:,_Y_/%G_A4I_\ )%?;U% 'Q#_PI;]HS_G\\6?^%2G_ ,D4?\*6_:,_
MY_/%G_A4I_\ )%?;U% 'Q#_PI;]HS_G\\6?^%2G_ ,D4?\*6_:,_Y_/%G_A4
MI_\ )%?;U% 'Q#_PI;]HS_G\\6?^%2G_ ,D4?\*6_:,_Y_/%G_A4I_\ )%?;
MU% 'Q#_PI;]HS_G\\6?^%2G_ ,D4?\*6_:,_Y_/%G_A4I_\ )%?;U% 'Q#_P
MI;]HS_G\\6?^%2G_ ,D4?\*6_:,_Y_/%G_A4I_\ )%?;U% 'Q#_PI;]HS_G\
M\6?^%2G_ ,D4?\*6_:,_Y_/%G_A4I_\ )%?;U% 'Q#_PI;]HS_G\\6?^%2G_
M ,D4?\*6_:,_Y_/%G_A4I_\ )%?;U% 'Q#_PI;]HS_G\\6?^%2G_ ,D4?\*6
M_:,_Y_/%G_A4I_\ )%?;U% 'Q#_PI;]HS_G\\6?^%2G_ ,D4?\*6_:,_Y_/%
MG_A4I_\ )%?;U% 'Q#_PI;]HS_G\\6?^%2G_ ,D4?\*6_:,_Y_/%G_A4I_\
M)%?;U% 'Q#_PI;]HS_G\\6?^%2G_ ,D4?\*6_:,_Y_/%G_A4I_\ )%?;U% '
MQ#_PI;]HS_G\\6?^%2G_ ,D4?\*6_:,_Y_/%G_A4I_\ )%?;U% 'Q#_PI;]H
MS_G\\6?^%2G_ ,D4?\*6_:,_Y_/%G_A4I_\ )%?;U% 'Q#_PI;]HS_G\\6?^
M%2G_ ,D4?\*6_:,_Y_/%G_A4I_\ )%?;U% 'Q#_PI;]HS_G\\6?^%2G_ ,D4
M?\*6_:,_Y_/%G_A4I_\ )%?;U% 'Q#_PI;]HS_G\\6?^%2G_ ,D4?\*6_:,_
MY_/%G_A4I_\ )%?;U% 'Q#_PI;]HS_G\\6?^%2G_ ,D4?\*6_:,_Y_/%G_A4
MI_\ )%?;U% 'Q#_PI;]HS_G\\6?^%2G_ ,D4?\*6_:,_Y_/%G_A4I_\ )%?;
MU% 'Q#_PI;]HS_G\\6?^%2G_ ,D4?\*6_:,_Y_/%G_A4I_\ )%?;U% 'Q#_P
MI;]HS_G\\6?^%2G_ ,D4?\*6_:,_Y_/%G_A4I_\ )%?;U% 'Q#_PI;]HS_G\
M\6?^%2G_ ,D4?\*6_:,_Y_/%G_A4I_\ )%?;U% 'Q#_PI;]HS_G\\6?^%2G_
M ,D4?\*6_:,_Y_/%G_A4I_\ )%?;U% 'Q#_PI;]HS_G\\6?^%2G_ ,D4?\*6
M_:,_Y_/%G_A4I_\ )%?;U% 'Q#_PI;]HS_G\\6?^%2G_ ,D4?\*6_:,_Y_/%
MG_A4I_\ )%?;U% 'Q#_PI;]HS_G\\6?^%2G_ ,D4?\*6_:,_Y_/%G_A4I_\
M)%?;U% 'Q#_PI;]HS_G\\6?^%2G_ ,D4?\*6_:,_Y_/%G_A4I_\ )%?;U% '
MQ#_PI;]HS_G\\6?^%2G_ ,D4?\*6_:,_Y_/%G_A4I_\ )%?;U% 'Q#_PI;]H
MS_G\\6?^%2G_ ,D4?\*6_:,_Y_/%G_A4I_\ )%?;U% 'Q#_PI;]HS_G\\6?^
M%2G_ ,D4?\*6_:,_Y_/%G_A4I_\ )%?;U% 'Q#_PI;]HS_G\\6?^%2G_ ,D4
M?\*6_:,_Y_/%G_A4I_\ )%?;U% 'Q#_PI;]HS_G\\6?^%2G_ ,D4?\*6_:,_
MY_/%G_A4I_\ )%?;U% 'Q#_PI;]HS_G\\6?^%2G_ ,D4?\*6_:,_Y_/%G_A4
MI_\ )%?;U% 'Q#_PI;]HS_G\\6?^%2G_ ,D4?\*6_:,_Y_/%G_A4I_\ )%?;
MU% 'Q#_PI;]HS_G\\6?^%2G_ ,D4?\*6_:,_Y_/%G_A4I_\ )%?;U% 'Q#_P
MI;]HS_G\\6?^%2G_ ,D4?\*6_:,_Y_/%G_A4I_\ )%?;U% 'Q#_PI;]HS_G\
M\6?^%2G_ ,D4?\*6_:,_Y_/%G_A4I_\ )%?;U% 'Q#_PI;]HS_G\\6?^%2G_
M ,D4?\*6_:,_Y_/%G_A4I_\ )%?;U% 'Q#_PI;]HS_G\\6?^%2G_ ,D4?\*6
M_:,_Y_/%G_A4I_\ )%?;U% 'Q#_PI;]HS_G\\6?^%2G_ ,D4?\*6_:,_Y_/%
MG_A4I_\ )%?;U% 'Q#_PI;]HS_G\\6?^%2G_ ,D4?\*6_:,_Y_/%G_A4I_\
M)%?;U% 'Q#_PI;]HS_G\\6?^%2G_ ,D4?\*6_:,_Y_/%G_A4I_\ )%?;U% '
MQ#_PI;]HS_G\\6?^%2G_ ,D4?\*6_:,_Y_/%G_A4I_\ )%?;U% 'Q#_PI;]H
MS_G\\6?^%2G_ ,D4?\*6_:,_Y_/%G_A4I_\ )%?;U% 'Q#_PI;]HS_G\\6?^
M%2G_ ,D4?\*6_:,_Y_/%G_A4I_\ )%?;U% 'Q#_PI;]HS_G\\6?^%2G_ ,D4
M?\*6_:,_Y_/%G_A4I_\ )%?;U% 'Q#_PI;]HS_G\\6?^%2G_ ,D4?\*6_:,_
MY_/%G_A4I_\ )%?;U% 'Q#_PI;]HS_G\\6?^%2G_ ,D4?\*6_:,_Y_/%G_A4
MI_\ )%?;U% 'Q#_PI;]HS_G\\6?^%2G_ ,D4?\*6_:,_Y_/%G_A4I_\ )%?;
MU% 'Q#_PI;]HS_G\\6?^%2G_ ,D4?\*6_:,_Y_/%G_A4I_\ )%?;U% 'Q#_P
MI;]HS_G\\6?^%2G_ ,D4?\*6_:,_Y_/%G_A4I_\ )%?;U% 'Q#_PI;]HS_G\
M\6?^%2G_ ,D4?\*6_:,_Y_/%G_A4I_\ )%?;U% 'Q#_PI;]HS_G\\6?^%2G_
M ,D4?\*6_:,_Y_/%G_A4I_\ )%?;U% 'Q#_PI;]HS_G\\6?^%2G_ ,D4?\*6
M_:,_Y_/%G_A4I_\ )%?;U% 'Q#_PI;]HS_G\\6?^%2G_ ,D4?\*6_:,_Y_/%
MG_A4I_\ )%?;U% 'Q#_PI;]HS_G\\6?^%2G_ ,D4?\*6_:,_Y_/%G_A4I_\
M)%?;U% 'Q#_PI;]HS_G\\6?^%2G_ ,D4?\*6_:,_Y_/%G_A4I_\ )%?;U% '
MQ#_PI;]HS_G\\6?^%2G_ ,D4?\*6_:,_Y_/%G_A4I_\ )%?;U% 'Q#_PI;]H
MS_G\\6?^%2G_ ,D4?\*6_:,_Y_/%G_A4I_\ )%?;U% 'Q#_PI;]HS_G\\6?^
M%2G_ ,D4?\*6_:,_Y_/%G_A4I_\ )%?;U% 'Q#_PI;]HS_G\\6?^%2G_ ,D4
M?\*6_:,_Y_/%G_A4I_\ )%?;U% 'Q#_PI;]HS_G\\6?^%2G_ ,D4?\*6_:,_
MY_/%G_A4I_\ )%?;U% 'Q#_PI;]HS_G\\6?^%2G_ ,D4?\*6_:,_Y_/%G_A4
MI_\ )%?;U% 'Q#_PI;]HS_G\\6?^%2G_ ,D4?\*6_:,_Y_/%G_A4I_\ )%?;
MU% 'Q#_PI;]HS_G\\6?^%2G_ ,D4?\*6_:,_Y_/%G_A4I_\ )%?;U% 'Q#_P
MI;]HS_G\\6?^%2G_ ,D4?\*6_:,_Y_/%G_A4I_\ )%?;U% 'Q#_PI;]HS_G\
M\6?^%2G_ ,D4?\*6_:,_Y_/%G_A4I_\ )%?;U% 'Q#_PI;]HS_G\\6?^%2G_
M ,D4?\*6_:,_Y_/%G_A4I_\ )%?;U% 'Q#_PI;]HS_G\\6?^%2G_ ,D4?\*6
M_:,_Y_/%G_A4I_\ )%?;U% 'Q#_PI;]HS_G\\6?^%2G_ ,D4?\*6_:,_Y_/%
MG_A4I_\ )%?;U% 'Q#_PI;]HS_G\\6?^%2G_ ,D4?\*6_:,_Y_/%G_A4I_\
M)%?;U% 'Q#_PI;]HS_G\\6?^%2G_ ,D4?\*6_:,_Y_/%G_A4I_\ )%?;U% '
MQ#_PI;]HS_G\\6?^%2G_ ,D4?\*6_:,_Y_/%G_A4I_\ )%?;U% 'Q#_PI;]H
MS_G\\6?^%2G_ ,D4?\*6_:,_Y_/%G_A4I_\ )%?;U% 'Q#_PI;]HS_G\\6?^
M%2G_ ,D4?\*6_:,_Y_/%G_A4I_\ )%?;U% 'Q#_PI;]HS_G\\6?^%2G_ ,D4
M?\*6_:,_Y_/%G_A4I_\ )%?;U% 'Q#_PI;]HS_G\\6?^%2G_ ,D4?\*6_:,_
MY_/%G_A4I_\ )%?;U% 'Q#_PI;]HS_G\\6?^%2G_ ,D4?\*6_:,_Y_/%G_A4
MI_\ )%?;U% 'Q#_PI;]HS_G\\6?^%2G_ ,D4?\*6_:,_Y_/%G_A4I_\ )%?;
MU% 'Q#_PI;]HS_G\\6?^%2G_ ,D4?\*6_:,_Y_/%G_A4I_\ )%?;U% 'Q#_P
MI;]HS_G\\6?^%2G_ ,D4?\*6_:,_Y_/%G_A4I_\ )%?;U% 'Q#_PI;]HS_G\
M\6?^%2G_ ,D4?\*6_:,_Y_/%G_A4I_\ )%?;U% 'Q#_PI;]HS_G\\6?^%2G_
M ,D4?\*6_:,_Y_/%G_A4I_\ )%?;U% 'Q#_PI;]HS_G\\6?^%2G_ ,D4?\*6
M_:,_Y_/%G_A4I_\ )%?;U% 'Q#_PI;]HS_G\\6?^%2G_ ,D4?\*6_:,_Y_/%
MG_A4I_\ )%?;U% 'Q#_PI;]HS_G\\6?^%2G_ ,D4?\*6_:,_Y_/%G_A4I_\
M)%?;U% 'Q#_PI;]HS_G\\6?^%2G_ ,D4?\*6_:,_Y_/%G_A4I_\ )%?;U% '
MQ#_PI;]HS_G\\6?^%2G_ ,D4?\*6_:,_Y_/%G_A4I_\ )%?;U% 'Q#_PI;]H
MS_G\\6?^%2G_ ,D4?\*6_:,_Y_/%G_A4I_\ )%?;U% 'Q#_PI;]HS_G\\6?^
M%2G_ ,D4?\*6_:,_Y_/%G_A4I_\ )%?;U% 'Q#_PI;]HS_G\\6?^%2G_ ,D4
M?\*6_:,_Y_/%G_A4I_\ )%?;U% 'Q#_PI;]HS_G\\6?^%2G_ ,D4?\*6_:,_
MY_/%G_A4I_\ )%?;U% 'Q#_PI;]HS_G\\6?^%2G_ ,D4?\*6_:,_Y_/%G_A4
MI_\ )%?;U% 'Q#_PI;]HS_G\\6?^%2G_ ,D4?\*6_:,_Y_/%G_A4I_\ )%?;
MU% 'Q#_PI;]HS_G\\6?^%2G_ ,D4?\*6_:,_Y_/%G_A4I_\ )%?;U% 'Q#_P
MI;]HS_G\\6?^%2G_ ,D4?\*6_:,_Y_/%G_A4I_\ )%?;U% 'Q#_PI;]HS_G\
M\6?^%2G_ ,D4?\*6_:,_Y_/%G_A4I_\ )%?;U% 'Q#_PI;]HS_G\\6?^%2G_
M ,D4?\*6_:,_Y_/%G_A4I_\ )%?;U% 'Q#_PI;]HS_G\\6?^%2G_ ,D4?\*6
M_:,_Y_/%G_A4I_\ )%?;U% 'Q#_PI;]HS_G\\6?^%2G_ ,D4?\*6_:,_Y_/%
MG_A4I_\ )%?;U% 'Q#_PI;]HS_G\\6?^%2G_ ,D4?\*6_:,_Y_/%G_A4I_\
M)%?;U% 'Q#_PI;]HS_G\\6?^%2G_ ,D4?\*6_:,_Y_/%G_A4I_\ )%?;U% '
MQ#_PI;]HS_G\\6?^%2G_ ,D4?\*6_:,_Y_/%G_A4I_\ )%?;U% 'Q#_PI;]H
MS_G\\6?^%2G_ ,D4?\*6_:,_Y_/%G_A4I_\ )%?;U% 'Q#_PI;]HS_G\\6?^
M%2G_ ,D4?\*6_:,_Y_/%G_A4I_\ )%?;U% 'Q#_PI;]HS_G\\6?^%2G_ ,D4
M?\*6_:,_Y_/%G_A4I_\ )%?;U% 'Q#_PI;]HS_G\\6?^%2G_ ,D4?\*6_:,_
MY_/%G_A4I_\ )%?;U% 'Q#_PI;]HS_G\\6?^%2G_ ,D4?\*6_:,_Y_/%G_A4
MI_\ )%?;U% 'Q#_PI;]HS_G\\6?^%2G_ ,D4?\*6_:,_Y_/%G_A4I_\ )%?;
MU% 'Q#_PI;]HS_G\\6?^%2G_ ,D4?\*6_:,_Y_/%G_A4I_\ )%?;U% 'Q#_P
MI;]HS_G\\6?^%2G_ ,D4?\*6_:,_Y_/%G_A4I_\ )%?;U% 'Q#_PI;]HS_G\
M\6?^%2G_ ,D4?\*6_:,_Y_/%G_A4I_\ )%?;U% 'Q#_PI;]HS_G\\6?^%2G_
M ,D4?\*6_:,_Y_/%G_A4I_\ )%?;U% 'Q#_PI;]HS_G\\6?^%2G_ ,D4?\*6
M_:,_Y_/%G_A4I_\ )%?;U% 'Q#_PI;]HS_G\\6?^%2G_ ,D4?\*6_:,_Y_/%
MG_A4I_\ )%?;U% 'Q#_PI;]HS_G\\6?^%2G_ ,D4?\*6_:,_Y_/%G_A4I_\
M)%?;U% 'Q#_PI;]HS_G\\6?^%2G_ ,D4?\*6_:,_Y_/%G_A4I_\ )%?;U% '
MQ#_PI;]HS_G\\6?^%2G_ ,D4?\*6_:,_Y_/%G_A4I_\ )%?;U% 'Q#_PI;]H
MS_G\\6?^%2G_ ,D4?\*6_:,_Y_/%G_A4I_\ )%?;U% 'Q#_PI;]HS_G\\6?^
M%2G_ ,D4?\*6_:,_Y_/%G_A4I_\ )%?;U% 'Q#_PI;]HS_G\\6?^%2G_ ,D4
M?\*6_:,_Y_/%G_A4I_\ )%?;U% 'Q#_PI;]HS_G\\6?^%2G_ ,D4?\*6_:,_
MY_/%G_A4I_\ )%?;U% 'Q#_PI;]HS_G\\6?^%2G_ ,D4?\*6_:,_Y_/%G_A4
MI_\ )%?;U% 'Q#_PI;]HS_G\\6?^%2G_ ,D4?\*6_:,_Y_/%G_A4I_\ )%?;
MU% 'Q#_PI;]HS_G\\6?^%2G_ ,D4?\*6_:,_Y_/%G_A4I_\ )%?;U% 'Q#_P
MI;]HS_G\\6?^%2G_ ,D4?\*6_:,_Y_/%G_A4I_\ )%?;U% 'Q#_PI;]HS_G\
M\6?^%2G_ ,D4?\*6_:,_Y_/%G_A4I_\ )%?;U% 'Q#_PI;]HS_G\\6?^%2G_
M ,D4?\*6_:,_Y_/%G_A4I_\ )%?;U% 'Q#_PI;]HS_G\\6?^%2G_ ,D4?\*6
M_:,_Y_/%G_A4I_\ )%?;U% 'Q#_PI;]HS_G\\6?^%2G_ ,D4?\*6_:,_Y_/%
MG_A4I_\ )%?;U% 'Q#_PI;]HS_G\\6?^%2G_ ,D4?\*6_:,_Y_/%G_A4I_\
M)%?;U% 'Q#_PI;]HS_G\\6?^%2G_ ,D4?\*6_:,_Y_/%G_A4I_\ )%?;U% '
MQ#_PI;]HS_G\\6?^%2G_ ,D4?\*6_:,_Y_/%G_A4I_\ )%?;U% 'Q#_PI;]H
MS_G\\6?^%2G_ ,D4?\*6_:,_Y_/%G_A4I_\ )%?;U% 'Q#_PI;]HS_G\\6?^
M%2G_ ,D4?\*6_:,_Y_/%G_A4I_\ )%?;U% 'Q#_PI;]HS_G\\6?^%2G_ ,D4
M?\*6_:,_Y_/%G_A4I_\ )%?;U% 'Q#_PI;]HS_G\\6?^%2G_ ,D4?\*6_:,_
MY_/%G_A4I_\ )%?;U% 'Q#_PI;]HS_G\\6?^%2G_ ,D4?\*6_:,_Y_/%G_A4
MI_\ )%?;U% 'Q#_PI;]HS_G\\6?^%2G_ ,D4?\*6_:,_Y_/%G_A4I_\ )%?;
MU% 'Q#_PI;]HS_G\\6?^%2G_ ,D4?\*6_:,_Y_/%G_A4I_\ )%?;U% 'Q#_P
MI;]HS_G\\6?^%2G_ ,D4?\*6_:,_Y_/%G_A4I_\ )%?;U% 'Q#_PI;]HS_G\
M\6?^%2G_ ,D4?\*6_:,_Y_/%G_A4I_\ )%?;U% 'Q#_PI;]HS_G\\6?^%2G_
M ,D4?\*6_:,_Y_/%G_A4I_\ )%?;U% 'Q#_PI;]HS_G\\6?^%2G_ ,D4?\*6
M_:,_Y_/%G_A4I_\ )%?;U% 'Q#_PI;]HS_G\\6?^%2G_ ,D4?\*6_:,_Y_/%
MG_A4I_\ )%?;U% 'Q#_PI;]HS_G\\6?^%2G_ ,D4?\*6_:,_Y_/%G_A4I_\
M)%?;U% 'Q#_PI;]HS_G\\6?^%2G_ ,D4?\*6_:,_Y_/%G_A4I_\ )%?;U% '
MQ#_PI;]HS_G\\6?^%2G_ ,D4?\*6_:,_Y_/%G_A4I_\ )%?;U% 'Q#_PI;]H
MS_G\\6?^%2G_ ,D4?\*6_:,_Y_/%G_A4I_\ )%?;U% 'Q#_PI;]HS_G\\6?^
M%2G_ ,D4?\*6_:,_Y_/%G_A4I_\ )%?;U% 'Q#_PI;]HS_G\\6?^%2G_ ,D4
M?\*6_:,_Y_/%G_A4I_\ )%?;U% 'Q#_PI;]HS_G\\6?^%2G_ ,D4?\*6_:,_
MY_/%G_A4I_\ )%?;U% 'Q#_PI;]HS_G\\6?^%2G_ ,D4?\*6_:,_Y_/%G_A4
MI_\ )%?;U% 'Q#_PI;]HS_G\\6?^%2G_ ,D4?\*6_:,_Y_/%G_A4I_\ )%?;
MU% 'Q#_PI;]HS_G\\6?^%2G_ ,D4?\*6_:,_Y_/%G_A4I_\ )%?;U% 'Q#_P
MI;]HS_G\\6?^%2G_ ,D4?\*6_:,_Y_/%G_A4I_\ )%?;U% 'Q#_PI;]HS_G\
M\6?^%2G_ ,D4?\*6_:,_Y_/%G_A4I_\ )%?;U% 'Q#_PI;]HS_G\\6?^%2G_
M ,D4?\*6_:,_Y_/%G_A4I_\ )%?;U% 'Q#_PI;]HS_G\\6?^%2G_ ,D4?\*6
M_:,_Y_/%G_A4I_\ )%?;U% 'Q#_PI;]HS_G\\6?^%2G_ ,D4?\*6_:,_Y_/%
MG_A4I_\ )%?;U% 'Q#_PI;]HS_G\\6?^%2G_ ,D4?\*6_:,_Y_/%G_A4I_\
M)%?;U% 'Q#_PI;]HS_G\\6?^%2G_ ,D4?\*6_:,_Y_/%G_A4I_\ )%?;U% '
MQ#_PI;]HS_G\\6?^%2G_ ,D4?\*6_:,_Y_/%G_A4I_\ )%?;U% 'Q#_PI;]H
MS_G\\6?^%2G_ ,D4?\*6_:,_Y_/%G_A4I_\ )%?;U% 'Q#_PI;]HS_G\\6?^
M%2G_ ,D4?\*6_:,_Y_/%G_A4I_\ )%?;U% 'Q#_PI;]HS_G\\6?^%2G_ ,D4
M?\*6_:,_Y_/%G_A4I_\ )%?;U% 'Q#_PI;]HS_G\\6?^%2G_ ,D4?\*6_:,_
MY_/%G_A4I_\ )%?;U% 'Q#_PI;]HS_G\\6?^%2G_ ,D4?\*6_:,_Y_/%G_A4
MI_\ )%?;U% 'Q#_PI;]HS_G\\6?^%2G_ ,D4?\*6_:,_Y_/%G_A4I_\ )%?;
MU% 'Q#_PI;]HS_G\\6?^%2G_ ,D4?\*6_:,_Y_/%G_A4I_\ )%?;U% 'Q#_P
MI;]HS_G\\6?^%2G_ ,D4?\*6_:,_Y_/%G_A4I_\ )%?;U% 'Q#_PI;]HS_G\
M\6?^%2G_ ,D4?\*6_:,_Y_/%G_A4I_\ )%?;U% 'B'[&O@OXC>$/^$D_X6!-
MJTWVC[-]@^VZJM]C;YWF;<2/MZQYZ9XZXX]OHHH **** "BBB@ HHHH ^$/^
M#A;_ (*@>/O^"37[%_ACXC?#G1_!^M:WK7C6U\-SP>)+6YN;5+>6QO[AG58)
MX7$@>UC )<C!;Y22"/3_ /@C/^VMXJ_X*)?\$V?AO\8O&VG^']+\3>,/[3^V
M6NB0306$7V;5+RSC\M)I99!F.W0G=(V6+$8& /B'_@]6_P"467@'_LJNG?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M??\ /FC_ . S_P#E@?\ $*<I_P"?E3[X_P#R!][?\-I?#/\ Z&7_ ,I]U_\
M&J/^&TOAG_T,O_E/NO\ XU7P311_Q'3/O^?-'_P&?_RP/^(4Y3_S\J??'_Y
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M_B%.4_\ /RI]\?\ Y ^]O^&TOAG_ -#+_P"4^Z_^-4?\-I?#/_H9?_*?=?\
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M S_^6!_Q"G*?^?E3[X__ "!][?\ #:7PS_Z&7_RGW7_QJC_AM+X9_P#0R_\
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MPVE\,_\ H9?_ "GW7_QJO@FBC_B.F??\^:/_ (#/_P"6!_Q"G*?^?E3[X_\
MR!^@&A_M<?#WQ)K=GIUEX@\Z\U"=+:"/[#<KYDCL%49,8 R2!DD"O2*_.#X&
M_P#):_!__8;LO_1Z5^C]?L'AIQEC>(L+6K8V,(N$DER)I6:OK>4C\WXXX9PN
M35Z5+"RDU)-OF:>SMI9(****_3#X<**** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?'WQQ\1M=\;?'"TUOQ_X@O\ Q)J$%AK&EQVL-Q>7,EQ*D2OISNL8>1@H9V(
M&6)Y(!^IU%?RA?\ !,;_ ((J?"S]M'_@M!^T)^SGXIU_X@6'@GX3?\)'_9%]
MI5]:1:K<_P!G:[;:=!]HDDMI(FW0S,S[(DRX!&T94_N=_P $O_\ @WI^"_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MP]\0Z?XJ\&^*K07FF:G9L3'<)DJP*L \<B.K(\;A9(Y$='575E'85Y?^Q?\
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MI_Y19>/O^RJZC_Z:-'H _7ZBBB@#^>/_ )SK?]UX_P#=@JI\69K_ /X)0_\
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M+&TZ7QN]N_PNWXCJ62HREM_P3]K/^"HW_!4;_AVO_P (+_Q0O_":?\)I]O\
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MZC7PG_P0%^.-C\&O^"B&DV.I"TCM_'NDW7AE+JYO%MDM)G,5S#C<,2/++:I
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MKX!_X,J?^467C[_LJNH_^FC1Z /O[]N?_@J/\"?^":__  B__"Z_'7_"%_\
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MP7\,^'[C7K>WEE@FC35([C28B7,>42\MDNYK*X:+RQ+):CS(D,4<<)_P0O\
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M<6-U>7\5S-KVES_9[1GD^T71D^S7 VS-;V9OI8+B.VNV*V\CF6( _=ZBBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M3],U"^L]!^)6FW^ISV]N\L>G6[:?J=NLTS*"(XS//!$'; ,DT:YW.H/Z'?\
M!/SXZ>%?VE_V'OA+XZ\$Z7X?\/\ AGQ)X5T^YL]$T2YAN+#P[B!$DTR-H42/
M_1)%>V*JB;&@92B%2H /QA_X*3_\$O?B/_P;KZP/VI?V._'?B#3_ (9:?JMO
M+XY\#ZWJK7%A&LMU)!:))%NC^WZ>/MOV4)*7O+=I5F29V=YK?]3OVW?C7I?[
M2G_!#7XO?$;0K?4+31/'WP*UGQ)I\%_&D=U#;WGA^:XB2549T60)(H8*[ $'
M#$<GR#_@ZG\6:7X<_P""'/Q<L]0U+3[&\UZ[T*PTR"XN$BDU&X76K*X:&%6(
M,D@@@GE*+DB.&1L;48C@/V1/@IJOP!_X-#M6T+6+C3[F\OO@5XL\21O9N[QB
MWU6TU+5+="653YBP7D2N "!(KA690&(!^=__  ;H?\$O=>_X*N_L/>/?!?C[
MQW\0/ O[/?A[Q7<RI8>#=5CLIO&FN7,&E23)J E::*2WL(=/L)(4DM,F74'=
M)LQ,E?0'_!S#^Q5X5_X)V_\ ! 'X+?!WP3J'B#5/#/@_XJQ?8[K6YX9[^7[3
M::_>2>8\,449Q)<.!MC7"A0<G)/L'_!E3_RBR\??]E5U'_TT:/1_P>K?\HLO
M /\ V573O_31K% 'U?\ LZ?M0:7^Q7_P;]?"_P"+&L+I\UGX!^!6A:Q':7FH
MIIT>IW$>B6QM[(3LK!)+B?RH$PK$R3(%5V(4_GA_P2J_X)4_\/\ K^TOVR/V
MR-2\0>+/^$LU6YTWP?X/TW4/[-T&/1[7SK<JI@E:ZBMX[MIEBA62"3S+.2:9
M[K[4S-[A_P %!O">J^-/^#.S0+/1],U#5KR'X/\ @&_D@L[=YY$M[9]&N+B8
MJH)$<4$4LKN>$CC=F(521]/_ /!O%\1]+^*G_!%S]G_5-'\,:?X1L[7P_)H\
MEC9E/+GN+&\N+*XO3MC0>9=SV\MT^5)\RY?<TC9D8 _+#_@N]_P0FL_^"67[
M"?Q$\?\ [.?C#X@6/PY\;:K9V'Q,\%:KJ%K>:4FF-J$4^F36[2*DW^B7ZV\"
M%C<7+)>',JQBY\[[_P#B)^S1_P -=_\ !JWX?\"QVGB#4=0O/@!X?U72['1(
MO.O]0U'3])L]1LK:./8YD\VZM88S&B[W5V52K%6!_P '8'Q2T'X?_P#!$KXC
M:3J]]]CU#QQJNB:)HD7DR2?;;Q-3M[]HLJI"8M;&ZDW.57]UMSN95;Z?_P""
M3O\ RBR_9I_[)5X7_P#31:T ?.'_  :X_M>W'[6G_!'[P-!J4VH7>M_"F[N/
M %]<7%K!;QRI9K%+9+"(C\T<>GW-C"7=5D:2&0MN/[Q_R@_X*=_M>^,I_P#@
MMYJG[7;S>,-/^#O[,_Q@\/\ PC1K:U%EJ=XEHM[/J]A9/&5ANHW-KJID6:X$
MAAU:T215CEV1_0'[ 7QRM_\ @AO^T_\ \%+/@Y:ZAI]C9_#WP_-\3_AUIE_J
MD]QX7TY%B+6-G*UQ-',;RX&K:#:,$S).]L8_.9DA9^@^#?\ P2\TJZ_X,[-?
MTO7-$T_PSXKU;P_J'QL>^N(DU:1KBW=KVSN8?WI6VDNM%M;6U)B9#''<R;XR
MYFC< _0__@OQ\=/^&=_^"-O[0GB#^R_[8_M#PK+X8\C[3]G\O^UY8])\_=L;
M/D_;?-V8&_RMFY-V]?S@^*_[-'_#+_\ P9+7.G7%IX?AU;Q=I6A^,K^ZTJ+;
M_:']I^)=/O+62X<HC27"6,MG [,&V_9PBLR(A/E_[5?[4&J_\%?/V)?^"8GP
M'U9=0U2\^+GB!)O'0L]1?5_%T5OHURV@R:R9&5BD=Q!_;%X\L\$@5K9R9&6W
MF9_TO_X.CO\ E!1\<_\ N ?^I!IE &?_ ,&SWBS2_ 7_  ;_ 'P?UW7=2T_1
M=$T6T\27^H:A?W"6UK86\6O:H\LTLKD)'&B*S,[$!0"20!7PA^P1^S?KW_!U
MM^T=XR_:!_:/O/$&B_!+X::K%H'@;P'H.I1QV'F[HKJ[M)9O]?\ \>_V47,Z
MQ0RW+7D?E30):I GTA_P2G\)ZKX]_P"#034-"T+3-0UK6]:^&OQ"L-/T^PMW
MN;J_N);S6TBABB0%Y)'=E544$L2  2:Z#_@ST^(^E^./^"/T>EZ?X8T_0;SP
M;XUU;1]3OK<IYGB2X=;>]6]FVQJ?,6"\@M1N:0^791_,%VQH >'_ /!53_@W
M4\*_L)?LL?&CXX?LF^(OB!X!\06?A6\L_$'@_P#M:&_T'5/"\UI]GUFUS>?O
M_P#CW\R]S-/.1);XAC67[.T/U_\ \&N/_*"CX&?]Q_\ ]2#4Z]?_ ."UOQ2T
M'X/_ /!(_P#:-U;Q%??V=I]Y\/\ 5M$BE\F2;?>:A;/86<6(U8CS+JY@CW$;
M5W[F*J&8>0?\&N/_ "@H^!G_ ''_ /U(-3H ^(+CPIKW_!U;_P %'/BSX/\
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MAS^S?L=Y\.]>^W7\5G/]@UB9/[.B?.ZZE\^"+,,>!N$7F2G<-L;<X[CX:?\
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M7\PN;H)J,-LD$DMP)9#<27$%O%=L[E9 ;PHZAXV)^C_V\?\ @G)X)_X*+?\
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M08Y8X9HOJ"B@#\H?@7^RY_P5P^"?PLU3PM<?'/\ 9?\ ''VC2HM*TK5_$_\
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MDL->6UZE^VE_R<QXE_[=?_26&O+:_@WC#_D?8W_K]5_]+D?UEPW_ ,BG"_\
M7N'_ *2@HHHKYT]H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .I^!O\ R6OP?_V&
M[+_T>E?H_7YP? W_ )+7X/\ ^PW9?^CTK]'Z_ISP'_W#%?XX_P#I)^&^+/\
MO=#_  O\PHHHK]X/R4**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\X/^#C#
M_@BIXJ_X+!_"SX9_\*_U_P /Z'XV^'>JWGE_\)#?36NE3Z=>PQ_:<^1;3RM<
M":TL_+QM0(T^[<2F/H__ ()&?L0ZK_P3C_X)U?#/X-:[KFG^(M;\(6ET^H7U
MA"\=JUQ=WMQ>RQQ;_G:.-[EHED8(9!&'*1EO+7Z0HH ^0/\ @N7_ ,$V+S_@
MJE_P3[USX9Z"?#]OXVM]5T_6_"]_K=[=6MAIMY#,(YI9#;I(S;K&:]B"M'(N
MZ93@%5=//_\ @WA_X))^*O\ @D;^RQXT\+?$"3X?ZKXV\6>*WU635_##33^?
MIRVEM%;6TT\]O!*WE3"\=8R"B?:7*G,CBOO^B@#C_C]\ ?!O[4OP:\0_#WXA
M>'M/\5>#?%5H;+4],O%)CN$R&4AE(>.1'5721"LD<B(Z,KJK#\L?V;_^"2_[
M?_\ P3&\=WGA/]G'X\_!_P 3?L]Z5JMW?^'O"OQ.2[DF6*YC):&<VMBTL7ES
M,TF+2ZABEE5IC%&9Y83^OU% 'XXZS_P;U_M#?\%)_P!KC2?B%^W3\:/!_BCP
M;X0NVDT7P+X 6ZCT^2UEDEFFLEEDBMGLX]XM4:8"XNKB&,(UQ&\44H_3[]MW
MX*:K^TI^Q?\ %[X<Z%<:?::WX_\ !6L^&]/GOW>.UAN+RQFMXGE9%=UC#R*6
M*HQ !PI/!]0HH ^$/^#>G_@E_P"/O^"37[%_B?X<_$;5_!^M:WK7C6Z\203^
M&[JYN;5+>6QL+=49IX(7$@>UD) 0C!7YB20#_@X6_P""7_C[_@K+^Q?X8^'/
MPYU?P?HNMZ+XUM?$D\_B2ZN;:U>WBL;^W9%:""9S(7NHR 4 P&^8$ '[OHH
M\?\ V3OV:/\ A5'[ OPT^#OCJT\/^)?^$:^'^E^#?$-KY7VS2M5\C3HK.YCV
M3(OFV\FUQMDC&Y&PRC)%?FC^S-_P0]_;,_X))?&76(?V3?CO\+_$7P=UZ[?5
M;KPG\4+:\BC:X(GAC61;."4F2. VQ>ZMI;0W$D*"2'RXD0_L=10!^,/[6_\
MP;Z?M-?\%*OA%\1O%'[17Q<^'_BSXVKY=A\*M%TBZO=/\#^!+.34K:ZO9CMM
M5GEN)+=9;5#)#*WEQQ&66=_*>U_4[]B+X*:K^S7^Q?\ "'X<Z[<:?=ZWX \%
M:-X;U">P=Y+6:XL[&&WE>)G5':,O&Q4LBD@C*@\#U"B@#\@?^"[/_!M9XJ_X
M*F_MP^#_ (I> /%OP_\ !.GWVE6NB>-?M^GS)?OY$[;=1B\E"+ZX^RRB$1SO
M!M6QMT\XJW[G];O"?A/2_ 7A73="T+3-/T71-%M(K#3]/L+=+:UL+>) D4,4
M2 )'&B*JJB@!0   !6A10!^./_!'3_@V8\0_\$VO^"HWB#XN>(]8\'^)OA[H
M-IK%O\/%AUB]EU_3WN)E@MI[U!:V]L\G]FR7<4H5GC$DV43A73[N_P""S'[%
M7BK_ (*)?\$V?B1\'?!.H>']+\3>,/[,^QW6MSS06$7V;5+.\D\QX8I9!F.W
M<#;&V6*@X&2/J"B@#Y?_ .",_P"Q5XJ_X)V_\$V?AO\ !WQMJ'A_5/$W@_\
MM/[9=:)/-/82_:=4O+R/RWFBBD.([A =T:X8,!D8)^(=3_X((?M'?L&?MP^*
M?BU^Q%\9/A_X1\,_$757U'Q!X!\8:<]IHD$ GCN8[!$M+>:.6W$CW<<;1QVD
M]K;R>5',QDDD/Z_44 ?DC^T+_P $7OVL/^"H,'CB?]K#XJ?"^\TO1_#]^_PQ
M\ ^ 9]0L?"]EXEGTZ2UM]2U&66W6[>.WDVS*K-<MON)@ICA\RVN/L[_@C/\
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M^1/EO_AVM_U.G_E(_P#M]'_#M;_J=/\ RD?_ &^OJ2BC_B$_"G_0+_Y4J?\
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MT"_^5*G_ ,F'_$0L_P#^@C_R2'_R)\M_\.UO^IT_\I'_ -OH_P"':W_4Z?\
ME(_^WU]244?\0GX4_P"@7_RI4_\ DP_XB%G_ /T$?^20_P#D3Y;_ .':W_4Z
M?^4C_P"WT?\ #M;_ *G3_P I'_V^OJ2BC_B$_"G_ $"_^5*G_P F'_$0L_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !RCV8'[N45^$?\ PU[\6?\ HJ'Q$_\ "DO/_CE'_#7OQ9_Z*A\1/_"DO/\
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M^&O?BS_T5#XB?^%)>?\ QRC_ (:]^+/_ $5#XB?^%)>?_'*/9@?NY17X1_\
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M)>?_ !RC_AKWXL_]%0^(G_A27G_QRCV8'[N45^$?_#7OQ9_Z*A\1/_"DO/\
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M*2\_^.4?\->_%G_HJ'Q$_P#"DO/_ (Y1[,#]W**_"/\ X:]^+/\ T5#XB?\
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MG_QRCV8'[N45^$?_  U[\6?^BH?$3_PI+S_XY1_PU[\6?^BH?$3_ ,*2\_\
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M_P ->_%G_HJ'Q$_\*2\_^.4?\->_%G_HJ'Q$_P#"DO/_ (Y1[,#]W**_"/\
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MG_QRC_AKWXL_]%0^(G_A27G_ ,<H]F!^[E%?A'_PU[\6?^BH?$3_ ,*2\_\
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MXL_]%0^(G_A27G_QRCV8'[N45^$?_#7OQ9_Z*A\1/_"DO/\ XY1_PU[\6?\
MHJ'Q$_\ "DO/_CE'LP/W<HK\(_\ AKWXL_\ 14/B)_X4EY_\<H_X:]^+/_14
M/B)_X4EY_P#'*/9@?NY17X1_\->_%G_HJ'Q$_P#"DO/_ (Y1_P ->_%G_HJ'
MQ$_\*2\_^.4>S _=RBOPC_X:]^+/_14/B)_X4EY_\<H_X:]^+/\ T5#XB?\
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M%0^(G_A27G_QRC_AKWXL_P#14/B)_P"%)>?_ !RCV8'[N45^$?\ PU[\6?\
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M1_PU[\6?^BH?$3_PI+S_ ..4>S _=RBOPC_X:]^+/_14/B)_X4EY_P#'*/\
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M_#7OQ9_Z*A\1/_"DO/\ XY1_PU[\6?\ HJ'Q$_\ "DO/_CE'LP/W<HK\(_\
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MI^)+:2"Z@U0V-@LL"J]G:'RQ MJP/EL,R-\YQM7/_P"#H[_E!1\<_P#N ?\
MJ0:97@'_  94_P#*++Q]_P!E5U'_ --&CT ?K]1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M  U3\4/^BD>/?_"@N_\ XY7!44?VEB_^?LO_  )_YA_9N$_Y]1_\!7^1WO\
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MBD>/?_"@N_\ XY7!44?VEB_^?LO_  )_YA_9N$_Y]1_\!7^1WO\ PU3\4/\
MHI'CW_PH+O\ ^.4?\-4_%#_HI'CW_P *"[_^.5P5%']I8O\ Y^R_\"?^8?V;
MA/\ GU'_ ,!7^1WO_#5/Q0_Z*1X]_P#"@N__ (Y1_P -4_%#_HI'CW_PH+O_
M ..5P5%']I8O_G[+_P "?^8?V;A/^?4?_ 5_D=[_ ,-4_%#_ **1X]_\*"[_
M /CE'_#5/Q0_Z*1X]_\ "@N__CE<%11_:6+_ .?LO_ G_F']FX3_ )]1_P#
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M:6+_ .?LO_ G_F']FX3_ )]1_P# 5_D=[_PU3\4/^BD>/?\ PH+O_P".4?\
M#5/Q0_Z*1X]_\*"[_P#CE<%11_:6+_Y^R_\  G_F']FX3_GU'_P%?Y'>_P##
M5/Q0_P"BD>/?_"@N_P#XY1_PU3\4/^BD>/?_  H+O_XY7!44?VEB_P#G[+_P
M)_YA_9N$_P"?4?\ P%?Y'>_\-4_%#_HI'CW_ ,*"[_\ CE'_  U3\4/^BD>/
M?_"@N_\ XY7!44?VEB_^?LO_  )_YA_9N$_Y]1_\!7^1WO\ PU3\4/\ HI'C
MW_PH+O\ ^.4?\-4_%#_HI'CW_P *"[_^.5P5%']I8O\ Y^R_\"?^8?V;A/\
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MCWJBBBOWH_ PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M#I]Q;W6J:'K6LWUVE]IMU""9$MYIT1W-M.)H&<A"WDORO7^B>OQ)_P"#B/\
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MQF8!68;&EMW*G.2I4D*25']#F@?";PWX:^$]EX%M]'M)/".GZ3'H,6EW0-W
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MM_$$GAG1\^+?#SZEK<=S]CL[>YABMIVAA7R3<7UAJ>G2RR)Y3+]CC1X\@+$
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M[/FNZ[J6H:UK>M?#7PY?ZAJ%_</<W5_<2Z7;/+-+*Y+R2.[,S.Q)8DDDDU^
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M.],5H(Y(Q:6[7$$\=Z Q5"J;G'F'_#9'_!9+_HT[]G__ ,&]M_\ -#0!Q_\
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MY9Z;)9V4=U-)#IXFO;M;J*\M8I;B!+C-Q#)'<)+)&\G[J'H/^"J'[&G[=_\
MP67_ &8/%L/C;X2^#_A;HG@Z[M]3\!?#72_%^GZEK^MZR)=/MWO-0U%O]":S
MCL;G6S&D4MI()&0/',$C=@#]+O\ @D[_ ,HLOV:?^R5>%_\ TT6M?D#_ ,&,
M?_-T7_<J?^YJOV>_X)[?"W7O@=^P+\#_  3XIL?[+\3>#_A_H.B:O9^='/\
M9+RVTZWAGB\R-FC?;(C+N1F4XR"1@U^</_!J5_P2X^.W_!-?_A?7_"ZO O\
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M-\=!_P""CWCO2?B]\,_%7_"G?VA/#.RXMO$EI%(D.ORVT>;$73PLLL%Q#,D
MCOHM\L42E3',(X!#\X:)_P %@OVM/^"+_P"T_P"$_ O[?'_"'^.OA;\1+NZ3
M2_B-X7@M_M5H8XK$R2);VL<#R6=L\ZK+'+91W#&:5XGN%B2&3Z?_ &F_B[_P
M4,_9Z_X**^*;_P"&WPC\'_M!?LXZ]:6%QI.D/XBTOP[J?A]TLFAN(([N9XI!
M))> W#F:&\C,)B2-X6,@3YP_:R_8L_;:_P""\/QV\(?#_P"/OPQ\/_LS?LR^
M&-57Q/=QZ;XCTSQ%KVH3QVZVX@6YAEDW7#>==B)_L\$$4=Q(TJW,D,*2 '[/
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!^2/_  4Y
M_P"3X?&__;A_Z06U>"U[U_P4Y_Y/A\;_ /;A_P"D%M7@M?R3Q)_R-\5_U\G_
M .E,_KKAK_D487_KW3_])04445XI[04444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?K=_P3&_
MY,>\$?\ ;_\ ^E]S7Y(U^MW_  3&_P"3'O!'_;__ .E]S7Z=X4?\C>I_U[?_
M *5 _+_%C_D44_\ KXO_ $F9[U1117]!'\]A1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110!^0/_!N)_P I3?\ @IQ_V55/_3OXDKY__P""^G_*
MTU^Q7_W(W_J77U?;_P#P13_8*^+'[)'[?7[=7C;XA>%/^$?\,_&3X@+K?@^\
M_M.SN_[7LQJ.MS&7RX)7DA_=WENVV94;]YC&58#R#_@KO_P2X^.W[4'_  7T
M_9@^-?@7P+_;GPR^'?\ PBG_  D.L_VUI]K_ &?]B\17=[<_N)ITGDV6\J/^
M[C;=NVKN8%0 ?K]7X _\$"_^5IK]M3_N>?\ U+K&OW^K\@?^"1'_  2X^.W[
M+_\ P7T_:?\ C7XZ\"_V'\,OB)_PE?\ PCVL_P!M:?=?VA]M\16E[;?N(9WG
MCWV\3O\ O(UV[=K;6(4@'E_PTUGP;I?_  >]_$*#Q1I.H:EK>I>'XK?PC<6[
ME8]+U0>$]/EDGF D3=&=/CU&$ K(/,GC.P$"2/\ <ZOS@_X+L_\ !&37OVW]
M8\'_ !^^">K?V!^TU\%_LMWX9-U)&]AX@BL[IKVWM&2?=!%<1W#/)#*Z^4[2
M-%.#&Z2V_(:-^W'_ ,%5(/@UJUCJ'[%/PONOB%-=J^F:U;^/=-@T:SM\Q;HY
MM.;4WFFD($X$BWL0!DC.P^6PD /O[]M;]E_2_P!M3]D?XC?"?6&T^&S\?>'[
MO1X[N\TY-1CTRXDC(M[T0,RAY+>?RITPRD20H59& 8?EC_P01_X*%_\ #$G_
M  1M_:!\'_$JU\/Z?XV_8GU77+._\/27WV'[1YLMQ<6MK+?DRVSW%SJPU"SC
M-N7_ -7 !&Y=&E_3[]@K_A<DO[)WA2Z_:!_X1^/XNZE]LU'7K31-OV#2OM%Y
M//;6$97(;[+:R06Y8/+N:!CYT^?.?\(?^"ZG[(VO?\/VXO@+\(=8\0>&?#_[
M;&E>'+[X@Z7I>EQWUAYJZS,)M2^Q1(F?L_\ 9IU"68N)=TE^S3I%/*M 'Z ?
M\&L/[-'BKPE^QMXV^/GQ*M/^+F_M0>*[CQE?W\D4UI<W^G;G-K)+:E(X(?-N
M)M0NHVMTV207T#!BNQ(_C_\ X+Z?\K37[%?_ '(W_J77U?N]\)_A;H/P.^%G
MAGP3X6L?[+\,^#]*M=$TBS\Z2?[)9VT*0P1>9(S2/MC15W.S,<9))R:_/#_@
MO[_P2\^*'[4OQ"^!/[0'P!T3P?KWQB_9_P#$$&I1Z%JD45K)XJMTO;6ZMXGO
M&EA!CM9X9'\B26,-'=W31R))A)@#ZO\ ^"L7_*++]I;_ +)5XH_]-%U7X0_\
M$ O^"27Q4_;H_8>U#QC\*?VT/C!\!M/L_%=YI6M>&-$T^[AL#J,<%K)]IC>V
MU> 3;[66T!D>&-PR,F&6-'?]OO\ @G'\=OVH/C9_PD7_  T=\#?#_P %_P"R
M-*TB'2_[-\2VNM?\)#J+?;/[3N%^SSR?9K<;;+RK>3<Z;Y,SSY_=_G#X4_X)
MN?MY_P#!$W]H[XB-^QSHOP_^+GP+^)&JW6I:=X-UO53'#X4^:%H6DCO+VVD%
MPD;-:B:&ZF^T16RO<(KB!8P#H/BE_P &MGQ]^./@2^\+>-O^"B?Q@\8>&=4\
MO[9I&MZ3J.H6%WY<BRQ^9!-K31OMD1'&X'#(I'(!K[^^)?\ P3&T'XP?\$C[
M;]E+Q%K7]HZ?9_#_ $WP;%KWV.2'9>:?;0)9ZE]FCG4GR[JV@N/(,VUMGELS
M*6S\H_&OX_?\%5/VGO%5OX7^'/P!^%_[,>B:I:*D_BSQ)XQTWQ7=:3<1.\S2
M*T#2)Y<R)';B,Z;.5,C-O0$/#^IU 'R!X9_8L_X><_\ !./X6^$_VU_AC]H\
M;:/Y&H:_HW_"1[=VL6B7%D-0\_2988O])ADDN/(C8QQ?:O+P3&&'/_\ $-Y^
MQ+_PM/\ X3'_ (4'X?\ [6_M7^V?L_\ :VI_V5Y_G>=L_L[[3]C^S[N/LWD^
M1L^3R]GRU]OT4 ?/_P#P4ZL_C)XF_8V\4>%O@'IOG?$WQUY7AFPU>34ET^V\
M)07;>5=:O+.)XIT^S6YE>-K433K/Y!6"10X'H'[*O[-'A7]C?]G'P7\+?!-I
M]C\,^!]*ATJSW10QS76Q?WES/Y*1QM<32%YI9%1?,EED<C+&O0** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OD
M#_@JW_P3B^*G_!0/_A O^%9_M.?$#]G'_A$?[0_M+_A&$NV_X2'[3]E\KSOL
M]]:_ZCR)-N[?_P ?#XV\[OK^B@#\@?\ B'$_:F_Z2<?M ?\ ?G5__EY1_P 0
MXG[4W_23C]H#_OSJ_P#\O*_7ZB@#\@?^(<3]J;_I)Q^T!_WYU?\ ^7E'_$.)
M^U-_TDX_: _[\ZO_ /+ROU^HH _.#]@K_@BG\??V2/VL?"GQ"\;?MU?&#XR>
M&?#_ -L^V>#];CU$6&K^=9SV\?F&;59X_P!U)*DPW1-\T*XVG##]'Z** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?DC_P %.?\
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M_P C4?ZEYW_T#2_#_,/]=,C_ .@F/X_Y'R117UO_ ,.9OBA_T'O 7_@;=_\
MR-1_PYF^*'_0>\!?^!MW_P#(U'^I>=_] TOP_P P_P!=,C_Z"8_C_D?)%%?6
M_P#PYF^*'_0>\!?^!MW_ /(U'_#F;XH?]![P%_X&W?\ \C4?ZEYW_P! TOP_
MS#_73(_^@F/X_P"1\D45];_\.9OBA_T'O 7_ (&W?_R-1_PYF^*'_0>\!?\
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M,C_Z"8_C_D?)%%?6_P#PYF^*'_0>\!?^!MW_ /(U'_#F;XH?]![P%_X&W?\
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M[P%_X&W?_P C4?ZEYW_T#2_#_,/]=,C_ .@F/X_Y'R117UO_ ,.9OBA_T'O
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M#/ZO44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M:Q11G$EQ,VXJ6._!.   #]'Z*** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P" MQ_\?H_X>?>/O^@1X/\ _ 6X_P#C]?=U%',NP'PC_P //O'W_0(\'_\
M@+<?_'Z/^'GWC[_H$>#_ /P%N/\ X_7W=11S+L!\(_\ #S[Q]_T"/!__ ("W
M'_Q^C_AY]X^_Z!'@_P#\!;C_ ./U]W44<R[ ?"/_  \^\??] CP?_P" MQ_\
M?H_X>?>/O^@1X/\ _ 6X_P#C]?=U%',NP'PC_P //O'W_0(\'_\ @+<?_'Z/
M^'GWC[_H$>#_ /P%N/\ X_7W=11S+L!\(_\ #S[Q]_T"/!__ ("W'_Q^C_AY
M]X^_Z!'@_P#\!;C_ ./U]W44<R[ ?"/_  \^\??] CP?_P" MQ_\?H_X>?>/
MO^@1X/\ _ 6X_P#C]?=U%',NP'PC_P //O'W_0(\'_\ @+<?_'Z/^'GWC[_H
M$>#_ /P%N/\ X_7W=11S+L!\(_\ #S[Q]_T"/!__ ("W'_Q^C_AY]X^_Z!'@
M_P#\!;C_ ./U]W44<R[ ?"/_  \^\??] CP?_P" MQ_\?H_X>?>/O^@1X/\
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M ("W'_Q^C_AY]X^_Z!'@_P#\!;C_ ./U]W44<R[ ?"/_  \^\??] CP?_P"
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M_P#C]?=U%',NP'PC_P //O'W_0(\'_\ @+<?_'Z/^'GWC[_H$>#_ /P%N/\
MX_7W=11S+L!\(_\ #S[Q]_T"/!__ ("W'_Q^C_AY]X^_Z!'@_P#\!;C_ ./U
M]W44<R[ ?"/_  \^\??] CP?_P" MQ_\?H_X>?>/O^@1X/\ _ 6X_P#C]?=U
M%',NP'PC_P //O'W_0(\'_\ @+<?_'Z/^'GWC[_H$>#_ /P%N/\ X_7W=11S
M+L!\(_\ #S[Q]_T"/!__ ("W'_Q^C_AY]X^_Z!'@_P#\!;C_ ./U]W44<R[
M?"/_  \^\??] CP?_P" MQ_\?H_X>?>/O^@1X/\ _ 6X_P#C]?=U%',NP'PC
M_P //O'W_0(\'_\ @+<?_'Z/^'GWC[_H$>#_ /P%N/\ X_7W=11S+L!\(_\
M#S[Q]_T"/!__ ("W'_Q^C_AY]X^_Z!'@_P#\!;C_ ./U]W44<R[ ?"/_  \^
M\??] CP?_P" MQ_\?H_X>?>/O^@1X/\ _ 6X_P#C]?=U%',NP'PC_P //O'W
M_0(\'_\ @+<?_'Z/^'GWC[_H$>#_ /P%N/\ X_7W=11S+L!\(_\ #S[Q]_T"
M/!__ ("W'_Q^C_AY]X^_Z!'@_P#\!;C_ ./U]W44<R[ ?"/_  \^\??] CP?
M_P" MQ_\?H_X>?>/O^@1X/\ _ 6X_P#C]?=U%',NP'PC_P //O'W_0(\'_\
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M_P#\!;C_ ./U]W44<R[ ?"/_  \^\??] CP?_P" MQ_\?H_X>?>/O^@1X/\
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M ("W'_Q^C_AY]X^_Z!'@_P#\!;C_ ./U]W44<R[ ?"/_  \^\??] CP?_P"
MMQ_\?H_X>?>/O^@1X/\ _ 6X_P#C]?=U%',NP'PC_P //O'W_0(\'_\ @+<?
M_'Z/^'GWC[_H$>#_ /P%N/\ X_7W=11S+L!\(_\ #S[Q]_T"/!__ ("W'_Q^
MC_AY]X^_Z!'@_P#\!;C_ ./U]W44<R[ ?"/_  \^\??] CP?_P" MQ_\?H_X
M>?>/O^@1X/\ _ 6X_P#C]?=U%',NP'PC_P //O'W_0(\'_\ @+<?_'Z/^'GW
MC[_H$>#_ /P%N/\ X_7W=11S+L!\(_\ #S[Q]_T"/!__ ("W'_Q^C_AY]X^_
MZ!'@_P#\!;C_ ./U]W44<R[ ?"/_  \^\??] CP?_P" MQ_\?H_X>?>/O^@1
MX/\ _ 6X_P#C]?=U%',NP'PC_P //O'W_0(\'_\ @+<?_'Z/^'GWC[_H$>#_
M /P%N/\ X_7W=11S+L!\(_\ #S[Q]_T"/!__ ("W'_Q^C_AY]X^_Z!'@_P#\
M!;C_ ./U]W44<R[ ?"/_  \^\??] CP?_P" MQ_\?H_X>?>/O^@1X/\ _ 6X
M_P#C]?=U%',NP'PC_P //O'W_0(\'_\ @+<?_'Z/^'GWC[_H$>#_ /P%N/\
MX_7W=11S+L!\(_\ #S[Q]_T"/!__ ("W'_Q^C_AY]X^_Z!'@_P#\!;C_ ./U
M]W44<R[ ?"/_  \^\??] CP?_P" MQ_\?H_X>?>/O^@1X/\ _ 6X_P#C]?=U
M%',NP'PC_P //O'W_0(\'_\ @+<?_'Z/^'GWC[_H$>#_ /P%N/\ X_7W=11S
M+L!\(_\ #S[Q]_T"/!__ ("W'_Q^C_AY]X^_Z!'@_P#\!;C_ ./U]W44<R[
M?"/_  \^\??] CP?_P" MQ_\?H_X>?>/O^@1X/\ _ 6X_P#C]?=U%',NP'PC
M_P //O'W_0(\'_\ @+<?_'Z/^'GWC[_H$>#_ /P%N/\ X_7W=11S+L!\(_\
M#S[Q]_T"/!__ ("W'_Q^C_AY]X^_Z!'@_P#\!;C_ ./U]W44<R[ ?"/_  \^
M\??] CP?_P" MQ_\?H_X>?>/O^@1X/\ _ 6X_P#C]?=U%',NP'PC_P //O'W
M_0(\'_\ @+<?_'Z/^'GWC[_H$>#_ /P%N/\ X_7W=11S+L!\(_\ #S[Q]_T"
M/!__ ("W'_Q^C_AY]X^_Z!'@_P#\!;C_ ./U]W44<R[ ?"/_  \^\??] CP?
M_P" MQ_\?H_X>?>/O^@1X/\ _ 6X_P#C]?=U%',NP'PC_P //O'W_0(\'_\
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M_P#\!;C_ ./U]W44<R[ ?"/_  \^\??] CP?_P" MQ_\?H_X>?>/O^@1X/\
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M ("W'_Q^C_AY]X^_Z!'@_P#\!;C_ ./U]W44<R[ ?"/_  \^\??] CP?_P"
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M_P#C]?=U%',NP'PC_P //O'W_0(\'_\ @+<?_'Z/^'GWC[_H$>#_ /P%N/\
MX_7W=11S+L!\(_\ #S[Q]_T"/!__ ("W'_Q^C_AY]X^_Z!'@_P#\!;C_ ./U
M]W44<R[ ?"/_  \^\??] CP?_P" MQ_\?H_X>?>/O^@1X/\ _ 6X_P#C]?=U
M%',NP'PC_P //O'W_0(\'_\ @+<?_'Z/^'GWC[_H$>#_ /P%N/\ X_7W=11S
M+L!\(_\ #S[Q]_T"/!__ ("W'_Q^C_AY]X^_Z!'@_P#\!;C_ ./U]W44<R[
M?"/_  \^\??] CP?_P" MQ_\?H_X>?>/O^@1X/\ _ 6X_P#C]?=U%',NP'PC
M_P //O'W_0(\'_\ @+<?_'Z/^'GWC[_H$>#_ /P%N/\ X_7W=11S+L!\(_\
M#S[Q]_T"/!__ ("W'_Q^C_AY]X^_Z!'@_P#\!;C_ ./U]W44<R[ ?"/_  \^
M\??] CP?_P" MQ_\?H_X>?>/O^@1X/\ _ 6X_P#C]?=U%',NP'PC_P //O'W
M_0(\'_\ @+<?_'Z/^'GWC[_H$>#_ /P%N/\ X_7W=11S+L!\(_\ #S[Q]_T"
M/!__ ("W'_Q^C_AY]X^_Z!'@_P#\!;C_ ./U]W44<R[ ?"/_  \^\??] CP?
M_P" MQ_\?H_X>?>/O^@1X/\ _ 6X_P#C]?=U%',NP'PC_P //O'W_0(\'_\
M@+<?_'Z/^'GWC[_H$>#_ /P%N/\ X_7W=11S+L!\(_\ #S[Q]_T"/!__ ("W
M'_Q^C_AY]X^_Z!'@_P#\!;C_ ./U]W44<R[ ?"/_  \^\??] CP?_P" MQ_\
M?H_X>?>/O^@1X/\ _ 6X_P#C]?=U%',NP'PC_P //O'W_0(\'_\ @+<?_'Z/
M^'GWC[_H$>#_ /P%N/\ X_7W=11S+L!\(_\ #S[Q]_T"/!__ ("W'_Q^C_AY
M]X^_Z!'@_P#\!;C_ ./U]W44<R[ ?"/_  \^\??] CP?_P" MQ_\?H_X>?>/
MO^@1X/\ _ 6X_P#C]?=U%',NP'PC_P //O'W_0(\'_\ @+<?_'Z/^'GWC[_H
M$>#_ /P%N/\ X_7W=11S+L!\(_\ #S[Q]_T"/!__ ("W'_Q^C_AY]X^_Z!'@
M_P#\!;C_ ./U]W44<R[ ?"/_  \^\??] CP?_P" MQ_\?H_X>?>/O^@1X/\
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M ("W'_Q^C_AY]X^_Z!'@_P#\!;C_ ./U]W44<R[ ?"/_  \^\??] CP?_P"
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M_P#C]?=U%',NP'PC_P //O'W_0(\'_\ @+<?_'Z/^'GWC[_H$>#_ /P%N/\
MX_7W=11S+L!\(_\ #S[Q]_T"/!__ ("W'_Q^C_AY]X^_Z!'@_P#\!;C_ ./U
M]W44<R[ ?"/_  \^\??] CP?_P" MQ_\?H_X>?>/O^@1X/\ _ 6X_P#C]?=U
M%',NP'PC_P //O'W_0(\'_\ @+<?_'Z/^'GWC[_H$>#_ /P%N/\ X_7W=11S
M+L!\(_\ #S[Q]_T"/!__ ("W'_Q^C_AY]X^_Z!'@_P#\!;C_ ./U]W44<R[
M?"/_  \^\??] CP?_P" MQ_\?H_X>?>/O^@1X/\ _ 6X_P#C]?=U%',NP'PC
M_P //O'W_0(\'_\ @+<?_'Z/^'GWC[_H$>#_ /P%N/\ X_7W=11S+L!\(_\
M#S[Q]_T"/!__ ("W'_Q^C_AY]X^_Z!'@_P#\!;C_ ./U]W44<R[ ?"/_  \^
M\??] CP?_P" MQ_\?H_X>?>/O^@1X/\ _ 6X_P#C]?=U%',NP'PC_P //O'W
M_0(\'_\ @+<?_'Z/^'GWC[_H$>#_ /P%N/\ X_7W=11S+L!\(_\ #S[Q]_T"
M/!__ ("W'_Q^C_AY]X^_Z!'@_P#\!;C_ ./U]W44<R[ ?"/_  \^\??] CP?
M_P" MQ_\?H_X>?>/O^@1X/\ _ 6X_P#C]?=U%',NP'PC_P //O'W_0(\'_\
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M_P#\!;C_ ./U]W44<R[ ?"/_  \^\??] CP?_P" MQ_\?H_X>?>/O^@1X/\
M_ 6X_P#C]?=U%',NP'PC_P //O'W_0(\'_\ @+<?_'Z/^'GWC[_H$>#_ /P%
MN/\ X_7W=11S+L!\(_\ #S[Q]_T"/!__ ("W'_Q^C_AY]X^_Z!'@_P#\!;C_
M ./U]W44<R[ ?"/_  \^\??] CP?_P" MQ_\?H_X>?>/O^@1X/\ _ 6X_P#C
M]?=U%',NP'PC_P //O'W_0(\'_\ @+<?_'Z/^'GWC[_H$>#_ /P%N/\ X_7W
M=11S+L!\(_\ #S[Q]_T"/!__ ("W'_Q^C_AY]X^_Z!'@_P#\!;C_ ./U]W44
M<R[ ?"/_  \^\??] CP?_P" MQ_\?H_X>?>/O^@1X/\ _ 6X_P#C]?=U%',N
MP'PC_P //O'W_0(\'_\ @+<?_'Z/^'GWC[_H$>#_ /P%N/\ X_7W=11S+L!\
M(_\ #S[Q]_T"/!__ ("W'_Q^C_AY]X^_Z!'@_P#\!;C_ ./U]W44<R[ ?"/_
M  \^\??] CP?_P" MQ_\?H_X>?>/O^@1X/\ _ 6X_P#C]?=U%',NP'PC_P /
M/O'W_0(\'_\ @+<?_'Z/^'GWC[_H$>#_ /P%N/\ X_7W=11S+L!\(_\ #S[Q
M]_T"/!__ ("W'_Q^C_AY]X^_Z!'@_P#\!;C_ ./U]W44<R[ ?"/_  \^\??]
M CP?_P" MQ_\?H_X>?>/O^@1X/\ _ 6X_P#C]?=U%',NP'PC_P //O'W_0(\
M'_\ @+<?_'Z/^'GWC[_H$>#_ /P%N/\ X_7W=11S+L!\(_\ #S[Q]_T"/!__
M ("W'_Q^C_AY]X^_Z!'@_P#\!;C_ ./U]W44<R[ ?"/_  \^\??] CP?_P"
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M_P#C]?=U%',NP'PC_P //O'W_0(\'_\ @+<?_'Z/^'GWC[_H$>#_ /P%N/\
MX_7W=11S+L!\(_\ #S[Q]_T"/!__ ("W'_Q^C_AY]X^_Z!'@_P#\!;C_ ./U
M]W44<R[ ?"/_  \^\??] CP?_P" MQ_\?H_X>?>/O^@1X/\ _ 6X_P#C]?=U
M%',NP'PC_P //O'W_0(\'_\ @+<?_'Z/^'GWC[_H$>#_ /P%N/\ X_7W=11S
M+L!\(_\ #S[Q]_T"/!__ ("W'_Q^C_AY]X^_Z!'@_P#\!;C_ ./U]W44<R[
M?"/_  \^\??] CP?_P" MQ_\?H_X>?>/O^@1X/\ _ 6X_P#C]?=U%',NP'PC
M_P //O'W_0(\'_\ @+<?_'Z/^'GWC[_H$>#_ /P%N/\ X_7W=11S+L!\(_\
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M[OHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M*;[^R_#/@_2KK6]7O/)DG^R6=M"\T\OEQJTC[8T9MJ*S'& "<"OPA_X)/_\
M!;K]K#]L#_@LE\(M \=>)?[)^"7QR_X27Q/X>\*?V=H]QY6CPQ:W';0?;(;5
M+H_9[O37BWR&.23[+O92D@W '[_4444 %%%?@#_P0+_Y6FOVU/\ N>?_ %+K
M&@#]_J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\0?^"OO[6/Q4
M^&?_  43^(>B>&_B7\0/#^BV/]F_9[#3?$-W:6L&_3+1VV1QR!5W.S,<#DL3
MU)KYJ_X;L^-__19/BK_X5E__ /':]5_X+:?\I.OB9_W"_P#TTV=?*M?MF4X6
MB\%1;@K\D>B[(^5Q%2:JRU>[_,]5_P"&[/C?_P!%D^*O_A67_P#\=H_X;L^-
M_P#T63XJ_P#A67__ ,=KRJBO0^IT/Y%]R,?:3[L]5_X;L^-__19/BK_X5E__
M /':/^&[/C?_ -%D^*O_ (5E_P#_ !VO*J*/J=#^1?<@]I/NSU7_ (;L^-__
M $63XJ_^%9?_ /QVC_ANSXW_ /19/BK_ .%9?_\ QVO*J*/J=#^1?<@]I/NS
MU7_ANSXW_P#19/BK_P"%9?\ _P =H_X;L^-__19/BK_X5E__ /':\JHH^IT/
MY%]R#VD^[/5?^&[/C?\ ]%D^*O\ X5E__P#':/\ ANSXW_\ 19/BK_X5E_\
M_':\JHH^IT/Y%]R#VD^[/5?^&[/C?_T63XJ_^%9?_P#QVC_ANSXW_P#19/BK
M_P"%9?\ _P =KRJBCZG0_D7W(/:3[L]5_P"&[/C?_P!%D^*O_A67_P#\=H_X
M;L^-_P#T63XJ_P#A67__ ,=KRJBCZG0_D7W(/:3[L]5_X;L^-_\ T63XJ_\
MA67_ /\ ':/^&[/C?_T63XJ_^%9?_P#QVO*J*/J=#^1?<@]I/NSU7_ANSXW_
M /19/BK_ .%9?_\ QVC_ (;L^-__ $63XJ_^%9?_ /QVO*J*/J=#^1?<@]I/
MNSU7_ANSXW_]%D^*O_A67_\ \=H_X;L^-_\ T63XJ_\ A67_ /\ ':\JHH^I
MT/Y%]R#VD^[/5?\ ANSXW_\ 19/BK_X5E_\ _':/^&[/C?\ ]%D^*O\ X5E_
M_P#':\JHH^IT/Y%]R#VD^[/5?^&[/C?_ -%D^*O_ (5E_P#_ !VC_ANSXW_]
M%D^*O_A67_\ \=KRJBCZG0_D7W(/:3[L]5_X;L^-_P#T63XJ_P#A67__ ,=H
M_P"&[/C?_P!%D^*O_A67_P#\=KRJBCZG0_D7W(/:3[L]5_X;L^-__19/BK_X
M5E__ /':/^&[/C?_ -%D^*O_ (5E_P#_ !VO*J*/J=#^1?<@]I/NSU7_ (;L
M^-__ $63XJ_^%9?_ /QVC_ANSXW_ /19/BK_ .%9?_\ QVO*J*/J=#^1?<@]
MI/NSU7_ANSXW_P#19/BK_P"%9?\ _P =H_X;L^-__19/BK_X5E__ /':\JHH
M^IT/Y%]R#VD^[/5?^&[/C?\ ]%D^*O\ X5E__P#':/\ ANSXW_\ 19/BK_X5
ME_\ _':\JHH^IT/Y%]R#VD^[/5?^&[/C?_T63XJ_^%9?_P#QVC_ANSXW_P#1
M9/BK_P"%9?\ _P =KRJBCZG0_D7W(/:3[L]5_P"&[/C?_P!%D^*O_A67_P#\
M=H_X;L^-_P#T63XJ_P#A67__ ,=KRJBCZG0_D7W(/:3[L]5_X;L^-_\ T63X
MJ_\ A67_ /\ ':/^&[/C?_T63XJ_^%9?_P#QVO*J*/J=#^1?<@]I/NSU7_AN
MSXW_ /19/BK_ .%9?_\ QVC_ (;L^-__ $63XJ_^%9?_ /QVO*J*/J=#^1?<
M@]I/NSU7_ANSXW_]%D^*O_A67_\ \=H_X;L^-_\ T63XJ_\ A67_ /\ ':\J
MHH^IT/Y%]R#VD^[/5?\ ANSXW_\ 19/BK_X5E_\ _':/^&[/C?\ ]%D^*O\
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MCKOB?4/&VM^%?#]AH^H>(K\.+K7[BWMHX9;V7?)(_F3.C2-ND<Y<Y9CR>PH
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M%8O^467[2W_9*O%'_IHNJ^ ?^#*G_E%EX^_[*KJ/_IHT>@#]?J*** "BBB@
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MY:32Q1G$EPA.Z1<*&(R< @'L%%?/_P#P2X_;G_X>4?L)^!?C5_PB_P#PA?\
MPFGV_P#XDW]I?VE]C^RZA<V7^O\ *BW[OL^__5KC?MYQN/T!0 4444 %%%%
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M  7D_P""<7C[_@J5^P9-\+_ASXVT_P &ZVOB"QUB>+4YKF'3-?MX?,5K*Z>
M.ZQAY([E<Q2@S6<(VJ2)8P#[/HKC_P!GKX<:K\'/@%X'\(Z[XGU#QMK?A7P_
M8:/J'B*_#BZU^XM[:.&6]EWR2/YDSHTC;I'.7.68\GL* "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH _('_ (/5O^467@'_ +*KIW_IHUBO?_\
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M_@_PSI?E_;-7UO48=/L+3S)%BC\R>9EC3=(Z(-Q&6=0.2!7G_P"P5XR^,GQ
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M[!_X5?\ $W4/.N/^$K\*PI;_ &VZ?[3)YE_9X$%WON+CS99,1W4OE(GVE%%
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MG/CWQ;HUKI^C?#FW\B]0MLL+1!->7,[VQ@65+@ V4F;>2(SR0_M=_P $G?\
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MFZW:V-Q,DLO]F7=U+:[[:.!S##YT<FH$CS&W2E 9>/\ ^"='_!9O]H+X!_\
M!1RW_8[_ &VM)\/KXPUK=%X3\?V,<.FVWB"5WN)+=W/[JVN+>[51;VSVT44J
MSQ);RPO/)*8?U^K\,?\ @\8\3>,O!?Q]_8EUCX<QZA-\0M)\0:Y>>&(["P%_
M=/JD=SH+V@BMRCB:0SB,+&48.<+M;." >H?\'6O_  5'^.W_  37_P"%"_\
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M_P#XA<?V$_\ HAO_ )>?B#_Y.H /^(HW]A/_ *+E_P"69X@_^0:\ _X,J?\
ME%EX^_[*KJ/_ *:-'KW_ /XA<?V$_P#HAO\ Y>?B#_Y.KP#_ (,J?^467C[_
M +*KJ/\ Z:-'H ] _P""JO\ P55^,GB_]LG3?V-_V-]-\WX[2_9M2\8>,-2T
M]9-*\ Z<RPW 9A/%)$VZ&:%I9FCD1$GCAA2:ZG58//\ ]L7X<_\ !3_]A?\
M9QA^,6G_ +47P_\ C!#\/]*;Q-X[\)7?@32M(A$%JL,UU!:SI;K)>6XC%T9'
M\RQG,4(,2F:143X/_9H\#_M1_M'_ /!P+^V+>?LX_&OP?X%^+&D^(/$5A<3^
M,TFOY+_P_#K:VXA@:33[V%8[8V^FQ!&\MUC\I8@T:R!/O#_AC;_@LE_T=C^S
M_P#^"BV_^9Z@#[^_X)B_\%"_"O\ P5 _8V\+_%SPM:_V3_:WFV>KZ))?0W=S
MX?U&%MD]K*T9_P!V6,NL;R0302&./S H_%'_ ((__P#!8[_@HS_P4CU'X@_#
MGP-J7@_QEXBN+2"<^/?%NC6NGZ-\.;?R+U"VRPM$$UY<SO;&!94N #929MY(
MC/)#^G__  ;T_P#!+_Q]_P $FOV+_$_PY^(VK^#]:UO6O&MUXD@G\-W5S<VJ
M6\MC86ZHS3P0N) ]K(2 A&"OS$D@?GA_P8Q_\W1?]RI_[FJ .P_X*._M=?\
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MVW\^6]\(P^!=&M;":)%G:-+/4YK%?-N)-MNH2>WMH@TS[I@L8>3Z/_X(<?\
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M3:0R7$GFPB22XG22&.-9D"%7EE=%2-)_,(/V>?\ @KI\;_'>D>(M3^/?[/\
M\%_#^O\ V&74O#>B:)%JTWA>)HXA<)&ESI]Q]HN$_>,4.H-$\NY4F6(J5 /H
M_P#X(-_\%0-5_P""LO[!D/Q&\2Z/I^B^,M%\07WAOQ!!IEJ]MICW$7EW$3VJ
MR3S2F,VEU:AC(X/G";"A I/YH?\ ! O_ )6FOVU/^YY_]2ZQKZ _X,J?^467
MC[_LJNH_^FC1Z^?_ /@@7_RM-?MJ?]SS_P"I=8T ?O\ 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% 'X _\ !;3_ )2=?$S_ +A?_IILZ^5:^JO^
M"VG_ "DZ^)G_ '"__339U\JU^Z91_N-'_!'_ -)1\CB?XTO5_F%%%%>@8A11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MT6RLX=&TZX6Q&E6&GPV<#QR7$LEKK9F:>PE18MF)DD,8'0?\',/@WXR?#_\
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M0?I__@WBT;P;H/\ P1<_9_@\":MJ&M:))X?DN+FXO$*R1ZI+>7$NJ0 &./\
M=PZ@]W"AVD&.)"'D!$C 'Y8?\%WO$'[<W[&W["?Q$\$_M&>.OA_\>/A%\9=5
ML_#WA[Q+I5G;:)JOAB\LM0BU.V>XM(;6$-]LM;.X5X5:X6)X01<)M"W7Z'ZQ
MXY^*'PK_ .#83P;XN^#?B33_  C\0O!?P*\->)+'5+RVBN8X+>QTRRN[U!'+
M#-&TDEG#<QH'C(\R1,LGWUT/^#H[_E!1\<_^X!_ZD&F5[?\ \$RO">E^/?\
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MJVH:EK>I>-=6N/%UO<(5CTO5 MO%'!"3&FZ,Z?'ITQ(:0>9/(-X(,<8!X?\
M\%5%_P""@G_!/G]ECXT>(?B9\7?A_P#M*?L]^)/"MYX(U)/[#LO"VO:/_;%I
M]ABU7R+>V"CR+Z>.+REN;GS8Y<F.(L9;;Z__ .#7'_E!1\#/^X__ .I!J=>_
M_P#!6+_E%E^TM_V2KQ1_Z:+JO /^#7'_ )04? S_ +C_ /ZD&IT >(?MA_\
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M+P3=_;/#/CC2H=5L]TL,DUKO7]Y;3^2\D:W$,@>&6-7;RY8I$)RIKT"OE_\
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M7\8:+HFB^((?$D$_ANZMK:Z>XBMKFW5&:>"9#&4NI"0$!R%^8 $'\ ?VM/\
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MRR-/'9VCRR3O(H,;1$1BU4J[&5E3]+_^#H[_ )04?'/_ +@'_J0:90!\(?\
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MW^VM,U&70-/_ +3D1+Q+-D2:TV2>;"WV61LO&T:21Q$E7\HGXJ\;_P#!1O\
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M7<*DNP%_TOHH _+'_@D[^Q?\>OVB/^"EWCK]MS]I;P?I_P /;S7O#Z:!\.?
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MWMKJPN(M+MDEAEB<!XY$=65D8 J000"*]PHH **** /Q!_X(D_LG?%3X4?\
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M$;P/XP\ :W=_$J_OX-/\2:-<Z5=36[:7I2+,L4Z([1EXY%#@8)C89RIQX?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ]5_83_P"3WO@W_P!C
MSHG_ *7P5_2G7\UG["?_ ">]\&_^QYT3_P!+X*_I3K\UXZ_CTO1_F>]E/P2]
M0HHHKX4]8**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\?_;\^/OBK]E_]C;XA
M>.O O@KQ!\1/&VAZ4W_"/>'M&T>;5[G4-1E98+;?;0NDLENDTJ23^6P=8(YF
M7)4 ^P44 ?S0_P#!)O\ :;_::_X)N?%/XO?$SQ3^P/\ M ?%_P"+OQDU5[_5
M_%$WAZ]T3[-%),]S/#!#'HLIB\^ZE:68)(L3^3:@1)Y 9ON#_B([_:F_Z1C_
M +0'_?W5_P#Y1U^OU% 'P!^RK^U5\5/^"T?[+'[1'PS^)G[._P 0/V5?[6\*
MR>&--U+Q/#=W?]H_VM:7]M+/#%<6=EYGV79&S(KG=YR M'D$_&'_  1M_;,_
M:7_X(]?!JY_9U^.?[(/[2'C#1/!]W=7VA:[X \-IXACLDNS!=#3U-NJVMQ'Y
MLU[.UP+V61))A 8P$_=_N=10!^ /[7WPU_:X_;N_X*:_L3_'SQ]\#OB!X#\,
MP_$#28K/P/8P7.O0^"-'MKW1;V36=3N(<QVMQ>27=TDB3VUI)%%H\2R*YC+#
MZP_X.Z_V>_'W[2G_  3;\$Z%\.? _C#Q_K=I\2K"_GT_PWHUSJMU#;KI>JHT
MS10([K&'DC4N1@&11G+#/ZG44 >'_P#!,KPGJO@+_@FW^SYH6NZ9J&BZWHOP
MU\.6&H:??V[VUU87$6EVR2PRQ. \<B.K*R, 5(((!%>X444 ?D#_ ,'/'@+X
MJ?\ #4_[$WQ,^&?P?^('Q@_X4_XKU+Q/J6F^&-'N[W_CWN]#N8H)I;>&;[/Y
MWV:15=D/W7(5MI%'_$1W^U-_TC'_ &@/^_NK_P#RCK]?J* /S0^+^H_%S_@O
M1_P1#^.WAG7?@AXP_9Y^(5_=FST'PQXD$CW6N/IS:?JML5:\AL1''=3HUH)&
M'EQE6<LVUD'B'_!.C_@K+^T=^PO^QM;_  7^+O[$_P"U!XO\;?!_2F\->'M7
M\,>%7O=*\0_96N(K:":>&!8H+>&%+.W6ZMS?>>BO-\QP)/V>HH _#'X-?LW?
MM1^-_P#@YM^!_P =OC)\-?&&AV?B/P_K%Y?65G!-J_AWX96ZV.O:=9:0=5BD
MFM&DDCAMKMRC0A[C5GQ!&SX.A_P>4_LG?%3]J#_AG'_A6?PT^('Q$_L/_A)O
M[2_X1CP]=ZO_ &?YO]D>5YWV>-_+W^5)MW8W>6^,[3C]OJ* /RQ^''_!9+]J
M/]E?PKXG^'/QZ_8[^.'Q,^*7@*T^PZ?XP^&/AZ;4_"_Q!N%25HKIY4A5+*.5
M/LI=H4G(>6?-M;-']E'A_P"PM^RK^TU_P68_X*KZ+^T[^U!X+\0?"?X4_ _5
M3<>!/A]KMK>Z?-'>(%FM1;POY$K>5,+:YN+Z5 MS+!% L;0JT5I^WU% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 ?C#_P=Q?L(?%3XT?\*$^,7P1\'^(->\;> =5NM*O+KP;I-W=>
M*H-_E7FG7*/:1-*MO:S6MV1(TB^3->H4&97(^K_^#;?]B_5?V(?^"2W@/0O%
M'@_4/!/COQ5=WWBCQ-I]_(YNC<7%PR6SRQ,[?9Y/[/AL%:$!"A0B1%E\RON^
MB@#\X/\ @Z@_8S\5?MF?\$J+RU\$Z;X@\0>)O ?BO2_$]GH.B:+-JM_KV3+I
MTD$<4)\Q=D>H/<%U1\+:L"H#%TX#_@U2_9A^(_P_^%G[07Q>^-/AWX@>%_B[
M\9/B TVMVGB?0VT3[;%!#]K6^AM6@B*^;=:I?AF7]U^Y145-C;OU>HH ^?\
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MH36>D_!_6?"OAC0K!9[^Z=(]%FM;2TB!+S32$".-02TCG'+,>?I"B@#\L?\
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M:7;)+#+$X#QR(ZLK(P!4@@@$5[A10!_/C_P<2_\ !.K]I>U_X*C:]XP_9O\
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M!JMWJGA[PSI5O/JFJIX<^R6]Q;?:+>%IKF74 SW$3PK!#,SQ!1:QL0A^H**
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M-U:^$=&>4RQV]U)J30PM-&K_ &9I4ECLXPKS9N8Q&)']O_X**?\ !=GX<?\
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M.H6__$[^']_97^E74:1^8OVBZALYH6=E+^2Z3!V1"NZ2"$DD)@];_P $,O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_EQ:3_\ )5?O]11_KOCOY(?=+_Y(/[)H]W^'^1^ /_#DO]IW_HF?_EQ:3_\
M)5'_  Y+_:=_Z)G_ .7%I/\ \E5^_P!11_KOCOY(?=+_ .2#^R:/=_A_D?@#
M_P .2_VG?^B9_P#EQ:3_ /)5'_#DO]IW_HF?_EQ:3_\ )5?O]11_KOCOY(?=
M+_Y(/[)H]W^'^1^ /_#DO]IW_HF?_EQ:3_\ )5'_  Y+_:=_Z)G_ .7%I/\
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M_EQ:3_\ )5?O]11_KOCOY(?=+_Y(/[)H]W^'^1^ /_#DO]IW_HF?_EQ:3_\
M)5'_  Y+_:=_Z)G_ .7%I/\ \E5^_P!11_KOCOY(?=+_ .2#^R:/=_A_D?@#
M_P .2_VG?^B9_P#EQ:3_ /)5'_#DO]IW_HF?_EQ:3_\ )5?O]11_KOCOY(?=
M+_Y(/[)H]W^'^1^ /_#DO]IW_HF?_EQ:3_\ )5'_  Y+_:=_Z)G_ .7%I/\
M\E5^_P!11_KOCOY(?=+_ .2#^R:/=_A_D?@#_P .2_VG?^B9_P#EQ:3_ /)5
M'_#DO]IW_HF?_EQ:3_\ )5?O]11_KOCOY(?=+_Y(/[)H]W^'^1^ /_#DO]IW
M_HF?_EQ:3_\ )5'_  Y+_:=_Z)G_ .7%I/\ \E5^_P!11_KOCOY(?=+_ .2#
M^R:/=_A_D?@#_P .2_VG?^B9_P#EQ:3_ /)5'_#DO]IW_HF?_EQ:3_\ )5?O
M]11_KOCOY(?=+_Y(/[)H]W^'^1^ /_#DO]IW_HF?_EQ:3_\ )5'_  Y+_:=_
MZ)G_ .7%I/\ \E5^_P!11_KOCOY(?=+_ .2#^R:/=_A_D?@#_P .2_VG?^B9
M_P#EQ:3_ /)5'_#DO]IW_HF?_EQ:3_\ )5?O]11_KOCOY(?=+_Y(/[)H]W^'
M^1^ /_#DO]IW_HF?_EQ:3_\ )5'_  Y+_:=_Z)G_ .7%I/\ \E5^_P!11_KO
MCOY(?=+_ .2#^R:/=_A_D?@#_P .2_VG?^B9_P#EQ:3_ /)5'_#DO]IW_HF?
M_EQ:3_\ )5?O]11_KOCOY(?=+_Y(/[)H]W^'^1^ /_#DO]IW_HF?_EQ:3_\
M)5'_  Y+_:=_Z)G_ .7%I/\ \E5^_P!11_KOCOY(?=+_ .2#^R:/=_A_D?@#
M_P .2_VG?^B9_P#EQ:3_ /)5'_#DO]IW_HF?_EQ:3_\ )5?O]11_KOCOY(?=
M+_Y(/[)H]W^'^1^ /_#DO]IW_HF?_EQ:3_\ )5'_  Y+_:=_Z)G_ .7%I/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 9_BSPGI?CWPKJ6A:[IFGZUHFM6DMAJ&GW]NES:W]O*A26&6)P4DC=&961
M@0P)!!!KR_X6_P#!/;X!? [QW8^*?!/P/^#_ (/\3:7YGV/5]$\&Z=I]_:>9
M&T4GESPPK(FZ-W0[2,J[ \$BO8** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_<]'*P/KZBOD'_AZS_U(?_E;_P#N>C_AZS_U(?\ Y6__ +GHY6!]?45\@_\
M#UG_ *D/_P K?_W/1_P]9_ZD/_RM_P#W/1RL#Z^HKY!_X>L_]2'_ .5O_P"Y
MZ/\ AZS_ -2'_P"5O_[GHY6!]?45\@_\/6?^I#_\K?\ ]ST?\/6?^I#_ /*W
M_P#<]'*P/KZBOD'_ (>L_P#4A_\ E;_^YZ/^'K/_ %(?_E;_ /N>CE8'U]17
MR#_P]9_ZD/\ \K?_ -ST?\/6?^I#_P#*W_\ <]'*P/KZBOD'_AZS_P!2'_Y6
M_P#[GH_X>L_]2'_Y6_\ [GHY6!]?45\@_P##UG_J0_\ RM__ '/1_P /6?\
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MX>L_]2'_ .5O_P"YZ/\ AZS_ -2'_P"5O_[GHY6!]?45\@_\/6?^I#_\K?\
M]ST?\/6?^I#_ /*W_P#<]'*P/KZBOD'_ (>L_P#4A_\ E;_^YZL6O_!4O[3'
MN_X07;SC_D-?_:*.5H#ZVHKY-_X>A_\ 4C_^5G_[11_P]#_ZD?\ \K/_ -HJ
M0/K*BODW_AZ'_P!2/_Y6?_M%'_#T/_J1_P#RL_\ VB@#ZRHKY-_X>A_]2/\
M^5G_ .T4?\/0_P#J1_\ RL__ &B@#ZRHKY-_X>A_]2/_ .5G_P"T4?\ #T/_
M *D?_P K/_VB@#ZRHKY-_P"'H?\ U(__ )6?_M%'_#T/_J1__*S_ /:* /K*
MBODW_AZ'_P!2/_Y6?_M%'_#T/_J1_P#RL_\ VB@#ZRHKY-_X>A_]2/\ ^5G_
M .T4?\/0_P#J1_\ RL__ &B@#ZRHKY-_X>A_]2/_ .5G_P"T4?\ #T/_ *D?
M_P K/_VB@#ZRHKY-_P"'H?\ U(__ )6?_M%'_#T/_J1__*S_ /:* /K*BODW
M_AZ'_P!2/_Y6?_M%'_#T/_J1_P#RL_\ VB@#ZRHKY-_X>A_]2/\ ^5G_ .T4
M?\/0_P#J1_\ RL__ &B@#ZRHKY-_X>A_]2/_ .5G_P"T4?\ #T/_ *D?_P K
M/_VB@#ZRHKY-_P"'H?\ U(__ )6?_M%'_#T/_J1__*S_ /:* /K*BODW_AZ'
M_P!2/_Y6?_M%'_#T/_J1_P#RL_\ VB@#ZRHKY-_X>A_]2/\ ^5G_ .T4?\/0
M_P#J1_\ RL__ &B@#ZRHKY-_X>A_]2/_ .5G_P"T4?\ #T/_ *D?_P K/_VB
M@#ZRHKY-_P"'H?\ U(__ )6?_M%'_#T/_J1__*S_ /:* /K*BODW_AZ'_P!2
M/_Y6?_M%'_#T/_J1_P#RL_\ VB@#ZRHKY-_X>A_]2/\ ^5G_ .T4?\/0_P#J
M1_\ RL__ &B@#ZRHKY-_X>A_]2/_ .5G_P"T4?\ #T/_ *D?_P K/_VB@#ZR
MHKY-_P"'H?\ U(__ )6?_M%'_#T/_J1__*S_ /:* /K*BODW_AZ'_P!2/_Y6
M?_M%'_#T/_J1_P#RL_\ VB@#ZRHKY-_X>A_]2/\ ^5G_ .T4?\/0_P#J1_\
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M#ZRHKY-_X>A_]2/_ .5G_P"T4?\ #T/_ *D?_P K/_VB@#ZRHKY-_P"'H?\
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MX>L_]2'_ .5O_P"YZ/\ AZS_ -2'_P"5O_[GHY6!]?45\@_\/6?^I#_\K?\
M]ST?\/6?^I#_ /*W_P#<]'*P/KZBOD'_ (>L_P#4A_\ E;_^YZ/^'K/_ %(?
M_E;_ /N>CE8'U]17R#_P]9_ZD/\ \K?_ -ST?\/6?^I#_P#*W_\ <]'*P/KZ
MBOD'_AZS_P!2'_Y6_P#[GH_X>L_]2'_Y6_\ [GHY6!]?45\@_P##UG_J0_\
MRM__ '/1_P /6?\ J0__ "M__<]'*P/KZBOD'_AZS_U(?_E;_P#N>C_AZS_U
M(?\ Y6__ +GHY6!]?45\@_\ #UG_ *D/_P K?_W/1_P]9_ZD/_RM_P#W/1RL
M#Z^HKY!_X>L_]2'_ .5O_P"YZ/\ AZS_ -2'_P"5O_[GHY6!]?45\@_\/6?^
MI#_\K?\ ]ST?\/6?^I#_ /*W_P#<]'*P/KZBOD'_ (>L_P#4A_\ E;_^YZ/^
M'K/_ %(?_E;_ /N>CE8'U]17R#_P]9_ZD/\ \K?_ -ST?\/6?^I#_P#*W_\
M<]'*P/KZBOD'_AZS_P!2'_Y6_P#[GH_X>L_]2'_Y6_\ [GHY6!]?45\@_P##
MUG_J0_\ RM__ '/1_P /6?\ J0__ "M__<]'*P/KZBOD'_AZS_U(?_E;_P#N
M>C_AZS_U(?\ Y6__ +GHY6!]?45\@_\ #UG_ *D/_P K?_W/1_P]9_ZD/_RM
M_P#W/1RL#Z^HKY!_X>L_]2'_ .5O_P"YZ/\ AZS_ -2'_P"5O_[GHY6!]?45
M\@_\/6?^I#_\K?\ ]ST?\/6?^I#_ /*W_P#<]'*P/KZBOD'_ (>L_P#4A_\
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M?\/6?^I#_P#*W_\ <]'*P/KZBOD'_AZS_P!2'_Y6_P#[GH_X>L_]2'_Y6_\
M[GHY6!]?45\@_P##UG_J0_\ RM__ '/1_P /6?\ J0__ "M__<]'*P/KZBOD
M'_AZS_U(?_E;_P#N>C_AZS_U(?\ Y6__ +GHY6!]?45\@_\ #UG_ *D/_P K
M?_W/1_P]9_ZD/_RM_P#W/1RL#Z^HKY!_X>L_]2'_ .5O_P"YZ/\ AZS_ -2'
M_P"5O_[GHY6!]?45\@_\/6?^I#_\K?\ ]ST?\/6?^I#_ /*W_P#<]'*P/KZB
MOD'_ (>L_P#4A_\ E;_^YZ/^'K/_ %(?_E;_ /N>CE8'U]17R#_P]9_ZD/\
M\K?_ -ST?\/6?^I#_P#*W_\ <]'*P/KZBOD'_AZS_P!2'_Y6_P#[GH_X>L_]
M2'_Y6_\ [GHY6!]?45\@_P##UG_J0_\ RM__ '/1_P /6?\ J0__ "M__<]'
M*P/KZBOD'_AZS_U(?_E;_P#N>C_AZS_U(?\ Y6__ +GHY6!]?45\@_\ #UG_
M *D/_P K?_W/1_P]9_ZD/_RM_P#W/1RL#Z^HKY!_X>L_]2'_ .5O_P"YZ/\
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M '/1_P /6?\ J0__ "M__<]'*P/KZBOD'_AZS_U(?_E;_P#N>C_AZS_U(?\
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M_<]'*P/KZBOD'_AZS_U(?_E;_P#N>C_AZS_U(?\ Y6__ +GHY6!]?45\@_\
M#UG_ *D/_P K?_W/1_P]9_ZD/_RM_P#W/1RL#Z^HKY!_X>L_]2'_ .5O_P"Y
MZ/\ AZS_ -2'_P"5O_[GHY6!]?45\@_\/6?^I#_\K?\ ]ST?\/6?^I#_ /*W
M_P#<]'*P/KZBOD'_ (>L_P#4A_\ E;_^YZ/^'K/_ %(?_E;_ /N>CE8'U]17
MR#_P]9_ZD/\ \K?_ -ST?\/6?^I#_P#*W_\ <]'*P/KZBOD'_AZS_P!2'_Y6
M_P#[GH_X>L_]2'_Y6_\ [GHY6!]?45\@_P##UG_J0_\ RM__ '/1_P /6?\
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MX>L_]2'_ .5O_P"YZ/\ AZS_ -2'_P"5O_[GHY6!]?45\@_\/6?^I#_\K?\
M]ST?\/6?^I#_ /*W_P#<]'*P/KZBOD'_ (>L_P#4A_\ E;_^YZ/^'K/_ %(?
M_E;_ /N>CE8'U]17R#_P]9_ZD/\ \K?_ -ST?\/6?^I#_P#*W_\ <]'*P/KZ
MBOD'_AZS_P!2'_Y6_P#[GH_X>L_]2'_Y6_\ [GHY6!]?45\@_P##UG_J0_\
MRM__ '/1_P /6?\ J0__ "M__<]'*P/KZBOD'_AZS_U(?_E;_P#N>C_AZS_U
M(?\ Y6__ +GHY6!]?45\@_\ #UG_ *D/_P K?_W/1_P]9_ZD/_RM_P#W/1RL
M#Z^HKY!_X>L_]2'_ .5O_P"YZ/\ AZS_ -2'_P"5O_[GHY6!]?45\@_\/6?^
MI#_\K?\ ]ST?\/6?^I#_ /*W_P#<]'*P/KZBOD'_ (>L_P#4A_\ E;_^YZ/^
M'K/_ %(?_E;_ /N>CE8'U]17R#_P]9_ZD/\ \K?_ -ST?\/6?^I#_P#*W_\
M<]'*P/KZBOD'_AZS_P!2'_Y6_P#[GH_X>L_]2'_Y6_\ [GHY6!]?45\@_P##
MUG_J0_\ RM__ '/1_P /6?\ J0__ "M__<]'*P/KZBOD'_AZS_U(?_E;_P#N
M>C_AZS_U(?\ Y6__ +GHY6!]?45\@_\ #UG_ *D/_P K?_W/1_P]9_ZD/_RM
M_P#W/1RL#Z^HKY!_X>L_]2'_ .5O_P"YZ/\ AZS_ -2'_P"5O_[GHY6!]?45
M\@_\/6?^I#_\K?\ ]ST?\/6?^I#_ /*W_P#<]'*P/KZBOD'_ (>L_P#4A_\
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M  SWX!_Z$?P?_P"":W_^(KL**+@<?_PSWX!_Z$?P?_X)K?\ ^(H_X9[\ _\
M0C^#_P#P36__ ,178447 X__ (9[\ _]"/X/_P#!-;__ !%'_#/?@'_H1_!_
M_@FM_P#XBNPHHN!Q_P#PSWX!_P"A'\'_ /@FM_\ XBC_ (9[\ _]"/X/_P#!
M-;__ !%=A11<#C_^&>_ /_0C^#__  36_P#\11_PSWX!_P"A'\'_ /@FM_\
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M#C_^&>_ /_0C^#__  36_P#\11_PSWX!_P"A'\'_ /@FM_\ XBNPHHN!Q_\
MPSWX!_Z$?P?_ .":W_\ B*/^&>_ /_0C^#__  36_P#\178447 X_P#X9[\
M_P#0C^#_ /P36_\ \11_PSWX!_Z$?P?_ .":W_\ B*["BBX''_\ #/?@'_H1
M_!__ ()K?_XBC_AGOP#_ -"/X/\ _!-;_P#Q%=A11<#C_P#AGOP#_P!"/X/_
M /!-;_\ Q%'_  SWX!_Z$?P?_P"":W_^(KL**+@<?_PSWX!_Z$?P?_X)K?\
M^(IR? 'P&@^7P3X17Z:/;_\ Q%==10!R?_"A/ O_ $)?A/\ \%%O_P#$4?\
M"A/ O_0E^$__  46_P#\17644 <G_P *$\"_]"7X3_\ !1;_ /Q%'_"A/ O_
M $)?A/\ \%%O_P#$5UE% ')_\*$\"_\ 0E^$_P#P46__ ,11_P *$\"_]"7X
M3_\ !1;_ /Q%=910!R?_  H3P+_T)?A/_P %%O\ _$4?\*$\"_\ 0E^$_P#P
M46__ ,17644 <G_PH3P+_P!"7X3_ /!1;_\ Q%'_  H3P+_T)?A/_P %%O\
M_$5UE% ')_\ "A/ O_0E^$__  46_P#\11_PH3P+_P!"7X3_ /!1;_\ Q%=9
M10!R?_"A/ O_ $)?A/\ \%%O_P#$4?\ "A/ O_0E^$__  46_P#\17644 <G
M_P *$\"_]"7X3_\ !1;_ /Q%'_"A/ O_ $)?A/\ \%%O_P#$5UE% ')_\*$\
M"_\ 0E^$_P#P46__ ,11_P *$\"_]"7X3_\ !1;_ /Q%=910!R?_  H3P+_T
M)?A/_P %%O\ _$4?\*$\"_\ 0E^$_P#P46__ ,17644 <G_PH3P+_P!"7X3_
M /!1;_\ Q%'_  H3P+_T)?A/_P %%O\ _$5UE% ')_\ "A/ O_0E^$__  46
M_P#\11_PH3P+_P!"7X3_ /!1;_\ Q%=910!R?_"A/ O_ $)?A/\ \%%O_P#$
M4?\ "A/ O_0E^$__  46_P#\17644 <G_P *$\"_]"7X3_\ !1;_ /Q%'_"A
M/ O_ $)?A/\ \%%O_P#$5UE% ')_\*$\"_\ 0E^$_P#P46__ ,11_P *$\"_
M]"7X3_\ !1;_ /Q%=910!R?_  H3P+_T)?A/_P %%O\ _$4?\*$\"_\ 0E^$
M_P#P46__ ,17644 <G_PH3P+_P!"7X3_ /!1;_\ Q%'_  H3P+_T)?A/_P %
M%O\ _$5UE% ')_\ "A/ O_0E^$__  46_P#\11_PH3P+_P!"7X3_ /!1;_\
MQ%=910!R?_"A/ O_ $)?A/\ \%%O_P#$4?\ "A/ O_0E^$__  46_P#\1764
M4 <G_P *$\"_]"7X3_\ !1;_ /Q%'_"A/ O_ $)?A/\ \%%O_P#$5UE% ')_
M\*$\"_\ 0E^$_P#P46__ ,11_P *$\"_]"7X3_\ !1;_ /Q%=910!R?_  H3
MP+_T)?A/_P %%O\ _$4?\*$\"_\ 0E^$_P#P46__ ,17644 <G_PH3P+_P!"
M7X3_ /!1;_\ Q%'_  H3P+_T)?A/_P %%O\ _$5UE% ')_\ "A/ O_0E^$__
M  46_P#\11_PH3P+_P!"7X3_ /!1;_\ Q%=910!R?_"A/ O_ $)?A/\ \%%O
M_P#$4?\ "A/ O_0E^$__  46_P#\17644 <G_P *$\"_]"7X3_\ !1;_ /Q%
M'_"A/ O_ $)?A/\ \%%O_P#$5UE% ')_\*$\"_\ 0E^$_P#P46__ ,11_P *
M$\"_]"7X3_\ !1;_ /Q%=910!R?_  H3P+_T)?A/_P %%O\ _$4?\*$\"_\
M0E^$_P#P46__ ,17644 <G_PH3P+_P!"7X3_ /!1;_\ Q%'_  H3P+_T)?A/
M_P %%O\ _$5UE% ')_\ "A/ O_0E^$__  46_P#\11_PH3P+_P!"7X3_ /!1
M;_\ Q%=910!R?_"A/ O_ $)?A/\ \%%O_P#$4?\ "A/ O_0E^$__  46_P#\
M17644 <G_P *$\"_]"7X3_\ !1;_ /Q%'_"A/ O_ $)?A/\ \%%O_P#$5UE%
M ')_\*$\"_\ 0E^$_P#P46__ ,11_P *$\"_]"7X3_\ !1;_ /Q%=910!R?_
M  H3P+_T)?A/_P %%O\ _$4?\*$\"_\ 0E^$_P#P46__ ,17644 <G_PH3P+
M_P!"7X3_ /!1;_\ Q%'_  H3P+_T)?A/_P %%O\ _$5UE% ')_\ "A/ O_0E
M^$__  46_P#\11_PH3P+_P!"7X3_ /!1;_\ Q%=910!R?_"A/ O_ $)?A/\
M\%%O_P#$4U_@!X#D^]X)\(M]='M__B*ZZB@#C_\ AGOP#_T(_@__ ,$UO_\
M$4?\,]^ ?^A'\'_^":W_ /B*["BBX''_ /#/?@'_ *$?P?\ ^":W_P#B*/\
MAGOP#_T(_@__ ,$UO_\ $5V%%%P./_X9[\ _]"/X/_\ !-;_ /Q%'_#/?@'_
M *$?P?\ ^":W_P#B*["BBX''_P##/?@'_H1_!_\ X)K?_P"(H_X9[\ _]"/X
M/_\ !-;_ /Q%=A11<#C_ /AGOP#_ -"/X/\ _!-;_P#Q%'_#/?@'_H1_!_\
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M!_\ X)K?_P"(H_X9[\ _]"/X/_\ !-;_ /Q%=A11<#C_ /AGOP#_ -"/X/\
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M_@__ ,$UO_\ $4?\,]^ ?^A'\'_^":W_ /B*["BBX''_ /#/?@'_ *$?P?\
M^":W_P#B*/\ AGOP#_T(_@__ ,$UO_\ $5V%%%P./_X9[\ _]"/X/_\ !-;_
M /Q%'_#/?@'_ *$?P?\ ^":W_P#B*["BBX''_P##/?@'_H1_!_\ X)K?_P"(
MH_X9[\ _]"/X/_\ !-;_ /Q%=A11<#C_ /AGOP#_ -"/X/\ _!-;_P#Q%'_#
M/?@'_H1_!_\ X)K?_P"(KL**+@<?_P ,]^ ?^A'\'_\ @FM__B*/^&>_ /\
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M_P#XBC_AGOP#_P!"/X/_ /!-;_\ Q%=A11<#C_\ AGOP#_T(_@__ ,$UO_\
M$4?\,]^ ?^A'\'_^":W_ /B*["BBX''_ /#/?@'_ *$?P?\ ^":W_P#B*/\
MAGOP#_T(_@__ ,$UO_\ $5V%%%P./_X9[\ _]"/X/_\ !-;_ /Q%'_#/?@'_
M *$?P?\ ^":W_P#B*["BBX''_P##/?@'_H1_!_\ X)K?_P"(H_X9[\ _]"/X
M/_\ !-;_ /Q%=A11<#C_ /AGOP#_ -"/X/\ _!-;_P#Q%'_#/?@'_H1_!_\
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M!_\ X)K?_P"(H_X9[\ _]"/X/_\ !-;_ /Q%=A11<#C_ /AGOP#_ -"/X/\
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M_@__ ,$UO_\ $4?\,]^ ?^A'\'_^":W_ /B*["BBX''_ /#/?@'_ *$?P?\
M^":W_P#B*/\ AGOP#_T(_@__ ,$UO_\ $5V%%%P./_X9[\ _]"/X/_\ !-;_
M /Q%'_#/?@'_ *$?P?\ ^":W_P#B*["BBX''_P##/?@'_H1_!_\ X)K?_P"(
MH_X9[\ _]"/X/_\ !-;_ /Q%=A11<#C_ /AGOP#_ -"/X/\ _!-;_P#Q%'_#
M/?@'_H1_!_\ X)K?_P"(KL**+@<?_P ,]^ ?^A'\'_\ @FM__B*/^&>_ /\
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M_P#XBC_AGOP#_P!"/X/_ /!-;_\ Q%=A11<#C_\ AGOP#_T(_@__ ,$UO_\
M$4?\,]^ ?^A'\'_^":W_ /B*["BBX''_ /#/?@'_ *$?P?\ ^":W_P#B*/\
MAGOP#_T(_@__ ,$UO_\ $5V%%%P./_X9[\ _]"/X/_\ !-;_ /Q%'_#/?@'_
M *$?P?\ ^":W_P#B*["BBX''_P##/?@'_H1_!_\ X)K?_P"(H_X9[\ _]"/X
M/_\ !-;_ /Q%=A11<#C_ /AGOP#_ -"/X/\ _!-;_P#Q%'_#/?@'_H1_!_\
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M!_\ X)K?_P"(H_X9[\ _]"/X/_\ !-;_ /Q%=A11<#C_ /AGOP#_ -"/X/\
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M_@__ ,$UO_\ $4?\,]^ ?^A'\'_^":W_ /B*["BBX''_ /#/?@'_ *$?P?\
M^":W_P#B*/\ AGOP#_T(_@__ ,$UO_\ $5V%%%P./_X9[\ _]"/X/_\ !-;_
M /Q%'_#/?@'_ *$?P?\ ^":W_P#B*["BBX''_P##/?@'_H1_!_\ X)K?_P"(
MH_X9[\ _]"/X/_\ !-;_ /Q%=A11<#C_ /AGOP#_ -"/X/\ _!-;_P#Q%'_#
M/?@'_H1_!_\ X)K?_P"(KL**+@<?_P ,]^ ?^A'\'_\ @FM__B*/^&>_ /\
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M_P#XBC_AGOP#_P!"/X/_ /!-;_\ Q%=A11<#C_\ AGOP#_T(_@__ ,$UO_\
M$4?\,]^ ?^A'\'_^":W_ /B*["BBX''_ /#/?@'_ *$?P?\ ^":W_P#B*/\
MAGOP#_T(_@__ ,$UO_\ $5V%%%P./_X9[\ _]"/X/_\ !-;_ /Q%'_#/?@'_
M *$?P?\ ^":W_P#B*["BBX''_P##/?@'_H1_!_\ X)K?_P"(H_X9[\ _]"/X
M/_\ !-;_ /Q%=A11<#C_ /AGOP#_ -"/X/\ _!-;_P#Q%'_#/?@'_H1_!_\
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M!_\ X)K?_P"(H_X9[\ _]"/X/_\ !-;_ /Q%=A11<#C_ /AGOP#_ -"/X/\
M_!-;_P#Q%'_#/?@'_H1_!_\ X)K?_P"(KL**+@<?_P ,]^ ?^A'\'_\ @FM_
M_B*/^&>_ /\ T(_@_P#\$UO_ /$5V%%%P./_ .&>_ /_ $(_@_\ \$UO_P#$
M4?\ #/?@'_H1_!__ ()K?_XBNPHHN!Q__#/?@'_H1_!__@FM_P#XBC_AGOP#
M_P!"/X/_ /!-;_\ Q%=A11<#C_\ AGOP#_T(_@__ ,$UO_\ $4?\,]^ ?^A'
M\'_^":W_ /B*["BBX''_ /#/?@'_ *$?P?\ ^":W_P#B*/\ AGOP#_T(_@__
M ,$UO_\ $5V%%%P./_X9[\ _]"/X/_\ !-;_ /Q%'_#/?@'_ *$?P?\ ^":W
M_P#B*["BBX''_P##/?@'_H1_!_\ X)K?_P"(H_X9[\ _]"/X/_\ !-;_ /Q%
M=A11<#C_ /AGOP#_ -"/X/\ _!-;_P#Q%'_#/?@'_H1_!_\ X)K?_P"(KL**
M+@<?_P ,]^ ?^A'\'_\ @FM__B*/^&>_ /\ T(_@_P#\$UO_ /$5V%%%P./_
M .&>_ /_ $(_@_\ \$UO_P#$4?\ #/?@'_H1_!__ ()K?_XBNPHHN!Q__#/?
M@'_H1_!__@FM_P#XBC_AGOP#_P!"/X/_ /!-;_\ Q%=A11<#C_\ AGOP#_T(
M_@__ ,$UO_\ $4?\,]^ ?^A'\'_^":W_ /B*["BBX''_ /#/?@'_ *$?P?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M ,!C_D'UFM_,_O9]5?\ #[3]IW_HIG_ENZ3_ /(M'_#[3]IW_HIG_ENZ3_\
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M]GU5_P /M/VG?^BF?^6[I/\ \BT?\/M/VG?^BF?^6[I/_P BU\JT4?V1@?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH _+'_@[K_:%\??LU_P#!-OP3KOPY\<>,/ &MW?Q*L+"?4/#>LW.E
M74UNVEZJ[0M+ Z.T9>.-BA."8U.,J,>W_P#!N'\6?%7QQ_X(Q_!OQ3XV\3>(
M/&'B;5/[;^V:OK>HS:A?W?EZYJ$4?F3S,TC[8T1!N)PJ*!P *\__ .#H#]@K
MXL?\%$OV!?"/@GX.^%/^$P\3:7\0+/6[JS_M.ST_RK./3M2A>7S+J6*,XDN(
M5VABQWY P"1[!_P05_9<\=_L6_\ !)[X4_#/XF:'_P (WXV\-?VO_:6F_;;>
M\^S>?K%]<Q?O;>22)MT,T;?*YQNP<$$  ^OZ*** "BBB@ HHHH **** "BBB
M@#X _P"#H[_E!1\<_P#N ?\ J0:97@'_  94_P#*++Q]_P!E5U'_ --&CU]O
M?\%F/V*O%7_!1+_@FS\2/@[X)U#P_I?B;QA_9GV.ZUN>:"PB^S:I9WDGF/#%
M+(,QV[@;8VRQ4' R1YA_P;T_\$O_ !]_P2:_8O\ $_PY^(VK^#]:UO6O&MUX
MD@G\-W5S<VJ6\MC86ZHS3P0N) ]K(2 A&"OS$D@ 'W?1110!^.O[3G_!PA\9
M_@O^TG\0O!VE^&?AC<:9X3\3:EHUG+=:=?-/)#;W4D*-(5O%4N50$D*H)S@
M<5]4_P#!'3_@JGKW_!0K_A-M'\;:;X2T7Q-X9^S7EG'I$LD/]H6<N])"+>:2
M23]S(B!Y%<K_ *5$I5" 7_+G7] L?%?_  6YO=+U2QM-2TS4OCC):WEG=0K-
M!=0R:\5>.1&!5T9205((()!XK7_X)M_%F;_@G+_P5+AT?Q5K%I9Z99ZO?^!/
M%%W;&(V;*9F@$IEN GEVZ7D5O,TOR,(HFX()1OT+%Y1A9X1QI02J<JDGU??\
MK?,\"CBZJJIS?NWL?T(5^*?C[_@Y;^+'_"=ZU_PBWA/X=_\ ",_;Y_[(_M72
M[S[?]C\QO(^T>7>^7YWE[=^SY=V<<8K]!/\ @M#^T+#^SS_P3O\ '<HDM%U/
MQE!_PB>G0W,$LJ7#7H9)P/+QL=;,74BLY"AHE!W$A&_!OQ)\+M>\#_LP>%?%
M5Q?:M:Z)\0M>U&&'3)(9(;6\_LN*U6.^5BVV?#ZC=PJP7]V8IE#$NZKYO#>6
MT*M.57$13N[1OY*[_#\CIS'$3C)1INUE=G[R?\$AOVXO%G[?G[-FN>,?&.G^
M'=-U/3?$T^C11:-!-# T,=K:3!F$LLK;]T[@D,!@+QG)/(_\%0?^"R?AO]@J
M\7PCX=T^T\9?$JY@:66Q:Y,=GX?5XB8);LJ"SNS&-A;J49HLL7B#1&3QK_@A
M#\4O^%'?\$GOC!XV^P_VI_PA^O:UK?V/SO(^U_9M'L9O*\S:VS=LV[MK8SG!
MZ5^;7[*7PBU7_@HC^WEH/A_Q!JO_ !,/B)KUQJ>OZ@NRUDE3][>WSQ!(FC29
MHTF\L>7Y8D9 0JYQ>'R?#SQE>I55J5/I\K_<B:F+J*C",?BD>S?$O_@X"_:4
M\=Z[#>:7XB\.^"[>. 0M8Z-H-O+!*P9B96-X+B3>0P4@.%PBX4'<6]$_81_X
M+D_M >*/VD_!?@[Q5K'AWQCIGCCQ-I.C32ZCHT5O/IL,UTL,K6YM/(7>RRYS
M*L@!C7  W!OU<T:7X)?L ^!-)\,QZA\._A/HEYN:SMKS4+;2_P"TGBCBCDE+
MS.K7$P00AY7+R'Y"S$D&LGQ9^UW^S9X]_LW^W?BA\#]:_L6_BU73_M_B/2[G
M[!>19\JYBWR'RYDW-MD7#+DX(S6$LRPM2#A3P?NO9]?7X?U-(X>K&5Y5=>W]
M/] _X*0?M+Z]^Q]^Q?XR^(WAFTTF^UOP[]A^S0:G%)+:OYU];V[[UC=&.$E8
MC#CD#J,@_E;_ ,1+?QV_Z%/X2_\ @KU#_P"3:_0/_@M=K]CXK_X)*_$35-+O
M;34M,U*#1KJSO+699H+J&35;%DDC=25=&4@A@2""".*_/S_@VD_Y/K\6?]B'
M>?\ IPTZKR?#X99=4Q->FI.+>^G1:?B3BZE3ZQ&G"5DU_F'_ !$M_';_ *%/
MX2_^"O4/_DVOT#_X)W_\%D_A]^WSKO\ PB[:?>>!_'P@>Y31[ZY2X@U%59RP
MM+@!3,Z1*LCHT<; ,Q42)&[K[C^U5^QY\/OVSOAQ<^&_'F@6FI1M!+#8ZBL2
M+J6C-(48RVDY4M$^Z.,D#*OL"NKIE3_.O+K.O?L _MM:A)X9U;[9K?PG\6W5
MG;7C));1ZE]DN7A<2QQR!A#.B,DD8DYCE=-Q!)K7"X? 9I1G&C3]G4CM9Z>7
MKYZ7[$U*E?#33G+FBS^@;]O;]O;P;_P3_P#@W)XF\32?;M6OM\&@Z#!*$NM;
MN% )53@^7"FY3),01&&489WCC?\ (N?_ (+)_MC?'.\\3>)/!]U>6N@Z# EU
MJEOX;\&P7VFZ!"(FS)++-#/)$C"&60M-*1Q)C"KA>N_X.5?BS-XH_:]\(^$8
M=8M+W3/"?AI;E[&$Q,^FWUW/(9A(5&]7>WALFV.>%V,H D);])/^"17P.L?@
M/_P3O^&-C9FTFN/$.DQ>)KZZALUMGNIK\"Y'F8),CQ1210>8QRRVZ<* %7&C
M3PV P$,35IJ<ZCV>R7W=OQ?8J<JE>NZ<9<JCV/GC_@D)_P %I[_]KCQM;_"_
MXG6MI!XZN8"VB:MIUJT<&N""WWSI<1@E8KC;')-O0)"XW*%B*HLOVK^TO^U;
MX!_8^\"6GB;XC:]_PCNB7U^FF07/V&YN]]P\<DBIL@C=AE(I#D@#Y<9R0#_/
M'_Q(?V+O^"DW_,6O_#/PG^)?_3.6_N;/3M4_[9QM,T</^PI8_P (Z?O)_P %
M#OV$;'_@H3\)_#G@[5/$5YX;TS1_$UMKMY+:VJSSWD,<-Q"]O&68+$[+<$B4
MK(%*C,;CBL\YR_"4<53GK&G-7=NGIOW6EBL'B*LZ4EO*)^;?[:__  <9>,/B
M%>6NF_ ^QO/ .F6EQYTVL:K;VEYJ6I+Y2CROL[K+!;HLADR0TK/MB(:(;T;]
M&?\ @E+\<_%7[2G[ W@+QMXVU3^VO$VM?VA]LO/LT-MYWE:C=0Q_NX42-<1Q
MHORJ,XR<DDG\N?\ @MM^PA\/OV"/AQ\%O#O@6SO&DU*XU^YU+5M1=)M2U1@=
M.\L2R(B+LC5BJ(BJJY9L;WD=_P!&?^"&7_*++X7?]Q;_ -.][6F;4<'_ &93
MK86%DY6N]W;F6KWUM>Q.%G5^LRA5?3Y=#T_]O#]M?PW^P1^S[>>.O$5K>:E(
MUPNG:3IML"KZI?2)(\<)DP5B3;'([2,#M6-L*[[(W_)>'_@L-^V?^U9KMS>?
M#73+R.WT>"*&^L?!?@K^U8(6=I"DLQGCNI$=PK*!O52(>%R&)]E_X.C/^:&_
M]Q__ -QE?3W_  0._L'_ (=E^#?[(_LG^T/M^I_VW]C\OSOMGVV;;]IV\^=]
ME^RXW_-Y7D_P[:G"T\/A,MCC9TU4E)VUV6K7Z?>RJDJE7$NBI<J2Z?+_ #/)
M?^"3_P#P7&_X:3\56?PW^,#:3I/C*]\JWT'6[>/[-:Z]*$5#!.N2L5W(X+(4
MVQ2ES&J1N(UE_22OYS?^"DOCK2_A?_P57^(?B;X8W7V&3P[XMCU.VN?*>7[/
MK,)BDO'V7 .[;J"W!P08SC"@Q[17]&5<N?X&E2=.O1CRJHKV[/3_ #^\TP-:
M4N:$W=Q>_<*^;_V^?^"H'@'_ ()Z>*OA3X:\2Z/XP\5>,OC5X@'AOPEX?\-V
MML]UJ%QOAC+M+=SV]K%&LMS:QDR3*<W"D*461D^D*_+'_@E+<Q_\%+_^"P/[
M2?[5NL6>GZMX4^%%V/@Y\)M0MKS3M2T\6]LTKZA>6\L<0F,DHEBGCG#8$.M7
M$"R3HOR?.GH'T?\ \%6_^"U?PL_X(^?\(%_PLS0/B!KG_"Q/[0_LW_A&+&TN
MO(^Q?9?-\[[1<P;<_:X]NW=G:^=N!GY@^%O_  >2?LC_ ! \=V.D:MIOQ@\#
MZ?>>9YNMZWX=MIK"RVQLX\Q;*[N;D[V4(/+A?YG4MM7<R_+_ /P?.?\ -KO_
M '-?_N%K]WOBE\)_"OQQ\"7WA;QMX9\/^,/#.J>7]LTC6].AU"PN_+D66/S(
M)E:-]LB(XW X9%(Y - &?\ ?C]X-_:E^#7A[XA?#WQ#I_BKP;XJM!>:9J=FQ
M,=PF2K JP#QR(ZLCQN%DCD1T=5=64?G#^T+_ ,'=?[-O[-?Q]\<?#G7?!/QP
MN];\ ^(+_P -ZA/8:/I<EK-<6=S);RO$SZBCM&7C8J61201E0>!\W_\ !M#\
M1;S]GS_@M!^V1^S/X6C^Q_"+1]5\0:OI&DS7=U<_V-+I>NQZ; (#)*P'F6MR
MJ3.ZM++]CM<R?NR&Y_\ X(%_\K37[:G_ '//_J76- 'V?\%/^#MG]BWXJ>%;
MC4-=\8>,/AK>0W;6Z:9XD\*WD]U.@1&$ZMIRW</EDLR@-(LF8VR@4JS?H?\
M"WXL^%?CCX$L?%/@GQ-X?\8>&=4\S['J^B:C#J%A=^7(T4GESPLT;[9$=#M)
MPR,#R"*X_P#:@_8I^$?[:GA5='^+'PY\'^/K.&TNK*TDUC3(Y[K3$ND5)S:7
M!'G6LCA(SYD#I(#'&P8,BD?CC^SQJ=Y_P;_?\'$&E_LX^'O%/V']F7]HS[-J
M^E^'K^6ZU9M$O+U)[2R$3; \-PVIV@M Y,JO9R6YN)'DB66$ _=ZBBB@#/\
M%GBS2_ 7A74M=UW4M/T71-%M);_4-0O[A+:UL+>)"\LTLKD)'&B*S,[$!0"2
M0!7S_P#L1?\ !5/X1_\ !0_XR_%[P?\ "G4M0\11_!J[L+/4]?2*/^QM7>[%
MSM-A,LA>>-'M)D:0HD;D*T32QLLA\P_X**?\$2=!_P""H?[4_A7Q1\4OB?\
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M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#XP_P""T?\ P6D\&_\
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ME7*Q@2"+0_X)5?\ !?OQ5^T3^V3J7[+/[2GPM_X5'^T)I7VF.%=-$TFE:U/
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M3=5NI-1^R2W.C>&_">CJNF_8IKK[9<B.ZN+R2358XXH[^&118F3RG16W<_\
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M5\/^&/$]YJ,4UOJL>HZN8V2>RN$G:(V\,-[8N4EMP[O%<1AD#)*H!^KU?/\
M_P %3O /QD^*7_!/OXH>'_V?M:_X1_XNZEI0CT&\6\6RF.)HVN88+A@1!<2V
MHGBBE)3RY98W\V';YJ=!_P % _VE_P#AC?\ 8>^+7Q2CN_#]GJ'@?PKJ&JZ7
M_;<OEV%UJ*0/]BMI/GC+>==&&$1HZO(TJHIW,M?".C?\%HOC1!_P;AZM^V1J
M&F_"^Z^(4UVKZ9H]OHM]!HUG;_\ "11:,T<R-?/--(0)YA(LL0!DC78?+9I
M#[._X)8^ ?C)\+?^"??PO\/_ +0.M?\ "0?%W3=*,>O7C7BWLPS-(UM#/<*
M)[B*U,$4LH+^9+%(_FS;O-?Z KY?_P"",_[:WBK_ (*)?\$V?AO\8O&VG^']
M+\3>,/[3^V6NB0306$7V;5+RSC\M)I99!F.W0G=(V6+$8& /D'XI?\%S?CC^
MV?\ MPWWPA_8'^'OP_\ BEX?\!^7%XU^(/BQISX;MI9IUA5[::&Y@W6\6)CO
M3SI;L1SM;0O%!YLP!]W?\%-?%FJ^ O\ @FW^T'KNA:EJ&BZWHOPU\1W^GZA8
M7#VUU87$6EW+Q312H0\<B.JLKJ05(!!!%>(?\&X?Q9\5?''_ ((Q_!OQ3XV\
M3>(/&'B;5/[;^V:OK>HS:A?W?EZYJ$4?F3S,TC[8T1!N)PJ*!P *^,/^"E_[
M?O[=7[+O[-7QLT']IKX'?"_5O@OXO\%:KX,A\=?"N:XDCT[5-3TV2&RN)HKN
M[>X6S%Q(+:5IK>W DD4I)(?*BN/J_P#X-<?^4%'P,_[C_P#ZD&IT ??]%?F#
M_P %"O\ @N;\1S^V3:_LU?L4?#WP_P#'+XS:)]HN_&5QJ3,V@^'(H%(DM&E6
MYMHQ<)(T:RRR3I%#(8[;$MQ*T<''_M4_\%3_ -O;_@EEXJ\.^-/VB/@Y\#_'
M'P!CN[:#Q3XB^%/]I-=:2+AY854?;KH/'(CK&VZ6W%O*988/M$<DP* 'ZW45
MS_PG^*6@_''X6>&?&WA:^_M3PSXPTJUUO2+SR9(/M=G<PI-!+Y<BK(FZ-U;:
MZJPS@@'(KH* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MKO2;[6_#OV?[3/IDLDMJ_G6T5PFQI$1CA)5!R@Y!ZC!/T[\%/^#@O]H+X/\
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M_B:"VUB&]L'N['[#+:W:9GV%7B07)M=KJZ?O/+0DARC?GCXW_P"#E;XO:_\
M#BTTW1_"/@?0/$<D%U#J.L+'/<H6<X@EM+>1]L+Q*>1,UPLC ':JY0Z9+',_
MJ]L+RN#;WZ/^O7O;<G&?5O:?O;W\NI\E_MC_ +,5C\!?VQ-<^%/@C5+SQY)H
M]Q8Z1#<6L:SSZEJ3VT'VB&.*'=AQ>/+$(06="HC8NZDG^FJOQU_X(E_\$UO'
M'C[]H+3?C]\5-)O&T$02:_H-QK%Q'<7GB'4IW;R[V2*0/(40&2X660QNTK6L
ML9D7<:_8JL>)L9&I.G04N9P6K[MVO^7XV-,MI.*E.UN9Z+R"OS@_X-/_ (6Z
M#\/_ /@B5\.=6TBQ^QZAXXU76];UN7SI)/MMXFIW%@LN&8A,6MC:Q[4"K^ZW
M8W,S-^C]?EC_ ,&IWCG5? 7[,'QC_9N\6>)-/UKQE^S/\2M4\-RVEA;.MK86
M$LKE'BG,,?GQRZA!J[J9,S*,!E1#$M?+GI'R?_P?.?\ -KO_ '-?_N%KW#Q+
M\??^"S?QCTZ/PO:_!'X'_">36KNVMV\76=_I]S)H"&>,O.8YM5O4:,(&#@6D
M\GEE_+0R;"/#_P#@^<_YM=_[FO\ ]PM?O]0!\8?\$7/^"2-O_P $MO@UXBNO
M$7BC4/'_ ,:/BM=Q:U\0_%%Q>SW$>HWJF9UBA\T[VCC>YN"9Y1YUQ)-)(^T-
M'##^:'_! O\ Y6FOVU/^YY_]2ZQK]_J_EQ_9+_X*@> ?^"37_!P[^UY\1OB-
MH_C#6M$UKQ!XR\-P0>&[6VN;I+B7Q+%<*[+//"@C"6L@)#DY*_*020 ?U'5^
M./\ P75UFX^/W_!>W_@GK\(_"^DZA?>*_!7B!?'^H,[P0VITMM2M9Y6C=Y 6
MDA@T&_E="H)'E"/S'?8#Q9_P=QZ7^T'X5U+0OV5_V;_CA\6/BE':2W*:??Z&
MC6NEVX0H+^6+3IKNXFCCN)+56BQ '$I'GQMMW>O_ /!)W_@D5\4/"/[;7CK]
ML3]JC4?!^J?'CX@VB0:9X?T&UBET_P %V\EM;QLHE9"1>101+8AH)' A2?=<
M79N69 #T#_@J!_P5E^-'["'Q]T?PC\.?V//BA^T%HFI>'X=8G\1>&WOEM;*X
M>YN86LF\C3;I/,1((Y#F0'$Z_*!@L?\ !+__ (*R_&C]N_X^ZQX1^(W['GQ0
M_9]T33?#\VL0>(O$CWS6M[<)<VT*V2^?IMJGF.D\D@Q(3B!OE(R5^[Z* "OR
M!_X-Q/\ E*;_ ,%./^RJI_Z=_$E?K]7Y _\ !N)_RE-_X*<?]E53_P!._B2@
M#]?J*** /#_^"BO[(?PC_;:_9'\6>#/C;#I\7@2*TDU6XUFXNH[*3PL\$;L-
M4ANI!LMI($,C&1LQF,R)(KQ/(C?AC^RU^U+XV_X*F_&SX0_LQ_M.?%[Q!-^R
MQ-JNIP^#?&4WA^_\.S?M+RZ9?QP6%C>7\S_[K%5*RM*B12,]^]O<)^O_ /P4
MF_X)L^*O^"E?Q3^'GA;Q3\0_[)_9ETGS-5\;>"=*AFM-5\;:C#-$]E;7%ZLG
M_(/^\[QH(W1X009))(9K'T_]KS_@G5\(_P!MK]D>;X)>,_">GQ>!(K2&WT:W
MTJ".RD\+/!&8K6?3BJ;+:2!#M0*IC,9:)T>)WC8 ]@\)^$]+\!>%=-T+0M,T
M_1=$T6TBL-/T^PMTMK6PMXD"10Q1( D<:(JJJ* %    %:%>'_\ !/'X+?%S
M]GC]F#2O!GQH^)6G_%KQ7X?N[JSL_$L.GR6EU?Z6DK+8F]:21S->& (TLG!R
MVQFG='NKCW"@#\<?^#F?Q9I?@+_@I)_P39UW7=2T_1=$T7XE7%_J&H7]PEM:
MV%O%JGAQY9I97(2.-$5F9V("@$D@"OV.KY _X+??\$MO^'N'[#UU\-[/Q)_P
MBWB;1-5B\3^&[N9=UA+J,$%Q D%X K2"WDCN95+Q_/&Q20+*$,,GPA^R9_P<
MS:K^P9IWA?X$_MO?"7XH?#_XA>%+2QT1O%HC?5(]?MXIYK-]8NA,XFDC @5F
MNK1[T7<BW,D87Y(R ?M=17Y8_&O_ (.Q/@E/XJM_!W[._@7XH?M-?$+5K1;C
M2=,\-Z'<V%K>.KNUQ S31&]$D5M%).3%931D;1O7]XT?ZG4 ?@#_ ,$"_P#E
M::_;4_[GG_U+K&OU^_X*Q?\ *++]I;_LE7BC_P!-%U7Y _\ ! O_ )6FOVU/
M^YY_]2ZQK]?O^"L7_*++]I;_ +)5XH_]-%U0!\ _\&5/_*++Q]_V574?_31H
M]?K]7\R/_!O3_P '"WP7_P""37[%_B?X<_$;PQ\4-:UO6O&MUXD@G\-Z=8W-
MJEO+8V%NJ,T]Y"XD#VLA("$8*_,22!^I_P"R'_P= ? +]M'_ (6A_P (MX1^
M,%A_PJ?X?ZK\1]7_ +5TK3HOM.G:=Y7GQ6_EWTFZX;SEV*^Q#@Y=>,@'QA_P
M6K_X*'?"_7O^#C+]GOP7\6M5U#P3\+?V5[M/$FK:]!I\LUU)K-Q:V^KVZ!81
M</+9L]MH\1"P)(#)>#<%\N5>@_X+[_\ !7_]BG_@I?\ \$T?%W@/PK\7M/U;
MXA:/=VGB3PC%>>'/$=C&+^V?;(@<60C,DMG+>0()_P!R)+A&9H]HE3L/^#;G
M_@G[X)_;7^!/Q<_:B^/7PE^'_C#Q-^T+\0-2UO3;?6]$L-8TJRLX[B8RRV$5
MPLTUKOOY[^)UED+.EG;G& ))/T>_X=._LL_]&T_L_P#_ (;S2/\ Y'H X#_@
M@W^V9_PW1_P2H^$?C"\U'^T?$VEZ4/#'B1IM:_M:_.HZ>?LKSWDI D6XNHXX
MKPI(-X6\0EG!$C_.'[0O_!?/]I+X.?'WQQX1T+_@G=\</&VB>%?$%_H^G^(K
M"75!:Z_;V]S)#%>Q;-&D3RYD19%VR.,.,,PY/A__  0[\:Z=_P $O/\ @N;^
MTU^Q?>3?9/#/C353XB^'UC:ZK?7MAI>RV;4(;)8Y8V(N)-(N8O.N)'7YM(6,
MO.6B:OV^H ^ /"G_  7'O/!?_!,KXB?M"?'CX+^(/V>=6\)ZK=:)H'@KQ9>W
M4%_XQO%LH9[.*V:6QAE_TF:22+<EO(L2VT\K'9%)L^8/^",GQY^#_P 0?'>K
M?M@_M9?'S]G^7]HSQYOA\+Z7=_$32A#\-?#C1XAL;6R:;_0+B3S+CS%9Y)EB
MD"R,D\]\LGZ??MJ_L%?"?_@HE\+-/\$_&+PI_P )AX9TO58];M;/^T[S3_*O
M(X9H4E\RUEBD.([B9=I8J=^2,@$?,'_$+C^PG_T0W_R\_$'_ ,G4 ?&'[*'[
M;OP7\.?\'8'[37Q&U#XO?"^Q^'NO?#6SL-,\3W'BJQBT;4;A;?PT&AANVE$,
MD@,$X**Y(,,G'R-C]3O^"L7_ "BR_:6_[)5XH_\ 31=5^,/[-/\ P1F_9L^(
M'_!RW^T)^S]J_P -_MGPB\#_  _M-;T30?\ A(-4C^Q7CP>'W:7[2MR+E\M?
M71VO*R_O>GRKM_4__@X1_:@TO]E3_@C]\;M4U!=/N;SQ=X?F\%:98W&HI927
MUQJJFR;R=RL99(()I[HQ*I+QVDG**&D4 Y__ (-E_%FJ^-/^"'/P(O-8U+4-
M6O(;35K".>\N'GD2WMM:O[>WA#,21'%!%%$B#A(XT50%4 ?=]?+_ /P19_9H
M_P"&1/\ @E1\"? LEIX@T[4+/PK;:KJECK<7DW^GZCJ!;4;VVDCV(8_*NKJ:
M,1NN]%158LP9C]04 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M-821^=!'&+"P@MC+)YSQPSR2K)YD4\@!\W_\%]/^5IK]BO\ [D;_ -2Z^KZ
M_P"#U;_E%EX!_P"RJZ=_Z:-8KY__ ."^G_*TU^Q7_P!R-_ZEU]7T!_P>K?\
M*++P#_V573O_ $T:Q0!T'[</Q2U[X/\ _!G[HNK>';[^SM0O/@KX*T267R8Y
MM]GJ$>E6%Y%B16 \RUN9X]P&Y=^Y2K!6'O\ _P &Y/P,\*_ C_@C;\%;?PMJ
MGA_7_P#A*-*;Q/J^JZ5;0P_:M1O)6EG@N&C=_,N+/*V#N[;_ /0 I6/8(T/@
MS^QUH/\ P4 _X-Z?A7\'?$4WV/3_ !Q\%?#-I%>[))/[,O$TJSFL[ORXY(C+
MY%U%!-Y1D59/*V,=K,#^>'_!''_@M;;_ /!&CX9Z;^R5^V)\/?&'P>N_!=W?
MR^'_ !&='GN;6>RFN[Z>5[E(R\DT9O!-%!=V*3PS"11A%A:>4 ^W_P#@ZG\)
MZ7XC_P""'/Q<O-0TS3[Z\T&[T*_TR>XMTEDTZX;6K*W::%F!,<A@GGB+K@F.
M:1<[78'Z/_X)._\ *++]FG_LE7A?_P!-%K7XP_\ !=[_ (*D^*O^"P/["?Q$
MN/@+X;\0:5^S+\&=5L[GQMXXUMIM,_X3746U"*RLM,L+=6/G6Z_:X+]UN5#K
MMMVD2UDCA6Z_9[_@D[_RBR_9I_[)5X7_ /31:T ?0%%%% 'X _\ ! O_ )6F
MOVU/^YY_]2ZQK]_J_ '_ ((%_P#*TU^VI_W//_J76-?O]0!^0/\ P94_\HLO
M'W_95=1_]-&CU[__ ,'1W_*"CXY_]P#_ -2#3*_,#_@EQ^VK_P 0PW[</QF_
M9W_:*T_X@-X"\5:K97OAOQ#:P;[".!)YK=-;6P$K@V]W:LCS/;22SQ-IRVYC
MFDC*Q>H?\%\_^"O=O_P4V_X)U?$KP[^SMI/C#4?@[X,N]/U'QW\1M4T&>PT#
M7D2]TN.WT33WFMVD:\^V:E:7,@E^R2)'ISE//CEY /UN_P""3O\ RBR_9I_[
M)5X7_P#31:U^0/\ P8Q_\W1?]RI_[FJ_7[_@D[_RBR_9I_[)5X7_ /31:U^0
M/_!C'_S=%_W*G_N:H ^W_P#@[ ^%N@_$#_@B5\1M6U>Q^V:AX'U71-;T27SI
M(_L5X^IV]@TN%8!\VM]=1[7#+^]W8W*K+]'_ /!'CPGI?@O_ ()0_LVV>CZ9
MI^DV<WPUT"_D@L[=((WN+G3X;BXF*J #)+/++*[GEY)'9B68D^(?\'1W_*"C
MXY_]P#_U(-,KW_\ X)._\HLOV:?^R5>%_P#TT6M 'YX_M7^$]+\.?\'FW[,M
MYI^F:?8WFO?#6\O]3GM[=(I-1N%T_P 2VZS3,H!DD$$$$0=LD1PQKG:B@<?_
M ,%PO#MG^U1_P<H_L9?!GQ]XB\/Z?\,M/TJU\2)8:W86MQ87UY+J%])-8R"4
MIYW]H_V386(CD9U#2KLC=G9)/0/VR/\ E<D_9._[)5??^DWBNN@_X.3?^"4?
MQ'_:)UCX=_M0?L_1?:/C;\!_+NCIT-NUW?ZU9VET+VT>SAD+P27%G<&>46YA
M+7*W#KEWCA@E /U>K\(?^#P_Q_\ \,O_ +4_[&/QB\.Z+X?F\;>$=5U758KJ
M\L]W]H?V9=Z/>6=M<O&4EDMTFEG(C$B[?M$Q4J78GZ ^!?\ P>*?LI_$3X6:
MIJWC"W^('P\\3:+I45VV@W.CG4O[:O#"[RVFG7-L6C?;(@C66\%FK^;$Q"#S
M/+^?_P!G?6_C)_P<?_\ !7#X4_''4O OB#X=_LG_ +/>JOXA\&WE];K9W.M3
MQ7(:,I<-%(MY<3WVGV_VF*%C!:P6KQ"59V66Y .?_P"#YS_FUW_N:_\ W"U^
M]WA/PGI?@+PKINA:%IFGZ+HFBVD5AI^GV%NEM:V%O$@2*&*) $CC1%5510 H
M    K\$?^#YS_FUW_N:__<+7[_4 ?C#_ ,%F_P#@E'^T%\$O^"DVD_MV_LIQ
M?\)UXVT_9=>)/"5W;PW$T*VVE_8G>UA)1KJWN+&(V\EO$WVQ990UN7,H^S>W
M_P#!/W_@Y6\&_M._M/I\#/C+\+O&'[-7QBOKL6VF:+XHE+VMX\D4$EK;/--#
M;307EP)6,44MN(Y L029I)XXCT'[3?\ P<:?"_\ 84_X**^*?@3\<O"/C#X?
M:)I]I87_ (?\=I:RZCIFMV\]DT\LTEO'$+B.-+A3:(]NMT'F27>81&V/SP_X
M+,_M9>!/^#E#X[?"?X!?LJ^$/$'COQMX2U6YU*7XA:DEQI.@Z/H\]O;B\9H9
M!YOV?SOL_FS7$$<B264<5NEP;M0P!_0]1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% 'X _\%M/^4G7Q,_[A?_IILZ^5:^JO^"VG_*3K
MXF?]PO\ ]--G7RK7[IE'^XT?\$?_ $E'R.)_C2]7^84445Z!B%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% 'JO["?_)[WP;_['G1/_2^"OZ4Z_FL_83_Y/>^#?_8\
MZ)_Z7P5_2G7YKQU_'I>C_,][*?@EZA1117PIZP4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M:?8V?[,?C6\U[Q/XEL)I[RUE1;:>TNS% (!,T<(T&256"F247 'E(R8?X_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M]1E6V/EK;6&8(GMF9]/A7<RW5S)%^C]% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH ]5_83_Y/>^#?_8\Z)_Z7P5_2G7\UG["?_)[WP;_
M .QYT3_TO@K^E.OS7CK^/2]'^9[V4_!+U"BBBOA3U@HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% 'PA_P<+?MK> ?V$/V+_#'B[XC? KP?\ M!:)J7C6UT>#P[XD:V6U
MLKA[&_F6]7S[2Z3S$2"2,8C!Q.WS 9#?&'[+G_!X?^RS\)/@3H?A_P#X4'\0
M/A?_ &?]H_XICP3IFD7&@Z9ON)9/]'?S[//F;_-?_1H\22R#Y\;V_5[]M7]@
MKX3_ /!1+X6:?X)^,7A3_A,/#.EZK'K=K9_VG>:?Y5Y'#-"DOF6LL4AQ'<3+
MM+%3OR1D CY@_P"(7']A/_HAO_EY^(/_ ).H T/B7_P<+?!?X5_\$T?A[^U1
MJ'ACXH3?#WXE>()?#>F:?;Z=8MK,%Q&^H(SS1->+"L>=-GP5F8X>/Y1EMOSA
M_P 1JW[+/_0@_M ?^"/2/_EG7V]XR_X(S?LV?$#]C;PG^S]J_P -_MGPB\#Z
MK)K>B:#_ ,)!JD?V*\=KMVE^TK<BY?+7UT=KRLO[WI\J[?(/^(7']A/_ *(;
M_P"7GX@_^3J -#X:?\'"WP7^*G_!-'XA?M4:?X8^*$/P]^&OB"+PWJ>GW&G6
M*ZS/<2/IZ*\,2WC0M'G4H,EIE.$D^4X7=\X?\1JW[+/_ $(/[0'_ ((](_\
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M;_H8?B)_X'V?_P BT?\ #CCX3?\ 0P_$3_P/L_\ Y%H]T#SO_A_;_P!4I_\
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M]4I_\N?_ .Y*]$_X<<?";_H8?B)_X'V?_P BT?\ #CCX3?\ 0P_$3_P/L_\
MY%H]T#SO_A_;_P!4I_\ +G_^Y*/^']O_ %2G_P N?_[DKT3_ (<<?";_ *&'
MXB?^!]G_ /(M'_#CCX3?]##\1/\ P/L__D6CW0/._P#A_;_U2G_RY_\ [DH_
MX?V_]4I_\N?_ .Y*]$_X<<?";_H8?B)_X'V?_P BT?\ #CCX3?\ 0P_$3_P/
ML_\ Y%H]T#SO_A_;_P!4I_\ +G_^Y*/^']O_ %2G_P N?_[DKT3_ (<<?";_
M *&'XB?^!]G_ /(M'_#CCX3?]##\1/\ P/L__D6CW0/._P#A_;_U2G_RY_\
M[DH_X?V_]4I_\N?_ .Y*]$_X<<?";_H8?B)_X'V?_P BT?\ #CCX3?\ 0P_$
M3_P/L_\ Y%H]T#SO_A_;_P!4I_\ +G_^Y*/^']O_ %2G_P N?_[DKT3_ (<<
M?";_ *&'XB?^!]G_ /(M'_#CCX3?]##\1/\ P/L__D6CW0/._P#A_;_U2G_R
MY_\ [DH_X?V_]4I_\N?_ .Y*]$_X<<?";_H8?B)_X'V?_P BT?\ #CCX3?\
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M_;_U2G_RY_\ [DH_X?V_]4I_\N?_ .Y*]$_X<<?";_H8?B)_X'V?_P BT?\
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M']O_ %2G_P N?_[DKT3_ (<<?";_ *&'XB?^!]G_ /(M'_#CCX3?]##\1/\
MP/L__D6CW0/._P#A_;_U2G_RY_\ [DH_X?V_]4I_\N?_ .Y*]$_X<<?";_H8
M?B)_X'V?_P BT?\ #CCX3?\ 0P_$3_P/L_\ Y%H]T#SO_A_;_P!4I_\ +G_^
MY*/^']O_ %2G_P N?_[DKT3_ (<<?";_ *&'XB?^!]G_ /(M'_#CCX3?]##\
M1/\ P/L__D6CW0/._P#A_;_U2G_RY_\ [DH_X?V_]4I_\N?_ .Y*]$_X<<?"
M;_H8?B)_X'V?_P BT?\ #CCX3?\ 0P_$3_P/L_\ Y%H]T#SO_A_;_P!4I_\
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M]4I_\N?_ .Y*]$_X<<?";_H8?B)_X'V?_P BT?\ #CCX3?\ 0P_$3_P/L_\
MY%H]T#SO_A_;_P!4I_\ +G_^Y*/^']O_ %2G_P N?_[DKT3_ (<<?";_ *&'
MXB?^!]G_ /(M'_#CCX3?]##\1/\ P/L__D6CW0/._P#A_;_U2G_RY_\ [DH_
MX?V_]4I_\N?_ .Y*]$_X<<?";_H8?B)_X'V?_P BT?\ #CCX3?\ 0P_$3_P/
ML_\ Y%H]T#SO_A_;_P!4I_\ +G_^Y*/^']O_ %2G_P N?_[DKT3_ (<<?";_
M *&'XB?^!]G_ /(M'_#CCX3?]##\1/\ P/L__D6CW0/._P#A_;_U2G_RY_\
M[DH_X?V_]4I_\N?_ .Y*]$_X<<?";_H8?B)_X'V?_P BT?\ #CCX3?\ 0P_$
M3_P/L_\ Y%H]T#SO_A_;_P!4I_\ +G_^Y*/^']O_ %2G_P N?_[DKT3_ (<<
M?";_ *&'XB?^!]G_ /(M'_#CCX3?]##\1/\ P/L__D6CW0/._P#A_;_U2G_R
MY_\ [DH_X?V_]4I_\N?_ .Y*]$_X<<?";_H8?B)_X'V?_P BT?\ #CCX3?\
M0P_$3_P/L_\ Y%H]T#SO_A_;_P!4I_\ +G_^Y*/^']O_ %2G_P N?_[DKT3_
M (<<?";_ *&'XB?^!]G_ /(M'_#CCX3?]##\1/\ P/L__D6CW0/._P#A_;_U
M2G_RY_\ [DH_X?V_]4I_\N?_ .Y*]$_X<<?";_H8?B)_X'V?_P BT?\ #CCX
M3?\ 0P_$3_P/L_\ Y%H]T#SO_A_;_P!4I_\ +G_^Y*/^']O_ %2G_P N?_[D
MKT3_ (<<?";_ *&'XB?^!]G_ /(M'_#CCX3?]##\1/\ P/L__D6CW0/._P#A
M_;_U2G_RY_\ [DH_X?V_]4I_\N?_ .Y*]$_X<<?";_H8?B)_X'V?_P BT?\
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M']O_ %2G_P N?_[DKT3_ (<<?";_ *&'XB?^!]G_ /(M'_#CCX3?]##\1/\
MP/L__D6CW0/._P#A_;_U2G_RY_\ [DH_X?V_]4I_\N?_ .Y*]$_X<<?";_H8
M?B)_X'V?_P BT?\ #CCX3?\ 0P_$3_P/L_\ Y%H]T#SO_A_;_P!4I_\ +G_^
MY*/^']O_ %2G_P N?_[DKT3_ (<<?";_ *&'XB?^!]G_ /(M'_#CCX3?]##\
M1/\ P/L__D6CW0/._P#A_;_U2G_RY_\ [DH_X?V_]4I_\N?_ .Y*]$_X<<?"
M;_H8?B)_X'V?_P BT?\ #CCX3?\ 0P_$3_P/L_\ Y%H]T#SO_A_;_P!4I_\
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M]4I_\N?_ .Y*]$_X<<?";_H8?B)_X'V?_P BT?\ #CCX3?\ 0P_$3_P/L_\
MY%H]T#SO_A_;_P!4I_\ +G_^Y*/^']O_ %2G_P N?_[DKT3_ (<<?";_ *&'
MXB?^!]G_ /(M'_#CCX3?]##\1/\ P/L__D6CW0/._P#A_;_U2G_RY_\ [DH_
MX?V_]4I_\N?_ .Y*]$_X<<?";_H8?B)_X'V?_P BT?\ #CCX3?\ 0P_$3_P/
ML_\ Y%H]T#SO_A_;_P!4I_\ +G_^Y*/^']O_ %2G_P N?_[DKT3_ (<<?";_
M *&'XB?^!]G_ /(M'_#CCX3?]##\1/\ P/L__D6CW0/._P#A_;_U2G_RY_\
M[DH_X?V_]4I_\N?_ .Y*]$_X<<?";_H8?B)_X'V?_P BT?\ #CCX3?\ 0P_$
M3_P/L_\ Y%H]T#SO_A_;_P!4I_\ +G_^Y*/^']O_ %2G_P N?_[DKT3_ (<<
M?";_ *&'XB?^!]G_ /(M'_#CCX3?]##\1/\ P/L__D6CW0/._P#A_;_U2G_R
MY_\ [DH_X?V_]4I_\N?_ .Y*]$_X<<?";_H8?B)_X'V?_P BT?\ #CCX3?\
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M_;_U2G_RY_\ [DH_X?V_]4I_\N?_ .Y*]$_X<<?";_H8?B)_X'V?_P BT?\
M#CCX3?\ 0P_$3_P/L_\ Y%H]T#SO_A_;_P!4I_\ +G_^Y*/^']O_ %2G_P N
M?_[DKT3_ (<<?";_ *&'XB?^!]G_ /(M'_#CCX3?]##\1/\ P/L__D6CW0/.
M_P#A_;_U2G_RY_\ [DH_X?V_]4I_\N?_ .Y*]$_X<<?";_H8?B)_X'V?_P B
MT?\ #CCX3?\ 0P_$3_P/L_\ Y%H]T#SO_A_;_P!4I_\ +G_^Y*/^']O_ %2G
M_P N?_[DKT3_ (<<?";_ *&'XB?^!]G_ /(M'_#CCX3?]##\1/\ P/L__D6C
MW0/._P#A_;_U2G_RY_\ [DH_X?V_]4I_\N?_ .Y*]$_X<<?";_H8?B)_X'V?
M_P BT?\ #CCX3?\ 0P_$3_P/L_\ Y%H]T#SO_A_;_P!4I_\ +G_^Y*/^']O_
M %2G_P N?_[DKT3_ (<<?";_ *&'XB?^!]G_ /(M'_#CCX3?]##\1/\ P/L_
M_D6CW0/._P#A_;_U2G_RY_\ [DH_X?V_]4I_\N?_ .Y*]$_X<<?";_H8?B)_
MX'V?_P BT?\ #CCX3?\ 0P_$3_P/L_\ Y%H]T#SO_A_;_P!4I_\ +G_^Y*/^
M']O_ %2G_P N?_[DKT3_ (<<?";_ *&'XB?^!]G_ /(M'_#CCX3?]##\1/\
MP/L__D6CW0/._P#A_;_U2G_RY_\ [DH_X?V_]4I_\N?_ .Y*]$_X<<?";_H8
M?B)_X'V?_P BT?\ #CCX3?\ 0P_$3_P/L_\ Y%H]T#SO_A_;_P!4I_\ +G_^
MY*/^']O_ %2G_P N?_[DKT3_ (<<?";_ *&'XB?^!]G_ /(M'_#CCX3?]##\
M1/\ P/L__D6CW0/._P#A_;_U2G_RY_\ [DH_X?V_]4I_\N?_ .Y*]$_X<<?"
M;_H8?B)_X'V?_P BT?\ #CCX3?\ 0P_$3_P/L_\ Y%H]T#SO_A_;_P!4I_\
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M]4I_\N?_ .Y*]$_X<<?";_H8?B)_X'V?_P BT?\ #CCX3?\ 0P_$3_P/L_\
MY%H]T#SO_A_;_P!4I_\ +G_^Y*/^']O_ %2G_P N?_[DKT3_ (<<?";_ *&'
MXB?^!]G_ /(M'_#CCX3?]##\1/\ P/L__D6CW0/._P#A_;_U2G_RY_\ [DH_
MX?V_]4I_\N?_ .Y*]$_X<<?";_H8?B)_X'V?_P BT?\ #CCX3?\ 0P_$3_P/
ML_\ Y%H]T#SO_A_;_P!4I_\ +G_^Y*/^']O_ %2G_P N?_[DKT3_ (<<?";_
M *&'XB?^!]G_ /(M'_#CCX3?]##\1/\ P/L__D6CW0/._P#A_;_U2G_RY_\
M[DH_X?V_]4I_\N?_ .Y*]$_X<<?";_H8?B)_X'V?_P BT?\ #CCX3?\ 0P_$
M3_P/L_\ Y%H]T#SO_A_;_P!4I_\ +G_^Y*/^']O_ %2G_P N?_[DKT3_ (<<
M?";_ *&'XB?^!]G_ /(M'_#CCX3?]##\1/\ P/L__D6CW0/._P#A_;_U2G_R
MY_\ [DH_X?V_]4I_\N?_ .Y*]$_X<<?";_H8?B)_X'V?_P BT?\ #CCX3?\
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M_;_U2G_RY_\ [DH_X?V_]4I_\N?_ .Y*]$_X<<?";_H8?B)_X'V?_P BT?\
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M']O_ %2G_P N?_[DKT3_ (<<?";_ *&'XB?^!]G_ /(M'_#CCX3?]##\1/\
MP/L__D6CW0/._P#A_;_U2G_RY_\ [DH_X?V_]4I_\N?_ .Y*]$_X<<?";_H8
M?B)_X'V?_P BT?\ #CCX3?\ 0P_$3_P/L_\ Y%H]T#SO_A_;_P!4I_\ +G_^
MY*/^']O_ %2G_P N?_[DKT3_ (<<?";_ *&'XB?^!]G_ /(M'_#CCX3?]##\
M1/\ P/L__D6CW0/._P#A_;_U2G_RY_\ [DH_X?V_]4I_\N?_ .Y*]$_X<<?"
M;_H8?B)_X'V?_P BT?\ #CCX3?\ 0P_$3_P/L_\ Y%H]T#SO_A_;_P!4I_\
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M]4I_\N?_ .Y*]$_X<<?";_H8?B)_X'V?_P BT?\ #CCX3?\ 0P_$3_P/L_\
MY%H]T#SO_A_;_P!4I_\ +G_^Y*/^']O_ %2G_P N?_[DKT3_ (<<?";_ *&'
MXB?^!]G_ /(M'_#CCX3?]##\1/\ P/L__D6CW0/._P#A_;_U2G_RY_\ [DH_
MX?V_]4I_\N?_ .Y*]$_X<<?";_H8?B)_X'V?_P BT?\ #CCX3?\ 0P_$3_P/
ML_\ Y%H]T#SO_A_;_P!4I_\ +G_^Y*/^']O_ %2G_P N?_[DKT3_ (<<?";_
M *&'XB?^!]G_ /(M'_#CCX3?]##\1/\ P/L__D6CW0/._P#A_;_U2G_RY_\
M[DH_X?V_]4I_\N?_ .Y*]$_X<<?";_H8?B)_X'V?_P BT?\ #CCX3?\ 0P_$
M3_P/L_\ Y%H]T#SO_A_;_P!4I_\ +G_^Y*/^']O_ %2G_P N?_[DKT3_ (<<
M?";_ *&'XB?^!]G_ /(M'_#CCX3?]##\1/\ P/L__D6CW0/._P#A_;_U2G_R
MY_\ [DH_X?V_]4I_\N?_ .Y*]$_X<<?";_H8?B)_X'V?_P BT?\ #CCX3?\
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M_;_U2G_RY_\ [DH_X?V_]4I_\N?_ .Y*]$_X<<?";_H8?B)_X'V?_P BT?\
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M']O_ %2G_P N?_[DKT3_ (<<?";_ *&'XB?^!]G_ /(M'_#CCX3?]##\1/\
MP/L__D6CW0/._P#A_;_U2G_RY_\ [DH_X?V_]4I_\N?_ .Y*]$_X<<?";_H8
M?B)_X'V?_P BT?\ #CCX3?\ 0P_$3_P/L_\ Y%H]T#SO_A_;_P!4I_\ +G_^
MY*/^']O_ %2G_P N?_[DKT3_ (<<?";_ *&'XB?^!]G_ /(M'_#CCX3?]##\
M1/\ P/L__D6CW0/._P#A_;_U2G_RY_\ [DH_X?V_]4I_\N?_ .Y*]$_X<<?"
M;_H8?B)_X'V?_P BT?\ #CCX3?\ 0P_$3_P/L_\ Y%H]T#SO_A_;_P!4I_\
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M]4I_\N?_ .Y*]$_X<<?";_H8?B)_X'V?_P BT?\ #CCX3?\ 0P_$3_P/L_\
MY%H]T#SO_A_;_P!4I_\ +G_^Y*/^']O_ %2G_P N?_[DKT3_ (<<?";_ *&'
MXB?^!]G_ /(M'_#CCX3?]##\1/\ P/L__D6CW0/._P#A_;_U2G_RY_\ [DH_
MX?V_]4I_\N?_ .Y*]$_X<<?";_H8?B)_X'V?_P BT?\ #CCX3?\ 0P_$3_P/
ML_\ Y%H]T#SO_A_;_P!4I_\ +G_^Y*/^']O_ %2G_P N?_[DKT3_ (<<?";_
M *&'XB?^!]G_ /(M'_#CCX3?]##\1/\ P/L__D6CW0/._P#A_;_U2G_RY_\
M[DH_X?V_]4I_\N?_ .Y*]$_X<<?";_H8?B)_X'V?_P BT?\ #CCX3?\ 0P_$
M3_P/L_\ Y%H]T#SO_A_;_P!4I_\ +G_^Y*/^']O_ %2G_P N?_[DKT3_ (<<
M?";_ *&'XB?^!]G_ /(M'_#CCX3?]##\1/\ P/L__D6CW0/._P#A_;_U2G_R
MY_\ [DH_X?V_]4I_\N?_ .Y*]$_X<<?";_H8?B)_X'V?_P BT?\ #CCX3?\
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M_;_U2G_RY_\ [DH_X?V_]4I_\N?_ .Y*]$_X<<?";_H8?B)_X'V?_P BT?\
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M']O_ %2G_P N?_[DKT3_ (<<?";_ *&'XB?^!]G_ /(M'_#CCX3?]##\1/\
MP/L__D6CW0/._P#A_;_U2G_RY_\ [DH_X?V_]4I_\N?_ .Y*]$_X<<?";_H8
M?B)_X'V?_P BT?\ #CCX3?\ 0P_$3_P/L_\ Y%H]T#SO_A_;_P!4I_\ +G_^
MY*/^']O_ %2G_P N?_[DKT3_ (<<?";_ *&'XB?^!]G_ /(M'_#CCX3?]##\
M1/\ P/L__D6CW0/._P#A_;_U2G_RY_\ [DH_X?V_]4I_\N?_ .Y*]$_X<<?"
M;_H8?B)_X'V?_P BT?\ #CCX3?\ 0P_$3_P/L_\ Y%H]T#SO_A_;_P!4I_\
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M]4I_\N?_ .Y*]$_X<<?";_H8?B)_X'V?_P BT?\ #CCX3?\ 0P_$3_P/L_\
MY%H]T#SO_A_;_P!4I_\ +G_^Y*/^']O_ %2G_P N?_[DKT3_ (<<?";_ *&'
MXB?^!]G_ /(M'_#CCX3?]##\1/\ P/L__D6CW0/._P#A_;_U2G_RY_\ [DH_
MX?V_]4I_\N?_ .Y*]$_X<<?";_H8?B)_X'V?_P BT?\ #CCX3?\ 0P_$3_P/
ML_\ Y%H]T#SO_A_;_P!4I_\ +G_^Y*/^']O_ %2G_P N?_[DKT3_ (<<?";_
M *&'XB?^!]G_ /(M'_#CCX3?]##\1/\ P/L__D6CW0/._P#A_;_U2G_RY_\
M[DH_X?V_]4I_\N?_ .Y*]$_X<<?";_H8?B)_X'V?_P BT?\ #CCX3?\ 0P_$
M3_P/L_\ Y%H]T#SO_A_;_P!4I_\ +G_^Y*/^']O_ %2G_P N?_[DKT3_ (<<
M?";_ *&'XB?^!]G_ /(M'_#CCX3?]##\1/\ P/L__D6CW0/._P#A_;_U2G_R
MY_\ [DH_X?V_]4I_\N?_ .Y*]$_X<<?";_H8?B)_X'V?_P BT?\ #CCX3?\
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M_;_U2G_RY_\ [DH_X?V_]4I_\N?_ .Y*]$_X<<?";_H8?B)_X'V?_P BT?\
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M']O_ %2G_P N?_[DKT3_ (<<?";_ *&'XB?^!]G_ /(M'_#CCX3?]##\1/\
MP/L__D6CW0/._P#A_;_U2G_RY_\ [DH_X?V_]4I_\N?_ .Y*]$_X<<?";_H8
M?B)_X'V?_P BT?\ #CCX3?\ 0P_$3_P/L_\ Y%H]T#SO_A_;_P!4I_\ +G_^
MY*/^']O_ %2G_P N?_[DKT3_ (<<?";_ *&'XB?^!]G_ /(M'_#CCX3?]##\
M1/\ P/L__D6CW0/._P#A_;_U2G_RY_\ [DH_X?V_]4I_\N?_ .Y*]$_X<<?"
M;_H8?B)_X'V?_P BT?\ #CCX3?\ 0P_$3_P/L_\ Y%H]T#SO_A_;_P!4I_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MY^-__0J_"K_P6W__ ,FT?ZG9CV7WA_:=#S^X_:FBOQ6_XB.?C?\ ]"K\*O\
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M"K\*O_!;?_\ R;1_J=F/9?>']IT//[C]J:*_%;_B(Y^-_P#T*OPJ_P#!;?\
M_P FT?\ $1S\;_\ H5?A5_X+;_\ ^3:/]3LQ[+[P_M.AY_<?M317XK?\1'/Q
MO_Z%7X5?^"V__P#DVC_B(Y^-_P#T*OPJ_P#!;?\ _P FT?ZG9CV7WA_:=#S^
MX_:FBOQ6_P"(CGXW_P#0J_"K_P %M_\ _)M'_$1S\;_^A5^%7_@MO_\ Y-H_
MU.S'LOO#^TZ'G]Q^U-%?BM_Q$<_&_P#Z%7X5?^"V_P#_ )-H_P"(CGXW_P#0
MJ_"K_P %M_\ _)M'^IV8]E]X?VG0\_N/VIHK\5O^(CGXW_\ 0J_"K_P6W_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M]1Q//[/V<N:U[6=[=[6V\R?;T[<W,K>I]#T5\E_\/S?V6?\ HJ/_ );>K_\
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M'U#Q%?AQ=:_<6_A_5(9;V7?)(_F3.C2-ND<Y<Y9CR0#]KJ*_$'_@GM_P:@?
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M1110 4444 %%%% !1110 45\@?\ !.+_ (*M_P##P+]J?]ISX9_\(%_PB/\
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M+_X-<_\ FN7_ ' /_<G7DTZBJ9-B)Q7*G.]NUW#3Y'5*+CC*<6[^[^C/DO\
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M:4.5SNN9IZ)[(_%__@AE_P I3?A=_P!Q;_TT7M?H=_P<M_\ )BGA/_L?+/\
M]-^HU^7/_!+_ /:%\-_LK?MV_#_QUXNDO+?PYH]Q=0WT]M 9WMEN+.>U$I0?
M,R(TRNP4,VU6VJ[84_:W_!>7_@HQ\(_VG?V>/"7@?X?^)O\ A*M6CUZU\17,
MUI:R+:V=O]@F"(\D@7]\WVQ/W:AC&8I4E\MU"'T,PPU66<4:D8MQ25W;16;Z
M_,PP]2*PDXMZW_R-;_@US_YKE_W /_<G7P]\??">O>/?^"L/C70O"VI?V+XF
MUKXM7UAI&H?:)+;[!>2ZQ(D$WFQ@R1[)&5MZ LN,@$@5]P_\&N?_ #7+_N ?
M^Y.ODO\ YSK?]UX_]V"JHR<<SQ4ETBO_ $E$R5\/27F_S/JG_@J5_P $6/A3
M^RK^PE=>-_ ]UXBM=>\"W$+7USJ-U]L?Q%#=7D4 250$CA>$S*4>%%!5&5U=
MF$B?)?\ P22_8VL?V^?V@M4^'?B+Q-XBT+PC:Z2_B;4;72I%5]1FMG6V@_U@
M:-70WTC"1HW(4RH OFEE_7/_ (+F_P#*++XH_P#<)_\ 3O95^>/_  ;2?\GU
M^+/^Q#O/_3AIU<>7X_$3RFM6G)N2;LWNM$_UT[=#;$4*:Q4():.WZGG?_!:3
M_@GKH/[!?QV\/_\ "%VNK0^"?&EA/>6GV^^CN?LUY'</Y]K%@"40Q0RV>TR[
MF;S#^\<AMOZ>?\$X]'U7]K7_ ((J^'?#.L:Q]GN_%'A+5_",>H?9$?[%;K+>
M:=;GRE*!_*@2(8)!?9EFW$M7S#_P=&?\T-_[C_\ [C*YWQ9\3/%GPX_X-H_
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M/A[X3UZ2TL/#-A=O%]LOS'9RW4DI((BAD@%O$QAVS2;1^\B\E-_UI_P<M_\
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M97^>V>*/4N0^*7[+GBK_ (-T?'=]\8OV>-#\0>,/V3-4\N?XJ?"B*]FU"_\
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MY+"[GLKJ+5+^&5%N(KB)',,EM MQ=JQ*!C:!!(CNAK\\/^#>_P#X*S?L8_\
M!+S_ ()QZ/X)\8_'3R_'OBG5;GQ9XGLX_#.N7EMI=Y<)#"EK%(FG*#Y=K;6R
MR8:5?/\ /*2O&4- 'J'_  :6?&'5?A#IW[0W[(OC/6=/OO%?P%\:W;V)377N
M8[FW:>2SO8["UE1)$LX+RT\YI% #2:LI=(W?,G['5_-C^T-_P5C^ /P:_P"#
MC+X>_M6?"+XK:AXR^'OCZT@T7XF6B6^KZ4VE)]E33'EDADL(S<6<<"6-ZD"?
M:))+BPESY.8"/Z3J /Y OV8_V>->^'__  2/\&_MB>!=+\/W?B;]FO\ : DN
MM62\L8_]-LWMO#TMB]S,)HII;>"_B2(6\>YO^)K,ZF(+(S?U>_LJ_M+^%?VR
M/V<?!?Q2\$W?VSPSXXTJ'5;/=+#)-:[U_>6T_DO)&MQ#('AEC5V\N6*1"<J:
M_*'_ (- OA;H/QQ_X(O_ !D\$^*;'^U/#/C#X@:WHFKV?G20?:[.YT+289XO
M,C99$W1NR[D96&<@@X-:'_!JW\6_$/[,?BKXZ_L0_$YM0A^(7P;\076O:2LT
MU[):W6ER/#!<&R2:!!#9B<V]W$Q*FY&L^:L0Q([ 'O\ _P '-7[7MQ^SY_P3
M1UKX?^%9M0NOBE^T!=Q> /"VC:7:P7^H:HETZ+J"I:N3+)&]HTEKO@CDD2:_
MM0-C2*Z_EA_P3D_9[U[]B[_@Z(^ ?P'US7O[?_X4OX5ET2"1?+>&VEO/"5_K
M=_%!(L$+R6_]IZKJ#Q-,GFB*2-6)V#'UA\.-*U7_ (+7_P#!S%XG\1:Q%J$7
MP7_89N_[-T_3YY7B6?Q!!=2I%*8DO/EDDU"VN+D3Q(4DM]'LX9XP7KR__G>N
M_P _]$^H ^__ /@Z._Y04?'/_N ?^I!IE>__ /!)W_E%E^S3_P!DJ\+_ /IH
MM:\ _P"#H[_E!1\<_P#N ?\ J0:97O\ _P $G?\ E%E^S3_V2KPO_P"FBUH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\ ?^#/G]L7X<?LT?\
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M&+.3PSKEG;:I>6Z30O:RR/IS >9:W-RL>6B7S_(+RI&'-?H?_P $ OV\K?\
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M@\.^)+Q&6]MTBMIEB7SX[6Z^V/%/).(!:D?9X&F\PC(7]#Z_ 'X0?M8_$?\
M;1_X.EOV3_''Q,^!_B#X :M<?#_5K2P\-ZWJ+75_<V<5IXG NY$>WMY;??-Y
MZ"*6)6*PK("4E0G]_J "BBB@#Y__ ."L7_*++]I;_LE7BC_TT75> ?\ !KC_
M ,H*/@9_W'__ %(-3KW_ /X*Q?\ *++]I;_LE7BC_P!-%U7@'_!KC_R@H^!G
M_<?_ /4@U.@#/_;)_P""YOC+X1?MM:Q\!/@C^RO\4/C_ .,O!]WIUGXIO;.[
M&EZ-HSZE;6]SIY-VD%RB1R)-*'DNQ:QQFW<[G0,Z< W_  <D>)OV<_VN/#?P
MN_:H_9;\8?L[V?BZ[ATW3/$\OBNTUG1FN))+0-*]VT5M:-9P1W:R7$\%Q,8"
M C1[BVSO_P!L/_@Y$^$?[.?[3^O? SP'X'^*'Q\^,6DVEPD6B^ M+CO[5M4B
MBFD?399A(9A)$(LW#06]P(!O!#212Q)^6'_!P;_P4_\ CC^WS^P+HND_$3]D
M#X@?L]^&?#_Q TV[77O$^I3C[?>/IVJI%:0VUS86LDFZ,3R-+&76/R45PIFC
MR ?N]_P5'_;G_P"':_["?CKXU?\ "+_\)I_PA?V#_B3?VE_9OVS[5J%M9?Z_
MRI=FW[1O_P!6V=FWC.X?$/P\_P"#H#_AHGX1?"6'X-_L_P#B#XO?'3XC?:KS
M6/AWX?\ $/F0^!M.BU*73XKK4=3^R&.#S9!;R 2PQI%%<"2:2)# T_K_ /P=
M'?\ *"CXY_\ < _]2#3*Y_\ X-/_ (6Z#\/_ /@B5\.=6TBQ^QZAXXU76];U
MN7SI)/MMXFIW%@LN&8A,6MC:Q[4"K^ZW8W,S, <!XN_X.;=>_8__ &CM.\#?
MM:?LK?$#]GW2=8Q%9^)+77(_%%A++NM3(ZO#;PQ7%O##<AYGLY;B6-@L?DL[
M$+^EW[0OQKTO]FOX!>./B-KMOJ%WHG@'P_?^)-0@L(TDNIK>SMI+B5(E=D1I
M"D;!0SJ"2,L!R/A#_@[ ^%N@_$#_ ((E?$;5M7L?MFH>!]5T36]$E\Z2/[%>
M/J=O8-+A6 ?-K?74>UPR_O=V-RJR]!_P1@_;IT'PO_P;[_"#XO?%K6O#_@SP
MSX'\*RZ1?ZAMDCMH;/2;V?2;4[2SR27$L=K -D>6EGEVQQY=(Z /,/AQ_P %
M[OVE_P!H7PKXG\8?#+_@GG\4/$7P]T:T_MC3-7UCQ<FA77B#2Y$EFM;FTM)K
M%C>22P1A_)L7NB#)&JL_F1E_;_\ @D1_P6]\*_\ !5#6/&G@V\\#^(/A'\7?
MAO\ \C)X/UV[ADFA_P!*GMW^SD^5<R^0T42W'F6L/D2W,49W9#'YPN?^#IS5
M?CIX5L]=_9N_8Q_:0^-FB17<]AK&H/ICV5KIUPB0ND,<MA#J*22%)=SHYB*
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MB:19^=)/]DL[;4?$4,$7F2,TC[8T5=SLS'&22<FO'_\ G>N_S_T3Z@#];O\
M@J!_P4=TO_@F7\ M'\77G@GQA\1M;\7^((?"'ACP[X;A22ZU;6;FVN9K2W;)
MWK'(]L8RT4<T@,B[89#Q7QC\1?\ @OM^U9\)/V<8_BQXD_X)S_$#2?!/[]KB
M>;QT/M^F10K.TMQ>6 TPWEI;HMO*QGN(8X@NQM^)(RWV=_P4P_X*I_"/_@E#
M\&K'QA\4M2U"236KO['HN@:/%'<ZSKC@IYQMX9)(T\N%'#R22.D: HNXR2Q1
MR?&,'_!QA\<?BWX[TB/X0_\ !/?]H#QIX)\6?86\-^)-;DGT"'4XKJ.(I<2.
M+"XLX+<M(2)S=M$8@LK.@)"@'W=_P3Q_X*!> ?\ @II^S!I7Q6^'+ZA%HFI7
M=U83Z?J9MEU/2;B"5D:&ZB@FF2&1D\N94+DF&>%\ .*]PK\@?^#*G_E%EX^_
M[*KJ/_IHT>OU^H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH ^$_B]_P &^'P8^-/Q8\4>,=4\
M3?$^WU/Q9J]WK-Y%:ZC8K!'-<3/,ZQAK-F"!G( +,0,9)/-?=E%%=.(QE:NH
MQJR;4=O+^K&=.C"#;@K7/._VK?V:-!_;!^ 6O?#GQ-=ZM8Z)XB^S_:9],ECB
MND\FYBN$V-(CH,O$H.4/!/0X(\\_8*_X)I>!?^"=W_"5_P#"$ZMXMU3_ (3#
M[)]L_MNZMY_*^S>?Y?E^3!%C/VA\[MV<+C'.?H>BE'%5HT704O=>K72^G^2!
MTX.?.UJ>'_MH?\$\/A?^W?X5%CXVT7R=6A\E;7Q#IBQ0:S9)&[L(DG9'W0GS
M)08I%:/,A8*'"NORM#_P;/?!A==N9)/&GQ/;3&@B6WMUN[%9XI@TGFN\OV4J
MZ,IA"H(U*&-R6<.!'^C-%=&'S3%T(>SI5&EV(J86E-\THZGDO[(?[$/PX_8=
M\"3:%\/M#_L_^T/)?4]0N)FN+_5I8HPBR32M_P "81H$B1I9"B)O;/<?%GX3
M>&_CK\.-8\(^+M'M->\.:] ;:^L;D'9*N00000R.K!65U(9&564JR@CHJ*Y)
MUJDJGM92;EO>^OWFL814>5+0_-O_ (AF/A/_ ,)W]H_X3[XB?\(S]@\O[!NL
M_M_VSS,^=]J\GR_)\OY?*\C=N^;S<?)7W9^T+^S;X'_:L^'$GA+X@^';3Q)H
M,EQ'="WF>2)X9HR=LD<L;+)$X!9=R,I*NZG*NP/<45TXC,L56E&52;;CL]K?
M<9T\/3@FHK?<_-O6/^#9CX3S^*M'FT_Q]\1+71(?/_M6TN&LY[J]R@$/D3K"
MB0;'R7WQ3;P0!Y9&X_0W["__  28^%__  3^\=ZUXF\'WGBW5M;UJP&F-<ZW
M?13?9;<R+(Z1I#%$OSO'$27#$>4H4J"X;Z>HK2MF^,JP]G4J-HF&%HP?-&.I
MXU^VO^PA\/OV]_AQ:^'?'5G>+)IMQ]ITW5M.=(=2TMB5\P12.CKLD50KHZLK
M85L;TC=/ _V)O^"%_@7]C+X^V?Q&MO&7BWQ!K>A7][)HT$J6]O:P6<]M);K#
M<*$9YID260F5'B5CM_=* 0WW#16-/,,33HNA";Y7T]=RI8>G*?.UJ?-O[<7_
M  2J^%/[?FNZ?K7C&/Q%IOB/38([*+5M&U#R9VM(VF<6[1RK+!L\R=W+"(29
M"C?MRI\E^"?_  ;W? SX8>$-2M];?Q%XSU[5M);3GU2_FCC33)I+:6":YLK9
M4\M')E,D?VC[08FCB96W*6;[LHJZ>:8N%/V4*C4>U_Z^X4L-2E+G<5<^-?V4
MO^"'?PG_ &/OC[H/Q&\,^(?B)?:WX=^T?9H-3O[.6U?SK:6W?>L=JCG"2L1A
MQR!U&0>=^+W_  ;X?!CXT_%CQ1XQU3Q-\3[?4_%FKW>LWD5KJ-BL$<UQ,\SK
M&&LV8(&<@ LQ QDD\U]V457]K8SG]K[1\UK7\MQ?5:/+R\NA^>/_ !#2? G_
M *&SXM?^#33_ /Y"KZI_8=_8=\)_L!_"?4/!W@[4/$6I:9J6KR:S++K,\,TZ
MS20PPE5,442[-L"$ J3DMSC 'LM%1B,SQ5>'LZLVUV*IX>E!\T%9GP]^U)_P
M0-^#?[2?Q,U+QA;:AXM\'ZWKM^+_ %5=/O%N+6_EDNS/=S%+A7=)I4>1%*.L
M49\MO*8*R.7?_!OI^S[/\&X/"4,/BVSO%OX[^Y\21W\,FLWOEBX"0L\D+0QP
MXN/F2&*/>882Y9D!/W#16BSC&J*@JCLMM?Z_$GZI1O?E1\\?L%?\$TO O_!.
M[_A*_P#A"=6\6ZI_PF'V3[9_;=U;S^5]F\_R_+\F"+&?M#YW;LX7&.<^>?\
M#COX3_\ #6'_  N+_A(?B)_PDW_"6_\ "9?9?M]G]@^V?;/MGE[/LOF>3YG&
MWS-VWC=GFOLJBLO[2Q*G*ISN\M&^Z*^KT[*-M%L>=_M6_LT:#^V#\ M>^'/B
M:[U:QT3Q%]G^TSZ9+'%=)Y-S%<)L:1'09>)0<H>">AP1XW^P[_P2&^&O[ ?Q
M8U#QCX.USQQJ6IZEI,FC2Q:S>6LT"PR30S%E$5O$V_= @!+$8+<9P1]445G3
MQE:%)T(2:B]UW*E1@Y*;6J/GC]O7_@FEX%_X*(_\(I_PFVK>+=+_ .$/^U_8
M_P"Q+JW@\W[3Y'F>9YT$N<?9TQMVXRV<\8Z+X5_L(?#[X9_L=P? NXL[SQ9X
M!C@N;:6#7'26>Y6>YDNB6>)(PKI+)N1XPK(41E(=0U>RT4?7*_LXT>9\L7=+
ML^Z^]A[&',YVU9^<T/\ P;/?!A==N9)/&GQ/;3&@B6WMUN[%9XI@TGFN\OV4
MJZ,IA"H(U*&-R6<.!'UOQ4_X-XO@'\3/&T^L6]UXX\)V\D%M;1:7H=[:16-L
ML%O' "HEMI)&=Q'O=Y)&9Y'=V)+&ONRBNMYUCF^;VK,?J="UN5'C7[<7[#OA
M/]OSX3Z?X.\8ZAXBTW3--U>/68I=&GAAG::.&:$*QEBE79MG<D!0<A><9!^>
M)O\ @WB^ <_PGMO"[77C@7%KJ\NJIKRWMHNK,LD,<36CR"V\M[<&)9%5HRR.
M7*NHD=6^[**PHYEB:,%"E-I+70TGAZ<WS25V?"?[/7_!O=\#/@QXOCUO7G\1
M?$.XM;B26VLM;FC738P+D2VY>")%,SI$J1N)7:&7,C&%0RHGW9116>*QE?$2
MYJ\G)^95.C"FK05@K\H?^"]'_"5?\$[?VX?@'^W=X7_X2#5/#/@_R_AQ\4-(
MLO.G67P]<SRRQRB"/RHSB2XN0&NKE81>#2<(3N)_5ZL_Q9X3TOQ[X5U+0M=T
MS3]:T36K26PU#3[^W2YM;^WE0I+#+$X*21NC,K(P(8$@@@US&@>$_%FE^/?"
MNFZ[H6I:?K6B:U:17^GZA87"7-K?V\J!XIHI4)22-T965U)# @@D&O@#]O'_
M (-A/V7/V^/C+>_$#5-/\8?#WQ7K=W/?Z[=^#-2ALX]?N)1&#-/!<07$*29C
M9R\"1&62>5Y3*[;A]W_"WX3^%?@=X$L?"W@GPSX?\'^&=+\S['I&B:=#I]A:
M>9(TLGEP0JL:;I'=SM RSL3R2:Z"@#\T/B/_ ,&N?PC^/WBKPQJ'Q8^.?[6'
MQBL_"EW]HM-,\:_$"/5+4H[Q-/!N-HLT4<XAC60P212$*N'5E5A[_P#MT?\
M!&WX1_MZ?L7^ O@)KMSXP\(_#WX:W>GW&@P^&]1C6ZMDL;&>PMH&FO(KDR1K
M!.P)8&1BBDN?FW?6%% 'Y _\05/[+/\ T/W[0'_@\TC_ .5E?;W_  3U_P""
M.?[/O_!,#[5>?";P3_9_B;5-*M](U7Q)J5]-J&JZI%%@L6>1C'!YL@625+9(
M8G=(R8\11A/J"B@ KQ_]O7]BKPK_ ,%$OV3O%?P=\;:AX@TOPSXP^Q_;+K1)
MX8+^+[->07D?EO-%+&,R6Z [HVRI8#!P1[!10!Q_[/7P4TO]FOX!>!_ASH5Q
MJ%WHG@#P_8>&]/GOW22ZFM[.VCMXGE9%1&D*1J6*HH))PH' ^$/V]?\ @U_^
M 7_!1+]K'Q7\8O&WB[XP:7XF\8?8_MEKHFJZ=!81?9K."SC\M)K&609CMT)W
M2-EBQ&!@#]'Z* /R!_X@J?V6?^A^_: _\'FD?_*ROL[PU_P1M^$>A?\ !*^3
M]D&ZN?&&M?"V2TN;=;N\U&-=9C>749-32<30Q1Q>9#=NKH#$8R(D61)%+AOK
M"B@#\T/#7_!L-X!\%_!J3X<Z/^TY^V?I/P]FM+FPD\,6?Q%MH-&>WN3(;B$V
MBV(A,<IEE+H4PYD?<#N.?J__ ()Z_P#!,7X-_P#!+[X677A;X1^%_P"R?[6^
MSR:WJ]Y<-=ZKX@GAA$2S7,[?\#<11"."-YIC'%'YC _0%% !1110 4444 %%
M%% ''_'[X ^#?VI?@UXA^'OQ"\/:?XJ\&^*K0V6IZ9>*3'<)D,I#*0\<B.JN
MDB%9(Y$1T9756'YX^ /^#4?X'_ [XIZUXM^%OQ@_:@^$.H:UY\.SP;XX@TW[
M)9RS++]A2;[&UR]NK)%A9I9&/E(79V&ZOT^HH ^$/V%/^#=WX"_L(?M/W7QH
MT_5?BA\1OBE+=SW]MXB\:^(_MMU97%S%<PWDW^CQ0+/)<)=2>8]TLQR%92C;
MBW'_ +>O_!K_ / +_@HE^UCXK^,7C;Q=\8-+\3>,/L?VRUT35=.@L(OLUG!9
MQ^6DUC+(,QVZ$[I&RQ8C P!^C]% 'Y0_"W_@S;_9'^'_ ([L=7U;4OC!XXT^
MS\SS=$UOQ%;0V%[NC9!YC65I;7(V,P<>7,GS(H;<NY6_2[X _ 'P;^RU\&O#
MWP]^'OA[3_"O@WPK:"RTS3+-2([=,EF)9B7DD=V9WD<M))([N[,[,Q["B@#Y
M/_X*I?\ !&WX1_\ !7SPKX/T_P")USXPTF\\"W=S<:3J?AO48[6ZB2Y2-;B!
MEFBFA:.0PV[$F/S%,"[756D5_$/'_P#P;/\ PX^./]BV?Q2_:&_; ^+WAG1=
M5@U?_A&_&7Q(74M*NY8MPPZ?95D3=&\L9>%XY0DKA)$)S7Z/T4 <?\ ?@#X-
M_9:^#7A[X>_#WP]I_A7P;X5M!9:9IEFI$=NF2S$LQ+R2.[,[R.6DDD=W=F=F
M8_F#_P $M/">J_\ !6#_ (+ _$C]N+7M,U"'X3_#^TE\ _ ^>XMWMX]8MT:X
MM[K5(6Q;S/'B2])2Y@D DU>2(2>9887]7O%GA/2_'OA74M"UW3-/UK1-:M);
M#4-/O[=+FUO[>5"DL,L3@I)&Z,RLC A@2""#6?\ "WX3^%?@=X$L?"W@GPSX
M?\'^&=+\S['I&B:=#I]A:>9(TLGEP0JL:;I'=SM RSL3R2: .@HHHH ****
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M$**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** /5?V$_^3WO@W_V/.B?^E\%?TIU_-9^
MPG_R>]\&_P#L>=$_]+X*_I3K\UXZ_CTO1_F>]E/P2]0HHHKX4]8**** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MJ>7]LTC6].AU"PN_+D66/S()E:-]LB(XW X9%(Y - 'Q!_P:X_\ *"CX&?\
M<?\ _4@U.OO^N?\ A;\)_"OP.\"6/A;P3X9\/^#_  SI?F?8](T33H=/L+3S
M)&ED\N"%5C3=([N=H&6=B>23704 %%%% !1110 4444 %%%% !1110 4444
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M6?\ "]O^%I?\*T^'_P#PLW_H;O\ A'K3^WO^/?[+_P ?OE^?_P >_P"Y^_\
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MM=BPP230!Z!7X _\[UW^?^B?5^_U>?\ _#)WPL_X7M_PM+_A6GP__P"%F_\
M0W?\(]:?V]_Q[_9?^/WR_/\ ^/?]S]__ %?R?=XH _*'_@Z+_86^(_A_XV?"
M#]MSX3Z+_P )9JWP!^R3>)=)N"T\-I9Z;?G4K*^%M&J2R6Z32W0NV6;<D1A=
M51(YYD^O_@7_ ,'&W[&WQW^%FJ>*;?XU>'_"_P#8&E1:KJND>)XY=)U6UWPO
M*UM#!(O^GW$?ENC1V!N?GV!2WF1E_M^OG_\ X=._LL_]&T_L_P#_ (;S2/\
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M_JL'A/P ]AJ;333>'+,+$+J6&.62)/M<-GI3GS&\X2VUQ^ZMT<+( ??]%%%
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MW*:?YJ'SXOM-OIM\OGQ(WE;,DAB@;[?^(O\ P<;?L;?#_P#9QC^)D7QJ\/\
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M\0+[Q9KUAI&IM>0V-F9))+:U(666!-MQ<:A*GE22L8KJ(22LZ[(P#[_HHHH
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M?>%O&WAGP_XP\,ZIY?VS2-;TZ'4+"[\N198_,@F5HWVR(CC<#AD4CD UY_\
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M:6[\NV#W+?8&U'3[SRO+VW.SR06S(%^[_P!IG_@O]\!?#GP:T>'X,_$;P?\
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MPHQV% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MT1OX5?\ A)6'_P :H_UZH?\ /I_>@_LF?\R/YK**_I3_ .&$_@A_T1OX5?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MFGZ3:R2")9KRY2"-G()"AF(&< G'7 /I0!H45R?_  OSP+_T.GA/_P &]O\
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M"#2K":ZNIH;:UMHVEFFE<)'$BC+,S'@  $DG@ 4 345R?_"_/ O_ $.GA/\
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MN"/6H?%'C[0O _D?VUK6DZ/]JW>3]MO([?SMN-VW>1G&X9QTR/6@#6HKD_\
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MV00000>010!T]%<Q8?&SP9JM_#:VOB[PQ<W5S(L4,,6J0/)*['"JJALDDD
M<DFNAO\ 4(-*L)KJZFAMK6VC:6::5PD<2*,LS,>   22> !0!-17)_\ "_/
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MQYEO=:C##+'D!AE68$9!!&1T(-5?^%^>!?\ H=/"?_@WM_\ XN@#K***Y/\
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M/(##*LP(R"",CH0: .BHKD_^%^>!?^AT\)_^#>W_ /BZZR@ HKD_^%^>!?\
MH=/"?_@WM_\ XNK6A?%WPGXHU6*QTWQ/X=U&^GSY=O:ZC#-+)@%CA58DX ).
M!T!- '1454UW7['POI4M]J5[::=8P8\RXNIEABCR0HRS$ 9) &3U(%<]_P +
M\\"_]#IX3_\ !O;_ /Q= '645D^%_'VA>.//_L76M)UC[+M\[[%>1W'D[L[=
MVPG&=IQGK@^E'BCQ]H7@?R/[:UK2='^U;O)^VWD=OYVW&[;O(SC<,XZ9'K0!
MK45R?_"_/ O_ $.GA/\ \&]O_P#%UT.A:_8^*-*BOM-O;34;&?/EW%K,LT4F
M"5.&4D'!!!P>H(H MT5SNN_%WPGX7U66QU+Q/X=TZ^@QYEO=:C##+'D!AE68
M$9!!&1T(-16'QL\&:K?PVMKXN\,7-U<R+%##%JD#R2NQPJJH;)))  '))H Z
M>BBN3_X7YX%_Z'3PG_X-[?\ ^+H ZRBL/PU\3?#?C2_:UT?Q!H>K74<9E:&S
MOXIY%0$ L55B<9(&>F2/6M'7=?L?"^E2WVI7MIIUC!CS+BZF6&*/)"C+,0!D
MD 9/4@4 6Z*Y/_A?G@7_ *'3PG_X-[?_ .+K<\->+M)\:6#76CZII^K6L<AB
M::SN4GC5P 2I921G!!QUP1ZT :%%9/BCQ]H7@?R/[:UK2='^U;O)^VWD=OYV
MW&[;O(SC<,XZ9'K63_POSP+_ -#IX3_\&]O_ /%T =914-AJ$&JV$-U:S0W-
MK<QK+#-$X>.5&&596'!!!!!'!!K#UWXN^$_"^JRV.I>)_#NG7T&/,M[K4889
M8\@,,JS C(((R.A!H Z*BN8L/C9X,U6_AM;7Q=X8N;JYD6*&&+5('DE=CA55
M0V222  .2373T %%<G_POSP+_P!#IX3_ /!O;_\ Q=:'AKXF^&_&E^UKH_B#
M0]6NHXS*T-G?Q3R*@(!8JK$XR0,],D>M &Y1537=?L?"^E2WVI7MIIUC!CS+
MBZF6&*/)"C+,0!DD 9/4@5SW_"_/ O\ T.GA/_P;V_\ \70!UE%9_AKQ=I/C
M2P:ZT?5-/U:UCD,336=RD\:N "5+*2,X(..N"/6H?%'C[0O _D?VUK6DZ/\
M:MWD_;;R.W\[;C=MWD9QN&<=,CUH UJ*Y/\ X7YX%_Z'3PG_ .#>W_\ BZZ:
MPU"#5;"&ZM9H;FUN8UEAFB</'*C#*LK#@@@@@C@@T 345SNN_%WPGX7U66QU
M+Q/X=TZ^@QYEO=:C##+'D!AE68$9!!&1T(-16'QL\&:K?PVMKXN\,7-U<R+%
M##%JD#R2NQPJJH;)))  '))H Z>BH;_4(-*L)KJZFAMK6VC:6::5PD<2*,LS
M,>   22> !7,_P#"_/ O_0Z>$_\ P;V__P 70!UE%8?AKXF^&_&E^UKH_B#0
M]6NHXS*T-G?Q3R*@(!8JK$XR0,],D>M7/$OB[2?!=@MUK&J:?I-K)((EFO+E
M((V<@D*&8@9P"<=< ^E &A17)_\ "_/ O_0Z>$__  ;V_P#\76YX:\7:3XTL
M&NM'U33]6M8Y#$TUG<I/&K@ E2RDC."#CK@CUH T**P_$OQ-\-^"[];76/$&
MAZ3=21B58;R_B@D9"2 P5F!QD$9Z9!]*S_\ A?G@7_H=/"?_ (-[?_XN@#K*
M*AL-0@U6PANK6:&YM;F-989HG#QRHPRK*PX(((((X(-<]?\ QL\&:5?S6MUX
MN\,6UU;2-%-#+JD"21.IPRLI;(((((/((H Z>BN8L/C9X,U6_AM;7Q=X8N;J
MYD6*&&+5('DE=CA550V222  .2370W^H0:58375U-#;6MM&TLTTKA(XD499F
M8\   DD\ "@":BN3_P"%^>!?^AT\)_\ @WM__BZT/#7Q-\-^-+]K71_$&AZM
M=1QF5H;._BGD5 0"Q56)QD@9Z9(]: -RBL_Q+XNTGP78+=:QJFGZ3:R2")9K
MRY2"-G()"AF(&< G'7 /I6'_ ,+\\"_]#IX3_P#!O;__ != '645G^&O%VD^
M-+!KK1]4T_5K6.0Q--9W*3QJX )4LI(S@@XZX(]:I^)?B;X;\%WZVNL>(-#T
MFZDC$JPWE_%!(R$D!@K,#C((STR#Z4 ;E%<G_P +\\"_]#IX3_\ !O;_ /Q=
M=-8:A!JMA#=6LT-S:W,:RPS1.'CE1AE65AP00001P0: )J*YB_\ C9X,TJ_F
MM;KQ=X8MKJVD:*:&75($DB=3AE92V00000>0170V&H0:K80W5K-#<VMS&LL,
MT3AXY4895E8<$$$$$<$&@":BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M6+[7+:ZMK1;-5LYHDC**[N"0T;'.9#WQ@#BO5** /GG_ (=J^!?^@MXL_P#
MJW_^,5[MX1\-0>"_">EZ/:M-):Z3:16<+2D&1DC0(I8@ 9P!G  SV%:%% 'A
M7B[_ ()]>#/&GBS5-8NM3\3QW6K7<MY,L5Q (U>1R[!082<9)QDDX[FM'X4_
ML0>$_@_X^L/$6FZAXBGOM.\SRTNIX6B;?&T9R%B4]'.,$<X^E>R44 9_B[PU
M!XT\)ZIH]TTT=KJUI+9S-$0)%21"C%201G!.,@C/8UX3_P .U? O_06\6?\
M@5;_ /QBOH:B@#SWX#?LU:%^SQ_:O]BW>K77]L>3YWVV6-]OE;]NW8BXSYAS
MG/0=*T/CA\#])^/OA.WT?6+C4+:UMKM;Q6LY$20NJ.@!+*PQB0]LY YKLJ*
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M=_X=J^!?^@MXL_\  JW_ /C%?0U% !7SS_P[5\"_]!;Q9_X%6_\ \8KZ&HH
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MEK/"L2[(UC& T3'H@SDGG/TKV2B@#YY_X=J^!?\ H+>+/_ JW_\ C%?0U%%
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MG)/-=E10!Y7\</V1?#?Q]\66^L:Q?:Y;75M:+9JMG-$D917=P2&C8YS(>^,
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MTKV2B@#YY_X=J^!?^@MXL_\  JW_ /C%?0U%% 'SS_P[5\"_]!;Q9_X%6_\
M\8KHOA3^Q!X3^#_CZP\1:;J'B*>^T[S/+2ZGA:)M\;1G(6)3T<XP1SCZ5[)1
M0!SOQ6^&MC\8/ -_X=U*:[@L=1\OS'M6595V2+(,%E8=4&<@\9^M>-_\.U?
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M&@12Q  S@#. !GL*\K^*W[$'A/XP>/K_ ,1:EJ'B*"^U'R_,2UGA6)=D:QC
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M &?XN\-0>-/">J:/=--':ZM:2V<S1$"14D0HQ4D$9P3C((SV->$_\.U? O\
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M,8C';.2>:YWXX?LB^&_C[XLM]8UB^URVNK:T6S5;.:)(RBN[@D-&QSF0]\8
MXKU2B@#YY_X=J^!?^@MXL_\  JW_ /C%>[>$?#4'@OPGI>CVK326NDVD5G"T
MI!D9(T"*6( &< 9P ,]A6A10!X5XN_X)]>#/&GBS5-8NM3\3QW6K7<MY,L5Q
M (U>1R[!082<9)QDDX[FO9?"/AJ#P7X3TO1[5II+72;2*SA:4@R,D:!%+$ #
M. ,X &>PK0HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MB:/^J)_^7A_]PU^5=%'^JN5_\^O_ ":7^8?VAB/YOP7^1^JG_$31_P!43_\
M+P_^X:/^(FC_ *HG_P"7A_\ <-?E711_JKE?_/K_ ,FE_F']H8C^;\%_D?JI
M_P 1-'_5$_\ R\/_ +AH_P"(FC_JB?\ Y>'_ -PU^5=%'^JN5_\ /K_R:7^8
M?VAB/YOP7^1^JG_$31_U1/\ \O#_ .X:/^(FC_JB?_EX?_<-?E711_JKE?\
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MB:/^J)_^7A_]PU^5=%'^JN5_\^O_ ":7^8?VAB/YOP7^1^JG_$31_P!43_\
M+P_^X:/^(FC_ *HG_P"7A_\ <-?E711_JKE?_/K_ ,FE_F']H8C^;\%_D?JI
M_P 1-'_5$_\ R\/_ +AH_P"(FC_JB?\ Y>'_ -PU^5=%'^JN5_\ /K_R:7^8
M?VAB/YOP7^1^JG_$31_U1/\ \O#_ .X:/^(FC_JB?_EX?_<-?E711_JKE?\
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M$WE7$.H6L:V[[(X+&!0H78\GZ?4 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'X _P#!
M;3_E)U\3/^X7_P"FFSKY5KZJ_P""VG_*3KXF?]PO_P!--G7RK7[IE'^XT?\
M!'_TE'R.)_C2]7^84445Z!B%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_2G^PG
M_P F0_!O_L1M$_\ 2""O5:\J_83_ .3(?@W_ -B-HG_I!!7JM?@>+_CS]7^9
M]A2^!>@4445SF@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_P#P="^&/C9X!^+'POU[X+_M$6G]D^+I_!VJZ'=6NB7%S'%;SB^9+EOL\?\
M:$.GZI/>N(#();D+YQCG#_T'5^&/_!??_@W'^ /[/G_!-'Q=\2/@)\.=0\*^
M,OA[=VFM7JV=_J^NR:II>_R+N(I<7<B01Q).+QYPC%([%P=J,[K^CW_!$?\
M;RN/^"CG_!-'X;?$C6+S3[OQDUI)HOBI;>[@FD75+-S!++,D*1I;R7*+%>"
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M_5^./_!S-^R'\7/A7\??A+^W1\#X=0U;Q%\![1;?Q181W4FV#2[:YDNHYS!
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MS7LO?%EUXNO=&CT&?44G2\U&R5[BX3[5]H\K3=-EMW9GADBNF^SE(IB_V?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M\JU]5?\ !;3_ )2=?$S_ +A?_IILZ^5:_=,H_P!QH_X(_P#I*/D<3_&EZO\
M,****] Q"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _I3_83_Y,A^#?_8C:)_Z0
M05ZK7E7["?\ R9#\&_\ L1M$_P#2""O5:_ \7_'GZO\ ,^PI? O0****YS0*
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^?_C;
M_P $N/@3^T9\3]3\9>,O O\ ;'B36/*^V7G]M:A;^=Y420I\D4Z(N(XT7Y5&
M<9.223RO_#DO]F+_ *)G_P"7%JW_ ,E5]545W0S3&PBHQK226B2D]/Q,7AZ3
M=W%?<CY5_P"')?[,7_1,_P#RXM6_^2J/^')?[,7_ $3/_P N+5O_ )*KZJHJ
MO[7QW_/Z?_@4O\P^K4?Y5]R/E7_AR7^S%_T3/_RXM6_^2J/^')?[,7_1,_\
MRXM6_P#DJOJJBC^U\=_S^G_X%+_,/JU'^5?<CY5_X<E_LQ?]$S_\N+5O_DJC
M_AR7^S%_T3/_ ,N+5O\ Y*KZJHH_M?'?\_I_^!2_S#ZM1_E7W(^5?^')?[,7
M_1,__+BU;_Y*H_X<E_LQ?]$S_P#+BU;_ .2J^JJ*/[7QW_/Z?_@4O\P^K4?Y
M5]R/E7_AR7^S%_T3/_RXM6_^2J/^')?[,7_1,_\ RXM6_P#DJOJJBC^U\=_S
M^G_X%+_,/JU'^5?<CY5_X<E_LQ?]$S_\N+5O_DJC_AR7^S%_T3/_ ,N+5O\
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M/[7QW_/Z?_@4O\P^K4?Y5]R/E7_AR7^S%_T3/_RXM6_^2J/^')?[,7_1,_\
MRXM6_P#DJOJJBC^U\=_S^G_X%+_,/JU'^5?<CY5_X<E_LQ?]$S_\N+5O_DJC
M_AR7^S%_T3/_ ,N+5O\ Y*KZJHH_M?'?\_I_^!2_S#ZM1_E7W(^5?^')?[,7
M_1,__+BU;_Y*H_X<E_LQ?]$S_P#+BU;_ .2J^JJ*/[7QW_/Z?_@4O\P^K4?Y
M5]R/E7_AR7^S%_T3/_RXM6_^2J/^')?[,7_1,_\ RXM6_P#DJOJJBC^U\=_S
M^G_X%+_,/JU'^5?<CY5_X<E_LQ?]$S_\N+5O_DJC_AR7^S%_T3/_ ,N+5O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P#0Z>$__!O;_P#Q='_"_/ O_0Z>$_\ P;V__P 77SS_ ,.O/^IX_P#*-_\
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M_P#%U\\_\.O/^IX_\HW_ -OH_P"'7G_4\?\ E&_^WT ?0W_"_/ O_0Z>$_\
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M/_#KS_J>/_*-_P#;Z/\ AUY_U/'_ )1O_M] 'T-_POSP+_T.GA/_ ,&]O_\
M%T?\+\\"_P#0Z>$__!O;_P#Q=?//_#KS_J>/_*-_]OH_X=>?]3Q_Y1O_ +?0
M!]#?\+\\"_\ 0Z>$_P#P;V__ ,71_P +\\"_]#IX3_\ !O;_ /Q=?//_  Z\
M_P"IX_\ *-_]OH_X=>?]3Q_Y1O\ [?0!]#?\+\\"_P#0Z>$__!O;_P#Q='_"
M_/ O_0Z>$_\ P;V__P 77SS_ ,.O/^IX_P#*-_\ ;Z/^'7G_ %/'_E&_^WT
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M>$__  ;V_P#\71_POSP+_P!#IX3_ /!O;_\ Q=?//_#KS_J>/_*-_P#;Z/\
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M_P#0Z>$__!O;_P#Q='_"_/ O_0Z>$_\ P;V__P 77SS_ ,.O/^IX_P#*-_\
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M_P#%U\\_\.O/^IX_\HW_ -OH_P"'7G_4\?\ E&_^WT ?0W_"_/ O_0Z>$_\
MP;V__P 71_POSP+_ -#IX3_\&]O_ /%U\\_\.O/^IX_\HW_V^C_AUY_U/'_E
M&_\ M] 'T-_POSP+_P!#IX3_ /!O;_\ Q='_  OSP+_T.GA/_P &]O\ _%U\
M\_\ #KS_ *GC_P HW_V^C_AUY_U/'_E&_P#M] 'T-_POSP+_ -#IX3_\&]O_
M /%T?\+\\"_]#IX3_P#!O;__ !=?//\ PZ\_ZGC_ ,HW_P!OH_X=>?\ 4\?^
M4;_[?0!]#?\ "_/ O_0Z>$__  ;V_P#\71_POSP+_P!#IX3_ /!O;_\ Q=?/
M/_#KS_J>/_*-_P#;Z/\ AUY_U/'_ )1O_M] 'T-_POSP+_T.GA/_ ,&]O_\
M%T?\+\\"_P#0Z>$__!O;_P#Q=?//_#KS_J>/_*-_]OH_X=>?]3Q_Y1O_ +?0
M!]#?\+\\"_\ 0Z>$_P#P;V__ ,71_P +\\"_]#IX3_\ !O;_ /Q=?//_  Z\
M_P"IX_\ *-_]OH_X=>?]3Q_Y1O\ [?0!]#?\+\\"_P#0Z>$__!O;_P#Q='_"
M_/ O_0Z>$_\ P;V__P 77SS_ ,.O/^IX_P#*-_\ ;Z/^'7G_ %/'_E&_^WT
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M>$__  ;V_P#\71_POSP+_P!#IX3_ /!O;_\ Q=?//_#KS_J>/_*-_P#;Z/\
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M_P#0Z>$__!O;_P#Q='_"_/ O_0Z>$_\ P;V__P 77SS_ ,.O/^IX_P#*-_\
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M_P#%U\\_\.O/^IX_\HW_ -OH_P"'7G_4\?\ E&_^WT ?0W_"_/ O_0Z>$_\
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M/_#KS_J>/_*-_P#;Z/\ AUY_U/'_ )1O_M] 'T-_POSP+_T.GA/_ ,&]O_\
M%T?\+\\"_P#0Z>$__!O;_P#Q=?//_#KS_J>/_*-_]OH_X=>?]3Q_Y1O_ +?0
M!]#?\+\\"_\ 0Z>$_P#P;V__ ,71_P +\\"_]#IX3_\ !O;_ /Q=?//_  Z\
M_P"IX_\ *-_]OH_X=>?]3Q_Y1O\ [?0!]#?\+\\"_P#0Z>$__!O;_P#Q='_"
M_/ O_0Z>$_\ P;V__P 77SS_ ,.O/^IX_P#*-_\ ;Z/^'7G_ %/'_E&_^WT
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M>$__  ;V_P#\71_POSP+_P!#IX3_ /!O;_\ Q=?//_#KS_J>/_*-_P#;Z/\
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M_P#0Z>$__!O;_P#Q='_"_/ O_0Z>$_\ P;V__P 77SS_ ,.O/^IX_P#*-_\
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M_P#%U\\_\.O/^IX_\HW_ -OH_P"'7G_4\?\ E&_^WT ?0W_"_/ O_0Z>$_\
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M/_#KS_J>/_*-_P#;Z/\ AUY_U/'_ )1O_M] 'T-_POSP+_T.GA/_ ,&]O_\
M%T?\+\\"_P#0Z>$__!O;_P#Q=?//_#KS_J>/_*-_]OH_X=>?]3Q_Y1O_ +?0
M!]#?\+\\"_\ 0Z>$_P#P;V__ ,71_P +\\"_]#IX3_\ !O;_ /Q=?//_  Z\
M_P"IX_\ *-_]OH_X=>?]3Q_Y1O\ [?0!]#?\+\\"_P#0Z>$__!O;_P#Q='_"
M_/ O_0Z>$_\ P;V__P 77SS_ ,.O/^IX_P#*-_\ ;Z/^'7G_ %/'_E&_^WT
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M>$__  ;V_P#\71_POSP+_P!#IX3_ /!O;_\ Q=?//_#KS_J>/_*-_P#;Z/\
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M_P#0Z>$__!O;_P#Q='_"_/ O_0Z>$_\ P;V__P 77SS_ ,.O/^IX_P#*-_\
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M_P#%U\\_\.O/^IX_\HW_ -OH_P"'7G_4\?\ E&_^WT ?0W_"_/ O_0Z>$_\
MP;V__P 71_POSP+_ -#IX3_\&]O_ /%U\\_\.O/^IX_\HW_V^C_AUY_U/'_E
M&_\ M] 'T-_POSP+_P!#IX3_ /!O;_\ Q='_  OSP+_T.GA/_P &]O\ _%U\
M\_\ #KS_ *GC_P HW_V^C_AUY_U/'_E&_P#M] 'T-_POSP+_ -#IX3_\&]O_
M /%T?\+\\"_]#IX3_P#!O;__ !=?//\ PZ\_ZGC_ ,HW_P!OH_X=>?\ 4\?^
M4;_[?0!]#?\ "_/ O_0Z>$__  ;V_P#\71_POSP+_P!#IX3_ /!O;_\ Q=?/
M/_#KS_J>/_*-_P#;Z/\ AUY_U/'_ )1O_M] 'T-_POSP+_T.GA/_ ,&]O_\
M%T?\+\\"_P#0Z>$__!O;_P#Q=?//_#KS_J>/_*-_]OH_X=>?]3Q_Y1O_ +?0
M!]#?\+\\"_\ 0Z>$_P#P;V__ ,71_P +\\"_]#IX3_\ !O;_ /Q=?//_  Z\
M_P"IX_\ *-_]OH_X=>?]3Q_Y1O\ [?0!]#?\+\\"_P#0Z>$__!O;_P#Q='_"
M_/ O_0Z>$_\ P;V__P 77SS_ ,.O/^IX_P#*-_\ ;Z/^'7G_ %/'_E&_^WT
M?0W_  OSP+_T.GA/_P &]O\ _%T?\+\\"_\ 0Z>$_P#P;V__ ,77SS_PZ\_Z
MGC_RC?\ V^C_ (=>?]3Q_P"4;_[?0!]#?\+\\"_]#IX3_P#!O;__ !='_"_/
M O\ T.GA/_P;V_\ \77SS_PZ\_ZGC_RC?_;Z/^'7G_4\?^4;_P"WT ?0W_"_
M/ O_ $.GA/\ \&]O_P#%T?\ "_/ O_0Z>$__  ;V_P#\77SS_P .O/\ J>/_
M "C?_;Z/^'7G_4\?^4;_ .WT ?0W_"_/ O\ T.GA/_P;V_\ \71_POSP+_T.
MGA/_ ,&]O_\ %U\\_P##KS_J>/\ RC?_ &^C_AUY_P!3Q_Y1O_M] 'T-_P +
M\\"_]#IX3_\ !O;_ /Q='_"_/ O_ $.GA/\ \&]O_P#%U\\_\.O/^IX_\HW_
M -OH_P"'7G_4\?\ E&_^WT ?0W_"_/ O_0Z>$_\ P;V__P 71_POSP+_ -#I
MX3_\&]O_ /%U\\_\.O/^IX_\HW_V^C_AUY_U/'_E&_\ M] 'T-_POSP+_P!#
MIX3_ /!O;_\ Q='_  OSP+_T.GA/_P &]O\ _%U\\_\ #KS_ *GC_P HW_V^
MC_AUY_U/'_E&_P#M] 'T-_POSP+_ -#IX3_\&]O_ /%T?\+\\"_]#IX3_P#!
MO;__ !=?//\ PZ\_ZGC_ ,HW_P!OH_X=>?\ 4\?^4;_[?0!]#?\ "_/ O_0Z
M>$__  ;V_P#\71_POSP+_P!#IX3_ /!O;_\ Q=?//_#KS_J>/_*-_P#;Z/\
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M_P#0Z>$__!O;_P#Q='_"_/ O_0Z>$_\ P;V__P 77SS_ ,.O/^IX_P#*-_\
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M_P#%U\\_\.O/^IX_\HW_ -OH_P"'7G_4\?\ E&_^WT ?0W_"_/ O_0Z>$_\
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M/_#KS_J>/_*-_P#;Z/\ AUY_U/'_ )1O_M] 'T-_POSP+_T.GA/_ ,&]O_\
M%T?\+\\"_P#0Z>$__!O;_P#Q=?//_#KS_J>/_*-_]OH_X=>?]3Q_Y1O_ +?0
M!]#?\+\\"_\ 0Z>$_P#P;V__ ,71_P +\\"_]#IX3_\ !O;_ /Q=?//_  Z\
M_P"IX_\ *-_]OH_X=>?]3Q_Y1O\ [?0!]#?\+\\"_P#0Z>$__!O;_P#Q='_"
M_/ O_0Z>$_\ P;V__P 77SS_ ,.O/^IX_P#*-_\ ;Z/^'7G_ %/'_E&_^WT
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M>$__  ;V_P#\71_POSP+_P!#IX3_ /!O;_\ Q=?//_#KS_J>/_*-_P#;Z/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MEA]<H?S(^_Z*^ /^(CGX(?\ 0J_%7_P6V'_R;1_Q$<_!#_H5?BK_ ."VP_\
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M_!$;]O#Q)^S)^U7X=\"R7EY>> ?B3J\.E7VEB,3"WOKC$%M=PAG41.)3"DK
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M=6_M#XF^%?[,\4Z//?VMGI%_J>AZC:HT9BL(+>#=;Q8@G%T XD75K?E5\HN
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M_9VH[O-\OS_^/V;'G8_=X\I/0/\ @CO_ ,%7/BQJ/[9/C[]C7]K*7P_-\?/
M/G7^E>*--N+.WL_&%F5BN5A6&,1 W M;B.XB$,*LUJLGG102VTC3 'Z?45\(
M?M#?MD_%S]A'_@K3\/='\>:QI_BC]F?]I:[@\*^&I$T.2"Z^&OB6.W1(;22X
M@A<74>I3G*"=PP+2L###92&X^[Z "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** /5?V$_^3WO@W_V/.B?^E\%?TIU_-9^PG_R>]\&_^QYT3_TO@K^E.OS7
MCK^/2]'^9[V4_!+U"BBBOA3U@HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***\?_
M &U?V]?A/_P3N^%FG^-OC%XK_P"$/\,ZIJL>B6MY_9EYJ'FWDD,TR1>7:Q2R
M#,=O,VXJ%&S!.2 0#V"BN?\ A/\ %+0?CC\+/#/C;PM??VIX9\8:5:ZWI%YY
M,D'VNSN84F@E\N15D3=&ZMM=589P0#D5S_[4?[4?@3]B[X$ZY\3/B9KG_"->
M"?#?V?\ M+4OL5Q>?9O/N(K:+]U;QR2MNFFC7Y4.-V3@ D 'H%%>?_LN?M1^
M!/VT?@3H?Q,^&>N?\)+X)\2?:/[-U+[%<6?VGR+B6VE_=7$<<J[9H9%^9!G;
MD9!!.A\?OC]X-_9:^#7B'XA?$+Q#I_A7P;X5M#>:GJ=XQ$=NF0J@*H+R2.[*
MB1H&DDD=$16=E4@'845Y_P#LN?M1^!/VT?@3H?Q,^&>N?\)+X)\2?:/[-U+[
M%<6?VGR+B6VE_=7$<<J[9H9%^9!G;D9!!/H% !1110 445\@?\%J_P#@JW_P
MY\_98T#XF?\ "!?\+$_MSQ7;^&/[-_MO^R/(\VTO+GS_ #?L\^['V3;LV#/F
M9W#;@@'U_17G_P"R=\=/^&H/V6/AI\3/[+_L/_A8GA72_$_]F_:?M7]G_;;2
M*Y\CS=B>9L\W;OV+NVYVKG ] H **^?_ /@J/^W/_P .U_V$_'7QJ_X1?_A-
M/^$+^P?\2;^TO[-^V?:M0MK+_7^5+LV_:-_^K;.S;QG</0/V3OCI_P -0?LL
M?#3XF?V7_8?_  L3PKI?B?\ LW[3]J_L_P"VVD5SY'F[$\S9YNW?L7=MSM7.
M  >@4444 %%%>'_\%(?VWM+_ ."</[$OC[XT:QH>H>);/P5:0O'I=G,D,E]<
M7%S#:6\9D;(CC,\\6^0*Y2/>RI(P", >X45X?_P3>_;>TO\ X*/?L2^ ?C1H
M^AZAX:L_&MI,\FEWDR326-Q;W,UI<1B1<"2,3P2[)"J%X]C,D;$HON% !17G
M_P"UC\=/^&7_ -ECXE_$S^R_[<_X5WX5U3Q/_9OVG[+_ &A]BM);GR/-V/Y>
M_P K;OV-MW9VMC!\_P#^"7'[<_\ P\H_83\"_&K_ (1?_A"_^$T^W_\ $F_M
M+^TOL?V74+FR_P!?Y46_=]GW_P"K7&_;SC<0#Z HHHH **** "BBB@ HHHH
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M[]N_;NVKG&<#I7P]_P &TG_)]?BS_L0[S_TX:=7UI^VI_P JX^C?]B'X-_\
M1^EU\E_\&TG_ "?7XL_[$.\_].&G5I@XJ.4XF,=E*7Y1(K-O%4V^R_4_<*OY
M?OVVM L?"G[9WQ<TO2[&TTW3--\:ZS:V=G:PK#!:PQWTRI'&B@*B*H "@
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MZ/XKM;N?0?%FF6 G^RZ?JEOL9A$TJ@F.6"6WN%4-*(Q<B(RR/&[5]85^*/\
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MPKX-\*VAO-3U.\8B.W3(50%4%Y)'=E1(T#222.B(K.RJ0#YP_9-_X+7?!O\
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MFR2/[5>:I;0S*OEM)(%\FU%K;93:LGV;S-BM(PK[?KX@_P"#=7]L70?VR/\
M@D?\)[G2(?L>H?#?2K?X>ZW9[Y)/LMYI=M#"K>8T<8;SK4VMSA-RQ_:?+WLT
M;&OM^@#X _X.CO\ E!1\<_\ N ?^I!IE'_!KC_R@H^!G_<?_ /4@U.C_ (.C
MO^4%'QS_ .X!_P"I!IE'_!KC_P H*/@9_P!Q_P#]2#4Z /M_XL?"W0?CC\+/
M$W@GQ38_VIX9\8:5=:)J]GYTD'VNSN87AGB\R-ED3=&[+N1E89R"#@U^0/\
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MH5)/^"L7_*++]I;_ +)5XH_]-%U7@'_!KC_R@H^!G_<?_P#4@U.@#[_HHHH
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M0UKQ!X:\;>/-5LO!^@ZQI"QB;3)9R]Q<R&1F#0[K&TO(TFB!ECEDB9-A'FH
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M)+=ZM!&+J8PE#'J$5U="X6]4F5MKI)O_ '+P 'T__P '1W_*"CXY_P#< _\
M4@TRC_@UQ_Y04? S_N/_ /J0:G7B'_!6;]KVW_;T_P"#377OBY#-I\UYXT\/
M^&;C5EL+6>VM;;5(_$&FP:A!$DY,@CBO(KB)268,(P0[J0[=_P#\&^WQKTO]
MFO\ X-J_ OQ&UVWU"[T3P#X?\7>)-0@L(TDNIK>SUC5KB5(E=D1I"D;!0SJ"
M2,L!R #ZO_;5_P""IW[/O_!.[^SX_C%\4/#_ (/U#5/+:UTO9-J&JRQ2><$N
M/L5JDMR+<M;S)YYC$0=-A?<0I\@^%O\ P<A_L2_&#QW8^'=)^/GA^SU#4?,\
MJ76])U/0[!-D;2'S+R]MH;:+*H0/,D7<Q55RS*I^$/\ @V9_8'TK_@H;X5^+
M7[67[4'AO3_C)XR^)?B!M'TF3QQX=2^M3;VR1M<7MJDV;62-Y62TC\J!1:C2
MY(8F5&DB7]'O^"J?_!'?X1_\%7O@UJ6C^,-'T_1?'<=HD6@>.K/3XVUG0WB,
MKPH9/E>XL]\TI>T=Q&XE=E,<HCFC /K"OE_PI_P6?_9?\7_&SXB?#V/XO^']
M+\3?"?[5_P ):NMVUUHMAHGV:_ATZ;S+Z\BBM#B\N(81LE;>TB[=PYKY!_X-
M"/VZ;S]I[_@G'J'PY\0:U_:GB;X'ZJND6Z2+=27,>AW*&73C+-*S1OMD2^MH
MTB*B*"S@0QJ-K/\ G_\ \$S?V.M!_;6_X.@OVG/#_B^;[9X)\.>*_&/B37O#
M<R226'C"*W\21BVL;Q%D19+=+Z6SO#'*LL4C6"(\;!LJ ?N]^PQ_P5'^!/\
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MHEK<RF1@7-UY@54D45\0?\%(/^" 7B'Q_P"%?VDOV@_CU\=O&'Q.TOPGX?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !117C_ .VK^WK\)_\ @G=\+-/\
M;?&+Q7_PA_AG5-5CT2UO/[,O-0\V\DAFF2+R[6*609CMYFW%0HV8)R0" >P4
M5\ ?\11O["?_ $7+_P LSQ!_\@T?\11O["?_ $7+_P LSQ!_\@T ??\ 17P!
M_P 11O["?_1<O_+,\0?_ "#1_P 11O["?_1<O_+,\0?_ "#0!]_T5\0?"?\
MX.//V,?CC\4_#/@GPM\9/[4\3>,-5M=$TBS_ .$2UR#[7>7,R0P1>9)9+&FZ
M1U7<[*HSDD#)K[?H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@/V<O'.GZA:ZW\ _&JI(MQK OH]->\-S!<:;"B[HHXX;O3+F8M%(T<LE[(P
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M4_$FHQW5U*ELDBV\"K#%#"L<9FN&!$?F,9VW.RK&J 'YH_\ !%;X6Z]\'_\
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MX-\56@O-,U.S8F.X3)5@58!XY$=61XW"R1R(Z.JNK*.PH _('_@W$_Y2F_\
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MLP_M'W;ZCI>HZ/HD%MI^F(;C[1!);PPB1VCTM[RYLY+6)XY##,EP(&S;0O\
MM=^P5^Q5X5_X)V_LG>%/@[X)U#Q!JGAGP?\ ;/L=UK<\,]_+]IO)[R3S'ABB
MC.)+AP-L:X4*#DY)T/VO/V+_ (7_ +>GP:F^'_Q<\'Z?XT\*37<-^MI<22V\
MEM<1$E)H9X72:&0 NA>)U+1R2(24D=6 .P^%OQ9\*_''P)8^*?!/B;P_XP\,
MZIYGV/5]$U&'4+"[\N1HI/+GA9HWVR(Z':3AD8'D$5^"/_!\GXLTN\\5?LTZ
M%#J6GRZWIMIXDO[O3TN$:ZM;>=]+2":2('>L<CVUPJ.0 Q@E )*-CZ0_X@J?
MV6?^A^_: _\ !YI'_P K*]/_ &7_ /@TS_8__9P\5-K&J:#XP^*UY#=VM[8Q
M^-=96>UL'@=GQ]GLXK:&XCE)421W231L(U7:%:0. <!_P>.?M>V_P5_X)HZ5
M\+;>;3VUOXU>((+>2UN+6=Y/[+TUX[ZXGAD4B*.1+M=,C(D)+1W$FU"07CX_
MX3_\&5/P"_X59X9_X3KQ]\8/^$V_LJU_X2'^PM<T[^RO[1\E/M/V3SM,\W[/
MYV_R_,^?9MW<YK[N_:6_X(V_"/\ :T_X*%_#3]I+QG<^,+KQE\*;2SM]&TFW
MU&.WT:5[.ZN;RUGF18OM#21W%SY@"SK&QAC5T9-ZO]84 ?@C_P %*/\ @T4^
M"_[-?[!GQ5^(WPQ\;?%"[\9> /#\_B2V@\4:Q8R:9-;V>+B\1UM].25I#:1W
M B =09C%N8)N(^[_ /@V7_;6_P"&T?\ @D?X!^T:?]@U;X3X^'%_Y<'E6US_
M &=;6_V66+,LC-NL9K/S&;9F<3[45-F?O^OD_P#X)H_\$;?A'_P2?\5?%#4/
MA/<^,%L_BE=VEQ=Z9K&HQWEKHZ6KW;006C")9O+47DBYGDFD(2/+EMS, ?G#
M_P &S:W'_!,O_@I=^TY^Q?X^\2:A)K:W=MK'A&.XNX(=/U9+9)'DN8;<7,GE
MWEYI]UI]T88_,D$-G()64VP%?=__  <5?MBZ#^QO_P $C_BQ<ZO#]LU#XD:5
M<?#W1+/?)']JO-4MIH6;S%CD"^3:BZN</M63[-Y>]6D4UT'_  5)_P""(/P/
M_P""N'_"-WGQ(M?$&B>)O"^8;3Q)X8N(+/59;,[R;&9YH9HY;<2.9%5D+1OO
M,;()9A)X?\ ?^#8WX7VOQ"\/>/OVC/B1\4/VK_B%H-H+2.Y\=ZM++HRB.]-S
M;[+-I)9C'&"R-;W%U/;R&:X9HOW@5 #V#_@WU_8\U7]B'_@DM\*/"/B70=/\
M/^,M4M)_$GB""&R>UNC<7UQ)<1)>K)''+]LAM'M;:42*2AM?+#,D:FO3_P#@
MK%_RBR_:6_[)5XH_]-%U7T!7'_M"_!32_P!I3X!>./ASKMQJ%IHGC_P_?^&]
M0GL'2.ZAM[RVDMY7B9U=%D"2,5+(P! RI'! /RQ_X,J?^467C[_LJNH_^FC1
MZ^WO^"QG_!0O_AV!_P $^_&WQ9L[7P_JGB;3_LVF^&]*U>^^S0ZIJ-S,D2*%
M!$D_E1F6Y>&,J[Q6LH#QC,B:'_!+_P#X)?\ @'_@DU\ M8^'/PYU?QAK6B:U
MX@F\23S^)+JVN;I+B6VMK=D5H((4$82UC(!0G);YB" #_@J!_P $O_ /_!67
MX!:/\.?B-J_C#1=$T7Q!#XD@G\-W5M;73W$5M<VZHS3P3(8REU(2 @.0OS
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M** "BBB@#U7]A/\ Y/>^#?\ V/.B?^E\%?TIU_-9^PG_ ,GO?!O_ +'G1/\
MTO@K^E.OS7CK^/2]'^9[V4_!+U"BBBOA3U@HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_!WQMJ'B#2_#/C#[']LNM$GA@OXOLUY!>1^6\T4L8S);H#NC;*E@,'!''_\
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M _\ !67X!:/\.?B-J_C#1=$T7Q!#XD@G\-W5M;73W$5M<VZHS3P3(8REU(2
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M>ZUK%K?>+I4AO[?4?(BNGM?*6.2[MEEE)A:29FS([F.'ROM_]GKX*:7^S7\
MO _PYT*XU"[T3P!X?L/#>GSW[I)=36]G;1V\3RLBHC2%(U+%44$DX4#@ 'X
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MZ$]V8;K4WO(?LMS<1A4<^7:07#3NS!8R5BB,B//'G/\ ^#7'_E!1\#/^X_\
M^I!J='PE_P"#<3X'_#OQ'\5/$GB#Q7\8/BIX]^+'A6\\'WGC'QWX@@UK7M%L
M[NQDL+B2RG:V4)<-:NL0FE25DCC$:[8WE23Z?_8*_8J\*_\ !.W]D[PI\'?!
M.H>(-4\,^#_MGV.ZUN>&>_E^TWD]Y)YCPQ11G$EPX&V-<*%!R<D@'X@_\&VG
M[+?PL^%'[9/[0W[*?[3G@7X/^)?B;X:U6WD\)V'BKP9:7ESJOD+=#4)K"ZO;
M19Y;>2W6PNHHF8;H&>XBB"FX>OV.\6?\$ROV0_ 7A74M=UW]GO\ 9OT71-%M
M);_4-0O_  +HMM:V%O$A>6:65X D<:(K,SL0% )) %>8?\%)_P#@WO\ V<?^
M"H?CL>,?&VC^(/"_CV3[/'>>)O"=^EC?ZI!!')''#<I-'-;2X5T'FM#Y^VW@
M02B- E>0:W_P:C_ _P"('_""V?CKXP?M0?$CPS\.O*AT3PWXG\<07>E65FOD
MAK&%%LTDMK>2."*-EMGA;9&@5E*J5 /T.^ /A/P#X+^#7AZS^%NF>#])^'LU
MH+_0H/"MO;0:,]O<DW FMEMP(3'*93+OCX<R%LG=D]A7/_"?X6Z#\#OA9X9\
M$^%K'^R_#/@_2K71-(L_.DG^R6=M"D,$7F2,TC[8T5=SLS'&22<FN@H ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?Q=\<:5'HFMZ]_:=Y)]MLT6T18OLS2FV3"V-J-R1*W[KK\S;O8*** "BBB@
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M5'^N.7=W]P?V97\OO/Q6HK]J?^(<;X(?]#5\5?\ P96'_P A4?\ $.-\$/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH ***^&?^(DW]BO\ Z+1_Y:.N
M_P#R%6M.A4J?PXM^B;"Z6Y]S45\,_P#$2;^Q7_T6C_RT==_^0J/^(DW]BO\
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M/_+1UW_Y"H_XB3?V*_\ HM'_ ):.N_\ R%1]1Q/_ #[E]S_R#F1]S45\,_\
M$2;^Q7_T6C_RT==_^0J/^(DW]BO_ *+1_P"6CKO_ ,A4?4<3_P ^Y?<_\@YD
M?<U%?#/_ !$F_L5_]%H_\M'7?_D*C_B)-_8K_P"BT?\ EHZ[_P#(5'U'$_\
M/N7W/_(.9'W-17PS_P 1)O[%?_1:/_+1UW_Y"H_XB3?V*_\ HM'_ ):.N_\
MR%1]1Q/_ #[E]S_R#F1]S45\,_\ $2;^Q7_T6C_RT==_^0J/^(DW]BO_ *+1
M_P"6CKO_ ,A4?4<3_P ^Y?<_\@YD?<U%?#/_ !$F_L5_]%H_\M'7?_D*C_B)
M-_8K_P"BT?\ EHZ[_P#(5'U'$_\ /N7W/_(.9'W-17PS_P 1)O[%?_1:/_+1
MUW_Y"H_XB3?V*_\ HM'_ ):.N_\ R%1]1Q/_ #[E]S_R#F1]S45\,_\ $2;^
MQ7_T6C_RT==_^0J/^(DW]BO_ *+1_P"6CKO_ ,A4?4<3_P ^Y?<_\@YD?<U%
M?#/_ !$F_L5_]%H_\M'7?_D*C_B)-_8K_P"BT?\ EHZ[_P#(5'U'$_\ /N7W
M/_(.9'W-17PS_P 1)O[%?_1:/_+1UW_Y"H_XB3?V*_\ HM'_ ):.N_\ R%1]
M1Q/_ #[E]S_R#F1]S45\,_\ $2;^Q7_T6C_RT==_^0J/^(DW]BO_ *+1_P"6
MCKO_ ,A4?4<3_P ^Y?<_\@YD?<U%?#/_ !$F_L5_]%H_\M'7?_D*C_B)-_8K
M_P"BT?\ EHZ[_P#(5'U'$_\ /N7W/_(.9'W-17PS_P 1)O[%?_1:/_+1UW_Y
M"H_XB3?V*_\ HM'_ ):.N_\ R%1]1Q/_ #[E]S_R#F1]S45\,_\ $2;^Q7_T
M6C_RT==_^0J/^(DW]BO_ *+1_P"6CKO_ ,A4?4<3_P ^Y?<_\@YD?<U%?#/_
M !$F_L5_]%H_\M'7?_D*C_B)-_8K_P"BT?\ EHZ[_P#(5'U'$_\ /N7W/_(.
M9'W-17PS_P 1)O[%?_1:/_+1UW_Y"H_XB3?V*_\ HM'_ ):.N_\ R%1]1Q/_
M #[E]S_R#F1]S45\,_\ $2;^Q7_T6C_RT==_^0J/^(DW]BO_ *+1_P"6CKO_
M ,A4?4<3_P ^Y?<_\@YD?<U%?#/_ !$F_L5_]%H_\M'7?_D*C_B)-_8K_P"B
MT?\ EHZ[_P#(5'U'$_\ /N7W/_(.9'W-17PS_P 1)O[%?_1:/_+1UW_Y"H_X
MB3?V*_\ HM'_ ):.N_\ R%1]1Q/_ #[E]S_R#F1]S45\,_\ $2;^Q7_T6C_R
MT==_^0J/^(DW]BO_ *+1_P"6CKO_ ,A4?4<3_P ^Y?<_\@YD?<U%?#/_ !$F
M_L5_]%H_\M'7?_D*C_B)-_8K_P"BT?\ EHZ[_P#(5'U'$_\ /N7W/_(.9'W-
M17PS_P 1)O[%?_1:/_+1UW_Y"H_XB3?V*_\ HM'_ ):.N_\ R%1]1Q/_ #[E
M]S_R#F1]S45\,_\ $2;^Q7_T6C_RT==_^0J/^(DW]BO_ *+1_P"6CKO_ ,A4
M?4<3_P ^Y?<_\@YD?<U%?#/_ !$F_L5_]%H_\M'7?_D*C_B)-_8K_P"BT?\
MEHZ[_P#(5'U'$_\ /N7W/_(.9'W-17PS_P 1)O[%?_1:/_+1UW_Y"H_XB3?V
M*_\ HM'_ ):.N_\ R%1]1Q/_ #[E]S_R#F1]S45\,_\ $2;^Q7_T6C_RT==_
M^0J/^(DW]BO_ *+1_P"6CKO_ ,A4?4<3_P ^Y?<_\@YD?<U%?#/_ !$F_L5_
M]%H_\M'7?_D*C_B)-_8K_P"BT?\ EHZ[_P#(5'U'$_\ /N7W/_(.9'W-17PS
M_P 1)O[%?_1:/_+1UW_Y"H_XB3?V*_\ HM'_ ):.N_\ R%1]1Q/_ #[E]S_R
M#F1]S45\,_\ $2;^Q7_T6C_RT==_^0J/^(DW]BO_ *+1_P"6CKO_ ,A4?4<3
M_P ^Y?<_\@YD?<U%?#/_ !$F_L5_]%H_\M'7?_D*C_B)-_8K_P"BT?\ EHZ[
M_P#(5'U'$_\ /N7W/_(.9'W-17PS_P 1)O[%?_1:/_+1UW_Y"H_XB3?V*_\
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M/_+1UW_Y"H_XB3?V*_\ HM'_ ):.N_\ R%1]1Q/_ #[E]S_R#F1]S45\,_\
M$2;^Q7_T6C_RT==_^0J/^(DW]BO_ *+1_P"6CKO_ ,A4?4<3_P ^Y?<_\@YD
M?<U%?#/_ !$F_L5_]%H_\M'7?_D*C_B)-_8K_P"BT?\ EHZ[_P#(5'U'$_\
M/N7W/_(.9'W-17PS_P 1)O[%?_1:/_+1UW_Y"H_XB3?V*_\ HM'_ ):.N_\
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M?4<3_P ^Y?<_\@YD?<U%?#/_ !$F_L5_]%H_\M'7?_D*C_B)-_8K_P"BT?\
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M_P#(5'U'$_\ /N7W/_(.9'W-17PS_P 1)O[%?_1:/_+1UW_Y"H_XB3?V*_\
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M/_+1UW_Y"H_XB3?V*_\ HM'_ ):.N_\ R%1]1Q/_ #[E]S_R#F1]S45\,_\
M$2;^Q7_T6C_RT==_^0J/^(DW]BO_ *+1_P"6CKO_ ,A4?4<3_P ^Y?<_\@YD
M?<U%?#/_ !$F_L5_]%H_\M'7?_D*C_B)-_8K_P"BT?\ EHZ[_P#(5'U'$_\
M/N7W/_(.9'W-17PS_P 1)O[%?_1:/_+1UW_Y"H_XB3?V*_\ HM'_ ):.N_\
MR%1]1Q/_ #[E]S_R#F1]S45\,_\ $2;^Q7_T6C_RT==_^0J/^(DW]BO_ *+1
M_P"6CKO_ ,A4?4<3_P ^Y?<_\@YD?<U%?#/_ !$F_L5_]%H_\M'7?_D*C_B)
M-_8K_P"BT?\ EHZ[_P#(5'U'$_\ /N7W/_(.9'W-17PS_P 1)O[%?_1:/_+1
MUW_Y"H_XB3?V*_\ HM'_ ):.N_\ R%1]1Q/_ #[E]S_R#F1]S45\,_\ $2;^
MQ7_T6C_RT==_^0J/^(DW]BO_ *+1_P"6CKO_ ,A4?4<3_P ^Y?<_\@YD?<U%
M?#/_ !$F_L5_]%H_\M'7?_D*C_B)-_8K_P"BT?\ EHZ[_P#(5'U'$_\ /N7W
M/_(.9'W-17PS_P 1)O[%?_1:/_+1UW_Y"H_XB3?V*_\ HM'_ ):.N_\ R%1]
M1Q/_ #[E]S_R#F1]S45\,_\ $2;^Q7_T6C_RT==_^0J/^(DW]BO_ *+1_P"6
MCKO_ ,A4?4<3_P ^Y?<_\@YD?<U%?#/_ !$F_L5_]%H_\M'7?_D*C_B)-_8K
M_P"BT?\ EHZ[_P#(5'U'$_\ /N7W/_(.9'W-17PS_P 1)O[%?_1:/_+1UW_Y
M"H_XB3?V*_\ HM'_ ):.N_\ R%1]1Q/_ #[E]S_R#F1]S45\,_\ $2;^Q7_T
M6C_RT==_^0J/^(DW]BO_ *+1_P"6CKO_ ,A4?4<3_P ^Y?<_\@YD?<U%?#/_
M !$F_L5_]%H_\M'7?_D*C_B)-_8K_P"BT?\ EHZ[_P#(5'U'$_\ /N7W/_(.
M9'W-17PS_P 1)O[%?_1:/_+1UW_Y"H_XB3?V*_\ HM'_ ):.N_\ R%1]1Q/_
M #[E]S_R#F1]S45\,_\ $2;^Q7_T6C_RT==_^0J/^(DW]BO_ *+1_P"6CKO_
M ,A4?4<3_P ^Y?<_\@YD?<U%?#/_ !$F_L5_]%H_\M'7?_D*C_B)-_8K_P"B
MT?\ EHZ[_P#(5'U'$_\ /N7W/_(.9'W-17PS_P 1)O[%?_1:/_+1UW_Y"H_X
MB3?V*_\ HM'_ ):.N_\ R%1]1Q/_ #[E]S_R#F1]S45\,_\ $2;^Q7_T6C_R
MT==_^0J/^(DW]BO_ *+1_P"6CKO_ ,A4?4<3_P ^Y?<_\@YD?<U%?#/_ !$F
M_L5_]%H_\M'7?_D*C_B)-_8K_P"BT?\ EHZ[_P#(5'U'$_\ /N7W/_(.9'W-
M17PS_P 1)O[%?_1:/_+1UW_Y"H_XB3?V*_\ HM'_ ):.N_\ R%1]1Q/_ #[E
M]S_R#F1]S45\,_\ $2;^Q7_T6C_RT==_^0J/^(DW]BO_ *+1_P"6CKO_ ,A4
M?4<3_P ^Y?<_\@YD?<U%?#/_ !$F_L5_]%H_\M'7?_D*C_B)-_8K_P"BT?\
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M_P#(5'U'$_\ /N7W/_(.9'W-17PS_P 1)O[%?_1:/_+1UW_Y"H_XB3?V*_\
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M/_+1UW_Y"H_XB3?V*_\ HM'_ ):.N_\ R%1]1Q/_ #[E]S_R#F1]S45\,_\
M$2;^Q7_T6C_RT==_^0J/^(DW]BO_ *+1_P"6CKO_ ,A4?4<3_P ^Y?<_\@YD
M?<U%?#/_ !$F_L5_]%H_\M'7?_D*C_B)-_8K_P"BT?\ EHZ[_P#(5'U'$_\
M/N7W/_(.9'W-17PS_P 1)O[%?_1:/_+1UW_Y"H_XB3?V*_\ HM'_ ):.N_\
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M?4<3_P ^Y?<_\@YD?<U%?#/_ !$F_L5_]%H_\M'7?_D*C_B)-_8K_P"BT?\
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M_P#(5'U'$_\ /N7W/_(.9'W-17PS_P 1)O[%?_1:/_+1UW_Y"H_XB3?V*_\
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M/_+1UW_Y"H_XB3?V*_\ HM'_ ):.N_\ R%1]1Q/_ #[E]S_R#F1]S45\,_\
M$2;^Q7_T6C_RT==_^0J/^(DW]BO_ *+1_P"6CKO_ ,A4?4<3_P ^Y?<_\@YD
M?<U%?#/_ !$F_L5_]%H_\M'7?_D*C_B)-_8K_P"BT?\ EHZ[_P#(5'U'$_\
M/N7W/_(.9'W-17PS_P 1)O[%?_1:/_+1UW_Y"H_XB3?V*_\ HM'_ ):.N_\
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M?4<3_P ^Y?<_\@YD?<U%?#/_ !$F_L5_]%H_\M'7?_D*C_B)-_8K_P"BT?\
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M9/\ IW^/_ #V/F?PST5_<Q11_K)_T[_'_@!['S/X9Z*_N8HH_P!9/^G?X_\
M #V/F?PST5_<Q11_K)_T[_'_ ( >Q\S^&>BO[F**/]9/^G?X_P# #V/F?PST
M5_<Q11_K)_T[_'_@!['S/X9Z*_N8HH_UD_Z=_C_P ]CYG\,]%?W,44?ZR?\
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M/^G?X_\  #V/F?PST5_<Q11_K)_T[_'_ ( >Q\S^&>BO[F**/]9/^G?X_P#
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MGHK^YBBC_63_ *=_C_P ]CYG\,]%?W,44?ZR?]._Q_X >Q\S^&>BO[F**/\
M63_IW^/_   ]CYG\,]%?W,44?ZR?]._Q_P" 'L?,_AGHK^YBBC_63_IW^/\
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M_P!._P ?^ 'L?,_AGHK^YBBC_63_ *=_C_P ]CYG\,]%?W,44?ZR?]._Q_X
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M?]._Q_X >Q\S^&>BO[F**/\ 63_IW^/_   ]CYG\,]%?W,44?ZR?]._Q_P"
M'L?,_AGHK^YBBC_63_IW^/\ P ]CYG\,]%?W,44?ZR?]._Q_X >Q\S^&>BO[
MF**/]9/^G?X_\ /8^9_#/17]S%%'^LG_ $[_ !_X >Q\S^&>BO[F**/]9/\
MIW^/_ #V/F?PST5_<Q11_K)_T[_'_@!['S/X9Z*_N8HH_P!9/^G?X_\  #V/
MF?PST5_<Q11_K)_T[_'_ ( >Q\S^&>BO[F**/]9/^G?X_P# #V/F?PST5_<Q
M11_K)_T[_'_@!['S/X9Z*_N8HH_UD_Z=_C_P ]CYG\,]%?W,44?ZR?\ 3O\
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M_IW^/_ #V/F?PST5_<Q11_K)_P!._P ?^ 'L?,_AGHK^YBBC_63_ *=_C_P
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 445Y5^W9_R9#\9/^Q&UO\
M]()ZTHT_:5(P[M+[R92LFSU6BOY5Z*^^_P!0_P#I_P#^2_\ VQX_]L?W/Q_X
M!_5117\J]%'^H?\ T_\ _)?_ +8/[8_N?C_P#^JBBOY5Z*/]0_\ I_\ ^2__
M &P?VQ_<_'_@']5%%?RKT4?ZA_\ 3_\ \E_^V#^V/[GX_P# /ZJ**_E7HH_U
M#_Z?_P#DO_VP?VQ_<_'_ (!_5117\J]%'^H?_3__ ,E_^V#^V/[GX_\  /ZJ
M**_E7HH_U#_Z?_\ DO\ ]L']L?W/Q_X!_5117\J]%'^H?_3_ /\ )?\ [8/[
M8_N?C_P#^JBBOY5Z*/\ 4/\ Z?\ _DO_ -L']L?W/Q_X!_5117\J]%'^H?\
MT_\ _)?_ +8/[8_N?C_P#^JBBOY5Z*/]0_\ I_\ ^2__ &P?VQ_<_'_@']5%
M%?RKT4?ZA_\ 3_\ \E_^V#^V/[GX_P# /ZJ**_E7HH_U#_Z?_P#DO_VP?VQ_
M<_'_ (!_5117\J]%'^H?_3__ ,E_^V#^V/[GX_\  /ZJ**_E7HH_U#_Z?_\
MDO\ ]L']L?W/Q_X!_5117\J]%'^H?_3_ /\ )?\ [8/[8_N?C_P#^JBBOY5Z
M*/\ 4/\ Z?\ _DO_ -L']L?W/Q_X!_5117\J]%'^H?\ T_\ _)?_ +8/[8_N
M?C_P#^JBBOY5Z*/]0_\ I_\ ^2__ &P?VQ_<_'_@']5%%?RKT4?ZA_\ 3_\
M\E_^V#^V/[GX_P# /ZJ**_E7HH_U#_Z?_P#DO_VP?VQ_<_'_ (!_5117\J]%
M'^H?_3__ ,E_^V#^V/[GX_\  /ZJ****_/3V@HHK\D?^"G/_ "?#XW_[</\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MB@ HHHH **** "OUN_X)C?\ )CW@C_M__P#2^YK\D:_6[_@F-_R8]X(_[?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MU)^KI8CE^SO\MS*_X*R?\$F_AS^PC^SIHOB[PCK7C74M2U+Q'!H\L6L7=M-
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MX1_M/[5_:-S_ &S86&EVGEZA-:1?//;MLW;(Q\SG+O@=0*Z#4?\ @C+^S/\
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MU[K[#:^(+X_;9A+Y<B6D,;W%SY;;' E,,4@CW*5WE-V%R1^A/_!=6:Q^/W[
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MI)!"?F,'F&(>'HUZ6(<JLI6<&T[J[6R5UHKM_D=]2C#GE"4+12WU[?<?-/\
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M]E/XF?%2[&KQV7A^_BT[0K"'48_-61Y(U)NF-OB14%S;D&,1ERDHQ'E2-_\
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M\?\ C.Z^(_\ P1XUOQ%?1V\5[KU_/J-PD"E8DDF\1M(P0$DA06. 23CN:G\
M0ZI^RS_P2*OM<TNW_LGQ%K=K_:$DPN'9_P#3KF.WBN49'_=R"T>%DVD;652R
M[MP/T.8</Y=B<QIUZ=/V>'CAU7DHWU5Y.U^C:MVT3MJ?.Y?Q!F6&RZI0J5/:
M8B6(="+E;1VBKVZI._?5J^AYWXE_8Z_9M^"UO;Z;XV^,&KW7B!)9X+K^QS%(
ML4D;X9'@BAN'@9<JI$CY9E<C&"J^=_M9_LO?#7X<_"_3?&7PT^('_"5:;=75
MK8W&GS2PW%U:M/%<3+)(T>QHLK#M\J2(,"'RW!4>1_!GX%>*OV@_%%QHOA#2
M_P"U]2M;5KV6'[3#;[85=$+;I75?O2(, YYZ<&NN^)W["GQ4^#?@>^\2>)/"
MW]FZ+IOE_:+C^TK.;R]\BQK\L<K,<NZC@'&<],FOF*U=XK"3G0RU*E9VG%5&
MXV6K<[M.W6Z7GW/J*-!83%TX8C,VZMU>$G32E=Z)0LFK]+-^78\Z\ >#+KXC
M^/-$\.V,EO%>Z]?P:=;O.Q6)))I%C4N0"0H+#) )QV/2OK_]MO\ X)F^%_V?
M/@'>^+_"VK:]=7&D74'VR+5;J)T:WD?R?W8C@4^9YLD1^9@-H?J<"L#_ ()#
M_#JQU#XP>)/'6K36%OIO@/2R_GW%RT/V2:X#KYQ/">6L$=R&+G"[U.#C<OJG
M["W[24G[87B3XR>"?$D-Q:P^.8KG5HI+79YMG:R116#P&3 5FCA^RK&WE?,4
MD9R20#ZW#62X"K@%3Q:3JXIS5)_R\B>OSGI;K;<\GB;.\?2Q[J8-M4L*H.JO
MYN=K3Y0UOTOL?GI7TQJO[&?A?3/^%"Z/;W^O:SXE^*GV74=8CM9XA_9>GR^6
M[,EN(G=<1R2'SG<I_HDK;,$B/YW\5>&+[P3XHU+1=4@^RZEI%U+97<.]7\J:
M-RCKN4E3AE(R"0<<$UWFL?MB?$;7_C!I7CZ[\1>=XLT2U:RLK[[!:KY,+"4%
M?+$8C;B>7EE)^;KP,?(996P=#GCCH-R;BMMDI7GNU[UE9*W5ZKK]AF='&U^2
M6!J)12D]W[S<;0V3]V[NVGT6CZ'[7OPR\+_!CX^:UX5\)76H:AINA>7;RW5W
M>Q73S7&P-*,Q1HJ;&;RBAW$-$V2,[5\SK0\5>)[[QMXHU+6M4G^U:EJ]U+>W
M<VQ4\V:1R[MM4!1EF)P  ,\ 5GUY^.K4ZN(G4I1Y8MMI=E?1?)'H8&C4I8>%
M*M+FDDDWW=M7\WJ%%?4'@#]A#X<^+_ >B:M??M!^"=%O=4L(+NXT^=;7S;"2
M2-7:%\WBG<A)4Y53D=!TK7_X=W?"_P#Z.6\!?]\6G_R=7M4^$<SG%3C&-GK_
M !*?_P F>)4XNRN$G"4I76G\.I_\@?)%%:_C_P .VOA#QYK>DV.I6^M66EW\
M]I;ZA!CRK^..1D69,,PVN &&&88/4]:R*^=J0<).$MUH?1TYJ<5..SU/8_V&
M/V9K7]JOXZ+X=U*[N+/1[.PGU&_>VE$=R8UVQJ(BR.N[S98LAAC8'YS@'I_^
M"AG[&>E_LC>*/#?]@W^H7VB^(+6;;_:$Z2727$+KYF=D2*(RDL.WJ<A\X&,^
MM_LJZS_PR)_P3>\6_$JW>PC\2^,KIK?29/M6)#L<VL(\N12C20R?:Y]BJV]%
M^8X!V3ZE>2?M=?\ !)=7BM;A=8^%<L<9CA*0PS+8Q*K.=[,646,Y=L%6,J':
M,85OTG#Y'@GD_P!5<;XJ5-UT]=(IJT5W<HINW2_4_-<1GN.6<_6HRMA(U%0:
MTUDT[R?91DTK];=#X3HKUS]A3X8Z'\9/VJ?"WAOQ)8_VEHNI?:_M%OYTD/F;
M+.>1?FC96&'13P1G&.F17T#\>?@M^SS^R/\ &B^A\9Z!XFUB'6HEN=(T/2;N
M5[?3K/RX4\Z:226*0S/<QWF LTBA,953MKY;+^&Z^*P3S#VD(4U/D;DVK.R=
M]$]-4M+N_2VI]5F'$E#"XU9?[.<ZCASI12=U=JVK6NC>ME;K?0^(J[;PW^S]
MXF\4?!?Q!\0;>UMT\*^&Y4MKF[DN%#/.TEN@A2,$N6_TE'R0$VAOFW *?H']
MMG]E+P#IO[._A7XL_"NTU"ST+5/)BO;%97O8X%E5R)9)#)(89(Y0()%+,N]D
M4;6!W^Y^ _'GP'N?V#O&NIZ9X*\36_PSM]9CCU;29)W-Y=76^RVNC?:B0H+6
MYXE7_5MQ_>]? \'?[56P^,JQCRTW.+3=I7BW&2?*[Q5O>T3[)GCX[C+_ &6C
MB<%2G+FJ*$DXJ\6I)2BUS*TW?W=6K[M'Q#^R7_PK/_A<$/\ PMC^T/\ A%?L
MLVW[/YOE_:,#9YWD_OO+QOQY?._R\_)OKOO@;\,?AG\9/^"A-KX;T6QU#4OA
MKJ5U>?9;>\FEADD1+*:0896641B5,IN(<H$#_-N%=;^R%\(OA+^U%^V9XKL;
M'PKJ$?@"/0?MNF:9>WD\4]M,C6<;LSQSLQR[S$ R,,..!@ 4/V1?#%CX)_X*
MLC1=+@^RZ;I&OZ[96D.]G\J&."\1%W,2QPJ@9))..2:O+<ME!8.-6-*=*6(4
M>9)N4K22:;:2=-K5+[T9YEF49O&2I2JPJQP[ERMI1C>+::2;:J)Z-W]&>9_M
MU_#'0_@W^U3XI\-^&['^S=%TW[)]GM_.DF\O?9P2-\TC,QR[L>2<9QTP*\CK
M[T_;#T#X/_"K]K7Q%X@^+5GKWBNX\66MM<:7HVCJT::?;QP0P&XN)?-A+2/+
M!,J(C,%5&9LETVY'QT_9 ^%/Q?\ V1YOB9\&+:XT^;0HGN[VR:\DF9XT"M<0
MSK/*QBF@3,@V,0Z@@"021N#-N$ZU3%XN>%E3O"4Y>S3]]04G:T4K;6:2=TM+
M7T*RGBVC3P>$ABH5+3C"/M&O<<W%7O)OF^*Z;:LWK>VI\145],?L&?L=^'?C
M3X7\4>/O'UUJ%GX(\'?/(EJP'VUHD$]P)"NZ41I#MR$4,_G#8X*$'OOA=XA_
M9%^*OQ$T;PW;?#GQ=IMWKETEE;3WMW<^0)G.V-6,=Z[#<Y50=I + DA<L/*P
M?"U:O1I5JE:G2]K\"G)IRUM>RB[*^S=K[['J8WBJA0K5:-.C4J^R^-PBFHZ7
MM=R5W;=*]MMSXIHKW+]J_P#8EUC]G_\ : TSPCI#7&M67BR6-?#T\B^4UPTD
MOE"WD=@L7G(Q4,00NUXW(3?M7WKXP_!W]FO]BRW\/>%_''AOQ-XS\3W5A]LN
M;RSFGB:12[*)&07,42*S+(J(FYE6+YR20SJCPKC)3K1Q$HTE1:4G-M*[V2LG
M=O?16MKU15;BO!QA1EAXRJNLFXJ"3=ENW=JR6VKO?2VC.*_9,_9C\#_$W]A#
MXF>,]<T/[=XE\/\ ]J?V?>?;+B/[/Y.GQ31_(CA&VR,S?,ISG!R.*^2*_3'X
M+Z3X)M?^">GQ<U'X?W&H?\(UKUKKE_#I]^4-WHK?81$UK(4D?./*$B%CN\N6
M/=N/SMXIX#_9C^'_ ,:?^";VM>,]#T.PL_'_ (;M9_[0O/ME\L<;VCK-)\CN
MT;22685OE79OFP-F,)]'FW##K8?#4L+R*<:,IMK[?*^C2]YM;7L[;VLSYO*>
M*%1Q&)JXKG<)5HP2?V.9=4W[J3WM=7VO='QS17T%_P $X/V9--_:6^.D]OXB
MLKB\\,:%827=]&%E6*XD;$<,+31LIC8EFE'.6%NPP1DCROX\:AX5U/XP>()/
M ^G_ -E^$UNC%I</GS3;X4 02[IOW@\TJ9-K<IYFW^&OB*F5U:>!ACYM*,Y.
M,5KS/EWE:UN5/3>]^EM3[>GFM*ICYY?!-RA%2D[+E7-M&][\S6NUK=;Z'(T4
M45YIZ85^MW_!,;_DQ[P1_P!O_P#Z7W-?DC7ZW?\ !,;_ ),>\$?]O_\ Z7W-
M?IWA1_R-ZG_7M_\ I4#\O\6/^113_P"OB_\ 29GO5%%%?T$?SV>"?\%$_P#D
MBFE_]AN+_P!$7%?&5?9O_!1/_DBFE_\ 8;B_]$7%?&5?R#XS?\E)+_!#\C^C
M/#/_ )$D?\4@HHHK\I/T **** "BBB@ KRG]N+]I'_AD7]D_QM\0TM?MUWX?
ML1]AA:+S(WNYI$M[;S%WH3$)I8S)M8-L#[<M@'U:O/OVD?V6? ?[77@:U\-_
M$/0O^$@T6QODU*&W^VW%ILN$CDC5]T$B,<)+(,$X^;.,@$=^5U,+#&4IXY-T
ME).223;BG=I7:6JTWTW.3'QQ$L-4CA6E4::BWHDVM&[)[;['S1\5?^"BWCCP
M'\'_ -EN&"/PHWC_ /:(OM/\ZZDT6X?1]*M+D6YDVP"]68RQ&^M0,RE9!',3
MY6Y%%K_@K5_P4$^(W[$6N?"W2_AQX=\/^)-2^($]_:FTU"PNKR>::)K-8([=
M()HV+NURPVX8L=H&._T%)^QW\-6^-GA7XB1^%;2U\6>!])&AZ#<VL\UO!IEB
M$FC6".VC=8-BI<3*,QG 88QM7'YX_P#!SG_S1'_N._\ N-K]%X1IY1FN?X+!
M0H>Z_:N?,E9R:J2BDD_A@E%+57:>BZ_&<15,QR_*,3B95?>7LU&S=TDX1;NU
MO)N3>CTMJS[8_P""9'[9%Q^W+^R?IOC35!I,/B6&^N]-UNUTVVG@M;.XCD+1
MH@E9RV;:2V<D.PS(1D$%5]7^.?QGT/\ 9W^#_B/QQXDN/L^B^&;&2^N-KQK)
M-M'RPQ^8RJTLCE8XU+#<[HN<D5^<W_!.ZRN/^"?/_!7'XE_ V?0_L?AKXF[]
M0\-20QSRK';VZW-Y9!9IF4O$ML]U!(P64FX@"AB%=CZ!_P %V?BYJGBS2/AG
M^SUX8OM)M]:^,FNVT-^UQ=)_HUNMS#';+-&(WD2*6Z=7$R8/^@R* X+@<^.X
M2H5N)Z>$PNF&KVJQ>BM2:<Y=[<J4HKS2ZLVPG$56ED4\1B-:]*]-KO43Y8]O
MB;BWZL\__P""=7_!;+XJ_M=?MD>#_AYXD\/_  ^L=%\0?;?M$VFV-Y'=)Y-C
M<7"[&DNG49>)0<J>">AP1]L?MV?MV>#_ -@GX/R>)/$DGV[5K[?#H>APRA+K
M6;A0"54X/EQ)N4R3$$(& PSO'&_YX_"7X;V/P;_X.*_#/@_2Y;NXTWPKI-KH
M]I+=,K3R0V_@U(4:0JJJ7*H"2% )S@#I53XLW.A_MU_\'".E^&-<O/[>\'^&
M;[^R(;9K.-8_^)7937<]G(DD7[Z(ZA'<I)O#;T=PK;=A'UF;<*Y1C,WI8FC2
M]EA8X18F<8WNU>3Y;]&U9='9.UF?/Y?G^8X;+JE"I4Y\1+$.C%RMH[15[=4G
M?YM7T/8?!7_!1C]L_P#:5O+O6?AE^SOX?L/"<D%K=6!\1B:)YX9HMRR174]S
M9QW2.59PT,>%5XP<Y5F]B_8!_;E^-/QB^..M?#?XU?"3_A ]:L;&^U2SU:W@
MN;2QOTM;BSMWAA24RK<8>YWF>*=D*M& N"';Z!_:1_:F\!_LC>!K7Q)\0]=_
MX1_1;Z^338;C[%<7>^X>.214VP1NPRD4AR1CY<9R0#Y]\$/^"IOP'_:.^*&E
M^#/!GCK^V?$NL^;]CL_[%U"W\[RHGF?YY8$1<1QNWS,,XP,D@'XO$8IX[ U:
MF%R=1HI.U2"JMPY5JY5+N,K;NZ6F_<^FHT%A<7"%?,FZEU>$G32E=Z)0LFK]
M+-^78UOV[/V[/!_[!/P?D\2>))/MVK7V^'0]#AE"76LW"@$JIP?+B3<IDF((
M0,!AG>.-_CWX8_\ !1+]MW]H[[=K'@/]G_PI%X:E\N\TZ36K6XL_.M)]SVYC
MN+F\MDN_W8!,D*!3E6VH'4'RCXLW.A_MU_\ !PCI?AC7+S^WO!_AF^_LB&V:
MSC6/_B5V4UW/9R))%^^B.H1W*2;PV]'<*VW81^PM=F.H8#AO!8:G5PL:^)KT
MU5;J<W+",G[L5%..NCYFW=/RT.;"U<7G>*K3IUY4J%*;@E#EO)QWDY-/3562
M5K>>I\N_\$X_VM/BU^T!KGQ$\+_&;X?VG@/Q9X'GM)(A:V\]O!?VUPUU$&C6
M5Y!(BRV<V)XI6CD# *!L+/XGHG_!6KXC:A_P3B^(7QZU+1?!/AVX7Q)%H_@7
M1;ZSN@FHP_:(1*S3-<(;UQ%)<+F!(@K6,[$$!DC^^/'G@C2_B;X&UKPWKEK]
MNT7Q!8SZ;J%OYCQ_:+>:-HY$W(0R[D9AE2",Y!!YKRGQ%_P3J^#?BS]G?0?A
M/J'@_P"T> /#-\VI:;I?]K7R_9KAFG9G\Y9A,V3<S\,Y'S].%QX^#SK(WB)5
M\5A>52J4GRQ5XQA!-U%'FDG>I*VCVC=*71^CB,LS548TL/B+N,*BYI.S<I-<
MC=HO2$;Z]79V.V_9N\2^*O&GP"\'ZUXXM;2P\6:UI-OJ&J65OITVGII\TR"0
MVQAFDDD1X@PC;<V2R,=J9V+VU%<_\6O&-]\//A5XF\0:7HMWXDU+0])NM0M-
M(M=WGZK-%"\B6T>U7;?(RA!A&.6&%/0_'SOB*[]G%+F>B5DE=Z+HDE]Q])&U
M&BN=M\JU>[=EOYLZ"BOS[_X?!_''_HROXK?]_-0_^5E=#\)?^"J?QC^(?Q5\
M,^']4_9%^)GAO3=<U:UT^[U>Z>^\C2H99DC>YDW:<B[(U8N<NHPIRPZCZBIP
M'G5.#J2A"R5W^]HO;TJ7/!I\6Y9.2A&4KO3^'4_^0/N.BBBOCSZ0^/?^"OG_
M  4BUS_@GSX&\%_\(GI6DZGXE\77UQL_M:VDFL8[2VC3SL^7-$XE,D]OM^\I
M42YP=N>V_P""6_[;-]^WE^RU'XPUG3[33?$6FZM<Z/JT5E T-DTR;)HV@#RR
M/L\B> $NP/F"3 V[2?D?X?>&_P#AX1_P7B\5:]J4>K3>#_@+BWLTFL?+CCN[
M"8110--"XV[M0:[NXS(SM(D!0IMW+'4_X)7:=#^P-_P55^+G[/US?VEQIOB*
M!)M&N)%EN+NY:WC-[9Q-(J)&K_8+JX:8M&%,D("-T#_L>,X9RV/#\L#"'^W4
MJ4,1*23NXR;YH/MR0E%O=-_.WYKA\\QLLXCBI2_V6I4E1BM/BBE:7_;TE)+J
M?<?_  45_:1US]D7]C?QA\0_#=KI-]K7A_[%]GAU**22U?SKZWMVWK&Z,<)*
MQ&&'('49!_/OP1_P6/\ VQOB;X7M=<\-_ G2?$&BWV_[/J&F^"M;N[6XV.R-
MLDCN2K;75E.#P5(Z@U]A_P#!;O\ Y1?_ !._[A7_ *=K*C_@B)_RB_\ AC_W
M%?\ T[7M>=D4LNP'"SS7$X2%>H\1[/WKZ1]FI=/-?BSNS:.-Q>?K 4,1*E!4
M>?W;:OG<>OD_P/*/V=?^"[VEW_Q0L_A_\<O >K?"'Q4WV6UFO;LNEC%<21%V
MDN8IUCFLHG)B*%O. 68%Y%1#(?OG7M>L?"NAWFJ:I>6FFZ;IL#W5W=W4RPP6
ML**6>21V(545026)  !)KX<_X."_V>=+^)O[$Y\=32?9]:^&=]#<6K[7?[1;
MWD\%K/;X#A5W.UO+O*N1]GVC D8U\N_M??M;WVM?\$(O@7X?FOK33]7\93C1
MY;&WM&9+_2=%FF@W%W#A'$L.FNQ#JS,S;1LWJ.B'"> SZC@\=E,'0]K5]C4A
M=S49*+FY1;UMR)R:>B>ETDV\)<0XO**F)PF8257V=/VD)647)-\O+*VE^9I7
MW>]G>Q[%XW_X+6_%7X__ !@NO#W[,GPC_P"$VT72[Y+&;6M2T^\NH[OSBJ03
M.L;PK81,Z3D-<R'<@#,(2CJ.J\*_MS_M@_#/XX_#_3?B]\$?"FF>"_%VNVNB
MWFHZ*LLW]G_:;B&U222XBN[F*#$MQ$0LRKYN&1"#EE^@O^"67P9T/X)?L#?#
M&ST.W\O^W]"M?$6H3.D8FN[N]A2XD9V15W[=ZQ(6RPBBB4LVW-?05>5FN?9/
MA<14P&$R^G*E#FAS2<W4E:ZYN9-)-O6W*TME8]#+\IS+$488O$8R:J2M+EBH
MJ"O9\MK-M6TW5]W<****_.C[,**** "BBB@ HHHH ]2_8M_Y.8\-?]O7_I+-
M7WM7P3^Q;_R<QX:_[>O_ $EFK[VK^K/ O_D0UO\ K]+_ -(IG\_^*W_(VI_]
M>U_Z5,****_:#\S"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "O*OV[/\ DR'XR?\ 8C:W
M_P"D$]>JUY5^W9_R9#\9/^Q&UO\ ]()ZZ,'_ !X>J_,BI\#]#^:RBBBOWP^.
M"BBB@ HHHH **** "OU4_P""67_*$/\ :._[F;_TP6U?E77T!\ O^"COCC]G
M/]ECQK\(M$TOPK=>&_'?V[[?<WUM<27T/VNTCM)/*=)D08CC4KN1L,23D<#R
M<ZP=3$T%3I;J47\D]3IPM6-.?-+LSZ__ ."3?B/_ (;;_P"">?Q>_9MU>32I
M+_2;%[SPNMY??9\>>[SQ$I"@E:*VU&..9Y"9,_:T1EVA4;BO^"U?C'2?@;\+
M/@[^S7X;U*UNK?X=Z5%J'B$6=E;V\%S>F$103.J,TD-PX:\N)(V(W"^C<F0L
M&7X__9+_ &K/%7[&7QJL?'7A%K634K.":UEM+TS&ROX94*F.=(I(VD0-LD"E
ML"2*-N=HK*_:*^/WB+]J/XU>(/'OBJ2UDUWQ%.LTXM8!#!"J(L444:\D)'&B
M("Q9B$!9F8ECQT\GG',G7O\ NM9)?WVK-V]+N_=FLL4G0Y/M;?+<_1__ (*F
M_P#*$/\ 9Q_[EG_TP7->@?$?X;ZI_P %;_\ @CIX!C\%Z[_:7C3PG]CN+V#5
M;E)+K5-3L+26TN;>:;S&\J6;S3/&\QRXDA+^6)2Z?G7\??\ @H[XX_:,_98\
M%?"+6]+\*VOAOP)]A^P7-C;7$=]-]DM)+2/S7>9T.8Y&+;47+ $8'!Y3]DW]
MM+XA_L4^.)M;\ ZU]@^W^2FI6%Q$+BQU6*.0.L<T;?\  E$B%)5620(Z;VSQ
MQR/$K#1<&E5A-RC?5--[/U-/K4.=W^%I)G/^#_BS\1OV:]<UK2] \3>-? .I
M-/\ 9=7M-/U&ZTJ<S0,Z^7.B,C;XV:0;7&5+,.,FOTU_X+$?VY_PYZ^!?_"3
M?VM_PDGV[0/[6_M3S/MWVO\ L2[\[S_,^?S?,W;]_P V[.><UXI_Q$<_&_\
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MI-V=F['IG_!&;_DY_7O^Q6N/_2NSH_9P_P"4P.H_]C3XB_\ 1=]7G7AO]O\
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M3AE$S!=N#=<CG<WS=X\\>:Q\3_&&H>(/$&H7&J:QJDIFN;F8_-(W   & J@
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M3,]ZHHHK^@C^>SP3_@HG_P D4TO_ +#<7_HBXKXRK[-_X*)_\D4TO_L-Q?\
MHBXKXRK^0?&;_DI)?X(?D?T9X9_\B2/^*04445^4GZ %%%% !1110 4444 %
M?E+_ ,'.?_-$?^X[_P"XVOU:KY]_;K_X)N^!_P#@H/\ \(K_ ,)GJOBS3/\
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M.-+^)O\ P2'\:>)-#NOMVB^(+'0]2T^X\MX_M%O-J5C)&^UP&7<C*<, 1G!
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ KRK]NS_DR'XR?]B-K?_I!/7JM>5?MV?\F0_&3_
M +$;6_\ T@GKHP?\>'JOS(J? _0_FLHHHK]\/C@HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M/4OV+?\ DYCPU_V]?^DLU?>U?!/[%O\ R<QX:_[>O_26:OO:OZL\"_\ D0UO
M^OTO_2*9_/\ XK?\C:G_ ->U_P"E3"BBBOV@_,PHHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M[)G_ #(_FLHK^E/_ (83^"'_ $1OX5?^$E8?_&J/^&$_@A_T1OX5?^$E8?\
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MO_1%Q7QE7Z<>(O"NE^,+);75M-T_5+>-Q*L5W;I.BN 0&"L",X)&>N":QO\
MA1O@G_H3_"W_ (*8/_B*_%..O"S%9]FCS"C7C!.,59IMZ>A^G\*\>X?*< L'
M4I2D[MW374_."BOT?_X4;X)_Z$_PM_X*8/\ XBC_ (4;X)_Z$_PM_P""F#_X
MBOC_ /B ^/\ ^@J'_@,CZ3_B+.$_Y\2^]'YP45^C_P#PHWP3_P!"?X6_\%,'
M_P 11_PHWP3_ -"?X6_\%,'_ ,11_P 0'Q__ $%0_P# 9!_Q%G"?\^)?>C\X
M**_1_P#X4;X)_P"A/\+?^"F#_P"(H_X4;X)_Z$_PM_X*8/\ XBC_ (@/C_\
MH*A_X#(/^(LX3_GQ+[T?G!17Z/\ _"C?!/\ T)_A;_P4P?\ Q%'_  HWP3_T
M)_A;_P %,'_Q%'_$!\?_ -!4/_ 9!_Q%G"?\^)?>C\X**_1__A1O@G_H3_"W
M_@I@_P#B*/\ A1O@G_H3_"W_ (*8/_B*/^(#X_\ Z"H?^ R#_B+.$_Y\2^]'
MYP45^C__  HWP3_T)_A;_P %,'_Q%'_"C?!/_0G^%O\ P4P?_$4?\0'Q_P#T
M%0_\!D'_ !%G"?\ /B7WH_."BOT?_P"%&^"?^A/\+?\ @I@_^(H_X4;X)_Z$
M_P +?^"F#_XBC_B ^/\ ^@J'_@,@_P"(LX3_ )\2^]'YP45^C_\ PHWP3_T)
M_A;_ ,%,'_Q%'_"C?!/_ $)_A;_P4P?_ !%'_$!\?_T%0_\  9!_Q%G"?\^)
M?>C\X**_1_\ X4;X)_Z$_P +?^"F#_XBC_A1O@G_ *$_PM_X*8/_ (BC_B ^
M/_Z"H?\ @,@_XBSA/^?$OO1^<%%?H_\ \*-\$_\ 0G^%O_!3!_\ $4?\*-\$
M_P#0G^%O_!3!_P#$4?\ $!\?_P!!4/\ P&0?\19PG_/B7WH_."BOT?\ ^%&^
M"?\ H3_"W_@I@_\ B*/^%&^"?^A/\+?^"F#_ .(H_P"(#X__ *"H?^ R#_B+
M.$_Y\2^]'YP45^C_ /PHWP3_ -"?X6_\%,'_ ,11_P *-\$_]"?X6_\ !3!_
M\11_Q ?'_P#05#_P&0?\19PG_/B7WH_."BOT?_X4;X)_Z$_PM_X*8/\ XBC_
M (4;X)_Z$_PM_P""F#_XBC_B ^/_ .@J'_@,@_XBSA/^?$OO1^<%%?H__P *
M-\$_]"?X6_\ !3!_\11_PHWP3_T)_A;_ ,%,'_Q%'_$!\?\ ]!4/_ 9!_P 1
M9PG_ #XE]Z/S@HK]'_\ A1O@G_H3_"W_ (*8/_B*/^%&^"?^A/\ "W_@I@_^
M(H_X@/C_ /H*A_X#(/\ B+.$_P"?$OO1^<%%?H__ ,*-\$_]"?X6_P#!3!_\
M11_PHWP3_P!"?X6_\%,'_P 11_Q ?'_]!4/_  &0?\19PG_/B7WH_."BOT?_
M .%&^"?^A/\ "W_@I@_^(H_X4;X)_P"A/\+?^"F#_P"(H_X@/C_^@J'_ (#(
M/^(LX3_GQ+[T?G!17Z/_ /"C?!/_ $)_A;_P4P?_ !%'_"C?!/\ T)_A;_P4
MP?\ Q%'_ ! ?'_\ 05#_ ,!D'_$6<)_SXE]Z/S@HK]'_ /A1O@G_ *$_PM_X
M*8/_ (BC_A1O@G_H3_"W_@I@_P#B*/\ B ^/_P"@J'_@,@_XBSA/^?$OO1^<
M%%?H_P#\*-\$_P#0G^%O_!3!_P#$4?\ "C?!/_0G^%O_  4P?_$4?\0'Q_\
MT%0_\!D'_$6<)_SXE]Z/S@HK]'_^%&^"?^A/\+?^"F#_ .(H_P"%&^"?^A/\
M+?\ @I@_^(H_X@/C_P#H*A_X#(/^(LX3_GQ+[T?&7[%O_)S'AK_MZ_\ 26:O
MO:L'1?A5X7\-ZG'>Z=X;T'3[R'/ESVVGQ12QY!4X95!&02..Q-;U?L/A]PE6
MX=RZ>"K5%-RFYW2:5G&*MK_A/S?C#B*GG.,CBJ4'%**C9Z[.3OIZA1117W1\
MH%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
K %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>mgnx-20181231_g2.jpg
<TEXT>
begin 644 mgnx-20181231_g2.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X )D%D
M;V)E &3      0, %00#!@H-   U%@  TOL  0WC  %*(O_; (0  0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0(" @(" @("
M @(" P,# P,# P,# P$! 0$! 0$" 0$" @(! @(# P,# P,# P,# P,# P,#
M P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#_\( $0@!.@*\ P$1
M  (1 0,1 ?_$ 3\  0 # 0 # 0$!           '" D&! 4* P(! 0$  @,!
M 0$!            !@<$!0@) P(!$   !@$" @D"!@$$ P$    " P0%!@<!
M  A -1 @,!(3%#0V-Q$54#$S%A<X(6" H#)P(B,8$0 !! $"! ,#" 8$"08(
M#P$" 0,$!081$@ A$P<Q(A1!(Q40,%$R0K46=B! 83,D=5*RM AQ@6)R0S1T
M)1>14W.&ML9@L8+31#4FEE!P@*'ADJ)C@Y.S5-4G-Q@2  $! P8'"PD' P4!
M 0    $" !$#$"$Q01($0%%A<;$R$S"!D:'!T7*R,W,44/#A(D)28B-T(/&"
M)#0%%<+2)8"@DD-CHE03 0 ! P(#" ,!  ,! 0    $1 "$Q05$087$@,$#P
M@9&AL5#!T>%@@/&@</_:  P# 0 "$0,1   !W\
M
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M?(=[^:;HTD_/Z   \(^5*:QKU/2--<WI]CIWR[>'"_G]1!M\'3F/[31G^?T
M>D/7G2E#2^)_A^AQ!V! )_A8H  X$[4B4X M">*?V<2?F0@263,  5B*.4U.
M;^1?;8TVW#+MR_256X&Z2M954QSG[!H_Z%>D*K[\  &#4;VL[>=?4/0:_)I'
MZ$\RV(FL?ME1U@31KLK,>_*YW!V&,  (7,.Y?HKV[C SFBNZTOT6QP-Z,I^3
M9Y%8^I>R/JVI^PY9  !@_L,3//J2C?<['#[7FBZ=$HION?G,<FS+^%4H')=[
M<3[@"A92,T0,_2/SJ"!CMS2\K"2X:7@ &3)4<UJ,_B.R*COBP9YIPQIT3^
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M>L=:41I3Q;?5YZ LJ@?2E4[9]>TC84_@^<FN)3>_S\Z7X_;X4/\ HIR]'O\
M&P]*SSA\GY9^7E7VZ&?C@   "M)C!*=-?;?:RANFV%WHCO,.+RK"3+6@<7UE
M-OIVH2U;4 ^9N0Z>"NH*1\?X_2W7+EX^/B9-V)Q'/7?G]5A@TC^@;%^P
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M?\X^II"C^R\GT\Y'H)QO>FCW.UH55]$N8/UV^!J[34YI))-7(5SP71W]?P
M#T)[X  '-'SE;C T:E^BI)J<Z[$.WV&73E)R%+-!I?QOT7D%=5:R=;U?3CS3
M=$MQW<W#F\=K9@9-AX3(M2_S_0  (X.Y/. !E :OG^'/F)L6W$]^<O4E)NW>
M?=K8QM<\)=IN Z7J;+G=ZGK+AKO:+DN_=*#HC. N^2        4\,OH3OO;[
MW7WLW.#5;SCZFD*/[+R?3SD>@G&]Z:/<[6A6'T2Y@L9.(]5B"2&8YMH=DLSX
M   #Y@3Z?@  "KIBGN=?TN)]]7<')^;OIRDY"EF@TOXWZ+QWNVLY9MN 3YS3
M=&CL/D.<V_UEBM-L-Q,?Z@  "IID*?1$>4 90&KY4\ZDI>9?<XVEN_E?#]_X
M^<_H6L]H['BE6]?E8U;_ $OV#U3/*<&G!G 7?)         !0 JIYQ]32%']
MEY/IYR/03C>]-'N=K0K#Z)<P;M3^-    #Y]S*8U^-XP   "GY\U_3E)R%+-
M!I?QOT7C9>%8S);$"GSFFZ/I2ALC    ]*?/V"A1N":I &9!SI(I>PI85,J*
M:Z50_=9!6A$M I['<^9EH+C;7"QVB>[^JO2;'.(DXK :XGN@        4 *J
M><?4TA1_9>3Z><CT$XWO31[G:T*P^B7,&[4_C0    &"YO0    "G)\VW3M)
M2#*]#I?QOT7C9>%8S);$"GSFFZ/I2ALC     I49LF_1_H !68\4R-BVWV1I
MN<5+WNOR<LB+_41*-1\6&\UGT#RC4>F_/]C&!26QGR^FFP         !0 JI
MYQ]32%']EZWT\Y'ICQ=?.AG/]EUA]$N8-VI_&@         !2 ^=?J*CNYDV
METOXWZ+QLO"L9DMB!3YS3='TI0V1@    <X= ?V   9"_']V&HJPIDU^3A-^
MO[[V+;G7[K*E_FIZ/IRQU2V#JOLL6BNDV.RT3W=DP         "@!53SCZFD
M*/[+U'IYR/3KBR^]"*!LFL/HES!NU/XT          *0'SK]14=W,FTNE_&_
M1>-EX5C,EL0*P7,]U?29#Y"        !Q9B/6TIUHKN38^SN/6 XDZ!@^:Z"
M/>_.;*O=>\^1/7DNU\KR9SGF?"D,(D7T0:_*          H 54\X^II"C^R]
M1Z><CTZXLOO0B@;)K#Z)<P;M3^-          "D!\Z_45'=S)M+I?QOT7C9>
M%8S);$"LES'=GT>1/?@        1R8B5I*KO1?;X[W9 M%_-_JCSOC],(?4[
MCBRW4]%PM6<UNM2=F7MF6@IG$=Y](&KS0         ,YROWFWU5V.GSO4>GG
M(].N++[T(H&R:P^B7,&[4_C0          I ?.OU%1W<R;2Z7\;]%XV7A6,R
M6Q K)<QW9]'D3WX         J>047_, :VE7BXGWO+:T,Q)M:!WC@DJW@T6T
MS2-"R7@         #. @KS8ZLZS59GJ/3SD>G7%E]Z$4#9-9?1?ES=:=1X
M        4@/G7ZBH[L9!J=4>/>A\4KPK&9+8@5DN8[L^CR)[\
M5))X(>)P.O           !G 05YL=6=9JLSU'IYR/3KBR^]"*!LFM?HYRSNA
M-="          *0'SK]14=U^_P!5JSQ]T-B9>%8S);$"LES'=GT>1/?@
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M"$"%M@           0X<V6'..*ZEN3^@          1R>B)+(9)F/\/[/;
M                                      &?1PI48\LC8YPF(WW
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ME3IC] >.>0         97%.C0D_4Y [$C(S)-6B/3PR="S1G>>W-6#V
M !E<58+NGNB,B6B'C.\T*/0GYEA"Q1GD>V-03I0     97%2"^IYYP!(Q%!F
MX:7'+GH3V!,9[,G0IV=D:3@      RH/'*R$T$7DVDV$&'KSNSVI2P^@<Q^(
MR-L3I0     #*@Z0H\6:*W%J21CCR&"63WQ30WW,JR"S9 D@     &5!YQ4(
ML 0<6,)8(N(_)3/:D?'"G\FM)DD2*:\       CLD0CLD0   $9DF
M $=DB$=DB    C,DP       $=DB$=DB               RC.I)X../<GJ"
M*"_ACL2Z20:4@        S3.8+.'$GDGX$7&AIB*6)(\-FSR      0J92EX
MS^STYV1"Q*A9 SI.J)&)P.#.+.G(L/2'/'.DQ&BX      ,\R'RH9/1Z8J,7
M^+K&<Q_)WQL2        "EY4,@,DLYXJF:!FAYCL>Q)@-:#J      #%HJX:
M*&1Q:HZ$[HN*9NFAA7<D@H03^>$6&*W'7'4'L#5L        @$CTN   5^+
M@         $(D.ET  "OQ8$       'XF<QH,>Y      /6$2$W
M
M                      __V@ ( 0$  04"_P!AN<X#A9=U2(%C:Z-KRB[1
MYLZNH\M:7EH?D7:N-U5.TK&AZ9Y A[1\L> 1E6RR!BDB+\*W.RU_?)0@HRN$
M:%E<W3;3.T2Q*XH^RW(V\YL>H_0,,2-Z@MUVXRL@XI23V>[>Q7EM FAK$03
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M"4:Y$=^CLJ^+(IZC6U7YSXAXJ^N9 N4;<:V.DR>G*H2G8Q@..(W8?"4"]C2
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M8:HXHH!)8QX!C"G_ #^#(A8$1I8G\,6,YQEF<L."?4B:_"'UT20U<H3)RTI
MQ@+ Z. W%2  C!$E!)!H[.!&]=1C/?T09]>AT1>5-TSKOKV!YP$Y2@\:DW&,
MBRW(\)"<YQC!@\C%HO&< _!2#LDC"+ PB#@83BLDC1+#$*A.H+5$F%@- YH!
MMZGJXQG.69LPWI]2)T\06DB?P0Z6J/IV(P8&'.,ASC/TT6/OA/) H*4$#3&X
MSD.6]9A83UG1=YHW3.AZ#S.]G1!?U_"$:CP\Z4$X/!G&0Y87/R9VG1O XIC
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M!G>P,(1A6I!)#M-2WS)6AB" *Y6)8=IJ0^7+SG <#'D8M$E]S' 1]$4L69
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M1K0H:TFAK*J"UDT,+Q"JI&,8F3'@SH4&,*('H4'%C"/9F=)QCT5_:<*6>O\
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M&B<-V5':5]Q7O:HU.K)D>=$-4TW"+\9QQI2'7FFNJ?/.5\[/\:;ELKM=;;L
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MKANO(W&:0?Z;\A41/V(O&,XZIHXM#C]-2JX.JBXM771H.]%71="Z&OZ)HV2
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MWD2>847>R>[<TZ.K3C2HJ+IIK\.I.K9VD_2)%:ALNO%U9"]($;$0W/ODI:
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MN%-RB-71IA&=$#.,NU[]:L>JG(Z\V!R3E.,@8DO2Y[N.X62779<<PKK*XO\
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MZJ3;&N06E@@"(NY#+=RUTV\^(.=8)T;M^ZE^EJEL:NR=K8SL27&:M8]X,:1
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M.C?=<KGA:4+!.G7N;=O(N6GCQ@K%2W,%[-LWH&:F+.B/0IZ([$M6]ST)\1<
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MA'VZ7#SM+1?3@ 3C)%%!B"@BY&@B4N+@BE[E>8-Z\0_JH$;2"VOL8(R-%0*
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M\"=?_8:BU('&U!_S]O"5QZ)I4_P^S;*8D48TO1JLQ4J]@6)&$,BH0 $-I B
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MPAR@@(0(%C,:4!F&^E'JYCF'XEVWX(\I0%97'([T(I-8X?Y-GCVNDX=;_/\
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M;_>FA-<X"$=+%Z\&WK("%>@(D0PP)0)!-HTJ7J/'BPR\&E 8!T# 8DF;SE=
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MAA\1Q-"Q5NX1QQF' A1+:3<L'R"D5X(CL<0QZYV91616CXCK",M6%<I6&(X
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MVW6+8X0IWX'0Z3OMIF:D5DNA!\W])K2+G7GZY_\ E3__V@ , P$  A$#$0
M$
M
M                (      (      !      !
MJ@    !E@     .L     %2    (!(  () ( (     !LZ    (?P     .L
M@   !,?     )   (( !  )    H+QP   "T:2   &9B>    FC^@     !(
M   )  !(  (OJ.(   !ASD  !)@X=    ;,O@ !! (!   ()!!)(  !I^R@
M +ONNH   #*JXP !P4!C    !(      )      -RYP0!#\EVP   !&DA6
M2.\B    !  ! !         !/9?H K)E"    !!I 1 /6I=     ! !/)!(
M       !?3*4'FD8@     ),#<P202\     ! !$PD4         )8,<!VYU
M      !.F]Y"A<(     !  /CVR          _I/+X^\       !X 829N
M !  ! !+?&M          "1/+XK    (   )] 92:8   !( !!)#+L+
M      !/+X    !)    ! 8B0     ! !( !R!D((         !/+X
M    !(8B0        ! N8#KP          !/'X           *8B0
M  "_0!-H          !/-X           *8C          #\7+W<
M  !/-X           *8C0        !$1ABE6           ?-X
M *8C0         ( P_)(          !O-^           *XC0
M)(            !O-V           +HC0           ((            !C
M-V           +HC0          ( )(           )M-           !*PI
M@          ! (!           !(!            )             )!
M                                        !
M                         !        !  !  ((!( (  !(  ( !! ) !
M    !   ! ())    !!)))!)) !)(   ! )) ))!!!)(    !!!  )))
M !( !  )!! !!(    !! ((((( )        (!
M                                (  !!()(      ! !!()!)
M!    !(!(       !)!!((!       ! ( !  ((     !(((! ())
M((   !        !!    (       !!               (( !)
M)   )      !( (  !(!!(        )!)!(         )))(!        ! (
M) )))!        !   (          (  !                !
M
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M7=4/QV.[YRXNU:>$2%,F\\6_<(Z;@&HQM0B$ H%M^C9*;-J84:@)@   @ @
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MU>'P,C2V19-8,UJW^-Z,C(E$+A!TR)-B[0@T.(50OCKTD2CB5R+%'= S#%K
M&8I&0QD,L,'J<U"6%[P3_P!%W WP7KB2HZ4(B"U=LE[KXW[!X8DPSX[Z (!S
M!I$$ ! 4$B$B(V:1_J@I-$F\K%**$T^%+*:2 !VC\+0I]26MOL4MS(BP'"MV
M) D46FX!BFD)+"068( ITM61 'I-C$6$CN)5&::I2.&>,B;0HZZR-[J,"]I2
M=!SPY0  2K8*-F:)@S-T&@,R3*"@>0L<E8.3*T$F&&D+FV<800W9 /\ X8B\
MHE!I;([S@3*.I%*X"MO(6HI.SM20+5L,FC4A1.?U%VBT*!W:6L^:)M!#[ (
M#+B?[4\+DK4)X-FWZ*K\!30U]J9O.64AM9BT@*4AS/,(6GQA45">X$KM$0
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M,5&'WC5@  2_\\&VH(G!\<,T@-AY)U$[)G7_  T2,H;E>6+Z?V/](AP&H=&
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M)!31*VJHZ]"+-$!5F8X3QCA$\$>@MW.H!J;*"%F 4?Q2(14)0F IFY%U0GZ
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MIS$%D:1(@X /@ML2&@4!P+6@4A1"C6IJX+;LHE[B_L-ZG4"8/%X$"B5R$-:
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MF1HH6C)9QGOA',1M *RZ0&PD <R1\BP.W92J+,*[28,IF" 5!U" 0%:?5]!
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MU$N-%A'Q("@Q()V1A"*)G* Z=B-)HHM9E([9!(V4&BJ314\'=216WAUTV]H
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M:40%< R<H][S!NI4Y$]: ^$GPP!8()(-)0(;P+JK>AT7(HG+?*[^P<//=O9
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&_P"5/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>mgnx-20181231_g3.jpg
<TEXT>
begin 644 mgnx-20181231_g3.jpg
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M  (1 0,1 ?_$ /8  0 " P$!               $!0$#!@(' 0$  P$! 0
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MH     :3!")9)  !H-Q@@E@        #YP8-);'DMRB/9..H.&+(B%&?50
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MSE]OALO2\IS#(3DR9-75YOCT?!D;\V9>83^;6^\#U++OY)/5AXK/01;:
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MNC00S8<X79 .G)H    .0*DM2O/).)YX*$Z,C@]E4=8<X3R2<N79#+@O0
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MV3^LG9/_ * [[]1O9OZK4[-_4:G:*G31->V<WHHWN%;FWDT7-F(G^UI__]H
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ME'I)+AK-PVG4VCG AI+#?T#<(-PR%&IT92QS)W1>>H,VGEVT-?MT+3)58&)
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MT.OOMGSMP\T5(VA#1 _F8=O6V%7-O=("7T-\Z5)P!EMPB]=9LUVMNXS0VA8
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MFE3IICX4-C\"5 V>MR_4M>C#U\^5SZ<'!OZ1B&D&X;YZ"S.>$9G6R^BY'N$
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M*OI%Y"=9D@1&AJ'8U71LVNK '52_I[D;*;5L8N.?.7FD43-F#/S:*NPN@VJ
M1 #60JZN6M9EL=;9+U5 JN7TF7U8K&-#70<R[\C= ;WH92&$WL,M6Z)E_P <
M6#$H<0%)MQMD2+,LR^M5<>QH&O)/T>)^N>:H77Q ,%] I$^6)E9AA9?68SOR
M8$J&]S:KYIC7M1TO4:/C8 0B#2*YL/0"M B7B7A6(#E Q ,0!Z5P#:PIR*R@
M=;*J>,X.9Q93_EJD.LLL^L.01JN":>E:QLM'J+ '-+Y'%,O6<4"J\BQW8N[,
M/F<%-Z[D8;5ZK%3S5K'H!>:.&2^"64%$Z&FG\2INM!3KI)@F)[ND*RD((C/
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MDDDDDDDDDD D   $DDDDDDDDDDD$D@D DDDDDDDDDD$D$ @ DDDDDDDDDD$
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MKD00,Y:RE1VP4W&P\:+A55,TTF;_  @"<%^A26'!RMEZB..( ZWY240?@/,
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MSU')\N:6)QN#MU^L2L=:+5[KXU*^!@&@/WUE93Q\>CW[?*O0PP7+H[=?  H
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M+6-=@N&-B!(]+( %&O\ XH, ER+UKKFJ^I+*8PU:PNH:O+Q46F6,P9#R<Z&
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MXS1UC5Z$>L9S)9M=W!A.U:LWQ?.51C$OY<* ==C XMJBKE:U<PKG!$ZV!Z[
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MJ2Z>Y_R8_P#X'/WA&F"8P! ;12>JL_$ NWW!UOI7_D3+[S!^ACKN/CR5._\
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D$%OWFX]K/XN%PR[X/[^)B*.@P?\ ??YL:@7]&+DM_P#Y+__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>mgnx-20181231_g4.jpg
<TEXT>
begin 644 mgnx-20181231_g4.jpg
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M  (1 0,1 ?_$ /4  0 " P$!               $!0(#!@$' 0$  P$! 0
M             0(#! 4&$  !! $!!@4"!0,% 0     "  $#! 41$" P0!(&
M,3(3%!4A-% B,S46<)!!8",D)39&$0 ! @0"!@<%!@,&!04    ! @, $1($
M(3$005%A(A,@<8&1,A0%,$"Q4B.AP4)B<C/1@K)0X<)3<W3P\4,D%6"2LX0&
M$@ ! @4%               14"$0($"0 6!P@*!A$P$  @(! P(%!0 " P$
M   ! !$A,4$046%Q@2 P0)&A\+'!T>%0\6!PD(#_V@ , P$  A$#$0   ?J@
M     !$,"<0R0;"("6           "A.?.N.1+HK@#M0           12@+P
MX8DE.=$#LP                           #!&BT:P9DBLYI
M \177K7WK&M7 TR&V&PD5M84M8TMDD        "#:M-KG#F*'2*N\:)C9#89
MHE1-C2;2MI=9N,[SZ7        I],ZO2G-Z1S6E<C:;(;#8C,SAF9%G2UO2U
MGG>ZST       I=,ZW2G$[137KMAN-ALAL,T9PS,S(R-\+W+2UI>[RT
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M7)K<9W          $4J4192H= D            #PI41")+I8F8
M    5Y6(ARVE[$S0            8%$B)**3X6R;             &LYU$:7
MA(+>)L0            0RJ1<)@H@E^G<            #G$"4:3TOD@
M       <V@;C0#I4@            <\CP$.70Q,T             IT1R+*5
M#H$@            >%*B(19=;$Y@            %>5B(<I$.F3Z
M    #24J(LHY8PODY@            KBJ1!ED3X7J=P            (Y2(G
ME#*=#H4Y@             $,])8
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M@(96G1'/%B;B@.J/2M!B69RA?F1S9;FXLBO*PZ,                __]H
M" $!  $% N+);JQ$-ZD1*:Y4@<)(Y!7NZ_NH;=>:3F,CC*$X=M8R@>+R%GVU
M'!8>I/2M2T\)CCRF7IE_]=@OW'F+7VO;#.V#NU_<U,9FH\;6S75EL+$':D[Z
M/_+,$SMD?QES 4]J!E[R%>\A36H'0F!<P[LS2719'8E+8Y@*]S77N($Q@6P+
M$HH+HIB8FY.:T((Y#-Y9XHFERZ.U8DW0FE%!>)1S1R(#('AM"7)6+6NRWEF9
M.1&3)DV_%;)D),35[3CR%FQU)WT5_(O,[)DR9-P(I2C>.03&M8Z>-;FZ666O
M:NR9,FX<<C@0DQ#4FU;AF; !$Y%?M>WKIDR9-Q*\O23.[/&;&'"NR?59:?U+
M3)DRCC.0Y:5J$0H7#!Q=GBBDD+@USZPI2:%PC+J.0V"-W<B9,F6+^_FEA@&V
M1#7N0^L6-.2.X7FX%8M)!+I)GU;@62Z85DRZ:3)DR902E#*1.9AD91CDEDE.
M"4H9?%U#5GF;V\S2R4[48KT9/3V,^CLJI:P\"\_Y%F/M&0B[OZ4,*]RFEB)2
M1=.]4$"QX31G;HN7OR@'H*4Y,=MA?6*B_P"7@7O%9%@.#IHH(/3C'&3.TM>6
M)58/5-P!AGB87W!F-HHI"C,[TY"O5/TMM?\ 1H^;@7O'S/?#JIB"K&TEIG1"
M)#!!Z+$I_P!/=9G=-&2](EH[;E?]&CY^!?\ */A8?2!U')Z<D<C$S/L)E-Y-
MP!U<64H:@F/5$/2^P&T"BW!RTP0U/DK"]Z,L#HE4F<$))G7BIVT'< =&9E+^
MFU>1T4$@KQC4(]4BIMI%P.Y1+T&=,Z=$H_+!-T(23.C!C$P<"V1#]1!TP[-5
MJOR+H9U5CT91CTQ\"S7CL07*<U.9G3HE%Y559WC%TSJ6)I!:M*[C4%,(BM5J
MNI=2GM!&P6I%"+F3?1ZP=4O"R-..U7G@D@D1*'P5'RDR%TRU6JZEU)S9/*K4
MY,(LF5(.FN?A5CZ(]VED&M397*#CX9LA5BHPY#)R$3Z".7M#/D:0&SMHB4:%
M]51\I+P75].I=287=3: *=V9B)S-F4$7J2"X+H<FWL7?I5KTYV[N9=K/PV3R
MP$W7D8Y[$U=LB8,8SCTS$A3.J,S$B4GE8B9!U.S,F4A]9*U(A9,M5U+!SE.^
M\]:N[B "N@>IJE5C4=:O$ZO-I<)?Y9U6-VF](G15F=BI.F!Q3,K)=(/,+([!
M:-J[LB?1M5JL!2.&'BYRD0RNH<0XU#Q,[/5H%&0)VU9@4D8NK=GT41N3ZIWU
M=FV15;=EX.V[!*KA:-=^.-:L)*6F)*>*2-!L=$2R0DTVJU0LF6%QXR;,1?DN
MP9C+RTBR&2"K5KOG?5F>5HHKV3BR'&OM_L1["=,!R$=$Y!_CT;ODZ@UK3,JE
M<K$\<8QQK"9&"G$%6_?N#'=:A/<KVLDPVZBI^U?+<:ZW_&B'07=&2J0>E'LS
M&,.RH\5?(L=C@J!RU@F]-T9*E#UGS;OHTA]1$Z^I%59FBYNQ(B=&2A'15?+S
M1OH+NC)>+@JO-R-J!.F$Y#EC].8%5\>:L3^FG_.\'I]%Z%B44<A**/H'FK):
MV102.*=U!(XS<W;^Z'83JLSG8YN]]P#?1W1NJD'I1\W<CUE=$2I0]9\V[Z-(
M?41.OJ1 # /-V)$[HR4(Z,WAS4I] NZ(D/U(4'DYJTZ)T3J-"H?T^:GB]07K
M6'>*DPQLSB0H&Z0YV6K'(\58 _TOW'=DJ8J&WF*.0L]SX^O+=[AJ598,O1FH
M9GN(+>/#(05[=?+5I[D?<U26Q+W,7RIF(!6/,YLO=EB,?4[BJ6;,_<U&(PS%
M(L;E\XV0KS%6DSUONFD*P]Z+'=OU>Y*=B?\ DQEE;V<K59V[BQWQM+,!96,R
M4.1K[W=>MB:CV]0HR]I1M*J.1K8Z_+5LU^TK%FGD,F]Z"MW50"<\%V[D\9[/
MM^Y7^9R44DV/P6?QM/%Y^:(<UCK$5ON'&EZ?;]^%X>VBLULEW%4]2Q?'(4X^
MU\O''5L8^:/(=T=LW*[Y&'I'*6*W;PXC"9J2&A7ECE@WGCC<D  #'7@,R$2$
M8(03PPO(  #1UZ\9-7@:1/6K/))#%*S1QLO1AZ"CC(!AB%#'&":M692112L,
M<8NU>!I)*U>0I(()6>"%X]WN'*7*+>_A^/P&6MVPKWLSDF>7(U\95M=R34S[
MAB^&:]EJ=G.9JW3&P5UZOO<O3OF8@'RUWX23*9NG5R%_(_*!D\A4MK*YNW!,
M@M5SG@M5YWR-^>OD%)G9QS&5R(8^J(]SD(]73<'-'/C\AD;-?%WFO4MF:9GR
M0.;C4A*67"&-O!U)[,F-Q%NM7P3Q2_ 9^0)B[L_9-0]O9@^+RF:ZOB+W3_$*
MV$L6ZMMV;NG/31V[+_-^\[J^U7<G7[SM_P!G\5FW9LQ=O15J88_,GA<C<]SB
MLT4I48Y,W)2MU6N1]N2=,G;?Z>R6K!+)[.K[J*K!%):P6)M20XRC!7#M_# 1
M1QG'4PV,J2V:L%J&S2JVH:F%Q=20Q$QHXMXZ  (!<Q6/N'4Q]*ILLU*]D5'3
MK1V(*=:N5S&TKJ;M[#,W@H:-2"+^-83K  C"WA,7<E]FU:GC:(T:2L2^C7PF
M8^2BM9[TLOD,M[>>K8S+SS9>_P#)4,OZ]@\W>,GS%-L=A\F=\/F[\RIVXK=6
M3(/\D^8R,EQL^)8OYG*1P5[$5B"_D(:4>'R+Y"F1@*(P%Y) CCBR^5MC;R.7
MABQF1R=Q8;(OD*62NC2I8G(^^K++9P*,UG(/7NK(?88Z0<>01EK7=@[LGMY:
MKE:/_J+CC)W3VT0!B^UA_P"C[904LKCHNUXR#"8O\V<J?*?,7<:]'MZ&2*+#
MX*3(5\%7*62'M#]FS%:M/CNWY#OWNX!,L-ASC/%9;]KP'[-VA^S=PSG+=QUJ
M2//?)Y0([-R#V7<$X3X92QC+%-A*4V/FQU>5[^*J7E#@*T=BS@:L]NCC*=)K
M/;]*>:&*.&*E0@IJ? UIYA$1%ZEB'-5J$%>Q<J16ZP]M8],S"RQ]""C7OT(;
ML4V-KR6G9G;^-U!)ZD;TZM:.K7C[9IQ#5Q=>M8MX^"T:NT8;D>2J6+EO\!__
MV@ ( 0(  04"_H?HM%HM.:T6F_HM.5TVZ;^FW3DF;8S</38[<@S;&;CNW&;8
MS<B_&;D7XK;&W=5KQ7Y$MC)D7"?AML;?TW=5JM=]^"VP=S1:)GWG\4_@O\[C
M\%MC.OJG)>Z9!(Q*:3I;K=0RZ[^F\Z?@ML;98\J9]%+)U;(?-NN3,NI:[KI^
M"VQMD@=3.VFY#YMR:3IV0%H2T3;C\$5TK3;+%U)VVQ>;<,M747F>P*&<77^=
MK\$-Z:+7:):.):MLL'O [Z:I^(S[UEOKLCDZ7><45ET[Z[L<3DNE/L?AL^]:
MX @[H:R&(6VNG3\1GW;6_ &K[S\E:'9$WYG!G4K,S[(PZ6WC;C-X;2'5GA=1
M!TK52^95@6F^;\8'V=2U1%MU1AU(*R9M-UW76G+D-=FJ?='=,N;U76AV._/"
M2ZF1%K_>+__:  @! P !!0+^A^JU6JUYK7@Z\KKPM=NO):\?7D'Y%N,_)M^&
M/P-.*W(MM=-PFX;\'7=TV:;[<%][7@-L;?;@ON:+T71 [*,-5TLI TW]=]N"
M^Y%XIV0!ILD\-UF=:+3>;@ON"^CL^Y)X;D8:[)1^BUW6X+[H'IN2>&X(Z,I/
M!H711.VZW!?>C/3:3:HATVPCO%XZ)N2A\-AAJO2=- F;3=(]%KM;AOO0<!RT
M3S)S=]UN(^[!OREHV\W)0/L/P8G91N[ML,M7WFY)GT7J(RU6B#P4Q<!N,[;-
M-C;=$):)YM_1:<EIO/NLW-Z+3\!=EHF;^\7_ /_:  @! @(&/P+G2\&B,Z<]
M0?8F038J61'I\(!D9"->]^__V@ ( 0,"!C\"LY': = [_]H " $! 08_ O:T
MN/(0K8I0!@)3<-E1P "TZ)/OMM$Y5J"?C%2%!:=HQ&CRM?UZ:Z/R[8=;:74M
MDTNC8?>77W6$K="#QG/ 81:W2V$FXFI7,US2LR^$/OC-M!4.O5";R\0+BYN9
MK4IS&%*9:DFK@:'XEJ[X9<]19:%L\H():*JD$_-/[H_^K_BCU?\ U_X^\O?H
M5\(M@<#Q_P#R*AZWRYJ"F?6(38^I(6PZQ@E5)(4-4I0';5M9Y;M="A)2@F8,
MN^$-A+Q>60.3]68._5A$Y8>5S_FCU:8S>P^W^VL2!'BC7&N/%&!!]XF<!' )
M[X\7=HXE =<?N)[X_<3WQ@H'1@KOCC$MXB8,Q[I).*HFHSB;BI1)I':K^$<2
MSU##HX*,<8GU1PG'9$TF425@KW*E&6LZ*+?$ZU_PBI1F3K/LI+Q&W7$QB(I7
MX=ON%"?#K,3.4%MK!K;M]KAVB)B*%>'X>VH&9ST>7;. _</W>WF.T1,1RSF,
MO:%1U05',P5#QG!'7[C(^$Q,9B H>S".TZ*!X6\.W7T A FHY"*G&E)3M@+2
MTHI.1B1$B,Q%+:2I6P>RWB"C;E[,JVPI9R2)P5',XGH,?JB[3SN:MXD!L R3
MCOBSI)'T]77#!4M"'5- N%9IG"6 H4E7$4ZY#;L@]?L9;8"MD3]BKNT.;Y#[
M>BEU/B3B)PI9S49GMA"*&SRQ)"BF9$%;AJ4=<)<3XDY3TDMHJ S@-%!#AR$5
M+;(&W1S:>#*K3/0-V'L4C?H_F&B0Q)CZO&OY!]YCA;0.R.-L#>G" 0:D'(])
M\+70FI/%*<6J$$J#>%9UP0/"2JL:I;X+@<1+4B?%"BLSDX .[H)A0]BCMT24
MJE(,RK./&OKE!4QQN*\.H@1,J$XXQAMU1CX1G%,L-D3&714T/ K$]D!:?$G*
M"G!(5XJ1*>CE?@)J[>@F%>Q1$M4.#9CW:"K*29)&BE6(,*&<SAH/3V=<82/1
M3"NKV*3UZ%]1T!7? (R/0/3ZM$EY;8EI V0L]7L:E9SDD;XU=4+2KA7+#9I_
M+T#TSM.$;(V]4?IT :)[3[%E7X0H@]O_ "Z4CX=-,4G3/I+^V.$SW05'7H2G
M9[%3+GA5'+<_E5J(Z1W:9:]1C*.(SC =':K9!GC/.!+OB7= V#'V92H8C%)B
ME?8=O15$_881*>*M*3K,=43UJZ5TV$4^6<Y<YY[X2OEEU:S)+8P. F3V 1YU
M:OH4A8.V>4()].4AA9'&7$U '6403*J0\(S,,MW=D;=NX50TNM*^+4"!E$B.
M%61V'HKZ?YCHF<H*M 3JUG=%*2,-4=9 Z?J8N'D-%5P9!1E"G+-#;S5FCE_4
M)":G1Q2E/5A#MFM,WO3'TJ6V,9M>(?&&;BQ]0'$I"?+"F9F<20>(0MQ]3 L4
M5*F OF!(VZHLW;:[\^XMZ7(*@L(2K-2:92EOBDPM.Q1'V] I/CV[=!C QCIG
MW:.6/YNB0X9EGP]O3F6D$G,TB.%(3/.4%4A4<SKBL,H"_FI$^_14VTA!.92D
M#0_^M7QZ");8PB2HX5=\2.8T2RG&&.B9SZ*GG!)3N0W#^/MO,H$T*\>XZ/KI
MQ<QWIV1P$*'= <=.(R2-.,;XI3XS$SB>C]%I2AMU=^43?<#8V#B,!036L9*7
MC_=[A4EI"5?,$B>B:.$_9 J';T:M2AAT2^\F:,D _'0XXM(24.J;$MB8;0RW
MS52+CPV-)S,(=0GG+>(1;H'XE*RA'F!;<D^,(KJ'?@8464A3LN!*C(3ZX8M;
MU+)\R%%"F:N&@3XJO;]1'0I2)Q2IN8WQE+=..4D2 2-"6DZ\SL$);1@E(D-#
MS+Z7 LOK4/IJ.!WRB\NFW$LMJG;)#B*IMISEE@3%O]-3KWI-Q)2 ,5MC6GLB
MT<LW'RX74\]OZ@2$#:,H<N+FZ5<, ?M!I,QCGPXF46ZO20X6R%"\4L+IIU";
MF,Y[/;K_ .-<3TX^-7BTI=:_=2)%.T13RB-YP$?,ZKQ*^X>[TG\6GF*\*<NO
MWR<3T2$2V>^4CMTSUF#[V3T5>]D:*4YP4;-!][D/$8FK&. 4[8"P>,:HP3$M
M>OWM6[09:] &I6!]\5OE\.@G=B??!O3T,?&KQ>^(.J6GF*\*<NOWR9B>BF E
M.0]\I';IGK/OD]>KHIZO>QT4^]X9C*)4PJ>*U"4]D$',: /?JLE;1$\S_P"E
MW'&E4.DI2A76?X18-W%SYA%Y34T1BFK#[)P\R4N*=9532D#B.['5K@,<MQU^
M52VFQ,IU\4&^2N3"?'/,2U'?'*MDNM..K2$%0IJ3M21O$6_I4EJ?+8XAX9 :
MS.?X8N+5(4%6W[JS*COG ;89>=05!'.2GAF8Y+3#J[=H'FI2B;A5U82$%:\$
MI$U'<(<?:N396:54M!(Q/P^,5>I7!N'*B$2&)V#5]L-VP;=0^Y.:%)E3(3QQ
MUP^W0ZMQA5*DI .69SR&^/\ R%12Q+7G.<I=\,6UJEUAQUU,JN&:3@)2WQ;6
MP<>#MNBJA,N7_-C.+A#0<5RTJ ? X*Y8"?7"+J\6H\U1(&:CJ $]R8:MPTZA
M]TD<M292D)S..4H+3;#J[9 DI*4<=>W&4A'EPARXN)3+3(J(&^//S5RJJ*)<
M5?R[(<G;O,<M-9YB98;H+[25)2%%/'NZ=A8 _O.35N_#/[3'FBI;KJ1@XZ9R
MB[]04/J/ND [O$?C'JSEY,714>4D@\0F3(=>$)J!'.N XH?DID)]J1'I5K:<
M5NQC5*0X9&78$Q=O7)/"V$L( )),DR ZX]6NP/JW"C/J&*OZC%I9-+_[A0,V
MY'Q8J5CE%^7E4W#[E+2)'(%1,7+3?C6VH)ZY0BVN5%MYHJJ12<9J)U=<>FN7
M.%HD5SU3G_RB\OY288:X21+^;M ,>I^H+_=N2I,^O#XJCTU*I\I2ZW9?FFH?
M88L$VV-O;)*@J4AALW @"/7+QO%:&UM,D;92$O\ V0;-O&Z=5]42RXLY]0 C
MT9NXPM60*]DQ*<.W2!])AJ3:B)3GK[9F+WF*E=73IH;D<A4HQZCYJ^58K4LS
MPQ4F9R.K5#-DI\M-/?68>5.95\QPWY1<NWKA=MF%A#+TL53U?"&W6_VW$A2=
M6!QZ844@J&2I8Z)(2$C8,("UMI4L9*(!,%*A4DY@P*6TIIP3(#" X4)+@R7+
M'OB2$A(V#""IMI*%',I $<T-IYGSR$^_1S"T@N?/2)]\2<0E8&I0G"I)'%XL
M,^N**$T?++#NBA204?*1AW0"E"4R$A(:MD&A(3/.6$&32.(S/",3MBEQ 6G8
MH3@E*0"<R(+@;2'#FN0GWQ4XTA:AD5)!B3C:5@9!0!CE%M/*^20I[NDQY4))
M<KJJ$_")QY[_ *7+YOV3E%RJ\"4<FDX"4@1/&"]9<NVM)R;6X"I2Y:XN7;HM
MJN&D+4@M@T\*9B<X1>(\NXE8JY/$%2^$X/J#:/J3Y?)/^9L^^+9/J'+6S=*H
MFV""A9R&\0X+9F?*I+CRQP<1P VF ;0(+YE^Y.G'/*+5F\4T\W=FD<L%)2?X
M8PI:C)*1-1W"'_4J4IQG;HE^"J0JWPU?7(8=M5TE8;J"P%=>$6]E9%L<YNNI
MP'5/9U0S;>IH;HN#2U<-3E5L4#H2BW9DT'4M./.# E6I ZM>A=NE8+S>*V]8
M$+#*POEFE<M1V1Z?;HE1<J4')Y\,LN_1R0E/D$N)MUN:^8H'7N,<XIK432VV
M/Q*.J.;7;(4<>00KN)@5>+7**;13+3$O&L%2I]647K)"!>VJB@+'@4?^!#=Q
M*E1P6G8H9C3Z4#B"XN?<('_YXSF+F1_VX^I'KS+?B7P)[4$"&[9I\V]PUPN4
M^-,E;#MCUIMYXO\ (YK:%JV!)BV6\XE"4MXS,.791)M=X+@)_)E'IC31"UN7
M*'$R^4:^K&'>M']4)"ET5)I!G(XC5OBS6A]5TX^OE%#YK<"3K2<Q%W3GRE=T
ML?L@4Y>7:_PQ;>=O5/6P2A2;<("!E@"1G%E/ <A7^*+&QMR''^>'%TXT)3M[
MXP\MY.K\_,I^$XM/]TW\%:&/(5?^3H7.C_*EK^Z&?*^"7'MK_%/?'H\_G<_P
MP]<5 \M),M^K[84UY=!#Q\P7:OJ5'BG+;*/3/4O$EEY"K@=6!^T0J_M+U2$(
M1-*42I5%FY:FW56PA3A?KJ*B/RPEM5RMAQO%SRZZ<QKW1>622EQJV6*'TB55
M6<Y9G"+Z7[?FW:.K#2TXXBI;)FV=A@W?+'F"FDN;H=<;12MXS<.TP77K<%PY
MJ!*9]=)$+MVF0EIT2<3MGAUQ4+5$QMF?L,X+:D@H(D4ZI1S;=@(<^;$]TYR@
MLOHK;.:>J.0^W6U\O5',M[<)7J49J/95."A0FE0D1NA=A=4O6P4>5G.B<P%9
M8B$H2))2))&X0%W+(<4D2!QR[(/EF4MSS(S[\]"4OHK"%!:?U#7H7<)1]=S!
M:]<H<4RB@NFIR6L[90CS30<HG1.>$\\NJ"!;"2A)6*NO;NB0A;+;0#3A)6C,
M&>><5^5$_P!2I=TY0E"!2A(DE(U 1S;ABMSYIJ'P(A;/IZ$-+EP3P%6TYF&[
M=)G3XE;5',Z'793Y:2J74)PX5-\IQLB:)SX5":3VPWZ>AJL**$N.3\)7_=#=
MJPR;F\=Q2T#( ;5'5"47-HA#2LW4.3I[(?LK6T2]R DE173X@#]\*M+ADVMX
MD5<M1F"-J5:XN%65H'K:U44N.%4BHISI$(OR3RG/ G\15\LML/*4UR2TX6Z9
MS.&V'7K*S#MHP2DK*Y*53G2(;N6O X)C[Q#=BTBM127'E?(G5VDQ=6]K9I>%
MJ0%'F4YY9]47%XEHAVV-+K"CDJ<LX%R_Z=_VI%16VX%$).,Z80^T:FW!-)@*
M6"I:S2TTG%2E;!'F"CEFHIIG/*!4H)GE. %* *O"#KA3BS2A FI6X1SK*Q!M
MOP*=72I74(+PL4\M+?,<FZ)IPFH=D-.+M$MVK@GS>9,[N'K@7)1RYJ(IG/*'
M;E6- P3M.0$%:D<IUM9;=;SDH:&6$HYKKA%0RI23*9BW9<1]&YX4N['-22-^
MBY_TE_TQZ?=K--O=6Y;>/YD8I/W1Z;=N?NWMYSCU'PCNB[#F"G64\B>P2F!V
MB+1EUUM;%TM0 "9$)3O[8]3_ $-?TIBQ2UBXRA9>(U)(,IQ<5_\ 3=<YL,5#
M6HB?ZC'J'^Z7%PVRZR+&:G.<N=: <\,C#%6%52AU%1CU92O&"TD?II_NCU7R
M!9'&CF%ZK?*FF+ZMSFOO'F/.9345"&W'OVDL)KGLIBW+%KYDK4HTUAN29YXP
MA;[/)=UMS"Z=68W0G]:H>3<&A"15S/E(R,<^^5.YMVTBW;(EPD?N;YQ=!&='
MV X_9%H6_#RDCM D?MB\_P!!S^@Q:?HA/ZU1:63;2GZ#YA]I&9"<A#J76%6R
M+]-24+_S$9]\.N7'IQ:0V@J!#J7)JU"0A*G X;UZX0[<+4@@8?A3U:H;N6Y@
MAU"V@H2,P9=FA;2O"L%)[8;L%U<EJ5!GQ8;^V+:<QY504T!NA)>!#B/ Z@TK
M';#=PX^_<.-8M\YRJ7PARZYKS;KLJ^6NG(2^Z%<A$E+\:SBH]9,..5NM<[]]
MMI=*%_J$):;%+:!)(W"'>5/ZRRXN>TPI;[S[K:E5>74Y]/N@)2))&  CS;*:
MF;A%%SB,"GPJW[(N+A$Z[D@N3RX=G?"[=V?+<SEGMA/,4Z^A/A;<62GNP@ "
M0&0T>79G1,GBQ.,!IXJY8(44I,JI:C#-UBAYC!)1AP_*=T2.4*Y#]Q;(49EI
MIRE/=!M#/E%OE3UTRISA%NW.AL23/.*6[BY0G8ER0^$*N$J6MU2$ME2S/A2)
M?=##CDPNW56VI.&.A+;LY(6'!+:F+5JF5FTKG.KF,5)\*99]?]A?_]H " $!
M P$_(?F\\_Q,^%(L#185= 7T.: %G[B$''3B>YTX5VMO*LJK?F%@JR)NQD.W
M'U-=HJS8_"#@0%>Q_:D3,CUU0_E.&,AHM #C1+,YE7P;;:/L3ATW&+D1\]"_
M&?O]3S_19PV$,QQ 5' ^QH'V9?3#,%M*W]0B9(M)4N^\BGN#4YK[K+<Y]J[+
M\HLH V><_P#-?S&-3N#T&/\ U)^H3L#U&?A,?J+\G<9@+/=@_N;>AVPZ?G!!
M/^@0?^A/QD(]-F)VR(S%CU"51=P^DM/XHGH )5X>#E]#<9TC]6']SAEZ#[%0
M@0(33[Q=GV8? CO@S\L&&98$I?7N'Z%0+=1+O7WOI% MU&6K0N0_E'B][(P0
M00(0A"&,DJ?TY]X$>SF4#7PY$$2S(Z?GW%</<_R %*&58^5.'1_S!!!!! A"
M$(=++K[#/N+.TNVYZ?TU\[*_>=C_ 'HS]I'+_3F""""! A"$(0Z_[:(>ULSS
MW/<[>WS-0 FX MA-..\N?;<+6W*[8(((($"$(0Z'P?\ 5RPVU9"<Z&SL_+L#
MQ]SCH[)AKZMOX]H(((PA]'M9P1*YC[PB[6!=D3NPDPCY(+8N"Y2-.R$(?%2W
MVV6#K/U'^?*4"W1N.URN;E _8N+#;J>7,$$$_6>)LBH 7RN%GB/*HFTD.:-R
MLT/K'8&8"7*[F/SW[PA\?CF/OQ&$VK@ -.3Y-BY?W=,:W5]Q?X@@@@E<MO()
MO!E7=7-$*"]$L9KMJ4Q[-AJHJB[<PC0D4A/YCO !Q?I%0#O8/6KZ4W(;1:OJ
MP#8V1"":<SR?]C_/D^I+?8_WI>OG]I@A(] "<IY>@@ TGN?O,']LWM/T6/A\
MPA"$)LB593V,S6R.4^SM.#6<S.!96.1A=&*_F60'8@&H?!8?%?;$]!H_?_KY
M+P?IKICYFAY8QZPU6^A7]R]5')R/(,H#O-9?NQ7D:.5+SR_XDI GBQ.5?CLP
MA"$IZM,.;TFQ\NT#3QC]Y,] GADN]"O@_>?NQ8?!\G\1_B/H._,K0T#[K_8C
MI;@E(:>-!1TT0:23.U+%XKGH%_HYA"$.FF%B\U3OA.X]!BBDI^ 5[G[S]!Y^
M2:[']/VAH_> E+*J]2NA^-,#PQ*[R#TMRKIR$.F^T= %><SH0W<.1$L>SU\-
M@GXA^_R7F:CN$.(78J>$2G8_)U!0<O9V\PT$;'720%,<KVA"$"Y0'2L %X >
M8=D/5_EPBTIRP^^OP].RUV^ATO>Z_&/DL#^4!C]WPD:HRYGXZ@S6+TQ8.3\P
MZ6_@G+*@$N,,H44U^F)4OUC<;:L#TZ>.&?7GY)J8:LV.Q/1B$\;/W1_),QU/
MW(1MN[X/'5+,P(-#"N74)GTA@A%$$89894%]D_S,%4>]+'XWX$]%8]_+V_WY
M=[3&-CXE#O/&.Y'H61YA-?R2MI[]'3H989-MZ:EZ8L<'/0$*@PVOOB<G.4SK
MO/IQ\31&S5L?05&JDHV":SC(G"IAE%:!W;AO1/1VEE<EW'/:1*,'!=%LS.(&
M6+##;U8^YT6_%+B=L="J_6:G/$_(/YZ%M?$"AC*G4\%,:9Y>QT18!E8Z.='8
MZ2:C;M<I4* 4!X(B!Q/JP**^)!I!:3.KE, ZT7$A;F@+-G7,P.+ 7L3-I7;#
M"!2FHE>R4 **5QYQ*C99[.MDG63&NEF8KS7IT%2],4E4M[!W\]#KT)O CM+?
M2H%NC<1>/[.EZ>I_ Z C-AL:>\J3._/FO=*^-OG$B*^M2_S"Z M[M0$)81"U
M:MG)]:C;V7$$1+'9&NTR+ZH'2D56H\*KHNN@1UE)[+3'@I?%ON3@CXP_N>\1
MTMH.14,=,"),=I89%E89ZHQEG%:]^SF?=\Y8BGAP8M\,"M!:Z)JOLG_09X.]
M<O<AL'N3/=8I_$S'?V3+:[HU:T+5X(M>S:QGT(Z6 MU+#H0"ON5^4K_T)F@_
M,;KG(P?!C\/GH)3D=D\;Y#[@Z?8@_3$T@+HX10U%T@;UK>F$C+T@@XA8:Q3=
M/&H  !0:('J$O6"G-YS"=H\O- *K.<11R<ZW<^"LQS&VNG5F>1B%X2R%P&C4
M(^Y:U8I:QT)S\^Z_=?Q_,RJ:.CF:;?2)#=M']S*6/L_RPK:1RW=YSTN63Z!M
M^T+"F#P=!J/@*T!HCB6WC=1,LJJ6"+<^+/!\Z!Z0CQ]8Y3:&YF(NRHRTT$XG
M]Q-9 D5O5^ 7S[/!3^$S#;UCW ?P/;KC6VICF*>XL]1+^Z/\1$K[ #]CZ<JR
M:5%T,99/?_CZP$6C<5G['CHM+FE0Z5?67/$?EU"A:"P^?J_#I.=Z Q4>1Z?5
MJ=M,2K#N&CM?8\LY(PSWQ%"W\5]6),FOP=XBG%SQ^U0Z'L'>4Y&!MLF 1\UC
M[SO997U;6>P/MT!CW)WH8ME'U@KP%^SI7HUAK\;_ 'ZPTG8_=E%WGK/N _I[
M?67;HK^\72QED]_^/K 30;B,_8\=.ACGF%50T?67/$?EUC.?\(K#W/J[7DQU
M4,SHZ';>'U;6>*>FZT1='X7U?84E8>^RH>NV[%NT(.DI)G.^89^NN[]X]8CM
MQ+_XNFT9MC8U[&59K2-+U9;<TXAVD-BP5\5-JF-!P(:[A37:5/.V-+L!?(UN
M:MP@-50>(?6)=)!"%[A;T30*%CV6/?9Q.7+U^HRHUGF8*-=C!$\'<7Z^9P%K
M[1TK+!7WI;YTO4+9)DJ^ \"U7OJ//*K<MOH-5<.K=:S.MTKRTA9V9:XC1+SI
MB8U!S:XB38J9TNC:59;957C, RZ+F[<O(H:_&8BAO]:N0>3=2@Y8".S[-*O4
MW3WVTX0O=SU_VR5ZUB(M#@G>PO*L[U%2]K^\=K5])67Z@%:-E*5GXQ0[6<,#
M[)64N0::R@!QWN"Y\1LX'J_C$*L8#0D"@MOBJE6+6>1?<$?:6/IO;@;8=SZP
MA1=$=!.<J]8CS'S+9]BI&[DJJ"&G8UF)M+KLH"PK &^TSD'QRG1[ZA8?;-7
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M%14L +ZP3!SVA:531NM80=85!@ T!T%JR&V3;($PKE,;#"J0-5M\67#3?A$
M6L(Z26BXRU7T+^8W3L;7=S.:YG.:ENGEQ.<9[L^ 2XX8?2%8-T7NQB+_ )8P
ML<-C19T:4W+IXN'&8ILSW8C;U85_P7__V@ ( 0(# 3\A_P#1U2TO+RTKZD^"
MJ5\!^ED! A-'PUTI*C]>%^D!3\U(GSP=.;YZ=#\PZ"_H1T3Y9Z''P+ ,KT7Y
M20_+/BT@74V8J@Q?TK;IO\*7UA42^J"4@>E_#M\OMT9:ZGKEN&6?&5AZ5RO@
M/S/)B7'H C;IZ,TVV6MVW&[SX:B2O2OGO<WZ&J>>CJS<MCXZ/'XMHA*<9E9?
MSV3;IB8ZIWU)I^&E1MBW%HX>CV17\V+8"8O6I9%'75\"T7,]T.%Z,P_F,UI\
MS7JZ/R^_Q;9_J)TJNR'<=:"%E_ QF>471^2-2SX@#YZM=Q!EW%:5'5N^M2HI
MX@2O'01?+J8/P[D/AJ5- 1.53C.N_0OGQ$F_NA N5*E2YFG1*Z'1:Z+YHPU\
M&(Z+!ZS?$JG15S ]#X:/G:O@)A@G$VMO3LZ6M^.BOBL^=CJ,<H3@Z#&#]4':
MQ %&OA&,(_06Z$KX7CX>+ZV5G2@N+?UM7_V-A__:  @! P,!/R'_ -6 Q?P7
MUN'TIB^E_(7T/HCT7\L>A] 7S[Z+YRZ/SSHOKQZ'RUT?A26Z5\HB^AVC&";?
M3C\(]2P>I:5%=*^@'K0=%D3XM)>2;2I>/@/F=3$.S<);&6?$P54WC7PW!ENE
M_ ?+]1Z9^WH"4S-Z;_B5HE_BGRYZYR6=6;_ANYU EGIZ'=$KYU<OK?\ $'KM
M^ +F(Z+[XGQT+9T/H%FDZ@]*51%3UM8KX2"GA!T/DL3X'HE]'4#!V%S %'PG
MZHV]X?-#X'IJQ^,MH?'P,0@^8.KTU>M_!C#;]2V'1TYI&6!Z:F2Z'POYSOX&
M5D"SV_1KZ5E.E?$?HH.C"/:Q^"+?PATGT"NC ?#M_P !6Z4KH%_772TH_P#L
M7__:  P# 0 "$0,1   0DDDDDDDDD@$DDDDDDDDDDD@$ $DDDDDDDDDDDDDD
M  DDDDDDDDDDDDDDDDDDDDDDDDDDDDDY2KDDDDDDDDDDDC8I$]V\DDDDDDDD
MD4^DVLP!DDDDDDDD#H7.Q+<1PDDDDDDDUEQ&5_8%TDDDDDDE.PYV);0A.<DD
MDDD> .(RO[ %$1DDDDD)NCX,GZ$!O?DDDD@#QU"/%8 H/"DDDDC.T9<%?75-
M_=LDDDG)+5=O["_^_I4DDDA/O8S3Z HO]K\DDDE>1,QW8@+<]I<DDDAZ%-*?
M0EWYUJDDDDFGD%(;$F8U=)TDDDEO :])$/1%+],DDDG0$YD1%8>>U(DDDDD&
M"IP8J7?OYFDDD$ 'FV\V>BG-/\DD@@DC*=4:<1[D%$DDD  D.%5D0&';K$DD
MDDDD&1CO YZG.DDDDDDD&E!_*X;HD $DDDDDDDU_2@L,@ DDDDDDDD#9$DKD
MDDDDDDDDDD#KDDDDDDDDDDDDDD[,DDDDDDDDDDDDDBYLDDDDDDDDDDDDDGI^
MDDDDDDDDDDDDDC-JDDDDDDDDDDDDDGG8DDDDDDDDDDDDD?[\DDDDDDDDDDDD
MD;;\DDDDDDDDDDDDD;=$DDDDDDDDDDDDD[ODDDDDDDDDDDDDD_(DDDDDDDDD
MDDDDB]<DDDDDDDDDDDDDG)8DDDDDDDDDDDDDSM\DDDDDDDDDDDDD'YXDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD@$@ @D
M@@DD$ DDDD@D$    @@$$$$DDD$@$D$ $ D$ @$DD $$@D$$$D $$$ DD@@$
M D@ @DD@D@$$@@@D@$ $$$  $@D$$D  @D$D @ D$ D$$D$@D$DD D@D$ DD
M  D@D$D $@$D@@@DDDDDDDDDDDDDDDDD_]H " $! P$_$/FI00$<:&TIB;X@
M/T U5: Z!L:Q@[@QG&3GT[*CT_46HF'3E!0@82[4#OR^IKI0Q"]HGHAX)BI.
MMNK-'I"F-A0^KX:C%ZK;@BN4V+5YK00KE+:U8PPRO:@-$4E# >M9<IX,.;H?
MJCU*(+40-K#!+ U%ID8?FQ.1ZF=P8K;G;/@5J&K"P7?$J$DD$Q56=XTT7 6I
M4/.ZT%@.B?;!7P>%Q:"8$!M%W_S7VS2_=,1F[(_-5 .+^0?RP1S7RC^&8S*\
M _-5-EO8%^Q]0Z*-I1^9;._0IM^)9C/XOXR^[%5MRNV?J@3ND2:N?#'W&+49
M/!^[.:O7\8P4;-RA /\ 59U[2M?S?D#9^84<-)9](W1/#G-Y3;X)<VN#H]#1
M+V=L;])M>T71:#.^R8]X><]R?LK[PJVY7*O6C&"L-+]P$K.4OVC3^(9A[L3[
M._:6_P#)6GPFF/T6P<KQ>GZ% @ M7 !%N"!WX=A^\0( +5P 1E!V%:\7;RX]
M8V;K8I[OP@1AA@C4)29$PD>M:.UZP//0$12U/GU>Y#3@+#(CR?/?,A1<S@_2
MX% JM0!E58M%U*TG+R=ISSV/B(",$$$$"6"M[='ZY@!,:3:[,4\AS\G^7SFQ
M(\7+QZ]%!Y:=IS5[?DQPW\5!1AA@@@@0A];-< [,8:SL[CR/DB9$5MP?N_9\
MSFV =W@]V+C:$]813:LX.'8_PYE^ZI4;5<JK\9!1@@@@00(0C7&2F_8?[E^H
M">28#J^@;/O\N]^/O6GL9]^ES2L<-3]ZO@(OMAU " +P+.JZ$6%^9B .\[@#
M;$U(AH&$3(D+""B%1M>Q+@*2D\D$$$"$(0BVM^YUI]R6IQ>U9/?]GRG34"KL
M$W).#L<'L3\(3C?PGD>&"V?N_ 0?M?W2_P# 4V!KN">':!D((1'38D#8'ELL
M*99^#Q+K?\4PQ,C(77,'ZSE!! @0AU<VX[^C/])KU0\TZ]XVMF)W$L^2X30@
M]]/XOH[51>PG[GPP <JNAL"L@DJXPHHL*CM;-4F'2[RVL^(L\KJ<8 "@#@(>
M;5 -BL@3AFP)57=;@@]E -*761&S"!Q6U9PF-W,X>BHG=.AZ]$4-0*2O!>77
M$.FAY>H-S*T 'PYCW6[5[L?L^2IW,OL=" #@+Y+?XZ#^5 UJL!@U=MA]@Y])
M@>/C]\G,>"+W5Y<64P,L2O8X$,$$$$$$B*-"(;UN(!]1N:VV)4%8N#:5DYH7
MHXJZW&)RG/4-=UGPB935044!0'I\#*=OZ'I'>)]MI\DG8 OO_CIL_P#J, H;
M+!VB-4'U4QBQM*8,I6KW_3LP0U+=T&_O#Y2E-L>O\,+.@B&%7D\RF.]CW5#0
MTM/[3PPP001'*.-K%T>-1; L0LOR2^HP$@[H6^\(1V@"N 9[5\.S=HM]E_OY
M/Z3WBR!K"SEVA9.$' ;_ "0)F<G=)C-2S=[!]W[RRH#D-J$+YB<5'D-SE"L\
M4GV00000)^,P6%JJ[P/S+#(=C67!!PE?!0?"^Z8<O8%>OR2#]K[@D>5I;WS#
MW71:;*/W@ HT0UBXESB?[@-34N26P04QGG3IGX!^Y!!! F<\KR]H( %!H)4_
M%=Z;_$+&S#-H+9L[W&N0V&D=/7O$IZAF9/0/R?DY 0GO<'!5KZ1A0'!:E'=6
MX8VX!M3-%Y'&F:0X8KZE\B](78%HTC+8_P!#SVGHT'N0001D 6N A$[-O=Z5
MC1::U=L'B7SU'G\(=D'*+KV:8LSK%_:_/3%5C\L?OKI>)E ^*?N'Y)WK1.@:
MWH>4)I-6"_$O[P*MIA[WGTAH(V.1)?'MPT.Q[RCEH>!PGB"!&Q+K \QU-'S_
M % \ML008<+8XM:K+9"M:&7%[>\)*L6[ Y^[ 5HRNB=Z!/R?E\E-C?:$^K )
M+YJL!R,?H"??":35F:\*&!14SRB\=&\G>JN8?Z8Q:U2]>SE]I7I?/[YMA<R[
M;^^X,&'WGF@(->=;?>FB!S7'&L&\)!1A4Q]R7O-YD_DF6E_T8_#Y>0<3L8S?
MTXYCJX:?-_[#B:PX8%[=_P!B&+TSWZC_ %+OV7\]%45VQ$"$<SS32A. +Y<$
MW'(&'=?QT:R;9,[=6IZ5!5>P'WE(=4W;.#[9^($(3"@M X&LPGA'['UVIAVC
M-(A.EJZRY O<K4A(9#"$&_8IGS62 I?X M#S!]KS15#C/!S,\J3O<N/3MB,K
ME:G6L31F-]7XEXW7W0_H>(Y0$M6SX@ >(7>*5D^(GEK]V4C.@G(;?XEKERQS
MJ+V 9F)L5=HT2B&%YG@+;/V/,&Z %-!1IA%[7W?1[$ !@"@^('@>-44(LN<H
M%1MC*$#$?NUL.U2S 6&.':VO4^.$T(!4#18I9V$!==-1K @;QD15"('.&#O9
M[Y'A/)/8H1=A?XG*4OTB"(TFF%O %QJ6.R\O,Y0UO*/OB48!VO'VU,YW# 8/
M3I!;T%IX",;P#P-=&0]D/O\ R2FI00BP<2J4&0-(RA[-H6&B^P%OCM\;ZT4T
M-JK+!2557IC +?,+F0,#H MKBXP:&SS:[IDL[P^PD0L1PB,PVS*K>2/1G0!P
MT)?@S1C8\]-(0CKD0>XQYM3A6I3]O8M!Z78P2IG /Y$%A@ 4R35*VLSQ X+1
M;>TL@*.=$2@/ VOJP*2FQE5E) J]#JJ8<#TOD!U:U=@^<'$;3=8P-"&>]]R'
MG*H"U70$26I'@H*#CD5OO3&1><A'U!/LQ2%6Q!W -<!,!#<K(7ZB7!ZO0_F8
M39%&WWB.,B+&P8Y6,)7:K5Z+4^EZ](M)0+67PIP5\-1[Q<#,HM/9?QF$!:!D
M'(@/9R._SW1@$0L1V) 1@J6L[:C$$1+'",LD%SS7M_"(6UJ,MI=GI,1TC"5#
M"K;KCL^XY]^BS@VS&=-+J-V=F6Q8>;[0^PJ H T 3.&?L4)=6VF;AQRXLR.[
M&&Y>'?(#18>4:_>(-)V':&6P5!XN*,V4I\$H]OMN/E_$#C31. OY[]0!N%D#
M;%*)4,N2$P\#G,5F]U/A%%/DA9^[+_@?F@80=&RTVS>WMT,/[WHRG]/RQ/3@
M@Y6>Z\O1+WBOLDA7,IVNLD+GK"/:925WD#!XSQ:+K^>/AOP8KS<8_P!=^2@&
M)VOA!8E<0:0[&@7Q?S_)J7LG[1#&CL.Q*QB:,K@"4Z=#=OTO?J".W 9*"4"&
M]W#(==4P.]F?NACS@90,Y,Y;>?IR&M]@-JPPE YCO<K!UW?3]_UCXT=KP3%(
M..T-$J&#82R]CEA,:6/L-_GZS*7*SG@>TI&5WF7/]0=I9V ?N?Y]73VV3UXC
M*I:Y5Y90.91WH=3 3U0+[7_?U>=)E/)DCMP#".QCMVY>#E. F>T5#X(;_,Q$
M1P0'U7_/JR>+B70<OXEJ;SAGZR#RZC9]3M]XF%=L#O/<CAE5-@/58@BDPAW[
M'@^K/EBO[ 7]UCP1/:2'A7,=M2KE7:QP,#@-Z?9^LNO_ $#^$:T2@E0PVV[.
MQI]Z?6=ODW7('\1BW"_:5C%6C*X E"G0W)V_5OZS@HWG5@_,,)4.8[W*Q==W
MT_=]8^%':F.6\=@:)0,LK2\]ARRGP@<^5\NWZS*7*SG@>TK&;\RW'O\ C@3Q
M</W/JR$[!Y>?:.JK:Y5Y94.95Y'NN[%@GF"W['U9.^!ZV2D<QEDVX[&91'@B
M5GP^RGU:@(M*=-['UE^!YC]UPD[>= K?/JQZCRN$:9>@%K@".AI>YR_GZZM+
M2#5@:H[@<(>#1Z!_XO0R&.FK;F=1^Z0K*U7,HAD0Q0V.@7GIHT:JX]+6DLH2
M0.TM1EHJ*!8XYUJ[0)R*NR:?<G !302^&\T?-/FJM\!N^SO Q^HVII P=J3*
M%\$!:N\=<9 UQ!W-56VG,%T:+>M0CNIPPZKT(E)5;JJXH$MV PP7;,<H6Q9$
MQBZM ;[$,9V%9+/D&)I]*W 0K%-PX'-:RQ%0.U:JEJ=W68235.?/\9O.R/R6
MP-O8:H%P(8S$RE0*7QH-:EU!+H.34VC.R ;A%"@I(0-I5V5ABU"'H3,38#V/
MC.!ASHW#8V+HMJEH1G(=BC!BSN?CM<O#_KSNRL *&U;A$&)6<E2#SNSCXW6*
M^I8-0]E>T;BX $@*V8W@XJ#(1G&Y0N 8U^R/H+LP0)!+1D&!EC&@0O4<!B^\
M!?:0H+&[A8X]4HE085T.#=0NT.S*STV?FA?1E+T$@&F,-RX42Z:N1WQ H\B#
M?<+Y*<._Y189T'%I$0L&-D?;"G1:@M31K4M35R"P4%*KL2J R*T19._]D'Z[
MJ<-WWZ>(I0#5(L5695:-9$XZBT=KSIKO+@>KH#2PY<NWB5;.O<MA-C"M++@_
M\#0Z"U<M7G"=>A(ZT!5"V(T\08K QY6)E@W"K# JU:AP[K::#L4E@QYG8S9"
MC)V&3J(4 UJO9Q:^-@F,$.\I3?$/L)$+$<(C Q&J72[: E,N@$S):#V8B2PI
M[8!$]8TVF7,I:11MP3<6(>V$*F>&!B-4NEVT!.7),MV)?>60'J5Q39M^_3+E
MQSKHVT^LHM$W#@$#YBB5((-00*'!=SS(OG[RPY9U'!4-ST4&A6J@<#/\\B K
MP,3^,/:0+?6# $!#3=4\ARY@T<"=&@(L[P4,@D#00"TU<;LJMG@HVWY8)MZ,
M[=)"?@EC0"$"DP!BBH7-<M0^P@ H P 'PY>#&#CF_N03S8A=+X[GK6XOHHU*
M6O\ !/B'HM&R$8JO9Q=&#-PX6L$DU*%:[S8[[KD<<PQ=(Y4"J4RR! T4]A8E
M%245N)0N6]MX@P[RIYG\XJ@';I J!J(MWU;JYP!.^&BH,EEU>N31:_3"O07$
M)1Q1M*M5P4:@67LQ\025$SGQF"BGD2M@ ZN44A/6JR- !*,\Y$5B6A.YQU9Z
M^,BRTO5$J;4%JF3O$J#2UBLI85FF/BKC@A6!9W8]+Z#3JB# 4:G'F.:+[(:F
MJ%)-:,9J4^6#=+*8NXE\P@66J*UR*1;5LS SP)2E5!OSZRU"\"\<P#)BQHU!
M]A#>0S,U2[9L=2PY=0 1/)$ZI')>JX\?C$$PQI %AH,B6)HH%,WQ;FN4V,8Q
M*B0/"$@Y^ F"9%C@%O$=\L\ G\41*>8^2#=2I9:%=,='82@5@8OB+?1&#\Q9
M*ZN'LWR7/WFG+^H]<1+[*[[L,9?=,0-M*(289(/-C"[HV :&6/A!P8DRZJKF
MO1>-WUW8X>>NJ(4N(G83FY]1E4/V;/Z]_H(1QP@ .18XJ$[Y3/[XF3UT1( F
M*'-EY8G^CD>58K"N,&K]MZIMMJ:.T];$2T[D'.;N&D@!H6@GG13$T<?'TM0P
M[M9XE?<CO#6OXEWU'D-BA ! V#E#1.545I?8+JZQ=1>0V*%$$A0N$?DG^BP&
MRC2&?S<72MB&5FL9<;RE]R,-(;%6;QABH9) (F4&Z#6N,:@S#72!K> 7N 48
MF0$1*"Y&#KA9%2FQW,:0;&N,DCU&.!2$=<<[@N)6J@(C]5 !+;@5+,1;MC /
M8Q2*3#=HK#P]!ESC10MP-V.E-Q8FM-0J:#!VC_ A9BK8F;S0G[46.63W':!O
M02DRKM^T0Z!P:@#  2NLDB2QZ@",>(NLK91OXP3QA"##Y2AW  $.CYWC1I05
MF!]CXB-$IWR*T&"71-5=I9F<M5Z*.AD$\:.\--7A*>SW;CN%]CB*]L)W:,@J
MF8_$NVB<%90#(XX;<+'T3L H(.'8+W%WLE$ZX>-)B67+<S2" .Z/1::)\B$G
M2.Y=PF,U+.\@?Y$TX-8<UF*OS6DAH :(1O:V)\[$ RL-^X-*JO4,JE2V*=D!
MZDJJNHT46**8-=(=HP.^XQ,+57&<YG=Y"5!C$/[RQ #MU7*0W0IX7@#I+!PX
MEL!AUM&]<K@_$>>DKF"]V_2:5QGWU8+?!-+>T4%*BLFIL9#RQ7H$P1[%E:)Q
M5JE\[@8NL5'57918SQ%J&WYNLK0\+N6^&.(,+MMOM UB],%6J:I6U@S+Y@?=
MS0)\3=G'2G-R_2F/NNI>U@U&;;S$*6**VE<]3;)#9CRJA_>C?6RRO O:(%H3
M@I)V=W3'=V8]A,R1I,T%G;I :!""TA3U;B/;WEESGL&ZYQJ16A04#55)U@H]
M$#D AUR$%&ZER[H*7AC=LW[#PRF?E[E+"3%7$K%2O(@=A2 I/U3$I%T2!3B&
M7.U7&A:?\@5)SYU'*U"""T^%2 T!PW,Z0H%^!#)O@U/U7LC9SOH7D5,*9#W1
MK9/8BJX$L_T@8H9;<!P. @<0V9IP#RZH$'ZKV3;"PD6%1L'\(?["C<F4[-YP
M\3%B?4D,9OEP#4H><8-)'7<W-=@V:2T5O8IR&O7H_@?W5K<1IK"%*4<*T<DH
M=C!Z2&,#6P!@J&LO:[+>,<7F@EYC"9I@%-3$UJ(NA*4[2M4;=RS%K3XJ6J,Z
M*/%P6H3DD.5N5):KMN6NTZHE%MKY7+.&D[K5IHPP1&HK(F5T71)CQ@!] P %
M!*37A#Q32J"+(6TQ>48, -9!G=K$)8,JC+ &3Q%+^U?.J5J#C4,,X\%4!@ P
M!T?U,'8W@-8[0.,ICGR(<T)G/!+;$CG$L!6H85;4! 5&%!2([&68PWXC*LZ\
M-1N(U7;)0;[XW&L1T"@K@ N>T&@"AX;&DM@P/X **R[R]R!YB# 5:]5Q7171
M >8S7R!*7#;8P;86J.!PV5_P7__:  @! @,!/Q#_ -'"8=8&2CZ@+B<P!T!E
M^TOVB/1#.Q$KZ1W< U$=3NP+CX4,1Q%(AW'-?14Y>G*P*^5V8E2W)]!5EZ;C
MOYH,HEV3YU^>G,^?9$J4Y^8+:@42]]#81+E#7R^3I5;O\ !;-(Q%I8-P M^5
M4S!?RQ14"VIKX-L:RJJ$?4E9PI<!D:^2+(EE1^2+Z!8^$A3 HJ)5;<P!1"%/
M7>,P7>(C ]*W7/5.AKY(Y^ 0%L\<=YYJ)_R30<)\3047%C/,! [JF ,.WP;P
MY/D\^C:+GA(7W*%H(=\0G+/9W/M*_EC8/,N$NCSW/[^%*W 2F -]$7?/P;34
M^3SCE7$P$J(?=G^8D!M0F JK+UO_ *A&/=_9^+\U#!RU[,SO60#KX-IK\E5<
M-$%B,!.?'K$ 4(G13\W^'X6_Q([_ -1U:VP5X+_'2G.T$7U6V/7R5HE"H,$U
M&,'4#\^(B1*2)!J._7^ T6B*[]O2+"659"^/]B-"^@_NI5"IZ/\ (= Z.BS\
ME908,8]"/&_3W[1QIB1A"[0]K?QX>M8=N7T@QZ*@1D,U^KES2I9CHK;^2ZLA
MFR#&/5$#(S$B2F,K9W_V$LE\&_\ />8PO)R_U^\3+:E2H000Q7-_KO" 8-)0
M,S!J5'RVD;&,KH,_ABB1E2H00G3,;GT!E_K]YI;/=S_D"!':FERY^8_1Z.:?
M@?PZ$P-]!T$$PY_.]OY@ HUT$"5+B.V5%?-H;CL/B,(,:EH4^_\ U",4['[9
MFIW]_ON5NJM^L6"0&5@ =\^O/00(18L-6<_.?V"/09JK24A"0QE;^(04M[Q9
MAS&GK_D%*D"!%J7+@JCCYPMNSH!P@S0.E3.W,@X[HMR.PQ?O  4)<6X'0&V'
MP?0LH4KT0W 3'PX)+EP(1##W^F/@( T]&6@0F416_3'P/4L740+N.O'U3_P#
M_P"0/UQ_SI_P!\#]8=7_ ,[/^!N7_P#K;__:  @! P,!/Q#_ -'*$I*RLI!'
MZA:G9BWK9*2^@R=V#?TE$4Q:C*OPBP@#!26;^BXCH_+=V#*L/T%N#HL?F%(-
MRG#\ZG'1?/50;G'\Q:(MQ>C\^I@U%9\OBZ+X N*;((748)U\IV3B^6MO5ZZH
M@O-W'@EE=ZC2D?DK,&GY2HZ:?#0W%N#KB(MLH;ZII+W7,%LZ6J^.IT6/DO'3
M2,"YR,L\ EVS[2O/'Q 7< @<2\N-V13GW^#2+Y/#HXYQ*[V/YJ++4&,88[\3
M=Z;_ *E% KTA/F?CX154H;BW2U5\&ORG"&%\S,Z41[808B"QE$;M_$8;_5S\
M6U&5[*]<2W$1-_!K-ODFZCS'72N@ )I@]7Z7K\.4T?F %&H3/.72S&DO5U#$
MY?)=%Q<R.A$H=X:6:@S<->A\"(#;"(?I@1A 6X$.M#U?Y<%M+/$_#T%O0X^2
M<='H3:7^3^)9!@.^8CV=<@XU" Z7+AR:E';J"CY(LJ.,>AU.!Y08,J;OAE4J
MO+J'R[],?K\2L%!+ERY<+[]D9*[@-QR7!;\NPB=#J6#R0082Y<N7!L@A,&_6
M;1H\8B]#B;R@^92]#J_8_P QBAEZ+ERIDC^ BJV]*J,"^@S\U+(E,(] OD:8
MPT/:OOB;H)<&[U"*"W1%3[/3H>8]:EQ7SMT.IG80ZT1C8:$8K@[0G<!WZ2H=
M02I4I+^=FN$L&94M>ALG<BX&8J50QE:VLJ$>BNH/F"?0 ..@NHPY^$Q4J/2[
<+],_ RR6ERHRY4"BOK=@@W$]]_\ A5_^.W__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>mgnx-20181231_g5.jpg
<TEXT>
begin 644 mgnx-20181231_g5.jpg
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M  (1 0,1 ?_$ /H  0 " P$!               $!0$#!@(' 0$  P$! 0
M             0(#! 4&$  ! P,# @0$!0,% 0     ! @,$ !$%$# 2(!-
M(10&,2(R%4$C,S0U4!8V8'" 0R0E$0 ! @0"!0@(! ('" ,    ! @, $1($
M(3$005%Q$R P88&1(C(%0*&Q0E(C,Q3!T6)RLB10\.'Q@D-38)*BPG.#LW0T
M%242   & @(" @,            00!$A,0%A(#!0@*!1<0(B$P$  @$"! 4%
M 0$  P$    ! !$A,4$046%Q(#"!D:% \+'!T>'Q4'" 8/_:  P# 0 "$0,1
M   !^J         \D<WF34;R*"4           #0?.#Z&<0=04)%)IVH
M       !QYV!P1<G G0EB=@                          >40[1%M75,>
M3T;HF76TNML@         'A%3I2OO6):*ZT1YC!NA)B9U9DQ-E2]IG;TD
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M]%MYH    Y28E0A2VEY$S0"DS[OFO)]+4VY=<U&09B<@EQI:QIW?3X/0[>:
M   !S2-A9)CHMDY !SV7I<%R_05\UCSGK4RG9%I"\N+='IP=ET>)-O@
M-9J)(   -,7Y[+TJ?/MB5V](GWY[6_'>:<$BV8         %&<D=0;S20"T/
M!2'8'$'2&DK@=F        #BBN*L^@'SDN"P-1U1S9#/9+!VH        -)&
M-Q$./.L)()Y7$LADP&X
M%8<\=:#<<H=0#60C8<X=< #DCHBH.@(9/!Z/8   ."/13E>8+0CD0ZL]$(^A
M'Q<WEF4I*+0JRN.A(Y>'7$T   %66!$*(LC!6EH:#>;R"0"X-A1EP1205I(-
MIX+\]        %(0"&69%.L,@            BG/G*&3LR86H
M /!$.>+<@G3        $,I#V=&9/)Z,$0F '+FTC%H:B]!%.=-Q+*TL2\
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M!1D(<-M64P<AAF?DXZI./P68@C'>Y' _%3#;?EXO_(/:'\-X)EAEE!Q\$O\
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M*-@_\0 H &F83Q:W/WX9IHK?QWE",OR"N7=ZW_".HT(#HXC:ME\+XCB9J%6
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MI8]W1'NP8!T#6_,W/7SN5^H),(D-YQ(W9CYSN2FWURJ8^82*@H.A_P"$_]H
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M*N-&'IW\-O=&G\\E^ XE<0\;U$+IF!&M(>)2U'V5_LK_ ,3'EF.J</',J+Q
M\BKF/DTX4TC6S;M,[4)E-['=><4I\(^ 'D57- HKR5H.9&0;(V6X_P"1.G_J
M9K.LP7D_0KER><RY^'J\RMZ^?J=OH<!R\_4[?07$Z_0%G] +/T%?+Z#2]?QY
MXF4/H-+U^@7;] L/O;SI.YOT-:]8<>8103*[?14#O*GR@@5/LB_H]:U1 13R
M"5!;@GVQ?TJ;C\(39D@14O+P<)H)SHCWTYFU4+HN(ULG6^&/,^&;46.THFIK
M_P#O7__:  P# 0 "$0,1   0DDDDDDDDD@@DDDDDDDDDDDDDD@$@$DDDDDDD
MDDDDDDDD$DDDDDDDDDDDDDDDDDDDDDDDDDDGW?\ 5))))))))))(^H2WMIY)
M)))))))%DN-C^"Q))))))));SCM2^'/I))))))-?YQMI4T[G)))))(XD<=JX
M@YO'))))))R7.-BNB0(\I))))'D#J,:^@DE_Y))))$2HQL>V! U]=))))"<=
M1B-0(R#[3)( ("=&P"X^)&];K()((+,'ME1["G1:G))! 6(0J*CCJO+;#)))
M"ZBXK239!K34;)(?G4)2Q6\,MC_89)(!HJ+&9FWWUH1D)))G)W, JN%E5%#B
MI)*6?/-.H,L@UX@9))$!=^DI+/(T2WB+)))Z@=WEE6Y#S01I))(MF#4I>KC"
MQ3+)))$:9GH>/]^2?6Y))) %C8OQ*DKP07V)))-L^M3$] ))!77))((+5G\:
M%W9)(7KI))5U*8EUB>9))&[Y))BMW!2,^B))(#SY))_3T^I3$O9))&3Y)(VX
M+5F\+9I)))[Q)(6GQ*>ET[)))("^)(S4LW!:ES))))*WQ)$13D^(E9))))+R
M=)*>(:EZ!)))))/]Q)(>0U@<I))))) ))))*;L*Y))))))))))()() ) )))
M))))))()( !())))))))))  !)(! )))))))))))))))))))))))))))))))
M)))))))))))  )) ()()!  ))))(!) )!)))!!))))))!( )!(   )!)))))
M)))(  )))))))))))))(  !))))))))))))(! )))))))))(!  ))))))(()
M))))! )!(!()!!)))))))() )( ) ))))))))))))))))))))/_:  @! 0,!
M/Q#Z(%M6(+FJ@X% S&H72:EB0IX6$W5 )@U@ +K@<-V"6G*0<L?@9"U* JJI
M>GU(I+5 =NE6QLPYWN0:ZM/:8:5J4/:O,=X!H0IBS251C8-%L?(W02NXN474
M2%*)4#'3A;*+0I:<7.HV+<JY?5QUH>DC4 6-F%X5Q_:T!8T;-J&>2BRAI72U
M"S1@QA1IY,!M=H+I&A>J@R7:V748W8(;R$K=;5K08N__ "W7.:!\Q1.V:]U(
M_P!+N_"-.^R[W/N+]3[(OJ(>CG"GP3\HZ#K88]RSWA]YT01]3Z:G[9O5Z!JQ
M1[-E]C0^8V4=45^9>@O+?\E\(\HC<(]58,8OK?A!4:WC.I^4*T?=6@O4;^(3
MD^1KW*CNPIA[FC&LP>5]GI[0+I@2SZ.VJW_LO2-D)NZ!R#8BJXEU7I=A[^DN
M2>BHCW'I1TA5MRNKX C!+B)A,C.=E,KZ:HE-5=A'HA*+0([U%"NM]H^>   :
MH+V+OZ%WR ?Q/M4555M<JRK,+)D6CLK_ ,<RR)JLJ7*JZ^&",,,$I%I%.XU-
M" 34K-AH1!K"$3H=L[Z3'DN0P'D_9Y^8,67I?XBJJMKE6;G$/)>J<^;TY^.@
M+7YP#=@MFC8Y0KSPN%'PL0J]:FS9HRY@HE5%^X8/Q&AR'L35EY9GK5Z,'O+]
MJ%O9(2PI!V>9T?-:/%=<W8.[&"MKZ!L'0AB6<MU7P7WJ7[JE1M5RJOCH*5FC
M[*XN;.S,5@U,PQEG5E<E<UA1>;57-:T1T+<7-KVH4:<Q*S+KU8E0./:;&O+]
M*1\P^VD7'?7V]):HZ7NZ_P"1L 8#1')YEG]'OC!Z'YX7#S3M?0>L]J\= 1AY
M^"M *%"@5<>H!L6-EL6&ND5FHKLK"D!T)?*;V8QR][)MJ+>W4]5EJMP',MZ1
M_LZL$9NP*-1)VSSD-?[$67J?.Y/1_/EZG.[0N:X6[BW-9@O<>J?8KQ] &&&"
M""8?=FK"-ZO@E]N,^\([+'^1^+B754/9?#R[$/PTR_'!B&J5S*/SX] 1A@@@
M@C5NE8FDQAZLTQJ#J-1J#2U\-) #T;A)+ 1Z,9YL>N_R\IV[A$[@.!-DZ7I^
M/0$O&V@F8H*NT"YT8KW0V.6T5%X91K2YC+&(]]H(B<'L!$$"(]11-B:O1!,%
M477=@%(2A!Z?4E!MZRU3-356SVXJ_E/NO2,ES#L#^<0G@D#@(65FA,VTR6HJ
M!?&AWY0VF:(UX!"MBVAY06%+8Z%.96X,9TS+:2-J0-I# +7#9%&T&&ELFPN
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M$F:C;"O88.-#\S\C]3[QSXIPSJV2*O>(Q$:?I1-5J8U7<0A"912V72@!G*"
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M(_:_(BH7\4UO8)U!DK0'UE;(5V(#6I:\7,\_L-0V/,LG0(#0YC'0I-66.NT
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2<H_LTC\K\X^(I:?;EI_]Z__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>mgnx-20181231_g6.jpg
<TEXT>
begin 644 mgnx-20181231_g6.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_X1#R17AI9@  34T *@    @ ! $[  (
M   -   (2H=I  0    !   (6)R=  $    :   0T.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $IO:&XN4V-A
M;&QO;@    60 P "    %   $*:0!  "    %   $+J2D0 "     S(V  "2
MD@ "     S(V  #J'  '   (#   ")H     '.H    (
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M_P"%U>(O^?+2_P#OU)_\<KSRDS1[6?</['R__GTCT3_A=7B+_GRTO_OU)_\
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M$2[41>BBNVE1Y'S7N?GN<9S];I>P47%IZ_(GHHHKI/E@HHHH **** "C%%%
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MQ'Q9\27GACP3]JT^\ALI9[J&W:XEB\WRD=L.P3^(@9.#[T >>Z=8^"];\9:
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M=!Y([B*,\.KQG!_$9%=W8Z[I>HQJUG?029[!QD?A04:%%&110 4444 %%%%
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MVE)#M=I=8U+:5LEXR%7J6/Y<5Z+5/5=)L-;T]['5[2*\M7(+0S+N5L'(X^M
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MO"R7>HWNI6D[PW-W:K;2IG"2A6R">^<9'T-8&G>"CILS7,]M:Q1D%72-5_>
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@!&&88_E6I110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>mgnx-20181231_g7.jpg
<TEXT>
begin 644 mgnx-20181231_g7.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ K\2?&/[?7[1G_!;S_@L[K'_!,7]G?X^>)?AG\ ?AHFI3?$'6? 6H
M_8M8\4Q:?-';7&V\3YX8)+J:.W18V"F)FE8.2JI^VU?SE?\ !";PGK'_  30
M_P"#DWXK?LF_M%R-I-_XPT+7]$\*WFHJ8TU<RZA:ZE8SQ.W#+<6UK(5YY=@G
MW_EH _6_XO\ _!(?X=>&_@#K/AS]@?XH>/O@U\0X-&G'ACQ9H/Q%U:9)[SRS
MY:ZC#=7$T5[&[A0[R(TJCYHW1@#7=S?M7?!?]@']C_X2G]LSXB_\(YK5]X<T
M/P]:Z1)!/J&JZOK?V2&)K.VMK599[N<R_*?+5N6!) .:]V\<>./!WPS\':I\
M0OB%XGL=%T+1;&6]U?5]3N5AM[.WC4L\LCL0%55!))K\8O\ @M7J?B;6?^#C
MG]@JX\12R/X#FETFX\--,KK&VK-K4AG(# 8?:-+XZ_<SVH _5C]GC]N']FS]
MI_QCXF^%_P +_'$\?C+P5)&GB_P-XBT>ZTG6M'\Q0T<DUE>1QS")U9&295:-
MPZE6.17DC?\ !<S_ ()=#Q7XQ^'H_:7D'BCP&)U\2>$Y_!.M0:K%-#)Y4EM%
M:2V:RW,ZL&S#$KN%1W("([+^?FKW7Q!3_@]8LX?A?+*EF_PY5/'HM00CZ?\
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MW_!-N/X]I-=>*[KPGCQ:NIJ6EEO&L/#WV@3ANLA<MO!ZL6KW+_@HC:VVE_\
M!WW^RK;:9;QVT:?#S3$2.! BJH?7U"@#H-H"X]!B@#]PJ^<OBK_P5?\ V'/A
M#\0O&7PQUWXG:IJVI_#:P2^^)C^$?!NJ:U;>#[5\D2ZE<6-O+%:@!79E9MZ+
M&[LJJC,/HJY^T_9I/L>SSMA\KS<[=V.,XYQFOY[/^#?R3Q9_P[X_X*4>(?CJ
M9AXVET?5SX[DU0'[1]K72=::?SP><B9KC.>^Z@#]5/\ @J9_P4I\%?LU?\$N
MO%O[7W[/OQ)M]4O/$/@^<_"WQ+H6ES:M937LT#&"Y,D$4L4:)S('G*Q;HPC'
M)VGXE_X-^?@)_P -S?"CX$_\%"-4_;)^*=O\3?A\WB&+XN:<\=\+?QN]WK6I
MM:"\O;E1'?(ENL2%8FF6,1)'^Y=:\&_X)PR?$M_^#//]HI?':W0TM-7\0#P7
M]H4A#IF-.+^5G@I]N-_DCC?O[@U^BW_!KC_R@H^!G_<S?^I/JU '2?\ !>G_
M (*MO_P2:_8ID^*G@K2K/4OB!XMU0:'X"L+\;H(KEHGDEO9D!!>*"-<[1]Z1
MXE. Q(\M_P""4G_!-#_AI/\ 99\%_MP?\%,/B[X]^+OQ0^)V@VWB:&/7/&VH
M6NF>&[*\03VMM8V-G-%! ?)>-V(3*NS! @'/B7_!Z%^RS\3OBY^QG\-_VC?
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M/#GQGEU#X16[SK<^,+'PKJLR0"&9H)7DMTM3<)&DBLK2-&$&,DX(->3^,/\
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M'/#]UINC>.O']_J\7AJ]L6U8ZD\,VHSRM!;21364ARYPT<F2%1 OY"_M1_\
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MV;?VT= T/1/V@_AXNJS^%=:BUGPEK=E?SV.IZ#J,3*T=U9WELZ36\@9$;Y6
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M?:A*J[5>XNKAWEF*K\JAFVHORH%7BO5)HEGB:%RP#J5)1RIP?0CD'W'-.HH
M^3O$/_!$+_@FKXL_:8B_;*\1?!?Q-=_%*"_M[V'QS+\7O%/]H1S01K%$RR#4
M^ L:*@4#;L&W&.*^H;SPIX>U3PI+X'US2TU+2;G3VL;RRU4F[6ZMVC\MXYC,
M6,P9"0V\L6R=V<FM"B@#Y0\/?\$4O^">_AP>%= C^&&M7W@_P-XFE\1>#/AM
MK'C+4;WPUHVJR%V:ZATZ:9H<AI965&#1H99"B+N.?1?VV?\ @GA^QW_P43\$
MZ5X _:_^#5MXLL="U WVASC4+FRN]/G( 9H;FUDCFC#!5#*&VMM7()52/:J*
M /F;]HS_ (([_P#!.+]K+X;>"_A+\?\ ]FNSU_1?A]<3S>%4?7-0@N;=IV#W
M/F74-PL]QYSJ'E,SN97&]B7^:JGA;_@BM_P2^\"?M&>&/VK/ 7[(N@:!XU\'
MV=O;Z!>:%=75G:0+!'Y<+M912K;2R(H&)'C9R0&)+*I'U)10!\W_  O_ ."2
MG[!7P9_:MU+]N#X<_";7+'XJ:RTQUCQ?-\2?$%S-?K+LWQS13W[PRQGRX_W;
M(4'EK@#:,>^>-/!^D^/?#5UX4UR[U2"UNU"RRZ+KEWIMRH!!^2YM)8YHSQU1
MU)&1T)K4HH ^7OV0_P#@C3_P3I_8,^(-Y\4/V2/@GK/@O6=2B2/5)K+XF>(I
MX;]%?>JW$%QJ$D,X#$D"1&QN;U.7_%O_ ((U_P#!.#XW?M4Q?MN^._V>IH_B
MM#=6US'XU\/>-M;T:Z$]N@2*8C3[R!#($54+E=S*H5B0,5]/44 ?*'[9W_!$
MS_@G+^WK\4=(^.'[0OP3NI_&6CPP01>*=!\2WVF7US##CRTGEMI5,Q4 !9&S
M*H  < 8KU;7OV%?V1O$_[*MQ^Q%K_P "-$NOA7=V'V2Y\(2I)Y,J^:)_-:3=
MYIG\\"<W&_SC-^]W[_FKUFB@#PGX)?\ !-']B7]GO]G+6_V3?AK\#[=/ 7B3
M29-+U[1-9U:\U,WMDPD'V9YKN:280J)I=D:N%C,KE I8D^&Z-_P;<_\ !'C3
M_A,WP2UO]ER\USP\NLG4K*WUGQ[K4DNGR$.#';3)=I);Q-O)>.-E65EC:7S&
MCC9?NBB@#YO^/?\ P23_ &!_VH?V??!?[*_Q\^$&L>)? /P]\K_A$O#M[\1M
M?5+,Q0O!$SR1WRRW#1Q2/&C3/(41RJD XKV?X9_!KP'\(/A+IGP/\ 0:K:^'
M-&TE=-TR"Z\1WUW<V]JJ;$C6[N)GN?E7"JQDW( -I&!CJ:* /E'X1_\ !$?_
M ()I_ CPY\1_"?PD^!6N:)8?%W1WTOXD06WQ2\2L=>M6:0LDS/J+,"?.F!=2
MKE9I5+;9'!](_8H_X)^?LE_\$[? &I_"S]CSX9W?A+P[K&J_VE?:1)XKU34H
M3=F-8VF07]S/Y+,B(&\O;NV+NSM&/9J* "BBB@ HHHH **** "BBB@ HHHH
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M_%_A^^UWQ!?))9^"O#UI92O%>Z@0 GVF9%V6T"LRL[NP+ %8P[D+7QO^V/\
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MBWP+8)?>*? VN^$=1T_7;.TDC$D5PNG7$"7,\<BLNQX4<,S!!\YVUYQ\(_\
M@M?_ ,$TOCQ?>,=+^$/[0&HZ[=?#W1+K5_&UK:?#KQ )=&L[=BL\DZ-8 IL(
M(*XW94\<''!?";_@G9:Z?_P4Z\,?\%2/&O[<]EXG\4>*/ $OA[3= \.^%8+#
M3_$.E?9S,LJ%;J=I%3,4WF E3MB'&Y<_ES_P6H\-^ ?^":__  6RM_V\_AOH
MFM:K\)_&6JZ5I?[1VA: 9(+.6^NBMY=Z1-(A"S/=6MK!J$EHQPY;][^[N "
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M&WA#?\$2O@&5(/\ Q3^H=/\ L+WM?$'_  >K_+\*?V<9#PH^(&J98]!^XM:
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M/%?Q8U;7KB[DUGX0:[X3UC33X2(U/&V<WZK&\EHP-E$L:(4C9P5'0?5'C?\
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MEMJVN22:C?:?:EKBZEB2XDC\V>0*'?:F^1$!!95/Q5_P>T?\F"_"C_LL"_\
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M^T/"T^B?$S7M(CTZ[\J2$SI#I][!%YABEEB+E23'+(A)5V!]9HH Y35_@?\
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M?"30O@7\&]*OM/\ "WAG3HM/T'3;_7KW46LK2)%CB@2:\FEE\M$555"Y"JH
M  KP_P"*7_!'W]AKXK>)O'GB*^\#^(-"A^*TL<GQ4T3P?XTU'2=.\7LCE]U]
M;6LR1N[%GWN@1Y1(X=FW'/T_10!B_#[X<^ OA/X$TKX7_#/P=IN@^'-#L(['
M1]$TJS2"UL[=%VI%'&H"JH'8"O M&_X),?L=_#SXA:W\3_V>M)\6?"75/$TY
MG\20?"OQQJ&B:=J<N,>;+I\,OV/S!DXD6%7Y//)KZ7HH ^>_V;_^"6/[#?[*
M_P 8=4_:-^%_P9-S\2=;>9]8^(OBO7;W6M;NFE&V5C=WTTKQ[E 4B/:"HQC'
M%<?^V5_P0_\ ^";G[>'QJLOVB_C]\#;AO'%H(%F\2^&_$=[I-U?)" L:W#6D
MJ>8RJJHLG$JJJJ' 50/K2B@#P+XV?\$O_P!A?]H;]FC1OV.OBG\#1<?#/0;A
M+C3_  CI/B34]+MC,C,PDF-C<PO<N79I"TS.6D9I&)<ECQ/Q=_X(<?\ !,;X
M]?"7P'\"?B_\ -7U[PC\,;"2R\":%>?$_P 2"'28'VY5-NH@OPB*&<L51512
M% %?6=% 'S7^U'_P2*_8%_;3\2^$?&/[3_PEU[Q;JG@2U6#PC>W?Q-\10OIH
M!C;S$,%^F9F:&)FF;,CF-2S,0#1^W1_P2._8)_X*.>'= T3]K+X+MX@NO"UM
M]G\/^(8M;N[?5+6$XW1M=QRB2=3C)68R L2^-Q+5]*44 ?._A3_@E3^PKX-_
M9.U/]BC2?@J'^'^NWUG>^(K&[UJ\FO-7N;6>WGAFN;UY3<R.KVL !\P;5C5%
MVJ !>^#W_!-G]EGX.?%:_P#CG!HOB+Q7XPOO"@\+Q^(_B)XPO_$%W9Z&&9CI
MT$E_+*8X69F+_P <A8[V;->]44 ?#'_!+?\ X).?!']AC]I?XJ_M$_ +X)77
MPS\(^,M&TW1/#/@R\UJXO+J:.WFN+BYU2Y$T\QMS/)-%'#;AP8X;96D2.25X
MT^IOVF/V7/@M^U_\+-0^"?Q_T/5M5\+:O;O;ZMH^F^*]2TI+Z%L;HIFL+B%I
M4.T91B5ZC')SZ#10!\]_LG_\$M?V)_V&? ^M_#3]D_X>^)/!>@>(99IM4TC3
MOB?XBD@:>6)(GN(UFOW$$YCCC7SHMD@$:88;1CCOA/\ \$-/^"87P,^$_CWX
M&?";]G[5]$\)?%"RBM/'NAVGQ0\2&+5X8RQ57+:B64_.ZDH5+*[*Q*DBOK6B
M@#PK]G[_ ()I_L2?LP?LX:Y^R'\'/@?%:_#/Q(;C^VO!FM:]J&L65P)UVS*%
MU"XG**XY94*@GYL9YKS#]DG_ ((,?\$POV(_B^/C=\ /@)=V>M6]W]JTF+5_
M%6H:C::7/M91-!;W,SQB558A97#2("=K+DY^Q** /F3P#_P2$_X)\_"C]I'X
MH_M=>%_@/'_PF'Q<TS4+/QU+<7]S<6]Y!?,'U!8[9G*(;EQNDVC+$G& Q!\]
M_P""1O\ P2Q^%'_!/OXB?&+XK_!CX.W7PX\,?$FZT:V\,^ [_7IM1N[*QTZ*
MXS>74DL\VR>YGO)V$(D<10QP E9&EC3[=HH X3]I/]F;X$_M@?!K6/V??VDO
MAM8>+/"&O1HFI:/J!=5<HP='22-EDBD5E#+(C*ZD9!%>2P_\$AO^"?L7[(UU
M^PN?@K?M\,;][9M2T'_A.=:2:]6W8/!#->)>"ZD@C8 I;M*85(&$&!7TK10!
M\E^+_P#@AK_P3$\??LT>%OV.?&/[/^L:A\,?!6L7&J^%_!\_Q0\2?9;"[F\S
M?*N-1WM_K9MH9BJ>?+L"^8^[NOC[_P $R?V)OVH/V7-%_8W^.OP:'B/P'X:@
M@C\-V>IZY?37NEF&,QQ/#?/,;I76,E-QE)*?*VY>*]ZHH \#_89_X)F_L<_\
M$Z?#5UX=_9=^&<VFRWT*PWFKZOK%SJ5]) IREN)[EW:*!3R(8]D>[YMNXDGT
MSX\? CX;_M*?#'4_@Y\6[;6+GP[K-O);ZK9:-XHU#2'NX)(WBDADFL)X96B=
M'96C+[6!Y!P,=A10!R'P,^!GP[_9Q^&FF_"#X40:Q!X?T>WCM]+M-:\4:AJ\
MEK!'&D<<*3W\\THC5$553?M7' &3FOIO[.?P;T;]H34OVIM'\$VUIXZUKPQ#
MX?UG7+<E'O["&8S0I*H.UVC9F"N1N"MMR5"@=O10!\D0_P#!"+_@DFGQ<\9_
M'&[_ &)O"][XC\>QWR^(KC49[JY@/VQ'2Z>WMY)FALWD$DF9+=(W7>=I6M+X
M>?\ !%[_ ()O_"K]FJ__ &1O 7[/K:?X$U3Q';:[?Z:GBG4WN);ZWE$MO*+Q
M[DW,7EN R".10K9(P68GZEHH \6^ '[ G[/'[.OQ;UK]H#PQ:^)-?\>Z[HL&
MBWGC3QUXMOM<U./2H6WQV$4]Y+(T-N'_ 'A1,>8_SN78 CRC5O\ @A+_ ,$T
M=2^,'C/XS6?P5U+2KOXA1R_\)MH&B>+]1L]%UF9]Y\^XTZ*=;:5U:1Y%#(46
M1O,"!_FK[ HH ^8?@Y_P1L_X)P? ?]FOQ?\ LA_#?]G..W^'?CZ$)XQ\-WWB
M74[N+4W&W$S&>Y=HYAY<9$L11U,:%2-BXX6\_P"#=3_@C/>_!.V^ ,G[$.B1
MZ%:ZLNIK=6^M:C%J<MRJLH,NH)<"ZF3:[@1/*T8W$A0<$?;%% 'SQ^U7_P $
MK?V&OVS/@[X4^"'QQ^#"7&D^ Y(Y/ ]YI6J7-EJ&A.JJNZWNX9%F&X(A<,S!
MV168,RJP_(/]H#]GSX??L]_\'1WP&UGX0:)K]QX&\,Z;I]OXO\<:MJ-_JZKJ
MA34HY6U#5;IY6><>9;HQEE/EC8GRJH4?T!T4 %>%?M??\$U?V*/VZ[_1_$?[
M2?P/L]6\0^'71_#OB_3+^YTS6M+9'\Q#!?V4D5P@5_G5-Y4-\VW/->ZT4 >!
M>!?^";G[.OA;7M&\3>-=:^(/Q%N_#EW'=>'U^*GQ+U?Q%;:=<QX,=S':WMP]
MOYZ$ I.T;2H1E7!YKH?VI_V&OV:?VR7\,:I\<O DESK?@?5UU7P1XJTC4[C3
MM6T"\#(WG6MW;.DL>3&A9,F-]B[E;:,>N44 >._LV?L'_LU?LJ:UXO\ &GPK
M\(WK^*_B!>_:_''C?7=:N=0UK6I0-J^=>3NTJH@X2*,I''_"JGFN"^"7_!&_
M_@GE^SC\2?&?QA^"7P?\0>'_ !1\0[*]M?&FN6GQ3\2-<:JEW(99VD:34&Q(
MTA+B5<2*Q+*RGFOI^B@#Y0^$G_!$7_@FA\!_@IXX_9T^$'P'UK0/!/Q(MU@\
M;>'K'XH>)!!JL84J5<G42R;D)1MA7>A*ME>*^=_^"MG["G[-7["W_!!KXV_L
MS_L9_#'4M#TOQ ED^C^$8/$&J:Q)<W\FIV;R+;1W<]Q(&*1O(RQ8&$9R.":_
M3>B@#\@/^"-/_!(;]A7]KG_@EE\&3^TA\/O$MUJNB3SW_C;X>3>,]6L-,N=6
MAOKM+>XU+1EG2 W'V?:!*T2O)$P#,Z&OTO\ VF?V+_V8/VPO@C_PSI^T1\'M
M+U_P?$\$EAI.'M3ITL*E89;26W9)+62-255XF0A69<[20?4** /#?@?_ ,$[
M?V9O@7\;[[]IO3=&USQ-\2;_ $6'1CX\\>>);K6M3MM-B!V6=O+=.PMHLEBP
MB"F0L2Y<G-<9X\_X(X?L-?$>;Q7:>)O#'B\Z)X_\53>(_B#X1M/B-J\&B^)]
M1DO3>&:\L4N1 _[XJ<*J[ECC1]RHH'U+10!\W?M5?\$C?^"?O[;'B[PKXW_:
M4^"%[KU_X'MU@\&BS\=:WIEOHB*8B/LMO87L,,!S##\R("?*3)^45H?M6?\
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M?@X-$^%>I:=<6.K>&]#UV_L9-0AG4K<"XN[>=+F9IE)61GE+2*=K$CBO<**
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M5]^K\*/^"$GBWQ#9_P#!SA^W#X%MKB4:3J,_BZ_O8@3L:XMO%5K'"Q]PEU<
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M V:*QO\ A!='_P"?J]_\"FH_X071_P#GZO?_  *:@#9HK&_X071_^?J]_P#
MIJ/^$%T?_GZO?_ IJ -FBL;_ (071_\ GZO?_ IJ/^$%T?\ Y^KW_P "FH V
M:*QO^$%T?_GZO?\ P*:C_A!='_Y^KW_P*:@#9HK&_P"$%T?_ )^KW_P*:C_A
M!='_ .?J]_\  IJ -FBL;_A!='_Y^KW_ ,"FH_X071_^?J]_\"FH V:*QO\
MA!='_P"?J]_\"FH_X071_P#GZO?_  *:@#9HK&_X071_^?J]_P# IJ/^$%T?
M_GZO?_ IJ -FBL;_ (071_\ GZO?_ IJ/^$%T?\ Y^KW_P "FH V:*QO^$%T
M?_GZO?\ P*:C_A!='_Y^KW_P*:@#9HK&_P"$%T?_ )^KW_P*:C_A!='_ .?J
M]_\  IJ -FBL;_A!='_Y^KW_ ,"FH_X071_^?J]_\"FH V:*QO\ A!='_P"?
MJ]_\"FH_X071_P#GZO?_  *:@#9HK&_X071_^?J]_P# IJ/^$%T?_GZO?_ I
MJ -FBL;_ (071_\ GZO?_ IJ/^$%T?\ Y^KW_P "FH V:*QO^$%T?_GZO?\
MP*:C_A!='_Y^KW_P*:@#9HK&_P"$%T?_ )^KW_P*:C_A!='_ .?J]_\  IJ
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MZO?_  *:@#9HK&_X071_^?J]_P# IJ/^$%T?_GZO?_ IJ -FBL;_ (071_\
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M071_^?J]_P# IJ/^$%T?_GZO?_ IJ -FBL;_ (071_\ GZO?_ IJ/^$%T?\
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MO?\ P*:C_A!='_Y^KW_P*:@#9HK&_P"$%T?_ )^KW_P*:C_A!='_ .?J]_\
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M1M^76$C6%2*XNB%DN)%!9MJ1AO+C5:^EOB?_ ,$W_P!N/_@IO_P1,U_X ?\
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MFTF'_CTJ5[9^R;_P4>^!'[9'C>]^'_POT#Q19:AI^D-J-Q_;FGP11^4LL<1
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MG-5_X)+?L :J2Y^ PMW/\=KXCU%,?\!^T;?TJ?JN?Q^&LG_7^$R_U;\:\/\
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M;J.QO+B W$4T%PB2&)BX\F,[3LP?S_\ ^"5O_!,_XD_&;]M7]FC_ (*7ZC\
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ME_X#&M>$S&%#<*HDVC>$;(![X) R*=7VI_-&Q^:7[8'_  6M^//[/7QT\4?
MSPY\&] ^T>&]3>T&HZI>2S+<K@,DOEHL>P,C*VW<<9ZFOC[]J?\ X*?_ +5_
M[7?@Q_AQ\3?$&E6?AZ6ZCN)]'T+2Q!',\9)3>[,\C*"<[2^W*J<9 (_8[QS^
MP'^QW\3OBAJ7QE^(GP&T?6_$>K-"VH7^IO-,LQBB2)/W+.8AA(T'"#.,G)))
M^//'W_!ODWCOQOJWC,_M6:?I8U34);E-,TGX8I!:V:NQ*PQ1I?A4C0$*H X
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MO_ 8ULT4 8WV'QS_ -!RR_\  8T?8?'/_0<LO_ 8ULT4 8WV'QS_ -!RR_\
M 8T?8?'/_0<LO_ 8ULT4 8WV'QS_ -!RR_\  8T?8?'/_0<LO_ 8ULT4 8WV
M'QS_ -!RR_\  8T?8?'/_0<LO_ 8ULT4 8WV'QS_ -!RR_\  8T?8?'/_0<L
MO_ 8ULT4 8WV'QS_ -!RR_\  8T?8?'/_0<LO_ 8ULT4 8WV'QS_ -!RR_\
M 8T?8?'/_0<LO_ 8ULT4 8WV'QS_ -!RR_\  8T?8?'/_0<LO_ 8ULT4 8WV
M'QS_ -!RR_\  8T?8?'/_0<LO_ 8ULT4 8WV'QS_ -!RR_\  8T?8?'/_0<L
MO_ 8ULT4 8WV'QS_ -!RR_\  8T?8?'/_0<LO_ 8ULT4 8WV'QS_ -!RR_\
M 8T?8?'/_0<LO_ 8ULT4 8WV'QS_ -!RR_\  8T?8?'/_0<LO_ 8ULT4 8WV
M'QS_ -!RR_\  8T?8?'/_0<LO_ 8U7^)'Q:^&'P>T(^)?BGX_P!)\/V(SMN-
M5ODA#D?PH&.7;_94$^U?'GQ[_P""Y/P)\%^?H_P)\&ZCXQO5!6/4;P&QL >S
M#>#-)@]MB9[-7+B,;A<*KU9I?G]VY\[GG%G#G#<.;,<3&F_Y;WD_2*O)_=8^
MR_L/CG_H.67_ (#&O)?CU^VK\%?V;DFM_BA\=="AU&)3_P 2/3X3=7Q/93#%
MDQY[%]J^]?F1\4/^"@W[=_[7NN-X)T#Q'JL,5]E8O"W@&QEB\Q3P5/E;IY5Q
MU#.P]J[3X#?\$6?VI?BH\6M?%:]L? NG2D,_]I-]JOW!/401M@'U$DB-STKR
M)9S7Q+Y<'2<O-[?UZM'Y=7\6,YS^J\/PIELZSV]I-6BO5)I+RYIQ]#NOC9_P
M74\>W;3:3\ / 5O:1'*IK/B2%7FQZK;QL54]P6=QZK7B_P ,O'G_  4D_:Y^
M+^B?%#PG-XM\87F@:Y!?V4C?N-(M9XY P4_<MH@<$$<$J2.>:_03X#?\$B_V
M/?@MY.IZWX2F\::K$0QO?%3B:$-WVVR@1;<]G5R/6OIK3M-T[1[&+2])L(;6
MV@0)!;VT02.-1T"JH  ]A1'+<QQ4E+%5;+M'^K?F.CP!QWQ+6CB.),S<(IIJ
ME1TM9W6R4$UT=I^ID6MMX^FMHYKC4[.&1XP7B,&2A(Y7(X..F14GV'QS_P!!
MRR_\!C6S17T)^XK1&-]A\<_]!RR_\!C1]A\<_P#0<LO_  &-;-% S&^P^.?^
M@Y9?^ QH^P^.?^@Y9?\ @,:V:* ,;[#XY_Z#EE_X#&C[#XY_Z#EE_P" QK9H
MH QOL/CG_H.67_@,:/L/CG_H.67_ (#&MFB@#&^P^.?^@Y9?^ QH^P^.?^@Y
M9?\ @,:V:R_$_C3PGX,_L_\ X2OQ!:Z?_:VJ1:=IOVJ4+]INY<^7"F>KMM.!
MWQ2<HQ5VRZ=.I6FH4TVWT6K(OL/CG_H.67_@,:/L/CG_ *#EE_X#&MFBF08W
MV'QS_P!!RR_\!C1]A\<_]!RR_P# 8ULT4 8WV'QS_P!!RR_\!C1]A\<_]!RR
M_P# 8ULT4 8WV'QS_P!!RR_\!C1]A\<_]!RR_P# 8ULT4 8WV'QS_P!!RR_\
M!C1]A\<_]!RR_P# 8ULT4 8WV'QS_P!!RR_\!C1]A\<_]!RR_P# 8ULT4 8W
MV'QS_P!!RR_\!C1]A\<_]!RR_P# 8ULT4 8WV'QS_P!!RR_\!C1]A\<_]!RR
M_P# 8ULT4 8WV'QS_P!!RR_\!C1]A\<_]!RR_P# 8ULT4 8WV'QS_P!!RR_\
M!C1]A\<_]!RR_P# 8ULT4 8WV'QS_P!!RR_\!C1]A\<_]!RR_P# 8ULT4 8W
MV'QS_P!!RR_\!C1]A\<_]!RR_P# 8ULT4 8WV'QS_P!!RR_\!C1]A\<_]!RR
M_P# 8ULT4 8WV'QS_P!!RR_\!C1]A\<_]!RR_P# 8ULT4 95E:>+DND>^U:U
M>$-^\1(""1[&M6BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MG1N[)R7NM_W9J\9?]NMFC1117:?-!1110 4444 %%%% !1110 4444 %%%%
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MB?\ !-SXJ?$GXS?L9^#_ !Y\8;F]G\3SK>1:O/J%KY,LKQWDR(Y7:H&8A&>
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M04444 %%%% !1110 4444 %%?.'_  ]O_P"">_\ T<#_ .6IJW_R+1_P]O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **XWXP?M#?
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M&A^IDN 1^5>W_MK?LAZ!^VC\+=/^%_B'Q?<Z)#8:_%JBWMI:+,Y*0S1; &8
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M;>C;T;7Y.WX'Z9EWCOXJ9;91S%S7:<*<[_-QYON9\^_\$T/V2_&?[&/[-?\
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MG<M"L6 % RARPSFE\'_\$>_V!OV2] B^(O[;'Q^LK^*/&Z3Q)K<.@Z3O&#M
M,HDD.>WFX(ZIS7RZO[0__!S-_P %'#M^$_PON/A#X6NQE;RVTE= C\OD*XN=
M09[R3_>M^#UP!72_"[_@UK^)/Q5\2+\1/^"@7[<NK>(-5G(^WV_ADS7MS*.O
M_(1U'+=2>#;GUSS7J+P7X(R;&3Q7$N:T85&[NG2OB)WZIJ-HQ;_O<R/N7XW^
M([X>P^2X+$2I4:,%!."4).*VO/6>BT7*XZ):7U/:/B/_ ,' G_!(K]C+0I?
MG[,_A^X\4O#A1I_PZ\,)9V1D&>9+BX$*R?[Z"7.[OSCYPU/_ (+R_P#!7?\
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M%W_%GBWQUH_ARR_9WTS3;/4-5M[:XFN?$4EP\4<DJJS#$,8R <\CM7NN@_\
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MQX^ O_!?']IWP#Y&E?&SPEHWCJQ3:LEVJC3[\CH3OB4Q-QZQ D]37VI\!O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M;)U^+Q]_P4<_;G,+LWF#3DOKC7[J#_IFJN\5M;=Q^Z+J/0YK[!_9Q_X-R_\
M@F-\ Q#J'B+X9:G\1=4BP?MWCS5#/%NXSBU@$5N5ST#HY [GK7U6*X5\(\MH
M^RSG,)XZ6C=/#0Y876J_>STDK]8V=C\OR+B3B3AW,8X_*:CH54I)2T;M)-/2
MS6S^3U5FDS\[OA]_P5Q\/:1XBC\ _P#!)7_@E-!J7B16Q:^)O%]E<^)-9?)Q
MY@@MN;8]#\LQC!_AP*]'3]B'_@Y!_P""C6+O]I/]H"?X8^&;O!?2K[7%TM&A
M/\/V#2E+2$9^[<E6XY/ K]G_  '\.?A]\+/#L7@_X8^!-&\.:3!_J-+T+3(K
M2WCX ^6.)54< =!VK9JJ'B#D'#M/V7"^24,-;:=1>VJ>J<K*+\K-'/F>,S?/
M<4\3FF*J5ZCW<I-O[VVS\M/V<_\ @U1_8[\ M#J_[2/Q<\5_$6^4[IK&R*Z-
MI\A/4,L327!^HG7Z<\?>G[/'["_['O[)]LD/[._[.7A3PM,B;#J5CI2-?2+C
M&'NY-T\G4_><]:]7HKY7/>.>+^);K,<;4J1?V;\L/_ (VC^!RT\/1I?#$***
M*^4-@HIKR1QX\R15W-A=QQD^E.H ***^(/B5_P %S?@1X,UR_P##?A_X-^+M
M1O-.NY;:<7SVMI&9(V*MAEDE.,@]5'TKGQ&+P^%2=65KGA9YQ-D7#5*%3,ZZ
MI*5[7N[VM>R2;TNC[?HK\QO%G_!??XC7>Y? O[.VB6'/R-JVMS7?'N(TA_G7
MF'BS_@M1^W!XB+?V/K?AO00<X_LKP\C[?_ EI>E>;//\NALV_1?YV/@<9XV<
M"8;^'4G5_P ,&O\ TOD/K+]K?_@L+_PRS^T)X@^ _P#PSM_;O]A?9/\ B:_\
M)=]E\_S[2&X_U7V23;M\[;]XYVYXS@>;_P#$0-_U:3_Y?O\ ]P5\"?%GXE_$
M7XP?$#4/B1\6-<GU+Q!J?E-?WMQ;I$\H6)(XSM154 1H@& !@"N<KYZKGF8.
MK)TYVC=V5H[=.A^%9GXQ<;U<RK3P>*<*+G)PBZ=*\8-OE3]QZI63U?J]S]Z/
MV7?VI?#W[1/[//A_X]ZWI]EX5771=DZ7=ZRDP@\F[FM_]:R1[MWE;ONC&['.
M,GU0$$9!R#T-?AS\$/\ @FW^UU^T+X T_P"*7PU^'MI/X?U4R_8-1NM=M(1+
MY4KPO\C2>8N)(W7E1G&1D$$_MQX7AU.W\,Z=;ZU&J7B6,*W:HVX"4( P!'49
MSS7T^5XS$XNG^]@U9+7^;SV7KIW/Z(\.N*\^XFP%\RP<J7+"FU4DFE6;3YIQ
M7)&*3LI)1NK2TT+U>)?&S_@HI^R'^SWXXO?AI\4OBC)9:_IZQ-=Z9#H5[.R"
M2-94.^.$QG*.IX;OCJ#7MM?&_P"UY_P2/L?VLOV@-1^-]Y\='T&/4+2VA?2X
M/#8N&S#$L>[S3<(.0HXV<>M=.-GC(4D\-%2E?KV^]'T'%N)XJPN61GP_1A5K
MN234W9*%G=ZSAJGR]7N]'TOZO_P6Q_8DTUB+.\\5:A[VF@;<_P#?V1*Y?6?^
M"\G[,=ME=!^%7CJ[(Z&YMK.!3^5PY_2LK2/^"!WP8@9?[?\ CQXHN1GYA9V-
MM!GZ;A)BNHT?_@A?^Q[IQ5]0\6>/+\C[RW&L6J*?^_=JI'YUY5^(9](K[O\
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MBE\7M9^LU_[;&)^8FB?\$"/B7/C_ (2/]HG0K3^]]BT2:XQ_WT\>:^D?V/\
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MKLRGC3$93'E6 P=1?WL)0_%PA!OYNYX-/@GA*C_"P5*/I"/^1^#&E:;_ ,'
M_P"RB4;Q7_P3G\!^,XK9LJ8/A)H&IF0#U.A[)#D8ZG=QZUUN@?\ !QO^TY^S
M=)%9_M,?\$IM+T"5&"3-I]G>^&R&SSM2ZMIR#T^4M^-?MU39X(+F%K>YA22-
MU*O&Z@JP/4$'J*^BCQ[PGB_^1CPYAI?]>7/#_P#I+D>E1R?#83_=TH_]NQ_R
M1^6_PS_X.O\ ]A_Q&8[;XH?!#XC>&9G^]-9VUGJ-O']6$\<GY1FOH3X;?\%]
MO^"3OQ,$45G^U?9:/<R8#6OB70[^P\LG^])+ (OQ#D"O:?B5^P#^PY\8=[_$
MW]D/X;ZS-(26O+OP;9_:,GKB81B09]FKY[^)7_!NI_P2>^(F^:Q_9^OO#-S(
M26N?#7BN_B_**:62)?P05?UOP9S#^+AL7A7_ -.YTZD5Z\]I6]-3KY<='9Q?
MK='TY\-OVO?V4?C(L9^$W[3'@'Q*TF-D>A^+[*Z?)[%8Y"P/L1FODO\ ;Q^
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M9*S1]$%%%%( HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M==QO92DW&-]^6/PQOULD%%%%=A\Z%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 >%> ?^4@WQ _[$32O_1C
M5[K7A7@'_E(-\0/^Q$TK_P!&-7NM !1110 45C>._B+\/OA;X>E\7?$WQUHW
MAS28#B;5-=U.*SMXS@GYI)651T/4]J_*_P#X*C?\%C_#WBCQCI_PZ_82_;3L
M[G3H=*F;Q</"L#(T$JR )(FH-$ RLK8_<2?*4R3\PIXFCF%'*ZN84L-4J4Z=
MN9PBVE=I*[V6K2U9]+P?PU5XQXCH9/1KPI3JWM*HVH^[%R>R;O9.RZO2Z/TS
M^,_[2'P(_9XT5M>^-?Q6T7P[ (R\<5_> 3S@=?*A7,LI]D5C[5\1?'[_ (."
M_A5X=\[1_P!G'X3ZAXCN!E4UCQ#)]BM >S+$NZ65?9O*-?E;X47XR_M,^*;D
M?!KX;>-_BGK<LQ^VW7A[2KC4%5^/FGNR#&@Y&69^,CUKZ5^#W_!!+_@IG\;A
M'>_%'7_!OP<TF7[\5U=C6=653C!$=N3!T]9E8'].##Y!QYG"4ZD*>747]O$2
MY)6[QIVE5DFMG"E)>9^ZOACP&\/M<ZQ\LSQ,?^75#X+]FX2LFGNIUE_AW/M;
MX'?\%ZOV3="_9LM?B!^VA\7-)\->,QJ-W;W'AW1M*NIYKI5??#)#!&LKK&8W
M1-[L%WH^6%?/?QL_X.L-"US6QX%_8A_9 \0>*M4NI/+L+SQ7-Y32OS]RQL_-
MDE!QD?O4;'4"O4_AG_P;D?\ !-[X#:>/B-^UW\3M>^($T!476H^-?$HTG2T<
MD;<)"Z.O/\+SN#TQ7T/X#_:'_P""2W['6B/H7P;\2?#/PK:A0LT?@;1TE:?&
M.7:RB=I6X'S,6)]:_4\MQWA9PKEU*&+A4S'%17O2E+V%!OO%?Q&N_.E?LKV7
M\Q\9<0Y!//L3BL/*&"PTY.4*<YQO"+Z7;2LG>UMEI=VN?F!\0_@)_P '#'_!
M7W4M*U/XO?#33/ 'ARS\PZ3_ ,)!I4&A0:>)]OF,J.LNI'<$3.0WW%Q@]?8O
M@/\ \&H'@ZYO8_%/[9/[6NN^([Z4!KO3?!UHMNNX?PM>7?FO*N!C_51G'0CK
M7V+XN_X+:_L5>'0PT23Q7K[ X7^S-"$8/OFYDBP/PS[5Y?XN_P""_/A"W#1^
M _V;]2O,G"2ZOX@CML>Y6.*7/TW#ZUSXGQJQ6"<UDM/#X",M']7I14Y);<U2
MTI-Z+6ZV/AL?XH<&T<+##8S-?:TZ=^6'-.I&-VV^6,%**NVV[;MML][_ &<O
M^"1'_!.7]EGR;OX5?LK>&GU*'E=;\10-JUZ'XRZRWAD,1X_Y9[!Z 5](*JHH
M1%  &  . *_*7Q;_ ,%W_P!IC4R8_!WPP\&:3&?XKF&YNI1]&\Y%_-37G&O?
M\%8_^"@/CNY^PZ1\5/L1D)VVNA>';4,?H3$\G_CU?FN9\:U,UK^VQE:I6GWD
MW)_?)W/E<1XW<#X7W:$:M3_#!+_TJ4?R/VBHK\V?^"7OQ(_;N\8_M40:I\=K
MCXDZCX7OM"O(I;C7[6\&FPRX62-P'40HQ,>T$ 'YR!]XU^DU5@\6L91]HHM:
MVU/O^$^):7%>5O'4Z,Z2YG&TU9Z)._H[E#Q5XGT+P3X8U'QGXHU!;33-)L)K
MW4;MD9A#!$A>1R%!) 52> 3Q7S-XM_X+*_L*^&BZZ7XXUG763MI'AV=<GT!N
M!$#^>*^D/B%X2M_'_@'7/ EW(J1:WH]S82NR;@JS1-&21QGANE?"'A#_ (($
M> K7:WCW]HS5[_NZ:/H45ICV#2239^N/PK''3S*,HK"Q375OI^*/(XQQ?B!0
MKT:?#M"G.,D^>4VKQ=U:UYQW7]V6W0T/%_\ P7Q^#5BK_P#"!? ;Q-J;#[G]
MKZA;V(;Z^7Y^/UKRSQ;_ ,%[?CC?;AX&^!_A73 ?NG5+JYO2O_?#0@G\*^DO
M"O\ P10_8D\/*HUBP\4:Z002=4U\IN]O]&2*O3O"7_!.C]A_P5M_L;]FKPU-
MLZ?VM;O?_G]J:3/XUP?5\_J_%545Y?\ #?J?&/(O&S,OX^8TJ,>T4K_A3O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MTM &S16-_P )/K'_ $)U[_WTM'_"3ZQ_T)U[_P!]+0!LT5C?\)/K'_0G7O\
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M[Z6@#9HK&_X2?6/^A.O?^^EH_P"$GUC_ *$Z]_[Z6@#9HK&_X2?6/^A.O?\
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MX2?6/^A.O?\ OI:/^$GUC_H3KW_OI: -FBL;_A)]8_Z$Z]_[Z6C_ (2?6/\
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M^$N7Q2U@5_XI[[!]D^S?:?\ IXFW[OM'^SC9WSQTG@'_ )2#?$#_ +$32O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% 'A7@'_ )2#?$#_ +$32O\ T8U>ZUX5X!_Y2#?$#_L1-*_]
M&-7NM !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M+-K.AZ8^F:@R#CS6LKHB*XW==\4L28Z*<U^D'[)7_!37]A[]MNUAC_9\^/\
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MMUY/1DSA"HK25S\4O&W_  0<_P""GG_!/WQ%=?$__@EC^U[?ZO:"0S2>&FU
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#PKP#_RD&^('_8B:5_Z
M,:O=:\*\ _\ *0;X@?\ 8B:5_P"C&KW6@ HHHH **** "BBB@ HHHH ****
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M0EQU3^!FN!J?X<2OUB@^N1ZPDOD?M-17XL_\/L_^"_7A'Y/'7_!+'<B=9O\
MA4'B:#</]_[0RGJ.0*/^(EG_ (*!>$OF^(W_  3-$2Q_Z[]QJMECO_RUA?''
MKGUH_P"(,\:3_@>QJ?X:]-_G)!]>H+>Z^3/VFHK\8-._X.YKO3;@:?XZ_P""
M?4]M*O\ K&M_B,58=C^[DTX$=_XO;WKK] _X.W_V<;C;_P )1^R1XVL\_?\
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M45ZU'B;B3#_PL;6CZ5)K\I$.E2>\5]Q\6:W_ ,&\W_!(76][_P##)WV21O\
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MELVOF?BS_P (9_P=U>".=)\5_P!KQQ=?].\'W&\#K_Q\@,>GUYXYS2']HO\
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MG^[)&Q4_@:U*^&G"=.3C)6:Z,Z-PHHHJ0"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@#PKP#_ ,I!OB!_V(FE?^C&KW6O"O /_*0;X@?]B)I7_HQJ
M]UH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MO?I75U\!6HUL/4=.K%QDMTU9KY,Z$TU=!11168PHHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MQ83)]&05ZC7Y_BL'B\#6=+$TY0FMU).+^YV9TJ49*Z84445SC"BBB@ HHHH
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MG7O_ 'TM;-% &-_PD^L?]"=>_P#?2T?\)/K'_0G7O_?2ULT4 8W_  D^L?\
M0G7O_?2T?\)/K'_0G7O_ 'TM;-% &-_PD^L?]"=>_P#?2T?\)/K'_0G7O_?2
MULT4 8W_  D^L?\ 0G7O_?2T?\)/K'_0G7O_ 'TM;-% &-_PD^L?]"=>_P#?
M2T?\)/K'_0G7O_?2ULT4 8W_  D^L?\ 0G7O_?2T?\)/K'_0G7O_ 'TM;-%
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MG7O_ 'TM;-% &-_PD^L?]"=>_P#?2T?\)/K'_0G7O_?2ULT4 8W_  D^L?\
M0G7O_?2T?\)/K'_0G7O_ 'TM;-% &-_PD^L?]"=>_P#?2T?\)/K'_0G7O_?2
MULT4 8W_  D^L?\ 0G7O_?2T?\)/K'_0G7O_ 'TM;-% &-_PD^L?]"=>_P#?
M2T?\)/K'_0G7O_?2ULT4 8W_  D^L?\ 0G7O_?2T?\)/K'_0G7O_ 'TM;-%
M&-_PD^L?]"=>_P#?2T?\)/K'_0G7O_?2ULT4 8W_  D^L?\ 0G7O_?2T?\)/
MK'_0G7O_ 'TM;-% &-_PD^L?]"=>_P#?2T?\)/K'_0G7O_?2ULT4 8W_  D^
ML?\ 0G7O_?2T?\)/K'_0G7O_ 'TM;-% &-_PD^L?]"=>_P#?2T?\)/K'_0G7
MO_?2ULT4 8W_  D^L?\ 0G7O_?2T?\)/K'_0G7O_ 'TM;-% &-_PD^L?]"=>
M_P#?2T?\)/K'_0G7O_?2ULT4 8W_  D^L?\ 0G7O_?2T?\)/K'_0G7O_ 'TM
M;-% &-_PD^L?]"=>_P#?2T?\)/K'_0G7O_?2ULT4 8W_  D^L?\ 0G7O_?2T
M?\)/K'_0G7O_ 'TM;-% &-_PD^L?]"=>_P#?2T?\)/K'_0G7O_?2ULT4 8W_
M  D^L?\ 0G7O_?2T?\)/K'_0G7O_ 'TM;-% &-_PD^L?]"=>_P#?2T?\)/K'
M_0G7O_?2ULT4 85SKU_>6[VEYX'N98I4*R12!65U/!!!X(KYW^//_!+C_@GO
M^TBMQ+\3_P!A/PX;VYR9=5T&R&DWC.?XVGLC$[L/]LL/4$<5]2T5WX#-,SRJ
MM[7!5YTI=X2<7]\6B90A-6DKGY&_''_@UF_9J\422:I^SS\5/'_@B\+;X;?6
M(K?5[6)AR @'D3 =.6E8CKSTKS8?\$WO^#BS]C,+/^RQ^UOJ7C/2;)O] T=/
M%A?:@'>RU<&U4<?=5VS7[=T5^@X7Q?XSA25''3IXNFOL8BG"HOOLI/\ \".:
M6"H-WC>+\G8_$V'_ (+N_P#!8[]BZ4:?^WE^P5_:FFVK!9M9NO#MYHCW'J5O
M8EELW^J1XS7MWP5_X.K_ -B'QP(K+XQ_"CQKX&NG_P!;<"*/4[*/_MI!B8_]
M^*_4*6*.:-H9HU='4JZ,,A@>H([UX'\;/^"6/_!.W]H<W$_Q6_8^\#W=U=?\
M?&IZ=I"Z=>2'U-S9F*4GWW9KJ7%?AGG"MFN2NA-[SPU1K[J4_<7WL7L<5#X*
ME_5?J1_ O_@I]^Q7^TJT-O\ !/X^^%=;O+C'DZ4->AM[YL]/]%G*3?\ CE>T
M_P#"3ZQ_T)U[_P!]+7YG?'C_ (-2OV+?'/G7_P !_C%XT\!7<F?+MKPQ:Q8Q
M>F(Y/+G/XSFOG/XC_P#!*/\ X+9_\$RO &L_%C]EK]M>\U_PKX9LVO)=#\-:
MUJ'VAX4Y9QI,T<EO)M7YB SD -V!JZ7!GAYGU10R;.O9U)-)4\33<7=Z).I'
MW-]-$)U\337OT[KNG^A^QOQ6_:K^#OP%NO#T'QT\7Z=X17Q5K<6D:%+K=^D(
MN[R3[L:Y_#+'"KD9(R,^DU_()^U?^VC^TS^V_P"/K;XE_M/_ !4N_$^JV5@M
MG8M);PV\%K".JQ00(D4>X_,Q506/)SQ7[%?\&W?_  54^.W[0GF_L1?&[PWK
M7BC_ (1?13<Z!X^CB:;[%9QX5;34)#^"PRDEFQL(. P]WC#P*S7A7A2.:QKQ
MJU*:;K16D8J^C@W9R2^U=)O=+H9T,PA6K<EK)['ZXT445^"GHA1110 4444
M%%%% !1110 4444 %%%% !1110 4444 >%> ?^4@WQ _[$32O_1C5[K7A7@'
M_E(-\0/^Q$TK_P!&-7NM !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 ?D=_P54_X-N_^&A/CMIO
MQN_8BNM%\+_\)1K2)X^T"^;R;.R\QLR:I:JH^I>W7&YB&3&6 _0?]@[]@[X$
M_P#!/;X$V7P1^".C?W9]?U^ZC7[9K5YMPUQ.P_$*@^6-?E'<GVJBOL<WX]XI
MSW(J&48W$.5"CLNLOY>=[RY5I&^WF]3"&'HTZCG%:L****^.-PHHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** /"O /_*0;X@?]B)I7_HQJ]UKPKP#
M_P I!OB!_P!B)I7_ *,:O=: "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** /"O /_*0;X@?]B)I7_HQJ]UK
MPKP#_P I!OB!_P!B)I7_ *,:O=: "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** /"O /_*0;X@?]B)I7_HQ
MJ]UKPKP#_P I!OB!_P!B)I7_ *,:O=: "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /"O /_*0;X@?]B)I
M7_HQJ]UKPKP#_P I!OB!_P!B)I7_ *,:O=: "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /"O /_*0;X@?
M]B)I7_HQJ]UKPKP#_P I!OB!_P!B)I7_ *,:O=: "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MRBO _P#AKSXY?]&+^.__  )A_P */^&O/CE_T8OX[_\  F'_  H ]\HKP/\
MX:\^.7_1B_CO_P "8?\ "C_AKSXY?]&+^.__  )A_P * /?**\#_ .&O/CE_
MT8OX[_\  F'_  H_X:\^.7_1B_CO_P "8?\ "@#WRBO _P#AKSXY?]&+^.__
M  )A_P */^&O/CE_T8OX[_\  F'_  H ]\HKP/\ X:\^.7_1B_CO_P "8?\
M"C_AKSXY?]&+^.__  )A_P * /?**\#_ .&O/CE_T8OX[_\  F'_  H_X:\^
M.7_1B_CO_P "8?\ "@#WRBO _P#AKSXY?]&+^.__  )A_P */^&O/CE_T8OX
M[_\  F'_  H ]\HKP/\ X:\^.7_1B_CO_P "8?\ "C_AKSXY?]&+^.__  )A
M_P * /?**\#_ .&O/CE_T8OX[_\  F'_  H_X:\^.7_1B_CO_P "8?\ "@#W
MRBO _P#AKSXY?]&+^.__  )A_P */^&O/CE_T8OX[_\  F'_  H ]\HKP/\
MX:\^.7_1B_CO_P "8?\ "C_AKSXY?]&+^.__  )A_P * /?**\#_ .&O/CE_
MT8OX[_\  F'_  H_X:\^.7_1B_CO_P "8?\ "@#WRBO _P#AKSXY?]&+^.__
M  )A_P */^&O/CE_T8OX[_\  F'_  H ]\HKP/\ X:\^.7_1B_CO_P "8?\
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M'?\ X$P_X4 >^45X'_PUY\<O^C%_'?\ X$P_X4?\->?'+_HQ?QW_ .!,/^%
M'OE%>!_\->?'+_HQ?QW_ .!,/^%'_#7GQR_Z,7\=_P#@3#_A0![Y17@?_#7G
MQR_Z,7\=_P#@3#_A1_PUY\<O^C%_'?\ X$P_X4 >^45X'_PUY\<O^C%_'?\
MX$P_X4?\->?'+_HQ?QW_ .!,/^% 'OE%?-7@C]O7XF_$'29=;\*_L8^+[^VA
MO);62:ROXI$66-MKH25'S \$8X]:V?\ AKSXY?\ 1B_CO_P)A_PH ]\HKP/_
M (:\^.7_ $8OX[_\"8?\*/\ AKSXY?\ 1B_CO_P)A_PH ]\HKP/_ (:\^.7_
M $8OX[_\"8?\*/\ AKSXY?\ 1B_CO_P)A_PH ]\HKP/_ (:\^.7_ $8OX[_\
M"8?\*/\ AKSXY?\ 1B_CO_P)A_PH ]\HKP/_ (:\^.7_ $8OX[_\"8?\*/\
MAKSXY?\ 1B_CO_P)A_PH ]\HKP/_ (:\^.7_ $8OX[_\"8?\*/\ AKSXY?\
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M  )A_P * /?**\#_ .&O/CE_T8OX[_\  F'_  H_X:\^.7_1B_CO_P "8?\
M"@#WRBO _P#AKSXY?]&+^.__  )A_P */^&O/CE_T8OX[_\  F'_  H ]\HK
MP/\ X:\^.7_1B_CO_P "8?\ "C_AKSXY?]&+^.__  )A_P * /?**\#_ .&O
M/CE_T8OX[_\  F'_  H_X:\^.7_1B_CO_P "8?\ "@#WRBO _P#AKSXY?]&+
M^.__  )A_P */^&O/CE_T8OX[_\  F'_  H ]\HKP/\ X:\^.7_1B_CO_P "
M8?\ "C_AKSXY?]&+^.__  )A_P * /?**\#_ .&O/CE_T8OX[_\  F'_  H_
MX:\^.7_1B_CO_P "8?\ "@#WRBO _P#AKSXY?]&+^.__  )A_P *S/&'[<_Q
M6\#>&;WQ;XE_8J\965A80F6YNKN^A2*-<XRS!3@<^AH ^CZ*^?-._;*^-&J:
M?!J=E^P[XXEAN85EADCNX2KJP!!!QR"#4_\ PUY\<O\ HQ?QW_X$P_X4 >^4
M5X'_ ,->?'+_ *,7\=_^!,/^%'_#7GQR_P"C%_'?_@3#_A0![Y17@?\ PUY\
M<O\ HQ?QW_X$P_X4?\->?'+_ *,7\=_^!,/^% 'OE%>!_P##7GQR_P"C%_'?
M_@3#_A1_PUY\<O\ HQ?QW_X$P_X4 >^45X'_ ,->?'+_ *,7\=_^!,/^%'_#
M7GQR_P"C%_'?_@3#_A0![Y17@?\ PUY\<O\ HQ?QW_X$P_X4?\->?'+_ *,7
M\=_^!,/^% 'OE%>!_P##7GQR_P"C%_'?_@3#_A1_PUY\<O\ HQ?QW_X$P_X4
M >^45X'_ ,->?'+_ *,7\=_^!,/^%'_#7GQR_P"C%_'?_@3#_A0![Y17@?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ KPK_@GK_R1+5O^Q[UG_P!*37NM0:=I>F:1 ;;2=.@M8VD9VCMX512Q
M.2V% Y)ZGO0!/1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 >%?\ !/7_ )(EJW_8]ZS_ .E)KW6H-.TO
M3-(@-MI.G06L;2,[1V\*HI8G);"@<D]3WJ>@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \G_;H_Y-&\>_\
M8"?_ -#6N[^%O_),O#G_ & ;/_T2E;%_86.J6<FGZG90W-O*NV6">,.CCT*G
M@BGQ1101+!!&J(BA41!@*!T '84 .HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\G_;H_P"31O'O_8"?_P!#
M6O6*BO["QU2SDT_4[*&YMY5VRP3QAT<>A4\$4 8_PM_Y)EX<_P"P#9_^B4K=
MIL444$2P01JB(H5$08"@= !V%.H **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** /)_VZ/^31O'O_8"?_T-:[OX
M6_\ ),O#G_8!L_\ T2E;%_86.J6<FGZG90W-O*NV6">,.CCT*G@BGQ1101+!
M!&J(BA41!@*!T '84 .HHHH **** "BBB@ HKYQ_:(_X*O?L/?LS?M(^ _V0
M?'OQ>@O?B5\0_$]CH>C>$-!5;JYM);N988IKPA@EK%N=?]8PD8'*(_-+_P %
M$?V_=<_8C\)Z-I_PH_98\;_&OXB^*1=/X9^'?@2T=II;:U$9N;RYG6.06MM&
M9H$,A1RTD\2*IW$@ ^C:*^,/^"-__!9GX;_\%=O WC2;3?@SK7PZ\;_#G4[>
MS\:^"]9N_M7V,W!G$#QW'E1&0%K:=&5HHW1XB"N"K-T2_M'_ +:'QWA^-WAG
M]ECP_P"#([_P[\6_^$'\!>(?$\$XLM+AMM&LKC4M3OTC<O=[+Z6ZM8HH0FYU
MB#X42. #ZMHK\V?^"/?[7?\ P5-\1?M[?'[_ ()]?\%%-7\->.C\)K'3KZU^
M)?A/0TLK437J0SP63>5'$C&2VG$H4QB2,P2JS."IKS[XO_M=?MV?"?\ X.=/
M@7^R#\8OVCX[[X6^+_!.HZOI?A;PWH;:5IXDFT[5XHX[E3/-)>RI<6*$/(^T
M&0%(X^X!^LEQ<6]I$9[J=(T!&7D8*!DX')]ZYGQ=\<_@G\/_ !?I?P^\>?&'
MPMHFOZV0-%T/5_$%M;7E^2VT""&1P\N6&!M!YXKY\_X*EE?';? #]F2/,Q^)
M'[17AW^T+)3S+IVBBX\1W)8=T_XE$:-CG]X*^"?^#BS_ ((T_LK6'[$_Q+_;
MEG;Q-X@_:&U+QMID^B>*9-;NI)]5GOM7M[.WT2WL!(T(ABMIA% D2"4?9D8N
MW[S< ?KM\9OCG\)_V>_"$?CKXQ>-+;1=.GU*WTZQ,L<DLU]?7#B."TMH(E:6
MYN)'.U(8D>1S]U363\%_VKOV=_V@_!^N>.OA-\5=-U'3_"^I7.G^*Q<B2RN-
M!O+?/GV]_;W*QS64L8&YDG1&"X;&"#7Y%_\ !8CQ?\>_V9/B%_P2@^'_ ,:_
M%ESJ%YX=\;Z*WQ)U&ZNS/_:&LV/_  CUK/<22,3N<B>_(D))/G.>W/4_L1>+
MO&GP'_X.TOVG_P!GC2[F2/PK\2/ ]KXAN[ $B*6\2QTRYCN<=-RM<WL>?^FK
M4 ?>?[,G_!6_]C#]L?\ :^\8_L9_LW^-[OQ-K_@/P\VJ^(=:M;/9I@VW,=NT
M$,KD-.ZO(I9T0Q888D8D@>4_\%0/^"O/[0_[$.E>(_&'[-W_  3K\2?&'PC\
M/-K?$[QTOB6'2]-T<[4D>" >7-/>/&DB--+'$8;?)5V+)*L?RM^SLC?!+_@\
MH^,VA1%DM?B7\'4DMT<?>;[!H]RY'K^]L)N>P)'J:_0G_@JY^R9^T3^W!^Q/
MXT_9C_9S^.^D> M0\5Z-/9:C=ZMX>:]74;=UPUEY@E7[)',-T;S".5@K_*O!
M! /0_P!C+]J3P9^VQ^RQX%_:M^'^BZAIND>.O#\.IVNG:H@%Q:ELJ\3[20Q5
MU9=PX8 ,."*]-K\_?^#:W]I+]H7X_P#_  3FE\'?M,^$]/TGQ'\'O'^H?#A$
MTW2H;**6VTNWM G[J!5A!B,SVQ,2A#]FSC.XG] J "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHKYOTO\ X*Q_L,^*/VXM(_X)X_#[XQ6WBCXEZG9W
MMQ=67AT+<V>EBUMVG>.YN0PC64HCXB0NZE3O5!@T ?2%%?%O_!47_@KAXT_8
M#NIO#'P+_81^('QVU[2/#@\0^,D\+>9:Z9X9THM*J37EZEM<;)7\F9UA$9/E
MQ/(Q5<$^C?\ !+/_ (*2?"?_ (*J?LE:=^U1\)_#>H:&KZG<:3K_ (>U.022
MZ5J, 1I(/-4!9EV2Q2+(H&5E7*JP9% /HRBOACPA^T-_P4\_;C_8Q\/>//V/
M+KX<^"M=\<ZCXCU"T^('B?3)[BQTC0H=6N;;1X[>T#2&YO;BU2&=YGS @60[
M&,D:##_X(.?MJ?\ !03]L+X#_%GPO^VQI6AR^,OA?\1-0\):5\0M.T@1:;X@
MN+;?',PBA\I)U@G3#/"(E=)$7"NKL0#] Z9-<6]N46>=$,C[(P[ ;FP3@9ZG
M@\>U?E1_P39_:V_;7UK_ (.&/VD_V)OVM_VBG\867A'X=PWOA33;#2O[*TNT
MA,VF3HT%B)9-CF'4D#2/)+(P09D(  ^I_P!JN"_^+W_!3K]GCX*Z'?+"_@?P
MKXQ^(]]-+!YD=M<+:0:#I\A3($AWZQ=N%)&?(//&0 ?1+?'/X)+\2Q\%V^,7
MA4>,6C\P>$SXAMO[3*;=^[[+O\W&WYL[>G/2LWXT_M,_!/\ 9]N]&TGXH^+Y
M;?5/$<EPGA_0=*T>[U/4]3\B/S9VM[*RBEN)DBC^>1TC*QJ06*@BOQ5_X+1_
M\$0_@I^S7X\_9H\;?\$_=3\66?[0OCKXZ6FF7'B2_P#%=W>ZCKTS1S7MSKUP
M97(BDMY84EDDA6.-4G;*X"X]L_:<^+/C'1?^#P3]GSP5XBNIH]#G^"%_9:-"
M_P#J_P!_9ZY,\BC^\\ULD9(SGRE';@ _3OP9^U5^S?\ $+X"0?M1^"_C9X<U
M#X>7-D;N+Q?#J:"R$8?8P9R1L=9 8S&V'5P4*AOEKS7]@#_@J#^RQ_P4Q3Q]
MJG[*6M:GJNC_  _\1QZ->:U?Z>;6+49'A$HGMD<^;Y)^90TB1L2C87&"?S]_
MX-=O&/B;X??M2?MP?L/ZEJ$SZ)\/_C5->:!9.#LMY)+_ %.SNB ?NAELK0@#
MC@FH_P#@VLD'PN_X*5?\%"?V;'C\J#2_C"+W2(>F($U36H2WT,;6Q'']* /M
M+_@L]_P5E\"?\$C?V7(/C-JGA:/Q-XJUW5H]/\(^$VNS#]M8,AN9Y'4,4AAB
M8$L <R2PIQY@(^MM,U&RUC3;?5]-G$MO=0)-;RKT=& 93^((-?SO?\%[?^"A
M_P $OVM?V=OCWX!O_A#\4;CX@Z+\0;70=$O9? LG]@^%M'T?5G@827Q;:LMY
M(UQ.[JI#&2T@)(MU<_LY_P $E_VFK[]KK_@GE\+?C=J7PR\3>%)K[PI:6SV/
MBG3C;37?D0I$+V$=)+:X"B:&0</'(IH ^C**** "BBB@ HHHH **** "BBB@
M HHHH **** "BBHKZ^LM,LIM2U*\BM[:WB:6XN)Y B1(HRS,QX4  DD\ "@"
M6BOG?]E[_@J=^Q;^VA^TAXY_9B_9C^*(\7ZS\.]-@N_$>KZ7#NTO,DSPF*"X
M)Q<LC*-S1AHAO4"0G('S?_P4U_X+Z^)_V!/&.O6_PT_X)U_$/XK>"? U[;V/
MQ$^)]C=OINA:->2[,VL5Q]DG6YEC\R-).8T25Q$7WY  /T8HKP?PU^WY\(OB
M5_P3GNO^"C_PX:Z_X1#_ (5E?^,+6+6+;RIXHK6UEFDAF0,0'1X7C;:Q4E3M
M9@0Q\!_; \6_\%K_ ![^R/HOC?\ 9-\:?"[X9Z]H7PML/$/CS7?$VD//+JVM
M?81<WECIT$RSPV=K&0R^;<AW9W" H(FD< ^]J*^.O^"2/[67[8'_  4#_P""
M5O@W]HKXGZ7HO@KXE>)+6[BM]8OO#<L]A=Q173Q0ZDMBMQ"Y66)0P42HK-EU
M_=LJU\^_\&TW[8O[57[3^H?M0^#_ -L3XSW_ (T\8>!OC MG+<W:K#%9Q&.6
MV\FWMDQ':P;[&1A&B@;F<G<Q8D _40W%NMPMJTZ"5D++&6&XJ, D#K@9'YBN
M8\'?'3X)?$3Q9J?@+X?_ !B\*Z[KNBY_MG1='\0VUU=V&&VGSH8W9XL,<?,!
MSQ7REXI^&5Q^UU_P4Y^-OA6U\;ZKX;LO!'[/V@>!I=;T28)>P2:]J%WJ.IBV
MD_Y83&RLM/59>6C:5)%R5Q7P[XM_X)#_  9_8B_X.$_V7-(_X)F:+JWA"TNO
M#6J>(OBEH\/B"[O(;+1K3$#3RO<222A+QI#;;68HTH4@+R: /UB^/7[</[+/
M[,NK7&A?&GXK1:7>6.A_VUJUM:Z5=W[Z5I?F^5_:%Z+2&7[%:>9E?M$_EQ95
MOF^5L7_C'^U]^S'\ ?@0?VF_BU\;O#^E> VTU+^U\3"]%Q;WMN\7FH]MY.]K
MK='\ZB$.67D CFOR.^ ^K>+OC;_P7?\ ^"D'[,7CV=[R?QC\"+O3M.L[ALC[
M%%9V=I!$@/13%?J<#@ER>IS7I?\ P:_>,/$7[7O_  09\2_ 7QEJ4M[%H.N>
M)_ =@]S\S)9W%C!=+%D]57^TF51T"A5'"@4 ?H9^P?\ MP?!C_@HE^S=IG[4
M_P  4U1?"^L:GJ-G8#6;58+EOLEY+:F1HU=M@<Q>8H)#;)%W!3E1\0^*_P#@
MNM^W_P#$#XY:G\+/V-O^"*/Q$\9^%;;QE<Z)I/Q9U?4+RTT/4[>*[:V_M&)A
MIYC:W;:9,B<X7WKD_P#@S\\8:WXW_P""/WB7P'I6KC3=3\-?%/7-*L;F:U\W
M[(\ME8W22F(LN\+)<L=N5SM(R.M>)_'[_@A!_P %3_\ @F-\)-3_ &N?V!O^
M"O'CKQ1>_#G2YM:U#P)KR7-G:WUC:(9Y8TA-Y<6UR BN1;2Q!6Q@-N(% '[L
M45Y_^R=\6?$7Q[_98^&GQT\8>'/['U?QI\/]&U[5-(V,OV&YO+&&XE@PW(V/
M(RX/(V\UZ!0 4444 %%%% !1110 4444 %%%% !1110 4444 %%8_C[X@^!/
MA5X.U#XA_$WQEI?A_0=)MS/J>LZU?1VUK:Q#J\DLA"H/<GO7C_["O_!2+]E;
M_@H]I/C3Q/\ LG>+KS7]%\$>*/[!OM:GT]K>"]G^SQS^;;"0B1X<2;0[HFYD
M;:"NUB >\45^6'[8/_!SA:?LA?%JPN?$G_!-_P"*5Y\#K[Q-)HMI\<KN4V-I
MJDD3LLL^G6TELR7D)$<CQ,UQ$9HT+J,5]I?MT?M7^(/@C^QLWQV^ $FEZKK_
M (EU/PYI/P_75+662VO;S6M3L[&U9HU:-V7%V)"N5.$/IB@#WVBOS3_X+3?M
M!?\ !:#]GSX.>,OVQ?V3?'?PX\!?#CX87D;3>&=?T4:CKGBFU6=();IWD1X;
M>)I7'E01E96B_>-*CN(5^@OB9\9?VV/B+_P2;C_:3^'DFD_"SXLW/P:_X2G4
M],U;PL^J'3]0&EFZ>SA@EGC$3F4; TPE\L'#Q.0: /JJH9]1T^V6=[F_AC%M
M%YER7E \I,$[FR?E& >3QP?2O@/_ (-E_P!JGXM_M??\$J]#^)WQV^)6I^+O
M%MOXVU^SUK7=9O#/<SN;UKE%9B?E58[E$1  J(J*H"J!5[P+^REX$_X*0:]^
MT_)\6_$.LV_@GQ5\?(/#.MZ1HFH26CZ]HGAK2K:Q?39+B%EEB@?5?MLDGELK
M,J-%D!V( /L_X:_&;X/_ !FL;K4_@_\ %?PUXKMK&X\B^N/#6NV]_';RXSY;
MM [!&Q_"<&O/?B-_P4+_ &,_A)XZN?AW\1/CMINF7UAKMGHNK7<MG<OIVE:E
M=H'MK*\OTB-I97$B%66*>5'(=3C#+G\S/^"8'_!/;P_^Q3_P<@?&SP!^Q0VK
M:1\%O"_PJL9/%^B/J\]U:6>IZ@EO-::<SRLS2.H$UQ&9"SI&7&[YOF^1/@=J
MGBC]H_\ X(I_\%,_#7Q",EUXJL?C0GC#6#<',L=Q_:4-Q*Q[C_CPF7L,9'K0
M!^]/[<7_  4._9*_X)U_"JX^+?[5/Q3@T2S2,M8Z7;0M<ZAJ+YPJ06T>7;+$
M+O.V-2PWNH.:[/\ 9T^/_@K]I;]G'P3^T[X-CGLM \<^#M/\1V$6IM&LUI;7
M5LEPL<VQF19$5]KX8@,K<D#-?F9XE\>^+_VW/^#074?B!\1+J;4]:?X$S2ZC
M>W.3+=2:'>,OVARW+.W]G"1F_B)+=ZK_  '^+'COQ5_P9WS^./AU=W":K8_L
M_P"NZ2LUH3YD=O97-W87!!!R-MO!*<CIC/&* /M_]E/]O#5_V^O$NI^,_P!D
M_P )Z<_P<\/^()=*?XGZ_-*3XIN;=MMRFD6<84M;(V8_MTTBJ9 P2&55+#Z5
MK^;GP3^T1^T__P $X_\ @C%^QI_P4<_8Z_:-\;W6C-XVO?"OC_X4:AJ$5SHF
MH[[_ %&0PQV8B A9VLKM?,&92;F-PX8 G^D:@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH ***XC]H7]I+X#_LG_  MU'XU?M'?%31_!_A?2XRUWJVLW
M7EIG!(CC49>:0X.V.-6=CPJDT =O17BO[+G[?W[-_P"UQ^QW'^W;\,_$-[:?
M#E[;6+J34]=LOL\L%KIMU<V]Q<21*S,B'[+)*H/SF-D+*K$J/B/P]_P<LSZ%
M^VSX%_9>_:A_X)I_%;X0>%OBCJ\.G_#SQWXU9H+C43/,D$$LNGO;)Y*&26(2
M;)Y7A\Q2RT ?J-17B'[5_P"T7X\^$OQ@^!'P9^&%EIMQJ?Q3^)\FEZN-2MWD
M^SZ'9Z1?ZC?3Q['7;(/LT$2LVY09QD$D5^?_ /P5*_;._P""]G[$_B_X?_M;
M^#U^&MY\.?%OQ#LO#6G?L_Z;HK7>N7+78EDMK>YNC&6DNY(H9 YM95CADVA5
MG16D8 _6^BOA[_@X'^+O[9W[/W_!,OX@_M ?L@_&FR\$ZAX7TZTFU1U\."[U
M*X@FO8+:5;:Y:;R[,I'.TAD\F5SL^1HC\]>O?\$JOC'JOQK_ ."8_P "/C%X
MS\3S:EJ>J?"31)M>UC4;LRRW-Y'91QW,\LKDEG:5)&9F)))))SF@#W#Q'XU\
M&^#O#]]XM\7>+=,TK2M,4MJ6IZE?QP6]H!C)ED=@L8&1]XCJ*A\ _$;X>_%;
MPS#XU^%WCS1O$FC7+,+?5M U2&\M92IPP66%F1L'@X/%?GM^R7_P3C^ ?_!3
M7]@;P/\ $']KVPUG6O"GQ#\;>+?BCJ/@BWU>ZTZUU6[US59KG3+FX>VDCE/V
M73W2..,,$)E+'.U:^8_^"0?[,?Q5_8J^&'_!2BV_9S\8ZX_PO\*WOB'1/A";
MR]:7S-9TRQU'SIXV  :2+=90/,@'F-$ >8L  _5GPS_P4%_8X\8?$S2/A)X>
M^.>G3ZOXBU*^T[PS.UG<QZ?KE[9,5N[2PU!XA:7T\+!EDA@ED="C@J"K8X7_
M (*(_P#!7O\ 8D_X)D:'8S?M&_$2237M6N$@TCPAH$*W.HW#,5^=U+*EO$ V
MXR3.@*@[=Y&T_@[\1?%'B"?_ (-,OV?/BSX"U::P\1_!S]IBXFTO5[0[9K&1
MKK5[E65NQ$UU;N#ZJM??O_!U=(/VA/\ @A-X#^/#6"K(OC'PMXF.Q<>4+S3K
MF$CGD#-X!CZ>E 'WE_P5$_X*'K_P38^ VA_%^R_9^\2_$_5O$OC2V\-:%X-\
M),?MUW=36MU<Y0+'(S!8[20D*A/Y5\X_L ?\%K?VS/VR?VZ=%_9+^,W_  2H
M\3? W3M1\&:EXFDU+QSKMT;]["V>*!98[6;3[8A6N+BWC))(&XX)(K[E_9Y\
M5Z=\8_@)\.OC%?6D%Q<:SX.TW5[6YDC#-$UU91NS(3DJ2LA!(/()%?-/[-L,
M?QF_X+9?M&_&B:42P?"CX:^$OAKHTB ;1+=^?KNH*".X,]B">N1M/W* /M&B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **\7_;=_P""@_[(_P#P
M3N^%<GQ;_:P^,%AX;L2&&FZ=DS:AJLH'^JM;9,R3,3@$@;%SEV49-2^-/VWO
MA-X-_8JL/VY_[#\1:GX9UGPII>M^']#T?2_M6KZJVI+!]@L;>WB9A+=3R7,$
M*HK%=\@^;;EJ /8Z*_.#]A+_ (.#Y/VF?V^S_P $Y?VHOV#/''P&^(.J64]W
MX1L_$^I&[.I1Q6TEV1,AMH#;,UO%)(A'FQL8V7>&VAOJ?XN_M,_%#PQ^V1HG
M[.WPP\%6NOVT'P=\1>,_$FG_ .KO+FYAN["TTFSMYF<10^?)+?[FD4C%NIRH
M#9 />**_*'QA^UE_P75_9(_X*R_ KX(?M$^*?A?\1/AW\?\ 6+RV3PA\/_#T
MD7_"+6MH8#>SK<2QK<L+:.YBE\V5W254D'EQ';@_X.JOVI?V^_V,OV6O"7QA
M_9K_ &B$\)^$M7\?VF@Z]IOA_0VAU:;?:W%TK-J1G8Q1$V;H4ABB8AP&D8$K
M0!^KU<[X_P#B[\)_A1X7'CCXI?$_P[X:T4RK$-8U_6H+.U+MG"^;,ZIN.#@9
MR<&N"_;7_:%T_P" O["?Q0_:<TJ^!3PU\,=6UW2I0<&:6.QDEMU7/=Y/+49[
ML*^5/$'_  0:_8]_: _9*^&?PZ_;@FUS5-/^&/P.TOPUH&GQ^(KC3;3PM>16
MF=0UA1%*$ENY9 A9IP\:K;(NS&\L ?>R>./!4G@T_$6/Q?I;>'ETXWYUT:A&
M;,6@0R&X\_=L\H("Q?.W:,YQ7FOP3_;S_9*_:'\=1?#+X3?&.UOO$%UX>CU_
M2])OM-N[";5M(D8HFI6*W<47V^S9A@7-OYD1R/G^89_$+X&>%?VF?V?_ /@S
M1^,FM^(]<U8P>*_$PN_!$=W)('M?"M[J^D6,JQQOS'#.5U"8*,*4O#(,[\F?
M]KWXS>,/AC>?\$@/VW/AM?-#J-QX0TGPSKES;-@3PK'HMK=6S8(&V5+F^3;V
MRWI0!^N?Q]_X+!?L/?L_?M7^ ?V(]<^(\FM?$KX@^*+;1+'0/#\ G73))I3$
M)+V8LL<($@V>6&:;<0/+QDB?]NC_ (*5^"_V._C;\&_V6M(\)6_B+XC_ !Q\
M2OI?A'3-1UL:;86D41C$UW=W(BF=%!E18XTB=II"4&W!8? '_!T;&?A9^VK^
MP7^U-:Y3_A%_C$T=[)CY2$U'1KN,'IVAGR.X/M7H/_!T7\#/V:?CQX0_9^^&
MWBN;6-*^-GC/XMV7A;X)^*=&OA;II,][<VL=U<7K$$O:QDVS[4VS>:(O+909
M,@'UE^QY_P %)+O]H+]LSXT_L!?%OX/)X/\ B-\&I+&ZN'TO6GU+3=;TF\AC
MFM[R&9X(&B?;-%OA=#@R#:[X?9]35^*?_!$;XF_M??L3_P#!83XI_P#!-3_@
MH-X9TKQ=\1OB!X<@\16_QNAFFN-3\0VFGVL<%FLUQ*<RVGV6*14!5'BFBD5_
M,:0LO[64 %%%% !1110 4444 ?C7_P '5%K:?"WX]_L/_M0V=FEN?!7QP=I[
MF*,+RUYI=Z-Q&,G-E(PYZECW)K]=_B)XS\"?"KP=K'Q>^(6I6NF:5X=T>XO=
M6U>XC_X]K.)#+*20"Q4!,[1G) P"<5\D?\%G/^"2FN?\%??ACX0^"]Y\?K3X
M=Z-X3\5IX@&JVOA9]3U"XG6WF@$*$W4"0)B8L6Q(2R+]W'/H?[:W_!/:\_X*
M%?LH6O[)_P"T?^TIXITO3+J[MIO&.I?#&SM]'D\0+!AE@D6Z6]\J$RA)613R
MT:C(4$$ \#_X(]_ CP/^R)K?Q:_:-_:"U73O"7Q9_:H^(FL>/;SP!<7*?;=
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MB#I?ASPI))>2^&_A[>6FG6>J:BZ!!=SK<V]TYV(9%C3?\@ED^8EB:YO]E?\
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MKQ'JFGZ5/)<Z?HEH)KF2SLEE=(GN&5KJ:2679$':0*%Q&';F?V0_^"/OCO\
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MDVE^$C?7\]UY)B&)GNXTB0!F./*8DA3N&"#ZG^U=_P $\OA/^W=\(/"W@/\
M:NU.>^\2>#-=M]=\+^/?!<1T?4-&U6!@8[RTWO<"-L!=R/YD;%0Q3*IM^@**
M /&_A/\ L/?"+X:?M ZI^UIK^K:UXU^*6K>&K?P[-X\\726S7D&DPN9%LK>*
MT@M[:VB,K-(_E0JTCMERV ![)110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !17%?\-&_ G_A>W_#,?\ PM;1?^%@?V+_ &O_ ,(G]M7[9]CW8\W9
M^NW[VWYL;>:[6M:M"O0Y?:P<>9)JZ:NGLU?=/H]A)I[!11160PHKY>_X**?\
M%9_V=?\ @E[8Z1X@_:B\">/%T/7'DCT[Q!X;T2WO[5I(_+WHX6X$L)!EC&9$
M56+85F->Z?"?XY?##XU?!#0/VB_ /BFWN/"'B7PW;Z[IFKS.(T^PS0B99'R?
MW>$/S _=((.,&@#K:*^/OV#?^"VG[)'_  4C^+WB+X-?LL>$?'^I7WA)!)XF
MO]7T"#3[;3HS*T2N_GW*RMN=& 1(V<8Y48./L&@ HHHH **** "BO#OVM_\
M@HA^S#^QAX@\,?#WXJ^)]0U'QOXXNOL_@GX=^$M)EU/7==DSC]Q:P@E8P0<S
M2F.(;3EQ@US/Q7_X*@?#3]F_0].\1?M8?L^?%;X8V>MW\&GZ#=:[X>L]3M[Z
M^G8)#:&XT6\OH;261V"J+MX%8YPW!( /I>BBB@ HHKYZ_9$_X*;?LT?ML?'W
MXP_LW?!=?$B^(O@AXA&C>,&UK0S;6\T_FSPE[:3<QD026TRY<(QVA@I4AJ /
MH6BBB@ HHKY\_P""A?\ P4C^"/\ P3+^%]K\;?VD?!OC"3PA<ZE#I[Z_X;TZ
MVNX[>[E$ACADB-PDP)$3'>(R@R 6!(% 'T'17"_LV?'G0_VGO@EX=^/OA+P=
MKNC:'XLTFVU7P_'XBAMXKFZL+B".>"Y\N&:7RU>.12$<K(,'<B\9[J@ HHHH
M **;++%!$TTTBHB*6=V. H'4D]A7SA\5/^"HGP#^&7[-NK?MAZ?X)\:^+/AA
MI&H"T?QEX2TFWN;>]S<QVBSVD4EQ'/>0-<RB)9H8W1RK.A:/#D ^D:*\/_X)
M^_\ !0O]FS_@IC\!3^T5^R[KM_=Z%%K5QI-[!JUD+:[L[N$(S1RQ!FVDI)%(
MO)RLBGV'DVJ_\%ROV-4_;Y?_ ()J^"O#_COQ7\4QJ4]C!8:!H4'V.XG@MY+B
MY5+JYN(8\0+#<+(Q("O;RIDE: /LFBO$?VO?^"A/[,7[$?\ PC>B_&KQ5?2^
M*?&M\MCX(\!>&M*EU/7?$%T2 (K6T@#,WS$*9&*Q D N"0#ROQ7_ ."H'PY_
M9O\ "-KX\_:Q_9S^+7PPT?4;J&TTK4M>\.V>IP7-W,0L-L\FBWE\EG)(Y5%-
MV8$+L%W T ?3%%?(W_!0#_@M'^R7_P $R/B-X<\!?M>^%_'NA6OBTO\ \(]X
MILO#L=YI=VL9C$Y$D,YD4PF5-Z-&'PP*JP92?7OC]^V-X ^ WP<T7X^P>#?$
M?CCPIKUUIL%AJO@&*TOE;^T;BWMK!P'N8S)'/-=0JKQAU&_<Q5?FH ];HKXR
M_;L_X+D_LI?\$W/&WAKP'^US\,?B;X=NO%VEQWN@W</AZTNK.XR$\Z#[1%=M
M$LL#N(Y5+84X8%HW21O7_P!H+]N/PY^SD_P[L_%7P)^(>LWOQ.UJ+1O#.G>%
M+"PU"?\ M%X);C[/*$O,(%@@FE><%K=$C):4#% 'MU%>>^%OVE_AUK_QFN/V
M=]<BO_#GC>+1$UFT\.:_'''+J.G$JKW5I)%))%<I%*PBE$;EHG*[U59(F?T*
M@ HHHH **** "BBB@ HKQ3XN?\%$_P!CGX%?$+4/A5\5?C#_ &5K^E>5]OL/
M^$?U"?RO-B29/GAMW1LQR(W#'&<'!!%<W_P]O_X)[_\ 1P/_ ):FK?\ R+7-
M+&X.$G&52*:\U_F?/UN+>%<-6E1K8^C&<6TTZM---.S33E=-/1IZIGT?17-_
M"/XN?#WXZ_#W3_BK\*O$']JZ!JOF_8+_ .R2P>;Y4KPO\DR(ZXDC=>5&<9&0
M0:Z2NB,HSBI1=TSVZ-:CB:,:U&2E"23333335TTUHTUJFM&@HHKXZU[_ (+D
M?L3^ /V[['_@G/\ &B#QAX#^(^IWT%IIR^*]&ABTVYDN(]]KLO(9Y(V$^52,
M@X,C!#M;*AFI]BT5Y3\6OVKM,^$?QS\%? 2^^"_CC6-1\?27*>']5T.TL9+#
M=;1>=<B:66[C:#RXOG.]!O\ NQ^8WRUZM0 4444 %%?.7B;_ (*??L]>"?\
M@HAX6_X)B^,?#GBW3OB7XUT6?6/##3:7 ^FWUA%;WL[7 N(YV**1I]T@5T5]
MT>"H!!/T;0 4444 %%0ZCJ.GZ1I\^K:M?0VMK:PM-<W-Q*$CAC4%F=F; 50
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M7 .&52"* /HJBBB@ HHHH **** "BBB@ HHHH **R_\ A-/"?_"9_P#"NO\
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M !8#_D)_\??_ !./O_\ ((Z?^37_ #S[>97ZP^$_V0?V4_ OAFP\'>$_V;_
M]EINF6J6]E:Q^%[4B.-1@#+(2Q]6)))R22237ZIXD^(?A/G.'P<)8-XQJ-UR
M2=)THM:0;2O?O"UHVN<F%PV,@Y>]R_C<_-/_ (BX/V=O^C1?&O\ X/+3_"OU
M:^'_ (NMOB!X"T3QY9V;V\.MZ1;7\5O*P+1+-$L@4D<$@-C\*P?^&;/V=/\
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M&U/P#'X8UK4]+L#8F58X%BCNH8GEG\F5&2.5,O(%= >1Q7RUX+_X(6ZCK?\
MPS3X"_:;_:)TWQEX"_96EEN/ NAZ3X.DT^YUZY5X#92ZG+)>3H5MEMXAY<2*
M)CN+%5;RJ /CC]A+Q#XG^-__  >&_'37?CD[/J/@;PIK5IX*MKKD6EK!]@L[
M80@YV![2XFF.W&3/(W\;5^DG_!1[_@H=_P $[/V:#I7[,_[>VLZQ90_$@>3X
M>L!X&U:_AUB6&6W;%O-9V\BF:*:6V8 ,'1VC/!P:S_VKO^"37A_XJ?MB^'/^
M"D/[+?Q7_P"%5_'?PY:FRN_$$FA#5-)\3V!A\G[)JECYL+3#RL1K-%+'(BA>
M6,<1C\U_;D_X(U?&[_@J!\:O@O\ %3]K_P#:0\*^'K#X*ZQ=ZCIFB_#;P=<^
M=JTMQ-8ROYMS>WCK"H.GQ *L+D!WRQXP <M^T3_P4V^)/Q/_ ."PD7_!.#P7
MXP\>>"?!?ACX/MXJ\1WO@+P3-J/B+4M7N5@-K;O%]EG>VMH(KJ*9@(P6D4QR
M-M.P_.7_  44_P""IO\ P6._9C_X(=_"/]JGQ]JFL_!OX[/\7AX.\;6M]X+T
MIX]:LC8ZE<1WIM;VTF6%W%I;G,.Q-QFPNTJJ?9G[<W_!&KX@_&W]OKPE_P %
M.OV+OVMS\'_BUX?T9=(UE[_PBFM:9KMF%>,+-"9HB&,,C1-DL&5(BOEO&'+?
M^"HO_!&7XH_\%0_V,O"/[*?Q(_;>;3M2T7QTGBSQ%XSO/AZ+Q]2O4M+JUC@M
MK2*_MXK&U1+MPL8,K$1H6=Y#+)( >1? []K#]NKX)_\ !Q$/^"=WQB_:NO?B
M3X,\8?"4^(KRVU+PU8V,6E:BL,LO^@);QAX8%,+(L<DDK%'_ 'CRNHDKS/\
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MG)9Z8([?4WNX@D;NKR2,BVSM<2PIN<J]P3NRH)\"\>_\$5?BUXQ_X+(>'_\
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M0'Q&^+/CCXW>&M=T'QU>6%S9>&]-\!3V%QI36UHMKS=OJ,XN ZQHQS"F"#C
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MA.%F675[KS[NY:2=UG<+$I5(RJ-N=E!H ^'/#?[:O_!33X^?&#_@HC\)I?\
M@H/XFT'0?V:-)UC5/A^^D>#/#\6H>99_VE);V\MRM@NZW(M%64!?.?";98\2
M"7RKX[?\%;?^"IO@S_@B[^SI_P %<8OVQ)QXBU3XJMX3UGP38^$M-ATK6[2#
M^U ]Q?9A:22YF;2B&,311(D_[N)'4R-]]_#+_@A=\3OAM\0?VOOB);?MG:%=
M7/[6VAZE8:I WPGF1/#;7;70,D7_ !.";D+%>3+M;9E@C9 4HWG/Q/\ ^#:/
MQI\3?^"3WPW_ ."4UU^WAIEIHOP[^(EWXKA\7)\(I&NKYY?MY2W,)U@+&%.I
M7!+[F+!8@ NUBX!I?\%(_P!L']O+P/\ \%U/V?OV"/V?OVM;_P %^ OBWX/E
MNO$5@O@_1K]K61/[15Y;:6YM&F24I:JR;Y'C67#,CINB;A/V:_\ @KG^TW^Q
M[^TQ^VU^Q_\ M2?$B_\ B]IO[./@:_\ &_P^\1ZY9VUOJUW:1K;M'I]Y+:11
M12[C?6@\T1J5(E.-I1(^<_X*H:)\4-3_ .#E[]B_P_X<^)NEZ3XP'PSG\OQ$
M?#WG6?VM3K!+-9/<;C!(RLAB$X<(Y"S*X$@^POV7_P#@BOX/\%_%#]HWX_\
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M_CRS59H@I:,G5-?^8;@1D=>01Z@UYGX<_P""D?\ P5O^,?\ P3U_:Z_:AO\
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MA']HCXZ?M*?!K_@H'X+N-<^/&J7&HZY%K7P'N)HM*N9+RYNE>U"^(%SL:[E
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M71O+IKN.Y*6]BM[%Y$:F)516GDV[Y6.XOP ?,WA3_@H-\<?@[^RY_P $T/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M(CQ%K'@^RN;X&, 1GSY(C)\H "_-P ,8Q7>T44 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% '"_$C]E[]F?XR>((?%GQ>_9V\"^*M5MXQ';ZGXD\(V5]<1(#D*LDT3,H
M!Y !KMK2TM+"UBL+"VC@@@C6.&&% J1H!@*H'   P *DHH **** "BBB@ HH
MHH **** "BBB@ HHHH *;/!!=0/;7,*21R(5DCD4%64C!!!Z@BG44 <!X/\
MV3_V6?AYXM_X3[P!^S5\/]#UW>7_ +:T?P;8VUWN/5O.CB#Y.3SGO70Z-\*_
MAAX=\<:I\3?#_P .-!L?$FN11QZWXAL]'@BOM02, (L\ZJ))0H4 !F(  QTK
M>HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
J**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>mgnx-20181231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2018-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:mgnx="http://macrogenics.com/20181231"
  xmlns:srt="http://fasb.org/srt/2018-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2018-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="mgnx-20181231.xsd" xlink:type="simple"/>
    <context id="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i59ab418442044814b66164966b88c82b_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromCollaborativeAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="ie7004ecc84cf491ab540ef15e8620bb5_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i10db7e65a275498b9298e6467e2ddd37_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i7d107c99b86241459c22fe452644f3a9_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="id8704ce91d804afb8569a95732959fd8_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:LesLaboratoiresServierAndInstitutDeRecherchesServierServierMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="icd9b6aa45a364d0c9cd302c42a5acd28_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i8986558becfd44b1af99bbdfcf581445_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ib59b65ae84da4d388e5723647e6142e6_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i4e5cae6e220c436aabafd5c2f3481b6c_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mgnx:LaboratoryAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i3e13e524660f42568e18e289608955ea_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i956d155068494f53b5097a07d15631f3_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="idbcb1304940d4ff0baeab52d79003f28_D20160101-20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromCollaborativeAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="i4f8ff4c21a3f4b04bcd0190d63617d17_D20160101-20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="ieb5bf739a8ce42039763affce9678d7c_I20180101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InitialApplicationPeriodCumulativeEffectTransitionAxis">us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-01-01</instant>
        </period>
    </context>
    <context id="ic3082c4bbda4473cb69446b2be52ec61_I20180101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-01-01</instant>
        </period>
    </context>
    <context id="i58ed5a015dbf42e19178b051b82c9683_I20180101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <instant>2018-01-01</instant>
        </period>
    </context>
    <context id="ia6869870ff9d444da346b6b8718b80f3_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromCollaborativeAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InitialApplicationPeriodCumulativeEffectTransitionAxis">us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i8195466a5e2c4a458ca23edc5bbb7661_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromCollaborativeAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InitialApplicationPeriodCumulativeEffectTransitionAxis">us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ic2e9f102d8434edb8909ccdd833da1f3_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InitialApplicationPeriodCumulativeEffectTransitionAxis">us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i5f8c7c83e37647699033616fbb46b432_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InitialApplicationPeriodCumulativeEffectTransitionAxis">us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i1158af44c1a44a528cf5faac76fc6bf6_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InitialApplicationPeriodCumulativeEffectTransitionAxis">us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i540a17d5cd3043469a51f6ba7e3d31b5_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InitialApplicationPeriodCumulativeEffectTransitionAxis">us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="if637c63a87b147fa81aa860bc98e569f_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromGovernmentAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="id7600d6be2eb4b27a2ed9c725fbeef09_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ic847642706c0496581735d8af543077a_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="iae2c0abc66c64857918562886c9ab108_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i4d00247415ba468e829a69e2a8739d09_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i4f49a198b4bb493aad3c0563be1a1b1c_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="if008fb95c70d4d6292a3deb9038402f2_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="ia589fee494a140259bbf8dd10ad98449_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ic4ae66e3b1a040229462cc9b00c106f7_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i989637b0c825400daad1d79fd200cfc7_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mgnx:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i17b1fb07ad7e461f85ee4cfd5083f136_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mgnx:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i7ebe96cc613b4300bdf8831b4feca588_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromGovernmentAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="iba7f249ad22445ea80c87ac974f09d4e_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="id2ed58086aad4a0d93e3102ea5a382bc_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="id0aa3dc3a1594241a90d2f208fc88fcf_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="iacc09d395c06412b8bc32c6bcf83092c_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="iaaa703135e5d42e3ad357819a2febb2b_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mgnx:UndesignatedPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i774ad7d035574588abdffa05896955f7_D20170426-20170426">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-04-26</startDate>
            <endDate>2017-04-26</endDate>
        </period>
    </context>
    <context id="i300212ce6416414283af0aa5ceb5e231_I20170426">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-04-26</instant>
        </period>
    </context>
    <context id="i1805f20c3a7b4d11b92ee3e187db18fe_D20170503-20170503">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-05-03</startDate>
            <endDate>2017-05-03</endDate>
        </period>
    </context>
    <context id="ie86be88df16c4586b769baf5bf4e5efe_D20180402-20180402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:FirmCommitmentPublicUnderwrittenOfferMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-02</startDate>
            <endDate>2018-04-02</endDate>
        </period>
    </context>
    <context id="ib0101bc440ae4fdeb05d3353b727f0aa_I20180402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:FirmCommitmentPublicUnderwrittenOfferMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-04-02</instant>
        </period>
    </context>
    <context id="i4d5db08e41a54c13a242bb974c98539c_D20160101-20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromGovernmentAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="ic563779cd1db4959a683e3166bd53d26_D20180402-20180402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-02</startDate>
            <endDate>2018-04-02</endDate>
        </period>
    </context>
    <context id="i0e9ac3017eb644d2bd213ae5a7dabd47_I20180402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-04-02</instant>
        </period>
    </context>
    <context id="i5511585976c54c42a03fe4ab0e7c9ec2_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mgnx:UndesignatedPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i37bd3dc2e0684382887e9c7141114e64_I20170518">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:TwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-05-18</instant>
        </period>
    </context>
    <context id="i225dfbff0423412ab9af487587a7a9dc_D20170501-20170531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:TwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-05-01</startDate>
            <endDate>2017-05-31</endDate>
        </period>
    </context>
    <context id="ice18cbfc8512491798f071290230dc95_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:TwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i0a9a71bb02554506a053e4b037c5a59c_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:EquityIncentivePlan2003Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i88e7a08234064f55a3fdcac46083d417_I20131031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:StockIncentivePlan2013Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2013-10-31</instant>
        </period>
    </context>
    <context id="ie68e03dfcb1349ea9e266215200f7c25_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:StockIncentivePlan2013Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ibb0c6525ae294173b7c08c959023d2af_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:StockIncentivePlan2013Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i080c9b1552014463931d10056bb7ec5b_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i69306bd3d52e4181a64ce4721f855103_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i0d5ecf2823e14c18aa6e251ac3292d51_D20160101-20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="i39e8ac06cdc74d939adfabe112ffd6a7_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i0c6d01ca77d7471c9706048782093e73_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i4f0c15f62cd64843837881b925628364_D20160101-20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="i4cee00b7a03d43ceb837d6f99f3c2a60_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i10e48d6d5c37418f95625e0a3c0c6c4a_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="iec5a69bea85a43309bedfd363a2e23bd_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i460fef2e524d4f6fa38ec2499a0ea689_D20160101-20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="iaf5d0e8fdf374dc09283fd669e2ebf19_D20160101-20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="i43aa52214f03439db001c28c7a57ad3c_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="ibdb75168d0e0440c8357fec9636573d7_D20160101-20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="i109fced96e334bd2802e9cb0d4aa822f_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">mgnx:DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="if3a4a990231244d6b62fcda57ef5cfdb_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">mgnx:DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">mgnx:TaxYear2025To2037Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="icbf9b06e7c13465a9c3facc8db2be168_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">mgnx:DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">mgnx:IndefiniteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="iea603775d4f04ce4a2e3d875e241c0c8_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i62c4c7c8c31a462dab6a1676f99a1b7c_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i0986b0c4e51f4d2cb580f8bcf9218691_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i0229ee301314485e8d01bc8ad76d9aca_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i44dc827b9c5849c9874770cafc78df7e_D20171001-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i31ded4a9b84e45a8a97b0a276a851d4a_I20151231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-12-31</instant>
        </period>
    </context>
    <context id="i591dac725a2648e68258b7105447f85d_I20171031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-31</instant>
        </period>
    </context>
    <context id="i82b03c819e73441db6d085233d218937_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ia93c5065a4f94e9f9e0c596d50d7aa2f_D20171001-20171031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-01</startDate>
            <endDate>2017-10-31</endDate>
        </period>
    </context>
    <context id="i91850bdafeb5443c8e0569e57b38e238_D20171001-20171031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-01</startDate>
            <endDate>2017-10-31</endDate>
        </period>
    </context>
    <context id="iff7efae7eb26446bbaa573fe3861e53c_I20171031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-31</instant>
        </period>
    </context>
    <context id="if61293acd6f643bf8daf43be5cf2bd6e_D20171001-20171031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-01</startDate>
            <endDate>2017-10-31</endDate>
        </period>
    </context>
    <context id="i8eb24f3f49444597a89f49edae260720_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i6a111d57d3bf49428df5748987d6471b_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="idd27a98828844b21ad9d5646ef79f6e2_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012ClinicalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i6011d16a582a445fa400c0dfcf98028a_D20120901-20120930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ServierDARTMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2012-09-01</startDate>
            <endDate>2012-09-30</endDate>
        </period>
    </context>
    <context id="idd7e0c72464e4f8b8d5b13e3c2810e9d_I20151231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-12-31</instant>
        </period>
    </context>
    <context id="id5778ce3b2cd44b79c13685e1d2a707d_I20120930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ServierDARTMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2012-09-30</instant>
        </period>
    </context>
    <context id="ia01940c5140d475d823101c59b4c6ee3_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ServierAgreementMGD007OptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i9d3ce417f9d9482d96c963058758500b_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ServierAgreementMGD007OptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i5e802bb4cb124fb3a1bf94de3a31e858_D20160101-20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ServierAgreementMGD007OptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="ida270b9128b24424808f7af121ae03e7_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ServierAgreementMGD007OptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i3dae8b73ee0b42df83fe2e75389bd1b7_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ServierAgreementMGD007OptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i98b48a96e93a4ea59eb53d0d51847ea3_I20151231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ServierDARTMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-12-31</instant>
        </period>
    </context>
    <context id="i3b00e539a3324792b34321e6c7168fb8_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ServierDARTMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i6c17e3fb438e49b4bf933e03642b33d6_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ServierDARTMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i09a4e2abc6f64d09984d04c7e51e159a_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ServierDARTMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="iaa9ee01ece97464eaf75135e2a56dadd_I20151231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-12-31</instant>
        </period>
    </context>
    <context id="i77625ed2e7734703b52942e3929dec22_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ServierDARTMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i0dd3b4b1fefc4e54956a0cd97918d963_D20160101-20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ServierDARTMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="i7c0265f36dcf411893aa87db114e0f16_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ServierDARTMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i87ceca0edd234d059fdd917ce29f5f4b_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ServierDARTMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i625f3d08dc954d518764769a7feaeefc_D20160101-20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ServierDARTMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="i29ff7281a75a4936a4be6c1359e216e9_D20181101-20181130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabsCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-11-01</startDate>
            <endDate>2018-11-30</endDate>
        </period>
    </context>
    <context id="i7e972d120beb4fdaae31b0300fbc48ee_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabsCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="id73733a0f1994e42b2954427356cb7e5_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabsCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i8ae89b363134495b9cc3cdf7d4ce1a06_D20180101-20180131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-01-31</endDate>
        </period>
    </context>
    <context id="i77f6204290544a298e027e842269f6bc_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i7766301ab52344be8fc41112ad51fe12_I20151231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-12-31</instant>
        </period>
    </context>
    <context id="i097ea6f211524140a29381dc3bce7129_D20171201-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i5a4fe51377ba48ef83d87242a98d90ec_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i9b14f1378bdc4abf90dd05dd5956ca30_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i47f11d0af1aa4444aae4bba0ddf73a6c_D20180501-20180531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ProventionPRV3279Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ProventionLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-01</startDate>
            <endDate>2018-05-31</endDate>
        </period>
    </context>
    <context id="id16ca02732fe4f1b8d21590f441cb5dd_I20180531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ProventionPRV3279Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ProventionLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-31</instant>
        </period>
    </context>
    <context id="i575e134561384052b8d5150268d0bc0c_D20180501-20180531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ProventionPRV031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:AssetPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-01</startDate>
            <endDate>2018-05-31</endDate>
        </period>
    </context>
    <context id="ie95e8086ae9b4cd69fc3763d4b03138b_I20180531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ProventionPRV031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:AssetPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-31</instant>
        </period>
    </context>
    <context id="i918dca9fcdce44a999dec3002edfedac_I20180531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-31</instant>
        </period>
    </context>
    <context id="ie23f02f7751b4b5d8b10bc0c6f10cf97_D20180501-20180531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-01</startDate>
            <endDate>2018-05-31</endDate>
        </period>
    </context>
    <context id="i5c503df7c4d74a6aa791c924760e58de_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i3f3f783c3c6749bfb8eab89b1ec2d1ab_I20151231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-12-31</instant>
        </period>
    </context>
    <context id="i9c0bb24d85b742029840e8ff19e39e21_D20141201-20141231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:JanssenMGD011AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-12-01</startDate>
            <endDate>2014-12-31</endDate>
        </period>
    </context>
    <context id="iad112c3f4a95410eb177b18bf2a325e8_D20160101-20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:JanssenMGD011AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="iba7d66ba85e246e0b3b81bde3c507cd4_D20150101-20150131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:JanssenMGD011AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-01-01</startDate>
            <endDate>2015-01-31</endDate>
        </period>
    </context>
    <context id="i36abedfa020b41798bb4a1de0b5826b9_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:JanssenMGD011AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="iafa5f3f8c3964fd3a2fb20d5a78444ae_D20160101-20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:JanssenMGD011AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="i0dbfb405829a4954939345567d9ffa41_D20160701-20160731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:JanssenMGD015AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-01</startDate>
            <endDate>2016-07-31</endDate>
        </period>
    </context>
    <context id="i5bd2775f85934df4a35546668e5cf0a5_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:JanssenMGD015AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i6635b351add74cb695103957cc02cac1_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:JanssenMGD015AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="ibdc4a8d5c6b240faac1049620a8692b6_D20160101-20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:JanssenMGD015AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="ife0dac9d3bf74657b071534f4d2516f1_I20151231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <instant>2015-12-31</instant>
        </period>
    </context>
    <context id="ie5dd3f325a0e4bb2bd1f768f5d1cfb31_D20150915-20150915">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-09-15</startDate>
            <endDate>2015-09-15</endDate>
        </period>
    </context>
    <context id="ib0d39c7c6f4e42388328978bd1a0c321_D20150915-20150915">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-09-15</startDate>
            <endDate>2015-09-15</endDate>
        </period>
    </context>
    <context id="icbe3942778e048a7812d0b367cba79e4_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="iae19a3f2560f46ea9ce3d9769293ef55_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i8a451cc24b4245fe93b83bc7127cf807_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i355ceffdd61e4654b0c765f0f6734378_D20160101-20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="i121ff22ae7d04521bf402d62951d21e4_D20150701-20150731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <startDate>2015-07-01</startDate>
            <endDate>2015-07-31</endDate>
        </period>
    </context>
    <context id="ic26431cbd9dd45ba8f73dd80dc1df8ec_D20170721-20170721">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <startDate>2017-07-21</startDate>
            <endDate>2017-07-21</endDate>
        </period>
    </context>
    <context id="i6ada94a697084172b90c7bcf3c82fe1e_D20120101-20121231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <startDate>2012-01-01</startDate>
            <endDate>2012-12-31</endDate>
        </period>
    </context>
    <context id="ie5d0cd6221f843248de666cd76601d1f_D20160101-20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="i8b9c8e543ab44629819b1e0b7554ce96_D20180101-20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="ie7fccf344bc24f03934ea77078a49726_D20180401-20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="i98edd9ec68b24ced9b531e766587d469_D20180701-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i724f8d5b79f44384afe7b27042231bfe_D20181001-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="icfb4268699e645dc87743a7e862848d6_D20170101-20170331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-03-31</endDate>
        </period>
    </context>
    <context id="icc68311eb541421f98636ba4e9bffdb3_D20170401-20170630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <startDate>2017-04-01</startDate>
            <endDate>2017-06-30</endDate>
        </period>
    </context>
    <context id="i1bf42114bac84fe587857eea6b6d8228_D20170701-20170930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <startDate>2017-07-01</startDate>
            <endDate>2017-09-30</endDate>
        </period>
    </context>
    <context id="ib42a39a1f0994e319ac400bbdfb12754_D20171001-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <startDate>2017-10-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i7ed315b7b06447388b74464c7e252a0a_D20190201-20190228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:FollowUpOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-01</startDate>
            <endDate>2019-02-28</endDate>
        </period>
    </context>
    <context id="i6fdc91e82d3b4cb9ab3b078b4413a743_I20190228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:FollowUpOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-28</instant>
        </period>
    </context>
    <context id="i3fee8e2719b04b64aa1e5c31ae4f97c4_D20160101-20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="i1b259175425444a1a2fc354b79a24aa5_D20190201-20190228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-01</startDate>
            <endDate>2019-02-28</endDate>
        </period>
    </context>
    <context id="i008460346dd94dac853841c05961f142_I20190228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-28</instant>
        </period>
    </context>
    <context id="i6f0312cdde5044c9b7c7f5d13093d50d_D20160101-20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="ifb20c231125a4e898c5b8db3e1022b77_D20160101-20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="i67cbca56d50744e8b64a458a586e3167_D20160101-20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="i77cf90a50960481db6ce7911359972c3_I20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="i8afec271b7854f828af67c5a11b81082_I20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="icb708ebbd06146938a5c8f2f100e1e48_I20180629">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <instant>2018-06-29</instant>
        </period>
    </context>
    <context id="if1ab14db8127453db201fbbcb4274eeb_I20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="ibf25f45131ee4daea309661157e678a9_I20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="i278d12a3934249bdb7dd8e95eabc5377_I20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="iaa98382ff57d452ab6942c773d605ba7_I20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="iab5813033cd8418a851f487e53ebb255_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i556705a1d9294485b49514caece35ad9_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i9132a8fb91054a248c772c0da0d524ec_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="ic816b5e523774458b622b435dcd2e03b_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i506eefa849b64cf7a445dd7f7221c8a5_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i94911b2192424281937290aad92f9145_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i1cf8820c35a34978979d81f8780ea221_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i800361a265974a11ad8699946c8502e8_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="ie5fd1b1d68244c1fb5c42ba60484c135_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i9c61e1783f5a42efa8b8f1b1d3450e3f_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i7250145010e441dcb223b7e59056d359_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ied344051463c48e98fa4145c7382285a_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ib9de5f176a0348ab931fab4225555181_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i449b3691440b4861a36b0b93e9837dbe_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i2441bc1dd5c841d99c40a2087f89589a_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="id2b1c6462f71494a98dce8bac5aef0c8_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i2a9c1de71523428a8c0011a2811fe66c_I20190222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <instant>2019-02-22</instant>
        </period>
    </context>
    <context id="i5fefb74c168342b7b60f52ca08b1b7fc_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i73f75e4bcf834fc4bca320dd6083848a_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="icb8cb5ee17f94fffbdcab3e5ff465890_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ie553de76ecaa42e2af8bd7cfe6d9d352_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i48784f16cceb4a92949dfc57c3d660b6_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i4a8fd95d96b9467b946bd865997ab910_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i0e1afaa0aa004fcc98602893dc6bf0af_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i5c80cf2c50cc438b8e0cd14b52a82cf0_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i8b30daf53dd540e8972913308cc2a710_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="id926749df69c4fffbb4a92f70f45021f_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i9885584d437f4fdbb9821f6883801e5e_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="id8224ea921344b21b249696a5b1fee59_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i19bf1b5616d54d289ec50510e079bd27_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i6e342386069b4859b038021f1292bc8e_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i836203a185014b4a9e662c9f5457029d_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i15cd0dab53764d82a187cc3da46a3761_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i69e6f22f5f224360a82e4379d7fff4b7_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i12ae7112f1294c1ba9b38f26417d21a2_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ica70e0e9496b4c8ab1c2aeea43e1c55e_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="id2873baa5a4b4d10bf1a5d20be263861_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i7057397719af459ca7328a1c440a0efa_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i3aaec4d2a9ba4186b6b54303daa9284f_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i567c39ea2c894aa18c58e1478aeb50bb_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i052ba9dcbb294d688f1b07ef8ae85f64_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i39e9aef5cb214c03982914e5c0e5ef26_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="idddbaa15d66240498398d35f3a8f6a97_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="id6c7535f08114b6b99ac9c52d559c896_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i4b9777bbf6064d76be88747d34359989_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="ic0acfc838ca543a182c2f9a125366f7f_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i2f7cc4428c0c44c98d1a04ac21c0f886_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i813c2a024ec84a0dab992916df676184_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i86696714ee304524b3bf18cd3b8cebf9_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i32a16b54a03b4f8dabcc3d55d161cd66_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i4c57ebf1216b40e69585d4723b4b1234_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="ifb6cc9cda6124764a79895164b99ed24_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="ife3b143f5c324bffabb232b405ceac51_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i637fb60ec9d345b0aac156800fca7529_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i997657dcf4ae43db9ded89ab3af4df74_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i024ac39056e24d43aed54ab33d2c004e_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i606378e8044a40e5ad3ac2c0df524b2b_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="ieb0bea730e3444a5b0d8559d16ad126c_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromCollaborativeAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i03cbd7f054ef4c669ff9c36ff8cd01c0_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ie58f40d5d6224b7abe4022753c84d444_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i43068aee063d4a2d8d23dac8a2f9b677_D20160101-20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="iaa0ada014a394dada260f448e299bd8c_D20160101-20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="i2e50d0e2361047e2a2d2ee358cd59223_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:ProventionBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i7736e7c7780143f290e418da33ef66f3_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:ProventionBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i84d9b24bd0d14ea7ae88c496301087d9_D20160101-20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:ProventionBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="ief319720f28440d5a5dd754bc9ebb8b9_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:ZaiLabLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ia281f1996f934569aa16a3fd2044a2b2_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:ZaiLabLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i14ad06e9a84b4f2b9de71683c59af5f7_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="molecule">
        <measure>mgnx:Molecule</measure>
    </unit>
    <unit id="lease">
        <measure>mgnx:Lease</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="segment">
        <measure>mgnx:Segment</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF8xMy9mcmFnOjcwZWQwODAzYjM4NzQxNzliMDdlNGFjZWFjYmZmNzFkL3RhYmxlOjI1YzFhODU2ZDViNDRmNmY4ZWY1ZmQxMzkxZmRjYWU0L3RhYmxlcmFuZ2U6MjVjMWE4NTZkNWI0NGY2ZjhlZjVmZDEzOTFmZGNhZTRfMi0xLTEtMS0w_4abcb9e6-3ace-4f97-a89b-8799341ccbe1">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF8xMy9mcmFnOjcwZWQwODAzYjM4NzQxNzliMDdlNGFjZWFjYmZmNzFkL3RhYmxlOjI1YzFhODU2ZDViNDRmNmY4ZWY1ZmQxMzkxZmRjYWU0L3RhYmxlcmFuZ2U6MjVjMWE4NTZkNWI0NGY2ZjhlZjVmZDEzOTFmZGNhZTRfNC0xLTEtMS0w_ae7a8af2-34e8-46f1-9bed-3f26d1a39ae9">2018</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF8xMy9mcmFnOjcwZWQwODAzYjM4NzQxNzliMDdlNGFjZWFjYmZmNzFkL3RhYmxlOjI1YzFhODU2ZDViNDRmNmY4ZWY1ZmQxMzkxZmRjYWU0L3RhYmxlcmFuZ2U6MjVjMWE4NTZkNWI0NGY2ZjhlZjVmZDEzOTFmZGNhZTRfNS0xLTEtMS0w_45b47dbe-66c8-4884-92bd-84d667714747">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF8xMy9mcmFnOjcwZWQwODAzYjM4NzQxNzliMDdlNGFjZWFjYmZmNzFkL3RhYmxlOjI1YzFhODU2ZDViNDRmNmY4ZWY1ZmQxMzkxZmRjYWU0L3RhYmxlcmFuZ2U6MjVjMWE4NTZkNWI0NGY2ZjhlZjVmZDEzOTFmZGNhZTRfOS0xLTEtMS0w_699d3b4c-3acb-4462-95f2-8f45cdd280e7">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityCurrentReportingStatus
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF8xMy9mcmFnOjcwZWQwODAzYjM4NzQxNzliMDdlNGFjZWFjYmZmNzFkL3RhYmxlOjI1YzFhODU2ZDViNDRmNmY4ZWY1ZmQxMzkxZmRjYWU0L3RhYmxlcmFuZ2U6MjVjMWE4NTZkNWI0NGY2ZjhlZjVmZDEzOTFmZGNhZTRfMTAtMS0xLTEtMA_00e9af53-8b91-4066-a5c8-d0f4430c0fa4">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityVoluntaryFilers
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF8xMy9mcmFnOjcwZWQwODAzYjM4NzQxNzliMDdlNGFjZWFjYmZmNzFkL3RhYmxlOjI1YzFhODU2ZDViNDRmNmY4ZWY1ZmQxMzkxZmRjYWU0L3RhYmxlcmFuZ2U6MjVjMWE4NTZkNWI0NGY2ZjhlZjVmZDEzOTFmZGNhZTRfMTEtMS0xLTEtMA_41ef0d53-a37a-4a44-81f0-687bcdb532c9">No</dei:EntityVoluntaryFilers>
    <dei:EntityFilerCategory
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF8xMy9mcmFnOjcwZWQwODAzYjM4NzQxNzliMDdlNGFjZWFjYmZmNzFkL3RhYmxlOjI1YzFhODU2ZDViNDRmNmY4ZWY1ZmQxMzkxZmRjYWU0L3RhYmxlcmFuZ2U6MjVjMWE4NTZkNWI0NGY2ZjhlZjVmZDEzOTFmZGNhZTRfMTItMS0xLTEtMA_4b9e9760-b851-4dfa-b24e-07889a8832f2">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntityEmergingGrowthCompany
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF8xMy9mcmFnOjcwZWQwODAzYjM4NzQxNzliMDdlNGFjZWFjYmZmNzFkL3RhYmxlOjI1YzFhODU2ZDViNDRmNmY4ZWY1ZmQxMzkxZmRjYWU0L3RhYmxlcmFuZ2U6MjVjMWE4NTZkNWI0NGY2ZjhlZjVmZDEzOTFmZGNhZTRfMTMtMS0xLTEtMA_35be98f7-cb0b-44a9-aabf-2397c1d1467c">false</dei:EntityEmergingGrowthCompany>
    <dei:EntitySmallBusiness
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF8xMy9mcmFnOjcwZWQwODAzYjM4NzQxNzliMDdlNGFjZWFjYmZmNzFkL3RhYmxlOjI1YzFhODU2ZDViNDRmNmY4ZWY1ZmQxMzkxZmRjYWU0L3RhYmxlcmFuZ2U6MjVjMWE4NTZkNWI0NGY2ZjhlZjVmZDEzOTFmZGNhZTRfMTQtMS0xLTEtMA_e81dce3b-5894-44ec-94f6-b07032b5b15f">false</dei:EntitySmallBusiness>
    <dei:EntityShellCompany
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF8xMy9mcmFnOjcwZWQwODAzYjM4NzQxNzliMDdlNGFjZWFjYmZmNzFkL3RhYmxlOjI1YzFhODU2ZDViNDRmNmY4ZWY1ZmQxMzkxZmRjYWU0L3RhYmxlcmFuZ2U6MjVjMWE4NTZkNWI0NGY2ZjhlZjVmZDEzOTFmZGNhZTRfMTUtMS0xLTEtNjAzMA_e7461d8c-bde9-4fc4-9eef-07fa04818393">false</dei:EntityShellCompany>
    <dei:EntityRegistrantName
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF8xMy9mcmFnOjcwZWQwODAzYjM4NzQxNzliMDdlNGFjZWFjYmZmNzFkL3RleHRyZWdpb246NzBlZDA4MDNiMzg3NDE3OWIwN2U0YWNlYWNiZmY3MWRfNTQ5NzU1ODE0MDI1_cae6355d-9773-4b28-bc38-c2bfc8888c28">MACROGENICS INC</dei:EntityRegistrantName>
    <dei:EntityCentralIndexKey
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF8xMy9mcmFnOjcwZWQwODAzYjM4NzQxNzliMDdlNGFjZWFjYmZmNzFkL3RleHRyZWdpb246NzBlZDA4MDNiMzg3NDE3OWIwN2U0YWNlYWNiZmY3MWRfNTQ5NzU1ODE0MDI0_95e3faed-cce0-4ca8-9162-4c6fc7dd9c13">0001125345</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF8xMy9mcmFnOjcwZWQwODAzYjM4NzQxNzliMDdlNGFjZWFjYmZmNzFkL3RleHRyZWdpb246NzBlZDA4MDNiMzg3NDE3OWIwN2U0YWNlYWNiZmY3MWRfNTQ5NzU1ODE0MDIz_d4c94da5-681a-45b8-9961-91ea9b3ce4dd">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentPeriodEndDate
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF8xMy9mcmFnOjcwZWQwODAzYjM4NzQxNzliMDdlNGFjZWFjYmZmNzFkL3RleHRyZWdpb246NzBlZDA4MDNiMzg3NDE3OWIwN2U0YWNlYWNiZmY3MWRfMjE5OTAyMzI1NTg4Ng_4fe69217-b808-45d7-bcb0-db99834bffa6">2018-12-31</dei:DocumentPeriodEndDate>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MjEvZnJhZzpkMjA4OGQ1M2E5NGE0ZmQwODNkMzcwODk0YjI5YzQ1Ny90YWJsZTphNmVhYjYxZWY1Mzc0M2Y4YmExNzI3ZjA3OTVlNzIxMi90YWJsZXJhbmdlOmE2ZWFiNjFlZjUzNzQzZjhiYTE3MjdmMDc5NWU3MjEyXzItMS0xLTEtMA_39473a47-9679-44c8-bd78-fa837504a40a"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i7057397719af459ca7328a1c440a0efa_I20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MjEvZnJhZzpkMjA4OGQ1M2E5NGE0ZmQwODNkMzcwODk0YjI5YzQ1Ny90YWJsZTphNmVhYjYxZWY1Mzc0M2Y4YmExNzI3ZjA3OTVlNzIxMi90YWJsZXJhbmdlOmE2ZWFiNjFlZjUzNzQzZjhiYTE3MjdmMDc5NWU3MjEyXzItMy0xLTEtMA_3bb77058-35d1-47ea-9a63-3cb4e2ccea1e"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MjEvZnJhZzpkMjA4OGQ1M2E5NGE0ZmQwODNkMzcwODk0YjI5YzQ1Ny90YWJsZTphNmVhYjYxZWY1Mzc0M2Y4YmExNzI3ZjA3OTVlNzIxMi90YWJsZXJhbmdlOmE2ZWFiNjFlZjUzNzQzZjhiYTE3MjdmMDc5NWU3MjEyXzMtMS0xLTEtMA_8b425423-8d9c-4815-bc6c-d00550b5f16d"
      unitRef="shares">125000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i7057397719af459ca7328a1c440a0efa_I20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MjEvZnJhZzpkMjA4OGQ1M2E5NGE0ZmQwODNkMzcwODk0YjI5YzQ1Ny90YWJsZTphNmVhYjYxZWY1Mzc0M2Y4YmExNzI3ZjA3OTVlNzIxMi90YWJsZXJhbmdlOmE2ZWFiNjFlZjUzNzQzZjhiYTE3MjdmMDc5NWU3MjEyXzMtMy0xLTEtMA_453a209d-96c9-4d67-8d21-27aa852dd8cf"
      unitRef="shares">125000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MjEvZnJhZzpkMjA4OGQ1M2E5NGE0ZmQwODNkMzcwODk0YjI5YzQ1Ny90YWJsZTphNmVhYjYxZWY1Mzc0M2Y4YmExNzI3ZjA3OTVlNzIxMi90YWJsZXJhbmdlOmE2ZWFiNjFlZjUzNzQzZjhiYTE3MjdmMDc5NWU3MjEyXzQtMS0xLTEtMA_62f70c40-b2d7-4f97-b6b2-7696ee0f4d7f"
      unitRef="shares">42353301</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i7057397719af459ca7328a1c440a0efa_I20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MjEvZnJhZzpkMjA4OGQ1M2E5NGE0ZmQwODNkMzcwODk0YjI5YzQ1Ny90YWJsZTphNmVhYjYxZWY1Mzc0M2Y4YmExNzI3ZjA3OTVlNzIxMi90YWJsZXJhbmdlOmE2ZWFiNjFlZjUzNzQzZjhiYTE3MjdmMDc5NWU3MjEyXzQtMy0xLTEtMA_3c386ef8-3ad8-4495-a9a0-771331fc59e0"
      unitRef="shares">36859077</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities
      contextRef="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82MTAvZnJhZzo0MDllMTRiNWFjNjI0Nzg1OTBkZTdhMzM5MWRmN2QxMi90ZXh0cmVnaW9uOjQwOWUxNGI1YWM2MjQ3ODU5MGRlN2EzMzkxZGY3ZDEyXzE1_9d65f311-1a99-4ed6-98d1-3340822cc0f5"
      unitRef="usd">0</us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities>
    <us-gaap:ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleCarryingValueOfAsset
      contextRef="i7057397719af459ca7328a1c440a0efa_I20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82MTAvZnJhZzo0MDllMTRiNWFjNjI0Nzg1OTBkZTdhMzM5MWRmN2QxMi90ZXh0cmVnaW9uOjQwOWUxNGI1YWM2MjQ3ODU5MGRlN2EzMzkxZGY3ZDEyXzE2MQ_ddb5a483-80f4-463f-b020-0ada6e818f95"
      unitRef="usd">0</us-gaap:ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleCarryingValueOfAsset>
    <us-gaap:AssetsHeldForSaleNotPartOfDisposalGroup
      contextRef="i7057397719af459ca7328a1c440a0efa_I20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82MTAvZnJhZzo0MDllMTRiNWFjNjI0Nzg1OTBkZTdhMzM5MWRmN2QxMi90ZXh0cmVnaW9uOjQwOWUxNGI1YWM2MjQ3ODU5MGRlN2EzMzkxZGY3ZDEyXzE4OA_02e51b89-d510-47b6-8a9f-77657717db4a"
      unitRef="usd">0</us-gaap:AssetsHeldForSaleNotPartOfDisposalGroup>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="i7057397719af459ca7328a1c440a0efa_I20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82MTAvZnJhZzo0MDllMTRiNWFjNjI0Nzg1OTBkZTdhMzM5MWRmN2QxMi90ZXh0cmVnaW9uOjQwOWUxNGI1YWM2MjQ3ODU5MGRlN2EzMzkxZGY3ZDEyXzIxNA_93c75bda-9848-44e4-8f7a-26b406d5059d"
      unitRef="usd">0</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities
      contextRef="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82MzUvZnJhZzo0ZGRlNWRiZTQyMzY0ODE1OGU5ZjMyYTM0NDZlMmVmMC90ZXh0cmVnaW9uOjRkZGU1ZGJlNDIzNjQ4MTU4ZTlmMzJhMzQ0NmUyZWYwXzE1_377cae13-7bbd-424b-845c-95a36b4237bc"
      unitRef="usd">0</us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i5511585976c54c42a03fe4ab0e7c9ec2_I20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82NzIvZnJhZzplODZiZjBhMTZiOGU0OGZiYTM0ZWJjMTIyODUxMWZiYy90ZXh0cmVnaW9uOmU4NmJmMGExNmI4ZTQ4ZmJhMzRlYmMxMjI4NTExZmJjXzE1_5ee6f61f-29da-4635-89d0-507d7498c978"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="iaaa703135e5d42e3ad357819a2febb2b_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82NzIvZnJhZzplODZiZjBhMTZiOGU0OGZiYTM0ZWJjMTIyODUxMWZiYy90ZXh0cmVnaW9uOmU4NmJmMGExNmI4ZTQ4ZmJhMzRlYmMxMjI4NTExZmJjXzEwOA_c6c1cca4-532b-4919-99b2-0cd9aa09205e"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i5511585976c54c42a03fe4ab0e7c9ec2_I20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82NzIvZnJhZzplODZiZjBhMTZiOGU0OGZiYTM0ZWJjMTIyODUxMWZiYy90ZXh0cmVnaW9uOmU4NmJmMGExNmI4ZTQ4ZmJhMzRlYmMxMjI4NTExZmJjXzIwMQ_c26df693-86fc-43ca-a707-7a235155185c"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82NzIvZnJhZzplODZiZjBhMTZiOGU0OGZiYTM0ZWJjMTIyODUxMWZiYy90ZXh0cmVnaW9uOmU4NmJmMGExNmI4ZTQ4ZmJhMzRlYmMxMjI4NTExZmJjXzQ3NA_00dd9f6e-c22e-41ed-8293-c6a58bbf251c"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i10e48d6d5c37418f95625e0a3c0c6c4a_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82OTcvZnJhZzplYmQ2MGE1MTA0Yjc0MDk0ODY1MDczNTY0MWU5YmRiNC90YWJsZTo5Y2ZlMzA1NTZjZmQ0NDY5OTg3YjA2NGFkMTgyZDY2Ny90YWJsZXJhbmdlOjljZmUzMDU1NmNmZDQ0Njk5ODdiMDY0YWQxODJkNjY3XzItMS0xLTEtMA_7b988feb-9c2d-4d42-b1d8-3af89502618e"
      unitRef="number">0.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="iec5a69bea85a43309bedfd363a2e23bd_D20170101-20171231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82OTcvZnJhZzplYmQ2MGE1MTA0Yjc0MDk0ODY1MDczNTY0MWU5YmRiNC90YWJsZTo5Y2ZlMzA1NTZjZmQ0NDY5OTg3YjA2NGFkMTgyZDY2Ny90YWJsZXJhbmdlOjljZmUzMDU1NmNmZDQ0Njk5ODdiMDY0YWQxODJkNjY3XzItMy0xLTEtMA_35047219-7d83-4c97-b8e2-1ab61b95ee9b"
      unitRef="number">0.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i460fef2e524d4f6fa38ec2499a0ea689_D20160101-20161231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82OTcvZnJhZzplYmQ2MGE1MTA0Yjc0MDk0ODY1MDczNTY0MWU5YmRiNC90YWJsZTo5Y2ZlMzA1NTZjZmQ0NDY5OTg3YjA2NGFkMTgyZDY2Ny90YWJsZXJhbmdlOjljZmUzMDU1NmNmZDQ0Njk5ODdiMDY0YWQxODJkNjY3XzItNS0xLTEtMA_de9f751a-246b-4b07-ab41-56de38b26c1c"
      unitRef="number">0.64</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i4cee00b7a03d43ceb837d6f99f3c2a60_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82OTcvZnJhZzplYmQ2MGE1MTA0Yjc0MDk0ODY1MDczNTY0MWU5YmRiNC90YWJsZTo5Y2ZlMzA1NTZjZmQ0NDY5OTg3YjA2NGFkMTgyZDY2Ny90YWJsZXJhbmdlOjljZmUzMDU1NmNmZDQ0Njk5ODdiMDY0YWQxODJkNjY3XzMtMS0xLTEtMA_c717be97-afb8-4755-99b9-2a380163913b"
      unitRef="number">0.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i43aa52214f03439db001c28c7a57ad3c_D20170101-20171231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82OTcvZnJhZzplYmQ2MGE1MTA0Yjc0MDk0ODY1MDczNTY0MWU5YmRiNC90YWJsZTo5Y2ZlMzA1NTZjZmQ0NDY5OTg3YjA2NGFkMTgyZDY2Ny90YWJsZXJhbmdlOjljZmUzMDU1NmNmZDQ0Njk5ODdiMDY0YWQxODJkNjY3XzMtMy0xLTEtMA_40f1a4a8-f981-412f-8700-e379b38d58fe"
      unitRef="number">0.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="ibdb75168d0e0440c8357fec9636573d7_D20160101-20161231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82OTcvZnJhZzplYmQ2MGE1MTA0Yjc0MDk0ODY1MDczNTY0MWU5YmRiNC90YWJsZTo5Y2ZlMzA1NTZjZmQ0NDY5OTg3YjA2NGFkMTgyZDY2Ny90YWJsZXJhbmdlOjljZmUzMDU1NmNmZDQ0Njk5ODdiMDY0YWQxODJkNjY3XzMtNS0xLTEtMA_c936f23a-d3fd-43d3-b529-00fb6cc3a224"
      unitRef="number">0.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i10e48d6d5c37418f95625e0a3c0c6c4a_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82OTcvZnJhZzplYmQ2MGE1MTA0Yjc0MDk0ODY1MDczNTY0MWU5YmRiNC90YWJsZTo5Y2ZlMzA1NTZjZmQ0NDY5OTg3YjA2NGFkMTgyZDY2Ny90YWJsZXJhbmdlOjljZmUzMDU1NmNmZDQ0Njk5ODdiMDY0YWQxODJkNjY3XzUtMS0xLTEtMA_b40d51fe-9340-40e3-9c54-b8c1019eefe6"
      unitRef="number">0.024</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="iec5a69bea85a43309bedfd363a2e23bd_D20170101-20171231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82OTcvZnJhZzplYmQ2MGE1MTA0Yjc0MDk0ODY1MDczNTY0MWU5YmRiNC90YWJsZTo5Y2ZlMzA1NTZjZmQ0NDY5OTg3YjA2NGFkMTgyZDY2Ny90YWJsZXJhbmdlOjljZmUzMDU1NmNmZDQ0Njk5ODdiMDY0YWQxODJkNjY3XzUtMy0xLTEtMA_28313de3-5c2c-4b0e-bdd2-3a69e0c33f73"
      unitRef="number">0.019</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i460fef2e524d4f6fa38ec2499a0ea689_D20160101-20161231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82OTcvZnJhZzplYmQ2MGE1MTA0Yjc0MDk0ODY1MDczNTY0MWU5YmRiNC90YWJsZTo5Y2ZlMzA1NTZjZmQ0NDY5OTg3YjA2NGFkMTgyZDY2Ny90YWJsZXJhbmdlOjljZmUzMDU1NmNmZDQ0Njk5ODdiMDY0YWQxODJkNjY3XzUtNS0xLTEtMA_1e4b7193-eafc-4aa9-8908-0f4ebfde848b"
      unitRef="number">0.012</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i4cee00b7a03d43ceb837d6f99f3c2a60_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82OTcvZnJhZzplYmQ2MGE1MTA0Yjc0MDk0ODY1MDczNTY0MWU5YmRiNC90YWJsZTo5Y2ZlMzA1NTZjZmQ0NDY5OTg3YjA2NGFkMTgyZDY2Ny90YWJsZXJhbmdlOjljZmUzMDU1NmNmZDQ0Njk5ODdiMDY0YWQxODJkNjY3XzYtMS0xLTEtMA_b6310395-0803-4ccd-95a8-38b147084802"
      unitRef="number">0.031</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i43aa52214f03439db001c28c7a57ad3c_D20170101-20171231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82OTcvZnJhZzplYmQ2MGE1MTA0Yjc0MDk0ODY1MDczNTY0MWU5YmRiNC90YWJsZTo5Y2ZlMzA1NTZjZmQ0NDY5OTg3YjA2NGFkMTgyZDY2Ny90YWJsZXJhbmdlOjljZmUzMDU1NmNmZDQ0Njk5ODdiMDY0YWQxODJkNjY3XzYtMy0xLTEtMA_5af8b728-11d4-4b6f-af41-30a2d0ca30a9"
      unitRef="number">0.023</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="ibdb75168d0e0440c8357fec9636573d7_D20160101-20161231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82OTcvZnJhZzplYmQ2MGE1MTA0Yjc0MDk0ODY1MDczNTY0MWU5YmRiNC90YWJsZTo5Y2ZlMzA1NTZjZmQ0NDY5OTg3YjA2NGFkMTgyZDY2Ny90YWJsZXJhbmdlOjljZmUzMDU1NmNmZDQ0Njk5ODdiMDY0YWQxODJkNjY3XzYtNS0xLTEtMA_21fbacb4-45ed-4711-bd7e-220811df3b84"
      unitRef="number">0.024</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MjIvZnJhZzpmYTcyOTAzNzI5NmM0NmRjODQ1ZmVmNDdhMGMxOWRlNi90YWJsZTo3MzUyYmUyMDQzNWM0YzNkYmE1NGQ0MjIyYWZmYzMyOS90YWJsZXJhbmdlOjczNTJiZTIwNDM1YzRjM2RiYTU0ZDQyMjJhZmZjMzI5XzEtMi0xLTEtMA_73a05b40-7ccb-4db6-ba4f-69ffb697826b"
      unitRef="usd">0</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="iaf5d0e8fdf374dc09283fd669e2ebf19_D20160101-20161231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MjIvZnJhZzpmYTcyOTAzNzI5NmM0NmRjODQ1ZmVmNDdhMGMxOWRlNi90YWJsZTo3MzUyYmUyMDQzNWM0YzNkYmE1NGQ0MjIyYWZmYzMyOS90YWJsZXJhbmdlOjczNTJiZTIwNDM1YzRjM2RiYTU0ZDQyMjJhZmZjMzI5XzEtMy0xLTEtMA_609b3aaa-81b1-40ea-af4b-3678a0ac5bc9"
      unitRef="usd">0</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MjIvZnJhZzpmYTcyOTAzNzI5NmM0NmRjODQ1ZmVmNDdhMGMxOWRlNi90YWJsZTpkNDI3NWVlNWJiYTk0NDI3ODk2N2M1NmU0NmM0OWFkZC90YWJsZXJhbmdlOmQ0Mjc1ZWU1YmJhOTQ0Mjc4OTY3YzU2ZTQ2YzQ5YWRkXzEtMi0xLTEtMA_90c60848-44b3-4965-996f-eb818f71f736"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="iaf5d0e8fdf374dc09283fd669e2ebf19_D20160101-20161231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MjIvZnJhZzpmYTcyOTAzNzI5NmM0NmRjODQ1ZmVmNDdhMGMxOWRlNi90YWJsZTpkNDI3NWVlNWJiYTk0NDI3ODk2N2M1NmU0NmM0OWFkZC90YWJsZXJhbmdlOmQ0Mjc1ZWU1YmJhOTQ0Mjc4OTY3YzU2ZTQ2YzQ5YWRkXzEtMy0xLTEtMA_312841f4-490e-4fa8-a64a-3f721d2e7741"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <dei:DocumentType
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF8xL2ZyYWc6ZTM3ZjkzM2UxNDcxNGE3MWIzYzBlYjBlYWE0NjBhYmQvdGV4dHJlZ2lvbjplMzdmOTMzZTE0NzE0YTcxYjNjMGViMGVhYTQ2MGFiZF84Nw_ae66b717-cc63-4e89-b80f-dab3ad4cd8e9">10-K</dei:DocumentType>
    <dei:EntityPublicFloat
      contextRef="icb708ebbd06146938a5c8f2f100e1e48_I20180629"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF8xL2ZyYWc6ZTM3ZjkzM2UxNDcxNGE3MWIzYzBlYjBlYWE0NjBhYmQvdGV4dHJlZ2lvbjplMzdmOTMzZTE0NzE0YTcxYjNjMGViMGVhYTQ2MGFiZF8xNjQ5MjY3NDQ1MTMw_49e5a11e-f8dc-4d15-9d13-b944877083ca"
      unitRef="usd">842500000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i2a9c1de71523428a8c0011a2811fe66c_I20190222"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF8xL2ZyYWc6ZTM3ZjkzM2UxNDcxNGE3MWIzYzBlYjBlYWE0NjBhYmQvdGV4dHJlZ2lvbjplMzdmOTMzZTE0NzE0YTcxYjNjMGViMGVhYTQ2MGFiZF8zMTI5_a8b7086e-f654-42e0-84e0-f5afe4b500e1"
      unitRef="shares">48780321</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MDgvZnJhZzo3Njg0MzE5YmEwOWQ0NmI4ODAwOTcwNWFiODM5Y2I4Ny90YWJsZTpkOThmOTg5ZjM5ZjE0MDVkODJhNThkOGIxNzhlMzFiOC90YWJsZXJhbmdlOmQ5OGY5ODlmMzlmMTQwNWQ4MmE1OGQ4YjE3OGUzMWI4XzQtMS0xLTEtMA_5b15c368-021b-4e2d-abd7-a6d015d3422c"
      unitRef="usd">220128000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i7057397719af459ca7328a1c440a0efa_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MDgvZnJhZzo3Njg0MzE5YmEwOWQ0NmI4ODAwOTcwNWFiODM5Y2I4Ny90YWJsZTpkOThmOTg5ZjM5ZjE0MDVkODJhNThkOGIxNzhlMzFiOC90YWJsZXJhbmdlOmQ5OGY5ODlmMzlmMTQwNWQ4MmE1OGQ4YjE3OGUzMWI4XzQtMy0xLTEtMA_93d7447d-f9dd-432f-bfe1-679c67d5c860"
      unitRef="usd">211727000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesCurrent
      contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MDgvZnJhZzo3Njg0MzE5YmEwOWQ0NmI4ODAwOTcwNWFiODM5Y2I4Ny90YWJsZTpkOThmOTg5ZjM5ZjE0MDVkODJhNThkOGIxNzhlMzFiOC90YWJsZXJhbmdlOmQ5OGY5ODlmMzlmMTQwNWQ4MmE1OGQ4YjE3OGUzMWI4XzUtMS0xLTEtMA_bd835bd7-33ff-4e9a-8bca-1d6425932bfa"
      unitRef="usd">12735000</us-gaap:AvailableForSaleSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesCurrent
      contextRef="i7057397719af459ca7328a1c440a0efa_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MDgvZnJhZzo3Njg0MzE5YmEwOWQ0NmI4ODAwOTcwNWFiODM5Y2I4Ny90YWJsZTpkOThmOTg5ZjM5ZjE0MDVkODJhNThkOGIxNzhlMzFiOC90YWJsZXJhbmdlOmQ5OGY5ODlmMzlmMTQwNWQ4MmE1OGQ4YjE3OGUzMWI4XzUtMy0xLTEtMA_a09bd003-96b0-4c3b-bdb8-397514e0e6a5"
      unitRef="usd">93394000</us-gaap:AvailableForSaleSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MDgvZnJhZzo3Njg0MzE5YmEwOWQ0NmI4ODAwOTcwNWFiODM5Y2I4Ny90YWJsZTpkOThmOTg5ZjM5ZjE0MDVkODJhNThkOGIxNzhlMzFiOC90YWJsZXJhbmdlOmQ5OGY5ODlmMzlmMTQwNWQ4MmE1OGQ4YjE3OGUzMWI4XzYtMS0xLTEtMA_259b2c04-d37e-4e3a-b22e-d7042c6e0e4a"
      unitRef="usd">29583000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i7057397719af459ca7328a1c440a0efa_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MDgvZnJhZzo3Njg0MzE5YmEwOWQ0NmI4ODAwOTcwNWFiODM5Y2I4Ny90YWJsZTpkOThmOTg5ZjM5ZjE0MDVkODJhNThkOGIxNzhlMzFiOC90YWJsZXJhbmdlOmQ5OGY5ODlmMzlmMTQwNWQ4MmE1OGQ4YjE3OGUzMWI4XzYtMy0xLTEtMA_9a0f8695-9e63-4654-924e-7937ad845ffb"
      unitRef="usd">13643000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MDgvZnJhZzo3Njg0MzE5YmEwOWQ0NmI4ODAwOTcwNWFiODM5Y2I4Ny90YWJsZTpkOThmOTg5ZjM5ZjE0MDVkODJhNThkOGIxNzhlMzFiOC90YWJsZXJhbmdlOmQ5OGY5ODlmMzlmMTQwNWQ4MmE1OGQ4YjE3OGUzMWI4XzctMS0xLTEtMA_459c1eda-dba7-4278-887c-443048608138"
      unitRef="usd">6406000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="i7057397719af459ca7328a1c440a0efa_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MDgvZnJhZzo3Njg0MzE5YmEwOWQ0NmI4ODAwOTcwNWFiODM5Y2I4Ny90YWJsZTpkOThmOTg5ZjM5ZjE0MDVkODJhNThkOGIxNzhlMzFiOC90YWJsZXJhbmdlOmQ5OGY5ODlmMzlmMTQwNWQ4MmE1OGQ4YjE3OGUzMWI4XzctMy0xLTEtMA_32e9e6bb-8d79-4875-a4f7-e73510203733"
      unitRef="usd">3151000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:OtherAssets
      contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MDgvZnJhZzo3Njg0MzE5YmEwOWQ0NmI4ODAwOTcwNWFiODM5Y2I4Ny90YWJsZTpkOThmOTg5ZjM5ZjE0MDVkODJhNThkOGIxNzhlMzFiOC90YWJsZXJhbmdlOmQ5OGY5ODlmMzlmMTQwNWQ4MmE1OGQ4YjE3OGUzMWI4XzgtMS0xLTEtMA_fb715e15-0733-4fd6-801e-19583ea7b1b0"
      unitRef="usd">272000</us-gaap:OtherAssets>
    <us-gaap:OtherAssets
      contextRef="i7057397719af459ca7328a1c440a0efa_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MDgvZnJhZzo3Njg0MzE5YmEwOWQ0NmI4ODAwOTcwNWFiODM5Y2I4Ny90YWJsZTpkOThmOTg5ZjM5ZjE0MDVkODJhNThkOGIxNzhlMzFiOC90YWJsZXJhbmdlOmQ5OGY5ODlmMzlmMTQwNWQ4MmE1OGQ4YjE3OGUzMWI4XzgtMy0xLTEtMA_a3119b7f-a2d5-4ac4-867b-5a62785dcb80"
      unitRef="usd">383000</us-gaap:OtherAssets>
    <us-gaap:AssetsCurrent
      contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MDgvZnJhZzo3Njg0MzE5YmEwOWQ0NmI4ODAwOTcwNWFiODM5Y2I4Ny90YWJsZTpkOThmOTg5ZjM5ZjE0MDVkODJhNThkOGIxNzhlMzFiOC90YWJsZXJhbmdlOmQ5OGY5ODlmMzlmMTQwNWQ4MmE1OGQ4YjE3OGUzMWI4XzktMS0xLTEtMA_0d6ca7e4-ec69-43e9-b716-460f1ca7608e"
      unitRef="usd">269124000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i7057397719af459ca7328a1c440a0efa_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MDgvZnJhZzo3Njg0MzE5YmEwOWQ0NmI4ODAwOTcwNWFiODM5Y2I4Ny90YWJsZTpkOThmOTg5ZjM5ZjE0MDVkODJhNThkOGIxNzhlMzFiOC90YWJsZXJhbmdlOmQ5OGY5ODlmMzlmMTQwNWQ4MmE1OGQ4YjE3OGUzMWI4XzktMy0xLTEtMA_b05e39b5-3976-4cd9-a8d9-da4e303ec5f2"
      unitRef="usd">322298000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MDgvZnJhZzo3Njg0MzE5YmEwOWQ0NmI4ODAwOTcwNWFiODM5Y2I4Ny90YWJsZTpkOThmOTg5ZjM5ZjE0MDVkODJhNThkOGIxNzhlMzFiOC90YWJsZXJhbmdlOmQ5OGY5ODlmMzlmMTQwNWQ4MmE1OGQ4YjE3OGUzMWI4XzExLTEtMS0xLTA_adc550ba-a6ca-4425-8797-fb00b31ff703"
      unitRef="usd">56712000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i7057397719af459ca7328a1c440a0efa_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MDgvZnJhZzo3Njg0MzE5YmEwOWQ0NmI4ODAwOTcwNWFiODM5Y2I4Ny90YWJsZTpkOThmOTg5ZjM5ZjE0MDVkODJhNThkOGIxNzhlMzFiOC90YWJsZXJhbmdlOmQ5OGY5ODlmMzlmMTQwNWQ4MmE1OGQ4YjE3OGUzMWI4XzExLTMtMS0xLTA_0033a857-38bc-4273-b96f-218c3db281d2"
      unitRef="usd">49983000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MDgvZnJhZzo3Njg0MzE5YmEwOWQ0NmI4ODAwOTcwNWFiODM5Y2I4Ny90YWJsZTpkOThmOTg5ZjM5ZjE0MDVkODJhNThkOGIxNzhlMzFiOC90YWJsZXJhbmdlOmQ5OGY5ODlmMzlmMTQwNWQ4MmE1OGQ4YjE3OGUzMWI4XzEzLTEtMS0xLTA_2d059c38-9685-45a7-8a81-6c40297a67d2"
      unitRef="usd">6294000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i7057397719af459ca7328a1c440a0efa_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MDgvZnJhZzo3Njg0MzE5YmEwOWQ0NmI4ODAwOTcwNWFiODM5Y2I4Ny90YWJsZTpkOThmOTg5ZjM5ZjE0MDVkODJhNThkOGIxNzhlMzFiOC90YWJsZXJhbmdlOmQ5OGY5ODlmMzlmMTQwNWQ4MmE1OGQ4YjE3OGUzMWI4XzEzLTMtMS0xLTA_a6e811ec-c1ab-41be-91b1-416d6ad1ec33"
      unitRef="usd">1602000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MDgvZnJhZzo3Njg0MzE5YmEwOWQ0NmI4ODAwOTcwNWFiODM5Y2I4Ny90YWJsZTpkOThmOTg5ZjM5ZjE0MDVkODJhNThkOGIxNzhlMzFiOC90YWJsZXJhbmdlOmQ5OGY5ODlmMzlmMTQwNWQ4MmE1OGQ4YjE3OGUzMWI4XzE0LTEtMS0xLTA_ee59a3c5-ee06-4014-bba2-e00f4d138fe7"
      unitRef="usd">332130000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i7057397719af459ca7328a1c440a0efa_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MDgvZnJhZzo3Njg0MzE5YmEwOWQ0NmI4ODAwOTcwNWFiODM5Y2I4Ny90YWJsZTpkOThmOTg5ZjM5ZjE0MDVkODJhNThkOGIxNzhlMzFiOC90YWJsZXJhbmdlOmQ5OGY5ODlmMzlmMTQwNWQ4MmE1OGQ4YjE3OGUzMWI4XzE0LTMtMS0xLTA_64fa7a4b-5392-40bc-9266-76968a2cc639"
      unitRef="usd">373883000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MDgvZnJhZzo3Njg0MzE5YmEwOWQ0NmI4ODAwOTcwNWFiODM5Y2I4Ny90YWJsZTpkOThmOTg5ZjM5ZjE0MDVkODJhNThkOGIxNzhlMzFiOC90YWJsZXJhbmdlOmQ5OGY5ODlmMzlmMTQwNWQ4MmE1OGQ4YjE3OGUzMWI4XzE4LTEtMS0xLTA_645f9cd2-ce31-4bf9-bfa7-582715481341"
      unitRef="usd">4005000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i7057397719af459ca7328a1c440a0efa_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MDgvZnJhZzo3Njg0MzE5YmEwOWQ0NmI4ODAwOTcwNWFiODM5Y2I4Ny90YWJsZTpkOThmOTg5ZjM5ZjE0MDVkODJhNThkOGIxNzhlMzFiOC90YWJsZXJhbmdlOmQ5OGY5ODlmMzlmMTQwNWQ4MmE1OGQ4YjE3OGUzMWI4XzE4LTMtMS0xLTA_08ccc166-fd9a-4448-a212-a196c12dabda"
      unitRef="usd">2451000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MDgvZnJhZzo3Njg0MzE5YmEwOWQ0NmI4ODAwOTcwNWFiODM5Y2I4Ny90YWJsZTpkOThmOTg5ZjM5ZjE0MDVkODJhNThkOGIxNzhlMzFiOC90YWJsZXJhbmdlOmQ5OGY5ODlmMzlmMTQwNWQ4MmE1OGQ4YjE3OGUzMWI4XzE5LTEtMS0xLTA_6b938fe4-644b-4264-97fe-6cd88fed2b53"
      unitRef="usd">33021000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i7057397719af459ca7328a1c440a0efa_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MDgvZnJhZzo3Njg0MzE5YmEwOWQ0NmI4ODAwOTcwNWFiODM5Y2I4Ny90YWJsZTpkOThmOTg5ZjM5ZjE0MDVkODJhNThkOGIxNzhlMzFiOC90YWJsZXJhbmdlOmQ5OGY5ODlmMzlmMTQwNWQ4MmE1OGQ4YjE3OGUzMWI4XzE5LTMtMS0xLTA_710e475c-3607-47ae-a7df-d84cad173360"
      unitRef="usd">38581000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DeferredRevenueCurrent
      contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MDgvZnJhZzo3Njg0MzE5YmEwOWQ0NmI4ODAwOTcwNWFiODM5Y2I4Ny90YWJsZTpkOThmOTg5ZjM5ZjE0MDVkODJhNThkOGIxNzhlMzFiOC90YWJsZXJhbmdlOmQ5OGY5ODlmMzlmMTQwNWQ4MmE1OGQ4YjE3OGUzMWI4XzIwLTEtMS0xLTA_3d60bc98-3548-45ae-b0aa-2b8b54e27887"
      unitRef="usd">21721000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:DeferredRevenueCurrent
      contextRef="i7057397719af459ca7328a1c440a0efa_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MDgvZnJhZzo3Njg0MzE5YmEwOWQ0NmI4ODAwOTcwNWFiODM5Y2I4Ny90YWJsZTpkOThmOTg5ZjM5ZjE0MDVkODJhNThkOGIxNzhlMzFiOC90YWJsZXJhbmdlOmQ5OGY5ODlmMzlmMTQwNWQ4MmE1OGQ4YjE3OGUzMWI4XzIwLTMtMS0xLTA_c84f250e-14dd-4157-a1d3-95865d1db6ca"
      unitRef="usd">7202000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:DeferredRentCreditCurrent
      contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MDgvZnJhZzo3Njg0MzE5YmEwOWQ0NmI4ODAwOTcwNWFiODM5Y2I4Ny90YWJsZTpkOThmOTg5ZjM5ZjE0MDVkODJhNThkOGIxNzhlMzFiOC90YWJsZXJhbmdlOmQ5OGY5ODlmMzlmMTQwNWQ4MmE1OGQ4YjE3OGUzMWI4XzIxLTEtMS0xLTA_b42c9ca0-696d-4bfd-b67c-44b9ce80f332"
      unitRef="usd">1018000</us-gaap:DeferredRentCreditCurrent>
    <us-gaap:DeferredRentCreditCurrent
      contextRef="i7057397719af459ca7328a1c440a0efa_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MDgvZnJhZzo3Njg0MzE5YmEwOWQ0NmI4ODAwOTcwNWFiODM5Y2I4Ny90YWJsZTpkOThmOTg5ZjM5ZjE0MDVkODJhNThkOGIxNzhlMzFiOC90YWJsZXJhbmdlOmQ5OGY5ODlmMzlmMTQwNWQ4MmE1OGQ4YjE3OGUzMWI4XzIxLTMtMS0xLTA_06b381fb-3588-4e0b-bbf0-53070a290b7b"
      unitRef="usd">1048000</us-gaap:DeferredRentCreditCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MDgvZnJhZzo3Njg0MzE5YmEwOWQ0NmI4ODAwOTcwNWFiODM5Y2I4Ny90YWJsZTpkOThmOTg5ZjM5ZjE0MDVkODJhNThkOGIxNzhlMzFiOC90YWJsZXJhbmdlOmQ5OGY5ODlmMzlmMTQwNWQ4MmE1OGQ4YjE3OGUzMWI4XzIzLTEtMS0xLTA_394a4647-4717-4401-aaae-dc2784d0ce02"
      unitRef="usd">175000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i7057397719af459ca7328a1c440a0efa_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MDgvZnJhZzo3Njg0MzE5YmEwOWQ0NmI4ODAwOTcwNWFiODM5Y2I4Ny90YWJsZTpkOThmOTg5ZjM5ZjE0MDVkODJhNThkOGIxNzhlMzFiOC90YWJsZXJhbmdlOmQ5OGY5ODlmMzlmMTQwNWQ4MmE1OGQ4YjE3OGUzMWI4XzIzLTMtMS0xLTA_e96ffc35-ba76-45b1-9a4d-1478e3e60560"
      unitRef="usd">473000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MDgvZnJhZzo3Njg0MzE5YmEwOWQ0NmI4ODAwOTcwNWFiODM5Y2I4Ny90YWJsZTpkOThmOTg5ZjM5ZjE0MDVkODJhNThkOGIxNzhlMzFiOC90YWJsZXJhbmdlOmQ5OGY5ODlmMzlmMTQwNWQ4MmE1OGQ4YjE3OGUzMWI4XzI0LTEtMS0xLTA_793b3e36-1bde-41f2-9dd4-72fc9b466251"
      unitRef="usd">59940000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i7057397719af459ca7328a1c440a0efa_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MDgvZnJhZzo3Njg0MzE5YmEwOWQ0NmI4ODAwOTcwNWFiODM5Y2I4Ny90YWJsZTpkOThmOTg5ZjM5ZjE0MDVkODJhNThkOGIxNzhlMzFiOC90YWJsZXJhbmdlOmQ5OGY5ODlmMzlmMTQwNWQ4MmE1OGQ4YjE3OGUzMWI4XzI0LTMtMS0xLTA_6e9ae849-253e-458c-ab4c-eb8b33b57f76"
      unitRef="usd">49755000</us-gaap:LiabilitiesCurrent>
    <us-gaap:DeferredRevenueNoncurrent
      contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MDgvZnJhZzo3Njg0MzE5YmEwOWQ0NmI4ODAwOTcwNWFiODM5Y2I4Ny90YWJsZTpkOThmOTg5ZjM5ZjE0MDVkODJhNThkOGIxNzhlMzFiOC90YWJsZXJhbmdlOmQ5OGY5ODlmMzlmMTQwNWQ4MmE1OGQ4YjE3OGUzMWI4XzI2LTEtMS0xLTA_5cd0e08b-0ea4-454a-bf2a-00e8b2fe562e"
      unitRef="usd">19001000</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:DeferredRevenueNoncurrent
      contextRef="i7057397719af459ca7328a1c440a0efa_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MDgvZnJhZzo3Njg0MzE5YmEwOWQ0NmI4ODAwOTcwNWFiODM5Y2I4Ny90YWJsZTpkOThmOTg5ZjM5ZjE0MDVkODJhNThkOGIxNzhlMzFiOC90YWJsZXJhbmdlOmQ5OGY5ODlmMzlmMTQwNWQ4MmE1OGQ4YjE3OGUzMWI4XzI2LTMtMS0xLTA_d9754e34-3270-46f3-aae4-3e8121b566a5"
      unitRef="usd">13637000</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:DeferredRentCreditNoncurrent
      contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MDgvZnJhZzo3Njg0MzE5YmEwOWQ0NmI4ODAwOTcwNWFiODM5Y2I4Ny90YWJsZTpkOThmOTg5ZjM5ZjE0MDVkODJhNThkOGIxNzhlMzFiOC90YWJsZXJhbmdlOmQ5OGY5ODlmMzlmMTQwNWQ4MmE1OGQ4YjE3OGUzMWI4XzI3LTEtMS0xLTA_1181d43f-a1b8-40b8-b072-6230f8648a10"
      unitRef="usd">10312000</us-gaap:DeferredRentCreditNoncurrent>
    <us-gaap:DeferredRentCreditNoncurrent
      contextRef="i7057397719af459ca7328a1c440a0efa_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MDgvZnJhZzo3Njg0MzE5YmEwOWQ0NmI4ODAwOTcwNWFiODM5Y2I4Ny90YWJsZTpkOThmOTg5ZjM5ZjE0MDVkODJhNThkOGIxNzhlMzFiOC90YWJsZXJhbmdlOmQ5OGY5ODlmMzlmMTQwNWQ4MmE1OGQ4YjE3OGUzMWI4XzI3LTMtMS0xLTA_e1140280-7538-46b9-86a9-16b88bc6d187"
      unitRef="usd">11253000</us-gaap:DeferredRentCreditNoncurrent>
    <us-gaap:Liabilities
      contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MDgvZnJhZzo3Njg0MzE5YmEwOWQ0NmI4ODAwOTcwNWFiODM5Y2I4Ny90YWJsZTpkOThmOTg5ZjM5ZjE0MDVkODJhNThkOGIxNzhlMzFiOC90YWJsZXJhbmdlOmQ5OGY5ODlmMzlmMTQwNWQ4MmE1OGQ4YjE3OGUzMWI4XzI5LTEtMS0xLTA_6067c7a2-8046-4e2d-b5ac-45bccaf7c92b"
      unitRef="usd">89253000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i7057397719af459ca7328a1c440a0efa_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MDgvZnJhZzo3Njg0MzE5YmEwOWQ0NmI4ODAwOTcwNWFiODM5Y2I4Ny90YWJsZTpkOThmOTg5ZjM5ZjE0MDVkODJhNThkOGIxNzhlMzFiOC90YWJsZXJhbmdlOmQ5OGY5ODlmMzlmMTQwNWQ4MmE1OGQ4YjE3OGUzMWI4XzI5LTMtMS0xLTA_7dd44f75-4d93-46a3-82db-01ca4b79c481"
      unitRef="usd">74645000</us-gaap:Liabilities>
    <us-gaap:CommonStockValue
      contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MDgvZnJhZzo3Njg0MzE5YmEwOWQ0NmI4ODAwOTcwNWFiODM5Y2I4Ny90YWJsZTpkOThmOTg5ZjM5ZjE0MDVkODJhNThkOGIxNzhlMzFiOC90YWJsZXJhbmdlOmQ5OGY5ODlmMzlmMTQwNWQ4MmE1OGQ4YjE3OGUzMWI4XzMyLTEtMS0xLTA_c0bd525e-d02f-4320-8a7c-c38805c8aed9"
      unitRef="usd">424000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i7057397719af459ca7328a1c440a0efa_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MDgvZnJhZzo3Njg0MzE5YmEwOWQ0NmI4ODAwOTcwNWFiODM5Y2I4Ny90YWJsZTpkOThmOTg5ZjM5ZjE0MDVkODJhNThkOGIxNzhlMzFiOC90YWJsZXJhbmdlOmQ5OGY5ODlmMzlmMTQwNWQ4MmE1OGQ4YjE3OGUzMWI4XzMyLTMtMS0xLTA_76695ab5-3fe4-47c5-af73-63943b680fec"
      unitRef="usd">369000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MDgvZnJhZzo3Njg0MzE5YmEwOWQ0NmI4ODAwOTcwNWFiODM5Y2I4Ny90YWJsZTpkOThmOTg5ZjM5ZjE0MDVkODJhNThkOGIxNzhlMzFiOC90YWJsZXJhbmdlOmQ5OGY5ODlmMzlmMTQwNWQ4MmE1OGQ4YjE3OGUzMWI4XzMzLTEtMS0xLTA_3fc1040c-abdd-4a2e-a5a3-c87adeec53a0"
      unitRef="usd">732727000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i7057397719af459ca7328a1c440a0efa_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MDgvZnJhZzo3Njg0MzE5YmEwOWQ0NmI4ODAwOTcwNWFiODM5Y2I4Ny90YWJsZTpkOThmOTg5ZjM5ZjE0MDVkODJhNThkOGIxNzhlMzFiOC90YWJsZXJhbmdlOmQ5OGY5ODlmMzlmMTQwNWQ4MmE1OGQ4YjE3OGUzMWI4XzMzLTMtMS0xLTA_7174e0f0-7721-49d4-9162-5f076b494f05"
      unitRef="usd">611270000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MDgvZnJhZzo3Njg0MzE5YmEwOWQ0NmI4ODAwOTcwNWFiODM5Y2I4Ny90YWJsZTpkOThmOTg5ZjM5ZjE0MDVkODJhNThkOGIxNzhlMzFiOC90YWJsZXJhbmdlOmQ5OGY5ODlmMzlmMTQwNWQ4MmE1OGQ4YjE3OGUzMWI4XzM0LTEtMS0xLTA_e542ce67-7b89-47cd-bf09-1e94c11d3210"
      unitRef="usd">-3000</us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i7057397719af459ca7328a1c440a0efa_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MDgvZnJhZzo3Njg0MzE5YmEwOWQ0NmI4ODAwOTcwNWFiODM5Y2I4Ny90YWJsZTpkOThmOTg5ZjM5ZjE0MDVkODJhNThkOGIxNzhlMzFiOC90YWJsZXJhbmdlOmQ5OGY5ODlmMzlmMTQwNWQ4MmE1OGQ4YjE3OGUzMWI4XzM0LTMtMS0xLTA_ad8e12a3-2032-43b9-a96d-cc1bbf95ce41"
      unitRef="usd">-61000</us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MDgvZnJhZzo3Njg0MzE5YmEwOWQ0NmI4ODAwOTcwNWFiODM5Y2I4Ny90YWJsZTpkOThmOTg5ZjM5ZjE0MDVkODJhNThkOGIxNzhlMzFiOC90YWJsZXJhbmdlOmQ5OGY5ODlmMzlmMTQwNWQ4MmE1OGQ4YjE3OGUzMWI4XzM1LTEtMS0xLTA_8119eeff-f193-416b-9e01-9a2dd32da6f0"
      unitRef="usd">-490271000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i7057397719af459ca7328a1c440a0efa_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MDgvZnJhZzo3Njg0MzE5YmEwOWQ0NmI4ODAwOTcwNWFiODM5Y2I4Ny90YWJsZTpkOThmOTg5ZjM5ZjE0MDVkODJhNThkOGIxNzhlMzFiOC90YWJsZXJhbmdlOmQ5OGY5ODlmMzlmMTQwNWQ4MmE1OGQ4YjE3OGUzMWI4XzM1LTMtMS0xLTA_2a1dc813-d1a2-4521-b345-bb3aa154a7be"
      unitRef="usd">-312340000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MDgvZnJhZzo3Njg0MzE5YmEwOWQ0NmI4ODAwOTcwNWFiODM5Y2I4Ny90YWJsZTpkOThmOTg5ZjM5ZjE0MDVkODJhNThkOGIxNzhlMzFiOC90YWJsZXJhbmdlOmQ5OGY5ODlmMzlmMTQwNWQ4MmE1OGQ4YjE3OGUzMWI4XzM2LTEtMS0xLTA_15210384-5e91-4311-b0df-652215303126"
      unitRef="usd">242877000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7057397719af459ca7328a1c440a0efa_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MDgvZnJhZzo3Njg0MzE5YmEwOWQ0NmI4ODAwOTcwNWFiODM5Y2I4Ny90YWJsZTpkOThmOTg5ZjM5ZjE0MDVkODJhNThkOGIxNzhlMzFiOC90YWJsZXJhbmdlOmQ5OGY5ODlmMzlmMTQwNWQ4MmE1OGQ4YjE3OGUzMWI4XzM2LTMtMS0xLTA_fcdbe758-984d-490f-bf51-fb2691e09556"
      unitRef="usd">299238000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MDgvZnJhZzo3Njg0MzE5YmEwOWQ0NmI4ODAwOTcwNWFiODM5Y2I4Ny90YWJsZTpkOThmOTg5ZjM5ZjE0MDVkODJhNThkOGIxNzhlMzFiOC90YWJsZXJhbmdlOmQ5OGY5ODlmMzlmMTQwNWQ4MmE1OGQ4YjE3OGUzMWI4XzM3LTEtMS0xLTA_a3be70c6-1e98-476b-96eb-13be321f5dbb"
      unitRef="usd">332130000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i7057397719af459ca7328a1c440a0efa_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MDgvZnJhZzo3Njg0MzE5YmEwOWQ0NmI4ODAwOTcwNWFiODM5Y2I4Ny90YWJsZTpkOThmOTg5ZjM5ZjE0MDVkODJhNThkOGIxNzhlMzFiOC90YWJsZXJhbmdlOmQ5OGY5ODlmMzlmMTQwNWQ4MmE1OGQ4YjE3OGUzMWI4XzM3LTMtMS0xLTA_965500e8-8b98-4dca-8566-266857dfb5f2"
      unitRef="usd">373883000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="ieb0bea730e3444a5b0d8559d16ad126c_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MzUvZnJhZzo4ZWUzNTdhMzJkMWI0ZGFkODM2NjUyNzM4MGIyZWFlMy90YWJsZTplOWI2MjkzZDQxYjk0Y2NjOWExMTY3YTA2YzM3YjI5NC90YWJsZXJhbmdlOmU5YjYyOTNkNDFiOTRjY2M5YTExNjdhMDZjMzdiMjk0XzMtMS0xLTEtMA_cb95960e-a027-4675-a94f-4f3a3618dc00"
      unitRef="usd">58644000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i59ab418442044814b66164966b88c82b_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MzUvZnJhZzo4ZWUzNTdhMzJkMWI0ZGFkODM2NjUyNzM4MGIyZWFlMy90YWJsZTplOWI2MjkzZDQxYjk0Y2NjOWExMTY3YTA2YzM3YjI5NC90YWJsZXJhbmdlOmU5YjYyOTNkNDFiOTRjY2M5YTExNjdhMDZjMzdiMjk0XzMtMy0xLTEtMA_5e473ecd-6d5b-418e-ac88-06394c0639d3"
      unitRef="usd">155516000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="idbcb1304940d4ff0baeab52d79003f28_D20160101-20161231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MzUvZnJhZzo4ZWUzNTdhMzJkMWI0ZGFkODM2NjUyNzM4MGIyZWFlMy90YWJsZTplOWI2MjkzZDQxYjk0Y2NjOWExMTY3YTA2YzM3YjI5NC90YWJsZXJhbmdlOmU5YjYyOTNkNDFiOTRjY2M5YTExNjdhMDZjMzdiMjk0XzMtNS0xLTEtMA_f4a01164-493c-4863-8322-91700109fa76"
      unitRef="usd">86582000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if637c63a87b147fa81aa860bc98e569f_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MzUvZnJhZzo4ZWUzNTdhMzJkMWI0ZGFkODM2NjUyNzM4MGIyZWFlMy90YWJsZTplOWI2MjkzZDQxYjk0Y2NjOWExMTY3YTA2YzM3YjI5NC90YWJsZXJhbmdlOmU5YjYyOTNkNDFiOTRjY2M5YTExNjdhMDZjMzdiMjk0XzQtMS0xLTEtMA_f2fb272a-3cce-41e7-aeaa-1639323d722f"
      unitRef="usd">1477000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7ebe96cc613b4300bdf8831b4feca588_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MzUvZnJhZzo4ZWUzNTdhMzJkMWI0ZGFkODM2NjUyNzM4MGIyZWFlMy90YWJsZTplOWI2MjkzZDQxYjk0Y2NjOWExMTY3YTA2YzM3YjI5NC90YWJsZXJhbmdlOmU5YjYyOTNkNDFiOTRjY2M5YTExNjdhMDZjMzdiMjk0XzQtMy0xLTEtMA_b356a88b-906c-4d29-8940-9f9382f3cbdf"
      unitRef="usd">2226000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4d5db08e41a54c13a242bb974c98539c_D20160101-20161231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MzUvZnJhZzo4ZWUzNTdhMzJkMWI0ZGFkODM2NjUyNzM4MGIyZWFlMy90YWJsZTplOWI2MjkzZDQxYjk0Y2NjOWExMTY3YTA2YzM3YjI5NC90YWJsZXJhbmdlOmU5YjYyOTNkNDFiOTRjY2M5YTExNjdhMDZjMzdiMjk0XzQtNS0xLTEtMA_0e7b2c80-60c0-4d2f-b2ee-029419e54d25"
      unitRef="usd">5298000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MzUvZnJhZzo4ZWUzNTdhMzJkMWI0ZGFkODM2NjUyNzM4MGIyZWFlMy90YWJsZTplOWI2MjkzZDQxYjk0Y2NjOWExMTY3YTA2YzM3YjI5NC90YWJsZXJhbmdlOmU5YjYyOTNkNDFiOTRjY2M5YTExNjdhMDZjMzdiMjk0XzUtMS0xLTEtMA_c012c026-c22b-426d-86a0-4b2705b74bc6"
      unitRef="usd">60121000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MzUvZnJhZzo4ZWUzNTdhMzJkMWI0ZGFkODM2NjUyNzM4MGIyZWFlMy90YWJsZTplOWI2MjkzZDQxYjk0Y2NjOWExMTY3YTA2YzM3YjI5NC90YWJsZXJhbmdlOmU5YjYyOTNkNDFiOTRjY2M5YTExNjdhMDZjMzdiMjk0XzUtMy0xLTEtMA_1b90623e-9f41-4d72-8614-7fcaaaa2dad3"
      unitRef="usd">157742000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iaf5d0e8fdf374dc09283fd669e2ebf19_D20160101-20161231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MzUvZnJhZzo4ZWUzNTdhMzJkMWI0ZGFkODM2NjUyNzM4MGIyZWFlMy90YWJsZTplOWI2MjkzZDQxYjk0Y2NjOWExMTY3YTA2YzM3YjI5NC90YWJsZXJhbmdlOmU5YjYyOTNkNDFiOTRjY2M5YTExNjdhMDZjMzdiMjk0XzUtNS0xLTEtMA_852a6458-ddfa-4a41-b350-e06f2c14b9cd"
      unitRef="usd">91880000</us-gaap:Revenues>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MzUvZnJhZzo4ZWUzNTdhMzJkMWI0ZGFkODM2NjUyNzM4MGIyZWFlMy90YWJsZTplOWI2MjkzZDQxYjk0Y2NjOWExMTY3YTA2YzM3YjI5NC90YWJsZXJhbmdlOmU5YjYyOTNkNDFiOTRjY2M5YTExNjdhMDZjMzdiMjk0XzgtMS0xLTEtMA_ff25326c-7331-4f95-8e12-9db8b0e1dd9c"
      unitRef="usd">190827000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MzUvZnJhZzo4ZWUzNTdhMzJkMWI0ZGFkODM2NjUyNzM4MGIyZWFlMy90YWJsZTplOWI2MjkzZDQxYjk0Y2NjOWExMTY3YTA2YzM3YjI5NC90YWJsZXJhbmdlOmU5YjYyOTNkNDFiOTRjY2M5YTExNjdhMDZjMzdiMjk0XzgtMy0xLTEtMA_ead3de1f-5e9a-4dd3-b47f-c391156ab603"
      unitRef="usd">147232000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="iaf5d0e8fdf374dc09283fd669e2ebf19_D20160101-20161231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MzUvZnJhZzo4ZWUzNTdhMzJkMWI0ZGFkODM2NjUyNzM4MGIyZWFlMy90YWJsZTplOWI2MjkzZDQxYjk0Y2NjOWExMTY3YTA2YzM3YjI5NC90YWJsZXJhbmdlOmU5YjYyOTNkNDFiOTRjY2M5YTExNjdhMDZjMzdiMjk0XzgtNS0xLTEtMA_ad0d4310-fd52-4f76-b7e5-c394467bc79d"
      unitRef="usd">122091000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MzUvZnJhZzo4ZWUzNTdhMzJkMWI0ZGFkODM2NjUyNzM4MGIyZWFlMy90YWJsZTplOWI2MjkzZDQxYjk0Y2NjOWExMTY3YTA2YzM3YjI5NC90YWJsZXJhbmdlOmU5YjYyOTNkNDFiOTRjY2M5YTExNjdhMDZjMzdiMjk0XzktMS0xLTEtMA_b4f04e1f-0020-478d-a991-bb98426bda6d"
      unitRef="usd">40500000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MzUvZnJhZzo4ZWUzNTdhMzJkMWI0ZGFkODM2NjUyNzM4MGIyZWFlMy90YWJsZTplOWI2MjkzZDQxYjk0Y2NjOWExMTY3YTA2YzM3YjI5NC90YWJsZXJhbmdlOmU5YjYyOTNkNDFiOTRjY2M5YTExNjdhMDZjMzdiMjk0XzktMy0xLTEtMA_4807d02d-984c-44a6-ab8d-7ec7d9479d48"
      unitRef="usd">32653000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="iaf5d0e8fdf374dc09283fd669e2ebf19_D20160101-20161231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MzUvZnJhZzo4ZWUzNTdhMzJkMWI0ZGFkODM2NjUyNzM4MGIyZWFlMy90YWJsZTplOWI2MjkzZDQxYjk0Y2NjOWExMTY3YTA2YzM3YjI5NC90YWJsZXJhbmdlOmU5YjYyOTNkNDFiOTRjY2M5YTExNjdhMDZjMzdiMjk0XzktNS0xLTEtMA_bd1dce49-6e37-4f4f-b9cf-a50e54c8e385"
      unitRef="usd">29831000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MzUvZnJhZzo4ZWUzNTdhMzJkMWI0ZGFkODM2NjUyNzM4MGIyZWFlMy90YWJsZTplOWI2MjkzZDQxYjk0Y2NjOWExMTY3YTA2YzM3YjI5NC90YWJsZXJhbmdlOmU5YjYyOTNkNDFiOTRjY2M5YTExNjdhMDZjMzdiMjk0XzEwLTEtMS0xLTA_c174ee33-a711-4cff-9798-bdc66e8ad429"
      unitRef="usd">231327000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MzUvZnJhZzo4ZWUzNTdhMzJkMWI0ZGFkODM2NjUyNzM4MGIyZWFlMy90YWJsZTplOWI2MjkzZDQxYjk0Y2NjOWExMTY3YTA2YzM3YjI5NC90YWJsZXJhbmdlOmU5YjYyOTNkNDFiOTRjY2M5YTExNjdhMDZjMzdiMjk0XzEwLTMtMS0xLTA_571bbbbc-b7a1-4fd7-a76a-76dd55c51e8f"
      unitRef="usd">179885000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="iaf5d0e8fdf374dc09283fd669e2ebf19_D20160101-20161231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MzUvZnJhZzo4ZWUzNTdhMzJkMWI0ZGFkODM2NjUyNzM4MGIyZWFlMy90YWJsZTplOWI2MjkzZDQxYjk0Y2NjOWExMTY3YTA2YzM3YjI5NC90YWJsZXJhbmdlOmU5YjYyOTNkNDFiOTRjY2M5YTExNjdhMDZjMzdiMjk0XzEwLTUtMS0xLTA_2c65d75e-7b5b-4a89-b067-2f7aee323ae3"
      unitRef="usd">151922000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MzUvZnJhZzo4ZWUzNTdhMzJkMWI0ZGFkODM2NjUyNzM4MGIyZWFlMy90YWJsZTplOWI2MjkzZDQxYjk0Y2NjOWExMTY3YTA2YzM3YjI5NC90YWJsZXJhbmdlOmU5YjYyOTNkNDFiOTRjY2M5YTExNjdhMDZjMzdiMjk0XzEyLTEtMS0xLTA_23bb7e38-26a5-4cdb-8992-ba4e389729a5"
      unitRef="usd">-171206000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MzUvZnJhZzo4ZWUzNTdhMzJkMWI0ZGFkODM2NjUyNzM4MGIyZWFlMy90YWJsZTplOWI2MjkzZDQxYjk0Y2NjOWExMTY3YTA2YzM3YjI5NC90YWJsZXJhbmdlOmU5YjYyOTNkNDFiOTRjY2M5YTExNjdhMDZjMzdiMjk0XzEyLTMtMS0xLTA_b131a3b8-8837-4a74-af5e-fe2a36092c24"
      unitRef="usd">-22143000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="iaf5d0e8fdf374dc09283fd669e2ebf19_D20160101-20161231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MzUvZnJhZzo4ZWUzNTdhMzJkMWI0ZGFkODM2NjUyNzM4MGIyZWFlMy90YWJsZTplOWI2MjkzZDQxYjk0Y2NjOWExMTY3YTA2YzM3YjI5NC90YWJsZXJhbmdlOmU5YjYyOTNkNDFiOTRjY2M5YTExNjdhMDZjMzdiMjk0XzEyLTUtMS0xLTA_b881e8dc-0a7a-4d46-98db-57739454646d"
      unitRef="usd">-60042000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MzUvZnJhZzo4ZWUzNTdhMzJkMWI0ZGFkODM2NjUyNzM4MGIyZWFlMy90YWJsZTplOWI2MjkzZDQxYjk0Y2NjOWExMTY3YTA2YzM3YjI5NC90YWJsZXJhbmdlOmU5YjYyOTNkNDFiOTRjY2M5YTExNjdhMDZjMzdiMjk0XzE0LTEtMS0xLTA_9b0e79a6-b385-409e-bc66-ea97527e5803"
      unitRef="usd">-247000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MzUvZnJhZzo4ZWUzNTdhMzJkMWI0ZGFkODM2NjUyNzM4MGIyZWFlMy90YWJsZTplOWI2MjkzZDQxYjk0Y2NjOWExMTY3YTA2YzM3YjI5NC90YWJsZXJhbmdlOmU5YjYyOTNkNDFiOTRjY2M5YTExNjdhMDZjMzdiMjk0XzE0LTMtMS0xLTA_69e78635-a9e4-4b77-a4ad-f092e6a7aeff"
      unitRef="usd">2517000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="iaf5d0e8fdf374dc09283fd669e2ebf19_D20160101-20161231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MzUvZnJhZzo4ZWUzNTdhMzJkMWI0ZGFkODM2NjUyNzM4MGIyZWFlMy90YWJsZTplOWI2MjkzZDQxYjk0Y2NjOWExMTY3YTA2YzM3YjI5NC90YWJsZXJhbmdlOmU5YjYyOTNkNDFiOTRjY2M5YTExNjdhMDZjMzdiMjk0XzE0LTUtMS0xLTA_d0d6abf7-1176-45ff-9efb-4cc99ec8cca7"
      unitRef="usd">1514000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MzUvZnJhZzo4ZWUzNTdhMzJkMWI0ZGFkODM2NjUyNzM4MGIyZWFlMy90YWJsZTplOWI2MjkzZDQxYjk0Y2NjOWExMTY3YTA2YzM3YjI5NC90YWJsZXJhbmdlOmU5YjYyOTNkNDFiOTRjY2M5YTExNjdhMDZjMzdiMjk0XzE1LTEtMS0xLTA_5111dcb5-b11a-498e-a2cc-b099669b4f22"
      unitRef="usd">-171453000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MzUvZnJhZzo4ZWUzNTdhMzJkMWI0ZGFkODM2NjUyNzM4MGIyZWFlMy90YWJsZTplOWI2MjkzZDQxYjk0Y2NjOWExMTY3YTA2YzM3YjI5NC90YWJsZXJhbmdlOmU5YjYyOTNkNDFiOTRjY2M5YTExNjdhMDZjMzdiMjk0XzE1LTMtMS0xLTA_3e12925c-e0c4-463a-81f6-c5dcb5946e4d"
      unitRef="usd">-19626000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="iaf5d0e8fdf374dc09283fd669e2ebf19_D20160101-20161231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MzUvZnJhZzo4ZWUzNTdhMzJkMWI0ZGFkODM2NjUyNzM4MGIyZWFlMy90YWJsZTplOWI2MjkzZDQxYjk0Y2NjOWExMTY3YTA2YzM3YjI5NC90YWJsZXJhbmdlOmU5YjYyOTNkNDFiOTRjY2M5YTExNjdhMDZjMzdiMjk0XzE1LTUtMS0xLTA_f825d796-ba20-4b99-8a79-a9d05a1a0b62"
      unitRef="usd">-58528000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MzUvZnJhZzo4ZWUzNTdhMzJkMWI0ZGFkODM2NjUyNzM4MGIyZWFlMy90YWJsZTplOWI2MjkzZDQxYjk0Y2NjOWExMTY3YTA2YzM3YjI5NC90YWJsZXJhbmdlOmU5YjYyOTNkNDFiOTRjY2M5YTExNjdhMDZjMzdiMjk0XzE4LTEtMS0xLTA_07183e70-4966-44e4-b678-0b8e1360dc3f"
      unitRef="usd">58000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MzUvZnJhZzo4ZWUzNTdhMzJkMWI0ZGFkODM2NjUyNzM4MGIyZWFlMy90YWJsZTplOWI2MjkzZDQxYjk0Y2NjOWExMTY3YTA2YzM3YjI5NC90YWJsZXJhbmdlOmU5YjYyOTNkNDFiOTRjY2M5YTExNjdhMDZjMzdiMjk0XzE4LTMtMS0xLTA_222e704e-546a-4972-a93d-ac70d992ed4b"
      unitRef="usd">21000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="iaf5d0e8fdf374dc09283fd669e2ebf19_D20160101-20161231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MzUvZnJhZzo4ZWUzNTdhMzJkMWI0ZGFkODM2NjUyNzM4MGIyZWFlMy90YWJsZTplOWI2MjkzZDQxYjk0Y2NjOWExMTY3YTA2YzM3YjI5NC90YWJsZXJhbmdlOmU5YjYyOTNkNDFiOTRjY2M5YTExNjdhMDZjMzdiMjk0XzE4LTUtMS0xLTA_c87f8315-0be6-49ba-8c1a-7c03a0a36e50"
      unitRef="usd">-77000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MzUvZnJhZzo4ZWUzNTdhMzJkMWI0ZGFkODM2NjUyNzM4MGIyZWFlMy90YWJsZTplOWI2MjkzZDQxYjk0Y2NjOWExMTY3YTA2YzM3YjI5NC90YWJsZXJhbmdlOmU5YjYyOTNkNDFiOTRjY2M5YTExNjdhMDZjMzdiMjk0XzE5LTEtMS0xLTA_880d921d-dfa4-4a13-b5d6-ee6433417c6a"
      unitRef="usd">-171395000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MzUvZnJhZzo4ZWUzNTdhMzJkMWI0ZGFkODM2NjUyNzM4MGIyZWFlMy90YWJsZTplOWI2MjkzZDQxYjk0Y2NjOWExMTY3YTA2YzM3YjI5NC90YWJsZXJhbmdlOmU5YjYyOTNkNDFiOTRjY2M5YTExNjdhMDZjMzdiMjk0XzE5LTMtMS0xLTA_8a0571eb-3c4e-401f-a4c7-0ad6f11bd24c"
      unitRef="usd">-19605000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="iaf5d0e8fdf374dc09283fd669e2ebf19_D20160101-20161231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MzUvZnJhZzo4ZWUzNTdhMzJkMWI0ZGFkODM2NjUyNzM4MGIyZWFlMy90YWJsZTplOWI2MjkzZDQxYjk0Y2NjOWExMTY3YTA2YzM3YjI5NC90YWJsZXJhbmdlOmU5YjYyOTNkNDFiOTRjY2M5YTExNjdhMDZjMzdiMjk0XzE5LTUtMS0xLTA_52ac9a75-661e-47a9-9834-058b5c52efd7"
      unitRef="usd">-58605000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MzUvZnJhZzo4ZWUzNTdhMzJkMWI0ZGFkODM2NjUyNzM4MGIyZWFlMy90YWJsZTplOWI2MjkzZDQxYjk0Y2NjOWExMTY3YTA2YzM3YjI5NC90YWJsZXJhbmdlOmU5YjYyOTNkNDFiOTRjY2M5YTExNjdhMDZjMzdiMjk0XzIzLTEtMS0xLTA_ec315529-8454-4c6f-b366-e0584c112881"
      unitRef="usdPerShare">-4.19</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
      contextRef="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MzUvZnJhZzo4ZWUzNTdhMzJkMWI0ZGFkODM2NjUyNzM4MGIyZWFlMy90YWJsZTplOWI2MjkzZDQxYjk0Y2NjOWExMTY3YTA2YzM3YjI5NC90YWJsZXJhbmdlOmU5YjYyOTNkNDFiOTRjY2M5YTExNjdhMDZjMzdiMjk0XzIzLTMtMS0xLTA_edaf2459-92d6-4438-945b-17edeb70925c"
      unitRef="usdPerShare">-0.54</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
      contextRef="iaf5d0e8fdf374dc09283fd669e2ebf19_D20160101-20161231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MzUvZnJhZzo4ZWUzNTdhMzJkMWI0ZGFkODM2NjUyNzM4MGIyZWFlMy90YWJsZTplOWI2MjkzZDQxYjk0Y2NjOWExMTY3YTA2YzM3YjI5NC90YWJsZXJhbmdlOmU5YjYyOTNkNDFiOTRjY2M5YTExNjdhMDZjMzdiMjk0XzIzLTUtMS0xLTA_2be7fa2c-da7e-43c1-a5e3-83e2e5efd6f6"
      unitRef="usdPerShare">-1.69</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MzUvZnJhZzo4ZWUzNTdhMzJkMWI0ZGFkODM2NjUyNzM4MGIyZWFlMy90YWJsZTplOWI2MjkzZDQxYjk0Y2NjOWExMTY3YTA2YzM3YjI5NC90YWJsZXJhbmdlOmU5YjYyOTNkNDFiOTRjY2M5YTExNjdhMDZjMzdiMjk0XzI0LTEtMS0xLTA_395015ab-245d-4611-9162-07f4cf8d403a"
      unitRef="shares">40925318</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MzUvZnJhZzo4ZWUzNTdhMzJkMWI0ZGFkODM2NjUyNzM4MGIyZWFlMy90YWJsZTplOWI2MjkzZDQxYjk0Y2NjOWExMTY3YTA2YzM3YjI5NC90YWJsZXJhbmdlOmU5YjYyOTNkNDFiOTRjY2M5YTExNjdhMDZjMzdiMjk0XzI0LTMtMS0xLTA_d811ea40-357a-460a-8374-82e80c106991"
      unitRef="shares">36095080</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="iaf5d0e8fdf374dc09283fd669e2ebf19_D20160101-20161231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81MzUvZnJhZzo4ZWUzNTdhMzJkMWI0ZGFkODM2NjUyNzM4MGIyZWFlMy90YWJsZTplOWI2MjkzZDQxYjk0Y2NjOWExMTY3YTA2YzM3YjI5NC90YWJsZXJhbmdlOmU5YjYyOTNkNDFiOTRjY2M5YTExNjdhMDZjMzdiMjk0XzI0LTUtMS0xLTA_cbaa2d88-f556-4423-a7a9-b7cbd7db8983"
      unitRef="shares">34685274</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:SharesIssued
      contextRef="i31ded4a9b84e45a8a97b0a276a851d4a_I20151231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzMtMS0xLTEtMA_bb05cc1a-c3b2-4909-834a-8436c31fa06a"
      unitRef="shares">34345754</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i31ded4a9b84e45a8a97b0a276a851d4a_I20151231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzMtMy0xLTEtMA_6cd98261-82ed-4112-bff7-e6f97ebe93b4"
      unitRef="usd">343000</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="idd7e0c72464e4f8b8d5b13e3c2810e9d_I20151231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzMtNS0xLTEtMA_147e14e5-992f-4669-a572-41400265a0f3"
      unitRef="shares">0</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="idd7e0c72464e4f8b8d5b13e3c2810e9d_I20151231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzMtNy0xLTEtMA_b9e792da-6df1-4b39-a79f-7495c2b23c99"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iaa9ee01ece97464eaf75135e2a56dadd_I20151231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzMtOS0xLTEtMA_3733d569-fd9c-4c26-a6b6-d5d96e5bb24e"
      unitRef="usd">547185000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7766301ab52344be8fc41112ad51fe12_I20151231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzMtMTEtMS0xLTA_c374c1ee-43ce-406c-a6c7-eff465991561"
      unitRef="usd">-234186000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3f3f783c3c6749bfb8eab89b1ec2d1ab_I20151231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzMtMTMtMS0xLTA_772ef08b-1657-4e49-bdf5-3712a329b235"
      unitRef="usd">-5000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ife0dac9d3bf74657b071534f4d2516f1_I20151231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzMtMTUtMS0xLTA_17ff99eb-8395-42b2-ace3-f2eb17f8f007"
      unitRef="usd">313337000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ie5d0cd6221f843248de666cd76601d1f_D20160101-20161231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzQtOS0xLTEtMA_5ee49c99-e42a-4ef3-94aa-3f223a32d613"
      unitRef="usd">12165000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="iaf5d0e8fdf374dc09283fd669e2ebf19_D20160101-20161231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzQtMTUtMS0xLTA_114d4de6-acf2-4d2b-92c1-de08b064c3e8"
      unitRef="usd">12165000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <mgnx:StockIssuedDuringPeriodSharesStockPlanActivity
      contextRef="i3fee8e2719b04b64aa1e5c31ae4f97c4_D20160101-20161231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzYtMS0xLTEtMA_edc04b5b-f382-44d9-aa5a-26869f87d958"
      unitRef="shares">524853</mgnx:StockIssuedDuringPeriodSharesStockPlanActivity>
    <mgnx:StockIssuedDuringPeriodValueStockPlanActivity
      contextRef="i3fee8e2719b04b64aa1e5c31ae4f97c4_D20160101-20161231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzYtMy0xLTEtMA_5dc65ed5-462d-4060-917c-c45f70173227"
      unitRef="usd">6000</mgnx:StockIssuedDuringPeriodValueStockPlanActivity>
    <mgnx:StockIssuedDuringPeriodSharesStockPlanActivity
      contextRef="i6f0312cdde5044c9b7c7f5d13093d50d_D20160101-20161231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzYtNS0xLTEtMA_8712e379-417f-466e-98c6-8ae94cb79f9c"
      unitRef="shares">1862</mgnx:StockIssuedDuringPeriodSharesStockPlanActivity>
    <mgnx:StockIssuedDuringPeriodValueStockPlanActivity
      contextRef="i6f0312cdde5044c9b7c7f5d13093d50d_D20160101-20161231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzYtNy0xLTEtMA_fbbfb601-490a-4934-8cb6-3aa215190a79"
      unitRef="usd">-39000</mgnx:StockIssuedDuringPeriodValueStockPlanActivity>
    <mgnx:StockIssuedDuringPeriodValueStockPlanActivity
      contextRef="ie5d0cd6221f843248de666cd76601d1f_D20160101-20161231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzYtOS0xLTEtMA_a0e67db9-9566-437f-b115-58a776e0b89d"
      unitRef="usd">1887000</mgnx:StockIssuedDuringPeriodValueStockPlanActivity>
    <mgnx:StockIssuedDuringPeriodValueStockPlanActivity
      contextRef="iaf5d0e8fdf374dc09283fd669e2ebf19_D20160101-20161231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzYtMTUtMS0xLTA_6640b9bf-1dcb-4db2-81c0-554268d2e540"
      unitRef="usd">1854000</mgnx:StockIssuedDuringPeriodValueStockPlanActivity>
    <us-gaap:TreasuryStockSharesRetired
      contextRef="i6f0312cdde5044c9b7c7f5d13093d50d_D20160101-20161231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzctNS0xLTEtMA_efe12eff-dde2-4227-82cc-a02454e46159"
      unitRef="shares">1862</us-gaap:TreasuryStockSharesRetired>
    <us-gaap:TreasuryStockRetiredParValueMethodAmount
      contextRef="i6f0312cdde5044c9b7c7f5d13093d50d_D20160101-20161231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzctNy0xLTEtMA_a58d5dad-f1a4-4a52-b010-48e1646732b6"
      unitRef="usd">-39000</us-gaap:TreasuryStockRetiredParValueMethodAmount>
    <us-gaap:TreasuryStockRetiredParValueMethodAmount
      contextRef="ie5d0cd6221f843248de666cd76601d1f_D20160101-20161231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzctOS0xLTEtMA_8b1f3b7d-4c60-43f1-8e5a-3a796b947039"
      unitRef="usd">39000</us-gaap:TreasuryStockRetiredParValueMethodAmount>
    <us-gaap:TreasuryStockRetiredParValueMethodAmount
      contextRef="iaf5d0e8fdf374dc09283fd669e2ebf19_D20160101-20161231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzctMTUtMS0xLTA_c78df953-3d8e-4fe5-be6f-3732fb196804"
      unitRef="usd">0</us-gaap:TreasuryStockRetiredParValueMethodAmount>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="ifb20c231125a4e898c5b8db3e1022b77_D20160101-20161231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzgtMTMtMS0xLTA_9fd34fc6-1b66-460c-bc48-c7c3bf59d289"
      unitRef="usd">-77000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="iaf5d0e8fdf374dc09283fd669e2ebf19_D20160101-20161231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzgtMTUtMS0xLTA_5af1576d-5575-40ef-8b08-dcaa2aed9742"
      unitRef="usd">-77000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:NetIncomeLoss
      contextRef="i67cbca56d50744e8b64a458a586e3167_D20160101-20161231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzktMTEtMS0xLTA_0cf99b10-7b35-4708-8bee-0e2534f67a62"
      unitRef="usd">-58528000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="iaf5d0e8fdf374dc09283fd669e2ebf19_D20160101-20161231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzktMTUtMS0xLTA_7acf5c35-1a06-4989-baf0-feab951e53b8"
      unitRef="usd">-58528000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="i77cf90a50960481db6ce7911359972c3_I20161231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzEwLTEtMS0xLTA_bc91d1d2-6ae7-4f17-afdb-018507982656"
      unitRef="shares">34870607</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i77cf90a50960481db6ce7911359972c3_I20161231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzEwLTMtMS0xLTA_59388ec8-1ba3-4f2a-8ed1-3f5c6794b59b"
      unitRef="usd">349000</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="i8afec271b7854f828af67c5a11b81082_I20161231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzEwLTUtMS0xLTA_5a705e13-9469-4472-a6c2-39f194d33697"
      unitRef="shares">0</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i8afec271b7854f828af67c5a11b81082_I20161231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzEwLTctMS0xLTA_56a7adf3-8cf4-4838-8a3d-5165021fccb2"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if1ab14db8127453db201fbbcb4274eeb_I20161231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzEwLTktMS0xLTA_571d229b-2a0a-4300-9f61-adb40cfb5a15"
      unitRef="usd">561198000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ibf25f45131ee4daea309661157e678a9_I20161231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzEwLTExLTEtMS0w_d0e69682-c3eb-436a-840f-271fb92705a0"
      unitRef="usd">-292714000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i278d12a3934249bdb7dd8e95eabc5377_I20161231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzEwLTEzLTEtMS0w_fe96ebd5-6b7c-4bb9-a47d-00599a4c11f0"
      unitRef="usd">-82000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iaa98382ff57d452ab6942c773d605ba7_I20161231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzEwLTE1LTEtMS0w_83983312-216f-44b3-8d2d-56f05c9c3815"
      unitRef="usd">268751000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="iab5813033cd8418a851f487e53ebb255_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzExLTktMS0xLTA_06e513f0-1184-413a-b447-1c7c0d082910"
      unitRef="usd">14744000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzExLTE1LTEtMS0w_f69ac534-ab0b-4ff0-accf-66b21f20bbaf"
      unitRef="usd">14744000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i556705a1d9294485b49514caece35ad9_D20170101-20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzEyLTEtMS0xLTA_41052f2e-2b96-4db3-a2a5-f073aa0b8966"
      unitRef="shares">1699284</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i556705a1d9294485b49514caece35ad9_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzEyLTMtMS0xLTA_991564a1-8162-45d0-8c6f-75c48a5b2cea"
      unitRef="usd">17000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="iab5813033cd8418a851f487e53ebb255_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzEyLTktMS0xLTA_ba89a743-5889-4cd0-8717-989e8bf98042"
      unitRef="usd">34227000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzEyLTE1LTEtMS0w_b67e833c-51a0-4b1e-bb9b-4d7d642269ed"
      unitRef="usd">34244000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <mgnx:StockIssuedDuringPeriodSharesStockPlanActivity
      contextRef="i556705a1d9294485b49514caece35ad9_D20170101-20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzEzLTEtMS0xLTA_910a64ee-5f2f-4014-9d6b-9d8dca5b19b1"
      unitRef="shares">289186</mgnx:StockIssuedDuringPeriodSharesStockPlanActivity>
    <mgnx:StockIssuedDuringPeriodValueStockPlanActivity
      contextRef="i556705a1d9294485b49514caece35ad9_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzEzLTMtMS0xLTA_848776bc-6b89-41aa-982f-c27e5f8a2437"
      unitRef="usd">3000</mgnx:StockIssuedDuringPeriodValueStockPlanActivity>
    <mgnx:StockIssuedDuringPeriodSharesStockPlanActivity
      contextRef="i9132a8fb91054a248c772c0da0d524ec_D20170101-20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzEzLTUtMS0xLTA_bf6127ab-09d6-4ffd-a96e-a5468c958ded"
      unitRef="shares">1862</mgnx:StockIssuedDuringPeriodSharesStockPlanActivity>
    <mgnx:StockIssuedDuringPeriodValueStockPlanActivity
      contextRef="i9132a8fb91054a248c772c0da0d524ec_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzEzLTctMS0xLTA_a45ef941-ab83-4d1a-87cb-dc8ef0150cd8"
      unitRef="usd">-40000</mgnx:StockIssuedDuringPeriodValueStockPlanActivity>
    <mgnx:StockIssuedDuringPeriodValueStockPlanActivity
      contextRef="iab5813033cd8418a851f487e53ebb255_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzEzLTktMS0xLTA_03c560f6-95e9-4f0f-af93-15e80eac8cc7"
      unitRef="usd">1141000</mgnx:StockIssuedDuringPeriodValueStockPlanActivity>
    <mgnx:StockIssuedDuringPeriodValueStockPlanActivity
      contextRef="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzEzLTE1LTEtMS0w_8041e6c6-3426-4247-8cfd-de660c4d495f"
      unitRef="usd">1104000</mgnx:StockIssuedDuringPeriodValueStockPlanActivity>
    <us-gaap:TreasuryStockSharesRetired
      contextRef="i9132a8fb91054a248c772c0da0d524ec_D20170101-20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzE0LTUtMS0xLTA_50e34cea-be8e-48bd-a8aa-7559295b1820"
      unitRef="shares">1862</us-gaap:TreasuryStockSharesRetired>
    <us-gaap:TreasuryStockRetiredParValueMethodAmount
      contextRef="i9132a8fb91054a248c772c0da0d524ec_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzE0LTctMS0xLTA_dc881c6f-4e4c-495f-bad3-64315953814f"
      unitRef="usd">-40000</us-gaap:TreasuryStockRetiredParValueMethodAmount>
    <us-gaap:TreasuryStockRetiredParValueMethodAmount
      contextRef="iab5813033cd8418a851f487e53ebb255_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzE0LTktMS0xLTA_99bed41d-37bb-4b0e-a216-5fc24258e485"
      unitRef="usd">40000</us-gaap:TreasuryStockRetiredParValueMethodAmount>
    <us-gaap:TreasuryStockRetiredParValueMethodAmount
      contextRef="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzE0LTE1LTEtMS0w_a26c1eb4-2cd6-41de-91e6-1ebed49a8b31"
      unitRef="usd">0</us-gaap:TreasuryStockRetiredParValueMethodAmount>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="ic816b5e523774458b622b435dcd2e03b_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzE1LTEzLTEtMS0w_64250066-7fdc-47b7-9a4c-9c2da88c15da"
      unitRef="usd">21000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzE1LTE1LTEtMS0w_e927a1cd-6216-459f-82a3-1ae589ce2140"
      unitRef="usd">21000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:NetIncomeLoss
      contextRef="i506eefa849b64cf7a445dd7f7221c8a5_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzE2LTExLTEtMS0w_7f659d48-a117-4e22-a4bb-23cd7c44f9f8"
      unitRef="usd">-19626000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzE2LTE1LTEtMS0w_e0e9ccce-1424-4796-8e15-6feb10761e82"
      unitRef="usd">-19626000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="i94911b2192424281937290aad92f9145_I20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzE3LTEtMS0xLTA_ef209e03-75ee-43c1-897e-78eb44c252cf"
      unitRef="shares">36859077</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i94911b2192424281937290aad92f9145_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzE3LTMtMS0xLTA_06c42ac6-7fae-4575-a53e-639b7c0c9c7b"
      unitRef="usd">369000</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="i1cf8820c35a34978979d81f8780ea221_I20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzE3LTUtMS0xLTA_56365589-00f1-4147-a821-08b10b4d59ec"
      unitRef="shares">0</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i1cf8820c35a34978979d81f8780ea221_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzE3LTctMS0xLTA_e8646bad-f44a-4a7d-abe2-a74c0b595847"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i800361a265974a11ad8699946c8502e8_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzE3LTktMS0xLTA_dcca6b45-8fee-4583-9d8b-5f585f821749"
      unitRef="usd">611270000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie5fd1b1d68244c1fb5c42ba60484c135_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzE3LTExLTEtMS0w_16e84727-0554-4796-a972-98c13a9a92d7"
      unitRef="usd">-312340000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9c61e1783f5a42efa8b8f1b1d3450e3f_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzE3LTEzLTEtMS0w_3caf56d3-d723-452a-9e72-33fe341248b6"
      unitRef="usd">-61000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7057397719af459ca7328a1c440a0efa_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzE3LTE1LTEtMS0w_51349617-5fe9-4afb-a64c-37b15bee7b98"
      unitRef="usd">299238000</us-gaap:StockholdersEquity>
    <us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption
      contextRef="ie5fd1b1d68244c1fb5c42ba60484c135_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzE4LTExLTEtMS03MDM_309c2dc1-7a0c-45b8-8f22-af8703792053"
      unitRef="usd">-6478000</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
    <us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption
      contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzE4LTE1LTEtMS02MDU4_05dbc602-fe67-4923-a2ba-e65f74bf5f7d"
      unitRef="usd">-6478000</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i7250145010e441dcb223b7e59056d359_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzE4LTktMS0xLTA_75ccb138-187c-4507-b6e0-fa608328c70e"
      unitRef="usd">16520000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzE4LTE1LTEtMS0w_69590b60-987e-4b36-bc33-b282d86d05a1"
      unitRef="usd">16520000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ied344051463c48e98fa4145c7382285a_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzE5LTEtMS0xLTA_f896cad3-73cc-418d-ad3e-9a3ef6b89359"
      unitRef="shares">5175000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ied344051463c48e98fa4145c7382285a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzE5LTMtMS0xLTA_4769669d-e15b-43bb-bce4-9957c1cde52e"
      unitRef="usd">52000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i7250145010e441dcb223b7e59056d359_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzE5LTktMS0xLTA_41a284f1-8c0b-4ab9-a37b-62a19293c06e"
      unitRef="usd">103207000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzE5LTE1LTEtMS0w_0e3cd8fc-45ae-4077-8cce-811a53b62f2f"
      unitRef="usd">103259000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <mgnx:StockIssuedDuringPeriodSharesStockPlanActivity
      contextRef="ied344051463c48e98fa4145c7382285a_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzIwLTEtMS0xLTA_188990d7-5926-460a-b40c-e04f80413033"
      unitRef="shares">319224</mgnx:StockIssuedDuringPeriodSharesStockPlanActivity>
    <mgnx:StockIssuedDuringPeriodValueStockPlanActivity
      contextRef="ied344051463c48e98fa4145c7382285a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzIwLTMtMS0xLTA_df58d02c-c532-49aa-98fc-407a1d572f43"
      unitRef="usd">3000</mgnx:StockIssuedDuringPeriodValueStockPlanActivity>
    <mgnx:StockIssuedDuringPeriodSharesStockPlanActivity
      contextRef="ib9de5f176a0348ab931fab4225555181_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzIwLTUtMS0xLTA_846ac187-f956-4e2b-8e78-41841a947e91"
      unitRef="shares">11070</mgnx:StockIssuedDuringPeriodSharesStockPlanActivity>
    <mgnx:StockIssuedDuringPeriodValueStockPlanActivity
      contextRef="ib9de5f176a0348ab931fab4225555181_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzIwLTctMS0xLTA_8d511747-5e96-4a65-b674-e4fc57994741"
      unitRef="usd">-260000</mgnx:StockIssuedDuringPeriodValueStockPlanActivity>
    <mgnx:StockIssuedDuringPeriodValueStockPlanActivity
      contextRef="i7250145010e441dcb223b7e59056d359_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzIwLTktMS0xLTA_d7c60cea-a9ec-45ee-94b0-25b6c2c4f715"
      unitRef="usd">1990000</mgnx:StockIssuedDuringPeriodValueStockPlanActivity>
    <mgnx:StockIssuedDuringPeriodValueStockPlanActivity
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzIwLTE1LTEtMS0w_6e720a37-bde8-4a75-a08d-77061145d9a7"
      unitRef="usd">1733000</mgnx:StockIssuedDuringPeriodValueStockPlanActivity>
    <us-gaap:TreasuryStockSharesRetired
      contextRef="ib9de5f176a0348ab931fab4225555181_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzIxLTUtMS0xLTA_f0699535-07ea-45c4-b37c-ac5e7a50424f"
      unitRef="shares">11070</us-gaap:TreasuryStockSharesRetired>
    <us-gaap:TreasuryStockRetiredParValueMethodAmount
      contextRef="ib9de5f176a0348ab931fab4225555181_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzIxLTctMS0xLTA_a1e15238-20d8-4114-a223-47aa6f9f1e94"
      unitRef="usd">-260000</us-gaap:TreasuryStockRetiredParValueMethodAmount>
    <us-gaap:TreasuryStockRetiredParValueMethodAmount
      contextRef="i7250145010e441dcb223b7e59056d359_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzIxLTktMS0xLTA_ed2bae49-a527-4eb1-bb23-b5e5e9787663"
      unitRef="usd">260000</us-gaap:TreasuryStockRetiredParValueMethodAmount>
    <us-gaap:TreasuryStockRetiredParValueMethodAmount
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzIxLTE1LTEtMS0w_cb1381b6-ca38-4206-a0a6-5bd2cce5fdee"
      unitRef="usd">0</us-gaap:TreasuryStockRetiredParValueMethodAmount>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="i449b3691440b4861a36b0b93e9837dbe_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzIyLTEzLTEtMS0w_54f32fab-5450-4fe0-95f1-0e210a0224cf"
      unitRef="usd">58000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzIyLTE1LTEtMS0w_6b87d47c-9ce7-426e-bce3-7825f29642af"
      unitRef="usd">58000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:NetIncomeLoss
      contextRef="i2441bc1dd5c841d99c40a2087f89589a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzIzLTExLTEtMS0w_137d95df-0ebf-4e83-9926-27074b999049"
      unitRef="usd">-171453000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzIzLTE1LTEtMS0w_03124a6f-d581-4bff-8023-8ffb27792ab5"
      unitRef="usd">-171453000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="id2b1c6462f71494a98dce8bac5aef0c8_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzI0LTEtMS0xLTA_461cb633-225f-480f-969a-b53f62804bc3"
      unitRef="shares">42353301</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="id2b1c6462f71494a98dce8bac5aef0c8_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzI0LTMtMS0xLTA_5a014938-b170-4800-ae7a-4d9e9fe37bdd"
      unitRef="usd">424000</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="i5fefb74c168342b7b60f52ca08b1b7fc_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzI0LTUtMS0xLTA_05e1ad41-e73b-491e-af88-97dc5c957eac"
      unitRef="shares">0</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i5fefb74c168342b7b60f52ca08b1b7fc_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzI0LTctMS0xLTA_e9b8b014-373d-478d-95d4-691b79edea80"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i73f75e4bcf834fc4bca320dd6083848a_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzI0LTktMS0xLTA_05260c46-6cf0-4095-815b-748d03423146"
      unitRef="usd">732727000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="icb8cb5ee17f94fffbdcab3e5ff465890_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzI0LTExLTEtMS0w_57f8d85b-c384-4fdd-92d5-07a9e5dd9624"
      unitRef="usd">-490271000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie553de76ecaa42e2af8bd7cfe6d9d352_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzI0LTEzLTEtMS0w_bc2d2dab-4ccc-4185-8fdc-d3a80bfb9d3a"
      unitRef="usd">-3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NDcvZnJhZzo4ZjAxYTU1MjRmZDI0OTk4OGU3ZjU4NTQ2MGQ4ODc4MS90YWJsZToyY2M5NjI1N2EyNDQ0NjA2ODBiNjMyOGE1NzZiZjliYS90YWJsZXJhbmdlOjJjYzk2MjU3YTI0NDQ2MDY4MGI2MzI4YTU3NmJmOWJhXzI0LTE1LTEtMS0w_63debbe1-99e5-48fc-9bd7-6d367b1a96b4"
      unitRef="usd">242877000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzMtMS0xLTEtMA_3839f3a4-578b-46b5-a6ce-295e25f67921"
      unitRef="usd">-171453000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzMtMy0xLTEtMA_3a34732b-ed9a-4a05-b46d-659dab4295e6"
      unitRef="usd">-19626000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="iaf5d0e8fdf374dc09283fd669e2ebf19_D20160101-20161231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzMtNS0xLTEtMA_ea69a792-d0f6-4c31-9fbd-bd43047305a6"
      unitRef="usd">-58528000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzUtMS0xLTEtMA_7acb6d66-d319-4fb6-9ec8-add6b18f8c5e"
      unitRef="usd">8279000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzUtMy0xLTEtMA_077b4bfb-004c-4fad-86f5-498dc2f327a8"
      unitRef="usd">7228000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="iaf5d0e8fdf374dc09283fd669e2ebf19_D20160101-20161231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzUtNS0xLTEtMA_c978a03b-6ac0-4f83-9518-658ce261d5de"
      unitRef="usd">7608000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzYtMS0xLTEtMA_50cf2a3c-891e-4c8f-b791-5c6634fc3264"
      unitRef="usd">16520000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzYtMy0xLTEtMA_a5d5971f-b253-4f53-ae7a-04b73810d75a"
      unitRef="usd">14744000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="iaf5d0e8fdf374dc09283fd669e2ebf19_D20160101-20161231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzYtNS0xLTEtMA_368e49c9-2cad-4861-8062-438e2625c8f8"
      unitRef="usd">12165000</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzgtMS0xLTEtMA_28b26d83-de4d-4d1e-97bc-d9e65617f864"
      unitRef="usd">15941000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzgtMy0xLTEtMA_a19a451b-2bb9-436b-8920-bdd6695681ef"
      unitRef="usd">10878000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="iaf5d0e8fdf374dc09283fd669e2ebf19_D20160101-20161231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzgtNS0xLTEtMA_8862c67a-ab67-43f3-95b8-33642c565edf"
      unitRef="usd">1540000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzktMS0xLTEtMA_666b0b36-5737-4f68-bad0-817fd13bed78"
      unitRef="usd">3255000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzktMy0xLTEtMA_d15f4ca8-b72f-4791-b51a-4d8df3c703d6"
      unitRef="usd">-332000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="iaf5d0e8fdf374dc09283fd669e2ebf19_D20160101-20161231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzktNS0xLTEtMA_f4dda0e3-0b15-4d5e-a198-ecf4321d04c5"
      unitRef="usd">1677000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzExLTEtMS0xLTA_898307e8-3fcf-423b-9107-3b433a79a4cf"
      unitRef="usd">4580000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzExLTMtMS0xLTA_7761b464-c1c0-40dc-8bfc-81a3cb429b15"
      unitRef="usd">-262000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="iaf5d0e8fdf374dc09283fd669e2ebf19_D20160101-20161231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzExLTUtMS0xLTA_44d62d18-9950-4d07-9138-a64c230ca7cd"
      unitRef="usd">-276000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzEyLTEtMS0xLTA_ce6e96fc-56ce-4ef7-a4e8-c0ae65ba2328"
      unitRef="usd">1554000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzEyLTMtMS0xLTA_c31b7ae9-395d-4189-8dab-c8b35c5146f0"
      unitRef="usd">-1544000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="iaf5d0e8fdf374dc09283fd669e2ebf19_D20160101-20161231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzEyLTUtMS0xLTA_7db0a7c0-87a1-40a0-a66c-82d11febac31"
      unitRef="usd">2232000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzEzLTEtMS0xLTA_95f6f971-1e56-4603-ba1e-79b08ea914da"
      unitRef="usd">3506000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzEzLTMtMS0xLTA_89b8977f-31a3-4c15-8bf4-de0dfdff8213"
      unitRef="usd">12832000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="iaf5d0e8fdf374dc09283fd669e2ebf19_D20160101-20161231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzEzLTUtMS0xLTA_2c57e4a3-bd66-4a6e-9c46-464cda80233a"
      unitRef="usd">4659000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzE1LTEtMS0xLTA_0a4535d3-6165-4e87-aa3c-a4a82a0c6b9c"
      unitRef="usd">13405000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzE1LTMtMS0xLTA_3dd67c97-96fc-47b7-9a11-c523ce698a23"
      unitRef="usd">6533000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="iaf5d0e8fdf374dc09283fd669e2ebf19_D20160101-20161231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzE1LTUtMS0xLTA_9e5b2ae7-bbda-4725-98df-90f441e809d6"
      unitRef="usd">-4191000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <mgnx:IncreaseDecreaseInDeferredRent
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzE2LTEtMS0xLTA_04bf8056-6d1e-4d9a-8250-5f276d3c3cf0"
      unitRef="usd">-971000</mgnx:IncreaseDecreaseInDeferredRent>
    <mgnx:IncreaseDecreaseInDeferredRent
      contextRef="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzE2LTMtMS0xLTA_41537f2a-ab8a-4d18-8e10-21e5f5825933"
      unitRef="usd">6115000</mgnx:IncreaseDecreaseInDeferredRent>
    <mgnx:IncreaseDecreaseInDeferredRent
      contextRef="iaf5d0e8fdf374dc09283fd669e2ebf19_D20160101-20161231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzE2LTUtMS0xLTA_ede4d34b-c125-4cac-ae07-2c2dd0015c13"
      unitRef="usd">-1134000</mgnx:IncreaseDecreaseInDeferredRent>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzE3LTEtMS0xLTA_c71cecba-56aa-4e37-a4bd-769a6de28821"
      unitRef="usd">-298000</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities
      contextRef="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzE3LTMtMS0xLTA_11195fb8-3c1a-4c52-87db-68b8810320f7"
      unitRef="usd">-1593000</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities
      contextRef="iaf5d0e8fdf374dc09283fd669e2ebf19_D20160101-20161231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzE3LTUtMS0xLTA_3a6580c2-d061-488c-be8a-0296d8fbf0a7"
      unitRef="usd">-3549000</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzE4LTEtMS0xLTA_727423a8-9bdd-4818-8133-a9fc93aa2c93"
      unitRef="usd">-153234000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
    <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
      contextRef="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzE4LTMtMS0xLTA_d53d630a-c927-49cd-8801-c8d7689d36b7"
      unitRef="usd">14405000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
    <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
      contextRef="iaf5d0e8fdf374dc09283fd669e2ebf19_D20160101-20161231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzE4LTUtMS0xLTA_f805f2ac-8eb1-46f3-9af2-317f02cdd9d8"
      unitRef="usd">-43679000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzIxLTEtMS0xLTA_2fe21985-20fc-4a6d-a2be-7a7f822a04d3"
      unitRef="usd">132750000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzIxLTMtMS0xLTA_4c873aa6-7448-4e8f-8efa-3ceb28939ec8"
      unitRef="usd">135122000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="iaf5d0e8fdf374dc09283fd669e2ebf19_D20160101-20161231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzIxLTUtMS0xLTA_32778d63-b286-4771-b558-3612c566410b"
      unitRef="usd">347762000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzIyLTEtMS0xLTA_54697c0a-c5b3-428c-a4cb-e89c6c909459"
      unitRef="usd">214348000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzIyLTMtMS0xLTA_3766e288-28ea-457a-b5c4-e0b21f5e7531"
      unitRef="usd">242401000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="iaf5d0e8fdf374dc09283fd669e2ebf19_D20160101-20161231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzIyLTUtMS0xLTA_3a14a9b0-5c5b-40dc-a7c3-ff2d6526ae39"
      unitRef="usd">288894000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzIzLTEtMS0xLTA_400c7167-aae4-4b53-88f6-417d45b95e71"
      unitRef="usd">24954000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzIzLTMtMS0xLTA_cd7fee8d-be75-42b2-9c3b-a42f277395ae"
      unitRef="usd">29403000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="iaf5d0e8fdf374dc09283fd669e2ebf19_D20160101-20161231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzIzLTUtMS0xLTA_d54429e0-66c1-47cb-a6e3-7221c1eb629f"
      unitRef="usd">11381000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzI0LTEtMS0xLTA_94c15471-00c9-488d-8ebc-d2e6b0d69219"
      unitRef="usd">56644000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
    <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
      contextRef="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzI0LTMtMS0xLTA_f4fa9b26-a4bb-4bbe-8149-9d4626a48069"
      unitRef="usd">77876000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
    <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
      contextRef="iaf5d0e8fdf374dc09283fd669e2ebf19_D20160101-20161231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzI0LTUtMS0xLTA_a644ff01-c5ba-43e8-aecd-e607cf9d26a2"
      unitRef="usd">-70249000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzI3LTEtMS0xLTA_c1f92f9c-67bf-4ac1-8b12-d4c28d0d95f5"
      unitRef="usd">103259000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzI3LTMtMS0xLTA_5c1e207e-7be6-4b23-8c08-ba74b1eff7fd"
      unitRef="usd">34244000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="iaf5d0e8fdf374dc09283fd669e2ebf19_D20160101-20161231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzI3LTUtMS0xLTA_728c747a-a0e0-42f3-8b70-1eb61f5df12f"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <mgnx:ProceedsfromStockOptionsExercisedAndESPPPurchases
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzI4LTEtMS0xLTA_82084f22-8a89-4382-9c07-ded204d90b67"
      unitRef="usd">1992000</mgnx:ProceedsfromStockOptionsExercisedAndESPPPurchases>
    <mgnx:ProceedsfromStockOptionsExercisedAndESPPPurchases
      contextRef="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzI4LTMtMS0xLTA_046e427d-78a2-4326-b44e-0b98147f796f"
      unitRef="usd">1144000</mgnx:ProceedsfromStockOptionsExercisedAndESPPPurchases>
    <mgnx:ProceedsfromStockOptionsExercisedAndESPPPurchases
      contextRef="iaf5d0e8fdf374dc09283fd669e2ebf19_D20160101-20161231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzI4LTUtMS0xLTA_a8cbb39b-2542-417c-8c08-bedf0e797b37"
      unitRef="usd">1893000</mgnx:ProceedsfromStockOptionsExercisedAndESPPPurchases>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzI5LTEtMS0xLTA_7cbe0bd4-93e5-4d30-b29b-c57e6a04ef69"
      unitRef="usd">260000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzI5LTMtMS0xLTA_0d23290f-1d40-45bf-8118-3dcd8711b983"
      unitRef="usd">40000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="iaf5d0e8fdf374dc09283fd669e2ebf19_D20160101-20161231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzI5LTUtMS0xLTA_25f7836a-8d28-4964-8a27-1e31918262d1"
      unitRef="usd">39000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzMwLTEtMS0xLTA_b36f5210-aafc-4866-9a86-6071773161be"
      unitRef="usd">104991000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
    <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
      contextRef="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzMwLTMtMS0xLTA_074a9455-5f08-49ba-842e-5bb77f433bee"
      unitRef="usd">35348000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
    <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
      contextRef="iaf5d0e8fdf374dc09283fd669e2ebf19_D20160101-20161231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzMwLTUtMS0xLTA_fd7e00c4-cc82-48c1-a9d2-7b645f35c050"
      unitRef="usd">1854000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzMxLTEtMS0xLTA_a9ea94e7-6b26-42af-8a6d-d9fdd4377ff1"
      unitRef="usd">8401000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease
      contextRef="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzMxLTMtMS0xLTA_d9a42052-c84e-4e30-9239-78095b14c479"
      unitRef="usd">127629000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease
      contextRef="iaf5d0e8fdf374dc09283fd669e2ebf19_D20160101-20161231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzMxLTUtMS0xLTA_4b0a36cd-7f63-4893-a544-13dedb29e5d0"
      unitRef="usd">-112074000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i7057397719af459ca7328a1c440a0efa_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzMyLTEtMS0xLTA_825cfa0f-6d0d-4025-8e9b-f960a56d43e9"
      unitRef="usd">211727000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="iaa98382ff57d452ab6942c773d605ba7_I20161231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzMyLTMtMS0xLTA_0f9a6fed-2944-41ca-99da-5b2dcb3e59af"
      unitRef="usd">84098000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ife0dac9d3bf74657b071534f4d2516f1_I20151231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzMyLTUtMS0xLTA_787aa5a6-9738-4e45-b5be-19626fd9a9b2"
      unitRef="usd">196172000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzMzLTEtMS0xLTA_90b11745-5d23-4ac6-9335-2df4c4b5e16c"
      unitRef="usd">220128000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i7057397719af459ca7328a1c440a0efa_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzMzLTMtMS0xLTA_dd77be48-316a-4eef-bc93-4c960ed2604a"
      unitRef="usd">211727000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="iaa98382ff57d452ab6942c773d605ba7_I20161231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzMzLTUtMS0xLTA_e2a2182b-2e17-4b3a-a758-9a28bb8c331d"
      unitRef="usd">84098000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <mgnx:FairValueOfWarrantsReceived
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzM1LTEtMS0xLTYwNjA_93ac4ea9-4123-4e25-9325-81c8aaabee22"
      unitRef="usd">6130000</mgnx:FairValueOfWarrantsReceived>
    <mgnx:FairValueOfWarrantsReceived
      contextRef="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzM1LTMtMS0xLTYwNjc_bcf86bbc-e241-4980-921e-c39f634500ae"
      unitRef="usd">0</mgnx:FairValueOfWarrantsReceived>
    <mgnx:FairValueOfWarrantsReceived
      contextRef="iaf5d0e8fdf374dc09283fd669e2ebf19_D20160101-20161231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81NjAvZnJhZzpjZjM5OWUwMGE3MWQ0OTZiYjMxZWNkYmI4NGRhYmUwYy90YWJsZTo5NWEwYWYzMTVjMTI0NDFmYmExYTQ3NmU4MWUwODgyNy90YWJsZXJhbmdlOjk1YTBhZjMxNWMxMjQ0MWZiYTFhNDc2ZTgxZTA4ODI3XzM1LTUtMS0xLTYwNjk_985a3088-2fb2-4378-8ef2-3aa86e553f73"
      unitRef="usd">0</mgnx:FairValueOfWarrantsReceived>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81ODYvZnJhZzo4YWNhYmQxMjk3MWY0MTU2YTQ0NzczODViY2IxMmQ3NC90ZXh0cmVnaW9uOjhhY2FiZDEyOTcxZjQxNTZhNDQ3NzM4NWJjYjEyZDc0XzgwOQ_4cf802f4-2ec3-41e5-964e-2ce17bbcef6a">Organization and Nature of OperationsMacroGenics, Inc. (the Company) is incorporated in the state of Delaware. The Company is a biopharmaceutical company focused on discovering and developing innovative antibody-based therapeutics designed to modulate the human immune response for the treatment of cancer. The Company currently has a pipeline of product candidates in human clinical testing that have been created primarily using its proprietary technology platforms. The Company believes its programs have the potential to have a meaningful effect on treating patients' unmet medical needs as monotherapy or, in some cases, in combination with other therapeutic agents.</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90ZXh0cmVnaW9uOjIxM2RlYmY3Njg3MzQ3NmE5YTk0YzgyMTZiN2I4YTlmXzQxNDQx_fc98c50d-19a8-49d1-8c61-aeb9dd1d8db4">Summary of Significant Accounting Policies&lt;div style="margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Basis of Presentation and Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;The consolidated financial statements include the accounts of MacroGenics, Inc. and its wholly owned subsidiary, MacroGenics UK Limited.&#160; All intercompany accounts and transactions have been eliminated in consolidation. The Company currently operates in one operating segment. Operating segments are defined as components of an enterprise about which separate discrete information is available for the chief operating decision maker, or decision making group, in deciding how to allocate resources and assessing performance. The Company views its operations and manages its business in one segment, which is developing monoclonal antibody-based therapeutics for cancer, autoimmune and infectious diseases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;The preparation of the financial statements in accordance with generally accepted accounting principles (GAAP) requires the Company to make estimates and judgments in certain circumstances that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. In preparing these consolidated financial statements, management has made its best estimates and judgments of certain amounts included in the financial statements, giving due consideration to materiality. On an ongoing basis, the Company evaluates its estimates, including those related to revenue recognition, fair values of assets, stock-based compensation, income taxes, preclinical study and clinical trial accruals and other contingencies. Management bases its estimates on historical experience or on various other assumptions that it believes to be reasonable under the circumstances. Actual results could differ from these estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Cash, Cash Equivalents and Marketable Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;The Company considers all investments in highly liquid financial instruments with a maturity of 90 days or less at the date of purchase to be cash equivalents. Cash and cash equivalents includes investments in money market funds with commercial banks and financial institutions, securities issued by the U.S. government and its agencies, Government Sponsored Enterprise agency debt obligations and corporate debt obligations. Cash equivalents are stated at amortized cost, plus accrued interest, which approximates fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:25pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;The Company carries marketable securities classified as available-for-sale at fair value as determined by prices for identical or similar securities at the balance sheet date. Marketable securities consist of Level 2 financial instruments in the fair-value hierarchy. The Company records unrealized gains and losses as a component of other comprehensive loss within the statements of operations and comprehensive loss and as a separate component of stockholders' equity. Realized gains or losses on available-for-sale securities are determined using the specific identification method and the Company includes net realized gains and losses in other income (expense).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;At each balance sheet date, the Company assesses available-for-sale securities in an unrealized loss position to determine whether the unrealized loss is other-than-temporary. The Company considers factors including: the significance of the decline in value compared to the cost basis, underlying factors contributing to a decline in the prices of securities in a single asset class, the length of time the market value of the security has been less than its cost basis, the security's relative performance versus its peers, sector or asset class, expected market volatility and the market and economy in general. The Company also evaluates whether it is more likely than not that it will be required to sell a security prior to recovery of its fair value.&#160; An impairment loss is recognized at the time the Company determines that a decline in the fair value below its cost basis is other-than-temporary. There were no unrealized losses at December&#160;31, 2018 or &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;2017&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt; that the Company determined to be other-than-temporary.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Accounts Receivable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;Accounts receivable that management has the intent and ability to collect are reported in the consolidated balance sheets at outstanding amounts, less an allowance for doubtful accounts. The Company writes off uncollectible receivables when the likelihood of collection is remote.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;The Company evaluates the collectability of accounts receivable on a regular basis. The allowance, if any, is based upon various factors including the financial condition and payment history of customers, an overall review of collections experience on other accounts and economic factors or events expected to affect future collections experience. No allowance was recorded as of December&#160;31, 2018 or 2017, as the Company has a history of collecting on all outstanding accounts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;The Company's financial instruments consist of cash and cash equivalents, marketable securities, accounts receivable, accounts payable and accrued expenses.&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;The carrying amount of accounts receivable, accounts payable and accrued expenses are generally considered to be representative of their respective fair values because of their short-term nature.&#160;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt; The Company accounts for recurring and non-recurring fair value measurements in accordance with the Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 820, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;"&gt;Fair Value Measurements and Disclosures&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt; (ASC 820). ASC 820 defines fair value, establishes a fair value hierarchy for assets and liabilities measured at fair value, and requires expanded disclosures about fair value measurements. The ASC 820 hierarchy ranks the quality of reliability of inputs, or assumptions, used in the determination of fair value and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following three categories:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:54pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;"&gt;Level 1 &#x2013; Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:54pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;"&gt;Level 2 &#x2013; Fair value is determined by using inputs other than Level 1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models, such as interest rates and yield curves that can be corroborated by observable market data.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:54pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;"&gt;Level 3 &#x2013; Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgments to be made by a reporting entity &#x2013; e.g., determining an appropriate adjustment to a discount factor for illiquidity associated with a given security.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;The Company evaluates financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them each reporting period. This determination requires the Company to make subjective judgments as to the significance of inputs used in determining fair value and where such inputs lie within the ASC 820 hierarchy.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;Financial assets measured at fair value on a recurring basis were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:36.325991%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.747430%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.121586%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.565345%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.268429%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.271659%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.121586%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.977974%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair Value Measurement at December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;"&gt;Quoted Prices in&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;"&gt;Active Markets for&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;"&gt;Identical Assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;"&gt;Significant Other&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;"&gt;Observable Inputs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;"&gt;Significant&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;"&gt;Unobservable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;"&gt;Inputs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;46,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;46,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;100,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;100,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Common stock warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;"&gt;Total assets measured at fair value &lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;"&gt;(a)&lt;/sup&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;160,849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;46,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;112,702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:36.325991%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.747430%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.121586%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.565345%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.268429%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.271659%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.121586%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.977974%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair Value Measurement at December 31, 2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;"&gt;Quoted Prices in&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;"&gt;Active Markets for&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;"&gt;Identical Assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;"&gt;Significant Other&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;"&gt;Observable Inputs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;"&gt;Significant&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;"&gt;Unobservable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;"&gt;Inputs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;61,512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;61,512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;78,418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;78,418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;"&gt;Total assets measured at fair value &lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;"&gt;(&lt;/sup&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;"&gt;b)&lt;/sup&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;155,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;61,512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;94,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;(a) Total assets measured at fair value at December&#160;31, 2018 includes approximately $146.2 million reported in cash and cash equivalents on the balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;(b) Total assets measured at fair value at December&#160;31, 2017 includes approximately $62.5 million reported in cash and cash equivalents on the balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:15pt;margin-bottom:15pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;The fair value of Level 2 securities is determined from market pricing and other observable market inputs for similar securities obtained from various third-party data providers. These inputs either represent quoted prices for similar assets in active markets or have been derived from observable market data.  &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;The fair value of Level 3 securities is determined using the Black-Scholes option-pricing model.  There were no transfers between levels during the periods presented.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents, marketable securities and accounts receivable. &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;The Company maintains&#160;its cash and money market funds with financial institutions that are federally insured. While balances deposited in these institutions often exceed Federal Deposit Insurance Corporation limits, the Company has not experienced any losses on related accounts to date.&#160;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;The Company's investment policy limits investments to certain types of debt securities issued by the U.S. government, its agencies and institutions with investment-grade credit ratings and places restrictions on maturities and concentration by type and issuer.&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt; The counterparties are various corporations, financial institutions and government agencies of high credit standing.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;The Company's revenue relates to agreements with various collaborators and&#160;contracts and research grants received from U.S. government agencies.&#160;The following table includes those collaborators that represent more than 10% of total revenue earned in the periods indicated:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.269006%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:67.219440%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:7.720177%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.536377%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:7.720177%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.683652%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:7.720177%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;height:13pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2016&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Incyte Corporation (Incyte)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;68%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Janssen Biotech, Inc. (Janssen)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;*&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;*&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;85%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Provention Bio, Inc. (Provention)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;The following table includes those counterparties that represent more than 10% of accounts receivable at the date indicated:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:73.806452%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.730205%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533138%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.730205%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2017&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Zai Lab Limited (Zai Lab)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;76%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Incyte&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;16%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (Roche)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;73%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Les Laboratoires Servier and Institut de Recherches Servier (Servier)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;*&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;* Balance is less than 10%&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Property, Equipment and Software&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;Property, equipment and software are stated at cost. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation or amortization are removed from the accounts and any resulting gain or loss is credited or charged to operations. Repairs and maintenance costs are expensed as incurred.&#160;Depreciation and amortization are computed using the straight-line method over the following estimated useful lives:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:48.000000%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:48.000000%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Furniture&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Laboratory and office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Shorter of lease term or useful life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;The Company assesses the recoverability of its long-lived assets in accordance with the provisions of ASC 360, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;"&gt;Property, Plant and Equipment&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;. ASC 360 requires that long-lived assets be reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of the long-lived asset is measured by a comparison of the carrying amount of the asset to future undiscounted net cash flows expected to be generated by the asset or asset group. If carrying value exceeds the sum of undiscounted cash flows, the Company then determines the fair value of the underlying asset group. Any impairment to be recognized is measured by the amount by which the carrying amount of the asset group exceeds the estimated fair value of the asset group. Assets to be disposed of are reported at the lower of the carrying amount or fair value, less costs to sell. For the years ended&#160;December&#160;31, 2018,&#160;2017 and 2016, the Company determined that there were no impaired assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Income Taxes&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;Deferred tax assets and liabilities are determined based on differences between the financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. The effect on deferred tax assets and liabilities of a change in tax rates is recognized as income in the period that such tax rate changes are enacted. The measurement of a deferred tax asset is reduced, if necessary, by a valuation allowance if it is more likely than not that some portion or all of the deferred tax asset will not be realized. Financial statement recognition of a tax position taken or expected to be taken in a tax return is determined based on a more-likely-than-not threshold of that position being sustained. If the tax position meets this threshold, the benefit to be recognized is measured as the largest amount that is more likely than not to be realized upon ultimate settlement. The Company's policy is to record interest and penalties related to uncertain tax positions as a component of income tax expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Revenues&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:40.5pt;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;Beginning on January 1, 2018, the Company&#160;recognizes revenue under Accounting Standards Update (ASU) No. 2014-09, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;"&gt;Revenue from Contracts with Customer&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;s and all related amendments (collectively ASC 606) when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services.&#160;&#160;To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation.  The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;The Company enters into licensing agreements that are within the scope of ASC 606, under which it may license rights to research, develop, manufacture and commercialize its product candidates to third parties. The terms of these arrangements typically include payment to the Company of one or more of the following: non-refundable, upfront license fees; reimbursement of certain costs; customer option exercise fees; development, regulatory and commercial milestone payments;&#160;and royalties on net sales of licensed products.   The Company may also enter into development and manufacturing service agreements&#160;with its collaborators.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;For each arrangement that results in revenues, the Company identifies all performance obligations, which may include a license to intellectual property and know-how, research and development activities, transition activities and/or manufacturing services. In order to determine the transaction price, in addition to any upfront payment, the Company estimates the amount of variable consideration at the outset of the contract either utilizing the expected value or most likely amount method, depending&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt; on the facts and circumstances relative to the contract. The Company constrains (reduces) the estimates of variable consideration such that it is probable that a significant reversal of previously recognized revenue will not occur. When determining if variable consideration should be constrained, management considers whether there are factors outside the Company&#x2019;s control that could result in a significant reversal of revenue. In making these assessments, the Company considers the likelihood and magnitude of a potential reversal of revenue. These estimates are re-assessed each reporting period as required. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;Once the estimated transaction price is established, amounts are allocated to the performance obligations that have been identified. The transaction price is generally allocated to each separate performance obligation on a relative standalone selling price basis. The Company must develop assumptions that require judgment to determine the standalone selling price in order to account for these agreements. To determine the standalone selling price, the Company&#x2019;s assumptions may include (i)  the probability of obtaining marketing approval for the product candidate, (ii) estimates regarding the timing and the expected costs to develop and commercialize the product candidate, and (iii) estimates of future cash flows from potential product sales with respect to the product candidate. Standalone selling prices used to perform the initial allocation are not updated after contract inception. The Company does not include a financing component to its estimated transaction price at contract inception unless it estimates that certain performance obligations will not be satisfied within one year.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;Amounts received prior to revenue recognition are recorded as deferred revenue. Amounts expected to be recognized as revenue within the 12&#160;months following the balance sheet date are classified as current portion of deferred revenue in the accompanying consolidated balance sheets. Amounts not expected to be recognized as revenue within the 12&#160;months following the balance sheet date are classified as deferred revenue, net of current portion. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;"&gt;Licenses. &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;If the license to the Company&#x2019;s intellectual property is determined to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and when (or as) the customer is able to use and benefit from the license. In assessing whether a promise or performance obligation is distinct from the other promises, the Company considers factors such as the research, development, manufacturing and commercialization capabilities of the licensee and the availability of the associated expertise in the general marketplace. In addition, the Company considers whether the licensee can benefit from a promise for its intended purpose without the receipt of the remaining promise, whether the value of the promise is dependent on the unsatisfied promise, whether there are other vendors that could provide the remaining promise, and whether it is separately identifiable from the remaining promise. For licenses that are combined with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. The measure of progress, and thereby periods over which revenue should be recognized, are subject to estimates by management and may change over the course of the research and development and licensing agreement. Such a change could have a material impact on the amount of revenue the Company records in future periods. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;"&gt;Research, Development and/or Manufacturing Services. &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;The promises under the Company&#x2019;s agreements may include research and development or manufacturing services to be performed by the Company on behalf of the counterparty. If these services are determined to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes the transaction price allocated to these services as revenue over time based on an appropriate measure of progress when the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date.  If these services are determined not to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes the transaction price allocated to the combined performance obligation as the related performance obligations are satisfied. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;"&gt;Customer Options. &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;If an arrangement contains customer options, the Company evaluates whether the options are material rights because they allow the customer to acquire additional goods or services for free or at a discount. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the outset of the arrangement. The Company allocates the transaction price to material rights based on the relative standalone selling price, which is determined based on the identified discount and the probability that the customer will exercise the option. Amounts allocated to a material right are not recognized as revenue until, at the earliest, the option is exercised.  If the options are deemed not to be a material right, they are excluded as performance obligations at the outset of the arrangement. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;"&gt;Milestone Payments. &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;At the inception of each arrangement that includes development milestone payments, the Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt; occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. At the end of each subsequent reporting period, the Company reevaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;"&gt;Royalties. &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;For arrangements that include sales-based royalties which are the result of a customer-vendor relationship and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied or partially satisfied. To date, the Company has not recognized any royalty revenue resulting from any of its licensing arrangements. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;The Company analyzes its collaboration arrangements to assess whether such arrangements involve joint operating activities performed by parties who are both active participants in the activities and are both exposed to significant risks and rewards dependent on the commercial success of such activities. Such arrangements generally are within the scope of ASC 808, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;"&gt;Collaborative Arrangements&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt; (ASC 808). While ASC 808 defines collaborative arrangements and provides guidance on income statement presentation, classification, and disclosures related to such arrangements, it does not address recognition and measurement matters, such as (1)&#160;determining the appropriate unit of accounting or (2) when the recognition criteria are met. Therefore, the accounting for these arrangements is either based on an analogy to other accounting literature or an accounting policy election by the Company. The Company accounts for certain components of the collaboration agreement that are reflective of a vendor-customer relationship (e.g., licensing arrangement) based on an analogy to ASC 606. The Company accounts for other components based on a reasonable, rational and consistently applied accounting policy election.&#160;&#160; Reimbursements from the counter-party that are the result of a collaborative relationship with the counter-party, instead of a customer relationship, such as co-development activities, are recorded as a reduction to research and development expense as the services are performed.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;For a complete discussion of accounting for revenue from collaborative and other agreements, see Note 8, Collaboration and Other Agreements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Research and Development Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;Research and development expenditures are expensed as incurred. Research and development costs primarily consist of employee related expenses, including salaries and benefits, expenses incurred under agreements with contract research organizations, investigative sites and consultants that conduct the Company's clinical trials, the cost of acquiring and manufacturing clinical trial materials and other allocated expenses, license fees for and milestone payments related to in-licensed products and technologies, stock-based compensation expense, and costs associated with non-clinical activities and regulatory approvals.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;Right-to-develop agreements may contain cost-sharing provisions whereby the Company and the collaborator share the cost of research and development activities.&#160; Reimbursement of research and development expenses received in connection with these agreements is recorded as a reduction of such expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Comprehensive Loss&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;Comprehensive loss represents net loss adjusted for the change during the periods attributed to unrealized gains and losses on available-for-sale securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Stock-based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;Stock-based payments are accounted for in accordance with the provisions of ASC 718, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;"&gt;Compensation &#x2013; Stock Compensation&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;. The fair value of stock-based payments is estimated, on the date of grant, using the Black-Scholes model. The resulting fair value is recognized ratably over the requisite service period, which is generally the vesting period of the option.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;For all time-vesting awards granted, expense is amortized using the straight-line attribution method. For awards that contain a performance condition, expense is amortized using the accelerated attribution method. Recognition of stock-based compensation expense is based on the value of the portion of stock-based awards that is ultimately expected to vest during the period.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;The Company utilizes the Black-Scholes model for estimating fair value of its stock options granted. Option valuation models, including the Black-Scholes model, require the input of highly subjective assumptions, and changes in the assumptions used can materially affect the grant-date fair value of an award. These assumptions include the risk-free rate of interest, expected dividend yield, expected volatility and the expected life of the award.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Net Loss Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;Basic loss per common share is determined by dividing loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted loss per share is computed by dividing the loss attributable to common stockholders by the weighted-average number of common share equivalents outstanding for the period. The treasury stock method is used to determine the dilutive effect of the Company's stock option grants.  5,273,964 stock options (common stock equivalents) were excluded from the calculation of diluted net loss per share for the year ended &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;December&#160;31, 2018&#160;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;because their inclusion would have been anti-dilutive.  4,504,642 stock options and 3,838,060 stock options were excluded from the calculation of diluted net loss per share for the years ended December&#160;31, 2017 and 2016, respectively,&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;because their inclusion would have been anti-dilutive.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Recently Adopted Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;In May 2014, the FASB issued ASC 606. The Company adopted ASC 606 on January 1, 2018 using the modified retrospective method for all contracts that were not completed as of January 1, 2018. For contracts that were modified before the effective date, the Company reflected the aggregate effect of all modifications when identifying performance obligations and allocating transaction price in accordance with available practical expedients.  &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;Comparative prior period information continues to be reported under the accounting standards in effect for the period presented. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;As a result of applying the modified retrospective method to adopt the new guidance, the following adjustments were made to accounts on the consolidated balance sheet as of January 1, 2018 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Arial;font-size:10pt;line-height:232%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853801%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:52.465593%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.641288%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532064%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.641288%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.678477%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.641288%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;"&gt;Pre-Adoption&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;"&gt;ASC 606 Adjustment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;"&gt;Post-Adoption&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;"&gt;Deferred revenue, current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;"&gt;Deferred revenue, net of current portion&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;13,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;19,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;"&gt;Accumulated deficit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(312,340)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(6,478)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(318,818)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;The transition adjustment resulted primarily from changes in &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;the pattern of revenue recognition for upfront fees and license grant fees.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;The following table shows the impact of adoption to the consolidated statement of income and balance sheet (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Arial;font-size:10pt;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:42.199706%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.096916%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534214%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:16.942731%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534214%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:19.292217%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;height:13pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Year Ended December 31, 2018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;As Reported&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balances Without Adoption of ASC 606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Effect of Change Higher/(Lower)&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Revenue from collaborative agreements&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;58,644&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;58,104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;540&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net loss&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(171,453)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(171,993)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(540)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Basic and diluted net loss per common share&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(4.19)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(4.20)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:21pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="height:21pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;height:13pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;As of December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;As Reported&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balances Without Adoption of ASC 606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Effect of Change Higher/(Lower)&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Deferred revenue, current&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;21,721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;22,210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(489)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Deferred revenue, net of current portion&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;19,001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accumulated deficit&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(490,271)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(484,332)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(5,939)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Arial;font-size:10pt;line-height:232%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;The following table presents changes in the Company&#x2019;s contract liabilities during the year ended December 31, 2018 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Arial;font-size:10pt;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:41.024963%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.530103%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534214%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:7.397944%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534214%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.572687%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534214%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.271659%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance at Beginning of Period&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Additions&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Deductions&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance at End of Period&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160; Deferred revenue (current and non-current)&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;27,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;22,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(9,588)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;40,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Arial;font-size:10pt;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;During the year ended December 31, 2018, the Company recognized $9.6 million in revenue as a result of changes in the contract liability balance.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;In May 2017, the FASB issued ASU 2017-09, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;"&gt;Compensation &#x2013; Stock Compensation (Topic 718): Scope Modification Accounting&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;. The new standard is intended to reduce the diversity in practice and cost and complexity when applying the guidance in Topic 718 to a change to the terms or conditions of a share-based payment award. The new standard was effective beginning January 1, 2018. The adoption of this standard did not have a material impact on the Company&#x2019;s financial position or results of operations upon adoption. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;On December 22, 2017, the Tax Cuts and Jobs Act of 2017 (the Tax Act) was signed into law making significant changes to the Internal Revenue Code, which included how the U.S. imposes income tax on multinational corporations.  Key changes in the Tax Act which are relevant to the Company, and generally effective January 1, 2018, include a flat corporate income tax rate of 21% to replace the marginal rates that range from 15% to 35% and the elimination of the corporate alternative minimum tax.  The Tax Act also imposes limits on executive compensations and interest expense deductions, while permitting the immediate expensing for the cost of new investments in certain property acquired after September 27, 2017.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;On December 22, 2017, the SEC issued Staff Accounting Bulletin No. 118 (SAB 118) to address the application of U.S. GAAP in situations when a registrant does not have the necessary information available, prepared, or analyzed (including computations) in reasonable detail to complete the accounting for certain income tax effects of the Tax Act.  SAB 118 allowed registrants to include a provisional amount to account for the implications of the Tax Act where a reasonable estimate can be made and required the completion of the accounting no later than one year from the date of the enactment of the Tax Act, or December 22, 2018. The Company has recognized the provisional tax impacts related to the re-measurement of its U.S. deferred tax assets and liabilities to 21% in 2017 and included these amounts in its consolidated financial statements for the year ended December 31, 2017.  This change in value of these deferred tax assets and liabilities was offset by a corresponding change in valuation allowance, thus no tax expense or benefit was recorded. The Company completed its evaluation of the effects of the Tax Act during the fourth quarter of 2018, and the provisional amounts the Company accounted for in its December 31, 2017 provision were finalized with no adjustments.  &#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Recently Issued Accounting Standards &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;"&gt;In February 2016, the FASB issued ASU No. 2016-02, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:115%;"&gt;Leases&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;"&gt; (ASU 2016-02) that provides principles for the recognition, measurement, presentation and disclosure of leases for both lessees and lessors.  ASU 2016-02 requires a lessee to recognize assets and liabilities on the balance sheet for operating leases and changes many key definitions, including the definition of a lease. ASU 2016-02 includes a short-term lease exception for leases with an original term of 12 months or less, in which a lessee can make an accounting policy election not to recognize lease assets and lease liabilities. Lessees will continue to differentiate between finance leases (previously referred to as capital leases) and operating leases, using classification criteria that are substantially similar to the previous guidance. Originally, entities were required to adopt ASU 2016-02 using a modified retrospective transition approach for all leases existing at, or entered into after, the date of initial application. However, in July 2018, the FASB issued ASU 2018-11, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:115%;"&gt;Leases (Topic 842): Targeted Improvements,&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;"&gt; which now allows entities the option of recognizing the cumulative effect of applying the new standard as an adjustment to the opening balance of retained earnings in the year of adoption while continuing to present all prior periods under previous lease accounting guidance. In July 2018, the FASB also issued ASU 2018-10, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:115%;"&gt;Codification Improvements to Topic 842, Leases, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;"&gt;which clarifies how to apply certain aspects of ASU 2016-02. ASU 2016-02, ASU 2018-10 and ASU 2018-11 (now commonly referred to as ASC Topic 842 (ASC 842)) is effective for the Company&#x2019;s fiscal year beginning January 1, 2019. Although early adoption is permitted, the Company has not elected to do so. The Company plans to elect the transition option provided under ASU 2018-11, which will not require adjustments to comparative periods nor require modified disclosures in those comparative periods. Upon adoption, the Company expects to elect the transition package of practical expedients permitted within the new standard, which among other things, allows the carryforward of the historical lease classification.  &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:115%;"&gt;Based on its current lease portfolio, the Company estimates that the adoption ASC 842 will result in approximately $16.0 million of right of use assets and $28.0 million of lease liabilities being reflected on its consolidated balance sheet at the date of adoption. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;"&gt;In November 2018, the FASB issued ASU 2018-18, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:115%;"&gt;Collaborative Arrangements (Topic 808)&#x2014;Clarifying the interaction between Topic 808 and Topic 606&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;"&gt; (ASU 2018-18). The amendments provide guidance on whether certain&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;"&gt; transactions between collaborative arrangement participants should be accounted for as revenue under ASC 606. It also specifically (i) addresses when the participant should be considered a customer in the context of a unit of account, (ii) adds unit-of-account guidance in ASC 808 to align with guidance in ASC 606, and (iii) precludes presenting revenue from a collaborative arrangement together with revenue recognized under ASC 606 if the collaborative arrangement participant is not a customer. The guidance will be effective for fiscal years beginning after December 15, 2019. Early adoption is permitted and should be applied retrospectively. The Company does not anticipate the adoption of this standard will have a material impact on its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:5pt;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;The Company has evaluated all other ASUs issued through the date the consolidated financials were issued and believes that the adoption of these will not have a material impact on the Company's consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90ZXh0cmVnaW9uOjIxM2RlYmY3Njg3MzQ3NmE5YTk0YzgyMTZiN2I4YTlmXzQxNDQy_85324903-a6c2-4a88-9ce1-77b4d2bb8b29">&lt;div style="margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Basis of Presentation and Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;The consolidated financial statements include the accounts of MacroGenics, Inc. and its wholly owned subsidiary, MacroGenics UK Limited.&#160; All intercompany accounts and transactions have been eliminated in consolidation. The Company currently operates in one operating segment. Operating segments are defined as components of an enterprise about which separate discrete information is available for the chief operating decision maker, or decision making group, in deciding how to allocate resources and assessing performance. The Company views its operations and manages its business in one segment, which is developing monoclonal antibody-based therapeutics for cancer, autoimmune and infectious diseases.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90ZXh0cmVnaW9uOjIxM2RlYmY3Njg3MzQ3NmE5YTk0YzgyMTZiN2I4YTlmXzM2MA_d84fe185-6040-466c-8995-d54e7d4110ba"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NumberOfOperatingSegments
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90ZXh0cmVnaW9uOjIxM2RlYmY3Njg3MzQ3NmE5YTk0YzgyMTZiN2I4YTlmXzY5MQ_d84fe185-6040-466c-8995-d54e7d4110ba"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:UseOfEstimates
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90ZXh0cmVnaW9uOjIxM2RlYmY3Njg3MzQ3NmE5YTk0YzgyMTZiN2I4YTlmXzQxNDQz_be9910b9-ffc0-4d2a-b305-5a38ca6692af">&lt;div style="margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;The preparation of the financial statements in accordance with generally accepted accounting principles (GAAP) requires the Company to make estimates and judgments in certain circumstances that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. In preparing these consolidated financial statements, management has made its best estimates and judgments of certain amounts included in the financial statements, giving due consideration to materiality. On an ongoing basis, the Company evaluates its estimates, including those related to revenue recognition, fair values of assets, stock-based compensation, income taxes, preclinical study and clinical trial accruals and other contingencies. Management bases its estimates on historical experience or on various other assumptions that it believes to be reasonable under the circumstances. Actual results could differ from these estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90ZXh0cmVnaW9uOjIxM2RlYmY3Njg3MzQ3NmE5YTk0YzgyMTZiN2I4YTlmXzQxNDQ0_65d15092-5b21-4fbe-a7d6-cece6e460207">&lt;div style="margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Cash, Cash Equivalents and Marketable Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;The Company considers all investments in highly liquid financial instruments with a maturity of 90 days or less at the date of purchase to be cash equivalents. Cash and cash equivalents includes investments in money market funds with commercial banks and financial institutions, securities issued by the U.S. government and its agencies, Government Sponsored Enterprise agency debt obligations and corporate debt obligations. Cash equivalents are stated at amortized cost, plus accrued interest, which approximates fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:25pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;The Company carries marketable securities classified as available-for-sale at fair value as determined by prices for identical or similar securities at the balance sheet date. Marketable securities consist of Level 2 financial instruments in the fair-value hierarchy. The Company records unrealized gains and losses as a component of other comprehensive loss within the statements of operations and comprehensive loss and as a separate component of stockholders' equity. Realized gains or losses on available-for-sale securities are determined using the specific identification method and the Company includes net realized gains and losses in other income (expense).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;At each balance sheet date, the Company assesses available-for-sale securities in an unrealized loss position to determine whether the unrealized loss is other-than-temporary. The Company considers factors including: the significance of the decline in value compared to the cost basis, underlying factors contributing to a decline in the prices of securities in a single asset class, the length of time the market value of the security has been less than its cost basis, the security's relative performance versus its peers, sector or asset class, expected market volatility and the market and economy in general. The Company also evaluates whether it is more likely than not that it will be required to sell a security prior to recovery of its fair value.&#160; An impairment loss is recognized at the time the Company determines that a decline in the fair value below its cost basis is other-than-temporary. There were no unrealized losses at December&#160;31, 2018 or &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;2017&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt; that the Company determined to be other-than-temporary.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90ZXh0cmVnaW9uOjIxM2RlYmY3Njg3MzQ3NmE5YTk0YzgyMTZiN2I4YTlmXzM5NjQ_d100fc20-02d7-4c70-b97c-c180f4c03a73"
      unitRef="usd">0</us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90ZXh0cmVnaW9uOjIxM2RlYmY3Njg3MzQ3NmE5YTk0YzgyMTZiN2I4YTlmXzQxNDQ1_0922a557-2555-453b-ab33-ac160d2f0aea">&lt;div style="margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Accounts Receivable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;Accounts receivable that management has the intent and ability to collect are reported in the consolidated balance sheets at outstanding amounts, less an allowance for doubtful accounts. The Company writes off uncollectible receivables when the likelihood of collection is remote.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;The Company evaluates the collectability of accounts receivable on a regular basis. The allowance, if any, is based upon various factors including the financial condition and payment history of customers, an overall review of collections experience on other accounts and economic factors or events expected to affect future collections experience. No allowance was recorded as of December&#160;31, 2018 or 2017, as the Company has a history of collecting on all outstanding accounts.&lt;/span&gt;&lt;/div&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90ZXh0cmVnaW9uOjIxM2RlYmY3Njg3MzQ3NmE5YTk0YzgyMTZiN2I4YTlmXzQ3MDU_b6e7930b-6468-4289-807b-cc0151b08d59"
      unitRef="usd">0</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90ZXh0cmVnaW9uOjIxM2RlYmY3Njg3MzQ3NmE5YTk0YzgyMTZiN2I4YTlmXzQxNDQ2_7a3125d0-f0fb-4ece-a137-24991a170345">&lt;div style="margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;The Company's financial instruments consist of cash and cash equivalents, marketable securities, accounts receivable, accounts payable and accrued expenses.&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;The carrying amount of accounts receivable, accounts payable and accrued expenses are generally considered to be representative of their respective fair values because of their short-term nature.&#160;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt; The Company accounts for recurring and non-recurring fair value measurements in accordance with the Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 820, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;"&gt;Fair Value Measurements and Disclosures&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt; (ASC 820). ASC 820 defines fair value, establishes a fair value hierarchy for assets and liabilities measured at fair value, and requires expanded disclosures about fair value measurements. The ASC 820 hierarchy ranks the quality of reliability of inputs, or assumptions, used in the determination of fair value and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following three categories:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:54pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;"&gt;Level 1 &#x2013; Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:54pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;"&gt;Level 2 &#x2013; Fair value is determined by using inputs other than Level 1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models, such as interest rates and yield curves that can be corroborated by observable market data.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:54pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;"&gt;Level 3 &#x2013; Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgments to be made by a reporting entity &#x2013; e.g., determining an appropriate adjustment to a discount factor for illiquidity associated with a given security.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;The Company evaluates financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them each reporting period. This determination requires the Company to make subjective judgments as to the significance of inputs used in determining fair value and where such inputs lie within the ASC 820 hierarchy.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90ZXh0cmVnaW9uOjIxM2RlYmY3Njg3MzQ3NmE5YTk0YzgyMTZiN2I4YTlmXzE1MzkzMTYyOTQxNzMy_6858f260-287b-41bf-9461-2c0b58755337">&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;Financial assets measured at fair value on a recurring basis were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:36.325991%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.747430%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.121586%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.565345%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.268429%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.271659%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.121586%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.977974%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair Value Measurement at December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;"&gt;Quoted Prices in&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;"&gt;Active Markets for&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;"&gt;Identical Assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;"&gt;Significant Other&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;"&gt;Observable Inputs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;"&gt;Significant&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;"&gt;Unobservable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;"&gt;Inputs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;46,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;46,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;100,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;100,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Common stock warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;"&gt;Total assets measured at fair value &lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;"&gt;(a)&lt;/sup&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;160,849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;46,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;112,702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:36.325991%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.747430%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.121586%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.565345%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.268429%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.271659%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.121586%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.977974%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair Value Measurement at December 31, 2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;"&gt;Quoted Prices in&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;"&gt;Active Markets for&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;"&gt;Identical Assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;"&gt;Significant Other&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;"&gt;Observable Inputs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;"&gt;Significant&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;"&gt;Unobservable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;"&gt;Inputs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;61,512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;61,512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;78,418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;78,418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;"&gt;Total assets measured at fair value &lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;"&gt;(&lt;/sup&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;"&gt;b)&lt;/sup&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;155,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;61,512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;94,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;(a) Total assets measured at fair value at December&#160;31, 2018 includes approximately $146.2 million reported in cash and cash equivalents on the balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;(b) Total assets measured at fair value at December&#160;31, 2017 includes approximately $62.5 million reported in cash and cash equivalents on the balance sheet.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i48784f16cceb4a92949dfc57c3d660b6_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTo1YTIyZWFmOWY2Mzg0YjQxOTc2ODIyYzcxOTMxNzk3My90YWJsZXJhbmdlOjVhMjJlYWY5ZjYzODRiNDE5NzY4MjJjNzE5MzE3OTczXzQtMS0xLTEtMA_3d3ee037-b05a-470c-b222-cdeb66738e02"
      unitRef="usd">46257000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i4a8fd95d96b9467b946bd865997ab910_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTo1YTIyZWFmOWY2Mzg0YjQxOTc2ODIyYzcxOTMxNzk3My90YWJsZXJhbmdlOjVhMjJlYWY5ZjYzODRiNDE5NzY4MjJjNzE5MzE3OTczXzQtMy0xLTEtMA_143cda57-b2cb-405d-80af-b689e6a2cc54"
      unitRef="usd">46257000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i0e1afaa0aa004fcc98602893dc6bf0af_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTo1YTIyZWFmOWY2Mzg0YjQxOTc2ODIyYzcxOTMxNzk3My90YWJsZXJhbmdlOjVhMjJlYWY5ZjYzODRiNDE5NzY4MjJjNzE5MzE3OTczXzQtNS0xLTEtMA_3ab66356-d9fb-47cc-b7bf-069a3bead6af"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i5c80cf2c50cc438b8e0cd14b52a82cf0_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTo1YTIyZWFmOWY2Mzg0YjQxOTc2ODIyYzcxOTMxNzk3My90YWJsZXJhbmdlOjVhMjJlYWY5ZjYzODRiNDE5NzY4MjJjNzE5MzE3OTczXzQtNy0xLTEtMA_328b9426-0a4e-4497-b471-bdc0eacb7353"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8b30daf53dd540e8972913308cc2a710_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTo1YTIyZWFmOWY2Mzg0YjQxOTc2ODIyYzcxOTMxNzk3My90YWJsZXJhbmdlOjVhMjJlYWY5ZjYzODRiNDE5NzY4MjJjNzE5MzE3OTczXzUtMS0xLTEtMA_2f72228c-8762-43d1-9616-d794cb4841ef"
      unitRef="usd">12488000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9885584d437f4fdbb9821f6883801e5e_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTo1YTIyZWFmOWY2Mzg0YjQxOTc2ODIyYzcxOTMxNzk3My90YWJsZXJhbmdlOjVhMjJlYWY5ZjYzODRiNDE5NzY4MjJjNzE5MzE3OTczXzUtMy0xLTEtMA_7e0da6d5-62ba-47a4-8107-00aa381af620"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id8224ea921344b21b249696a5b1fee59_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTo1YTIyZWFmOWY2Mzg0YjQxOTc2ODIyYzcxOTMxNzk3My90YWJsZXJhbmdlOjVhMjJlYWY5ZjYzODRiNDE5NzY4MjJjNzE5MzE3OTczXzUtNS0xLTEtMA_d7c798eb-c1f9-413d-812c-1e38732a3718"
      unitRef="usd">12488000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i19bf1b5616d54d289ec50510e079bd27_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTo1YTIyZWFmOWY2Mzg0YjQxOTc2ODIyYzcxOTMxNzk3My90YWJsZXJhbmdlOjVhMjJlYWY5ZjYzODRiNDE5NzY4MjJjNzE5MzE3OTczXzUtNy0xLTEtMA_f1813106-4952-41eb-96b1-daf0065f76b2"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6e342386069b4859b038021f1292bc8e_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTo1YTIyZWFmOWY2Mzg0YjQxOTc2ODIyYzcxOTMxNzk3My90YWJsZXJhbmdlOjVhMjJlYWY5ZjYzODRiNDE5NzY4MjJjNzE5MzE3OTczXzctMS0xLTEtMA_7496d69f-0761-413d-82b8-636507fe87e3"
      unitRef="usd">100214000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i836203a185014b4a9e662c9f5457029d_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTo1YTIyZWFmOWY2Mzg0YjQxOTc2ODIyYzcxOTMxNzk3My90YWJsZXJhbmdlOjVhMjJlYWY5ZjYzODRiNDE5NzY4MjJjNzE5MzE3OTczXzctMy0xLTEtMA_cbdacaa1-807d-4fb8-97c2-b18bb8c58043"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i15cd0dab53764d82a187cc3da46a3761_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTo1YTIyZWFmOWY2Mzg0YjQxOTc2ODIyYzcxOTMxNzk3My90YWJsZXJhbmdlOjVhMjJlYWY5ZjYzODRiNDE5NzY4MjJjNzE5MzE3OTczXzctNS0xLTEtMA_0756aca8-7106-42f4-83a7-f00d0ad161f3"
      unitRef="usd">100214000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i69e6f22f5f224360a82e4379d7fff4b7_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTo1YTIyZWFmOWY2Mzg0YjQxOTc2ODIyYzcxOTMxNzk3My90YWJsZXJhbmdlOjVhMjJlYWY5ZjYzODRiNDE5NzY4MjJjNzE5MzE3OTczXzctNy0xLTEtMA_41525fc4-fa99-40d4-b002-b57de7df16c1"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <mgnx:WarrantsFairValueDisclosure
      contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTo1YTIyZWFmOWY2Mzg0YjQxOTc2ODIyYzcxOTMxNzk3My90YWJsZXJhbmdlOjVhMjJlYWY5ZjYzODRiNDE5NzY4MjJjNzE5MzE3OTczXzgtMS0xLTEtMjI1NA_358c341d-faf0-4e41-b44f-c339c7fe1484"
      unitRef="usd">1890000</mgnx:WarrantsFairValueDisclosure>
    <mgnx:WarrantsFairValueDisclosure
      contextRef="i12ae7112f1294c1ba9b38f26417d21a2_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTo1YTIyZWFmOWY2Mzg0YjQxOTc2ODIyYzcxOTMxNzk3My90YWJsZXJhbmdlOjVhMjJlYWY5ZjYzODRiNDE5NzY4MjJjNzE5MzE3OTczXzgtMy0xLTEtNjA3Ng_03f60169-c831-4631-b076-96fefe5b8a18"
      unitRef="usd">0</mgnx:WarrantsFairValueDisclosure>
    <mgnx:WarrantsFairValueDisclosure
      contextRef="ica70e0e9496b4c8ab1c2aeea43e1c55e_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTo1YTIyZWFmOWY2Mzg0YjQxOTc2ODIyYzcxOTMxNzk3My90YWJsZXJhbmdlOjVhMjJlYWY5ZjYzODRiNDE5NzY4MjJjNzE5MzE3OTczXzgtNS0xLTEtNjExMw_69f748c1-8f5f-425b-b9c6-6a511f7d3ee4"
      unitRef="usd">0</mgnx:WarrantsFairValueDisclosure>
    <mgnx:WarrantsFairValueDisclosure
      contextRef="id2873baa5a4b4d10bf1a5d20be263861_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTo1YTIyZWFmOWY2Mzg0YjQxOTc2ODIyYzcxOTMxNzk3My90YWJsZXJhbmdlOjVhMjJlYWY5ZjYzODRiNDE5NzY4MjJjNzE5MzE3OTczXzgtNy0xLTEtMjI1NA_b2e95cd4-0070-4e70-8639-27c5e066a6f9"
      unitRef="usd">1890000</mgnx:WarrantsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTo1YTIyZWFmOWY2Mzg0YjQxOTc2ODIyYzcxOTMxNzk3My90YWJsZXJhbmdlOjVhMjJlYWY5ZjYzODRiNDE5NzY4MjJjNzE5MzE3OTczXzgtMS0xLTEtMA_e7d186f8-c3bc-4adf-b127-76fe288e363d"
      unitRef="usd">160849000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i12ae7112f1294c1ba9b38f26417d21a2_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTo1YTIyZWFmOWY2Mzg0YjQxOTc2ODIyYzcxOTMxNzk3My90YWJsZXJhbmdlOjVhMjJlYWY5ZjYzODRiNDE5NzY4MjJjNzE5MzE3OTczXzgtMy0xLTEtMA_aa0feb97-e988-49d5-a263-4b11b8a260e3"
      unitRef="usd">46257000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ica70e0e9496b4c8ab1c2aeea43e1c55e_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTo1YTIyZWFmOWY2Mzg0YjQxOTc2ODIyYzcxOTMxNzk3My90YWJsZXJhbmdlOjVhMjJlYWY5ZjYzODRiNDE5NzY4MjJjNzE5MzE3OTczXzgtNS0xLTEtMA_3924f900-4dac-42a2-9f46-b318541b52e7"
      unitRef="usd">112702000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="id2873baa5a4b4d10bf1a5d20be263861_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTo1YTIyZWFmOWY2Mzg0YjQxOTc2ODIyYzcxOTMxNzk3My90YWJsZXJhbmdlOjVhMjJlYWY5ZjYzODRiNDE5NzY4MjJjNzE5MzE3OTczXzgtNy0xLTEtMA_04bef749-4a11-461d-8822-10c0b3610a81"
      unitRef="usd">1890000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i3aaec4d2a9ba4186b6b54303daa9284f_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTo2MTNkYjQ4N2U5MjY0YjFlOTQ5MjQ4MWU3NGY0MTQxOS90YWJsZXJhbmdlOjYxM2RiNDg3ZTkyNjRiMWU5NDkyNDgxZTc0ZjQxNDE5XzQtMS0xLTEtMA_bd36cbc1-061f-4cba-85f3-c571623fbe4b"
      unitRef="usd">61512000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i567c39ea2c894aa18c58e1478aeb50bb_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTo2MTNkYjQ4N2U5MjY0YjFlOTQ5MjQ4MWU3NGY0MTQxOS90YWJsZXJhbmdlOjYxM2RiNDg3ZTkyNjRiMWU5NDkyNDgxZTc0ZjQxNDE5XzQtMy0xLTEtMA_a85eabd3-3833-455e-a3dd-236336d08013"
      unitRef="usd">61512000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i052ba9dcbb294d688f1b07ef8ae85f64_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTo2MTNkYjQ4N2U5MjY0YjFlOTQ5MjQ4MWU3NGY0MTQxOS90YWJsZXJhbmdlOjYxM2RiNDg3ZTkyNjRiMWU5NDkyNDgxZTc0ZjQxNDE5XzQtNS0xLTEtMA_c17521fa-e4f6-48d9-b245-b11d965286b7"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i39e9aef5cb214c03982914e5c0e5ef26_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTo2MTNkYjQ4N2U5MjY0YjFlOTQ5MjQ4MWU3NGY0MTQxOS90YWJsZXJhbmdlOjYxM2RiNDg3ZTkyNjRiMWU5NDkyNDgxZTc0ZjQxNDE5XzQtNy0xLTEtMA_35921836-abf1-47e5-8b9a-4f8b4ec335c1"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecurities
      contextRef="idddbaa15d66240498398d35f3a8f6a97_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTo2MTNkYjQ4N2U5MjY0YjFlOTQ5MjQ4MWU3NGY0MTQxOS90YWJsZXJhbmdlOjYxM2RiNDg3ZTkyNjRiMWU5NDkyNDgxZTc0ZjQxNDE5XzUtMS0xLTEtMA_a210a379-cc1b-40d9-9e7f-f7a6533ef0ca"
      unitRef="usd">3989000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="id6c7535f08114b6b99ac9c52d559c896_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTo2MTNkYjQ4N2U5MjY0YjFlOTQ5MjQ4MWU3NGY0MTQxOS90YWJsZXJhbmdlOjYxM2RiNDg3ZTkyNjRiMWU5NDkyNDgxZTc0ZjQxNDE5XzUtMy0xLTEtMA_8799a290-2c2d-4b80-9589-33ddb6e6c5b0"
      unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="i4b9777bbf6064d76be88747d34359989_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTo2MTNkYjQ4N2U5MjY0YjFlOTQ5MjQ4MWU3NGY0MTQxOS90YWJsZXJhbmdlOjYxM2RiNDg3ZTkyNjRiMWU5NDkyNDgxZTc0ZjQxNDE5XzUtNS0xLTEtMA_4fe24f7b-fc80-4034-8793-8f84a1aeee7f"
      unitRef="usd">3989000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="ic0acfc838ca543a182c2f9a125366f7f_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTo2MTNkYjQ4N2U5MjY0YjFlOTQ5MjQ4MWU3NGY0MTQxOS90YWJsZXJhbmdlOjYxM2RiNDg3ZTkyNjRiMWU5NDkyNDgxZTc0ZjQxNDE5XzUtNy0xLTEtMA_8c6ecb92-fba6-41f4-b7ef-854afb1002fa"
      unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="i2f7cc4428c0c44c98d1a04ac21c0f886_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTo2MTNkYjQ4N2U5MjY0YjFlOTQ5MjQ4MWU3NGY0MTQxOS90YWJsZXJhbmdlOjYxM2RiNDg3ZTkyNjRiMWU5NDkyNDgxZTc0ZjQxNDE5XzYtMS0xLTEtMA_c5bcf043-9114-43ad-9b1a-ef0220ed1a25"
      unitRef="usd">11991000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="i813c2a024ec84a0dab992916df676184_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTo2MTNkYjQ4N2U5MjY0YjFlOTQ5MjQ4MWU3NGY0MTQxOS90YWJsZXJhbmdlOjYxM2RiNDg3ZTkyNjRiMWU5NDkyNDgxZTc0ZjQxNDE5XzYtMy0xLTEtMA_f98f9853-275b-4c14-9f9e-dc8d34135672"
      unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="i86696714ee304524b3bf18cd3b8cebf9_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTo2MTNkYjQ4N2U5MjY0YjFlOTQ5MjQ4MWU3NGY0MTQxOS90YWJsZXJhbmdlOjYxM2RiNDg3ZTkyNjRiMWU5NDkyNDgxZTc0ZjQxNDE5XzYtNS0xLTEtMA_47e15791-454c-4ef3-8a07-0ae95a84deb0"
      unitRef="usd">11991000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="i32a16b54a03b4f8dabcc3d55d161cd66_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTo2MTNkYjQ4N2U5MjY0YjFlOTQ5MjQ4MWU3NGY0MTQxOS90YWJsZXJhbmdlOjYxM2RiNDg3ZTkyNjRiMWU5NDkyNDgxZTc0ZjQxNDE5XzYtNy0xLTEtMA_7be78a52-5613-4598-95cb-79f431564129"
      unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="i4c57ebf1216b40e69585d4723b4b1234_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTo2MTNkYjQ4N2U5MjY0YjFlOTQ5MjQ4MWU3NGY0MTQxOS90YWJsZXJhbmdlOjYxM2RiNDg3ZTkyNjRiMWU5NDkyNDgxZTc0ZjQxNDE5XzctMS0xLTEtMA_799c6cfd-38a6-46e1-913a-73cd11e5ecf7"
      unitRef="usd">78418000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="ifb6cc9cda6124764a79895164b99ed24_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTo2MTNkYjQ4N2U5MjY0YjFlOTQ5MjQ4MWU3NGY0MTQxOS90YWJsZXJhbmdlOjYxM2RiNDg3ZTkyNjRiMWU5NDkyNDgxZTc0ZjQxNDE5XzctMy0xLTEtMA_bfa11ac1-f639-48f2-a74c-9449a047fc0e"
      unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="ife3b143f5c324bffabb232b405ceac51_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTo2MTNkYjQ4N2U5MjY0YjFlOTQ5MjQ4MWU3NGY0MTQxOS90YWJsZXJhbmdlOjYxM2RiNDg3ZTkyNjRiMWU5NDkyNDgxZTc0ZjQxNDE5XzctNS0xLTEtMA_dcfed84c-e29e-471f-bffa-2476f5413c7e"
      unitRef="usd">78418000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="i637fb60ec9d345b0aac156800fca7529_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTo2MTNkYjQ4N2U5MjY0YjFlOTQ5MjQ4MWU3NGY0MTQxOS90YWJsZXJhbmdlOjYxM2RiNDg3ZTkyNjRiMWU5NDkyNDgxZTc0ZjQxNDE5XzctNy0xLTEtMA_94ee0858-6471-4e1d-b51f-96e803c7222e"
      unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i7057397719af459ca7328a1c440a0efa_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTo2MTNkYjQ4N2U5MjY0YjFlOTQ5MjQ4MWU3NGY0MTQxOS90YWJsZXJhbmdlOjYxM2RiNDg3ZTkyNjRiMWU5NDkyNDgxZTc0ZjQxNDE5XzgtMS0xLTEtMA_1205d312-dd98-469c-b1ff-0109375dfcdd"
      unitRef="usd">155910000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i997657dcf4ae43db9ded89ab3af4df74_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTo2MTNkYjQ4N2U5MjY0YjFlOTQ5MjQ4MWU3NGY0MTQxOS90YWJsZXJhbmdlOjYxM2RiNDg3ZTkyNjRiMWU5NDkyNDgxZTc0ZjQxNDE5XzgtMy0xLTEtMA_994df209-05a7-4827-a858-155879f4ca79"
      unitRef="usd">61512000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i024ac39056e24d43aed54ab33d2c004e_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTo2MTNkYjQ4N2U5MjY0YjFlOTQ5MjQ4MWU3NGY0MTQxOS90YWJsZXJhbmdlOjYxM2RiNDg3ZTkyNjRiMWU5NDkyNDgxZTc0ZjQxNDE5XzgtNS0xLTEtMA_fb66856a-a61c-48a2-b61b-ab5e97b2a131"
      unitRef="usd">94398000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i606378e8044a40e5ad3ac2c0df524b2b_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTo2MTNkYjQ4N2U5MjY0YjFlOTQ5MjQ4MWU3NGY0MTQxOS90YWJsZXJhbmdlOjYxM2RiNDg3ZTkyNjRiMWU5NDkyNDgxZTc0ZjQxNDE5XzgtNy0xLTEtMA_96da9e00-0555-4e96-8f86-83c8b869b44d"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90ZXh0cmVnaW9uOjIxM2RlYmY3Njg3MzQ3NmE5YTk0YzgyMTZiN2I4YTlmXzI3NDg3NzkxMTEyOTY_b8de7f41-766d-445d-904f-47c457f3caaa"
      unitRef="usd">146200000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i7057397719af459ca7328a1c440a0efa_I20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90ZXh0cmVnaW9uOjIxM2RlYmY3Njg3MzQ3NmE5YTk0YzgyMTZiN2I4YTlmXzc1MDM_d2671c73-e4fe-40b9-adda-8a86dc69c620"
      unitRef="usd">62500000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90ZXh0cmVnaW9uOjIxM2RlYmY3Njg3MzQ3NmE5YTk0YzgyMTZiN2I4YTlmXzQxNDQ5_4c6ebf2a-14e7-4cf7-97a7-add8539b3d4a">&lt;div style="margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents, marketable securities and accounts receivable. &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;The Company maintains&#160;its cash and money market funds with financial institutions that are federally insured. While balances deposited in these institutions often exceed Federal Deposit Insurance Corporation limits, the Company has not experienced any losses on related accounts to date.&#160;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;The Company's investment policy limits investments to certain types of debt securities issued by the U.S. government, its agencies and institutions with investment-grade credit ratings and places restrictions on maturities and concentration by type and issuer.&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt; The counterparties are various corporations, financial institutions and government agencies of high credit standing.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90ZXh0cmVnaW9uOjIxM2RlYmY3Njg3MzQ3NmE5YTk0YzgyMTZiN2I4YTlmXzQxNDUw_6e075025-90d9-4d56-8ac3-c66a2894e548">The following table includes those collaborators that represent more than 10% of total revenue earned in the periods indicated:&lt;div style="margin-bottom:9pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.269006%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:67.219440%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:7.720177%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.536377%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:7.720177%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.683652%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:7.720177%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;height:13pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2016&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Incyte Corporation (Incyte)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;68%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Janssen Biotech, Inc. (Janssen)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;*&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;*&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;85%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Provention Bio, Inc. (Provention)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;The following table includes those counterparties that represent more than 10% of accounts receivable at the date indicated:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:73.806452%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.730205%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533138%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.730205%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2017&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Zai Lab Limited (Zai Lab)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;76%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Incyte&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;16%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (Roche)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;73%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Les Laboratoires Servier and Institut de Recherches Servier (Servier)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;*&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;* Balance is less than 10%</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i03cbd7f054ef4c669ff9c36ff8cd01c0_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTo4NzcwMmFhNTI5ZDQ0Njg1ODc1MDBkMjRiNWE3Mjc2Yy90YWJsZXJhbmdlOjg3NzAyYWE1MjlkNDQ2ODU4NzUwMGQyNGI1YTcyNzZjXzItMS0xLTEtMA_64dbce1f-5f1b-4565-b885-bf4c1bc01d72"
      unitRef="number">0.68</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ie58f40d5d6224b7abe4022753c84d444_D20170101-20171231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTo4NzcwMmFhNTI5ZDQ0Njg1ODc1MDBkMjRiNWE3Mjc2Yy90YWJsZXJhbmdlOjg3NzAyYWE1MjlkNDQ2ODU4NzUwMGQyNGI1YTcyNzZjXzItMy0xLTEtNTYz_a7796733-4b2b-4b32-bffa-092c358a086b"
      unitRef="number">0.96</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i43068aee063d4a2d8d23dac8a2f9b677_D20160101-20161231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTo4NzcwMmFhNTI5ZDQ0Njg1ODc1MDBkMjRiNWE3Mjc2Yy90YWJsZXJhbmdlOjg3NzAyYWE1MjlkNDQ2ODU4NzUwMGQyNGI1YTcyNzZjXzItNS0xLTEtNjExNg_4b84994b-b118-49e3-a973-3309908201da"
      unitRef="number">0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="iaa0ada014a394dada260f448e299bd8c_D20160101-20161231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTo4NzcwMmFhNTI5ZDQ0Njg1ODc1MDBkMjRiNWE3Mjc2Yy90YWJsZXJhbmdlOjg3NzAyYWE1MjlkNDQ2ODU4NzUwMGQyNGI1YTcyNzZjXzMtNS0xLTEtMA_65f88054-5af1-4c7c-88d6-1690831e4452"
      unitRef="number">0.85</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i2e50d0e2361047e2a2d2ee358cd59223_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTo4NzcwMmFhNTI5ZDQ0Njg1ODc1MDBkMjRiNWE3Mjc2Yy90YWJsZXJhbmdlOjg3NzAyYWE1MjlkNDQ2ODU4NzUwMGQyNGI1YTcyNzZjXzUtMS0xLTEtMA_8d3cc3db-f9e0-4a65-8707-98b1179f4305"
      unitRef="number">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i7736e7c7780143f290e418da33ef66f3_D20170101-20171231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTo4NzcwMmFhNTI5ZDQ0Njg1ODc1MDBkMjRiNWE3Mjc2Yy90YWJsZXJhbmdlOjg3NzAyYWE1MjlkNDQ2ODU4NzUwMGQyNGI1YTcyNzZjXzUtMy0xLTEtMA_5fd81e92-6361-4d56-a760-9df766562255"
      unitRef="number">0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i84d9b24bd0d14ea7ae88c496301087d9_D20160101-20161231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTo4NzcwMmFhNTI5ZDQ0Njg1ODc1MDBkMjRiNWE3Mjc2Yy90YWJsZXJhbmdlOjg3NzAyYWE1MjlkNDQ2ODU4NzUwMGQyNGI1YTcyNzZjXzUtNS0xLTEtMA_5b4b6b87-6521-4f0d-ad2a-72394c1d32fc"
      unitRef="number">0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ief319720f28440d5a5dd754bc9ebb8b9_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTo1NTdhMzAyNDJlNWE0MjQ4ODc0OTc2NmNkYWM3NzY5YS90YWJsZXJhbmdlOjU1N2EzMDI0MmU1YTQyNDg4NzQ5NzY2Y2RhYzc3NjlhXzItMS0xLTEtMA_b38cb87d-ca75-4580-81aa-a5c08723a99f"
      unitRef="number">0.76</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ia281f1996f934569aa16a3fd2044a2b2_D20170101-20171231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTo1NTdhMzAyNDJlNWE0MjQ4ODc0OTc2NmNkYWM3NzY5YS90YWJsZXJhbmdlOjU1N2EzMDI0MmU1YTQyNDg4NzQ5NzY2Y2RhYzc3NjlhXzItMy0xLTEtMA_cef80289-1516-4a86-bfbe-9cb49ede7b6d"
      unitRef="number">0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i14ad06e9a84b4f2b9de71683c59af5f7_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTo1NTdhMzAyNDJlNWE0MjQ4ODc0OTc2NmNkYWM3NzY5YS90YWJsZXJhbmdlOjU1N2EzMDI0MmU1YTQyNDg4NzQ5NzY2Y2RhYzc3NjlhXzMtMS0xLTEtMA_1bc6400a-7558-4bde-979b-6c7b9206f3f9"
      unitRef="number">0.16</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ie7004ecc84cf491ab540ef15e8620bb5_D20170101-20171231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTo1NTdhMzAyNDJlNWE0MjQ4ODc0OTc2NmNkYWM3NzY5YS90YWJsZXJhbmdlOjU1N2EzMDI0MmU1YTQyNDg4NzQ5NzY2Y2RhYzc3NjlhXzMtMy0xLTEtMA_967cfdb1-b8a5-4b8a-aee6-42cda2ca122a"
      unitRef="number">0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i10db7e65a275498b9298e6467e2ddd37_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTo1NTdhMzAyNDJlNWE0MjQ4ODc0OTc2NmNkYWM3NzY5YS90YWJsZXJhbmdlOjU1N2EzMDI0MmU1YTQyNDg4NzQ5NzY2Y2RhYzc3NjlhXzQtMS0xLTEtMTYxNA_d8d7217a-a8c7-45a9-ab9f-40e09f9c29cc"
      unitRef="number">0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i7d107c99b86241459c22fe452644f3a9_D20170101-20171231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTo1NTdhMzAyNDJlNWE0MjQ4ODc0OTc2NmNkYWM3NzY5YS90YWJsZXJhbmdlOjU1N2EzMDI0MmU1YTQyNDg4NzQ5NzY2Y2RhYzc3NjlhXzQtMy0xLTEtMA_6f1ab327-c349-4a19-8688-32bcaa12685e"
      unitRef="number">0.73</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="id8704ce91d804afb8569a95732959fd8_D20170101-20171231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTo1NTdhMzAyNDJlNWE0MjQ4ODc0OTc2NmNkYWM3NzY5YS90YWJsZXJhbmdlOjU1N2EzMDI0MmU1YTQyNDg4NzQ5NzY2Y2RhYzc3NjlhXzUtMy0xLTEtMTYxNA_8476199f-3fcc-4c44-bc8c-14c85baafcd5"
      unitRef="number">0.12</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90ZXh0cmVnaW9uOjIxM2RlYmY3Njg3MzQ3NmE5YTk0YzgyMTZiN2I4YTlmXzQxNDUx_f9b91b1a-ed63-4a04-b446-030892e80eb4">Property, Equipment and SoftwareProperty, equipment and software are stated at cost. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation or amortization are removed from the accounts and any resulting gain or loss is credited or charged to operations. Repairs and maintenance costs are expensed as incurred.</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <mgnx:PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90ZXh0cmVnaW9uOjIxM2RlYmY3Njg3MzQ3NmE5YTk0YzgyMTZiN2I4YTlmXzIxOTkwMjM0MTQ2OTA_82bdd9ee-80df-4794-ac00-fae5029018cc">Depreciation and amortization are computed using the straight-line method over the following estimated useful lives:&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:48.000000%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:48.000000%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Furniture&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Laboratory and office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Shorter of lease term or useful life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</mgnx:PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="icd9b6aa45a364d0c9cd302c42a5acd28_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTo2NjkwZWQxNTRhOGQ0ZDEzYmY2ODM0ODc2NjkxOTFmZS90YWJsZXJhbmdlOjY2OTBlZDE1NGE4ZDRkMTNiZjY4MzQ4NzY2OTE5MWZlXzAtMS0xLTEtMA_6be17bdd-73eb-4746-8210-d02852e5d4c7">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i8986558becfd44b1af99bbdfcf581445_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTo2NjkwZWQxNTRhOGQ0ZDEzYmY2ODM0ODc2NjkxOTFmZS90YWJsZXJhbmdlOjY2OTBlZDE1NGE4ZDRkMTNiZjY4MzQ4NzY2OTE5MWZlXzEtMS0xLTEtMA_e93930fe-2dc2-42bf-99ad-5f4d81a2f80c">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ib59b65ae84da4d388e5723647e6142e6_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTo2NjkwZWQxNTRhOGQ0ZDEzYmY2ODM0ODc2NjkxOTFmZS90YWJsZXJhbmdlOjY2OTBlZDE1NGE4ZDRkMTNiZjY4MzQ4NzY2OTE5MWZlXzItMS0xLTEtMA_1d67763a-cd19-4a43-97c7-6b494aa139ba">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i4e5cae6e220c436aabafd5c2f3481b6c_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTo2NjkwZWQxNTRhOGQ0ZDEzYmY2ODM0ODc2NjkxOTFmZS90YWJsZXJhbmdlOjY2OTBlZDE1NGE4ZDRkMTNiZjY4MzQ4NzY2OTE5MWZlXzMtMS0xLTEtMA_29348f16-efe1-4099-9ac5-2d7458318da0">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90ZXh0cmVnaW9uOjIxM2RlYmY3Njg3MzQ3NmE5YTk0YzgyMTZiN2I4YTlmXzQxNDUz_118e6759-af92-466e-bcd3-2677c0b69cac">&lt;div style="margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;The Company assesses the recoverability of its long-lived assets in accordance with the provisions of ASC 360, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;"&gt;Property, Plant and Equipment&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;. ASC 360 requires that long-lived assets be reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of the long-lived asset is measured by a comparison of the carrying amount of the asset to future undiscounted net cash flows expected to be generated by the asset or asset group. If carrying value exceeds the sum of undiscounted cash flows, the Company then determines the fair value of the underlying asset group. Any impairment to be recognized is measured by the amount by which the carrying amount of the asset group exceeds the estimated fair value of the asset group. Assets to be disposed of are reported at the lower of the carrying amount or fair value, less costs to sell. For the years ended&#160;December&#160;31, 2018,&#160;2017 and 2016, the Company determined that there were no impaired assets.&lt;/span&gt;&lt;/div&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleCarryingValueOfAsset
      contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90ZXh0cmVnaW9uOjIxM2RlYmY3Njg3MzQ3NmE5YTk0YzgyMTZiN2I4YTlmXzEwNzUx_e5791973-520a-4ea9-940a-0ae367633c69"
      unitRef="usd">0</us-gaap:ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleCarryingValueOfAsset>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90ZXh0cmVnaW9uOjIxM2RlYmY3Njg3MzQ3NmE5YTk0YzgyMTZiN2I4YTlmXzQxNDU0_4b76ed62-9309-4e89-ba2b-eb693e95c81d">&lt;div style="margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Income Taxes&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;Deferred tax assets and liabilities are determined based on differences between the financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. The effect on deferred tax assets and liabilities of a change in tax rates is recognized as income in the period that such tax rate changes are enacted. The measurement of a deferred tax asset is reduced, if necessary, by a valuation allowance if it is more likely than not that some portion or all of the deferred tax asset will not be realized. Financial statement recognition of a tax position taken or expected to be taken in a tax return is determined based on a more-likely-than-not threshold of that position being sustained. If the tax position meets this threshold, the benefit to be recognized is measured as the largest amount that is more likely than not to be realized upon ultimate settlement. The Company's policy is to record interest and penalties related to uncertain tax positions as a component of income tax expense.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90ZXh0cmVnaW9uOjIxM2RlYmY3Njg3MzQ3NmE5YTk0YzgyMTZiN2I4YTlmXzQxNDU1_239547e5-3b50-476d-99f7-58e533b75507">&lt;div style="margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Revenues&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:40.5pt;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;Beginning on January 1, 2018, the Company&#160;recognizes revenue under Accounting Standards Update (ASU) No. 2014-09, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;"&gt;Revenue from Contracts with Customer&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;s and all related amendments (collectively ASC 606) when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services.&#160;&#160;To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation.  The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;The Company enters into licensing agreements that are within the scope of ASC 606, under which it may license rights to research, develop, manufacture and commercialize its product candidates to third parties. The terms of these arrangements typically include payment to the Company of one or more of the following: non-refundable, upfront license fees; reimbursement of certain costs; customer option exercise fees; development, regulatory and commercial milestone payments;&#160;and royalties on net sales of licensed products.   The Company may also enter into development and manufacturing service agreements&#160;with its collaborators.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;For each arrangement that results in revenues, the Company identifies all performance obligations, which may include a license to intellectual property and know-how, research and development activities, transition activities and/or manufacturing services. In order to determine the transaction price, in addition to any upfront payment, the Company estimates the amount of variable consideration at the outset of the contract either utilizing the expected value or most likely amount method, depending&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt; on the facts and circumstances relative to the contract. The Company constrains (reduces) the estimates of variable consideration such that it is probable that a significant reversal of previously recognized revenue will not occur. When determining if variable consideration should be constrained, management considers whether there are factors outside the Company&#x2019;s control that could result in a significant reversal of revenue. In making these assessments, the Company considers the likelihood and magnitude of a potential reversal of revenue. These estimates are re-assessed each reporting period as required. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;Once the estimated transaction price is established, amounts are allocated to the performance obligations that have been identified. The transaction price is generally allocated to each separate performance obligation on a relative standalone selling price basis. The Company must develop assumptions that require judgment to determine the standalone selling price in order to account for these agreements. To determine the standalone selling price, the Company&#x2019;s assumptions may include (i)  the probability of obtaining marketing approval for the product candidate, (ii) estimates regarding the timing and the expected costs to develop and commercialize the product candidate, and (iii) estimates of future cash flows from potential product sales with respect to the product candidate. Standalone selling prices used to perform the initial allocation are not updated after contract inception. The Company does not include a financing component to its estimated transaction price at contract inception unless it estimates that certain performance obligations will not be satisfied within one year.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;Amounts received prior to revenue recognition are recorded as deferred revenue. Amounts expected to be recognized as revenue within the 12&#160;months following the balance sheet date are classified as current portion of deferred revenue in the accompanying consolidated balance sheets. Amounts not expected to be recognized as revenue within the 12&#160;months following the balance sheet date are classified as deferred revenue, net of current portion. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;"&gt;Licenses. &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;If the license to the Company&#x2019;s intellectual property is determined to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and when (or as) the customer is able to use and benefit from the license. In assessing whether a promise or performance obligation is distinct from the other promises, the Company considers factors such as the research, development, manufacturing and commercialization capabilities of the licensee and the availability of the associated expertise in the general marketplace. In addition, the Company considers whether the licensee can benefit from a promise for its intended purpose without the receipt of the remaining promise, whether the value of the promise is dependent on the unsatisfied promise, whether there are other vendors that could provide the remaining promise, and whether it is separately identifiable from the remaining promise. For licenses that are combined with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. The measure of progress, and thereby periods over which revenue should be recognized, are subject to estimates by management and may change over the course of the research and development and licensing agreement. Such a change could have a material impact on the amount of revenue the Company records in future periods. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;"&gt;Research, Development and/or Manufacturing Services. &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;The promises under the Company&#x2019;s agreements may include research and development or manufacturing services to be performed by the Company on behalf of the counterparty. If these services are determined to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes the transaction price allocated to these services as revenue over time based on an appropriate measure of progress when the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date.  If these services are determined not to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes the transaction price allocated to the combined performance obligation as the related performance obligations are satisfied. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;"&gt;Customer Options. &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;If an arrangement contains customer options, the Company evaluates whether the options are material rights because they allow the customer to acquire additional goods or services for free or at a discount. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the outset of the arrangement. The Company allocates the transaction price to material rights based on the relative standalone selling price, which is determined based on the identified discount and the probability that the customer will exercise the option. Amounts allocated to a material right are not recognized as revenue until, at the earliest, the option is exercised.  If the options are deemed not to be a material right, they are excluded as performance obligations at the outset of the arrangement. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;"&gt;Milestone Payments. &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;At the inception of each arrangement that includes development milestone payments, the Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt; occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. At the end of each subsequent reporting period, the Company reevaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;"&gt;Royalties. &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;For arrangements that include sales-based royalties which are the result of a customer-vendor relationship and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied or partially satisfied. To date, the Company has not recognized any royalty revenue resulting from any of its licensing arrangements. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;The Company analyzes its collaboration arrangements to assess whether such arrangements involve joint operating activities performed by parties who are both active participants in the activities and are both exposed to significant risks and rewards dependent on the commercial success of such activities. Such arrangements generally are within the scope of ASC 808, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;"&gt;Collaborative Arrangements&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt; (ASC 808). While ASC 808 defines collaborative arrangements and provides guidance on income statement presentation, classification, and disclosures related to such arrangements, it does not address recognition and measurement matters, such as (1)&#160;determining the appropriate unit of accounting or (2) when the recognition criteria are met. Therefore, the accounting for these arrangements is either based on an analogy to other accounting literature or an accounting policy election by the Company. The Company accounts for certain components of the collaboration agreement that are reflective of a vendor-customer relationship (e.g., licensing arrangement) based on an analogy to ASC 606. The Company accounts for other components based on a reasonable, rational and consistently applied accounting policy election.&#160;&#160; Reimbursements from the counter-party that are the result of a collaborative relationship with the counter-party, instead of a customer relationship, such as co-development activities, are recorded as a reduction to research and development expense as the services are performed.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;For a complete discussion of accounting for revenue from collaborative and other agreements, see Note 8, Collaboration and Other Agreements.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90ZXh0cmVnaW9uOjIxM2RlYmY3Njg3MzQ3NmE5YTk0YzgyMTZiN2I4YTlmXzQxNDU2_939e04cf-d45f-4e1d-b5c0-7389745fb06a">&lt;div style="margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Research and Development Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;Research and development expenditures are expensed as incurred. Research and development costs primarily consist of employee related expenses, including salaries and benefits, expenses incurred under agreements with contract research organizations, investigative sites and consultants that conduct the Company's clinical trials, the cost of acquiring and manufacturing clinical trial materials and other allocated expenses, license fees for and milestone payments related to in-licensed products and technologies, stock-based compensation expense, and costs associated with non-clinical activities and regulatory approvals.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;Right-to-develop agreements may contain cost-sharing provisions whereby the Company and the collaborator share the cost of research and development activities.&#160; Reimbursement of research and development expenses received in connection with these agreements is recorded as a reduction of such expenses.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90ZXh0cmVnaW9uOjIxM2RlYmY3Njg3MzQ3NmE5YTk0YzgyMTZiN2I4YTlmXzQxNDU3_0389f585-1933-4797-b7fa-c941fb582192">&lt;div style="margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Comprehensive Loss&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;Comprehensive loss represents net loss adjusted for the change during the periods attributed to unrealized gains and losses on available-for-sale securities.&lt;/span&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90ZXh0cmVnaW9uOjIxM2RlYmY3Njg3MzQ3NmE5YTk0YzgyMTZiN2I4YTlmXzQxNDU4_09a1bcaa-8609-4eb2-861d-ceaca534457d">&lt;div style="margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Stock-based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;Stock-based payments are accounted for in accordance with the provisions of ASC 718, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;"&gt;Compensation &#x2013; Stock Compensation&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;. The fair value of stock-based payments is estimated, on the date of grant, using the Black-Scholes model. The resulting fair value is recognized ratably over the requisite service period, which is generally the vesting period of the option.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;For all time-vesting awards granted, expense is amortized using the straight-line attribution method. For awards that contain a performance condition, expense is amortized using the accelerated attribution method. Recognition of stock-based compensation expense is based on the value of the portion of stock-based awards that is ultimately expected to vest during the period.&lt;/span&gt;&lt;/div&gt;The Company utilizes the Black-Scholes model for estimating fair value of its stock options granted. Option valuation models, including the Black-Scholes model, require the input of highly subjective assumptions, and changes in the assumptions used can materially affect the grant-date fair value of an award. These assumptions include the risk-free rate of interest, expected dividend yield, expected volatility and the expected life of the award.</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90ZXh0cmVnaW9uOjIxM2RlYmY3Njg3MzQ3NmE5YTk0YzgyMTZiN2I4YTlmXzQxNDU5_13d90d7e-f3ab-4452-9cf1-e775b35eaaee">&lt;div style="margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Net Loss Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;Basic loss per common share is determined by dividing loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted loss per share is computed by dividing the loss attributable to common stockholders by the weighted-average number of common share equivalents outstanding for the period. The treasury stock method is used to determine the dilutive effect of the Company's stock option grants.  5,273,964 stock options (common stock equivalents) were excluded from the calculation of diluted net loss per share for the year ended &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;December&#160;31, 2018&#160;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;because their inclusion would have been anti-dilutive.  4,504,642 stock options and 3,838,060 stock options were excluded from the calculation of diluted net loss per share for the years ended December&#160;31, 2017 and 2016, respectively,&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;because their inclusion would have been anti-dilutive.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i3e13e524660f42568e18e289608955ea_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90ZXh0cmVnaW9uOjIxM2RlYmY3Njg3MzQ3NmE5YTk0YzgyMTZiN2I4YTlmXzI3NDg3NzkyMjA3MDc_3c3ba971-2c9b-44c7-abd2-44641654b9de"
      unitRef="shares">5273964</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i956d155068494f53b5097a07d15631f3_D20170101-20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90ZXh0cmVnaW9uOjIxM2RlYmY3Njg3MzQ3NmE5YTk0YzgyMTZiN2I4YTlmXzI3NDg3NzkyMjA5MjA_98955524-9a1f-4cab-b02d-e14e0284eae3"
      unitRef="shares">4504642</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i4f8ff4c21a3f4b04bcd0190d63617d17_D20160101-20161231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90ZXh0cmVnaW9uOjIxM2RlYmY3Njg3MzQ3NmE5YTk0YzgyMTZiN2I4YTlmXzI3NDg3NzkyMjA5NDE_10233662-2ae5-4bb6-b4cc-ee44c1c3f12d"
      unitRef="shares">3838060</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90ZXh0cmVnaW9uOjIxM2RlYmY3Njg3MzQ3NmE5YTk0YzgyMTZiN2I4YTlmXzE1MzkzMTYyOTQxNzI4_b60199d8-0392-4e44-b92b-c29202ef18a4">&lt;div style="text-indent:36pt;text-align:justify;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;As a result of applying the modified retrospective method to adopt the new guidance, the following adjustments were made to accounts on the consolidated balance sheet as of January 1, 2018 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Arial;font-size:10pt;line-height:232%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853801%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:52.465593%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.641288%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532064%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.641288%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.678477%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.641288%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;"&gt;Pre-Adoption&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;"&gt;ASC 606 Adjustment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;"&gt;Post-Adoption&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;"&gt;Deferred revenue, current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;"&gt;Deferred revenue, net of current portion&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;13,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;19,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;"&gt;Accumulated deficit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(312,340)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(6,478)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(318,818)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;The transition adjustment resulted primarily from changes in &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;the pattern of revenue recognition for upfront fees and license grant fees.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;The following table shows the impact of adoption to the consolidated statement of income and balance sheet (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Arial;font-size:10pt;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:42.199706%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.096916%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534214%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:16.942731%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534214%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:19.292217%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;height:13pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Year Ended December 31, 2018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;As Reported&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balances Without Adoption of ASC 606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Effect of Change Higher/(Lower)&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Revenue from collaborative agreements&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;58,644&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;58,104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;540&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net loss&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(171,453)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(171,993)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(540)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Basic and diluted net loss per common share&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(4.19)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(4.20)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:21pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="height:21pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;height:13pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;As of December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;As Reported&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balances Without Adoption of ASC 606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Effect of Change Higher/(Lower)&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Deferred revenue, current&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;21,721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;22,210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(489)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Deferred revenue, net of current portion&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;19,001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accumulated deficit&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(490,271)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(484,332)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(5,939)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock>
    <us-gaap:DeferredRevenueCurrent
      contextRef="ieb5bf739a8ce42039763affce9678d7c_I20180101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZToyZDYyODg1MGI2OGQ0NDUxYjQ5MmMwMmYxMjk4NGM0Yi90YWJsZXJhbmdlOjJkNjI4ODUwYjY4ZDQ0NTFiNDkyYzAyZjEyOTg0YzRiXzEtMS0xLTEtNjA4MQ_290cab2c-a500-4e97-8044-19430e5287a4"
      unitRef="usd">7202000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:DeferredRevenueCurrent
      contextRef="ic3082c4bbda4473cb69446b2be52ec61_I20180101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZToyZDYyODg1MGI2OGQ0NDUxYjQ5MmMwMmYxMjk4NGM0Yi90YWJsZXJhbmdlOjJkNjI4ODUwYjY4ZDQ0NTFiNDkyYzAyZjEyOTg0YzRiXzEtMy0xLTEtNjEyNw_e6938d60-5790-4573-832f-c9866de82405"
      unitRef="usd">540000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:DeferredRevenueCurrent
      contextRef="i58ed5a015dbf42e19178b051b82c9683_I20180101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZToyZDYyODg1MGI2OGQ0NDUxYjQ5MmMwMmYxMjk4NGM0Yi90YWJsZXJhbmdlOjJkNjI4ODUwYjY4ZDQ0NTFiNDkyYzAyZjEyOTg0YzRiXzEtNS0xLTEtNjEyOQ_c26fbd18-d192-4aa9-a770-9cc0751e5259"
      unitRef="usd">7742000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:DeferredRevenueNoncurrent
      contextRef="ieb5bf739a8ce42039763affce9678d7c_I20180101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZToyZDYyODg1MGI2OGQ0NDUxYjQ5MmMwMmYxMjk4NGM0Yi90YWJsZXJhbmdlOjJkNjI4ODUwYjY4ZDQ0NTFiNDkyYzAyZjEyOTg0YzRiXzItMS0xLTEtNjEyMw_a65b8652-4373-4eb4-b887-91a5a09d44c7"
      unitRef="usd">13637000</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:DeferredRevenueNoncurrent
      contextRef="ic3082c4bbda4473cb69446b2be52ec61_I20180101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZToyZDYyODg1MGI2OGQ0NDUxYjQ5MmMwMmYxMjk4NGM0Yi90YWJsZXJhbmdlOjJkNjI4ODUwYjY4ZDQ0NTFiNDkyYzAyZjEyOTg0YzRiXzItMy0xLTEtNjEzMQ_e9310710-a380-4329-9934-e8b830426dea"
      unitRef="usd">5939000</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:DeferredRevenueNoncurrent
      contextRef="i58ed5a015dbf42e19178b051b82c9683_I20180101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZToyZDYyODg1MGI2OGQ0NDUxYjQ5MmMwMmYxMjk4NGM0Yi90YWJsZXJhbmdlOjJkNjI4ODUwYjY4ZDQ0NTFiNDkyYzAyZjEyOTg0YzRiXzItNS0xLTEtNjEzMw_3f312f78-c1cc-4be7-a2a1-3d8752a84202"
      unitRef="usd">19576000</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ieb5bf739a8ce42039763affce9678d7c_I20180101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZToyZDYyODg1MGI2OGQ0NDUxYjQ5MmMwMmYxMjk4NGM0Yi90YWJsZXJhbmdlOjJkNjI4ODUwYjY4ZDQ0NTFiNDkyYzAyZjEyOTg0YzRiXzMtMS0xLTEtNjEyNQ_44898e75-5744-4b7f-b88e-f98a91b9181b"
      unitRef="usd">-312340000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ic3082c4bbda4473cb69446b2be52ec61_I20180101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZToyZDYyODg1MGI2OGQ0NDUxYjQ5MmMwMmYxMjk4NGM0Yi90YWJsZXJhbmdlOjJkNjI4ODUwYjY4ZDQ0NTFiNDkyYzAyZjEyOTg0YzRiXzMtMy0xLTEtNjEzNQ_ba3961fa-a5c1-426e-8a60-9efbd03ba210"
      unitRef="usd">-6478000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i58ed5a015dbf42e19178b051b82c9683_I20180101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZToyZDYyODg1MGI2OGQ0NDUxYjQ5MmMwMmYxMjk4NGM0Yi90YWJsZXJhbmdlOjJkNjI4ODUwYjY4ZDQ0NTFiNDkyYzAyZjEyOTg0YzRiXzMtNS0xLTEtNjEzNw_275804a4-ea16-4858-b7e5-d65eb665e73a"
      unitRef="usd">-318818000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:Revenues
      contextRef="ieb0bea730e3444a5b0d8559d16ad126c_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTozODNmZGYwNDBkMjM0ZDg5OTBmNjk3NmU5OWYxOGZjYy90YWJsZXJhbmdlOjM4M2ZkZjA0MGQyMzRkODk5MGY2OTc2ZTk5ZjE4ZmNjXzgtMS0xLTEtMTUxMQ_0af2975e-1a6b-4496-ac62-8a455ac528cd"
      unitRef="usd">58644000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia6869870ff9d444da346b6b8718b80f3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTozODNmZGYwNDBkMjM0ZDg5OTBmNjk3NmU5OWYxOGZjYy90YWJsZXJhbmdlOjM4M2ZkZjA0MGQyMzRkODk5MGY2OTc2ZTk5ZjE4ZmNjXzItMy0xLTEtNjE2Mw_9d5395bd-7355-4727-9ac2-777633b81b33"
      unitRef="usd">58104000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8195466a5e2c4a458ca23edc5bbb7661_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTozODNmZGYwNDBkMjM0ZDg5OTBmNjk3NmU5OWYxOGZjYy90YWJsZXJhbmdlOjM4M2ZkZjA0MGQyMzRkODk5MGY2OTc2ZTk5ZjE4ZmNjXzItNS0xLTEtNjE3MA_ac712970-5b86-45f1-b1b7-6c2664b1d784"
      unitRef="usd">540000</us-gaap:Revenues>
    <us-gaap:NetIncomeLoss
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTozODNmZGYwNDBkMjM0ZDg5OTBmNjk3NmU5OWYxOGZjYy90YWJsZXJhbmdlOjM4M2ZkZjA0MGQyMzRkODk5MGY2OTc2ZTk5ZjE4ZmNjXzktMS0xLTEtMTUxMQ_efc3fc49-78d2-46c3-bce7-723092ceaf1d"
      unitRef="usd">-171453000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ic2e9f102d8434edb8909ccdd833da1f3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTozODNmZGYwNDBkMjM0ZDg5OTBmNjk3NmU5OWYxOGZjYy90YWJsZXJhbmdlOjM4M2ZkZjA0MGQyMzRkODk5MGY2OTc2ZTk5ZjE4ZmNjXzMtMy0xLTEtNjE4OA_cbd32179-b5d5-438e-bc04-235a81e6dd71"
      unitRef="usd">-171993000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i5f8c7c83e37647699033616fbb46b432_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTozODNmZGYwNDBkMjM0ZDg5OTBmNjk3NmU5OWYxOGZjYy90YWJsZXJhbmdlOjM4M2ZkZjA0MGQyMzRkODk5MGY2OTc2ZTk5ZjE4ZmNjXzMtNS0xLTEtNjE5MA_dcd13121-b545-4c56-a568-b8b30a265373"
      unitRef="usd">-540000</us-gaap:NetIncomeLoss>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTozODNmZGYwNDBkMjM0ZDg5OTBmNjk3NmU5OWYxOGZjYy90YWJsZXJhbmdlOjM4M2ZkZjA0MGQyMzRkODk5MGY2OTc2ZTk5ZjE4ZmNjXzEwLTEtMS0xLTE1MTE_6d4a8c3d-477d-4b15-a8ca-028e026adbca"
      unitRef="usdPerShare">-4.19</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
      contextRef="ic2e9f102d8434edb8909ccdd833da1f3_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTozODNmZGYwNDBkMjM0ZDg5OTBmNjk3NmU5OWYxOGZjYy90YWJsZXJhbmdlOjM4M2ZkZjA0MGQyMzRkODk5MGY2OTc2ZTk5ZjE4ZmNjXzQtMy0xLTEtNjE5Mg_ddf5630f-f904-4404-8ecc-07e19e0fae6f"
      unitRef="usdPerShare">-4.20</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
      contextRef="i5f8c7c83e37647699033616fbb46b432_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTozODNmZGYwNDBkMjM0ZDg5OTBmNjk3NmU5OWYxOGZjYy90YWJsZXJhbmdlOjM4M2ZkZjA0MGQyMzRkODk5MGY2OTc2ZTk5ZjE4ZmNjXzQtNS0xLTEtNjE5NA_7efa876d-f76e-470b-a4ba-d8ea7470bc83"
      unitRef="usdPerShare">0.01</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
    <us-gaap:DeferredRevenueCurrent
      contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTozODNmZGYwNDBkMjM0ZDg5OTBmNjk3NmU5OWYxOGZjYy90YWJsZXJhbmdlOjM4M2ZkZjA0MGQyMzRkODk5MGY2OTc2ZTk5ZjE4ZmNjXzgtMS0xLTEtNjE5Ng_6b2c59cf-c321-4308-9d84-f8620ab62702"
      unitRef="usd">21721000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:DeferredRevenueCurrent
      contextRef="i1158af44c1a44a528cf5faac76fc6bf6_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTozODNmZGYwNDBkMjM0ZDg5OTBmNjk3NmU5OWYxOGZjYy90YWJsZXJhbmdlOjM4M2ZkZjA0MGQyMzRkODk5MGY2OTc2ZTk5ZjE4ZmNjXzgtMy0xLTEtNjIwMg_a46f2201-3425-4cb3-ab78-6cb5b9f13fd9"
      unitRef="usd">22210000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:DeferredRevenueCurrent
      contextRef="i540a17d5cd3043469a51f6ba7e3d31b5_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTozODNmZGYwNDBkMjM0ZDg5OTBmNjk3NmU5OWYxOGZjYy90YWJsZXJhbmdlOjM4M2ZkZjA0MGQyMzRkODk5MGY2OTc2ZTk5ZjE4ZmNjXzgtNS0xLTEtNjIwNA_5f8cc177-1ff2-4ae8-ad6b-a53cec11c30b"
      unitRef="usd">-489000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:DeferredRevenueNoncurrent
      contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTozODNmZGYwNDBkMjM0ZDg5OTBmNjk3NmU5OWYxOGZjYy90YWJsZXJhbmdlOjM4M2ZkZjA0MGQyMzRkODk5MGY2OTc2ZTk5ZjE4ZmNjXzktMS0xLTEtNjE5OA_4f49d574-3a64-4614-b54a-422c5d118956"
      unitRef="usd">19001000</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:DeferredRevenueNoncurrent
      contextRef="i1158af44c1a44a528cf5faac76fc6bf6_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTozODNmZGYwNDBkMjM0ZDg5OTBmNjk3NmU5OWYxOGZjYy90YWJsZXJhbmdlOjM4M2ZkZjA0MGQyMzRkODk5MGY2OTc2ZTk5ZjE4ZmNjXzktMy0xLTEtNjIwNg_c9f464c1-1c7a-43fd-9267-a5221ce79c07"
      unitRef="usd">12573000</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:DeferredRevenueNoncurrent
      contextRef="i540a17d5cd3043469a51f6ba7e3d31b5_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTozODNmZGYwNDBkMjM0ZDg5OTBmNjk3NmU5OWYxOGZjYy90YWJsZXJhbmdlOjM4M2ZkZjA0MGQyMzRkODk5MGY2OTc2ZTk5ZjE4ZmNjXzktNS0xLTEtNjIwOA_38075b96-4a8f-41d5-b033-a14e5f0e17fd"
      unitRef="usd">6428000</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTozODNmZGYwNDBkMjM0ZDg5OTBmNjk3NmU5OWYxOGZjYy90YWJsZXJhbmdlOjM4M2ZkZjA0MGQyMzRkODk5MGY2OTc2ZTk5ZjE4ZmNjXzE2LTEtMS0xLTE1MTE_be5eb039-9ac0-4c8b-bf4c-7c836eaff4e0"
      unitRef="usd">-490271000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i1158af44c1a44a528cf5faac76fc6bf6_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTozODNmZGYwNDBkMjM0ZDg5OTBmNjk3NmU5OWYxOGZjYy90YWJsZXJhbmdlOjM4M2ZkZjA0MGQyMzRkODk5MGY2OTc2ZTk5ZjE4ZmNjXzEwLTMtMS0xLTYyMTA_ef2b58c8-9aba-4205-af62-c7b9fb7c4aec"
      unitRef="usd">-484332000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i540a17d5cd3043469a51f6ba7e3d31b5_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTozODNmZGYwNDBkMjM0ZDg5OTBmNjk3NmU5OWYxOGZjYy90YWJsZXJhbmdlOjM4M2ZkZjA0MGQyMzRkODk5MGY2OTc2ZTk5ZjE4ZmNjXzEwLTUtMS0xLTYyMTI_de474ea5-358b-4a4b-9ef7-bdf71570586e"
      unitRef="usd">-5939000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90ZXh0cmVnaW9uOjIxM2RlYmY3Njg3MzQ3NmE5YTk0YzgyMTZiN2I4YTlmXzE1MzkzMTYyOTM5NjA2_6b2faee2-914b-4b30-ab29-98ca2a35d324">&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;The following table presents changes in the Company&#x2019;s contract liabilities during the year ended December 31, 2018 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Arial;font-size:10pt;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:41.024963%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.530103%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534214%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:7.397944%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534214%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.572687%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534214%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.271659%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance at Beginning of Period&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Additions&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Deductions&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance at End of Period&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160; Deferred revenue (current and non-current)&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;27,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;22,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(9,588)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;40,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i7057397719af459ca7328a1c440a0efa_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTozMTkwNDU0NjBiMzI0ZGFjOWY5NmFiZDU5ODE3YTdlOS90YWJsZXJhbmdlOjMxOTA0NTQ2MGIzMjRkYWM5Zjk2YWJkNTk4MTdhN2U5XzEtMS0xLTEtMTUxMQ_dc41c4c6-5528-455d-8b71-2ac97215b2ef"
      unitRef="usd">27318000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTozMTkwNDU0NjBiMzI0ZGFjOWY5NmFiZDU5ODE3YTdlOS90YWJsZXJhbmdlOjMxOTA0NTQ2MGIzMjRkYWM5Zjk2YWJkNTk4MTdhN2U5XzEtMy0xLTEtMTUxMQ_05de90d0-5589-4096-a2f5-2c709391a1d3"
      unitRef="usd">22992000</us-gaap:ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTozMTkwNDU0NjBiMzI0ZGFjOWY5NmFiZDU5ODE3YTdlOS90YWJsZXJhbmdlOjMxOTA0NTQ2MGIzMjRkYWM5Zjk2YWJkNTk4MTdhN2U5XzEtNS0xLTEtMTUxMQ_5e871f3c-3102-460e-bcd8-67477d0aea9d"
      unitRef="usd">9588000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiability
      contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90YWJsZTozMTkwNDU0NjBiMzI0ZGFjOWY5NmFiZDU5ODE3YTdlOS90YWJsZXJhbmdlOjMxOTA0NTQ2MGIzMjRkYWM5Zjk2YWJkNTk4MTdhN2U5XzEtNy0xLTEtMTUxMQ_30b3dce4-831f-455b-a884-1e35c5913143"
      unitRef="usd">40722000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90ZXh0cmVnaW9uOjIxM2RlYmY3Njg3MzQ3NmE5YTk0YzgyMTZiN2I4YTlmXzI3NDg3NzkyMjIzMjI_0680de15-e441-4ec4-a013-c57becbb69b2"
      unitRef="usd">9600000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF81OTgvZnJhZzoyMTNkZWJmNzY4NzM0NzZhOWE5NGM4MjE2YjdiOGE5Zi90ZXh0cmVnaW9uOjIxM2RlYmY3Njg3MzQ3NmE5YTk0YzgyMTZiN2I4YTlmXzQxNDYy_4fc67a3c-b393-4061-9ee0-4c80e303b7c5">&lt;div style="margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Recently Issued Accounting Standards &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;"&gt;In February 2016, the FASB issued ASU No. 2016-02, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:115%;"&gt;Leases&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;"&gt; (ASU 2016-02) that provides principles for the recognition, measurement, presentation and disclosure of leases for both lessees and lessors.  ASU 2016-02 requires a lessee to recognize assets and liabilities on the balance sheet for operating leases and changes many key definitions, including the definition of a lease. ASU 2016-02 includes a short-term lease exception for leases with an original term of 12 months or less, in which a lessee can make an accounting policy election not to recognize lease assets and lease liabilities. Lessees will continue to differentiate between finance leases (previously referred to as capital leases) and operating leases, using classification criteria that are substantially similar to the previous guidance. Originally, entities were required to adopt ASU 2016-02 using a modified retrospective transition approach for all leases existing at, or entered into after, the date of initial application. However, in July 2018, the FASB issued ASU 2018-11, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:115%;"&gt;Leases (Topic 842): Targeted Improvements,&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;"&gt; which now allows entities the option of recognizing the cumulative effect of applying the new standard as an adjustment to the opening balance of retained earnings in the year of adoption while continuing to present all prior periods under previous lease accounting guidance. In July 2018, the FASB also issued ASU 2018-10, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:115%;"&gt;Codification Improvements to Topic 842, Leases, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;"&gt;which clarifies how to apply certain aspects of ASU 2016-02. ASU 2016-02, ASU 2018-10 and ASU 2018-11 (now commonly referred to as ASC Topic 842 (ASC 842)) is effective for the Company&#x2019;s fiscal year beginning January 1, 2019. Although early adoption is permitted, the Company has not elected to do so. The Company plans to elect the transition option provided under ASU 2018-11, which will not require adjustments to comparative periods nor require modified disclosures in those comparative periods. Upon adoption, the Company expects to elect the transition package of practical expedients permitted within the new standard, which among other things, allows the carryforward of the historical lease classification.  &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:115%;"&gt;Based on its current lease portfolio, the Company estimates that the adoption ASC 842 will result in approximately $16.0 million of right of use assets and $28.0 million of lease liabilities being reflected on its consolidated balance sheet at the date of adoption. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;"&gt;In November 2018, the FASB issued ASU 2018-18, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:115%;"&gt;Collaborative Arrangements (Topic 808)&#x2014;Clarifying the interaction between Topic 808 and Topic 606&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;"&gt; (ASU 2018-18). The amendments provide guidance on whether certain&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;"&gt; transactions between collaborative arrangement participants should be accounted for as revenue under ASC 606. It also specifically (i) addresses when the participant should be considered a customer in the context of a unit of account, (ii) adds unit-of-account guidance in ASC 808 to align with guidance in ASC 606, and (iii) precludes presenting revenue from a collaborative arrangement together with revenue recognized under ASC 606 if the collaborative arrangement participant is not a customer. The guidance will be effective for fiscal years beginning after December 15, 2019. Early adoption is permitted and should be applied retrospectively. The Company does not anticipate the adoption of this standard will have a material impact on its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:5pt;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;The Company has evaluated all other ASUs issued through the date the consolidated financials were issued and believes that the adoption of these will not have a material impact on the Company's consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82MjMvZnJhZzo1YTgzOGJhYzMwZmY0YzQ5YjJmMmU4MTZkM2UwMGQxNy90ZXh0cmVnaW9uOjVhODM4YmFjMzBmZjRjNDliMmYyZTgxNmQzZTAwZDE3XzczNA_75e5bf17-c3f7-4940-8e17-d61c46f711ad">Marketable Securities&lt;div style="margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;Available-for-sale marketable securities as of December&#160;31, 2018 and 2017 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:48.807636%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.747430%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534214%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.747430%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534214%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.747430%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534214%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.747430%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:16pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;height:16pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;"&gt;Fair&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12,738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-bottom:9pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-bottom:9pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:48.807636%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.747430%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534214%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.747430%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534214%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.747430%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534214%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.747430%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;height:13pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;"&gt;Fair&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;77,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(50)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;77,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;93,455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(63)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;93,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:15pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;All of the Company's available-for-sale securities held at &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;&#160;and 2017&#160;had maturity dates of less than one year.  &lt;/span&gt;&lt;/div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;All available-for-sale securities in an unrealized loss position as of &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt; and 2017 were in a loss position for less than twelve months.&#160; There were no unrealized losses at &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;December&#160;31, 2018&lt;/span&gt; or 2017 that the Company determined to be other-than-temporary.  The Company recorded interest income of $2.3 million, $2.4 million and $2.3 million during the years ended December&#160;31, 2018, 2017 and 2016, respectively, which is included in other income (expense) on the consolidated statements of operations and comprehensive loss.</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:AvailableForSaleSecuritiesTextBlock
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82MjMvZnJhZzo1YTgzOGJhYzMwZmY0YzQ5YjJmMmU4MTZkM2UwMGQxNy90ZXh0cmVnaW9uOjVhODM4YmFjMzBmZjRjNDliMmYyZTgxNmQzZTAwZDE3XzczNQ_8c85e699-310d-481a-aa54-37c915cef514">&lt;div style="margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;Available-for-sale marketable securities as of December&#160;31, 2018 and 2017 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:48.807636%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.747430%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534214%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.747430%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534214%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.747430%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534214%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.747430%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:16pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;height:16pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;"&gt;Fair&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12,738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-bottom:9pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-bottom:9pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:48.807636%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.747430%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534214%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.747430%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534214%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.747430%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534214%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.747430%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;height:13pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;"&gt;Fair&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;77,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(50)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;77,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;93,455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(63)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;93,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;All of the Company's available-for-sale securities held at &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;December&#160;31, 2018&lt;/span&gt;&#160;and 2017&#160;had maturity dates of less than one year.</us-gaap:AvailableForSaleSecuritiesTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="id7600d6be2eb4b27a2ed9c725fbeef09_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82MjMvZnJhZzo1YTgzOGJhYzMwZmY0YzQ5YjJmMmU4MTZkM2UwMGQxNy90YWJsZTo2NDEwZmUyMzk5NzQ0NWY4YjQzYjJkYjlmODI4YzEzMy90YWJsZXJhbmdlOjY0MTBmZTIzOTk3NDQ1ZjhiNDNiMmRiOWY4MjhjMTMzXzQtMS0xLTEtMA_957b0ec9-2b23-4291-a844-3ed0faa900ef"
      unitRef="usd">12738000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="id7600d6be2eb4b27a2ed9c725fbeef09_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82MjMvZnJhZzo1YTgzOGJhYzMwZmY0YzQ5YjJmMmU4MTZkM2UwMGQxNy90YWJsZTo2NDEwZmUyMzk5NzQ0NWY4YjQzYjJkYjlmODI4YzEzMy90YWJsZXJhbmdlOjY0MTBmZTIzOTk3NDQ1ZjhiNDNiMmRiOWY4MjhjMTMzXzQtMy0xLTEtMA_3a6652c5-1da7-4a25-9033-c66e6a9767e6"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="id7600d6be2eb4b27a2ed9c725fbeef09_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82MjMvZnJhZzo1YTgzOGJhYzMwZmY0YzQ5YjJmMmU4MTZkM2UwMGQxNy90YWJsZTo2NDEwZmUyMzk5NzQ0NWY4YjQzYjJkYjlmODI4YzEzMy90YWJsZXJhbmdlOjY0MTBmZTIzOTk3NDQ1ZjhiNDNiMmRiOWY4MjhjMTMzXzQtNS0xLTEtMA_3b8f6639-12df-4d83-b698-3f005aa09f8a"
      unitRef="usd">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id7600d6be2eb4b27a2ed9c725fbeef09_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82MjMvZnJhZzo1YTgzOGJhYzMwZmY0YzQ5YjJmMmU4MTZkM2UwMGQxNy90YWJsZTo2NDEwZmUyMzk5NzQ0NWY4YjQzYjJkYjlmODI4YzEzMy90YWJsZXJhbmdlOjY0MTBmZTIzOTk3NDQ1ZjhiNDNiMmRiOWY4MjhjMTMzXzQtNy0xLTEtMA_9434529b-b267-43e2-bc48-8572471c375d"
      unitRef="usd">12735000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ic847642706c0496581735d8af543077a_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82MjMvZnJhZzo1YTgzOGJhYzMwZmY0YzQ5YjJmMmU4MTZkM2UwMGQxNy90YWJsZTpiZWJlOGE0MWIyMGM0YzY1ODJkYTk5NTg0Yzc1M2Q2Yi90YWJsZXJhbmdlOmJlYmU4YTQxYjIwYzRjNjU4MmRhOTk1ODRjNzUzZDZiXzItMS0xLTEtMA_5701e208-85b1-4d8c-9bdc-88dd07ca32aa"
      unitRef="usd">3995000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ic847642706c0496581735d8af543077a_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82MjMvZnJhZzo1YTgzOGJhYzMwZmY0YzQ5YjJmMmU4MTZkM2UwMGQxNy90YWJsZTpiZWJlOGE0MWIyMGM0YzY1ODJkYTk5NTg0Yzc1M2Q2Yi90YWJsZXJhbmdlOmJlYmU4YTQxYjIwYzRjNjU4MmRhOTk1ODRjNzUzZDZiXzItMy0xLTEtMA_05dcb930-b003-43b0-be0a-975ccfc5944e"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ic847642706c0496581735d8af543077a_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82MjMvZnJhZzo1YTgzOGJhYzMwZmY0YzQ5YjJmMmU4MTZkM2UwMGQxNy90YWJsZTpiZWJlOGE0MWIyMGM0YzY1ODJkYTk5NTg0Yzc1M2Q2Yi90YWJsZXJhbmdlOmJlYmU4YTQxYjIwYzRjNjU4MmRhOTk1ODRjNzUzZDZiXzItNS0xLTEtMA_c0dda6da-64a4-4b73-ac0b-ecea2a6a56e1"
      unitRef="usd">6000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic847642706c0496581735d8af543077a_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82MjMvZnJhZzo1YTgzOGJhYzMwZmY0YzQ5YjJmMmU4MTZkM2UwMGQxNy90YWJsZTpiZWJlOGE0MWIyMGM0YzY1ODJkYTk5NTg0Yzc1M2Q2Yi90YWJsZXJhbmdlOmJlYmU4YTQxYjIwYzRjNjU4MmRhOTk1ODRjNzUzZDZiXzItNy0xLTEtMA_81decdd1-c526-4961-949b-0b4d5cf9ba23"
      unitRef="usd">3989000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="iae2c0abc66c64857918562886c9ab108_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82MjMvZnJhZzo1YTgzOGJhYzMwZmY0YzQ5YjJmMmU4MTZkM2UwMGQxNy90YWJsZTpiZWJlOGE0MWIyMGM0YzY1ODJkYTk5NTg0Yzc1M2Q2Yi90YWJsZXJhbmdlOmJlYmU4YTQxYjIwYzRjNjU4MmRhOTk1ODRjNzUzZDZiXzMtMS0xLTEtMA_6370ee77-7ce1-4c89-95d0-b00b28f87f18"
      unitRef="usd">11998000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="iae2c0abc66c64857918562886c9ab108_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82MjMvZnJhZzo1YTgzOGJhYzMwZmY0YzQ5YjJmMmU4MTZkM2UwMGQxNy90YWJsZTpiZWJlOGE0MWIyMGM0YzY1ODJkYTk5NTg0Yzc1M2Q2Yi90YWJsZXJhbmdlOmJlYmU4YTQxYjIwYzRjNjU4MmRhOTk1ODRjNzUzZDZiXzMtMy0xLTEtMA_f0b9289a-85ac-4f16-bc37-aa3173d5caa5"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="iae2c0abc66c64857918562886c9ab108_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82MjMvZnJhZzo1YTgzOGJhYzMwZmY0YzQ5YjJmMmU4MTZkM2UwMGQxNy90YWJsZTpiZWJlOGE0MWIyMGM0YzY1ODJkYTk5NTg0Yzc1M2Q2Yi90YWJsZXJhbmdlOmJlYmU4YTQxYjIwYzRjNjU4MmRhOTk1ODRjNzUzZDZiXzMtNS0xLTEtMA_fbf85b73-6369-4e80-b59b-843619b14458"
      unitRef="usd">7000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iae2c0abc66c64857918562886c9ab108_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82MjMvZnJhZzo1YTgzOGJhYzMwZmY0YzQ5YjJmMmU4MTZkM2UwMGQxNy90YWJsZTpiZWJlOGE0MWIyMGM0YzY1ODJkYTk5NTg0Yzc1M2Q2Yi90YWJsZXJhbmdlOmJlYmU4YTQxYjIwYzRjNjU4MmRhOTk1ODRjNzUzZDZiXzMtNy0xLTEtMA_e4ba5493-b3ba-499d-84ae-acbadd65c0bc"
      unitRef="usd">11991000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i4d00247415ba468e829a69e2a8739d09_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82MjMvZnJhZzo1YTgzOGJhYzMwZmY0YzQ5YjJmMmU4MTZkM2UwMGQxNy90YWJsZTpiZWJlOGE0MWIyMGM0YzY1ODJkYTk5NTg0Yzc1M2Q2Yi90YWJsZXJhbmdlOmJlYmU4YTQxYjIwYzRjNjU4MmRhOTk1ODRjNzUzZDZiXzQtMS0xLTEtMA_07975abe-e403-471e-9113-4f2fbefe2c38"
      unitRef="usd">77462000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i4d00247415ba468e829a69e2a8739d09_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82MjMvZnJhZzo1YTgzOGJhYzMwZmY0YzQ5YjJmMmU4MTZkM2UwMGQxNy90YWJsZTpiZWJlOGE0MWIyMGM0YzY1ODJkYTk5NTg0Yzc1M2Q2Yi90YWJsZXJhbmdlOmJlYmU4YTQxYjIwYzRjNjU4MmRhOTk1ODRjNzUzZDZiXzQtMy0xLTEtMA_4be97cf7-6012-4db3-a07f-38a49b82dff0"
      unitRef="usd">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i4d00247415ba468e829a69e2a8739d09_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82MjMvZnJhZzo1YTgzOGJhYzMwZmY0YzQ5YjJmMmU4MTZkM2UwMGQxNy90YWJsZTpiZWJlOGE0MWIyMGM0YzY1ODJkYTk5NTg0Yzc1M2Q2Yi90YWJsZXJhbmdlOmJlYmU4YTQxYjIwYzRjNjU4MmRhOTk1ODRjNzUzZDZiXzQtNS0xLTEtMA_b858af6c-cf04-4ce1-9ca6-77e463ad30bc"
      unitRef="usd">50000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4d00247415ba468e829a69e2a8739d09_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82MjMvZnJhZzo1YTgzOGJhYzMwZmY0YzQ5YjJmMmU4MTZkM2UwMGQxNy90YWJsZTpiZWJlOGE0MWIyMGM0YzY1ODJkYTk5NTg0Yzc1M2Q2Yi90YWJsZXJhbmdlOmJlYmU4YTQxYjIwYzRjNjU4MmRhOTk1ODRjNzUzZDZiXzQtNy0xLTEtMA_269726d2-7341-4bd6-9ac2-dbea957daaa7"
      unitRef="usd">77414000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i7057397719af459ca7328a1c440a0efa_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82MjMvZnJhZzo1YTgzOGJhYzMwZmY0YzQ5YjJmMmU4MTZkM2UwMGQxNy90YWJsZTpiZWJlOGE0MWIyMGM0YzY1ODJkYTk5NTg0Yzc1M2Q2Yi90YWJsZXJhbmdlOmJlYmU4YTQxYjIwYzRjNjU4MmRhOTk1ODRjNzUzZDZiXzUtMS0xLTEtMA_5f00053b-b48e-423f-b55f-d6b48e17ac86"
      unitRef="usd">93455000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i7057397719af459ca7328a1c440a0efa_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82MjMvZnJhZzo1YTgzOGJhYzMwZmY0YzQ5YjJmMmU4MTZkM2UwMGQxNy90YWJsZTpiZWJlOGE0MWIyMGM0YzY1ODJkYTk5NTg0Yzc1M2Q2Yi90YWJsZXJhbmdlOmJlYmU4YTQxYjIwYzRjNjU4MmRhOTk1ODRjNzUzZDZiXzUtMy0xLTEtMA_53e83e5b-51c4-40ae-9580-7b9bdf5f3099"
      unitRef="usd">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i7057397719af459ca7328a1c440a0efa_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82MjMvZnJhZzo1YTgzOGJhYzMwZmY0YzQ5YjJmMmU4MTZkM2UwMGQxNy90YWJsZTpiZWJlOGE0MWIyMGM0YzY1ODJkYTk5NTg0Yzc1M2Q2Yi90YWJsZXJhbmdlOmJlYmU4YTQxYjIwYzRjNjU4MmRhOTk1ODRjNzUzZDZiXzUtNS0xLTEtMA_05c8320a-e922-4a7a-9ae2-e6b91ffffb02"
      unitRef="usd">63000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7057397719af459ca7328a1c440a0efa_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82MjMvZnJhZzo1YTgzOGJhYzMwZmY0YzQ5YjJmMmU4MTZkM2UwMGQxNy90YWJsZTpiZWJlOGE0MWIyMGM0YzY1ODJkYTk5NTg0Yzc1M2Q2Yi90YWJsZXJhbmdlOmJlYmU4YTQxYjIwYzRjNjU4MmRhOTk1ODRjNzUzZDZiXzUtNy0xLTEtMA_84806449-cd56-4fd2-90d0-41ad8925f40d"
      unitRef="usd">93394000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82MjMvZnJhZzo1YTgzOGJhYzMwZmY0YzQ5YjJmMmU4MTZkM2UwMGQxNy90ZXh0cmVnaW9uOjVhODM4YmFjMzBmZjRjNDliMmYyZTgxNmQzZTAwZDE3XzUwMA_17c9e8bd-3a53-4891-a668-5e19c8c177f4"
      unitRef="usd">0</us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities>
    <us-gaap:InterestIncomeOther
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82MjMvZnJhZzo1YTgzOGJhYzMwZmY0YzQ5YjJmMmU4MTZkM2UwMGQxNy90ZXh0cmVnaW9uOjVhODM4YmFjMzBmZjRjNDliMmYyZTgxNmQzZTAwZDE3XzYzMA_8d72a13e-4c84-47a1-aa18-015a9bd0f8ce"
      unitRef="usd">2300000</us-gaap:InterestIncomeOther>
    <us-gaap:InterestIncomeOther
      contextRef="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82MjMvZnJhZzo1YTgzOGJhYzMwZmY0YzQ5YjJmMmU4MTZkM2UwMGQxNy90ZXh0cmVnaW9uOjVhODM4YmFjMzBmZjRjNDliMmYyZTgxNmQzZTAwZDE3XzYzNA_b93528d7-d3db-42d6-b547-291392253666"
      unitRef="usd">2400000</us-gaap:InterestIncomeOther>
    <us-gaap:InterestIncomeOther
      contextRef="iaf5d0e8fdf374dc09283fd669e2ebf19_D20160101-20161231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82MjMvZnJhZzo1YTgzOGJhYzMwZmY0YzQ5YjJmMmU4MTZkM2UwMGQxNy90ZXh0cmVnaW9uOjVhODM4YmFjMzBmZjRjNDliMmYyZTgxNmQzZTAwZDE3XzY0MQ_cb643ae4-7736-41d0-86f1-6c3df23e12b8"
      unitRef="usd">2300000</us-gaap:InterestIncomeOther>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82NDgvZnJhZzo1NjdmZTIxZGIwYTU0ZGNlYjZlMmZkOWI1MmMwYmJhYy90ZXh0cmVnaW9uOjU2N2ZlMjFkYjBhNTRkY2ViNmUyZmQ5YjUyYzBiYmFjXzc0Nw_4f9ae054-1d1e-44f4-bca8-91922347847c">Property, Equipment and SoftwareProperty, equipment and software consists of the following (in thousands):&lt;div style="margin-bottom:9pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:73.806452%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.730205%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533138%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.730205%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2017&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Furniture and office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;656&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Lab equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;36,062&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;20,549&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;48,328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;17,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;32,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Property, equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;94,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;78,902&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Less accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(37,935)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(28,919)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Property, equipment and software, net&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;56,712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;49,983&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;Construction in progress at December 31, 2017 consisted of the costs incurred for the build-out of a manufacturing suite at the Company's headquarters building in Rockville, Maryland, which was completed in mid-2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;We had $0.6 million in property, equipment and software at December&#160;31, 2018 that was purchased in 2018 but was not paid for by year end.&#160; Property, equipment and software balance at December&#160;31, 2017 includes approximately $9.6 million in assets that were purchased in 2017 but were not paid for by year end.  Depreciation and amortization expense related to property, equipment and software for the years ended December&#160;31, 2018, 2017 and 2016 was $9.2 million, $7.0 million and $6.8 million, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82NDgvZnJhZzo1NjdmZTIxZGIwYTU0ZGNlYjZlMmZkOWI1MmMwYmJhYy90ZXh0cmVnaW9uOjU2N2ZlMjFkYjBhNTRkY2ViNmUyZmQ5YjUyYzBiYmFjXzE1OTQyOTE4NjAzNTg4_b4417821-d53c-4403-bbde-bf466aa99414">Property, equipment and software consists of the following (in thousands):&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:73.806452%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.730205%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533138%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.730205%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2017&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Furniture and office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;656&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Lab equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;36,062&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;20,549&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;48,328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;17,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;32,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Property, equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;94,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;78,902&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Less accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(37,935)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(28,919)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Property, equipment and software, net&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;56,712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;49,983&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i4f49a198b4bb493aad3c0563be1a1b1c_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82NDgvZnJhZzo1NjdmZTIxZGIwYTU0ZGNlYjZlMmZkOWI1MmMwYmJhYy90YWJsZTo0NTNjNzRkMjk5OGQ0ZDJlOGVhNTM1M2JiYzc5ZmM4Ni90YWJsZXJhbmdlOjQ1M2M3NGQyOTk4ZDRkMmU4ZWE1MzUzYmJjNzlmYzg2XzItMS0xLTEtMA_af3a0846-8e25-4e03-92ae-17fe5017dec3"
      unitRef="usd">2360000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="if008fb95c70d4d6292a3deb9038402f2_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82NDgvZnJhZzo1NjdmZTIxZGIwYTU0ZGNlYjZlMmZkOWI1MmMwYmJhYy90YWJsZTo0NTNjNzRkMjk5OGQ0ZDJlOGVhNTM1M2JiYzc5ZmM4Ni90YWJsZXJhbmdlOjQ1M2M3NGQyOTk4ZDRkMmU4ZWE1MzUzYmJjNzlmYzg2XzItMy0xLTEtMA_29d24c49-9979-4234-ac29-0511e58bda41"
      unitRef="usd">2261000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ia589fee494a140259bbf8dd10ad98449_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82NDgvZnJhZzo1NjdmZTIxZGIwYTU0ZGNlYjZlMmZkOWI1MmMwYmJhYy90YWJsZTo0NTNjNzRkMjk5OGQ0ZDJlOGVhNTM1M2JiYzc5ZmM4Ni90YWJsZXJhbmdlOjQ1M2M3NGQyOTk4ZDRkMmU4ZWE1MzUzYmJjNzlmYzg2XzMtMS0xLTEtMA_96d211f5-94cb-4fa2-a914-567558f4debb"
      unitRef="usd">7011000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ic4ae66e3b1a040229462cc9b00c106f7_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82NDgvZnJhZzo1NjdmZTIxZGIwYTU0ZGNlYjZlMmZkOWI1MmMwYmJhYy90YWJsZTo0NTNjNzRkMjk5OGQ0ZDJlOGVhNTM1M2JiYzc5ZmM4Ni90YWJsZXJhbmdlOjQ1M2M3NGQyOTk4ZDRkMmU4ZWE1MzUzYmJjNzlmYzg2XzMtMy0xLTEtMA_4253a701-561a-4c00-b3e5-ca0b37b45952"
      unitRef="usd">5111000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i989637b0c825400daad1d79fd200cfc7_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82NDgvZnJhZzo1NjdmZTIxZGIwYTU0ZGNlYjZlMmZkOWI1MmMwYmJhYy90YWJsZTo0NTNjNzRkMjk5OGQ0ZDJlOGVhNTM1M2JiYzc5ZmM4Ni90YWJsZXJhbmdlOjQ1M2M3NGQyOTk4ZDRkMmU4ZWE1MzUzYmJjNzlmYzg2XzQtMS0xLTEtMA_8f7faa3d-59dd-411a-9c0e-5646640d02c1"
      unitRef="usd">668000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i17b1fb07ad7e461f85ee4cfd5083f136_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82NDgvZnJhZzo1NjdmZTIxZGIwYTU0ZGNlYjZlMmZkOWI1MmMwYmJhYy90YWJsZTo0NTNjNzRkMjk5OGQ0ZDJlOGVhNTM1M2JiYzc5ZmM4Ni90YWJsZXJhbmdlOjQ1M2M3NGQyOTk4ZDRkMmU4ZWE1MzUzYmJjNzlmYzg2XzQtMy0xLTEtMA_3bf171d5-d1de-47fd-be3e-a316fd9f3ff4"
      unitRef="usd">656000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="iba7f249ad22445ea80c87ac974f09d4e_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82NDgvZnJhZzo1NjdmZTIxZGIwYTU0ZGNlYjZlMmZkOWI1MmMwYmJhYy90YWJsZTo0NTNjNzRkMjk5OGQ0ZDJlOGVhNTM1M2JiYzc5ZmM4Ni90YWJsZXJhbmdlOjQ1M2M3NGQyOTk4ZDRkMmU4ZWE1MzUzYmJjNzlmYzg2XzUtMS0xLTEtMA_e265dad4-c584-4926-a35e-cd1d4244afba"
      unitRef="usd">36062000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="id2ed58086aad4a0d93e3102ea5a382bc_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82NDgvZnJhZzo1NjdmZTIxZGIwYTU0ZGNlYjZlMmZkOWI1MmMwYmJhYy90YWJsZTo0NTNjNzRkMjk5OGQ0ZDJlOGVhNTM1M2JiYzc5ZmM4Ni90YWJsZXJhbmdlOjQ1M2M3NGQyOTk4ZDRkMmU4ZWE1MzUzYmJjNzlmYzg2XzUtMy0xLTEtMA_f49fe8d3-0d5a-4612-acd5-da4e883605c0"
      unitRef="usd">20549000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="id0aa3dc3a1594241a90d2f208fc88fcf_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82NDgvZnJhZzo1NjdmZTIxZGIwYTU0ZGNlYjZlMmZkOWI1MmMwYmJhYy90YWJsZTo0NTNjNzRkMjk5OGQ0ZDJlOGVhNTM1M2JiYzc5ZmM4Ni90YWJsZXJhbmdlOjQ1M2M3NGQyOTk4ZDRkMmU4ZWE1MzUzYmJjNzlmYzg2XzYtMS0xLTEtMA_751db86b-8ae1-4855-8de7-a80d405c3356"
      unitRef="usd">48328000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="iacc09d395c06412b8bc32c6bcf83092c_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82NDgvZnJhZzo1NjdmZTIxZGIwYTU0ZGNlYjZlMmZkOWI1MmMwYmJhYy90YWJsZTo0NTNjNzRkMjk5OGQ0ZDJlOGVhNTM1M2JiYzc5ZmM4Ni90YWJsZXJhbmdlOjQ1M2M3NGQyOTk4ZDRkMmU4ZWE1MzUzYmJjNzlmYzg2XzYtMy0xLTEtMA_a2553e87-61d3-47f0-b803-ca95ab7e683e"
      unitRef="usd">17525000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:ConstructionInProgressGross
      contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82NDgvZnJhZzo1NjdmZTIxZGIwYTU0ZGNlYjZlMmZkOWI1MmMwYmJhYy90YWJsZTo0NTNjNzRkMjk5OGQ0ZDJlOGVhNTM1M2JiYzc5ZmM4Ni90YWJsZXJhbmdlOjQ1M2M3NGQyOTk4ZDRkMmU4ZWE1MzUzYmJjNzlmYzg2XzctMS0xLTEtMA_d817ed3a-c36a-45c2-ba8c-c7f5d9f04854"
      unitRef="usd">218000</us-gaap:ConstructionInProgressGross>
    <us-gaap:ConstructionInProgressGross
      contextRef="i7057397719af459ca7328a1c440a0efa_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82NDgvZnJhZzo1NjdmZTIxZGIwYTU0ZGNlYjZlMmZkOWI1MmMwYmJhYy90YWJsZTo0NTNjNzRkMjk5OGQ0ZDJlOGVhNTM1M2JiYzc5ZmM4Ni90YWJsZXJhbmdlOjQ1M2M3NGQyOTk4ZDRkMmU4ZWE1MzUzYmJjNzlmYzg2XzctMy0xLTEtMA_05e911c0-4d3b-4b07-b56b-1a268764f832"
      unitRef="usd">32800000</us-gaap:ConstructionInProgressGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82NDgvZnJhZzo1NjdmZTIxZGIwYTU0ZGNlYjZlMmZkOWI1MmMwYmJhYy90YWJsZTo0NTNjNzRkMjk5OGQ0ZDJlOGVhNTM1M2JiYzc5ZmM4Ni90YWJsZXJhbmdlOjQ1M2M3NGQyOTk4ZDRkMmU4ZWE1MzUzYmJjNzlmYzg2XzgtMS0xLTEtMA_598db1ae-526e-436d-959a-e219bab86e96"
      unitRef="usd">94647000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i7057397719af459ca7328a1c440a0efa_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82NDgvZnJhZzo1NjdmZTIxZGIwYTU0ZGNlYjZlMmZkOWI1MmMwYmJhYy90YWJsZTo0NTNjNzRkMjk5OGQ0ZDJlOGVhNTM1M2JiYzc5ZmM4Ni90YWJsZXJhbmdlOjQ1M2M3NGQyOTk4ZDRkMmU4ZWE1MzUzYmJjNzlmYzg2XzgtMy0xLTEtMA_56b85f7f-9ebf-470e-b4c7-4563c33c2c91"
      unitRef="usd">78902000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82NDgvZnJhZzo1NjdmZTIxZGIwYTU0ZGNlYjZlMmZkOWI1MmMwYmJhYy90YWJsZTo0NTNjNzRkMjk5OGQ0ZDJlOGVhNTM1M2JiYzc5ZmM4Ni90YWJsZXJhbmdlOjQ1M2M3NGQyOTk4ZDRkMmU4ZWE1MzUzYmJjNzlmYzg2XzktMS0xLTEtMA_df80fcfe-3177-4d2b-862d-a6d67a961998"
      unitRef="usd">37935000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i7057397719af459ca7328a1c440a0efa_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82NDgvZnJhZzo1NjdmZTIxZGIwYTU0ZGNlYjZlMmZkOWI1MmMwYmJhYy90YWJsZTo0NTNjNzRkMjk5OGQ0ZDJlOGVhNTM1M2JiYzc5ZmM4Ni90YWJsZXJhbmdlOjQ1M2M3NGQyOTk4ZDRkMmU4ZWE1MzUzYmJjNzlmYzg2XzktMy0xLTEtMA_29fd7901-22a7-4770-9527-481a055253ab"
      unitRef="usd">28919000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82NDgvZnJhZzo1NjdmZTIxZGIwYTU0ZGNlYjZlMmZkOWI1MmMwYmJhYy90YWJsZTo0NTNjNzRkMjk5OGQ0ZDJlOGVhNTM1M2JiYzc5ZmM4Ni90YWJsZXJhbmdlOjQ1M2M3NGQyOTk4ZDRkMmU4ZWE1MzUzYmJjNzlmYzg2XzEwLTEtMS0xLTA_0933cd4b-b53e-4840-ba74-088150a88f74"
      unitRef="usd">56712000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i7057397719af459ca7328a1c440a0efa_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82NDgvZnJhZzo1NjdmZTIxZGIwYTU0ZGNlYjZlMmZkOWI1MmMwYmJhYy90YWJsZTo0NTNjNzRkMjk5OGQ0ZDJlOGVhNTM1M2JiYzc5ZmM4Ni90YWJsZXJhbmdlOjQ1M2M3NGQyOTk4ZDRkMmU4ZWE1MzUzYmJjNzlmYzg2XzEwLTMtMS0xLTA_821fcd96-164c-49a0-9e82-9dc774455349"
      unitRef="usd">49983000</us-gaap:PropertyPlantAndEquipmentNet>
    <mgnx:PropertyPlantAndEquipmentNonCashAdditions
      contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82NDgvZnJhZzo1NjdmZTIxZGIwYTU0ZGNlYjZlMmZkOWI1MmMwYmJhYy90ZXh0cmVnaW9uOjU2N2ZlMjFkYjBhNTRkY2ViNmUyZmQ5YjUyYzBiYmFjXzMzMg_8a2afb91-f6ba-40e0-9212-cfcda9fde4f5"
      unitRef="usd">600000</mgnx:PropertyPlantAndEquipmentNonCashAdditions>
    <mgnx:PropertyPlantAndEquipmentNonCashAdditions
      contextRef="i7057397719af459ca7328a1c440a0efa_I20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82NDgvZnJhZzo1NjdmZTIxZGIwYTU0ZGNlYjZlMmZkOWI1MmMwYmJhYy90ZXh0cmVnaW9uOjU2N2ZlMjFkYjBhNTRkY2ViNmUyZmQ5YjUyYzBiYmFjXzUyMg_805bd26e-abe0-43d0-96c5-188c8fddb43a"
      unitRef="usd">9600000</mgnx:PropertyPlantAndEquipmentNonCashAdditions>
    <us-gaap:Depreciation
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82NDgvZnJhZzo1NjdmZTIxZGIwYTU0ZGNlYjZlMmZkOWI1MmMwYmJhYy90ZXh0cmVnaW9uOjU2N2ZlMjFkYjBhNTRkY2ViNmUyZmQ5YjUyYzBiYmFjXzcxOQ_c71c791c-b771-45ea-9ee2-faef9811741f"
      unitRef="usd">9200000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82NDgvZnJhZzo1NjdmZTIxZGIwYTU0ZGNlYjZlMmZkOWI1MmMwYmJhYy90ZXh0cmVnaW9uOjU2N2ZlMjFkYjBhNTRkY2ViNmUyZmQ5YjUyYzBiYmFjXzcyMw_bbade065-0d06-4738-b072-7964907ec712"
      unitRef="usd">7000000.0</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="iaf5d0e8fdf374dc09283fd669e2ebf19_D20160101-20161231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82NDgvZnJhZzo1NjdmZTIxZGIwYTU0ZGNlYjZlMmZkOWI1MmMwYmJhYy90ZXh0cmVnaW9uOjU2N2ZlMjFkYjBhNTRkY2ViNmUyZmQ5YjUyYzBiYmFjXzczMA_994d06ea-854d-4b6b-ad70-050ae71ab48c"
      unitRef="usd">6800000</us-gaap:Depreciation>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82NjAvZnJhZzpiMTI4ZDRiZDkxZWQ0OTQ3OTk2OWMwMTRkYzJkMWViZC90ZXh0cmVnaW9uOmIxMjhkNGJkOTFlZDQ5NDc5OTY5YzAxNGRjMmQxZWJkXzE1OTQyOTE4NjEwMjc2_bdf75b16-2525-4bf0-8e13-0118e4cf59e3">Stockholders' Equity&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;&#160;The Company's amended and restated certificate of incorporation authorizes 125,000,000 shares of common stock, and 5,000,000 shares of undesignated preferred stock, both with a par value of $.01 per share.&#160;&#160;There were no shares of undesignated preferred stock issued or outstanding as of December&#160;31, 2018 or 2017.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;On April 26, 2017, the Company entered into a definitive agreement with an institutional healthcare investor to purchase 1,100,000 shares of its common stock at a purchase price of $21.50 per share in a registered direct offering. Proceeds to the Company, before deducting estimated offering expenses, were $23.7 million. The shares were offered pursuant to the Company&#x2019;s effective shelf registration on Form S-3 that was filed with the SEC on November 2, 2016.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;On May 3, 2017, the Company entered into a sales agreement with an agent to sell, from time to time, shares of its common stock having an aggregate sales price of up to $75.0 million through an &#x201c;at the market offering&#x201d; (ATM Offering) as defined in Rule 415 under the Securities Act of 1933, as amended.  The shares that may be sold under the sales agreement would be issued and sold pursuant to the Company's shelf registration statement on Form S-3 that was filed with the SEC on November 2, 2016. During the year ended December 31, 2017, the Company sold 599,284 shares of common stock resulting in net proceeds of $10.8 million related to the ATM Offering.&#160;&lt;/span&gt;&lt;/div&gt;On April 2, 2018, the Company completed a firm-commitment underwritten public offering, in which the Company sold 4,500,000 shares of its common stock at a price of $21.25 per share.  Additionally, the underwriters of the offering exercised the full amount of their over-allotment option resulting in the sale of an additional 675,000 shares of the Company's common stock at a price of $21.25 per share.  Upon closing, the Company received net proceeds of approximately $103.0&#160;million from this offering, net of underwriting discounts and commissions and other offering expenses.</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82NjAvZnJhZzpiMTI4ZDRiZDkxZWQ0OTQ3OTk2OWMwMTRkYzJkMWViZC90ZXh0cmVnaW9uOmIxMjhkNGJkOTFlZDQ5NDc5OTY5YzAxNGRjMmQxZWJkXzEwNQ_11bfcd29-dafa-4adf-8da4-4fed5321e518"
      unitRef="shares">125000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="iaaa703135e5d42e3ad357819a2febb2b_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82NjAvZnJhZzpiMTI4ZDRiZDkxZWQ0OTQ3OTk2OWMwMTRkYzJkMWViZC90ZXh0cmVnaW9uOmIxMjhkNGJkOTFlZDQ5NDc5OTY5YzAxNGRjMmQxZWJkXzEzNg_856c1a61-b365-48d6-b542-e60866daf6c1"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="iaaa703135e5d42e3ad357819a2febb2b_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82NjAvZnJhZzpiMTI4ZDRiZDkxZWQ0OTQ3OTk2OWMwMTRkYzJkMWViZC90ZXh0cmVnaW9uOmIxMjhkNGJkOTFlZDQ5NDc5OTY5YzAxNGRjMmQxZWJkXzIwNA_872a11c1-7245-4e8b-b5c8-000f711013d7"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesIssued
      contextRef="iaaa703135e5d42e3ad357819a2febb2b_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82NjAvZnJhZzpiMTI4ZDRiZDkxZWQ0OTQ3OTk2OWMwMTRkYzJkMWViZC90ZXh0cmVnaW9uOmIxMjhkNGJkOTFlZDQ5NDc5OTY5YzAxNGRjMmQxZWJkXzIzMA_2c79fea5-c16b-4826-bcbb-55c2d9417c2d"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i774ad7d035574588abdffa05896955f7_D20170426-20170426"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82NjAvZnJhZzpiMTI4ZDRiZDkxZWQ0OTQ3OTk2OWMwMTRkYzJkMWViZC90ZXh0cmVnaW9uOmIxMjhkNGJkOTFlZDQ5NDc5OTY5YzAxNGRjMmQxZWJkXzE3NTk_e0fa09fa-0178-4763-bb09-fab137e4dde8"
      unitRef="shares">1100000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="i300212ce6416414283af0aa5ceb5e231_I20170426"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82NjAvZnJhZzpiMTI4ZDRiZDkxZWQ0OTQ3OTk2OWMwMTRkYzJkMWViZC90ZXh0cmVnaW9uOmIxMjhkNGJkOTFlZDQ5NDc5OTY5YzAxNGRjMmQxZWJkXzE4MTI_d644d05a-1223-4933-b83d-0d64ed00ccb3"
      unitRef="usdPerShare">21.50</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i774ad7d035574588abdffa05896955f7_D20170426-20170426"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82NjAvZnJhZzpiMTI4ZDRiZDkxZWQ0OTQ3OTk2OWMwMTRkYzJkMWViZC90ZXh0cmVnaW9uOmIxMjhkNGJkOTFlZDQ5NDc5OTY5YzAxNGRjMmQxZWJkXzE5MzQ_b3e98758-046f-4e53-8ccf-a535b1a042b8"
      unitRef="usd">23700000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <mgnx:CommonStockMaximumAmountAvailableForIssuance
      contextRef="i1805f20c3a7b4d11b92ee3e187db18fe_D20170503-20170503"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82NjAvZnJhZzpiMTI4ZDRiZDkxZWQ0OTQ3OTk2OWMwMTRkYzJkMWViZC90ZXh0cmVnaW9uOmIxMjhkNGJkOTFlZDQ5NDc5OTY5YzAxNGRjMmQxZWJkXzIyNTA_8c01ebd9-72da-4dfb-95f8-cabeea8e2087"
      unitRef="usd">75000000.0</mgnx:CommonStockMaximumAmountAvailableForIssuance>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i1805f20c3a7b4d11b92ee3e187db18fe_D20170503-20170503"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82NjAvZnJhZzpiMTI4ZDRiZDkxZWQ0OTQ3OTk2OWMwMTRkYzJkMWViZC90ZXh0cmVnaW9uOmIxMjhkNGJkOTFlZDQ5NDc5OTY5YzAxNGRjMmQxZWJkXzI2MTI_d09428fe-2658-4349-8e06-0f97546a23a7"
      unitRef="shares">599284</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i1805f20c3a7b4d11b92ee3e187db18fe_D20170503-20170503"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82NjAvZnJhZzpiMTI4ZDRiZDkxZWQ0OTQ3OTk2OWMwMTRkYzJkMWViZC90ZXh0cmVnaW9uOmIxMjhkNGJkOTFlZDQ5NDc5OTY5YzAxNGRjMmQxZWJkXzI2Njc_497f4742-8d2b-4762-88ca-3eded4d8bdbd"
      unitRef="usd">10800000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="ie86be88df16c4586b769baf5bf4e5efe_D20180402-20180402"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82NjAvZnJhZzpiMTI4ZDRiZDkxZWQ0OTQ3OTk2OWMwMTRkYzJkMWViZC90ZXh0cmVnaW9uOmIxMjhkNGJkOTFlZDQ5NDc5OTY5YzAxNGRjMmQxZWJkXzI3NDg3NzkwNzU1NDM_383716c4-cf38-4b9f-8949-31e2ea5ff7a6"
      unitRef="shares">4500000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="ib0101bc440ae4fdeb05d3353b727f0aa_I20180402"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82NjAvZnJhZzpiMTI4ZDRiZDkxZWQ0OTQ3OTk2OWMwMTRkYzJkMWViZC90ZXh0cmVnaW9uOmIxMjhkNGJkOTFlZDQ5NDc5OTY5YzAxNGRjMmQxZWJkXzI3NDg3NzkwNzU1NjA_633b36ad-9b8f-4feb-9a41-e272103348cc"
      unitRef="usdPerShare">21.25</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="ic563779cd1db4959a683e3166bd53d26_D20180402-20180402"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82NjAvZnJhZzpiMTI4ZDRiZDkxZWQ0OTQ3OTk2OWMwMTRkYzJkMWViZC90ZXh0cmVnaW9uOmIxMjhkNGJkOTFlZDQ5NDc5OTY5YzAxNGRjMmQxZWJkXzI3NDg3NzkwNzU1Njk_0bbec367-3f8e-4fdd-818e-43dd5b2f3daa"
      unitRef="shares">675000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i0e9ac3017eb644d2bd213ae5a7dabd47_I20180402"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82NjAvZnJhZzpiMTI4ZDRiZDkxZWQ0OTQ3OTk2OWMwMTRkYzJkMWViZC90ZXh0cmVnaW9uOmIxMjhkNGJkOTFlZDQ5NDc5OTY5YzAxNGRjMmQxZWJkXzI3NDg3NzkwNzU1Nzc_18e80e15-2f46-44d7-a8f4-27ba5b8ba66e"
      unitRef="usdPerShare">21.25</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="ie86be88df16c4586b769baf5bf4e5efe_D20180402-20180402"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82NjAvZnJhZzpiMTI4ZDRiZDkxZWQ0OTQ3OTk2OWMwMTRkYzJkMWViZC90ZXh0cmVnaW9uOmIxMjhkNGJkOTFlZDQ5NDc5OTY5YzAxNGRjMmQxZWJkXzI3NDg3NzkwNzU1OTM_e46906ab-2b65-4844-bc42-bd5f30fd31bf"
      unitRef="usd">103000000.0</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90ZXh0cmVnaW9uOmI5MjNjYzI4YTQ4OTQ0ODg5ZWJhNTRkYjU5NTFkNjRhXzY1NTc_3ce78871-54a9-420c-a564-29dfb5040540">Stock-based Compensation&lt;div style="margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;In May 2017, the Company&#x2019;s stockholders approved the 2016 Employee Stock Purchase Plan (the 2016 ESPP). The 2016 ESPP is structured as a qualified employee stock purchase plan under Section 423 of the Internal Revenue Code of 1986, as amended, and is not subject to the provisions of the Employee Retirement Income Security Act of 1974.  The Company reserved 800,000 shares of common stock for issuance under the 2016 ESPP. The 2016 ESPP allows eligible employees to purchase shares of the Company&#x2019;s common stock at a discount through payroll deductions of up to 10% of their eligible compensation, subject to any plan limitations. The 2016 ESPP provides for six-month offering periods ending on May 31 and November 30 of each year.  At the end of each offering period, employees are able to purchase shares at 85% of the fair market&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt; value of the Company&#x2019;s common stock on the last day of the offering period.  During the year ended December&#160;31, 2018, employees purchased 44,862 shares of common stock under the 2016 ESPP for net proceeds to the Company of approximately $0.8 million.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;"&gt;Employee Stock Option Plans&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;Effective February 2003, the Company implemented the 2003 Equity Incentive Plan (2003 Plan), and it was amended and approved by the Company's stockholders in 2005. Stock options granted under the 2003 Plan may be either incentive stock options as defined by the Internal Revenue Code (IRC), or non-qualified stock options.  In 2013, the 2003 Plan was terminated, and no further awards may be issued under the plan.  Any shares of common stock subject to awards under the 2003 Plan that expire, terminate, or are otherwise surrendered, canceled, forfeited or repurchased without having been fully exercised, or resulting in any common stock being issued, will become available for issuance under the 2013 Stock Incentive Plan (2013 Plan), up to a specified number of shares.&#160; As of December&#160;31, 2018, under the 2003 Plan, there were options to purchase an aggregate of 746,803 shares of common stock outstanding at a weighted average exercise price of $2.03 per share.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;In October 2013, the Company implemented the 2013  Plan.&#160;&#160;The 2013 Plan provides for the grant of stock options and other stock-based awards, as well as cash-based performance awards. The aggregate number of shares of common stock initially available for issuance pursuant to awards under the 2013 Plan was 1,960,168 shares.&#160;&#160;The number of shares of common stock reserved for issuance will automatically increase on January 1 of each year from January 1, 2014 through and including January 1, 2023, by the lesser of (a) 1,960,168 shares, (b) 4.0% of the total number of shares of common stock outstanding on December 31 of the preceding calendar year, or (c) the number of shares of common stock determined by the Board of Directors. During the year ended December&#160;31, 2018, the maximum number of shares of common stock authorized to be issued by the Company under the 2013 Plan was increased to 8,244,131.&#160;&#160;If an option expires or terminates for any reason without having been fully exercised, if any shares of restricted stock are forfeited, or if any award terminates, expires or is settled without all or a portion of the shares of common stock covered by the award being issued, such shares are available for the grant of additional awards. However, any shares that are withheld (or delivered) to pay withholding taxes or to pay the exercise price of an option are not available for the grant of additional awards. As of December&#160;31, 2018, under the 2013 Plan, there were options to purchase an aggregate of 4,527,161 shares of common stock outstanding at a weighted average exercise price of $25.56 per share.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;The following stock-based compensation amounts were recognized for the periods indicated (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:61.343109%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.730205%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533138%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.730205%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533138%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.730205%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2016&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;General and administrative&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;16,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;14,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;"&gt;Employee Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model using the assumptions in the following table:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:61.343109%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.730205%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533138%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.730205%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533138%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.730205%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2016&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;68% - 72%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;67% - 68%&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;64% - 69%&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.4% - 3.1%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.9% - 2.3%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.2% - 2.4%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6.25 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6.25 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6.25 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;"&gt;Expected Dividend Yield&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt; &#x2013; The Company has never declared or paid dividends and has no plans to do so in the foreseeable future.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;"&gt;Expected Volatility&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt; &#x2013; Volatility is a measure of the amount by which a financial variable such as a share price has fluctuated (historical volatility) or is expected to fluctuate (expected volatility) during a period.&#160;&#160;As the Company does not yet have sufficient history of its own volatility, the Company has identified several public entities of similar size, complexity and stage of development and estimates volatility based on the volatility of these companies.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;"&gt;Risk-Free Interest Rate&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt; &#x2013; This is the U.S. Treasury rate for the week of each option grant during the year, having a term that most closely resembles the expected life of the option.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;"&gt;Expected Term&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt; &#x2013; This is the period of time that the options granted are expected to remain unexercised. Options granted have a maximum term of ten years. The Company uses a simplified method to calculate the average expected term.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;In addition to the assumptions above, the Company estimates the forfeiture rate based on turnover data with further consideration given to the class of the employees to whom the options were granted.&#160;&#160;The forfeiture rate is the estimated percentage of options granted that is expected to be forfeited or canceled on an annual basis before becoming fully vested.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;The following table summarizes stock option activity for 2018:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:48.807636%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.747430%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534214%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.747430%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534214%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.747430%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534214%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.747430%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;"&gt;Weighted-Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;"&gt;Exercise Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;"&gt;Weighted-Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;"&gt;Contractual Term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;"&gt;(Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;"&gt;Aggregate Intrinsic Value&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Outstanding, December 31, 2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,504,642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;19.79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,269,844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;27.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(285,432)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Forfeited or expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(215,090)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;24.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Outstanding, December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,273,964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;22.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,969&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2018:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Exercisable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,544,139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;20.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,969&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Vested and expected to vest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,086,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;22.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,969&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;During 2018, 2017 and 2016 the Company issued 274,362, 253,036 and 526,715 net shares of common stock, respectively, in conjunction with stock option exercises.&#160;&#160;The Company received cash proceeds from the exercise of stock options of approximately $0.9 million, $0.5 million and $1.9 million during 2018, 2017 and 2016, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;The weighted-average grant-date fair value of options granted during 2018, 2017 and 2016 was $17.90, $12.53 and $15.17 per share, respectively. The total intrinsic value of options exercised during 2018, 2017 and 2016 was approximately $5.2 million, $4.2 million and $10.8 million, respectively.&#160;&#160;The total fair value of stock options which vested during 2018, 2017 and 2016 was $16.4 million, $14.6 million and $11.6 million, respectively.&#160;&#160;As of December&#160;31, 2018, the total unrecognized compensation expense related to non-vested stock options, net of related forfeiture estimates, was $24.2 million, which the Company expects to recognize over a weighted-average period of approximately 2.6 years.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i37bd3dc2e0684382887e9c7141114e64_I20170518"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90ZXh0cmVnaW9uOmI5MjNjYzI4YTQ4OTQ0ODg5ZWJhNTRkYjU5NTFkNjRhXzQyMg_54c4f2c6-f662-4d0d-bf0b-f413a8acc638"
      unitRef="shares">800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <mgnx:EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent
      contextRef="i225dfbff0423412ab9af487587a7a9dc_D20170501-20170531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90ZXh0cmVnaW9uOmI5MjNjYzI4YTQ4OTQ0ODg5ZWJhNTRkYjU5NTFkNjRhXzYyMQ_b7c36614-3835-4687-bda3-0e90711360ba"
      unitRef="number">0.10</mgnx:EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="i225dfbff0423412ab9af487587a7a9dc_D20170501-20170531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90ZXh0cmVnaW9uOmI5MjNjYzI4YTQ4OTQ0ODg5ZWJhNTRkYjU5NTFkNjRhXzg2OA_a3ff23a3-5cc9-44b2-937c-ad33052d8c80"
      unitRef="number">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="ice18cbfc8512491798f071290230dc95_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90ZXh0cmVnaW9uOmI5MjNjYzI4YTQ4OTQ0ODg5ZWJhNTRkYjU5NTFkNjRhXzEwMTM_9c4d3ae9-90ce-4e14-bba9-b51dd594694b"
      unitRef="shares">44862</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="ice18cbfc8512491798f071290230dc95_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90ZXh0cmVnaW9uOmI5MjNjYzI4YTQ4OTQ0ODg5ZWJhNTRkYjU5NTFkNjRhXzExMDg_230f65e6-d670-4bcc-b9f1-d76b966d11f5"
      unitRef="usd">800000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i0a9a71bb02554506a053e4b037c5a59c_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90ZXh0cmVnaW9uOmI5MjNjYzI4YTQ4OTQ0ODg5ZWJhNTRkYjU5NTFkNjRhXzIyNzM_5f711b81-4bbf-4d49-96e2-f6a6f5bd6c12"
      unitRef="shares">746803</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i0a9a71bb02554506a053e4b037c5a59c_I20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90ZXh0cmVnaW9uOmI5MjNjYzI4YTQ4OTQ0ODg5ZWJhNTRkYjU5NTFkNjRhXzIzNTE_1afbf72e-e976-44af-a8f0-1a15f86a5868"
      unitRef="usdPerShare">2.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i88e7a08234064f55a3fdcac46083d417_I20131031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90ZXh0cmVnaW9uOmI5MjNjYzI4YTQ4OTQ0ODg5ZWJhNTRkYjU5NTFkNjRhXzI2NzM_3ff16964-e807-440d-b486-1dd09a75d225"
      unitRef="shares">1960168</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <mgnx:CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance
      contextRef="ie68e03dfcb1349ea9e266215200f7c25_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90ZXh0cmVnaW9uOmI5MjNjYzI4YTQ4OTQ0ODg5ZWJhNTRkYjU5NTFkNjRhXzI4Nzk_405bdded-333b-4f9f-a232-86d0ad64b287"
      unitRef="shares">1960168</mgnx:CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance>
    <mgnx:PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan
      contextRef="ibb0c6525ae294173b7c08c959023d2af_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90ZXh0cmVnaW9uOmI5MjNjYzI4YTQ4OTQ0ODg5ZWJhNTRkYjU5NTFkNjRhXzI4OTQ_cc61b7ea-f6ef-4862-9b45-7aefd9ebb6f4"
      unitRef="number">0.040</mgnx:PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan>
    <mgnx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease
      contextRef="ibb0c6525ae294173b7c08c959023d2af_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90ZXh0cmVnaW9uOmI5MjNjYzI4YTQ4OTQ0ODg5ZWJhNTRkYjU5NTFkNjRhXzMyMzE_792241e7-848e-4fae-a17a-b0535b6c0fd1"
      unitRef="shares">8244131</mgnx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ie68e03dfcb1349ea9e266215200f7c25_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90ZXh0cmVnaW9uOmI5MjNjYzI4YTQ4OTQ0ODg5ZWJhNTRkYjU5NTFkNjRhXzM4MjY_fa3dcbc5-4c03-4624-87ab-5398bf52c274"
      unitRef="shares">4527161</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ie68e03dfcb1349ea9e266215200f7c25_I20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90ZXh0cmVnaW9uOmI5MjNjYzI4YTQ4OTQ0ODg5ZWJhNTRkYjU5NTFkNjRhXzM5MDQ_09d2fec4-fae7-4bd2-8af1-532be5fa5483"
      unitRef="usdPerShare">25.56</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90ZXh0cmVnaW9uOmI5MjNjYzI4YTQ4OTQ0ODg5ZWJhNTRkYjU5NTFkNjRhXzE1OTQyOTE4NjEwNTc2_52d94200-b75a-4552-9b7f-67045a21f3a8">&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;The following stock-based compensation amounts were recognized for the periods indicated (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:61.343109%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.730205%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533138%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.730205%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533138%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.730205%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2016&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;General and administrative&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;16,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;14,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i080c9b1552014463931d10056bb7ec5b_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90YWJsZTplNGJlNDg5YmU5Yzk0YjUzOWI1NWY5M2RjNWQ0ZDFmNS90YWJsZXJhbmdlOmU0YmU0ODliZTljOTRiNTM5YjU1ZjkzZGM1ZDRkMWY1XzMtMS0xLTEtMA_5daadb42-ecb0-423f-8904-44100e0c1830"
      unitRef="usd">7919000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i69306bd3d52e4181a64ce4721f855103_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90YWJsZTplNGJlNDg5YmU5Yzk0YjUzOWI1NWY5M2RjNWQ0ZDFmNS90YWJsZXJhbmdlOmU0YmU0ODliZTljOTRiNTM5YjU1ZjkzZGM1ZDRkMWY1XzMtMy0xLTEtMA_7412e917-1466-4c3e-9d01-13bfc2e43d5c"
      unitRef="usd">7388000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i0d5ecf2823e14c18aa6e251ac3292d51_D20160101-20161231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90YWJsZTplNGJlNDg5YmU5Yzk0YjUzOWI1NWY5M2RjNWQ0ZDFmNS90YWJsZXJhbmdlOmU0YmU0ODliZTljOTRiNTM5YjU1ZjkzZGM1ZDRkMWY1XzMtNS0xLTEtMA_167f1052-42eb-4f99-8c3c-d77d3919c77d"
      unitRef="usd">5778000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i39e8ac06cdc74d939adfabe112ffd6a7_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90YWJsZTplNGJlNDg5YmU5Yzk0YjUzOWI1NWY5M2RjNWQ0ZDFmNS90YWJsZXJhbmdlOmU0YmU0ODliZTljOTRiNTM5YjU1ZjkzZGM1ZDRkMWY1XzQtMS0xLTEtMA_5176725b-0065-45a5-a02b-498f13108755"
      unitRef="usd">8601000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i0c6d01ca77d7471c9706048782093e73_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90YWJsZTplNGJlNDg5YmU5Yzk0YjUzOWI1NWY5M2RjNWQ0ZDFmNS90YWJsZXJhbmdlOmU0YmU0ODliZTljOTRiNTM5YjU1ZjkzZGM1ZDRkMWY1XzQtMy0xLTEtMA_5470205d-6301-4323-ae2d-981f65b74da3"
      unitRef="usd">7356000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i4f0c15f62cd64843837881b925628364_D20160101-20161231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90YWJsZTplNGJlNDg5YmU5Yzk0YjUzOWI1NWY5M2RjNWQ0ZDFmNS90YWJsZXJhbmdlOmU0YmU0ODliZTljOTRiNTM5YjU1ZjkzZGM1ZDRkMWY1XzQtNS0xLTEtMA_a610e328-a651-4a61-852b-9a910de2493c"
      unitRef="usd">6387000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90YWJsZTplNGJlNDg5YmU5Yzk0YjUzOWI1NWY5M2RjNWQ0ZDFmNS90YWJsZXJhbmdlOmU0YmU0ODliZTljOTRiNTM5YjU1ZjkzZGM1ZDRkMWY1XzUtMS0xLTEtMA_efc6d388-aa94-4fc8-b24a-325a9dfdba20"
      unitRef="usd">16520000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90YWJsZTplNGJlNDg5YmU5Yzk0YjUzOWI1NWY5M2RjNWQ0ZDFmNS90YWJsZXJhbmdlOmU0YmU0ODliZTljOTRiNTM5YjU1ZjkzZGM1ZDRkMWY1XzUtMy0xLTEtMA_b83d376b-98fb-44de-b1ba-2aa1f4e4b916"
      unitRef="usd">14744000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iaf5d0e8fdf374dc09283fd669e2ebf19_D20160101-20161231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90YWJsZTplNGJlNDg5YmU5Yzk0YjUzOWI1NWY5M2RjNWQ0ZDFmNS90YWJsZXJhbmdlOmU0YmU0ODliZTljOTRiNTM5YjU1ZjkzZGM1ZDRkMWY1XzUtNS0xLTEtMA_44d88ff9-c8e6-4945-bb6d-bdfd38f61e03"
      unitRef="usd">12165000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90ZXh0cmVnaW9uOmI5MjNjYzI4YTQ4OTQ0ODg5ZWJhNTRkYjU5NTFkNjRhXzE1OTQyOTE4NjEwNTc3_1b4e803f-411a-4b3e-8186-16b4f89b0ec1">&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model using the assumptions in the following table:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:61.343109%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.730205%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533138%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.730205%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533138%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.730205%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2016&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;68% - 72%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;67% - 68%&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;64% - 69%&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.4% - 3.1%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.9% - 2.3%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.2% - 2.4%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6.25 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6.25 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6.25 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90YWJsZTplNGJmMTc5OWVmYWM0NjVkOTRiYWI5ZWE1ZDRkMWVlNS90YWJsZXJhbmdlOmU0YmYxNzk5ZWZhYzQ2NWQ5NGJhYjllYTVkNGQxZWU1XzItMS0xLTEtMA_eee94b73-b3bb-4ef3-bc75-70005328f53c"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90YWJsZTplNGJmMTc5OWVmYWM0NjVkOTRiYWI5ZWE1ZDRkMWVlNS90YWJsZXJhbmdlOmU0YmYxNzk5ZWZhYzQ2NWQ5NGJhYjllYTVkNGQxZWU1XzItMy0xLTEtMA_e8e2beea-ed20-4843-8b86-113c0a904d30"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="iaf5d0e8fdf374dc09283fd669e2ebf19_D20160101-20161231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90YWJsZTplNGJmMTc5OWVmYWM0NjVkOTRiYWI5ZWE1ZDRkMWVlNS90YWJsZXJhbmdlOmU0YmYxNzk5ZWZhYzQ2NWQ5NGJhYjllYTVkNGQxZWU1XzItNS0xLTEtMA_ae47d61a-c93a-45fe-8e1a-8c72e509ced2"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90YWJsZTplNGJmMTc5OWVmYWM0NjVkOTRiYWI5ZWE1ZDRkMWVlNS90YWJsZXJhbmdlOmU0YmYxNzk5ZWZhYzQ2NWQ5NGJhYjllYTVkNGQxZWU1XzUtMS0xLTEtMA_326baf22-02dc-4142-90bf-9d66779903f4">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90YWJsZTplNGJmMTc5OWVmYWM0NjVkOTRiYWI5ZWE1ZDRkMWVlNS90YWJsZXJhbmdlOmU0YmYxNzk5ZWZhYzQ2NWQ5NGJhYjllYTVkNGQxZWU1XzUtMy0xLTEtMA_ac99f4c0-e593-4f7b-b7bc-8910b19606c4">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="iaf5d0e8fdf374dc09283fd669e2ebf19_D20160101-20161231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90YWJsZTplNGJmMTc5OWVmYWM0NjVkOTRiYWI5ZWE1ZDRkMWVlNS90YWJsZXJhbmdlOmU0YmYxNzk5ZWZhYzQ2NWQ5NGJhYjllYTVkNGQxZWU1XzUtNS0xLTEtMA_e86b0c4d-7758-4300-a010-be62409d3ddb">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="i4cee00b7a03d43ceb837d6f99f3c2a60_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90ZXh0cmVnaW9uOmI5MjNjYzI4YTQ4OTQ0ODg5ZWJhNTRkYjU5NTFkNjRhXzUxMzk_076fbb78-8d1e-410a-a55b-719803b79a4b">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <mgnx:ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90ZXh0cmVnaW9uOmI5MjNjYzI4YTQ4OTQ0ODg5ZWJhNTRkYjU5NTFkNjRhXzE1OTQyOTE4NjEwNTc4_0f4c68ba-e487-4c98-b96b-ded6ff2512e4">&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;The following table summarizes stock option activity for 2018:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:48.807636%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.747430%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534214%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.747430%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534214%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.747430%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534214%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.747430%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;"&gt;Weighted-Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;"&gt;Exercise Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;"&gt;Weighted-Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;"&gt;Contractual Term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;"&gt;(Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;"&gt;Aggregate Intrinsic Value&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Outstanding, December 31, 2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,504,642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;19.79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,269,844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;27.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(285,432)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Forfeited or expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(215,090)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;24.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Outstanding, December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,273,964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;22.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,969&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2018:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Exercisable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,544,139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;20.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,969&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Vested and expected to vest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,086,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;22.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,969&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</mgnx:ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i7057397719af459ca7328a1c440a0efa_I20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90YWJsZTo5ZWE1OTM0ZjYzOWI0ZGNmOTJlMTE5NWQxMzZhYzY1Ny90YWJsZXJhbmdlOjllYTU5MzRmNjM5YjRkY2Y5MmUxMTk1ZDEzNmFjNjU3XzEtMS0xLTEtMA_65bec360-499c-4acb-8485-29ead08b12ae"
      unitRef="shares">4504642</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i7057397719af459ca7328a1c440a0efa_I20171231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90YWJsZTo5ZWE1OTM0ZjYzOWI0ZGNmOTJlMTE5NWQxMzZhYzY1Ny90YWJsZXJhbmdlOjllYTU5MzRmNjM5YjRkY2Y5MmUxMTk1ZDEzNmFjNjU3XzEtMy0xLTEtMA_3383bfd8-28ce-4793-a4cb-52fef72db918"
      unitRef="usdPerShare">19.79</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90YWJsZTo5ZWE1OTM0ZjYzOWI0ZGNmOTJlMTE5NWQxMzZhYzY1Ny90YWJsZXJhbmdlOjllYTU5MzRmNjM5YjRkY2Y5MmUxMTk1ZDEzNmFjNjU3XzEtNS0xLTEtMA_1cc2aed6-7348-4fe3-aeff-f458ef9a1aa8">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90YWJsZTo5ZWE1OTM0ZjYzOWI0ZGNmOTJlMTE5NWQxMzZhYzY1Ny90YWJsZXJhbmdlOjllYTU5MzRmNjM5YjRkY2Y5MmUxMTk1ZDEzNmFjNjU3XzItMS0xLTEtMA_ae74c6a7-19a7-4094-aee2-5649b9a14bd1"
      unitRef="shares">1269844</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90YWJsZTo5ZWE1OTM0ZjYzOWI0ZGNmOTJlMTE5NWQxMzZhYzY1Ny90YWJsZXJhbmdlOjllYTU5MzRmNjM5YjRkY2Y5MmUxMTk1ZDEzNmFjNjU3XzItMy0xLTEtMA_8cf0393b-fd61-48b0-a3cf-e39845fa6cda"
      unitRef="usdPerShare">27.18</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90YWJsZTo5ZWE1OTM0ZjYzOWI0ZGNmOTJlMTE5NWQxMzZhYzY1Ny90YWJsZXJhbmdlOjllYTU5MzRmNjM5YjRkY2Y5MmUxMTk1ZDEzNmFjNjU3XzMtMS0xLTEtMA_607aab0e-4778-4fbe-9021-e7777cb79db8"
      unitRef="shares">285432</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90YWJsZTo5ZWE1OTM0ZjYzOWI0ZGNmOTJlMTE5NWQxMzZhYzY1Ny90YWJsZXJhbmdlOjllYTU5MzRmNjM5YjRkY2Y5MmUxMTk1ZDEzNmFjNjU3XzMtMy0xLTEtMA_32b72eb0-9356-46fb-a13f-b9055a004d4b"
      unitRef="usdPerShare">4.22</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90YWJsZTo5ZWE1OTM0ZjYzOWI0ZGNmOTJlMTE5NWQxMzZhYzY1Ny90YWJsZXJhbmdlOjllYTU5MzRmNjM5YjRkY2Y5MmUxMTk1ZDEzNmFjNjU3XzQtMS0xLTEtMA_f0c11b58-2a51-43c5-b9d0-b77d3485f314"
      unitRef="shares">215090</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90YWJsZTo5ZWE1OTM0ZjYzOWI0ZGNmOTJlMTE5NWQxMzZhYzY1Ny90YWJsZXJhbmdlOjllYTU5MzRmNjM5YjRkY2Y5MmUxMTk1ZDEzNmFjNjU3XzQtMy0xLTEtMA_81d62785-576e-4dcd-928f-6e76ad444c4a"
      unitRef="usdPerShare">24.43</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90YWJsZTo5ZWE1OTM0ZjYzOWI0ZGNmOTJlMTE5NWQxMzZhYzY1Ny90YWJsZXJhbmdlOjllYTU5MzRmNjM5YjRkY2Y5MmUxMTk1ZDEzNmFjNjU3XzUtMS0xLTEtMA_a02696da-dd19-4ca6-ba17-812c878babba"
      unitRef="shares">5273964</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90YWJsZTo5ZWE1OTM0ZjYzOWI0ZGNmOTJlMTE5NWQxMzZhYzY1Ny90YWJsZXJhbmdlOjllYTU5MzRmNjM5YjRkY2Y5MmUxMTk1ZDEzNmFjNjU3XzUtMy0xLTEtMA_c842b2a2-77cb-4efd-96db-fff9b85a520a"
      unitRef="usdPerShare">22.23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90YWJsZTo5ZWE1OTM0ZjYzOWI0ZGNmOTJlMTE5NWQxMzZhYzY1Ny90YWJsZXJhbmdlOjllYTU5MzRmNjM5YjRkY2Y5MmUxMTk1ZDEzNmFjNjU3XzUtNS0xLTEtMA_04901d3f-9017-4f95-b162-615e3ce53491">P6Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90YWJsZTo5ZWE1OTM0ZjYzOWI0ZGNmOTJlMTE5NWQxMzZhYzY1Ny90YWJsZXJhbmdlOjllYTU5MzRmNjM5YjRkY2Y5MmUxMTk1ZDEzNmFjNjU3XzUtNy0xLTEtMA_d9aa3357-043a-4b52-bb07-24d7ba23f729"
      unitRef="usd">7969000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90YWJsZTo5ZWE1OTM0ZjYzOWI0ZGNmOTJlMTE5NWQxMzZhYzY1Ny90YWJsZXJhbmdlOjllYTU5MzRmNjM5YjRkY2Y5MmUxMTk1ZDEzNmFjNjU3XzgtMS0xLTEtMA_cd46334b-efe6-4761-b1c6-44a6b70a46dc"
      unitRef="shares">3544139</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90YWJsZTo5ZWE1OTM0ZjYzOWI0ZGNmOTJlMTE5NWQxMzZhYzY1Ny90YWJsZXJhbmdlOjllYTU5MzRmNjM5YjRkY2Y5MmUxMTk1ZDEzNmFjNjU3XzgtMy0xLTEtMA_dd159f59-3cd0-4d65-8fa8-bb519f28cf8d"
      unitRef="usdPerShare">20.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90YWJsZTo5ZWE1OTM0ZjYzOWI0ZGNmOTJlMTE5NWQxMzZhYzY1Ny90YWJsZXJhbmdlOjllYTU5MzRmNjM5YjRkY2Y5MmUxMTk1ZDEzNmFjNjU3XzgtNS0xLTEtMA_6a1fa66f-7dc6-4cb7-b6ab-2431a39dae26">P5Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90YWJsZTo5ZWE1OTM0ZjYzOWI0ZGNmOTJlMTE5NWQxMzZhYzY1Ny90YWJsZXJhbmdlOjllYTU5MzRmNjM5YjRkY2Y5MmUxMTk1ZDEzNmFjNjU3XzgtNy0xLTEtMA_955049f2-260d-4477-abfc-5675114fcce0"
      unitRef="usd">7969000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90YWJsZTo5ZWE1OTM0ZjYzOWI0ZGNmOTJlMTE5NWQxMzZhYzY1Ny90YWJsZXJhbmdlOjllYTU5MzRmNjM5YjRkY2Y5MmUxMTk1ZDEzNmFjNjU3XzktMS0xLTEtMA_a121c927-ff7d-4828-ad4f-9d6f779c3f87"
      unitRef="shares">5086009</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90YWJsZTo5ZWE1OTM0ZjYzOWI0ZGNmOTJlMTE5NWQxMzZhYzY1Ny90YWJsZXJhbmdlOjllYTU5MzRmNjM5YjRkY2Y5MmUxMTk1ZDEzNmFjNjU3XzktMy0xLTEtMA_99227824-6ebd-4a3d-a1fd-c4dde6f10dbd"
      unitRef="usdPerShare">22.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90YWJsZTo5ZWE1OTM0ZjYzOWI0ZGNmOTJlMTE5NWQxMzZhYzY1Ny90YWJsZXJhbmdlOjllYTU5MzRmNjM5YjRkY2Y5MmUxMTk1ZDEzNmFjNjU3XzktNS0xLTEtMA_d03462e9-564b-42ec-ac2a-f746fefe356a">P6Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90YWJsZTo5ZWE1OTM0ZjYzOWI0ZGNmOTJlMTE5NWQxMzZhYzY1Ny90YWJsZXJhbmdlOjllYTU5MzRmNjM5YjRkY2Y5MmUxMTk1ZDEzNmFjNjU3XzktNy0xLTEtMA_431f338a-a247-466b-ae2b-7ae33b44bd3f"
      unitRef="usd">7969000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90ZXh0cmVnaW9uOmI5MjNjYzI4YTQ4OTQ0ODg5ZWJhNTRkYjU5NTFkNjRhXzU3MjA_d363e164-e7e1-4d33-97f2-394e508f3e4c"
      unitRef="shares">274362</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90ZXh0cmVnaW9uOmI5MjNjYzI4YTQ4OTQ0ODg5ZWJhNTRkYjU5NTFkNjRhXzU3MjQ_ce0d48cf-53c3-4383-8ec6-d93c8b2b4dd7"
      unitRef="shares">253036</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="iaf5d0e8fdf374dc09283fd669e2ebf19_D20160101-20161231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90ZXh0cmVnaW9uOmI5MjNjYzI4YTQ4OTQ0ODg5ZWJhNTRkYjU5NTFkNjRhXzU3MzE_040c7c50-8f3e-4819-b2fd-5ed2056a2c68"
      unitRef="shares">526715</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90ZXh0cmVnaW9uOmI5MjNjYzI4YTQ4OTQ0ODg5ZWJhNTRkYjU5NTFkNjRhXzU5MjM_5c37b79b-f01a-405f-9a6b-d484efb2a9ee"
      unitRef="usd">900000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90ZXh0cmVnaW9uOmI5MjNjYzI4YTQ4OTQ0ODg5ZWJhNTRkYjU5NTFkNjRhXzU5Mjc_9f117940-a6cd-4530-904e-1b161f1beaf6"
      unitRef="usd">500000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="iaf5d0e8fdf374dc09283fd669e2ebf19_D20160101-20161231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90ZXh0cmVnaW9uOmI5MjNjYzI4YTQ4OTQ0ODg5ZWJhNTRkYjU5NTFkNjRhXzU5MzQ_5ded3c2b-f057-4216-9f18-6bb4e5ac588c"
      unitRef="usd">1900000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90ZXh0cmVnaW9uOmI5MjNjYzI4YTQ4OTQ0ODg5ZWJhNTRkYjU5NTFkNjRhXzYwNjE_83259ea1-15c7-4165-8a36-c1f72578bf56"
      unitRef="usdPerShare">17.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90ZXh0cmVnaW9uOmI5MjNjYzI4YTQ4OTQ0ODg5ZWJhNTRkYjU5NTFkNjRhXzYwNjU_00f7462f-98e4-499f-9607-fe72d3a1c4f6"
      unitRef="usdPerShare">12.53</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="iaf5d0e8fdf374dc09283fd669e2ebf19_D20160101-20161231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90ZXh0cmVnaW9uOmI5MjNjYzI4YTQ4OTQ0ODg5ZWJhNTRkYjU5NTFkNjRhXzYwNzI_459212ec-6523-4b40-ba3a-4c1d9495569e"
      unitRef="usdPerShare">15.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90ZXh0cmVnaW9uOmI5MjNjYzI4YTQ4OTQ0ODg5ZWJhNTRkYjU5NTFkNjRhXzYxODY_7f9f3c29-6eb4-438d-bacd-4c5f208521cb"
      unitRef="usd">5200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90ZXh0cmVnaW9uOmI5MjNjYzI4YTQ4OTQ0ODg5ZWJhNTRkYjU5NTFkNjRhXzYxOTA_a8fed63a-5178-4d22-bf91-9af5ea89be71"
      unitRef="usd">4200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="iaf5d0e8fdf374dc09283fd669e2ebf19_D20160101-20161231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90ZXh0cmVnaW9uOmI5MjNjYzI4YTQ4OTQ0ODg5ZWJhNTRkYjU5NTFkNjRhXzYxOTc_910a6138-e4a8-40fc-8315-3d236b207e38"
      unitRef="usd">10800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90ZXh0cmVnaW9uOmI5MjNjYzI4YTQ4OTQ0ODg5ZWJhNTRkYjU5NTFkNjRhXzYyOTI_dbbb5697-1c4b-4a4d-a324-34e771ab6fb4"
      unitRef="usd">16400000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90ZXh0cmVnaW9uOmI5MjNjYzI4YTQ4OTQ0ODg5ZWJhNTRkYjU5NTFkNjRhXzYyOTY_1380bdde-b51f-43c2-8020-17f3dc854106"
      unitRef="usd">14600000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="iaf5d0e8fdf374dc09283fd669e2ebf19_D20160101-20161231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90ZXh0cmVnaW9uOmI5MjNjYzI4YTQ4OTQ0ODg5ZWJhNTRkYjU5NTFkNjRhXzYzMDM_938eb0d9-ff75-49c1-9d8b-5e8da8ffaa03"
      unitRef="usd">11600000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90ZXh0cmVnaW9uOmI5MjNjYzI4YTQ4OTQ0ODg5ZWJhNTRkYjU5NTFkNjRhXzY0NjM_19ab1f51-089b-4235-a2be-b4274d3ee210"
      unitRef="usd">24200000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF82ODUvZnJhZzpiOTIzY2MyOGE0ODk0NDg4OWViYTU0ZGI1OTUxZDY0YS90ZXh0cmVnaW9uOmI5MjNjYzI4YTQ4OTQ0ODg5ZWJhNTRkYjU5NTFkNjRhXzY1NTQ_ef378ce7-db3a-4c15-ad95-b157e0df3029">P2Y7M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90ZXh0cmVnaW9uOmI0ZjY4YmIzMzBkMzRkMWZiM2QyZDdiYjQ5YmI3ZWM5XzQ3MzI_7e443723-df68-4078-abfb-132378f36db8">Income Taxes&#160;For the years ended December&#160;31, 2018, 2017 and 2016 there was no provision for income taxes due to taxable losses generated, fully offset by a valuation allowance.&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;The significant components of the Company's deferred income tax assets (liabilities) were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:73.806452%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.730205%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533138%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.730205%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2017&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Deferred income tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Federal U.S. net operating loss carryforward&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;87,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;50,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;State net operating loss carryforward&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;22,809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Research and development credit, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;29,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;21,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Orphan drug credit, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;22,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;21,708&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Deferred rent&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,385&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,982&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;155&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gross deferred income tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;176,131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;113,258&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(172,457)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(112,453)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net deferred income tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;805&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Deferred income tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1,911)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Prepaid expenditures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1,763)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(805)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gross deferred income tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(3,674)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(805)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net deferred income tax asset/(liability)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;"&gt;The Company recognizes valuation allowances to reduce deferred tax assets to the amount that is more likely than not to be realized. In assessing the likelihood of realization, management considers (i) future reversals of existing taxable temporary differences; (ii) future taxable income exclusive of reversing temporary difference and carryforwards; (iii) taxable income in prior carryback years if carryback is permitted under applicable tax law; and (iv) tax planning strategies. The Company's net deferred income tax asset is not more likely than not to be utilized due to the lack of sufficient sources of future taxable income and cumulative book losses which have resulted over the years. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;"&gt;As of December&#160;31, 2018, the Company has U.S. federal and state net operating loss (NOL) carryforwards of approximately $415.6 million.  Of these NOLs, $237.8 million&#160;will expire in various years beginning in 2025 through 2037. $177.8 million of NOLs were generated post&#160;December 31, 2017 and carryforward indefinitely.  In addition, the Company has U.S. federal tax credits of $52.3 million which will expire in various years beginning in 2022 through 2038.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;The use of the Company's U.S. federal NOL and tax credit carryforwards in future years are restricted due to changes in the Company's ownership and tax attributes acquired through the Company's acquisitions. As of December&#160;31, 2018, $13.5 million of the Company's U.S. Federal NOLs are limited for use over the years 2019 &#x2013; 2028 in which a range of such amounts could be utilized on an annual basis of $0.2 million to $1.4 million. The remaining $402.1 million of NOLs is not limited and can be offset against future taxable income, subject to certain limitations for newly enacted tax legislation.  The Company adopted ASU 2016-09 as of January 1, 2017.  Accordingly, the Company recognized the previously unrecognized excess tax benefits of approximately $18.6 million ($6.5 million tax effected) recorded as deferred tax assets with a corresponding offsetting full valuation allowance at the beginning of 2017 without any tax impact.&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;The reconciliation of the reported estimated income tax benefit to the amount that would result by applying the U.S. federal statutory tax rate to the net income is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:61.343109%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.730205%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533138%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.730205%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533138%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.730205%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2016&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;United States federal tax at statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(36,005)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(6,869)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(20,489)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;State taxes (net of federal benefit)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(11,133)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(735)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(3,116)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Deferred income tax adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(4,435)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;173&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Deferred state blended rate adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(485)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(32)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Deferred federal rate change reduction in corporate rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;39,447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Research credit, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(8,466)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(8,455)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(2,551)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Orphan drug credit, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(872)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1,853)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(571)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other permanent items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Equity-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,067&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;60,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(24,000)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;24,444&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Income tax expense/(benefit)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;A reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:61.343109%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.730205%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533138%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.730205%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533138%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.730205%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2016&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Increases for current year tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;308&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Increases/(decreases) for prior year tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(268)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,465&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;As of December&#160;31, 2018 and 2017, of the total gross unrecognized tax benefits, approximately $4.5 million and $3.4 million would favorably impact the Company's effective income tax rate, respectively. Although, due to the Company's determination that the deferred income tax asset would not more likely than not be realized, a valuation allowance would be recorded, therefore, zero net impact would result within the Company's effective income tax rate. The Company's uncertain income tax position liability has been recorded to deferred income taxes to offset the tax attribute carryforward amounts.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;For the years ended December&#160;31, 2018, 2017 and 2016, the Company has not recognized any interest or penalties related to the uncertain income tax positions due to the fact such position is related to tax attribute carryforwards which have not yet been utilized. The Company does not expect its unrecognized income tax position to significantly decrease within the next twelve months.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;The Company's U.S. Federal and state income tax returns from 2001&#160;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;forward remain open to examination due to the carryover of unused net operating losses and tax credits.&lt;/span&gt;&lt;/div&gt;As more fully described in Note 2 to the consolidated financial statements, the Tax Act was signed into law making significant changes to the Internal Revenue Code on December 22, 2017.  Under ASC 740, the effects of the new legislation are to be recognized in the period of enactment.  As such, recognition of the tax impact of the Tax Act was required in the interim and annual periods that include December 22, 2017.  As a result, the Company revalued the deferred tax asset as of December 31, 2017, fully offset by a valuation allowance without impact to the financial statements.</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90ZXh0cmVnaW9uOmI0ZjY4YmIzMzBkMzRkMWZiM2QyZDdiYjQ5YmI3ZWM5XzY2_678d1df5-8681-4ec1-b140-bb5327712ae3"
      unitRef="usd">0</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90ZXh0cmVnaW9uOmI0ZjY4YmIzMzBkMzRkMWZiM2QyZDdiYjQ5YmI3ZWM5XzE1MzkzMTYyODA2MzMy_6fe35d26-7f37-40c6-931d-3b08eb99e7d3">&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;The significant components of the Company's deferred income tax assets (liabilities) were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:73.806452%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.730205%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533138%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.730205%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2017&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Deferred income tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Federal U.S. net operating loss carryforward&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;87,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;50,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;State net operating loss carryforward&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;22,809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Research and development credit, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;29,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;21,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Orphan drug credit, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;22,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;21,708&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Deferred rent&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,385&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,982&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;155&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gross deferred income tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;176,131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;113,258&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(172,457)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(112,453)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net deferred income tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;805&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Deferred income tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1,911)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Prepaid expenditures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1,763)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(805)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gross deferred income tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(3,674)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(805)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net deferred income tax asset/(liability)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic
      contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZTpmMThmN2Q2NTczNGY0NDM3YmY2ZTIzYjg3MzQ3OTVkMi90YWJsZXJhbmdlOmYxOGY3ZDY1NzM0ZjQ0MzdiZjZlMjNiODczNDc5NWQyXzMtMS0xLTEtMA_a8be6003-2dff-4ea7-967a-42c37a62c829"
      unitRef="usd">87284000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic
      contextRef="i7057397719af459ca7328a1c440a0efa_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZTpmMThmN2Q2NTczNGY0NDM3YmY2ZTIzYjg3MzQ3OTVkMi90YWJsZXJhbmdlOmYxOGY3ZDY1NzM0ZjQ0MzdiZjZlMjNiODczNDc5NWQyXzMtMy0xLTEtMA_d95d6bac-f5f4-4d03-a271-5692f3321ca8"
      unitRef="usd">50346000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
      contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZTpmMThmN2Q2NTczNGY0NDM3YmY2ZTIzYjg3MzQ3OTVkMi90YWJsZXJhbmdlOmYxOGY3ZDY1NzM0ZjQ0MzdiZjZlMjNiODczNDc5NWQyXzQtMS0xLTEtMA_92d41715-99dc-46c6-8b7b-523685597171"
      unitRef="usd">22809000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
      contextRef="i7057397719af459ca7328a1c440a0efa_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZTpmMThmN2Q2NTczNGY0NDM3YmY2ZTIzYjg3MzQ3OTVkMi90YWJsZXJhbmdlOmYxOGY3ZDY1NzM0ZjQ0MzdiZjZlMjNiODczNDc5NWQyXzQtMy0xLTEtMA_070ddf5b-0978-4362-ac5b-1f183e9a437e"
      unitRef="usd">7551000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZTpmMThmN2Q2NTczNGY0NDM3YmY2ZTIzYjg3MzQ3OTVkMi90YWJsZXJhbmdlOmYxOGY3ZDY1NzM0ZjQ0MzdiZjZlMjNiODczNDc5NWQyXzUtMS0xLTEtMA_18946647-3383-47ab-8d89-35a17572332c"
      unitRef="usd">29750000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="i7057397719af459ca7328a1c440a0efa_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZTpmMThmN2Q2NTczNGY0NDM3YmY2ZTIzYjg3MzQ3OTVkMi90YWJsZXJhbmdlOmYxOGY3ZDY1NzM0ZjQ0MzdiZjZlMjNiODczNDc5NWQyXzUtMy0xLTEtMA_515e01df-67d9-410d-88d0-e09cc314f681"
      unitRef="usd">21284000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsOther
      contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZTpmMThmN2Q2NTczNGY0NDM3YmY2ZTIzYjg3MzQ3OTVkMi90YWJsZXJhbmdlOmYxOGY3ZDY1NzM0ZjQ0MzdiZjZlMjNiODczNDc5NWQyXzYtMS0xLTEtMA_c4c53c69-cd7d-4bc3-bde8-60489a74ef33"
      unitRef="usd">22580000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsOther>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsOther
      contextRef="i7057397719af459ca7328a1c440a0efa_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZTpmMThmN2Q2NTczNGY0NDM3YmY2ZTIzYjg3MzQ3OTVkMi90YWJsZXJhbmdlOmYxOGY3ZDY1NzM0ZjQ0MzdiZjZlMjNiODczNDc5NWQyXzYtMy0xLTEtMA_ce719036-9feb-4612-a5a9-07f4bc913281"
      unitRef="usd">21708000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsOther>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent
      contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZTpmMThmN2Q2NTczNGY0NDM3YmY2ZTIzYjg3MzQ3OTVkMi90YWJsZXJhbmdlOmYxOGY3ZDY1NzM0ZjQ0MzdiZjZlMjNiODczNDc5NWQyXzctMS0xLTEtMA_2f652e7a-8e71-4bf3-a987-22840f8d13c1"
      unitRef="usd">3118000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent
      contextRef="i7057397719af459ca7328a1c440a0efa_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZTpmMThmN2Q2NTczNGY0NDM3YmY2ZTIzYjg3MzQ3OTVkMi90YWJsZXJhbmdlOmYxOGY3ZDY1NzM0ZjQ0MzdiZjZlMjNiODczNDc5NWQyXzctMy0xLTEtMA_65856730-84e5-43be-b4f4-1a0b98e57acd"
      unitRef="usd">3385000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZTpmMThmN2Q2NTczNGY0NDM3YmY2ZTIzYjg3MzQ3OTVkMi90YWJsZXJhbmdlOmYxOGY3ZDY1NzM0ZjQ0MzdiZjZlMjNiODczNDc5NWQyXzgtMS0xLTEtMA_67f673c9-bd5f-4f37-9a44-f8df008feb12"
      unitRef="usd">3736000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="i7057397719af459ca7328a1c440a0efa_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZTpmMThmN2Q2NTczNGY0NDM3YmY2ZTIzYjg3MzQ3OTVkMi90YWJsZXJhbmdlOmYxOGY3ZDY1NzM0ZjQ0MzdiZjZlMjNiODczNDc5NWQyXzgtMy0xLTEtMA_d1ecd77f-28d6-4260-8b44-dca4437384ec"
      unitRef="usd">2982000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZTpmMThmN2Q2NTczNGY0NDM3YmY2ZTIzYjg3MzQ3OTVkMi90YWJsZXJhbmdlOmYxOGY3ZDY1NzM0ZjQ0MzdiZjZlMjNiODczNDc5NWQyXzktMS0xLTEtMA_feb33eab-95e4-4f6d-8145-2ce7b0068f9a"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="i7057397719af459ca7328a1c440a0efa_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZTpmMThmN2Q2NTczNGY0NDM3YmY2ZTIzYjg3MzQ3OTVkMi90YWJsZXJhbmdlOmYxOGY3ZDY1NzM0ZjQ0MzdiZjZlMjNiODczNDc5NWQyXzktMy0xLTEtMA_1575f622-94ad-49dc-afb9-3214a0593f6c"
      unitRef="usd">155000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZTpmMThmN2Q2NTczNGY0NDM3YmY2ZTIzYjg3MzQ3OTVkMi90YWJsZXJhbmdlOmYxOGY3ZDY1NzM0ZjQ0MzdiZjZlMjNiODczNDc5NWQyXzEwLTEtMS0xLTA_2c69d4c6-8729-4359-8f19-ddc06d3f9af5"
      unitRef="usd">6854000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="i7057397719af459ca7328a1c440a0efa_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZTpmMThmN2Q2NTczNGY0NDM3YmY2ZTIzYjg3MzQ3OTVkMi90YWJsZXJhbmdlOmYxOGY3ZDY1NzM0ZjQ0MzdiZjZlMjNiODczNDc5NWQyXzEwLTMtMS0xLTA_860b4f5c-4243-498c-b8de-bcef6e3a9d0c"
      unitRef="usd">5847000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZTpmMThmN2Q2NTczNGY0NDM3YmY2ZTIzYjg3MzQ3OTVkMi90YWJsZXJhbmdlOmYxOGY3ZDY1NzM0ZjQ0MzdiZjZlMjNiODczNDc5NWQyXzExLTEtMS0xLTA_e8809f42-69a8-4919-a052-524ce807d64e"
      unitRef="usd">176131000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i7057397719af459ca7328a1c440a0efa_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZTpmMThmN2Q2NTczNGY0NDM3YmY2ZTIzYjg3MzQ3OTVkMi90YWJsZXJhbmdlOmYxOGY3ZDY1NzM0ZjQ0MzdiZjZlMjNiODczNDc5NWQyXzExLTMtMS0xLTA_1400bcc9-1f86-4da9-872d-12e4cc3034f8"
      unitRef="usd">113258000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZTpmMThmN2Q2NTczNGY0NDM3YmY2ZTIzYjg3MzQ3OTVkMi90YWJsZXJhbmdlOmYxOGY3ZDY1NzM0ZjQ0MzdiZjZlMjNiODczNDc5NWQyXzEyLTEtMS0xLTA_34ee440b-615e-43f7-8bd6-80d569a55159"
      unitRef="usd">172457000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i7057397719af459ca7328a1c440a0efa_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZTpmMThmN2Q2NTczNGY0NDM3YmY2ZTIzYjg3MzQ3OTVkMi90YWJsZXJhbmdlOmYxOGY3ZDY1NzM0ZjQ0MzdiZjZlMjNiODczNDc5NWQyXzEyLTMtMS0xLTA_07ccff5a-1b96-4f28-8943-bd3c95a375ff"
      unitRef="usd">112453000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZTpmMThmN2Q2NTczNGY0NDM3YmY2ZTIzYjg3MzQ3OTVkMi90YWJsZXJhbmdlOmYxOGY3ZDY1NzM0ZjQ0MzdiZjZlMjNiODczNDc5NWQyXzEzLTEtMS0xLTA_69fdb66a-4754-42a2-9efc-b3afda12050f"
      unitRef="usd">3674000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="i7057397719af459ca7328a1c440a0efa_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZTpmMThmN2Q2NTczNGY0NDM3YmY2ZTIzYjg3MzQ3OTVkMi90YWJsZXJhbmdlOmYxOGY3ZDY1NzM0ZjQ0MzdiZjZlMjNiODczNDc5NWQyXzEzLTMtMS0xLTA_ce5c49bb-6a07-4721-b7b3-8ec1f6d41b5b"
      unitRef="usd">805000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZTpmMThmN2Q2NTczNGY0NDM3YmY2ZTIzYjg3MzQ3OTVkMi90YWJsZXJhbmdlOmYxOGY3ZDY1NzM0ZjQ0MzdiZjZlMjNiODczNDc5NWQyXzE2LTEtMS0xLTM5NzE_fde696d3-c6bf-4a97-9f86-dd65e0d6fdd9"
      unitRef="usd">1911000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="i7057397719af459ca7328a1c440a0efa_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZTpmMThmN2Q2NTczNGY0NDM3YmY2ZTIzYjg3MzQ3OTVkMi90YWJsZXJhbmdlOmYxOGY3ZDY1NzM0ZjQ0MzdiZjZlMjNiODczNDc5NWQyXzE2LTMtMS0xLTM5NzE_9c88bb2c-c437-426a-9e80-05dc5c7fe622"
      unitRef="usd">0</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPrepaidExpenses
      contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZTpmMThmN2Q2NTczNGY0NDM3YmY2ZTIzYjg3MzQ3OTVkMi90YWJsZXJhbmdlOmYxOGY3ZDY1NzM0ZjQ0MzdiZjZlMjNiODczNDc5NWQyXzE2LTEtMS0xLTA_ae0d8604-d46f-4134-901f-f8e4572768b3"
      unitRef="usd">1763000</us-gaap:DeferredTaxLiabilitiesPrepaidExpenses>
    <us-gaap:DeferredTaxLiabilitiesPrepaidExpenses
      contextRef="i7057397719af459ca7328a1c440a0efa_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZTpmMThmN2Q2NTczNGY0NDM3YmY2ZTIzYjg3MzQ3OTVkMi90YWJsZXJhbmdlOmYxOGY3ZDY1NzM0ZjQ0MzdiZjZlMjNiODczNDc5NWQyXzE2LTMtMS0xLTA_437f7314-1e03-4bc0-9e4b-5a0db74cc2da"
      unitRef="usd">805000</us-gaap:DeferredTaxLiabilitiesPrepaidExpenses>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZTpmMThmN2Q2NTczNGY0NDM3YmY2ZTIzYjg3MzQ3OTVkMi90YWJsZXJhbmdlOmYxOGY3ZDY1NzM0ZjQ0MzdiZjZlMjNiODczNDc5NWQyXzE3LTEtMS0xLTA_0ff69b22-9e97-474e-8d09-ee7ba9c6fa74"
      unitRef="usd">3674000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="i7057397719af459ca7328a1c440a0efa_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZTpmMThmN2Q2NTczNGY0NDM3YmY2ZTIzYjg3MzQ3OTVkMi90YWJsZXJhbmdlOmYxOGY3ZDY1NzM0ZjQ0MzdiZjZlMjNiODczNDc5NWQyXzE3LTMtMS0xLTA_ed5a9632-8448-43fe-a640-cb62444dd7f4"
      unitRef="usd">805000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZTpmMThmN2Q2NTczNGY0NDM3YmY2ZTIzYjg3MzQ3OTVkMi90YWJsZXJhbmdlOmYxOGY3ZDY1NzM0ZjQ0MzdiZjZlMjNiODczNDc5NWQyXzE4LTEtMS0xLTA_07fdba8e-3da2-4201-bbbd-e7ccecbad5e1"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="i7057397719af459ca7328a1c440a0efa_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZTpmMThmN2Q2NTczNGY0NDM3YmY2ZTIzYjg3MzQ3OTVkMi90YWJsZXJhbmdlOmYxOGY3ZDY1NzM0ZjQ0MzdiZjZlMjNiODczNDc5NWQyXzE4LTMtMS0xLTA_82cd9ed8-f75c-4175-94e5-b6963b1497dd"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration
      contextRef="i109fced96e334bd2802e9cb0d4aa822f_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90ZXh0cmVnaW9uOmI0ZjY4YmIzMzBkMzRkMWZiM2QyZDdiYjQ5YmI3ZWM5XzEyOTA_1689e4ab-08e2-44f1-967f-95445a4c6aaa"
      unitRef="usd">415600000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration
      contextRef="if3a4a990231244d6b62fcda57ef5cfdb_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90ZXh0cmVnaW9uOmI0ZjY4YmIzMzBkMzRkMWZiM2QyZDdiYjQ5YmI3ZWM5XzI3NDg3NzkwODMzNTY_1fbfbcde-0240-467c-81b9-6d1f50e44b78"
      unitRef="usd">237800000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration
      contextRef="icbf9b06e7c13465a9c3facc8db2be168_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90ZXh0cmVnaW9uOmI0ZjY4YmIzMzBkMzRkMWZiM2QyZDdiYjQ5YmI3ZWM5XzI3NDg3NzkwODMzNzI_75776794-bb02-40eb-b0ec-7659aea3a3ff"
      unitRef="usd">177800000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="iea603775d4f04ce4a2e3d875e241c0c8_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90ZXh0cmVnaW9uOmI0ZjY4YmIzMzBkMzRkMWZiM2QyZDdiYjQ5YmI3ZWM5XzE0MTI_19219829-c2a9-434e-a6b1-2373352aa4c7"
      unitRef="usd">52300000</us-gaap:TaxCreditCarryforwardAmount>
    <mgnx:OperatingLossCarryforwardsLimitationsOnUseAmount
      contextRef="i62c4c7c8c31a462dab6a1676f99a1b7c_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90ZXh0cmVnaW9uOmI0ZjY4YmIzMzBkMzRkMWZiM2QyZDdiYjQ5YmI3ZWM5XzE2OTc_cefeb950-b77d-4801-b62f-509ecd6d6274"
      unitRef="usd">13500000</mgnx:OperatingLossCarryforwardsLimitationsOnUseAmount>
    <mgnx:OperatingLossCarryforwardsAnnualLimitationAmount
      contextRef="i0986b0c4e51f4d2cb580f8bcf9218691_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90ZXh0cmVnaW9uOmI0ZjY4YmIzMzBkMzRkMWZiM2QyZDdiYjQ5YmI3ZWM5XzE4NTE_273b54fa-12a1-4ddf-aa9c-702276583d2f"
      unitRef="usd">200000</mgnx:OperatingLossCarryforwardsAnnualLimitationAmount>
    <mgnx:OperatingLossCarryforwardsAnnualLimitationAmount
      contextRef="i0229ee301314485e8d01bc8ad76d9aca_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90ZXh0cmVnaW9uOmI0ZjY4YmIzMzBkMzRkMWZiM2QyZDdiYjQ5YmI3ZWM5XzE4NTc_e99d8dfe-16b5-4c1b-a1ac-4d06627ce4dc"
      unitRef="usd">1400000</mgnx:OperatingLossCarryforwardsAnnualLimitationAmount>
    <mgnx:OperatingLossCarryforwardsNotSubjectToLimitation
      contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90ZXh0cmVnaW9uOmI0ZjY4YmIzMzBkMzRkMWZiM2QyZDdiYjQ5YmI3ZWM5XzE4NzU_ddab8cb1-4ec5-4712-ad48-44b93852b555"
      unitRef="usd">402100000</mgnx:OperatingLossCarryforwardsNotSubjectToLimitation>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90ZXh0cmVnaW9uOmI0ZjY4YmIzMzBkMzRkMWZiM2QyZDdiYjQ5YmI3ZWM5XzIxNzQ_b4295b09-c5d1-4a94-afae-8da18d384a32"
      unitRef="usd">18600000</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount>
    <mgnx:EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTaxBenefitTaxEffectedAmount
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90ZXh0cmVnaW9uOmI0ZjY4YmIzMzBkMzRkMWZiM2QyZDdiYjQ5YmI3ZWM5XzIxNzg_86732701-175b-4d1e-870d-a090b4c0764f"
      unitRef="usd">6500000</mgnx:EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTaxBenefitTaxEffectedAmount>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90ZXh0cmVnaW9uOmI0ZjY4YmIzMzBkMzRkMWZiM2QyZDdiYjQ5YmI3ZWM5XzE1MzkzMTYyODA2MzMz_2806e6a0-707b-4e8a-a8a2-e1f117fabdf2">&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;The reconciliation of the reported estimated income tax benefit to the amount that would result by applying the U.S. federal statutory tax rate to the net income is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:61.343109%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.730205%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533138%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.730205%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533138%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.730205%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2016&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;United States federal tax at statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(36,005)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(6,869)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(20,489)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;State taxes (net of federal benefit)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(11,133)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(735)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(3,116)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Deferred income tax adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(4,435)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;173&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Deferred state blended rate adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(485)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(32)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Deferred federal rate change reduction in corporate rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;39,447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Research credit, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(8,466)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(8,455)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(2,551)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Orphan drug credit, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(872)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1,853)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(571)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other permanent items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Equity-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,067&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;60,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(24,000)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;24,444&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Income tax expense/(benefit)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZToxMDU3OWFjNGM4OGM0YzkwOWYxMDY1YjY4ODRhNTVlMS90YWJsZXJhbmdlOjEwNTc5YWM0Yzg4YzRjOTA5ZjEwNjViNjg4NGE1NWUxXzMtMS0xLTEtMA_4e4bcc17-4f00-4a0b-90dc-e60e5e9111d7"
      unitRef="usd">-36005000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZToxMDU3OWFjNGM4OGM0YzkwOWYxMDY1YjY4ODRhNTVlMS90YWJsZXJhbmdlOjEwNTc5YWM0Yzg4YzRjOTA5ZjEwNjViNjg4NGE1NWUxXzMtMy0xLTEtMA_6612c2c3-e399-411a-bafa-c344d70ad76f"
      unitRef="usd">-6869000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="iaf5d0e8fdf374dc09283fd669e2ebf19_D20160101-20161231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZToxMDU3OWFjNGM4OGM0YzkwOWYxMDY1YjY4ODRhNTVlMS90YWJsZXJhbmdlOjEwNTc5YWM0Yzg4YzRjOTA5ZjEwNjViNjg4NGE1NWUxXzMtNS0xLTEtMA_7bb06b38-19b8-4ebe-b8a1-b3e817b3659f"
      unitRef="usd">-20489000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZToxMDU3OWFjNGM4OGM0YzkwOWYxMDY1YjY4ODRhNTVlMS90YWJsZXJhbmdlOjEwNTc5YWM0Yzg4YzRjOTA5ZjEwNjViNjg4NGE1NWUxXzQtMS0xLTEtMA_f3050192-c29d-4eab-b57c-cd2ea294d323"
      unitRef="usd">-11133000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZToxMDU3OWFjNGM4OGM0YzkwOWYxMDY1YjY4ODRhNTVlMS90YWJsZXJhbmdlOjEwNTc5YWM0Yzg4YzRjOTA5ZjEwNjViNjg4NGE1NWUxXzQtMy0xLTEtMA_e3b6aa8f-1929-4a40-8eec-4b9a407c2c45"
      unitRef="usd">-735000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="iaf5d0e8fdf374dc09283fd669e2ebf19_D20160101-20161231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZToxMDU3OWFjNGM4OGM0YzkwOWYxMDY1YjY4ODRhNTVlMS90YWJsZXJhbmdlOjEwNTc5YWM0Yzg4YzRjOTA5ZjEwNjViNjg4NGE1NWUxXzQtNS0xLTEtMA_1a41c4ce-7d3e-4684-8cfb-6a5a22e6b0ba"
      unitRef="usd">-3116000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <mgnx:EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZToxMDU3OWFjNGM4OGM0YzkwOWYxMDY1YjY4ODRhNTVlMS90YWJsZXJhbmdlOjEwNTc5YWM0Yzg4YzRjOTA5ZjEwNjViNjg4NGE1NWUxXzUtMS0xLTEtMA_699999ae-850f-479f-bc45-a0d5cc0d488d"
      unitRef="usd">-4435000</mgnx:EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount>
    <mgnx:EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount
      contextRef="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZToxMDU3OWFjNGM4OGM0YzkwOWYxMDY1YjY4ODRhNTVlMS90YWJsZXJhbmdlOjEwNTc5YWM0Yzg4YzRjOTA5ZjEwNjViNjg4NGE1NWUxXzUtMy0xLTEtMA_3be9d29c-f54e-47f6-af24-2a23904a3091"
      unitRef="usd">607000</mgnx:EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount>
    <mgnx:EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount
      contextRef="iaf5d0e8fdf374dc09283fd669e2ebf19_D20160101-20161231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZToxMDU3OWFjNGM4OGM0YzkwOWYxMDY1YjY4ODRhNTVlMS90YWJsZXJhbmdlOjEwNTc5YWM0Yzg4YzRjOTA5ZjEwNjViNjg4NGE1NWUxXzUtNS0xLTEtMA_54a3fdb2-635d-4b03-b029-3b6e11f99d0f"
      unitRef="usd">173000</mgnx:EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount>
    <mgnx:EffectiveIncomeTaxReconciliationStateDeferredTaxesAdjustmentsAmount
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZToxMDU3OWFjNGM4OGM0YzkwOWYxMDY1YjY4ODRhNTVlMS90YWJsZXJhbmdlOjEwNTc5YWM0Yzg4YzRjOTA5ZjEwNjViNjg4NGE1NWUxXzYtMS0xLTEtMA_26a94562-a0fd-4c09-8a40-0e8575c7c38e"
      unitRef="usd">0</mgnx:EffectiveIncomeTaxReconciliationStateDeferredTaxesAdjustmentsAmount>
    <mgnx:EffectiveIncomeTaxReconciliationStateDeferredTaxesAdjustmentsAmount
      contextRef="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZToxMDU3OWFjNGM4OGM0YzkwOWYxMDY1YjY4ODRhNTVlMS90YWJsZXJhbmdlOjEwNTc5YWM0Yzg4YzRjOTA5ZjEwNjViNjg4NGE1NWUxXzYtMy0xLTEtMA_30c1b089-4f95-40d9-b57d-c2c001db3210"
      unitRef="usd">485000</mgnx:EffectiveIncomeTaxReconciliationStateDeferredTaxesAdjustmentsAmount>
    <mgnx:EffectiveIncomeTaxReconciliationStateDeferredTaxesAdjustmentsAmount
      contextRef="iaf5d0e8fdf374dc09283fd669e2ebf19_D20160101-20161231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZToxMDU3OWFjNGM4OGM0YzkwOWYxMDY1YjY4ODRhNTVlMS90YWJsZXJhbmdlOjEwNTc5YWM0Yzg4YzRjOTA5ZjEwNjViNjg4NGE1NWUxXzYtNS0xLTEtMA_eb42a570-c309-47ef-b9dd-a9d780275ad4"
      unitRef="usd">32000</mgnx:EffectiveIncomeTaxReconciliationStateDeferredTaxesAdjustmentsAmount>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZToxMDU3OWFjNGM4OGM0YzkwOWYxMDY1YjY4ODRhNTVlMS90YWJsZXJhbmdlOjEwNTc5YWM0Yzg4YzRjOTA5ZjEwNjViNjg4NGE1NWUxXzctMS0xLTEtMA_24fd43ae-dcae-43ea-9492-9e7cd7041941"
      unitRef="usd">0</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate
      contextRef="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZToxMDU3OWFjNGM4OGM0YzkwOWYxMDY1YjY4ODRhNTVlMS90YWJsZXJhbmdlOjEwNTc5YWM0Yzg4YzRjOTA5ZjEwNjViNjg4NGE1NWUxXzctMy0xLTEtMA_c9976cb3-878f-47a1-81af-586c728bc772"
      unitRef="usd">39447000</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate
      contextRef="iaf5d0e8fdf374dc09283fd669e2ebf19_D20160101-20161231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZToxMDU3OWFjNGM4OGM0YzkwOWYxMDY1YjY4ODRhNTVlMS90YWJsZXJhbmdlOjEwNTc5YWM0Yzg4YzRjOTA5ZjEwNjViNjg4NGE1NWUxXzctNS0xLTEtMA_67708562-0ec6-42dc-be97-c2ed8b38afa2"
      unitRef="usd">0</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZToxMDU3OWFjNGM4OGM0YzkwOWYxMDY1YjY4ODRhNTVlMS90YWJsZXJhbmdlOjEwNTc5YWM0Yzg4YzRjOTA5ZjEwNjViNjg4NGE1NWUxXzgtMS0xLTEtMA_f8e2352b-0812-40aa-94bc-3a4934f88522"
      unitRef="usd">8466000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZToxMDU3OWFjNGM4OGM0YzkwOWYxMDY1YjY4ODRhNTVlMS90YWJsZXJhbmdlOjEwNTc5YWM0Yzg4YzRjOTA5ZjEwNjViNjg4NGE1NWUxXzgtMy0xLTEtMA_50284858-4918-47f9-b50e-f6e580eee2ae"
      unitRef="usd">8455000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="iaf5d0e8fdf374dc09283fd669e2ebf19_D20160101-20161231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZToxMDU3OWFjNGM4OGM0YzkwOWYxMDY1YjY4ODRhNTVlMS90YWJsZXJhbmdlOjEwNTc5YWM0Yzg4YzRjOTA5ZjEwNjViNjg4NGE1NWUxXzgtNS0xLTEtMA_cba78d12-e1f8-45e6-ad37-59bd4d80d61b"
      unitRef="usd">2551000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsOther
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZToxMDU3OWFjNGM4OGM0YzkwOWYxMDY1YjY4ODRhNTVlMS90YWJsZXJhbmdlOjEwNTc5YWM0Yzg4YzRjOTA5ZjEwNjViNjg4NGE1NWUxXzExLTEtMS0xLTA_73eaccb3-c883-4302-b672-45fbce633873"
      unitRef="usd">872000</us-gaap:IncomeTaxReconciliationTaxCreditsOther>
    <us-gaap:IncomeTaxReconciliationTaxCreditsOther
      contextRef="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZToxMDU3OWFjNGM4OGM0YzkwOWYxMDY1YjY4ODRhNTVlMS90YWJsZXJhbmdlOjEwNTc5YWM0Yzg4YzRjOTA5ZjEwNjViNjg4NGE1NWUxXzExLTMtMS0xLTA_dc1c6a22-305b-4508-b5d5-3470a0b0b3e7"
      unitRef="usd">1853000</us-gaap:IncomeTaxReconciliationTaxCreditsOther>
    <us-gaap:IncomeTaxReconciliationTaxCreditsOther
      contextRef="iaf5d0e8fdf374dc09283fd669e2ebf19_D20160101-20161231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZToxMDU3OWFjNGM4OGM0YzkwOWYxMDY1YjY4ODRhNTVlMS90YWJsZXJhbmdlOjEwNTc5YWM0Yzg4YzRjOTA5ZjEwNjViNjg4NGE1NWUxXzExLTUtMS0xLTA_fcabfceb-55d3-4e83-b181-726380d491f0"
      unitRef="usd">571000</us-gaap:IncomeTaxReconciliationTaxCreditsOther>
    <us-gaap:IncomeTaxReconciliationOtherReconcilingItems
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZToxMDU3OWFjNGM4OGM0YzkwOWYxMDY1YjY4ODRhNTVlMS90YWJsZXJhbmdlOjEwNTc5YWM0Yzg4YzRjOTA5ZjEwNjViNjg4NGE1NWUxXzEyLTEtMS0xLTA_7e1e2b3d-e696-4395-be6c-e35cd32e7102"
      unitRef="usd">148000</us-gaap:IncomeTaxReconciliationOtherReconcilingItems>
    <us-gaap:IncomeTaxReconciliationOtherReconcilingItems
      contextRef="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZToxMDU3OWFjNGM4OGM0YzkwOWYxMDY1YjY4ODRhNTVlMS90YWJsZXJhbmdlOjEwNTc5YWM0Yzg4YzRjOTA5ZjEwNjViNjg4NGE1NWUxXzEyLTMtMS0xLTA_d6a09879-ad97-496b-a252-10f920ca4df9"
      unitRef="usd">276000</us-gaap:IncomeTaxReconciliationOtherReconcilingItems>
    <us-gaap:IncomeTaxReconciliationOtherReconcilingItems
      contextRef="iaf5d0e8fdf374dc09283fd669e2ebf19_D20160101-20161231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZToxMDU3OWFjNGM4OGM0YzkwOWYxMDY1YjY4ODRhNTVlMS90YWJsZXJhbmdlOjEwNTc5YWM0Yzg4YzRjOTA5ZjEwNjViNjg4NGE1NWUxXzEyLTUtMS0xLTA_d7b19a34-58f9-4466-88ac-e13956992c07"
      unitRef="usd">145000</us-gaap:IncomeTaxReconciliationOtherReconcilingItems>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZToxMDU3OWFjNGM4OGM0YzkwOWYxMDY1YjY4ODRhNTVlMS90YWJsZXJhbmdlOjEwNTc5YWM0Yzg4YzRjOTA5ZjEwNjViNjg4NGE1NWUxXzEzLTEtMS0xLTA_548a6593-d49f-4ef9-a8fa-9247a018980d"
      unitRef="usd">758000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZToxMDU3OWFjNGM4OGM0YzkwOWYxMDY1YjY4ODRhNTVlMS90YWJsZXJhbmdlOjEwNTc5YWM0Yzg4YzRjOTA5ZjEwNjViNjg4NGE1NWUxXzEzLTMtMS0xLTA_446cdf27-4c3b-4564-af85-c95d5dec2c78"
      unitRef="usd">2067000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="iaf5d0e8fdf374dc09283fd669e2ebf19_D20160101-20161231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZToxMDU3OWFjNGM4OGM0YzkwOWYxMDY1YjY4ODRhNTVlMS90YWJsZXJhbmdlOjEwNTc5YWM0Yzg4YzRjOTA5ZjEwNjViNjg4NGE1NWUxXzEzLTUtMS0xLTA_cf7d028d-7973-4fb2-85f4-382b19481203"
      unitRef="usd">1997000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZToxMDU3OWFjNGM4OGM0YzkwOWYxMDY1YjY4ODRhNTVlMS90YWJsZXJhbmdlOjEwNTc5YWM0Yzg4YzRjOTA5ZjEwNjViNjg4NGE1NWUxXzE0LTEtMS0xLTA_fc72b5fb-2d05-4a5d-b926-e6b024f5ef7d"
      unitRef="usd">60005000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZToxMDU3OWFjNGM4OGM0YzkwOWYxMDY1YjY4ODRhNTVlMS90YWJsZXJhbmdlOjEwNTc5YWM0Yzg4YzRjOTA5ZjEwNjViNjg4NGE1NWUxXzE0LTMtMS0xLTA_1e2728fc-f9a4-4171-9825-f732520453f2"
      unitRef="usd">-24000000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="iaf5d0e8fdf374dc09283fd669e2ebf19_D20160101-20161231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZToxMDU3OWFjNGM4OGM0YzkwOWYxMDY1YjY4ODRhNTVlMS90YWJsZXJhbmdlOjEwNTc5YWM0Yzg4YzRjOTA5ZjEwNjViNjg4NGE1NWUxXzE0LTUtMS0xLTA_bb4255d5-fbb2-4761-9b32-f2d74b5309cc"
      unitRef="usd">24444000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZToxMDU3OWFjNGM4OGM0YzkwOWYxMDY1YjY4ODRhNTVlMS90YWJsZXJhbmdlOjEwNTc5YWM0Yzg4YzRjOTA5ZjEwNjViNjg4NGE1NWUxXzE1LTEtMS0xLTA_e564d7c9-8ec8-442d-b851-86c9140a9218"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZToxMDU3OWFjNGM4OGM0YzkwOWYxMDY1YjY4ODRhNTVlMS90YWJsZXJhbmdlOjEwNTc5YWM0Yzg4YzRjOTA5ZjEwNjViNjg4NGE1NWUxXzE1LTMtMS0xLTA_14aa8b38-ceca-4778-ae3f-0f26dcd334ec"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="iaf5d0e8fdf374dc09283fd669e2ebf19_D20160101-20161231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZToxMDU3OWFjNGM4OGM0YzkwOWYxMDY1YjY4ODRhNTVlMS90YWJsZXJhbmdlOjEwNTc5YWM0Yzg4YzRjOTA5ZjEwNjViNjg4NGE1NWUxXzE1LTUtMS0xLTA_7599707f-7e2f-49cc-a771-7f863ef0de67"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90ZXh0cmVnaW9uOmI0ZjY4YmIzMzBkMzRkMWZiM2QyZDdiYjQ5YmI3ZWM5XzE1MzkzMTYyODA2MzM0_7a3aafb9-def3-4db5-a89c-f82c76b336fd">&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;A reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:61.343109%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.730205%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533138%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.730205%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533138%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.730205%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2016&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Increases for current year tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;308&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Increases/(decreases) for prior year tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(268)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,465&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i7057397719af459ca7328a1c440a0efa_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZTpjN2M1OGZmZWZhODE0M2E0OTRiZWY2NmU1ZThjODEwZi90YWJsZXJhbmdlOmM3YzU4ZmZlZmE4MTQzYTQ5NGJlZjY2ZTVlOGM4MTBmXzItMS0xLTEtMA_290f7685-87ea-447f-ba5b-816f7d8db870"
      unitRef="usd">3395000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="iaa98382ff57d452ab6942c773d605ba7_I20161231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZTpjN2M1OGZmZWZhODE0M2E0OTRiZWY2NmU1ZThjODEwZi90YWJsZXJhbmdlOmM3YzU4ZmZlZmE4MTQzYTQ5NGJlZjY2ZTVlOGM4MTBmXzItMy0xLTEtMA_754ab482-c232-4d3d-b85a-be4cb9ea1277"
      unitRef="usd">2465000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ife0dac9d3bf74657b071534f4d2516f1_I20151231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZTpjN2M1OGZmZWZhODE0M2E0OTRiZWY2NmU1ZThjODEwZi90YWJsZXJhbmdlOmM3YzU4ZmZlZmE4MTQzYTQ5NGJlZjY2ZTVlOGM4MTBmXzItNS0xLTEtMA_22dff0f8-07a3-400b-bea6-984b91e2f50c"
      unitRef="usd">2425000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZTpjN2M1OGZmZWZhODE0M2E0OTRiZWY2NmU1ZThjODEwZi90YWJsZXJhbmdlOmM3YzU4ZmZlZmE4MTQzYTQ5NGJlZjY2ZTVlOGM4MTBmXzMtMS0xLTEtMA_0cb3f648-37c7-459a-bf15-6a0411159be2"
      unitRef="usd">642000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZTpjN2M1OGZmZWZhODE0M2E0OTRiZWY2NmU1ZThjODEwZi90YWJsZXJhbmdlOmM3YzU4ZmZlZmE4MTQzYTQ5NGJlZjY2ZTVlOGM4MTBmXzMtMy0xLTEtMA_38b35e71-d2b8-4107-8f63-41c2ca2cf126"
      unitRef="usd">569000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="iaf5d0e8fdf374dc09283fd669e2ebf19_D20160101-20161231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZTpjN2M1OGZmZWZhODE0M2E0OTRiZWY2NmU1ZThjODEwZi90YWJsZXJhbmdlOmM3YzU4ZmZlZmE4MTQzYTQ5NGJlZjY2ZTVlOGM4MTBmXzMtNS0xLTEtMA_969e2ef4-a93f-416b-8d54-462171637093"
      unitRef="usd">308000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZTpjN2M1OGZmZWZhODE0M2E0OTRiZWY2NmU1ZThjODEwZi90YWJsZXJhbmdlOmM3YzU4ZmZlZmE4MTQzYTQ5NGJlZjY2ZTVlOGM4MTBmXzQtMS0xLTEtMA_ab56c58f-4b1f-484b-be2f-8831b67bfc17"
      unitRef="usd">281000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZTpjN2M1OGZmZWZhODE0M2E0OTRiZWY2NmU1ZThjODEwZi90YWJsZXJhbmdlOmM3YzU4ZmZlZmE4MTQzYTQ5NGJlZjY2ZTVlOGM4MTBmXzQtMy0xLTEtMA_ab3f20c0-66cc-473b-a1d4-e353691b83b3"
      unitRef="usd">361000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="iaf5d0e8fdf374dc09283fd669e2ebf19_D20160101-20161231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZTpjN2M1OGZmZWZhODE0M2E0OTRiZWY2NmU1ZThjODEwZi90YWJsZXJhbmdlOmM3YzU4ZmZlZmE4MTQzYTQ5NGJlZjY2ZTVlOGM4MTBmXzQtNS0xLTEtMA_1edfaff9-c337-417f-b062-61c16622243c"
      unitRef="usd">268000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZTpjN2M1OGZmZWZhODE0M2E0OTRiZWY2NmU1ZThjODEwZi90YWJsZXJhbmdlOmM3YzU4ZmZlZmE4MTQzYTQ5NGJlZjY2ZTVlOGM4MTBmXzYtMS0xLTEtMA_e326fb22-2abc-4029-94dc-67d1892b8892"
      unitRef="usd">4318000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i7057397719af459ca7328a1c440a0efa_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZTpjN2M1OGZmZWZhODE0M2E0OTRiZWY2NmU1ZThjODEwZi90YWJsZXJhbmdlOmM3YzU4ZmZlZmE4MTQzYTQ5NGJlZjY2ZTVlOGM4MTBmXzYtMy0xLTEtMA_18d84c92-bec3-4ff7-aea0-6d53b22966da"
      unitRef="usd">3395000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="iaa98382ff57d452ab6942c773d605ba7_I20161231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90YWJsZTpjN2M1OGZmZWZhODE0M2E0OTRiZWY2NmU1ZThjODEwZi90YWJsZXJhbmdlOmM3YzU4ZmZlZmE4MTQzYTQ5NGJlZjY2ZTVlOGM4MTBmXzYtNS0xLTEtMA_bbb12525-ccbc-43e9-86c5-9f01a3b2cbbb"
      unitRef="usd">2465000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90ZXh0cmVnaW9uOmI0ZjY4YmIzMzBkMzRkMWZiM2QyZDdiYjQ5YmI3ZWM5XzMwMDA_210a1bf0-2086-4977-b22b-097d1f96a833"
      unitRef="usd">4500000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="i7057397719af459ca7328a1c440a0efa_I20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83MTAvZnJhZzpiNGY2OGJiMzMwZDM0ZDFmYjNkMmQ3YmI0OWJiN2VjOS90ZXh0cmVnaW9uOmI0ZjY4YmIzMzBkMzRkMWZiM2QyZDdiYjQ5YmI3ZWM5XzMwMDc_cdb4e5fd-242e-4b5b-8aa0-adefa3adc88b"
      unitRef="usd">3400000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <mgnx:CollaborationAndLicenseAgreementsDisclosureTextBlock
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzMwMzA1_04debd13-3bd8-4c8a-b899-97a08a1b0406">Collaboration and Other Agreements&lt;div style="margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Incyte&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;In October 2017, the Company entered into an exclusive global collaboration and license agreement with Incyte for MGA012&#160;(also known as INCMGA0012), an investigational monoclonal antibody that inhibits programmed cell death protein 1 (PD-1) (Incyte Agreement). Incyte has obtained exclusive worldwide rights for the development and commercialization of MGA012 in all indications, while the Company retains the right to develop its pipeline assets in combination with MGA012.  The Company received a $150.0 million upfront payment from Incyte when the transaction closed in the fourth quarter of 2017.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;Under the terms of the Incyte Agreement, Incyte will lead global development of MGA012.  Assuming successful development and commercialization by Incyte, the Company could receive up to approximately $420.0 million in development and regulatory milestones, and up to $330.0 million in commercial milestones. As of December&#160;31, 2018, the Company has recognized $15.0 million in development milestones under this agreement.  If commercialized, the Company would be eligible to receive tiered royalties of 15% to 24% on any global net sales. The Company retains the right to develop its pipeline assets in combination with MGA012, with Incyte commercializing MGA012 and the Company commercializing its asset(s), if any such potential combinations are approved. In addition, the Company retains the right to manufacture a portion of both companies' global commercial supply needs of MGA012, subject to a separate commercial supply agreement. Finally, Incyte funded the Company's activities related to the ongoing monotherapy clinical study and will continue to fund certain related clinical activities. &#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:42pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;Upon the adoption of ASC 606, the Company evaluated the Incyte Agreement under the provisions of ASC 606 and identified the following two performance obligations under the agreement: (i) the license of MGA012 and (ii) the performance of certain clinical activities through a brief technology transfer period.  The Company determined that the license and clinical activities are separate performance obligations because they are capable of being distinct, and are distinct in the context of the contract. The license has standalone functionality as it is sublicensable, Incyte has significant capabilities in performing clinical trials, and Incyte is capable of performing these activities without the Company's involvement; the Company performed the activities during the transfer period as a matter of convenience.  The Company determined that the transaction price of the Incyte Agreement at inception was $154.0 million, consisting of the consideration to which the Company was entitled in exchange for the license and an estimate of the consideration for clinical activities to be performed.  The transaction price was allocated to each performance obligation based on their relative standalone selling price.  The standalone selling price of the license was determined using the adjusted market assessment approach considering similar collaboration and license agreements.  The standalone selling price for agreed-upon clinical activities to be performed was determined using the expected cost approach based on similar arrangements the Company has with other parties.  The potential development and regulatory milestone payments are &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;fully constrained until the Company concludes that achievement of the milestone is probable and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;and as such have been excluded from the transaction price.  Any consideration related to sales-based milestones and royalties will be recognized when the related sales occur, as they were determined to relate predominantly to the license granted to Incyte and, therefore, have also been excluded from the transaction price.  The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur. &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;During the&#160;year ended December&#160;31, 2018, it became probable that a significant reversal of cumulative revenue would not occur for three development milestones totaling &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;$15.0 million&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt; related to MGA012 meeting certain clinical proof-of-concept criteria. &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;&#160;Therefore&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt; the associated consideration was added to the estimated transaction price and was recognized as revenue.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:42pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;The Company recognized the &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;$150.0 million&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt; allocated to the &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;license when it satisfied its performance obligation and transferred the license to Incyte in December 2017.  The $4.0 million allocated to the clinical activities&#160;was recognized over the period from the effective date of the agreement until such time as the clinical activities were transferred to Incyte using an input method according to research and development costs incurred to date compared to estimated total research and development costs.  These clinical activities were substantially completed as of June 30, 2018.  Prior to the adoption of ASC 606 on January 1, 2018, the accounting for this agreement did not materially differ from the accounting under ASC 606.  The Company recognized revenue of&#160;$18.8 million&#160;and $151.1 million&#160;under the Incyte Agreement during the years ended December&#160;31, 2018 and&#160;2017, respectively.   The revenue recognized during the year ended December&#160;31, 2018 included milestone revenue of $15.0 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:42pt;margin-top:9pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;The Company also has an agreement with Incyte, which was signed in 2018, under which the Company is to perform development and&#160;manufacturing services for Incyte&#x2019;s clinical needs of MGA012.  The Company evaluated this agreement under ASC 606 and identified one performance obligation under the agreement - to perform services related to manufacturing the clinical supply of MGA012.  The transaction price is based on the costs incurred to develop and manufacture drug product and drug substance, and is recognized over time as the services are provided, as the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date.   During the year ended December&#160;31, 2018, the Company recognized revenue of $22.2 million for services performed under this agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Servier &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;In September 2012, the Company entered into a collaboration agreement with Servier and granted it exclusive options to obtain three separate exclusive licenses to develop and commercialize DART molecules, consisting of those designated by the Company as flotetuzumab (also known as MGD006 or S80880) and MGD007, as well as a third DART molecule, in all countries other than the United States, Canada, Mexico, Japan, South Korea and India (Servier Agreement). During 2014, Servier exercised its exclusive option to develop and commercialize flotetuzumab.  During 2016 Servier notified the Company&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt; that it did not intend to exercise the option for the third DART molecule, and in November 2018, Servier notified the Company that it did not intend to exercise the option for MGD007.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;Upon execution of the agreement, Servier made a nonrefundable payment of $20.0 million to the Company. In addition, if Servier successfully develops, obtains regulatory approval for, and commercializes flotetuzumab, the Company will be eligible to receive up to&#160;$22.5 million in clinical milestone payments, $76.0 million in regulatory milestone payments&#160;and $210.0 million in sales milestone payments. In addition to these milestones, the Company and Servier will share Phase 2 and Phase 3 development costs.&#160; Under this agreement, Servier would be obligated to pay the Company from low double-digit to mid-teen royalties on net product sales in its territories.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;Upon the adoption of ASC&#160;606, the Company evaluated the Servier Agreement under the provisions of ASC 606 and concluded that Servier is a customer prior to the exercise of any of the three options.  The Company identified the following material promises under the arrangement for each of the three molecules:  (i) a limited evaluation license to conduct activities under the research plan and  (ii)  research and development services concluding with an option trigger data package.  The Servier Agreement also provided exclusive options for an exclusive license to research, develop, manufacture and commercialize each subject molecule. The Company evaluated these options and concluded that the options were not issued at a significant and incremental discount, and therefore do not provide material rights.  As such, they are excluded as performance obligations at the outset of the arrangement. The Company determined that each license and the related research and development services were not distinct from one another, as the license has limited value without the performance of the research and development activities.  As such, the Company determined that these promises should be combined into a single performance obligation for each molecule, resulting in a total of three performance obligations; one for flotetuzumab, one for MGD007, and one for the third DART molecule. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;The Company determined that the $20.0 million&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;upfront payment from Servier constituted the entirety of the consideration to be included in the transaction price as of the outset of the arrangement, and the transaction price was allocated to the three performance obligations based on their relative standalone selling price. &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;The milestone payments that the Company was eligible to receive prior to the exercise of the options were excluded from the transaction price, as all milestone amounts were fully constrained based on the probability of achievement. &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt; Two milestones were achieved in 2014 when the INDs for flotetuzumab and MGD007 were cleared by the Food and Drug Administration (FDA).  Upon achievement of each milestone, the constraint related to the $5.0 million milestone payment was removed and the transaction price was re-assessed. This variable consideration was allocated to each specific performance obligation in accordance with ASC 606.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:9pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;Revenue associated with each performance obligation is being recognized as the research and development services are provided using an input method according to research and development costs incurred to date compared to estimated total research and development costs. The transfer of control occurs over this time period and, in management&#x2019;s judgment, is the best measure of progress towards satisfying the performance obligation.  The full transaction price allocated to flotetuzumab and the third DART molecule was recognized as revenue prior to the adoption of ASC 606 on January 1, 2018 as the option periods had ended. The development period for MGD007 was estimated to be 75 months, ending in December 2018, therefore the transaction price allocated to MGD007 was&#160;being recognized through that date.  When Servier notified the Company that it was not exercising the option for MGD007 in November 2018, the Company recognized the remaining deferred revenue related to MGD007.  Upon the adoption of ASC 606 on January 1, 2018, the pattern of revenue recognition for the upfront fee and the accounting for the milestones received in 2014 changed, but there was no material impact to revenue recognized during the year ended December 31, 2018.  During the years ended December 31, 2018, 2017 and 2016 the Company recognized revenue of $1.9 million, $1.1 million&#160;and $1.1 million, respectively, related to the MGD007 option.  At December 31, 2018, no revenue related to the MGD007 option was deferred.  The deferred revenue balance related to the MGD007 option as of December 31, 2017, prior to the adoption of ASC 606, was $1.1 million, all of which was current.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:9pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;As discussed above, in 2014, Servier exercised its option to obtain a license to develop and commercialize flotetuzumab in its territories and paid the Company a $15.0 million license grant fee.  Upon exercise, the Company's contractual obligations include (i) granting Servier an exclusive license to its intellectual property, (ii) technical, scientific and intellectual property support to the research plan and (iii)  participation on an executive committee and a research and development committee. Under the terms of the Servier Agreement, the Company and Servier will share costs incurred to develop flotetuzumab during the license term. Due to the fact that both parties share costs and are exposed to significant risks and rewards dependent on the commercial success of the product, the Company determined that the arrangement is a collaborative arrangement within the scope of ASC 808.  The arrangement consists of two components; the license of flotetuzumab and the research and development activities, including committee participation, to support the research plan.  &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;Under the provisions of ASC 808, the Company has determined that it will use ASC 606 by analogy to recognize the revenue related to the license.  The Company evaluated its performance obligation to provide Servier with an exclusive license to &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;develop and commercialize flotetuzumab and determined that its transaction price is equal to the license grant fee payment of $15.0 million and Servier consumes the benefits of the license over time as the research and development activities are&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt; performed. Therefore, the Company will recognize the transaction price over the development period, using an input method according to research and development costs incurred to date compared to estimated total research and development costs. The additional potential clinical, regulatory and sales milestones are &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;fully constrained &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;and have been excluded from the transaction price.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:9pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;Prior to the adoption of ASC 606 on January 1, 2018, the Company recognized the license grant fee over the expected period of development on a straight-line basis. The deferred revenue balance related to the flotetuzumab license grant fee as of December 31, 2017, prior to the adoption of ASC 606, was $7.4 million. The adoption of ASC 606 increased that balance by approximately $6.4&#160;million. The adoption of ASC 606 increased revenue recognized during the year ended December 31, 2018 by $0.1&#160;million, and it will increase the revenue to be recognized in the future as the pattern of revenue recognition has changed. During the years ended December 31, 2018, 2017 and 2016 the Company recognized revenue of $1.2 million, $1.4 million, and $2.2 million, respectively, related to the flotetuzumab license grant fee.  At December 31, 2018, $12.6 million of revenue related to the flotetuzumab license grant fee was deferred, $0.9 million of which was current and $11.7 million of which was non-current.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;The research and development activities component of the arrangement is not analogous to ASC 606, therefore the Company will follow its policy to record expense incurred as research and development expense and reimbursements received from Servier will be recognized as an offset to research and development expense on the consolidated statement of operations and comprehensive loss during the development period.  During the three years ended December 31, 2018, 2017&#160;and 2016&#160;the Company recorded approximately $6.0 million, $3.2 million and $2.6 million, respectively, as an offset to research and development expense under this collaborative arrangement.&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Zai Lab  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;In November 2018, the Company entered into a collaboration and license agreement with Zai Lab (Zai Lab Agreement) under which Zai Lab obtained regional development and commercialization rights in mainland China, Hong Kong, Macau and Taiwan for (i) margetuximab, an immune-optimized anti-HER2 monoclonal antibody, (ii) MGD013, a bispecific DART molecule designed to provide coordinate blockade of PD-1 and LAG-3 for the potential treatment of a range of solid tumors and hematological malignancies, and (iii) an undisclosed multi-specific TRIDENT molecule in preclinical development. Zai Lab will lead clinical development of these molecules in its territory. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:5pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;Under the terms of the Zai Lab Agreement, Zai Lab paid the Company an upfront payment of $25.0&#160;million, less foreign withholding tax of $2.50&#160;million, which was received in January 2019.  Assuming successful development and commercialization of margetuximab, MGD013 and the TRIDENT molecule, the Company could receive up to $140.0 million in development and regulatory milestones. In addition, Zai Lab would pay the Company double-digit royalties on annual net sales of the assets, which may be subject to adjustment in specified circumstances.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:5pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;The Company evaluated the Zai Lab Agreement under the provisions of ASC 606 and identified the following material promises under the arrangement for each of the two product candidates, margetuximab and MGD013:  (i)  an exclusive license to develop and commercialize the product candidate in Zai Lab&#x2019;s territory and (ii) certain research and development activities.  The Company determined that each license and the related research and development activities were not distinct from one another, as the license has limited value without the performance of the research and development activities.  As such, the Company determined that these promises should be combined into a single performance obligation for each product candidate.  Activities related to margetuximab and MGD013 are separate performance obligations from each other because they are capable of being distinct, and are distinct in the context of the contract.  The Company evaluated the promises related to the TRIDENT molecule and determined they were immaterial in context of the contract, therefore there is no performance obligation related to that molecule.  The Company determined that the $25.0 million (less foreign withholding tax of $2.5 million) upfront payment from Zai Lab constituted the entirety of the consideration to be included in the transaction price as of the outset of the arrangement, and the transaction price was allocated to the two performance obligations based on their relative standalone selling price.  The standalone selling price of the performance obligations was determined using the adjusted market assessment approach considering similar collaboration and license agreements.  The potential development and regulatory milestone payments are fully constrained until the Company concludes that achievement of the milestone is probable, and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such have been excluded from the transaction price.  Any consideration related to royalties will be recognized when the related sales occur, as they were determined to relate predominantly to the license granted to Zai Lab and, therefore, have also been excluded from the transaction price.  The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;&#160;&#160;Due to the relatively short-term nature of the recognition period, the revenue associated with the MGD013 performance obligation is being recognized on a straight-line basis as the Company performs research and development&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt; activities under the agreement.  The fixed consideration related to the margetuximab performance obligation is also being recognized on a straight-line basis as the Company performs research and development activities under the agreement.  Straight-line recognition is materially consistent with the pattern of performance of the research and development activities of each product candidate.  The variable consideration related to the margetuximab performance obligation will be recognized upon certain regulatory achievements.  During the year ended December 31, 2018, the Company recognized revenue of $1.3 million related to the Zai Lab Agreement.  At December 31, 2018, $21.1 million of revenue was deferred under this agreement, $16.1 million of which was current.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Roche&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;In December 2017, the Company entered into a research collaboration and license agreement with Roche to jointly discover and develop novel bispecific molecules to undisclosed targets (Roche Agreement).  During the research term, both companies will leverage their respective platforms, including the Company's DART platform and Roche's CrossMAb and DutaFab technologies to select a bispecific format and lead product candidate.  Roche would then further develop and commercialize any such product candidate.  Each company will be responsible for their own expenses during the research period. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;Under the terms of the Roche Agreement, Roche received rights to use certain of the Company&#x2019;s intellectual property rights to exploit collaboration compounds and products, and paid the Company an upfront payment of $10.0 million which was received in January 2018. The Company will also be eligible to receive up to $370.0 million in potential milestone payments and royalties on future sales.  As of December&#160;31, 2018, the Company has not recognized any milestone revenue under this agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;Upon the adoption of ASC 606, the Company evaluated the Roche Agreement under the provisions of ASC 606 and identified the following promises under the agreement: (i) the non-exclusive, non-transferable, non-sublicensable license to the Company's intellectual property and (ii) the performance of certain activities during the research period.  The Company determined that the license is capable of being distinct, but is not distinct in the context of the contract because it has limited value to Roche without the research activities required to be performed by the Company.  Therefore, the Company concluded that there is one performance obligation under the agreement.  The Company determined that the transaction price of the Roche Agreement was $10.0 million.  The potential milestone payments are &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;fully constrained &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;and have been excluded from the transaction price.  Any consideration related to sales-based royalties will be recognized when the related sales occur as they were determined to relate predominantly to the license granted to Roche and therefore have also been excluded from the transaction price.    &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;The $10.0 million transaction price is being recognized over the expected research period, which is 30 months, using a cost-based input method to measure performance.   Prior to the adoption of ASC 606 on January 1, 2018, the accounting for this agreement did not materially differ from the accounting under ASC 606. The Company recognized revenue under this agreement of  $4.0 million during the year ended December&#160;31, 2018.  At December&#160;31, 2018, $6.0 million of revenue was deferred under this agreement, $4.0 million of which was current and $2.0 million of which was non-current.&#160;At December&#160;31, 2017, $10.0 million of revenue was deferred under this agreement,  $4.0 million of which was current and $6.0 million of which was non-current.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Provention&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;In May 2018, the Company entered into a license agreement with Provention pursuant to which the Company granted Provention exclusive global rights for the purpose of developing and commercializing MGD010 (renamed PRV-3279), a CD32B x CD79B DART molecule being developed for the treatment of autoimmune indications (Provention License Agreement).  As partial consideration for the Provention License Agreement, Provention granted the Company a warrant to purchase shares of Provention&#x2019;s common stock at an exercise price of $2.50 per share. The warrant expires on May 7, 2025.  If Provention successfully develops, obtains regulatory approval for, and commercializes PRV-3279, the Company will be eligible to receive up to $65.0 million in development and regulatory milestones and up to $225.0 million in commercial milestones.  As of December 31, 2018, the Company has not recognized any milestone revenue under this agreement.  If commercialized, the Company would be eligible to receive single-digit royalties on net sales of the product.  The license agreement may be terminated by either party upon a material breach or bankruptcy of the other party, by Provention without cause upon prior notice to the Company, and by the Company in the event that Provention challenges the validity of any licensed patent under the agreement, but only with respect to the challenged patent.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;&#160;Also in May 2018, the Company entered into an asset purchase agreement with Provention pursuant to which Provention acquired the Company&#x2019;s interest in teplizumab (renamed PRV-031), a monoclonal antibody being developed for the treatment of type 1 diabetes (Asset Purchase Agreement).  As partial consideration for the Asset Purchase Agreement, Provention granted the Company a warrant to purchase shares of Provention&#x2019;s common stock at an exercise price of $2.50 per&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt; share.  The warrant expires on May 7, 2025.  If Provention successfully develops, obtains regulatory approval for, and commercializes PRV-031, the Company will be eligible to receive up to $170.0 million in regulatory milestones and up to $225.0 million in commercial milestones.  If commercialized, the Company would be eligible to receive single-digit royalties on net sales of the product.  Provention has also agreed to pay third-party obligations, including low single-digit royalties, a portion of which is creditable against royalties payable to the Company, aggregate milestone payments of up to approximately $1.3 million and other consideration, for certain third-party intellectual property under agreements Provention is assuming pursuant to the Asset Purchase Agreement. Further, Provention is required to pay the Company a low double-digit percentage of certain consideration to the extent it is received in connection with a future grant of rights to PRV-031 by Provention to a third party. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;The Company evaluated the Provention License Agreement and Asset Purchase Agreement under the provisions of ASC 606 and determined that they should be accounted for as a single contract and identified two performance obligations within that contract: (i) the license of MGD010 and (ii) the title to teplizumab.  The Company determined that the transaction price of the Provention agreements was $6.1 million, based on the Black-Scholes valuation of the warrants to purchase a total of 2,432,688 shares of Provention's common stock.  The transaction price was allocated to each performance obligation based on the number of shares of common stock the Company is entitled to purchase under each warrant.  The potential development and regulatory milestone payments are fully constrained until the Company concludes that achievement of the milestone is probable and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such have been excluded from the transaction price.  Any consideration related to sales-based milestones and royalties will be recognized when the related sales occur, therefore they have also been excluded from the transaction price.  The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;The Company recognized revenue of $6.1 million when it satisfied its performance obligations and transferred the MGD010 license and teplizumab assets to Provention in May 2018.  The warrants are reported in other assets on the balance sheet at December&#160;31, 2018 and will be revalued at each reporting period until exercised or the warrants lapse.  &#160;The Company revalued the warrants based on current Black-Scholes parameters&#160;as of December&#160;31, 2018,&#160;and recorded a decrease of $4.2 million in other assets.  This revaluation is reflected in other income (expense) on the consolidated statements of operations and comprehensive loss for the year ended December&#160;31, 2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Janssen&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#ee2724;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;In December 2014, the Company entered into a collaboration and license agreement with Janssen for the development and commercialization of MGD011 (also known as JNJ-64052781 or duvortuxizumab), a product candidate that incorporates the Company's proprietary DART technology to simultaneously target CD19 and CD3 for the potential treatment of B-cell hematological malignancies (MGD011 Agreement). The Company contemporaneously entered into an agreement with JJDC under which JJDC agreed to purchase 1,923,077 new shares of the Company's common stock for proceeds of $75.0 million.&#160;&#160;Upon closing the transaction in January 2015, the Company received a $50.0 million upfront payment from Janssen as well as the $75.0 million investment in the Company's common stock.&#160;&#160; In August 2017, Janssen notified the Company that they were terminating the MGD011 Agreement.&#160;No revenue was recognized under the MGD011 Agreement during the years ended December 31, 2017 and 2018.  The Company recognized revenue of &#160;$2.0 million&#160;during the year ended December 31, 2016.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;In May 2016, the Company entered into a collaboration and license agreement with Janssen, a related party through ownership of the Company's common stock, for the development and commercialization of MGD015, a product candidate that incorporates the Company's proprietary DART technology to simultaneously target CD3 and an undisclosed tumor target for the potential treatment of various hematological malignancies and solid tumors (MGD015 Agreement). Under the MGD015 Agreement, the Company granted an exclusive license to Janssen to develop and commercialize MGD015.  The Company received a $75.0 million upfront payment from Janssen upon closing the transaction, which was recognized as revenue in 2016.  In January 2018, Janssen notified the Company that they were terminating the MGD015 Agreement. No&#160;revenue was recognized under the MGD015 Agreement during the year ended December 31, 2018. The Company recognized revenue of $0.6 million and&#160;$75.8 million&#160;during the years ended December 31, 2017 and 2016, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;The revenue under both the MGD011 and MGD015 Agreements was fully recognized prior to the adoption of ASC&#160;606.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;NIAID Contract&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;The Company entered into a contract with the National Institute of Allergy and Infectious Diseases (NIAID), effective as of September&#160;15, 2015,&#160;to perform product development and to advance up to two DART molecules, including MGD014. Under this contract, the Company will develop these product candidates for Phase 1/2 clinical trials as therapeutic agents, in combination with latency reversing treatments, to deplete cells infected with human immunodeficiency virus (HIV) infection. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt; NIAID does not receive goods or services from the Company under this contract, therefore the Company does not consider NIAID to be a customer and concluded this contract is outside the scope of ASC 606.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;This contract includes a base period of $7.5 million to support development of MGD014 through IND application submission with the FDA, as well as up to $17.0 million in additional development funding via NIAID options. Should NIAID fully exercise such options, the Company could receive total payments of up to $24.5 million. The total potential period of performance under the award is from September 15, 2015 through September&#160;14, 2022.  During the year ended December 31, 2017, NIAID exercised the first option in the amount of $10.8 million. The Company recognized revenue of $1.3 million, $1.7 million and $5.1 million under this contract during the years ended December&#160;31, 2018, 2017 and 2016, respectively.&lt;/span&gt;&lt;/div&gt;</mgnx:CollaborationAndLicenseAgreementsDisclosureTextBlock>
    <mgnx:NonRefundableUpfrontFees
      contextRef="i44dc827b9c5849c9874770cafc78df7e_D20171001-20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzUyNQ_d27b3381-eb6e-4ce0-9bac-4e8781ecf5b1"
      unitRef="usd">150000000.0</mgnx:NonRefundableUpfrontFees>
    <mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement
      contextRef="i591dac725a2648e68258b7105447f85d_I20171031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzgzNQ_bca0ccf7-a68d-41c9-9a4b-98422ca81e64"
      unitRef="usd">420000000.0</mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement>
    <mgnx:PotentialCommercialMilestonePaymentsUnderAgreement
      contextRef="i591dac725a2648e68258b7105447f85d_I20171031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3Xzg5MA_e5e92156-8366-437f-992c-828f537284c6"
      unitRef="usd">330000000.0</mgnx:PotentialCommercialMilestonePaymentsUnderAgreement>
    <mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized
      contextRef="i82b03c819e73441db6d085233d218937_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzMyOTg1MzQ5NzIyMzQ_8cb8bd2b-484f-446a-9a32-dc768d3280ed"
      unitRef="usd">15000000.0</mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized>
    <mgnx:ProceedsfromRoyaltiesPercent
      contextRef="ia93c5065a4f94e9f9e0c596d50d7aa2f_D20171001-20171031"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzEzODE_586daebe-816b-48a2-bf41-8ca4f1f81b55"
      unitRef="number">0.15</mgnx:ProceedsfromRoyaltiesPercent>
    <mgnx:ProceedsfromRoyaltiesPercent
      contextRef="i91850bdafeb5443c8e0569e57b38e238_D20171001-20171031"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzEzODc_f117cddc-d82a-41ec-b201-393321972d40"
      unitRef="number">0.24</mgnx:ProceedsfromRoyaltiesPercent>
    <mgnx:CollaborativeAgreementTransactionPrice
      contextRef="iff7efae7eb26446bbaa573fe3861e53c_I20171031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzMyOTg1MzQ5NzIyNTE_48d05c3c-46d7-44da-a8db-8716eed7876d"
      unitRef="usd">154000000.0</mgnx:CollaborativeAgreementTransactionPrice>
    <mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized
      contextRef="i82b03c819e73441db6d085233d218937_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzMyOTg1MzQ5NzIyNTQ_8cb8bd2b-484f-446a-9a32-dc768d3280ed"
      unitRef="usd">15000000.0</mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized>
    <mgnx:NonRefundableUpfrontFees
      contextRef="i44dc827b9c5849c9874770cafc78df7e_D20171001-20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzMyOTg1MzQ5NzIyNzA_d27b3381-eb6e-4ce0-9bac-4e8781ecf5b1"
      unitRef="usd">150000000.0</mgnx:NonRefundableUpfrontFees>
    <us-gaap:RevenueRecognitionMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount
      contextRef="if61293acd6f643bf8daf43be5cf2bd6e_D20171001-20171031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzMyOTg1MzQ5NzIyODc_b8238625-c9d7-4098-bb76-442e8fd9ee37"
      unitRef="usd">4000000.0</us-gaap:RevenueRecognitionMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount>
    <us-gaap:Revenues
      contextRef="i8eb24f3f49444597a89f49edae260720_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzMyOTg1MzQ5NzIzNzc_851e0ddb-34a2-4fc2-a60a-dc98997d8a22"
      unitRef="usd">18800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6a111d57d3bf49428df5748987d6471b_D20170101-20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzMyOTg1MzQ5NzIzMTY_a8c6ef15-f6a0-4822-a823-92464af4b8a4"
      unitRef="usd">151100000</us-gaap:Revenues>
    <mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized
      contextRef="i82b03c819e73441db6d085233d218937_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzM4NDgyOTA4NDE5NzA_8cb8bd2b-484f-446a-9a32-dc768d3280ed"
      unitRef="usd">15000000.0</mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized>
    <us-gaap:Revenues
      contextRef="idd27a98828844b21ad9d5646ef79f6e2_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzMyOTg1MzQ5NzIzODE_813c68f6-03d8-4194-9d5a-96221a7833f9"
      unitRef="usd">22200000</us-gaap:Revenues>
    <mgnx:NonRefundableUpfrontFees
      contextRef="i6011d16a582a445fa400c0dfcf98028a_D20120901-20120930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzE3MTQ0_e20a75af-8bff-4c10-83b2-bdf8391ba08a"
      unitRef="usd">20000000.0</mgnx:NonRefundableUpfrontFees>
    <mgnx:PotentialClinicalMilestonePaymentsUnderAgreement
      contextRef="id5778ce3b2cd44b79c13685e1d2a707d_I20120930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzE3MjQy_08ad33e1-90d8-4e4c-bce3-d445a98441cc"
      unitRef="usd">22500000</mgnx:PotentialClinicalMilestonePaymentsUnderAgreement>
    <mgnx:PotentialRegulatoryMilestonePaymentsUnderAgreement
      contextRef="id5778ce3b2cd44b79c13685e1d2a707d_I20120930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzE3Mjc3_c512d925-586b-4271-b6ce-431270e862b6"
      unitRef="usd">76000000.0</mgnx:PotentialRegulatoryMilestonePaymentsUnderAgreement>
    <mgnx:PotentialSalesMilestonePaymentsUnderAgreement
      contextRef="id5778ce3b2cd44b79c13685e1d2a707d_I20120930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzE3MzE3_cf0411cb-a2c4-438b-bf2e-79174c2377bf"
      unitRef="usd">210000000.0</mgnx:PotentialSalesMilestonePaymentsUnderAgreement>
    <mgnx:NonRefundableUpfrontFees
      contextRef="i6011d16a582a445fa400c0dfcf98028a_D20120901-20120930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzU0OTc1NTk3MTc4Ng_1579b4ac-e547-4e9e-8cf1-2bec386c39b8"
      unitRef="usd">20000000.0</mgnx:NonRefundableUpfrontFees>
    <mgnx:MilestonePayment
      contextRef="i6011d16a582a445fa400c0dfcf98028a_D20120901-20120930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzU0OTc1NTk3MTgwMQ_a64c0cab-9e38-4c24-9b6c-b5132e373473"
      unitRef="usd">5000000.0</mgnx:MilestonePayment>
    <us-gaap:Revenues
      contextRef="ia01940c5140d475d823101c59b4c6ee3_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzU0OTc1NTk3MTg4MA_f83274a3-c45b-445b-858f-315ef5a153c0"
      unitRef="usd">1900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9d3ce417f9d9482d96c963058758500b_D20170101-20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzU0OTc1NTk3MTg2Ng_cb645608-3a61-4bd2-8e4d-4579e587e4df"
      unitRef="usd">1100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5e802bb4cb124fb3a1bf94de3a31e858_D20160101-20161231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzU0OTc1NTk3MTg1Mg_035942d3-6a28-4361-b342-284214d0ec8a"
      unitRef="usd">1100000</us-gaap:Revenues>
    <us-gaap:ContractWithCustomerLiability
      contextRef="ida270b9128b24424808f7af121ae03e7_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzU0OTc1NTk3MTgyMg_a8d20ce1-e0bf-4071-a835-e2f380be7b10"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:DeferredRevenueCurrent
      contextRef="i3dae8b73ee0b42df83fe2e75389bd1b7_I20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzU0OTc1NTk3MTgzOA_02e4c669-c804-4586-8299-72186d9ff2a6"
      unitRef="usd">1100000</us-gaap:DeferredRevenueCurrent>
    <mgnx:OptionExerciseFee
      contextRef="i98b48a96e93a4ea59eb53d0d51847ea3_I20151231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzU0OTc1NTk3MTgxNw_952b7f51-0a2d-4eb9-9e64-0c23c9f416fe"
      unitRef="usd">15000000.0</mgnx:OptionExerciseFee>
    <us-gaap:DeferredRevenue
      contextRef="i3b00e539a3324792b34321e6c7168fb8_I20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzI3NDg3NzkyMjkwOTc_3151f796-ca37-4351-8733-2c6c5b3d0c86"
      unitRef="usd">7400000</us-gaap:DeferredRevenue>
    <us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress
      contextRef="i6c17e3fb438e49b4bf933e03642b33d6_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzI3NDg3NzkyMjkxNjU_62b22102-b63e-4bbb-8ee2-489582989292"
      unitRef="usd">6400000</us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i6c17e3fb438e49b4bf933e03642b33d6_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzI3NDg3NzkyMjkyNjU_a8203951-ef59-4bef-b9d6-be7c8652899f"
      unitRef="usd">100000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:Revenues
      contextRef="i09a4e2abc6f64d09984d04c7e51e159a_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzI3NDg3NzkyMjk4OTU_5e1f0919-0a4a-4ee1-b888-e21ec5761ec4"
      unitRef="usd">1200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i77625ed2e7734703b52942e3929dec22_D20170101-20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzI3NDg3NzkyMjk4OTk_176b64d1-3db0-416d-8a55-442f41483404"
      unitRef="usd">1400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0dd3b4b1fefc4e54956a0cd97918d963_D20160101-20161231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzI3NDg3NzkyMjk5MDc_52cddb32-880d-427e-9053-f6b62373b840"
      unitRef="usd">2200000</us-gaap:Revenues>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i7c0265f36dcf411893aa87db114e0f16_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzI3NDg3NzkyMjk5OTM_7bede7d1-913e-4494-9843-18a2a2dcf4f7"
      unitRef="usd">12600000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i7c0265f36dcf411893aa87db114e0f16_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzI3NDg3NzkyMzAwNjU_1787b9f6-7640-4ee5-b093-0badc503ac24"
      unitRef="usd">900000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i7c0265f36dcf411893aa87db114e0f16_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzI3NDg3NzkyMzAwOTM_2945e6d3-28b1-432d-8fb4-6acff37d5da4"
      unitRef="usd">11700000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <mgnx:CollaborationArrangementOffsetToResearchAndDevelopmentCosts
      contextRef="i6c17e3fb438e49b4bf933e03642b33d6_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzQzOTgwNDY2MDA0ODE_bc9beb8d-95cd-404c-9ba0-bc48693454b0"
      unitRef="usd">6000000.0</mgnx:CollaborationArrangementOffsetToResearchAndDevelopmentCosts>
    <mgnx:CollaborationArrangementOffsetToResearchAndDevelopmentCosts
      contextRef="i87ceca0edd234d059fdd917ce29f5f4b_D20170101-20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzQzOTgwNDY2MDA1MTk_9acd8b41-16d8-48d0-a266-0050f10911fe"
      unitRef="usd">3200000</mgnx:CollaborationArrangementOffsetToResearchAndDevelopmentCosts>
    <mgnx:CollaborationArrangementOffsetToResearchAndDevelopmentCosts
      contextRef="i625f3d08dc954d518764769a7feaeefc_D20160101-20161231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzQzOTgwNDY2MDA1MzQ_4dcb6784-f90b-4b83-8126-5caee174c0fd"
      unitRef="usd">2600000</mgnx:CollaborationArrangementOffsetToResearchAndDevelopmentCosts>
    <mgnx:NonRefundableUpfrontFees
      contextRef="i29ff7281a75a4936a4be6c1359e216e9_D20181101-20181130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzY1OTcwNjk5MzA4NjI_7b000da2-87e5-4943-950d-8b216ea6d09a"
      unitRef="usd">25000000.0</mgnx:NonRefundableUpfrontFees>
    <mgnx:NonrefundablePaymentTaxWithholding
      contextRef="i29ff7281a75a4936a4be6c1359e216e9_D20181101-20181130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzY1OTcwNjk5MzA4OTg_17087981-fe18-4a02-a0c4-948445331445"
      unitRef="usd">2500000</mgnx:NonrefundablePaymentTaxWithholding>
    <mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement
      contextRef="i7e972d120beb4fdaae31b0300fbc48ee_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzY1OTcwNjk5MzEwNzU_86f37c5a-3a14-4c5a-9fba-103f0c9d995d"
      unitRef="usd">140000000.0</mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement>
    <mgnx:NonRefundableUpfrontFees
      contextRef="i29ff7281a75a4936a4be6c1359e216e9_D20181101-20181130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzY1OTcwNjk5MzI0NDc_7b000da2-87e5-4943-950d-8b216ea6d09a"
      unitRef="usd">25000000.0</mgnx:NonRefundableUpfrontFees>
    <mgnx:NonrefundablePaymentTaxWithholding
      contextRef="i29ff7281a75a4936a4be6c1359e216e9_D20181101-20181130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzY1OTcwNjk5MzI0ODM_17087981-fe18-4a02-a0c4-948445331445"
      unitRef="usd">2500000</mgnx:NonrefundablePaymentTaxWithholding>
    <us-gaap:Revenues
      contextRef="id73733a0f1994e42b2954427356cb7e5_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzY1OTcwNjk5MzQ1Mjg_e8c46488-e65d-4ce0-9040-68cab7d8dc42"
      unitRef="usd">1300000</us-gaap:Revenues>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i7e972d120beb4fdaae31b0300fbc48ee_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzY1OTcwNjk5MzQ1ODg_1a04f8f6-2cde-43d9-bea7-e578db445b02"
      unitRef="usd">21100000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i7e972d120beb4fdaae31b0300fbc48ee_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzY1OTcwNjk5MzQ2Mzc_37ab8596-cf42-4089-95e4-06ef43133581"
      unitRef="usd">16100000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <mgnx:NonRefundableUpfrontFees
      contextRef="i8ae89b363134495b9cc3cdf7d4ce1a06_D20180101-20180131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzI3NDg3NzkyMTUwMzM_36679533-589e-48c1-b819-f457e47795e5"
      unitRef="usd">10000000.0</mgnx:NonRefundableUpfrontFees>
    <mgnx:PotentialMilestonePaymentsandRoyaltiesonFutureSalesunderAgreement
      contextRef="i77f6204290544a298e027e842269f6bc_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzI3NDg3NzkyMTUxMjM_45972fd9-950f-4089-a3be-da2ee1f649a1"
      unitRef="usd">370000000.0</mgnx:PotentialMilestonePaymentsandRoyaltiesonFutureSalesunderAgreement>
    <mgnx:NonRefundableUpfrontFees
      contextRef="i8ae89b363134495b9cc3cdf7d4ce1a06_D20180101-20180131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzI3NDg3NzkyMTU5OTc_b49fc543-9fad-4237-b35c-3998479bf445"
      unitRef="usd">10000000.0</mgnx:NonRefundableUpfrontFees>
    <mgnx:NonRefundableUpfrontFees
      contextRef="i8ae89b363134495b9cc3cdf7d4ce1a06_D20180101-20180131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzI3NDg3NzkyMTYzNjM_b49fc543-9fad-4237-b35c-3998479bf445"
      unitRef="usd">10000000.0</mgnx:NonRefundableUpfrontFees>
    <mgnx:UpfrontPaymentRecognitionPeriod
      contextRef="i097ea6f211524140a29381dc3bce7129_D20171201-20171231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzI3NDg3NzkyMTY0NDg_56f1aec2-4f41-4523-9e1d-8421e089e5ec">P30M</mgnx:UpfrontPaymentRecognitionPeriod>
    <us-gaap:Revenues
      contextRef="i5a4fe51377ba48ef83d87242a98d90ec_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzI3NDg3NzkyMTY3MTQ_80b16e99-8b30-4720-9e5e-eeade368aa3f"
      unitRef="usd">4000000.0</us-gaap:Revenues>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i77f6204290544a298e027e842269f6bc_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzI3NDg3NzkyMTY3NTE_7ac127c3-33d0-4aeb-9770-1de0c4bf9916"
      unitRef="usd">6000000.0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i77f6204290544a298e027e842269f6bc_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzI3NDg3NzkyMTY4MDA_600cbe92-b637-4244-87f9-a3a74e13219b"
      unitRef="usd">4000000.0</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i77f6204290544a298e027e842269f6bc_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzI3NDg3NzkyMTY4Mjg_3ea32612-a8c1-4bf7-86fe-f2a7230ffad9"
      unitRef="usd">2000000.0</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:DeferredRevenue
      contextRef="i9b14f1378bdc4abf90dd05dd5956ca30_I20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzI3NDg3NzkyMTY4NjQ_7e5c5d4c-4d0a-4089-b196-9f2a06d3b583"
      unitRef="usd">10000000.0</us-gaap:DeferredRevenue>
    <us-gaap:DeferredRevenueCurrent
      contextRef="i9b14f1378bdc4abf90dd05dd5956ca30_I20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzI3NDg3NzkyMTY5MTQ_f7dc4473-5f89-4c6a-bff7-b21f66fa887e"
      unitRef="usd">4000000.0</us-gaap:DeferredRevenueCurrent>
    <us-gaap:DeferredRevenueNoncurrent
      contextRef="i9b14f1378bdc4abf90dd05dd5956ca30_I20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzI3NDg3NzkyMTY5NDI_27f806cb-7020-479b-b729-65e20d2bea90"
      unitRef="usd">6000000.0</us-gaap:DeferredRevenueNoncurrent>
    <mgnx:CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare
      contextRef="i47f11d0af1aa4444aae4bba0ddf73a6c_D20180501-20180531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzQzOTgwNDY2Njk5MTc_69f83b4c-1da1-4126-83da-6fdf1720bbd5"
      unitRef="usdPerShare">2.50</mgnx:CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare>
    <mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement
      contextRef="id16ca02732fe4f1b8d21590f441cb5dd_I20180531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzQzOTgwNDY2Njk5MzU_c9195d13-7575-4e62-adb7-af5e3935dd13"
      unitRef="usd">65000000.0</mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement>
    <mgnx:PotentialCommercialMilestonePaymentsUnderAgreement
      contextRef="id16ca02732fe4f1b8d21590f441cb5dd_I20180531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzQzOTgwNDY2Njk5NTI_89d8368e-6237-450e-b1ff-72884b82faa0"
      unitRef="usd">225000000.0</mgnx:PotentialCommercialMilestonePaymentsUnderAgreement>
    <mgnx:CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare
      contextRef="i575e134561384052b8d5150268d0bc0c_D20180501-20180531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzQzOTgwNDY2Njk5NjA_29f01b72-d889-40f6-8780-61bedb0851f2"
      unitRef="usdPerShare">2.50</mgnx:CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare>
    <mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement
      contextRef="ie95e8086ae9b4cd69fc3763d4b03138b_I20180531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzQzOTgwNDY2Njk5NzY_fbcb10b6-6eed-4783-bda8-b44b9f144dbc"
      unitRef="usd">170000000.0</mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement>
    <mgnx:PotentialCommercialMilestonePaymentsUnderAgreement
      contextRef="ie95e8086ae9b4cd69fc3763d4b03138b_I20180531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzQzOTgwNDY2Njk5OTM_ffec0cc1-0462-4f71-b662-8219ef42401a"
      unitRef="usd">225000000.0</mgnx:PotentialCommercialMilestonePaymentsUnderAgreement>
    <mgnx:PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement
      contextRef="ie95e8086ae9b4cd69fc3763d4b03138b_I20180531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzQzOTgwNDY2NzAwMDg_b2dbf843-428e-4572-907b-f16c47e89eea"
      unitRef="usd">1300000</mgnx:PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement>
    <mgnx:CollaborativeAgreementTransactionPrice
      contextRef="i918dca9fcdce44a999dec3002edfedac_I20180531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzQzOTgwNDY2NzAwMjM_57a85b0f-34e4-47d5-bf5b-7d3c36f6cbbd"
      unitRef="usd">6100000</mgnx:CollaborativeAgreementTransactionPrice>
    <mgnx:CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares
      contextRef="i918dca9fcdce44a999dec3002edfedac_I20180531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzQzOTgwNDY2NzAwMzU_15da8e2b-4db0-4413-a071-dc1c04b6fb83"
      unitRef="shares">2432688</mgnx:CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares>
    <us-gaap:Revenues
      contextRef="ie23f02f7751b4b5d8b10bc0c6f10cf97_D20180501-20180531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzQzOTgwNDY2NzAwNTE_3335534b-5a21-4f43-aabf-8a6f158ab6ec"
      unitRef="usd">6100000</us-gaap:Revenues>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="i5c503df7c4d74a6aa791c924760e58de_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzQzOTgwNDY2NzAwNjY_2bbffab8-0d58-4dc8-8ab8-67fe7c0b5f7e"
      unitRef="usd">-4200000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i9c0bb24d85b742029840e8ff19e39e21_D20141201-20141231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzMyOTg1MzQ5NjkyNzY_388caaa8-3271-44d3-b95a-3a7818b0c149"
      unitRef="shares">1923077</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i9c0bb24d85b742029840e8ff19e39e21_D20141201-20141231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzMyOTg1MzQ5NjkzMzY_5fce28a3-2119-411a-8d1e-c24f699cc331"
      unitRef="usd">75000000.0</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <mgnx:NonRefundableUpfrontFees
      contextRef="iad112c3f4a95410eb177b18bf2a325e8_D20160101-20161231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzMyOTg1MzQ5Njk0MTA_f05f82a7-7ff0-4e50-8011-15795ef4b883"
      unitRef="usd">50000000.0</mgnx:NonRefundableUpfrontFees>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="iba7d66ba85e246e0b3b81bde3c507cd4_D20150101-20150131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzMyOTg1MzQ5Njk0NTc_c13555f0-b76d-43af-99db-5bb19ecc31cc"
      unitRef="usd">75000000.0</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:Revenues
      contextRef="i36abedfa020b41798bb4a1de0b5826b9_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzU0OTc1NTk3MTcyNw_5bba558c-5461-49fe-aeaa-2802b2c8895c"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iafa5f3f8c3964fd3a2fb20d5a78444ae_D20160101-20161231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzU0OTc1NTk3MTcyMg_f07604a6-b522-4b29-a6ae-877b30d15a74"
      unitRef="usd">2000000.0</us-gaap:Revenues>
    <mgnx:NonRefundableUpfrontFees
      contextRef="i0dbfb405829a4954939345567d9ffa41_D20160701-20160731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzMyOTg1MzQ5NzAxOTQ_4c48f1e8-e7dc-4bf5-a328-37caa29d4b74"
      unitRef="usd">75000000.0</mgnx:NonRefundableUpfrontFees>
    <us-gaap:Revenues
      contextRef="i5bd2775f85934df4a35546668e5cf0a5_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzU0OTc1NTk3MTc2Nw_c77edbb9-e21b-4f52-a822-14379849743f"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6635b351add74cb695103957cc02cac1_D20170101-20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzU0OTc1NTk3MTc0NA_29ca3929-feec-4d0a-99ca-df238ddaf4f1"
      unitRef="usd">600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibdc4a8d5c6b240faac1049620a8692b6_D20160101-20161231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzU0OTc1NTk3MTc2MA_03bdd0d7-5a0b-4340-8090-94a05c4ebb2d"
      unitRef="usd">75800000</us-gaap:Revenues>
    <mgnx:NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement
      contextRef="ie5dd3f325a0e4bb2bd1f768f5d1cfb31_D20150915-20150915"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzI5NDE1_097642b1-4dbf-49d9-9221-1434af522076"
      unitRef="molecule">2</mgnx:NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement>
    <mgnx:FundedValueOfBasePeriod
      contextRef="ie5dd3f325a0e4bb2bd1f768f5d1cfb31_D20150915-20150915"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzI5NzQz_402cd8bc-630d-4f9d-94de-6f6d438192f2"
      unitRef="usd">7500000</mgnx:FundedValueOfBasePeriod>
    <mgnx:AdditionalDevelopmentFundingOptionsUnderAgreement
      contextRef="ib0d39c7c6f4e42388328978bd1a0c321_D20150915-20150915"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzI5ODQ1_55b5b29b-623d-4a88-94b6-2ad55f34ec0a"
      unitRef="usd">17000000.0</mgnx:AdditionalDevelopmentFundingOptionsUnderAgreement>
    <mgnx:TotalPotentialValueUnderAgreement
      contextRef="ib0d39c7c6f4e42388328978bd1a0c321_D20150915-20150915"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzI5OTkz_df7bd22c-a40c-494c-a87d-339bed92d484"
      unitRef="usd">24500000</mgnx:TotalPotentialValueUnderAgreement>
    <mgnx:ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement
      contextRef="icbe3942778e048a7812d0b367cba79e4_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzMwMTcx_218c2ca3-c961-43dc-bb6e-64e33bf6d36a"
      unitRef="usd">10800000</mgnx:ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement>
    <us-gaap:Revenues
      contextRef="iae19a3f2560f46ea9ce3d9769293ef55_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzMwMjA5_f868acec-4ef7-43db-97f1-2c0bdbf1a472"
      unitRef="usd">1300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8a451cc24b4245fe93b83bc7127cf807_D20170101-20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzMwMjEz_d0701468-310d-487f-a83b-95e40be5016e"
      unitRef="usd">1700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i355ceffdd61e4654b0c765f0f6734378_D20160101-20161231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NDcvZnJhZzo3M2Q0NTBiYmY1NzU0MjBiODNhNzIyYTE1NjYxYTczNy90ZXh0cmVnaW9uOjczZDQ1MGJiZjU3NTQyMGI4M2E3MjJhMTU2NjFhNzM3XzMwMjIw_2cd2e840-bc14-4a2a-bdb3-50234874f7f7"
      unitRef="usd">5100000</us-gaap:Revenues>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NzIvZnJhZzo1ZGU1YzhjMGI3YzQ0YTMyODg2OTM5Nzc0M2Q5MmJiMy90ZXh0cmVnaW9uOjVkZTVjOGMwYjdjNDRhMzI4ODY5Mzk3NzQzZDkyYmIzXzI2MTQ_d6eeff55-3547-4b99-90fd-6adc8729bdea">Commitments and Contingencies&#160;&lt;div style="margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Operating Leases&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;The Company leases manufacturing, office and laboratory space in Rockville, Maryland under five leases that have terms that expire between 2019 and 2027 unless renewed.&#160;&#160;During the year ended December&#160;31, 2017, the&#160;Company entered into an agreement to sublease a portion of the space&#160;it leases.  As of December 31, 2018,&#160;the Company will receive $1.1 million in future payments under this sublease.  The Company also leases office and laboratory space in Brisbane, California under a lease that expires in November 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt; The Rockville leases include a lease executed in July 2015 for space that the Company uses as its headquarters with office, laboratory, and manufacturing space.&#160;&#160; Under the terms of the lease, which commenced on January&#160;1, 2016, the Company received an assignment fee from the former tenant and a tenant improvement allowance from the landlord totaling $5.1 million.&#160;&#160;During 2017, the Company executed a lease amendment for its headquarters building which extends the term of the lease to August 2027, restructures the rent due under the lease, and provides for an additional tenant improvement allowance from the landlord of $7.5 million.  The assignment fee and tenant improvement allowances have been recorded as deferred rent and are being recognized over the new lease term.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:3pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;All of the leases contain rent escalation clauses and certain leases contain rent abatements.&#160;&#160;For financial reporting purposes, rent expense is charged to operations on a straight-line basis over the term of the lease.&#160;&#160;As of December&#160;31, 2018 and 2017, the Company had recorded a deferred rent liability of $11.3 million and $12.3 million, respectively. Rent expense for the years ended December&#160;31, 2018, 2017 and 2016 was $4.4 million, $3.1 million and $3.0 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;Future minimum lease payments under noncancelable operating leases as of December&#160;31, 2018 are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:86.269795%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.730205%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,865&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;13,786&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;39,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Contingencies&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;From time to time, the Company may be subject to various litigation and related matters arising in the ordinary course of business. The Company does not believe it is currently subject to any material matters where there is at least a reasonable possibility that a material loss may be incurred.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <mgnx:NumberOfLease
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NzIvZnJhZzo1ZGU1YzhjMGI3YzQ0YTMyODg2OTM5Nzc0M2Q5MmJiMy90ZXh0cmVnaW9uOjVkZTVjOGMwYjdjNDRhMzI4ODY5Mzk3NzQzZDkyYmIzXzE1MA_0cab8532-9d36-42c9-b569-2ca6e552132d"
      unitRef="lease">5</mgnx:NumberOfLease>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals
      contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NzIvZnJhZzo1ZGU1YzhjMGI3YzQ0YTMyODg2OTM5Nzc0M2Q5MmJiMy90ZXh0cmVnaW9uOjVkZTVjOGMwYjdjNDRhMzI4ODY5Mzk3NzQzZDkyYmIzXzI3NDg3NzkwNzMxMDc_8f38218b-bee2-4280-9356-92e21b99a339"
      unitRef="usd">1100000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals>
    <us-gaap:PaymentsForProceedsFromTenantAllowance
      contextRef="i121ff22ae7d04521bf402d62951d21e4_D20150701-20150731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NzIvZnJhZzo1ZGU1YzhjMGI3YzQ0YTMyODg2OTM5Nzc0M2Q5MmJiMy90ZXh0cmVnaW9uOjVkZTVjOGMwYjdjNDRhMzI4ODY5Mzk3NzQzZDkyYmIzXzgxOQ_a4f33697-acc8-41d7-a875-205728b3fa20"
      unitRef="usd">5100000</us-gaap:PaymentsForProceedsFromTenantAllowance>
    <us-gaap:PaymentsForProceedsFromTenantAllowance
      contextRef="ic26431cbd9dd45ba8f73dd80dc1df8ec_D20170721-20170721"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NzIvZnJhZzo1ZGU1YzhjMGI3YzQ0YTMyODg2OTM5Nzc0M2Q5MmJiMy90ZXh0cmVnaW9uOjVkZTVjOGMwYjdjNDRhMzI4ODY5Mzk3NzQzZDkyYmIzXzEwODQ_39079c59-58ed-4d89-88f9-a627bbbae2de"
      unitRef="usd">7500000</us-gaap:PaymentsForProceedsFromTenantAllowance>
    <us-gaap:DeferredRentCredit
      contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NzIvZnJhZzo1ZGU1YzhjMGI3YzQ0YTMyODg2OTM5Nzc0M2Q5MmJiMy90ZXh0cmVnaW9uOjVkZTVjOGMwYjdjNDRhMzI4ODY5Mzk3NzQzZDkyYmIzXzIwODg_20050fc8-47e8-47ff-ab56-e115f6757c0a"
      unitRef="usd">11300000</us-gaap:DeferredRentCredit>
    <us-gaap:DeferredRentCredit
      contextRef="i7057397719af459ca7328a1c440a0efa_I20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NzIvZnJhZzo1ZGU1YzhjMGI3YzQ0YTMyODg2OTM5Nzc0M2Q5MmJiMy90ZXh0cmVnaW9uOjVkZTVjOGMwYjdjNDRhMzI4ODY5Mzk3NzQzZDkyYmIzXzIwOTU_1f5e14a9-c626-4f01-99f7-b1fbed9fe958"
      unitRef="usd">12300000</us-gaap:DeferredRentCredit>
    <us-gaap:OperatingLeasesRentExpenseNet
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NzIvZnJhZzo1ZGU1YzhjMGI3YzQ0YTMyODg2OTM5Nzc0M2Q5MmJiMy90ZXh0cmVnaW9uOjVkZTVjOGMwYjdjNDRhMzI4ODY5Mzk3NzQzZDkyYmIzXzIxNjQ_330efefb-7ad0-4ac5-88dc-c1a433e8fc46"
      unitRef="usd">4400000</us-gaap:OperatingLeasesRentExpenseNet>
    <us-gaap:OperatingLeasesRentExpenseNet
      contextRef="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NzIvZnJhZzo1ZGU1YzhjMGI3YzQ0YTMyODg2OTM5Nzc0M2Q5MmJiMy90ZXh0cmVnaW9uOjVkZTVjOGMwYjdjNDRhMzI4ODY5Mzk3NzQzZDkyYmIzXzIxNjg_25aad2dc-eea8-4abb-9fb1-74a5c62320df"
      unitRef="usd">3100000</us-gaap:OperatingLeasesRentExpenseNet>
    <us-gaap:OperatingLeasesRentExpenseNet
      contextRef="iaf5d0e8fdf374dc09283fd669e2ebf19_D20160101-20161231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NzIvZnJhZzo1ZGU1YzhjMGI3YzQ0YTMyODg2OTM5Nzc0M2Q5MmJiMy90ZXh0cmVnaW9uOjVkZTVjOGMwYjdjNDRhMzI4ODY5Mzk3NzQzZDkyYmIzXzIxNzU_c0cd305a-2315-440c-9dc2-4b13d1fa361a"
      unitRef="usd">3000000.0</us-gaap:OperatingLeasesRentExpenseNet>
    <us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NzIvZnJhZzo1ZGU1YzhjMGI3YzQ0YTMyODg2OTM5Nzc0M2Q5MmJiMy90ZXh0cmVnaW9uOjVkZTVjOGMwYjdjNDRhMzI4ODY5Mzk3NzQzZDkyYmIzXzE1OTQyOTE4NjA2NzQ3_638b7aae-019b-42b5-993b-5717aef7c2a4">&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;Future minimum lease payments under noncancelable operating leases as of December&#160;31, 2018 are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:86.269795%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.730205%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,865&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;13,786&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;39,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent
      contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NzIvZnJhZzo1ZGU1YzhjMGI3YzQ0YTMyODg2OTM5Nzc0M2Q5MmJiMy90YWJsZTphZTMyZWViMWUwMjQ0ZmQwOTFiMmQyZTZkMDcxNGVkYS90YWJsZXJhbmdlOmFlMzJlZWIxZTAyNDRmZDA5MWIyZDJlNmQwNzE0ZWRhXzAtMS0xLTEtMA_2c3a1a7a-e160-4e27-8b47-02a6298cde55"
      unitRef="usd">6323000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears
      contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NzIvZnJhZzo1ZGU1YzhjMGI3YzQ0YTMyODg2OTM5Nzc0M2Q5MmJiMy90YWJsZTphZTMyZWViMWUwMjQ0ZmQwOTFiMmQyZTZkMDcxNGVkYS90YWJsZXJhbmdlOmFlMzJlZWIxZTAyNDRmZDA5MWIyZDJlNmQwNzE0ZWRhXzEtMS0xLTEtMA_4119c33a-7011-4aad-b7da-73ea3effbe9e"
      unitRef="usd">4757000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears
      contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NzIvZnJhZzo1ZGU1YzhjMGI3YzQ0YTMyODg2OTM5Nzc0M2Q5MmJiMy90YWJsZTphZTMyZWViMWUwMjQ0ZmQwOTFiMmQyZTZkMDcxNGVkYS90YWJsZXJhbmdlOmFlMzJlZWIxZTAyNDRmZDA5MWIyZDJlNmQwNzE0ZWRhXzItMS0xLTEtMA_98ab460c-a1dc-4757-abcb-42fbfcc013d2"
      unitRef="usd">4724000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears
      contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NzIvZnJhZzo1ZGU1YzhjMGI3YzQ0YTMyODg2OTM5Nzc0M2Q5MmJiMy90YWJsZTphZTMyZWViMWUwMjQ0ZmQwOTFiMmQyZTZkMDcxNGVkYS90YWJsZXJhbmdlOmFlMzJlZWIxZTAyNDRmZDA5MWIyZDJlNmQwNzE0ZWRhXzMtMS0xLTEtMA_0960fcba-6c35-4a49-8360-c3d395ec2294"
      unitRef="usd">4865000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears
      contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NzIvZnJhZzo1ZGU1YzhjMGI3YzQ0YTMyODg2OTM5Nzc0M2Q5MmJiMy90YWJsZTphZTMyZWViMWUwMjQ0ZmQwOTFiMmQyZTZkMDcxNGVkYS90YWJsZXJhbmdlOmFlMzJlZWIxZTAyNDRmZDA5MWIyZDJlNmQwNzE0ZWRhXzQtMS0xLTEtMA_fffaaac2-387e-41de-9e7a-630c7494a5d2"
      unitRef="usd">4680000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter
      contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NzIvZnJhZzo1ZGU1YzhjMGI3YzQ0YTMyODg2OTM5Nzc0M2Q5MmJiMy90YWJsZTphZTMyZWViMWUwMjQ0ZmQwOTFiMmQyZTZkMDcxNGVkYS90YWJsZXJhbmdlOmFlMzJlZWIxZTAyNDRmZDA5MWIyZDJlNmQwNzE0ZWRhXzUtMS0xLTEtMA_5cd83f7f-f638-44ff-ba22-2bfac0a08025"
      unitRef="usd">13786000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDue
      contextRef="id926749df69c4fffbb4a92f70f45021f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83NzIvZnJhZzo1ZGU1YzhjMGI3YzQ0YTMyODg2OTM5Nzc0M2Q5MmJiMy90YWJsZTphZTMyZWViMWUwMjQ0ZmQwOTFiMmQyZTZkMDcxNGVkYS90YWJsZXJhbmdlOmFlMzJlZWIxZTAyNDRmZDA5MWIyZDJlNmQwNzE0ZWRhXzYtMS0xLTEtMA_792646f4-528c-423c-9b86-c6ddfc7a25ee"
      unitRef="usd">39135000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83ODQvZnJhZzpmNTg2NmU3ZGFkMzI0YzRlODBjNzdhMDhiMjkyZWMwOC90ZXh0cmVnaW9uOmY1ODY2ZTdkYWQzMjRjNGU4MGM3N2EwOGIyOTJlYzA4XzY0NQ_8c470d44-4d99-4c6e-b1a1-708ced6ead83">Employee Benefit PlanIn 2002, the Company established the MacroGenics 401(k) Plan (the Plan) for its employees under Section 401(k) of the IRC. Under this Plan, all employees at least 21 years of age are eligible to participate in the Plan, starting on the first day of each month. Employees may contribute up to 100% of their salary, subject to government maximums.Employees are 100% vested in their contributions to the Plan. The Company's contribution to the Plan, as determined by the Board of Directors, is discretionary. The Company's contributions to the Plan totaled $1.3 million, $1.1 million and $1.0 million for the years ended December&#160;31, 2018, 2017 and 2016, respectively.</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <mgnx:EmployeesEligibleAgeToParticipateInBenefitPlan
      contextRef="i6ada94a697084172b90c7bcf3c82fe1e_D20120101-20121231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83ODQvZnJhZzpmNTg2NmU3ZGFkMzI0YzRlODBjNzdhMDhiMjkyZWMwOC90ZXh0cmVnaW9uOmY1ODY2ZTdkYWQzMjRjNGU4MGM3N2EwOGIyOTJlYzA4XzE5NA_2b10b975-4c0d-47bd-b1ba-831a88c1d2ff">P21Y</mgnx:EmployeesEligibleAgeToParticipateInBenefitPlan>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
      contextRef="i6ada94a697084172b90c7bcf3c82fe1e_D20120101-20121231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83ODQvZnJhZzpmNTg2NmU3ZGFkMzI0YzRlODBjNzdhMDhiMjkyZWMwOC90ZXh0cmVnaW9uOmY1ODY2ZTdkYWQzMjRjNGU4MGM3N2EwOGIyOTJlYzA4XzMyMw_d11544c1-17b0-4e82-b44e-87b4286a8de4"
      unitRef="number">1</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
    <mgnx:DefinedContributionPlanEmployeesContributionVestedPercentage
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83ODQvZnJhZzpmNTg2NmU3ZGFkMzI0YzRlODBjNzdhMDhiMjkyZWMwOC90ZXh0cmVnaW9uOmY1ODY2ZTdkYWQzMjRjNGU4MGM3N2EwOGIyOTJlYzA4XzM5MA_dc7ab68c-7e3a-4394-8bfd-18d53229de03"
      unitRef="number">1</mgnx:DefinedContributionPlanEmployeesContributionVestedPercentage>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83ODQvZnJhZzpmNTg2NmU3ZGFkMzI0YzRlODBjNzdhMDhiMjkyZWMwOC90ZXh0cmVnaW9uOmY1ODY2ZTdkYWQzMjRjNGU4MGM3N2EwOGIyOTJlYzA4XzU4Mw_18a07b19-2880-4aa7-9366-371e0d47aaa4"
      unitRef="usd">1300000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="i46333bd2ad2648f189ddebf4a2207c55_D20170101-20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83ODQvZnJhZzpmNTg2NmU3ZGFkMzI0YzRlODBjNzdhMDhiMjkyZWMwOC90ZXh0cmVnaW9uOmY1ODY2ZTdkYWQzMjRjNGU4MGM3N2EwOGIyOTJlYzA4XzU4Nw_8a781501-9443-4d31-a1de-a12386b2afa3"
      unitRef="usd">1100000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="iaf5d0e8fdf374dc09283fd669e2ebf19_D20160101-20161231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83ODQvZnJhZzpmNTg2NmU3ZGFkMzI0YzRlODBjNzdhMDhiMjkyZWMwOC90ZXh0cmVnaW9uOmY1ODY2ZTdkYWQzMjRjNGU4MGM3N2EwOGIyOTJlYzA4XzU5NA_4b60c745-282a-40ab-a0bc-5d2b592e0fb3"
      unitRef="usd">1000000.0</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:QuarterlyFinancialInformationTextBlock
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83OTYvZnJhZzo1OTVjZDUzNjhiMGY0OWE0YTAwMWNhZmQzY2I5YTQ1ZS90ZXh0cmVnaW9uOjU5NWNkNTM2OGIwZjQ5YTRhMDAxY2FmZDNjYjlhNDVlXzIxOTkwMjMyNTU2MTY_2625cb88-c813-49f4-9b45-ceff197602c4">Quarterly Financial Information (unaudited)&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:48.807636%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.747430%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534214%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.747430%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534214%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.747430%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534214%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.747430%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;"&gt;1st Quarter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;"&gt;2nd Quarter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;"&gt;3rd Quarter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;"&gt;4th Quarter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands, except per share data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;18,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;20,798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(49,536)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(43,244)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(34,029)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(44,644)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net loss per share, basic and diluted &lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1.34)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1.03)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.81)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1.06)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;152,359&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(37,655)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(40,654)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(47,043)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;105,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net income (loss) per share, basic&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1.08)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1.14)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1.28)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net income (loss) per share, diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1.08)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1.14)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1.28)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:QuarterlyFinancialInformationTextBlock>
    <us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83OTYvZnJhZzo1OTVjZDUzNjhiMGY0OWE0YTAwMWNhZmQzY2I5YTQ1ZS90ZXh0cmVnaW9uOjU5NWNkNTM2OGIwZjQ5YTRhMDAxY2FmZDNjYjlhNDVlXzIxOTkwMjMyNTU2MTc_4a8531d1-ebae-4e88-8fbf-d30b6c983303">&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:48.807636%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.747430%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534214%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.747430%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534214%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.747430%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534214%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.747430%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;"&gt;1st Quarter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;"&gt;2nd Quarter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;"&gt;3rd Quarter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;"&gt;4th Quarter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands, except per share data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;18,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;20,798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(49,536)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(43,244)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(34,029)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(44,644)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net loss per share, basic and diluted &lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1.34)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1.03)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.81)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1.06)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;152,359&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(37,655)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(40,654)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(47,043)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;105,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net income (loss) per share, basic&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1.08)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1.14)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1.28)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net income (loss) per share, diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1.08)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1.14)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1.28)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock>
    <us-gaap:Revenues
      contextRef="i8b9c8e543ab44629819b1e0b7554ce96_D20180101-20180331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83OTYvZnJhZzo1OTVjZDUzNjhiMGY0OWE0YTAwMWNhZmQzY2I5YTQ1ZS90YWJsZTo2ZDAyNmFiMDJjZWE0MjUyOGU3NTU3ODk4YjYzMzQyNi90YWJsZXJhbmdlOjZkMDI2YWIwMmNlYTQyNTI4ZTc1NTc4OThiNjMzNDI2XzMtMS0xLTEtMA_582d6f82-cd86-44e6-aa38-e6a0e0f206f5"
      unitRef="usd">4695000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie7fccf344bc24f03934ea77078a49726_D20180401-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83OTYvZnJhZzo1OTVjZDUzNjhiMGY0OWE0YTAwMWNhZmQzY2I5YTQ1ZS90YWJsZTo2ZDAyNmFiMDJjZWE0MjUyOGU3NTU3ODk4YjYzMzQyNi90YWJsZXJhbmdlOjZkMDI2YWIwMmNlYTQyNTI4ZTc1NTc4OThiNjMzNDI2XzMtMy0xLTEtMA_f415da6d-fcfd-4548-a7ad-a2c33dca9494"
      unitRef="usd">18834000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i98edd9ec68b24ced9b531e766587d469_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83OTYvZnJhZzo1OTVjZDUzNjhiMGY0OWE0YTAwMWNhZmQzY2I5YTQ1ZS90YWJsZTo2ZDAyNmFiMDJjZWE0MjUyOGU3NTU3ODk4YjYzMzQyNi90YWJsZXJhbmdlOjZkMDI2YWIwMmNlYTQyNTI4ZTc1NTc4OThiNjMzNDI2XzMtNS0xLTEtMA_73b3a659-415b-446e-b4f2-14e5d66f0fa0"
      unitRef="usd">20798000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i724f8d5b79f44384afe7b27042231bfe_D20181001-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83OTYvZnJhZzo1OTVjZDUzNjhiMGY0OWE0YTAwMWNhZmQzY2I5YTQ1ZS90YWJsZTo2ZDAyNmFiMDJjZWE0MjUyOGU3NTU3ODk4YjYzMzQyNi90YWJsZXJhbmdlOjZkMDI2YWIwMmNlYTQyNTI4ZTc1NTc4OThiNjMzNDI2XzMtNy0xLTEtMA_415d9b62-43df-4b01-b5c4-25e324d44d21"
      unitRef="usd">15794000</us-gaap:Revenues>
    <us-gaap:NetIncomeLoss
      contextRef="i8b9c8e543ab44629819b1e0b7554ce96_D20180101-20180331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83OTYvZnJhZzo1OTVjZDUzNjhiMGY0OWE0YTAwMWNhZmQzY2I5YTQ1ZS90YWJsZTo2ZDAyNmFiMDJjZWE0MjUyOGU3NTU3ODk4YjYzMzQyNi90YWJsZXJhbmdlOjZkMDI2YWIwMmNlYTQyNTI4ZTc1NTc4OThiNjMzNDI2XzQtMS0xLTEtMA_8c667151-487e-4f50-ad00-f765a5a3ebab"
      unitRef="usd">-49536000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie7fccf344bc24f03934ea77078a49726_D20180401-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83OTYvZnJhZzo1OTVjZDUzNjhiMGY0OWE0YTAwMWNhZmQzY2I5YTQ1ZS90YWJsZTo2ZDAyNmFiMDJjZWE0MjUyOGU3NTU3ODk4YjYzMzQyNi90YWJsZXJhbmdlOjZkMDI2YWIwMmNlYTQyNTI4ZTc1NTc4OThiNjMzNDI2XzQtMy0xLTEtMA_4821a726-625c-4b21-b2ed-7a739f396aad"
      unitRef="usd">-43244000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i98edd9ec68b24ced9b531e766587d469_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83OTYvZnJhZzo1OTVjZDUzNjhiMGY0OWE0YTAwMWNhZmQzY2I5YTQ1ZS90YWJsZTo2ZDAyNmFiMDJjZWE0MjUyOGU3NTU3ODk4YjYzMzQyNi90YWJsZXJhbmdlOjZkMDI2YWIwMmNlYTQyNTI4ZTc1NTc4OThiNjMzNDI2XzQtNS0xLTEtMA_27ce1a0a-820b-4d80-89d9-275770c55be3"
      unitRef="usd">-34029000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i724f8d5b79f44384afe7b27042231bfe_D20181001-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83OTYvZnJhZzo1OTVjZDUzNjhiMGY0OWE0YTAwMWNhZmQzY2I5YTQ1ZS90YWJsZTo2ZDAyNmFiMDJjZWE0MjUyOGU3NTU3ODk4YjYzMzQyNi90YWJsZXJhbmdlOjZkMDI2YWIwMmNlYTQyNTI4ZTc1NTc4OThiNjMzNDI2XzQtNy0xLTEtMA_c0d71e36-bd2c-4d63-bae9-f9e2b41a2004"
      unitRef="usd">-44644000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i8b9c8e543ab44629819b1e0b7554ce96_D20180101-20180331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83OTYvZnJhZzo1OTVjZDUzNjhiMGY0OWE0YTAwMWNhZmQzY2I5YTQ1ZS90YWJsZTo2ZDAyNmFiMDJjZWE0MjUyOGU3NTU3ODk4YjYzMzQyNi90YWJsZXJhbmdlOjZkMDI2YWIwMmNlYTQyNTI4ZTc1NTc4OThiNjMzNDI2XzUtMS0xLTEtMA_2db347b5-a75d-4027-9f4f-86f3cad87b0c"
      unitRef="usdPerShare">-1.34</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="ie7fccf344bc24f03934ea77078a49726_D20180401-20180630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83OTYvZnJhZzo1OTVjZDUzNjhiMGY0OWE0YTAwMWNhZmQzY2I5YTQ1ZS90YWJsZTo2ZDAyNmFiMDJjZWE0MjUyOGU3NTU3ODk4YjYzMzQyNi90YWJsZXJhbmdlOjZkMDI2YWIwMmNlYTQyNTI4ZTc1NTc4OThiNjMzNDI2XzUtMy0xLTEtMA_8c987898-415d-4d3c-9450-21b2e1729702"
      unitRef="usdPerShare">-1.03</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i98edd9ec68b24ced9b531e766587d469_D20180701-20180930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83OTYvZnJhZzo1OTVjZDUzNjhiMGY0OWE0YTAwMWNhZmQzY2I5YTQ1ZS90YWJsZTo2ZDAyNmFiMDJjZWE0MjUyOGU3NTU3ODk4YjYzMzQyNi90YWJsZXJhbmdlOjZkMDI2YWIwMmNlYTQyNTI4ZTc1NTc4OThiNjMzNDI2XzUtNS0xLTEtMA_5dd41eea-36aa-482b-ae61-936c41f0d18e"
      unitRef="usdPerShare">-0.81</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i724f8d5b79f44384afe7b27042231bfe_D20181001-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83OTYvZnJhZzo1OTVjZDUzNjhiMGY0OWE0YTAwMWNhZmQzY2I5YTQ1ZS90YWJsZTo2ZDAyNmFiMDJjZWE0MjUyOGU3NTU3ODk4YjYzMzQyNi90YWJsZXJhbmdlOjZkMDI2YWIwMmNlYTQyNTI4ZTc1NTc4OThiNjMzNDI2XzUtNy0xLTEtMA_6df40bc8-f66d-48ca-837f-924537d554b6"
      unitRef="usdPerShare">-1.06</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:Revenues
      contextRef="icfb4268699e645dc87743a7e862848d6_D20170101-20170331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83OTYvZnJhZzo1OTVjZDUzNjhiMGY0OWE0YTAwMWNhZmQzY2I5YTQ1ZS90YWJsZTo2ZDAyNmFiMDJjZWE0MjUyOGU3NTU3ODk4YjYzMzQyNi90YWJsZXJhbmdlOjZkMDI2YWIwMmNlYTQyNTI4ZTc1NTc4OThiNjMzNDI2XzktMS0xLTEtMA_04c542a1-d117-49af-9a7a-6a607bca9e4d"
      unitRef="usd">2055000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icc68311eb541421f98636ba4e9bffdb3_D20170401-20170630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83OTYvZnJhZzo1OTVjZDUzNjhiMGY0OWE0YTAwMWNhZmQzY2I5YTQ1ZS90YWJsZTo2ZDAyNmFiMDJjZWE0MjUyOGU3NTU3ODk4YjYzMzQyNi90YWJsZXJhbmdlOjZkMDI2YWIwMmNlYTQyNTI4ZTc1NTc4OThiNjMzNDI2XzktMy0xLTEtMA_da8e9264-1c3a-4b3d-a210-5dc8f1a46afa"
      unitRef="usd">1666000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1bf42114bac84fe587857eea6b6d8228_D20170701-20170930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83OTYvZnJhZzo1OTVjZDUzNjhiMGY0OWE0YTAwMWNhZmQzY2I5YTQ1ZS90YWJsZTo2ZDAyNmFiMDJjZWE0MjUyOGU3NTU3ODk4YjYzMzQyNi90YWJsZXJhbmdlOjZkMDI2YWIwMmNlYTQyNTI4ZTc1NTc4OThiNjMzNDI2XzktNS0xLTEtMA_4d5724de-8dbe-4b5f-b9c8-76c28d46fe7c"
      unitRef="usd">1663000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib42a39a1f0994e319ac400bbdfb12754_D20171001-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83OTYvZnJhZzo1OTVjZDUzNjhiMGY0OWE0YTAwMWNhZmQzY2I5YTQ1ZS90YWJsZTo2ZDAyNmFiMDJjZWE0MjUyOGU3NTU3ODk4YjYzMzQyNi90YWJsZXJhbmdlOjZkMDI2YWIwMmNlYTQyNTI4ZTc1NTc4OThiNjMzNDI2XzktNy0xLTEtMA_30d42ed0-ca29-4905-908f-5dcb7a7bcacd"
      unitRef="usd">152359000</us-gaap:Revenues>
    <us-gaap:NetIncomeLoss
      contextRef="icfb4268699e645dc87743a7e862848d6_D20170101-20170331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83OTYvZnJhZzo1OTVjZDUzNjhiMGY0OWE0YTAwMWNhZmQzY2I5YTQ1ZS90YWJsZTo2ZDAyNmFiMDJjZWE0MjUyOGU3NTU3ODk4YjYzMzQyNi90YWJsZXJhbmdlOjZkMDI2YWIwMmNlYTQyNTI4ZTc1NTc4OThiNjMzNDI2XzEwLTEtMS0xLTA_9258e77a-be41-4971-b2d7-a41deec636e2"
      unitRef="usd">-37655000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="icc68311eb541421f98636ba4e9bffdb3_D20170401-20170630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83OTYvZnJhZzo1OTVjZDUzNjhiMGY0OWE0YTAwMWNhZmQzY2I5YTQ1ZS90YWJsZTo2ZDAyNmFiMDJjZWE0MjUyOGU3NTU3ODk4YjYzMzQyNi90YWJsZXJhbmdlOjZkMDI2YWIwMmNlYTQyNTI4ZTc1NTc4OThiNjMzNDI2XzEwLTMtMS0xLTA_54dff957-fc53-4da6-b49a-2e4b7c4e249b"
      unitRef="usd">-40654000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i1bf42114bac84fe587857eea6b6d8228_D20170701-20170930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83OTYvZnJhZzo1OTVjZDUzNjhiMGY0OWE0YTAwMWNhZmQzY2I5YTQ1ZS90YWJsZTo2ZDAyNmFiMDJjZWE0MjUyOGU3NTU3ODk4YjYzMzQyNi90YWJsZXJhbmdlOjZkMDI2YWIwMmNlYTQyNTI4ZTc1NTc4OThiNjMzNDI2XzEwLTUtMS0xLTA_73753da6-cdc4-412b-95dc-dc7465b1ed5c"
      unitRef="usd">-47043000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ib42a39a1f0994e319ac400bbdfb12754_D20171001-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83OTYvZnJhZzo1OTVjZDUzNjhiMGY0OWE0YTAwMWNhZmQzY2I5YTQ1ZS90YWJsZTo2ZDAyNmFiMDJjZWE0MjUyOGU3NTU3ODk4YjYzMzQyNi90YWJsZXJhbmdlOjZkMDI2YWIwMmNlYTQyNTI4ZTc1NTc4OThiNjMzNDI2XzEwLTctMS0xLTA_0fbaa809-a214-4131-a568-ceb36db27794"
      unitRef="usd">105727000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="icfb4268699e645dc87743a7e862848d6_D20170101-20170331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83OTYvZnJhZzo1OTVjZDUzNjhiMGY0OWE0YTAwMWNhZmQzY2I5YTQ1ZS90YWJsZTo2ZDAyNmFiMDJjZWE0MjUyOGU3NTU3ODk4YjYzMzQyNi90YWJsZXJhbmdlOjZkMDI2YWIwMmNlYTQyNTI4ZTc1NTc4OThiNjMzNDI2XzExLTEtMS0xLTA_30071b9c-5ac5-479d-815d-21172014d5e8"
      unitRef="usdPerShare">-1.08</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="icc68311eb541421f98636ba4e9bffdb3_D20170401-20170630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83OTYvZnJhZzo1OTVjZDUzNjhiMGY0OWE0YTAwMWNhZmQzY2I5YTQ1ZS90YWJsZTo2ZDAyNmFiMDJjZWE0MjUyOGU3NTU3ODk4YjYzMzQyNi90YWJsZXJhbmdlOjZkMDI2YWIwMmNlYTQyNTI4ZTc1NTc4OThiNjMzNDI2XzExLTMtMS0xLTA_d82d6b01-3296-4835-b539-a9f7fd746d2d"
      unitRef="usdPerShare">-1.14</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i1bf42114bac84fe587857eea6b6d8228_D20170701-20170930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83OTYvZnJhZzo1OTVjZDUzNjhiMGY0OWE0YTAwMWNhZmQzY2I5YTQ1ZS90YWJsZTo2ZDAyNmFiMDJjZWE0MjUyOGU3NTU3ODk4YjYzMzQyNi90YWJsZXJhbmdlOjZkMDI2YWIwMmNlYTQyNTI4ZTc1NTc4OThiNjMzNDI2XzExLTUtMS0xLTA_dd534bef-cb28-438f-863f-9ea03e250da0"
      unitRef="usdPerShare">-1.28</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ib42a39a1f0994e319ac400bbdfb12754_D20171001-20171231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83OTYvZnJhZzo1OTVjZDUzNjhiMGY0OWE0YTAwMWNhZmQzY2I5YTQ1ZS90YWJsZTo2ZDAyNmFiMDJjZWE0MjUyOGU3NTU3ODk4YjYzMzQyNi90YWJsZXJhbmdlOjZkMDI2YWIwMmNlYTQyNTI4ZTc1NTc4OThiNjMzNDI2XzExLTctMS0xLTA_867b73f2-3426-417c-a511-a8e440f7cce4"
      unitRef="usdPerShare">2.87</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="icfb4268699e645dc87743a7e862848d6_D20170101-20170331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83OTYvZnJhZzo1OTVjZDUzNjhiMGY0OWE0YTAwMWNhZmQzY2I5YTQ1ZS90YWJsZTo2ZDAyNmFiMDJjZWE0MjUyOGU3NTU3ODk4YjYzMzQyNi90YWJsZXJhbmdlOjZkMDI2YWIwMmNlYTQyNTI4ZTc1NTc4OThiNjMzNDI2XzEyLTEtMS0xLTA_5644e30d-6205-41bd-aa2a-38a0e4cdcb1a"
      unitRef="usdPerShare">-1.08</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="icc68311eb541421f98636ba4e9bffdb3_D20170401-20170630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83OTYvZnJhZzo1OTVjZDUzNjhiMGY0OWE0YTAwMWNhZmQzY2I5YTQ1ZS90YWJsZTo2ZDAyNmFiMDJjZWE0MjUyOGU3NTU3ODk4YjYzMzQyNi90YWJsZXJhbmdlOjZkMDI2YWIwMmNlYTQyNTI4ZTc1NTc4OThiNjMzNDI2XzEyLTMtMS0xLTA_456e59a3-aeda-4f35-aa9a-7070de53defb"
      unitRef="usdPerShare">-1.14</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i1bf42114bac84fe587857eea6b6d8228_D20170701-20170930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83OTYvZnJhZzo1OTVjZDUzNjhiMGY0OWE0YTAwMWNhZmQzY2I5YTQ1ZS90YWJsZTo2ZDAyNmFiMDJjZWE0MjUyOGU3NTU3ODk4YjYzMzQyNi90YWJsZXJhbmdlOjZkMDI2YWIwMmNlYTQyNTI4ZTc1NTc4OThiNjMzNDI2XzEyLTUtMS0xLTA_ed861afd-f094-4837-a0f6-7f9690da7edc"
      unitRef="usdPerShare">-1.28</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ib42a39a1f0994e319ac400bbdfb12754_D20171001-20171231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF83OTYvZnJhZzo1OTVjZDUzNjhiMGY0OWE0YTAwMWNhZmQzY2I5YTQ1ZS90YWJsZTo2ZDAyNmFiMDJjZWE0MjUyOGU3NTU3ODk4YjYzMzQyNi90YWJsZXJhbmdlOjZkMDI2YWIwMmNlYTQyNTI4ZTc1NTc4OThiNjMzNDI2XzEyLTctMS0xLTA_0d3505d8-18d9-4a0b-b6ef-b4b64bbc2436"
      unitRef="usdPerShare">2.80</us-gaap:EarningsPerShareDiluted>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF84NzAvZnJhZzozMDMwOTJjNzA1M2I0Zjg2YjJlOWNmZTU5YWY2NjNiNy90ZXh0cmVnaW9uOjMwMzA5MmM3MDUzYjRmODZiMmU5Y2ZlNTlhZjY2M2I3XzIxOTkwMjMyNTk1NDg_213f32d7-cab3-4240-82c7-4ae867f416df">Subsequent EventIn February 2019, the Company completed a follow-on equity offering, in which the Company sold 5,500,000 shares of its common stock at a price of $20.00 per share.  Additionally, the underwriters of the offering exercised the full amount of their over-allotment option resulting in the sale of an additional 825,000 shares of the Company&#x2019;s common stock at a price of $20.00 per share.  The Company received net proceeds of $118.5 million from this offering, net of underwriting discounts and commissions and other estimated offering expenses.</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i7ed315b7b06447388b74464c7e252a0a_D20190201-20190228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF84NzAvZnJhZzozMDMwOTJjNzA1M2I0Zjg2YjJlOWNmZTU5YWY2NjNiNy90ZXh0cmVnaW9uOjMwMzA5MmM3MDUzYjRmODZiMmU5Y2ZlNTlhZjY2M2I3XzU0OTc1NTgxNzg3NQ_69ed7190-b896-4858-bab1-3bd226bd70f0"
      unitRef="shares">5500000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i6fdc91e82d3b4cb9ab3b078b4413a743_I20190228"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF84NzAvZnJhZzozMDMwOTJjNzA1M2I0Zjg2YjJlOWNmZTU5YWY2NjNiNy90ZXh0cmVnaW9uOjMwMzA5MmM3MDUzYjRmODZiMmU5Y2ZlNTlhZjY2M2I3XzU0OTc1NTgxNzg4Mw_bcca5c7f-917f-4ea7-bd82-9b0abc440bfd"
      unitRef="usdPerShare">20.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i1b259175425444a1a2fc354b79a24aa5_D20190201-20190228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF84NzAvZnJhZzozMDMwOTJjNzA1M2I0Zjg2YjJlOWNmZTU5YWY2NjNiNy90ZXh0cmVnaW9uOjMwMzA5MmM3MDUzYjRmODZiMmU5Y2ZlNTlhZjY2M2I3XzU0OTc1NTgxNzg2NA_e06559fb-02a6-49cd-a7a8-964303ee8669"
      unitRef="shares">825000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i008460346dd94dac853841c05961f142_I20190228"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF84NzAvZnJhZzozMDMwOTJjNzA1M2I0Zjg2YjJlOWNmZTU5YWY2NjNiNy90ZXh0cmVnaW9uOjMwMzA5MmM3MDUzYjRmODZiMmU5Y2ZlNTlhZjY2M2I3XzU0OTc1NTgxNzg1NQ_ba2e6b10-ff79-4ed0-b554-d138fedd30c8"
      unitRef="usdPerShare">20.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i7ed315b7b06447388b74464c7e252a0a_D20190201-20190228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgxZjBlNTQ3YmViMzQ5ZjlhNWIwMDRhZTMxYzBjZmE0L3NlYzo4MWYwZTU0N2JlYjM0OWY5YTViMDA0YWUzMWMwY2ZhNF84NzAvZnJhZzozMDMwOTJjNzA1M2I0Zjg2YjJlOWNmZTU5YWY2NjNiNy90ZXh0cmVnaW9uOjMwMzA5MmM3MDUzYjRmODZiMmU5Y2ZlNTlhZjY2M2I3XzU0OTc1NTgxNzg0Ng_802e3805-74d0-4e21-a847-5bd43f1b117f"
      unitRef="usd">118500000</us-gaap:ProceedsFromIssuanceOfCommonStock>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6799015392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Feb. 22, 2019</div></th>
<th class="th"><div>Jun. 29, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_DocumentAndEntityInformationAbstract', window );"><strong>Document And Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">MACROGENICS INC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001125345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,780,321<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 842.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated), (5) Smaller Reporting Accelerated Filer or (6) Smaller Reporting Company and Large Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>State aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to price at which the common equity was last sold, or average bid and asked price of such common equity, as of the last business day of registrant's most recently completed second fiscal quarter. The public float should be reported on the cover page of the registrants form 10K.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if company meets the shell company criteria: a company with no or nominal operations, and with no or nominal assets or assets consisting solely of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a smaller reporting company with both a public float and revenues of less than $75 million.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Document and entity information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6798374368">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 220,128<span></span>
</td>
<td class="nump">$ 211,727<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">12,735<span></span>
</td>
<td class="nump">93,394<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">29,583<span></span>
</td>
<td class="nump">13,643<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">6,406<span></span>
</td>
<td class="nump">3,151<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssets', window );">Other current assets</a></td>
<td class="nump">272<span></span>
</td>
<td class="nump">383<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">269,124<span></span>
</td>
<td class="nump">322,298<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, equipment and software, net</a></td>
<td class="nump">56,712<span></span>
</td>
<td class="nump">49,983<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">6,294<span></span>
</td>
<td class="nump">1,602<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">332,130<span></span>
</td>
<td class="nump">373,883<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">4,005<span></span>
</td>
<td class="nump">2,451<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">33,021<span></span>
</td>
<td class="nump">38,581<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue</a></td>
<td class="nump">21,721<span></span>
</td>
<td class="nump">7,202<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditCurrent', window );">Deferred rent</a></td>
<td class="nump">1,018<span></span>
</td>
<td class="nump">1,048<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">175<span></span>
</td>
<td class="nump">473<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">59,940<span></span>
</td>
<td class="nump">49,755<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="nump">19,001<span></span>
</td>
<td class="nump">13,637<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditNoncurrent', window );">Deferred rent, net of current portion</a></td>
<td class="nump">10,312<span></span>
</td>
<td class="nump">11,253<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">89,253<span></span>
</td>
<td class="nump">74,645<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.01 par value -- 125,000,000 shares authorized, 42,353,301 and 36,859,077 shares outstanding at December 31, 2018 and December 31, 2017, respectively</a></td>
<td class="nump">424<span></span>
</td>
<td class="nump">369<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">732,727<span></span>
</td>
<td class="nump">611,270<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(61)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(490,271)<span></span>
</td>
<td class="num">(312,340)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">242,877<span></span>
</td>
<td class="nump">299,238<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 332,130<span></span>
</td>
<td class="nump">$ 373,883<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130549-203045<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated unrealized gain (loss), after tax, on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669686-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=d3e681-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669646-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6801-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt and equity securities categorized neither as trading securities nor held-to-maturity securities and intended be sold or mature one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For a classified balance sheet, the cumulative difference as of the balance sheet date between the payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, within one year of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902458&amp;loc=d3e39927-112707<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCreditCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For a classified balance sheet, the cumulative difference between the rental income or payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, more than one year after the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.26(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902458&amp;loc=d3e39927-112707<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCreditNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6787-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6808545088">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">125,000,000<span></span>
</td>
<td class="nump">125,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">42,353,301<span></span>
</td>
<td class="nump">36,859,077<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6797907344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 60,121<span></span>
</td>
<td class="nump">$ 157,742<span></span>
</td>
<td class="nump">$ 91,880<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">190,827<span></span>
</td>
<td class="nump">147,232<span></span>
</td>
<td class="nump">122,091<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">40,500<span></span>
</td>
<td class="nump">32,653<span></span>
</td>
<td class="nump">29,831<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total costs and expenses</a></td>
<td class="nump">231,327<span></span>
</td>
<td class="nump">179,885<span></span>
</td>
<td class="nump">151,922<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(171,206)<span></span>
</td>
<td class="num">(22,143)<span></span>
</td>
<td class="num">(60,042)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income</a></td>
<td class="num">(247)<span></span>
</td>
<td class="nump">2,517<span></span>
</td>
<td class="nump">1,514<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(171,453)<span></span>
</td>
<td class="num">(19,626)<span></span>
</td>
<td class="num">(58,528)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized loss on investments</a></td>
<td class="nump">58<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="num">(77)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Comprehensive loss</a></td>
<td class="num">$ (171,395)<span></span>
</td>
<td class="num">$ (19,605)<span></span>
</td>
<td class="num">$ (58,605)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare', window );">Basic and diluted net loss per common share (in usd per share)</a></td>
<td class="num">$ (4.19)<span></span>
</td>
<td class="num">$ (0.54)<span></span>
</td>
<td class="num">$ (1.69)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Basic and diluted weighted average number of common shares</a></td>
<td class="nump">40,925,318<span></span>
</td>
<td class="nump">36,095,080<span></span>
</td>
<td class="nump">34,685,274<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mgnx_RevenueFromCollaborativeAgreementsMember', window );">Revenue from collaborative agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 58,644<span></span>
</td>
<td class="nump">$ 155,516<span></span>
</td>
<td class="nump">$ 86,582<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mgnx_RevenueFromGovernmentAgreementsMember', window );">Revenue from government agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 1,477<span></span>
</td>
<td class="nump">$ 2,226<span></span>
</td>
<td class="nump">$ 5,298<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each basic and diluted share of common stock or unit when the per share amount is the same for both basic and diluted shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities. Excludes amounts related to other than temporary impairment (OTTI) loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mgnx_RevenueFromCollaborativeAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mgnx_RevenueFromCollaborativeAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mgnx_RevenueFromGovernmentAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mgnx_RevenueFromGovernmentAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6805840896">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Treasury Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2015</a></td>
<td class="nump">$ 313,337<span></span>
</td>
<td class="nump">$ 343<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 547,185<span></span>
</td>
<td class="num">$ (234,186)<span></span>
</td>
<td class="num">$ (5)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Dec. 31, 2015</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,345,754<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">12,165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_StockIssuedDuringPeriodValueStockPlanActivity', window );">Stock plan related activity</a></td>
<td class="nump">1,854<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="num">$ (39)<span></span>
</td>
<td class="nump">1,887<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity', window );">Stock plan related activity (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">524,853<span></span>
</td>
<td class="nump">1,862<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockRetiredParValueMethodAmount', window );">Retirement of treasury stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39<span></span>
</td>
<td class="num">(39)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesRetired', window );">Retirement of treasury stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,862)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized gain on investments</a></td>
<td class="num">(77)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(77)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(58,528)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(58,528)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2016</a></td>
<td class="nump">268,751<span></span>
</td>
<td class="nump">$ 349<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">561,198<span></span>
</td>
<td class="num">(292,714)<span></span>
</td>
<td class="num">(82)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Dec. 31, 2016</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,870,607<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">14,744<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,744<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of offering costs</a></td>
<td class="nump">34,244<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,227<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of offering costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,699,284<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_StockIssuedDuringPeriodValueStockPlanActivity', window );">Stock plan related activity</a></td>
<td class="nump">1,104<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="num">$ (40)<span></span>
</td>
<td class="nump">1,141<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity', window );">Stock plan related activity (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">289,186<span></span>
</td>
<td class="nump">1,862<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockRetiredParValueMethodAmount', window );">Retirement of treasury stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
<td class="num">(40)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesRetired', window );">Retirement of treasury stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,862)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized gain on investments</a></td>
<td class="nump">21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(19,626)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19,626)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2017</a></td>
<td class="nump">299,238<span></span>
</td>
<td class="nump">$ 369<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">611,270<span></span>
</td>
<td class="num">(312,340)<span></span>
</td>
<td class="num">(61)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Dec. 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,859,077<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative effect of adoption of accounting standards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,478)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">16,520<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,520<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of offering costs</a></td>
<td class="nump">103,259<span></span>
</td>
<td class="nump">$ 52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">103,207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of offering costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_StockIssuedDuringPeriodValueStockPlanActivity', window );">Stock plan related activity</a></td>
<td class="nump">1,733<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="num">$ (260)<span></span>
</td>
<td class="nump">1,990<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity', window );">Stock plan related activity (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">319,224<span></span>
</td>
<td class="nump">11,070<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockRetiredParValueMethodAmount', window );">Retirement of treasury stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 260<span></span>
</td>
<td class="num">(260)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesRetired', window );">Retirement of treasury stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,070)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized gain on investments</a></td>
<td class="nump">58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(171,453)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(171,453)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2018</a></td>
<td class="nump">242,877<span></span>
</td>
<td class="nump">$ 424<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 732,727<span></span>
</td>
<td class="num">$ (490,271)<span></span>
</td>
<td class="num">$ (3)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,353,301<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative effect of adoption of accounting standards</a></td>
<td class="num">$ (6,478)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued due to stock plan related activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_StockIssuedDuringPeriodSharesStockPlanActivity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_StockIssuedDuringPeriodValueStockPlanActivity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares issued due to stock plan related activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_StockIssuedDuringPeriodValueStockPlanActivity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) from recognition of equity-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=109196918&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109196918&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=79507207&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) to equity or (increase) decrease to net assets, resulting from the cumulative effect adjustment of a new accounting principle applied in the period of adoption.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockRetiredParValueMethodAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease of par value, additional paid in capital (APIC) and retained earnings of common and preferred stock retired from treasury when treasury stock is accounted for under the par value method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockRetiredParValueMethodAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesRetired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common and preferred stock retired from treasury during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesRetired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of investments, not including unrealized gains or losses on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, held at each balance sheet date and included in earnings for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6808947168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (171,453)<span></span>
</td>
<td class="num">$ (19,626)<span></span>
</td>
<td class="num">$ (58,528)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash provided by (used in) operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">8,279<span></span>
</td>
<td class="nump">7,228<span></span>
</td>
<td class="nump">7,608<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">16,520<span></span>
</td>
<td class="nump">14,744<span></span>
</td>
<td class="nump">12,165<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(15,941)<span></span>
</td>
<td class="num">(10,878)<span></span>
</td>
<td class="num">(1,540)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses</a></td>
<td class="num">(3,255)<span></span>
</td>
<td class="nump">332<span></span>
</td>
<td class="num">(1,677)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="num">(4,580)<span></span>
</td>
<td class="nump">262<span></span>
</td>
<td class="nump">276<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">1,554<span></span>
</td>
<td class="num">(1,544)<span></span>
</td>
<td class="nump">2,232<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">3,506<span></span>
</td>
<td class="nump">12,832<span></span>
</td>
<td class="nump">4,659<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue</a></td>
<td class="nump">13,405<span></span>
</td>
<td class="nump">6,533<span></span>
</td>
<td class="num">(4,191)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_IncreaseDecreaseInDeferredRent', window );">Deferred rent</a></td>
<td class="num">(971)<span></span>
</td>
<td class="nump">6,115<span></span>
</td>
<td class="num">(1,134)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities', window );">Other liabilities</a></td>
<td class="num">(298)<span></span>
</td>
<td class="num">(1,593)<span></span>
</td>
<td class="num">(3,549)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations', window );">Net cash provided by (used in) operating activities</a></td>
<td class="num">(153,234)<span></span>
</td>
<td class="nump">14,405<span></span>
</td>
<td class="num">(43,679)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of marketable securities</a></td>
<td class="num">(132,750)<span></span>
</td>
<td class="num">(135,122)<span></span>
</td>
<td class="num">(347,762)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Proceeds from sales and maturities of marketable securities</a></td>
<td class="nump">214,348<span></span>
</td>
<td class="nump">242,401<span></span>
</td>
<td class="nump">288,894<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property, equipment and software</a></td>
<td class="num">(24,954)<span></span>
</td>
<td class="num">(29,403)<span></span>
</td>
<td class="num">(11,381)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">56,644<span></span>
</td>
<td class="nump">77,876<span></span>
</td>
<td class="num">(70,249)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of offering costs</a></td>
<td class="nump">103,259<span></span>
</td>
<td class="nump">34,244<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases', window );">Proceeds from stock option exercises and ESPP purchases</a></td>
<td class="nump">1,992<span></span>
</td>
<td class="nump">1,144<span></span>
</td>
<td class="nump">1,893<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Purchase of treasury stock</a></td>
<td class="num">(260)<span></span>
</td>
<td class="num">(40)<span></span>
</td>
<td class="num">(39)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations', window );">Net cash provided by financing activities</a></td>
<td class="nump">104,991<span></span>
</td>
<td class="nump">35,348<span></span>
</td>
<td class="nump">1,854<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net change in cash and cash equivalents</a></td>
<td class="nump">8,401<span></span>
</td>
<td class="nump">127,629<span></span>
</td>
<td class="num">(112,074)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">211,727<span></span>
</td>
<td class="nump">84,098<span></span>
</td>
<td class="nump">196,172<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">220,128<span></span>
</td>
<td class="nump">211,727<span></span>
</td>
<td class="nump">84,098<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Non-cash operating and investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_FairValueOfWarrantsReceived', window );">Fair value of warrants received</a></td>
<td class="nump">$ 6,130<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_FairValueOfWarrantsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value Of Warrants Received</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_FairValueOfWarrantsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_IncreaseDecreaseInDeferredRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in deferred rent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_IncreaseDecreaseInDeferredRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Stock Options Exercised And ESPP Purchases</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3536-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy an employee's income tax withholding obligation as part of a net-share settlement of a share-based award.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3291-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 25<br> -Paragraph 19A<br> -URI http://asc.fasb.org/extlink&amp;oid=107668666&amp;loc=SL79513924-113897<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109979856&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3151-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3179-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109979856&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6811827072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Nature of Operations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization and Nature of Operations</a></td>
<td class="text">Organization and Nature of OperationsMacroGenics, Inc. (the Company) is incorporated in the state of Delaware. The Company is a biopharmaceutical company focused on discovering and developing innovative antibody-based therapeutics designed to modulate the human immune response for the treatment of cancer. The Company currently has a pipeline of product candidates in human clinical testing that have been created primarily using its proprietary technology platforms. The Company believes its programs have the potential to have a meaningful effect on treating patients' unmet medical needs as monotherapy or, in some cases, in combination with other therapeutic agents.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6807324928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Basis of Presentation and Principles of Consolidation</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The consolidated financial statements include the accounts of MacroGenics, Inc. and its wholly owned subsidiary, MacroGenics UK Limited.&#160; All intercompany accounts and transactions have been eliminated in consolidation. The Company currently operates in one operating segment. Operating segments are defined as components of an enterprise about which separate discrete information is available for the chief operating decision maker, or decision making group, in deciding how to allocate resources and assessing performance. The Company views its operations and manages its business in one segment, which is developing monoclonal antibody-based therapeutics for cancer, autoimmune and infectious diseases.</span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Use of Estimates</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The preparation of the financial statements in accordance with generally accepted accounting principles (GAAP) requires the Company to make estimates and judgments in certain circumstances that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. In preparing these consolidated financial statements, management has made its best estimates and judgments of certain amounts included in the financial statements, giving due consideration to materiality. On an ongoing basis, the Company evaluates its estimates, including those related to revenue recognition, fair values of assets, stock-based compensation, income taxes, preclinical study and clinical trial accruals and other contingencies. Management bases its estimates on historical experience or on various other assumptions that it believes to be reasonable under the circumstances. Actual results could differ from these estimates.</span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Cash, Cash Equivalents and Marketable Securities</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Company considers all investments in highly liquid financial instruments with a maturity of 90 days or less at the date of purchase to be cash equivalents. Cash and cash equivalents includes investments in money market funds with commercial banks and financial institutions, securities issued by the U.S. government and its agencies, Government Sponsored Enterprise agency debt obligations and corporate debt obligations. Cash equivalents are stated at amortized cost, plus accrued interest, which approximates fair value.</span></div><div style="text-indent:25pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Company carries marketable securities classified as available-for-sale at fair value as determined by prices for identical or similar securities at the balance sheet date. Marketable securities consist of Level 2 financial instruments in the fair-value hierarchy. The Company records unrealized gains and losses as a component of other comprehensive loss within the statements of operations and comprehensive loss and as a separate component of stockholders' equity. Realized gains or losses on available-for-sale securities are determined using the specific identification method and the Company includes net realized gains and losses in other income (expense).</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;">At each balance sheet date, the Company assesses available-for-sale securities in an unrealized loss position to determine whether the unrealized loss is other-than-temporary. The Company considers factors including: the significance of the decline in value compared to the cost basis, underlying factors contributing to a decline in the prices of securities in a single asset class, the length of time the market value of the security has been less than its cost basis, the security's relative performance versus its peers, sector or asset class, expected market volatility and the market and economy in general. The Company also evaluates whether it is more likely than not that it will be required to sell a security prior to recovery of its fair value.&#160; An impairment loss is recognized at the time the Company determines that a decline in the fair value below its cost basis is other-than-temporary. There were no unrealized losses at December&#160;31, 2018 or </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">2017</span><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;"> that the Company determined to be other-than-temporary.</span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Accounts Receivable</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Accounts receivable that management has the intent and ability to collect are reported in the consolidated balance sheets at outstanding amounts, less an allowance for doubtful accounts. The Company writes off uncollectible receivables when the likelihood of collection is remote.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Company evaluates the collectability of accounts receivable on a regular basis. The allowance, if any, is based upon various factors including the financial condition and payment history of customers, an overall review of collections experience on other accounts and economic factors or events expected to affect future collections experience. No allowance was recorded as of December&#160;31, 2018 or 2017, as the Company has a history of collecting on all outstanding accounts.</span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Fair Value of Financial Instruments</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Company's financial instruments consist of cash and cash equivalents, marketable securities, accounts receivable, accounts payable and accrued expenses.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;">The carrying amount of accounts receivable, accounts payable and accrued expenses are generally considered to be representative of their respective fair values because of their short-term nature.&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> The Company accounts for recurring and non-recurring fair value measurements in accordance with the Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 820, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Fair Value Measurements and Disclosures</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> (ASC 820). ASC 820 defines fair value, establishes a fair value hierarchy for assets and liabilities measured at fair value, and requires expanded disclosures about fair value measurements. The ASC 820 hierarchy ranks the quality of reliability of inputs, or assumptions, used in the determination of fair value and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following three categories:</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">Level 1 &#8211; Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities.</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">Level 2 &#8211; Fair value is determined by using inputs other than Level 1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models, such as interest rates and yield curves that can be corroborated by observable market data.</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">Level 3 &#8211; Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgments to be made by a reporting entity &#8211; e.g., determining an appropriate adjustment to a discount factor for illiquidity associated with a given security.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Company evaluates financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them each reporting period. This determination requires the Company to make subjective judgments as to the significance of inputs used in determining fair value and where such inputs lie within the ASC 820 hierarchy.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Financial assets measured at fair value on a recurring basis were as follows (in thousands):</span></div><div style="margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"><tr><td style="width:1.0%;"/><td style="width:36.325991%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.747430%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.121586%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.565345%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.268429%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.271659%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.121586%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.977974%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value Measurement at December 31, 2018</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Quoted Prices in</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Active Markets for</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Identical Assets</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Significant Other</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Observable Inputs</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Significant</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Unobservable</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Inputs</span></div></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 3</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Assets:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">46,257&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">46,257&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S Treasury securities</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">12,488&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">12,488&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">100,214&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">100,214&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Common stock warrants</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1,890&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1,890&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">Total assets measured at fair value </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(a)</sup></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">160,849&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">46,257&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">112,702&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1,890&#160;</span></td></tr></table></div><div style="margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"><tr><td style="width:1.0%;"/><td style="width:36.325991%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.747430%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.121586%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.565345%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.268429%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.271659%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.121586%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.977974%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value Measurement at December 31, 2017</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Quoted Prices in</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Active Markets for</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Identical Assets</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Significant Other</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Observable Inputs</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Significant</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Unobservable</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Inputs</span></div></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 3</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Assets:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">61,512&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">61,512&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S Treasury securities</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">3,989&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">3,989&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Government-sponsored enterprises</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">11,991&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">11,991&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">78,418&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">78,418&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">Total assets measured at fair value </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(</sup><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">b)</sup></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">155,910&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">61,512&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">94,398&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td></tr></table></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">(a) Total assets measured at fair value at December&#160;31, 2018 includes approximately $146.2 million reported in cash and cash equivalents on the balance sheet.</span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">(b) Total assets measured at fair value at December&#160;31, 2017 includes approximately $62.5 million reported in cash and cash equivalents on the balance sheet.</span></div><div style="text-indent:36pt;margin-top:15pt;margin-bottom:15pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The fair value of Level 2 securities is determined from market pricing and other observable market inputs for similar securities obtained from various third-party data providers. These inputs either represent quoted prices for similar assets in active markets or have been derived from observable market data.  </span><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;">The fair value of Level 3 securities is determined using the Black-Scholes option-pricing model.  There were no transfers between levels during the periods presented.&#160;</span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Concentration of Credit Risk</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents, marketable securities and accounts receivable. </span><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Company maintains&#160;its cash and money market funds with financial institutions that are federally insured. While balances deposited in these institutions often exceed Federal Deposit Insurance Corporation limits, the Company has not experienced any losses on related accounts to date.&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Company's investment policy limits investments to certain types of debt securities issued by the U.S. government, its agencies and institutions with investment-grade credit ratings and places restrictions on maturities and concentration by type and issuer.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> The counterparties are various corporations, financial institutions and government agencies of high credit standing.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Company's revenue relates to agreements with various collaborators and&#160;contracts and research grants received from U.S. government agencies.&#160;The following table includes those collaborators that represent more than 10% of total revenue earned in the periods indicated:</span></div><div style="margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.269006%;"><tr><td style="width:1.0%;"/><td style="width:67.219440%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:7.720177%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.536377%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:7.720177%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.683652%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:7.720177%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;height:13pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2016</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Incyte Corporation (Incyte)</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">68%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">96&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Janssen Biotech, Inc. (Janssen)</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">*&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">*&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">85%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Provention Bio, Inc. (Provention)</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">10%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The following table includes those counterparties that represent more than 10% of accounts receivable at the date indicated:</span></div><div style="margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"><tr><td style="width:1.0%;"/><td style="width:73.806452%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.730205%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533138%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.730205%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Zai Lab Limited (Zai Lab)</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">76%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Incyte</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">16%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (Roche)</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">73%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Les Laboratoires Servier and Institut de Recherches Servier (Servier)</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">*&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">12%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">* Balance is less than 10%&#160;</span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Property, Equipment and Software</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Property, equipment and software are stated at cost. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation or amortization are removed from the accounts and any resulting gain or loss is credited or charged to operations. Repairs and maintenance costs are expensed as incurred.&#160;Depreciation and amortization are computed using the straight-line method over the following estimated useful lives:</span></div><div style="margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"><tr><td style="width:1.0%;"/><td style="width:48.000000%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:48.000000%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Computer equipment</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">3 years</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Software</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">3 years</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Furniture</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">10 years</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Laboratory and office equipment</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">5 years</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Leasehold improvements</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Shorter of lease term or useful life</span></td></tr></table></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Impairment of Long-Lived Assets</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Company assesses the recoverability of its long-lived assets in accordance with the provisions of ASC 360, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Property, Plant and Equipment</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">. ASC 360 requires that long-lived assets be reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of the long-lived asset is measured by a comparison of the carrying amount of the asset to future undiscounted net cash flows expected to be generated by the asset or asset group. If carrying value exceeds the sum of undiscounted cash flows, the Company then determines the fair value of the underlying asset group. Any impairment to be recognized is measured by the amount by which the carrying amount of the asset group exceeds the estimated fair value of the asset group. Assets to be disposed of are reported at the lower of the carrying amount or fair value, less costs to sell. For the years ended&#160;December&#160;31, 2018,&#160;2017 and 2016, the Company determined that there were no impaired assets.</span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Income Taxes</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Deferred tax assets and liabilities are determined based on differences between the financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. The effect on deferred tax assets and liabilities of a change in tax rates is recognized as income in the period that such tax rate changes are enacted. The measurement of a deferred tax asset is reduced, if necessary, by a valuation allowance if it is more likely than not that some portion or all of the deferred tax asset will not be realized. Financial statement recognition of a tax position taken or expected to be taken in a tax return is determined based on a more-likely-than-not threshold of that position being sustained. If the tax position meets this threshold, the benefit to be recognized is measured as the largest amount that is more likely than not to be realized upon ultimate settlement. The Company's policy is to record interest and penalties related to uncertain tax positions as a component of income tax expense.</span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Revenues</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#160;</span></div><div style="text-indent:40.5pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Beginning on January 1, 2018, the Company&#160;recognizes revenue under Accounting Standards Update (ASU) No. 2014-09, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Revenue from Contracts with Customer</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">s and all related amendments (collectively ASC 606) when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services.&#160;&#160;To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation.  The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. </span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Company enters into licensing agreements that are within the scope of ASC 606, under which it may license rights to research, develop, manufacture and commercialize its product candidates to third parties. The terms of these arrangements typically include payment to the Company of one or more of the following: non-refundable, upfront license fees; reimbursement of certain costs; customer option exercise fees; development, regulatory and commercial milestone payments;&#160;and royalties on net sales of licensed products.   The Company may also enter into development and manufacturing service agreements&#160;with its collaborators.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">For each arrangement that results in revenues, the Company identifies all performance obligations, which may include a license to intellectual property and know-how, research and development activities, transition activities and/or manufacturing services. In order to determine the transaction price, in addition to any upfront payment, the Company estimates the amount of variable consideration at the outset of the contract either utilizing the expected value or most likely amount method, depending</span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> on the facts and circumstances relative to the contract. The Company constrains (reduces) the estimates of variable consideration such that it is probable that a significant reversal of previously recognized revenue will not occur. When determining if variable consideration should be constrained, management considers whether there are factors outside the Company&#8217;s control that could result in a significant reversal of revenue. In making these assessments, the Company considers the likelihood and magnitude of a potential reversal of revenue. These estimates are re-assessed each reporting period as required. </span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Once the estimated transaction price is established, amounts are allocated to the performance obligations that have been identified. The transaction price is generally allocated to each separate performance obligation on a relative standalone selling price basis. The Company must develop assumptions that require judgment to determine the standalone selling price in order to account for these agreements. To determine the standalone selling price, the Company&#8217;s assumptions may include (i)  the probability of obtaining marketing approval for the product candidate, (ii) estimates regarding the timing and the expected costs to develop and commercialize the product candidate, and (iii) estimates of future cash flows from potential product sales with respect to the product candidate. Standalone selling prices used to perform the initial allocation are not updated after contract inception. The Company does not include a financing component to its estimated transaction price at contract inception unless it estimates that certain performance obligations will not be satisfied within one year.</span></div><div style="text-indent:36pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Amounts received prior to revenue recognition are recorded as deferred revenue. Amounts expected to be recognized as revenue within the 12&#160;months following the balance sheet date are classified as current portion of deferred revenue in the accompanying consolidated balance sheets. Amounts not expected to be recognized as revenue within the 12&#160;months following the balance sheet date are classified as deferred revenue, net of current portion. </span></div><div style="text-indent:36pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Licenses. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">If the license to the Company&#8217;s intellectual property is determined to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and when (or as) the customer is able to use and benefit from the license. In assessing whether a promise or performance obligation is distinct from the other promises, the Company considers factors such as the research, development, manufacturing and commercialization capabilities of the licensee and the availability of the associated expertise in the general marketplace. In addition, the Company considers whether the licensee can benefit from a promise for its intended purpose without the receipt of the remaining promise, whether the value of the promise is dependent on the unsatisfied promise, whether there are other vendors that could provide the remaining promise, and whether it is separately identifiable from the remaining promise. For licenses that are combined with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. The measure of progress, and thereby periods over which revenue should be recognized, are subject to estimates by management and may change over the course of the research and development and licensing agreement. Such a change could have a material impact on the amount of revenue the Company records in future periods. </span></div><div style="text-indent:36pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Research, Development and/or Manufacturing Services. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The promises under the Company&#8217;s agreements may include research and development or manufacturing services to be performed by the Company on behalf of the counterparty. If these services are determined to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes the transaction price allocated to these services as revenue over time based on an appropriate measure of progress when the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date.  If these services are determined not to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes the transaction price allocated to the combined performance obligation as the related performance obligations are satisfied. </span></div><div style="text-indent:36pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Customer Options. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">If an arrangement contains customer options, the Company evaluates whether the options are material rights because they allow the customer to acquire additional goods or services for free or at a discount. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the outset of the arrangement. The Company allocates the transaction price to material rights based on the relative standalone selling price, which is determined based on the identified discount and the probability that the customer will exercise the option. Amounts allocated to a material right are not recognized as revenue until, at the earliest, the option is exercised.  If the options are deemed not to be a material right, they are excluded as performance obligations at the outset of the arrangement. </span></div><div style="text-indent:36pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Milestone Payments. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">At the inception of each arrangement that includes development milestone payments, the Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. At the end of each subsequent reporting period, the Company reevaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. </span></div><div style="text-indent:36pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Royalties. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">For arrangements that include sales-based royalties which are the result of a customer-vendor relationship and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied or partially satisfied. To date, the Company has not recognized any royalty revenue resulting from any of its licensing arrangements. </span></div><div style="text-indent:36pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Company analyzes its collaboration arrangements to assess whether such arrangements involve joint operating activities performed by parties who are both active participants in the activities and are both exposed to significant risks and rewards dependent on the commercial success of such activities. Such arrangements generally are within the scope of ASC 808, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Collaborative Arrangements</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> (ASC 808). While ASC 808 defines collaborative arrangements and provides guidance on income statement presentation, classification, and disclosures related to such arrangements, it does not address recognition and measurement matters, such as (1)&#160;determining the appropriate unit of accounting or (2) when the recognition criteria are met. Therefore, the accounting for these arrangements is either based on an analogy to other accounting literature or an accounting policy election by the Company. The Company accounts for certain components of the collaboration agreement that are reflective of a vendor-customer relationship (e.g., licensing arrangement) based on an analogy to ASC 606. The Company accounts for other components based on a reasonable, rational and consistently applied accounting policy election.&#160;&#160; Reimbursements from the counter-party that are the result of a collaborative relationship with the counter-party, instead of a customer relationship, such as co-development activities, are recorded as a reduction to research and development expense as the services are performed.</span></div><div style="text-indent:36pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">For a complete discussion of accounting for revenue from collaborative and other agreements, see Note 8, Collaboration and Other Agreements.</span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Research and Development Costs</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Research and development expenditures are expensed as incurred. Research and development costs primarily consist of employee related expenses, including salaries and benefits, expenses incurred under agreements with contract research organizations, investigative sites and consultants that conduct the Company's clinical trials, the cost of acquiring and manufacturing clinical trial materials and other allocated expenses, license fees for and milestone payments related to in-licensed products and technologies, stock-based compensation expense, and costs associated with non-clinical activities and regulatory approvals.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Right-to-develop agreements may contain cost-sharing provisions whereby the Company and the collaborator share the cost of research and development activities.&#160; Reimbursement of research and development expenses received in connection with these agreements is recorded as a reduction of such expenses.</span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Comprehensive Loss</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;">Comprehensive loss represents net loss adjusted for the change during the periods attributed to unrealized gains and losses on available-for-sale securities.</span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Stock-based Compensation</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Stock-based payments are accounted for in accordance with the provisions of ASC 718, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Compensation &#8211; Stock Compensation</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">. The fair value of stock-based payments is estimated, on the date of grant, using the Black-Scholes model. The resulting fair value is recognized ratably over the requisite service period, which is generally the vesting period of the option.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">For all time-vesting awards granted, expense is amortized using the straight-line attribution method. For awards that contain a performance condition, expense is amortized using the accelerated attribution method. Recognition of stock-based compensation expense is based on the value of the portion of stock-based awards that is ultimately expected to vest during the period.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Company utilizes the Black-Scholes model for estimating fair value of its stock options granted. Option valuation models, including the Black-Scholes model, require the input of highly subjective assumptions, and changes in the assumptions used can materially affect the grant-date fair value of an award. These assumptions include the risk-free rate of interest, expected dividend yield, expected volatility and the expected life of the award.</span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Net Loss Per Share</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Basic loss per common share is determined by dividing loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted loss per share is computed by dividing the loss attributable to common stockholders by the weighted-average number of common share equivalents outstanding for the period. The treasury stock method is used to determine the dilutive effect of the Company's stock option grants.  5,273,964 stock options (common stock equivalents) were excluded from the calculation of diluted net loss per share for the year ended </span><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;">December&#160;31, 2018&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">because their inclusion would have been anti-dilutive.  4,504,642 stock options and 3,838,060 stock options were excluded from the calculation of diluted net loss per share for the years ended December&#160;31, 2017 and 2016, respectively,</span><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">because their inclusion would have been anti-dilutive.</span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Recently Adopted Accounting Standards</span></div><div style="text-indent:36pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">In May 2014, the FASB issued ASC 606. The Company adopted ASC 606 on January 1, 2018 using the modified retrospective method for all contracts that were not completed as of January 1, 2018. For contracts that were modified before the effective date, the Company reflected the aggregate effect of all modifications when identifying performance obligations and allocating transaction price in accordance with available practical expedients.  </span><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;">Comparative prior period information continues to be reported under the accounting standards in effect for the period presented. </span></div><div style="text-indent:36pt;text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;">As a result of applying the modified retrospective method to adopt the new guidance, the following adjustments were made to accounts on the consolidated balance sheet as of January 1, 2018 (in thousands):</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Arial;font-size:10pt;line-height:232%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853801%;"><tr><td style="width:1.0%;"/><td style="width:52.465593%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.641288%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532064%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.641288%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.678477%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.641288%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Pre-Adoption</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">ASC 606 Adjustment</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Post-Adoption</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">Deferred revenue, current</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">7,202&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">540&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">7,742&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">Deferred revenue, net of current portion</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">13,637&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">5,939&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">19,576&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">Accumulated deficit</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(312,340)</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(6,478)</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(318,818)</span></td></tr></table></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;">The transition adjustment resulted primarily from changes in </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">the pattern of revenue recognition for upfront fees and license grant fees.  </span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;">The following table shows the impact of adoption to the consolidated statement of income and balance sheet (in thousands):</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Arial;font-size:10pt;line-height:120%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"><tr><td style="width:1.0%;"/><td style="width:42.199706%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.096916%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:16.942731%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:19.292217%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;height:13pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December 31, 2018&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">As Reported&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Balances Without Adoption of ASC 606&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Effect of Change Higher/(Lower)&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenue from collaborative agreements&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">58,644&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">58,104&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">540&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(171,453)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(171,993)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(540)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Basic and diluted net loss per common share&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(4.19)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(4.20)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">0.01&#160;</span></td></tr><tr><td colspan="3" style="height:21pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="height:21pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;height:13pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">As of December 31, 2018</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">As Reported&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Balances Without Adoption of ASC 606&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Effect of Change Higher/(Lower)&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred revenue, current&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">21,721&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">22,210&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(489)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred revenue, net of current portion&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">19,001&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">12,573&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">6,428&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated deficit&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(490,271)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(484,332)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(5,939)</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr></table></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Arial;font-size:10pt;line-height:232%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;">The following table presents changes in the Company&#8217;s contract liabilities during the year ended December 31, 2018 (in thousands):</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Arial;font-size:10pt;line-height:120%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"><tr><td style="width:1.0%;"/><td style="width:41.024963%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:17.530103%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:7.397944%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.572687%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.271659%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at Beginning of Period&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Additions&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Deductions&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at End of Period&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160; Deferred revenue (current and non-current)&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">27,318&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">22,992&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(9,588)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">40,722&#160;</span></td></tr></table></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Arial;font-size:10pt;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;">During the year ended December 31, 2018, the Company recognized $9.6 million in revenue as a result of changes in the contract liability balance.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">In May 2017, the FASB issued ASU 2017-09, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Compensation &#8211; Stock Compensation (Topic 718): Scope Modification Accounting</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">. The new standard is intended to reduce the diversity in practice and cost and complexity when applying the guidance in Topic 718 to a change to the terms or conditions of a share-based payment award. The new standard was effective beginning January 1, 2018. The adoption of this standard did not have a material impact on the Company&#8217;s financial position or results of operations upon adoption. </span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">On December 22, 2017, the Tax Cuts and Jobs Act of 2017 (the Tax Act) was signed into law making significant changes to the Internal Revenue Code, which included how the U.S. imposes income tax on multinational corporations.  Key changes in the Tax Act which are relevant to the Company, and generally effective January 1, 2018, include a flat corporate income tax rate of 21% to replace the marginal rates that range from 15% to 35% and the elimination of the corporate alternative minimum tax.  The Tax Act also imposes limits on executive compensations and interest expense deductions, while permitting the immediate expensing for the cost of new investments in certain property acquired after September 27, 2017.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">On December 22, 2017, the SEC issued Staff Accounting Bulletin No. 118 (SAB 118) to address the application of U.S. GAAP in situations when a registrant does not have the necessary information available, prepared, or analyzed (including computations) in reasonable detail to complete the accounting for certain income tax effects of the Tax Act.  SAB 118 allowed registrants to include a provisional amount to account for the implications of the Tax Act where a reasonable estimate can be made and required the completion of the accounting no later than one year from the date of the enactment of the Tax Act, or December 22, 2018. The Company has recognized the provisional tax impacts related to the re-measurement of its U.S. deferred tax assets and liabilities to 21% in 2017 and included these amounts in its consolidated financial statements for the year ended December 31, 2017.  This change in value of these deferred tax assets and liabilities was offset by a corresponding change in valuation allowance, thus no tax expense or benefit was recorded. The Company completed its evaluation of the effects of the Tax Act during the fourth quarter of 2018, and the provisional amounts the Company accounted for in its December 31, 2017 provision were finalized with no adjustments.  &#160;</span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Recently Issued Accounting Standards </span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">In February 2016, the FASB issued ASU No. 2016-02, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:115%;">Leases</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;"> (ASU 2016-02) that provides principles for the recognition, measurement, presentation and disclosure of leases for both lessees and lessors.  ASU 2016-02 requires a lessee to recognize assets and liabilities on the balance sheet for operating leases and changes many key definitions, including the definition of a lease. ASU 2016-02 includes a short-term lease exception for leases with an original term of 12 months or less, in which a lessee can make an accounting policy election not to recognize lease assets and lease liabilities. Lessees will continue to differentiate between finance leases (previously referred to as capital leases) and operating leases, using classification criteria that are substantially similar to the previous guidance. Originally, entities were required to adopt ASU 2016-02 using a modified retrospective transition approach for all leases existing at, or entered into after, the date of initial application. However, in July 2018, the FASB issued ASU 2018-11, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:115%;">Leases (Topic 842): Targeted Improvements,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;"> which now allows entities the option of recognizing the cumulative effect of applying the new standard as an adjustment to the opening balance of retained earnings in the year of adoption while continuing to present all prior periods under previous lease accounting guidance. In July 2018, the FASB also issued ASU 2018-10, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:115%;">Codification Improvements to Topic 842, Leases, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">which clarifies how to apply certain aspects of ASU 2016-02. ASU 2016-02, ASU 2018-10 and ASU 2018-11 (now commonly referred to as ASC Topic 842 (ASC 842)) is effective for the Company&#8217;s fiscal year beginning January 1, 2019. Although early adoption is permitted, the Company has not elected to do so. The Company plans to elect the transition option provided under ASU 2018-11, which will not require adjustments to comparative periods nor require modified disclosures in those comparative periods. Upon adoption, the Company expects to elect the transition package of practical expedients permitted within the new standard, which among other things, allows the carryforward of the historical lease classification.  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:115%;">Based on its current lease portfolio, the Company estimates that the adoption ASC 842 will result in approximately $16.0 million of right of use assets and $28.0 million of lease liabilities being reflected on its consolidated balance sheet at the date of adoption. </span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">In November 2018, the FASB issued ASU 2018-18, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:115%;">Collaborative Arrangements (Topic 808)&#8212;Clarifying the interaction between Topic 808 and Topic 606</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;"> (ASU 2018-18). The amendments provide guidance on whether certain</span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;"> transactions between collaborative arrangement participants should be accounted for as revenue under ASC 606. It also specifically (i) addresses when the participant should be considered a customer in the context of a unit of account, (ii) adds unit-of-account guidance in ASC 808 to align with guidance in ASC 606, and (iii) precludes presenting revenue from a collaborative arrangement together with revenue recognized under ASC 606 if the collaborative arrangement participant is not a customer. The guidance will be effective for fiscal years beginning after December 15, 2019. Early adoption is permitted and should be applied retrospectively. The Company does not anticipate the adoption of this standard will have a material impact on its consolidated financial statements.</span></div><div style="text-indent:36pt;margin-top:5pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Company has evaluated all other ASUs issued through the date the consolidated financials were issued and believes that the adoption of these will not have a material impact on the Company's consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6811846256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Marketable Securities</a></td>
<td class="text">Marketable Securities<div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;">Available-for-sale marketable securities as of December&#160;31, 2018 and 2017 were as follows (in thousands):</span></div><div style="margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"><tr><td style="width:1.0%;"/><td style="width:48.807636%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.747430%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.747430%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.747430%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.747430%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="height:16pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;height:16pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2018</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Amortized</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Cost</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Gross</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Unrealized</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Gains</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Gross</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Unrealized</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Losses</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Fair</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Value</span></div></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">12,738&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(3)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">12,735&#160;</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div><div style="text-align:center;margin-bottom:9pt;"><span><br/></span></div><div style="text-align:center;margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"><tr><td style="width:1.0%;"/><td style="width:48.807636%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.747430%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.747430%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.747430%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.747430%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;height:13pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2017</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Amortized</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Cost</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Gross</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Unrealized</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Gains</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Gross</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Unrealized</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Losses</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Fair</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Value</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. Treasury securities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">3,995&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(6)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">3,989&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Government-sponsored enterprises</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">11,998&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(7)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">11,991&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">77,462&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(50)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">77,414&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">93,455&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(63)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">93,394&#160;</span></td></tr></table></div><div style="margin-top:15pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">All of the Company's available-for-sale securities held at </span><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;">December&#160;31, 2018</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#160;and 2017&#160;had maturity dates of less than one year.  </span></div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">All available-for-sale securities in an unrealized loss position as of </span><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;">December&#160;31, 2018</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> and 2017 were in a loss position for less than twelve months.&#160; There were no unrealized losses at </span><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;">December&#160;31, 2018</span> or 2017 that the Company determined to be other-than-temporary.  The Company recorded interest income of $2.3 million, $2.4 million and $2.3 million during the years ended December&#160;31, 2018, 2017 and 2016, respectively, which is included in other income (expense) on the consolidated statements of operations and comprehensive loss.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for  investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2176304<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6807324928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Equipment and Software<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property, Equipment and Software</a></td>
<td class="text">Property, Equipment and SoftwareProperty, equipment and software consists of the following (in thousands):<div style="margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"><tr><td style="width:1.0%;"/><td style="width:73.806452%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.730205%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533138%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.730205%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Computer equipment</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2,360&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2,261&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Software</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">7,011&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">5,111&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Furniture and office equipment</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">668&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">656&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Lab equipment</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">36,062&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">20,549&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Leasehold improvements</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">48,328&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">17,525&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Construction in progress</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">218&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">32,800&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Property, equipment and software</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">94,647&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">78,902&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Less accumulated depreciation and amortization</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(37,935)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(28,919)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Property, equipment and software, net</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">56,712&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">49,983&#160;</span></td></tr></table></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Construction in progress at December 31, 2017 consisted of the costs incurred for the build-out of a manufacturing suite at the Company's headquarters building in Rockville, Maryland, which was completed in mid-2018.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">We had $0.6 million in property, equipment and software at December&#160;31, 2018 that was purchased in 2018 but was not paid for by year end.&#160; Property, equipment and software balance at December&#160;31, 2017 includes approximately $9.6 million in assets that were purchased in 2017 but were not paid for by year end.  Depreciation and amortization expense related to property, equipment and software for the years ended December&#160;31, 2018, 2017 and 2016 was $9.2 million, $7.0 million and $6.8 million, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6811835568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">Stockholders' Equity<div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#160;The Company's amended and restated certificate of incorporation authorizes 125,000,000 shares of common stock, and 5,000,000 shares of undesignated preferred stock, both with a par value of $.01 per share.&#160;&#160;There were no shares of undesignated preferred stock issued or outstanding as of December&#160;31, 2018 or 2017.</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">On April 26, 2017, the Company entered into a definitive agreement with an institutional healthcare investor to purchase 1,100,000 shares of its common stock at a purchase price of $21.50 per share in a registered direct offering. Proceeds to the Company, before deducting estimated offering expenses, were $23.7 million. The shares were offered pursuant to the Company&#8217;s effective shelf registration on Form S-3 that was filed with the SEC on November 2, 2016.</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">On May 3, 2017, the Company entered into a sales agreement with an agent to sell, from time to time, shares of its common stock having an aggregate sales price of up to $75.0 million through an &#8220;at the market offering&#8221; (ATM Offering) as defined in Rule 415 under the Securities Act of 1933, as amended.  The shares that may be sold under the sales agreement would be issued and sold pursuant to the Company's shelf registration statement on Form S-3 that was filed with the SEC on November 2, 2016. During the year ended December 31, 2017, the Company sold 599,284 shares of common stock resulting in net proceeds of $10.8 million related to the ATM Offering.&#160;</span></div>On April 2, 2018, the Company completed a firm-commitment underwritten public offering, in which the Company sold 4,500,000 shares of its common stock at a price of $21.25 per share.  Additionally, the underwriters of the offering exercised the full amount of their over-allotment option resulting in the sale of an additional 675,000 shares of the Company's common stock at a price of $21.25 per share.  Upon closing, the Company received net proceeds of approximately $103.0&#160;million from this offering, net of underwriting discounts and commissions and other offering expenses.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6807405648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-based Compensation</a></td>
<td class="text">Stock-based Compensation<div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Employee Stock Purchase Plan</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">In May 2017, the Company&#8217;s stockholders approved the 2016 Employee Stock Purchase Plan (the 2016 ESPP). The 2016 ESPP is structured as a qualified employee stock purchase plan under Section 423 of the Internal Revenue Code of 1986, as amended, and is not subject to the provisions of the Employee Retirement Income Security Act of 1974.  The Company reserved 800,000 shares of common stock for issuance under the 2016 ESPP. The 2016 ESPP allows eligible employees to purchase shares of the Company&#8217;s common stock at a discount through payroll deductions of up to 10% of their eligible compensation, subject to any plan limitations. The 2016 ESPP provides for six-month offering periods ending on May 31 and November 30 of each year.  At the end of each offering period, employees are able to purchase shares at 85% of the fair market</span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> value of the Company&#8217;s common stock on the last day of the offering period.  During the year ended December&#160;31, 2018, employees purchased 44,862 shares of common stock under the 2016 ESPP for net proceeds to the Company of approximately $0.8 million.  </span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Employee Stock Option Plans</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Effective February 2003, the Company implemented the 2003 Equity Incentive Plan (2003 Plan), and it was amended and approved by the Company's stockholders in 2005. Stock options granted under the 2003 Plan may be either incentive stock options as defined by the Internal Revenue Code (IRC), or non-qualified stock options.  In 2013, the 2003 Plan was terminated, and no further awards may be issued under the plan.  Any shares of common stock subject to awards under the 2003 Plan that expire, terminate, or are otherwise surrendered, canceled, forfeited or repurchased without having been fully exercised, or resulting in any common stock being issued, will become available for issuance under the 2013 Stock Incentive Plan (2013 Plan), up to a specified number of shares.&#160; As of December&#160;31, 2018, under the 2003 Plan, there were options to purchase an aggregate of 746,803 shares of common stock outstanding at a weighted average exercise price of $2.03 per share.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">In October 2013, the Company implemented the 2013  Plan.&#160;&#160;The 2013 Plan provides for the grant of stock options and other stock-based awards, as well as cash-based performance awards. The aggregate number of shares of common stock initially available for issuance pursuant to awards under the 2013 Plan was 1,960,168 shares.&#160;&#160;The number of shares of common stock reserved for issuance will automatically increase on January 1 of each year from January 1, 2014 through and including January 1, 2023, by the lesser of (a) 1,960,168 shares, (b) 4.0% of the total number of shares of common stock outstanding on December 31 of the preceding calendar year, or (c) the number of shares of common stock determined by the Board of Directors. During the year ended December&#160;31, 2018, the maximum number of shares of common stock authorized to be issued by the Company under the 2013 Plan was increased to 8,244,131.&#160;&#160;If an option expires or terminates for any reason without having been fully exercised, if any shares of restricted stock are forfeited, or if any award terminates, expires or is settled without all or a portion of the shares of common stock covered by the award being issued, such shares are available for the grant of additional awards. However, any shares that are withheld (or delivered) to pay withholding taxes or to pay the exercise price of an option are not available for the grant of additional awards. As of December&#160;31, 2018, under the 2013 Plan, there were options to purchase an aggregate of 4,527,161 shares of common stock outstanding at a weighted average exercise price of $25.56 per share.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The following stock-based compensation amounts were recognized for the periods indicated (in thousands):</span></div><div style="margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"><tr><td style="width:1.0%;"/><td style="width:61.343109%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.730205%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533138%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.730205%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533138%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.730205%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2016</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">7,919&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">7,388&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">5,778&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">General and administrative&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">8,601&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">7,356&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">6,387&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total stock-based compensation expense</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">16,520&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">14,744&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">12,165&#160;</span></td></tr></table></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Employee Stock Options</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model using the assumptions in the following table:</span></div><div style="margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"><tr><td style="width:1.0%;"/><td style="width:61.343109%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.730205%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533138%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.730205%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533138%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.730205%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2016</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected dividend yield</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">0%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">0%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">0%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected volatility</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">68% - 72%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">67% - 68%</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">64% - 69%</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Risk-free interest rate</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2.4% - 3.1%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1.9% - 2.3%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1.2% - 2.4%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected term</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">6.25 years</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">6.25 years</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">6.25 years</span></td></tr></table></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">Expected Dividend Yield</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> &#8211; The Company has never declared or paid dividends and has no plans to do so in the foreseeable future.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">Expected Volatility</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> &#8211; Volatility is a measure of the amount by which a financial variable such as a share price has fluctuated (historical volatility) or is expected to fluctuate (expected volatility) during a period.&#160;&#160;As the Company does not yet have sufficient history of its own volatility, the Company has identified several public entities of similar size, complexity and stage of development and estimates volatility based on the volatility of these companies.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">Risk-Free Interest Rate</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> &#8211; This is the U.S. Treasury rate for the week of each option grant during the year, having a term that most closely resembles the expected life of the option.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">Expected Term</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> &#8211; This is the period of time that the options granted are expected to remain unexercised. Options granted have a maximum term of ten years. The Company uses a simplified method to calculate the average expected term.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">In addition to the assumptions above, the Company estimates the forfeiture rate based on turnover data with further consideration given to the class of the employees to whom the options were granted.&#160;&#160;The forfeiture rate is the estimated percentage of options granted that is expected to be forfeited or canceled on an annual basis before becoming fully vested.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The following table summarizes stock option activity for 2018:</span></div><div style="margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"><tr><td style="width:1.0%;"/><td style="width:48.807636%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.747430%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.747430%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.747430%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.747430%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Weighted-Average</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Exercise Price</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Weighted-Average</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Remaining</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Contractual Term</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">(Years)</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Aggregate Intrinsic Value</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">(in thousands)</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding, December 31, 2017</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">4,504,642&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">19.79&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">7.0</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Granted</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1,269,844&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">27.18&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Options exercised</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(285,432)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">4.22&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Forfeited or expired</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(215,090)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">24.43&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding, December 31, 2018</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">5,273,964&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">22.23&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">6.8</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">7,969&#160;</span></td></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2018:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Exercisable</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">3,544,139&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">20.60&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">5.9</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">7,969&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Vested and expected to vest</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">5,086,009&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">22.10&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">6.7</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">7,969&#160;</span></td></tr></table></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">During 2018, 2017 and 2016 the Company issued 274,362, 253,036 and 526,715 net shares of common stock, respectively, in conjunction with stock option exercises.&#160;&#160;The Company received cash proceeds from the exercise of stock options of approximately $0.9 million, $0.5 million and $1.9 million during 2018, 2017 and 2016, respectively.</span></div><div style="text-indent:36pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The weighted-average grant-date fair value of options granted during 2018, 2017 and 2016 was $17.90, $12.53 and $15.17 per share, respectively. The total intrinsic value of options exercised during 2018, 2017 and 2016 was approximately $5.2 million, $4.2 million and $10.8 million, respectively.&#160;&#160;The total fair value of stock options which vested during 2018, 2017 and 2016 was $16.4 million, $14.6 million and $11.6 million, respectively.&#160;&#160;As of December&#160;31, 2018, the total unrecognized compensation expense related to non-vested stock options, net of related forfeiture estimates, was $24.2 million, which the Company expects to recognize over a weighted-average period of approximately 2.6 years.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -URI http://asc.fasb.org/subtopic&amp;trid=2208855<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6807395088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes&#160;For the years ended December&#160;31, 2018, 2017 and 2016 there was no provision for income taxes due to taxable losses generated, fully offset by a valuation allowance.<div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The significant components of the Company's deferred income tax assets (liabilities) were as follows (in thousands):</span></div><div style="margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"><tr><td style="width:1.0%;"/><td style="width:73.806452%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.730205%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533138%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.730205%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred income tax assets:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Federal U.S. net operating loss carryforward</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">87,284&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">50,346&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">State net operating loss carryforward</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">22,809&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">7,551&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development credit, net</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">29,750&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">21,284&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Orphan drug credit, net</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">22,580&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">21,708&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred rent</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">3,118&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">3,385&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred revenue</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">3,736&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2,982&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Depreciation</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">155&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">6,854&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">5,847&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross deferred income tax assets</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">176,131&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">113,258&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Valuation allowance</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(172,457)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(112,453)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Net deferred income tax assets</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">3,674&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">805&#160;</span></td></tr><tr><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred income tax liabilities:</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Depreciation</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,911)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid expenditures</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,763)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(805)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross deferred income tax liabilities</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(3,674)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(805)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Net deferred income tax asset/(liability)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td></tr></table></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">The Company recognizes valuation allowances to reduce deferred tax assets to the amount that is more likely than not to be realized. In assessing the likelihood of realization, management considers (i) future reversals of existing taxable temporary differences; (ii) future taxable income exclusive of reversing temporary difference and carryforwards; (iii) taxable income in prior carryback years if carryback is permitted under applicable tax law; and (iv) tax planning strategies. The Company's net deferred income tax asset is not more likely than not to be utilized due to the lack of sufficient sources of future taxable income and cumulative book losses which have resulted over the years. </span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">As of December&#160;31, 2018, the Company has U.S. federal and state net operating loss (NOL) carryforwards of approximately $415.6 million.  Of these NOLs, $237.8 million&#160;will expire in various years beginning in 2025 through 2037. $177.8 million of NOLs were generated post&#160;December 31, 2017 and carryforward indefinitely.  In addition, the Company has U.S. federal tax credits of $52.3 million which will expire in various years beginning in 2022 through 2038.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The use of the Company's U.S. federal NOL and tax credit carryforwards in future years are restricted due to changes in the Company's ownership and tax attributes acquired through the Company's acquisitions. As of December&#160;31, 2018, $13.5 million of the Company's U.S. Federal NOLs are limited for use over the years 2019 &#8211; 2028 in which a range of such amounts could be utilized on an annual basis of $0.2 million to $1.4 million. The remaining $402.1 million of NOLs is not limited and can be offset against future taxable income, subject to certain limitations for newly enacted tax legislation.  The Company adopted ASU 2016-09 as of January 1, 2017.  Accordingly, the Company recognized the previously unrecognized excess tax benefits of approximately $18.6 million ($6.5 million tax effected) recorded as deferred tax assets with a corresponding offsetting full valuation allowance at the beginning of 2017 without any tax impact.&#160;&#160;</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The reconciliation of the reported estimated income tax benefit to the amount that would result by applying the U.S. federal statutory tax rate to the net income is as follows (in thousands):</span></div><div style="margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"><tr><td style="width:1.0%;"/><td style="width:61.343109%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.730205%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533138%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.730205%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533138%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.730205%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2016</span></td></tr><tr><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">United States federal tax at statutory rate</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(36,005)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(6,869)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(20,489)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">State taxes (net of federal benefit)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(11,133)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(735)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(3,116)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred income tax adjustments</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(4,435)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">607&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">173&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred state blended rate adjustments</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(485)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(32)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred federal rate change reduction in corporate rate</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">39,447&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Research credit, net</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(8,466)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(8,455)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(2,551)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Orphan drug credit, net</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(872)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,853)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(571)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Other permanent items</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">148&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">276&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">145&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Equity-based compensation</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">758&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2,067&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1,997&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Change in valuation allowance</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">60,005&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(24,000)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">24,444&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Income tax expense/(benefit)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td></tr></table></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">A reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows (in thousands):</span></div><div style="margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"><tr><td style="width:1.0%;"/><td style="width:61.343109%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.730205%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533138%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.730205%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533138%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.730205%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2016</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Beginning balance</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">3,395&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2,465&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2,425&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Increases for current year tax positions</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">642&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">569&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">308&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Increases/(decreases) for prior year tax positions</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">281&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">361&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(268)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Ending balance</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">4,318&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">3,395&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2,465&#160;</span></td></tr></table></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">As of December&#160;31, 2018 and 2017, of the total gross unrecognized tax benefits, approximately $4.5 million and $3.4 million would favorably impact the Company's effective income tax rate, respectively. Although, due to the Company's determination that the deferred income tax asset would not more likely than not be realized, a valuation allowance would be recorded, therefore, zero net impact would result within the Company's effective income tax rate. The Company's uncertain income tax position liability has been recorded to deferred income taxes to offset the tax attribute carryforward amounts.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">For the years ended December&#160;31, 2018, 2017 and 2016, the Company has not recognized any interest or penalties related to the uncertain income tax positions due to the fact such position is related to tax attribute carryforwards which have not yet been utilized. The Company does not expect its unrecognized income tax position to significantly decrease within the next twelve months.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Company's U.S. Federal and state income tax returns from 2001&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;">forward remain open to examination due to the carryover of unused net operating losses and tax credits.</span></div>As more fully described in Note 2 to the consolidated financial statements, the Tax Act was signed into law making significant changes to the Internal Revenue Code on December 22, 2017.  Under ASC 740, the effects of the new legislation are to be recognized in the period of enactment.  As such, recognition of the tax impact of the Tax Act was required in the interim and annual periods that include December 22, 2017.  As a result, the Company revalued the deferred tax asset as of December 31, 2017, fully offset by a valuation allowance without impact to the financial statements.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6811831248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and Other Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_CollaborationAndLicenseAgreementsAbstract', window );"><strong>Collaboration and License Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock', window );">Collaboration and Other Agreements</a></td>
<td class="text">Collaboration and Other Agreements<div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Incyte</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">In October 2017, the Company entered into an exclusive global collaboration and license agreement with Incyte for MGA012&#160;(also known as INCMGA0012), an investigational monoclonal antibody that inhibits programmed cell death protein 1 (PD-1) (Incyte Agreement). Incyte has obtained exclusive worldwide rights for the development and commercialization of MGA012 in all indications, while the Company retains the right to develop its pipeline assets in combination with MGA012.  The Company received a $150.0 million upfront payment from Incyte when the transaction closed in the fourth quarter of 2017.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Under the terms of the Incyte Agreement, Incyte will lead global development of MGA012.  Assuming successful development and commercialization by Incyte, the Company could receive up to approximately $420.0 million in development and regulatory milestones, and up to $330.0 million in commercial milestones. As of December&#160;31, 2018, the Company has recognized $15.0 million in development milestones under this agreement.  If commercialized, the Company would be eligible to receive tiered royalties of 15% to 24% on any global net sales. The Company retains the right to develop its pipeline assets in combination with MGA012, with Incyte commercializing MGA012 and the Company commercializing its asset(s), if any such potential combinations are approved. In addition, the Company retains the right to manufacture a portion of both companies' global commercial supply needs of MGA012, subject to a separate commercial supply agreement. Finally, Incyte funded the Company's activities related to the ongoing monotherapy clinical study and will continue to fund certain related clinical activities. &#160;</span></div><div style="text-indent:42pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Upon the adoption of ASC 606, the Company evaluated the Incyte Agreement under the provisions of ASC 606 and identified the following two performance obligations under the agreement: (i) the license of MGA012 and (ii) the performance of certain clinical activities through a brief technology transfer period.  The Company determined that the license and clinical activities are separate performance obligations because they are capable of being distinct, and are distinct in the context of the contract. The license has standalone functionality as it is sublicensable, Incyte has significant capabilities in performing clinical trials, and Incyte is capable of performing these activities without the Company's involvement; the Company performed the activities during the transfer period as a matter of convenience.  The Company determined that the transaction price of the Incyte Agreement at inception was $154.0 million, consisting of the consideration to which the Company was entitled in exchange for the license and an estimate of the consideration for clinical activities to be performed.  The transaction price was allocated to each performance obligation based on their relative standalone selling price.  The standalone selling price of the license was determined using the adjusted market assessment approach considering similar collaboration and license agreements.  The standalone selling price for agreed-upon clinical activities to be performed was determined using the expected cost approach based on similar arrangements the Company has with other parties.  The potential development and regulatory milestone payments are </span><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;">fully constrained until the Company concludes that achievement of the milestone is probable and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">and as such have been excluded from the transaction price.  Any consideration related to sales-based milestones and royalties will be recognized when the related sales occur, as they were determined to relate predominantly to the license granted to Incyte and, therefore, have also been excluded from the transaction price.  The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur. </span><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;">During the&#160;year ended December&#160;31, 2018, it became probable that a significant reversal of cumulative revenue would not occur for three development milestones totaling </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">$15.0 million</span><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;"> related to MGA012 meeting certain clinical proof-of-concept criteria. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#160;Therefore</span><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;"> the associated consideration was added to the estimated transaction price and was recognized as revenue.  </span></div><div style="text-indent:42pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Company recognized the </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">$150.0 million</span><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;"> allocated to the </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">license when it satisfied its performance obligation and transferred the license to Incyte in December 2017.  The $4.0 million allocated to the clinical activities&#160;was recognized over the period from the effective date of the agreement until such time as the clinical activities were transferred to Incyte using an input method according to research and development costs incurred to date compared to estimated total research and development costs.  These clinical activities were substantially completed as of June 30, 2018.  Prior to the adoption of ASC 606 on January 1, 2018, the accounting for this agreement did not materially differ from the accounting under ASC 606.  The Company recognized revenue of&#160;$18.8 million&#160;and $151.1 million&#160;under the Incyte Agreement during the years ended December&#160;31, 2018 and&#160;2017, respectively.   The revenue recognized during the year ended December&#160;31, 2018 included milestone revenue of $15.0 million.</span></div><div style="text-indent:42pt;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Company also has an agreement with Incyte, which was signed in 2018, under which the Company is to perform development and&#160;manufacturing services for Incyte&#8217;s clinical needs of MGA012.  The Company evaluated this agreement under ASC 606 and identified one performance obligation under the agreement - to perform services related to manufacturing the clinical supply of MGA012.  The transaction price is based on the costs incurred to develop and manufacture drug product and drug substance, and is recognized over time as the services are provided, as the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date.   During the year ended December&#160;31, 2018, the Company recognized revenue of $22.2 million for services performed under this agreement. </span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Servier </span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">In September 2012, the Company entered into a collaboration agreement with Servier and granted it exclusive options to obtain three separate exclusive licenses to develop and commercialize DART molecules, consisting of those designated by the Company as flotetuzumab (also known as MGD006 or S80880) and MGD007, as well as a third DART molecule, in all countries other than the United States, Canada, Mexico, Japan, South Korea and India (Servier Agreement). During 2014, Servier exercised its exclusive option to develop and commercialize flotetuzumab.  During 2016 Servier notified the Company</span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> that it did not intend to exercise the option for the third DART molecule, and in November 2018, Servier notified the Company that it did not intend to exercise the option for MGD007.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Upon execution of the agreement, Servier made a nonrefundable payment of $20.0 million to the Company. In addition, if Servier successfully develops, obtains regulatory approval for, and commercializes flotetuzumab, the Company will be eligible to receive up to&#160;$22.5 million in clinical milestone payments, $76.0 million in regulatory milestone payments&#160;and $210.0 million in sales milestone payments. In addition to these milestones, the Company and Servier will share Phase 2 and Phase 3 development costs.&#160; Under this agreement, Servier would be obligated to pay the Company from low double-digit to mid-teen royalties on net product sales in its territories.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Upon the adoption of ASC&#160;606, the Company evaluated the Servier Agreement under the provisions of ASC 606 and concluded that Servier is a customer prior to the exercise of any of the three options.  The Company identified the following material promises under the arrangement for each of the three molecules:  (i) a limited evaluation license to conduct activities under the research plan and  (ii)  research and development services concluding with an option trigger data package.  The Servier Agreement also provided exclusive options for an exclusive license to research, develop, manufacture and commercialize each subject molecule. The Company evaluated these options and concluded that the options were not issued at a significant and incremental discount, and therefore do not provide material rights.  As such, they are excluded as performance obligations at the outset of the arrangement. The Company determined that each license and the related research and development services were not distinct from one another, as the license has limited value without the performance of the research and development activities.  As such, the Company determined that these promises should be combined into a single performance obligation for each molecule, resulting in a total of three performance obligations; one for flotetuzumab, one for MGD007, and one for the third DART molecule. </span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Company determined that the $20.0 million</span><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">upfront payment from Servier constituted the entirety of the consideration to be included in the transaction price as of the outset of the arrangement, and the transaction price was allocated to the three performance obligations based on their relative standalone selling price. </span><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;">The milestone payments that the Company was eligible to receive prior to the exercise of the options were excluded from the transaction price, as all milestone amounts were fully constrained based on the probability of achievement. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> Two milestones were achieved in 2014 when the INDs for flotetuzumab and MGD007 were cleared by the Food and Drug Administration (FDA).  Upon achievement of each milestone, the constraint related to the $5.0 million milestone payment was removed and the transaction price was re-assessed. This variable consideration was allocated to each specific performance obligation in accordance with ASC 606.</span></div><div style="text-indent:36pt;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Revenue associated with each performance obligation is being recognized as the research and development services are provided using an input method according to research and development costs incurred to date compared to estimated total research and development costs. The transfer of control occurs over this time period and, in management&#8217;s judgment, is the best measure of progress towards satisfying the performance obligation.  The full transaction price allocated to flotetuzumab and the third DART molecule was recognized as revenue prior to the adoption of ASC 606 on January 1, 2018 as the option periods had ended. The development period for MGD007 was estimated to be 75 months, ending in December 2018, therefore the transaction price allocated to MGD007 was&#160;being recognized through that date.  When Servier notified the Company that it was not exercising the option for MGD007 in November 2018, the Company recognized the remaining deferred revenue related to MGD007.  Upon the adoption of ASC 606 on January 1, 2018, the pattern of revenue recognition for the upfront fee and the accounting for the milestones received in 2014 changed, but there was no material impact to revenue recognized during the year ended December 31, 2018.  During the years ended December 31, 2018, 2017 and 2016 the Company recognized revenue of $1.9 million, $1.1 million&#160;and $1.1 million, respectively, related to the MGD007 option.  At December 31, 2018, no revenue related to the MGD007 option was deferred.  The deferred revenue balance related to the MGD007 option as of December 31, 2017, prior to the adoption of ASC 606, was $1.1 million, all of which was current.</span></div><div style="text-indent:36pt;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">As discussed above, in 2014, Servier exercised its option to obtain a license to develop and commercialize flotetuzumab in its territories and paid the Company a $15.0 million license grant fee.  Upon exercise, the Company's contractual obligations include (i) granting Servier an exclusive license to its intellectual property, (ii) technical, scientific and intellectual property support to the research plan and (iii)  participation on an executive committee and a research and development committee. Under the terms of the Servier Agreement, the Company and Servier will share costs incurred to develop flotetuzumab during the license term. Due to the fact that both parties share costs and are exposed to significant risks and rewards dependent on the commercial success of the product, the Company determined that the arrangement is a collaborative arrangement within the scope of ASC 808.  The arrangement consists of two components; the license of flotetuzumab and the research and development activities, including committee participation, to support the research plan.  </span><span style="background-color:#ffffff;color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Under the provisions of ASC 808, the Company has determined that it will use ASC 606 by analogy to recognize the revenue related to the license.  The Company evaluated its performance obligation to provide Servier with an exclusive license to </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">develop and commercialize flotetuzumab and determined that its transaction price is equal to the license grant fee payment of $15.0 million and Servier consumes the benefits of the license over time as the research and development activities are</span></div><div style="margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> performed. Therefore, the Company will recognize the transaction price over the development period, using an input method according to research and development costs incurred to date compared to estimated total research and development costs. The additional potential clinical, regulatory and sales milestones are </span><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;">fully constrained </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">and have been excluded from the transaction price.&#160;</span></div><div style="text-indent:36pt;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Prior to the adoption of ASC 606 on January 1, 2018, the Company recognized the license grant fee over the expected period of development on a straight-line basis. The deferred revenue balance related to the flotetuzumab license grant fee as of December 31, 2017, prior to the adoption of ASC 606, was $7.4 million. The adoption of ASC 606 increased that balance by approximately $6.4&#160;million. The adoption of ASC 606 increased revenue recognized during the year ended December 31, 2018 by $0.1&#160;million, and it will increase the revenue to be recognized in the future as the pattern of revenue recognition has changed. During the years ended December 31, 2018, 2017 and 2016 the Company recognized revenue of $1.2 million, $1.4 million, and $2.2 million, respectively, related to the flotetuzumab license grant fee.  At December 31, 2018, $12.6 million of revenue related to the flotetuzumab license grant fee was deferred, $0.9 million of which was current and $11.7 million of which was non-current.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The research and development activities component of the arrangement is not analogous to ASC 606, therefore the Company will follow its policy to record expense incurred as research and development expense and reimbursements received from Servier will be recognized as an offset to research and development expense on the consolidated statement of operations and comprehensive loss during the development period.  During the three years ended December 31, 2018, 2017&#160;and 2016&#160;the Company recorded approximately $6.0 million, $3.2 million and $2.6 million, respectively, as an offset to research and development expense under this collaborative arrangement.</span><span style="background-color:#ffffff;color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#160;</span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Zai Lab  </span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">In November 2018, the Company entered into a collaboration and license agreement with Zai Lab (Zai Lab Agreement) under which Zai Lab obtained regional development and commercialization rights in mainland China, Hong Kong, Macau and Taiwan for (i) margetuximab, an immune-optimized anti-HER2 monoclonal antibody, (ii) MGD013, a bispecific DART molecule designed to provide coordinate blockade of PD-1 and LAG-3 for the potential treatment of a range of solid tumors and hematological malignancies, and (iii) an undisclosed multi-specific TRIDENT molecule in preclinical development. Zai Lab will lead clinical development of these molecules in its territory. </span></div><div style="text-indent:36pt;margin-top:5pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Under the terms of the Zai Lab Agreement, Zai Lab paid the Company an upfront payment of $25.0&#160;million, less foreign withholding tax of $2.50&#160;million, which was received in January 2019.  Assuming successful development and commercialization of margetuximab, MGD013 and the TRIDENT molecule, the Company could receive up to $140.0 million in development and regulatory milestones. In addition, Zai Lab would pay the Company double-digit royalties on annual net sales of the assets, which may be subject to adjustment in specified circumstances.</span></div><div style="text-indent:36pt;margin-top:5pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Company evaluated the Zai Lab Agreement under the provisions of ASC 606 and identified the following material promises under the arrangement for each of the two product candidates, margetuximab and MGD013:  (i)  an exclusive license to develop and commercialize the product candidate in Zai Lab&#8217;s territory and (ii) certain research and development activities.  The Company determined that each license and the related research and development activities were not distinct from one another, as the license has limited value without the performance of the research and development activities.  As such, the Company determined that these promises should be combined into a single performance obligation for each product candidate.  Activities related to margetuximab and MGD013 are separate performance obligations from each other because they are capable of being distinct, and are distinct in the context of the contract.  The Company evaluated the promises related to the TRIDENT molecule and determined they were immaterial in context of the contract, therefore there is no performance obligation related to that molecule.  The Company determined that the $25.0 million (less foreign withholding tax of $2.5 million) upfront payment from Zai Lab constituted the entirety of the consideration to be included in the transaction price as of the outset of the arrangement, and the transaction price was allocated to the two performance obligations based on their relative standalone selling price.  The standalone selling price of the performance obligations was determined using the adjusted market assessment approach considering similar collaboration and license agreements.  The potential development and regulatory milestone payments are fully constrained until the Company concludes that achievement of the milestone is probable, and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such have been excluded from the transaction price.  Any consideration related to royalties will be recognized when the related sales occur, as they were determined to relate predominantly to the license granted to Zai Lab and, therefore, have also been excluded from the transaction price.  The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur.</span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#160;&#160;Due to the relatively short-term nature of the recognition period, the revenue associated with the MGD013 performance obligation is being recognized on a straight-line basis as the Company performs research and development</span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> activities under the agreement.  The fixed consideration related to the margetuximab performance obligation is also being recognized on a straight-line basis as the Company performs research and development activities under the agreement.  Straight-line recognition is materially consistent with the pattern of performance of the research and development activities of each product candidate.  The variable consideration related to the margetuximab performance obligation will be recognized upon certain regulatory achievements.  During the year ended December 31, 2018, the Company recognized revenue of $1.3 million related to the Zai Lab Agreement.  At December 31, 2018, $21.1 million of revenue was deferred under this agreement, $16.1 million of which was current.</span></div><div style="margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Roche</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">In December 2017, the Company entered into a research collaboration and license agreement with Roche to jointly discover and develop novel bispecific molecules to undisclosed targets (Roche Agreement).  During the research term, both companies will leverage their respective platforms, including the Company's DART platform and Roche's CrossMAb and DutaFab technologies to select a bispecific format and lead product candidate.  Roche would then further develop and commercialize any such product candidate.  Each company will be responsible for their own expenses during the research period. </span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Under the terms of the Roche Agreement, Roche received rights to use certain of the Company&#8217;s intellectual property rights to exploit collaboration compounds and products, and paid the Company an upfront payment of $10.0 million which was received in January 2018. The Company will also be eligible to receive up to $370.0 million in potential milestone payments and royalties on future sales.  As of December&#160;31, 2018, the Company has not recognized any milestone revenue under this agreement.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Upon the adoption of ASC 606, the Company evaluated the Roche Agreement under the provisions of ASC 606 and identified the following promises under the agreement: (i) the non-exclusive, non-transferable, non-sublicensable license to the Company's intellectual property and (ii) the performance of certain activities during the research period.  The Company determined that the license is capable of being distinct, but is not distinct in the context of the contract because it has limited value to Roche without the research activities required to be performed by the Company.  Therefore, the Company concluded that there is one performance obligation under the agreement.  The Company determined that the transaction price of the Roche Agreement was $10.0 million.  The potential milestone payments are </span><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;">fully constrained </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">and have been excluded from the transaction price.  Any consideration related to sales-based royalties will be recognized when the related sales occur as they were determined to relate predominantly to the license granted to Roche and therefore have also been excluded from the transaction price.    </span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The $10.0 million transaction price is being recognized over the expected research period, which is 30 months, using a cost-based input method to measure performance.   Prior to the adoption of ASC 606 on January 1, 2018, the accounting for this agreement did not materially differ from the accounting under ASC 606. The Company recognized revenue under this agreement of  $4.0 million during the year ended December&#160;31, 2018.  At December&#160;31, 2018, $6.0 million of revenue was deferred under this agreement, $4.0 million of which was current and $2.0 million of which was non-current.&#160;At December&#160;31, 2017, $10.0 million of revenue was deferred under this agreement,  $4.0 million of which was current and $6.0 million of which was non-current.&#160;</span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Provention</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">In May 2018, the Company entered into a license agreement with Provention pursuant to which the Company granted Provention exclusive global rights for the purpose of developing and commercializing MGD010 (renamed PRV-3279), a CD32B x CD79B DART molecule being developed for the treatment of autoimmune indications (Provention License Agreement).  As partial consideration for the Provention License Agreement, Provention granted the Company a warrant to purchase shares of Provention&#8217;s common stock at an exercise price of $2.50 per share. The warrant expires on May 7, 2025.  If Provention successfully develops, obtains regulatory approval for, and commercializes PRV-3279, the Company will be eligible to receive up to $65.0 million in development and regulatory milestones and up to $225.0 million in commercial milestones.  As of December 31, 2018, the Company has not recognized any milestone revenue under this agreement.  If commercialized, the Company would be eligible to receive single-digit royalties on net sales of the product.  The license agreement may be terminated by either party upon a material breach or bankruptcy of the other party, by Provention without cause upon prior notice to the Company, and by the Company in the event that Provention challenges the validity of any licensed patent under the agreement, but only with respect to the challenged patent.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#160;Also in May 2018, the Company entered into an asset purchase agreement with Provention pursuant to which Provention acquired the Company&#8217;s interest in teplizumab (renamed PRV-031), a monoclonal antibody being developed for the treatment of type 1 diabetes (Asset Purchase Agreement).  As partial consideration for the Asset Purchase Agreement, Provention granted the Company a warrant to purchase shares of Provention&#8217;s common stock at an exercise price of $2.50 per</span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> share.  The warrant expires on May 7, 2025.  If Provention successfully develops, obtains regulatory approval for, and commercializes PRV-031, the Company will be eligible to receive up to $170.0 million in regulatory milestones and up to $225.0 million in commercial milestones.  If commercialized, the Company would be eligible to receive single-digit royalties on net sales of the product.  Provention has also agreed to pay third-party obligations, including low single-digit royalties, a portion of which is creditable against royalties payable to the Company, aggregate milestone payments of up to approximately $1.3 million and other consideration, for certain third-party intellectual property under agreements Provention is assuming pursuant to the Asset Purchase Agreement. Further, Provention is required to pay the Company a low double-digit percentage of certain consideration to the extent it is received in connection with a future grant of rights to PRV-031 by Provention to a third party. </span></div><div style="text-indent:36pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Company evaluated the Provention License Agreement and Asset Purchase Agreement under the provisions of ASC 606 and determined that they should be accounted for as a single contract and identified two performance obligations within that contract: (i) the license of MGD010 and (ii) the title to teplizumab.  The Company determined that the transaction price of the Provention agreements was $6.1 million, based on the Black-Scholes valuation of the warrants to purchase a total of 2,432,688 shares of Provention's common stock.  The transaction price was allocated to each performance obligation based on the number of shares of common stock the Company is entitled to purchase under each warrant.  The potential development and regulatory milestone payments are fully constrained until the Company concludes that achievement of the milestone is probable and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such have been excluded from the transaction price.  Any consideration related to sales-based milestones and royalties will be recognized when the related sales occur, therefore they have also been excluded from the transaction price.  The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur. </span></div><div style="text-indent:36pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Company recognized revenue of $6.1 million when it satisfied its performance obligations and transferred the MGD010 license and teplizumab assets to Provention in May 2018.  The warrants are reported in other assets on the balance sheet at December&#160;31, 2018 and will be revalued at each reporting period until exercised or the warrants lapse.  &#160;The Company revalued the warrants based on current Black-Scholes parameters&#160;as of December&#160;31, 2018,&#160;and recorded a decrease of $4.2 million in other assets.  This revaluation is reflected in other income (expense) on the consolidated statements of operations and comprehensive loss for the year ended December&#160;31, 2018.</span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Janssen</span><span style="background-color:rgb(255,255,255, 0.0);color:#ee2724;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">In December 2014, the Company entered into a collaboration and license agreement with Janssen for the development and commercialization of MGD011 (also known as JNJ-64052781 or duvortuxizumab), a product candidate that incorporates the Company's proprietary DART technology to simultaneously target CD19 and CD3 for the potential treatment of B-cell hematological malignancies (MGD011 Agreement). The Company contemporaneously entered into an agreement with JJDC under which JJDC agreed to purchase 1,923,077 new shares of the Company's common stock for proceeds of $75.0 million.&#160;&#160;Upon closing the transaction in January 2015, the Company received a $50.0 million upfront payment from Janssen as well as the $75.0 million investment in the Company's common stock.&#160;&#160; In August 2017, Janssen notified the Company that they were terminating the MGD011 Agreement.&#160;No revenue was recognized under the MGD011 Agreement during the years ended December 31, 2017 and 2018.  The Company recognized revenue of &#160;$2.0 million&#160;during the year ended December 31, 2016.  </span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">In May 2016, the Company entered into a collaboration and license agreement with Janssen, a related party through ownership of the Company's common stock, for the development and commercialization of MGD015, a product candidate that incorporates the Company's proprietary DART technology to simultaneously target CD3 and an undisclosed tumor target for the potential treatment of various hematological malignancies and solid tumors (MGD015 Agreement). Under the MGD015 Agreement, the Company granted an exclusive license to Janssen to develop and commercialize MGD015.  The Company received a $75.0 million upfront payment from Janssen upon closing the transaction, which was recognized as revenue in 2016.  In January 2018, Janssen notified the Company that they were terminating the MGD015 Agreement. No&#160;revenue was recognized under the MGD015 Agreement during the year ended December 31, 2018. The Company recognized revenue of $0.6 million and&#160;$75.8 million&#160;during the years ended December 31, 2017 and 2016, respectively. </span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The revenue under both the MGD011 and MGD015 Agreements was fully recognized prior to the adoption of ASC&#160;606.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">NIAID Contract</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Company entered into a contract with the National Institute of Allergy and Infectious Diseases (NIAID), effective as of September&#160;15, 2015,&#160;to perform product development and to advance up to two DART molecules, including MGD014. Under this contract, the Company will develop these product candidates for Phase 1/2 clinical trials as therapeutic agents, in combination with latency reversing treatments, to deplete cells infected with human immunodeficiency virus (HIV) infection. </span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> NIAID does not receive goods or services from the Company under this contract, therefore the Company does not consider NIAID to be a customer and concluded this contract is outside the scope of ASC 606.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">This contract includes a base period of $7.5 million to support development of MGD014 through IND application submission with the FDA, as well as up to $17.0 million in additional development funding via NIAID options. Should NIAID fully exercise such options, the Company could receive total payments of up to $24.5 million. The total potential period of performance under the award is from September 15, 2015 through September&#160;14, 2022.  During the year ended December 31, 2017, NIAID exercised the first option in the amount of $10.8 million. The Company recognized revenue of $1.3 million, $1.7 million and $5.1 million under this contract during the years ended December&#160;31, 2018, 2017 and 2016, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CollaborationAndLicenseAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CollaborationAndLicenseAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaboration and license agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6807316576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies&#160;<div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Operating Leases</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Company leases manufacturing, office and laboratory space in Rockville, Maryland under five leases that have terms that expire between 2019 and 2027 unless renewed.&#160;&#160;During the year ended December&#160;31, 2017, the&#160;Company entered into an agreement to sublease a portion of the space&#160;it leases.  As of December 31, 2018,&#160;the Company will receive $1.1 million in future payments under this sublease.  The Company also leases office and laboratory space in Brisbane, California under a lease that expires in November 2023.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> The Rockville leases include a lease executed in July 2015 for space that the Company uses as its headquarters with office, laboratory, and manufacturing space.&#160;&#160; Under the terms of the lease, which commenced on January&#160;1, 2016, the Company received an assignment fee from the former tenant and a tenant improvement allowance from the landlord totaling $5.1 million.&#160;&#160;During 2017, the Company executed a lease amendment for its headquarters building which extends the term of the lease to August 2027, restructures the rent due under the lease, and provides for an additional tenant improvement allowance from the landlord of $7.5 million.  The assignment fee and tenant improvement allowances have been recorded as deferred rent and are being recognized over the new lease term.</span></div><div style="text-indent:36pt;margin-top:3pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">All of the leases contain rent escalation clauses and certain leases contain rent abatements.&#160;&#160;For financial reporting purposes, rent expense is charged to operations on a straight-line basis over the term of the lease.&#160;&#160;As of December&#160;31, 2018 and 2017, the Company had recorded a deferred rent liability of $11.3 million and $12.3 million, respectively. Rent expense for the years ended December&#160;31, 2018, 2017 and 2016 was $4.4 million, $3.1 million and $3.0 million, respectively.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Future minimum lease payments under noncancelable operating leases as of December&#160;31, 2018 are as follows (in thousands):</span></div><div style="margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"><tr><td style="width:1.0%;"/><td style="width:86.269795%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.730205%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">6,323&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">4,757&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">4,724&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">4,865&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2023</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">4,680&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Thereafter</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">13,786&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">39,135&#160;</span></td></tr></table></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Contingencies</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">From time to time, the Company may be subject to various litigation and related matters arising in the ordinary course of business. The Company does not believe it is currently subject to any material matters where there is at least a reasonable possibility that a material loss may be incurred.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6811850864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Employee Benefit Plan</a></td>
<td class="text">Employee Benefit PlanIn 2002, the Company established the MacroGenics 401(k) Plan (the Plan) for its employees under Section 401(k) of the IRC. Under this Plan, all employees at least 21 years of age are eligible to participate in the Plan, starting on the first day of each month. Employees may contribute up to 100% of their salary, subject to government maximums.Employees are 100% vested in their contributions to the Plan. The Company's contribution to the Plan, as determined by the Board of Directors, is discretionary. The Company's contributions to the Plan totaled $1.3 million, $1.1 million and $1.0 million for the years ended December&#160;31, 2018, 2017 and 2016, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for pension and other postretirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6604915328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Quarterly Financial Information (Unaudited)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationTextBlock', window );">Quarterly Financial Information (Unaudited)</a></td>
<td class="text">Quarterly Financial Information (unaudited)<table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"><tr><td style="width:1.0%;"/><td style="width:48.807636%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.747430%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.747430%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.747430%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.747430%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">1st Quarter</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">2nd Quarter</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">3rd Quarter</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">4th Quarter</span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands, except per share data)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenue</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">4,695&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">18,834&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">20,798&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">15,794&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(49,536)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(43,244)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(34,029)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(44,644)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss per share, basic and diluted </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.34)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.03)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.81)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.06)</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenue</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2,055&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1,666&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1,663&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">152,359&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income (loss)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(37,655)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(40,654)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(47,043)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">105,727&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income (loss) per share, basic</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.08)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.14)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.28)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2.87&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income (loss) per share, diluted</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.08)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.14)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.28)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2.80&#160;</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -URI http://asc.fasb.org/topic&amp;trid=2126967<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6807379344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Event</a></td>
<td class="text">Subsequent EventIn February 2019, the Company completed a follow-on equity offering, in which the Company sold 5,500,000 shares of its common stock at a price of $20.00 per share.  Additionally, the underwriters of the offering exercised the full amount of their over-allotment option resulting in the sale of an additional 825,000 shares of the Company&#8217;s common stock at a price of $20.00 per share.  The Company received net proceeds of $118.5 million from this offering, net of underwriting discounts and commissions and other estimated offering expenses.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6808919904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation and Principles of Consolidation</a></td>
<td class="text"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Basis of Presentation and Principles of Consolidation</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The consolidated financial statements include the accounts of MacroGenics, Inc. and its wholly owned subsidiary, MacroGenics UK Limited.&#160; All intercompany accounts and transactions have been eliminated in consolidation. The Company currently operates in one operating segment. Operating segments are defined as components of an enterprise about which separate discrete information is available for the chief operating decision maker, or decision making group, in deciding how to allocate resources and assessing performance. The Company views its operations and manages its business in one segment, which is developing monoclonal antibody-based therapeutics for cancer, autoimmune and infectious diseases.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Use of Estimates</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The preparation of the financial statements in accordance with generally accepted accounting principles (GAAP) requires the Company to make estimates and judgments in certain circumstances that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. In preparing these consolidated financial statements, management has made its best estimates and judgments of certain amounts included in the financial statements, giving due consideration to materiality. On an ongoing basis, the Company evaluates its estimates, including those related to revenue recognition, fair values of assets, stock-based compensation, income taxes, preclinical study and clinical trial accruals and other contingencies. Management bases its estimates on historical experience or on various other assumptions that it believes to be reasonable under the circumstances. Actual results could differ from these estimates.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash, Cash Equivalents and Marketable Securities</a></td>
<td class="text"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Cash, Cash Equivalents and Marketable Securities</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Company considers all investments in highly liquid financial instruments with a maturity of 90 days or less at the date of purchase to be cash equivalents. Cash and cash equivalents includes investments in money market funds with commercial banks and financial institutions, securities issued by the U.S. government and its agencies, Government Sponsored Enterprise agency debt obligations and corporate debt obligations. Cash equivalents are stated at amortized cost, plus accrued interest, which approximates fair value.</span></div><div style="text-indent:25pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Company carries marketable securities classified as available-for-sale at fair value as determined by prices for identical or similar securities at the balance sheet date. Marketable securities consist of Level 2 financial instruments in the fair-value hierarchy. The Company records unrealized gains and losses as a component of other comprehensive loss within the statements of operations and comprehensive loss and as a separate component of stockholders' equity. Realized gains or losses on available-for-sale securities are determined using the specific identification method and the Company includes net realized gains and losses in other income (expense).</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;">At each balance sheet date, the Company assesses available-for-sale securities in an unrealized loss position to determine whether the unrealized loss is other-than-temporary. The Company considers factors including: the significance of the decline in value compared to the cost basis, underlying factors contributing to a decline in the prices of securities in a single asset class, the length of time the market value of the security has been less than its cost basis, the security's relative performance versus its peers, sector or asset class, expected market volatility and the market and economy in general. The Company also evaluates whether it is more likely than not that it will be required to sell a security prior to recovery of its fair value.&#160; An impairment loss is recognized at the time the Company determines that a decline in the fair value below its cost basis is other-than-temporary. There were no unrealized losses at December&#160;31, 2018 or </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">2017</span><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;"> that the Company determined to be other-than-temporary.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts Receivable</a></td>
<td class="text"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Accounts Receivable</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Accounts receivable that management has the intent and ability to collect are reported in the consolidated balance sheets at outstanding amounts, less an allowance for doubtful accounts. The Company writes off uncollectible receivables when the likelihood of collection is remote.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Company evaluates the collectability of accounts receivable on a regular basis. The allowance, if any, is based upon various factors including the financial condition and payment history of customers, an overall review of collections experience on other accounts and economic factors or events expected to affect future collections experience. No allowance was recorded as of December&#160;31, 2018 or 2017, as the Company has a history of collecting on all outstanding accounts.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Fair Value of Financial Instruments</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Company's financial instruments consist of cash and cash equivalents, marketable securities, accounts receivable, accounts payable and accrued expenses.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;">The carrying amount of accounts receivable, accounts payable and accrued expenses are generally considered to be representative of their respective fair values because of their short-term nature.&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> The Company accounts for recurring and non-recurring fair value measurements in accordance with the Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 820, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Fair Value Measurements and Disclosures</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> (ASC 820). ASC 820 defines fair value, establishes a fair value hierarchy for assets and liabilities measured at fair value, and requires expanded disclosures about fair value measurements. The ASC 820 hierarchy ranks the quality of reliability of inputs, or assumptions, used in the determination of fair value and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following three categories:</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">Level 1 &#8211; Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities.</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">Level 2 &#8211; Fair value is determined by using inputs other than Level 1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models, such as interest rates and yield curves that can be corroborated by observable market data.</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">Level 3 &#8211; Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgments to be made by a reporting entity &#8211; e.g., determining an appropriate adjustment to a discount factor for illiquidity associated with a given security.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Company evaluates financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them each reporting period. This determination requires the Company to make subjective judgments as to the significance of inputs used in determining fair value and where such inputs lie within the ASC 820 hierarchy.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Concentration of Credit Risk</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents, marketable securities and accounts receivable. </span><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Company maintains&#160;its cash and money market funds with financial institutions that are federally insured. While balances deposited in these institutions often exceed Federal Deposit Insurance Corporation limits, the Company has not experienced any losses on related accounts to date.&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Company's investment policy limits investments to certain types of debt securities issued by the U.S. government, its agencies and institutions with investment-grade credit ratings and places restrictions on maturities and concentration by type and issuer.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> The counterparties are various corporations, financial institutions and government agencies of high credit standing.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, Equipment and Software</a></td>
<td class="text">Property, Equipment and SoftwareProperty, equipment and software are stated at cost. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation or amortization are removed from the accounts and any resulting gain or loss is credited or charged to operations. Repairs and maintenance costs are expensed as incurred.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Impairment of Long-Lived Assets</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Company assesses the recoverability of its long-lived assets in accordance with the provisions of ASC 360, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Property, Plant and Equipment</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">. ASC 360 requires that long-lived assets be reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of the long-lived asset is measured by a comparison of the carrying amount of the asset to future undiscounted net cash flows expected to be generated by the asset or asset group. If carrying value exceeds the sum of undiscounted cash flows, the Company then determines the fair value of the underlying asset group. Any impairment to be recognized is measured by the amount by which the carrying amount of the asset group exceeds the estimated fair value of the asset group. Assets to be disposed of are reported at the lower of the carrying amount or fair value, less costs to sell. For the years ended&#160;December&#160;31, 2018,&#160;2017 and 2016, the Company determined that there were no impaired assets.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Income Taxes</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Deferred tax assets and liabilities are determined based on differences between the financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. The effect on deferred tax assets and liabilities of a change in tax rates is recognized as income in the period that such tax rate changes are enacted. The measurement of a deferred tax asset is reduced, if necessary, by a valuation allowance if it is more likely than not that some portion or all of the deferred tax asset will not be realized. Financial statement recognition of a tax position taken or expected to be taken in a tax return is determined based on a more-likely-than-not threshold of that position being sustained. If the tax position meets this threshold, the benefit to be recognized is measured as the largest amount that is more likely than not to be realized upon ultimate settlement. The Company's policy is to record interest and penalties related to uncertain tax positions as a component of income tax expense.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenues</a></td>
<td class="text"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Revenues</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#160;</span></div><div style="text-indent:40.5pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Beginning on January 1, 2018, the Company&#160;recognizes revenue under Accounting Standards Update (ASU) No. 2014-09, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Revenue from Contracts with Customer</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">s and all related amendments (collectively ASC 606) when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services.&#160;&#160;To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation.  The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. </span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Company enters into licensing agreements that are within the scope of ASC 606, under which it may license rights to research, develop, manufacture and commercialize its product candidates to third parties. The terms of these arrangements typically include payment to the Company of one or more of the following: non-refundable, upfront license fees; reimbursement of certain costs; customer option exercise fees; development, regulatory and commercial milestone payments;&#160;and royalties on net sales of licensed products.   The Company may also enter into development and manufacturing service agreements&#160;with its collaborators.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">For each arrangement that results in revenues, the Company identifies all performance obligations, which may include a license to intellectual property and know-how, research and development activities, transition activities and/or manufacturing services. In order to determine the transaction price, in addition to any upfront payment, the Company estimates the amount of variable consideration at the outset of the contract either utilizing the expected value or most likely amount method, depending</span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> on the facts and circumstances relative to the contract. The Company constrains (reduces) the estimates of variable consideration such that it is probable that a significant reversal of previously recognized revenue will not occur. When determining if variable consideration should be constrained, management considers whether there are factors outside the Company&#8217;s control that could result in a significant reversal of revenue. In making these assessments, the Company considers the likelihood and magnitude of a potential reversal of revenue. These estimates are re-assessed each reporting period as required. </span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Once the estimated transaction price is established, amounts are allocated to the performance obligations that have been identified. The transaction price is generally allocated to each separate performance obligation on a relative standalone selling price basis. The Company must develop assumptions that require judgment to determine the standalone selling price in order to account for these agreements. To determine the standalone selling price, the Company&#8217;s assumptions may include (i)  the probability of obtaining marketing approval for the product candidate, (ii) estimates regarding the timing and the expected costs to develop and commercialize the product candidate, and (iii) estimates of future cash flows from potential product sales with respect to the product candidate. Standalone selling prices used to perform the initial allocation are not updated after contract inception. The Company does not include a financing component to its estimated transaction price at contract inception unless it estimates that certain performance obligations will not be satisfied within one year.</span></div><div style="text-indent:36pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Amounts received prior to revenue recognition are recorded as deferred revenue. Amounts expected to be recognized as revenue within the 12&#160;months following the balance sheet date are classified as current portion of deferred revenue in the accompanying consolidated balance sheets. Amounts not expected to be recognized as revenue within the 12&#160;months following the balance sheet date are classified as deferred revenue, net of current portion. </span></div><div style="text-indent:36pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Licenses. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">If the license to the Company&#8217;s intellectual property is determined to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and when (or as) the customer is able to use and benefit from the license. In assessing whether a promise or performance obligation is distinct from the other promises, the Company considers factors such as the research, development, manufacturing and commercialization capabilities of the licensee and the availability of the associated expertise in the general marketplace. In addition, the Company considers whether the licensee can benefit from a promise for its intended purpose without the receipt of the remaining promise, whether the value of the promise is dependent on the unsatisfied promise, whether there are other vendors that could provide the remaining promise, and whether it is separately identifiable from the remaining promise. For licenses that are combined with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. The measure of progress, and thereby periods over which revenue should be recognized, are subject to estimates by management and may change over the course of the research and development and licensing agreement. Such a change could have a material impact on the amount of revenue the Company records in future periods. </span></div><div style="text-indent:36pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Research, Development and/or Manufacturing Services. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The promises under the Company&#8217;s agreements may include research and development or manufacturing services to be performed by the Company on behalf of the counterparty. If these services are determined to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes the transaction price allocated to these services as revenue over time based on an appropriate measure of progress when the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date.  If these services are determined not to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes the transaction price allocated to the combined performance obligation as the related performance obligations are satisfied. </span></div><div style="text-indent:36pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Customer Options. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">If an arrangement contains customer options, the Company evaluates whether the options are material rights because they allow the customer to acquire additional goods or services for free or at a discount. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the outset of the arrangement. The Company allocates the transaction price to material rights based on the relative standalone selling price, which is determined based on the identified discount and the probability that the customer will exercise the option. Amounts allocated to a material right are not recognized as revenue until, at the earliest, the option is exercised.  If the options are deemed not to be a material right, they are excluded as performance obligations at the outset of the arrangement. </span></div><div style="text-indent:36pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Milestone Payments. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">At the inception of each arrangement that includes development milestone payments, the Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. At the end of each subsequent reporting period, the Company reevaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. </span></div><div style="text-indent:36pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Royalties. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">For arrangements that include sales-based royalties which are the result of a customer-vendor relationship and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied or partially satisfied. To date, the Company has not recognized any royalty revenue resulting from any of its licensing arrangements. </span></div><div style="text-indent:36pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Company analyzes its collaboration arrangements to assess whether such arrangements involve joint operating activities performed by parties who are both active participants in the activities and are both exposed to significant risks and rewards dependent on the commercial success of such activities. Such arrangements generally are within the scope of ASC 808, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Collaborative Arrangements</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> (ASC 808). While ASC 808 defines collaborative arrangements and provides guidance on income statement presentation, classification, and disclosures related to such arrangements, it does not address recognition and measurement matters, such as (1)&#160;determining the appropriate unit of accounting or (2) when the recognition criteria are met. Therefore, the accounting for these arrangements is either based on an analogy to other accounting literature or an accounting policy election by the Company. The Company accounts for certain components of the collaboration agreement that are reflective of a vendor-customer relationship (e.g., licensing arrangement) based on an analogy to ASC 606. The Company accounts for other components based on a reasonable, rational and consistently applied accounting policy election.&#160;&#160; Reimbursements from the counter-party that are the result of a collaborative relationship with the counter-party, instead of a customer relationship, such as co-development activities, are recorded as a reduction to research and development expense as the services are performed.</span></div><div style="text-indent:36pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">For a complete discussion of accounting for revenue from collaborative and other agreements, see Note 8, Collaboration and Other Agreements.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Research and Development Costs</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Research and development expenditures are expensed as incurred. Research and development costs primarily consist of employee related expenses, including salaries and benefits, expenses incurred under agreements with contract research organizations, investigative sites and consultants that conduct the Company's clinical trials, the cost of acquiring and manufacturing clinical trial materials and other allocated expenses, license fees for and milestone payments related to in-licensed products and technologies, stock-based compensation expense, and costs associated with non-clinical activities and regulatory approvals.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Right-to-develop agreements may contain cost-sharing provisions whereby the Company and the collaborator share the cost of research and development activities.&#160; Reimbursement of research and development expenses received in connection with these agreements is recorded as a reduction of such expenses.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Comprehensive Loss</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;">Comprehensive loss represents net loss adjusted for the change during the periods attributed to unrealized gains and losses on available-for-sale securities.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Stock-based Compensation</a></td>
<td class="text"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Stock-based Compensation</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Stock-based payments are accounted for in accordance with the provisions of ASC 718, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Compensation &#8211; Stock Compensation</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">. The fair value of stock-based payments is estimated, on the date of grant, using the Black-Scholes model. The resulting fair value is recognized ratably over the requisite service period, which is generally the vesting period of the option.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">For all time-vesting awards granted, expense is amortized using the straight-line attribution method. For awards that contain a performance condition, expense is amortized using the accelerated attribution method. Recognition of stock-based compensation expense is based on the value of the portion of stock-based awards that is ultimately expected to vest during the period.</span></div>The Company utilizes the Black-Scholes model for estimating fair value of its stock options granted. Option valuation models, including the Black-Scholes model, require the input of highly subjective assumptions, and changes in the assumptions used can materially affect the grant-date fair value of an award. These assumptions include the risk-free rate of interest, expected dividend yield, expected volatility and the expected life of the award.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Net Loss Per Share</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Basic loss per common share is determined by dividing loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted loss per share is computed by dividing the loss attributable to common stockholders by the weighted-average number of common share equivalents outstanding for the period. The treasury stock method is used to determine the dilutive effect of the Company's stock option grants.  5,273,964 stock options (common stock equivalents) were excluded from the calculation of diluted net loss per share for the year ended </span><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;">December&#160;31, 2018&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">because their inclusion would have been anti-dilutive.  4,504,642 stock options and 3,838,060 stock options were excluded from the calculation of diluted net loss per share for the years ended December&#160;31, 2017 and 2016, respectively,</span><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">because their inclusion would have been anti-dilutive.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued Accounting Standards</a></td>
<td class="text"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Recently Issued Accounting Standards </span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">In February 2016, the FASB issued ASU No. 2016-02, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:115%;">Leases</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;"> (ASU 2016-02) that provides principles for the recognition, measurement, presentation and disclosure of leases for both lessees and lessors.  ASU 2016-02 requires a lessee to recognize assets and liabilities on the balance sheet for operating leases and changes many key definitions, including the definition of a lease. ASU 2016-02 includes a short-term lease exception for leases with an original term of 12 months or less, in which a lessee can make an accounting policy election not to recognize lease assets and lease liabilities. Lessees will continue to differentiate between finance leases (previously referred to as capital leases) and operating leases, using classification criteria that are substantially similar to the previous guidance. Originally, entities were required to adopt ASU 2016-02 using a modified retrospective transition approach for all leases existing at, or entered into after, the date of initial application. However, in July 2018, the FASB issued ASU 2018-11, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:115%;">Leases (Topic 842): Targeted Improvements,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;"> which now allows entities the option of recognizing the cumulative effect of applying the new standard as an adjustment to the opening balance of retained earnings in the year of adoption while continuing to present all prior periods under previous lease accounting guidance. In July 2018, the FASB also issued ASU 2018-10, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:115%;">Codification Improvements to Topic 842, Leases, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">which clarifies how to apply certain aspects of ASU 2016-02. ASU 2016-02, ASU 2018-10 and ASU 2018-11 (now commonly referred to as ASC Topic 842 (ASC 842)) is effective for the Company&#8217;s fiscal year beginning January 1, 2019. Although early adoption is permitted, the Company has not elected to do so. The Company plans to elect the transition option provided under ASU 2018-11, which will not require adjustments to comparative periods nor require modified disclosures in those comparative periods. Upon adoption, the Company expects to elect the transition package of practical expedients permitted within the new standard, which among other things, allows the carryforward of the historical lease classification.  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:115%;">Based on its current lease portfolio, the Company estimates that the adoption ASC 842 will result in approximately $16.0 million of right of use assets and $28.0 million of lease liabilities being reflected on its consolidated balance sheet at the date of adoption. </span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">In November 2018, the FASB issued ASU 2018-18, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:115%;">Collaborative Arrangements (Topic 808)&#8212;Clarifying the interaction between Topic 808 and Topic 606</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;"> (ASU 2018-18). The amendments provide guidance on whether certain</span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;"> transactions between collaborative arrangement participants should be accounted for as revenue under ASC 606. It also specifically (i) addresses when the participant should be considered a customer in the context of a unit of account, (ii) adds unit-of-account guidance in ASC 808 to align with guidance in ASC 606, and (iii) precludes presenting revenue from a collaborative arrangement together with revenue recognized under ASC 606 if the collaborative arrangement participant is not a customer. The guidance will be effective for fiscal years beginning after December 15, 2019. Early adoption is permitted and should be applied retrospectively. The Company does not anticipate the adoption of this standard will have a material impact on its consolidated financial statements.</span></div><div style="text-indent:36pt;margin-top:5pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Company has evaluated all other ASUs issued through the date the consolidated financials were issued and believes that the adoption of these will not have a material impact on the Company's consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 305<br> -SubTopic 10<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18726-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108315417&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109250915&amp;loc=d3e13279-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32247-109318<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32280-109318<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65884525&amp;loc=d3e40913-109327<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18726-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for trade and other accounts receivables. This disclosure may include the basis at which such receivables are carried in the entity's statements of financial position (for example, net realizable value), how the entity determines the level of its allowance for doubtful accounts, when impairments, charge-offs or recoveries are recognized, and the entity's income recognition policies for such receivables, including its treatment of related fees and costs, its treatment of premiums, discounts or unearned income, when accrual of interest is discontinued, how the entity records payments received on nonaccrual receivables and its policy for resuming accrual of interest on such receivables.  If the enterprise holds a large number of similar loans, disclosure may include the accounting policy for the anticipation of prepayments and significant assumptions underlying prepayment estimates for amortization of premiums, discounts, and nonrefundable fees and costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=84173941&amp;loc=d3e5212-111524<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84173941&amp;loc=SL6953423-111524<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84173941&amp;loc=d3e5093-111524<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6667052528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Summary of Fair Value Measurement Financial Assets</a></td>
<td class="text"><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Financial assets measured at fair value on a recurring basis were as follows (in thousands):</span></div><div style="margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"><tr><td style="width:1.0%;"/><td style="width:36.325991%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.747430%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.121586%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.565345%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.268429%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.271659%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.121586%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.977974%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value Measurement at December 31, 2018</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Quoted Prices in</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Active Markets for</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Identical Assets</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Significant Other</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Observable Inputs</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Significant</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Unobservable</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Inputs</span></div></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 3</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Assets:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">46,257&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">46,257&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S Treasury securities</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">12,488&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">12,488&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">100,214&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">100,214&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Common stock warrants</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1,890&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1,890&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">Total assets measured at fair value </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(a)</sup></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">160,849&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">46,257&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">112,702&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1,890&#160;</span></td></tr></table></div><div style="margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"><tr><td style="width:1.0%;"/><td style="width:36.325991%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.747430%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.121586%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.565345%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.268429%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.271659%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.121586%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.977974%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value Measurement at December 31, 2017</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Quoted Prices in</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Active Markets for</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Identical Assets</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Significant Other</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Observable Inputs</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Significant</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Unobservable</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Inputs</span></div></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 3</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Assets:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">61,512&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">61,512&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S Treasury securities</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">3,989&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">3,989&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Government-sponsored enterprises</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">11,991&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">11,991&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">78,418&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">78,418&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">Total assets measured at fair value </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(</sup><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">b)</sup></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">155,910&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">61,512&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">94,398&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td></tr></table></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">(a) Total assets measured at fair value at December&#160;31, 2018 includes approximately $146.2 million reported in cash and cash equivalents on the balance sheet.</span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">(b) Total assets measured at fair value at December&#160;31, 2017 includes approximately $62.5 million reported in cash and cash equivalents on the balance sheet.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Summary of Percentage of Customer Concentration</a></td>
<td class="text">The following table includes those collaborators that represent more than 10% of total revenue earned in the periods indicated:<div style="margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.269006%;"><tr><td style="width:1.0%;"/><td style="width:67.219440%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:7.720177%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.536377%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:7.720177%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.683652%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:7.720177%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;height:13pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2016</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Incyte Corporation (Incyte)</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">68%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">96&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Janssen Biotech, Inc. (Janssen)</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">*&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">*&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">85%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Provention Bio, Inc. (Provention)</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">10%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The following table includes those counterparties that represent more than 10% of accounts receivable at the date indicated:</span></div><div style="margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"><tr><td style="width:1.0%;"/><td style="width:73.806452%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.730205%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533138%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.730205%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Zai Lab Limited (Zai Lab)</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">76%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Incyte</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">16%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (Roche)</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">73%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Les Laboratoires Servier and Institut de Recherches Servier (Servier)</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">*&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">12%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div>* Balance is less than 10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock', window );">Estimated Useful Lives</a></td>
<td class="text">Depreciation and amortization are computed using the straight-line method over the following estimated useful lives:<table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"><tr><td style="width:1.0%;"/><td style="width:48.000000%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:48.000000%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Computer equipment</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">3 years</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Software</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">3 years</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Furniture</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">10 years</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Laboratory and office equipment</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">5 years</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Leasehold improvements</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Shorter of lease term or useful life</span></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock', window );">Schedule of New Accounting Pronouncements and Changes in Accounting Principles</a></td>
<td class="text"><div style="text-indent:36pt;text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;">As a result of applying the modified retrospective method to adopt the new guidance, the following adjustments were made to accounts on the consolidated balance sheet as of January 1, 2018 (in thousands):</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Arial;font-size:10pt;line-height:232%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853801%;"><tr><td style="width:1.0%;"/><td style="width:52.465593%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.641288%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532064%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.641288%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.678477%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.641288%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Pre-Adoption</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">ASC 606 Adjustment</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Post-Adoption</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">Deferred revenue, current</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">7,202&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">540&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">7,742&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">Deferred revenue, net of current portion</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">13,637&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">5,939&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">19,576&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">Accumulated deficit</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(312,340)</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(6,478)</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(318,818)</span></td></tr></table></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;">The transition adjustment resulted primarily from changes in </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">the pattern of revenue recognition for upfront fees and license grant fees.  </span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;">The following table shows the impact of adoption to the consolidated statement of income and balance sheet (in thousands):</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Arial;font-size:10pt;line-height:120%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"><tr><td style="width:1.0%;"/><td style="width:42.199706%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.096916%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:16.942731%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:19.292217%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;height:13pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December 31, 2018&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">As Reported&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Balances Without Adoption of ASC 606&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Effect of Change Higher/(Lower)&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenue from collaborative agreements&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">58,644&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">58,104&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">540&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(171,453)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(171,993)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(540)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Basic and diluted net loss per common share&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(4.19)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(4.20)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">0.01&#160;</span></td></tr><tr><td colspan="3" style="height:21pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="height:21pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;height:13pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">As of December 31, 2018</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">As Reported&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Balances Without Adoption of ASC 606&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Effect of Change Higher/(Lower)&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred revenue, current&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">21,721&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">22,210&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(489)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred revenue, net of current portion&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">19,001&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">12,573&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">6,428&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated deficit&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(490,271)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(484,332)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(5,939)</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Rollforward of Contract Liabilities</a></td>
<td class="text"><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;">The following table presents changes in the Company&#8217;s contract liabilities during the year ended December 31, 2018 (in thousands):</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Arial;font-size:10pt;line-height:120%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"><tr><td style="width:1.0%;"/><td style="width:41.024963%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:17.530103%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:7.397944%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.572687%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.271659%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at Beginning of Period&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Additions&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Deductions&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at End of Period&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160; Deferred revenue (current and non-current)&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">27,318&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">22,992&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(9,588)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">40,722&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Property plant and equipment estimated useful life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of contract balances and changes in contract balances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19279-110258<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2C<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=SL7498348-110258<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19190-110258<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109236672&amp;loc=d3e765-108305<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.10-01.(b)(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=27015980&amp;loc=d3e46468-122699<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22580-107794<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=109236672&amp;loc=d3e725-108305<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=109250915&amp;loc=d3e13537-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=109250915&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6327-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6442-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6807341584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesTextBlock', window );">Available-For-Sale Securities</a></td>
<td class="text"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;">Available-for-sale marketable securities as of December&#160;31, 2018 and 2017 were as follows (in thousands):</span></div><div style="margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"><tr><td style="width:1.0%;"/><td style="width:48.807636%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.747430%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.747430%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.747430%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.747430%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="height:16pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;height:16pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2018</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Amortized</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Cost</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Gross</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Unrealized</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Gains</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Gross</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Unrealized</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Losses</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Fair</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Value</span></div></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">12,738&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(3)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">12,735&#160;</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div><div style="text-align:center;margin-bottom:9pt;"><span><br/></span></div><div style="text-align:center;margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"><tr><td style="width:1.0%;"/><td style="width:48.807636%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.747430%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.747430%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.747430%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.747430%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;height:13pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2017</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Amortized</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Cost</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Gross</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Unrealized</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Gains</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Gross</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Unrealized</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Losses</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Fair</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Value</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. Treasury securities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">3,995&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(6)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">3,989&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Government-sponsored enterprises</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">11,998&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(7)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">11,991&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">77,462&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(50)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">77,414&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">93,455&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(63)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">93,394&#160;</span></td></tr></table></div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">All of the Company's available-for-sale securities held at </span><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:Times New Roman;font-size:10pt;line-height:120%;">December&#160;31, 2018</span>&#160;and 2017&#160;had maturity dates of less than one year.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6805873920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Equipment and Software (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment</a></td>
<td class="text">Property, equipment and software consists of the following (in thousands):<table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"><tr><td style="width:1.0%;"/><td style="width:73.806452%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.730205%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533138%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.730205%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Computer equipment</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2,360&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2,261&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Software</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">7,011&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">5,111&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Furniture and office equipment</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">668&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">656&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Lab equipment</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">36,062&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">20,549&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Leasehold improvements</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">48,328&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">17,525&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Construction in progress</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">218&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">32,800&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Property, equipment and software</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">94,647&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">78,902&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Less accumulated depreciation and amortization</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(37,935)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(28,919)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Property, equipment and software, net</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">56,712&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">49,983&#160;</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6808869984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-Based Compensation Expense</a></td>
<td class="text"><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The following stock-based compensation amounts were recognized for the periods indicated (in thousands):</span></div><div style="margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"><tr><td style="width:1.0%;"/><td style="width:61.343109%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.730205%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533138%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.730205%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533138%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.730205%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2016</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">7,919&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">7,388&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">5,778&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">General and administrative&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">8,601&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">7,356&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">6,387&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total stock-based compensation expense</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">16,520&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">14,744&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">12,165&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Employee Stock Options Award Valuation Assumptions</a></td>
<td class="text"><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model using the assumptions in the following table:</span></div><div style="margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"><tr><td style="width:1.0%;"/><td style="width:61.343109%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.730205%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533138%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.730205%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533138%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.730205%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2016</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected dividend yield</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">0%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">0%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">0%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected volatility</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">68% - 72%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">67% - 68%</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">64% - 69%</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Risk-free interest rate</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2.4% - 3.1%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1.9% - 2.3%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1.2% - 2.4%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected term</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">6.25 years</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">6.25 years</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">6.25 years</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of Stock Option and Restricted Stock Unit Activity</a></td>
<td class="text"><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The following table summarizes stock option activity for 2018:</span></div><div style="margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"><tr><td style="width:1.0%;"/><td style="width:48.807636%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.747430%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.747430%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.747430%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.747430%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Weighted-Average</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Exercise Price</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Weighted-Average</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Remaining</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Contractual Term</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">(Years)</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Aggregate Intrinsic Value</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">(in thousands)</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding, December 31, 2017</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">4,504,642&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">19.79&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">7.0</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Granted</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1,269,844&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">27.18&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Options exercised</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(285,432)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">4.22&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Forfeited or expired</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(215,090)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">24.43&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding, December 31, 2018</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">5,273,964&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">22.23&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">6.8</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">7,969&#160;</span></td></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2018:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Exercisable</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">3,544,139&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">20.60&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">5.9</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">7,969&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Vested and expected to vest</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">5,086,009&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">22.10&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">6.7</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">7,969&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Share Based Compensation Stock Options And Restricted Stock Units Activity Table [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6798296960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Components of the Company's Deferred Income Tax Assets (Liabilities)</a></td>
<td class="text"><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The significant components of the Company's deferred income tax assets (liabilities) were as follows (in thousands):</span></div><div style="margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"><tr><td style="width:1.0%;"/><td style="width:73.806452%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.730205%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533138%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.730205%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred income tax assets:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Federal U.S. net operating loss carryforward</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">87,284&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">50,346&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">State net operating loss carryforward</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">22,809&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">7,551&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development credit, net</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">29,750&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">21,284&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Orphan drug credit, net</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">22,580&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">21,708&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred rent</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">3,118&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">3,385&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred revenue</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">3,736&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2,982&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Depreciation</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">155&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">6,854&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">5,847&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross deferred income tax assets</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">176,131&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">113,258&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Valuation allowance</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(172,457)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(112,453)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Net deferred income tax assets</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">3,674&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">805&#160;</span></td></tr><tr><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred income tax liabilities:</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Depreciation</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,911)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid expenditures</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,763)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(805)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross deferred income tax liabilities</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(3,674)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(805)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Net deferred income tax asset/(liability)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Reconciliation of Reported Estimated Income Tax Benefit</a></td>
<td class="text"><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The reconciliation of the reported estimated income tax benefit to the amount that would result by applying the U.S. federal statutory tax rate to the net income is as follows (in thousands):</span></div><div style="margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"><tr><td style="width:1.0%;"/><td style="width:61.343109%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.730205%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533138%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.730205%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533138%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.730205%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2016</span></td></tr><tr><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">United States federal tax at statutory rate</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(36,005)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(6,869)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(20,489)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">State taxes (net of federal benefit)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(11,133)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(735)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(3,116)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred income tax adjustments</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(4,435)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">607&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">173&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred state blended rate adjustments</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(485)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(32)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred federal rate change reduction in corporate rate</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">39,447&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Research credit, net</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(8,466)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(8,455)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(2,551)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Orphan drug credit, net</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(872)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,853)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(571)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Other permanent items</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">148&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">276&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">145&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Equity-based compensation</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">758&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2,067&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1,997&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Change in valuation allowance</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">60,005&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(24,000)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">24,444&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Income tax expense/(benefit)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Reconciliation of the Beginning and Ending Amount of Gross Unrecognized Tax Benefits</a></td>
<td class="text"><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">A reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows (in thousands):</span></div><div style="margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"><tr><td style="width:1.0%;"/><td style="width:61.343109%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.730205%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533138%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.730205%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533138%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.730205%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2016</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Beginning balance</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">3,395&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2,465&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2,425&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Increases for current year tax positions</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">642&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">569&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">308&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Increases/(decreases) for prior year tax positions</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">281&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">361&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(268)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Ending balance</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">4,318&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">3,395&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2,465&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 217<br> -URI http://asc.fasb.org/extlink&amp;oid=109238393&amp;loc=d3e36027-109320<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6807361424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock', window );">Schedule of Minimum Future Lease Payments</a></td>
<td class="text"><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Future minimum lease payments under noncancelable operating leases as of December&#160;31, 2018 are as follows (in thousands):</span></div><div style="margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"><tr><td style="width:1.0%;"/><td style="width:86.269795%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.730205%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">6,323&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">4,757&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">4,724&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">4,865&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2023</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">4,680&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Thereafter</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">13,786&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">39,135&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for lessee's operating leases. Includes, but is not limited to, description of lessee's operating lease, existence and terms of renewal or purchase options and escalation clauses, restrictions imposed by lease, such as those concerning dividends, additional debt, and further leasing, rent holidays, rent concessions, or leasehold improvement incentives and unusual provisions or conditions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=115931803&amp;loc=d3e12069-110248<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41499-112717<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 1,3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84164451&amp;loc=d3e36991-112694<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6811805728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Quarterly Financial Information (Unaudited) (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock', window );">Company's Consolidated Quarterly Results of Operations</a></td>
<td class="text"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"><tr><td style="width:1.0%;"/><td style="width:48.807636%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.747430%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.747430%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.747430%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.747430%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">1st Quarter</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">2nd Quarter</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">3rd Quarter</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">4th Quarter</span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands, except per share data)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenue</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">4,695&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">18,834&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">20,798&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">15,794&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(49,536)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(43,244)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(34,029)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(44,644)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss per share, basic and diluted </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.34)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.03)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.81)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.06)</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenue</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2,055&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1,666&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1,663&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">152,359&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income (loss)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(37,655)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(40,654)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(47,043)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">105,727&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income (loss) per share, basic</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.08)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.14)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.28)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2.87&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income (loss) per share, diluted</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.08)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.14)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.28)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2.80&#160;</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109225645&amp;loc=d3e1280-108306<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6809356720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($) </div>
<div>Segment</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | Segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities', window );">Available-for-sale securities, other than temporary impairment losses</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Allowance recorded</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleCarryingValueOfAsset', window );">Impaired assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroup', window );">Assets held-for-sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized</a></td>
<td class="num">$ (9,588,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an unclassified balance sheet, a valuation allowance for receivables due a company that are expected to be uncollectible.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84173941&amp;loc=d3e5074-111524<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroup">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets held-for-sale that are not part of a disposal group.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 15<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=77912953&amp;loc=d3e400-110220<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsHeldForSaleNotPartOfDisposalGroup</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleCarryingValueOfAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount on the books of the entity of the impaired asset to be disposed of by a method other than sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2611-110228<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleCarryingValueOfAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount by which the fair value of an investment in debt and equity securities categorized as Available-for-sale is less than the amortized cost basis or carrying amount of that investment at the balance sheet date and the decline in fair value is deemed to be other than temporary, before considering whether or not such amount is recognized in earnings or other comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6817107664">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Summary of Fair Value Measurement Financial Asset and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 146,200<span></span>
</td>
<td class="nump">$ 62,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93,394<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_WarrantsFairValueDisclosure', window );">Common stock warrants</a></td>
<td class="nump">1,890<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">160,849<span></span>
</td>
<td class="nump">155,910<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">46,257<span></span>
</td>
<td class="nump">61,512<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,989<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="nump">12,488<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember', window );">Government-sponsored enterprises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,991<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,418<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="nump">100,214<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets, Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_WarrantsFairValueDisclosure', window );">Common stock warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">46,257<span></span>
</td>
<td class="nump">61,512<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets, Level 1 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">46,257<span></span>
</td>
<td class="nump">61,512<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets, Level 1 | U.S Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets, Level 1 | Government-sponsored enterprises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets, Level 1 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs, Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_WarrantsFairValueDisclosure', window );">Common stock warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">112,702<span></span>
</td>
<td class="nump">94,398<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs, Level 2 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs, Level 2 | U.S Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,989<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="nump">12,488<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs, Level 2 | Government-sponsored enterprises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,991<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs, Level 2 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,418<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="nump">100,214<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs, Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_WarrantsFairValueDisclosure', window );">Common stock warrants</a></td>
<td class="nump">1,890<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">1,890<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs, Level 3 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs, Level 3 | U.S Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs, Level 3 | Government-sponsored enterprises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs, Level 3 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_WarrantsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants, Fair Value Disclosure</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_WarrantsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109979856&amp;loc=d3e26610-111562<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6817135296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Summary of Collaborators that Represent More Than 10% of Total Revenue Earned (Details) - Sales revenue, net - Customer Concentration Risk<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=mgnx_IncyteCorporationMember', window );">Incyte Corporation (Incyte)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of all significant revenue earned</a></td>
<td class="nump">68.00%<span></span>
</td>
<td class="nump">96.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=mgnx_JanssenBiotechIncMember', window );">Janssen Biotech, Inc. (Janssen)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of all significant revenue earned</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=mgnx_ProventionBioMember', window );">Provention Bio, Inc. (Provention)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of all significant revenue earned</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=109250915&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109250915&amp;loc=d3e13537-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=mgnx_IncyteCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=mgnx_IncyteCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=mgnx_JanssenBiotechIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=mgnx_JanssenBiotechIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=mgnx_ProventionBioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=mgnx_ProventionBioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6809664224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Summary of Collaborators that Represent More Than 10% of Accounts Receivable (Details) - Customer Concentration Risk - Accounts receivable<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Zai Lab Limited (Zai Lab)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of significant accounts receivable</a></td>
<td class="nump">76.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Incyte Corporation (Incyte)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of significant accounts receivable</a></td>
<td class="nump">16.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (Roche)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of significant accounts receivable</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">73.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Les Laboratoires Servier and Institut de Recherches Servier (Servier)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of significant accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=109250915&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109250915&amp;loc=d3e13537-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=mgnx_ZaiLabLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=mgnx_ZaiLabLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=mgnx_IncyteCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=mgnx_IncyteCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=mgnx_F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=mgnx_F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=mgnx_LesLaboratoiresServierAndInstitutDeRecherchesServierServierMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=mgnx_LesLaboratoiresServierAndInstitutDeRecherchesServierServierMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6809531152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Estimated Useful Lives (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Software</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mgnx_LaboratoryAndOfficeEquipmentMember', window );">Laboratory and office equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mgnx_LaboratoryAndOfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=mgnx_LaboratoryAndOfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6802641344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from the Calculation of Diluted Loss Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive stock options</a></td>
<td class="nump">5,273,964<span></span>
</td>
<td class="nump">4,504,642<span></span>
</td>
<td class="nump">3,838,060<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6818037680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Adoption of 606 (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Jan. 01, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue, current</a></td>
<td class="nump">$ 21,721<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,202<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,721<span></span>
</td>
<td class="nump">$ 7,202<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,742<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="nump">19,001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,637<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,001<span></span>
</td>
<td class="nump">13,637<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,576<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(490,271)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(312,340)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(490,271)<span></span>
</td>
<td class="num">(312,340)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(318,818)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">15,794<span></span>
</td>
<td class="nump">$ 20,798<span></span>
</td>
<td class="nump">$ 18,834<span></span>
</td>
<td class="nump">$ 4,695<span></span>
</td>
<td class="nump">152,359<span></span>
</td>
<td class="nump">$ 1,663<span></span>
</td>
<td class="nump">$ 1,666<span></span>
</td>
<td class="nump">$ 2,055<span></span>
</td>
<td class="nump">60,121<span></span>
</td>
<td class="nump">157,742<span></span>
</td>
<td class="nump">$ 91,880<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(44,644)<span></span>
</td>
<td class="num">$ (34,029)<span></span>
</td>
<td class="num">$ (43,244)<span></span>
</td>
<td class="num">$ (49,536)<span></span>
</td>
<td class="nump">$ 105,727<span></span>
</td>
<td class="num">$ (47,043)<span></span>
</td>
<td class="num">$ (40,654)<span></span>
</td>
<td class="num">$ (37,655)<span></span>
</td>
<td class="num">$ (171,453)<span></span>
</td>
<td class="num">$ (19,626)<span></span>
</td>
<td class="num">$ (58,528)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare', window );">Basic and diluted net loss per common share (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (4.19)<span></span>
</td>
<td class="num">$ (0.54)<span></span>
</td>
<td class="num">$ (1.69)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis=us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member', window );">Pre-Adoption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue, current</a></td>
<td class="nump">22,210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,202<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="nump">12,573<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,573<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,637<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(484,332)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(484,332)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(312,340)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (171,993)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare', window );">Basic and diluted net loss per common share (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (4.20)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis=us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member', window );">Effect of Change Higher/(Lower)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue, current</a></td>
<td class="num">(489)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (489)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="nump">6,428<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,428<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">$ (5,939)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,939)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (540)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare', window );">Basic and diluted net loss per common share (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member', window );">Accounting Standards Update 2014-09</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">540<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,939<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (6,478)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mgnx_RevenueFromCollaborativeAgreementsMember', window );">Revenue from collaborative agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 58,644<span></span>
</td>
<td class="nump">$ 155,516<span></span>
</td>
<td class="nump">$ 86,582<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mgnx_RevenueFromCollaborativeAgreementsMember', window );">Revenue from collaborative agreements | Pre-Adoption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mgnx_RevenueFromCollaborativeAgreementsMember', window );">Revenue from collaborative agreements | Effect of Change Higher/(Lower)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 540<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each basic and diluted share of common stock or unit when the per share amount is the same for both basic and diluted shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis=us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis=us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis=us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis=us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mgnx_RevenueFromCollaborativeAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mgnx_RevenueFromCollaborativeAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6807367808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Signficant Accounting Policies - Contract With Customer Liability (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Beginning balance</a></td>
<td class="nump">$ 27,318<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination', window );">Additions</a></td>
<td class="nump">22,992<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Deductions</a></td>
<td class="num">(9,588)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Ending balance</a></td>
<td class="nump">$ 40,722<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130531-203044<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130532-203044<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration from customer has been received or is due, from business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6809189216">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Marketable Securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 93,455<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(63)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93,394<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,995<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,989<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember', window );">Government-sponsored enterprises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,998<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,991<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 12,738<span></span>
</td>
<td class="nump">77,462<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(50)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">$ 12,735<span></span>
</td>
<td class="nump">$ 77,414<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109979856&amp;loc=d3e26610-111562<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6802814144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities - Available-For-Sale Securities (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities', window );">Available-for-sale securities, other than temporary impairment losses</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeOther', window );">Interest Income, Other</a></td>
<td class="nump">$ 2,300,000<span></span>
</td>
<td class="nump">$ 2,400,000<span></span>
</td>
<td class="nump">$ 2,300,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income earned from interest bearing assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount by which the fair value of an investment in debt and equity securities categorized as Available-for-sale is less than the amortized cost basis or carrying amount of that investment at the balance sheet date and the decline in fair value is deemed to be other than temporary, before considering whether or not such amount is recognized in earnings or other comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6808805040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Equipment and Software (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, equipment and software</a></td>
<td class="nump">$ 94,647,000<span></span>
</td>
<td class="nump">$ 78,902,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConstructionInProgressGross', window );">Construction in progress</a></td>
<td class="nump">218,000<span></span>
</td>
<td class="nump">32,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation and amortization</a></td>
<td class="num">(37,935,000)<span></span>
</td>
<td class="num">(28,919,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, equipment and software, net</a></td>
<td class="nump">56,712,000<span></span>
</td>
<td class="nump">49,983,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PropertyPlantAndEquipmentNonCashAdditions', window );">Property and equipment purchased but not yet paid</a></td>
<td class="nump">600,000<span></span>
</td>
<td class="nump">9,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">9,200,000<span></span>
</td>
<td class="nump">7,000,000.0<span></span>
</td>
<td class="nump">$ 6,800,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, equipment and software</a></td>
<td class="nump">2,360,000<span></span>
</td>
<td class="nump">2,261,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, equipment and software</a></td>
<td class="nump">7,011,000<span></span>
</td>
<td class="nump">5,111,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mgnx_FurnitureAndOfficeEquipmentMember', window );">Furniture and office equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, equipment and software</a></td>
<td class="nump">668,000<span></span>
</td>
<td class="nump">656,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Lab equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, equipment and software</a></td>
<td class="nump">36,062,000<span></span>
</td>
<td class="nump">20,549,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, equipment and software</a></td>
<td class="nump">$ 48,328,000<span></span>
</td>
<td class="nump">$ 17,525,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PropertyPlantAndEquipmentNonCashAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PropertyPlantAndEquipmentNonCashAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionInProgressGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionInProgressGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mgnx_FurnitureAndOfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=mgnx_FurnitureAndOfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6805889872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 02, 2018</div></th>
<th class="th"><div>May 03, 2017</div></th>
<th class="th"><div>Apr. 26, 2017</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,000,000<span></span>
</td>
<td class="nump">125,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 103,259<span></span>
</td>
<td class="nump">$ 34,244<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=mgnx_UndesignatedPreferredStockMember', window );">Undesignated Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Undesignated preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Undesignated preferred stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Undesignated preferred stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Undesignated preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=mgnx_RegisteredDirectOfferingMember', window );">Registered Direct Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of offering costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued or sold (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Common stock purchase price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=mgnx_AtTheMarketOfferingMember', window );">At The Market Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of offering costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">599,284<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued or sold (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">599,284<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_CommonStockMaximumAmountAvailableForIssuance', window );">Common stock maximum amount available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Proceeds of stock sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=mgnx_FirmCommitmentPublicUnderwrittenOfferMember', window );">Firm Commitment Public Underwritten Offer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of common stock (in shares)</a></td>
<td class="nump">4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of common stock (in dollars per share)</a></td>
<td class="nump">$ 21.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Proceeds of stock sale</a></td>
<td class="nump">$ 103,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of common stock (in shares)</a></td>
<td class="nump">675,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of common stock (in dollars per share)</a></td>
<td class="nump">$ 21.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CommonStockMaximumAmountAvailableForIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Maximum Amount Available For Issuance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CommonStockMaximumAmountAvailableForIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=mgnx_UndesignatedPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=mgnx_UndesignatedPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=mgnx_RegisteredDirectOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=mgnx_RegisteredDirectOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=mgnx_AtTheMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=mgnx_AtTheMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=mgnx_FirmCommitmentPublicUnderwrittenOfferMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=mgnx_FirmCommitmentPublicUnderwrittenOfferMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6809588544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Employee Stock Purchase Plan (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>May 18, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 103,259<span></span>
</td>
<td class="nump">$ 34,244<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember', window );">2017 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-based compensation, number of shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent', window );">Common stock discount percent</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Percent of fair market value to purchase shares</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Common stock purchased by employees (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,862<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee Stock Purchase Plan, Maximum Annual Contributions Per Employee, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share instruments newly issued under a share-based compensation plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6809128320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Stock-Based Compensation Expense (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Oct. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based compensation arrangement by share-based payment award, options, outstanding, number (in shares)</a></td>
<td class="nump">5,273,964<span></span>
</td>
<td class="nump">4,504,642<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 22.23<span></span>
</td>
<td class="nump">$ 19.79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 16,520<span></span>
</td>
<td class="nump">$ 14,744<span></span>
</td>
<td class="nump">$ 12,165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mgnx_EquityIncentivePlan2003Member', window );">Equity Incentive Plan 2003</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based compensation arrangement by share-based payment award, options, outstanding, number (in shares)</a></td>
<td class="nump">746,803<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 2.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mgnx_StockIncentivePlan2013Member', window );">Stock Incentive Plan 2013</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-based compensation, number of shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,960,168<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease', window );">Increased number of shares authorized (in shares)</a></td>
<td class="nump">8,244,131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based compensation arrangement by share-based payment award, options, outstanding, number (in shares)</a></td>
<td class="nump">4,527,161<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 25.56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance', window );">Stock reserved for future issuance (in shares)</a></td>
<td class="nump">1,960,168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan', window );">Percentage of common stock share outstanding</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 7,919<span></span>
</td>
<td class="nump">7,388<span></span>
</td>
<td class="nump">5,778<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 8,601<span></span>
</td>
<td class="nump">$ 7,356<span></span>
</td>
<td class="nump">$ 6,387<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock Capital Shares Minimum Increase In Shares Reserved For Future Issuance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of shares of company's common stock outstanding for increase in shares reserved for issuance under stock plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award number of shares authorized after increase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=mgnx_EquityIncentivePlan2003Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=mgnx_EquityIncentivePlan2003Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=mgnx_StockIncentivePlan2013Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=mgnx_StockIncentivePlan2013Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6805913776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Option Pricing Assumptions (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">68.00%<span></span>
</td>
<td class="nump">67.00%<span></span>
</td>
<td class="nump">64.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">2.40%<span></span>
</td>
<td class="nump">1.90%<span></span>
</td>
<td class="nump">1.20%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">72.00%<span></span>
</td>
<td class="nump">68.00%<span></span>
</td>
<td class="nump">69.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">3.10%<span></span>
</td>
<td class="nump">2.30%<span></span>
</td>
<td class="nump">2.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Options granted, maximum term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6809187920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Stock Option and Restricted Stock Unit Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">December 31, 2016</a></td>
<td class="nump">4,504,642<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Granted</a></td>
<td class="nump">1,269,844<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised or RSUs vested</a></td>
<td class="num">(285,432)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited or expired</a></td>
<td class="num">(215,090)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">December 31, 2017</a></td>
<td class="nump">5,273,964<span></span>
</td>
<td class="nump">4,504,642<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable</a></td>
<td class="nump">3,544,139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest</a></td>
<td class="nump">5,086,009<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract', window );"><strong>Weighted-Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">December 31, 2016</a></td>
<td class="nump">$ 19.79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted</a></td>
<td class="nump">27.18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Options exercised or RSUs vested</a></td>
<td class="nump">4.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited or expired</a></td>
<td class="nump">24.43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">December 31, 2017</a></td>
<td class="nump">22.23<span></span>
</td>
<td class="nump">$ 19.79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable</a></td>
<td class="nump">20.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested and expected to vest</a></td>
<td class="nump">$ 22.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-average remaining contractual term, Outstanding</a></td>
<td class="text">6 years 9 months 18 days<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-average remaining contractual term, Exercisable</a></td>
<td class="text">5 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted-average remaining contractual term, Vested and expected to vest</a></td>
<td class="text">6 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value, Outstanding</a></td>
<td class="nump">$ 7,969<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value, Exercisable</a></td>
<td class="nump">7,969<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate intrinsic value, Vested and expected to vest</a></td>
<td class="nump">$ 7,969<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">274,362<span></span>
</td>
<td class="nump">253,036<span></span>
</td>
<td class="nump">526,715<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Cash proceeds from exercise of stock options</a></td>
<td class="nump">$ 900<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="nump">$ 1,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant-date fair value of options granted (in dollars per share)</a></td>
<td class="nump">$ 17.90<span></span>
</td>
<td class="nump">$ 12.53<span></span>
</td>
<td class="nump">$ 15.17<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value</a></td>
<td class="nump">$ 5,200<span></span>
</td>
<td class="nump">$ 4,200<span></span>
</td>
<td class="nump">$ 10,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Fair value of shares vested</a></td>
<td class="nump">16,400<span></span>
</td>
<td class="nump">$ 14,600<span></span>
</td>
<td class="nump">$ 11,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost related to non-vested stock-based compensation arrangements</a></td>
<td class="nump">$ 24,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation expense recognition period</a></td>
<td class="text">2 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized cost of unvested share-based compensation awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of stock options granted under share-based compensation arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of any shares forfeited. Shares issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6817097360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Components of the Company's Deferred Tax Assets (Liabilities) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Provision for federal or state income taxes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Deferred income tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic', window );">Federal U.S. net operating loss carryforward</a></td>
<td class="nump">87,284,000<span></span>
</td>
<td class="nump">50,346,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">State net operating loss carryforward</a></td>
<td class="nump">22,809,000<span></span>
</td>
<td class="nump">7,551,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credit, net</a></td>
<td class="nump">29,750,000<span></span>
</td>
<td class="nump">21,284,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther', window );">Orphan drug credit, net</a></td>
<td class="nump">22,580,000<span></span>
</td>
<td class="nump">21,708,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent', window );">Deferred rent</a></td>
<td class="nump">3,118,000<span></span>
</td>
<td class="nump">3,385,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Deferred revenue</a></td>
<td class="nump">3,736,000<span></span>
</td>
<td class="nump">2,982,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment', window );">Depreciation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">155,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">6,854,000<span></span>
</td>
<td class="nump">5,847,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Gross deferred income tax assets</a></td>
<td class="nump">176,131,000<span></span>
</td>
<td class="nump">113,258,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(172,457,000)<span></span>
</td>
<td class="num">(112,453,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred income tax assets</a></td>
<td class="nump">3,674,000<span></span>
</td>
<td class="nump">805,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract', window );"><strong>Deferred income tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Depreciation</a></td>
<td class="num">(1,911,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses', window );">Prepaid expenditures</a></td>
<td class="num">(1,763,000)<span></span>
</td>
<td class="num">(805,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Gross deferred income tax liabilities</a></td>
<td class="num">(3,674,000)<span></span>
</td>
<td class="num">(805,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred income tax asset/(liability)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_OperatingLossCarryforwardsNotSubjectToLimitation', window );">Remaining portion of net operating losses</a></td>
<td class="nump">402,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount', window );">Previously unrecognized excess tax benefits</a></td>
<td class="nump">18,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTaxBenefitTaxEffectedAmount', window );">Previously unrecognized excess tax benefits, tax effected portion</a></td>
<td class="nump">6,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember', window );">U.S. Federal and State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration', window );">Net operating loss carryforwards</a></td>
<td class="nump">415,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">U.S. Federal Government</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">US Federal tax credits carry forward</a></td>
<td class="nump">52,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount', window );">Net operating loss for limited use</a></td>
<td class="nump">13,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">U.S. Federal Government | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_OperatingLossCarryforwardsAnnualLimitationAmount', window );">Net operating losses limited for use utilized on an annual basis</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">U.S. Federal Government | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_OperatingLossCarryforwardsAnnualLimitationAmount', window );">Net operating losses limited for use utilized on an annual basis</a></td>
<td class="nump">1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=mgnx_TaxYear2025To2037Member', window );">Tax Year 2025 To 2037 | U.S. Federal and State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration', window );">Net operating loss carryforwards</a></td>
<td class="nump">237,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=mgnx_IndefiniteMember', window );">Indefinite | U.S. Federal and State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 177,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTaxBenefitTaxEffectedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Share-based Compensation, Excess Tax Benefit, Tax Effected Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTaxBenefitTaxEffectedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_OperatingLossCarryforwardsAnnualLimitationAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of net operating loss which are limited for use, utilized on a annual basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_OperatingLossCarryforwardsAnnualLimitationAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of net operating loss carryforward, which are limited for use over the range of years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_OperatingLossCarryforwardsNotSubjectToLimitation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforwards not subject to limitation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_OperatingLossCarryforwardsNotSubjectToLimitation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=115928272&amp;loc=d3e28680-109314<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115928272&amp;loc=d3e28680-109314<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115928272&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=115928272&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible tax credit carryforwards, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred rent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115928272&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax consequences attributable to taxable temporary differences derived from prepaid expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=115928272&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to excess tax benefit for share-based compensation cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=mgnx_TaxYear2025To2037Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=mgnx_TaxYear2025To2037Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=mgnx_IndefiniteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=mgnx_IndefiniteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6817159984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of Reported Estimated Income Tax Benefit (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">United States federal tax at statutory rate</a></td>
<td class="num">$ (36,005)<span></span>
</td>
<td class="num">$ (6,869)<span></span>
</td>
<td class="num">$ (20,489)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State taxes (net of federal benefit)</a></td>
<td class="num">(11,133)<span></span>
</td>
<td class="num">(735)<span></span>
</td>
<td class="num">(3,116)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount', window );">Deferred income tax adjustments</a></td>
<td class="num">(4,435)<span></span>
</td>
<td class="nump">607<span></span>
</td>
<td class="nump">173<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_EffectiveIncomeTaxReconciliationStateDeferredTaxesAdjustmentsAmount', window );">Deferred state blended rate adjustments</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(485)<span></span>
</td>
<td class="num">(32)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate', window );">Deferred federal rate change reduction in corporate rate</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">39,447<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">Research credit, net</a></td>
<td class="num">(8,466)<span></span>
</td>
<td class="num">(8,455)<span></span>
</td>
<td class="num">(2,551)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsOther', window );">Orphan drug credit, net</a></td>
<td class="num">(872)<span></span>
</td>
<td class="num">(1,853)<span></span>
</td>
<td class="num">(571)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherReconcilingItems', window );">Other permanent items</a></td>
<td class="nump">148<span></span>
</td>
<td class="nump">276<span></span>
</td>
<td class="nump">145<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Equity-based compensation</a></td>
<td class="nump">758<span></span>
</td>
<td class="nump">2,067<span></span>
</td>
<td class="nump">1,997<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">60,005<span></span>
</td>
<td class="num">(24,000)<span></span>
</td>
<td class="nump">24,444<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense/(benefit)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to deferred tax adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_EffectiveIncomeTaxReconciliationStateDeferredTaxesAdjustmentsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to deferred state blended rate adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_EffectiveIncomeTaxReconciliationStateDeferredTaxesAdjustmentsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32123-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32059-109318<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible equity-based compensation costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherReconcilingItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority noncontrolling interest income (loss), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, increase (decrease) in enacted tax rate, prior year income taxes, increase (decrease) in deferred tax asset valuation allowance, and other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherReconcilingItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6807352976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of the Beginning and Ending Amount of Gross Unrecognized Tax Benefits (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Beginning balance</a></td>
<td class="nump">$ 3,395,000<span></span>
</td>
<td class="nump">$ 2,465,000<span></span>
</td>
<td class="nump">$ 2,425,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Increases for current year tax positions</a></td>
<td class="nump">642,000<span></span>
</td>
<td class="nump">569,000<span></span>
</td>
<td class="nump">308,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Increases for prior year tax positions</a></td>
<td class="nump">281,000<span></span>
</td>
<td class="nump">361,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Decreases for prior year tax positions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(268,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Ending balance</a></td>
<td class="nump">4,318,000<span></span>
</td>
<td class="nump">3,395,000<span></span>
</td>
<td class="nump">2,465,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Gross unrecognized tax benefits</a></td>
<td class="nump">$ 4,500,000<span></span>
</td>
<td class="nump">3,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense', window );">Unrecognized interest or penalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=SL37586934-109318<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6809026896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and Other Agreements, Incyte Corporation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,794<span></span>
</td>
<td class="nump">$ 20,798<span></span>
</td>
<td class="nump">$ 18,834<span></span>
</td>
<td class="nump">$ 4,695<span></span>
</td>
<td class="nump">$ 152,359<span></span>
</td>
<td class="nump">$ 1,663<span></span>
</td>
<td class="nump">$ 1,666<span></span>
</td>
<td class="nump">$ 2,055<span></span>
</td>
<td class="nump">$ 60,121<span></span>
</td>
<td class="nump">$ 157,742<span></span>
</td>
<td class="nump">$ 91,880<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IncyteMGA012AgreementMember', window );">Incyte MGA012 Agreement | Incyte Corporation (Incyte)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NonRefundableUpfrontFees', window );">Non-refundable upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized', window );">Amounts recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_CollaborativeAgreementTransactionPrice', window );">Transaction price</a></td>
<td class="nump">$ 154,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount', window );">Clinical trial activities selling price amount</a></td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Incyte MGA012 Agreement | Incyte Corporation (Incyte)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement', window );">Potential development and regulatory milestone payments</a></td>
<td class="nump">420,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement', window );">Potential commercial milestone payments</a></td>
<td class="nump">$ 330,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_ProceedsfromRoyaltiesPercent', window );">Potential proceeds from royalties percent</a></td>
<td class="nump">24.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Incyte MGA012 Agreement | Incyte Corporation (Incyte)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_ProceedsfromRoyaltiesPercent', window );">Potential proceeds from royalties percent</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember', window );">Revenues From License Agreements | Incyte MGA012 Agreement | Incyte Corporation (Incyte)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,800<span></span>
</td>
<td class="nump">$ 151,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember', window );">Revenues From License Agreements | Incyte MGA012 Clinical Services | Incyte Corporation (Incyte)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CollaborativeAgreementTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement Transaction Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CollaborativeAgreementTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Development And Regulatory Milestone Payments Under Agreement, Recognized</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NonRefundableUpfrontFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Initial fee received from collaboration or license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NonRefundableUpfrontFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential Commercial Milestone Payments Under Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PotentialCommercialMilestonePaymentsUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential Development and Regulatory Milestone Payments Under Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ProceedsfromRoyaltiesPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Royalties, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_ProceedsfromRoyaltiesPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the value established as the selling price of the significant unit of accounting used to allocate the consideration of the multiple-deliverable arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IncyteMGA012AgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IncyteMGA012AgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mgnx_IncyteCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mgnx_IncyteCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IncyteMGA012ClinicalServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IncyteMGA012ClinicalServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6818105504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and Other Agreements, Zai Lab (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,794<span></span>
</td>
<td class="nump">$ 20,798<span></span>
</td>
<td class="nump">$ 18,834<span></span>
</td>
<td class="nump">$ 4,695<span></span>
</td>
<td class="nump">$ 152,359<span></span>
</td>
<td class="nump">$ 1,663<span></span>
</td>
<td class="nump">$ 1,666<span></span>
</td>
<td class="nump">$ 2,055<span></span>
</td>
<td class="nump">$ 60,121<span></span>
</td>
<td class="nump">$ 157,742<span></span>
</td>
<td class="nump">$ 91,880<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,318<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,722<span></span>
</td>
<td class="nump">$ 27,318<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ZaiLabsCollaborationAndLicenseAgreementMember', window );">Zai Lab Agreement | Zai Lab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NonRefundableUpfrontFees', window );">Non-refundable upfront payment</a></td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NonrefundablePaymentTaxWithholding', window );">Tax withholding</a></td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement', window );">Potential development and regulatory milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">140,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">140,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NonRefundableUpfrontFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Initial fee received from collaboration or license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NonRefundableUpfrontFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NonrefundablePaymentTaxWithholding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-refundable Payment, Tax Withholding</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NonrefundablePaymentTaxWithholding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential Development and Regulatory Milestone Payments Under Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130531-203044<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130532-203044<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130532-203044<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130531-203044<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ZaiLabsCollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ZaiLabsCollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mgnx_ZaiLabsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mgnx_ZaiLabsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6817599440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and Other Agreements, Servier (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2012</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Jan. 01, 2018</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,794,000<span></span>
</td>
<td class="nump">$ 20,798,000<span></span>
</td>
<td class="nump">$ 18,834,000<span></span>
</td>
<td class="nump">$ 4,695,000<span></span>
</td>
<td class="nump">$ 152,359,000<span></span>
</td>
<td class="nump">$ 1,663,000<span></span>
</td>
<td class="nump">$ 1,666,000<span></span>
</td>
<td class="nump">$ 2,055,000<span></span>
</td>
<td class="nump">$ 60,121,000<span></span>
</td>
<td class="nump">$ 157,742,000<span></span>
</td>
<td class="nump">$ 91,880,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue included in current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,721,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,202,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,721,000<span></span>
</td>
<td class="nump">7,202,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,742,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,722,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,318,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,722,000<span></span>
</td>
<td class="nump">27,318,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Increase in revenue recognized from ASC 606 adoption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,588,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgnx_ServierMember', window );">Servier | Servier DART</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NonRefundableUpfrontFees', window );">Non-refundable upfront payment</a></td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_MilestonePayment', window );">Milestone payment removed</a></td>
<td class="nump">5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_OptionExerciseFee', window );">Option exercise fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts', window );">Offset to research and development costs under collaboration arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000,000.0<span></span>
</td>
<td class="nump">3,200,000<span></span>
</td>
<td class="nump">2,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress', window );">Increase in balance related to adoption of ASC 606</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Increase in revenue recognized from ASC 606 adoption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgnx_ServierMember', window );">Servier | Maximum | Servier DART</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PotentialClinicalMilestonePaymentsUnderAgreement', window );">Potential clinical milestone payments under agreement</a></td>
<td class="nump">22,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PotentialRegulatoryMilestonePaymentsUnderAgreement', window );">Potential regulatory milestone payments under agreement</a></td>
<td class="nump">76,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PotentialSalesMilestonePaymentsUnderAgreement', window );">Potential sales milestone payments under agreement</a></td>
<td class="nump">$ 210,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember', window );">Revenues From License Agreements | Servier | Servier DART</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="nump">1,400,000<span></span>
</td>
<td class="nump">2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember', window );">Revenues From License Agreements | Servier | Servier Agreement - MGD007 Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,900,000<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue included in current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Refers to collaboration arrangement offset to research and development costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_MilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_MilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NonRefundableUpfrontFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Initial fee received from collaboration or license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NonRefundableUpfrontFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_OptionExerciseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment from collaborator upon exercise of option to develop and commercialize product.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_OptionExerciseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PotentialClinicalMilestonePaymentsUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total potential clinical milestone payments company could earn under agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PotentialClinicalMilestonePaymentsUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PotentialRegulatoryMilestonePaymentsUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total potential regulatory milestones company could earn under agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PotentialRegulatoryMilestonePaymentsUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PotentialSalesMilestonePaymentsUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total potential sales milestones company could earn under agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PotentialSalesMilestonePaymentsUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130531-203044<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130532-203044<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in measure of progress which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130532-203044<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130531-203044<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130549-203045<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130532-203044<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130531-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mgnx_ServierMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mgnx_ServierMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=mgnx_ServierDARTMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=mgnx_ServierDARTMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=mgnx_ServierAgreementMGD007OptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=mgnx_ServierAgreementMGD007OptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6810342096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and Other Agreements, Roche (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Jan. 01, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,794<span></span>
</td>
<td class="nump">$ 20,798<span></span>
</td>
<td class="nump">$ 18,834<span></span>
</td>
<td class="nump">$ 4,695<span></span>
</td>
<td class="nump">$ 152,359<span></span>
</td>
<td class="nump">$ 1,663<span></span>
</td>
<td class="nump">$ 1,666<span></span>
</td>
<td class="nump">$ 2,055<span></span>
</td>
<td class="nump">$ 60,121<span></span>
</td>
<td class="nump">$ 157,742<span></span>
</td>
<td class="nump">$ 91,880<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,318<span></span>
</td>
<td class="nump">40,722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,318<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,722<span></span>
</td>
<td class="nump">27,318<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue included in current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,202<span></span>
</td>
<td class="nump">21,721<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,202<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,721<span></span>
</td>
<td class="nump">7,202<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,742<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenue included in long-term liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,637<span></span>
</td>
<td class="nump">19,001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,637<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,001<span></span>
</td>
<td class="nump">13,637<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,576<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgnx_F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member', window );">Roche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NonRefundableUpfrontFees', window );">Non-refundable upfront payment</a></td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PotentialMilestonePaymentsandRoyaltiesonFutureSalesunderAgreement', window );">Potential milestone payments and royalties on future sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">370,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">370,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_UpfrontPaymentRecognitionPeriod', window );">Expected period of development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue included in current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenue included in long-term liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NonRefundableUpfrontFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Initial fee received from collaboration or license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NonRefundableUpfrontFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PotentialMilestonePaymentsandRoyaltiesonFutureSalesunderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential Milestone Payments and Royalties on Future Sales under Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PotentialMilestonePaymentsandRoyaltiesonFutureSalesunderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_UpfrontPaymentRecognitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Refers to upfront payment recognition period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_UpfrontPaymentRecognitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130531-203044<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130532-203044<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130532-203044<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130531-203044<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130549-203045<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130532-203044<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130531-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mgnx_F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mgnx_F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6810049136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and Other Agreements, Provention (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,794<span></span>
</td>
<td class="nump">$ 20,798<span></span>
</td>
<td class="nump">$ 18,834<span></span>
</td>
<td class="nump">$ 4,695<span></span>
</td>
<td class="nump">$ 152,359<span></span>
</td>
<td class="nump">$ 1,663<span></span>
</td>
<td class="nump">$ 1,666<span></span>
</td>
<td class="nump">$ 2,055<span></span>
</td>
<td class="nump">$ 60,121<span></span>
</td>
<td class="nump">$ 157,742<span></span>
</td>
<td class="nump">$ 91,880<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgnx_ProventionBioMember', window );">Provention Bio, Inc. (Provention)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_CollaborativeAgreementTransactionPrice', window );">Transaction price</a></td>
<td class="nump">$ 6,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares', window );">Stock warrants (in shares)</a></td>
<td class="nump">2,432,688<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair Value Adjustment of Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=mgnx_ProventionLicenseAgreementMember', window );">Provention License Agreement | Provention PRV3279 | Provention Bio, Inc. (Provention)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare', window );">Consideration received common stock warrant exercise price (in usd per share)</a></td>
<td class="nump">$ 2.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement', window );">Potential development and regulatory milestone payments</a></td>
<td class="nump">$ 65,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement', window );">Potential commercial milestone payments</a></td>
<td class="nump">$ 225,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=mgnx_AssetPurchaseAgreementMember', window );">Asset Purchase Agreement | Provention PRV031 | Provention Bio, Inc. (Provention)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare', window );">Consideration received common stock warrant exercise price (in usd per share)</a></td>
<td class="nump">$ 2.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement', window );">Potential development and regulatory milestone payments</a></td>
<td class="nump">$ 170,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement', window );">Potential commercial milestone payments</a></td>
<td class="nump">225,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement', window );">Potential milestone payment to third parties for intellectual property under agreement</a></td>
<td class="nump">1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember', window );">Revenues From License Agreements | Provention Bio, Inc. (Provention)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 6,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement Consideration Received Common Stock Warrant Exercise Price Per Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement Consideration Received Common Stock Warrants Number Of Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CollaborativeAgreementTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement Transaction Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CollaborativeAgreementTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential Commercial Milestone Payments Under Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PotentialCommercialMilestonePaymentsUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential Development and Regulatory Milestone Payments Under Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential Milestone Payment To Third Parties For Intellectual Property Under Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mgnx_ProventionBioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mgnx_ProventionBioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=mgnx_ProventionLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=mgnx_ProventionLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ProventionPRV3279Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ProventionPRV3279Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=mgnx_AssetPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=mgnx_AssetPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ProventionPRV031Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ProventionPRV031Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6810005424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and Other Agreements, Janssen Biotech, Inc. (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2016</div></th>
<th class="th"><div>Jan. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,794<span></span>
</td>
<td class="nump">$ 20,798<span></span>
</td>
<td class="nump">$ 18,834<span></span>
</td>
<td class="nump">$ 4,695<span></span>
</td>
<td class="nump">$ 152,359<span></span>
</td>
<td class="nump">$ 1,663<span></span>
</td>
<td class="nump">$ 1,666<span></span>
</td>
<td class="nump">$ 2,055<span></span>
</td>
<td class="nump">$ 60,121<span></span>
</td>
<td class="nump">$ 157,742<span></span>
</td>
<td class="nump">$ 91,880<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_JanssenMGD011AgreementMember', window );">Janssen MGD011 Agreement | Janssen Biotech Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,923,077<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Proceeds of stock sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NonRefundableUpfrontFees', window );">Non-refundable upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_JanssenMGD015AgreementMember', window );">Janssen MGD015 Agreement | Janssen Biotech Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NonRefundableUpfrontFees', window );">Non-refundable upfront payment</a></td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember', window );">Revenues From License Agreements | Janssen MGD011 Agreement | Janssen Biotech Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember', window );">Revenues From License Agreements | Janssen MGD015 Agreement | Janssen Biotech Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="nump">$ 75,800<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NonRefundableUpfrontFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Initial fee received from collaboration or license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NonRefundableUpfrontFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_JanssenMGD011AgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_JanssenMGD011AgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mgnx_JanssenBiotechIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mgnx_JanssenBiotechIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_JanssenMGD015AgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_JanssenMGD015AgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6809986144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and Other Agreements, NIAID Contract (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 15, 2015 </div>
<div>USD ($) </div>
<div>Molecule</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,794,000<span></span>
</td>
<td class="nump">$ 20,798,000<span></span>
</td>
<td class="nump">$ 18,834,000<span></span>
</td>
<td class="nump">$ 4,695,000<span></span>
</td>
<td class="nump">$ 152,359,000<span></span>
</td>
<td class="nump">$ 1,663,000<span></span>
</td>
<td class="nump">$ 1,666,000<span></span>
</td>
<td class="nump">$ 2,055,000<span></span>
</td>
<td class="nump">$ 60,121,000<span></span>
</td>
<td class="nump">$ 157,742,000<span></span>
</td>
<td class="nump">$ 91,880,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember', window );">NIAID</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement', window );">Commercialization of molecules | Molecule</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_FundedValueOfBasePeriod', window );">Base period value</a></td>
<td class="nump">$ 7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement', window );">Proceeds from additional development funding options under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember', window );">NIAID | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement', window );">Additional development funding options</a></td>
<td class="nump">17,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_TotalPotentialValueUnderAgreement', window );">Total potential value</a></td>
<td class="nump">$ 24,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember', window );">Revenues From License Agreements | NIAID</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="nump">$ 1,700,000<span></span>
</td>
<td class="nump">$ 5,100,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional funding available under agreement at counterparty's option</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercised Additional Development Funding Options Under Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_FundedValueOfBasePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Funded value of base period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_FundedValueOfBasePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of molecules to be developed and commercialized as per collaboration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_TotalPotentialValueUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Refers to total potential value under agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_TotalPotentialValueUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6809245440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jul. 21, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($) </div>
<div>Lease</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NumberOfLease', window );">Number of leases | Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals', window );">Future sublease payments to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromTenantAllowance', window );">Lease incentives</a></td>
<td class="num">$ (7,500)<span></span>
</td>
<td class="num">$ (5,100)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCredit', window );">Deferred rent liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,300<span></span>
</td>
<td class="nump">$ 12,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseNet', window );">Rent expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,400<span></span>
</td>
<td class="nump">$ 3,100<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract', window );"><strong>Future minimum rental payments required under all non-cancelable operating leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,323<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,757<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,724<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears', window );">2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,865<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears', window );">2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,680<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter', window );">Thereafter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,786<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39,135<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NumberOfLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of lease during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NumberOfLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative difference between the rental payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense over the term of the leased property by the lessor or lessee, respectively.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=77902458&amp;loc=d3e39896-112707<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractually required future rental payments receivable on noncancelable subleasing arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesRentExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41499-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesRentExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromTenantAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net cash outflow or inflow from monetary allowance granted by the landlord to a tenant to entice tenant to move into landlords building which will enable the tenant to prepare the leased premises for tenants occupancy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3213-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromTenantAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6666310112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plan (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2012</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan', window );">Eligible age to participate in plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">21 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent', window );">Percentage of employee contribution to salary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage', window );">Percentage of employee vested contribution</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Defined contribution plan, employer discretionary contribution amount</a></td>
<td class="nump">$ 1.3<span></span>
</td>
<td class="nump">$ 1.1<span></span>
</td>
<td class="nump">$ 1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage vested of employee's contributions to defined contribution plan</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Refers to minimum eligible age of employee to participate in benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6808826624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Quarterly Financial Information (Unaudited) (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 15,794<span></span>
</td>
<td class="nump">$ 20,798<span></span>
</td>
<td class="nump">$ 18,834<span></span>
</td>
<td class="nump">$ 4,695<span></span>
</td>
<td class="nump">$ 152,359<span></span>
</td>
<td class="nump">$ 1,663<span></span>
</td>
<td class="nump">$ 1,666<span></span>
</td>
<td class="nump">$ 2,055<span></span>
</td>
<td class="nump">$ 60,121<span></span>
</td>
<td class="nump">$ 157,742<span></span>
</td>
<td class="nump">$ 91,880<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (44,644)<span></span>
</td>
<td class="num">$ (34,029)<span></span>
</td>
<td class="num">$ (43,244)<span></span>
</td>
<td class="num">$ (49,536)<span></span>
</td>
<td class="nump">$ 105,727<span></span>
</td>
<td class="num">$ (47,043)<span></span>
</td>
<td class="num">$ (40,654)<span></span>
</td>
<td class="num">$ (37,655)<span></span>
</td>
<td class="num">$ (171,453)<span></span>
</td>
<td class="num">$ (19,626)<span></span>
</td>
<td class="num">$ (58,528)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share, basic and diluted (in usd per share)</a></td>
<td class="num">$ (1.06)<span></span>
</td>
<td class="num">$ (0.81)<span></span>
</td>
<td class="num">$ (1.03)<span></span>
</td>
<td class="num">$ (1.34)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income (loss) per share, basic (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.87<span></span>
</td>
<td class="num">$ (1.28)<span></span>
</td>
<td class="num">$ (1.14)<span></span>
</td>
<td class="num">$ (1.08)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income (loss) per share, diluted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.80<span></span>
</td>
<td class="num">$ (1.28)<span></span>
</td>
<td class="num">$ (1.14)<span></span>
</td>
<td class="num">$ (1.08)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1337-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=109256448&amp;loc=d3e4984-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=SL5780133-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=109256448&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1252-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6809532592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 02, 2018</div></th>
<th class="th"><div>Feb. 28, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 103,259<span></span>
</td>
<td class="nump">$ 34,244<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=mgnx_FollowUpOfferingMember', window );">Follow Up Offering | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 118,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of common stock (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of common stock (in shares)</a></td>
<td class="nump">675,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of common stock (in dollars per share)</a></td>
<td class="nump">$ 21.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">825,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of common stock (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=mgnx_FollowUpOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=mgnx_FollowUpOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>78
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M?_C=A-U@[-[^8^.KH&SAUUW(+U!+ P04    " "&@5I.F5R<(Q &  "<)P
M$P   'AL+W1H96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03
M<VEVV[29A.U.'X416(UL>621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS
M[BYBZ(:(E/)X8-DOV]:[MR_>X%<R)!%!,!FGK_# "J5,7K5::0##.'W)$Q+#
MW(*+"$MX%,O67.!;&B\CUNJTV]U6A&ELH1A'9&!]7BQH0-!445IO7R"TY1\S
M^!7+5(UEHP$35T$FN8BT\OELQ?S:WCYES^DZ'3*!;C ;6"!_SF^GY$Y:B.%4
MPL3 :F<_5FO'T=)(@(+)?90%NDGVH],5"#(-.SJ=6,YV?/;$[9^,RMIT-&T:
MX./Q>#BVR]*+<!P$X%&[GL*=]&R_I$$)M*-IT&38]MJND::JC5-/T_=]W^N;
M:)P*C5M/TVMWW=..B<:MT'@-OO%/A\.NB<:KT'3K:28G_:YKI.D6:$)&X^MZ
M$A6UY4#3( !8<';6S-(#EEXI^G64&MD=N]U!7/!8[CF)$?[&Q036:=(9EC1&
M<IV0!0X -\313%!\KT&VBN#"DM)<D-;/*;50&@B:R('U1X(AQ=RO_?67N\FD
M,WJ=?3K.:Y1_::L!I^V[F\^3_'/HY)^GD]=-0LYPO"P)\?LC6V&')VX[$W(Z
M'&="?,_V]I&E)3+/[_D*ZTX\9Q]6EK!=S\_DGHQR([O=]EA]]D]';B/7J<"S
M(M>41B1%G\@MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(
MWXV(]ZMOFCU7H5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU
M+,76>)7 \:V</!T3$LV4"P9!AI<D)A*I.7Y-2!/^*Z7:_IS30/"4+R3Z2I&/
M:;,CIW0FS>@S&L%&KQMUAVC2/'K^!?F<-0H<D1L= F<;LT8AA&F[\!ZO)(Z:
MK<(1*T(^8ADV&G*U%H&V<:F$8%H2QM%X3M*T$?Q9K#63/F#([,V1=<[6D0X1
MDEXW0CYBSHN0$;\>ACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*
MY \FIS_I,C0'HYI9";V$5FJ?JH<T/J@>,@H%\;D>/N5Z> HWEL:\4*Z">P'_
MT=HWPJOX@L Y?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=R
MS<C'5*^3*=@YG\#L_6@^GO'M^MDDA*^:62TC%I!+@;-!)+C\B\KP*L0)Z&1;
M)0G+5--E-XH2GD(;;NE3]4J5U^6ON2BX/%ODZ:^A=#XLS_D\7^>TS0LS0[=R
M2^JVE+ZU)CA*]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZ
MG=PZ.)Z8D;D*TU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCR
MHB'NH8:8S\-#AWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)2
M56 Q6\8#*Y"B?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYE
ML<%5'<]56_*POFH]M!5.S_Y9K<B?#!%.%@L22&.4%Z9*HO,94[[G*TG$53B_
M13.V$I<8O./FQW%.4[@2=K8/ C*YNSFI>F4Q9Z;RWRT,"2Q;B%D2XDU=[=7G
MFYRN>B)V^I=WP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5
M' 86%S+D4.Z2D 83 <V4R43P H)DIAR F/H+O?(,N2D5SJT^.7]%+(.&3E[2
M)1(4BK ,!2$7<N/O[Y-J=XS7^BR!;814,F35%\I#B<$],W)#V%0E\Z[:)@N%
MV^)4S;L:OB9@2\-Z;ITM)__;7M0]M!<]1O.CF> >LX=SFWJXPD6L_UC6'ODR
MWSEPVSK> U[F$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\
MU*M:I60K$3]+!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHS
MU8NL.8T*;T'50.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!
M4$L#!!0    ( (:!6DYL35KIP (  ,T*   8    >&PO=V]R:W-H965T<R]S
M:&5E=#$N>&UL?5;;CILP$/T5Q <LV%Q"5DFD7%2U4BM%6W7[[$V<!"U@:CO)
M]N]K#$M9SWA? C;GS/'8<YQ9W(5\51?.=?!65XU:AA>MV\<H4H<+KYEZ$"UO
MS)>3D#739BC/D6HE9T=+JJN(QG$>U:QLPM7"SNWE:B&NNBH;OI>!NM8UDW\W
MO!+W94C"]XFG\GS1W42T6K3LS']R_:O=2S.*QBC'LN:-*D432'Y:AFORN*-Q
M1["(YY+?U>0]Z%)Y$>*U&WP[+L.X6Q&O^$%W(9AYW/B65U47R:SCSQ T'#4[
MXO3]/?H7F[Q)YH4IOA75[_*H+\NP"(,C/[%KI9_$_2L?$LK"8,C^.[_QRL"[
ME1B-@ZB4_0T.5Z5%/40Q2ZG96_\L&_N\]U^R?*#A!#H0Z$B@Z:>$9" D(X%\
M3D@'0NH0HCX5NS<[IMEJ(<4]D/WQMJRK(O*8FMT_=)-VL^TWLSW*S-Y6\2*Z
M=6$&Q*9'T F"C(C(Q!X%*":PH8!./PIL(2+YB-A!1(HO(4%S3"P]F= SG)ZB
M]-32TPD]=[8((F:X0(8*9(!>. (0,<<%<E0@!W3BGC("\1SS#)680;YSSIL>
MDEE(TU="3 I<I$!%"BCBE,H&@7AJ98Y*S"$_<R002(Y+D!CW7 PCS%S7Q6"W
M"*%9DGI*EWCL3:"46UP8QE->!/7XFE 0@8)K!,%X*HS@-B8)C.#6&(;QJ>!N
M)]#,U"TR#..I,H);GD!'4[?.,(ROT'#?$^AJ"@H-8GR'CSN?0.M34&(0XQ/!
MG4^@K^G<%8$8GPCN?0*=G3AEO!TP4U^FQ:R($U^94?P.H/ .2,A'K=V R2=:
M14H?W!L@FOS7UUR>;1^E@H.X-K:)F\R.O=J:VE[A/[QO]'XP>2X;%;P(;3H.
MVQ><A-#<K"9^,#E?3&\Y#BI^TMWKS+S+OL'J!UJT0_,8C1WLZA]02P,$%
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MV6PQ9_\EO(4ZRD<GL8]M6_?3[V+[V@]M,[<2K335C^OQ>)J.E[G]]S Y .<
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M.NR'\=3%\^ZZ;[]>#.UY_B:1WSZ,K/\#4$L#!!0    ( (:!6DYRQ_DSY@$
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M@Z: 0:7M]&#F<O@3AT"+;KQDT'3397\ 4$L#!!0    ( (:!6D[QMFE G0,
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M)HP;,V%EWA+,IUFY=)< W"9TV"8 E_;NOQ*9"C538):R\'VF.&6FW*-TNEN
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M\S'I^::KC^,1<'0YAU[^#U!+ P04    " "&@5I.9DL\SJ\!  #2 P  &
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MO5;IX4/!KD%HP9QF3+;%K B&ZFN(;"_$*?N/GNW3#[L9'B+]L(V>)_L"^:Y
M'@7R-TO<P>3_%LDV/55@NSA-CM1FU'&2-]YU8.^S^"9_X?.T?^.V$]J1B_'X
MLK'_K3$>,)7D!D>HQP^V&A):'X[O\6SG,9L-;X;E!['U&U=_ %!+ P04
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MKN<:H[GX'W !X<.#$I^CTL+&%56#=5K.+%Z*9"_3SE7<Q^DF36?8-H#. +H
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MGNTX9J/A33?](#9_X^(/4$L#!!0    ( (:!6DY@OYJ&LP$  -(#   9
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M?C,$YS4*5Q3):MO6&(0WDA_!V8^ U,:QK0.!D@T=N  @(+OQJI)"(+RA ]<
M!"1XM(H' .&MWQHN PC(\<RN:"!HHZ0AN!(@(,TSNZB!(/MW\Q9W7DOYS=SV
MPBG9O3.MQF)U[B@.@;DS_\''=N0[X;>Z$\Z9277SFOOQRIBDRA?_29UAI3J@
M>=+0J]3#5(WYV :,$\GZJ<7QYCZK^ M02P,$%     @ AH%:3MN]X>/N 0
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MDXF.47 J[=<K.JDX<RHZ%4;>A[5N[-H[_1MMF1 Y0C02PO130NP(\0<!?TK
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MIE_J]E(UUV7_%:2_J8N=^<+C'3XS3?\'4$L#!!0    ( (:!6D[NRW\A]@$
M  L%   9    >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;'5478_;(!#\*\CO
M/6S\E42VI<N=JE9JI>BJ:Y^)LXFM ^,"B:__OH =UTVXE\"N9V=V"&PQ"/FF
M&@"-WCGK5!DT6O<;C%7= *?J0?30F2]'(3G5)I0GK'H)]."*.,,D##/,:=L%
M5>%R.UD5XJQ9V\%.(G7FG,H_6V!B*(,HN"9>VE.C;0)714]/\ /T:[^3)L(S
MRZ'ET*E6=$C"L0P>H\TVMW@'^-G"H!9[9)WLA7BSP==#&82V(6!0:\M S7*!
M)V#,$IDV?D^<P2QI"Y?[*_MGY]UXV5,%3X+]:@^Z*8-5@ YPI&>F7\3P!28_
M:8 F\]_@ LS ;2=&HQ9,N5]4GY46?&(QK7#Z/JYMY]9AXK^6^0O(5$#F C)Z
M&85<Y\]4TZJ08D!R//N>VK\XVA!S-K5-NJ-PWTSSRF0O51PE!;Y8H@FS'3%D
M@8EF!#;LLP3Q26S)77D<I7Z"V-MC[ CBI7Z<^ D2+T'B")+_.LAN3(Z8W&$Z
MAR%Y'*W\,JE7)O7(Y#<R(R9=RI#UFOAE,J],YI%9W<AD=S*?UNGJ S>Y5R;W
MR*QO9/*[0TO"G-RZP8O+R$&>W#-4J!;GSHV 179^Z8_$7>9_\'%,?*?RU'8*
M[84V3\)=W*,0&DPSX8.QVYC)- <,CMIN<[.7X_L< RWZ:?3@>?Y5?P%02P,$
M%     @ AH%:3ADRAS34 @  X L  !D   !X;"]W;W)K<VAE971S+W-H965T
M,S4N>&ULC5;;CILP$/T5Q'L7?.$6)9&ZJ:I6:J755FV?O8F3H 5,P4FV?U_;
ML(C8XXJ78)LS<V;,.;'7-]&]]F?.9?!65TV_"<]2MJLHZO=G7K/^0;2\46^.
MHJN95-/N%/5MQ]G!!-55A.,XC6I6-N%V;=:>NNU:7&15-ORI"_I+7;/N[R.O
MQ&T3HO!]X;D\G:5>B+;KEIWX#RY_MD^=FD53ED-9\Z8O11-T_+@)/Z+5#E,=
M8!"_2G[K9^- M_(BQ*N>?#ULPEA7Q"N^ESH%4X\KW_&JTIE4'7_&I.'$J0/G
MX_?LGTWSJID7UO.=J'Z7!WG>A'D8'/B172KY+&Y?^-A0$@9C]]_XE5<*KBM1
M''M1]>8WV%]Z*>HQBRJE9F_#LVS,\S:\2;(Q# [ 8P"> A#];P 9 X@5$ V5
MF58_,<FVZT[<@F[X6BW3HD KHC9SKQ?-WIEWJMM>K5ZW!,?KZ*H3C9C' 8-G
M&'R/V+D(0B9(I J8JL!@%=C$D[LJ$)R @ F(24#O$MA%#IC,8!J#*0A-$IB&
M@C04H"$6S8!)9C08IDA B@2@H!9%XE!\2#W[G8(D*4"26"2I0U(04E"8)@-I
M,H FA1/D8()\N2X*,$&Q0!>%TR@I"H\L4 R[*%X@C!$T)XH]+!ZOH@7:&$'W
MXO#0P&9$>($Z1M#]KN6%AP@V+7)=BVGF20$;$M'E"D&PX1#D..</SK4<0D61
M>YA@UR'(=HY*7-_Y5 *;#D&N<U22N2KQ[3QL390O44D.;IOO \$>1JZ),?7L
M/(;]B>/E,L&P^3!D/DLFCR-H?L8@G)'<VA;L>C3+:.HY)[#GS(1L2NR"7)O&
M=C$NQ%<(;&,,';[4+H2X@K.E#V$2C_@Q_'^ H1,ZL6NAX%>RQ0O U%="]@D8
MS:Y:^N[[G76GLNF#%R'5K<W<K8Y"2*Y2Q@^JM[.Z;D^3BA^E'F9JW UWSF$B
M13O>IZ/I4K_]!U!+ P04    " "&@5I.WN!VF@4"  !K!0  &0   'AL+W=O
M<FMS:&5E=',O<VAE970S-BYX;6R%5.UNFS 4?17$ ]3$AE!%!*E)-'72)D6=
MMOUVR V@VIC:3NC>?OZ@E!"6Y4=L7Y]S[KG&OEDGY*NJ '3PSEFCUF&E=;M"
M2!45<*H>1 N-V3D)R:DV2UDBU4J@1T?B#.$H6B).ZR;,,Q?;RSP39\WJ!O8R
M4&?.J?RS 2:Z=;@(/P(O=5EI&T!YUM(2?H#^V>ZE6:%!Y5AS:%0MFD#":1T^
M+5:[Q.(=X%<-G1K- UO)08A7N_AZ7(>1-00,"FT5J!DNL 7&K)"Q\=9KAD-*
M2QS//]2_N-I-+0>J8"O8[_JHJW7X& 9'.-$STR^B>X:^GB0,^N*_P068@5LG
M)D<AF'+_07%66O!>Q5CA]-V/=>/&SN^D<4^;)^">@ ?"8GF70'H"^23<SQ#W
MA'A"0+X4=S8[JFF>2=$%TG_=EMI+M%C%YO0+&W2'[?;,\2@3O>0$IQFZ6*$>
ML_$8/,(L!@0RZD,*/)=B@V_H^#K!]A9!R#5D=PM9IO,FR&R=Q/')N ;R#X%X
M5B!V O&X"I),#LIC4H=I'"::5'H/<64BF361W)@@^'%B(KE)@4ED?Q,K,[AX
M!K?[OYXWCD97CH,LW7-602'.C;9?;A0=.L83ME=V$M^83N(?_J>,;T/?J2SK
M1@4'H<V#<-?V)(0&8S-Z,#XKT_F&!8.3MM/4S*5__WZA1=NW-C3TU_PO4$L#
M!!0    ( (:!6DYM^,3 ,@,  $L-   9    >&PO=V]R:W-H965T<R]S:&5E
M=#,W+GAM;)5786^;,!#]*XCO*_9A#%1)I";1M$F;5&W:]IDF3H(*. .GZ?[]
M;$,IP4>4?@G8>7?W_,"/\^PLZ^?F((3R7LNB:N;^0:GC?1 TFX,HL^9.'D6E
M_]G)NLR4'M;[H#G6(MO:H+((@! >E%E>^8N9G7NL%S-Y4D5>B<?::TYEF=7_
MEJ*0Y[E/_;>)'_G^H,Q$L)@=L[WX*=2OXV.M1T&?99N7HFIR67FUV,W]!WJ_
M!F8"+.)W+L[-X-XS2WF2\MD,OF[G/C&,1"$VRJ3(].5%K$11F$R:Q]\NJ=_7
M-('#^[?LG^WB]6*>LD:L9/$GWZK#W$]\;RMVV:E0/^3YB^@6%/E>M_IOXD44
M&FZ8Z!H;633VU]N<&B7++HNF4F:O[36O[/7<_A.%71@> %T ] &47PT(NX#P
M/8!=#6!= !L%!.U2K#;K3&6+62W/7MT^WF-FWB)ZS[3Z&S-IQ;;_:7D:/?NR
M""&=!2\F48=9MA@88&B/"'3VO@1@)9;@A,-E@96+",-+R-J%\!@G$:+K#&U\
M."21<#P!0Q,PFX!=<"0CH5I,;#&5Q:2,LYB0$7#E N,D)3 $7E"*4$H10HF.
M*+68:% ):.(2<F$A&-@4(8X2X@BAT;-><J?2IS!.P\CEA" A26DZ22I&2<4.
M*386*78J13RFX%)R@2Q-DW"248(R2A"91N_[,G$J\<O'T1)R82F_\MA2E$^*
M\&$C/JE;"#!"+BXF"&Z=.CN 7WO?*,'=BSC4(8DF4DP8(+W=&2AJ< \4;O"&
M#G2Q$T..*(@!@=-I:7##HR$B33J1 K<\RCX@#6Y1%/,H1QK7?6)"*2*-"XPH
MO2(-;E,4\ZFIMP8W%1I_0!K<!2AF XXTB ]PQ+\Q7,2GA<&-@&).,+$JP'<D
MD-N% 7Q' KU!F YT\<7BA".>C2"!1&SZ,P+X+@=LET_T((#O2?A %P+XGH1;
M^A!P^PN6M!_TL3@NDL811*XXP:"C+$6]M]UZXVWDJ5*F,1O,]B>"!S =Z6A^
MJ4\*;5__GJ8]9GS/ZGU>-=Z35+K?M5WI3DHE-%%RIY_?09]L^D$A=LK<QOJ^
M;MO[=J#DL3NZ!/WY:?$?4$L#!!0    ( (:!6D[QFMB+> ,  $\0   9
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M]=0^B2)MAAN -H"S 0E&#:@VH/\-Z*A!H V":R,P;<"N-0BU07BM0:0-(L/
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M>]9N\+T">2V.["MO_M:.KYM,.TU_(GK**V;M"!>7KKH:CX1P+&)T7T0=,C'
MNTV!CUPN([&F[11K-YS4>D([W=^$]#]02P,$%     @ AH%:3F#%#NQ! P
M9PT  !D   !X;"]W;W)K<VAE971S+W-H965T-# N>&ULE5?;CMHP$/V5*!]
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MCD$=PA%N=KYBT-<IUO@D#!0_= SN(VYUA.>Z?<P/"(/ZF#L(H]BZ!S!>'_(
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MU]!6^PPNO@'1OH"+57?+_.&^N_1>)<7K=E>.GO*JRK/V[NLESRM59^Y_J5?
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MSWPA<\#T'?118;I%UMIM 4!P?TYZ)A4%0$Z"'HV>647A%W+2,X7('$,S)^:
M:3EY B"!/J<+ !22R,B<T_D<S&FYJ4]DE;5D^X)+3SNK[:GO$LO/26U]AD9S
M!*Q?H]$#M/XH3X_U9^F'V>;H^9B4F[2HK%?&Q>=M_06Z9HQ3$95[(1IA*TZ[
M[4-&UUS>AN*^;(Y\S0-G.W6<==HS]?0_4$L#!!0    ( (:!6DZ$P[5?% ,
M  X-   9    >&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;)67[7*B,!2&;X7A
M DH2"(&..K/:[]:93G=V]S?5J$R!N!"U>_>;0+1"#B[[1TA\WO?DY"0!1@=1
M?E0;SJ7SF6=%-78W4FZO/:]:;'B>5%=BRPOUSTJ4>2)5LUQ[U;;DR;(6Y9E'
M$ J]/$D+=S*J^U[+R4CL9)86_+5TJEV>)^6?*<_$8>QB]]CQEJXW4G=XD]$V
M6?/O7/[8OI:JY9U<EFG.BRH5A5/RU=C]AJ_GF&I!3?Q,^:$ZNW=T*N]"?.C&
MXW+L(CTBGO&%U!:)NNSYC&>9=E+C^&U,W5-,+3R_/[K?U<FK9-Z3BL]$]BM=
MRLW8C5QGR5?)+I-OXO# 34+4=4SV+WS/,X7KD:@8"Y%5]:^SV%52Y,9%#25/
M/IMK6M370_-/&!L9+"!&0$X"<EG@&X'_)< 7!8$1!$,%U CH4$%H!.%0 3,"
M-E00&4$T5! ;03Q4@-&Q<FBPY%1L/%AR+#<F@R7'@N-NQ;UF+=:+^R:1R614
MBH-3-OMSF^AC %\KE3+7O?5VJ?]4"[Q2O?L)]=G(VVLGPTP;AK28J,W,;,;'
MM,W<0#YQF[D%F "UF3N(P6WFWF:([[>9!\B'M)E'B.GX/$%,T&:>!\S/RX Q
MSZ%87SZ>*O:IX@2N.*D=_#.'@#'8P8<=_-HA.',(.V6<-0BKD:)&,&5Q@%"G
MEC<V2!"+(PN\!1RCR+<=[VPP"&-J<??0$(E/8XM\ ,@P]"WN$>1"BWN"<J;V
M")]M+D288 M\ 6>;!<0BYS89JVE$YV!K!03P"@BL%4"#$':@L ,=O@I#V"$$
MQM ]N1J&GL\T'(/!,1@0HW/R39DUI4S7LF]&(SA2!$3J;*KGR,H&H^A"J!@.
M%=NA:(^#?NZ!3PTTO'RX[\F#@7%TCO&I@5HY,W0A9]QSZF$"1"/=:,3>F<&E
M8N*>$Q+;1R2E?H]'SQ[#P7_,<<\NP_2?1_6S85JGA]_.V3R> ) !X!P *89F
MT3M[3=%?"O.D7*=%Y;P+J=YYZM>2E1"2*U-TI4PWZN/DU,CX2NI;IN[+Y@V]
M:4BQ-5\?WND3:/(74$L#!!0    ( (:!6D[]AR/:K (    *   9    >&PO
M=V]R:W-H965T<R]S:&5E=#4S+GAM;(U66V^;,!3^*XCW%7R%5$FD-6VT29M4
M;=KV["9.@@J8&2?I_OULH&FP#U5? C;?[1CGX/E9Z>?V(*6)7JJR;A?QP9CF
M-DG:S4%6HKU1C:SMDYW2E3!VJ/=)VV@IMAVI*A.<ICRI1%''RWDW]ZB7<W4T
M95'+1QVUQZH2^M^=+-5Y$:/X=>)'L3\8-Y$LYXW8RY_2_&H>M1TE%Y5M4<FZ
M+50=:;E;Q)_1[1HQ1^@0OPMY;J_N(U?*DU+/;O!UNXA3ETB6<F.<A+"7DUS)
MLG1*-L??032^>#KB]?VK^KHKWA;S)%JY4N6?8FL.BSB/HZW<B6-I?JCS%SD4
MQ.)HJ/Z;/,G2PET2Z[%19=O]1IMC:U0UJ-@HE7CIKT7=7<^#_BL-)N"!@"\$
MC-XED(% /DJ@ X&^$?B[!#80V$<=^$#@'B'I%ZM;_7MAQ'*NU3G2_09JA-NG
MZ);;][MQD]WK[)[9%]#:V=.2,3I/3DYHP-SU&#S"L#%F!6'X&',/8;(QYB'$
M8$+&F#6@0]_R)+;>2]$8+!IW N1* +$) 0(*D$Z CBK)O6I[#.LP=8^!+2AH
M00&+F6?18[(K"X32%'9AH L+77CJO7X6N'S*6.JA5@"*38;A8!@.A$%>R3Q8
M582('^:!APN#R528# R3 6&P%R8+PE :9,F"+ 3YH#4 2J?RYF#>/-C3C!-8
M8 8*S()B<(K\'1>".,$3-BB%.TX*&.'4[Q4ABF97W6+L--';$.3D[R@ 13-,
M)YS@AH(PY.1O%P!%<S[1%1#<>5#85JP3\9U"%.7YQ'Y"< -"0 ?BU#>BX?^1
M9#F?<(*;$ J[4,Y\H["_D!DB_N(E5]\]=S;Z+O2^J-OH21G[">T^=#NEC+22
MZ8V5/-CCV&50RIUQMYF]U_V9I!\8U0SGK>1RZ%O^!U!+ P04    " "&@5I.
M=38D&24"  !<!@  &0   'AL+W=O<FMS:&5E=',O<VAE970U-"YX;6R-5>F.
MVC 0?I4H#X#)O44AT@);M5(KH:W:_C;)0**UX]0V9/OV]1&R(7A7_8/MR7?,
M^!CRGO$740-([Y625JS]6LINA9 H:Z!8+%@'K?IR9)QBJ9;\A$3' 5>&1 D*
ME\L44=RT?I&;V)X7.3M+TK2PYYXX4XKYWPT0UJ_]P+\&GIM3+74 %7F'3_ #
MY,]NS]4*C2I50Z$5#6L]#L>U_QBLGC*--X!?#?1B,O=T)0?&7O3B:[7VESHA
M(%!*K8#5<($M$**%5!I_!DU_M-3$Z?RJ_MG4KFHY8 %;1GXWE:S7_H/O57#$
M9R*?6?\%AGH2WQN*_P87( JN,U$>)2/"_'KE64A&!Q65"L6O=FQ:,_;V2W:E
MN0GA0 A'0I!^2(@&0O1&B#\DQ ,A_E]",A"2&0'9VLUF[K#$1<Y9[W%['3JL
M;UVP2M1QE3IH3L=\4_LI5/12)&F2HXL6&C ;BPDGF&!$(*4^6H0NBTUX1P]O
M#;;WB"BZA>SN(6EV"WFZAR1IZDXT<NY%9 2B:9W)@UL@=@K$1B"^R6">I0OS
MCDGB-$D< I]F)@Y,MG2;I$Z3U"$0S*Z%"_..2>8TR1P"LZNQL9C48%I[)HO9
MW=BZ,+-D=Q:333&S5-'DR5#@)]._A%>R<ROUM9I$QQ;Y&.HG-XMO5.NTG>Y-
MQO;=[YB?FE9X!R;5@S;/[LB8!)7@<J'.K%:M?EP0.$H]S=2<VX9G%Y)U0R]'
MXQ]*\0]02P,$%     @ AH%:3O@SO/5. P  @0T  !D   !X;"]W;W)K<VAE
M971S+W-H965T-34N>&ULC9=;<Z(P%,>_"L/[2@@D 4>=J;;VYLYTNK.[SU2C
M,@7B0JR[WW[#1:HGIZT^",3?_UQR3C 9'53Y6FVEU,[?/"NJL;O5>C?TO&JY
ME7E2#=1.%N:7M2KS1)O'<N-5NU(FJT:49QXEA'MYDA;N9-2,/963D=KK+"WD
M4^E4^SQ/RG]3F:G#V/7=X\!SNMGJ>L";C';)1OZ0^N?NJ31/7F]EE>:RJ%)5
M.*5<C]TK?[B(:KX!?J7R4)W<.W4F+TJ]U@_WJ[%+ZH!D)I>ZMI"8RYN<R2RK
M#9DP_G0VW=YE+3R]/UJ?-[F;7%Z22LY4]CM=Z>W8C5QG)=?)/M//ZG GNWR8
MZW3)+^2;S Q>1V)\+%56-=_.<E]IE7=63"AY\K>]ID5S/73VCS)<0#L![07&
M]V>"H!,$[X+P4T'8"<)+!:P3L$L%O!/P2P6B$XA+!5$GB"X5Q)T@OE3@DV/E
MR+N$?R[IB^U?[.58;I\"B=<V5M.IUXE.)J-2'9RR76N[I%[2_M"HC/%ZM.G]
MYD?3K949?9LP$8R\M]I2QTQ;AIXP-([/F0>;\7O",R'T<5 TCBFU?9Q[F-E$
M0,@Y<XTQ_CES@S' UQQAP*3<8F8 <X<QX3ESCS$,3.Z7D_/X=< +&^$"+U&
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MR?>DW*1%Y;PH;;9FS>YIK926)G@R,.MJ:\Y#_4,FU[J^%>:^;$\%[8-6N^[
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MQKU+U*3<'ESFL2_QJ@ZLAJ[D7;E> 47ZGDZ\>6CC.E_?FJ_OD^%@.(+#J!+
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MBUD]SX&L@'Q%H"8FO$'I_1_\A?#8%CSNLNTM2#AX-_PDI%31&(<T*"9G![2
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M N1UA&>.UWB0?&0QX@60KPV=*^YB5S'@A1<A7'OPFM"L6I%,1"3@EBU=:T+
M?,<*K[MM.W^53GZ^NGIW"I %)H]V1,.)B+K#<26Y6Q6N_V_[U:V;%S;8H-:Z
M+*KE?H/ZTI(& ?*;,;'# 2MR%.8D[^NE8PD^M<)YJIZ!T.:6TE^JMR,.@DXB
M7!4N"^[(.W5BE6  %UH R8P!J,KCI"(5!"%FA;QHDP'=(&0!8/0"!!<D -&=
M"LUQ7+Q[MEN0B?"6['EM("+*L=,1P*6$%XKF 2XUTD+ TML2GU\@L4R#,\M1
M@&+* +.[A::R$(9!6><.GJ3PL9D,%3^@SBP;W3AI+#@NDF\[C#.I&#B3)ON"
MTZ&BIURY;O:K!Y8G':/&'2%*5OMLS6!4!X0<Z)(.[[4_A@6I+,&ND)/>%;"D
MB@9%A %63HI!A;]]AD/'>U:JDVZ_V3$-( PM&L_/ 0P+A "ZQ(F2[;>K7&B9
MQ6T@\<L&UHRT:+]ND(CNUXB5J'&P0L$XYA8Y2%"<3NF_R0LK2\.FC8_TVBEL
M(<T7?*B1#%K3$(D_Q>T=W/%U <-:3"ZVP(GW_!C1@TP516+"E\-DE3W4"*4U
M$KZ,K^E*!$S5> 0HL1+ &^K6#P3=ZWBA0#;S!U%/DQN K:P+M3?4N&#-BVS[
MB8$2[J-H]G1FJ5%I20-D-0H7_G%P/0CLN\*^,\&C-/G9_WB-0FF)_L07AMWA
MDP] Z!<@GBW6Q:WA%4X4;_TLD @4I$HD]15"5>P;=%=JX"B[-6!C)FY;DA/R
MVC&:; <"Y1?!;'_](A$ U"($0*>F#_<+D!S$*^;OCBV? 3LZ0YL!KLF/C,^L
M@)U7&Y(( )@ #*3?R+T Y[:L0L ?-0@HZZRR4PG.+,3"12%3A$&#I-/QSXA<
MD^S_"_+39-R#L$HI89UGO$X0)BKT[SR$L$!Z50$F[4,3JO" LB8U'O4()^B0
M;:#'M4((:74M1],CV:'C519'8"8G*@53=CDT!\G[<-%X&7G-*/"VC\["GN0X
M=W"LS-"Z=R Z@70MIX=R-K$1T"SNRA7+H%9GU-N*9I-^&*)<9'Q8R8EPYE,@
MAL ,,\#=-AJ$;(EEM;P3)^VU)O:VCWQ:.W7& CURVX9+DZN>TWJC$)I_!G1^
M>P9'B1>XBM#'4]8;D,G+JO8\\D>&IM-5V-1$-)+8&IEC&#=)T*^8D1*W@(NN
MC)EXR/H!3T>G0/Y6%8L]JZD@V]H1287D*XA8$\(EP5/&*XR<F&\ZPQ@(SRUJ
M?;# 8L/:C1!:9TRAW?!PK%N3WD&T'R%$Q-(NW#[_?<VR B*[$;03(*CU7A3A
M'#X3?6Z0\5;A&A%;ED@0=54ECH;RC$-(^86D/H!0N4'<5"$V/#40%THCY2@6
M "\O4%F&F[$N/N7K!]X8Z,Z.U]\7P$")R9.L2R=68PA7YF$#T$<-AHW@L$-B
ME[A%2X^OT,2Q@R^(GRC"B?3T#Z;\9._0X]"U.^15$3D^?$.;03(![2<\F(-X
M#3N_Q_]LR_@Z,+5NQY; 3M%#PFOI7.=*1(#N25U\TGL7NY5TQ'/Q^)% C=,A
M Q1NS?(ZJ1SHW$7% 8F<4QP$/H'@'M <VF(03<,">"H2SI:TR'MZ =G;JMPO
M&K3)J((>8MD]8 /=PAL IJRHP+WX;1'N\;((XXJ[LERQ3L*/LVY<Y9NRB9BX
M1U_>%#VO(/ NJ "(R!3@[]L]\F'"!A[3;0LD<%3B'U*<E07T_<X(P2TB%^DC
M %MV*M.![+('/BL2KQ\XX@H^;NBFHP[RF11,5!Y R0[W70>BN'*/P!3"UQPX
ME2X+S@35D*;V] +)(RN1-WLRHW;/,$C>E.9T[[-:) .6@LABVH/Z:9*%*B_;
M'>VF94HTEQ,.A4CFD(>,UW]1>NO-QJ^,8&-0 (AJM_!CI*1><W_:+?VE77AC
MOI0H0KYO4>@@XQ(*EP_^\O2@XI%#T@7V=@CEMHZF5.@,%!/?9^52 $0?VA;H
MH(M\F>UK\UQ]!Z3A# E5LB4K>\0G=(UXVRL$DC-X;\OMF?_&T-P-.7'ZK2J(
M*?YHC?GR6AW%R=,2_DE.7EY=/SWM?N)9N?*"V<G5];/3Y&(\3"T&O;;KH A
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MPD@@?Y;JG7/1#!$,:4,,*OA+[(V/P9&F"O;G[W=[I>'R&/MX60%)M0$"@DH
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M(&N4D>I&B09'C_4=1&GAR?$V*(<A80.*TC3KG)-Q0HU.%.C"I5M7/AJ8M5?
ML36AL@G3WV^=;FUVW17BZD/Q57)#ABFI%4]]_N<6=: ]9F8YRF9)F8.3UT$Y
M*KXSKN'CCG20DZOKCZ?)FW*  YZ?#2_3)"C#\<PII"2W/).@HD2H#444B8BL
M-03KY$3#<+#>$0DLL^'LE.D(&6QT%+8"2IAEN9;$P4V!B'=;HE:) COJ$$O)
MGLNVP4E7^0U.I)%9-A?#LSKQ/?(5T$-$19IHW!>A/)P+A6I>:V9 ".O-ZTC
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M]_>N-+LVC<0%$V:?(*.K3Y,K)TO!985KA<DP'*<5"B;)6R]&I1W>>Y_Y"2+
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M8G:&IP>>8%RC.M+0#\.;:[<X$AHNPV"],;\[\Q+;_@WHU'(6WB#I:HBX\5.
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M6\JU=0I&"G; 8 *23YU(&M/9F52>;NY#E$3D *T^JP-Y)"]L-6(IE9JCT?K
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MOT].;-]L_XDYLO^D":9ZF/]G9YC^4Z21ZL7]/S^/U/EQ]#JOL14@3'U&;8-
MJ3$-LRS:J3786KGBF!AUD8XF7Q,9TV>Z5+DAJJ9PP+[1&69K$E+P:&Z*+WF<
M.QK?(\NL^S<B>/&?MIOK8!)[5EB:W2<'BL?*:?>1Y?';!"X7#-8A B&8>^*S
MO@'2'62!"Q8X&=@;^SUE_=INIX^:2'U9[&@/+:VEU\PY'H5EE%V^M:W\VY5*
ME5(+E=%!<^8@>5\N[ZCF6Y E?- BY [Z:-,03P(O_ZTLN+X?AE-_EI0LU7:P
MC=?:&E6\P0!>M5:+AC"@3DYXX(Y<HP AD4BE41$EM5I(.Q655M0*AQ[1AJZ:
M]:L:H'Q?L\U'GZ.=T'+@EV=80O3U%0OMS_=-]A*.VE7GD2(9(.B@#AR8D0B5
M68H@@TK'/>$MLWK>W%&S6NYVUJ\T^II5[>%>L"04)N%PS>BZ,%U7 3J8?B8&
MQ\"ZZKW(8EKM,>9$AY7*%\ZR(L8]/&O,II:;&E9%=_IM=^"%'P(6NBZQ)'R
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MB47KM_OMMAU(6T_?EL, D1P"$FUD"<VARSA(7K*!,(U&LJIY'.>3M8O%P.J
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M*XD6-T!+L'8J!0(2A?*JKC?K%C>/>H5J7+C+_JS86JN.OM8:7+TY#CPA!\O
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M,HC*X84.F3G@:3$UF<$M@DF%7$@(1L_67-E1MC?:.695.K(GE=W 325603*
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M^%%FY]1P$1-G<5&!PF-PFD)G'0C1[ O0Q-78X[^3!L3E-*WK)OE%LW?AK-U
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M\2:B/A,>^:("SP_)3W_UZ+J#<5?I4JOHT3N@']R4[=+MP5KF2E^[K@W>4X^
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M;%]V++3COU DGN,?"Z>#1E/&>KYH8VI7'1^NYSZAYW _]S&G3M=SG]=[NGO
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M(..2GX2PYFLM@&OA>RT ;.&++8!LX9LM &WAJRV ;>&[+0!NX<LM@&[AVRT
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M;QNWGU!+ 0(4 Q0    ( (:!6DX?(\\#P    !,"   +              "
M 0    !?<F5L<R\N<F5L<U!+ 0(4 Q0    ( (:!6DXGZ(<.@@   +$    0
M              "  >D   !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @
MAH%:3@IF9>_N    *P(  !$              ( !F0$  &1O8U!R;W!S+V-O
M<F4N>&UL4$L! A0#%     @ AH%:3IE<G",0!@  G"<  !,
M ( !M@(  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " "&@5I.;$U:
MZ< "  #-"@  &               @ 'W"   >&PO=V]R:W-H965T<R]S:&5E
M=#$N>&UL4$L! A0#%     @ AH%:3DT<'Z7' P  )!$  !@
M ( ![0L  'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( (:!
M6DYRQ_DSY@$  /4$   8              "  >H/  !X;"]W;W)K<VAE971S
M+W-H965T,RYX;6Q02P$"% ,4    " "&@5I.\;9I0)T#  #W#@  &
M        @ $&$@  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%
M  @ AH%:3JF[N],R!0  K!H  !@              ( !V14  'AL+W=O<FMS
M:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    ( (:!6DYP>XTIQ 0  ),6   8
M              "  4$;  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"
M% ,4    " "&@5I.9DL\SJ\!  #2 P  &               @ $[(   >&PO
M=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ AH%:3J'OO@VT 0
MT@,  !@              ( !("(  'AL+W=O<FMS:&5E=',O<VAE970X+GAM
M;%!+ 0(4 Q0    ( (:!6D[9/Y]&M $  -(#   8              "  0HD
M  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4    " "&@5I.#;DH
MQ;0!  #2 P  &0              @ 'T)0  >&PO=V]R:W-H965T<R]S:&5E
M=#$P+GAM;%!+ 0(4 Q0    ( (:!6D[\Q'\RLP$  -(#   9
M  "  =\G  !X;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @
MAH%:3C$)&<NU 0  T@,  !D              ( !R2D  'AL+W=O<FMS:&5E
M=',O<VAE970Q,BYX;6Q02P$"% ,4    " "&@5I.MXJ35[4!  #2 P  &0
M            @ &U*P  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4
M Q0    ( (:!6D[ _P<,M $  -(#   9              "  :$M  !X;"]W
M;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%     @ AH%:3BW L$BT 0
MT@,  !D              ( !C"\  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX
M;6Q02P$"% ,4    " "&@5I.GR;S.[4!  #2 P  &0              @ %W
M,0  >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( (:!6DY@
MOYJ&LP$  -(#   9              "  6,S  !X;"]W;W)K<VAE971S+W-H
M965T,3<N>&UL4$L! A0#%     @ AH%:3FJNJG>V 0  T@,  !D
M     ( !334  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( (:!6DXO[_>WT@$  )P$   9              "
M >L_  !X;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @ AH%:
M3LG4+'G0 0  G 0  !D              ( !]$$  'AL+W=O<FMS:&5E=',O
M<VAE970R-"YX;6Q02P$"% ,4    " "&@5I.6HC$]K<!  #2 P  &0
M        @ '[0P  >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0
M   ( (:!6DXD#W.,N0$  -(#   9              "  >E%  !X;"]W;W)K
M<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @ AH%:3K]=/!$L @  FP8
M !D              ( !V4<  'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q0
M2P$"% ,4    " "&@5I.D6QZZ;D$  !#'   &0              @ $\2@
M>&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( (:!6D[1UBAL
M- (  #D'   9              "  2Q/  !X;"]W;W)K<VAE971S+W-H965T
M,CDN>&UL4$L! A0#%     @ AH%:3L Z!),_ @  K@<  !D
M ( !EU$  'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"% ,4    " "&
M@5I..^C971D"  #5!@  &0              @ $-5   >&PO=V]R:W-H965T
M<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    ( (:!6D[T[4>5 @(  "<%   9
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M970S-BYX;6Q02P$"% ,4    " "&@5I.;?C$P#(#  !+#0  &0
M    @ %J90  >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    (
M (:!6D[QFMB+> ,  $\0   9              "  =-H  !X;"]W;W)K<VAE
M971S+W-H965T,S@N>&UL4$L! A0#%     @ AH%:3IQ6GU1V @  ,@@  !D
M             ( !@FP  'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"
M% ,4    " "&@5I.8,4.[$$#  !G#0  &0              @ $O;P  >&PO
M=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    ( (:!6DXU)BN%B@(
M +8)   9              "  :=R  !X;"]W;W)K<VAE971S+W-H965T-#$N
M>&UL4$L! A0#%     @ AH%:3NU>).CQ P  Q1$  !D              ( !
M:'4  'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6Q02P$"% ,4    " "&@5I.
M34(5>$\$  "E%0  &0              @ &0>0  >&PO=V]R:W-H965T<R]S
M:&5E=#0S+GAM;%!+ 0(4 Q0    ( (:!6D[)R1FL" ,  - +   9
M      "  19^  !X;"]W;W)K<VAE971S+W-H965T-#0N>&UL4$L! A0#%
M  @ AH%:3A;MR^*% @  : @  !D              ( !58$  'AL+W=O<FMS
M:&5E=',O<VAE970T-2YX;6Q02P$"% ,4    " "&@5I.S)36IYH#  !B$
M&0              @ $1A   >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+
M 0(4 Q0    ( (:!6DX'TGWY2 ,  , -   9              "  >*'  !X
M;"]W;W)K<VAE971S+W-H965T-#<N>&UL4$L! A0#%     @ AH%:3K.XWHFH
M!   V1<  !D              ( !88L  'AL+W=O<FMS:&5E=',O<VAE970T
M."YX;6Q02P$"% ,4    " "&@5I.\<+#Y1,$  "H$P  &0
M@ % D   >&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0    ( (:!
M6DY]Y$IODP,  !P0   9              "  8J4  !X;"]W;W)K<VAE971S
M+W-H965T-3 N>&UL4$L! A0#%     @ AH%:3IG;7*!X P  7P\  !D
M         ( !5)@  'AL+W=O<FMS:&5E=',O<VAE970U,2YX;6Q02P$"% ,4
M    " "&@5I.A,.U7Q0#   .#0  &0              @ $#G   >&PO=V]R
M:W-H965T<R]S:&5E=#4R+GAM;%!+ 0(4 Q0    ( (:!6D[]AR/:K (    *
M   9              "  4Z?  !X;"]W;W)K<VAE971S+W-H965T-3,N>&UL
M4$L! A0#%     @ AH%:3G4V)!DE @  7 8  !D              ( !,:(
M 'AL+W=O<FMS:&5E=',O<VAE970U-"YX;6Q02P$"% ,4    " "&@5I.^#.\
M]4X#  "!#0  &0              @ &-I   >&PO=V]R:W-H965T<R]S:&5E
M=#4U+GAM;%!+ 0(4 Q0    ( (:!6DZ;QIJ?A0(  %X)   9
M  "  1*H  !X;"]W;W)K<VAE971S+W-H965T-38N>&UL4$L! A0#%     @
MAH%:3C28:^GTEP  ^%4" !0              ( !SJH  'AL+W-H87)E9%-T
M<FEN9W,N>&UL4$L! A0#%     @ AH%:3NA$"\T\ @  ? H   T
M     ( !]$(! 'AL+W-T>6QE<RYX;6Q02P$"% ,4    " "&@5I..#MA(9,$
M  "P)0  #P              @ %;10$ >&PO=V]R:V)O;VLN>&UL4$L! A0#
M%     @ AH%:3F4-O+_] 0  #2(  !H              ( !&TH! 'AL+U]R
M96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ AH%:3E7=Y!#9 0
MOB$  !,              ( !4$P! %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&
2     $$ 00"Y$0  6DX!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.10.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>234</ContextCount>
  <ElementCount>288</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>74</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="mgnx-20181231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/DocumentandEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="mgnx-20181231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="mgnx-20181231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="mgnx-20181231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="mgnx-20181231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="mgnx-20181231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="mgnx-20181231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Organization and Nature of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/OrganizationandNatureofOperations</Role>
      <ShortName>Organization and Nature of Operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="mgnx-20181231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2102102 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="mgnx-20181231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2113103 - Disclosure - Marketable Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/MarketableSecurities</Role>
      <ShortName>Marketable Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="mgnx-20181231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2117104 - Disclosure - Property, Equipment and Software</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/PropertyEquipmentandSoftware</Role>
      <ShortName>Property, Equipment and Software</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="mgnx-20181231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2120105 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="mgnx-20181231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2122106 - Disclosure - Stock-based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/StockbasedCompensation</Role>
      <ShortName>Stock-based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="mgnx-20181231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2128107 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="mgnx-20181231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2133108 - Disclosure - Collaboration and Other Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CollaborationandOtherAgreements</Role>
      <ShortName>Collaboration and Other Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="mgnx-20181231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2141109 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="mgnx-20181231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2144110 - Disclosure - Employee Benefit Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/EmployeeBenefitPlan</Role>
      <ShortName>Employee Benefit Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="mgnx-20181231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2146111 - Disclosure - Quarterly Financial Information (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/QuarterlyFinancialInformationUnaudited</Role>
      <ShortName>Quarterly Financial Information (Unaudited)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="mgnx-20181231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2149112 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="mgnx-20181231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2203201 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://macrogenics.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="mgnx-20181231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2304301 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://macrogenics.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="mgnx-20181231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2314302 - Disclosure - Marketable Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/MarketableSecuritiesTables</Role>
      <ShortName>Marketable Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://macrogenics.com/role/MarketableSecurities</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="mgnx-20181231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2318303 - Disclosure - Property, Equipment and Software (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/PropertyEquipmentandSoftwareTables</Role>
      <ShortName>Property, Equipment and Software (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://macrogenics.com/role/PropertyEquipmentandSoftware</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="mgnx-20181231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2323304 - Disclosure - Stock-based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/StockbasedCompensationTables</Role>
      <ShortName>Stock-based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://macrogenics.com/role/StockbasedCompensation</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="mgnx-20181231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2329305 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://macrogenics.com/role/IncomeTaxes</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="mgnx-20181231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2342306 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CommitmentsandContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://macrogenics.com/role/CommitmentsandContingencies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="mgnx-20181231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2347307 - Disclosure - Quarterly Financial Information (Unaudited) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/QuarterlyFinancialInformationUnauditedTables</Role>
      <ShortName>Quarterly Financial Information (Unaudited) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://macrogenics.com/role/QuarterlyFinancialInformationUnaudited</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="mgnx-20181231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2405401 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="mgnx-20181231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Summary of Significant Accounting Policies - Summary of Fair Value Measurement Financial Asset and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Summary of Fair Value Measurement Financial Asset and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="mgnx-20181231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Summary of Significant Accounting Policies - Summary of Collaborators that Represent More Than 10% of Total Revenue Earned (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Summary of Collaborators that Represent More Than 10% of Total Revenue Earned (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="mgnx-20181231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2408404 - Disclosure - Summary of Significant Accounting Policies - Summary of Collaborators that Represent More Than 10% of Accounts Receivable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofAccountsReceivableDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Summary of Collaborators that Represent More Than 10% of Accounts Receivable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="mgnx-20181231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2409405 - Disclosure - Summary of Significant Accounting Policies - Estimated Useful Lives (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Estimated Useful Lives (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="mgnx-20181231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2410406 - Disclosure - Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from the Calculation of Diluted Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromtheCalculationofDilutedLossPerShareDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from the Calculation of Diluted Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="mgnx-20181231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2411407 - Disclosure - Summary of Significant Accounting Policies - Adoption of 606 (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesAdoptionof606Details</Role>
      <ShortName>Summary of Significant Accounting Policies - Adoption of 606 (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="mgnx-20181231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2412408 - Disclosure - Summary of Signficant Accounting Policies - Contract With Customer Liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/SummaryofSignficantAccountingPoliciesContractWithCustomerLiabilityDetails</Role>
      <ShortName>Summary of Signficant Accounting Policies - Contract With Customer Liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="mgnx-20181231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2415409 - Disclosure - Marketable Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/MarketableSecuritiesDetails</Role>
      <ShortName>Marketable Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://macrogenics.com/role/MarketableSecuritiesTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="mgnx-20181231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2416410 - Disclosure - Marketable Securities - Available-For-Sale Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/MarketableSecuritiesAvailableForSaleSecuritiesDetails</Role>
      <ShortName>Marketable Securities - Available-For-Sale Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="mgnx-20181231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2419411 - Disclosure - Property, Equipment and Software (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails</Role>
      <ShortName>Property, Equipment and Software (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://macrogenics.com/role/PropertyEquipmentandSoftwareTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="mgnx-20181231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2421412 - Disclosure - Stockholders' Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/StockholdersEquityDetails</Role>
      <ShortName>Stockholders' Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://macrogenics.com/role/StockholdersEquity</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="mgnx-20181231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2424413 - Disclosure - Stock-based Compensation - Employee Stock Purchase Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/StockbasedCompensationEmployeeStockPurchasePlanDetails</Role>
      <ShortName>Stock-based Compensation - Employee Stock Purchase Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="mgnx-20181231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2425414 - Disclosure - Stock-based Compensation - Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stock-based Compensation - Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="mgnx-20181231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2426415 - Disclosure - Stock-based Compensation - Option Pricing Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/StockbasedCompensationOptionPricingAssumptionsDetails</Role>
      <ShortName>Stock-based Compensation - Option Pricing Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="mgnx-20181231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2427416 - Disclosure - Stock-based Compensation - Stock Option and Restricted Stock Unit Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails</Role>
      <ShortName>Stock-based Compensation - Stock Option and Restricted Stock Unit Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="mgnx-20181231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2430417 - Disclosure - Income Taxes - Components of the Company's Deferred Tax Assets (Liabilities) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Components of the Company's Deferred Tax Assets (Liabilities) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="mgnx-20181231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2431418 - Disclosure - Income Taxes - Reconciliation of Reported Estimated Income Tax Benefit (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails</Role>
      <ShortName>Income Taxes - Reconciliation of Reported Estimated Income Tax Benefit (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="mgnx-20181231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2432419 - Disclosure - Income Taxes - Reconciliation of the Beginning and Ending Amount of Gross Unrecognized Tax Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/IncomeTaxesReconciliationoftheBeginningandEndingAmountofGrossUnrecognizedTaxBenefitsDetails</Role>
      <ShortName>Income Taxes - Reconciliation of the Beginning and Ending Amount of Gross Unrecognized Tax Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="mgnx-20181231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2434420 - Disclosure - Collaboration and Other Agreements, Incyte Corporation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails</Role>
      <ShortName>Collaboration and Other Agreements, Incyte Corporation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="mgnx-20181231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2435421 - Disclosure - Collaboration and Other Agreements, Zai Lab (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails</Role>
      <ShortName>Collaboration and Other Agreements, Zai Lab (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="mgnx-20181231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2436422 - Disclosure - Collaboration and Other Agreements, Servier (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CollaborationandOtherAgreementsServierDetails</Role>
      <ShortName>Collaboration and Other Agreements, Servier (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="mgnx-20181231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2437423 - Disclosure - Collaboration and Other Agreements, Roche (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CollaborationandOtherAgreementsRocheDetails</Role>
      <ShortName>Collaboration and Other Agreements, Roche (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://macrogenics.com/role/CollaborationandOtherAgreements</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="mgnx-20181231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2438424 - Disclosure - Collaboration and Other Agreements, Provention (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CollaborationandOtherAgreementsProventionDetails</Role>
      <ShortName>Collaboration and Other Agreements, Provention (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="mgnx-20181231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2439425 - Disclosure - Collaboration and Other Agreements, Janssen Biotech, Inc. (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenBiotechIncDetails</Role>
      <ShortName>Collaboration and Other Agreements, Janssen Biotech, Inc. (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="mgnx-20181231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2440426 - Disclosure - Collaboration and Other Agreements, NIAID Contract (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails</Role>
      <ShortName>Collaboration and Other Agreements, NIAID Contract (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="mgnx-20181231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2443427 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CommitmentsandContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://macrogenics.com/role/CommitmentsandContingenciesTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="mgnx-20181231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2445428 - Disclosure - Employee Benefit Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/EmployeeBenefitPlanDetails</Role>
      <ShortName>Employee Benefit Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://macrogenics.com/role/EmployeeBenefitPlan</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="mgnx-20181231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2448429 - Disclosure - Quarterly Financial Information (Unaudited) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/QuarterlyFinancialInformationUnauditedDetails</Role>
      <ShortName>Quarterly Financial Information (Unaudited) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://macrogenics.com/role/QuarterlyFinancialInformationUnauditedTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="mgnx-20181231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2450430 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://macrogenics.com/role/SubsequentEvents</ParentRole>
      <Position>56</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="mgnx-20181231.htm">mgnx-20181231.htm</File>
    <File>exhibit1018to2018form1.htm</File>
    <File>exhibit1019to2018form1.htm</File>
    <File>mgnx-20181231.xsd</File>
    <File>mgnx-20181231_cal.xml</File>
    <File>mgnx-20181231_def.xml</File>
    <File>mgnx-20181231_lab.xml</File>
    <File>mgnx-20181231_pre.xml</File>
    <File>mgnxexhibit23-1201810xk.htm</File>
    <File>mgnxexhibit31-1201810xk.htm</File>
    <File>mgnxexhibit31-2201810xk.htm</File>
    <File>mgnxexhibit32-1201810xk.htm</File>
    <File>mgnxexhibit32-2201810xk.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/us-gaap/2018-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2018-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2018-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>84
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "mgnx-20181231.htm": {
   "axisCustom": 0,
   "axisStandard": 23,
   "contextCount": 234,
   "dts": {
    "calculationLink": {
     "local": [
      "mgnx-20181231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "mgnx-20181231_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2018/elts/srt-eedm1-def-2018-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-eedm-def-2018-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "mgnx-20181231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "mgnx-20181231_lab.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-doc-2018-01-31.xml",
      "https://xbrl.sec.gov/dei/2018/dei-doc-2018-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "mgnx-20181231_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-ref-2018-01-31.xml",
      "https://xbrl.sec.gov/dei/2018/dei-ref-2018-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "mgnx-20181231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd",
      "http://xbrl.fasb.org/srt/2018/elts/srt-roles-2018-01-31.xsd",
      "http://xbrl.fasb.org/srt/2018/elts/srt-types-2018-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2018/elts/us-parts-codification-2018-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2018/elts/us-roles-2018-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2018/elts/us-types-2018-01-31.xsd",
      "http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd",
      "https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd"
     ]
    }
   },
   "elementCount": 470,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2018-01-31": 31,
    "http://xbrl.sec.gov/dei/2018-01-31": 14,
    "total": 45
   },
   "keyCustom": 47,
   "keyStandard": 241,
   "memberCustom": 36,
   "memberStandard": 31,
   "nsprefix": "mgnx",
   "nsuri": "http://macrogenics.com/20181231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "contextRef": "ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Document and Entity Information",
     "role": "http://macrogenics.com/role/DocumentandEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "contextRef": "ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "contextRef": "ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2117104 - Disclosure - Property, Equipment and Software",
     "role": "http://macrogenics.com/role/PropertyEquipmentandSoftware",
     "shortName": "Property, Equipment and Software",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "contextRef": "ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "contextRef": "ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2120105 - Disclosure - Stockholders' Equity",
     "role": "http://macrogenics.com/role/StockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "contextRef": "ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "contextRef": "ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2122106 - Disclosure - Stock-based Compensation",
     "role": "http://macrogenics.com/role/StockbasedCompensation",
     "shortName": "Stock-based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "contextRef": "ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "contextRef": "ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2128107 - Disclosure - Income Taxes",
     "role": "http://macrogenics.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "contextRef": "ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "contextRef": "ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mgnx:CollaborationAndLicenseAgreementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2133108 - Disclosure - Collaboration and Other Agreements",
     "role": "http://macrogenics.com/role/CollaborationandOtherAgreements",
     "shortName": "Collaboration and Other Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "contextRef": "ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mgnx:CollaborationAndLicenseAgreementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "contextRef": "ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2141109 - Disclosure - Commitments and Contingencies",
     "role": "http://macrogenics.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "contextRef": "ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "contextRef": "ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2144110 - Disclosure - Employee Benefit Plan",
     "role": "http://macrogenics.com/role/EmployeeBenefitPlan",
     "shortName": "Employee Benefit Plan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "contextRef": "ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "contextRef": "ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:QuarterlyFinancialInformationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2146111 - Disclosure - Quarterly Financial Information (Unaudited)",
     "role": "http://macrogenics.com/role/QuarterlyFinancialInformationUnaudited",
     "shortName": "Quarterly Financial Information (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "contextRef": "ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:QuarterlyFinancialInformationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "contextRef": "ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2149112 - Disclosure - Subsequent Events",
     "role": "http://macrogenics.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "contextRef": "ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2203201 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "contextRef": "id926749df69c4fffbb4a92f70f45021f_I20181231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - CONSOLIDATED BALANCE SHEETS",
     "role": "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "contextRef": "id926749df69c4fffbb4a92f70f45021f_I20181231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2304301 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "role": "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2314302 - Disclosure - Marketable Securities (Tables)",
     "role": "http://macrogenics.com/role/MarketableSecuritiesTables",
     "shortName": "Marketable Securities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "contextRef": "ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2318303 - Disclosure - Property, Equipment and Software (Tables)",
     "role": "http://macrogenics.com/role/PropertyEquipmentandSoftwareTables",
     "shortName": "Property, Equipment and Software (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "contextRef": "ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2323304 - Disclosure - Stock-based Compensation (Tables)",
     "role": "http://macrogenics.com/role/StockbasedCompensationTables",
     "shortName": "Stock-based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2329305 - Disclosure - Income Taxes (Tables)",
     "role": "http://macrogenics.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2342306 - Disclosure - Commitments and Contingencies (Tables)",
     "role": "http://macrogenics.com/role/CommitmentsandContingenciesTables",
     "shortName": "Commitments and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "contextRef": "ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2347307 - Disclosure - Quarterly Financial Information (Unaudited) (Tables)",
     "role": "http://macrogenics.com/role/QuarterlyFinancialInformationUnauditedTables",
     "shortName": "Quarterly Financial Information (Unaudited) (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "contextRef": "ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405401 - Disclosure - Summary of Significant Accounting Policies (Details)",
     "role": "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesDetails",
     "shortName": "Summary of Significant Accounting Policies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "id926749df69c4fffbb4a92f70f45021f_I20181231",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Summary of Significant Accounting Policies - Summary of Fair Value Measurement Financial Asset and Liabilities (Details)",
     "role": "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails",
     "shortName": "Summary of Significant Accounting Policies - Summary of Fair Value Measurement Financial Asset and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "id926749df69c4fffbb4a92f70f45021f_I20181231",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "i03cbd7f054ef4c669ff9c36ff8cd01c0_D20180101-20181231",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407403 - Disclosure - Summary of Significant Accounting Policies - Summary of Collaborators that Represent More Than 10% of Total Revenue Earned (Details)",
     "role": "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedDetails",
     "shortName": "Summary of Significant Accounting Policies - Summary of Collaborators that Represent More Than 10% of Total Revenue Earned (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "i03cbd7f054ef4c669ff9c36ff8cd01c0_D20180101-20181231",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": null,
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "role": "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "ief319720f28440d5a5dd754bc9ebb8b9_D20180101-20181231",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408404 - Disclosure - Summary of Significant Accounting Policies - Summary of Collaborators that Represent More Than 10% of Accounts Receivable (Details)",
     "role": "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofAccountsReceivableDetails",
     "shortName": "Summary of Significant Accounting Policies - Summary of Collaborators that Represent More Than 10% of Accounts Receivable (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "ief319720f28440d5a5dd754bc9ebb8b9_D20180101-20181231",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "icd9b6aa45a364d0c9cd302c42a5acd28_D20180101-20181231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409405 - Disclosure - Summary of Significant Accounting Policies - Estimated Useful Lives (Details)",
     "role": "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails",
     "shortName": "Summary of Significant Accounting Policies - Estimated Useful Lives (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "icd9b6aa45a364d0c9cd302c42a5acd28_D20180101-20181231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "i3e13e524660f42568e18e289608955ea_D20180101-20181231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410406 - Disclosure - Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from the Calculation of Diluted Loss Per Share (Details)",
     "role": "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromtheCalculationofDilutedLossPerShareDetails",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from the Calculation of Diluted Loss Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "i3e13e524660f42568e18e289608955ea_D20180101-20181231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "contextRef": "id926749df69c4fffbb4a92f70f45021f_I20181231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredRevenueCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411407 - Disclosure - Summary of Significant Accounting Policies - Adoption of 606 (Details)",
     "role": "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesAdoptionof606Details",
     "shortName": "Summary of Significant Accounting Policies - Adoption of 606 (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "i58ed5a015dbf42e19178b051b82c9683_I20180101",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "i7057397719af459ca7328a1c440a0efa_I20171231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ContractWithCustomerLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412408 - Disclosure - Summary of Signficant Accounting Policies - Contract With Customer Liability (Details)",
     "role": "http://macrogenics.com/role/SummaryofSignficantAccountingPoliciesContractWithCustomerLiabilityDetails",
     "shortName": "Summary of Signficant Accounting Policies - Contract With Customer Liability (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:AvailableForSaleSecuritiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "i7057397719af459ca7328a1c440a0efa_I20171231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415409 - Disclosure - Marketable Securities (Details)",
     "role": "http://macrogenics.com/role/MarketableSecuritiesDetails",
     "shortName": "Marketable Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:AvailableForSaleSecuritiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "i7057397719af459ca7328a1c440a0efa_I20171231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416410 - Disclosure - Marketable Securities - Available-For-Sale Securities (Details)",
     "role": "http://macrogenics.com/role/MarketableSecuritiesAvailableForSaleSecuritiesDetails",
     "shortName": "Marketable Securities - Available-For-Sale Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "contextRef": "ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:InterestIncomeOther",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "id926749df69c4fffbb4a92f70f45021f_I20181231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419411 - Disclosure - Property, Equipment and Software (Details)",
     "role": "http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails",
     "shortName": "Property, Equipment and Software (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "id926749df69c4fffbb4a92f70f45021f_I20181231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "contextRef": "ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421412 - Disclosure - Stockholders' Equity (Details)",
     "role": "http://macrogenics.com/role/StockholdersEquityDetails",
     "shortName": "Stockholders' Equity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "iaaa703135e5d42e3ad357819a2febb2b_I20181231",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "contextRef": "ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424413 - Disclosure - Stock-based Compensation - Employee Stock Purchase Plan (Details)",
     "role": "http://macrogenics.com/role/StockbasedCompensationEmployeeStockPurchasePlanDetails",
     "shortName": "Stock-based Compensation - Employee Stock Purchase Plan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "i37bd3dc2e0684382887e9c7141114e64_I20170518",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "contextRef": "ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "role": "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "contextRef": "ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "mgnx:ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "id926749df69c4fffbb4a92f70f45021f_I20181231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425414 - Disclosure - Stock-based Compensation - Stock-Based Compensation Expense (Details)",
     "role": "http://macrogenics.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails",
     "shortName": "Stock-based Compensation - Stock-Based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426415 - Disclosure - Stock-based Compensation - Option Pricing Assumptions (Details)",
     "role": "http://macrogenics.com/role/StockbasedCompensationOptionPricingAssumptionsDetails",
     "shortName": "Stock-based Compensation - Option Pricing Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "mgnx:ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "i7057397719af459ca7328a1c440a0efa_I20171231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427416 - Disclosure - Stock-based Compensation - Stock Option and Restricted Stock Unit Activity (Details)",
     "role": "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails",
     "shortName": "Stock-based Compensation - Stock Option and Restricted Stock Unit Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "mgnx:ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "contextRef": "ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentIncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2430417 - Disclosure - Income Taxes - Components of the Company's Deferred Tax Assets (Liabilities) (Details)",
     "role": "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails",
     "shortName": "Income Taxes - Components of the Company's Deferred Tax Assets (Liabilities) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "contextRef": "ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentIncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431418 - Disclosure - Income Taxes - Reconciliation of Reported Estimated Income Tax Benefit (Details)",
     "role": "http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails",
     "shortName": "Income Taxes - Reconciliation of Reported Estimated Income Tax Benefit (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "i7057397719af459ca7328a1c440a0efa_I20171231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432419 - Disclosure - Income Taxes - Reconciliation of the Beginning and Ending Amount of Gross Unrecognized Tax Benefits (Details)",
     "role": "http://macrogenics.com/role/IncomeTaxesReconciliationoftheBeginningandEndingAmountofGrossUnrecognizedTaxBenefitsDetails",
     "shortName": "Income Taxes - Reconciliation of the Beginning and Ending Amount of Gross Unrecognized Tax Benefits (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "ife0dac9d3bf74657b071534f4d2516f1_I20151231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "contextRef": "i724f8d5b79f44384afe7b27042231bfe_D20181001-20181231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434420 - Disclosure - Collaboration and Other Agreements, Incyte Corporation (Details)",
     "role": "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
     "shortName": "Collaboration and Other Agreements, Incyte Corporation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "i44dc827b9c5849c9874770cafc78df7e_D20171001-20171231",
      "decimals": "-5",
      "lang": null,
      "name": "mgnx:NonRefundableUpfrontFees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "contextRef": "i724f8d5b79f44384afe7b27042231bfe_D20181001-20181231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2435421 - Disclosure - Collaboration and Other Agreements, Zai Lab (Details)",
     "role": "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails",
     "shortName": "Collaboration and Other Agreements, Zai Lab (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "i29ff7281a75a4936a4be6c1359e216e9_D20181101-20181130",
      "decimals": "-5",
      "lang": null,
      "name": "mgnx:NonRefundableUpfrontFees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "contextRef": "i724f8d5b79f44384afe7b27042231bfe_D20181001-20181231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2436422 - Disclosure - Collaboration and Other Agreements, Servier (Details)",
     "role": "http://macrogenics.com/role/CollaborationandOtherAgreementsServierDetails",
     "shortName": "Collaboration and Other Agreements, Servier (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "i6011d16a582a445fa400c0dfcf98028a_D20120901-20120930",
      "decimals": "-5",
      "lang": null,
      "name": "mgnx:NonRefundableUpfrontFees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "contextRef": "i724f8d5b79f44384afe7b27042231bfe_D20181001-20181231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2437423 - Disclosure - Collaboration and Other Agreements, Roche (Details)",
     "role": "http://macrogenics.com/role/CollaborationandOtherAgreementsRocheDetails",
     "shortName": "Collaboration and Other Agreements, Roche (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "i8ae89b363134495b9cc3cdf7d4ce1a06_D20180101-20180131",
      "decimals": "-5",
      "lang": null,
      "name": "mgnx:NonRefundableUpfrontFees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "contextRef": "ife0dac9d3bf74657b071534f4d2516f1_I20151231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "role": "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
     "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "contextRef": "ife0dac9d3bf74657b071534f4d2516f1_I20151231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "contextRef": "i724f8d5b79f44384afe7b27042231bfe_D20181001-20181231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2438424 - Disclosure - Collaboration and Other Agreements, Provention (Details)",
     "role": "http://macrogenics.com/role/CollaborationandOtherAgreementsProventionDetails",
     "shortName": "Collaboration and Other Agreements, Provention (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "i918dca9fcdce44a999dec3002edfedac_I20180531",
      "decimals": "-5",
      "lang": null,
      "name": "mgnx:CollaborativeAgreementTransactionPrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "contextRef": "i724f8d5b79f44384afe7b27042231bfe_D20181001-20181231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2439425 - Disclosure - Collaboration and Other Agreements, Janssen Biotech, Inc. (Details)",
     "role": "http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenBiotechIncDetails",
     "shortName": "Collaboration and Other Agreements, Janssen Biotech, Inc. (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "i9c0bb24d85b742029840e8ff19e39e21_D20141201-20141231",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "contextRef": "i724f8d5b79f44384afe7b27042231bfe_D20181001-20181231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2440426 - Disclosure - Collaboration and Other Agreements, NIAID Contract (Details)",
     "role": "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails",
     "shortName": "Collaboration and Other Agreements, NIAID Contract (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "ie5dd3f325a0e4bb2bd1f768f5d1cfb31_D20150915-20150915",
      "decimals": "INF",
      "lang": null,
      "name": "mgnx:NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "molecule",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "mgnx:NumberOfLease",
      "reportCount": 1,
      "unique": true,
      "unitRef": "lease",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2443427 - Disclosure - Commitments and Contingencies (Details)",
     "role": "http://macrogenics.com/role/CommitmentsandContingenciesDetails",
     "shortName": "Commitments and Contingencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "mgnx:NumberOfLease",
      "reportCount": 1,
      "unique": true,
      "unitRef": "lease",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "contextRef": "i6ada94a697084172b90c7bcf3c82fe1e_D20120101-20121231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mgnx:EmployeesEligibleAgeToParticipateInBenefitPlan",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2445428 - Disclosure - Employee Benefit Plan (Details)",
     "role": "http://macrogenics.com/role/EmployeeBenefitPlanDetails",
     "shortName": "Employee Benefit Plan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "contextRef": "i6ada94a697084172b90c7bcf3c82fe1e_D20120101-20121231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mgnx:EmployeesEligibleAgeToParticipateInBenefitPlan",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "contextRef": "i724f8d5b79f44384afe7b27042231bfe_D20181001-20181231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2448429 - Disclosure - Quarterly Financial Information (Unaudited) (Details)",
     "role": "http://macrogenics.com/role/QuarterlyFinancialInformationUnauditedDetails",
     "shortName": "Quarterly Financial Information (Unaudited) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "contextRef": "i724f8d5b79f44384afe7b27042231bfe_D20181001-20181231",
      "decimals": "2",
      "lang": null,
      "name": "us-gaap:EarningsPerShareBasicAndDiluted",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "contextRef": "ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2450430 - Disclosure - Subsequent Events (Details)",
     "role": "http://macrogenics.com/role/SubsequentEventsDetails",
     "shortName": "Subsequent Events (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "contextRef": "i7ed315b7b06447388b74464c7e252a0a_D20190201-20190228",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "contextRef": "ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "role": "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "contextRef": "ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "contextRef": "ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Organization and Nature of Operations",
     "role": "http://macrogenics.com/role/OrganizationandNatureofOperations",
     "shortName": "Organization and Nature of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "contextRef": "ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "contextRef": "ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2102102 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://macrogenics.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "contextRef": "ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "contextRef": "ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2113103 - Disclosure - Marketable Securities",
     "role": "http://macrogenics.com/role/MarketableSecurities",
     "shortName": "Marketable Securities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "contextRef": "ief5f4ba90c974d89882bbe46fb8a4b5b_D20180101-20181231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 74,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "If the value is true, then the document is an amendment to previously-filed/accepted document.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r310"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r310"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r310"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated), (5) Smaller Reporting Accelerated Filer or (6) Smaller Reporting Company and Large Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "State aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to price at which the common equity was last sold, or average bid and asked price of such common equity, as of the last business day of registrant's most recently completed second fiscal quarter. The public float should be reported on the cover page of the registrants form 10K.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r310"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r310"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if company meets the shell company criteria: a company with no or nominal operations, and with no or nominal assets or assets consisting solely of cash and cash equivalents.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r310"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates that the company is a smaller reporting company with both a public float and revenues of less than $75 million.",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Additional funding available under agreement at counterparty's option",
        "label": "Additional development funding options under agreement",
        "terseLabel": "Additional development funding options"
       }
      }
     },
     "localname": "AdditionalDevelopmentFundingOptionsUnderAgreement",
     "nsuri": "http://macrogenics.com/20181231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_AssetPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Asset Acquisition Agreement",
        "label": "Asset Purchase Agreement [Member]",
        "terseLabel": "Asset Purchase Agreement"
       }
      }
     },
     "localname": "AssetPurchaseAgreementMember",
     "nsuri": "http://macrogenics.com/20181231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsProventionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_AtTheMarketOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "At The Market Offering [Member]",
        "label": "At The Market Offering [Member]",
        "terseLabel": "At The Market Offering"
       }
      }
     },
     "localname": "AtTheMarketOfferingMember",
     "nsuri": "http://macrogenics.com/20181231",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_CollaborationAndLicenseAgreementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "",
        "label": "Collaboration and License Agreements [Abstract]",
        "terseLabel": "Collaboration and License Agreements [Abstract]"
       }
      }
     },
     "localname": "CollaborationAndLicenseAgreementsAbstract",
     "nsuri": "http://macrogenics.com/20181231",
     "xbrltype": "stringItemType"
    },
    "mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for collaboration and license agreements.",
        "label": "Collaboration And License Agreements Disclosure [Text Block]",
        "terseLabel": "Collaboration and Other Agreements"
       }
      }
     },
     "localname": "CollaborationAndLicenseAgreementsDisclosureTextBlock",
     "nsuri": "http://macrogenics.com/20181231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Refers to collaboration arrangement offset to research and development costs.",
        "label": "Collaboration Arrangement Offset to Research and Development Costs",
        "terseLabel": "Offset to research and development costs under collaboration arrangement"
       }
      }
     },
     "localname": "CollaborationArrangementOffsetToResearchAndDevelopmentCosts",
     "nsuri": "http://macrogenics.com/20181231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsServierDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Agreement Consideration Received Common Stock Warrant Exercise Price Per Share",
        "label": "Collaborative Agreement Consideration Received Common Stock Warrant Exercise Price Per Share",
        "terseLabel": "Consideration received common stock warrant exercise price (in usd per share)"
       }
      }
     },
     "localname": "CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare",
     "nsuri": "http://macrogenics.com/20181231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsProventionDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Agreement Consideration Received Common Stock Warrants Number Of Shares",
        "label": "Collaborative Agreement Consideration Received Common Stock Warrants Number Of Shares",
        "terseLabel": "Stock warrants (in shares)"
       }
      }
     },
     "localname": "CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares",
     "nsuri": "http://macrogenics.com/20181231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsProventionDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "mgnx_CollaborativeAgreementTransactionPrice": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Agreement Transaction Price",
        "label": "Collaborative Agreement Transaction Price",
        "terseLabel": "Transaction price"
       }
      }
     },
     "localname": "CollaborativeAgreementTransactionPrice",
     "nsuri": "http://macrogenics.com/20181231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsProventionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Common Stock Capital Shares Minimum Increase In Shares Reserved For Future Issuance",
        "label": "Common Stock Capital Shares Minimum Increase In Shares Reserved For Future Issuance",
        "terseLabel": "Stock reserved for future issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance",
     "nsuri": "http://macrogenics.com/20181231",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "mgnx_CommonStockMaximumAmountAvailableForIssuance": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Common Stock, Maximum Amount Available For Issuance",
        "label": "Common Stock, Maximum Amount Available For Issuance",
        "terseLabel": "Common stock maximum amount available for issuance"
       }
      }
     },
     "localname": "CommonStockMaximumAmountAvailableForIssuance",
     "nsuri": "http://macrogenics.com/20181231",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage vested of employee's contributions to defined contribution plan",
        "label": "Defined Contribution Plan, Employees Contribution, Vested Percentage",
        "terseLabel": "Percentage of employee vested contribution"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployeesContributionVestedPercentage",
     "nsuri": "http://macrogenics.com/20181231",
     "presentation": [
      "http://macrogenics.com/role/EmployeeBenefitPlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Development And Regulatory Milestone Payments Under Agreement, Recognized",
        "label": "Development And Regulatory Milestone Payments Under Agreement, Recognized",
        "terseLabel": "Amounts recognized"
       }
      }
     },
     "localname": "DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized",
     "nsuri": "http://macrogenics.com/20181231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_DocumentAndEntityInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Document and entity information.",
        "label": "Document And Entity Information [Abstract]"
       }
      }
     },
     "localname": "DocumentAndEntityInformationAbstract",
     "nsuri": "http://macrogenics.com/20181231",
     "xbrltype": "stringItemType"
    },
    "mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Domestic Tax Authority and State and Local Jurisdiction [Member] [Member]",
        "label": "Domestic Tax Authority and State and Local Jurisdiction [Member] [Member]",
        "terseLabel": "U.S. Federal and State"
       }
      }
     },
     "localname": "DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember",
     "nsuri": "http://macrogenics.com/20181231",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount": {
     "auth_ref": [],
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to deferred tax adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Deferred Tax Adjustments, Amount",
        "terseLabel": "Deferred income tax adjustments"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount",
     "nsuri": "http://macrogenics.com/20181231",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTaxBenefitTaxEffectedAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Share-based Compensation, Excess Tax Benefit, Tax Effected Amount",
        "label": "Effective Income Tax Rate Reconciliation, Share-based Compensation, Excess Tax Benefit, Tax Effected Amount",
        "terseLabel": "Previously unrecognized excess tax benefits, tax effected portion"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTaxBenefitTaxEffectedAmount",
     "nsuri": "http://macrogenics.com/20181231",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_EffectiveIncomeTaxReconciliationStateDeferredTaxesAdjustmentsAmount": {
     "auth_ref": [],
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to deferred state blended rate adjustments.",
        "label": "Effective Income Tax Reconciliation State Deferred Taxes Adjustments, Amount",
        "negatedLabel": "Deferred state blended rate adjustments"
       }
      }
     },
     "localname": "EffectiveIncomeTaxReconciliationStateDeferredTaxesAdjustmentsAmount",
     "nsuri": "http://macrogenics.com/20181231",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Employee Stock Purchase Plan, Maximum Annual Contributions Per Employee, Percent",
        "label": "Employee Stock Purchase Plan, Maximum Annual Contributions Per Employee, Percent",
        "terseLabel": "Common stock discount percent"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent",
     "nsuri": "http://macrogenics.com/20181231",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationEmployeeStockPurchasePlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Refers to minimum eligible age of employee to participate in benefit plan.",
        "label": "Employees Eligible Age To Participate In Benefit Plan",
        "terseLabel": "Eligible age to participate in plan"
       }
      }
     },
     "localname": "EmployeesEligibleAgeToParticipateInBenefitPlan",
     "nsuri": "http://macrogenics.com/20181231",
     "presentation": [
      "http://macrogenics.com/role/EmployeeBenefitPlanDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "mgnx_EquityIncentivePlan2003Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity Incentive Plan 2003",
        "label": "Equity Incentive Plan 2003 [Member]",
        "terseLabel": "Equity Incentive Plan 2003"
       }
      }
     },
     "localname": "EquityIncentivePlan2003Member",
     "nsuri": "http://macrogenics.com/20181231",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Exercised Additional Development Funding Options Under Agreement",
        "label": "Exercised Additional Development Funding Options Under Agreement",
        "terseLabel": "Proceeds from additional development funding options under agreement"
       }
      }
     },
     "localname": "ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement",
     "nsuri": "http://macrogenics.com/20181231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. [Member]",
        "label": "F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. [Member]",
        "terseLabel": "F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (Roche)",
        "verboseLabel": "Roche"
       }
      }
     },
     "localname": "F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member",
     "nsuri": "http://macrogenics.com/20181231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsRocheDetails",
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofAccountsReceivableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_FairValueOfWarrantsReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair Value Of Warrants Received",
        "label": "Fair Value Of Warrants Received",
        "verboseLabel": "Fair value of warrants received"
       }
      }
     },
     "localname": "FairValueOfWarrantsReceived",
     "nsuri": "http://macrogenics.com/20181231",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_FirmCommitmentPublicUnderwrittenOfferMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Firm Commitment Public Underwritten Offer",
        "label": "Firm Commitment Public Underwritten Offer [Member]",
        "terseLabel": "Firm Commitment Public Underwritten Offer"
       }
      }
     },
     "localname": "FirmCommitmentPublicUnderwrittenOfferMember",
     "nsuri": "http://macrogenics.com/20181231",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_FollowUpOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Follow Up Offering",
        "label": "Follow Up Offering [Member]",
        "terseLabel": "Follow Up Offering"
       }
      }
     },
     "localname": "FollowUpOfferingMember",
     "nsuri": "http://macrogenics.com/20181231",
     "presentation": [
      "http://macrogenics.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_FundedValueOfBasePeriod": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Funded value of base period",
        "label": "Funded Value of Base Period",
        "verboseLabel": "Base period value"
       }
      }
     },
     "localname": "FundedValueOfBasePeriod",
     "nsuri": "http://macrogenics.com/20181231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_FurnitureAndOfficeEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Furniture and office equipment are movable furniture, fixtures, or other equipment that have no permanent connection to the structure of a building or utilities. These items depreciate substantially but definitely are important costs to consider when valuing a company, especially in liquidation.",
        "label": "Furniture And Office Equipment [Member]",
        "terseLabel": "Furniture and office equipment"
       }
      }
     },
     "localname": "FurnitureAndOfficeEquipmentMember",
     "nsuri": "http://macrogenics.com/20181231",
     "presentation": [
      "http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_IncreaseDecreaseInDeferredRent": {
     "auth_ref": [],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in deferred rent.",
        "label": "Increase (Decrease) in Deferred Rent",
        "terseLabel": "Deferred rent"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredRent",
     "nsuri": "http://macrogenics.com/20181231",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_IncyteCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Incyte Corporation [Member]",
        "label": "Incyte Corporation [Member]",
        "terseLabel": "Incyte Corporation (Incyte)"
       }
      }
     },
     "localname": "IncyteCorporationMember",
     "nsuri": "http://macrogenics.com/20181231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofAccountsReceivableDetails",
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_IncyteMGA012AgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Incyte MGA012 Agreement",
        "label": "Incyte MGA012 Agreement [Member]",
        "terseLabel": "Incyte MGA012 Agreement"
       }
      }
     },
     "localname": "IncyteMGA012AgreementMember",
     "nsuri": "http://macrogenics.com/20181231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_IncyteMGA012ClinicalServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Incyte MGA012 Clinical Services",
        "label": "Incyte MGA012 Clinical Services [Member]",
        "terseLabel": "Incyte MGA012 Clinical Services"
       }
      }
     },
     "localname": "IncyteMGA012ClinicalServicesMember",
     "nsuri": "http://macrogenics.com/20181231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_IndefiniteMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indefinite",
        "label": "Indefinite [Member]",
        "terseLabel": "Indefinite"
       }
      }
     },
     "localname": "IndefiniteMember",
     "nsuri": "http://macrogenics.com/20181231",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_JanssenBiotechIncMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Counterparty in collaboration agreement",
        "label": "Janssen Biotech Inc [Member]",
        "terseLabel": "Janssen Biotech Inc.",
        "verboseLabel": "Janssen Biotech, Inc. (Janssen)"
       }
      }
     },
     "localname": "JanssenBiotechIncMember",
     "nsuri": "http://macrogenics.com/20181231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenBiotechIncDetails",
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_JanssenMGD011AgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Janssen MGD011 Agreement [Member]",
        "label": "Janssen MGD011 Agreement [Member]",
        "terseLabel": "Janssen MGD011 Agreement"
       }
      }
     },
     "localname": "JanssenMGD011AgreementMember",
     "nsuri": "http://macrogenics.com/20181231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenBiotechIncDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_JanssenMGD015AgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Janssen MGD015 Agreement [Member]",
        "label": "Janssen MGD015 Agreement [Member]",
        "terseLabel": "Janssen MGD015 Agreement"
       }
      }
     },
     "localname": "JanssenMGD015AgreementMember",
     "nsuri": "http://macrogenics.com/20181231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenBiotechIncDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_LaboratoryAndOfficeEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A facility that provides controlled conditions in which scientific or technological research, experiments, and measurement may be performed. and tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.",
        "label": "Laboratory and Office Equipment [Member]",
        "terseLabel": "Laboratory and office equipment"
       }
      }
     },
     "localname": "LaboratoryAndOfficeEquipmentMember",
     "nsuri": "http://macrogenics.com/20181231",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_LesLaboratoiresServierAndInstitutDeRecherchesServierServierMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Les Laboratoires Servier And Institut De Recherches Servier (Servier)",
        "label": "Les Laboratoires Servier And Institut De Recherches Servier (Servier) [Member]",
        "terseLabel": "Les Laboratoires Servier and Institut de Recherches Servier (Servier)"
       }
      }
     },
     "localname": "LesLaboratoiresServierAndInstitutDeRecherchesServierServierMember",
     "nsuri": "http://macrogenics.com/20181231",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofAccountsReceivableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_MilestonePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Milestone Payment",
        "label": "Milestone Payment",
        "terseLabel": "Milestone payment removed"
       }
      }
     },
     "localname": "MilestonePayment",
     "nsuri": "http://macrogenics.com/20181231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsServierDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents a collaborators with which entity has an agreement related to contracts and research grants received from U.S. government agencies.",
        "label": "National Institute of Allergy and Infectious Diseases [Member]",
        "terseLabel": "NIAID"
       }
      }
     },
     "localname": "NationalInstituteOfAllergyAndInfectiousDiseasesMember",
     "nsuri": "http://macrogenics.com/20181231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_NonRefundableUpfrontFees": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Initial fee received from collaboration or license agreement.",
        "label": "Non-refundable upfront payment",
        "terseLabel": "Non-refundable upfront payment"
       }
      }
     },
     "localname": "NonRefundableUpfrontFees",
     "nsuri": "http://macrogenics.com/20181231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenBiotechIncDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsRocheDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsServierDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_NonrefundablePaymentTaxWithholding": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Non-refundable Payment, Tax Withholding",
        "label": "Non-refundable Payment, Tax Withholding",
        "terseLabel": "Tax withholding"
       }
      }
     },
     "localname": "NonrefundablePaymentTaxWithholding",
     "nsuri": "http://macrogenics.com/20181231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_NumberOfLease": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the number of lease during the period.",
        "label": "Number of Lease",
        "terseLabel": "Number of leases"
       }
      }
     },
     "localname": "NumberOfLease",
     "nsuri": "http://macrogenics.com/20181231",
     "presentation": [
      "http://macrogenics.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of molecules to be developed and commercialized as per collaboration.",
        "label": "Number Of Molecules To Be Developed And Commercialized Under Agreement",
        "terseLabel": "Commercialization of molecules"
       }
      }
     },
     "localname": "NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement",
     "nsuri": "http://macrogenics.com/20181231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mgnx_OperatingLossCarryforwardsAnnualLimitationAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of net operating loss which are limited for use, utilized on a annual basis.",
        "label": "Operating Loss Carryforwards Annual Limitation Amount",
        "terseLabel": "Net operating losses limited for use utilized on an annual basis"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsAnnualLimitationAmount",
     "nsuri": "http://macrogenics.com/20181231",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of net operating loss carryforward, which are limited for use over the range of years.",
        "label": "Operating Loss Carryforwards Limitations On Use Amount",
        "terseLabel": "Net operating loss for limited use"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLimitationsOnUseAmount",
     "nsuri": "http://macrogenics.com/20181231",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_OperatingLossCarryforwardsNotSubjectToLimitation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Operating loss carryforwards not subject to limitation.",
        "label": "Operating Loss Carryforwards Not Subject To Limitation",
        "terseLabel": "Remaining portion of net operating losses"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsNotSubjectToLimitation",
     "nsuri": "http://macrogenics.com/20181231",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_OptionExerciseFee": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Payment from collaborator upon exercise of option to develop and commercialize product.",
        "label": "Option Exercise Fee",
        "terseLabel": "Option exercise fee"
       }
      }
     },
     "localname": "OptionExerciseFee",
     "nsuri": "http://macrogenics.com/20181231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsServierDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of shares of company's common stock outstanding for increase in shares reserved for issuance under stock plan.",
        "label": "Percentage Of Shares Of Companys Common Stock Outstanding For Increase In Shares Reserved For Issuance Under Stock Plan",
        "terseLabel": "Percentage of common stock share outstanding"
       }
      }
     },
     "localname": "PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan",
     "nsuri": "http://macrogenics.com/20181231",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mgnx_PotentialClinicalMilestonePaymentsUnderAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total potential clinical milestone payments company could earn under agreement.",
        "label": "Potential Clinical Milestone Payments Under Agreement",
        "terseLabel": "Potential clinical milestone payments under agreement"
       }
      }
     },
     "localname": "PotentialClinicalMilestonePaymentsUnderAgreement",
     "nsuri": "http://macrogenics.com/20181231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsServierDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_PotentialCommercialMilestonePaymentsUnderAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Potential Commercial Milestone Payments Under Agreement",
        "label": "Potential Commercial Milestone Payments Under Agreement",
        "terseLabel": "Potential commercial milestone payments"
       }
      }
     },
     "localname": "PotentialCommercialMilestonePaymentsUnderAgreement",
     "nsuri": "http://macrogenics.com/20181231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsProventionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Potential Development and Regulatory Milestone Payments Under Agreement",
        "label": "Potential Development and Regulatory Milestone Payments Under Agreement",
        "terseLabel": "Potential development and regulatory milestone payments"
       }
      }
     },
     "localname": "PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement",
     "nsuri": "http://macrogenics.com/20181231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsProventionDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Potential Milestone Payment To Third Parties For Intellectual Property Under Agreement",
        "label": "Potential Milestone Payment To Third Parties For Intellectual Property Under Agreement",
        "terseLabel": "Potential milestone payment to third parties for intellectual property under agreement"
       }
      }
     },
     "localname": "PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement",
     "nsuri": "http://macrogenics.com/20181231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsProventionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_PotentialMilestonePaymentsandRoyaltiesonFutureSalesunderAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Potential Milestone Payments and Royalties on Future Sales under Agreement",
        "label": "Potential Milestone Payments and Royalties on Future Sales under Agreement",
        "terseLabel": "Potential milestone payments and royalties on future sales"
       }
      }
     },
     "localname": "PotentialMilestonePaymentsandRoyaltiesonFutureSalesunderAgreement",
     "nsuri": "http://macrogenics.com/20181231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsRocheDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_PotentialRegulatoryMilestonePaymentsUnderAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total potential regulatory milestones company could earn under agreement",
        "label": "Potential Regulatory Milestone Payments Under Agreement",
        "terseLabel": "Potential regulatory milestone payments under agreement"
       }
      }
     },
     "localname": "PotentialRegulatoryMilestonePaymentsUnderAgreement",
     "nsuri": "http://macrogenics.com/20181231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsServierDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_PotentialSalesMilestonePaymentsUnderAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total potential sales milestones company could earn under agreement",
        "label": "Potential Sales Milestone Payments Under Agreement",
        "verboseLabel": "Potential sales milestone payments under agreement"
       }
      }
     },
     "localname": "PotentialSalesMilestonePaymentsUnderAgreement",
     "nsuri": "http://macrogenics.com/20181231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsServierDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_ProceedsfromRoyaltiesPercent": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Proceeds from Royalties, Percent",
        "label": "Proceeds from Royalties, Percent",
        "terseLabel": "Potential proceeds from royalties percent"
       }
      }
     },
     "localname": "ProceedsfromRoyaltiesPercent",
     "nsuri": "http://macrogenics.com/20181231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases": {
     "auth_ref": [],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Proceeds from Stock Options Exercised And ESPP Purchases",
        "label": "Proceeds from Stock Options Exercised And ESPP Purchases",
        "terseLabel": "Proceeds from stock option exercises and ESPP purchases"
       }
      }
     },
     "localname": "ProceedsfromStockOptionsExercisedAndESPPPurchases",
     "nsuri": "http://macrogenics.com/20181231",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Property plant and equipment estimated useful life.",
        "label": "Property Plant And Equipment Estimated Useful Life Table [Text Block]",
        "terseLabel": "Estimated Useful Lives"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock",
     "nsuri": "http://macrogenics.com/20181231",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "mgnx_PropertyPlantAndEquipmentNonCashAdditions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "label": "Property, Plant and Equipment, Non-cash Additions",
        "terseLabel": "Property and equipment purchased but not yet paid"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNonCashAdditions",
     "nsuri": "http://macrogenics.com/20181231",
     "presentation": [
      "http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_ProventionBioMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Provention Bio",
        "label": "Provention Bio [Member]",
        "terseLabel": "Provention Bio, Inc. (Provention)"
       }
      }
     },
     "localname": "ProventionBioMember",
     "nsuri": "http://macrogenics.com/20181231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsProventionDetails",
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_ProventionLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Provention License Agreement",
        "label": "Provention License Agreement [Member]",
        "terseLabel": "Provention License Agreement"
       }
      }
     },
     "localname": "ProventionLicenseAgreementMember",
     "nsuri": "http://macrogenics.com/20181231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsProventionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_ProventionPRV031Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Provention PRV031",
        "label": "Provention PRV031 [Member]",
        "terseLabel": "Provention PRV031"
       }
      }
     },
     "localname": "ProventionPRV031Member",
     "nsuri": "http://macrogenics.com/20181231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsProventionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_ProventionPRV3279Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Provention PRV3279",
        "label": "Provention PRV3279 [Member]",
        "terseLabel": "Provention PRV3279"
       }
      }
     },
     "localname": "ProventionPRV3279Member",
     "nsuri": "http://macrogenics.com/20181231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsProventionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_RegisteredDirectOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Registered Direct Offering [Member]",
        "label": "Registered Direct Offering [Member]",
        "terseLabel": "Registered Direct Offering"
       }
      }
     },
     "localname": "RegisteredDirectOfferingMember",
     "nsuri": "http://macrogenics.com/20181231",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_RevenueFromCollaborativeAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue From Collaborative Agreements",
        "label": "Revenue From Collaborative Agreements [Member]",
        "terseLabel": "Revenue from collaborative agreements"
       }
      }
     },
     "localname": "RevenueFromCollaborativeAgreementsMember",
     "nsuri": "http://macrogenics.com/20181231",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesAdoptionof606Details"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_RevenueFromGovernmentAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue From Government Agreements",
        "label": "Revenue From Government Agreements [Member]",
        "terseLabel": "Revenue from government agreements"
       }
      }
     },
     "localname": "RevenueFromGovernmentAgreementsMember",
     "nsuri": "http://macrogenics.com/20181231",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_RevenuesFromLicenseAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenues From License Agreements",
        "label": "Revenues From License Agreements [Member]",
        "terseLabel": "Revenues From License Agreements"
       }
      }
     },
     "localname": "RevenuesFromLicenseAgreementsMember",
     "nsuri": "http://macrogenics.com/20181231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenBiotechIncDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsProventionDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsServierDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule Of Share Based Compensation Stock Options And Restricted Stock Units Activity Table [Text Block]",
        "label": "Schedule Of Share Based Compensation Stock Options And Restricted Stock Units Activity Table [Text Block]",
        "terseLabel": "Schedule of Stock Option and Restricted Stock Unit Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://macrogenics.com/20181231",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "mgnx_ServierAgreementMGD007OptionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Servier Agreement - MGD007 Option",
        "label": "Servier Agreement - MGD007 Option [Member]",
        "terseLabel": "Servier Agreement - MGD007 Option"
       }
      }
     },
     "localname": "ServierAgreementMGD007OptionMember",
     "nsuri": "http://macrogenics.com/20181231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsServierDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_ServierDARTMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents agreement with Servier for DARTs",
        "label": "Servier DART [Member]",
        "terseLabel": "Servier DART"
       }
      }
     },
     "localname": "ServierDARTMember",
     "nsuri": "http://macrogenics.com/20181231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsServierDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_ServierMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Counterparty in collaboration agreement",
        "label": "Servier [Member]",
        "terseLabel": "Servier"
       }
      }
     },
     "localname": "ServierMember",
     "nsuri": "http://macrogenics.com/20181231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsServierDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award number of shares authorized after increase.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized After Increase",
        "terseLabel": "Increased number of shares authorized (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease",
     "nsuri": "http://macrogenics.com/20181231",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "mgnx_StockIncentivePlan2013Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock Incentive Plan 2013 [Member]",
        "label": "Stock Incentive Plan 2013 [Member]",
        "terseLabel": "Stock Incentive Plan 2013"
       }
      }
     },
     "localname": "StockIncentivePlan2013Member",
     "nsuri": "http://macrogenics.com/20181231",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_StockIssuedDuringPeriodSharesStockPlanActivity": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares issued due to stock plan related activity.",
        "label": "Stock Issued During Period Shares Stock Plan Activity",
        "terseLabel": "Stock plan related activity (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockPlanActivity",
     "nsuri": "http://macrogenics.com/20181231",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "mgnx_StockIssuedDuringPeriodValueStockPlanActivity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of shares issued due to stock plan related activity.",
        "label": "Stock Issued During Period Value Stock Plan Activity",
        "terseLabel": "Stock plan related activity"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockPlanActivity",
     "nsuri": "http://macrogenics.com/20181231",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_TaxYear2025To2037Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tax Year 2025 To 2037",
        "label": "Tax Year 2025 To 2037 [Member]",
        "terseLabel": "Tax Year 2025 To 2037"
       }
      }
     },
     "localname": "TaxYear2025To2037Member",
     "nsuri": "http://macrogenics.com/20181231",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_TotalPotentialValueUnderAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Refers to total potential value under agreement.",
        "label": "Total potential value of agreement",
        "terseLabel": "Total potential value"
       }
      }
     },
     "localname": "TotalPotentialValueUnderAgreement",
     "nsuri": "http://macrogenics.com/20181231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two Thousand Sixteen Employee Stock Purchase Plan [Member]",
        "label": "Two Thousand Sixteen Employee Stock Purchase Plan [Member]",
        "terseLabel": "2017 Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "TwoThousandSixteenEmployeeStockPurchasePlanMember",
     "nsuri": "http://macrogenics.com/20181231",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationEmployeeStockPurchasePlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_UndesignatedPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Undesignated Preferred Stock [Member]",
        "label": "Undesignated Preferred Stock [Member]",
        "terseLabel": "Undesignated Preferred Stock"
       }
      }
     },
     "localname": "UndesignatedPreferredStockMember",
     "nsuri": "http://macrogenics.com/20181231",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_UpfrontPaymentRecognitionPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Refers to upfront payment recognition period.",
        "label": "Upfront Payment Recognition Period",
        "terseLabel": "Expected period of development"
       }
      }
     },
     "localname": "UpfrontPaymentRecognitionPeriod",
     "nsuri": "http://macrogenics.com/20181231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsRocheDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "mgnx_WarrantsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Warrants, Fair Value Disclosure",
        "label": "Warrants, Fair Value Disclosure",
        "terseLabel": "Common stock warrants"
       }
      }
     },
     "localname": "WarrantsFairValueDisclosure",
     "nsuri": "http://macrogenics.com/20181231",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_ZaiLabLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Zai Lab Limited",
        "label": "Zai Lab Limited [Member]",
        "terseLabel": "Zai Lab Limited (Zai Lab)"
       }
      }
     },
     "localname": "ZaiLabLimitedMember",
     "nsuri": "http://macrogenics.com/20181231",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofAccountsReceivableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_ZaiLabsCollaborationAndLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Zai Labs Collaboration And License Agreement",
        "label": "Zai Labs Collaboration And License Agreement [Member]",
        "terseLabel": "Zai Lab Agreement"
       }
      }
     },
     "localname": "ZaiLabsCollaborationAndLicenseAgreementMember",
     "nsuri": "http://macrogenics.com/20181231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_ZaiLabsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Zai Labs",
        "label": "Zai Labs [Member]",
        "terseLabel": "Zai Lab"
       }
      }
     },
     "localname": "ZaiLabsMember",
     "nsuri": "http://macrogenics.com/20181231",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r40",
      "r78"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenBiotechIncDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsProventionDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsRocheDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsServierDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r118",
      "r169",
      "r173"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofAccountsReceivableDetails",
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsServierDetails",
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails",
      "http://macrogenics.com/role/StockbasedCompensationOptionPricingAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails",
      "http://macrogenics.com/role/IncomeTaxesReconciliationoftheBeginningandEndingAmountofGrossUnrecognizedTaxBenefitsDetails",
      "http://macrogenics.com/role/StockbasedCompensationOptionPricingAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofAccountsReceivableDetails",
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r117",
      "r169",
      "r172",
      "r305"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenBiotechIncDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsProventionDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsServierDetails",
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesAdoptionof606Details"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenBiotechIncDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsProventionDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsServierDetails",
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesAdoptionof606Details"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Range [Axis]",
        "terseLabel": "Range [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsServierDetails",
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails",
      "http://macrogenics.com/role/IncomeTaxesReconciliationoftheBeginningandEndingAmountofGrossUnrecognizedTaxBenefitsDetails",
      "http://macrogenics.com/role/StockbasedCompensationOptionPricingAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Range [Domain]",
        "terseLabel": "Range"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsServierDetails",
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails",
      "http://macrogenics.com/role/IncomeTaxesReconciliationoftheBeginningandEndingAmountofGrossUnrecognizedTaxBenefitsDetails",
      "http://macrogenics.com/role/StockbasedCompensationOptionPricingAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenBiotechIncDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsProventionDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsRocheDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsServierDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RestatementAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Restatement [Axis]",
        "terseLabel": "Restatement [Axis]"
       }
      }
     },
     "localname": "RestatementAxis",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RestatementDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Restatement [Domain]",
        "terseLabel": "Restatement [Domain]"
       }
      }
     },
     "localname": "RestatementDomain",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdate201409Member": {
     "auth_ref": [
      "r175"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accounting Standards Update 2014-09 Revenue from Contracts with Customers (Topic 606).",
        "label": "Accounting Standards Update 2014-09 [Member]",
        "terseLabel": "Accounting Standards Update 2014-09"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201409Member",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesAdoptionof606Details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofAccountsReceivableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r18",
      "r170"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.",
        "label": "Accounts Receivable, Net, Current",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r28",
      "r139"
     ],
     "calculation": {
      "http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r41",
      "r43",
      "r44",
      "r45"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated unrealized gain (loss), after tax, on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Accumulated Other Comprehensive Income (Loss), Debt Securities, Available-for-sale, Adjustment, after Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r42",
      "r45",
      "r46",
      "r255"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r19"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r81"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by new accounting pronouncement.",
        "label": "Adjustments for New Accounting Pronouncements [Axis]",
        "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesAdoptionof606Details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r181",
      "r182",
      "r210",
      "r211"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) from recognition of equity-based compensation.",
        "label": "Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash provided by (used in) operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r182",
      "r204",
      "r209"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.",
        "label": "Allocated Share-based Compensation Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivable": {
     "auth_ref": [
      "r38",
      "r122"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For an unclassified balance sheet, a valuation allowance for receivables due a company that are expected to be uncollectible.",
        "label": "Allowance for Doubtful Accounts Receivable",
        "terseLabel": "Allowance recorded"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r89"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Anti-dilutive stock options"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromtheCalculationofDilutedLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r89"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromtheCalculationofDilutedLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromtheCalculationofDilutedLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r89"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromtheCalculationofDilutedLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This item is to be populated with the collective of (i) types (categories) of arrangements of the entity applicable to its revenue-generating activities or operations and non-arrangement transactions, including but not limited to, for instance, sales of product manufactured by the entity, if such comparison of arrangements as a component of all transactions is provided by the entity.",
        "label": "Arrangements and Non-arrangement Transactions [Domain]",
        "terseLabel": "Arrangements and Non-arrangement Transactions [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsProventionDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsServierDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r115",
      "r287",
      "r298"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r3",
      "r5",
      "r39"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r258"
     ],
     "calculation": {
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total assets measured at fair value"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets [Abstract]"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsHeldForSaleNotPartOfDisposalGroup": {
     "auth_ref": [
      "r135"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of assets held-for-sale that are not part of a disposal group.",
        "label": "Assets Held-for-sale, Not Part of Disposal Group",
        "terseLabel": "Assets held-for-sale"
       }
      }
     },
     "localname": "AssetsHeldForSaleNotPartOfDisposalGroup",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r130"
     ],
     "calculation": {
      "http://macrogenics.com/role/MarketableSecuritiesDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r131"
     ],
     "calculation": {
      "http://macrogenics.com/role/MarketableSecuritiesDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r128"
     ],
     "calculation": {
      "http://macrogenics.com/role/MarketableSecuritiesDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.",
        "label": "Available-for-sale Securities",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "AvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt and equity securities categorized neither as trading securities nor held-to-maturity securities and intended be sold or mature one year or operating cycle, if longer.",
        "label": "Available-for-sale Securities, Current",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r126",
      "r129"
     ],
     "calculation": {
      "http://macrogenics.com/role/MarketableSecuritiesDetails_1": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Fair Value",
        "verboseLabel": "Securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesDetails",
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.",
        "label": "Available-for-sale Securities [Table Text Block]",
        "terseLabel": "Available-For-Sale Securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation and Principles of Consolidation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member": {
     "auth_ref": [
      "r174"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Calculated under guidance for revenue recognition in effect prior to change to new guidance for revenue from contract with customer when using transition method for cumulative effect in period including initial date of application.",
        "label": "Calculated under Revenue Guidance in Effect before Topic 606 [Member]",
        "terseLabel": "Pre-Adoption"
       }
      }
     },
     "localname": "CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesAdoptionof606Details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r1",
      "r25",
      "r71"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of period",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease": {
     "auth_ref": [],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.",
        "label": "Cash and Cash Equivalents, Period Increase (Decrease)",
        "totalLabel": "Net change in cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r9",
      "r72",
      "r74",
      "r119"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash, Cash Equivalents and Marketable Securities"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]",
        "terseLabel": "Collaboration and Other Agreements [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenBiotechIncDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsProventionDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsRocheDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsServierDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r145",
      "r146"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)",
        "verboseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r17",
      "r152"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r17"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.01 par value -- 125,000,000 shares authorized, 42,353,301 and 36,859,077 shares outstanding at December 31, 2018 and December 31, 2017, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CompensationRelatedCostsPolicyTextBlock": {
     "auth_ref": [
      "r73",
      "r186"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.",
        "label": "Compensation Related Costs, Policy [Policy Text Block]",
        "terseLabel": "Stock-based Compensation"
       }
      }
     },
     "localname": "CompensationRelatedCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Components of Deferred Tax Assets [Abstract]",
        "terseLabel": "Deferred income tax assets:"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Components of Deferred Tax Liabilities [Abstract]",
        "terseLabel": "Deferred income tax liabilities:"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive Loss"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer equipment"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails",
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r105",
      "r106",
      "r266",
      "r267"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofAccountsReceivableDetails",
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r105",
      "r106",
      "r266",
      "r267",
      "r306"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofAccountsReceivableDetails",
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r105",
      "r106",
      "r266",
      "r267",
      "r306"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofAccountsReceivableDetails",
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r100",
      "r295"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Concentration Risk [Line Items]",
        "terseLabel": "Concentration Risk [Line Items]"
       }
      }
     },
     "localname": "ConcentrationRiskLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofAccountsReceivableDetails",
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r105",
      "r106",
      "r266",
      "r267"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Percentage of all significant revenue earned",
        "verboseLabel": "Percentage of significant accounts receivable"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofAccountsReceivableDetails",
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTable": {
     "auth_ref": [
      "r103",
      "r105",
      "r106",
      "r107",
      "r266",
      "r268"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Concentration Risk [Table]",
        "terseLabel": "Concentration Risk [Table]"
       }
      }
     },
     "localname": "ConcentrationRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofAccountsReceivableDetails",
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r105",
      "r106",
      "r266",
      "r267"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofAccountsReceivableDetails",
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConstructionInProgressGross": {
     "auth_ref": [
      "r138"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress, Gross",
        "terseLabel": "Construction in progress"
       }
      }
     },
     "localname": "ConstructionInProgressGross",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "auth_ref": [
      "r168"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of contract balances and changes in contract balances.",
        "label": "Contract with Customer, Asset and Liability [Table Text Block]",
        "terseLabel": "Rollforward of Contract Liabilities"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r164",
      "r165",
      "r170"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsRocheDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsServierDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails",
      "http://macrogenics.com/role/SummaryofSignficantAccountingPoliciesContractWithCustomerLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress": {
     "auth_ref": [
      "r167"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in measure of progress which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Measure of Progress",
        "terseLabel": "Increase in balance related to adoption of ASC 606"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsServierDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r164",
      "r165",
      "r170"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Deferred revenue, current"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsRocheDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsServierDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination": {
     "auth_ref": [
      "r166"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration from customer has been received or is due, from business combination.",
        "label": "Contract with Customer, Liability, Increase (Decrease) for Contract Acquired in Business Combination",
        "terseLabel": "Additions"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignficantAccountingPoliciesContractWithCustomerLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r164",
      "r165",
      "r170"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Deferred revenue, noncurrent"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsRocheDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsServierDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r171"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "negatedLabel": "Deductions",
        "negatedTerseLabel": "Revenue recognized",
        "terseLabel": "Increase in revenue recognized from ASC 606 adoption"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsServierDetails",
      "http://macrogenics.com/role/SummaryofSignficantAccountingPoliciesContractWithCustomerLiabilityDetails",
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r176",
      "r178"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate debt securities",
        "verboseLabel": "Corporate debt securities"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesDetails",
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r54"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total costs and expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "terseLabel": "Costs and expenses:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) to equity or (increase) decrease to net assets, resulting from the cumulative effect adjustment of a new accounting principle applied in the period of adoption.",
        "label": "Cumulative Effect of New Accounting Principle in Period of Adoption",
        "terseLabel": "Cumulative effect of adoption of accounting standards"
       }
      }
     },
     "localname": "CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r77",
      "r245",
      "r247"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "terseLabel": "Provision for federal or state income taxes"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r104"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofAccountsReceivableDetails",
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r13",
      "r14",
      "r235",
      "r288",
      "r296"
     ],
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Gross deferred income tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRentCredit": {
     "auth_ref": [
      "r272"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative difference between the rental payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense over the term of the leased property by the lessor or lessee, respectively.",
        "label": "Deferred Rent Credit",
        "terseLabel": "Deferred rent liability"
       }
      }
     },
     "localname": "DeferredRentCredit",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRentCreditCurrent": {
     "auth_ref": [
      "r32",
      "r273"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For a classified balance sheet, the cumulative difference as of the balance sheet date between the payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, within one year of the balance sheet date.",
        "label": "Deferred Rent Credit, Current",
        "terseLabel": "Deferred rent"
       }
      }
     },
     "localname": "DeferredRentCreditCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRentCreditNoncurrent": {
     "auth_ref": [
      "r34",
      "r273"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For a classified balance sheet, the cumulative difference between the rental income or payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, more than one year after the balance sheet date.",
        "label": "Deferred Rent Credit, Noncurrent",
        "terseLabel": "Deferred rent, net of current portion"
       }
      }
     },
     "localname": "DeferredRentCreditNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.",
        "label": "Deferred Revenue",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "DeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsRocheDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsServierDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenueCurrent": {
     "auth_ref": [
      "r8"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.",
        "label": "Deferred Revenue, Current",
        "netLabel": "Deferred revenue, current",
        "terseLabel": "Deferred revenue",
        "verboseLabel": "Deferred revenue included in current liabilities"
       }
      }
     },
     "localname": "DeferredRevenueCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsRocheDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsServierDetails",
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesAdoptionof606Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenueNoncurrent": {
     "auth_ref": [
      "r8"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.",
        "label": "Deferred Revenue, Noncurrent",
        "netLabel": "Deferred revenue, net of current portion",
        "terseLabel": "Deferred revenue included in long-term liabilities",
        "verboseLabel": "Deferred revenue, net of current portion"
       }
      }
     },
     "localname": "DeferredRevenueNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsRocheDetails",
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesAdoptionof606Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsDeferredIncome": {
     "auth_ref": [
      "r217",
      "r243",
      "r244"
     ],
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.",
        "label": "Deferred Tax Assets, Deferred Income",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "DeferredTaxAssetsDeferredIncome",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r236"
     ],
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Gross deferred income tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r239"
     ],
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net deferred income tax asset/(liability)"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r237"
     ],
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Net deferred income tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic": {
     "auth_ref": [
      "r216",
      "r243",
      "r244"
     ],
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Domestic",
        "terseLabel": "Federal U.S. net operating loss carryforward"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal": {
     "auth_ref": [
      "r216",
      "r243",
      "r244"
     ],
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, State and Local",
        "terseLabel": "State net operating loss carryforward"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r217",
      "r243",
      "r244"
     ],
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment": {
     "auth_ref": [],
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Assets, Property, Plant and Equipment",
        "terseLabel": "Depreciation"
       }
      }
     },
     "localname": "DeferredTaxAssetsPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther": {
     "auth_ref": [
      "r241",
      "r243",
      "r244"
     ],
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible tax credit carryforwards, classified as other.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Other",
        "terseLabel": "Orphan drug credit, net"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsOther",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "auth_ref": [
      "r241",
      "r243",
      "r244"
     ],
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "terseLabel": "Research and development credit, net"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent": {
     "auth_ref": [
      "r216",
      "r243",
      "r244"
     ],
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred rent.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Deferred Rent",
        "terseLabel": "Deferred rent"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r238"
     ],
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPrepaidExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred tax consequences attributable to taxable temporary differences derived from prepaid expenses.",
        "label": "Deferred Tax Liabilities, Prepaid Expenses",
        "negatedLabel": "Prepaid expenditures"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPrepaidExpenses",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "auth_ref": [
      "r217",
      "r243",
      "r244"
     ],
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "negatedLabel": "Depreciation"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan.",
        "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount",
        "terseLabel": "Defined contribution plan, employer discretionary contribution amount"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/EmployeeBenefitPlanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.",
        "label": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent",
        "terseLabel": "Percentage of employee contribution to salary"
       }
      }
     },
     "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/EmployeeBenefitPlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r69",
      "r137"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r69",
      "r113"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization expense"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member": {
     "auth_ref": [
      "r174"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Effect in current period from application of guidance for revenue from contract with customer compared with guidance for revenue recognition applicable prior to change when using transition method for cumulative effect in period including initial date of application.",
        "label": "Difference between Revenue Guidance in Effect before and after Topic 606 [Member]",
        "terseLabel": "Effect of Change Higher/(Lower)"
       }
      }
     },
     "localname": "DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesAdoptionof606Details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r162",
      "r212"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.",
        "label": "Disclosure of Compensation Related Costs, Share-based Payments [Text Block]",
        "terseLabel": "Stock-based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Disclosure of Compensation Related Costs, Share-based Payments [Abstract]",
        "terseLabel": "Disclosure of Compensation Related Costs, Share-based Payments [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "U.S. Federal Government"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r52",
      "r82",
      "r85",
      "r86",
      "r87",
      "r88",
      "r92",
      "r293",
      "r304"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "verboseLabel": "Net income (loss) per share, basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/QuarterlyFinancialInformationUnauditedDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r87"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic and Diluted",
        "terseLabel": "Net loss per share, basic and diluted (in usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/QuarterlyFinancialInformationUnauditedDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r52",
      "r82",
      "r85",
      "r86",
      "r87",
      "r88",
      "r92",
      "r293",
      "r304"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "verboseLabel": "Net income (loss) per share, diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/QuarterlyFinancialInformationUnauditedDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r74",
      "r89",
      "r90",
      "r91"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount": {
     "auth_ref": [
      "r223"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to excess tax benefit for share-based compensation cost.",
        "label": "Effective Income Tax Rate Reconciliation, Share-based Compensation, Excess Tax Benefit, Amount",
        "terseLabel": "Previously unrecognized excess tax benefits"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]",
        "terseLabel": "Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r205"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unrecognized cost of unvested share-based compensation awards.",
        "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized",
        "terseLabel": "Unrecognized compensation cost related to non-vested stock-based compensation arrangements"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r205"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Unrecognized compensation expense recognition period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment [Member]",
        "terseLabel": "Lab equipment"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r152"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "auth_ref": [
      "r69",
      "r148"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.",
        "label": "Fair Value Adjustment of Warrants",
        "negatedLabel": "Fair Value Adjustment of Warrants"
       }
      }
     },
     "localname": "FairValueAdjustmentOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsProventionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r257",
      "r258",
      "r259",
      "r260",
      "r262",
      "r263"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.",
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "auth_ref": [
      "r257",
      "r258",
      "r259",
      "r260",
      "r262",
      "r263"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.",
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]",
        "terseLabel": "Summary of Fair Value Measurement Financial Assets"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r261",
      "r263"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Asset Class [Domain]",
        "terseLabel": "Asset Class [Domain]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r258",
      "r263"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Asset Class [Axis]",
        "terseLabel": "Asset Class [Axis]"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r176",
      "r177",
      "r178",
      "r259",
      "r280"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r176",
      "r177",
      "r178",
      "r259",
      "r281"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Quoted Prices in Active Markets for Identical Assets, Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r176",
      "r177",
      "r178",
      "r259",
      "r282"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Significant Other Observable Inputs, Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r176",
      "r177",
      "r178",
      "r259",
      "r283"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Significant Unobservable Inputs, Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r74",
      "r264",
      "r265"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r53"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleCarryingValueOfAsset": {
     "auth_ref": [
      "r136",
      "r141"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The carrying amount on the books of the entity of the impaired asset to be disposed of by a method other than sale.",
        "label": "Impaired Assets to be Disposed of by Method Other than Sale, Carrying Value of Asset",
        "terseLabel": "Impaired assets"
       }
      }
     },
     "localname": "ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleCarryingValueOfAsset",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r74",
      "r134",
      "r143"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income (loss) from continuing operations per each basic and diluted share of common stock or unit when the per share amount is the same for both basic and diluted shares.",
        "label": "Income (Loss) from Continuing Operations, Per Basic and Diluted Share",
        "terseLabel": "Basic and diluted net loss per common share (in usd per share)"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerBasicAndDilutedShare",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesAdoptionof606Details"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r142"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r250"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExaminationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Tax Examination [Line Items]",
        "terseLabel": "Income Tax Examination [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxExaminationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesReconciliationoftheBeginningandEndingAmountofGrossUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxExaminationTable": {
     "auth_ref": [
      "r227",
      "r246"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A summary of income tax examinations that an enterprise is currently subject to or that have been completed in the current period typically including a description of the examination, the jurisdiction conducting the examination, the tax year(s) under examination, the likelihood of an unfavorable settlement, the range of possible losses, the liability recorded, the Increase or Decrease in the liability from the prior period, and any penalties and interest that have been incurred or accrued.",
        "label": "Income Tax Examination [Table]",
        "terseLabel": "Income Tax Examination [Table]"
       }
      }
     },
     "localname": "IncomeTaxExaminationTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesReconciliationoftheBeginningandEndingAmountofGrossUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r77",
      "r114",
      "r248"
     ],
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "totalLabel": "Income tax expense/(benefit)"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r74",
      "r221",
      "r222",
      "r233",
      "r234",
      "r240",
      "r249",
      "r308"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r220",
      "r223",
      "r224"
     ],
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate": {
     "auth_ref": [
      "r219",
      "r223",
      "r224"
     ],
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount",
        "terseLabel": "Deferred federal rate change reduction in corporate rate"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInEnactedTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r76",
      "r223",
      "r224"
     ],
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "terseLabel": "United States federal tax at statutory rate"
       }
      }
     },
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "auth_ref": [
      "r223",
      "r224"
     ],
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible equity-based compensation costs.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Compensation Cost, Amount",
        "terseLabel": "Equity-based compensation"
       }
      }
     },
     "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationOtherReconcilingItems": {
     "auth_ref": [
      "r223",
      "r224"
     ],
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority noncontrolling interest income (loss), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, increase (decrease) in enacted tax rate, prior year income taxes, increase (decrease) in deferred tax asset valuation allowance, and other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount",
        "terseLabel": "Other permanent items"
       }
      }
     },
     "localname": "IncomeTaxReconciliationOtherReconcilingItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r76",
      "r223",
      "r224"
     ],
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount",
        "terseLabel": "State taxes (net of federal benefit)"
       }
      }
     },
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationTaxCreditsOther": {
     "auth_ref": [
      "r223",
      "r224"
     ],
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other tax credits.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Other, Amount",
        "negatedLabel": "Orphan drug credit, net"
       }
      }
     },
     "localname": "IncomeTaxReconciliationTaxCreditsOther",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": {
     "auth_ref": [
      "r223",
      "r224"
     ],
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount",
        "negatedLabel": "Research credit, net"
       }
      }
     },
     "localname": "IncomeTaxReconciliationTaxCreditsResearch",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedTerseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r68"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredRevenue": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.",
        "label": "Increase (Decrease) in Deferred Revenue",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherCurrentLiabilities": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in current liabilities classified as other.",
        "label": "Increase (Decrease) in Other Current Liabilities",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherCurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.",
        "label": "Increase (Decrease) in Prepaid Expense",
        "negatedLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis": {
     "auth_ref": [
      "r174"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information about effect of transition method for cumulative effect in initial period of application.",
        "label": "Initial Application Period Cumulative Effect Transition [Axis]",
        "terseLabel": "Initial Application Period Cumulative Effect Transition [Axis]"
       }
      }
     },
     "localname": "InitialApplicationPeriodCumulativeEffectTransitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesAdoptionof606Details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Effect of transition method for cumulative effect in initial period of application.",
        "label": "Initial Application Period Cumulative Effect Transition [Domain]",
        "terseLabel": "Initial Application Period Cumulative Effect Transition [Domain]"
       }
      }
     },
     "localname": "InitialApplicationPeriodCumulativeEffectTransitionDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesAdoptionof606Details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InterestIncomeOther": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of interest income earned from interest bearing assets classified as other.",
        "label": "Interest Income, Other",
        "terseLabel": "Interest Income, Other"
       }
      }
     },
     "localname": "InterestIncomeOther",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesAvailableForSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r132",
      "r285",
      "r294",
      "r307"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for  investments in certain debt and equity securities.",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "terseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecurities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r138"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails",
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r23",
      "r289",
      "r300"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r176"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Cash flows from financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations",
        "totalLabel": "Net cash provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Cash flows from investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations": {
     "auth_ref": [
      "r66",
      "r67",
      "r70"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations",
        "totalLabel": "Net cash provided by (used in) operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]",
        "terseLabel": "Operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r47",
      "r49",
      "r51",
      "r70",
      "r90",
      "r292",
      "r303"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      },
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://macrogenics.com/role/QuarterlyFinancialInformationUnauditedDetails",
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesAdoptionof606Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Issued Accounting Standards"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "Non-cash operating and investing activities:"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDue": {
     "auth_ref": [
      "r271",
      "r275"
     ],
     "calculation": {
      "http://macrogenics.com/role/CommitmentsandContingenciesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.",
        "label": "Operating Leases, Future Minimum Payments Due",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Future minimum rental payments required under all non-cancelable operating leases [Abstract]"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent": {
     "auth_ref": [
      "r271",
      "r275"
     ],
     "calculation": {
      "http://macrogenics.com/role/CommitmentsandContingenciesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments Due, Next Twelve Months",
        "terseLabel": "2019"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals": {
     "auth_ref": [
      "r276"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contractually required future rental payments receivable on noncancelable subleasing arrangements.",
        "label": "Operating Leases, Future Minimum Payments Due, Future Minimum Sublease Rentals",
        "verboseLabel": "Future sublease payments to be received"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears": {
     "auth_ref": [
      "r271",
      "r275"
     ],
     "calculation": {
      "http://macrogenics.com/role/CommitmentsandContingenciesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Five Years",
        "verboseLabel": "2023"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInFiveYears",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears": {
     "auth_ref": [
      "r271",
      "r275"
     ],
     "calculation": {
      "http://macrogenics.com/role/CommitmentsandContingenciesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Four Years",
        "verboseLabel": "2022"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInFourYears",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears": {
     "auth_ref": [
      "r271",
      "r275"
     ],
     "calculation": {
      "http://macrogenics.com/role/CommitmentsandContingenciesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Three Years",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInThreeYears",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears": {
     "auth_ref": [
      "r271",
      "r275"
     ],
     "calculation": {
      "http://macrogenics.com/role/CommitmentsandContingenciesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Two Years",
        "terseLabel": "2020"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInTwoYears",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter": {
     "auth_ref": [
      "r271",
      "r275"
     ],
     "calculation": {
      "http://macrogenics.com/role/CommitmentsandContingenciesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due Thereafter",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueThereafter",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock": {
     "auth_ref": [
      "r147",
      "r269",
      "r270",
      "r274",
      "r277"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure for lessee's operating leases. Includes, but is not limited to, description of lessee's operating lease, existence and terms of renewal or purchase options and escalation clauses, restrictions imposed by lease, such as those concerning dividends, additional debt, and further leasing, rent holidays, rent concessions, or leasehold improvement incentives and unusual provisions or conditions.",
        "label": "Lessee, Operating Lease, Disclosure [Table Text Block]",
        "terseLabel": "Schedule of Minimum Future Lease Payments"
       }
      }
     },
     "localname": "OperatingLeasesOfLesseeDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CommitmentsandContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OperatingLeasesRentExpenseNet": {
     "auth_ref": [
      "r274"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.",
        "label": "Operating Leases, Rent Expense, Net",
        "terseLabel": "Rent expense"
       }
      }
     },
     "localname": "OperatingLeasesRentExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Loss Carryforwards [Line Items]",
        "terseLabel": "Operating Loss Carryforwards [Line Items]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "auth_ref": [
      "r242"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Operating Loss Carryforwards [Table]",
        "terseLabel": "Operating Loss Carryforwards [Table]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r0",
      "r256"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Organization and Nature of Operations"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/OrganizationandNatureofOperations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssets": {
     "auth_ref": [
      "r12",
      "r286",
      "r297"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of assets classified as other.",
        "label": "Other Assets",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities. Excludes amounts related to other than temporary impairment (OTTI) loss.",
        "label": "Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, after Tax",
        "terseLabel": "Unrealized loss on investments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r48",
      "r50",
      "r252",
      "r253",
      "r254"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "terseLabel": "Other comprehensive loss:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r32"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount by which the fair value of an investment in debt and equity securities categorized as Available-for-sale is less than the amortized cost basis or carrying amount of that investment at the balance sheet date and the decline in fair value is deemed to be other than temporary, before considering whether or not such amount is recognized in earnings or other comprehensive income.",
        "label": "Other than Temporary Impairment Losses, Investments, Available-for-sale Securities",
        "terseLabel": "Available-for-sale securities, other than temporary impairment losses"
       }
      }
     },
     "localname": "OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesAvailableForSaleSecuritiesDetails",
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Over-Allotment Option [Member]",
        "terseLabel": "Over-Allotment Option"
       }
      }
     },
     "localname": "OverAllotmentOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails",
      "http://macrogenics.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsForProceedsFromTenantAllowance": {
     "auth_ref": [
      "r60",
      "r63"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Net cash outflow or inflow from monetary allowance granted by the landlord to a tenant to entice tenant to move into landlords building which will enable the tenant to prepare the leased premises for tenants occupancy.",
        "label": "Payments for (Proceeds from) Tenant Allowance",
        "negatedTerseLabel": "Lease incentives"
       }
      }
     },
     "localname": "PaymentsForProceedsFromTenantAllowance",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r65",
      "r180"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy an employee's income tax withholding obligation as part of a net-share settlement of a share-based award.",
        "label": "Payments Related to Tax Withholding for Share-based Compensation",
        "negatedLabel": "Purchase of treasury stock"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r58",
      "r61",
      "r127"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments to Acquire Debt Securities, Available-for-sale",
        "negatedTerseLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property, equipment and software"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r179"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for pension and other postretirement benefits.",
        "label": "Pension and Other Postretirement Benefits Disclosure [Text Block]",
        "terseLabel": "Employee Benefit Plan"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/EmployeeBenefitPlan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r183",
      "r206"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by plan name pertaining to equity-based compensation arrangements.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationEmployeeStockPurchasePlanDetails",
      "http://macrogenics.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the equity-based compensation arrangement plan.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationEmployeeStockPurchasePlanDetails",
      "http://macrogenics.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Undesignated preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Undesignated preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Undesignated preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Undesignated preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "auth_ref": [
      "r2",
      "r4",
      "r133"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense, Current",
        "terseLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "PrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock, net of offering costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://macrogenics.com/role/StockbasedCompensationEmployeeStockPurchasePlanDetails",
      "http://macrogenics.com/role/StockholdersEquityDetails",
      "http://macrogenics.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r58",
      "r59",
      "r127"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-sale",
        "terseLabel": "Proceeds from sales and maturities of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r64",
      "r207"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of stock options granted under share-based compensation arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Cash proceeds from exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r28",
      "r140"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Property, Plant and Equipment, Type [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails",
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r144"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property, Equipment and Software"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/PropertyEquipmentandSoftware"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r27",
      "r138"
     ],
     "calculation": {
      "http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property, equipment and software"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails",
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r10",
      "r11",
      "r140",
      "r302"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property, equipment and software, net",
        "totalLabel": "Property, equipment and software, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r26",
      "r74",
      "r140"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property, Equipment and Software"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r10",
      "r140"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/PropertyEquipmentandSoftwareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r10",
      "r138"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Property, Plant and Equipment, Type [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails",
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Estimated useful lives"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_QuarterlyFinancialInformationDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Quarterly Financial Information Disclosure [Abstract]"
       }
      }
     },
     "localname": "QuarterlyFinancialInformationDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_QuarterlyFinancialInformationTextBlock": {
     "auth_ref": [
      "r97"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.",
        "label": "Quarterly Financial Information [Text Block]",
        "terseLabel": "Quarterly Financial Information (Unaudited)"
       }
      }
     },
     "localname": "QuarterlyFinancialInformationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/QuarterlyFinancialInformationUnaudited"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]",
        "terseLabel": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]"
       }
      }
     },
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesReconciliationoftheBeginningandEndingAmountofGrossUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "auth_ref": [
      "r214",
      "r215"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by form of arrangement related to research and development.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenBiotechIncDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsProventionDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "auth_ref": [
      "r214",
      "r215"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenBiotechIncDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsProventionDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r213",
      "r309"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r74",
      "r213"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Costs"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r20",
      "r159",
      "r299"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesAdoptionof606Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue, Initial Application Period Cumulative Effect Transition [Line Items]",
        "terseLabel": "Revenue, Initial Application Period Cumulative Effect Transition [Line Items]"
       }
      }
     },
     "localname": "RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesAdoptionof606Details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information when using transition method for cumulative effect in initial period of application for revenue from contract with customer.",
        "label": "Revenue, Initial Application Period Cumulative Effect Transition [Table]",
        "terseLabel": "Revenue, Initial Application Period Cumulative Effect Transition [Table]"
       }
      }
     },
     "localname": "RevenueInitialApplicationPeriodCumulativeEffectTransitionTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesAdoptionof606Details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRecognitionMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the value established as the selling price of the significant unit of accounting used to allocate the consideration of the multiple-deliverable arrangement.",
        "label": "Revenue Recognition, Multiple-deliverable Arrangements, Determination of Selling Price, Amount",
        "terseLabel": "Clinical trial activities selling price amount"
       }
      }
     },
     "localname": "RevenueRecognitionMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r73",
      "r74",
      "r75"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.",
        "label": "Revenue Recognition, Policy [Policy Text Block]",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r55",
      "r111",
      "r112",
      "r116"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Revenues",
        "verboseLabel": "Revenue"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenBiotechIncDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsProventionDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsRocheDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsServierDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails",
      "http://macrogenics.com/role/QuarterlyFinancialInformationUnauditedDetails",
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesAdoptionof606Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenues:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Proceeds of stock sale",
        "verboseLabel": "Proceeds of stock sale"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenBiotechIncDetails",
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails",
      "http://macrogenics.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Sale of common stock (in shares)",
        "verboseLabel": "Sale of common stock (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenBiotechIncDetails",
      "http://macrogenics.com/role/StockholdersEquityDetails",
      "http://macrogenics.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Sale of common stock (in dollars per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails",
      "http://macrogenics.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SalesRevenueNetMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue from sale of goods and services rendered, in the normal course of business, after sales returns and allowances, and sales discounts, when it serves as a benchmark in a concentration of risk calculation.",
        "label": "Sales Revenue, Net [Member]",
        "terseLabel": "Sales revenue, net"
       }
      }
     },
     "localname": "SalesRevenueNetMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r89"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromtheCalculationofDilutedLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r251"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of contractual arrangements that involve two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity. Additionally, the element may include all other transactions of the entity categorized collectively, if such comparison of collaborative arrangements as a component of all transactions of the entity is desired.",
        "label": "Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]",
        "terseLabel": "Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsJanssenBiotechIncDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsProventionDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsRocheDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsServierDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r239"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Components of the Company's Deferred Income Tax Assets (Liabilities)"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r223"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Reconciliation of Reported Estimated Income Tax Benefit"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r182",
      "r203",
      "r209"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule that sets forth the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.",
        "label": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]",
        "terseLabel": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r182",
      "r203",
      "r209"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.",
        "label": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]",
        "terseLabel": "Schedule of Stock-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": {
     "auth_ref": [
      "r81",
      "r83",
      "r84",
      "r93",
      "r94",
      "r96"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.",
        "label": "Schedule of New Accounting Pronouncements and Changes in Accounting Principles [Table Text Block]",
        "terseLabel": "Schedule of New Accounting Pronouncements and Changes in Accounting Principles"
       }
      }
     },
     "localname": "ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r28",
      "r140"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails",
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock": {
     "auth_ref": [
      "r95"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.",
        "label": "Quarterly Financial Information [Table Text Block]",
        "terseLabel": "Company's Consolidated Quarterly Results of Operations"
       }
      }
     },
     "localname": "ScheduleOfQuarterlyFinancialInformationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/QuarterlyFinancialInformationUnauditedTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r183",
      "r206"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of an equity-based arrangement under which compensation is awarded to employees, typically comprised of compensation expense; changes in the quantity and fair value of the shares (or other type of equity) granted, exercised, forfeited, and issued and outstanding pertaining to that plan; and cash flow effects resulting from the equity-based payment arrangement. Component disclosures are by type of award and plan name.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationEmployeeStockPurchasePlanDetails",
      "http://macrogenics.com/role/StockbasedCompensationOptionPricingAssumptionsDetails",
      "http://macrogenics.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r198"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Employee Stock Options Award Valuation Assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r35",
      "r79",
      "r149",
      "r150",
      "r151",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in net income (trading) and investment in equity security with change in fair value recognized in net income (FV-NI).",
        "label": "Debt Securities, Trading, and Equity Securities, FV-NI [Table]",
        "terseLabel": "Debt Securities, Trading, and Equity Securities, FV-NI [Table]"
       }
      }
     },
     "localname": "ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "auth_ref": [
      "r232",
      "r246"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits.",
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "terseLabel": "Reconciliation of the Beginning and Ending Amount of Gross Unrecognized Tax Benefits"
       }
      }
     },
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": {
     "auth_ref": [
      "r103",
      "r105",
      "r106",
      "r107",
      "r266",
      "r268"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]",
        "terseLabel": "Summary of Percentage of Customer Concentration"
       }
      }
     },
     "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.",
        "label": "Share-based Compensation",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r201"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationOptionPricingAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r200"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationOptionPricingAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r202"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationOptionPricingAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationEmployeeStockPurchasePlanDetails",
      "http://macrogenics.com/role/StockbasedCompensationOptionPricingAssumptionsDetails",
      "http://macrogenics.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r185"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Share-based compensation, number of shares authorized (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationEmployeeStockPurchasePlanDetails",
      "http://macrogenics.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r190"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r190"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r195"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted-Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r193"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Forfeited or expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "auth_ref": [
      "r191"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Net number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures",
        "terseLabel": "Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r194"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average grant-date fair value of options granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r206"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r189",
      "r206"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "December 31, 2017",
        "periodStartLabel": "December 31, 2016",
        "terseLabel": "Share-based compensation arrangement by share-based payment award, options, outstanding, number (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails",
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r188"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "December 31, 2017",
        "periodStartLabel": "December 31, 2016",
        "terseLabel": "Weighted average exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails",
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r196"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, Vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r197"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r197"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "auth_ref": [
      "r206"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of share instruments newly issued under a share-based compensation plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period",
        "terseLabel": "Common stock purchased by employees (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationEmployeeStockPurchasePlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Options exercised or RSUs vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Forfeited or expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r184"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Options granted, maximum term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationOptionPricingAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r199",
      "r208"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "verboseLabel": "Expected term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationOptionPricingAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r206"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r206"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-average remaining contractual term, Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r197"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-average remaining contractual term, Outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r197"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-average remaining contractual term, Vested and expected to vest"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "auth_ref": [
      "r187"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value",
        "terseLabel": "Fair value of shares vested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent",
        "terseLabel": "Percent of fair market value to purchase shares"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationEmployeeStockPurchasePlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r152"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares, Issued",
        "periodEndLabel": "Balance (in shares)",
        "periodStartLabel": "Balance (in shares)"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued, Price Per Share",
        "terseLabel": "Common stock purchase price (in dollars per share)"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r80"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use.",
        "label": "Software and Software Development Costs [Member]",
        "terseLabel": "Software"
       }
      }
     },
     "localname": "SoftwareAndSoftwareDevelopmentCostsMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails",
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r15",
      "r16",
      "r17",
      "r152"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r37",
      "r152"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r16",
      "r17",
      "r152",
      "r159"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock, net of offering costs (in shares)",
        "verboseLabel": "Number of shares issued or sold (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r16",
      "r17",
      "r152",
      "r159"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of any shares forfeited. Shares issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.",
        "label": "Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r16",
      "r17",
      "r152",
      "r159",
      "r192"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Options exercised or RSUs vested"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r16",
      "r17",
      "r152",
      "r159"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock, net of offering costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).",
        "label": "Equity Option [Member]",
        "terseLabel": "Stock options"
       }
      }
     },
     "localname": "StockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromtheCalculationofDilutedLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r17",
      "r21",
      "r22",
      "r124"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r163"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r278"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r278"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r278"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Subsequent Events [Abstract]",
        "terseLabel": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r279"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails",
      "http://macrogenics.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r241"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "US Federal tax credits carry forward"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxPeriodAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information about the period subject to enacted tax laws.",
        "label": "Tax Period [Axis]",
        "terseLabel": "Tax Period [Axis]"
       }
      }
     },
     "localname": "TaxPeriodAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxPeriodDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identified tax period.",
        "label": "Tax Period [Domain]",
        "terseLabel": "Tax Period [Domain]"
       }
      }
     },
     "localname": "TaxPeriodDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "auth_ref": [
      "r18",
      "r24",
      "r74",
      "r120",
      "r121",
      "r123",
      "r125",
      "r291",
      "r301"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for trade and other accounts receivables. This disclosure may include the basis at which such receivables are carried in the entity's statements of financial position (for example, net realizable value), how the entity determines the level of its allowance for doubtful accounts, when impairments, charge-offs or recoveries are recognized, and the entity's income recognition policies for such receivables, including its treatment of related fees and costs, its treatment of premiums, discounts or unearned income, when accrual of interest is discontinued, how the entity records payments received on nonaccrual receivables and its policy for resuming accrual of interest on such receivables.  If the enterprise holds a large number of similar loans, disclosure may include the accounting policy for the anticipation of prepayments and significant assumptions underlying prepayment estimates for amortization of premiums, discounts, and nonrefundable fees and costs.",
        "label": "Trade and Other Accounts Receivable, Policy [Policy Text Block]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r284"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockMember": {
     "auth_ref": [
      "r36",
      "r161"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Treasury Stock [Member]",
        "terseLabel": "Treasury Stock"
       }
      }
     },
     "localname": "TreasuryStockMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockRetiredParValueMethodAmount": {
     "auth_ref": [
      "r17",
      "r152",
      "r160"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of decrease of par value, additional paid in capital (APIC) and retained earnings of common and preferred stock retired from treasury when treasury stock is accounted for under the par value method.",
        "label": "Treasury Stock, Retired, Par Value Method, Amount",
        "negatedLabel": "Retirement of treasury stock"
       }
      }
     },
     "localname": "TreasuryStockRetiredParValueMethodAmount",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockSharesRetired": {
     "auth_ref": [
      "r17",
      "r152",
      "r159"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of common and preferred stock retired from treasury during the period.",
        "label": "Treasury Stock, Shares, Retired",
        "negatedTerseLabel": "Retirement of treasury stock (in shares)"
       }
      }
     },
     "localname": "TreasuryStockSharesRetired",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Adoption and early adoption of sources of change to generally accepted accounting principles (GAAP) in the United States. The FASB released the FASB Accounting Standards Codification as the authoritative source of literature effective for interim and annual periods ending after September 15, 2009. As part of the Codification process, the FASB issues Accounting Standards Updates to amend the Codification but otherwise the Accounting Standards Updates are not authoritative in their own right. All previous accounting standards (such as FASB Statements of Financial Accounting Standards, FASB Interpretations, FASB Staff Positions, Emerging Issues Task Force Consensuses, other pronouncements of the FASB or other designated bodies, or other forms of GAAP are considered accounting pronouncements) were superseded upon the adoption of the Codification. For an interim period, references to the superseded standards are included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.",
        "label": "Type of Adoption [Domain]",
        "terseLabel": "Type of Adoption [Domain]"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesAdoptionof606Details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r251"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by category of arrangement, including but not limited to collaborative arrangements and non-collaborative arrangements.",
        "label": "Type of Arrangement and Non-arrangement Transactions [Axis]",
        "terseLabel": "Type of Arrangement and Non-arrangement Transactions [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsProventionDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsServierDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember": {
     "auth_ref": [
      "r176",
      "r290"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debentures, bonds and other debt securities issued by US government sponsored entities (GSEs), for example, but not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB). Excludes debt issued by the Government National Mortgage Association (GNMA or Ginnie Mae).",
        "label": "US Government-sponsored Enterprises Debt Securities [Member]",
        "terseLabel": "Government-sponsored enterprises",
        "verboseLabel": "Government-sponsored enterprises"
       }
      }
     },
     "localname": "USGovernmentSponsoredEnterprisesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesDetails",
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r176",
      "r178",
      "r290"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "US Treasury Securities [Member]",
        "terseLabel": "U.S. Treasury securities",
        "verboseLabel": "U.S Treasury securities"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesDetails",
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrealizedGainLossOnInvestments": {
     "auth_ref": [
      "r69"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of investments, not including unrealized gains or losses on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, held at each balance sheet date and included in earnings for the period.",
        "label": "Unrealized Gain (Loss) on Investments",
        "terseLabel": "Unrealized gain on investments"
       }
      }
     },
     "localname": "UnrealizedGainLossOnInvestments",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r218",
      "r228"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesReconciliationoftheBeginningandEndingAmountofGrossUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r229"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions",
        "negatedTerseLabel": "Decreases for prior year tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesReconciliationoftheBeginningandEndingAmountofGrossUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": {
     "auth_ref": [
      "r225"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense",
        "terseLabel": "Unrecognized interest or penalties"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesReconciliationoftheBeginningandEndingAmountofGrossUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r230"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "terseLabel": "Increases for current year tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesReconciliationoftheBeginningandEndingAmountofGrossUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r229"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "terseLabel": "Increases for prior year tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesReconciliationoftheBeginningandEndingAmountofGrossUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": {
     "auth_ref": [
      "r231"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.",
        "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate",
        "terseLabel": "Gross unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesReconciliationoftheBeginningandEndingAmountofGrossUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r98",
      "r99",
      "r101",
      "r102",
      "r108",
      "r109",
      "r110"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted",
        "terseLabel": "Basic and diluted weighted average number of common shares"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 7
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9031-108599"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9054-108599"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "305",
   "URI": "http://asc.fasb.org/extlink&oid=6375392&loc=d3e26790-107797"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84173941&loc=SL6953423-111524"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84173941&loc=d3e5212-111524"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84173941&loc=d3e5074-111524"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84173941&loc=d3e5093-111524"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=109979856&loc=d3e26610-111562"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=109979856&loc=d3e26853-111562"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=77912953&loc=d3e400-110220"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2611-110228"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=115931803&loc=d3e12069-110248"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/subtopic&trid=2208855"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=82913815&loc=SL49130531-203044"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=82913815&loc=SL49130532-203044"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130551-203045"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130551-203045"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130551-203045"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130545-203045"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130549-203045"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130549-203045"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=108792157&loc=SL49130690-203046-203046"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=108792157&loc=SL49130690-203046-203046"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(i)(1)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=112275985&loc=d3e4179-114921"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "http://asc.fasb.org/topic&trid=2235017"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19A",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=107668666&loc=SL79513924-113897"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=79507207&loc=d3e4534-113899"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f(1))",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=SL79508275-113901"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109196918&loc=d3e11149-113907"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109196918&loc=d3e11178-113907"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=115928272&loc=d3e28680-109314"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=115928272&loc=d3e28680-109314"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84176650&loc=SL37586934-109318"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84176650&loc=d3e32059-109318"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84176650&loc=d3e32123-109318"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84176650&loc=d3e32247-109318"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84176650&loc=d3e32280-109318"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=109238393&loc=d3e36027-109320"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "30",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=65884525&loc=d3e40913-109327"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19190-110258"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=SL7498348-110258"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19279-110258"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=109250915&loc=d3e13279-108611"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=109250915&loc=d3e13531-108611"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=109250915&loc=d3e13537-108611"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=109250915&loc=d3e13537-108611"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=84164451&loc=d3e36991-112694"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(Note 1,3)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=82846649&loc=d3e38371-112697"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(Note 3)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=82846649&loc=d3e38371-112697"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=77902458&loc=d3e39896-112707"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=77902458&loc=d3e39927-112707"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=77902758&loc=d3e41499-112717"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=d3e107207-111719"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=d3e107207-111719"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=d3e107207-111719"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=d3e107207-111719"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=68078379&loc=d3e122625-111746"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "http://asc.fasb.org/subtopic&trid=2176304"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6)(a)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(9))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/subtopic&trid=2209399"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(10))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=99384497&loc=SL65671331-158438"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "http://asc.fasb.org/subtopic&trid=2324412"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "740",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.26(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6787-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669646-108580"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669646-108580"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=d3e637-108580"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=d3e681-108580"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669686-108580"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL34724394-108580"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6801-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3151-108585"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3179-108585"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6904-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3179-108585"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3213-108585"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3213-108585"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3213-108585"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3255-108585"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3291-108585"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3521-108585"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3536-108585"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6911-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3044-108585"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4273-108586"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18726-107790"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(d),(e))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6935-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22580-107794"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=d3e1252-109256"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=SL5780133-109256"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=d3e1337-109256"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109256448&loc=d3e4984-109258"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=109236672&loc=d3e725-108305"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=109236672&loc=d3e765-108305"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=109225645&loc=d3e1280-108306"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.10-01.(b)(6))",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=27015980&loc=d3e46468-122699"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "270",
   "URI": "http://asc.fasb.org/topic&trid=2126967"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  }
 },
 "version": "2.0"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>85
<FILENAME>0001125345-19-000046-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001125345-19-000046-xbrl.zip
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M#Z[M_+MK.R^P^5$@=RIV1"P04 8?@\]W=#3#+4TCZ)?FY\95GS-^IAUEW+@
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ML8Z//$!!_KKL?QX>ONIWCUUO"8[;@*-U&1Q<>K FZ6;P)&ML9YO.^=1DW.I
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M:;9)Y6UP<^W4NPA)$KD-.JB4-Z]Q8S@S-J=!4T<"9TLB_XQ@>JC*^/.'3_#
MK4 'R@ 1QFGTCR+Q7.G@G;8@:N ]U4I&S"< "=0ZGIA4) D%S@;@T6HTHBR'
M).O@(B^>C%A0XV5.>UF%I"$PX043,H'EWG ?T/_4(1FB:^"6+@&VR*X@ES)
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MP^'DSIM5Y>71(*Y<+<4<O"8&O(\$?75EN7$RF,02:C&@($Q5;M\0Q>P*"M&
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MC2Y#9[;+(O^<U14=[;PU;.6$$9!(201X$C++$OU@N)ODHI$.HR/=UO-"O^_
M5 J=C.DSAWW:S_Z_NK-',51IGI,*I!7J\%S5B.1 7@8R^GN!/ N^/>MR=",K
MBIB.8YC/*$ RYT"$\/Q +G#.K<H\4 AI.3%^]>$OOB"6ASEI)H\Q/^2HCK(+
M6J":1\T&\2K_K"NS+,8<FQ#/%N&_@@5!?3HWAY@.6[?$\HZ0RN_H#^V9:(+S
MLBTNVRBVW:=S!W22N3%LH&S&W:+ET*.EJNS#C+,8RZ:,!6K15=[ E\<,'&^#
MN*/[VQ6@A7>8]S\<\_X;EO>&@>"E='C[V7KTZ&MG:X]GGXAQCV1%1<_13="#
M5UB,UY]>O,T.]J5JZ=G/'U__].+CQUX-TXU3+O(CWO4]@ WE.)W9P4/,+$I+
M=C0O(,MH_T@60L( V"KPR9RASJQ3:8O=AU7(MA"+TT)%%5<- %Q;58+=Y)H#
MDJ*QI(X$W;VW^;BI7Q55.6Y']_CY]^ XD>2E'^]=%/C?SD#LI*'NR3OP7?_5
M['4UWN</E8R.K4B0< Z?)'MWVI:3,F_*(@K*W[X)!],'3Q]/?K.&ER5/S\V-
M.Q')RF)/W"^R>3TC1_0YR88_9?S'0-CY41]N7<+'#V[N$HZR3Q]>/W_Q4URD
M;ODO&. CMI&O,,*!CKWW_N/36QIMM[R!RQF2$<NS)B>1<^\95/KJC,8U.\N>
ME:@?X=/ZIIP6>]R !";8VX+$&#T- J01OX_\O4F!E*$Z\>B&6\!"C'\0"+Q$
MW>)O1_+OK,H7EDL4YIQ,GB;U.7BKB3Z5>7@S#UUC=FJHEW@[S$YV66KFP+O!
M?LJE*E(VZ=TY%J2XN*T5+3(+\DRP8WF  -#A)",R.RWKY5E.+L>XZ"2;HHJ*
M#/]QARH#4FXH\D%HSX+R"F:74U'5Y]98;E6>UI/UGI2RX*#E2WYJB[(-NI <
M[LL6]:23@C:4=W4T_JQ<++J*?:0EO$3&)#* E>[#RH)18_@2C3A9XM"14W.6
MX\W9LEP6[-S0YP80;W1VY441\EQPR-('2"I\GT=2[]756(JWZ&&S)E^PQB#G
MDU]W6@ \C:'1A)8-^9)-B1J9EL&V J>@7Q?<JJN_*L7X3.O"R,%<P=NCFWGU
MLW5C3I([ P,++IXZW8-B%2J65MVB;O9<<@Y+,RLJ7T^5_?CBP^'P%D_)GR9_
M6.OKSH!S&=[I/JS=C^79X[T?CT;TM$5-KF@W+S*M WWV.),5P=/#<50TM.0R
M2E1:\0-07D6>5,'!-ZO&(5\\SZH.P5(\0VIY<'1YWMEJO50!BUHH$!'1QQ%?
M;6H9A07 N=2HV+@2=''"0O*CW(WXQ#5?V)6J=@LG$.[T*F9TZ>&B3YC#$)N@
MZ6R>&*\\RXEY6_LM'EQ^6\-TB?7&+% H4<SG])1\=68KF!UD.^^?[QWL8M"T
MBO9K^F>Y@%[)!6?&J*:0$; @D*Y)NR;EMD!([^#Q#VVR1+(B4JJPJ*MZ/.=\
MKU["TH9:5LQ-DV$H[DZ'!=-BSI_W/Z(6M)X([6/3S;+CR8).%\=7,;"=E\^/
M=X?%%1V%HL%VR9@0'9*R8T@(?G%84BY_-?PNII%7/.0]_MCF/-8RBXM"U^"<
M:TWVR,H !)R%;,[EM!76XF)X2U<7-4E_BQ"QZ;OU)A?5#,J"AX.E>'/\:@_7
MB*X!MIC^&_YT\NG-\=Z#_6R+$WDYA<$MTZA\<DP1#)=(:%UG+4<Z%B!N4PMT
M1']SK=[#)VPGIXMU,Y3&38F_8S3#\?>7X^S=$@4S L +VIGNSUDY/D/TG3>7
M7J6EH]FB6X7\)ETY;# ]Y4;,\=Y_3&JD$#B\/"A!./HQD9A#L,C<7\E]$-);
MR?6JZ)5L!.*[=.];J5$XXW U9O^YG,^UX$B$GGSLMT.Z[T[T[SC1;[LYJ9 @
MX(.Y:2>ZD-+P3NM38:!O*$J6<-A:!^PX+2M6,5 @.ZJKQ[D8!ESSG2J5&[%"
MY&MORN9=^,IDFQ5P<,CP&IL-T_ZN).C=H?T=A_;8)- $UM:XKG[I9K17-V+$
M=(AVCI^?[&Y>I0NU!8(%QG7["23-[+'6ZFCQ/7K%Y\OLU"1_I_;U>+VJ5_67
M4NK*O9R-)5O>W28O:#;3CZ@Q'BYM^.YFB.;FQ6%@-CLW_[5XZN_,4W^O]_LD
MW.\_Q?B\&1<9H;R5,'N0/7]!^[HLQRM-96BV&YG:KMT2$0E'Q3O,ZAV$1A7P
M:\(!;PJI%Z931+]NZT7AJP"91>YKIFN?)[E<S+*V&?_[O<6L^K)W>/_@R<'A
MT<'_G1WL_[*<W:-7K;;]*<UN'CY^K)G-1T\><$:7GOSK!3?_YE^WMX^'MW8G
MW\WH_[U]=4*39B*7*B.I$QV)/)MT]3AO%NLQLR:MYW6N2.?QO,C/^5@L"S)F
M)P5+&*[D@K](?EHJH3ZNJ]49/?)9/PIX2<SV=BSBJ2RBR_#(^6WUI'I.#B37
M0@ Q;]MB)7&D>G%J##Z\NF]?'=\_.)2@?>U*<C@ 63<6J9C-ZU/$4>U6I90?
M6=LM@:"4XFOZN#QU'[F^]<I$M]Y1VOT0J*+-8_5]_X?7/YW@2_0M_L7!#]ND
M]U<DW;\<YG"I,+AF>-+!C<-=7'?"Z@HZ^2V;)-V7<I&?_H5#/7Z:*I&E+%8Q
M5'2KMP;IU*/@P/:>$:@A_(:H<!+ZMK!""._BH+6BB6?TCZ8N6HCI60'I8D%%
M/!=C&C=:#6/!2(6""FQW'9\J+][/?@[IBDM"'VK7%D@\%I)0%+!$RY%:)!KK
M2D)]._08^7E7"U#CFH&GH$*@#" ,X/^C-XF8@8;(S8B5]"<M\LOQGC78666+
M I2*9;M(0:WF+H3/X2E[BV(B.0:SEL?T.ATG*=.3W5^3<[GV(WFE9#(?,)'&
MM&-O2=O! "0G_)D<HQ--%MP05^IU=6-1#M>'8QD8S,OBM.F02"0;^*D$\ZNJ
M!G_=) N[;1QR8M2]>__CZV-A(7Q_ABMWU,N);=Q/DCKI\5G$XZ-22)W%)?TN
M$NK)J_I/IR]K.H1^"FF::=FT*TV7KDFB3)9U*9D2<D](<LY"JH<S2,(SN3=%
MHJGMFO/RG)Z\\_[EQUWA"I5A2,K%"OU$-D6KK3_-Y1SIF+-B44M&;"W)[L8<
M99IG]\]N\)/[V7M[I3''^B>3[<P,/$U9\,[DV>&#;[@<D?8&OI=6!-/XDW<N
M>P_U8\ S=W[\\._W]Q\_&F5+^N_]HR,27#_5\/S6(TE7?6$H,QF43QY^PXO7
M>R(]CL3C!1*$Y#/0^)J J3YY?O#H.".Y_;=_>_K@\0\?7K]^3;['P<,G+^'E
M%?/"PAMTB"1!M@0HN.Y:AE:G19:3DA-C9YX?S6?FDIF%\J\8\( !+!8OO<2B
ME@)T6]9+302.-J;WE5TX.OSC=N'1$]V%^P]I%QQU["K>!%GMF%&DT2_*%19I
MRFGDHD5Q%(\# ?=&9KPN<EJ*%2+U^2]PKL>E\,J.H6H5?(A,)+)'>]V2'S8I
MA&2VER%=YL(X;"=<,T\*O6<'!#6TD\&;") ''/QXX=[AOK5&@\<IOW1_DF.&
M=&Y-TH]W&"PBY/54DYA0325"646M_1R4<A_S:4%6P=NZ*D&62OK]A)Z ]2M$
MWKQ\?LR'<<;8^DGV$I+I4T-2.?A-I4#T'7=).1N6!OPIG[$-QX /M!.!],%Y
M+4&X?'*>\]EBNRO(RU1(7IS5<@;<?>'CD$@KSO"RV!4;,23JUY*&#X!X.T62
MB ^PL.R-^/+9,3F4P+5R0OK9F^/=S+)1M%R893)M/1#""*O'!A?"=(AMJ)R2
MLWP^%7U('X4*NK7,OC%PEMS5HB+M,Z>U?WCT*)X 7,9$NA[>OZ_:C78<0(YQ
M@XJYGY@*]IA\>]J 4?:B QI.Z*?;,I=#J^^AZ]1)^7)/\^;;M+37<W)B_.';
MN_3P3:RL>H*YS/D#2-C0K<=I!GI0> 'M# 9 B F.0) >KD%;K 0S!=;9-.]#
MIQVG,[QSIRKJW7SR2W<.-P$ 01&GHSB:NBK<:'[[8"2:KA=N<])U)?M1U9+J
M(:>L"O"A9"V"Q%0AN/6=SA9@O9K<ZJ)DQ99>N291*4.QI5J68,KE2MY"4;S.
MSCB'R"7-3\,=973>3CL:^2B;%0O[-=Y#VT"SG.-'4E+@L5;);"/&T7!B*2Q8
M7S\G>X9"_.0Z/+W_S=8GY9-ZSS^M6)"O2,ZFRO#+##0.E?G93^C?E50S3HS,
M".'-5C2%A.+F]%EQ*$>JUODSMH\L#'-1BKU))A;>+1)L5W)C7B%F0*?VACE^
M'F&F0A&B8YM4//RJ5$R%X4QG37=A(VCR"[E-?.Y45 Y=Q*]!K^00;QE;6Q2?
M)2UWE@,^0=?TGY(_EP,[ZIW614[S[1;Z6YSQ20TX&%\X>J'$1:P^4(048CUQ
MT/O9"U-@R15'2'?9&BOOM&&"\O4V#?)K%DVM_9:#.<Y5RS@B*N\#7Z2@0FIG
M8HF/=KF7A<4]?+AIYM?MBB4, QN#SB9C'Z(%@ZO/@$K'U(>G1L[/F&3C(H^Y
MD*/_!W:I('Z9GQ]# ;9OP-MS;E1X>]EXJ/O4(Q\YS[J'&DO:2<$\OCG8=0T4
M-#MWFX3.P%T^%B,B^\^\XA@%>4BP$84@>MRM]NKI-)/:TD 3&KQ"U9[U*2H.
MQ),X>(+G/7S8V\.=O'6U6PRTI;UKQ]#G3.DTN(F,\=X-K]L380/-$,]$$M/P
M@<6#!^QZE<VB$/3G _0,L-]H+<7&E(2);^?=AP\&"H4_&]Q7.76'^X^_&:FP
M"1=):[KU <]//NQJM-+09]K5AIND.-?:^-]X7OHPCK\^>KI_\,T^UXKDXO'B
MY0_V'T.HK<[,WV;G DT-0G.6*%S)J.(=8E'-)S@X/%?=ST,\]_ HVWEXN'_X
MS:Y;:IT_S10?>7*X_^@;G@I&2K]XL$\[8",]]F7@_8/E;F<>'%5Y_,'1MJVF
M00,>QQ'P*DNDST)6[-U'%B:HJ6;7C:08^E5B5FKBA17#I5MBF-$^\6)>QN56
M)>H#?S;H<4\?N@5ZRFM'F[!(K4PI@4^\:]-&DUJL\8.'V6+VW>?9IO.'%297
M9C$+/O*ERFZ4D;@YTSM6D#VU5M/Y@A0=74!IX,DR(,%%[V>ON*KH".K@C"1&
MX5SM/>EG!$.1GMC&JG$I"9>#\WC_:1+.&D4U@'G+>BDV@:7#M.-XH3T;VR4.
M\1$.G@5/N/?'4O>\=57Y$V%69) N!RK_00)M);L<(J_:[*:8)$@)Z?$0 I#F
M=.=<!E*W<7^^.]+*+%FDZ.7(\1T(RFY)08^N9*64K1CM.>1'6H(SKFNPAHLM
MK^!NWNFRJHQ+-)_D2^&=@&SE<RQ7UBMLB<]B5K04PSCXU%CKW4>]#;+D[ <&
M'XOL1.DI(]DC:4D@$E76:S-089LE\1-(+>P-HU35^U:/KBD#U]&I2(%DY05+
MD7AA] 9-_],<W[YZ?O^ RTAX_;\('GX#36^I>X'WDVBO)O6"U.ED9.)^;IO_
M*^R Z]?ZI#A^(N>**UV S.&[$8L/()SP\<O;GO2/.L3QG L(SNA@CK(?T87G
MOVIX^&_S<=[Q(S[EY85LZ/_D9?:&OOE&::1V]!=TT^U/W*!B7N2388 3JDZ0
M0"B:IF3;&&0:D'$Y%UG2W^Z $U<!3AS^+P=.#,%$?1^-:LOYXT3%"@55S$+3
MU.RUS01.4!6KB[KYS,5H(8C-:7N8;73I[O\AE^YCW9&D^R^RHW-\\54#2^>$
M(YLG=;,TZ.K.JQ/HL&:1[_Y&J-&U.R^_$MXB1UN*_5Y:F=;M]M4VZS87*!!8
MS@?K*"4E@4^%DLE0JW=7,=FKF-0J"9A"X:H/K.GP$[XG PQT3"':"NOB_E,U
M.0 "_>MA55[X&=^0N*1Z?_ P0I1L8Q.-.D\.M2O@[.TA]U_\*B9,GI*S]:H9
M=BVGFKAJ\FWPK%MU+(8%$BSW3JZ$.DD'\08%KV@ UI$LMX9+OU8RV_,"_!,W
M8LJ\,QZNMR!+#]'#4=:29[C@NEX45,2PH@X4_6JUN]+X<[;S\>3DQY]V1R1F
MJKUV@70$?VW>,8T_^T [/WT\>7.RRU_J&K@<\S(@_/:S8QKY2C [!T=';IP^
M*)!$*8U59"-8PJ[RN_&JAL2%&PGK_;:Y'HRVP*I*N*,? A[91@S$_9+0ED5W
M!E-8X2353?CAS8$%BD;9(]Z.)]G.T='^T3>[_+ 8+]P,TNV\_]!R$*+IQ=P&
MCIVJ/Q<K_MN_/7ER_^$/$A$\N/^-O?]AMO. EGCC_?2R_>S=<'2RA1_*'@Z#
MQ0Z.OL'-.'CTS3!B(73W@[7(JSX,O8HKEM.]*Y113+>+#_CU;5=($?.5D3]9
M\^-LI]PO]D?Z6U[H!S]D!]_0E7W(:_R ]OCA_N/?L\9/9(D?7V&)>X.3A?LU
M*SZ08?T-LG);VC4):P[!\.!]<%16A[A.@WQVDF-XD&-^2B]T^'C_( GZB4KF
MD'BP,;=%#SWN*\"X< DA\UQ6.&2#74 V.6@#IRIO>95"F/B9J^GW0<0+(6FM
M-,:&\"Q8M$-\-FBT=$M^3Z!OM*F[Y)J>DBM958&X:3A.]@=A]F^BB2E6]!]
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MK8Q;.TR+J/P*'*MQZ(@NUWR4W'W\H>\BE5[*:H'3&FUY#-.)BG#VM8RC1CI
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M8W[WF,F*UK#NVODZZKE-XX8?T10.X8W?[M]CR\6][EXRYD77KHRT-]+2>D*
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M7 S,AT-IO=4'6"BM0.@VZ;(K&5XG-M?GT0*Y,9;726\CRDJRX!R(='Y"[)Z
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M<"$9WE%L*Q,.R!Q:*12U:43_ZSMY=/E,KS#1P2W;L4*],[IIVH[$?H7N!21
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MJDG:,?2LOM@X[W%H%];USGJ375*U=P.E\J5-13Q*\%< /&Z]:;SJDS=H7[H
M/N)3';"]*7F!,RM)#*3=B.1T23NB7D,C,\?=G>P#<$[8$A+)^98Q55HK+C^4
M$^LD$DA3:.W3JS+ 2J[<=WC.CTR3:@_)=HK]V;ZX!^\ F&;%\EI &S2$5U)-
MM#O:]N3_[,#O7FC.&F.9 *?(GSRF'6^ $JCYR;%,AAXU^)21,[GC(L;&MK?=
M(TM: YH$BRV+N.[?<KZ<8SF+%Q* \H(SF$ZB]3PS)!+W/I?CSYB;0!*;O%/2
MT].N'<(/?*SYW1^+<<=YQV/-8@VAP4)CK7"0>U>FW\)1W:ME4YX#B9_0X:,6
MR[,OZ!E]75GA]_NZ"4X0WGN<^D4RGE:(8$VHFXT0W;:_3OLG$UW"<"XYT;]*
M(ZC7J7!,#LJ@K+XHU(AL7.-Y9FW>O!H)8Z/U*_.O$ DSP*T^DI!!"M]VQ6MD
M7:A+WP\);&E@:/7G&S,RQAH_+&12S\%-8*C;7^B*MA-+UTGW "9,D/0JB6H4
M:' 7V*^M('I$!LL)EN!%X=O0)FUC\\V9\ 8P0&RCSZSE^Q@A*_0COJF<TXAN
M-V*//HA(,M3K!9#!P)+%@@\\]44'8"U-\&>T8=="EA<_[[I.M-K?DEF--WRD
MP(J8.#%B,":#X'>+Q1SI$ ULV&\H$@^0 :VT:\G&>4I#_0J<*L>QXY7OZ\Z;
M/T.O5$#&L+#<'(&]+?PC0HFD)4,=AZJW (QLLL?*V"&G@_VEX"0:Q4O$I%Y=
MF%R_Z+!N'&[W])*9/93PF#/&.@];Z5>B[9=%,_ZG3V+J7*N=DT_'8#NGXSDO
M/Q?6SR&P?NLUX)-HIH[0U/?.!<<+Y&B+!^D:"-,[!BB#X].7G)K(@DHX4UM/
M+]K:F/"Q:\A:X<-T\^'7!+8(O@1,RB*KR%%'">!&J+N0V;0>G;,QC<#9A%&[
MJITA/&-N+T,6X>#Q#WWZUM[">SY>G&[>0>/H08&>/$S8X.=SUTMW*P/SI52Y
MKT[>CWS=083D;T%4D3M\',)"6[:-]Y;7.9U<C]]QTVC9'BB\V;=3/:T7/_?.
M-3K"B.88:G0NK"9]IA^N,2D=YT_40MJ**/<<CG(!6DT&^&O[]OAX-S286NG%
MQ##I#YSPZ*$Y60Z$#DK'\5&B?Q2*"E*MR39SQ0"\Q1>PEXEP&6X4\>+GO4!N
M;GCPWCG[.1C-+WY.*LW7[:I8C-R=U::&6)LKK$P@I##4&P)YY/Z5K12#3@KW
M"YE[0*SZ4?FOA0_8RN HY&&E^P(MZ/>WLMETW(Y1H+#.=EY(5@D!IS+6_H4N
M%^9LG)A0BSXTGYD R,:OQ0O^F93^SLF/;]_K:5CD7SBQ%#CEU?S!1WH=U#!"
MF@(?CT#<1I]@ZVB"J1T>"!F?1A3%PV<UG7\N*NT]H8M?:50!0'U>BL" !(1R
MY'%# ]\R,K?Z0VVSQU![/#1I+R&.Z3DPU[9SH0\,&\+K*GI1_?A'CX5MT!&Y
MZ3-UG/L6/S"2',128I.*H(-I0=I^%\&CO8,'RJ*QGW":N7T0=O?30-:0+ (T
MFEVV/*@#YAS)-T4)=BQ0XXLTYEN_R'^)K0)4M;*?3OO3([L.EB_C8_%U1S77
MY$O."+HX.&LJCCZ/RX;N.<+98^U+16==TX&NC"/L_M3-TMB5C5[OX1]RZOXR
M^N?X$@<2B-^^_RA$]N 0Y;N?,,!-G2<D+>SK9@ES.J$L6<%>-VLOCXTJ7#E!
MD(2^2$$EXB*?D"Q]%Q_,$Y!;2$?BEWH=(D?&,N=CB-V2NV_>WY[&V5)V8A12
M>978.Y4P'[0(D"N?9]LGH&RT%47DH$R*&\W4X1 J)T:"<6SKIZL<*Y>UA?*'
MUV+"OGUARF"'?O?VQ:YRHO#++O*TH,4$UUO.X)T5\Z4586J5KI7))28EK13P
MXHN@=N(F\;PG!0DC(5!PC ^B'T1(^%N>3\YSH:2&96DE45V%XDXKE074?3][
M9E2!07SP#).39_0*!<L992V/R9IT-$Y41G*%D7YW0A^K9YW%:XT*UT4>K6A@
M7F &WKIPWH)VTNC:-EW#I58%^>K>"?>]IA7\7*Q3(Y[LI7955U9ZR*R92M@:
M31HER0NK0]OZ*Z73'>;A*YB'1S<.\_ 'K\DQ?*PKP=E@TMX0: )8TBZ*T:"6
M&G'ESB7MS7M1SLWBGXMB,U Z[(]HY^\4OYKB_0=<N*'NY %/&7&1-+TE)^3[
MG#L<W R(O*9NB_$6^-.5+)-KCWG_IEC_^Q1*=H(H8XYN(^\E9"AR\X./&=[Z
M-,!FQ"[&8$*(;Z21=ZVR5HC)TGMX$KVZ* )5[U"<8<KM19)POCA/$BKS8 PV
MFX2A.7 ZD:GV#VZ\DH9M55?%LNQEOM;^DF:FQ9QFB->YAJ&(4,8X.==ET[9S
MK^#"F@TV?,/*<[P^^"4M5TKZL%7=S/)*&8XXG-T?E=#.B27 9> <HRE#,#M:
M*_#50M=B4/RGW2=!_*^?3>AG6DLU]Q+@0SW Z8>1!N*T)-V36P34QVHMQ+JM
MLN\*]--O 6.*6C7JYNMH\#HCK;<<Z0/"UC(NDV5JIS 6NKW_C"R2M =R N@(
MLF,>.:KY01SA:LGZ&I^9E<-2L1_.E 9>C@1\JH(_H&UN]]7FT!E2'9'@$\VH
MA:J?%1 389I%.JW)NI3%8\I-=F?VL^,Y<'$SCJ4I\$CYZ^=80J7-\=>+7QF:
M7W#;JG!O6@$Y+#O:'*X9-U=Q_^/^R'>YB!F"[70?@N9;<F1:F"4+Y'-.)>]7
M!:_-@!Q[X<!-U,^+1XT&L; NKF0LEG8>TC,J4;K >.5C%"8I4*[:A@1:P)!$
M0 E][#TDW+/][+^U[4_K$R636GHM:*NI10'$6-DN-"S1%L5G30@PJ\,D[K(7
M=Z?P/%J.8W&658=\1@=$MF,<%@' JS4_5QB(';>4+2;+UV3E][.W7D1R^P-0
M=80S)CY2)D1!I:]SM)2:TH3S\2.OIKZH+M#) 'O)J&Q5 7J"-XE?_B+7]+V<
M(I%47KO(B<K7..>VV] "1E<QG7,=;SP!HD"D.4&2@8]G* 4_R4>K8E:S9\\D
M6"VK?-<>;),HQ[Z(OP+B@NA866A>$TP4G!.,&K%_A%6?8J<97RD-(<82F8R$
M<GHZ(3X$ZFD1MSQQ_,=S<KKWZ4[Q0O$A9 ):L5]<@V81439J,65D\7A4%MZ>
M% 4:"JMF-4VF2B<T3N @DI,G:?P%;[J,4/C:S^&EIK XJ2\#5\AMO5\RCW<=
MMQV<D''1,-#OM"OG$[;E@7;37.2'>OSYG$X F?IO\V8]9[LH*CJTNJ/W!G]0
M"3V%[(A!?#1+!>6I!9PTWA', +]Y#RAS"50RK'RZ4?.=K[R)3..F&[*R*]72
MH2S8CFKUG?2/>CSNEF4 =^7<W%9%;/%ER7J4)GEX__!Q(&>%IONBS5*8E8WC
MF"#4=@P0(,>H]F *9.@S!!"+TB5J5I\;PA7_/WMOVMS&D6V+_A6$WSWOV!$E
M'@T]V.UX'4'+EEOWV"T]61V.>%]N%( $6%:A"J<&TNA?_W*/N3,K"R35;).4
M\:';$@34D,/./:R]5O<$'RM/.76(QI<AT?A\#'4!UA!)LOL'UI^9)_\1O3G_
M_"]FG[_T<?.E"\\:H!KA9N2V @L2#-.Q&W[K9W"W]%]Z_O395[<;L_@Q@!&P
M8M6"*R=GO'XYK*C%9#'981/8GK]530<F32Y4MNFQ>8*?,I\K_(,"L_DG-QFV
MQRN/0MM=UB=-.H\G0EO#2.OP?M-5_;)L_*9_">I ;=?XH^+X'OJ[M^V\,)Z_
M>-P6_CMOF]J#>^P&_AR/\E=NV7D+SX;Y^?,"=R[ON?7BQ9_^@+T\3[ TY^3-
MB\6+IW^&GU]=> _WRA%=W8X$D5VS10\W#2AM(&G1Z_Z?_O1,+P9WA9KUV;=G
MX!V\O8 _K-VV<^YQ+YL?W):*^P &@HSEXUX^KS!WQ&@^_&_(U%;-95LSF$HT
M6KV+O!\E2U8'JN]=27(@I)[5@1^HG&1KT@+VKG5'_O)R["')R^=I1WRDP=TH
M%Y0A0=FE@[*@0ZN/@")IZ!_W2CK7U,OKP$KUN%<3>)M7;HF*ZZRE@NJ$5U=G
M/G3MVJUK( _F_3N<>F A\8NH^8"13VM^S$FV0-U$PHN8@.M;DL&"T+F%_ 5D
M0, 242FB%.V< RXM!^+)72L580)-87B'O8+^S,,B+M^0VQ+$H'WW*S>L!3 *
M0X!_^N[E%W\1EFRA=?//]0JX5Y\]??+?Q8)=;@3$3/[]_U7_>O*O7\*/ 9MR
MH-0(5U"$?Q/[#[2'6QC%F5<.WRYZL;W?="-#+WYBLM!G+^ [S_[X^?H+;<L(
M+ZXO?4Y)LF=?O?B#[7R K%A-.1Z=E<YF$B5"MA.Z 0ED "A?@-[VV537T \H
M2A9:74(N_\LU/H=UU+O5F8]EORB22Q8R"#)VG"90H9MT+"E$MM_HO'WIB$ :
MFD7$FL&@ILM(\P/^L<\6&:>Q6O\_GU7_Y^G_^?.7N1[XB($#=W/$)F'W]]#N
M__+BU%S_487F/S^X0O-=+X '=J2]?O_=CXMGYV=D)-^]_NF_%Z_.7[Y_\^XG
M^B0N>,^=VO#&SYY/7AD_NO<RZLRI)RY-8:I&<1YPPT3::TW6$V7Y"IM].:%@
M%5^$N9.47[C2$^X3^OB,L$NW,,+?7.K6\C;>:%6./<NP=N6:6#VY#9/*_KL=
M&DL?>I-X\PI%W8Q@SC$%:S.#]X#'N\$*?0?$G(MWCNBZ_0O"Y'W#@ZHYDV]M
MC$--R9R0$O$6/USP2Z%N>JDM5[<=FUD0T8-'"YP3'>E,YQF5>:WX?$2>:J+(
ML\5+_10)<\S@,TJVZ?U15E!\0OH4TL 4.O,Y^0BQB]\ @NN5,B?KZ,[W  12
MGU5NLHG8NEN4QU[ZTX&QOL=4(47]A6AB%7&&TY)Q!^VHWM4U?U=QWIE^12[;
M&"$8TT")*;K>@"@,/AP[O5^U+145J4'"0!F@W>+5M^=?X+^"N A^/]\06,2<
M46@H0108C#62YW-O$M8;N=G'!*Q$Q3:(VC:QC>8W0PX23+J"*=+$+^BAJBV.
M)&&'5I*('YB\[]QVFGSS@W]UQ2Y"DYTV(.),1%V3^1:CJ&-ROGWTS=%M?QEJ
MNULJ-JT3DYI,.>:FT39#ER;31%?-!5;(%EP/BZW&-UBXYW-1:PY!-H+<6!"N
M;?=/\!"3LU%V^J;J^H%37@=EFI;]_=.;MW][?8[4SY2]IH8TDE+F]A_LPXE
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M/>3:V=B%">J5/L<-+B,O?YJEWWZ61F"-]5Z3:T16#!ECXZ0LF%"L,8R-[CZ
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M]\*0D??9^, *<W;&B[V"K;$:$=:F=DH8>L607KOC8'<!: E==7/Z)54KMBN
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M2$P!:O<]_(^%1N((4C'F40./E<*BU(N(O=@[)8,YS>"=S" Z?YS8 %N@F%/
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M3T\;H+^-U1/5W+!^3-7*18E>;]!SCU48<7HP94L?'8X0*-UP#P$;.<:5C(#
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MQ?L(EBGU%L)$9096-JQ5492=B0@H;PJ&"G8)[LY0NBX(L]1>-2RKI[V/@JK
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MWT[-#+]]2705:3[C\K6MT_Y<\\[RP$SZ:T<J@#)SEG<E,)?C(89T8I@WI*P
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MK3UCFKGYQ*+/5)H1,H K5?L-6X%Z2H#LF8MT?H'6+518_.K 1%_' C($H%U
MYH<>A%8S<3K >V)V:(]]40(VE!T4)XALF,2+5Y!,$5J&,=_9ULV?XQV=O $5
MBP@$+J,M6PHL^8;0WWGQA?W8 ?Z<<I^Q(6"8Q$<^\WD-@.7MA26QOIJL&SM3
M=!70NM#F-L%VA8J\I-&//L\$X)X_5\F,)3*+HIF"^5](8QZ7=3I;4(:/RXIF
M"AB>%A&_F54C0J.A,O#V A;RB\D,A%<>JF6[SE: =?;"NHN-)G.&1VMJ)H6.
M_I/=Q8&C:[ WP)WR.S%W4Q+W*=,+'\OQV,58)YY_5I6-P#&<'"'#D]JQ$DF5
MO<>D4I53-VQ?[4%1C#1CPED]8O7]!DZ" .]NYR<4]&S [MNG*_!V7@B:+.GA
M-<&H!45$RF7F\D0"%@*$V"&/,(G9R83CJVY]P 5^JDY%,L/F?MWD7>DWP7S$
M[I/QX&T=S$")I_><+QCR@8#F91;)+M%!)#(Q6:*H#=FB/%G%.":N^^'%K.T#
MN4"_C'MJ-3I8 *B(%^0OGQS"_$ASKQ;WT>(8!ILZ]C35%#%F;G>KFRUV8X\'
M0H+S+.,7]19\SV$0:_'8*BR]^TP-EA8O<&Q^\\-Y J.GK['S*'MRNJVC55ZR
M<"4/R0%7@NEUXQ*7;'E&#236W'_6F!4<^3;\9J;M+8CASAD.%"_S5J&_<-H>
MWVML'.\:5A:,"FN1AR8'/B>1&\)^BZ0I2T0:-/Q-IT)= W#>8HG?N:J\!;[1
M/ +Q).EBLAR7?%YDM(B\*?-K^%%+IKY+H[C)@H(Y=0"Q]GX*,1%8+6NBX.(Q
ME*$A0:EH66=7?A_4$0TLX$[JIS+"IS3DQZ0AJ6>R9T*W UG,92?0_-A"H*D+
MAQJWD\8.R=(1F#6TM?J/#JUZ^ @V/54/'L1,1]2!/H)I&R1=+S5DNWZR\0CE
M1CQQ7MC3X%YN0E%7")C<U^6*')HY"W0J1SR,U2$YATRDC6K6X 9%OEK;)89"
MXYW*-%KZKS0L095W09$J<,V^GR-5W>3"&&@_JK+(N77<Q2IR4;T<>X%>(:S<
MM.O/9<KGX'9TK9&9$/TD+2[\4Z SWPO#-V5#1ZZ1I/BY&>_)>G@*XX:@A_RG
MHVYYV1F/*VHA2D(PA?5CSS\EE"51-)L)25W5:5<O(;*'V6+&OJNPF8$[).*&
M8N2OL4&>-6&I,[S'7P7B+\3-#1" 4':/%2OAG?SL8N\-9JVQI#/SC<NV'G><
M$D)#RK#QO)8VN6@,[(OB2=Q*:[>3U%)$_4ZS@C^%#H'0 <@%->_^4^<#2;O[
M#T&[DV1OH:+50PX>I,_+YH2WNA'>ZMF#PUO=NXV,ZIB,2,54)Z92C@"N2R*=
M4UE'3(X"K11?1(U/S'Z"5HMCS-I=HDI\-MB\<07RWAV/CZI)G@,ZI!OWPN=#
M7OIN/T*2JW'#5=NEVFXM=M6I NWJL(3:KS]OO'4JY@K"G%CP$2C644*;U:,Z
MR7]V6DO(#A1A^0_]X*!"+DE2BJ%1O0)Z"&4M1AAGRG65S/?2#RAS :V37=L@
M$"LT6'T>)J,'YFLJ_4-_DB@1V:ZBT.AHKX'H>#]#E)N3?&&%YP5>RI(0:A^A
MG]W1/]K.<=<A;2"]@62COBAD5_(K80F72B7EXK*$WC/T&5:PQ5;V&;$#J9<:
M5NCCUC0I\E&!\'HY:"I)1Q^=&G_J<3K.82\6BO[*^N38UMGGI_DR^\#?[5O7
M[ROFAM;?[KS; ,U1!5<H-UW9#]THV2[2L1AKX.(1M(>(1;6FHED.@U^Y/0F/
MXY0E3T=B%:&[T$X<KHRU+,!HW<7"Y9'>'\PHB),SO<^%]_W1NNKRF6>Z3AH0
MRWB_\\OPK@]WIY%MW)8,NJJR)XVCQO:P"ZFCQ*KJR!00M+WCFW-?')$(]9#_
MJZ'3@?V6F"ASQ4Q>G6%OIBDP#\'&2S4_RY#$9(N&, )R-)%T1)\R5",@7@HE
M.!+7_-   0K/O/PXZKT,-!EL/^;(<II#>"A>NAOJ,"M@N5=K1C6DBPJ<Z[ND
M27I VNADG+/:Z*\MX?=;)OS^E$!%U)-B:E=H\;B&T%LS$,XM@YVC!>R4DXS9
MTD4+%$GR@6,-DT#!9D[U+2;LZ;]/?7*8#ID#6\SQ.U?ZSFXW S<9Z<4;G!0G
MD;'"P,%M)M2@3&&;G3L#\T<6AO09=S[R*Z!B!R<I4&&UWJOK5#>=X54"A1"<
MF7C>$1-V0&%%TF$<VB4<U%+'EJ>_</74>5J@QM3BU0KX1OR,$.O-SOGA7//)
M. Y!)-E_SY\+4L)WS05616"HEQ43:&^2+^'? &S&Q&$5H.#]J>:@)I1%QTC;
M-S;3\^;A4K?H$:S12_HOU#UQHD<A'_G+P^&P<N!)4)H%YL</<'^!TX2IB<#"
M34-@&RN1/JJ!QJAA_.<('V13'$8'@Q"8]+3"BL#DP%HOW.EK!%:LZZ&B$=]&
M KPMP ^]*/>](7]Z5#'!6YY?FS*%Q@MX'<K#;.!Y:+!9BD+'H.K[T:TS#9/O
MHQ6>V="Z7!9FI=Q\FR_KUKMMD@@T;;69$!MF;IN0>5$S)#L>EFI-!0>@$@#
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M5JY&A[%!SA'4T] >0TJ?Q/T36ZB<(K";=^>9/Q9$Y!&\#PKHD=.&'$LGV9W
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M:"%VQ QL&]+MKE]UU3)@I(0@>^--=G>HB9]UO7CIK:6?OJ8J"54,65/*&)F
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M@0H\,.$@83U5H'#AIA"2R81_A$BQM)?G[#(EGCEO*PO,['9&B-*-A.AG<A,
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MM-=,IY1I(D9C8DSD8"V\XB/@?;EJT35UI:>O>M%F&+'J)+0B;T4'$_)E6ZB
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M#]SS#L\(<#O ''0J\5Q=9_B@XA*3X13/QTO0>K;H$YLF6PQLLL5*L@7M%^C
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M.9)4Z>PTY^5F4;EJJ%AO60% HJ%A-RW7V(?BC&\%O% *S\&$4X3'&2\9V9-
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M=;PLP!K>(% R*.^:BQP97#<!67TLBL0U>-)8?HP&-;#9RL+.9<'8IK#;R83
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MIW,XTAM8C!BI)C0(&A!+GS"^L^3>#$;O>__[RO]7ZU^C]JO;# X2]\)^65X
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M#OKF>1NB-<6>BB;KTPU^N'X 5@+\H,1SS/[1R<ITYBY$V5(C/S/$PP['$Y/
MC1D39.'Z'D,^N<D,2P#0\/-6[#POXK0=C5$A'Z+"O1SX+3Y#]T]#(-!$"/+]
M.+NX\/BS$%CF>GGK2]4X#ATRET (-3)5(W^H!,Y096FJ9UZQZ\S&-0BU7KC?
M#)#]C[&[6.T7O5?K]H)D K-;46@N<4(2"4IP<QL,DAPN@??@5W#+.@Q"1.SR
M ]LU>PNK3/=35,L>FQNBM25 Y7GBIW. =4VO=;-Z>=7OA=-)NK(@GA>J6B>F
M'#DW23*<L.O\ M:)3*N?RZ;-[\6$DC&=;IN41%>5;JSDSLM".'HR/%BEFU>/
MO*''?.-=%3/A.]688V$.5W9?R *S'10F;.@5K%9=@1Y_];&,("_FDYD=DC$R
MOR\46,$-)*/8D(<G^-R]E4_;#'GFY&4=>)D60:7X+.HV7_$&TTY*O#^_=))X
M LO],OQY")P9MCO=]K\N!\U_+RY?P:S3=5\5S=/N4)GI1_T6.0GPY+NOPUT8
MG&L6HLD+7HJPSV"?/FZTA$?S'"0;EXY5*<5\*F)JT(>5"<+ETU-DGRH6I>P,
M"1.M<S= :@LW4Q._#S (I]TZ_#LG*Y ,^%2>DF_4Y_DA^C&?.;9'W2XU)E<E
M0')W./TI#QV/L:^\^(G]157S$FKFFG)0$[8<1*.F'!..8^H9\N&[GQM+A4'S
MPLI)E1?OY$2#\0L5]^7>79,[%5*NEYF[MMR^]Y.LRVNZO.WZN;S:%3SJO;1(
MUY'<ELY//YV>H&?WX>S+\9>3L^-/SOOCB^/]MY$P^SD*"#C%,S1I 8Q!]Z&+
MQ0Q1$_!T"?L<PDVNMI71E$H<4I!,,F6GR'ZA;*P,Z>= GC:UC[3141@'.%*T
M5R0S/#2AU[BD]JN?J9XV<(Q64 (+F\@AH5)KT(\$$*J;6;J91U _A1?G&!6:
M%*K/0)2""B9@(?*4P \($G&-!8J<2 ?;RW$8(O;A=X$%@VBJZ?VFPMA[?+)7
M4Z>OJ--[#%H?E9_Y*!1F'U3%^36%D;A^N,XPU/V?Y&WKS4%IY\D;5GB1NPDT
M^V26MX9T/5F0^^\LY,(!<@#.8.#.H '>O*Z;_#5QWG-*I/(3CPGPV&?O7L_Z
MI(!]\CW'/OFJ^?ZJFE%K99/;IGG.0^3S;JXK'[$6KR!=[V9II%0=P?;S)V/*
MRCVDY-!%(MZH7\R@*=[_UE2;J+2P5T#@+M_X(:DO>J_<PT:C9KO3&;8&M).E
ML.NEGAJ2W.6:O,O]EGJK7_9:S:-.OWLT6G_)C???^.6P.3@Z&AUU[GE[J]F^
MZ<M^=] [ZM[S]EO&/6KW>OV>';<=]R..^S=:G;Q"8>FCIOG?5UWM]BIK$8W#
MSN*GMAZESL&/-C2.RNH$L49PKY"?\0-+90J&N<H:J[UJF]UB/-YDA17MM0WG
M@64=N#MIK2Q)K(G7&6R7>M(=VE_Z_1,#>Z<%JPCC96L)FDNCVG+"*!2F>-M+
M-[W4+O?'7NY;)MZ-JUW:;OA"()5#]JB#$]P+PJ)[N %9'U7@'DHQR_['9/_
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ML6FL;&]D':ZQ;BK-LFYKV.R;UI01C5#;:L,T_1JFW8>391M(6UYY, %L"$7
MW :%=\J'@>BP+Y04GD@6!89"\&QLA>=)@>E  /4&/#^G1O?.MQD&,=G@X=^[
M!=-U$B4R_*YMP6@<H-='1_\X?HQ>!]&UXT49T/#0 UJRH>![ARF&HPP+,8]-
M,2& A"@?("ZQ#S/"/ 0;]*C!!O'_N7Y-Q_OJ'2K]FNQ;38?-<% L7\"R5]O7
ML&+[VCP& [3'*3J?9(+-@?S@M3R>,]T"=:V.DX!R8'5TN_<JPR>P!.=P;X 7
MG<Q :3><OT;@//P]PE,J<(+<C!YPX?K70&S<. [\UW@:=PF:!77CF.-!E.IP
MB IYC@XD18$._WKZO5,5&FK 0^ IN VTNPU*TT@68H*1X>(V !/!D+'4-J#M
M,/(SB:+8H_W%&0?1Y(?K4= 5XT<TUD_''P^[.C!DI"68:1>N$[OA)=W(S172
M;(ZY3G1B+D#EXYDV.4ISLNLQ<4N=I,+@8?0P:PQ!)S*H,\] RQWJ:5Q\/WM_
M^L68B1\6SK<-#C4U(_. 1=5U97VY?"'!';U"&II0"Q<XEB7$@U(T#$\!.P4S
M!@]'01K@51P*P((NRI%Q?_+5^:[>4&:1F^36!Y#];^#VJF-AV$GO%S"BM#IS
MW;#\:S.H+#(5<249UVGW2G&=C>)-S:()I(6.WB"W\L(V7MBZW3#,"J$<Q1T*
MN2C"H6T!5H+IU'O_SI)4R:]<'Q@$]N-)-L<T%*#@ P\UVYT[G&JVNS><:NY3
MWO('G4[Z-4\SN35_KQXS*VSS&\SU>PE58R_/;[]2AA5-A!*#_20U\X(HR\0T
M$^2UC3P!UW'GZ&J2<HHN0]II.=:%^BS2RC",PEC@"2DEF&@W _=$:7? ^HVE
M_T0GJVQ#.-.,0GOJHL;Z; ;SQ+;"HX&;<-O.]&GQ!A908B195YR5TO%SV8NC
M(*I\F4[94AE6*H4BSW?Z+8KSE"=^'?GIS?.FF2"5G_?J^?LRID $P_"_F+G!
M5&G!T@,:!EOI)9@#*A7B6HH:"2 J(1PN]\,I98QDE/A-62>K)_SWR&&N^7(W
M:/3>H-$I)MLD>ZX'OJ^3 ,&SRY4#2)?\C+($LIA="G4,P/EWMXH3'40FHO H
M2C@P<BM-VQ2O _'5N7=Y+F8Y ;-XXB"F6 "0E"V0J1]0.B-J'XR65:6!Y@L.
M3V5C7"K&:.D, !YMI*G>/F?,D747I,[67J\(CAI)G5 ?CI>'\E?,N/-YX#+G
MN3*S!D,I?EAMLS,MI+)&56'RP<4'B*5\ +.73XWS>A;Z+A5SE7A&C+LIS4P^
MW>:/;',TU8&3T_DBB)9"'"K]K3C=X.-!X#?8SFZL4HK&(A13<.DV,WPMK[;*
M*]R\9^A[KS(-5!SHL%(F&*BR:"*#W+ \+0^?GH?GF(TMZW'P[!G8QN:ETNM@
M/PG)9RQ"NW0O>?_<8 .Q_'QZ?KX7:(;X.ERB#?\EU0/(0Q7D=)8*&:P+T"3&
MD([CSRG#@NP6R[VGY]X'7&04F:-TGA"K-5VJ"DFRL7*ZP(DS[$B]#J/XT@UE
MH"QQ#DZ^?TU>&[J63P@7;IPN'?#Q/(S4TB%F%/]0QG#!VS3-68K&%2W7VTI:
M\_1&> E[CPU3&NF]^%PW=(,EV(@-*OM%380V,:@9%E6L,@5#7@Y#76H8NW;G
MV(VL'LLXBA)7)53D[F#"D2^DB!E<EU]8ANV 82=T%&W$18JN9W%]Z[KPQ(R=
M76$L'E?\ J;D7JK@E2R9M4Q]>J9^DA' J2A8UJO:/H\K%B)CAS*$Z%6YYLQ;
M59WZ%O^V+-[]NJ52'9_Z+\O(J X4F:6D>U[)>+9:/.L)SHN2\U;H&TLN7\B,
MP+A1S<09.#+LI:MI8Q6G-\T<79%?9>_()U2%WN!I_A3/[T2(O\-(KS&H!52F
MI 29**6*HROJHE=/.E6NDZJ67OMV68LYEN5:*ZE-%,7#,\40(_E\W$H>G$T!
MWB@%N%?;%. Z+EI9)LA1]<HTNYNEF4.W:BDWC/0YS(J1=>2EA5D.0*Q?*K0,
M/8'%QAROOL) 8DKCF2K/*K=V<&46,'[H.E8;58.H!%\H/L",<;.=)<(X"@(:
M>*PW7;/(DW31S W)VC(.V"1]L4B[>*1'*3MQ-';'&'&CR<DD"Z*_P$K7%>*4
M:1-FH)#PQ*R"+A0G2N7;2D:DNU"O+69PH.G(7Y!"DF_3ZIPR'[3ZQ4PE6:6+
MN431M3/',*(J\5<SH/,%#D4Q.@Q<0"@3$Y^P,R0J1,X3204\$JHD0H.+TP-L
M\D4)TTD"URNAJK[G5[.X)4^5>F['B1]I\^)(P+$'3//I?!DS:N2!XIY7AIL3
M=(L3U(=-\E"15I1Y"*%L,WD8(;46+38=.O5#"75 ^=57(&L2YJ3A!.)2OABT
MA*"\^HRMD06HCJ6!Q%+(C&;<(HTW@RL4@SAL/QB@,KE7H,X 815-9-$FS!$>
M:9RGZ8OS4<% IH+0TE"%B^=W5OZ5)GP63A 9Z4#*\^O[RG.W%O+\51X%\YPD
M?U\7SL5]2K!-4G65S %1Z"AW1)+!*LLI0MB-EU*"E%#=VQ&Y4U):I_],DM).
MD)ZX7QU/J"H&]]5O$8BR4C?GAG7PM\R[S-,,3I.4:BWV7!=CEE<> _ZU@-=H
MAHS)'EN%IE1*N0J;$FXJ8@#=ABZITC)S)#@P\Q:NS")Q@46QE[OB;LZR!1A$
M$W^!>9[L^1%0&%@@BS0O8"]4-^%0C\&2 ,ZR'<QO<HURG&03/$P9!$@D+-+<
M_0%K6TE&P_EW061<3,1526R4BL$H<U2S*G"[P%1T&>M%9Y3K@SG[C$TZ)9<R
MDQO-8TK$(SK0D>":>W0&K,>H7?2[A&5QDIE0-U6,15VMD@'Q,KV)8;9(C/"?
M'ENE^?W$&*!PQ$7$8XU I,B#<C$#!1G%1AX/@L3QSAB2RX!VL3S!+E/O.L?X
M ](S!&H2$4J5+,C"U%(>+JC43,(=)J(X!%A^47C(J$:40:,2D,P7TD/T7;CW
M2P*JC)LY@\(9#!]'&;-VXL8Q8<OA(,1MG%7\+V$B:CI3KK<,:IB<:((.*P"/
MJB^9I@4@4A4,,4G!R\!8R>@\JL@TT3)A$+<<<'8JH65]!2USVVH!ZX82"ZF4
M,0_)F"))[A>E#*F1[7EL[1\$U>&"03B?8U(^&K2FRVEH,;7Q$)Y7,HG],1*2
M2NM\K-I)L?K-WUR9&NL#A2DM9FI5O)C*]N&J.1C5SD3MC9@6GY QOHPRA])N
M<4AT?(D9\3JQ5JXR!3J0C\H427R^0M=DEN?K"K_/5] U@LW)#$+2SCFZXRUS
MW]1H-HV>6EO-,J$<RX,Q-P]UTF,8>CM<%K\+&!,A7:IJ%1,W+\]!5)L.'Y8;
M9MHY2IX;>XGSQX(4R,'Q^1^O894TJ?SXL#5J[*1D?*.Z0,5/4H$GQ0SODPRV
M1#!-:G%,\NJ=W)6"0+O>+JPQCY=HH3;=.3X_<8Y:1Z]E=)[. '@NNB"8$BNB
M0,*.S:DJ_#**/$KP5Q@@A)6+,2$V/TAYR=TFT3N-[TE#DXU&+LFY%OROPD[,
M:Z1]@IKBS86+[1!&;N753<>Y, \_E/C%^<+CR&I,!7D&9CF!T:G;4)$B,^7.
MF$S +":3DRG4,$QNE1"2E/3S%$>=I&*1O*$B1@52JPA (G.0O);&L";U6ZY6
M+%PN7T&VGBR)5LB[YM/>REK!?!YI"1(*#.V)P,NN7NN,PNJ+5(!PXU=3J2(\
M=G7IDS0=(-%QMHALF_H)S,Q=\W"%PJ.>DUM,7 )6,&HK!DY 8(F1,2FG(JLB
MD"_5+RZ.=/WL\>D\"1\SJ/?<OI'5PUP[S$?<9!#D=3(Z[?S&)5&"$$)S5=7<
MY)"*.4BBC,\UBB _*U 2ZT[R(N/<7A4=% HYT0$H+/+E JTALL4XK5W5<&(E
M$_N^"'T.KD 4:W,V!T@D!,F\S*FAJY\"(ZW@+4S0GX\1\%(CKDMX2 ITOC4T
MZD+FCC*XAKS])CR'*C@MG:H@<6>+0))X.&%64)83&'*T=?X7>49@489$; 3[
M5%E55:REVN]5\D&=!ADRI38VMHU]74''IKM6X%2$4JU%S3I6)96N%BA*.JD(
M<A,;?H31]>$LNKZA9B[/+FZPFI3-2/+"+UFB5HWD14=EZ+/&Q7R"2JW;,!%*
MR., [[-4+%W8-7.GH:C3,69 T=*BC2#='W#),6RJ<?AX\W&$3Q&&+/4E9AJY
M)61#@+"3V\X+.\'E^@-M'?G&N0!#PFO(TSQR4"1<(AETM.S,TF%''?2K346-
M@2N 8,SP%Y#B(!:PP,3KDH.T?H*4_,];%^Y>-N-@HXR#OLTXN$O& 1]U!])&
M<@N!#%1>,>P4;-J+*XS<!<MBZ:^TY_! &G.8H\DDBT'PT6I2^H':F*R7<MWN
M2"\5A'\T](*Z/D%C3'?78(M<=0A"+8#0'#*60 X)S4C!%U!?(51(:V<HYT(Z
M3H;^4A4TE.?8R9IQX8HF)>+/P/N0>R+Z%ADC@[@&"$CE*R]*,4R7:@8/^<U"
MGMF78[!L!5.P>N]-SJ_A1!04HU=AQH.-#5^##/G)#&5$Q54)W;)LVJ_S4DI!
M6+DG^ZKNL?*MQ@F$^1KBBD:,7.,84*:,WB(HN.8&:*8EL(W+DXZ)4&%JS#8#
M<S '4BM'R"7#=4QM=2->^PK?V+MEJ%"!U!2*X)M%?_FF9YKK 5-!VX.W26',
MIAF#+F]5>@T'$O"9?#)*KH:9\R3O*6>;D%.<KQDPC=U89Q[)A"<=GE0[/R<7
MW *T5_FZ''BGL'FKC"8\Z9V"8R#S$E>;SK#)72[&KWQ94X;"5@F></PT!V*E
M!_@8QL!T Y9.LHYB[BF3+3BF2MM<;AYA-YX%>]8@<EY$U^;VIHS RFPE& 4+
M&H+_W+1 2=^6WP!>("'@7.>+6ZIFZ0:M6ZEZ4QF+W+=6#B=2!IME/,KI^ X5
MWW&.I\%@/T!)3H*MBE/QOI ?&WEB*J@D7^\DZGE:X-4YFMZSC=B)X;RW.]+?
M@Q'/$B-HM7*HR&<[+F7QX2$"<04>JI*##4S>\O!4B BU#W5S8@DS0O_%X\M\
M.B@&3S^E\O@;Y#NC!U^<Z_UWWWH<5U3(I:R,2.H#TCJ59I;VA-'6J_:&Z;1-
M[E]*7#PL@PLG:7Y&*?MI<,R:0L9K(YO:2- 2G/O\:TXWZ#7K D1<;U(V6=3<
M*.9H?@#S(64KI5'YF2IN1/B8Y3BE_A;CGA)=-$N$6?:?DT*^B%-AR>C$=:+,
M;5<1:3V-N-C@9@I+.#$VFK7EKDK<93BV& K4,0(C&%&-;:939_T<&4S.2F@K
MP+UR_<"P/"1\6(05OQ(L =9SHO64M/ND7;((W(DH9@NK(XI\6H:+DK\?-O8B
MS7.*HGWC4ZP([ 74ZHLL7N Y!BHRE6Y F\/"R-J82X-)/J51>*T,;DR5;4'O
MH26! 0V*088R.SO?5JN>)'TLYJ(J4#2\*H6'N&9,4BQEG2E%R*6MC!%7N:1(
M-+7 K#REZ7PP(:-TV+G066U%S@PGC0- <*MI,+.(TQM#-\WRV*Y^[!HI+U;1
M&#2_[4;S>$"V_@(-B.N)O.Y%Y#,\'7T*A"-4?WT=9Z6330SF >Y5'*0B1#_A
M)KPP**=;Y:E+,4K8S63EQ'4%TE# (+^10B.?H[H'\8/6N)UR>*' ?' W7C8D
MQM[*<PQ:F(F^%98-.U\58VBHQ1N+\5*.(&'*<*!4/<QLFZP,@P;)BH$%F%ON
MXZ4I)>RQ+U6JBN[--J%&5?FZ6Q=6U6!BA6,2,.-)N:G'\JI1G4E5'HX/EM!$
MK\D\[*DM&F7R.3D\FJ3#,[0[ONLMX'V1P!B5_ES8",YU5+HF)LI%KF\3 PK
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M&R?B/QD#.!3#4@4-#D:BUN$5)\ZE;MR8CF=H=R->I%-2TO51KZ1P+*I,@XB
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MB&$BZQQ1)-"3S_N@QHRECA$R$$^\HPO_: PU7*ZAV4_'>*E9(HUI:?-LCB-
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MD%5KQ75_Q+7;;ZYI]F3%U8IK[<2UW;&)V'M6A-I= \;SHN5XZX6HV_=.=TO
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MW#=,*!N;N='+>/QS*1N?>?'QF:_I3,2./Y]GH7#FD9<%;AK%SB*.+F-WGMC
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MR,DTBAT0QIG#13IZ5NT1S.)B!LS60\;WP,H WL&  V!--)TFL$" P9Y0W$Y
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M1@$LQ[&/SA-)%]()ZUA!,"9">$F^S7X0XSAS84'#;2-M%N&3<4%3U5PT^6&
M*Q:YK+>NXO1XIX,'-5A<J%@/=IJ$F1*N&&W@^6$0H]/&^KXDF]-2" )#=Q"0
MHY0!8P2X3*[0#D1ZY$H$Y43 ]HA:\>YN8DG-KW,1]WH_/$%)^Q!$UWON&Q2+
M\'B5%$KQ0)KF*.!2E&B%37'>-P8PRNOI&53>]=K]3JM_O\J[HUZSU1GUVIUM
M5-X-F\-AI]N_;U7?K95W_<YV*N^&S<$MSZ[KN.]$[SW+%VOW=YTOMD=51W6K
M8+/U3+:HY*:BDDTZR.Y+5K=E__,O9[/LWUY)F2WFL04HEI8OA);6";%%*_OO
M?^Q9><F66/Y%I!R&PR,DWV-\P(,,P^A^^/I-;=-9[?M?WOMM2ZZ[MQ+5)U]Y
MUL%3=C.QY0V;4&G/LL0/VOUNLU/S]D96JJU4WZT@I+<?+=BL8%O!OINZ[G7+
MS>B>EVNT);I)].X;;:?M$6_?.R#VCYI'-2^)M#PK\6PPJ'T9J^596;L/6F5;
MW/K)=Z;B!RI@>1)=_^Q[W[9;_>::XNIZ6=*6H1M"Q_2;7<O/Y\//=N4N_[Q\
M@BT>E^B*D@/5'.>UJO#CG/A2W8!MY%MSA_^E-XL;/B3P]2R@ENQ*L2MEHYVS
M,ZAK5,.N%;M6:K56#MKM#ORV3XU(5XOWJB"%])'Z\4JH8,?U=_O=R*]-]7"5
M"4E1[,B4)*.6U\!1B,4T$(0QX<XC+)FE\MAT!I?!9UA7")]G6(-(CT&T(UFI
M2F6(MU1TYR]JY 9^IK#")A+?A2K*/3_-8JRQQE+(10RN@K^ [[*$ZN7IQG5S
MH KN('#@.S_R$#N%RB:Q;-@MUNIB]7 0)3@:[]]9DLJ!A%%XR&](Q1PA/U2U
M\<U(9B(44Y\&H\NX?VGW@:\:OD1AL<@"8[[N+)PL4]' 4F[LU@JW*Q^HP#A=
M5MQT3@IDJZ2!MU'GVR,U:'R4'O.@?\.0)=R'O/YO;I@ ;?<*5J-BN><'5*N:
M:-\6/\^H<O'[%>=P94FYN6285FWE5Q(2N1(0;>ZFJKX?UNX:7)TJ9+U%%D]F
MU*!WW7T22N '3B' ",(L"D"[S7':$MY!0OY,W0DBSM"[C-;),.UQY@>H#U)N
MW0L$SN#BE.F29#YBBS"NP4RXWG\R&*@ .M%M<KE^CR8_KF#%P#+^[,;+ $;5
M=!S-!*5R-V$ TY&8P+]6DKL:>2Y_OBX*]]? S-V'<!+%R=GSU9X?43SKU3ZM
M.(FY"9.SM-*5)4";I'IX"6?#$"<39(-@=+ 3>2I -G]IM[K-KMI0C(V?'L-(
M'!)W3/Q$L)U$2B>.4VD ?&PR<V&/E%!9!#,R7P314@CY$'TM8I.8R^_1J"*5
MW#U)DZS0AA_W2[?7[.@-]R[D62NU%I/1Q&3LU!V3L5;*Y %KCN7Y\=?=D=RQ
MX9;;ED;ST5RW6S%4C]KWQ5!]\BWQ%M0<B3^5@8/U=0R+5X$0(>@F 5I=HNG_
MR6?0OKW?+K^:B%:E^4[R^0;Y? G-+?#GY"F!781"F_M=9#\ERDC,[:4UEB&]
MY_?83\9N"!^?@+J$A1#ZKI3=6\!_IAEZQ@Y"<,^S>7D8.7@5KUGV9<%!#^@Y
MJX.^ 7!K/Q&!^D?MGNQC?F=$H,Z@V6_W>^W1-A"!VNUFOS7J][;4&[[?[77:
M6X'6L0.W ]_2P"VTS=;0ED9/<SIQ$8&C;=.9G@,K/XD$(91A!&TRR2U7GP-7
MVVBP=CFX:SGZ'#C:18[V+4>?@*/#I^'H9\3V)LU;Q5:+"65QC"PM+2TM+2TM
M=T;+/<,JZPSV':OLB8S)@V<!4;9/E^YU?5!9*K<.M_2)SBEV5OJS>9KU$U&F
M)EG6]1.9[JC9?N$5!598]T58CQY2"&QEU<KJ$Q)FU.Q;6;6R:F75RJJ5U<<\
MF.LVA^O@(]:6]CUB_N*@^TSR%[].IX>_NP&5H9W/A$B=8Z._YW[G*OY#J*:V
MU!D7>^%&,-VQG&Y"TS7;F6*O2<<34^J3R3F F*T89ZH;K.QW2QF/T92^/"^6
MA9S^G,SP><Y)-)_[20*7WKW=Y#T$<MBO$DCS!8?TAH***[>XW!>A/;LX_>P,
MCIO.NO_^GS^.OUR<71Q?G/W?J7/\Y3U^\$G]_?[L_.33U_,_OI^>.\>_?_WC
MPOE\_/WOIQ?.][/SO^^WQ'^EUJ@^M[<<_QO["8/@7\\$]1=.?$_6F<!E7.]4
M[@7N)[+'+79 %[JLM-A"=Z5;JTR^52U]$R%^<.W:3W^.S9_]<(+-F'6!1_[N
MA I$L7Y,=WE-8./QI[ )8<6DG_R0#^>?9OJQ,8-%%/B3I1P]?YX7OG(+:4]0
M30:O4J/"!-9HQFGV5;V#N04TW'0IX&%8__8Q__)\ 7./8KC[%(/8\,)$\)5+
M>-VXD""-#7CC140MI\O?<3U9%/[_['UI4QM)MO9?J>#>]XX=H61R7]QSB: !
M>^AKP UX>MQ?.G(KD"TD1HMM_.O?S*H2DD!@"0140<YB&R25,L_RG"7/.>DO
MJGZSL-[!L#\J"#2S_<U;K_C]%J\ =\M?'!P>^=^8X'4U3F:O3X@]EB;_/9 O
MUDX7?"T6&9D325[TR92UW27V#<I^O4"2R(=^<;/W]"[NWZB.6?SO/95ENVS\
MBVP?G/;Z0Q 6?':EX?*R%W#!*YBKUJM.[UM)GO-^+V]W+J\\OZ%_,Y"A?7;F
M73M*!X(P7B$=>Q1[@8@53:^3-/O6&W7<E'F+2_?%W>C!M8MW:O?*B]-SW1Y_
M<Q:V,/++;ZRXKKOXEJ*-O2CMOXC$*SH?;]Q9=7E\1=*+LG_M6_&0?GDG^^RE
M\WIJLY>:,+/GV#1?;6[F)O6R 7R0]6;N\XWO#D9_&E&</^E[_R@F68F79I)E
MI>9O=_<W][=V-]]G1\'F[NSM[!\?%6;XZ..'#^^+GS<//V7;F\>;S;:WL=VD
MW0V2?%;>?EY=!%^9DZ#"<0I"Q,C8E!TOM#_-BCO2(T:^!2@#X4_,'T,:"50_
ME4:!KTIC\9NF2J.JI''KGYO[[W9* 0R^W^:[PYU*)/_8/?YGMKFU=? Q"&3\
MQ<'^^,?=_7?Q [6<J5(S8D^T?>)9+R[13Z_$^\'S>A05Q'.;'I^S05";8QT\
MV#\^/'A?*N&'PX.MG>T8?]5\&L+M.]QN#VRG=(J++M!>-;7G0VQH=W$"3[.-
MVT'AUG5UF1R9GOS1*P.#:JZ0_QX<OB+0+&<6C7]?M2V'?_7RX'WY?O!T3_4@
M\]$)+2.&8#Y+7S5\NAL[*"K/U$U(:Z=)>WY)VEN;+]>S@P4?$EU0'_W#,GZI
MNJZS.%"UURV\V1B7]HM\T?!4#XLES[7XX=/&C[^S'%E2> "ZVXV]P?T0?O8+
ME_QM^&QP\L'_%<0P/L3FQ6"#0+ARZ$/?VQALNU:YTL$@_C,$QW%>R0_OJD14
M?%P<R]2. Z:*90T#AR\'-PV"0QU\WO%"%LE3_6TPE>F*.ZPF317['HSLZ<S&
MX]:L'9V-RN"O[/\].QO%:555--A[  &*+GUL[RUV&Z>WA&T.BB"Z[T]TWY7!
M0,63B03,Q)^_ZLB@(CH*.ZO$L9BO<==UE;%1D+*BT[XBV:*"W)]2@JP2L;D"
MV/%??><.\Z)N,DRW?2Z-Q;AU+ 9)8S'N,S1ADB;:C1SM!E6J3.A=3::\[T97
MDE+Z(ZKYV7G'%Y"8G9\62-..OXD06")G,2FK&Y[J)UG#  0!+FPY"Z0;0*Q$
MJE<[AQ]>9X.+00PCJV%75:[OM!T .9B!CK81S.(,D-.($@&&?7^HQ^FB[C1>
MM:8'WL4L;C&AL'S\H 2MB$8VVHEB%&&)X68T:)?6>6J0WF3>0ECCU2V6.9K*
MPH^M6/4-,1$]; ^#\E>YX&J5%3YF,;\Z!;&EI0LK7L^RO4MC4MC.H?[B([?]
M>9'J\=TR05EL8V)1)\#[S4^;^R*U.UYV_'E0K#8R)NZH(GH<>SCUKK"(9CMU
M?XSG,?KOUI^/Y7$XGXV!5D$63"2."6QIE8F[DH[=F6QO?$#P),+>+OXV6)RG
ME:&T14K?38]SJT;%!0M?>C2W#]PJ'E/8X'$.-'QP+(2MJ!U1KB^-ZD76:7^)
MWD,Y8&_\@=(*M^ZZF;I/<KP=DR>Z%?9\>.FM7L7G<O=O+W=_.-Y]L]4BXMC$
M51VK1"4$Y2''()[VM*-'%D<O^4%,=K<'IV,L/0N0&V&W^-D%#S1"S^*R,^V?
M[BZL/NW)<76<EQ.\]PP1#1![E;^.4H^8JWX(<!A<]9/"-9^<;$\%!9<!P:8M
M]H\4H<5YN#XK5*_\]QC,)S!J+@K]FCQS, H:^[5PRL-SKFK3G;SK^ 8_-BG5
M2=WDD:87_/ZX9!><?COLQ3!ABI<30Q?6%?2_ZSNMG\9ZDV"B],;'\XQB!<%<
M3EP.W0N_TOU+0S]Y:Y"7834<LI"?[Q6/ST?]X!67*!H"JA#Y%0LHYN:>A*"X
M7V*9C6@=@3B\952,61J3;!RQ78[Y&I[VXBRC>"0ZCO:FPHT(E3</)YI)1B%Y
M-1G%Z,^24:06ZOP__R4QYD^2,+VVFMFB,KK."@J=5TY:=0 YBSUE!J#RE]K=
M:1%U/GRL4X3>_3)=4$3KNMTO,@?%<,4R&Q $>1!/]L<'S+&?I@J_+HM7@L#[
MX> *W"TV "Y)QT-*Q\_S4#/L+9R;,FL48;KK(T;'8_N(<[Y_UAXN!$SW@*"I
M5%$QYOJ\.DZ>'DA^U:S&91L?GW,6+&;P-LI*C:M+T*. :/WVCTG=U15TO\3]
MJX(<7WTX8:['Z47#A7EB:(. ?@V\*.2S/TGO#;T=R^RH.Q:%0@K_,VJ7<-8J
M1]OWIR'NBBC\;3#&NBH&C:43/RF;F*,A=SXFJH>L_.JMKFX!:!?J'L.Y8EIC
M0(AQG=+BP=N9OBBJ-RK.%1PH^)7%C/*$:-.^[8=^[[.WEYH<86"2@(V_F3T/
M*.K-BIF-X\1V!(W!J*AM&QO/HM)FG%LH0_VX-..+JK.P\+$[;B;[GXI=PX=<
MN]I\,52URL&6I2+%FV-.ISU!I,+1&_M7O?ZT>Q6_.!(A+#;:Y]GJK4[G.G6K
M[$LK!M1!$L.KV6GO6XBQPYO'3G:K%-5Y_)KY@N-Q74TKBQRI/,%Q?J=8UEF[
M>WE8,<DZVR"68S4M8'BNKA9[CX%01?LY&C)C9JHK+ ;C?,(J#EF?.$:<P,FT
M#8K)K<%-YUEW38W<>L U&RZ.A]&7!T[%:LH3E^%-2QZ-EQMS?1']IBI4)@%6
MD+)AJ0%5J6/\DH/^B>Y.6^/XYN,@,.Y;D/W)<5+V*JR49'D_!)#?>OTOK[-7
M6P='!Z_G97U!_,5)OXA.WXX_,!Z9?WE<$].%T[N;VH\)$5H0^1+>6[?2[L[Y
MG1AM3U3&3 Z1HI*-Z?@,9'SNB>QJY';JR'/DVE4TO]/O#H;9_^BS\U^R3V&W
M)ZWL_?L/955D(%?T'\O;4T[:@U@,&$!E9 +X3CNB>;M_5K"]0*+QH6>[/SYW
M+=/EL2!K?$07H3*6-9?E6!ECCU("0N;VC3SK$I!?Q]7$Q__<.<QV]]\>'.YM
M'N\>[#=;4VZH&KKD-+VY(6/>8>9/SFC3Z>OTZ2NM[>GK=7*M^)ARQ8HJBDG&
MXW1_'@SS!' /)X#[H03<S0G@O@V >[L"SZ-"1"]YV]GM4J4*3T#,.<0[+H.0
MHWC;0RR''R>LXR]_':>FMZ=3%'O:]GOO?+=M@]N_V[7KB]X*5#?I&=]%V.X6
MP=LJ3HL6%92G;2LL,P>5"W.-G3$E@\0OJW+V6Q-?\]);OSQ^*GV=A?SI*ZU.
M#^#?%X\-/O[E.E^OAZ55K1J%D+3F"/^K*7_\]>4Y6HQZ8S*PTYDD:*K8,WQP
MXH>OG,;7-O'3<]V:"VO1DS<ML:UY6=;BZ&X8@$O'DX>*[17NCQ.V4_A_$*@\
MB%]48=RKC]U"&8ZB_ST(LO!A:_/@U]=EL!5+/N+@O$(>9]IOK^>$;XL>(JS&
MJZ1:XU.YXH$S3Y_*9L?(Y;)@95R@>!Y VG<'47+*VRN+JW JW*X4M^B)&EY,
M72=5=!,5QW8ZA!'5DH>G,3U47OQ7E4 L4*O0NC0.X_5W>\/JF"XJ2A6PE+MY
MZTU_I/O595>8%X]0K9A5[Y<IAR!<H^Y_1O$>E%CL6:E96:C1Z_[<LM1&=A<P
M-+\677&1#97):<SF;L\F7=J+J83&G)*#Z0J#.^%?6=9;]K->IE'&TGPMZE\B
M+S*.J2LMB-!2;"R^.*DKN=SF':I+RHKN2XJ41_%ENV^E"U$3>A-/9#B'O(OO
MR,RDG")J%AV0,?>L;\@^3.<G+@&U ,&"\.41W4RM^'1RXVIJ=:;Z9#Y8%ZW*
MN7?Q>&ZZY[*COTT<4'U^'M9:7H-TORD&EX\L]M1TFQAS_J.BG.22PXL;Q8(
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M<"8(NS^/Z],33#_OMP,1SCM^L-YPW=:=06]&P4MI"%OMNT*3"Y)$<@;YZ;H
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M1WN'XIUB3'76RR^=W/->/VIF/1S<)E"T7C[LE3* --;MKC8.3[NRS#KHH30
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M;YJ[\^BGB#G+J=$*VH!+3BHI T1YRG,C-37,I$CIR3'JX\PI(D380LR!Q=@
MBKF+MX,'M KQ$V1&4&/YV@:'+82OSP!,6? $,(_N!'%"B'%8.\RIS)%4SGF3
M4XTQ%):Q%$?5 6 F<10R(8#"Q(? B:+@! D<  91('*KPW^PT^4YFV@)NE"B
M.(WU>@%:KG/FH)>YRTEP(RQ46)+<<:X\#LJ.5 IU:J#E4Z&.9%ASRB1P+M>
M:AIGC3((/.0YMH@:9=W:AD(M*5=Q6\NXKY:<S[L]^G'+:E>XEJ?3\(=V@AZ=
M8<^?#DE87IYVISS0XK=_#X;EC$/__=QW!W=MJWE^E]34Q9FN*?@D$7@I\503
M.)4*I>Y<*#7PNF]/"Q/@0H37Z9W'^JAT,-GXI'_)V,VNVYZP=:<T\BF$7RJ$
M/YFIF<HQ(YA;( A!@.:*@7B!&5#.2 ,]<D[9M0VD8$O6_C+EFOH6"5GJG>U/
MR+)"9)D< 7CMB/,HCS=[:$"=(\!0D0-+%$*,:\-A/ *@HH7)2H\ TFUC]=;N
MQ\WR)^U>G79/I?ZU@RY.;02Y8SCX#8(#(SR+VDTI%\8*Y8)V8]R":J$2@IKE
MMVH:X+SS7=_7G2*^T>ZLW6T/AN6,B'K4)#PSJ'K,$*=B;4"JS1G&)K"Z"UA]
MF0YR#,TAC:X(A!@"*J0#6BD$C%&28FZ<Y@&L*&PQN-+[)%Y._C1!2YUCG 0M
M*X:6291#)10.8A?O-;. 4LV!-@%?A+?"*1J\("K7-@AN<;;0U0HI+_\\U/LQ
M@YRDWJM5[ZDPQSCDK*<*<$]$"'-H#HRR.= ,>D:M]$2R>&UA2Y(GBW+JDTE=
M:3>'O7:67X]<ZTLJR'S,^*>HW0@85J%6*LQ<#K9VODU?H6>1H-X3 K1 "%";
MYT ))8%QEG,OM:-8!=PBJ$72L4YMCW5>$M0\9CR4H.;>4#.Y78X)9,)_+#!"
MQQ-D)P+H< T$=XXQRU#P@M<VD @^DF0UAYJD[L\Q/DKJ?F]U_WBI[MARY@3S
M0)@X05%+!0SD N!<Z.!Q8*)]T=F%6@JO8@38[:78CYL&6>%:7FH=_\M)B2=A
MJ:.P-(9A*5VTJ)B][PT&Y6C$WKF/F<]>MR:IHB90[]7CIH,&@3SA7TMX;P<E
M4[LGNUW;._.1V\F!6\Z!NYA.#6%BC/!$ LPU ]0Z Z12&!A-PV^5P$JS&*^A
M%H;7AYR]KDNH5E.#EE!E:5190>8GH<K3H,HD"V0009H8":2,!V5:4!!"? ]R
MCS7A(;RWF*YM8-Q"]/HY>&U )2GV*A5[!3F>I-A/H]B3?(^1$GGI+(!:Q#)^
MRH&2P6=@0A!%&>4TULYQV()S!OF\3IF>9KLSB0Z)#DE'4TIF24DZ&)[Z?M8N
M+'#VJJK?6<3+2U[6DR9EKKA2D8O[O6YOUJ5*985W\JK@=!)&&>B%TAP8(AF@
M4'E@+.? :R48%I[)V!R)Z?7:G-K$2C6U4 E!ZEQYDR!EQ9 RR<"$L%I(3N)]
ML)X":H0 FFH'\A!W>QZ"MR#A\>H*ANI>\)>TNZ&%-DF[5ZS=DS2,@XYKDPN
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M/.K DNKFHIEAZD[,0@ J"][[#$3/NJF]-#S"Z+B=/=UR:&<X"Z'"-KB\ W8
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M3L)73RG^EMJ?QT?L%@!; 'Q: )1)EH@L#?,<,ZFYD1%/5**RE&8J"\MSFEL
M?$H 7,B09=W+8V'B2,3*D#2*8\)3EA(A-2-IFB91I#*JHL@!( U; &P!L 7
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M3>%[N*ZT5'QLOW\MB/VC6 =:SL'JGO<M\!5X/;E.)UC*)JA3Z1;QP(WV?G;
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MPW!H*E^$5(;)5Z/Q,*R(^^<I@-43$8?R%D\*;77A>3<7@E[N&I!RE, <>2Y
M "*,(XU)1%$%7DHJA;(L"4!27.:F[O3T#E,>,?2E XZ'E'!>[H),$R4C')&
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MBO#Z<G>^&8$"7%Z+!"C5(3!,&.%<E4%Y3*Q3QDOAM7&F(X$')0&W&[3VRL>
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M/M-;>E2-DD( %X%.?#CH)_R;0'7VYL1QKW>6%Q:TX R&<PL$0%TV?Z4G#L8
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M?'5,1'>MAS4UQ&TOY,R\G*'\ /K8]V=3>EAU[**>(N>AV;(IJ05GH>X [7:
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M*V4ID6MQ&("#]D-_5%2C<-!E:ZUH4."5H"COZ.RC_M[;M*,=(%T/D(X7]*5
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M"GUZ&=FN"$B+*'81WIV"RE[5#VB_@4I"\3_A_2^+X8(!N!C$8K0?"AM@J'W
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M:.D!(F<O.;O?TD;%JTU[:-6KXY!NUXU?6Q*]69'$V, 9 M>URC=AD:=A$'[
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MC2<4)$@1NITMS^,NGUMZ37RA7O+SM&BH*<.ID=*WG<MH1!.II,E#AF3&<;1
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MG%/E$1=@>^=8&A1(9KGT*O=>7X/(%*5U"3E9]X.VDB-9=2C666%QGV,1NIA
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MU$Z->ZV?8AO43<KAFJCQVCV9]Q#2:GHR'U,TO;Y,8BD96#O'.17*2ZF1\9R
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M*VW(^87O#O2PU[]J771T=_F#;R@H_B^FYZ[@G]/A>>?E_P]02P,$%     @
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M.3F+*X3,D3 ;71"""FB3DFTPEEVRNVLS\HDU7XW"'V#JAQVD ]]WP^[CY,K
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M&@CA40J<6P#E1[G.Z2]_^G]02P,$%     @ AH%:3C!*)XMA90  63<$ !4
M  !M9VYX+3(P,3@Q,C,Q7V1E9BYX;6SLO5MW6SF2)OK>OR(G^W50B?NEUG3/
M4OI2Y3E.R\=V=LW,"U< "-CLDD@=DG*F^]>?P"9IRY0H\;)!ZN):M9R2+'-_
MB/@V$(&X_8__^>?YV4^?<3(=CD?_]K/X"__Y)QRE<1Z./O[;S[]_>,G\S__S
MW__E7_['?V/L?__Z[O5/S\?I\AQ'LY^>31!FF'_Z8SC[]-,_,D[_^5.9C,]_
M^L=X\L_A9V#LW[M_]&Q\\64R_/AI]I/DPJW^[>2O7#LK14&FC:E_B,Q\\I;9
MI'3V6)3TXK]__*L'GUV4D7$A!=/<1P922R9+#K)(H%\VW8>>#4?__&O](\(4
M?Z+%C:;=M__V\Z?9[.*OO_SRQQ]__.7/.#G[RWCR\1?)N?IE^=L_+W[]SVN_
M_X?J?EN$$'[I_O;KKTZ'-_TB?:SXY7__]OI]^H3GP(:CZ0Q&Z=L#Z/%Y]O4?
M7D5C?IG_)?WJ=/C7:??O7X\3S#KUW+F$G];^1OV.+7^-U1\Q(9D2?_ESFG_^
M]W_YZ:>YY&"2)N,S?(?EI\67O[][=1WI<#3[)0_/?UG\SB]P=D:(NT^8?;G
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M\^$*5?9%>/""E5Y%NE*XXDQ47KL(/%BM<XA2>_"8A:$#1AD_\""<@2A8<74
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MLOZ3]U[DH)B/)=<Q LB"A<)2<*:$VH'9;V*(/(YBIUW,C1[DVF/FP^TIR)N
M>EK%3ENI::.BEUUD?+!BI^!UY,4X!EW>/R1'>X\R3.J<;3&V)+>)67 ?%;]=
ML5/_>M]&M'W7Q_Q?&+Z&^'IX/IQA7O:P3%()R16KL5"FNXM_<H89R*AH*Q-%
MK':O75-2<<.'WY>2BJUD/NY18(>J5DLHP1@G6/+&U@XUA@R0$.A ,M9;(9"K
M.V.[#Z%:;6=%]B&XO@N<7O[E[^-2SF$T>@WOQND3OI[EO\ HK_R4H/_E*UKK
MG26'0_),=@<WM"]QC4S6$++4*A<7-U+SUH]^\ 1H*^R^NSZ]QNGK11["<(+3
M]SCY/,3)R2B_&DUGP]GE[#F2O_")#-E/7_]V\9\%>L%#]%G022648EK61M=>
M"$9?<$F\=NC\1E39&\J#I\YAE=&@M]2M65!9841M,P. +D$.F"=$+!8#2D9A
M1&S27NK!Y)_UFAZQJ^3O4?[9"R+].9 ]]/L4R^79Z^'G TPVO^VAA\H2VWCA
M*XE?UGINI;.%*]IKK/!9QNB2+CZ#T"D.2C0E<6\9*E.K*FAG@&0*0YF,!I%D
M\7S/Q*^WD_$%3F9?WI[5I8UR[:1Z4;-FOO$<=4!1=T54=9,*A;-0JK\CLQ.*
MA^"@2?7+W=#V+OVBC3E?GM&YL/99B_(60V]D](HYTA33VF46<S(,N3$V)FM"
M;C+5;5. ATH6ZYDMUPK#6NCCOJ21K5W2E6P',@6,S"(QD8UDVM5QK$!?.;)/
M3/1<"-^D*G4#;,>Z:6W#B7%;W30(PZQ?_;>$B$T@M@SX;H#Q.#'?WO6[*7_V
M5,Z1>&2<3DXIR631U2T1G/ED,LM>@H H0E"'W8:.G*!V'^BSC4Z:) R<7US.
M</(5VC(8B2IG],!H^4 F:JH#150M57 Y\1*L;S3UX&8\AW<0>]?=-4]Q?\&W
MZ)HP+K,_8(*TXN67S^OPW7&'\=EX.OLZ"\MQ%81&)F0.M7>$9R#)-%1@R/V)
MRH34I/YU8X2/CS-ME-,@A>WEY81D?=DA?3G\LWZU1!9MD.0R:.8*YW42O&(^
M1S+LLLT* DC3QNM<#^GQ\:0G\?=^R;VLM/M"N$Y+&29<W?UR 55 %B:S)MX*
M9Q@Q-3$#!B$F#SJL;"KK;K'O?-;C47L+X3:XE7Z-,,5/X[/\ZORB=J[KIL<O
M"[9I3T(N TO2)'+RHF<!03#:Q;A.,6>OFI@;MV!Z//SH6P'7N6&:>2_+J]>"
M Q<Y'6'%,D5$KD/)'(,$@9F$P'WBTD.3&8(;8+M'7.GGQJYO?=RC<,;RXFE<
M3NCG>7AV.1M^OC(+Z,6?Z>PR8ZXRGWW"9W"6+L^Z>,ZX/*^_C?GU>#I]BY/W
MGSH#K'5Q?1N\!RNU/X"X5^(O'#!K:R5F'S4 ,9UVKZ1D= E-T69@K$$=@V0I
MUD!<[6\6'-K:>U4F;WE*T>T9?[E]L2]IL7,'L%OI::DS0TAH7Y?Y[2W.5D7R
M_"R3+@NFNWBV"<!4B4+XDJP-38H)^UI ?[&</1'-;Y.U04-^M"5WR!>F8Q3D
M7EO#8HS.&0&*]L:V$9\^EG&HN-!16+P^>G1P!MR7&-.>"__UR\T?T%UP%F[(
M\"N1<>2T&6:2AP^D)(M!%1DX&85-.C(W7-/Q8UJ'9^IJE<D]84R+PJ4;D=4\
ML(6/M F^EN&RNP >)U9V;QBQ$5/W5.<Q:"=3%A)X9AYKI CHM MD>S(5"29J
M'4)H,\[U*'2[([3V8-FVC19;Q%]FX_3/TXLK&>O L21#SHI/3I,;K\F--YS3
MH6 Y>3DB:=/D?+Z&Y AC0'M5UJI9N9>D#[;!;/S*G)Q7SWL@$@?EK60R0V;:
M:<4@HV)!<1M!V.1EDQA_+^CO"\4.[.$<7O/WZ#[N)(\OYM<]EMOFMVDW/NU0
M=V%W+W7E)JN$[+D"",74$<0"K$W)0)0NQI*5&Q#-=)3*,^?KJ'ME(XL@4QW@
M$+TWW.92]KS)6C3T?U6E F<G%Q>TEHZ(1+_A.#^[/._NZS[CBU(PS3Y,@"R$
MA0 7[X87UD@O.9.:L&DE3=UB%4.)4AJP,=LFJ0+[0]]W3]\9P=P#Q!(QVMH-
MP%M/'J"GLZDXVEF*M@X%O?&N2;NH_6 ?ZG;JP,Q<W;4/J-MCWT/50JNWDW&^
M3+/3>:E3FF?'*6MS/7:8S7411@4RQ7(A/O&LA7,JPB8)]!O5C=\$X%@W/8?4
M_;A''?3<4&"!9UH3DN:(I@O+?!-0?7>46(OF\!TE]E?4=:WW).6#40 ,H9.>
MK%!7R)T"3;9)DH&1C^6Y25$YM8GC>A]5?TM/B0-I?AOA]MV48+'YS?V29?]T
MVNM./D[P^Z02DT00QC+A>6"TM17F=?9,Y80E"Z5T$7>9]5L]\;"EQSUI9]Q:
MM"WN*O)_7DYG':"7X\D;_..*LS,A!^=RE.9PYVW4! @9:ALU46S-1DTL:/*2
MR3,6P*,QL31I.K<5RB=D2K378H.<XIH$=UJ6+O0RG74#3"U#/3>!.E)XIYTN
MQXT4T6!?NA&;<MPKG^AMQ%#H]+7(0I'=#:^1&GB))3UL<MP5C#DN-[:1?[M&
ME[38]S,899CDZ>\7&69(:M,\+!M#:YV5C8K6*FMC(!#,6T,@B_29#G =1,NN
ME[>C._R]^/Z*O+GM98]::$"5[0_A>=,XD5SM#L*2JTVE>&WQ88U@7%L3#,@:
M&6C!G=W@/D%#YP!Z[;%89G?4RU:3&^!N:17M"OPXEM,AR+$W'_?0[+W8)Y?E
M*_2R<N!8F]YDVM^38\%(P40(H@1=M,M- AKWBY%WF&L/B9#;*+1%^?JB7 #S
M[R/ZQ,41\[?+80:R:5^-YJA_Q5*G^8TOALER^S7;(Q?,DC-=&[5I*2/S/$G&
MI56 3D6;VG3"WQGRX:W P]!BM3+^,#IMP,;G0X(V04+Y*\[^0!S=BOUDE$_*
M#">K:P";.0C!D@RJBLXP$,70DF1Q(29.UG8+7O8!_HDP].!Z;G"=]AQI"1/,
M"^C/+NF;T6R@N$H\!6!"QMJCT  #ERP3R(5!<"Z+)MF&-\,Y/)^.G%/0@U9:
M[&O?HWHS'J4%,.FX)B2)6:B#M@48%H!LCH3@2U \ F]R:[(6T5-GS(ZZ:;#!
MO*OY;2/,RVS%DY3FHL!,F(=I.!N48IT(0C'K:V?UB)9%#I8YB59*6K1738:=
MW0WMR=&H9VTUN U9"&@ZB,1KQWFBXY)6J ,DYKWT+*7HC8DA%][DMFT)X ER
M8P?)-V@@\@9GKT9I?(ZU('S 91)6:<$">;U,^QC(UH^)F62(CSHZ[9O8R=^A
M>')<V%T'#;J&?$,R3YBHX85+VKU.+W#>@;NFR/\*TV$B&WS13*#+F!_87!L"
M()G[UM82(D%[67"9.1%%TEQ8UZ;H=6?$3XYHA]'M=5+:QG40ZVH#Z@HGD&;_
M&,X^+0<9O!Y"')X-9U_Z*HO8Z^$]5TGT)XB5H@E$9Z.,(#176L4$*93$BX]>
M"2=2&@B)'C0/S%4?2LOL&93 6>91R8)2".^NKG8K9?\&DW\2R'AVI9)G%[W=
M^#G[J^!N>*O-[-%S7VA7UU;K%",H'P(OX)7%I$$-?,HBD> 8O<^::6<%\R9X
MIEQR220A2@J]2K,+!_8FT\6GM9'L35!72WP*B.+H# 7TVJO@$VH;"R^TJP+/
M8J"T]3%*S;RK\DW.,-K'R/PRD#,861O=]"K?/3:;VSZNC80WV1"2IVV_2(]8
MBC9>!Q>RC:(6B'H1G!W$E)TEEY@1S^ODGR18M"*Q9"4/29CH2]ZSBNI*:XC/
M!+@NXN5X\AZNKN7;P0G$"16@FP^"=5*(91!D9-QE4P1M;;Q-QM)6*/OK[$.V
M0ZZ)(=_*O$?Y=/8))XN_.)E.<39_F08I:(F<DQ'!:PZ*(F_$VTB;=_!D3L2"
M$9K<..V$]E"54.W8M;X93RNE';O6:;G2E\,1C!*9OG7JT^2R?F079C5:ZA)%
M(?/2>Z;!& 9(YBUF)Z7F2(=?DTNK-7B.W^NF&1%6N]KVH) 6*:?5\2EU?NBR
M#*!Z*>4&M-.:5#>]^:^64:D-UM(TG[G'Q1PGFZ<7EJQFM1Y;Q?>=MD4($[!X
M9F1U]!,H%B(Z)K/)QJ-TH)JD]=Q_NMZ1ZG/OV;J-9ANP]/?W'R8(T\O)EV_'
MR]=.YDDX!XF\>-&-=R0/-+K(A"G>$ZXHVO3%60_I"%G:1U/UN(F>FC#H;^//
M.!G5E;Z_&(^FXPGF%V0Q3BXFPVEU(./L&F9?DC8AD!2Z/Y!+%B-J)FW(T7)R
M&Y5MPZWMP3YIUC76;8.P^'(D-=X(SAHT8'Q@!1&8%C7)'7)@RKLBL]8.;!/O
M]E943YAA_6FK041\U=?_'N/)^7@R&_X7YCH7I@9*IH-L8NI&!D2="6]0A<6L
MD:68+( 54&(3UW5;H(<GW.$N4)HJK47UW.UXOZ6)_&TRGDY_'Y$9<%87\#<2
M^R)'%_X<)!\A1<RLU)ML;<&Q "&RH(1R"8(/;2JD>D'_A.G80+T-SM1=%U&C
MR]\6 3G'C"(QZ6M8T'-=1Z#4J<Q2%B6C+:Y-!6@?Z']PM$_U'N"POAK"NKJ<
M@=+<%9LYR[*F+WC:[X,GSREZ"5F2?:%XDPD%FP)\2DSK14EK,^'ZS#&Y*39Z
MVVIZ#?'>_: VP=\M%[@2%M9*6^NB<UID[0TGQS H'A(4E(A6#70F&AEGF$FU
M$8*4AD$6AGGO:F:3C]S;G2/ORPE+7R<KP;>ACKOHY=;/VU_\F\-=D;(3+ED9
MHZ8W1N?LH@XF%D[_A^Q]U /AP"O@M7-SXG5,%;*0R"DGR=.VG(+71C>1\NYY
M)!M\:EN);Y!7DC0Y"4(D JYTR3Y:QWD0*7FA#<]Y0-NCY(47ECD$IGDQ+.04
M&1:=L@_"HDY-Y+['YK/)Q[:5_"8;"]'9IA# YE"T,J6FFD@!BD/QCJR/00)M
MO"?*)U%-$>&1]A2@-T!)^CT,$M#LF6^RP7RXA)R\R6CJ %!%*&QF409.;U\R
MJ1I)()L4P-X-K;_,DO4C%;MP-$27+03-:L.VVD5-DC!48MD 5,LA09M2@DT!
M'BI_I&>VK$\:Z5$?]R5/9),A\CS3X5;/.%>',&LK$XM997)%;#3><H[8A&<;
M8#M^_DB?G-ATC.6.NFEPO[;)T-=-(+;,"MD XW&2/7K7[Z;\V5,Y1^*1Y!ZB
MC[Z^2M5K%84<5B=8,<I8<H[K1OZH^'-']L5]H,\V.FG10*4;+(*3U5GASCC:
M5SVI4MO..^#,UW:SSGNA5"'K-9465%F#YQX-6-Y5=]<BB_L+OL7\J86?<W+5
MY?F,9^,.8XU*+8.?JB@CK$#F5)1U]$A@D'(FR-IY),?=QC9SJ39%^/@XTT8Y
M/09DNA[6+R\G).C+#N9I*<.$JQS'Q)4@+YF)3']HVF&9)]^"(>VG/@#D BN>
MYYJ^X'<^ZO%PH(%H&T0Y5N$(+.A5BLP9S9E.6;'(,3,KK7<%4XZI22'+HZ5!
M'X)N4)K_&F&*G\9G^=7YQ63\^;M6]:XB\U(R8;6<%XD'(PE:T$ZGH+&T2::[
M!=/CXT-?"FA0I;]VZ5VX=F#)K7>T;;$<+>U84B@6O*Y$MKI./W8B-QE8>#NL
M>\20?N[@>M1"$S>D2]M+5<2O1H3UXP2GTSDT(,\+9$ 6B:VU9DB2!U;=,$5'
MG,5L1&SDBJS%].C8T9?\6R3W7.U$=#'!-.S:/]#79]C)?)0767/S[A3K!#5
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M,WF>C:>SZ3=QBQ*4@.*9Y2CIK:T9\"Y$6IV+(D"H1<\M3(^>U]%?]+L?8/.
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M!+293OX=BF-E;?2JWG%?8FYP[_X5S"+#>1,X+>N15O <IP)I#PVMT_4>XCV
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MI[@ 2\:0%S%R%GBFW=0I2^=A\2P7X%PFESE?8<N::YUMG_QX.-%>\#UZ=7>
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M\)JRRT4^#MF%N]R[-&93^QVXTKI9TH8>58Z45CECE&@HE=R5G606(]L[(M>
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M.]PVN)S=S3[[@/%VKFWTV-FEMKJAGZ&GG[JXE[4!:5Z5+E.B.86>,<1C07
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MI#;O(@298!%,449%E"0AQTX;@<^FR=3H<"TFR#LYFQ8S-Z#1L=[:EZV6Y@S
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M@:=W1%A+"6@MG;/C:0.UM1OJ"[[1G-):4/!C)_)/QMAJX%R+#6[/ ]O'-W7
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MW_[R^2_@C=1S0.<-KQDM'"R]JZ;%PO@>"^R!::]38Z_KSQKQ^J=:&;"MS;I
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M;Q_)-($T$C&4*N68(9ZQ).N(\XM#IJR;&#U(\\L8,24M<]:M!.]I^8=<&A5
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MP@#+*$HC&$L<0\0$A0P1"0FG<8;B.$:8SO13V<(Z,J:'&"Y?_+8P X9OKG6
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M*[OD:D]3LR:,H' G*?C2P]_W,JIV>QLO6 V\1)^%:8"-SE4LO*8&O-C9N$D
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M8K-^DCDXT*Q?(2^7,;*T)89%?F@KHY&^!+HMO_F%D7UF4JZ8'T"EQ2AUO7J
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M5^^=W4V-MQII9^W+$CVOBK7:Z/7'T6Z^ K7E=;TW (>^P-]A5XI:A4@UPLY
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MB=Z.U$+^N]Z#'&(\X(W'44?]5H6O\H=<;>7'U<*XVMX]/R\75;GRND1Y591
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M!TIJ&BU+DU!M5J[-O>.^06U_RC)AWG,NS7_7?_K%W$?^I2K[P_<99-:[+"&
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MM*68<XI-/P-J:5Z-.4BCI?'<#4Q;)Y,0H-:J'*.V7C-PE#1Q=I@UT6L&4*^
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M5_RI&68'Z9D/W#QKGW60[Z4'E2>:VYGZR)^''6M/=] 'IOU&<5!K#BYYF,W
M3OW*DZR8'7J@&>WU,QOP(C=@#\ ,5!"4=:E;(/A;/%YG['RN/B-K,.KR]3JC
M<[S^O9(4/6M3+Y?K/ZE&5S?[;KUE&[5=WG&^WNK56W<C%S],B<)YK&@4(LJ@
M"&@&$24AI'$<P2AD/!-*Z470*5K6KMNI+5@[J<N%2:/LN!Q9@FVWC/B'<&#Z
MWZ-GZ+D1&30R@[W0'LM-.X'DM<BT7<_CEI9V0N.DH+3;VST->IJO]':A:#*H
MF]+47&\CWBV66\V6<X9IFI%4P"0SD9THQI DRA1,0"1*,QIG*7>RP+O[FQH#
M?=;VSM*XFNRJ(LQ,'N(%KW*95$*7X4W;0O0NG7!M$"SM7'_0#FV8UI+NBR?,
MP)L=JK6\'HU(.V"\6GU7NAS73+/3_\2NLGRMQU7*AU__:ZW4$UVM/M&O:_XH
M/VW$KWKLCW[[<<5_K8^D$QX1$LL$1IF@$'&-.D6FF@+7%*04X22R2G_<K_NI
MT=*'7T$C*_Q$02DMT$J4\^?T+T81\$OYLTMM!/=10IC3A"1ZCTF$7B,PCB'E
M0L)$AC%->,92R>8_9,[6KS].;3$&O&<P @Z*N<7=UZ X#KQ67/K4?^WZUGO<
MC+D#[W!+-N@ C'1C-LQ N%VF]<:Q\V+-O=7Q+MEZ:WQPX=:_E=X)$Q<K6=Y%
MY NV+8-F],=4G]3DYEHBE^:W-']I/W3W9'8W\X") ..40L80@2AF II ;AB:
M>#\<42HRJW _/^),;?&OM0&\)2EXUH_,@*PUTCN3EDJ'3])2*>=\B[>,I]W^
M9;Q1&GC):@:H+22X+P>H408<:'/XY%WW /7)S>@!5\^I&F^1:.S,C1[0.Y/(
MT4>K_=CY/E]S*45A_"],)3V]I_N-;K;Y8O/R1=W]H(NE.5CZL,[-'[]);OZR
MD,5<[[PB0ED(DS#C$)EB-)AQ#J,P$"1&1&6QTUE03SFFQL>-&I7#6Z%EK;PL
MGBI=C(O%6NG_RO\I-T8A4.Q4<6/AON-F1[\CC,; O'LX$&6U3C,.C19F%-Y)
MM@%[X6=@IQA4ZQR:P?-'O#<BZI-Q^XHR*M7>B-<QQ][:7,]L9EM6R']M]7[L
MO0D7;_:*F*8RIC%D,<D@(B2 !$D*,QZ12(H4!YE;M>%SO4R-&/="@E)*QQ1#
M9X&TX[*;X1F8J8Z1&2!8NQ,"KXEVSG8T;K*<+EU/$MYT/GQ#"D-V/8D.NY!$
MYV^5:\*JS*C(]8\/:_.K5FZ=O\O%]T?SS ^9T^_RJWRB"W,Z7QJ'E&^V=/D@
M\Z=PCI,@49PD4$0B@@@G#&*]789*(A:S+."(),ZY#R>AVM3HK9$;TDIP$[55
M25YMN"O1@1;E:08J&$I[1-9 F#!$XY/2(_/:),;#)67;) 2>T@+@,==;Z]-Z
MW_JTS*^/$L$U0($:*;"#"K2P @8LS]GB)C7^WM/,34.[\?/334/O2^O\]"0<
M.3_R![K(_T:76WE7%-NG2JM&F;^ME[J9I=X+?:4;.>>A(I('"&8RT/L3Q#7I
M!)1!BFFF-RA!C,0X&9/M99Z:.;#CWA\[,4?*J>HPS@Y+]G1&;_IKL=$;E(J#
MEN:S_7J\5QX8[2>0B]5]J":1G=5!['^/?*WNX^ M@VN/KGLZO9>UJG;=[:/2
MYF$:F4(A!%(4)1!%L80D"0)(PX"G4<2C5&4NF<LN]N2T6HR0OZP,0 "T%!<\
M26IDU#;\!BA#)3^,\(Z^[A<QMN-\+\@-S-1-9;L6W>[E].C$?@T*KW[K%SL;
MUU7]FLXGWNE77^AI[6[6_)\?-2%)\6Z;:VNZBL(I._DL_RS_4LS#@ 6IXA@F
M+.00*6.O8J:@)(3+(,4\(,S)7K7I=6H6IY&JC.]8JS*'E399"J-'65"S3'>E
ME,RK\ZC"-7NJW3A8VI.^T1W:(C3R@DI@4$E<1SK.*MJ9 2UV]8"'/!&]8/)J
MC5EU/*X]Y8+%B47D]'(/__4[(<IH0+I\MR]G^V%;G@K4QP>_KT2KR/P\2VG&
M528AY3&"R"0(PI)D,$IHJB2B-+,K?]FO^ZDQUUZ!@WK JE*AJ27DX+WK/B#=
MS#4\S$.;2E8(@ZV1?Y^9:5#$'?RE!T5^)'_IU@@TJ-/&Z> 8=V/XEX%],G^F
M^>;E/XIZA#SY3??&L]-OVKW5\?RF>VM\X#?=OY6^QJ_>;)MVOJAR#3,9Q#4=
MO__75F_$'9,56;4U(<;:R6LLU[;$_P$JF0?)3N2$DE^;RZ;CD6TN!RQ.;2Z7
MEV^J#?1IP4VVFMVD:T($I90,D0!&)DX012B -$8""AS+D. (J5Y%@L[W-C6+
MJE7@I19XG\JN5U&<"R!;F$T^H1N8<[I0NZVFT 7X>A47NAW&\:L,V7^$?>L-
M=:-B67CH0B.O48&H6Y\+I8BNO-2#9D^+_;Z32N:Y%%^-$1_%69ID2,$D2S*(
M!$60!5D"8X99+,(0L\Q^']O=U]0HMI$-Y&Z<>@51"T;UA]/ ?'JAIO<.N:]>
MD7,@4W\(CD2E#X]2(]>@*79HBNHT<O-HW V?UWE9Z*5*U6>0%NUOU%<) SOP
M.AGW2A/C\:V=+@=L:_E*OQW?5UE(_=*CR:NQWV+6A=7G62JQXL04J\XD1#(,
M(>6$0$0I4BF/4T:MRB!8]38UOFV$K5+M[,5UN\?H!MAN*^T-MH'I]P"QEJ2@
M%M7?MMD*$9_;Y>X.1]TF6^E^O#VV>ZEG#B^E)-\L?LBJ^M0#_6E\-DS2PA5?
M+!?E2G7>2>3]3RZ+0K_P1JZD6FSJ>.TL"A3- @G3E$:FW&0"&0E22&@4ZPTV
MRXB;-Z!O :?&5/>Y_+%8;XOE"]BV<^S*4GJPH3\!J^1WO(3U/K)V?/>:XS4P
M1>Y4:ZKC:5E+ESQPJ-ZL(UENI63Y9JWFS'O0_E!#X#7)F6\9Q\V*-A#")VG4
MANJGK\%9UE[X:-+9TN7=\_-RP<O>JCORM]NGK?'\^R$KN1]RNBK*.Y"',E<J
M3;35&5 %>28X1*'Q$0^5TNM#DH8Q8VF4I6X6Z2WB3&TAJ+69@5H?T%*HR96]
M5PE4.H&]4N"/4BW+(T=/0VIK X\U4(,;R0./40]CV@>T?JWMFR0:V1SW@=ZI
MO>ZEU7X<O5LIWO^D3XL5W<]5_76+!(4QI+$B$$D3?9H)!GD4"H%IR%3JE!GK
M8D]38]:6M=82M1]?7H;7C@J]@#;\26P?O)RYZRH6/FGI<F>C,LY5G8_)Y/H+
MO=/LE>>0NN7*'7M7A]I4H'Y+\_Q%K?.RX,&W+?N'X:GU^Y_/BZI>^CS@BG-)
M"4P#DU.71M1X)\8PRI02(2*)1,@QS=X-XDR-<4SJ[_6NEGJ9!)RW57#.H'?+
M4-D1TW@#,#![[2Z,#'\U41_[PO9&&W"@CMZN5PJ9R/>]2EZ3Z'F UG,2O5LD
M&CN)G@?TSB31\]%J/^Z]W->GQ4I^W,BG8BXU@T929C!+1 I1%$:0FA-5BF,5
MQUKZ&#F5+[/H<VHLVC5IP1]&;%#*[6C"V:!OQYF>,1V8&&^'TYGY' #R26\V
MW8[*80XX'!.5RZO]V.C3@C(3K6O2/6*,9)HQ!A.2:M9)L((X"01D:8A2PEC$
MF%-,;:MM)W89+8IVN1?0C47:J-FQ14\L!F:%3Q8 .,_[,ZKZG-_MYD>=QV?T
M.IZOYQ[IZ=#/'Z78+N47=;?:+,IZ08L?K623[W_RY59(87)4FJ/_;>57]$4=
M%U^ISB?2(!"9D %D"34[MC0T=[*I2=B"TRA-A$1.I^]^Q9N:[=%H9P(*VOJU
M$L""1L,J9VQ+1_/2:9VB?@=.GK\".ZIZO;$=F.U>8UC=XTH&0=]K (I?"<>-
M5!D$W9.0EF%ZN76_:7P0BP_;S3:7ORU6BZ?M4YW4I7AG+BP>]$<B_UO2O)CS
M#&,1!4A;@@$SQ?L22&.&H-Z#AI*77IJXW_[36H:IK0E1$(5]MYKVP+MN/0>!
M<[RM:"G^#%0*@%J#)D>6_H-6PC@GEVJ 4H\AMJ?.( ZS7;47XY6VK\XX7=[.
MNC?5C_Q^__:0ESF27O;L6T=4Q1G!(1<)C .B((JY@$02"67&0T8I9C15=B7G
MKG?F,OO&*2_W^Z_?0"-M[[H2'>B2+"0Q9L*<6^H5A IS>"DXC#*4)903(9G3
M":8?;,=8*#2ROPX*K=T:X0>P@9>"WUL?8<L(]Y_4_CH:/CF]H[=1J?NZUL<,
M;?&&QW+1\X0F1*&80!;&FB4R&4*6(0X100%"5/$(AVX<?+:?Z=&ON2->5)X6
MOY@;XK^<UHDVM:'%>KG4BZ#?^M"W5(6>$'=<K 4]</WG(0CC?$>O7^OY$DUT
M/WRC[]JAA[/^Q=M<BL6F^+)YU*L?52(+ HP@9UFD*0.'D"9)# /&N$H3B97"
M\Y7\3C=2V%&&7<=67SZIOOQV]P/NH_+G1ZHY(M]^![R4M,S?U].EK1MU.\KP
MB.34@CK,'][6()=:^(_<<$-O$/>X[IY?QU?."HV+CG-V;_OVY*B.VS%+*)8\
MA6D:IA"%(84$953O@5(A9&;N5&,_7AR3O$7I=CGH<QUR#7#7T[.;81SOI,P=
M08_^&H-=)5SK<B)^&IV'_;:ON7&,D(OYNSIC1!4Y\'XEWIE*#%@)*4/,(44I
MU3LES"!-,P%)$#"5(AH*:E41\&(/4^.11L@FQN:]B5'OJH5@"60W6WB!9V!^
M<$;&FA.N:K]G@:*A@4+R7[^O?_RG?K=B /W#\<2_W.XH4_VJ6LWDOOY@/Y/A
M?VUIKN?,\N7#8D6U74*7'U>:+IY*ZV2?"MTQ8Z-CJQ/Z@G>2@YWHH"5[*TO_
M($D<>P+G<PET%6'4);$G/L=+9-]F^LVQIHK6WQ>;Q[?;8J,W GGCF/4RYRE-
MB,B8ML=C 1%#"C)S.T$(DUF4<2EI,J_R(GW;:+'M3//./EWFVW'/PTV]-_+[
M8E66\&-T::H!N-GBW2B'&8^$2$*3_D-IJ)D&." Q)()@',4ISV18HZR)]54P
M;OH=\'2A2MX\ +PRD2R5@L.D/"VGH8)$AC%,94!2)5!&D%,TIS=H1TZG5X;:
M^@36;KWU!M? JVLC)_A3"PH:26=@)ZN_E=0*$I_K9G>'HZZ25KH?KXEV+_7(
MP_EY:Z[KOJC?M 9\NY3%P_J-K%-'E64IWZZ?=%]F%3:YAHYR[3-$:2KT[C+$
M4IIR$T3O+CDU$>,8AS@-A%V]^=M%F1KMM&7=>80^-9HY)*>\;8"Z&6I<V >F
MKTH/\$6!G2;@80W>2+!3!FAMP*$ZH-2G5Q+KVT;&(:OH:",T4M+1>J3:$\+$
MTS+9I%^LRTSSPY&BU<TV-[?<;%U%5_K*/>H%XL[4I+?U,%[F4B]('"0V]=/B
MX*D+WNDUM=@L^)P$*8]#KFT(BC%$,8X@"R6#D50D$7I+PK#5HG:##%-;S3Y(
M#3E=@M);;=6=L6"PA 6[ ;(SNP>&?>C#6O?4!(T6KY*-X!C"5TI!L!-CJGD'
MCG&Z(=G 25,]#\".<DQ]49_EGW>\K!-E:MKEBQ5?/"_EQSHGU1=U)ZJJ47,I
M>)JE5,"89QE$4<0A"4D"E>;,,.$)%\PILTM_4:9&F*W,;K+*[*:M'5H+6_Z\
MTPH4&VWLN*=ZN6'<+,\M1AF-H0\U3E+L:?!-5<V](F"GB8D>J2_'3-"?\%4<
MS1^B7L]$^DLS[H')S:B=G*;<WN)MYJC)Z%^Y%KW=YJ:&PCR- XQ9D$)L4BJ@
MF)C#<!25X289C24)F%.EX8L]38TI>Y0[N8ZFFX5X$T9CV8%&R)U/82VG?TOO
M(A1#V'.GG;V*U791YTNVV>47>AS FNUNL?B^,B[ ]WG=0UG:K@[@R2C),JGM
M*\QQ !$*!60\XU PCB)&2(8DMSYCO=;;U-BA+2_8"5S5;70XJKL*LL4YJ4_H
M!B:-+M3ZU)N["I_#8:9/&$<ZK[P-3K>#2%MX.L\:KS8RWG&BK3X')X;6+PV:
MX^#@]]^V;&F>-MQ/E\4\IB)E 0ZA3$W))!%K>RT) RC#1$29"!/&'&/1/$CE
M,G?&B5RK8_6+6D[P7"M2G_?GDDMMA3N>&?H8/SL+<>0Q&7A9L$ZE8#(IG/RQ
MT0O4BHV>6\$&Y5?(M= IUA1S+]C@V#,7@U73_4A[OSW_UIR7_?XL] JA1P\%
MI#&6PR3!E,4P(K$)#"8)Q%%*H*!"A%C%:9I9&<M.O4[-:&X=;>VD!I78P,@-
M ^)&N';8VU&J=T0')DT+, ?(0."$DD_2L^MX5%ISPN*8N-Q>[NM"_/2T7I7V
MZ=_H<BOG,HU3K+" FG 2O647"62QR7T?2,:X)&'*K*H77^I@:H13R0<*(^ ,
M_#_!KT&H+;T<_##" @A!&"6S( C,_ZO,! 6@V\WC.C<7_C. HEF<Q+-8OV;\
M/N)TAA,R"[*L>7B]W92W)&86T@UXI\W&TH4D#F=F$N*Z$N7A;[.9MB^+YRID
M=WG9>]%N3"WO3&X8J:%O0JI!^E8-4BG=#'PLBFV'^=W#L?.\_GY].8_Z&-E]
M\[R&IQZ;%Y[KS3'/N7R4JV)7XNU^O5SPE^J?#_+GYHT6\Y]S36L)H:& /*'(
M>*]@2)60D-*,HX3&$6%.135M.YX@)^WE+OTEG G #G!K8O .X_"$T4*PDGD&
M*GG!'_6_C>"@E-RC]>,*EF=VL>M[;-9Q0N0,&[F][\G=[K/<S.,L"^)093 V
M!V1(FO"3#,4P"PE6H0RE$,0E4?RY3IS89X2,\29CDV@.BNO43:8^+RT%OM%%
MSH#J=L/9%ZJQ+C?;3FYE0215&BB5X_S=<KG^LS,FZG;'MA8N@WJNF7Y>US6M
MI>E5W[/VLWW+P';4(V_.;#@.I&(<\C 5$.& 0(P)ABP3D11<IIEP"D^SZ'-J
MQDHC<KF/$7NA70NT7@?;CC<\0S@PC1R@UY(7U (/<#[C )#?@JG7NQVY*JHU
M#J>E3^U?[>%743+8O?[$'FDA=^$$]2Q(PTQODF(&)2UO[U0$<40R2 -*8R0%
MC6.K7$M7>YH:T92R@D;87F%/G<!VTXM7N(8^][V 5!__B4[(''PG?$$WDM]$
M!>$=_]=V4=>TOOZ]N7E+V #2Z2G1V<!X7A(V>AQX2%B]T+.64)VB4YJX+$/&
MY5=RE^=Z:,M>WKSL'ZGO_NY,0,('NLC+HRXMW/:I=)<M#)WSC13O%C\60JZ$
MR98XCS -,LHPE"Q"FGTS"HGD$8Q"D3"<!H%R"[ :7.*IL7@C(Q"UD.!E(9>.
M7A3#C[.=K3FIT1MX42D5@<QH MK:@I:Z@+V ]G.URJ#4>0:,UM7I/6CI/0.[
M;Z)1O<Q,ZK'2T%C#Y+7XT.!"CUN/:*PQ."E1-%K'/2S]_X^N]&JX>K-8;R1_
M_+CBM6'%91PCHA)(*(H@4E1 RB(.PU"$,HA$((/,SD6OJYOI^=S5@H):TIDY
MNO\5_%+_VC(G?">R*M+(II1"+$0&4<@Y)&E ($J1WCZEL<)!8KU]\H#K&&ON
M$:HEJ!Z@M-@P>0!HX&7M##9]MDF7,'+8(7G :J3-T5OCEB+S9YIO7DS<X4%:
M"T ];Y2NX-*Y1[KT[GC;HRO2'^R,KCU[D_=A\;5T6#:9>ALJ1&$:)(C + HU
M 9(T@9@J4Z*$,XJI)(3U<3@\Z6AJ=-C(6;MP&T%[^12>(FJW:_"!T] G2 U$
M>QF'\Q2\",0 SH&G?;V&/^!%C2^X %Y^WHT2BGQCSJ[U^E 2]-W/13&G&<;<
M).O',4;:# H"B!%F,"*8I4P%BB,KA[\S;4]MXK?$ W\8 2U7^'.P=4_U&\$8
M_M+)%@?K.=VA<<<TUF^UIK#^K^/I>Z[9469LAS[-).UZI,=>\*O\OBCT-#"[
MR[R,[%<R7ZR^UVM+%*8T0CB# 3'W/M*</.(X@RE-LC"+.0VYLMZX=/<UO7G;
M2 LJ<4$CKX.%?@5>B\V,/] &G]^7\.JSM;D"G,,.QQ^ (VUT;@'2;9-C!TWG
M7N=*$^-M>>QT.=CY6+YR:^:2,HMRDVA#1BG.$I% 2CB&*,H$Q&E"89RP*""(
M1#*)^J4M:7<S-2Z]+:?T!2@#+H@(HM#DTE40*9)"DJ4*:MN1)Z'D0<*"^4I:
MIIB_ <A=6;JA<\H?PS@#_$I>$Q<\HT PACB%,F&F\DW M$V>:NM<10$*8\HQ
MMCS^]?=QCG, ?(RK<4!=;D7IB=I #)9U]FCG6L,7X+;;MM\.X<#+?BO?3OU-
M#IAKYQP&PR3:.>CIE;+LG-/V<HJ=LT_W6[M,O='BBVHE^#H;R)&(".E-? P)
M(WHM"T)-P)$D,#(EM&+,(Y4X'>79=3NUM:V4VCA@W^M6&^NP]*S<I44K__QV
MO2JT)H)VILB[93SL&,4_R@,SS [@O<CC1-6X(>63ARQ['I67W- XYBG'MWMZ
M8FU9(?^U-5ZQ/TR"A5:07T1"0K,(*LE"B&*)(-5F(^0X4[&,")/$R67^8D]3
M8Z>]H*"4U-'EZ2*@=ESC!::!Z>48(5/Z<P@VN8J%5S^>BYV-ZW]S3><3OYFK
M+_2\CA3_V!:;,NO*P_I.B-*[EB[OZ4)\7+VESXL-798..>S89^>KK+QQY3>9
M_UAP624X-76/OZ_*5JIH=ZZ"1 F$(0]#X^$184TP0D!-+T)A(1-,G/;U0PL\
M.9YJ.?#QEC:.=Z1##[/E7>N$!F_H.]N]JB9%V5Y98+0U^^=:WQFXY,LY SNM
M0:UVDU2ZI;C'"^"11L?K1?+0,H][(3W2")Q<;(_5;]_8SW(/7^S*TZJ,:?M4
M;[ 53R*(" L@)DRO+$$4BSC&29@Z5;@_[F!JBT CW__K&L9YA)L=2]^"QN!W
M:95H@U3EO:2WW[C+HSY&#K(\K^%I1.6%Y_J$3VX>'N5O-/^G/+ZK5$FJ$.4"
M1K'2IB%1(:1)&,*,QHBC(-5[4_N:?Q>[F=I<OML +2FH1.US=7X94(M;<R\P
M#6TZG46H5[CD1:A<8B5]0#96H&1/Z!R#):\ATATI>?'M$<,DKVEP&"-Y]>F>
MF^\R-\8\PFG& TFABIF"* X9I&E((4K2.(TBAG 2NZ2UJ9IUXKT1$MD\F#YZ
MI:VI8;+<8CHK/S2;=6OLODL[4-#K7JIJ>=P=SX$V)_N2P[_VG&4_Z&)IG'4_
MK/-O=*EW*GR;E]?5[R3;[/]KCE*<)LQ$$Z<L,^EC$"1$"A@&J9!)EG(5)F[W
M_+9=3^_F?R^;XURU!9NB,.684QA1LX5+#-@R26#$,4O2((FD<,IL.@34HQ3$
MW$7A#@2T)6T. -_ Q&H$ WO)9F"G U3K'!:T(Y#$G74=\?'*R[9]C\O<CHB<
M<+OK^S<DH3@YMCH-.&;' <=?FAAC4U"X,(+^72Z^/VZDN-,43+_+K_*)+E;:
M%GR[7I6[Y"U=/LC\*9RS$$6<AP@JG)FZOZ&$),T4)"@+$D4B_4_AG)9B7!VF
M1I.-W)!6@H.\D1SPO>A B_)D,ACL].V1R6+DC\6.GR?^"0Q,]1ZR77S9I[?8
M(3$##1:@!@/LT  M.(#!PW,"C-<92^\I,4968_PD&:\S3F?39KR2*/W6W7L]
M@3_K*?UN;=J?9RE)54H5Q(F2VMR/,TAQ3/4W);,@#<,X2YQN; Z;G]IJ9:0#
M1CSP1R6@Y:'E!?#LEHC^D S,W@YH.'/I>:5]TMQ1#Z,RT'GMCLGAPE,][FK>
M_VN[V+Q\U+*M3*D+T[ 1NSXS#Y">O-IVA6;.0H0Y@21)%8Q2ADC,"8D8MKZO
MZ>QJ:O.Y$A;LI 7E)VUD<+B,Z ;7XN[&&V0#S_?+:/6YP^F&S>$>QQM\(]WE
M]/CHW*YQK #IO,KI;F&\ZQPK30ZN=.S>Z$.A3\_+]8N49;V6)J^F:?XW^M/4
MLKM;K;2%51I;"[8MC;-[F3=OZ1^-1'/-J(J%&8$,Z7\@'.F?DL!83PF1YG(H
MM7/+]B?2U"BY72D*B$51NL^#YTI8%WKQ,EXV[#WV* S-\K5D=?7B77YCH](,
MU$J!2BMPH)9Q8@3-ZS-P_TICYK)TC#UV8RTQ8XVAX\+D$^[N!<Q+3R,N=#Z1
M.5P0O;;LMG *N9B_J[_X#YK*Z;)R(_V@?U?,)0J$2O0**#&2$#&60)Q1"2D/
M$!(1RU1@=5/8V<O4EK=&4%!)VOA]E[+:,64WJ-T+EC>HAKX"[(.2-1=9H; _
M:BB:LX9"\E^_KW_\IWZ_.F;0/QR?+G2W/0JA6*G7<(3=P_VG_8-^=8YP$ FE
M,I@B(2#*&(,D0 %,DRPD04@8DJGK3#<-3W9R&^'<9W.)E?T$=D5@K#G;J7RO
M2=K6U,.\+)L;?2JVE3@W^P[^WN]L_K/<O*7%XWV^-GFSQ9N7WPLI/JX^KG[(
MPH0@WYE"M^7ENUGO%ZNM_EU=MUTO^W,2IP&.F( 93P(]34FB-Z=1 C-J#@*I
M3)5,7/P5;Q/':7*/5+"/:W7 <ZV/N9C\95N425/^HO]?:P7H3BVWRX$;1\_N
M,F&\,1F8;LQP&$W ?7LX?F^&8Z<0V&LT WN=P%XI?Y<6?L#U><EQHT2C7HKX
M0>_X$L53J_T(^8'^K,RI^L*/)!%*,\4AI82;/%,"8I5)F)$P"P.F H(SE]O2
MH_:G9@^9HIVUZ=[OOO08/SN.NP&5@4G+!1!G]KF@MD\Z.>YB5'ZXH-_QA+_T
M6+\97%5"_K;+/NL6<7GA[0E]D96$X%LK4['_ ,PK,/C\0B]U->J7>D7?XR_V
MVN/]OMRWZV)3W*U$72^SF&O 6!8)"E% $$11%.M=.%8P$R)(4IXH;@H1V)OW
MQQU,S6"O I.XD;+,3B9K.=V6H!,8[6;^+> ,/.7?[A!Y?PT1YYE^26V?4_RD
MCU'G]B4-CR?UQ>?ZSN;\V91^D8=.]+6W!$,!4CS%,(IQ"I&V,2&3+(,Q9G%,
M$0\3&;A%.'7VY_(QCQ/6M!,7"!,]4O2,<NI&.4JP5()0*(FIY"*2%#)%0IB8
MLQ&,4L(X=;'>O6$\SKW\" C;<JLGW 8GV@:RHY"F 8J\6&'BEX6[.AR9DBUT
M/^5GFY=ZGL-N32-?5'V.L/K^37XOD_#,,\IBAL,,*IEJHJ980I)D&<2QE"%.
MTR1QHY"+/4V-/BI!35+3=2.JYI!*5L=CTHO@6IZ ^H!LZ,/-'5H[*<&W:VBY
M'U=>0\+K2>3%SL8]9+RF\\GYX=47;CE8>* _:P/QC5Q)M=C,,Q7)-$ A#**
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M[7;J?6KTN+L65E*4)QYE%A=>R@[T[[>\K%*Z6 &^R_&2=\U6#P-D:X@-!/O
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M49!YW'PXJ]H\<OB1O0B?<+E4WO6'U?H+7O*=(]ZWS<-,&J8HXH"*3.4CIA'
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M^P[ 7U?2-U7=C3ZLUCH'JG[S_%6.J<-1"2(ICQ((J"!,%?3+ 8E9!# -B[#
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M>P$)I_QX:JQIF>R"Q@><<^G[=NQ0KYM%E_71U71 *86"$0HR))D $B;I()4
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MBKI>-3EG:[Z.N_-T)6&OTGRO8NQU=[JF.MQ!"U>2A22F&4BQ"F:)"@H*7F2
MYE%"DCB!)$KM*\+]3;JW8BVL9>/6XSB:&;)7H^-Y">EKO?GLU'H6 _<5W5ZU
M/^M978]7;G/3E;6_I\HSU5$L_\W95_RCWYA2,2%,VJ$49#2* "Q8"' 1)B!/
M4<:+@D8P+A:/;;>1!J\;LY?_Q&@V#_C+,?T]ZV_X][)2J3$!P?*#,X?O5LB2
MM,!4$ H0%@3 /,: Q'DN@2X$HQ$+I0?0(?N^,BQ\X S7?D1_J,H1G$-JQJT.
M0/+,KD,)=:FC7D9WY'H!!)?T>FJH20GV@KXO*?;2UWTTFSL:9+'(HCCG*8(
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MN"[K;]6*U'RMJP[=5=*"W&_^_N997ZX=ZFY#1MK588Q$"CA3Q<ZS/ $DSV-
MPP(FC%&<Y9D-G_@2=&Z$I.4+VKV@<;MCWJ;4C,SF,%&>V=!JCJQYT#> +HG4
MFZR3,K%OQ%]2N??QW/60U$-(<W3;)^ZKDF;7*@;3E) \C4!&80P@2J3%&*J>
MM4E(!0II@I%1E=\K9)@;@W]>+9?2:E<!_FHW?]LO\=>QQN68>3$\#_&+MN\#
MDQ.=*%MZ5J[K5H?@3ZV%GQX_5Z#HNUGE)3%>O7>E(4XFK2Q-;S6.'.\J*@?Y
MBG_LD_#;>Y7D<U?U;67E%UI25_S>^NW+Y>HO58-C@1&-:8$1H!2G /(L!J0M
M]H00+!@A*(QLN/)ZD>9&G:WH:I/[J9=5E9YMA;4C30?S9<:AT\Z"9TI]+W3)
MLR<>M&KIZBB?<=-V3MMI)]W_[51M.RJK[[8Z!ELE@ZV6DI<?5 %;=[SK#GF7
M-.Q JDE9V1V*+TG:X9U''(M\735XN4T:T>;VMQ>95%&$(L%S@)DZCL<P ZA(
M"J!ZL7&8A"E*C4KNF0TW-Z[5 @>/VW0JQ;B&'&N(K\&9DU/4/'/C4<!T<?01
M\9T&3Z?Y*9-3%"<KR2K4X7.SDO\>P[5-UMM"Z^K(R1BJL^=-E^\RW6&3L49[
M)TWF5XWH X1_#/K;0!*%41Y!4""( $2"@:* %. L3RE/,>1F72\/[CPW0NV$
ML^@#M(?3>;:\2GO/Q-C)Y;H/T#%MK^X#M'?3Z?H '=-EKP_0T2^,]E37JEKQ
M.][^_Z[21T?=>=%@%VI!XI0EZE &<FG[0(ZD 20$!BP.B6JV 5%HM7EG//+<
M7MWV>'/TZ:\YXL8NI7L</9- +W/P4R_US\HY;)'MRQB;;(&.<0/MT'+L[1D.
M/K539X?)$=_-\@:GR&HXT;_*G_[K/_J_R/^HXE+_]1__ U!+ P04    " "&
M@5I.N']X1&V.  !-F08 %0   &UG;G@M,C Q.#$R,S%?<')E+GAM;.R]67-;
M29(N^-Z_(J?NZWAE[$M;=U^CMBQ-*T6-I.RZ=UY@L4KH! $V "J3_>O'XP#<
M"1++"9Q@V2VSHK@@S_'E"P]W#W>/?_F??YY-?OJ1YHOQ;/JO?Z%_)7_Y*4W#
M+(ZGW_[U+[]]?0?F+__SW_[IG_[E_P+X7Z\^?_CIS2Q<G*7I\J?7\^26*?[T
MQWCY_:>_Q[3X_:<\GYW]]/?9_/?Q#P?P;]U_]'IV?CD??_N^_(D1JN__=?[/
M1&C%:$X@I"Q?: 03C (5N(@F9<X,_;^__;-Q)FK//!#** AB/#@F&+ <+<O,
MX8=E]]#)>/K[/Y<OWBW23\C<=-']^*]_^;Y<GO_SSS__\<<??_W3SR=_G<V_
M_<P(X3]???HOZX__^>#S?_#NT]1:^W/WU^N/+L:/?1 ?2W_^7[]^^!*^IS,'
MX^EBZ::AO& Q_N=%]\L/L^"6G<R?I>NGC9\H/\'5QZ#\"B@#3O_ZYR+^Y=_^
MZ:>?5N*8SR;I<\H_E7]_^_S^^I5G+LQGW])T'!9_#;.SG\O??[Y2L)O&M]/E
M>'GY?IIG\[..6&2@>^#R\CS]ZU\6X[/S2;KZW?=YRO_ZE[-OTS^1$&HH6Y'Q
M/YY\WL\W1)[/TZ)\K/S^ _YB_=A"4U\$IS^7:1K32C17[YW,PIT/38IB9O.K
M_W+B?)ITOQT5WD97;SMYY&TG?K&<N[ <:94]Y8I#4+2 6A.P5 7P(E@=%?-$
ML>?DMO7;5D+<G9V8QM?/_XJ?'7FE"&/>@V04UQBG"BR/"1RGCDL='2?Y+M5%
M+0O42X?*10I__3;[\3,^]^?"2?FF8PG7[!J3_^/^.^_2?AL")_/PTVP>TQR-
MTM5+W3S<@</#!;'^Q,_G;HX/@O!]/(E7_W6Q3C45N9SU(->5TI"-O_R$TLAI
M/D_QPTIG&YGN.%ZB"4_=)P_!PPD2'0OA[R;NVT@@JXG9!,'H",(%#\:CJ592
M^>PU]3+Z'@!QYZ5;(8*]/$3L+]F!(7$EE4]I/IZA8.(;W/9'RKDH@LX(8L-!
M)"W Z.3 >QVDUBX2+GNT%7=>OA5$^,N#R.&2;@0J[\:+X";_.[GY._S-8D30
M_@G&.3B)0!>!$C N9^3#&DF)\S&X'L%R[_5;P46\7+@<(NVF +/"_8H)IIUP
MRA&@I!.*%^"$=9"RX :9"][%WB%SBX"M0"-?.FCVE?C L%F)Y7/Z-B[2F"X_
MNK,T,M$GM(D"Z4]H)Z/$"%$2!S%I(B+E/*L^C,QC[]X*+.KE@>5@.3>!D]<H
MGKF;O,?([\]_3Y?(@,HAHT%DUJ@"= K6,0W*9BVU],R+/ER71U^^%5+T2T7*
M(9(>&"JO+^;S.WOIE?MEHJ51. KHG@?DP08P$C=7&4@*UMED>.@!+9O>OQ5@
MS,L#3"_R;L*\_#U-)O\^G?TQ_9+<8C9-\?UB<9'FHRP<\D(X1)T1_-PGL)8%
MD,8S$C'DCXSW9F8V$+$5>NS+0T]_DF\"0NO%\#F=S^;+\?3;%]01>F341J:0
M%S#(#HCL+4I'"K!H4FG*&/?Y_CR:QVG8+C]'7BJ">A!\$P#ZC]GD O4ROWPW
MGN!C1R*A$ B-P*)&(QJL I.E!N]=<HF(S +M#3GW7KX=9%Y@3O=P43>!E8[N
MU[C5?IO-+T?"$\EB=F@AHP9!:4D;2 HD>DK1:C+M66](N?/J[7#R C.]AXJY
M"92\/4OS;V@1?YG/_EA^?ST[.W?3RU',5B3E(B@6,?9S7( )/ &7QG$E2^*I
MO]#I41*V0\T+3/[V)?8FT//ES$TFKRX6XVE:+$:!&&EUYJ %0Y$D@2+QP0&U
MZ(D9D;2.NC?4W'GU=FAY@;G?0\7<!DJ^HP-_C7'!F+&AHUF"P*_@2R*2(_G"
M<$.M(/V!Y-:;M\/("TSU'BCD)B""A)_-IE^6L_#[E^\HS\7IQ;+4TI3RI)%T
MQ.K$,AA>#CJR-F"CB:!UX)Y'GP4QO4'F*4JV@]"+30#WIH0F(/7IPD_&X=UD
MYI8CIC/E@3+PG @0T2OPQB/QZ,Q[PCS-O+^=Z=:+MP/,B\T#[ROBWO#Q+S\_
M$.P'_,6>%7&O3S]^.?WP_LW)U[=O7IU\./GX^NV7O[U]^_7+/N5PFQ_61RW<
MEJ0>6 AWL8!OSIV/2KHD%2R=YG?CJ9N&L9M\FBW&=Z D9"8Q)0,YHM\J HM@
M$560K'/"T*1=?B0/>K7$LEOX3MGK=Z[669HL%U>_N;_@=B%N7VMR]8Z3Q2(M
M%]>LIIQYRD2#M &CO!@%.$<=)$4"IUY0J1XYM#Z<U;MD#%-35PT35^:E!YD/
MN/_<I7Z==[QF@ML8T?4*H*A5N(DF D89"EE+'ER@D<9'XNJ^@'./FF'Q<XAZ
M'T7*(;)N #"OW>([;M7EG[?_=3'^X2;(S.)D^=K-YY?H@/V'FURD44JHX. S
M..%*AD P<%D12,$)GCW)T54QLEM1UP*@#D+!K+9*&L#9R0\WQE]/TKO9_ MR
M]"6%BSE:[70ENI'B3)FD(DBO2B$B+DJGL@.E+$U$TF3$(\=1/1BIYR@;IF2X
M'K[Z544+V IA=H%+Y',*"9<+<O8Q+:]Y,5PXXA)D% KZ A%#28]> 2$N*&4T
M"S<)NEYA]011PU085T147PIH $R?YNG<C>/;/\_3=)&NF" L4^]T *Z\!8&&
M%SSQ!JR24AD;J'^LQ/AP%#U*S3 5Q_7@<[C(&\#-Z?)[FJ]D,V(QD$"U@$"Y
M0Z_2EO8+-*(Y.*:TL";H1\['#T?++1J&*3"NAY%]Q=L ,NX(8Z2H5IR:"%Y1
M#P)##'!$1^#>>L^9)(S5<7-N4S%,17'%#6AO$>^/C]G237K:<6;G:;Z\_#1Q
MJ[0I.OWG)<6!F^@(O;#H)$I%"H)6,"1=DJ0&N%0.O7S+%'ND/K2/C6<S42TX
MQ+U$\+U)O@$K<\M ?IQ-PWHIN) 54]EB;$@B".$#V&@Y9"6S5$(++1\YP^IU
M)[JAI@6WMQ?<'"[K!@"SWDRU0&=<2 G9)S26RA!P3"+5P6?'M;64J7K[40NN
M;(_)P)VDV<#6\V'L_'C2Q?YH_KHCV.^S"0I]44SA\O):-![=+>*( 8SP. B)
M\C%)>5#)>1VL,9Q620!N2^"P6U+U0XDJ>FK !MWBZX$[J%00HE2AX2X,@D@"
M/AF!G 0=4%S<DD?.SGM%7%,'%W4@L!EGA^BC 61=I:0^N<N2C[H*#20C"@,"
MM,I>I9(UQT6HN80411+,4*-EG9.P1\EI!E$'*7M#,O  R;>!G_D%OO6!C$9&
M:I(DKJ]@+6[QQG.TXT(C7T00%6S.NHIAVDC1L'M?/13U(/\&@/1F_=K/Z4>:
M7EPO!R]$\E1%Q+\B*!MEP%%6\IP"^3+94EJEEN-Q<H:-S"I!J ?)-X6?Z?(U
M_CN^/EAQ,3H;=2P1!I+/+043M08KF'1>))5YE=A^(T7#!G/5472(_!L 4I>T
M>,2>!A-BSAB(R"Q*!652I?O#@\&H1"5!,%QY9"Q;3RFB/7>S:@<7E4#4A^P;
M@- C',0DN=)> #,6.7!2@B,^0*!4,)JR$J:*0[TG<*J=:50"SH$2;R#%=&\7
MOI4O33)IH4L;=."X$3N%CES$W=@G&C-51'A?I3)C(T7-.-+U OQ^M+$WK'ZD
MN9]5<XQN<>.U(X19!RZ4"J;,(W@G2N^TUMDF3I-/Q_&-6CG^.#*\#M1)6YO=
MB#CN#,T""79ETA"C)>:T0#5CU 6CG*_B:M^BH1GG^BC9QYTDWL N]X1$LN8^
MR(AR<"7*%"R#*WVSQA/*1+2*/#8"H8\&E8,.2X[A8M>#4D_Z:, ,W>J.7!5^
MZYP8M5:"+S/IN\)O(ST#:C >%2)GXJO$:_<)&;H/J!\%WZ^]/T3:#:#E),;N
MU-%-/KEQ?#]][<[':.-NL36*3#-A2(2D<HDY%0.K<96IG*W/+F4FJE04/4_:
MT(>X51#5LT9:P%@(%V<7DW([1Y?7*-W_\_0]31?C'^G]-,S.TH?98K&YS> D
M_N?%8KFNLSK-7]V?H\0D>H94 >,!)6RE J\R+[8^1<M=]G7JE"KP,JR;7PO%
M ^N\ =A_3DLWGJ;XULVGX^FWQ2V18-@S#N/2UDXR4U9#LJ4"3%D!1G )1!'J
MHA4Z/#:U_G 4/T_:L-%#)5#VK)$&,/904",C*6X#PH#V'CDP5(,EI+#A?+34
MX 91Q=U[2,JP84,E#!TH\09"S^?BJ9%ARI1;L) !X5$\T8"E/  ZMD9GC*Q5
MK-)Q\!QAS23LCY+1.%PWO6'M2.-+/G5Z^)Z6X^ F=YDX<);)W2=7'6SR!!/'
MG'(2/9JV<JF3Z<Z:%;5@LHO #88+ >.#G"LED>I/.;D5"J&T3^?=.V,7?G]*
M\VXDU,@Y25$ &K1Q?I4.-.@>0F"2!Z8B4Z&*9[4%;4/G07I&SQ,9D5ZTTX"7
M]6#@V,G%\OML/O[O%$<L428IAB+&ETFJ7 :PHAS;2F^L"E1)6SN[=I^FH=,B
MQP/80=IH$5BW)]EE[Z6GTD,P#!<)%>A'""F*H#QQ(C)-'YE 60%9NTX6K)BK
M.#:T]M7'"Y@<]^4K?OWU[<>O7T[?G7YZ^_GDZWO\Z\G'-Z]/?_WT^>W?WG[\
M\OX_WGXX_7+P6+D=WM2W:[8ODSVY:JM$US5LKS$:!&<^I@"FY*^$R@@EHS0$
MDHEPRFM=IR1\ SV'9R'6#_Q:4GDCIE0D5G4%1PIP85CP66.,0C37QAC)0I4.
MP;MD#.MF]:'YAZF'O<4\X%ZWF"]'G]/B6A)_CA>C+(G,/ A0C$8021*THB:#
M)T(JP7,4C]WL^P A^.A;Z,"?[B/CD7<WXGWOH<)9/_)L!PIO9F=N/!U9W)@%
M$@E).5.6! 'OA06KF.,R4D'D-L-/=@7#ZNW#P.%@'3Z.A3T$.C :/LUG\2(L
M,4I,\Q_CD#I))$Y+(;,$7M:"2#R!"^C3.YI(=U^HS-NTNFP%B,<(:"1^.LQ$
M'"S9-I#1I4%7'"S6\*;&FQ!%!A)+"C24[+T,9>R3B#+X(+S;QKW8!1X/J1C.
M;ARNV(<H.5#* T*E&R&^+DY^AW)Z/9O@7V=S5,6/=/)MGKJEM/@UG?DT'U%/
M0X[(A:&!(%.XK*R2 8)C)B>G+)K-YR*;G=XX.$P.U>RLMI@;PLXOLQ]I/NTV
MY/L<9650-L*!B@XWYT ">$T#Z"B0HL2(]7)7X&Q^W3 ;4'W4]"3@!A)WUYOT
MA_$TO<=O%R.3(ZJ;<8B)H-?%D@7C= +/79)<:TI"E3*YAZ0TDJ3;WW_I2<H-
MX&0-_IN105%[A_+0"&R?R\PG#8X[7<YO+;KE3M(ZN9'[A#02!N^IV =U/0=(
MN2&4C")%>Q==N2DV,1"DC#0,64 26I#(37;.UT3'L*@X3(T;,+&33!O PNO9
MHMM^U\-M;X3AO91&!0O2H6,O$C+C#7? 63*,!%U:0^L<!SU.4"-1<C\6I!>I
M-X">SZ@%)*!<!_ &%\!DUDVG7',URI13&3T'[20Z613C12-+LBEFJ3!,S"Q5
M:7)\DJIA;4X_BG]@>_K20@.0^B5-T]Q-D)>3>#:>CHM\2M1WQ4Z2,B7+-$19
MAN<R1\OL?X-?M$O<9F5EE3WK&;J&-4]58-6G)AH UGT9C;*PQB?G<#DP <+F
M4N7H#5!"RHU^@FIFC['##1L_58'.0;)NH&;Y]#P5K$^_W;2.C+CG/FG*04E=
MIG9+#X:ALQB)2S2YJ"*M4J;\""V-1-S]^$*'RKH%N)26HX^SZ>PN*U>&TGLA
MC<@HG9(R%QE%Y%6I&.+<".64T;**'_0T64.WW/0+HOXTT,!6]3$M;RV&J!1)
M.B'Z+4:D&$9:\,)*D$)EEZ,UK,X^=8>*H9MK>D7+_O)MQ=ALZ&^\ZEW\-)MW
MJEDNYV-_L2R9T:^S5:O S?ZND3K#(G ;<$O608'UG@'SRK-HF'2JRGBCGN@?
MMCNGAODZLDX;L'.]M>IZ96G.P90I"*GX"P2<U12"B8%18Z.LT]AZU)[L:DF)
M0="WPPJH!H7&E\ 6LA_%;&,L=[_@'N8 ?1F_"K&2,]D1+XWA59R# ^G>"O"]
M7P#?IO7>28<-." WS*U*,Z;H;U^@R[T.Y&;3Q:<T?^46XU 2DN/)Q3+%51\6
M"\SE)"C$<I0O*+5H(*B P)FAQ)A ZXQVV9OBK6!J7@A,CZ.W!FSJW]/XVW<D
M_N0',O8M?;PH)1^GN>/E5H?-/59'3%%#@HL0K,1E2",#3U@ J6R*W'CF7961
MY_N1NQ4T[0N!YA$T]L):I+Y\/7W][W\[_?#F[><O;__?W]Y__=]W&3FL+>J1
MI]=LA7J.F?X[U9^8EZ!8T*Z<6*";6';;<OLBRPR_DRH(]%2=J1+W;D5=SZU1
MVF:O):Z-;$K>RZ8,SO (S*04=0PFL"H]G2VU1O6/BF<:I781>@.[Y37U*XD4
M/W8V+:62JTIO+ZC*(J.)31A.<<7!T$0@$/R]\]K87&7PV9-4-0*H/=2]"3D'
MR[X!(-WC85W(&[32.7 'D8A8F%#@.$>5*X\AC^7<DBHW\SU*32/ .5S;L[Y%
MWP!^;G7#KZNTA5;*$%-NJ[2T7#\1RAPBBE^BY5HZR5RE$_I[E R+FQZTNWGP
MP!ZB;@ K7^?)+2[FE[=9,"FS'&. 8(@&X0D'1[4#28DD,2A+ZPRR?H268:N!
M^L?+H>)N #$;YMQ>M1!QD;I[M",3N(DS&<%81DLD:;0+(HA<Q5%^DJIARSSZ
M1U%_*F@ 3_>'>U[9T6Q)",E#+/DRD<H=S9X$H+@J6/2)>UYEU,;CY Q;X]$_
M@GH0>@/0V6)8\9JQ9"6ZA"@AI<MA%B,>K- $HHE!IE!J6NK,0M^6PF'+0BJ8
MJ"JJ:0!SCR1L77*.6'3TF/.\9/43>*(34.NEY8(GQ>K.S?FP4P?AL28@]!+/
M[R?E)G#R< :L(;BDN(7@32K7D"('WAE(C.6L:5".5"E?W',B[S&["'=2[A:3
MG7>0]-Y8.4_S\2PB,_-E/XCI)M>]7RPN4ASA-DRU*O<@V8!!0<2 TIAR-H-;
M,'<H+)/J))QO$=&(->D))?M*MQE\O%YMJ*5Q).<4EJ?Y8_IC?0D[^G"?YN-I
M&)]/<'?]U+WY-)_$V7E1U\A[FH4W"D(W64@;![Z,MLY>,1(E;L&LRHGL_B0W
M5YE_"/:.I+D&=KV;.K+%U]F&,+5;B=XM4BQ.(7J$G5H_)S3=B_$RK>=7K"3Q
M.879MVGWE/4U33095_)I-I<A[5H1\#0(B-0%PJQ,CE0I4*S-6'--!(?@O2D4
M-+ J.@]EM?6\N9B7%=^QU?&"EJ#[RV+$7*FVR 2L(A8$;D/@$M?@;12)2T7U
M5L,5]W,/GZ.NN;:%@SW&7O71+LA6?L\-5S9Y)71R0(BCR%6,8+S70*SAR3"A
M:9U;X+<CK[EFA HP.T0C0T_=>FKEK*X.F+CI24!7IX1ADG(B4@S(#\9BHE0Z
M6HX\9A]HTL+S?/\&RPW3MW9Z;7,ET?M@J+*T&\71:FD\9"W&Z!T-Q?=% RR,
M*6,2C0?J(\^&<**=. 1(&][;7-5RWTCJ0]X-;'UW3E4_I^482?CDYMTZ^34M
MO\_BR5F)M4:FS#>47('N2FL]Z:IJ49R,9T%B.?NH<JBT+8'-U2(?LOU5T<KN
M:+,KM$W3MW(8T3_>5FMHS=_(VBRE<02H\02$R!2\CA:RB"JQ8)V-57*\FTG:
M+M=+7B*H]A?]H3#ZVIOM^FV*'$W*)3B_N/&T-)6<3M]/?Z1U_#Q2UB3K0I?*
MSB""0U/LA<$?G38T>:-IE<.E9^C:#E4OY0BA3R4TL!_>;<O73.ED10+M;9G9
MT E&9K!:$LH58597,4F[CSV@+^4P87\![XV.'VGN9_7.)D/0QI92#Q.4*]V^
M 5R2#&A2,7A)6$A53@CV/9M\*:G_ T5]X.'3VVD_#L^=PS-OB<TQ:]"RS*S7
M&O=9FR383+04AEMIZT!EUZ-)^E+RY7N+MU=X'*<?[_7)E[^]^W#Z]UYO)[MY
M:,WNNPVD]]]T]]HMOK^;S/ZXF2&G,U$\1071<;09.970W"<@) I)DL]2U>T>
M>H2H'KR4\LQ/\]F/,8KOU>5OBQ3?3Z_'F*VS$>.T>*S%^EHT$OUZ;:(!%D4Y
MRY<1UXN4H)CUH2LTLE7FZ_9#?B.5.(=B[A$'Z=BZ;<[OSHQSS2V#K,J=IKX,
M;8S)@M-".D(9\W7N =W#[ZZ%KR%@\*2KOHM.FG#5[QREEW/P:1A/TAVFOLZV
ME/&U/*G(T0<;('=S4GPY,S#!%$ )]%RDRZ9^$45/S Q;I-8 P ='2 .&]TW"
M-X=Q)U7\?I(Z_4]+@GF^'/]W]_N1HDJ&4FCN4^$I6 U6T3*,-S(;#2?&54G^
M;T/<L&9Z> C-*NNS 8QV0=ZK^P5/(TUS\$D32#25)@M:FBP( 1I42B)Y;DV5
MMN['R1G6FC:'PQYTU@#R4'KEU"2]2:M_;\EK78QW<W-+)#R(', &6V9V6 %>
M^PR!!JM<9%+8*KGB[4D<MC"X.816TFV3J%U73"]0[FG\H^LQ\II%3URY%2B4
M\GVIP1&G04;F8U2Z\'P<O#XD;O"+S*L XUG\':BE=DYF'[+V:9[.W?CJ,H:1
MH)PK6GKV(R]C6HD$RP(!F1@Q5M+@CV4L[Q(V["8^&/ .T$X3526/"*YTSM[L
M'(M%6BY&6DBAI-&0$I7(5RINKZ004H@J6J9SG0+>[<@;=GL>#'L':ZI1!%X9
M\T_NLK/DB><LA"W7O48%@@BTY%YQ(!ZY840SPJN<0SQ+V;#],X-OMOOHIU4?
M;WZ!=(R='T\Z-WGD:7#.A@3:&H,\J0A.&PO,:L=CMBJD*G,FMR%NV+:8(6%W
MB)::1-Z;-2'K"TA'I620"TU+5&8!UY0%HY4'[W2RSI/H9:T9VT]3-FR/S&"8
M.T0_0[<[/,7-=#EB7@LEK$'W(*.K*K4!GS*N';3BQF5N<#EMU=[P]'N&;8RI
M#)R^Y=RDC5J-TKF8S[O2HQOCF[3WW)@ 6I9^#8H. *X%"SEP0[B.@8HJ!WI;
M4SAL)\VP8<&!^FH B(>=<HZ4CYG;<F>NR!Z7G25@+:X]Z;@).: %RU5*V \C
M>]A(MH&#Y2-JO8'+6#9PN^H"V%[@60KOHU' -?K"PK$$+ND,.FK<K(VD050I
MCNV'_$8F_ARI&JVF;ANPVI_<Y=4(CO!?%^-YVGS]UYODER/*-2&&)T@&?2*A
M14!?.FM0-*4<>5125ZE7VY'.)BO:JD)I=CR]MG/Z@A(.*<7NBJ7"U,DT_NJ6
MA:_+T[R9XY&,42G& R3NT<=W60%N1&@LHD4I6VJ-K^)L[$EOD^5K1T7S$?3<
MHC%&OE&0R\O2=[\L-[SC;\_/NBA5X<;FM :32W6)\!IL]!27;W*,.IX]J9+O
MW)[$)EWC04UP/]ILXA#H,/&.N#/%(6- F50@ JY+YS0#*Q-QN %A(%WEA.@P
MLH<]/FH T4?4>KO!WKOQU$W#]@(G1#"ART%;5A2$YQYL1H$;J[SF7G).:UTH
MWP/YC8S8/%*P5U.W+?@7M]RHTDB*O":4[,WU-"-C63D!=@@J1T!(1I A88&D
M)+E-TF96I53N6<J:#.BJPN4)%_APW0U]UG7%31%U1_UI-\EV\?;/- ]C%&YQ
MC[Y\^O3I8AZ^NT5QY:VV.B:-&U5 %REH HYP#BZD\J\IA3);'7_M_.HFHZ]C
M0.\(FFK!**[=],^INXCBZ^RK^_/OX^7W,H\!95F"RL<+_(F-)O"(@N2R7,%K
M*,:5/@-/F>:<;'!UK@O9E^ F [*CFM!C:+KE\&Q+82._/"I+&9#,D-^H,!PE
M7H#4@02G<'4?]7QB2[*;#,^.B>\C:KV!\*RPBGM/^:<D4GZX25G;JY&5]P_9
M1XZ8()C40(4MB<"@P?B8,6# N%=(%8QQ-1"]"Y&-3'?O.]2JIJ=F,7B"RW ^
MO\35M1I$3W)&)\@YX-+BPJ8F@@_, 8V&*)DI^D15AH]L15TC,]N/@[I#--/.
M%2];L9:LP^532FVST>B%IPR6!@LL&&%CN4O45CGBZ@]T]2>X#P.Z7333R&BW
MC[-I0*9N$KW3>.U5=)/-KL7GE8S!(U]$EBZ^:-%V<Q6 9^,))5FI5&?0TK84
M-C+XO?>$9A4-#9TF>N?&JU'0I_GON(;<=<=HBB/IN!8T1& 4G62A3"A.LH5(
M0J3$9AOE/9=N0T+HB9<,G'6LH]-9!0'W. :IWPF#I_-O;KH>!N*F\6.I&DBS
M?"MJO,/!=A,&GW]H'Q,&=R2]IPF#M]^*8>)B-AE'MYZL\ND6*Z=YC44WN39J
M-X!,V@?A6(2L9+D;($BPY7II18(D5@3+[F=K^]D&>J'^T-WR("+>C!=A,EN@
MJK^B1E]-NLR^%ACWL "!EGIS(P/X4J:5$BYRBMM"5E6Z>?MF9%AS>GQDW]^D
M!P5&;WMYOP;ZR\79F9M?SO*7\;?I.(]#J8VYN?40111*!=P>5GK+)_=AJO=A
MHB=[_? U-U"E2H68N@X5C&X-%> ,0:_ >\9%=M17FN"WD:2#QV,])=Z;92%U
M3CQ[!C()"T+FDLG42*JCG$5#C9)52BZV(V_@,6[]X.7!$*S^-?.B#59]PS6
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M261=<;->=D%9P6VV$$P91:PE"HNAM51>D"@IVLE@CX.LNX0U%ML<!(-G,7:
M3AK 6#FK6:S351_3\JIFDHD4++$0@Z<@;"#@G2TGSPF-L$PTU)DY]2@UK:'I
M$(7?GV!_L/0;@- CZ^TK_J?=4J,L6$X$AV0=^O3<:\!HD0 1GGF,)(53Q\G-
MW= T["GL<;:]O>3?(I0*(^MUEIAUU D#AN42%$H)1CD.-"FED@S,BDIWK&ZD
MJ37+M*?>GTWV[J>$%O"T#E,>L'35W"]=%LKZ5=6@T,R!)41!4%1C[&("IW5J
MX)ZFJS%<[:O_^[CJ41DM8.L^&Q^N*U*)89PDE!*N/@8"EQN8+#QH62:5,9?H
M5B<+AYNJ#SO5JE>K(SG&IK>?]%O$T:<T+[]PWQ(=,2%BB@H#%)W+93,\@LOE
M\C>6>8@VV62JS&9[BJC&K-.>BG\.3_MJX45?P;-CK</#6?:M%9!LIK#9 I(M
MA5J_@$311'7I"S)99MSKRS48G$1@0:OH",>MND[UVK$+2*P/,1DE0><RXBFP
M $XS)$T%;:W+)O,JL]U?6 ')+GC8LH!D%\FWN%7?BKB""S+$$(%+2M&9\0&\
M0YT3DEVF)F?-ZH02!V8ZCEUBLI/*=\AT["+_%J%T*\AR7CD6?8(4-?K%UB0,
MWKT$1:GRVC$9TI'LT0O(=.RD]QTR';LHH04\/1-<*_17.7$1LO.\5%:+4OA7
M[AA*42I#::X4DK[43,=.^M\QT[&+,EK UG,':MZ46]$\ V\"QD=<$_#22C!<
M*&]M\(KR(^U][9]P][P![J^))I%U[W M2<VX3!*MNTPE\B[=8@F7(B'*64)I
M9%5Z1E_X"?=.,-CUA'L7G32 L8?Q]-4QJZ-9%,^!&J-!4,' 2.,A4.*#\$RR
M5"6WMHF@UC!UB-KO]V;UH8/V.@B",89&R\'X',LX_016N0S!:IEMF>IKMMGW
M:G80'/L@>Y_=K0?I-MM!8(WP)$L-KJME=4$CP+D$)F)46:H<]#8;V#]0!\%.
M:MVJ@V 7&0]=./[_N3$^Y,/X;+Q,\6KV8F"<,L*A'#* B+A;.XP,P#'/<<G0
M3.]/;]U0+?S(PUOL'-A)7[,>A3>T\C=U/H3$G)2:0C!2E9D($K=6:]%H8C2(
M 6<B_-GCDX/;1X[<-; W"/H0XM! >/?7O\UR/G/3Z0?W>1:^IP_+^%<WC?=^
MBZS^]9H[9;1"%YZ1B/LJD6@_B4C C):&"1ZS]EM!9.=7M]AOL#=XZ@I^:%A]
M2(L/ZP/&,>KI2YK_&*?YR32^GRZ6X^7%\DVYKO1[FN/_K_ZZ_F?-+276FTAQ
M-Z:<@V!E(+6A%/ ;PG -Z:3-5C [F)1A*E8JP>ZXBFD@Z'ZB2L.7@@E&-40B
M"=IID<%UN[8+40K/4V;'*6GYT'1Q5*]IPOVDWR*.;I?E1)Y\$BHB\:ZK&G1@
M<"6 S])QYJFD=0H47F1QU$Z*WZ4X:A<M]-BM.41YU%LTUF?E]NW?%BE?3#Z,
M?QSA+NNG7GJ\(J:M6:]?ER2LI%JK!-H9"4(3 S9FW(5=I%3[Q"6IF;>M4)?T
M!;?]>#%!K^/3?':>YLO+3Y.BA6DLPT'/R[C[=<6LQ+7F#0?-F0 A= 0?@X1$
MI%0^*&ECE1O<MB6PV=JE73#SH$FKAG8:V%LW<G.KN@(]3LDB#4"C9$5N$HS#
M[S2ZP=(;0JFITF&Z!6W#8JT.*&9U-=0RZ&Z57D@M@N:< <NBQ#J4@ DR0C3,
M4>>IM?RXH&NE#JIW/&R+MSV5TP#>7L_.SB_P<=>L7!T\)AXQOG* XG(@9"A7
M>W /B>H82+;*5)I^_C@]C>)J7[T_B!\.5T(#6/HRR\L_4* HH:MOWY2+7&<=
M3Z]GB^7U;5J:<$M% LJB+1,&##C&.7 G#5&>2QNJ]*IN3>&PE5&U\59'40T@
M\-W%?#I>7G2<O1O_6;Z[XL0KRUC4 G0FI-R$SL%$CQY'5)$[ZYAT=:X/WTC2
ML/4)M3'6DRH&/S*X:DBZ1#Y.,X;_Z;Z5CMGQ[%@&%@6N$:HEX*H(()U,S@?C
MA+UGS#:="3S[KF$SL;4@4T/0#1BC#\DMTO?9)+X_.R]CO+K;TZ]ZN=%V)L(L
M!"8#1CT>X^WD**"U)2+X& VOXEX]0=.PL\]KFZ.^E-$ KC:*ZB:9G81-M!R_
M)5Y.PVPF8',I)$*S2SFQ5M?9[)XG;5C':MBLQ'[Z:1EQ5\GNG$;:$W0,LP*.
M9KI<-:;!!6=!AN2("8095^7>S2UH:S1XW!,.VZ)M3]V\[/[\]?J>Y1/\?1Q/
M+I;C'[?NVGG[9YA<Q!2+EI;?TVLW"1>3CK19?E,^C;S.%HM/:?[E>Q<4U>[6
MKT/O$7OWCR#P(W3REW!6Z02*E\YMG0)@C,(A\.AU]IHK524=<8P3LZ?U\@[U
MLLH^=4HYS>5*#J3G6B.K[5#()&,@"H-_@P+RGH+U2H+W7FM)'4<[5?=<K0\V
MFCU]VP5_FT_?CJ[I!CR3 WE^=?GX [J3@DPD1@79 TG$@X@H"F,C!94LS\P2
MC!BJS"6NR%,K9X+'A^K]AJM&<-/L$BI%GE>WO(=(F2,13"HG9BXHL.B3 O?(
M3A+"6EOGVLAG"!O8G+>"H*V0O:<Z&X#GE^4L_'YZ?JN1P9&4@[0,3- 8FUN!
MT9(D!,V (D(I&H2L8I<?4-(B /=5]'VOXB"I-P"; Y?G36P>%?<ZHNR8QA4H
MNNIV:1WP["DU.2AEJPR;Z8N!5A)N+WW+WP\1+W\EG)R5J&5$ W'<* 8LNH@A
MBN#@8N)EPIGRCJI@6)6:HUZH;]%0UP9>O^C? P4O.I%X$F?GJRR5(JIZ&O#1
MMQTOB?<\L_53<$%FZ3S7X$7IDD XH[.22O^6\5(K8[*J,LBF7@IN?6W%^RFN
M-#<Y.3_'QW<:Q#4UGL77%V==)O1'>IMS"LNO<S==C,O?5UM=RCYY589^&&5P
MJS/H>66-*SX+I1/%E:BK#"0[C.QF4VR[X.N^[3RB)@>>T_%I/HL787FZ:JX,
MJXI9KE0L=A]4+/1+;C&BB!F!0Z*@6G/OMFFJV&I$QV,$#(NI8RI_UJ,FVD#2
MHI08KCA87 T.E,@%,^@YZ(R!I!,>?& 6,+HT1 9<HWR;\'T7.#VD8KBQ'X<K
M]B%*#I3RT#5VZR6V<D*O1H#CBCKY-D]W"W5DH)9*!=00"[B ,A@1#? 84HZ4
M<Y'I<Q[93F\<'":':G966\PM!+CQ/R\6RXZ!=[/YQ_3'+3=@CE[MQ32LV%N-
M_J..,EM&_]&L2D5S "LPG,(0BCKBI?2YCJ.Y"Y7#)FT&V/+JZ[(!H)92QM-\
M%6VM%QO7Q' 3$L1D,YI^E<!FUF58)1..9)]##3P^1LS WGL]W<]Z5D0#8+H1
MSI>EFT8WCXO?SJ-;)M2W(/9JDK(0D2O/43:L#'UR%(R2R%1F)N+6(2RMW O^
M!'7#PNUP$#P^Q+-'C30 L]TW@=400QITF9P!09=A8Z2,OU"2 A%*6NE82636
MP-U^Y [;B3/@=GL$[;Y(#%\U'* (B2,)#0&-N%:#!BO+M>W6TFQ%%CI6R<'M
M2_"P!O488#H8OWMHM@$$7]7-IOC;%)6XMAB_7(RC0Z?H_73%Y:N4RSU9L_-Q
M4$1=G]O'G"(C(,IT-,&8!T," \(4=TESKT*="?%[D_S24+P/I.XW@!]'OPT@
M^<T864$]A/0J+?](:?HDKR?3>)+QY?=Y=BH21RD$9GD1M01'LT01L*RM#P3=
MM1J8[H/X84/[0=!]=)TW@/.]G;J;XWY#E60&5S83+"#'3);:*PZ))<:D4S[6
MZ4HXG/1AVY0']*>/K/4&</YF_=HUYZ\OYD5%(TYX(,$ZH,R7H8?2@=-! 4V$
MRN2TCK1*C>;CY+S0$\0]07'?^AZNH=UQ9E<XFZ9E#91]G$W#F@VFB4"Z RA7
M+D6G3H)U&#V$Y$RVG'A79]CA1HI>:.J^"M;VU-/@</M<:J"F*5Y5P9V$L!)<
MBLCA.(R7HYR5II9R4*9<J^"3 D^< LV28@Q%9'B5*]V>)^V%)K/Z 6#/FFM@
M@UT+=#'RN((T(0'=7I2(L"Z ,<Q "-Y(Z6W,I$I*]8J %^K4]86K/;30 'H^
MIN7[:9B=I=)E/2(L4,4%!:N=0__66S#$!Y!!(O:%U\)4B9OO4#'LG)F!<;2_
M/GH<#7Y()OV*]E4523GMND [>WJ>5L//2\'X*[<8!XSBU_W]7?WX2$4>.$L4
MJ%*EI8VBU;4Z@J:>!D&HTG6::?>F>"N8JG]0F!Y'SR^A0V!3S7R122DL_OMX
M^?WJ%I0/8^?'D_'RLJ^&@8->WGO_0'^BJ-].$(5(+K@(),N(T:WSX&.T(%V*
M41%NM*A255.OG>!)*8]8L+A;I 2$9PJ"$ F.DP3!.TX=YQ&WDBJG/$]1U6PS
MP"[H>.2NCY[TL+?Y.^_V@"]+-^\GW'V2)=P*YF5VWINT^O?=;'[U^9/P7Q=C
M)/K]]-7% O>=!9J",S^>=BH>E:F,.:H(6;&21R4"7,SEB,I$;[)0-E2905>%
MFV&S.D- ^2AZ;R!">E((:S?L<PJS;]/Q?Z<X\J6/*#ODR1&."UQGE+?68-'=
M83Z&)$6M"]=W('/8'- 0<#U,4P=D'+^5W%)])(Y*5MYDZB%);8OD,ACO&:"/
M+Y*ERFE=Q:,Y?(>OEA,:9(??10\'[O!OI[%:D/.KF_^.KKF?W.H&WR=>>?0Y
M?80>SQ/84Q3Q?OHCK<O.WR1_-4)S>7EK)L\5JI*RCBM*@)!2:^,QFK:2:%PU
MV9/ LY*TBO'?GL3#$SS7;WH_7;_K1A,/WCJ-K].\9-R_SEW$=7BR6"2D<;P(
MD]GB8IZ^HHY>X?-_'V7.%%I<#SR4_EMMT!#K1( E8I/(##FO5!!<AZ&AB]2J
M8/9A&J@!-#2:)7K,/G4%)+V9T?73:AG3QX@]ODG-7I1TH8>L2[6-"1(,3[Q(
M)Z9D7>2D2I'3\4SJR0\WGA198P3UQ=W1P/5Z<-DR)T0$3_&+4&4 M-<22"F-
MSH)PD:K$REO0]F(,W2Y(>M"ZT[..7I#-.B!7_=3C:EFMFOGD'<#FN3;.2MQ+
M6=<=1CQ^1RED&E+R-'@>:[LSE<W6S>2V]6Y^9Z,_77Y/\SO;_*IX,EB!>SC&
MV[B1H[?!20"C/(%HC8_*Y^1=E3ST7M2^&-.V"]HVSX>NI<<&DGCOQE,W#6,W
M>3]%D5T4H7:]15(PD3WZO509W!.<E. 2"Y"B1DF29*2M4J6U@9Y6QB]70\+]
M.\!Z4$L#Z.I.U_'--\,XRE%X?H2[16DJ7CS^IW4C1:94VI0-2%:.Y8/#5>V3
M!A9EE"8Q[7B5GL(^F1@6Q[V@ZOY$@*%4W "\?_ORM9SP7,QO;3W7-_4%JK4+
MH#6U980P ^>U!RJS,<B'IW5&+6\F:>"9 8/!9%9%9TV@[Y?9CS2?%LE\.9]-
M%S.DX>T47W ^'R]2YQL]X-'D(*2U*+7N2R(,O$\"F++1*R(,Y:H.+G<G=MBC
MXX806UG/#6#Y]6Q^7H9JI4>943)))XV%G)(K(R@9&!<M<*,SBT)HIRK5Z#Q!
MU; GQ<V@LS_--0##6T/7-^:U/ES7B3I',[?.@:$I@<A"@;/, ]%19NH=)74&
M4.U$92M3[(\5.=5380/XO,_2W35W<C:;+TL%1[F'O-08+T91^M!=]^I%Q/5G
M>2GE$*6J+BCG%'795PGC=R6TE?B^=\P\DR[O58'[ W2V=)-C /2FI^R7^6RQ
M^&V*KOBD,/P+;D/K(1WNSU$PW@6?(F1?LG;*:;#.>K"<<AV<-;;.#*Q>J&_%
MX X,Y0JJ;M\ ;V2Z-(3<,.UB]#'1 ,P$!<(04:[-SI 88YDSK[*N,UNP#^J'
M]7O;Q_?^JFZBEG*S6.\*8,1+8:B*Z)6QTJ]D<&>RAEKPAKG(3#DUKG*SZ;8$
M#EMA.1Q.>U'8"SJ&?XK_7@_HGW]1K:/['5D\_J&^RXRIS!-X)XJ58[1<DVY
M"DXUR5'(4*4]^GB'^JM0];N;?DUG)=\QOWQ_=N[&\^XZ>K3X:7&+EFM]X2ZP
MN*.OD0LF=;<_$9,8",HB^!P<*.,%AKB:1E;%M>V)_A=S\+\+(N];U"%TW8!O
M^[ZDE)&M50MS)X212UZ8,AXQB2+&X#-N3(2#C9*2X&06I,KE=8_0,O3XOZ-
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MVS1QG7FB@V%:;H62C:\8N!:@(D#ZD>K0V'@WGI^]GIV=C;NI$9\N_&0<?L,
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MULW3.E"=+!'@#;KL(@:D/D5T8ER.)*-?)72=T?UWR!CX_IR]U;D!%WO(=NC
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MO"<]6A7UX%/!TPWBB[>Y. W<&DTA<?4W:F=CHY20426FTSB3RX:C\;1?HDY
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MH;2IR83GIS8U;GKQ4.BX:Y8&$\/TC<AVF/NAIF3W(0,;E(>V=@2S(JUWR(.
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M%SP#*\F;52(@Q&@R!-3.>Z9)-TTGSZ3WTJ?0F:27[)='$\2HJ15-@KB(AMG
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M;7/LJY)6*+M_G]=,>*=GX+;7HT.;N=V'-C9V#VU]%).G S+'Z0@UDA5"B$I
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M4?'+-OL[]XV^X\:0LFV6D'$R73$WY^[YLX/CR;WS"3LC<P&4C#NC0PQ0<"&
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ME&4<_/1+]/K:OK';_QV,/@!02P,$%     @ AX%:3F2 Z>X'!   5A   !L
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M08_V0_>P6^AXR5.]B +?_S5NV'G#P4P*37"*G.O;&N,1DL9;[;",ST5D(S8
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MZ\TV(11&KBF-KE6C;@7&%?5"03N+J7K;F%F6 ;F1'I-DDZ&@-BC;UNM^0R'
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M<FTQ+FAT;5!+ 0(4 Q0    ( (:!6D[(.<))&PD  (MK   :
M  "  9X+  !E>&AI8FET,3 Q.71O,C Q.&9O<FTQ+FAT;5!+ 0(4 Q0    (
M (:!6D[&P.\#>U$# %!=(  1              "  ?$4  !M9VYX+3(P,3@Q
M,C,Q+FAT;5!+ 0(4 Q0    ( (:!6D[1.!%)&1,  .O%   1
M  "  9MF P!M9VYX+3(P,3@Q,C,Q+GAS9%!+ 0(4 Q0    ( (:!6D[4=)B3
MG1P  $8K 0 5              "  >-Y P!M9VYX+3(P,3@Q,C,Q7V-A;"YX
M;6Q02P$"% ,4    " "&@5I.,$HGBV%E  !9-P0 %0              @ &S
ME@, ;6=N>"TR,#$X,3(S,5]D968N>&UL4$L! A0#%     @ AH%:3MV&-BD
MXP  $F@) !4              ( !1_P# &UG;G@M,C Q.#$R,S%?;&%B+GAM
M;%!+ 0(4 Q0    ( (:!6DZX?WA$;8X  $V9!@ 5              "  7K?
M! !M9VYX+3(P,3@Q,C,Q7W!R92YX;6Q02P$"% ,4    " "'@5I.B/ EFT0$
M  #@'0  &P              @ $:;@4 ;6=N>&5X:&EB:70R,RTQ,C Q.#$P
M>&LN:'1M4$L! A0#%     @ AX%:3O9?'.@["   -BT  !L
M ( !EW(% &UG;GAE>&AI8FET,S$M,3(P,3@Q,'AK+FAT;5!+ 0(4 Q0    (
M (>!6DX,28K+)P@  *HM   ;              "  0M[!0!M9VYX97AH:6)I
M=#,Q+3(R,#$X,3!X:RYH=&U02P$"% ,4    " "'@5I.XV %T?X#  "6$
M&P              @ %K@P4 ;6=N>&5X:&EB:70S,BTQ,C Q.#$P>&LN:'1M
M4$L! A0#%     @ AX%:3F2 Z>X'!   5A   !L              ( !HH<%
M &UG;GAE>&AI8FET,S(M,C(P,3@Q,'AK+FAT;5!+!08     #0 - (<#  #B
%BP4    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
